"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A2,WO 2011/105724 A2,081-825-864-838-535,2011-09-01,2011,KR 2011001133 W,2011-02-22,KR 20100016823 A,2010-02-24,SCAFFOLD FOR ARTICULAR CARTILAGE REGENERATION AND METHOD FOR MANUFACTURING SAME,"The present invention relates to a scaffold for articular cartilage regeneration that can be applied to the intermediate layer region of an articular cartilage or both the superficial layer region and the intermediate layer region thereof, and a method for manufacturing same. The scaffold for regeneration of an articular cartilage of the present invention provides mechanical features that are sufficient for transplantation or regeneration of an articular cartilage, has an excellent cell survival rate, provides high volume of antioxidation glycosaminoglycans (GAGs) to cells, and applies specifically to the superficial layer region and the intermediate layer region of the articular cartilage, which allow for convenient cell adhesion, and further enables convenient realization of a biometric surface environment that is effective for growth and differentiation of a stem cell. Therefore, the scaffold for articular cartilage regeneration of the present invention is effective for regeneration of damaged articular cartilage, which is useful for stem cell treatment of articular cartilage damage and diseases, and is also useful as prosthesis for plastic surgery for the nose and ear.",TE BIOS CO LTD;;CHO MICHAEL,CHO MICHAEL,,https://lens.org/081-825-864-838-535,Patent Application,yes,0,5,6,6,0,A61F2/30756;;A61F2002/30766;;A61F2310/00365;;A61L27/24;;A61L27/3817;;A61L27/52;;A61L27/58;;A61L2430/06;;C12N5/0655;;C12N2533/10;;C12N2533/40;;C12N2533/54;;B82Y5/00;;Y10S977/752;;Y10S977/923;;A61L27/52;;C12N5/0662;;B82B3/00;;A61L27/14;;C12N5/0655;;A61F2/30756;;A61L27/52;;A61L27/58;;A61L27/3817;;A61F2310/00365;;A61L27/24;;A61F2002/30766;;A61L2430/06;;C12N2533/54;;C12N2533/40;;C12N2533/10;;B82Y5/00;;Y10S977/752;;Y10S977/923,A61F2/28;;A61L27/56;;A61L27/24;;A61L27/38,,0,0,,,,PENDING
2,US,A1,US 2013/0084636 A1,018-410-589-005-416,2013-04-04,2013,US 201113700972 A,2011-02-22,KR 20100016823 A;;KR 2011001133 W,2010-02-24,SCAFFOLD FOR ARTICULAR CARTILAGE REGENERATION AND METHOD FOR MANUFACTURING SAME,"Disclosed are scaffolds for regeneration of articular cartilage which are applicable to both the superficial zone and the middle zone of articular cartilage, and a method for manufacturing the same. The scaffolds have sufficient mechanical properties to support the implantation and regeneration of chondrocytes, and allow cells to show high cell viability with a high content of sulfated glycosaminoglycans (GAGs). In addition, being applicable to both the superficial zone and the middle zone of articular cartilage, the scaffolds facilitate cell adhesion and provide biomimetic surface environments that are effective for growing and differentiating stem cells. Therefore, the scaffolds are helpful in regenerating damaged articular cartilage, thus finding applications in stem cell therapy for articular cartilage damage and disease. Also, the application of the scaffolds can be extended to prostheses of the ear and the nose in plastic surgery.",CHO MICHAEL;;TE BIOS CO LTD,CHO MICHAEL,TE BIOS CO. LTD (2012-11-30),https://lens.org/018-410-589-005-416,Patent Application,yes,8,12,6,6,0,A61F2/30756;;A61F2002/30766;;A61F2310/00365;;A61L27/24;;A61L27/3817;;A61L27/52;;A61L27/58;;A61L2430/06;;C12N5/0655;;C12N2533/10;;C12N2533/40;;C12N2533/54;;B82Y5/00;;Y10S977/752;;Y10S977/923;;A61L27/52;;C12N5/0662;;B82B3/00;;A61L27/14;;C12N5/0655;;A61F2/30756;;A61L27/52;;A61L27/58;;A61L27/3817;;A61F2310/00365;;A61L27/24;;A61F2002/30766;;A61L2430/06;;C12N2533/54;;C12N2533/40;;C12N2533/10;;B82Y5/00;;Y10S977/752;;Y10S977/923,C12N5/0775,435/372;;435/366;;977/752;;977/923,5,4,049-513-250-453-515;;067-655-695-931-627;;129-301-827-865-457;;026-578-043-888-906,17722553;;pmc2673972;;15350098;;10.1021/la049424n;;10.1002/app.26633;;10.1089/ten.2006.12.91;;16499446,"McCullen et al. ""Characterization of electrospun nanocomposite scaffolds adn biocompatibility with adipose-derived human mesenchymal stem cells"" International Journal of Nanomedicine 2007: 2(2) 253-263;;Kim et al. ""Functionalized Multiwell Carbon Nanotube/Gold Nanoparticle Composites"" Langmuir 2004, 20, 8239-8242.;;Ming ""Chemical Modification of Multiwalled Carbon Nanotube with Liquid Phase Method"" Journal of Applied Polymer Science, Vol. 107, 1655-1660 (2008);;Roboz ""Cleaning, Sterilization, and Maintenance of Surgical Instruments 2001"";;Sahoo et al ""Characterization of a Novel Polymeric Scaffold for Potential Application in Tendon/Ligament Tissue Engineering"" Tissue Engineering Volumne 12, Number 1, 2006",DISCONTINUED
3,WO,A9,WO 2011/105724 A9,066-820-427-349-788,2011-10-27,2011,KR 2011001133 W,2011-02-22,KR 20100016823 A,2010-02-24,SCAFFOLD FOR ARTICULAR CARTILAGE REGENERATION AND METHOD FOR MANUFACTURING SAME,"The present invention relates to a scaffold for articular cartilage regeneration that can be applied to the intermediate layer region of an articular cartilage or both the superficial layer region and the intermediate layer region thereof, and a method for manufacturing same. The scaffold for regeneration of an articular cartilage of the present invention provides mechanical features that are sufficient for transplantation or regeneration of an articular cartilage, has an excellent cell survival rate, provides high volume of antioxidation glycosaminoglycans (GAGs) to cells, and applies specifically to the superficial layer region and the intermediate layer region of the articular cartilage, which allow for convenient cell adhesion, and further enables convenient realization of a biometric surface environment that is effective for growth and differentiation of a stem cell. Therefore, the scaffold for articular cartilage regeneration of the present invention is effective for regeneration of damaged articular cartilage, which is useful for stem cell treatment of articular cartilage damage and diseases, and is also useful as prosthesis for plastic surgery for the nose and ear.",TE BIOS CO LTD;;CHO MICHAEL,CHO MICHAEL,,https://lens.org/066-820-427-349-788,Search Report,yes,0,0,6,6,0,A61F2/30756;;A61F2002/30766;;A61F2310/00365;;A61L27/24;;A61L27/3817;;A61L27/52;;A61L27/58;;A61L2430/06;;C12N5/0655;;C12N2533/10;;C12N2533/40;;C12N2533/54;;B82Y5/00;;Y10S977/752;;Y10S977/923;;A61L27/52;;C12N5/0662;;B82B3/00;;A61L27/14;;C12N5/0655;;A61F2/30756;;A61L27/52;;A61L27/58;;A61L27/3817;;A61F2310/00365;;A61L27/24;;A61F2002/30766;;A61L2430/06;;C12N2533/54;;C12N2533/40;;C12N2533/10;;B82Y5/00;;Y10S977/752;;Y10S977/923,A61L27/56;;A61F2/28;;A61L27/24;;A61L27/38,,0,0,,,,PENDING
4,KR,A,KR 20110097662 A,057-916-165-799-577,2011-08-31,2011,KR 20110015478 A,2011-02-22,KR 20100016823 A,2010-02-24,SCAFFOLD FOR ARTICULAR CARTILAGE REGENERATION AND PROCESS FOR PREPARING THE SAME,,TE BIOS CO LTD,MICHAEL CHO,,https://lens.org/057-916-165-799-577,Patent Application,no,0,8,6,6,0,A61F2/30756;;A61F2002/30766;;A61F2310/00365;;A61L27/24;;A61L27/3817;;A61L27/52;;A61L27/58;;A61L2430/06;;C12N5/0655;;C12N2533/10;;C12N2533/40;;C12N2533/54;;B82Y5/00;;Y10S977/752;;Y10S977/923;;A61L27/52;;C12N5/0662;;B82B3/00;;A61L27/14;;C12N5/0655;;A61F2/30756;;A61L27/52;;A61L27/58;;A61L27/3817;;A61F2310/00365;;A61L27/24;;A61F2002/30766;;A61L2430/06;;C12N2533/54;;C12N2533/40;;C12N2533/10;;B82Y5/00;;Y10S977/752;;Y10S977/923,A61L27/14;;B82B3/00;;C12N5/0775,,0,0,,,,ACTIVE
5,WO,A3,WO 2011/105724 A3,058-444-151-548-404,2012-01-12,2012,KR 2011001133 W,2011-02-22,KR 20100016823 A,2010-02-24,SCAFFOLD FOR ARTICULAR CARTILAGE REGENERATION AND METHOD FOR MANUFACTURING SAME,"The present invention relates to a scaffold for articular cartilage regeneration that can be applied to the intermediate layer region of an articular cartilage or both the superficial layer region and the intermediate layer region thereof, and a method for manufacturing same. The scaffold for regeneration of an articular cartilage of the present invention provides mechanical features that are sufficient for transplantation or regeneration of an articular cartilage, has an excellent cell survival rate, provides high volume of antioxidation glycosaminoglycans (GAGs) to cells, and applies specifically to the superficial layer region and the intermediate layer region of the articular cartilage, which allow for convenient cell adhesion, and further enables convenient realization of a biometric surface environment that is effective for growth and differentiation of a stem cell. Therefore, the scaffold for articular cartilage regeneration of the present invention is effective for regeneration of damaged articular cartilage, which is useful for stem cell treatment of articular cartilage damage and diseases, and is also useful as prosthesis for plastic surgery for the nose and ear.",TE BIOS CO LTD;;CHO MICHAEL,CHO MICHAEL,,https://lens.org/058-444-151-548-404,Search Report,yes,4,0,6,6,0,A61F2/30756;;A61F2002/30766;;A61F2310/00365;;A61L27/24;;A61L27/3817;;A61L27/52;;A61L27/58;;A61L2430/06;;C12N5/0655;;C12N2533/10;;C12N2533/40;;C12N2533/54;;B82Y5/00;;Y10S977/752;;Y10S977/923;;A61L27/52;;C12N5/0662;;B82B3/00;;A61L27/14;;C12N5/0655;;A61F2/30756;;A61L27/52;;A61L27/58;;A61L27/3817;;A61F2310/00365;;A61L27/24;;A61F2002/30766;;A61L2430/06;;C12N2533/54;;C12N2533/40;;C12N2533/10;;B82Y5/00;;Y10S977/752;;Y10S977/923,A61L27/56;;A61F2/28;;A61L27/24;;A61L27/38,,1,1,088-915-709-226-372,10.1016/j.biomaterials.2007.09.021;;17928048,"ANDER ABARRATEGI ET AL., BIOMATERIALS, vol. 29, 2008, pages 94 - 102",PENDING
6,US,A1,US 2004/0093227 A1,065-432-949-351-884,2004-05-13,2004,US 29156902 A,2002-11-12,US 29156902 A,2002-11-12,Third party rental system,"
   The invention is designed to maximize equipment/asset utilization while managing and limiting over-production and manufacturing. The invention provides a venue for equipment/s owner/lessor to rent/lease out their equipment/s to prospective lessor/renter. Equipment/s or Asset/s ranging from but not limited to automobiles, cranes, boats, planes, jet ski, camper home, timeshare, club memberships, tools, tractors, bulldozers, pavers, trailers, Bikes, Convertibles, Vans, Trucks, etc. The invention allows idle equipment to be put to work thru a third party that will assure smooth transaction. The invention seeks to provide the following services to enable lease/rental agreements between Owner/Lessor and Lessee/Renters: Brokerage, Agency, Insurance, Bond, Escrow, Guarantee, Waivers, Storage, Maintenance, Conflict Arbitration, etc. The invention will allow for Lessor/Owner and Lessee/Renters to book/reserve/lease/rent their Equipment/Assets in an efficient and secure manner. 
",CHO MICHAEL,CHO MICHAEL,,https://lens.org/065-432-949-351-884,Patent Application,yes,3,10,1,1,0,G06Q10/10;;G06Q10/10;;G06Q30/0645;;G06Q30/0645,G06Q10/10;;G06Q30/06,705/1,0,0,,,,DISCONTINUED
7,US,B2,US 11376320 B2,067-797-370-976-089,2022-07-05,2022,US 202117249546 A,2021-03-04,US 202117249546 A;;US 202062985631 P;;US 202062989404 P;;US 202063198922 P,2020-03-05,Immunogenic and vaccine compositions against SARS-CoV-2,"Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.",UNIV IOWA STATE RES FOUND INC,CHO MICHAEL WAN,IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC (2021-02-25),https://lens.org/067-797-370-976-089,Granted Patent,yes,4,1,4,4,62,A61K39/12;;A61P31/14;;C12N2770/20034;;C07K2319/02;;C07K2319/21;;A61K2039/55583;;A61K2039/55505;;C07K14/001;;C07K14/165;;A61K39/215;;A61K2039/545;;C07K14/165,A61K39/215;;A61K39/00;;C07K14/165,,44,39,020-831-593-476-701;;097-258-170-192-920;;056-366-167-977-461;;073-641-442-560-346;;043-669-154-209-021;;027-526-994-561-142;;095-041-202-864-526;;060-195-793-341-138;;053-150-762-393-346;;102-155-474-475-804;;081-118-560-654-582;;109-175-133-197-204;;027-796-109-423-784;;090-366-759-947-066;;012-112-882-525-492;;060-928-640-668-012;;060-690-417-053-376;;033-588-559-144-185;;075-306-835-234-677;;006-755-769-762-287;;029-209-095-765-815;;145-981-274-752-47X;;003-562-380-249-039;;026-634-789-611-309;;048-033-531-726-453;;087-959-765-824-287;;014-512-193-944-451;;034-136-902-364-353;;052-094-947-371-821;;069-148-016-298-900;;038-614-799-214-11X;;023-897-237-567-798;;058-918-985-619-856;;003-012-254-183-351;;044-541-738-296-409;;043-497-006-941-730;;008-366-423-029-524;;014-430-640-876-384;;047-265-930-183-624,10.1101/2020.01.28.923011;;10.1080/22221751.2020.1729069;;32065055;;pmc7048180;;pmc5816147;;29378946;;10.1073/pnas.1711837115;;pmc404098;;10.1073/pnas.0401939101;;15096611;;17331558;;pmc7103356;;10.1016/j.virol.2007.01.012;;10.1186/1743-422x-7-299;;pmc2988023;;21047436;;24355931;;pmc4130269;;10.4161/hv.27464;;pmc3256278;;10.1002/rmv.706;;21905149;;10.1016/j.bbrc.2009.05.003;;19422787;;pmc2750803;;10.1016/j.vaccine.2006.10.031;;17092615;;pmc7115660;;15530413;;10.1016/j.bbrc.2004.10.052;;pmc7092874;;pmc7159299;;10.1016/s0140-6736(20)30183-5;;31986264;;pmc7981188;;16954221;;10.1074/jbc.m603275200;;10.1128/jvi.00304-08;;18463152;;pmc2493341;;10.1126/science.1116480;;16166518;;18018769;;10.1177/135965350701200702;;pmc2612543;;18824060;;10.1016/j.vaccine.2008.09.026;;19324051;;pmc7094495;;10.1016/j.jmb.2009.03.042;;10.1074/jbc.m600697200;;pmc8099238;;16597622;;10.1016/j.vaccine.2004.07.031;;pmc7115388;;15603894;;10.1101/2020.04.10.036418;;15314040;;10.1093/intimm/dxh143;;pmc7108621;;10.1016/j.cell.2018.12.028;;30712865;;pmc6751136;;10.1016/j.imlet.2004.06.014;;15388253;;pmc7112924;;10.1038/nature02463;;15024391;;pmc7095382;;28393837;;pmc5394239;;10.1038/ncomms15092;;14985131;;10.1016/j.bbrc.2004.01.166;;pmc7111006;;10.1016/j.vaccine.2004.11.073;;pmc7115646;;15837220;;32015507;;pmc7095418;;10.1038/s41586-020-2012-7;;10.14293/s2199-1006.1.sor-uncat.atfigj.v1.rpnimv;;10.3978/j.issn.2072-1439.2013.06.06;;pmc3747534;;23977435;;32225176;;10.1038/s41586-020-2180-5;;pmc7508516;;33010978;;10.1016/j.vaccine.2020.09.058;;pmc7202686;;32376603;;10.1126/science.abc1932;;10.1038/s41586-020-2179-y;;32225175;;pmc7328981;;10.1101/2020.02.16.951723;;pmc7091888;;32203189;;10.3410/f.737584329.793572872;;10.1038/s41423-020-0400-4;;pmc7102599;;10.1016/j.cell.2020.02.058;;32155444;;10.1126/science.abb2762;;pmc7164635;;32132184;;10.1038/s41586-020-2599-8;;32726802;;32132669;;pmc7091851;;10.1038/s41423-020-0385-z,"Tian et al., Emerging Microbes & Infections, Feb. 2020, 9(1):382-385. (Year: 2020).;;Garton et al., PNAS Feb. 13, 2018 115 (7) 1505-1510. (Year: 2018).;;Walls et al., bioRxiv Preprint, posted Feb. 20, 2020, https://doi.org/10.1101/2020.02.19.956581. (Year: 2020).;;Liu et al., ThermoFisher Scientific Poster, No. date provided.;;Bisht et al., “Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice”, PNAS, vol. 101, No. 17, pp. 6641-6646, Apr. 27, 2004.;;Callendret et al., “Heterologous virus RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS”, Virology, vol. 363, pp. 288-302, 2007.;;Cao et al., “Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients”, Virology Journal, vol. 7, No. 299, pp. 1-6, 2010.;;Chen et al., “Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate”, Human Vaccines & Immunotherapeutics, vol. 10, No. 3, pp. 648-658, Mar. 2014.;;Coughlin et al., “Neutralizing Human Monoclonal Antibodies to Severe Acute Respiratory Syndrome Coronavirus: Target, Mechanism of Action and Therapeutic Potential”, Rev. Med. Virol., vol. 22, No. 1, pp. 2-17, doi:10.1002/rmv.706, Jan. 2012.;;Du et al., “Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells”, Biochem Biophys Res. Commun., vol. 384, No. 4, pp. 486-490, doi:10.1016/j.bbrc.2009.05.003, Jul. 10, 2009.;;Du et al., “Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model”, Vaccine, vol. 25, pp. 2832-2838, 2007.;;He et al., “Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry”, Biochemical and Biophysical Research Communications, vol. 325, pp. 445-452, 2004.;;Huang et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”, Articles, vol. 395, pp. 497-506, Feb. 15, 2020.;;Hwang et al., “Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R*”, Journal of Biological Chemistry, vol. 281, No. 45, downloaded from http://www.jbc.org/ at Iowa State University on Mar. 3, 2020, Nov. 10, 2006.;;Lamirande et al., “A LIve Attenuated Severe Acute Respiratory Syndrome Coronavirus is Immunogenic and Efficacious in Golden Syrian Hamsters”, Journal of Virology, vol. 82, No. 15, pp. 7721-7724, Aug. 2008.;;Li et al., “Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor”, Science, vol. 309, downloaded from http://science.sciencemag.org/ on Mar. 3, 2020, Sep. 16, 2005.;;Lin et al., “Safety and immunogenicity from a Phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine”, Antiviral Therapy, vol. 12, pp. 1107-1113, 2007.;;Martin et al., “A SARS DNA Vaccine Induces Neutralizing Antibody and Cellular Immune Reponses in Healthy Adults in a Phase I Clinical Trial”, Vaccine, vol. 26, No. 50, pp. 6338-6343, doi:10.1016/j.vaccine.2008.09.026, Nov. 25, 2008.;;Pak et al., “Structural Insights into Immune Recognition of the Severe Acute Respiratory Syndrome Coronavirus S Protein Receptor Binding Domain”, J. Mol. Biol., vol. 388, pp. 815-823, doi:10.1016/j.jmb.2009.03.042, 2009.;;Prabakaran et al., “Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody”, The Journal of Biological Chemistry, vol. 281, No. 23, downloaded from http://vww.jbc.org/ at Iowa State University on Mar. 3, 2020, Jun. 9, 2006.;;Qu et al., “Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice”, Vaccine, vol. 23, pp. 924-931, 2005.;;Quinlan et al., “The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement”, https://doi.org/10.1101/2020.04.10.036418, Apr. 12, 2020.;;Takasuka et al., “A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice”, International Immunology, vol. 16, No. 10, pp. 1423-1430, doi:10.1093/intimm/dxh143, 2004.;;Walls et al., “Unexpected receptor functional mimicry elucidates activation of coronavirus fusion”, Cell, vol. 176, No. 5, pp. 1026-1039, doi:10.1016/j.cell.2018.12.028, Feb. 2019.;;Xiong et al., “Immunogenicity of SARS inactivated vaccine in BALB/c mice”, Immunology Letters, vol. 95, pp. 139-143, 2004.;;Yang et al., “A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice”, NATURE, vol. 428, pp. 561-564, Apr. 2004.;;Yuan et al., “Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains”, Nature Communications, vol. 8, No. 15092, pp. 1-9, Apr. 10, 2017.;;Zeng et al., “Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments”, Biochemical and Biophysical Research Communications, vol. 315, pp. 1134-1139, 2004.;;Zhang et al., “Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain”, Vaccine, vol. 23, pp. 3196-3201, 2005.;;Zhou et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin”, Nature, https://doi.org/10.1038/s41586-020-2012-7, Jan. 2020.;;Zhu et al., “Receptor-binding domain as a target for developing SARS vaccines”, Journal of Thoracic Disease, vol. 5, Suppl. 2, pp. S142-S148, doi:l0.3978/j.issn.2072-1439.2013.06.06, Aug. 2013.;;CD Creative Diagnostics Safety Data Sheet—“Recombinant 2019-nCoV Spike Protein Receptor Binding Domain [Fc]”, 6 pages, Jan. 28, 2018.;;CD Creative Diagnostics, “Recombinant SARS-CoV-2 Spike Protein Receptor Binding Domain [Fc] (DAGC089)”, https://www.creative-diagnostics.com, 2 pages, Jan. 1, 2020.;;International Searching Authority in connection with PCT/US2021/020826 filed Mar. 4, 2021, “International Search Report”, 18 pages, dated Jul. 2, 2021.;;Lan et al., “Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor”, Nature, vol. 581, 16 pages, May 14, 2020.;;Liu et al., “Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice”, Vaccine, vol. 38, Issue 46, pp. 7205-7212, Oct. 27, 2020.;;Gao et al., “Development of an inactivated vaccine candidate for SARS-CoV-2”, Science, vol. 369, pp. 77-81, Jul. 3, 2020.;;Shang et al., “Structural basis of receptor recognition by SARS-CoV-2”, Nature, vol. 581, pp. 221-224, May 14, 2020.;;Sun et al., “SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development”, https://doi.org/10.1101/2020.02.16.951723, pp. 1-18, Feb. 20, 2020.;;Tai et al., “Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine”, Cellular & Molecular Immunology, pp. 613-620, Mar. 19, 2020.;;Walls et al., “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein”, Cell, vol. 180, pp. 281-292, Apr. 16, 2020.;;Yan et al., “Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2”, Science, vol. 367, pp. 1444-1448, Mar. 27, 2020.;;Yang et al., “A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity”, Nature, vol. 586, pp. 572-577, Oct. 22, 2020.;;Zheng et al., “Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV”, Cellular & Molecular Immunology, vol. 17, pp. 536-538, Mar. 4, 2020.",ACTIVE
8,US,A,US 4952505 A,001-539-556-129-703,1990-08-28,1990,US 22982388 A,1988-08-08,US 22982388 A,1988-08-08,Fermentation of trichoderma reesei and apparatus therefor,"A process for producing enzyme cellulases by the fermentation of Trichoderma reesei in an aqueous nutrient medium containing assimilable sources of cellulose, nitrogen, phosphate, magnesium and iron in the presence of an oxygen containing atmosphere and a fermentation apparatus for the aerobic fermentation of microorganisms in a liquid medium at a pressure in excess of about 7 atmospheres. The method comprises fermenting the Trichoderma reesei at a temperature of between about 26.degree. C. and 31.degree. C. while maintaining the oxygen containing atmosphere at a pressure of about 1 atmosphere until the Trichoderma reesei enter the late stationary growth phase, thereafter, gradually and steadily increasing the pressure of the oxygen containing atmosphere until it is in excess of about 7 atmospheres and culturing the Trichoderma reesei at said increased pressure and at a temperature of between about 40.degree. C. and about 60.degree. C., thereby resulting in the production of enzyme cellulases by the Trichoderma reesei, and recovering the enzyme cellulases.",UNIV FLORIDA STATE,CHO MICHAEL Y,FLORIDA STATE UNIVERSITY TALLAHASSEE FORIDA (1988-07-29),https://lens.org/001-539-556-129-703,Granted Patent,yes,1,42,1,1,0,C12N1/145;;C12N9/2437;;C12N1/145;;C12N9/2437;;C12R2001/885;;C12R2001/885;;C12Y302/01004;;C12Y302/01004;;Y10S435/945;;Y10S435/945,C12N9/42,435/209;;435/945,12,9,091-335-749-357-286;;178-251-541-666-027;;041-501-522-274-109;;069-641-290-789-429;;015-769-903-828-552;;139-714-676-058-68X;;000-557-779-191-523;;004-907-155-168-475;;011-103-047-427-070,13416182;;pmc289787;;10.1128/jb.73.2.269-278.1957;;10.1002/bit.260161105;;4900824;;10.1016/s0006-3495(69)86466-0;;pmc1367648;;10.1128/aem.47.4.780-787.1984;;pmc239765;;16346516;;pmc2225837;;4972126;;10.1085/jgp.52.5.810;;16345337;;pmc243399;;10.1128/aem.37.1.42-49.1979;;10.1002/bit.260181209;;18576559;;10.1002/bit.260290905;;10.1128/jb.84.6.1228-1236.1962;;14003850;;pmc278050,"Gallo, Cellulase Production by the New Hyperproducing Strain of Trichoderma Reesei, MCG80 , Presented at 1982 Winter National Meeting American Institute of Chem. Eng., Orlando, Fl., Feb. 28 Mar. 3.;;Mandels et al., Induction of Cellulase in Trichoderma Viride as Influenced by Carbon Sources and Metals , J. Bacteriol, 1957, vol. 73, pp. 269 278.;;Mandels et al., Enzymatic Hydrolysis of Waste Cellulose , Biotech. Bioeng., 1974, vol. 16, pp. 1471 1493.;;Yayanos et al., A Study of the Effects of Hydrostatic Pressure on Macromolecular Synthesis in Escherichia Coli , Bio Physical Journal, 1969, vol. 9, pp. 1464 1482.;;Thom et al., Microbial Growth Modification by Compressed Gases and Hydrostatic Pressure , Environmental Microbiology, Apr. 1984, pp. 780 787.;;Fenn et al., Growth of Streptococcus Faecalis Under High Hydrostatic Pressure and High Partial Pressures of Inert Gases , Jour. of Gen. Physiology, 1968, vol. 52, pp. 810 824.;;Davidson et al., Effects of Elevated Pressures on Iron and Sulfur Oxidizing Bacteria , Biotech, Bioeng. Symp., 1981, No. 11, 603 618.;;Taylor, Growth of a bacterium Under a High Pressure Oxy Helium Atmosphere , Applied and Environmental Microbiology, Jan. 1979, vol. 37, No. 1, pp. 42 49.;;Sternberg, A Method for Increasing Cellulase Production by Trichoderma Viride , Biotech. Bioeng., 1976, vol. 18, pp. 1751 1760.;;Sturm et al., Growth of the Extreme Thermophile Sulfolobus Acidocaldarius in a Hyperbaric Helium Bioreactor , Submitted to Biotech. Bioeng., (Feb. 1986), Revised Apr. 1986.;;Sturm et al., Growth of Extremely Thermophilic Archaebacteria Under Elevated Hyperbaric Conditions , Submitted to Ann. N.Y. Acad. Sci. (Sep. 1986).;;Zobell et al., Growth, Reproduction, and Death Rates of Escherichia Coli at Increased Hydrostatic Pressures , J. Bacteriol, 1962, vol. 84, pp. 1228 1236.",EXPIRED
9,US,A1,US 2021/0275665 A1,156-635-299-146-502,2021-09-09,2021,US 202117249546 A,2021-03-04,US 202117249546 A;;US 202062985631 P;;US 202062989404 P;;US 202063198922 P,2020-03-05,IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2,"Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.",UNIV IOWA STATE RES FOUND INC,CHO MICHAEL WAN,IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC (2021-02-25),https://lens.org/156-635-299-146-502,Patent Application,yes,0,7,4,4,62,A61K39/12;;A61P31/14;;C12N2770/20034;;C07K2319/02;;C07K2319/21;;A61K2039/55583;;A61K2039/55505;;C07K14/001;;C07K14/165;;A61K39/215;;A61K2039/545;;C07K14/165,A61K39/215;;C07K14/165,,0,0,,,,ACTIVE
10,US,A1,US 2022/0323574 A1,124-029-027-954-361,2022-10-13,2022,US 202217804954 A,2022-06-01,US 202217804954 A;;US 202117249546 A;;US 202063198922 P;;US 202062989404 P;;US 202062985631 P,2020-03-05,IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2,"Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe Acute Respiratory Syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.",UNIV IOWA STATE RES FOUND INC,CHO MICHAEL WAN,IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC (2021-02-25),https://lens.org/124-029-027-954-361,Patent Application,yes,2,5,4,4,62,A61K39/12;;A61P31/14;;C12N2770/20034;;C07K2319/02;;C07K2319/21;;A61K2039/55583;;A61K2039/55505;;C07K14/001;;C07K14/165;;A61K39/215;;A61K2039/545;;C07K14/165,A61K39/215;;C07K14/165,,3,0,,,"Tai et al., Cellular & Molecular Immunology, March 19, 2020, 17:613-620. (Year: 2020);;Tian et al., bioRxiv preprint doi: https://doi.org/10.1101/2020.06.29.178509; this version posted June 30, 2020. (Year: 2020);;Yi et al., Cellular & Molecular Immunology, May 2020, 17:621-630. (Year: 2020)",PENDING
11,WO,A1,WO 2021/178637 A1,167-619-481-932-453,2021-09-10,2021,US 2021/0020826 W,2021-03-04,US 202062985631 P;;US 202062989404 P;;US 202063198922 P,2020-03-05,IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2,"Disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods include an immunogenic portion of the receptor-binding domain (RBD) of the SARS-CoV-2-2 (COVID-19) spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.",UNIV IOWA STATE RES FOUND INC,CHO MICHAEL WAN,,https://lens.org/167-619-481-932-453,Patent Application,yes,37,0,4,4,62,A61K39/12;;A61P31/14;;C12N2770/20034;;C07K2319/02;;C07K2319/21;;A61K2039/55583;;A61K2039/55505;;C07K14/001;;C07K14/165;;A61K39/215;;A61K2039/545;;C07K14/165,A61K39/12;;A61P31/14;;C07K14/00;;C07K14/165,,96,84,008-366-423-029-524;;003-012-254-183-351;;047-265-930-183-624;;044-541-738-296-409;;069-148-016-298-900;;058-918-985-619-856;;043-497-006-941-730;;023-897-237-567-798;;038-614-799-214-11X;;014-430-640-876-384;;082-973-508-234-496;;088-809-272-823-799;;081-118-560-654-582;;001-281-857-268-277;;034-136-902-364-353;;145-981-274-752-47X;;048-033-531-726-453;;090-366-759-947-066;;033-588-559-144-185;;109-175-133-197-204;;060-690-417-053-376;;095-041-202-864-526;;003-562-380-249-039;;102-155-474-475-804;;029-209-095-765-815;;007-187-520-287-234;;075-306-835-234-677;;014-512-193-944-451;;027-796-109-423-784;;026-634-789-611-309;;087-959-765-824-287;;071-082-928-720-919;;073-641-442-560-346;;056-366-167-977-461;;060-195-793-341-138;;043-669-154-209-021;;027-526-994-561-142;;053-150-762-393-346;;052-094-947-371-821;;012-112-882-525-492;;060-928-640-668-012;;069-148-016-298-900;;058-918-985-619-856;;043-497-006-941-730;;053-252-152-696-662;;085-004-943-658-732;;027-526-994-561-142;;053-150-762-393-346;;060-195-793-341-138;;027-422-597-517-328;;153-203-408-850-761;;020-831-593-476-701;;006-552-502-702-920;;065-954-164-133-324;;054-869-595-973-696;;013-024-799-186-238;;065-006-613-240-855;;104-344-331-331-876;;010-524-135-897-16X;;037-700-475-554-42X;;044-578-785-909-107;;009-609-511-631-603;;127-304-415-648-350;;102-155-474-475-804;;029-209-095-765-815;;007-187-520-287-234;;075-306-835-234-677;;014-512-193-944-451;;026-634-789-611-309;;087-959-765-824-287;;056-366-167-977-461;;043-669-154-209-021;;005-648-085-777-955;;023-897-237-567-798;;145-471-916-728-843;;110-899-035-374-296;;028-854-847-545-66X;;014-430-640-876-384;;038-614-799-214-11X;;003-711-731-357-514;;063-665-124-605-645;;067-457-103-652-329;;158-461-618-961-164;;006-228-493-610-527,10.1126/science.abb2762;;pmc7164635;;32132184;;10.1101/2020.02.16.951723;;32132669;;pmc7091851;;10.1038/s41423-020-0385-z;;pmc7091888;;32203189;;10.3410/f.737584329.793572872;;10.1038/s41423-020-0400-4;;32225176;;10.1038/s41586-020-2180-5;;10.1038/s41586-020-2179-y;;32225175;;pmc7328981;;pmc7102599;;10.1016/j.cell.2020.02.058;;32155444;;pmc7202686;;32376603;;10.1126/science.abc1932;;pmc7508516;;33010978;;10.1016/j.vaccine.2020.09.058;;10.1038/s41586-020-2599-8;;32726802;;10.1016/s0264-410x(97)00209-0;;9160526;;10339815;;10.1111/j.1574-6968.1999.tb13575.x;;10.1016/s0378-1097(99)00149-4;;pmc7159299;;10.1016/s0140-6736(20)30183-5;;31986264;;10.1056/nejmoa2001316;;pmc7121484;;31995857;;32015507;;pmc7095418;;10.1038/s41586-020-2012-7;;10.14293/s2199-1006.1.sor-uncat.atfigj.v1.rpnimv;;10.1016/j.cell.2018.12.028;;30712865;;pmc6751136;;28393837;;pmc5394239;;10.1038/ncomms15092;;10.1126/science.1116480;;16166518;;10.1074/jbc.m600697200;;pmc8099238;;16597622;;pmc7981188;;16954221;;10.1074/jbc.m603275200;;19324051;;pmc7094495;;10.1016/j.jmb.2009.03.042;;pmc3256278;;10.1002/rmv.706;;21905149;;10.1016/j.imlet.2004.06.014;;15388253;;pmc7112924;;15530413;;10.1016/j.bbrc.2004.10.052;;pmc7092874;;15314040;;10.1093/intimm/dxh143;;pmc7108621;;10.1089/104454904323145272;;15231072;;10.1016/j.vaccine.2004.07.031;;pmc7115388;;15603894;;10.1016/j.vaccine.2004.11.073;;pmc7115646;;15837220;;10.1128/jvi.00304-08;;18463152;;pmc2493341;;10.1038/nature02463;;15024391;;pmc7095382;;14985131;;10.1016/j.bbrc.2004.01.166;;pmc7111006;;10.1089/dna.2007.0616;;17665998;;17331558;;pmc7103356;;10.1016/j.virol.2007.01.012;;pmc404098;;10.1073/pnas.0401939101;;15096611;;10.1016/j.bbrc.2009.05.003;;19422787;;pmc2750803;;10.1186/1743-422x-7-299;;pmc2988023;;21047436;;24355931;;pmc4130269;;10.4161/hv.27464;;10.1016/j.vaccine.2006.10.031;;17092615;;pmc7115660;;10.3978/j.issn.2072-1439.2013.06.06;;pmc3747534;;23977435;;18018769;;10.1177/135965350701200702;;pmc2612543;;18824060;;10.1016/j.vaccine.2008.09.026;;32225176;;10.1038/s41586-020-2180-5;;10.1038/s41586-020-2179-y;;32225175;;pmc7328981;;pmc7102599;;10.1016/j.cell.2020.02.058;;32155444;;10.1101/2020.02.11.944462;;32075877;;10.1126/science.abb2507;;32511295;;pmc7217118;;pmc7164637;;10.1016/j.chom.2020.08.004;;10.1101/2020.06.25.172403;;32841605;;pmc7386495;;32743578;;pmc7443692;;24355931;;pmc4130269;;10.4161/hv.27464;;10.1016/j.vaccine.2006.10.031;;17092615;;pmc7115660;;10.1016/j.bbrc.2009.05.003;;19422787;;pmc2750803;;15474494;;pmc7092904;;10.1016/j.bbrc.2004.09.106;;16796401;;pmc1483912;;10.1371/journal.pmed.0030237;;10.1101/2020.01.28.923011;;10.1080/22221751.2020.1729069;;32065055;;pmc7048180;;10.1126/science.abb7269;;pmc7164391;;32245784;;10.1101/2020.03.13.991570;;10.2210/pdb6z97/pdb;;pmc7480219;;10.1016/j.chom.2020.07.002;;10.1016/j.chom.2020.06.010;;pmc7303615;;32585135;;32910920;;25046154;;pmc4125429;;10.1016/j.virol.2014.06.006;;10.1371/journal.pone.0128823;;26039641;;pmc4454676;;10.1186/s12977-014-0125-5;;25527085;;pmc4300834;;32930052;;pmc7534308;;10.1080/22221751.2020.1823890;;pmc7494283;;10.2210/pdb7jxc/pdb;;32991844;;10.1016/j.cell.2020.09.037;;10.2210/pdb7jx3/pdb;;32703908;;pmc7402622;;10.1126/science.abc5881;;10.2210/pdb7cab/pdb;;10.1038/s41594-020-0480-y;;32737466;;10.1038/s41594-020-0469-6;;32661423;;32422645;;10.1038/s41586-020-2349-y;;15530413;;10.1016/j.bbrc.2004.10.052;;pmc7092874;;15314040;;10.1093/intimm/dxh143;;pmc7108621;;10.1089/104454904323145272;;15231072;;10.1016/j.vaccine.2004.07.031;;pmc7115388;;15603894;;10.1016/j.vaccine.2004.11.073;;pmc7115646;;15837220;;10.1038/nature02463;;15024391;;pmc7095382;;14985131;;10.1016/j.bbrc.2004.01.166;;pmc7111006;;pmc404098;;10.1073/pnas.0401939101;;15096611;;10.1186/1743-422x-7-299;;pmc2988023;;21047436;;pmc7275151;;10.1016/j.cell.2020.06.008;;32778225;;pmc7202686;;32376603;;10.1126/science.abc1932;;pmc7449230;;32722908;;10.1056/nejmoa2024671;;10.1126/science.abc6284;;32434945;;pmc7243363;;10.1101/2020.05.13.093195;;32511340;;pmc7241103;;pmc8436420;;10.1038/s41586-020-2608-y;;32731258;;10.1038/s41586-020-2599-8;;32726802;;pmc7508516;;33010978;;10.1016/j.vaccine.2020.09.058;;10.1016/j.cell.2020.06.035;;32645327;;pmc7321023;;10.1002/adma.202005637;;33111375;;pmc7645956;;pmc7403570;;32759966;;10.1038/s41422-020-0387-5;;32785213;;10.1038/s41586-020-2639-4;;11090719;;10.1016/s0264-410x(00)00248-6,"ANONYMOUS: ""Recombinant SARS-CoV-2 Spike Protein Receptor Binding Domain [Fc] (DAGC089) 1 Creative Diagnostics"", 1 January 2020 (2020-01-01), pages 1 - 2, XP055816799, Retrieved from the Internet <URL:https://www.creative-diagnostics.com/pdf/DAGC089.pdf>;;YAN RENHONG ET AL: ""Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2"", SCIENCE, vol. 367, no. 6485, 4 March 2020 (2020-03-04), US, pages 1444 - 1448, XP055798878, ISSN: 0036-8075, Retrieved from the Internet <URL:https://science.sciencemag.org/content/sci/early/2020/03/03/science.abb2762.full.pdf?casa_token=vOrsB4hcYeoAAAAA:wQwsaeta8xhaxf5AfpGV-ZB-ZJ8CWtcGw9dkZjIDoQGHPmLpuAdpwTrJw6C4jzODk3qjNBWOvZJnZQ> DOI: 10.1126/science.abb2762;;SUN CHUNYUN ET AL: ""SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development"", BIORXIV, 20 February 2020 (2020-02-20), pages 1 - 18, XP055812679, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.02.16.951723v1.full.pdf> [retrieved on 20210610], DOI: 10.1101/2020.02.16.951723;;ZHENG MING ET AL: ""Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV"", CELLULAR & MOLECULAR IMMUNOLOGY, CHINESE SOCIETY OF IMMUNOLOGY, CH, vol. 17, no. 5, 4 March 2020 (2020-03-04), pages 536 - 538, XP037110610, ISSN: 1672-7681, [retrieved on 20200304], DOI: 10.1038/S41423-020-0385-Z;;WANBO TAI ET AL: ""Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine"", CELLULAR & MOLECULAR IMMUNOLOGY, vol. 17, no. 6, 19 March 2020 (2020-03-19), CH, pages 613 - 620, XP055727464, ISSN: 1672-7681, DOI: 10.1038/s41423-020-0400-4;;LAN JUN ET AL: ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor"", NATURE, MACMILLAN JOURNALS LTD., ETC, LONDON, vol. 581, no. 7807, 30 March 2020 (2020-03-30), pages 215 - 220, XP037182122, ISSN: 0028-0836, [retrieved on 20200330], DOI: 10.1038/S41586-020-2180-5;;SHANG JIAN ET AL: ""Structural basis of receptor recognition by SARS-CoV-2"", NATURE, MACMILLAN JOURNALS LTD., ETC, LONDON, vol. 581, no. 7807, 30 March 2020 (2020-03-30), pages 221 - 224, XP037113559, ISSN: 0028-0836, [retrieved on 20200330], DOI: 10.1038/S41586-020-2179-Y;;WALLS ALEXANDRA C ET AL: ""Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein"", CELL, ELSEVIER, AMSTERDAM NL, vol. 181, no. 2, 9 March 2020 (2020-03-09), pages 281, XP086136222, ISSN: 0092-8674, [retrieved on 20200309], DOI: 10.1016/J.CELL.2020.02.058;;GAO QIANG ET AL: ""Development of an inactivated vaccine candidate for SARS-CoV-2"", SCIENCE, vol. 369, no. 6499, 3 July 2020 (2020-07-03), US, pages 77 - 81, XP055785035, ISSN: 0036-8075, Retrieved from the Internet <URL:https://science.sciencemag.org/content/sci/369/6499/77.full.pdf> DOI: 10.1126/science.abc1932;;LIU XIANGLEI ET AL: ""Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice"", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 38, no. 46, 22 September 2020 (2020-09-22), pages 7205 - 7212, XP086292805, ISSN: 0264-410X, [retrieved on 20200922], DOI: 10.1016/J.VACCINE.2020.09.058;;YANG JINGYUN ET AL: ""A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity"", NATURE, vol. 586, no. 7830, 29 July 2020 (2020-07-29), pages 572 - 577, XP037341143, ISSN: 0028-0836, DOI: 10.1038/S41586-020-2599-8;;HUNTER ET AL.: ""The Theory and Practical Application of Adjuvants"", 1995, JOHN WILEY AND SONS, pages: 51 - 94;;TODD ET AL., VACCINE, vol. 15, 1997, pages 564 - 570;;TATUSOVA TATL MADDEN: ""BLAST 2 sequences--a new tool for comparing protein and nucleotide sequences"", FEMS MICROBIOL LETT, vol. 174, 1999, pages 247 - 250;;HENIKOFFHENIKOFF, PROC. NAT. ACAD. SCI. USA, vol. 325, no. 89, pages 10915 - 10919;;LEHNINGER: ""Biochemistry"", 1975, WORTH PUBLISHERS, INC., pages: 71 - 77;;""Protocols in Molecular Biology"", 1994, WILEY AND SONS;;SAMBROOKFREIFELDER ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS, pages: 238 - 246;;""Remington's Pharmaceutical Sciences"", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329;;HUANG, C.WANG, Y.LI, X.REN, L.ZHAO, J.HU, Y.ZHANG, L.FAN, G.XU, J.GU, X. ET AL.: ""Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."", LANCET, vol. 395, 2020, pages 497 - 506, XP086050317, DOI: 10.1016/S0140-6736(20)30183-5;;LI, Q.GUAN, X.WU, P.WANG, X.ZHOU, L.TONG, Y.REN, R.LEUNG, K. S. M.LAU, E. H. Y.WONG, J. Y. ET AL.: ""Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia"", NENGL J MED, vol. 382, 2020, pages 1199 - 1207;;GARDNER, L.: ""Johns Hopkins University Center for Systems Science and Engineering"", CORONAVIRUS COVID-19 GLOBAL CASES, 2020;;ZHOU, P.YANG, X. L.WANG, X. G.HU, B.ZHANG, L.ZHANG, W.SI, H. R.ZHU, Y.LI, B.HUANG, C. L. ET AL.: ""A pneumonia outbreak associated with a new coronavirus of probable bat origin"", NATURE, vol. 579, 2020, pages 270 - 273, XP037296454, DOI: 10.1038/s41586-020-2012-7;;WALLS, A. C.XIONG, X.PARK, Y. J.TORTORICI, M. A.SNIJDER, J.QUISPE, J.CAMERONI, E.GOPAL, R.DAI, M.LANZAVECCHIA, A.: ""Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion"", CELL, vol. 176, 2019, pages 1026 - 1039;;YUAN, Y.CAO, D.ZHANG, Y.MA, J.QI, J.WANG, Q.LU, G.WU, Y.YAN, J.SHI, Y.: ""Cryo-EM structures of MERS-CoV and SARS-CoV-2 spike glycoproteins reveal the dynamic receptor binding domains"", NAT COMMUN, vol. 8, 2017, pages 15092;;LI, F.LI, W.FARZAN, M.HARRISON, S. C.: ""Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"", SCIENCE, vol. 309, 2005, pages 1864 - 1868;;PRABAKARAN, P.GAN, J.FENG, Y.ZHU, Z.CHOUDHRY, V.XIAO, X.JI, X.DIMITROV, D. S.: ""Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody"", JBIOL CHEM, vol. 281, 2006, pages 15829 - 15836, XP002439740, DOI: 10.1074/jbc.M600697200;;HWANG, W. C.LIN, Y.SANTELLI, E.SUI, J.JAROSZEWSKI, L.STEC, B.FARZAN, M.MARASCO, W. A.LIDDINGTON, R. C.: ""Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R"", JBIOL CHEM, vol. 281, 2006, pages 34610 - 34616, XP055598159, DOI: 10.1074/jbc.M603275200;;PAK, J. E.SHARON, C.SATKUNARAJAH, M.AUPERIN, T. C.CAMERON, C. M.KELVIN, D. J.SEETHARAMAN, J.COCHRANE, A.PLUMMER, F. A.BERRY, J. D.: ""Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain"", J MOL BIOI, vol. 388, 2009, pages 815 - 823, XP026085429, DOI: 10.1016/j.jmb.2009.03.042;;COUGHLIN, M. M.PRABHAKAR, B. S.: ""Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential"", REV MED VIROL, vol. 22, 2012, pages 2 - 17;;XIONG, S.WANG, Y. F.ZHANG, M. Y.LIU, X. J.ZHANG, C. H.LIU, S. S.QIAN, C. W.LI, J. X.LU, J. H.WAN, Z. Y.: ""Immunogenicity of SARS inactivated vaccine in BALB/c mice"", IMMUNOL LETT, vol. 95, 2004, pages 139 - 143, XP004573829, DOI: 10.1016/j.imlet.2004.06.014;;HE, Y.ZHOU, Y.SIDDIQUI, P.JIANG, S.: ""Inactivated SARS-CoV-2 vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry"", BIOCHEM BIOPHYS RES COMMUN, vol. 325, 2004, pages 445 - 452, XP004626814, DOI: 10.1016/j.bbrc.2004.10.052;;TAKASUKA, N.FUJII, H.TAKAHASHI, Y.KASAI, M.MORIKAWA, S.ITAMURA, S.ISHII, K.SAKAGUCHI, M.OHNISHI, K.OHSHIMA, M.: ""A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice"", INT IMMUNOL, vol. 16, 2004, pages 1423 - 1430, XP002359304;;TANG, L.ZHU, Q.QIN, E.YU, M.DING, Z.SHI, H.CHENG, X.WANG, C.CHANG, G.ZHU, Q.: ""Inactivated SARS-CoV-2 vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice"", DNA CELL BIOL, vol. 23, 2004, pages 391 - 394;;QU, D.ZHENG, B.YAO, X.GUAN, Y.YUAN, Z. H.ZHONG, N. S.LU, L. W.XIE, J. P.WEN, Y. M.: ""Intranasal immunization with inactivated SARS-CoV-2 (SARS-associated coronavirus) induced local and serum antibodies in mice"", VACCINE, vol. 23, 2005, pages 924 - 931, XP004685029, DOI: 10.1016/j.vaccine.2004.07.031;;ZHANG, C. H.LU, J. H.WANG, Y. F.ZHENG, H. Y.XIONG, S.ZHANG, M. Y.LIU, X. J.LI, J. X.WAN, Z. Y.YAN, X. G.: ""Immune responses in Balb/c mice induced by a candidate SARS-CoV-2 inactivated vaccine prepared from F69 strain"", VACCINE, vol. 23, 2005, pages 3196 - 3201, XP004851707, DOI: 10.1016/j.vaccine.2004.11.073;;LAMIRANDE, E. W.DEDIEGO, M. L.ROBERTS, A.JACKSON, J. P.ALVAREZ, E.SHEAHAN, T.SHIEH, W. J.ZAKI, S. R.BARIC, R.ENJUANES, L.: ""A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters"", J VIROL, vol. 82, 2008, pages 7721 - 7724;;YANG, Z. Y.KONG, W. P.HUANG, Y.ROBERTS, A.MURPHY, B. R.SUBBARAO, K.NABEL, G. J.: ""A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice"", NATURE, vol. 428, 2004, pages 561 - 564, XP037065776, DOI: 10.1038/nature02463;;ZENG, F.CHOW, K. Y.HON, C. C.LAW, K. M.YIP, C. W.CHAN, K. H.PEIRIS, J. S.LEUNG, F. C.: ""Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV-2 spike gene fragments"", BIOCHEM BIOPHYS RES COMMUN, vol. 315, 2004, pages 1134 - 1139, XP004491605, DOI: 10.1016/j.bbrc.2004.01.166;;ZAKHARTCHOUK, A. N.VISWANATHAN, S.MOSHYNSKYY, I.PETRIC, M.BABIUK, L. A.: ""Optimization of a DNA vaccine against SARS"", DNA CELL BIOL, vol. 26, 2007, pages 721 - 726, XP055780557, DOI: 10.1089/dna.2007.0616;;CALLENDRET, B.LORIN, V.CHARNEAU, P.MARIANNEAU, P.CONTAMIN, H.BETTON, J. M.VAN DER WERF, S.ESCRIOU, N.: ""Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS"", VIROLOGY, vol. 363, 2007, pages 288 - 302, XP022083920, DOI: 10.1016/j.virol.2007.01.012;;BISHT, H.ROBERTS, A.VOGEL, L.BUKREYEV, A.COLLINS, P. L.MURPHY, B. R.SUBBARAO, K.MOSS, B.: ""Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice"", PROC NATLACADSCI USA, vol. 101, 2004, pages 6641 - 6646;;DU, L.ZHAO, G.LI, L.HE, Y.ZHOU, Y.ZHENG, B. J.JIANG, S.: ""Antigenicity and immunogenicity of SARS-CoV-2 S protein receptor-binding domain stably expressed in CHO cells"", BIOCHEM BIOPHYS RES COMMUN, vol. 384, 2009, pages 486 - 490, XP026136127, DOI: 10.1016/j.bbrc.2009.05.003;;CAO, Z.LIU, L.DU, L.ZHANG, C.JIANG, S.LI, T.HE, Y.: ""Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV-2 spike protein in recovered patients"", VIROL J, vol. 7, 2010, pages 299, XP021080229, DOI: 10.1186/1743-422X-7-299;;CHEN, W. H.DU, L.CHAG, S. M.MA, C.TRICOCHE, N.TAO, X.SEID, C. A.HUDSPETH, E. M.LUSTIGMAN, S.TSENG, C. T.: ""Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV-2 spike protein with deglycosylated forms as a SARS vaccine candidate"", HUM VACCIN IMMUNOTHER, vol. 10, 2014, pages 648 - 658;;DU, L.ZHAO, G.HE, Y.GUO, Y.ZHENG, B. J.JIANG, S.ZHOU, Y.: ""Receptor-binding domain of SARS-CoV-2 spike protein induces long-term protective immunity in an animal model."", VACCINE, vol. 25, 2007, pages 2832 - 2838, XP005939180, DOI: 10.1016/j.vaccine.2006.10.031;;ZHU, X.LIU, Q.DU, L.LU, L.JIANG, S.: ""Receptor-binding domain as a target for developing SARS vaccines"", J THORAC DIS, vol. 2, 2013, pages 142 - 148;;LIN, J. T.ZHANG, J. S.SU, N.XU, J. G.WANG, N.CHEN, J. T.CHEN, X.LIU, Y. X.GAO, H.JIA, Y. P. ET AL.: ""Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine"", ANTIVIR THER, vol. 12, 2007, pages 1107 - 1113;;MARTIN, J. E.LOUDER, M. K.HOLMAN, L. A.GORDON, I. J.ENAMA, M. E.LARKIN, B. D.ANDREWS, C. A.VOGEL, L.KOUP, R. A.ROEDERER, M.: ""A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial"", VACCINE, vol. 26, 2008, pages 6338 - 6343, XP025658429, DOI: 10.1016/j.vaccine.2008.09.026;;""GenBank"", Database accession no. MN908947.3;;J. LANJ. GEJ. YUS. SHANH. ZHOUS. FANQ. ZHANGX. SHIQ. WANGL. ZHANG: ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor"", NATURE, vol. 581, 2020, pages 215 - 220;;J. SHANGG. YEK. SHIY. WANC. LUOH. AIHARAQ. GENGA. AUERBACHF. LI: ""Structural basis of receptor recognition by SARS-CoV-2"", NATURE, vol. 581, 2020, pages 221 - 224;;A. C. WALLSY. J. PARKM. A. TORTORICIA. WALLA. T. MCGUIRED. VEESLER: ""Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein"", CELL, vol. 181, 2020, pages 281 - 292;;D. WRAPPN. WANGK. S. CORBETTJ. A. GOLDSMITHC. L. HSIEHO. ABIONAB. S. GRAHAMJ. S. MCLELLAN: ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"", SCIENCE, vol. 367, 2020, pages 1260 - 1263;;P. ZHAOJ. L. PRAISSMANO. C. GRANTY. CAIT. XIAOK. E. ROSENBALMK. AOKIB. P. KELLMANR. BRIDGERD. H. BAROUCH: ""Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor"", CELL HOST MICROBE, vol. 28, 2020, pages 586 - 601;;W. H. CHENL. DUS. M. CHAGC. MAN. TRICOCHEX. TAOC. A. SEIDE. M. HUDSPETHS. LUSTIGMANC. T. TSENG: ""Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate."", HUM VACCIN IMMUNOTHER, vol. 10, 2014, pages 648 - 658;;L. DUG. ZHAOY. HEY. GUOB. J. ZHENGS. JIANGY. ZHOU: ""Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model."", VACCINE, vol. 25, 2007, pages 2832 - 2838, XP005939180, DOI: 10.1016/j.vaccine.2006.10.031;;L. DUG. ZHAOL. LIY. HEY. ZHOUB. J. ZHENGS. JIANG: ""Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells."", BIOCHEM BIOPHYS RES COMMUN, vol. 384, 2009, pages 486 - 490, XP026136127, DOI: 10.1016/j.bbrc.2009.05.003;;Y. HEY. ZHOUS. LIUZ. KOUW. LIM. FARZANS. JIANG: ""Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine"", BIOCHEM BIOPHYS RES COMMUN, vol. 324, 2004, pages 773 - 781;;J. TER MEULENE. N. VAN DEN BRINKL. L. POONW. E. MARISSENC. S. LEUNGF. COXC. Y. CHEUNGA. Q. BAKKERJ. A. BOGAARDSE. VAN DEVENTER: ""Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants"", PLOSMED, vol. 3, 2006, pages e237;;X. TIANC. LIA. HUANGS. XIAS. LUZ. SHIL. LUS. JIANGZ. YANGY. WU: ""Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody"", EMERG MICROBES INFECT, vol. 9, 2020, pages 382 - 385, XP055736759, DOI: 10.1080/22221751.2020.1729069;;M. YUANN. C. WUX. ZHUC. D. LEER. T. Y. SOH. LVC. K. P. MOKI. A. WILSON: ""A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV."", SCIENCE, 2020;;J. HUOY. ZHAOJ. REND. ZHOUH. M. E. DUYVESTEYNH. M. GINNL. CARRIQUET. MALINAUSKASR. R. RUZAP. N. M. SHAH: ""Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike."", CELL HOST MICROBE, vol. 28, 2020, pages 445 - 454;;Y. QINM. B. BANASIKS. KIMA. PENN-NICHOLSONH. H. HABTEC. LABRANCHED. C. MONTEFIORIC. WANGM. W. CHO: ""Eliciting Neutralizing Antibodies with gp120 Outer Domain Constructs Based on M-Group Consensus Sequence"", VIROLOGY, 2014, pages 363 - 376, XP029014212, DOI: 10.1016/j.virol.2014.06.006;;Y. QINS. BANERJEEA. AGRAWALH. SHIM. BANASIKF. LINK. ROHLC. LABRANCHED. C. MONTEFIORIM. W. CHO: ""Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp 120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop"", PLOS ONE, vol. 10, 2015, pages e0128823;;Y. QINH. SHIS. BANERJEEA. AGRAWALM. BANASIKM. W. CHO: ""Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits"", RETROVIROLOGY, vol. 11, 2014, pages 125, XP021210108, DOI: 10.1186/s12977-014-0125-5;;L. A. JACKSONE. J. ANDERSONN. G. ROUPHAELP. C. ROBERTSM. MAKHENER. N. COLERM. P. MCCULLOUGHJ. D. CHAPPELLM. R. DENISONL. J. STEVEN: ""An mRNA Vaccine against SARS-CoV-2 - Preliminary Report"", NENGL J MED, 2020;;P. WANGL. LIUM. S. NAIRM. T. YINY. LUOQ. WANGT. YUANK. MORIA. G. SOLISM. YAMASHITA: ""SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease"", EMERGMICROBES INFECT, vol. 9, 2020, pages 2091 - 2093;;L. PICCOLIY. J. PARKM. A. TORTORICIN. CZUDNOCHOWSKIA. C. WALLSM. BELTRAMELLOC. SILACCI-FREGNID. PINTOL. E. ROSENJ. E. BOWEN: ""Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology"", CELL, vol. 183, 2020, pages 1024 - 1042;;Z. LVY. Q. DENGQ. YEL. CAOC. Y. SUNC. FANW. HUANGS. SUNY. SUNL. ZHU: ""Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody"", SCIENCE, vol. 369, 2020, pages 1505 - 1509;;D. ZHOUH. M. E. DUYVESTEYNC. P. CHENC. G. HUANGT. H. CHENS. R. SHIHY. C. LINC. Y. CHENGS. H. CHENGY. C. HUANG: ""Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient"", NAT STRUCT MOL BIOL, vol. 27, 2020, pages 950 - 958, XP037263526, DOI: 10.1038/s41594-020-0480-y;;J. HUOA. LE BASR. R. RUZAH. M. E. DUYVESTEYNH. MIKOLAJEKT. MALINAUSKAST. K. TANP. RIJALM. DUMOUXP. N. WARD: ""Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2"", NAT STRUCT MOL BIOL, vol. 27, 2020, pages 846 - 854;;D. PINTOY. J. PARKM. BELTRAMELLOA. C. WALLSM. A. TORTORICIS. BIANCHIS. JACONIK. CULAPF. ZATTAA. DE MARCO: ""Cross- neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody"", NATURE, vol. 583, 2020, pages 290 - 295;;Y. HEY. ZHOUP. SIDDIQUIS. JIANG: ""Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry"", BIOCHEM BIOPHYS RES COMMUN, vol. 325, 2004, pages 445 - 452, XP004626814, DOI: 10.1016/j.bbrc.2004.10.052;;N. TAKASUKAH. FUJIIY. TAKAHASHIM. KASAIS. MORIKAWAS. ITAMURAK. ISHIIM. SAKAGUCHIK. OHNISHIM. OHSHIMA: ""A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice"", INTIMMUNOL, vol. 16, 2004, pages 1423 - 1430, XP002359304;;L. TANGQ. ZHUE. QINM. YUZ. DINGH. SHIX. CHENGC. WANGG. CHANGQ. ZHU: ""Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice"", DNA CELL BIOL, vol. 23, 2004, pages 391 - 394;;D. QUB. ZHENGX. YAOY. GUANZ. H. YUANN. S. ZHONGL. W. LUJ. P. XIEY. M. WEN: ""Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice"", VACCINE, vol. 23, 2005, pages 924 - 931;;C. H. ZHANGJ. H. LUY. F. WANGH. Y. ZHENGS. XIONGM. Y. ZHANGX. J. LIUJ. X. LIZ. Y. WANX. G. YAN: ""Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain"", VACCINE, vol. 23, 2005, pages 3196 - 3201;;Z. Y. YANGW. P. KONGY. HUANGA. ROBERTSB. R. MURPHYK. SUBBARAOG. J. NABEL: ""A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice."", NATURE, vol. 428, 2004, pages 561 - 564;;F. ZENGK. Y. CHOWC. C. HONK. M. LAWC. W. YIPK. H. CHANJ. S. PEIRISF. C. LEUNG: ""Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments"", BIOCHEM BIOPHYS RES COMMUN, vol. 315, 2004, pages 1134 - 1139, XP004491605, DOI: 10.1016/j.bbrc.2004.01.166;;H. BISHTA. ROBERTSL. VOGELA. BUKREYEVP. L. COLLINSB. R. MURPHYK. SUBBARAOB. MOSS: ""Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice"", PROC NATL ACAD SCI USA, vol. 101, 2004, pages 6641 - 6646;;Z. CAOL. LIUL. DUC. ZHANGS. JIANGT. LIY. HE: ""Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients"", VIROL J, vol. 7, 2010, pages 299, XP021080229, DOI: 10.1186/1743-422X-7-299;;X. ZHUQ. LIUL. DUL. LUS. JIANG: ""Receptor-binding domain as a target for developing SARS vaccines."", J THORAC DIS, vol. 2, 2013, pages 142 - 148;;H. WANGY. ZHANGB. HUANGW. DENGY. QUANW. WANGW. XUY. ZHAON. LIJ. ZHANG: ""Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2."", CELL, vol. 182, 2020, pages 713 - 721;;Q. GAOL. BAOH. MAOL. WANGK. XUM. YANGY. LIL. ZHUN. WANGZ. LV: ""Development of an inactivated vaccine candidate for SARS-CoV-2."", SCIENCE, vol. 369, 2020, pages 77 - 81;;K. S. CORBETTB. FLYNNK. E. FOULDSJ. R. FRANCICAS. BOYOGLU-BARNUMA. P. WERNERB. FLACHS. O'CONNELLK. W. BOCKM. MINAI: ""Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates"", NENGL J MED, vol. 383, 2020, pages 1544 - 1555;;J. YUL. H. TOSTANOSKIL. PETERN. B. MERCADOK. MCMAHANS. H. MAHROKHIANJ. P. NKOLOLAJ. LIUZ. LIA. CHANDRASHEKAR: ""DNA vaccine protection against SARS-CoV-2 in rhesus macaques."", SCIENCE, vol. 369, 2020, pages 806 - 811;;N. VAN DOREMALENT. LAMBEA. SPENCERS. BELIJ-RAMMERSTORFERJ. N. PURUSHOTHAMJ. R. PORTV. A. AVANZATOT. BUSHMAKERA. FLAXMANM. ULASZEWS: ""ChAdOxl nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques."", NATURE, vol. 586, 2020, pages 578 - 582;;N. B. MERCADOR. ZAHNF. WEGMANNC. LOOSA. CHANDRASHEKARJ. YUJ. LIUL. PETERK. MCMAHANL. H. TOSTANOSKI: ""Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques."", NATURE, 2020;;J. YANGW. WANGZ. CHENS. LUF. YANGZ. BIL. BAOF. MOX. LIY. HUANG: ""A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity."", NATURE, vol. 586, 2020, pages 572 - 577;;X. LIUA. DRELICHW. LIC. CHENZ. SUNM. SHIC. ADAMSJ. W. MELLORSC. T. TSENGD. S. DIMITROV: ""Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice"", VACCINE, vol. 38, 2020, pages 7205 - 7212, XP086292805, DOI: 10.1016/j.vaccine.2020.09.058;;L. DAIT. ZHENGK. XUY. HANL. XUE. HUANGY. ANY. CHENGS. LIM. LIU: ""A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS"", CELL, vol. 182, 2020, pages 722 - 733;;W. C. HUANGS. ZHOUX. HEK. CHIEMM. T. MABROUKR. H. NISSLYI. M. BIRDM. STRAUSSS. SAMBHARAJ. ORTEGA: ""SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination"", ADVMATER, 2020, pages e2005637;;W. TAIX. ZHANGA. DRELICHJ. SHIJ. C. HSUL. LUCHSINGERC. D. HILLYERC. K. TSENGS. JIANGL. DU: ""A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2"", CELL RES, 2020;;M. J. MULLIGANK. E. LYKEN. KITCHINJ. ABSALONA. GURTMANS. LOCKHARTK. NEUZILV. RAABER. BAILEYK. A. SWANSON: ""Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults"", NATURE, vol. 586, 2020, pages 589 - 593;;P. G. SEFERIANM. L. MARTINEZ: ""Immune stimulating activity of two new chitosan containing adjuvant formulations"", VACCINE, vol. 19, 2000, pages 661 - 668",PENDING
12,WO,A3,WO 2011/053978 A3,113-145-032-939-210,2011-07-28,2011,US 2010/0055126 W,2010-11-02,US 25725909 P,2009-11-02,SYSTEM AND METHOD FOR WATER EXPULSION FROM UNDERWATER HYDROPOWER PLANT AND HYDROPOWER PLANT ASSOCIATED THEREWITH,"Systems and methods relate to utilizing fluid potential energy to produce large scale and sustainable hydroelectric power by employing a Cho-Venturi hydraulic ram (CVHR). The CVHR system includes a Cho-Venturi tube (CVT) in which a primary flow from a fluid at a head pressure at a depth in a body of the fluid combines with a recirculation flow in a throat section of the CVT. A pressure higher than the pressure outside the plant is generated at the end of a diverging section the CVT, which enables expulsion of the fluid discharged from hydraulic turbines under atmospheric pressure to the fluid depth while another portion of the fluid is recycled for power generation.",CHO MICHAEL Y;;CHO JOHN M,CHO MICHAEL Y;;CHO JOHN M,,https://lens.org/113-145-032-939-210,Search Report,yes,4,0,4,4,0,F03B17/06;;F03B17/06;;F03B13/10;;F03B13/10;;Y02E10/20;;Y02E10/20;;Y02E10/30;;Y10T137/0396;;Y10T137/0396,F03B13/10;;F03B17/06;;F03G7/04,,0,0,,,,PENDING
13,WO,A2,WO 2011/053978 A2,038-562-780-573-719,2011-05-05,2011,US 2010/0055126 W,2010-11-02,US 25725909 P,2009-11-02,SYSTEM AND METHOD FOR WATER EXPULSION FROM UNDERWATER HYDROPOWER PLANT AND HYDROPOWER PLANT ASSOCIATED THEREWITH,"Systems and methods relate to utilizing fluid potential energy to produce large scale and sustainable hydroelectric power by employing a Cho-Venturi hydraulic ram (CVHR). The CVHR system includes a Cho-Venturi tube (CVT) in which a primary flow from a fluid at a head pressure at a depth in a body of the fluid combines with a recirculation flow in a throat section of the CVT. A pressure higher than the pressure outside the plant is generated at the end of a diverging section the CVT, which enables expulsion of the fluid discharged from hydraulic turbines under atmospheric pressure to the fluid depth while another portion of the fluid is recycled for power generation.",CHO MICHAEL Y;;CHO JOHN M,CHO MICHAEL Y;;CHO JOHN M,,https://lens.org/038-562-780-573-719,Patent Application,yes,0,2,4,4,0,F03B17/06;;F03B17/06;;F03B13/10;;F03B13/10;;Y02E10/20;;Y02E10/20;;Y02E10/30;;Y10T137/0396;;Y10T137/0396,F03B13/10;;F03B17/06;;F03G7/04,,0,0,,,,PENDING
14,US,A1,US 2011/0110797 A1,069-756-579-401-827,2011-05-12,2011,US 93808210 A,2010-11-02,US 93808210 A;;US 25725909 P,2009-11-02,SYSTEM AND METHOD FOR WATER EXPULSION FROM UNDERWATER HYDROPOWER PLANT AND HYDROPOWER PLANT ASSOCIATED THEREWITH,"Systems and methods relate to utilizing fluid potential energy to produce large scale and sustainable hydroelectric power by employing a Cho-Venturi hydraulic ram (CVHR). The CVHR system includes a Cho-Venturi tube (CVT) in which a primary flow from a fluid at a head pressure at a depth in a body of the fluid combines with a recirculation flow in a throat section of the CVT. A pressure higher than the pressure outside the plant is generated at the end of a diverging section the CVT, which enables expulsion of the fluid discharged from hydraulic turbines under atmospheric pressure to the fluid depth while another portion of the fluid is recycled for power generation.",CHO MICHAEL Y;;CHO JOHN M,CHO MICHAEL Y;;CHO JOHN M,,https://lens.org/069-756-579-401-827,Patent Application,yes,20,12,4,4,0,F03B17/06;;F03B17/06;;F03B13/10;;F03B13/10;;Y02E10/20;;Y02E10/20;;Y02E10/30;;Y10T137/0396;;Y10T137/0396,E21B43/12;;F17D1/16,417/65;;137/14,0,0,,,,ACTIVE
15,US,B2,US 9127639 B2,111-439-514-661-603,2015-09-08,2015,US 93808210 A,2010-11-02,US 93808210 A;;US 25725909 P,2009-11-02,System and method for water expulsion from underwater hydropower plant and hydropower plant associated therewith,"Systems and methods relate to utilizing fluid potential energy to produce large scale and sustainable hydroelectric power by employing a Cho-Venturi hydraulic ram (CVHR). The CVHR system includes a Cho-Venturi tube (CVT) in which a primary flow from a fluid at a head pressure at a depth in a body of the fluid combines with a recirculation flow in a throat section of the CVT. A pressure higher than the pressure outside the plant is generated at the end of a diverging section the CVT, which enables expulsion of the fluid discharged from hydraulic turbines under atmospheric pressure to the fluid depth while another portion of the fluid is recycled for power generation.",CHO MICHAEL Y;;CHO JOHN M,CHO MICHAEL Y;;CHO JOHN M,,https://lens.org/111-439-514-661-603,Granted Patent,yes,23,5,4,4,0,F03B17/06;;F03B17/06;;F03B13/10;;F03B13/10;;Y02E10/20;;Y02E10/20;;Y02E10/30;;Y10T137/0396;;Y10T137/0396,F03B17/06;;F03B13/10,,7,0,,,"Munsen et al.; ""Fundamentals of Fluid Mechanics""; 3rd Edition, p. 131; John Wiley, 1998.;;Frank M. White; ""Fluid Mechanics""; 5th Edition; McGraw-Hill, pp. 421-422, 2003.;;Howard S. Bean; ""Their Theory and Application""; 6th Edition; pp. 230-232; 1971, ASME.;;Robert L. Dougherty; ""Fluid Mechanics With Engineering Application""; 8th Edition McGraw-Hill; pp. 419-421;1985.;;OFFSHORE-TECHNOLOGY.COM; http://www.offshore-technology.com/projects/hibernia/hibernia3.html; SPG Media Limited; Copyright 2007.;;http://statoil.no/STATOILCOM/SVG00990.NSF/Attachments/Troll/$FILE/Troll-illustrasjon.jpg; May 15, 2008.;;Notification of Transmittal of the International Search Report and The Written Opinion of the International Searching Authority, or the Declaration with mailing date of Jun. 1, 2011; International Application No. PCT/US2010/055126.",ACTIVE
16,EP,A4,EP 2771042 A4,024-485-937-396-462,2015-08-05,2015,EP 12842820 A,2012-10-26,US 201113284301 A;;US 2012/0062116 W,2011-10-28,A SUTURABLE HYBRID SUPERPOROUS HYDROGEL KERATOPROSTHESIS FOR CORNEA,,UNIV ILLINOIS,CHO MICHAEL;;ZELLANDER AMELIA,,https://lens.org/024-485-937-396-462,Search Report,no,2,0,10,12,0,A61L27/52;;A61L27/56;;A61L27/16;;A61L27/24;;A61L27/48;;A61L2430/16;;A61K35/12;;C12N11/04;;A61F2/142;;A61L27/14;;A61F2/142;;A61L27/52;;A61L27/56;;A61L27/24;;A61L2430/16;;A61K35/12;;A61L27/48;;A61L27/16;;C12N11/04,A61L27/56;;A61F2/14;;A61L27/14;;A61L27/16;;A61L27/24;;A61L27/48;;A61L27/52,,3,2,018-932-450-366-610;;014-240-229-798-817,11700803;;10.1016/s0142-9612(01)00168-5;;15348030;;10.1023/a:1008977818135,"CHIRILA T V: ""An overview of the development of artificial corneas with porous skirts and the use of PHEMA for such an application"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 24, 15 December 2001 (2001-12-15), pages 3311 - 3317, XP004309014, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(01)00168-5;;X LOU ET AL: ""Hydrophilic sponges based on 2-hydroxyethyl methacrylate Part VII: Modulation of sponge characteristics by changes in reactivity and hydrophilicity of crosslinking agents"", JOURNAL OF MATERIALS SCIENCE: MATERIALS IN MEDICINE, 1 May 2000 (2000-05-01), Boston, pages 319 - 325, XP055198182, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/15348030> [retrieved on 20150623], DOI: 10.1023/A:1008977818135;;See also references of WO 2013063390A1",DISCONTINUED
17,IN,A,IN 3269CHN2014 A,159-457-119-825-445,2015-07-03,2015,IN 3269CHN2014 A,2014-04-30,US 201113284301 A;;US 2012/0062116 W,2011-10-28,A SUTURABLE HYBRID SUPERPOROUS HYDROGEL KERATOPROSTHESIS FOR CORNEA,The present invention features a hybrid superporous hydrogel scaffold for cornea regeneration and a method for producing the same. The hybrid hydrogel is composed of a superporous poly (2 hydroxyethyl methacrylate) (PHEMA) and poly (methyl methacrylate) (PMMA) copolymer mixed with collagen. The hybrid scaffold can be used as a suturable hybrid corneal implant or keratoprosthesis.,UNIV ILLINOIS,CHO MICHAEL;;ZELLANDER AMELIA,,https://lens.org/159-457-119-825-445,Patent Application,no,0,0,10,12,0,A61L27/52;;A61L27/56;;A61L27/16;;A61L27/24;;A61L27/48;;A61L2430/16;;A61K35/12;;C12N11/04;;A61F2/142;;A61L27/14;;A61F2/142;;A61L27/52;;A61L27/56;;A61L27/24;;A61L2430/16;;A61K35/12;;A61L27/48;;A61L27/16;;C12N11/04,A61L27/56;;A61L27/14;;A61L27/52,,0,0,,,,PENDING
18,AU,A1,AU 2012/328583 A1,032-555-999-423-324,2014-05-22,2014,AU 2012/328583 A,2012-10-26,US 201113284301 A;;US 2012/0062116 W,2011-10-28,A suturable hybrid superporous hydrogel keratoprosthesis for cornea,The present invention features a hybrid superporous hydrogel scaffold for cornea regeneration and a method for producing the same. The hybrid hydrogel is composed of a superporous poly (2-hydroxyethyl methacrylate) (PHEMA) and poly (methyl methacrylate) (PMMA) copolymer mixed with collagen. The hybrid scaffold can be used as a suturable hybrid corneal implant or keratoprosthesis.,UNIV ILLINOIS,CHO MICHAEL;;ZELLANDER AMELIA,,https://lens.org/032-555-999-423-324,Patent Application,no,0,0,10,12,0,A61L27/52;;A61L27/56;;A61L27/16;;A61L27/24;;A61L27/48;;A61L2430/16;;A61K35/12;;C12N11/04;;A61F2/142;;A61L27/14;;A61F2/142;;A61L27/52;;A61L27/56;;A61L27/24;;A61L2430/16;;A61K35/12;;A61L27/48;;A61L27/16;;C12N11/04,A61L27/56;;A61F2/14;;A61L27/14;;A61L27/52,,0,0,,,,DISCONTINUED
19,CA,A1,CA 2853714 A1,089-950-301-137-560,2013-05-02,2013,CA 2853714 A,2012-10-26,US 201113284301 A;;US 2012/0062116 W,2011-10-28,A SUTURABLE HYBRID SUPERPOROUS HYDROGEL KERATOPROSTHESIS FOR CORNEA,The present invention features a hybrid superporous hydrogel scaffold for cornea regeneration and a method for producing the same. The hybrid hydrogel is composed of a superporous poly (2-hydroxyethyl methacrylate) (PHEMA) and poly (methyl methacrylate) (PMMA) copolymer mixed with collagen. The hybrid scaffold can be used as a suturable hybrid corneal implant or keratoprosthesis.,UNIV ILLINOIS,CHO MICHAEL;;ZELLANDER AMELIA,,https://lens.org/089-950-301-137-560,Patent Application,no,0,0,10,12,0,A61L27/52;;A61L27/56;;A61L27/16;;A61L27/24;;A61L27/48;;A61L2430/16;;A61K35/12;;C12N11/04;;A61F2/142;;A61L27/14;;A61F2/142;;A61L27/52;;A61L27/56;;A61L27/24;;A61L2430/16;;A61K35/12;;A61L27/48;;A61L27/16;;C12N11/04,A61L27/56;;A61F2/14;;A61L27/14;;A61L27/52,,0,0,,,,DISCONTINUED
20,EP,A1,EP 2771042 A1,138-438-208-798-981,2014-09-03,2014,EP 12842820 A,2012-10-26,US 201113284301 A;;US 2012/0062116 W,2011-10-28,A SUTURABLE HYBRID SUPERPOROUS HYDROGEL KERATOPROSTHESIS FOR CORNEA,,UNIV ILLINOIS,CHO MICHAEL;;ZELLANDER AMELIA,,https://lens.org/138-438-208-798-981,Patent Application,yes,0,0,10,12,0,A61L27/52;;A61L27/56;;A61L27/16;;A61L27/24;;A61L27/48;;A61L2430/16;;A61K35/12;;C12N11/04;;A61F2/142;;A61L27/14;;A61F2/142;;A61L27/52;;A61L27/56;;A61L27/24;;A61L2430/16;;A61K35/12;;A61L27/48;;A61L27/16;;C12N11/04,A61L27/56;;A61F2/14;;A61L27/14;;A61L27/16;;A61L27/24;;A61L27/48;;A61L27/52,,0,0,,,,DISCONTINUED
21,CN,A,CN 104144716 A,093-745-466-294-961,2014-11-12,2014,CN 201280060886 A,2012-10-26,US 2012/0062116 W;;US 201113284301 A,2011-10-28,A SUTURABLE HYBRID SUPERPOROUS HYDROGEL KERATOPROSTHESIS FOR CORNEA,The present invention features a hybrid superporous hydrogel scaffold for cornea regeneration and a method for producing the same. The hybrid hydrogel is composed of a superporous poly (2-hydroxyethyl methacrylate) (PHEMA) and poly (methyl methacrylate) (PMMA) copolymer mixed with collagen. The hybrid scaffold can be used as a suturable hybrid corneal implant or keratoprosthesis.,UNIV ILLINOIS,CHO MICHAEL;;ZELLANDER AMELIA,,https://lens.org/093-745-466-294-961,Patent Application,no,2,1,10,12,0,A61L27/52;;A61L27/56;;A61L27/16;;A61L27/24;;A61L27/48;;A61L2430/16;;A61K35/12;;C12N11/04;;A61F2/142;;A61L27/14;;A61F2/142;;A61L27/52;;A61L27/56;;A61L27/24;;A61L2430/16;;A61K35/12;;A61L27/48;;A61L27/16;;C12N11/04,A61L27/56;;A61F2/14;;A61L27/14;;A61L27/52,,0,0,,,,DISCONTINUED
22,DE,D1,DE 602005001527 D1,100-166-122-315-47X,2007-08-16,2007,DE 602005001527 T,2005-05-11,US 85909604 A,2004-06-03,Modulares Kraftstoffeinspritzventil mit einem Dämpfungselement und einem Verfahren zum Verringern von Geräuschen,,SIEMENS VDO AUTOMOTIVE CORP,CHO YONG;;DALLMEYER MICHAEL,,https://lens.org/100-166-122-315-47X,Granted Patent,no,0,0,7,7,0,F02M51/0682;;F02M55/00;;F02M61/16;;F02M61/165;;F02M2200/09;;F02M2200/27;;F02M2200/306;;F02M2200/505;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M2200/26;;F02M2200/315;;F02M61/16;;F02M2200/505;;F02M61/165;;F02M2200/27;;F02M55/00;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M51/0682;;F02M2200/306;;F02M2200/09;;F02M2200/26;;F02M2200/315,F02M51/06;;F02M55/02;;F02M55/00;;F02M55/04;;F02M61/16;;F02M63/00,,0,0,,,,ACTIVE
23,EP,A1,EP 1609982 A1,107-408-052-381-458,2005-12-28,2005,EP 05076117 A,2005-05-11,US 85909604 A,2004-06-03,Modular fuel injector with a damper member and method of reducing noise,"A fuel injector (100) includes a body (200), filter (230), and damper member (400). The body extends along a longitudinal axis between an inlet end and an outlet end and has a wall defining a flow passage extending therebetween. The filter (230) is disposed in the flow passage proximate the inlet end. The damper member (400) is secured to the flow passage between the inlet end and the filter. The damper member (400) has outer (404) and inner surfaces surrounding the longitudinal axis, the outer surface (404) being contiguous to the wall of the flow passage to define at least one circumferential band (L 1 ,L 2 ) about the longitudinal axis in the flow passage. The inner surface defines an aperture (408) that extends through the damper member (400) to permit fluid communication between the inlet end and the filter (230). A method of reducing sound in the valve group subassembly is also disclosed.",SIEMENS VDO AUTOMOTIVE CORP,CHO YONG;;DALLMEYER MICHAEL,,https://lens.org/107-408-052-381-458,Patent Application,yes,6,6,7,7,0,F02M51/0682;;F02M55/00;;F02M61/16;;F02M61/165;;F02M2200/09;;F02M2200/27;;F02M2200/306;;F02M2200/505;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M2200/26;;F02M2200/315;;F02M61/16;;F02M2200/505;;F02M61/165;;F02M2200/27;;F02M55/00;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M51/0682;;F02M2200/306;;F02M2200/09;;F02M2200/26;;F02M2200/315,F02M51/06;;F02M55/00;;F02M55/02;;F02M55/04;;F02M61/16;;F02M63/00,,0,0,,,,ACTIVE
24,US,A1,US 2016/0144069 A1,168-758-250-084-158,2016-05-26,2016,US 201615012110 A,2016-02-01,US 201615012110 A;;US 201113284301 A;;US 51114509 A;;US 8506408 P,2008-07-31,SUTURABLE HYBRID SUPERPOROUS HYDROGEL KERATOPROSTHESIS FOR CORNEA,The present invention features a superporous hydrogel scaffold for corneal regeneration or replacement and a method for producing the same. The superporous hydrogel is composed of a poly(2-hydroxyethyl methacrylate) (PHEMA) and poly(methyl methacrylate) (PMMA) copolymer mixed with collagen. The scaffold can be used as a suturable hybrid corneal implant or keratoprosthesis.,UNIV ILLINOIS,CHO MICHAEL;;ZELLANDER AMELIA,,https://lens.org/168-758-250-084-158,Patent Application,yes,3,9,1,12,0,A61L27/16;;A61L27/24;;A61L27/48;;C12N11/04;;A61F2/142;;A61L27/56;;A61L27/52;;A61L2430/16;;A61L27/56;;A61L27/52;;A61L2430/16;;C12N11/04;;A61F2/142;;A61L27/48;;A61L27/16;;A61L27/24,A61L27/26;;A61L27/52;;A61L27/56,,0,0,,,,DISCONTINUED
25,US,A1,US 2020/0136829 A1,136-003-638-763-978,2020-04-30,2020,US 201916656246 A,2019-10-17,US 201916656246 A;;US 201862750766 P,2018-10-25,Data Management System Using Multiple Blockchains,"A message is received containing a notification of a change to a longterm value. The one or more longterm accounts are updated. After updating the longterm blockchain, one or more transaction accounts are updated by an update amount, the update amount generated based on the change to the one or more longterm accounts such that a total value of all transaction accounts in the transaction blockchain is based on an aggregate measure of all of the longterm accounts in the longterm blockchain.",AMERICAN CRYPTOCOUPON INC,KEON NEIL;;CHO MICHAEL,PLUS PQ INC (2019-10-17),https://lens.org/136-003-638-763-978,Patent Application,yes,0,1,2,2,0,G06Q20/00;;G06Q20/401;;G06Q20/401;;H04L9/0637;;H04L9/3236;;H04L2209/56;;H04L9/50,H04L9/32;;G06Q20/40;;H04L9/06,,0,0,,,,DISCONTINUED
26,EP,B1,EP 1609982 B1,072-778-288-131-383,2007-07-04,2007,EP 05076117 A,2005-05-11,US 85909604 A,2004-06-03,Modular fuel injector with a damper member and method of reducing noise,,SIEMENS VDO AUTOMOTIVE CORP,CHO YONG;;DALLMEYER MICHAEL,,https://lens.org/072-778-288-131-383,Granted Patent,yes,6,0,7,7,0,F02M51/0682;;F02M55/00;;F02M61/16;;F02M61/165;;F02M2200/09;;F02M2200/27;;F02M2200/306;;F02M2200/505;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M2200/26;;F02M2200/315;;F02M61/16;;F02M2200/505;;F02M61/165;;F02M2200/27;;F02M55/00;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M51/0682;;F02M2200/306;;F02M2200/09;;F02M2200/26;;F02M2200/315,F02M55/02;;F02M51/06;;F02M55/00;;F02M55/04;;F02M61/16;;F02M63/00,,0,0,,,,ACTIVE
27,DE,T2,DE 602005001527 T2,052-423-812-823-418,2008-03-06,2008,DE 602005001527 T,2005-05-11,US 85909604 A,2004-06-03,Modulares Kraftstoffeinspritzventil mit einem Dämpfungselement und einem Verfahren zum Verringern von Geräuschen,,SIEMENS VDO AUTOMOTIVE CORP,CHO YONG;;DALLMEYER MICHAEL,,https://lens.org/052-423-812-823-418,Granted Patent,no,0,0,7,7,0,F02M51/0682;;F02M55/00;;F02M61/16;;F02M61/165;;F02M2200/09;;F02M2200/27;;F02M2200/306;;F02M2200/505;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M2200/26;;F02M2200/315;;F02M61/16;;F02M2200/505;;F02M61/165;;F02M2200/27;;F02M55/00;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M51/0682;;F02M2200/306;;F02M2200/09;;F02M2200/26;;F02M2200/315,F02M55/02;;F02M51/06;;F02M55/00;;F02M55/04;;F02M61/16;;F02M63/00,,0,0,,,,ACTIVE
28,WO,A1,WO 2020/086382 A1,106-927-968-894-825,2020-04-30,2020,US 2019/0056807 W,2019-10-17,US 201862750766 P,2018-10-25,DATA MANAGEMENT SYSTEM USING MULTIPLE BLOCK CHAINS,"A message is received containing a notification of a change to a longterm value. The one or more longterm accounts are updated. After updating the longterm blockchain, one or more transaction accounts are updated by an update amount, the update amount generated based on the change to the one or more longterm accounts such that a total value of all transaction accounts in the transaction blockchain is based on an aggregate measure of all of the longterm accounts in the longterm blockchain.",AMERICAN CRYPTOCOUPON INC,KEON NEIL;;CHO MICHAEL,,https://lens.org/106-927-968-894-825,Patent Application,yes,2,0,2,2,0,G06Q20/00;;G06Q20/401;;G06Q20/401;;H04L9/0637;;H04L9/3236;;H04L2209/56;;H04L9/50,G06Q20/00,,1,0,,,"M SCHENCK ET AL: ""Mosaic RUNNING META-BLOCKCHAINS TO SCALE DECENTRALIZED APPLICATIONS"", 11 October 2018 (2018-10-11), XP055663494, Retrieved from the Internet <URL:https://github.com/mosaicdao/mosaic-contracts/blob/develop/docs/mosaicv0.pdf> [retrieved on 20200130]",PENDING
29,KR,A,KR 20130016111 A,134-019-326-299-727,2013-02-14,2013,KR 20120085063 A,2012-08-03,KR 20110077225 A,2011-08-03,CALCIUM ALGINATE GEL,"PURPOSE: A calcium alginate gel is provided to show an immediate effect, to be safe, and to obtain natural appearance. CONSTITUTION: A calcium alginate gel comprises contains alginate and calcium. The calcium is cross-linked with the alginate. The viscosity and decomposition speed of a composition is controlled by reaction speed or reaction condition of gelation and/or the concentration of the calcium. The composition includes 1-5% of alginate and 10-100mM concentration of calcium. The composition can be decomposed by a calcium chelate.",TE BIOS CO LTD,MICHAEL CHO;;SHAN SUN,,https://lens.org/134-019-326-299-727,Patent Application,no,0,0,1,1,0,A61K8/19;;A61K9/0024;;A61K9/5036;;A61L27/20;;A61L27/38;;A61L27/3834;;A61L27/58,A61F2/02;;A61F2/12;;A61L27/38,,0,0,,,,DISCONTINUED
30,WO,A1,WO 2013/063390 A1,161-260-461-636-95X,2013-05-02,2013,US 2012/0062116 W,2012-10-26,US 201113284301 A,2011-10-28,A SUTURABLE HYBRID SUPERPOROUS HYDROGEL KERATOPROSTHESIS FOR CORNEA,The present invention features a hybrid superporous hydrogel scaffold for cornea regeneration and a method for producing the same. The hybrid hydrogel is composed of a superporous poly (2-hydroxyethyl methacrylate) (PHEMA) and poly (methyl methacrylate) (PMMA) copolymer mixed with collagen. The hybrid scaffold can be used as a suturable hybrid corneal implant or keratoprosthesis.,UNIV ILLINOIS,CHO MICHAEL;;ZELLANDER AMELIA,,https://lens.org/161-260-461-636-95X,Patent Application,yes,5,1,10,12,0,A61L27/52;;A61L27/56;;A61L27/16;;A61L27/24;;A61L27/48;;A61L2430/16;;A61K35/12;;C12N11/04;;A61F2/142;;A61L27/14;;A61F2/142;;A61L27/52;;A61L27/56;;A61L27/24;;A61L2430/16;;A61K35/12;;A61L27/48;;A61L27/16;;C12N11/04,A61L27/56;;A61F2/14;;A61L27/14;;A61L27/52,,1,0,,,See also references of EP 2771042A4,PENDING
31,US,A1,US 2021/0079323 A1,070-328-383-754-262,2021-03-18,2021,US 202017021771 A,2020-09-15,US 202017021771 A;;US 201962900597 P,2019-09-15,DEVICE AND USES THEREOF FOR TREATING DIABETES,Disclosed are devices for improving viability of isolated islets or β-cells and stimulating insulin production from isolated islets or β-cells and uses thereof for treating type 1 diabetes.,UNIV TEXAS,CHO MICHAEL;;LIEBMAN CALEB,BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (2020-09-02),https://lens.org/070-328-383-754-262,Patent Application,yes,2,0,2,2,0,C12M21/08;;C12M35/02;;C12M29/10;;C12N2506/45;;C12N5/0676;;C12N2529/10;;C12N2529/00;;C12N2513/00;;A61K35/39;;C12M1/42;;C12M35/02;;C12M23/34;;C12N2510/00;;C12N5/0676;;C12N2506/45;;A61K35/39,C12M1/42;;A61K35/39;;C12M1/00;;C12N5/071,,6,5,031-499-592-013-681;;055-965-326-221-548;;124-502-502-816-816;;099-873-132-634-799;;069-767-453-429-641,pmc2894473;;20606719;;10.4161/isl.1.2.9480;;10.1088/1742-6596/853/1/012024;;30090895;;pmc6171522;;10.1039/c8lc00507a;;10.1002/advs.201903783;;pmc7175256;;32328436;;11440274;;10.1055/s-2001-15284,"Kim et al. Islet architecture: a comparative study. Islets 2009, 1;2:129-136. (Year: 2009);;Pagliuca et al. Generation of functional pancreatic β cells in vitro. Cell 2014, 159;2:428-439. (Year: 2014);;Suhariningsih et al. Permanent electric field, direct electric field, and infrared to reduce blood glucose level and hepatic function in mus musculus with diabetic mellitus. Journal of Physics: Conference Series 2017, 853:012024. (Year: 2017);;Qiu et al. Microfluidic filter device with nylon mesh membranes efficiently dissociates cell aggregates and digested tissue into single cells. Lab on a Chip 2018, 18:2776. (Year: 2018);;Chen et al. Advanced Near-Infrared Light for Monitoring and Modulating the Spatiotemporal Dynamics of Cell Functions in Living Systems. Advanced Science News 2020, 7:e1093783 (1-27). (Year: 2020);;Adeghate et al. Effect of electrical field stimulation on insulin and glucagon secretion from the pancreas of normal and diabetic rats. Hormone and Metabolic Research 2001, 33:281-289. (Year: 2001)",ACTIVE
32,WO,A1,WO 2019/027496 A1,178-762-431-193-411,2019-02-07,2019,US 2018/0012567 W,2018-01-05,US 201715666535 A,2017-08-01,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,"A met hod and system for estimating fractional fat content, of an object. An energy emitter is used to direct an energy signal with an energy signal electric field strength toward the region of interest, wherein the region of interest has an object of interest, a reference, and a boundary between the object of interest and the reference. Next, a thermoacoustic or ultrasonic transducer is used to receive a thermoacoustic bipoiar signal from the boundary, wherein the thermoacoustic bipolar signal is induced by the energy signal. Finally, a machine is used to accept data from the energy emitter and thermoacoustic or ultrasonic transducer, correlate the thermoacoustic bipolar signal to an electric field strength of the reference at the boundary to generate a corrected thermoacoustic bipolar signal at the boundary, and calculate a fat concentration of the object of interest as a function of the corrected thermoacoustic bipolar signal at the boundary.",ENDRA LIFE SCIENCES INC,CHO JANG;;THORNTON MICHAEL,,https://lens.org/178-762-431-193-411,Patent Application,yes,4,7,7,7,0,A61B5/0095;;A61B5/4244;;A61B5/4872;;A61B5/7246;;A61B5/7485;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B5/7246;;A61B5/4244;;A61B8/5223;;A61B8/5261,A61B5/00;;A61B8/00;;A61B8/08,,0,0,,,,PENDING
33,KR,A,KR 20140093966 A,004-595-067-591-302,2014-07-29,2014,KR 20147014227 A,2012-10-26,US 201113284301 A;;US 2012/0062116 W,2011-10-28,A SUTURABLE HYBRID SUPERPOROUS HYDROGEL KERATOPROSTHESIS FOR CORNEA,,UNIV ILLINOIS,CHO MICHAEL;;ZELLANDER AMELIA,,https://lens.org/004-595-067-591-302,Patent Application,no,0,2,10,12,0,A61L27/52;;A61L27/56;;A61L27/16;;A61L27/24;;A61L27/48;;A61L2430/16;;A61K35/12;;C12N11/04;;A61F2/142;;A61L27/14;;A61F2/142;;A61L27/52;;A61L27/56;;A61L27/24;;A61L2430/16;;A61K35/12;;A61L27/48;;A61L27/16;;C12N11/04,A61L27/56;;A61F2/14;;A61L27/14;;A61L27/52,,0,0,,,,DISCONTINUED
34,US,B2,US 11834640 B2,117-845-437-082-270,2023-12-05,2023,US 202017021771 A,2020-09-15,US 202017021771 A;;US 201962900597 P,2019-09-15,Device and uses thereof for treating diabetes,Disclosed are devices for improving viability of isolated islets or β-cells and stimulating insulin production from isolated islets or β-cells and uses thereof for treating type 1 diabetes.,UNIV TEXAS,CHO MICHAEL;;LIEBMAN CALEB,BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (2020-09-02),https://lens.org/117-845-437-082-270,Granted Patent,yes,2,0,2,2,0,C12M21/08;;C12M35/02;;C12M29/10;;C12N2506/45;;C12N5/0676;;C12N2529/10;;C12N2529/00;;C12N2513/00;;A61K35/39;;C12M1/42;;C12M35/02;;C12M23/34;;C12N2510/00;;C12N5/0676;;C12N2506/45;;A61K35/39,C12M1/42;;A61K35/39;;C12M1/00;;C12N5/071,,216,183,031-499-592-013-681;;055-965-326-221-548;;124-502-502-816-816;;099-873-132-634-799;;069-767-453-429-641;;052-854-418-860-581;;199-073-491-340-16X;;060-899-643-580-059;;048-961-968-877-416;;016-450-556-501-986;;012-325-341-896-978;;132-707-167-432-338;;004-067-651-708-259;;084-683-355-387-770;;027-600-373-968-153;;128-809-871-172-253;;010-069-224-233-443;;021-667-798-811-176;;027-442-348-867-704;;072-844-300-789-210;;132-821-467-253-488;;067-998-960-591-761;;116-169-881-163-387;;053-539-051-480-000;;124-407-610-799-966;;014-459-872-266-728;;019-312-159-146-179;;057-566-980-626-069;;011-696-471-558-420;;069-180-328-587-568;;104-504-842-133-249;;028-160-207-868-851;;002-582-252-568-440;;072-566-840-463-548;;024-374-221-801-248;;004-217-118-774-275;;057-819-734-199-658;;044-979-468-092-954;;023-762-615-575-915;;072-368-893-801-953;;035-666-080-632-623;;116-868-121-312-813;;012-437-331-853-997;;041-602-033-131-003;;089-310-319-436-002;;066-992-042-228-396;;065-601-446-232-554;;055-108-780-039-176;;069-795-037-593-117;;016-116-648-997-081;;052-346-836-220-180;;110-204-847-726-652;;037-309-921-892-786;;007-456-026-245-488;;086-342-903-671-877;;037-838-797-925-133;;089-740-221-163-106;;057-489-552-418-267;;014-958-596-845-42X;;039-879-436-046-890;;102-464-899-507-321;;068-725-190-330-364;;055-142-529-941-214;;024-130-713-677-641;;021-815-063-908-665;;000-422-746-762-811;;084-221-887-385-358;;076-982-493-524-577;;126-217-758-188-681;;094-736-705-916-740;;006-489-921-605-763;;042-789-550-696-95X;;014-761-036-214-364;;023-638-049-142-091;;055-537-769-208-413;;111-262-931-280-333;;031-717-702-967-826;;010-154-579-187-905;;065-952-449-766-337;;076-677-741-590-952;;012-019-152-245-505;;016-866-215-834-87X;;012-332-719-103-120;;066-003-257-403-963;;064-227-500-489-323;;120-939-112-945-790;;010-858-884-704-513;;017-060-161-940-514;;006-046-651-131-816;;032-508-895-255-037;;061-781-015-847-712;;025-431-233-646-972;;016-095-683-961-471;;081-155-917-396-153;;037-870-925-245-731;;053-834-169-350-780;;005-597-255-073-073;;033-432-693-952-078;;083-565-066-055-135;;124-402-342-682-477;;028-231-677-013-896;;036-022-246-069-088;;043-604-064-981-416;;073-065-337-304-321;;054-691-319-637-420;;066-065-565-801-916;;030-240-720-391-697;;069-497-097-473-162;;003-908-071-858-696;;068-751-864-197-141;;002-314-869-945-831;;005-427-102-439-01X;;061-184-631-339-089;;063-901-293-967-016;;016-899-035-628-252;;015-529-385-228-115;;033-496-722-032-32X;;052-242-783-689-594;;002-202-545-190-077;;015-291-187-395-337;;009-326-467-451-954;;044-886-538-691-264;;037-292-464-836-739;;103-075-868-769-270;;038-832-927-288-582;;041-893-592-693-144;;046-421-850-941-080;;028-652-285-037-851;;046-019-874-791-245;;023-787-174-435-036;;061-930-524-173-759;;047-993-734-406-70X;;014-067-695-357-174;;002-986-103-018-761;;022-231-011-057-544;;162-081-120-942-839;;004-055-864-804-887;;012-989-903-323-146;;024-270-140-389-400;;027-687-481-768-794;;036-064-035-712-534;;053-444-974-664-543;;044-540-724-564-893;;047-941-815-986-908;;003-858-637-428-749;;147-057-690-067-622;;146-831-978-913-852;;045-455-828-545-806;;081-622-788-036-054;;043-527-052-521-619;;008-276-240-251-350;;090-986-895-939-690;;079-186-647-101-342;;061-711-766-537-295;;061-233-478-715-479;;060-586-962-615-952;;068-416-744-005-485;;002-263-984-290-394;;047-769-044-673-556;;047-217-940-334-055;;019-876-777-866-29X;;024-198-025-021-121;;029-819-729-875-10X;;117-444-463-183-537;;013-827-860-575-574;;160-728-299-950-194;;054-808-324-502-463;;000-885-795-208-420;;042-383-474-332-096;;024-897-624-564-198;;010-304-497-342-749;;043-094-301-443-025;;039-682-389-044-788;;062-776-369-788-289;;150-075-787-360-830;;053-197-956-693-118;;117-271-204-159-409;;000-064-519-416-516;;053-726-061-086-49X;;029-445-726-786-968;;074-175-004-846-88X;;121-467-822-414-55X;;040-615-365-064-245,pmc2894473;;20606719;;10.4161/isl.1.2.9480;;10.1088/1742-6596/853/1/012024;;30090895;;pmc6171522;;10.1039/c8lc00507a;;10.1002/advs.201903783;;pmc7175256;;32328436;;11440274;;10.1055/s-2001-15284;;pmc3056350;;10.3233/jad-2010-100465;;20421693;;10.15171/jlms.2019.s17;;24911037;;10.1097/tp.0000000000000217;;23541731;;pmc3718648;;10.1016/j.cub.2013.02.047;;10.1111/php.13032;;30281800;;10.1007/s00702-017-1751-6;;pmc5565669;;28707160;;pmc1160336;;8014906;;10.1113/jphysiol.1994.sp020036;;pmc6263229;;10.5152/eurasianjmed.2018.17397;;30515042;;10.1002/jbio.201500209;;26790619;;10.1530/eje-15-0378;;26431552;;10.1088/0967-3334/25/4/023;;15382843;;pmc2586567;;10.1529/biophysj.108.140863;;18805925;;10.1038/nrm1155;;12838342;;12838335;;10.1007/978-90-481-3271-3_12;;pmc3120131;;20217502;;20432533;;10.1038/nature08933;;pmc4959889;;10.1074/jbc.m511597200;;16407209;;21421919;;10.1101/cshperspect.a004168;;pmc3039526;;15355853;;10.1152/ajpcell.00139.2004;;10.1016/s0005-2728(00)00238-3;;11239484;;28765259;;10.1530/jme-17-0063;;16760264;;10.1152/ajpcell.00217.2006;;10.1101/cshperspect.a003947;;21746798;;pmc3140680;;pmc3608918;;23542897;;10.3389/fendo.2013.00037;;10.1080/03008200701424451;;17653975;;10.1016/s0006-3495(97)78199-2;;9284334;;pmc1181066;;30638362;;10.1021/acsami.8b21410;;20039269;;10.1002/jcp.22010;;pmc2932548;;10.1089/ars.2007.1959;;18331202;;19287398;;10.1038/nchembio.154;;10.2741/cho;;10.2741/a733;;11779692;;10.1016/s0006-3495(99)77278-4;;9916045;;pmc1300063;;8050677;;10.1096/fasebj.8.10.8050677;;10.1016/j.cell.2007.11.028;;18083096;;10.1249/mss.0b013e3181eeb61c;;21084931;;10.3410/f.3222964.3400067;;10.1073/pnas.0913107107;;20194741;;pmc2841940;;10.1007/978-3-540-34891-7_10;;pmc4458144;;17217057;;10746110;;10.1136/jech.54.3.173;;pmc1731634;;10.1016/j.cmet.2018.07.011;;30122556;;pmc6221994;;10.1016/j.biomaterials.2009.11.057;;20015544;;20719076;;10.3727/096368910x515872;;pmc5215870;;10.1109/jstqe.2016.2561201;;28070154;;21242257;;10.1113/jphysiol.2010.198804;;pmc3082093;;9257928;;pmc1564831;;10.1038/sj.bjp.0701272;;10.1152/ajpendo.00043.2021;;34280052;;10.1101/2020.03.11.986893;;10.1038/386855a0;;9126747;;10.1038/31960;;9582075;;22729857;;10.1007/978-1-4614-3573-0_6;;29594864;;10.1007/978-3-319-55858-5_10;;10.1186/s42492-019-0016-7;;pmc7099553;;32240414;;24583073;;10.1016/j.febslet.2014.02.035;;pmc4004767;;10.3390/membranes4030525;;pmc4194048;;25257900;;pmc2896931;;20497556;;10.1186/1742-4682-7-15;;26029113;;pmc4429568;;10.3389/fphys.2015.00143;;29394145;;pmc5895174;;10.1080/19382014.2018.1428511;;19540901;;10.1016/j.tox.2009.06.008;;pmc2944357;;20861159;;10.1101/cshperspect.a003962;;8446591;;pmc45963;;10.1073/pnas.90.5.1781;;15808343;;10.1016/j.tips.2005.02.005;;11815474;;10.2337/diabetes.51.2007.s144;;10.1016/j.tcb.2018.01.002;;29409699;;3494733;;10.1083/jcb.104.5.1291;;pmc2114476;;10.1002/humu.10277;;14517946;;pmc4556774;;10.1016/j.redox.2015.08.010;;26296072;;10.1111/php.12354;;25267311;;pmc4303996;;27973730;;10.1002/jbio.201670113;;pmc5215795;;28748217;;pmc5523874;;10.3934/biophy.2017.3.337;;29164625;;10.1111/php.12864;;pmc5844808;;pmc4909256;;10.1016/j.cels.2016.03.010;;27135540;;pmc3195476;;21968111;;10.1172/jci58400;;10.1101/gad.1102703;;12975316;;10.1016/j.ydbio.2017.06.034;;28669818;;22488690;;10.1002/lsm.22027;;10.1016/j.transproceed.2009.09.065;;20005390;;20225132;;pmc2885902;;10.1007/s00125-010-1685-0;;pmc5031557;;27452146;;10.1016/j.cmet.2016.06.020;;10.1007/s11064-006-9128-5;;16944320;;pmc1970866;;10.1210/er.2003-0008;;14671000;;pmc4226760;;10.1016/s0140-6736(13)62154-6;;24315620;;19757377;;10.1387/ijdb.092953hk;;10.1155/2010/453892;;20182627;;pmc2825658;;10.1103/physreve.72.051905;;16383643;;10.1109/jstqe.2013.2273411;;pmc1566353;;10.2307/3434469;;10.1289/ehp.99107s125;;10229704;;8355667;;10.1007/s00249-005-0001-2;;16044273;;10.1177/1534734605275733;;15860450;;28202025;;10.1186/s12896-017-0331-z;;pmc5312430;;10.1371/journal.pone.0005765;;19492056;;pmc2686162;;28931935;;10.1038/s41598-017-12335-1;;pmc5607285;;11872668;;10.2337/diabetes.51.3.691;;10.3171/jns.2004.101.3.0511;;15352610;;pmc2646066;;19073765;;10.2337/db07-1056;;25425556;;pmc4244194;;10.1091/mbc.e13-12-0708;;10.1007/s11684-011-0108-z;;21681673;;10.1016/j.mod.2005.01.001;;15939230;;20353787;;10.1016/j.febslet.2010.03.040;;24761350;;pmc3928784;;10.1089/wound.2013.0427;;19202557;;10.1002/jbt.20257;;6743751;;pmc1434994;;10.1016/s0006-3495(84)84270-8;;28452188;;10.1002/jcp.25975;;10.1016/s0303-2647(00)00090-3;;11004387;;25175349;;pmc4331044;;10.1016/j.bbabio.2014.08.005;;29603872;;pmc6055818;;10.1111/dom.13313;;15987799;;10.1152/physrev.00020.2004;;10.1002/lsm.23278;;32495397;;10.1111/ner.12438;;27150431;;10381592;;pmc2269443;;10.1111/j.1469-7793.1999.0463p.x;;10.1002/jbio.201700020;;28700117;;10.1038/nrm3031;;21179061;;19061483;;10.1042/bj20081386;;pmc2605959;;10.1242/jcs.01125;;15075225;;14690282;;10.1093/oxfordjournals.rpd.a006375;;10.1007/s10103-016-2097-2;;27770222;;pmc4355204;;25762681;;10.1523/jneurosci.1877-14.2015;;23802593;;pmc3780531;;10.1111/jcmm.12088;;10.1152/japplphysiol.00524.2016;;27633738;;pmc5142251;;29191919;;pmc5776665;;10.1530/ec-17-0347;;25226343;;10.1016/j.jphotobiol.2014.07.021;;30036491;;10.1016/j.pharmthera.2018.07.001;;pmc6263837;;25102241;;10.1089/pho.2014.3745;;24393785;;10.1038/nrendo.2013.256;;30565440;;10.4093/dmj.2018.0190;;pmc6300440;;8638942;;10.1006/abbi.1996.0146;;15341512;;10.1111/j.1471-4159.2004.02572.x;;pmc6021307;;29947172;;10.3803/enm.2018.33.2.147;;10.2337/diabetes.51.2007.s368;;012475777;;12475777;;pmc2965610;;10.1124/mi.10.4.4;;20729487;;pmc6672570;;10.1523/jneurosci.0095-07.2007;;17360926;;10.1089/ars.2017.7380;;29486595;;21944825;;10.1016/j.ceca.2011.08.005;;pmc3223281;;pmc3454471;;22286106;;10.1016/j.cellsig.2012.01.008;;pmc6424003;;10.1210/er.2018-00154;;30541144;;10.1083/jcb.200301063;;pmc2172922;;12707306;;10.2337/db14-0549;;pmc4207385;;24947367;;10.1007/s00125-003-1153-1;;12879249;;7684233;;10.1016/0896-6273(93)90197-y;;19855005;;pmc2776433;;10.1073/pnas.0904849106;;29327206;;pmc6041198;;10.1007/s12035-017-0852-4;;pmc3339194;;21892726;;10.1007/s00424-011-1013-7;;28303572;;pmc5430224;;10.1113/jp272781;;pmc3395247;;10.1155/2012/571067;;22811713;;10.1109/jproc.2004.829009;;11536285;;10.1002/bem.71;;10.1109/modsym.2004.1433545;;27834384;;10.1038/nrendo.2016.178;;pmc3199299;;21956634;;10.1002/lsm.21100;;10.1016/j.bbagen.2013.11.015;;24269537;;21126186;;pmc3151422;;10.1089/ars.2010.3648;;21737534;;10.1124/pr.110.003814;;pmc3141879;;pmc4413337;;10.1073/pnas.1421507112;;25848051;;10.1016/j.ceca.2012.03.003;;pmc3396849;;22502861;;27016063;;pmc5012938;;10.1016/j.ceca.2016.03.007;;29032331;;10.1016/j.biomaterials.2017.10.003;;24563333;;10.1007/s11892-014-0473-5;;10.1210/me.2002-0333;;12554769;;21159388;;10.1016/j.tips.2010.11.006;;10.1109/iembs.2009.5333949;;19964578;;pmc3979962;;10.1007/978-94-007-2888-2_40;;22453975;;10.1002/bem.22076;;28833306;;10.1089/ars.2009.2842;;pmc2861541;;19719386;;10.1016/j.jphotobiol.2017.04.014;;pmc5505738;;28441605;;16306339;;10.2337/diabetes.54.suppl_2.s40;;10.2337/diabetes.51.2007.s190;;11815480;;27960594;;10.1089/scd.2016.0115;;pmc5030629;;27650508;;10.1038/srep33719;;pmc3759232;;21396158;;10.3727/096368911x564994;;15561905;;10.2337/diabetes.53.suppl_3.s16;;10.3389/fendo.2020.00378;;pmc7296051;;32582035;;10.1038/ncb2614;;pmc3777337;;23143397;;10.1111/phpp.12282;;27943458;;17110622;;10.1634/stemcells.2006-0011;;27864646;;10.1007/s10103-016-2099-0;;20691662;;10.1016/j.bbrc.2010.07.126;;pmc2943231;;10.1016/j.bpj.2008.12.1320;;10.1002/(sici)1096-9101(1997)21:3<262::aid-lsm6>3.0.co;2-o;;9291083;;10.1002/(sici)1096-9101(1997)21:3<262::aid-lsm6>3.3.co;2-1;;10.1117/1.jbo.23.12.120901;;pmc8355782;;30550048;;29279388;;10.1073/pnas.1717192115;;pmc5777071;;pmc7028010;;10.1210/endocr/bqz028;;31796960,"Kim et al. Islet architecture: a comparative study. Islets 2009, 1;2:129-136. (Year: 2009).;;Pagliuca et al. Generation of functional pancreatic β cells in vitro. Cell 2014, 159;2:428-439. (Year: 2014).;;Suhariningsih et al. Permanent electric field, direct electric field, and infrared to reduce blood glucose level and hepatic function in mus musculus with diabetic mellitus. Journal of Physics: Conference Series 2017, 853:012024. (Year: 2017).;;Qiu et al. Microfluidic filter device with nylon mesh membranes efficiently dissociates cell aggregates and digested tissue into single cells. Lab on a Chip 2018, 18:2776. (Year: 2018).;;Chen et al. Advanced Near-Infrared Light for Monitoring and Modulating the Spatiotemporal Dynamics of Cell Functions in Living Systems. Advanced Science News 2020, 7:e1093783 (1-27). (Year: 2020).;;Adeghate et al. Effect of electrical field stimulation on insulin and glucagon secretion from the pancreas of normal and diabetic rats. Hormone and Metabolic Research 2001, 33:281-289. (Year: 2001).;;Adam-Vizi, Vera, and Anatoly A. Starkov. “Calcium and mitochondrial reactive oxygen species generation: how to read the facts.” Journal of Alzheimer's disease 20.s2 (2010): S413-S426.;;Ahrabi, Behnaz, et al. “The Effect of Photobiomodulation Therapy on the Differentiation, Proliferation, and Migration of the Mesenchymal Stem Cell: A Review.” Journal of Lasers in Medical Sciences 10.Suppl 1 (2019): S96S-103.;;Al-Adra, David P., et al. “Single-donor islet transplantation and long-term insulin independence in select patients with type 1 diabetes mellitus.” Transplantation 98.9 (2014): 1007-1012.;;Alessandra, Galli, et al. “Shaping Pancreatic β-Cell Differentiation and Functioning: The Influence of Mechanotransduction.” Cells 9.2 (2020): 413.;;Allen, Greg M., Alex Mogilner, and Julie A. Theriot. “Electrophoresis of cellular membrane components creates the directional cue guiding keratocyte galvanotaxis.” Current Biology 23.7 (2013): 560-568.;;Amaroli, Andrea, Sara Ferrando, and Stefano Benedicenti. “Photobiomodulation Affects Key Cellular Pathways of all Life-Forms: Considerations on Old and New Laser Light Targets and the Calcium Issue.” Photochemistry and photobiology 95.1 (2019): 455-459.;;Amon, A., and F. Alesch. “Systems for deep brain stimulation: review of technical features.” Journal of Neural Transmission 124.9 (2017): 1083-1091.;;Arava, Yoav, Rony Seger, and Michael D. Walker. “Grfβ, a novel regulator of calcium signaling, is expressed in pancreatic beta cells and brain.” Journal of Biological Chemistry 274.35 (1999): 24449-24452.;;Balke, C. William, Terrance M. Egan, and W. G. Wier. “Processes that remove calcium from the cytoplasm during excitation-contraction coupling in intact rat heart cells.” The Journal of physiology 474.3 (1994): 447-462.;;Bardaweel, Sanaa K., et al. “Reactive oxygen species: the dual role in physiological and pathological conditions of the human body.” The Eurasian Journal of Medicine 50.3 (2018): 193-201.;;Bartos, Adam, et al. “Pre-conditioning with near infrared photobiomodulation reduces inflammatory cytokines and markers of oxidative stress in cochlear hair cells.” Journal of biophotonics 9.11-12 (2016): 1125-1135.;;Baz, Baz, Jean-Pierre Riveline, and Jean-Francoise Gautier. “Gestational diabetes mellitus: definition, aetiological and clinical aspects.” Eur J Endocrinol 174.2 (2016): R43-51.;;Beebe, Stephen J., et al. “Nanosecond pulsed electric fields modulate cell function through intracellular signal transduction mechanisms.” Physiological measurement 25.4 (2004): 1077-1093.;;Benninger, Richard KP, et al. “Gap junction coupling and calcium waves in the pancreatic islet.” Biophysical journal 95.11 (2008): 5048-5061.;;Bensellam, Mohammed, Jean-Christophe Jonas, and D. Ross Laybutt. “Mechanisms of β-cell dedifferentiation in diabetes: recent findings and future research directions.” Journal of Endocrinology 236.2 (2018): R109-R143.;;Berridge, Michael J., Martin D. Bootman, and H. Llewelyn Roderick. “Calcium signalling: dynamics, homeostasis and remodelling.” Nature reviews Molecular cell biology 4.7 (2003): 517-529.;;Bertram, Richard, Arthur Sherman, and Leslie S. Satin. “Electrical bursting, calcium oscillations, and synchronization of pancreatic islets.” The Islets of Langerhans. Springer, Dordrecht, 2010. 261-279.;;Bluestone, Jeffrey A., Kevan Herold, and George Eisenbarth. “Genetics, pathogenesis and clinical interventions in type 1 diabetes.” Nature 464.7293 (2010): 1293-1300.;;Boucher, Marie-Josée, et al. “Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms.” Journal of Biological Chemistry 281.10 (2006): 6395-6403.;;Braun, Matthias, et al. “Voltage-gated ion channels in human pancreatic β-cells: electrophysiological characterization and role in insulin secretion.” Diabetes 57.6 (2008): 1618-1628.;;Brini, Marisa, and Ernesto Carafoli. “The plasma membrane Ca2+ ATPase and the plasma membrane sodium calcium exchanger cooperate in the regulation of cell calcium.” Cold Spring Harbor perspectives in biology 3.2 (2011): a004168.;;Brookes, Paul S., et al. “Calcium, ATP, and ROS: a mitochondrial love-hate triangle.” American Journal of Physiology—Cell Physiology 287.4 (2004): C817-C833.;;Brown, Guy C. “Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase.” Biochimica et Biophysica Acta (BBA)—Bioenergetics 1504.1 (2001): 46-57.;;Brüning, Dennis, et al. “Glucose but not KCI diminishes submembrane granule turnover in mouse beta-cells.” Journal of Molecular Endocrinology 59.3 (2017): 311-324.;;Camello-Almaraz, Cristina, et al. “Mitochondrial reactive oxygen species and Ca2+ signaling.” American Journal of Physiology—Cell Physiology 291.5 (2006): C1082-C1088.;;Catterall, William A. “Voltage-gated calcium channels.” Cold Spring Harbor perspectives in biology 3.8 (2011): a003947.;;Cerf, Marlon E. “Beta cell dysfunction and insulin resistance.” Frontiers in endocrinology 4 (2013): 37.;;Chao, Pen-hsiu Grace, et al. “Effects of applied DC electric field on ligament fibroblast migration and wound healing.” Connective tissue research 48.4 (2007): 188-197.;;Chay, Teresa Ree. “Effects of extracellular calcium on electrical bursting and intracellular and luminal calcium oscillations in insulin secreting pancreatic beta-cells.” Biophysical Journal 73.3 (1997): 1673-1688.;;Chen, Bo, et al. “Astrocyte Viability and Functionality in Spatially Confined Microcavitation Zone.” ACS applied materials & interfaces 11.5 (2019): 4889-4899.;;Chen, Jing-Bo, et al. “Multiple Ca2+ signaling pathways regulate intracellular Ca2+ activity in human cardiac fibroblasts.” Journal of cellular physiology 223.1 (2010): 68-75.;;Chen, Kejing, Roland N. Pittman, and Aleksander S. Popel. “Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective.” Antioxidants & redox signaling 10.7 (2008): 1185-1198.;;Chen, Shuibing, et al. “A small molecule that directs differentiation of human ESCs into the pancreatic lineage.” Nature chemical biology 5.4 (2009): 258-265.;;Cho, Michael R., et al. “Control of calcium entry in human fibroblasts by frequency-dependent electrical stimulation.” Front Biosci 7.1 (2002): 1-8.;;Cho, Michael R., et al. “Membrane dynamics of the water transport protein aquaporin-1 in intact human red cells.” Biophysical journal 76.2 (1999): 1136-1144.;;Cho, Michael R., et al. “Induced redistribution of cell surface receptors by alternating current electric fields.” The FASEB journal 8.10 (1994): 771-776.;;Clapham, David E. “Calcium signaling.” Cell 131.6 (2007): 1047-1058.;;Colberg, Sheri R., et al. “Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary.” Diabetes care 33.12 (2010): 2692-2696.;;Colsoul, Barbara, et al. “Loss of high-frequency glucose-induced Ca2+ oscillations in pancreatic islets correlates with impaired glucose tolerance in Trpm5−/− mice.” Proceedings of the National Academy of Sciences 107.11 (2010): 5208-5213.;;Colton, C. K., and M. X. Zhu. “2-Aminoethoxydiphenyl borate as a common activator of TRPV1, TRPV2, and TRPV3 channels.” Transient Receptor Potential (TRP) Channels. Springer, Berlin, Heidelberg, 2007. 173-187.;;Connolly, Vincent, et al. “Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas.” Journal of Epidemiology & Community Health 54.3 (2000): 173-177.;;Cox, Carly S., et al. “Mitohormesis in mice via sustained basal activation of mitochondrial and antioxidant signaling.” Cell metabolism 28.5 (2018): 776-786.;;Daoud, Jamal, et al. “The effect of extracellular matrix components on the preservation of human islet function in vitro.” Biomaterials 31.7 (2010): 1676-1682.;;Daoud, Jamal, Lawrence Rosenberg, and Maryam Tabrizian. “Pancreatic islet culture and preservation strategies: advances, challenges, and future outlook.” Cell transplantation 19.12 (2010): 1523-1535.;;De Freitas, Lucas Freitas, and Michael R. Hamblin. “Proposed mechanisms of photobiomodulation or low-level light therapy.” IEEE Journal of selected topics in quantum electronics 22.3 (2016): 348-364.;;Dean, P. M. “Ultrastructural morphometry of the pancreatic β-cell.” Diabetologia 9.2 (1973): 115-119.;;Dittami, Gregory M., et al. “Intracellular calcium transients evoked by pulsed infrared radiation in neonatal cardiomyocytes.” The Journal of physiology 589.6 (2011): 1295-1306.;;Docherty, R. J., J. C. Yeats, and A. S. Piper. “Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture.” British journal of pharmacology 121.7 (1997): 1461-67.;;Dolen{hacek over (s)}ek, Jurij, et al. “Glucose-dependent activation, activity, and deactivation of beta cell networks in acute mouse pancreas tissue slices.” bioRxiv (2020). Preprint available at: https://doi.org/10.1101/2020.03.11.986893.;;Dolmetsch, Ricardo E., et al. “Differential activation of transcription factors induced by Ca 2+ response amplitude and duration.” Nature 386.6627 (1997): 855-858.;;Dolmetsch, Ricardo E., Keli Xu, and Richard S. Lewis. “Calcium oscillations increase the efficiency and specificity of gene expression.” Nature 392.6679 (1998): 933-936.;;Dröse, Stefan, and Ulrich Brandt. “Molecular mechanisms of superoxide production by the mitochondrial respiratory chain.” Mitochondrial oxidative phosphorylation. Springer, New York, NY, 2012. 145-169.;;Enomoto, Masahiro, et al. “From stores to sinks: structural mechanisms of cytosolic calcium regulation.” Membrane Dynamics and Calcium Signaling. Springer, Cham, 2017. 215-251.;;Fan, L., et al., “Brief review of image denoising techniques”. Visual Computing for Industry, Biomedicine, and Art, 2019; 2(7).;;Farnsworth, Nikki L., and Richard KP Benninger. “New insights into the role of connexins in pancreatic islet function and diabetes.” FEBS letters 588.8 (2014): 1278-1287.;;Ferrandiz-Huertas, Clotilde, et al. “Trafficking of thermoTRP channels.” Membranes 4.3 (2014): 525-564.;;Fridlyand, Leonid E., and Louis H. Philipson. “Glucose sensing in the pancreatic beta cell: a computational systems analysis.” Theoretical Biology and Medical Modelling 7.1 (2010): 15.;;Fridlyand, Leonid E., Natalia Tamarina, and Louis H. Philipson. “Modeling of Ca2+ flux in pancreatic β-cells: role of the plasma membrane and intracellular stores.” American Journal of Physiology—Endocrinology and Metabolism 285.1 (2003): E138-E154.;;Fridlyand, Leonid E., N. Tamarina, and Louis H. Philipson. “Bursting and calcium oscillations in pancreatic β-cells: specific pacemakers for specific mechanisms.” American Journal of Physiology-Endocrinology and Metabolism 299.4 (2010): E517-E532.;;Funk, Richard HW. “Endogenous electric fields as guiding cue for cell migration.” Frontiers in physiology 6 (2015): 143. https://doi.org/10.3389/fphys.2015.00143/full.;;Gamble, Anissa, et al. “The journey of islet cell transplantation and future development.” Islets 10.2 (2018): 80-94.;;García-Montalvo, Eliud A., Hugo Reyes-Pérez, and Luz M. Del Razo. “Fluoride exposure impairs glucose tolerance via decreased insulin expression and oxidative stress.” Toxicology 263.2-3 (2009): 75-83.;;Gees, Maarten, Barbara Colsoul, and Bernd Nilius. “The role of transient receptor potential cation channels in Ca2+ signaling.” Cold Spring Harbor perspectives in biology 2.10 (2010): a003962.;;German, Michael S. “Glucose sensing in pancreatic islet beta cells: the key role of glucokinase and the glycolytic intermediates.” Proceedings of the National Academy of Sciences 90.5 (1993): 1781-1785.;;Ghafourifar, Pedram, and Enrique Cadenas. “Mitochondrial nitric oxide synthase.” Trends in pharmacological sciences 26.4 (2005): 190-195.;;Gilon, Patrick, et al. “Control mechanisms of the oscillations of insulin secretion in vitro and in vivo.” Diabetes 51.suppl 1 (2002): S144-S151.;;Giorgi, Carlotta, et al. “Calcium dynamics as a machine for decoding signals.” Trends in cell biology 28.4 (2018): 258-273.;;Giugni, Terrence D., Daniel L. Braslau, and Harry T. Haigler. “Electric field-induced redistribution and postfield relaxation of epidermal growth factor receptors on A431 cells.” The Journal of cell biology 104.5 (1987): 1291-1297.;;Gloyn, Anna L. “Glucokinase (GCK) mutations in hyper-and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy.” Human mutation 22.5 (2003): 353-362.;;Görlach, Agnes, et al. “Calcium and ROS: a mutual interplay.” Redox biology 6 (2015): 260-271.;;Guigas, Bruno, et al. “5-Aminoimidazole-4-Carboxamide-1-β-d-Ribofuranoside and Metformin Inhibit Hepatic Glucose Phosphorylation by an AMP-Activated Protein Kinase-Independent Effect on Glucokinase Translocation.” Diabetes 55.4 (2006): 865-874.;;Haltaufderhyde, Kirk, et al. “Opsin expression in human epidermal skin.” Photochemistry and photobiology 91.1 (2015): 117-123.;;Hamblin, Michael R. “Photobiomodulation or low-level laser therapy.” Journal of biophotonics 9.11-12 (2016): 1122-1124.;;Hamblin, Michael R. “Mechanisms and applications of the anti-inflammatory effects of photobiomodulation.” AIMS biophysics 4.3 (2017): 337-361.;;Hamblin, Michael R. “Mechanisms and mitochondrial redox signaling in photobiomodulation.” Photochemistry and photobiology 94.2 (2018): 199-212.;;Hannanta-anan, Pimkhuan, and Brian Y. Chow. “Optogenetic control of calcium oscillation waveform defines NFAT as an integrator of calcium load.” Cell systems 2.4 (2016): 283-288.;;Heit, Jeremy J., et al. “Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function.” Nature 443.7109 (2006): 345-349.;;Henquin, Jean-Claude, Nizar I. Mourad, and Myriam Nenquin. “Disruption and stabilization of β-cell actin microfilaments differently influence insulin secretion triggered by intracellular Ca2+ mobilization or store-operated Ca2+ entry.” FEBS letters 586.1 (2012): 89-95.;;Henquin, Jean-Claude, et al. “In vitro insulin secretion by pancreatic tissue from infants with diazoxide-resistant congenital hyperinsulinism deviates from model predictions.” The Journal of clinical investigation 121.10 (2011) 3932-3942.;;Hogan, Patrick G., et al. “Transcriptional regulation by calcium, calcineurin, and NFAT.” Genes & development 17.18 (2003): 2205-2232.;;Hopyan, Sevan. “Biophysical regulation of early limb bud morphogenesis.” Developmental Biology 429.2 (2017): 429-433.;;Houreld, Nicolette N., Roland T. Masha, and Heidi Abrahamse. “Low-intensity laser irradiation at 660 nm stimulates cytochrome c oxidase in stressed fibroblast cells.” Lasers in surgery and medicine 44.5 (2012): 429-434.;;Irani, S., et al. “Effect of low-level laser irradiation on in vitro function of pancreatic islets.” Transplantation proceedings. vol. 41. No. 10. Elsevier, 2009, 4313-4315.;;Jitrapakdee, S., et al. “Regulation of insulin secretion: role of mitochondrial signalling.” Diabetologia 53.6 (2010): 1019-1032.;;Johnston, Natalie R., et al. “Beta cell hubs dictate pancreatic islet responses to glucose.” Cell metabolism 24.3 (2016): 389-401.;;Jope, Richard S., Christopher J. Yuskaitis, and Eléonore Beurel. “Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.” Neurochemical research 32.4-5 (2007): 577-595.;;Kahl, Christina R., and Anthony R. Means. “Regulation of cell cycle progression by calcium/calmodulin-dependent pathways.” Endocrine reviews 24.6 (2003): 719-736.;;Kahn, Steven E., Mark E. Cooper, and Stefano Del Prato. “Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.” The Lancet 383.9922 (2014): 1068-1083.;;Kajiyama, Hiromitsu, et al. “Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice.” International Journal of Developmental Biology 54.4 (2009): 699-705.;;Kaneto, Hideaki, et al. “Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis.” Mediators of inflammation 2010 1-11.;;Kang, H., et al. “Glucose metabolism and oscillatory behavior of pancreatic islets.” Physical Review E 72.5 (2005): 051905.;;Karu, T., “Cellular and Molecular Mechanisms of Photobiomodulation (Low-Power Laser Therapy)”. IEEE Journal of Selected Topics in Quantum Electronics, 2014, 20(2), pp. 143-148.;;Kass, G. E., and Sten Orrenius. “Calcium signaling and cytotoxicity.” Environmental Health Perspectives 107.suppl 1 (1999): 25-35.;;Kazanietz, Marcelo G., et al. “Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes.” Molecular Pharmacology 44.2 (1993): 298-307.;;Kindzelskii, Andrei L., and Howard R. Petty. “Ion channel clustering enhances weak electric field detection by neutrophils: apparent roles of SKF96365-sensitive cation channels and myeloperoxidase trafficking in cellular responses.” European Biophysics Journal 35.1 (2005): 1-26.;;Kloth, Luther C. “Electrical stimulation for wound healing: a review of evidence from in vitro studies, animal experiments, and clinical trials.” The international journal of lower extremity wounds 4.1 (2005): 23-44.;;Koga, Tomoaki, et al. “Mild electrical stimulation with heat shock guides differentiation of embryonic stem cells into Pdx1-expressing cells within the definitive endoderm.” BMC biotechnology 17.1 (2017): 1-7.;;Kondo, Tatsuya, et al. “Hyperthermia with mild electrical stimulation protects pancreatic β-cells from cell stresses and apoptosis.” Diabetes 61.4 (2012): 838-847.;;Koyanagi, Masamichi, et al. “Wnt5a increases cardiac gene expressions of cultured human circulating progenitor cells via a PKC delta activation.” PloS one 4.6 (2009): e5765.;;Kushner, Jake A., et al. “Pdx1 restores β cell function in Irs2 knockout mice.” The Journal of clinical investigation 109.9 (2002): 1193-1201.;;Lawlor, Nathan, et al. “Alpha TC1 and Beta-TC-6 genomic profiling uncovers both shared and distinct transcriptional regulatory features with their primary islet counterparts.” Scientific reports 7.1 (2017): 1-14.;;Lawrence, Michael C., Harshika S. Bhatt, and Richard A. Easom. “NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1.” Diabetes 51.3 (2002): 691-698.;;Lawrence, Michael C., et al. “NFAT targets signaling molecules to gene promoters in pancreatic β-cells.” Molecular endocrinology 29.2 (2015): 274-288.;;Lee, Kendall H., et al. “Neurotransmitter release from high-frequency stimulation of the subthalamic nucleus.” Journal of neurosurgery 101.3 (2004): 511-517.;;Leloup, Corinne, et al. “Mitochondrial reactive oxygen species are obligatory signals for glucose-induced insulin secretion.” Diabetes 58.3 (2009): 673-681.;;Levin, Michael. “Molecular bioelectricity: how endogenous voltage potentials control cell behavior and instruct pattern regulation in vivo.” Molecular biology of the cell 25.24 (2014): 3835-3850.;;Li, Fang-Hui, et al. “Photobiomodulation on Bax and Bcl-2 Proteins and SIRT1/PGC-1α Axis mRNA Expression Levels of Aging Rat Skeletal Muscle.” International Journal of Photoenergy 2014 (2014), 1-8.;;Li, Li, and Jianxin Jiang. “Stem cell niches and endogenous electric fields in tissue repair.” Frontiers of Medicine 5.1 (2011): 40-44.;;Li, Wan-Chun, et al. “In vitro transdifferentiation of hepatoma cells into functional pancreatic cells.” Mechanisms of development 122.6 (2005): 835-847.;;Li, Zhushi, et al. “ROS leads to MnSOD upregulation through ERK2 translocation and p53 activation in selenite-induced apoptosis of NB4 cells.” FEBS letters 584.11 (2010): 2291-2297.;;Liang, Jiangang, Lei Liu, and Da Xing. “Photobiomodulation by low-power laser irradiation attenuates Aβ-induced cell apoptosis through the Akt/GSK3β/β-catenin pathway.” Free Radical Biology and Medicine 53.7 (2012): 1459-1467.;;Liebano, Richard Eloin, and Aline Fernanda Perez Machado. “Vascular endothelial growth factor release following electrical stimulation in human subjects.” Advances in wound care 3.2 (2014): 98-103.;;Liebman, Caleb, et al. “Altered β-Cell Calcium Dynamics via Electric Field Exposure.” Annals of Biomedical Engineering (2020): 1-9.;;Lim, Jinhwan, et al. “Effects of low-level light therapy on hepatic antioxidant defense in acute and chronic diabetic rats.” Journal of biochemical and molecular toxicology 23.1 (2009): 1-8.;;Lin-Liu, S., W. R. Adey, and M. M. Poo. “Migration of cell surface concanavalin A receptors in pulsed electric fields.” Biophysical journal 45.6 (1984): 1211-1217.;;Liu, Bo, et al. “The CaMK4/CREB/IRS-2 cascade stimulates proliferation and inhibits apoptosis of β-cells.” PLoS One 7.9 (2012): e45711.;;Llanos, Paola, et al. “Glucose-dependent insulin secretion in pancreatic β-cell islets from male rats requires Ca 2+ release via ROS-stimulated ryanodine receptors.” PLoS One 10.6 (2015): e0129238.;;Love, Maria R., et al. “Effects of electrical stimulation on cell proliferation and apoptosis.” Journal of cellular physiology 233.3 (2018): 1860-1876.;;Marhl, Marko, et al. “Complex calcium oscillations and the role of mitochondria and cytosolic proteins.” Biosystems 57.2 (2000): 75-86.;;Markwardt, Michele L., Kendra M. Seckinger, and Mark A. Rizzo. “Regulation of glucokinase by intracellular calcium levels in pancreatic β cells.” Journal of Biological Chemistry 291.6 (2016): 3000-3009.;;Mason, Maria G., Peter Nicholls, and Chris E. Cooper. “Re-evaluation of the near infrared spectra of mitochondrial cytochrome c oxidase: implications for non invasive in vivo monitoring of tissues.” Biochimica et Biophysica Acta (BBA)—Bioenergetics 1837.11 (2014): 1882-1891.;;Mathieu, Chantal, et al. “Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the Award programme.” Diabetes, Obesity and Metabolism 20.8 (2018): 2023-2028.;;Matschinsky, Franz M. “Regulation of pancreatic β-cell glucokinase: from basics to therapeutics.” Diabetes 51. suppl 3 (2002): S394-S404.;;McCaig, Colin D., et al. “Controlling cell behavior electrically: current views and future potential.” Physiological reviews (2005), 943-978.;;McColloch, Andrew, et al. “Alterted Adipogenesis of Human Mesenchymal Stem Cells by Photobiomodulation Using 1064 nm Laser Light.” Lasers in Surgery and Medicine (2020).;;De Meulenaer, Eric Cordemans, et al. “Effects of infrared light on insulin release, cationic fluxes and cellularity in insulin-producing cells.” Metabolic and Functional Research on Diabetes (Online) vol. 2 (2009): 63-70.;;Miller, Jonathan P., et al. “Parameters of spinal cord stimulation and their role in electrical charge delivery: a review.” Neuromodulation: Technology at the Neural Interface 19.4 (2016): 373-384.;;Mogami, Hideo, et al. “Calcium binding capacity of the cytosol and endoplasmic reticulum of mouse pancreatic acinar cells.” The Journal of physiology 518.2 (1999): 463-467.;;Moreau, David, et al. “Infrared neural stimulation induces intracellular Ca2+ release mediated by phospholipase C.” Journal of biophotonics 11.2 (2018): e201700020.;;Morth, J. Preben, et al. “A structural overview of the plasma membrane Na+, K+-ATPase and H+-ATPase ion pumps.” Nature reviews Molecular cell biology 12.1 (2011): 60-70.;;Murphy, Michael P. “How mitochondria produce reactive oxygen species.” Biochemical journal 417.1 (2009): 1-13.;;Murphy, Rinki, Sian Ellard, and Andrew T. Hattersley. “Clinical implications of a molecular genetic classification of monogenic β-cell diabetes.” Nature clinical practice Endocrinology & metabolism 4.4 (2008): 200-213.;;Mycielska, Maria E., and Mustafa BA Djamgoz. “Cellular mechanisms of direct-current electric field effects: galvanotaxis and metastatic disease.” Journal of cell science 117.9 (2004): 1631-1639.;;Nuccitelli, Richard. “Endogenous electric fields in embryos during development, regeneration and wound healing.” Radiation protection dosimetry 106.4 (2003): 375-383.;;Nurković, Jasmin, et al. “Combined effects of electromagnetic field and low-level laser increase proliferation and alter the morphology of human adipose tissue-derived mesenchymal stem cells.” Lasers in medical science 32.1 (2017): 151-160.;;Pai, Vaibhav P., et al. “Endogenous gradients of resting potential instructively pattern embryonic neural tissue via notch signaling and regulation of proliferation.” Journal of Neuroscience 35.10 (2015): 4366-4385.;;Pall, Martin L. “Electromagnetic fields act via activation of voltage-gated calcium channels to produce beneficial or adverse effects.” Journal of cellular and molecular medicine 17.8 (2013): 958-965.;;Pannala, Venkat R., Amadou KS Camara, and Ranjan K. Dash. “Modeling the detailed kinetics of mitochondrial cytochrome c oxidase: Catalytic mechanism and nitric oxide inhibition.” Journal of applied physiology 121.5 (2016): 1196-1207.;;Paschou, Stavroula A., et al. “On type 1 diabetes mellitus pathogenesis.” Endocrine connections 7.1 (2018): R38-R46.;;Passarella, Salvatore, and Tiina Karu. “Absorption of monochromatic and narrow band radiation in the visible and near IR by both mitochondrial and non-mitochondrial photoacceptors results in photobiomodulation.” Journal of Photochemistry and Photobiology B: Biology 140 (2014): 344-358.;;Pathak, Trayambak, and Mohamed Trebak. “Mitochondrial Ca2+ signaling.” Pharmacology & therapeutics 192 (2018): 112-123.;;Peplow, Philip V., and G. David Baxter. “Defining a therapeutic window for laser irradiation (810 nm) applied to the inguinal region to ameliorate diabetes in diabetic mice.” Photomedicine and laser surgery 32.9 (2014): 500-504.;;Pernicova, Ida, and Márta Korbonits. “Metformin—mode of action and clinical implications for diabetes and cancer.” Nature Reviews Endocrinology 10.3 (2014): 143-156.;;Pieralice, Silvia, and Paolo Pozzilli. “Latent autoimmune diabetes in adults: a review on clinical implications and management.” Diabetes & Metabolism Journal 42.6 (2018): 451-464.;;Poderoso, Juan José, et al. “Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles.” Archives of biochemistry and biophysics 328.1 (1996): 85-92.;;Poitout, Vincent, et al. “Morphological and functional characterization of βTC-6 cells—an insulin-secreting cell line derived from transgenic mice.” Diabetes 44.3 (1995): 306-313.;;Polster, Brian M., and Gary Fiskum. “Mitochondrial mechanisms of neural cell apoptosis.” Journal of neurochemistry 90.6 (2004): 1281-1289.;;Pozzilli, Paolo, and Silvia Pieralice. “Latent autoimmune diabetes in adults: current status and new horizons.” Endocrinology and Metabolism 33.2 (2018): 147-159.;;Proks, P., et al. “Sulfonylurea stimulation of insulin secretion. Diabetes. 51: S368-S376.” (2002): S368-S376.;;Putney, James W. “Pharmacology of store-operated calcium channels.” Molecular interventions 10.4 (2010): 209-218.;;Radman, Thomas, et al. “Spike timing amplifies the effect of electric fields on neurons: implications for endogenous field effects.” Journal of Neuroscience 27.11 (2007): 3030-3036.;;Rahman, Faiz Ur, et al. “Critical roles of carbon monoxide and nitric oxide in Ca2+ signaling for insulin secretion in pancreatic islets.” Antioxidants & redox signaling 30.4 (2019): 560-576.;;Ramadan, James W., et al. “The central role of calcium in the effects of cytokines on beta-cell function: implications for type 1 and type 2 diabetes.” Cell calcium 50.6 (2011): 481-490.;;Ray, Paul D., Bo-Wen Huang, and Yoshiaki Tsuji. “Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling.” Cellular signalling 24.5 (2012): 981-990.;;Rickels, Michael R., and R. Paul Robertson. “Pancreatic islet transplantation in humans: recent progress and future directions.” Endocrine Reviews 40.2 (2019): 631-668.;;Rizzo, Mark A., and David W. Piston. “Regulation of ß cell glucokinase by S-nitrosylation and association with nitric oxide synthase.” The Journal of cell biology 161.2 (2003): 243-248.;;Robertson, R. Paul, et al. “Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection.” Diabetes 52.3 (2003): 581-587.;;Rodriguez-Calvo, Teresa, et al. “Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes.” Diabetes 63.11 (2014): 3880-3890.;;Rorsman, Patrik, and Frances M. Ashcroft. “Pancreatic β-cell electrical activity and insulin secretion: of mice and men.” Physiological reviews 98.1 (2018): 117-214.;;Rorsman, Patrik, and Erik Renström. “Insulin granule dynamics in pancreatic beta cells.” Diabetologia 46.8 (2003): 1029-1045.;;Rorsman, Patrik, Matthias Braun, and Quan Zhang. “Regulation of calcium in pancreatic α-and β-cells in health and disease.” Cell calcium 51.3-4 (2012): 300-308.;;Rorsman, Patrik, et al. “Electrophysiology of pancreatic β-cells in intact mouse islets of Langerhans.” Progress in biophysics and molecular biology 107.2 (2011): 224-235.;;Rosenmund, C., and G. L. Westbrook. “Calcium-induced actin depolymerization reduces NMDA channel activity.” Neuron 10.5 (1993): 805-814.;;Sabatini, Paul V., Thilo Speckmann, and Francis C. Lynn. “Friend and foe: β-cell Ca2+ signaling and the development of diabetes.” Molecular Metabolism 21 (2019): 1-12.;;Sachdeva, Mira M., et al. “Pdx1 (MODY4) regulates pancreatic beta cell susceptibility to ER stress.” Proceedings of the National Academy of Sciences 106.45 (2009): 19090-19095.;;Saisho, Yoshifumi. “β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.” World journal of diabetes 6.1 (2015): 109.;;Salehpour, Farzad, et al. “Brain photobiomodulation therapy: a narrative review.” Molecular neurobiology 55.8 (2018): 6601-6636.;;Samways, Damien SK, and Terrance M. Egan. “Calcium-dependent decrease in the single-channel conductance of TRPV1.” Pflügers Archiv—European Journal of Physiology 462.5 (2011): 681-691.;;Santulli, Gaetano, et al. “Intracellular calcium release channels: an update.” The Journal of physiology 595.10 (2017): 3041-3051.;;Sarti, Paolo, et al. “The chemical interplay between nitric oxide and mitochondrial cytochrome c oxidase: reactions, effectors and pathophysiology.” International Journal of Cell Biology 2012 (2012).;;Schoenbach, Karl H., et al. “Ultrashort electrical pulses open a new gateway into biological cells.” Proceedings of the IEEE 92.7 (2004): 1122-1137.;;Schoenbach, Karl H., Stephen J. Beebe, and E. Stephen Buescher. “Intracellular effect of ultrashort electrical pulses.” Bioelectromagnetics: Journal of the Bioelectromagnetics Society, The Society for Physical Regulation in Biology and Medicine, The European Bioelectromagnetics Association 22.6 (2001): 440-448. et al.",ACTIVE
35,US,A1,US 2012/0071580 A1,159-056-912-223-83X,2012-03-22,2012,US 201113284301 A,2011-10-28,US 201113284301 A;;US 51114509 A;;US 8506408 P,2008-07-31,Suturable Hybrid Superporous Hydrogel Keratoprosthesis for Cornea,The present invention features a hybrid superporous hydrogel scaffold for cornea regeneration and a method for producing the same. The hybrid hydrogel is composed of a superporous poly(2-hydroxyethyl methacrylate) (PHEMA) and poly(methyl methacrylate) (PMMA) copolymer mixed with collagen. The hybrid scaffold can be used as a suturable hybrid corneal implant or keratoprosthesis.,CHO MICHAEL;;ZELLANDER AMELIA;;UNIV ILLINOIS,CHO MICHAEL;;ZELLANDER AMELIA,THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2011-11-29),https://lens.org/159-056-912-223-83X,Patent Application,yes,3,7,10,12,0,A61L27/52;;A61L27/56;;A61L27/16;;A61L27/24;;A61L27/48;;A61L2430/16;;A61K35/12;;C12N11/04;;A61F2/142;;A61L27/14;;A61F2/142;;A61L27/52;;A61L27/56;;A61L27/24;;A61L2430/16;;A61K35/12;;A61L27/48;;A61L27/16;;C12N11/04,A61L31/04,523/105,0,0,,,,DISCONTINUED
36,ZA,B,ZA 897437 B,169-401-325-579-951,1991-06-26,1991,ZA 897437 A,1989-09-29,GB 8822857 A,1988-09-29,PHARMACEUTICAL FORMULATIONS,,PATRALAN LTD,CHO YOUNG W;;YOUNG W CHO;;FLYNN MICHAEL J;;MICHAEL J FLYNN,,https://lens.org/169-401-325-579-951,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
37,WO,A2,WO 2011/085000 A2,007-892-380-631-550,2011-07-14,2011,US 2011/0020221 W,2011-01-05,US 29269610 P,2010-01-06,FATTY ACID DERIVATIVES AND ANALOGS OF DRUGS,"The present disclosure is directed to fatty acid-drug conjugates, the preparation and use thereof and long-chain (C 10-25 ), both saturated and unsaturated, fatty acids and anhydrides useful for preparing drug conjugates.",UNIV NORTH CAROLINA;;CHO MOO J;;HACKETT MICHAEL,CHO MOO J;;HACKETT MICHAEL,,https://lens.org/007-892-380-631-550,Patent Application,yes,0,6,6,6,0,A61K31/337;;A61K31/337;;A61P35/00,A61K31/337,,0,0,,,,PENDING
38,CN,A,CN 111050631 A,118-343-771-004-039,2020-04-21,2020,CN 201880050052 A,2018-01-05,US 201715666535 A;;US 2018/0012567 W,2017-08-01,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF OBJECT,"A method and system for estimating the fractional fat content of an object are disclosed. An energy emitter is used to direct an energy signal with an energy signal electric field strength toward theregion of interest, wherein the region of interest has an object of interest, a reference, and a boundary between the object of interest and the reference. Next, a thermo-acoustic or ultrasonic transducer is used to receive a thermo-acoustic bipolar signal from the boundary, wherein the thermo-acoustic bipolar signal is induced by the energy signal. Finally, a machine is used to accept data from the energy emitter and thermo-acoustic or ultrasonic transducer, correlate the thermo-acoustic bipolar signal to an electric field strength of the reference at the boundary to generate a corrected thermo-acoustic bipolar signal at the boundary, and calculate a fat concentration of the object of interest as a function of the corrected thermo-acoustic bipolar signal at the boundary.",ENDRA LIFE SCIENCES INC,CHO JANG;;THORNTON MICHAEL M,,https://lens.org/118-343-771-004-039,Patent Application,no,6,0,7,7,0,A61B5/0095;;A61B5/4244;;A61B5/4872;;A61B5/7246;;A61B5/7485;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B5/7246;;A61B5/4244;;A61B8/5223;;A61B8/5261,A61B5/00;;A61B8/00;;A61B8/08,,0,0,,,,ACTIVE
39,US,A,US 4940547 A,195-302-127-933-904,1990-07-10,1990,US 88280386 A,1986-07-07,US 88280386 A,1986-07-07,Use of inhibitory solvents in multi-membrane bioreactor,An immobilized liquid membrane is employed to allow use of a product-extracting solvent which is normally toxic toward a cell layer which produces the product in a membrane-moderated biological reaction.,CORNELL RES FOUNDATION INC,CHO TOOHYON;;SHULER MICHAEL L,CORNELL RESEARCH FOUNDATION INC. A CORP. OF NEW YORK (1986-06-27),https://lens.org/195-302-127-933-904,Granted Patent,yes,2,8,1,2,0,C12M29/04;;C12M29/04;;C02F3/102;;C02F3/102;;C02F3/208;;C02F3/208;;C12M23/04;;C12M23/04;;C12M47/10;;C12M47/10;;Y02W10/10;;Y02W10/10,C02F3/10;;C02F3/20;;C12M1/12;;C12M3/06,210/643;;435/161,15,8,004-112-095-763-045;;108-294-625-902-251;;108-294-625-902-251;;026-100-675-847-421;;019-998-154-042-492;;067-011-514-594-833;;137-933-050-464-499;;042-261-618-237-00X,10.1021/i200012a016;;10.1002/bit.260200508;;348245;;10.1002/bit.260200508;;348245;;10.1002/bit.260260309;;18551734;;10.1002/bit.260240710;;18546457;;10.1002/bit.260210808;;18553670;;10.1002/bit.260270311;;10.1002/bit.260100610,"Roddy, 1981, Ind. Eng. Chem. Process Des. Dev., 20:104 108.;;Matsumura et al., 3rd European Congress Biotechnol., 2:415 423.;;Slapack et al., Thermophilic Microbes in Ethanol Production , CRC Press Inc., Boco Raton, Fla., 1985, p. 135.;;Hahn Hagerdal et al., 1981, Biotechnol. Bioeng. Sympos., 11:651 661.;;Margaritis et al., 1978, Biotechnol. Bioeng., 20:727 753.;;Margaritis et al., 1978, Biotechnol. Bioeng., 20:727 753.;;Kyung et al., 1984, Biotechnol. Bioeng., 26:252 256.;;Murphy et al., Process Biotechnol., Nov./Dec. 1982.;;Minier et al., 1982, Biotechnol. Bioeng., 24:1565 1579.;;Brown et al., 1981, Euro. J. Appl. Microbiol. Biotechnol., 11:151 155.;;Ghose et al., 1979, Biotechnol. Bioeng., 27:1401 1420.;;Luong, 1985, Biotechnol. Bioeng., 27:280 285.;;Aiba et al., 1968, Biotechnol. Bioeng., 10:845 865.;;Holzberg et al., 1967, Biotechnol. Bioeng., 9:413 427.;;Wang et al., 1981, Biotechnol. Bioeng. Sympo., 11:555 565.",EXPIRED
40,US,S,US D0741628 S,057-448-666-852-773,2015-10-27,2015,US 201429498109 F,2014-07-31,US 201429498109 F,2014-07-31,Storage bin,,STEELCASE INC,HELD MICHAEL;;HO SIU CHO,STEELCASE INC (2014-08-05),https://lens.org/057-448-666-852-773,Design Right,no,0,11,3,3,0,,,0606;;D 6675,0,0,,,,ACTIVE
41,US,A1,US 2018/0354821 A1,002-798-579-226-234,2018-12-13,2018,US 201816107642 A,2018-08-21,US 201816107642 A;;US 201514607204 A;;US 201462023098 P;;US 201462039729 P,2014-07-10,ELECTROLYSIS ELECTRODE,"A water purification anode has a first semiconductor contacting a second semiconductor at a heterojunction. The second semiconductor includes TiO 2 and excludes bismuth and niobium. The first semiconductor includes iridium. In some instances, the anode includes a current collector in direct physical contact with the first semiconductor. The anode can be arranged in water such that at least one face of the second semiconductor is in direct physical contact with the water.",CALIFORNIA INST OF TECHN;;THE CALIFORNIA INSTITUTE OF TECH,HOFFMANN MICHAEL R;;CHO KANGWOO,THE CALIFORNIA INSTITUTE OF TECHNOLOGY (2015-01-23),https://lens.org/002-798-579-226-234,Patent Application,yes,0,0,8,8,0,C02F1/4674;;C02F2001/46138;;C02F2305/023;;C02F1/46109;;C02F2001/46133;;C02F2101/30;;C25B11/051;;C25B11/055;;C25B11/057;;C25B11/073;;C25B11/077;;C25B11/075;;C25B11/081;;C25B11/093;;C25B11/091;;C02F1/4674;;C02F2001/46138;;C02F2305/023;;C25B11/073;;C25B11/051;;C25B11/055;;C25B11/057;;C25B11/075;;C25B11/077;;C25B11/081;;C25B11/091;;C25B11/093;;C02F1/46109;;C02F2001/46133;;C02F2101/30,C02F1/461;;C02F1/467;;C02F101/30;;C25B11/04,,0,0,,,,PENDING
42,US,B2,US 10692097 B2,190-279-625-806-268,2020-06-23,2020,US 201414245567 A,2014-04-04,US 201414245567 A;;US 201361808488 P,2013-04-04,System and method for instantly measuring and updating customer loyalty for brands on a digital world map through utilization of color and digits,A system and method for instantly measuring and updating customer loyalty for one or more brands on a digital world map through utilization of color and digits is disclosed. The system may include a measuring and updating customer loyalty for one or more brands non-transitory storage media. The method may include uploading a measuring and updating customer loyalty for one or more brands non-transitory storage media onto a memory system declaring brand loyalty thereby increasing a brand's indicia color on a digital world map and retracting brand loyalty thereby decreasing the brand's indicia color on the digital world map.,SIGELAGELANI BHEKIMPILO M;;CHO MICHAEL,SIGELAGELANI BHEKIMPILO M;;CHO MICHAEL,,https://lens.org/190-279-625-806-268,Granted Patent,yes,8,1,2,2,0,G06Q30/0201;;G06Q30/0201,G06Q30/02,,0,0,,,,ACTIVE
43,US,A1,US 2022/0378696 A1,131-600-568-651-500,2022-12-01,2022,US 202017769892 A,2020-10-16,US 202017769892 A;;US 201962915986 P;;US 2020/0056065 W,2019-10-16,TARGET DELIVERY OF NON-BIOLOGICS THROUGH NANOTECHNOLOGY FOR TISSUE REPAIR,"Provided herein are compositions and methods for diagnosis and therapy through targeted nano-delivery to injured brain endothelium. In some aspects, the compositions comprise a population of polyester derived nanoparticles, wherein each polyester derived nanoparticle comprises a) a therapeutic agent encapsulated therein for treating traumatically injured, inflamed, diseased, or disrupted endothelial cells, and b) a targeting ligand bound to the nanoparticle, wherein the targeting ligand binds to a biomarker for the injured, inflamed, diseased, or disrupted endothelial cells, are provided. The nanoparticles can be used for targeting difficult-to-reach injury sites, including the blood brain barrier and brain tissue.",UNIV TEXAS,CHO MICHAEL;;INYANG EDIDIONG INWANG,,https://lens.org/131-600-568-651-500,Patent Application,yes,0,0,2,2,0,A61K9/0085;;A61K9/5153;;A61K47/62;;A61K47/6937;;A61K47/62;;A61K47/542;;A61K47/6937;;A61K47/60;;A61P25/00;;A61K9/0085;;A61K9/5153;;A61K31/198;;A61K31/765;;A61K38/178,A61K9/00;;A61K9/51;;A61K31/198;;A61K31/765;;A61K38/17;;A61K47/54;;A61K47/60;;A61K47/62;;A61K47/69;;A61P25/00,,0,0,,,,PENDING
44,EP,A2,EP 2521446 A2,086-428-762-943-513,2012-11-14,2012,EP 11732084 A,2011-01-05,US 29269610 P;;US 2011/0020221 W,2010-01-06,FATTY ACID DERIVATIVES AND ANALOGS OF DRUGS,,UNIV NORTH CAROLINA,CHO MOO J;;HACKETT MICHAEL,,https://lens.org/086-428-762-943-513,Patent Application,yes,0,0,6,6,0,A61K31/337;;A61K31/337;;A61P35/00,A01N25/26;;A61K31/20;;A61K31/35;;A61K31/44,,1,0,,,See references of WO 2011085000A3,DISCONTINUED
45,US,A1,US 2013/0053433 A1,081-211-277-761-477,2013-02-28,2013,US 201113520289 A,2011-01-05,US 201113520289 A;;US 29269610 P;;US 2011/0020221 W,2010-01-06,FATTY ACID DERIVATIVES AND ANALOGS OF DRUGS,"The present disclosure is directed to fatty acid-drug conjugates, the preparation and use thereof and long-chain (C 10-25 ), both saturated and unsaturated, fatty acids and anhydrides useful for preparing drug conjugates.",CHO MOO J;;HACKETT MICHAEL;;UNIV NORTH CAROLINA,CHO MOO J;;HACKETT MICHAEL,THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (2012-11-09),https://lens.org/081-211-277-761-477,Patent Application,yes,0,15,6,6,0,A61K31/337;;A61K31/337;;A61P35/00,A61K31/337;;A61P35/00;;C07D305/14,514/449;;549/510,0,0,,,,DISCONTINUED
46,US,B2,US 10200201 B2,016-643-246-140-450,2019-02-05,2019,US 201514680529 A,2015-04-07,KR 20140041525 A;;KR 20140087735 A,2014-04-07,"Method for application installation, electronic device, and certificate system","A method of managing application installation is provided. The method includes receiving an application by an electronic device, determining an application signature key included in the application, if the application signature key matches a development signature key among the development signature key and a commercial signature key, verifying the application signature key in relation to whether the electronic device corresponds to information on a test electronic device defined in the application signature key, and installing the application based on a verification result of the application signature key.",SAMSUNG ELECTRONICS CO LTD;;SAMSUNG ELECTRONICS CO LTD,CHO SUNG KYU;;PAK MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2015-08-04),https://lens.org/016-643-246-140-450,Granted Patent,yes,13,0,2,4,0,G06F8/61;;G06F8/61;;G06F21/51;;G06F21/51;;G06F2221/033;;G06F2221/033;;H04L9/3268;;H04L9/3268;;H04L9/3247,H04L9/32;;G06F8/61;;G06F21/51,,0,0,,,,ACTIVE
47,WO,A1,WO 2021/076952 A1,048-766-485-178-799,2021-04-22,2021,US 2020/0056065 W,2020-10-16,US 201962915986 P,2019-10-16,TARGET DELIVERY OF NON-BIOLOGICS THROUGH NANOTECHNOLOGY FOR TISSUE REPAIR,"Provided herein are compositions and methods for diagnosis and therapy through targeted nano-delivery to injured brain endothelium. In some aspects, the compositions comprise a population of polyester derived nanoparticles, wherein each polyester derived nanoparticle comprises a) a therapeutic agent encapsulated therein for treating traumatically injured, inflamed, diseased, or disrupted endothelial cells, and b) a targeting ligand bound to the nanoparticle, wherein the targeting ligand binds to a biomarker for the injured, inflamed, diseased, or disrupted endothelial cells, are provided. The nanoparticles can be used for targeting difficult-to-reach injury sites, including the blood brain barrier and brain tissue.",UNIV TEXAS,CHO MICHAEL;;INYANG EDIDIONG INWANG,,https://lens.org/048-766-485-178-799,Patent Application,yes,4,0,2,2,0,A61K9/0085;;A61K9/5153;;A61K47/62;;A61K47/6937;;A61K47/62;;A61K47/542;;A61K47/6937;;A61K47/60;;A61P25/00;;A61K9/0085;;A61K9/5153;;A61K31/198;;A61K31/765;;A61K38/178,A61L27/16;;A61L27/18;;A61L27/20,,0,0,,,,PENDING
48,WO,A3,WO 2011/085000 A3,001-041-707-066-714,2011-09-09,2011,US 2011/0020221 W,2011-01-05,US 29269610 P,2010-01-06,FATTY ACID DERIVATIVES AND ANALOGS OF DRUGS,"The present disclosure is directed to fatty acid-drug conjugates, the preparation and use thereof and long-chain (C 10-25 ), both saturated and unsaturated, fatty acids and anhydrides useful for preparing drug conjugates.",UNIV NORTH CAROLINA;;CHO MOO J;;HACKETT MICHAEL,CHO MOO J;;HACKETT MICHAEL,,https://lens.org/001-041-707-066-714,Search Report,yes,5,0,6,6,0,A61K31/337;;A61K31/337;;A61P35/00,A01N25/26;;A61K31/20;;A61K31/35;;A61K31/44,,0,0,,,,PENDING
49,WO,A1,WO 2022/198055 A1,086-485-263-897-787,2022-09-22,2022,US 2022/0020963 W,2022-03-18,US 202163163225 P,2021-03-19,"USES OF ANTAGONIST, NON-DEPLETING OX40 ANTIBODIES","The present disclosure provides methods of increasing the activity of regulatory T cells (Tregs), e.g., to treat autoimmune or inflammatory diseases or disorders, using antagonist, nondepleting antibodies and antigen-binding fragments thereof that specifically bind to OX40 (e.g., human OX40).",KSQ THERAPEUTICS INC,CHO JOHN;;MCCAUGHTRY THOMAS MICHAEL,,https://lens.org/086-485-263-897-787,Patent Application,yes,4,0,1,1,21,A61K35/17;;A61P37/00;;A61P37/06;;C12N15/113;;C12N2510/00;;C12N5/0637;;C12N2501/2302;;C12N2310/20;;C12N2320/12;;G01N33/505;;C07K14/70578;;C07K2317/76;;C07K16/2878;;A61K2039/505;;C07K2317/75;;C07K14/70575,A61K35/17;;A61K39/395;;A61P37/00;;A61P37/06;;C07K14/725;;C12N5/0783,,2,2,056-801-652-871-568;;013-390-039-358-834,10.4049/jimmunol.1300553;;23817421;;pmc3721124;;pmc3783213;;21491419;;10.1002/eji.201041205,"KINNEAR GILLIAN, WOOD KATHRYN J., FALLAH-ARANI FARNAZ, JONES NICK D.: ""A diametric role for OX40 in the response of effector/memory CD 4+ T cells and regulatory T cells to alloantigen"", J IMMUNOL., vol. 191, no. 3, 1 August 2013 (2013-08-01), pages 1465 - 1475, XP055972836, Retrieved from the Internet <URL:hftps://www.ncbi.nlm.nih.gov/pmc/articies/PMC3721124> [retrieved on 20220512];;HAMANO ET AL.: ""TNF by inducing co-stimulatory TNF receptor superfamily members TNFR2, 4-1 BB and OX40 augments the number and function of mouse CD 4+FoxP3+ regulatory T cells"", EUR J IMMUNOL., vol. 41, no. 7, July 2011 (2011-07-01), pages 2010 - 2020, XP071225678, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783213> [retrieved on 20220513]",PENDING
50,CA,A1,CA 2785834 A1,118-948-934-920-632,2011-07-14,2011,CA 2785834 A,2011-01-05,US 29269610 P;;US 2011/0020221 W,2010-01-06,FATTY ACID DERIVATIVES AND ANALOGS OF DRUGS,"The present disclosure is directed to fatty acid-drug conjugates, the preparation and use thereof and long-chain (C10-25), both saturated and unsaturated, fatty acids and anhydrides useful for preparing drug conjugates.",UNIV NORTH CAROLINA,CHO MOO J;;HACKETT MICHAEL,,https://lens.org/118-948-934-920-632,Patent Application,no,0,0,6,6,0,A61K31/337;;A61K31/337;;A61P35/00,A61K31/337;;A61K47/48,,0,0,,,,DISCONTINUED
51,WO,A1,WO 2016/007198 A1,107-760-274-515-493,2016-01-14,2016,US 2015/0013193 W,2015-01-28,US 201462039729 P;;US 201462023098 P,2014-07-10,ELECTROLYSIS ELECTRODE,"A water purification anode has a first semiconductor contacting a second semiconductor at a heteroj unction. The second semiconductor includes T1O2 and excludes bismuth and niobium. The first semiconductor includes iridium. In some instances, the anode includes a current collector in direct physical contact with the first semiconductor. The anode can be arranged in water such that at least one face of the second semiconductor is in direct physical contact with the water.",CALIFORNIA INST OF TECHN,HOFFMANN MICHAEL R;;CHO KANGWOO,,https://lens.org/107-760-274-515-493,Patent Application,yes,5,2,8,8,0,C02F1/4674;;C02F2001/46138;;C02F2305/023;;C02F1/46109;;C02F2001/46133;;C02F2101/30;;C25B11/051;;C25B11/055;;C25B11/057;;C25B11/073;;C25B11/077;;C25B11/075;;C25B11/081;;C25B11/093;;C25B11/091;;C02F1/4674;;C02F2001/46138;;C02F2305/023;;C25B11/073;;C25B11/051;;C25B11/055;;C25B11/057;;C25B11/075;;C25B11/077;;C25B11/081;;C25B11/091;;C25B11/093;;C02F1/46109;;C02F2001/46133;;C02F2101/30,C02F1/461;;C02F1/46,,0,0,,,,PENDING
52,US,A1,US 2015/0287049 A1,166-442-897-352-076,2015-10-08,2015,US 201414245567 A,2014-04-04,US 201414245567 A;;US 201361808488 P,2013-04-04,SYSTEM AND METHOD FOR INSTANTLY MEASURING AND UPDATING CUSTOMER LOYALTY FOR BRANDS ON A DIGITAL WORLD MAP THROUGH UTILIZATION OF COLOR AND DIGITS,A system and method for instantly measuring and updating customer loyalty for one or more brands on a digital world map through utilization of color and digits is disclosed. The system may include a measuring and updating customer loyalty for one or more brands non-transitory storage media. The method may include uploading a measuring and updating customer loyalty for one or more brands non-transitory storage media onto a memory system declaring brand loyalty thereby increasing a brand's indicia color on a digital world map and retracting brand loyalty thereby decreasing the brand's indicia color on the digital world map.,SIGELAGELANI BHEKIMPILO M;;CHO MICHAEL,SIGELAGELANI BHEKIMPILO M;;CHO MICHAEL,,https://lens.org/166-442-897-352-076,Patent Application,yes,5,0,2,2,0,G06Q30/0201;;G06Q30/0201,G06Q30/02,,0,0,,,,ACTIVE
53,US,B2,US 10059607 B2,179-970-165-686-194,2018-08-28,2018,US 201514607204 A,2015-01-28,US 201514607204 A;;US 201462023098 P;;US 201462039729 P,2014-07-10,Electrolysis electrode,"A water purification anode has a first semiconductor contacting a second semiconductor at a heterojunction. The second semiconductor includes TiO 2 and excludes bismuth and niobium. The first semiconductor includes iridium. In some instances, the anode includes a current collector in direct physical contact with the first semiconductor. The anode can be arranged in water such that at least one face of the second semiconductor is in direct physical contact with the water.",CALIFORNIA INST OF TECHN;;THE CALIFORNIA INSTITUTE OF TECH,HOFFMANN MICHAEL R;;CHO KANGWOO,THE CALIFORNIA INSTITUTE OF TECHNOLOGY (2015-01-23),https://lens.org/179-970-165-686-194,Granted Patent,yes,7,1,8,8,0,C02F1/4674;;C02F2001/46138;;C02F2305/023;;C02F1/46109;;C02F2001/46133;;C02F2101/30;;C25B11/051;;C25B11/055;;C25B11/057;;C25B11/073;;C25B11/077;;C25B11/075;;C25B11/081;;C25B11/093;;C25B11/091;;C02F1/4674;;C02F2001/46138;;C02F2305/023;;C25B11/073;;C25B11/051;;C25B11/055;;C25B11/057;;C25B11/075;;C25B11/077;;C25B11/081;;C25B11/091;;C25B11/093;;C02F1/46109;;C02F2001/46133;;C02F2101/30,C25B11/04;;C02F1/461;;C02F1/467;;C02F101/30;;C25B11/06;;C25B11/08,,3,1,041-349-990-201-775,10.1016/s0010-938x(03)00108-2,"Xu et al, “A Study on the Deactivation of an Iro2—Ta2O5 Coated Titanium Anode,” Corrosion Science 2003 45(12):2729-2740.;;Min, In Gyou, International Search Report and Written Opinion, PCT/US2015/013193, Korean Intellectual Property Office, dated May 7, 2015.;;Moon, Kihwan, International Preliminary Report on Patentability and Written Opinion, PCT/US2015/013193, The International Bureau of WIPO, dated Jan. 19, 2017.",ACTIVE
54,KR,A,KR 20150116371 A,007-968-742-919-18X,2015-10-15,2015,KR 20140087735 A,2014-07-11,KR 20140041525 A,2014-04-07,"METHOD FOR MANAGING APPLICATION INSTALLATION, ELECTRONIC DEVICE AND CERTIFICATION SYSTEM",According to a method for managing installation of an application includes the following steps; an application signature key is checked by an application; the application signature key is verified to confirm that an electronic device matches the information about a test electronic device defined in the application signature key if the application signature key matches a development signature key among the development signature key and a commercial signature key; and an application can be installed according to the verification result of the application signature key. Other embodiments can be included.,SAMSUNG ELECTRONICS CO LTD,CHO SUNG KYU;;PAK MICHAEL,,https://lens.org/007-968-742-919-18X,Patent Application,no,4,0,2,4,0,,G06F21/10;;G06F9/44,,0,0,,,,ACTIVE
55,US,A1,US 2015/0288528 A1,159-810-185-288-929,2015-10-08,2015,US 201514680529 A,2015-04-07,KR 20140041525 A;;KR 20140087735 A,2014-04-07,"METHOD FOR APPLICATION INSTALLATION, ELECTRONIC DEVICE, AND CERTIFICATE SYSTEM","A method of managing application installation is provided. The method includes receiving an application by an electronic device, determining an application signature key included in the application, if the application signature key matches a development signature key among the development signature key and a commercial signature key, verifying the application signature key in relation to whether the electronic device corresponds to information on a test electronic device defined in the application signature key, and installing the application based on a verification result of the application signature key.",SAMSUNG ELECTRONICS CO LTD,CHO SUNG KYU;;PAK MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2015-08-04),https://lens.org/159-810-185-288-929,Patent Application,yes,20,16,2,4,0,G06F8/61;;G06F8/61;;G06F21/51;;G06F21/51;;G06F2221/033;;G06F2221/033;;H04L9/3268;;H04L9/3268;;H04L9/3247,H04L9/32;;G06F9/445,,0,0,,,,ACTIVE
56,US,A1,US 2016/0009574 A1,048-469-735-251-67X,2016-01-14,2016,US 201514607204 A,2015-01-28,US 201514607204 A;;US 201462023098 P;;US 201462039729 P,2014-07-10,ELECTROLYSIS ELECTRODE,"A water purification anode has a first semiconductor contacting a second semiconductor at a heterojunction. The second semiconductor includes TiO 2 and excludes bismuth and niobium. The first semiconductor includes iridium. In some instances, the anode includes a current collector in direct physical contact with the first semiconductor. The anode can be arranged in water such that at least one face of the second semiconductor is in direct physical contact with the water.",CALIFORNIA INST OF TECHN,HOFFMANN MICHAEL R;;CHO KANGWOO,THE CALIFORNIA INSTITUTE OF TECHNOLOGY (2015-01-23),https://lens.org/048-469-735-251-67X,Patent Application,yes,1,6,8,8,0,C02F1/4674;;C02F2001/46138;;C02F2305/023;;C02F1/46109;;C02F2001/46133;;C02F2101/30;;C25B11/051;;C25B11/055;;C25B11/057;;C25B11/073;;C25B11/077;;C25B11/075;;C25B11/081;;C25B11/093;;C25B11/091;;C02F1/4674;;C02F2001/46138;;C02F2305/023;;C25B11/073;;C25B11/051;;C25B11/055;;C25B11/057;;C25B11/075;;C25B11/077;;C25B11/081;;C25B11/091;;C25B11/093;;C02F1/46109;;C02F2001/46133;;C02F2101/30,C02F1/461,,1,1,041-349-990-201-775,10.1016/s0010-938x(03)00108-2,"Xu et al, “A Study on the Deactivation of an Iro2–Ta2O5 Coated Titanium Anode,” Corrosion Science 2003 45(12):2729-2740",ACTIVE
57,EP,A3,EP 1359232 A3,146-042-650-808-109,2004-01-02,2004,EP 03015053 A,1998-01-30,EP 98903777 A;;US 3632997 P,1997-01-31,Method of improving fracture toughness in aluminium-lithium alloys,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",PECHINEY ROLLED PRODUCTS LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC (2012-01-04);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, US (2012-06-22);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, R, US (2012-06-22);;ALCAN ROLLED PRODUCTS - RAVENSWOOD, LLC (2006-09-06)",https://lens.org/146-042-650-808-109,Search Report,yes,3,0,18,18,0,C22C21/12;;C22F1/057,C22C21/12;;C22F1/057,,2,0,,,"""ALUMINUM AND ALUMINUM ALLOYS"", METALS AND ALLOYS IN THE UNIFIED NUMBERING SYSTEM, XX, XX, VOL. ED-7, PAGE(S) 30, XP002131452;;PETERS AND P-J WINKLER M: ""Aluminium-Lithium"", ALUMINIUM-LITHIUM CONFERENCE, DGM INFORMATIONSGESELLSCHAFT VERLAG, DE, VOL. 1, PAGE(S) 203-208, XP002131453",EXPIRED
58,DE,T2,DE 69836569 T2,098-280-229-006-297,2008-01-03,2008,DE 69836569 T,1998-01-30,US 3632997 P;;EP 03015053 A,1997-01-31,Verfahren zur Erhöhung der Bruchzähigkeit in Aluminium-Lithium-Legierungen,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,,https://lens.org/098-280-229-006-297,Granted Patent,no,0,0,18,18,0,C22C21/12;;C22F1/057,C22C21/00;;C22C21/12;;C22F1/057,,0,0,,,,EXPIRED
59,EP,B1,EP 1359232 B1,028-279-999-808-117,2006-11-29,2006,EP 03015053 A,1998-01-30,EP 98903777 A;;US 3632997 P,1997-01-31,Method of improving fracture toughness in aluminium-lithium alloys,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC (2012-01-04);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, US (2012-06-22);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, R, US (2012-06-22);;ALCAN ROLLED PRODUCTS - RAVENSWOOD, LLC (2006-09-06)",https://lens.org/028-279-999-808-117,Granted Patent,yes,3,0,18,18,0,C22C21/12;;C22F1/057,C22C21/00;;C22C21/12;;C22F1/057,,2,0,,,"""ALUMINUM AND ALUMINUM ALLOYS"" , METALS AND ALLOYS IN THE UNIFIED NUMBERING SYSTEM, XX, XX, VOL. ED-7, PAGE(S) 30 XP002131452 * alloy A92097 *;;PETERS AND P-J WINKLER M: ""Aluminium-Lithium"" , ALUMINIUM-LITHIUM CONFERENCE, DGM INFORMATIONSGESELLSCHAFT VERLAG, DE, VOL. 1, PAGE(S) 203-208 XP002131453",EXPIRED
60,DE,D1,DE 69836569 D1,160-692-739-594-073,2007-01-11,2007,DE 69836569 T,1998-01-30,US 3632997 P;;EP 03015053 A,1997-01-31,Verfahren zur Erhöhung der Bruchzähigkeit in Aluminium-Lithium-Legierungen,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,,https://lens.org/160-692-739-594-073,Granted Patent,no,0,0,18,18,0,C22C21/12;;C22F1/057,C22C21/00;;C22C21/12;;C22F1/057,,0,0,,,,EXPIRED
61,EP,A2,EP 1359232 A2,151-318-418-197-468,2003-11-05,2003,EP 03015053 A,1998-01-30,EP 98903777 A;;US 3632997 P,1997-01-31,Method of improving fracture toughness in aluminium-lithium alloys,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",PECHINEY ROLLED PRODUCTS LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC (2012-01-04);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, US (2012-06-22);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, R, US (2012-06-22);;ALCAN ROLLED PRODUCTS - RAVENSWOOD, LLC (2006-09-06)",https://lens.org/151-318-418-197-468,Patent Application,yes,0,4,18,18,0,C22C21/12;;C22F1/057,C22C21/12;;C22F1/057,,0,0,,,,EXPIRED
62,EP,B9,EP 1359232 B9,092-034-836-472-722,2014-09-10,2014,EP 03015053 A,1998-01-30,EP 98903777 A;;US 3632997 P,1997-01-31,Method of improving fracture toughness in aluminium-lithium alloys,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC (2012-01-04);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, US (2012-06-22);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, R, US (2012-06-22);;ALCAN ROLLED PRODUCTS - RAVENSWOOD, LLC (2006-09-06)",https://lens.org/092-034-836-472-722,Amended Patent,yes,3,0,18,18,0,C22C21/12;;C22F1/057,C22C21/00;;C22C21/12;;C22F1/057,,3,0,,,"""ALUMINUM AND ALUMINUM ALLOYS"" , METALS AND ALLOYS IN THE UNIFIED NUMBERING SYSTEM, XX, XX, VOL. ED-7, PAGE(S) 30 XP002131452 * alloy A92097 *;;PETERS AND P-J WINKLER M: ""Aluminium-Lithium"" , ALUMINIUM-LITHIUM CONFERENCE, DGM INFORMATIONSGESELLSCHAFT VERLAG, DE, VOL. 1, PAGE(S) 203-208 XP002131453;;'Teal Sheets, Registration Record Series, International Alloy Designations and Chemical Composition Limits for Wrought Aluminum and Wrought Aluminum Alloys.' THE ALUMINIUM ASSOCIATION April 2004, pages 3 - 13",EXPIRED
63,AT,T1,AT E346963 T1,058-831-102-214-432,2006-12-15,2006,AT 03015053 T,1998-01-30,US 3632997 P,1997-01-31,VERFAHREN ZUR ERHÖHUNG DER BRUCHZÄHIGKEIT IN ALUMINIUM-LITHIUM-LEGIERUNGEN,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,,https://lens.org/058-831-102-214-432,Granted Patent,no,0,0,18,18,0,C22C21/12;;C22F1/057,C22C21/12;;C22F1/057,,0,0,,,,EXPIRED
64,DE,T3,DE 69836569 T3,183-291-320-819-752,2014-07-31,2014,DE 69836569 T,1998-01-30,US 3632997 P;;EP 03015053 A,1997-01-31,Verfahren zur Erhöhung der Bruchzähigkeit in Aluminium-Lithium-Legierungen,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,,https://lens.org/183-291-320-819-752,Amended Patent,no,0,0,18,18,0,C22C21/12;;C22F1/057,C22C21/00;;C22C21/12;;C22F1/057,,0,0,,,,EXPIRED
65,ES,T3,ES 2278093 T3,180-952-174-822-633,2007-08-01,2007,ES 03015053 T,1998-01-30,US 3632997 P,1997-01-31,METODO PARA MEJORAR LA TENACIDAD EN ALEACIONES DE ALUMINIO-LITIO.,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,,https://lens.org/180-952-174-822-633,Granted Patent,no,0,0,18,18,0,C22C21/12;;C22F1/057,C22C21/00;;C22C21/12;;C22F1/057,,0,0,,,,EXPIRED
66,ES,T5,ES 2278093 T5,186-145-830-623-091,2014-07-16,2014,ES 03015053 T,1998-01-30,US 3632997 P,1997-01-31,Método de mejora de la tenacidad a la rotura en aleaciones de aluminio-litio,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",ALCAN ROLLED PRODUCTS RAVENSWOOD LLC;;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,,https://lens.org/186-145-830-623-091,Amended Patent,no,0,0,18,18,0,C22C21/12;;C22F1/057,C22C21/00;;C22C21/12;;C22F1/057,,0,0,,,,EXPIRED
67,EP,B2,EP 1359232 B2,090-982-015-027-338,2014-03-12,2014,EP 03015053 A,1998-01-30,EP 98903777 A;;US 3632997 P,1997-01-31,Method of improving fracture toughness in aluminium-lithium alloys,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD LLC,CHO ALEX;;SKILLINGBERG MICHAEL;;GREENE RICHARD;;NIEDZINSKI MICHAEL,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC (2012-01-04);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, US (2012-06-22);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, R, US (2012-06-22);;ALCAN ROLLED PRODUCTS - RAVENSWOOD, LLC (2006-09-06)",https://lens.org/090-982-015-027-338,Granted Patent,yes,0,0,18,18,0,C22C21/12;;C22F1/057,C22C21/00;;C22C21/12;;C22F1/057,,1,0,,,"""Teal Sheets, Registration Record Series, International Alloy Designations and Chemical Composition Limits for Wrought Aluminum and Wrought Aluminum Alloys."", THE ALUMINIUM ASSOCIATION, April 2004 (2004-04-01), pages 3 - 13",EXPIRED
68,WO,A1,WO 2007/078662 A1,009-759-811-113-975,2007-07-12,2007,US 2006/0047194 W,2006-12-11,US 31937805 A,2005-12-29,NOZZLE ASSEMBLY,"A nozzle assembly (2) includes a housing (4) defining a first fluid passage (18) in fluid communication with a second fluid passage (16), and a sleeve (8) disposed within the housing (4) and fluidly connected to the first and second fluid passages (18, 16). The housing (4) defines a radial fluid passage (53) proximate a front end (57) of the sleeve (8). The nozzle assembly (2) also includes at least one orifice (12) in selective communication with a regeneration device (82).",CATERPILLAR INC;;HARMON MICHAEL P;;LIANG CHO Y,HARMON MICHAEL P;;LIANG CHO Y,,https://lens.org/009-759-811-113-975,Patent Application,yes,5,0,5,5,0,F01N3/0253;;F01N3/36;;F01N2260/024;;F01N2610/03;;F01N2610/11;;F01N3/0253;;F01N2260/024;;F01N2610/11;;F01N3/36;;F01N2610/03,F01N3/36;;F01N3/025,,0,0,,,,PENDING
69,US,A1,US 2005/0269427 A1,130-821-412-433-614,2005-12-08,2005,US 85909604 A,2004-06-03,US 85909604 A,2004-06-03,Modular fuel injector with a damper member and method of reducing noise,"A fuel injector includes a body, filter, and damper member. The body extends along a longitudinal axis between an inlet end and an outlet end and has a wall defining a flow passage extending therebetween. The filter is disposed in the flow passage proximate the inlet end. The damper member is secured to the flow passage between the inlet end and the filter. The damper member has outer and inner surfaces surrounding the longitudinal axis, the outer surface being contiguous to the wall of the flow passage to define at least one circumferential band about the longitudinal axis in the flow passage. The inner surface defines an aperture that extends through the damper member to permit fluid communication between the inlet end and the filter. A damper member is also shown and described. A method of reducing sound in the valve group subassembly is also disclosed.",CHO YONG D;;DALLMEYER MICHAEL P,CHO YONG D;;DALLMEYER MICHAEL P,SIEMENS VDO AUTOMOTIVE CORPORATION (2006-09-26),https://lens.org/130-821-412-433-614,Patent Application,yes,13,11,7,7,0,F02M51/0682;;F02M55/00;;F02M61/16;;F02M61/165;;F02M2200/09;;F02M2200/27;;F02M2200/306;;F02M2200/505;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M2200/26;;F02M2200/315;;F02M61/16;;F02M2200/505;;F02M61/165;;F02M2200/27;;F02M55/00;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M51/0682;;F02M2200/306;;F02M2200/09;;F02M2200/26;;F02M2200/315,F02M51/06;;F02M55/00;;F02M55/02;;F02M55/04;;F02M61/16;;F02M63/00,239/533.2;;239/88;;239/533.12,0,0,,,,INACTIVE
70,US,B2,US 7128281 B2,134-972-023-574-046,2006-10-31,2006,US 85909604 A,2004-06-03,US 85909604 A,2004-06-03,Modular fuel injector with a damper member and method of reducing noise,"A fuel injector includes a body, filter, and damper member. The body extends along a longitudinal axis between an inlet end and an outlet end and has a wall defining a flow passage extending therebetween. The filter is disposed in the flow passage proximate the inlet end. The damper member is secured to the flow passage between the inlet end and the filter. The damper member has outer and inner surfaces surrounding the longitudinal axis, the outer surface being contiguous to the wall of the flow passage to define at least one circumferential band about the longitudinal axis in the flow passage. The inner surface defines an aperture that extends through the damper member to permit fluid communication between the inlet end and the filter. A damper member is also shown and described. A method of reducing sound in the valve group subassembly is also disclosed.",SIEMENS VDO AUTOMOTIVE CORP,CHO YONG D;;DALLMEYER MICHAEL P,SIEMENS VDO AUTOMOTIVE CORPORATION (2006-09-26),https://lens.org/134-972-023-574-046,Granted Patent,yes,17,14,7,7,0,F02M51/0682;;F02M55/00;;F02M61/16;;F02M61/165;;F02M2200/09;;F02M2200/27;;F02M2200/306;;F02M2200/505;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M2200/26;;F02M2200/315;;F02M61/16;;F02M2200/505;;F02M61/165;;F02M2200/27;;F02M55/00;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M51/0682;;F02M2200/306;;F02M2200/09;;F02M2200/26;;F02M2200/315,F02M39/00;;B05B1/30;;F02M47/02;;F02M51/06;;F02M55/00;;F02M55/02;;F02M55/04;;F02M59/00;;F02M61/16;;F02M63/00,239/585.1;;239/585.3;;239/585.4;;239/585.5;;239/88;;239/533.2;;239/533.3,0,0,,,,INACTIVE
71,CN,A,CN 111031895 A,047-999-728-164-297,2020-04-17,2020,CN 201880050042 A,2018-01-05,US 201715666546 A;;US 2018/0012575 W,2017-08-01,METHOD FOR ESTIMATING FRACTIONAL FAT CONTENT OF OBJECT,"The invention discloses a method for estimating fractional fat content of an object. An energy emitter is used to direct an energy signal toward the region of interest, wherein the region of interesthas an object of interest, a reference, and a boundary area with one or more boundary locations between the object of interest and the reference. Next, a plurality of thermoacoustic or ultrasonic transducers is used to receive a plurality of thermoacoustic bipolar signals from the one or more boundary locations, wherein the thermoacoustic bipolar signals are induced by the energy signal. A machineconfigured to accept data from the energy emitter and the plurality of thermoacoustic or ultrasonic transducers and calculate a fat concentration that is a function of the thermoacoustic bipolar signal at each respective boundary location and the distance or distances between locations.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/047-999-728-164-297,Patent Application,no,2,1,19,19,0,A61B5/0093;;A61B5/4872;;A61B5/0035;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/5223;;G16H50/30;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/0093;;H05K999/99,A61B5/00;;A61B8/00;;A61B8/08,,3,3,063-045-699-195-918;;022-033-200-797-157;;072-068-233-488-979,11386575;;10.1121/1.1360239;;10.1118/1.4966031;;27908189;;10.1109/tbme.2008.919112;;19126453,"IBRAHIM M. HALLAJ ET AL: ""Simulations of the thermo-acoustic lens effect during focused ultrasound surgery"", 《ACOUSTICAL SOCIETY OF AMERICA》;;ZIHUI CHI ET AL: ""Thermoacoustic imaging of rabbit knee joints"", 《AM. ASSOC. PHYS. MED.》;;YAO XIE ET AL: ""Adaptive and Robust Methods of Reconstruction (ARMOR) for Thermoacoustic Tomography"", 《IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING》",ACTIVE
72,EP,B1,EP 3668382 B1,032-659-489-354-572,2022-02-09,2022,EP 18840715 A,2018-01-05,US 201715666546 A;;US 2018/0012575 W,2017-08-01,METHOD FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/032-659-489-354-572,Granted Patent,yes,3,0,19,19,0,A61B5/0093;;A61B5/4872;;A61B5/0035;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/5223;;G16H50/30;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/0093;;H05K999/99,A61B5/00;;A61B8/00;;A61B8/08;;G16H50/30,,1,0,,,"XIE et al.: ""Adaptive and Robust Methods of Reconstruction (ARMOR) for Thermoacoustic Tomography"", IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, vol. 55, no. 12, December 2008 (2008-12), XP011342781, DOI: doi:10.1109/TBME.2008.919112",ACTIVE
73,CZ,B6,CZ 285237 B6,104-651-461-119-822,1999-06-16,1999,CS 554889 A,1989-09-29,GB 8822857 A,1988-09-29,PHARMACEUTICAL PREPARATION AND PROCESS FOR PREPARING A GELATINOUS CAPSULE AND PERORALLY OR RECTALLY ACCEPTABLE MEANS,"Farmaceutický prostředek, který sestává z mikroemulze obsahující hydrofilní fázi a hydrofobní fázi, přičemž /A/ hydrofilní fáze je dispergována v hydrofobní fázi, /B/ hydrofilní fáze obsahuje biologicky účinný materiál, a /C/ hydrofobní fáze obsahuje chylomikrony nebo materiál z něhož se chylomikrony tvoří in vivo.ŕ",PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/104-651-461-119-822,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
74,EP,B1,EP 0366277 B1,123-076-562-463-99X,1993-12-15,1993,EP 89309989 A,1989-09-29,GB 8822857 A,1988-09-29,Pharmaceutical formulations.,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/123-076-562-463-99X,Granted Patent,yes,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,1,0,,,"PATENT ABSTRACTS OF JAPAN, vol. 7, no. 97, (C-163)(1242), 23 April 1983#",EXPIRED
75,PT,B,PT 91850 B,150-699-054-103-197,1996-08-30,1996,PT 9185089 A,1989-09-29,GB 8822857 A,1988-09-29,PROCESSO PARA A PREPARACAO DE FORMULACOES FARMACEUTICAS COM MATERIAL BIOLOGICAMENTE ACTIVO PARTICULARMENTE MATERIAL PROTEINACEO,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/150-699-054-103-197,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
76,US,A1,US 2018/0246767 A1,156-544-545-290-89X,2018-08-30,2018,US 201715445907 A,2017-02-28,US 201715445907 A,2017-02-28,OPTIMIZED THREAD SCHEDULING ON PROCESSOR HARDWARE WITH PERFORMANCE-RELEVANT SHARED HARDWARE COMPONENTS,"To schedule a software thread for execution on a CPU in a multiprocessor system, a scheduler uses both software and hardware utilization information. For a thread, resource demands (including software and hardware resource demands) are determined based on measuring resource usage while the thread executes on the multiprocessor system without being isolated from any other threads that may run concurrently. For at least two processor cores, resource usage is calculated based on any threads already running on it. The software thread is assigned to a strand in the processor core with optimum available resources given the thread's resource demands.",ORACLE INT CORP,CHEW JONATHAN;;MICHAEL NICOLAS;;CHO JUNSANG,ORACLE INTERNATIONAL CORPORATION (2017-02-28),https://lens.org/156-544-545-290-89X,Patent Application,yes,0,4,2,2,0,G06F9/5044;;G06F9/5044;;G06F9/505;;G06F9/505;;G06F2209/483;;G06F2209/483;;G06F2209/501;;G06F2209/501;;Y02D10/00,G06F9/50;;G06F9/48,,0,0,,,,ACTIVE
77,WO,A2,WO 1990/003164 A2,161-465-332-982-820,1990-04-05,1990,GB 8901161 W,1989-09-29,GB 8822857 A,1988-09-29,PHARMACEUTICAL FORMULATIONS,"Orally or rectally administrable formulations of biologically active material comprise a water-in-oil microemulsion, wherein the hydrophilic phase of the microemulsion comprises the biologically active material and the hydrophobic phase comprises chylomicra or material capable of forming chylomicra in the intestinal mucosa after administration. The biologically active material may be any of a wide range of substances including insulin, calcitonin and somatotrophin or growth hormone. Formulations of the invention are particularly suitable for the oral administration of insulin in the treatment of diabetes.",PATRALAN LTD;;CHO YOUNG W;;FLYNN MICHAEL JOHN,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/161-465-332-982-820,Patent Application,yes,0,23,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,PENDING
78,JP,A,JP 2013118371 A,155-059-378-375-611,2013-06-13,2013,JP 2012255200 A,2012-11-21,US 201113309321 A,2011-12-01,BINARY THERMOELECTRIC MATERIAL CONTAINING NANOPARTICLES AND METHOD FOR MANUFACTURING THE SAME,"PROBLEM TO BE SOLVED: To provide a thermoelectric composite material having improved properties and a method for manufacturing the thermoelectric composite material, in a thermoelectric material comprising a binary main group matrix material and nanoparticles and/or nano-inclusions.SOLUTION: A thermoelectric composition contains a binary main group semiconductor material BiTe, and metal oxide nanoparticles represented by the formula MO, where M represents at least one element selected from the group consisting of the group 2 elements and the group 12 elements. The nanoparticles are dispersed in a matrix of the binary main group semiconductor material.",TOYOTA ENG & MFG NORTH AMERICA,MICHAEL PAUL LAW;;CHO LI KIM,,https://lens.org/155-059-378-375-611,Patent Application,no,22,1,6,6,0,B82Y30/00;;C04B35/547;;C04B2235/3284;;C04B2235/441;;C04B2235/444;;C04B2235/449;;C04B2235/80;;H10N10/852;;B82Y30/00;;C04B2235/3284;;C04B2235/441;;C04B2235/449;;C04B35/547;;C04B2235/444;;C04B2235/80;;H10N10/852,H01L35/16;;H01L35/34,,0,0,,,,INACTIVE
79,HU,A,HU T54033 A,185-407-187-759-854,1991-01-28,1991,HU 510789 A,1989-09-28,GB 8822857 A,1988-09-29,PROCESS FOR PRODUCING PHARMACEUTICAL COMPOSITIONS,,PATRALAN LTD,YOUNG W CHO;;FLYNN MICHAEL J,,https://lens.org/185-407-187-759-854,Unknown,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,DISCONTINUED
80,EP,B1,EP 3661416 B1,042-146-423-121-804,2022-02-09,2022,EP 18842400 A,2018-01-05,US 201715666535 A;;US 2018/0012567 W,2017-08-01,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/042-146-423-121-804,Granted Patent,yes,6,0,7,7,0,A61B5/0095;;A61B5/4244;;A61B5/4872;;A61B5/7246;;A61B5/7485;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B5/7246;;A61B5/4244;;A61B8/5223;;A61B8/5261,A61B5/00;;A61B8/00;;A61B8/08,,1,0,,,"NIE LIMING ET AL: ""In vivo detection and imaging of low-density foreign body with microwave-induced thermoacoustic tomography"", MEDICAL PHYSICS, AIP, MELVILLE, NY, US, vol. 36, no. 8, 1 July 2009 (2009-07-01), pages 3429-3437, XP012130131, ISSN: 0094-2405, DOI: 10.1118/1.3157204",ACTIVE
81,AT,T1,AT E98480 T1,060-967-552-038-725,1994-01-15,1994,AT 89309989 T,1989-09-29,EP 89309989 A;;GB 8822857 A,1988-09-29,ARZNEIMITTELFORMULIERUNGEN.,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/060-967-552-038-725,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
82,EP,A4,EP 3661416 A4,137-484-338-918-209,2021-04-14,2021,EP 18842400 A,2018-01-05,US 201715666535 A;;US 2018/0012567 W,2017-08-01,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/137-484-338-918-209,Search Report,no,2,0,7,7,0,A61B5/0095;;A61B5/4244;;A61B5/4872;;A61B5/7246;;A61B5/7485;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B5/7246;;A61B5/4244;;A61B8/5223;;A61B8/5261,A61B5/00;;A61B8/00;;A61B8/08,,1,1,026-967-440-875-147,19746776;;10.1118/1.3157204,"NIE LIMING ET AL: ""In vivo detection and imaging of low-density foreign body with microwave-induced thermoacoustic tomography"", MEDICAL PHYSICS, AIP, MELVILLE, NY, US, vol. 36, no. 8, 1 July 2009 (2009-07-01), pages 3429 - 3437, XP012130131, ISSN: 0094-2405, DOI: 10.1118/1.3157204",ACTIVE
83,PT,A,PT 91850 A,031-517-958-951-426,1990-03-30,1990,PT 9185089 A,1989-09-29,GB 8822857 A,1988-09-29,PROCESSO PARA A PREPARACAO DE FORMULACOES FARMACEUTICAS COM MATERIAL BIOLOGICAMENTE ACTIVO PARTICULARMENTE MATERIAL PROTEINACEO,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/031-517-958-951-426,Patent Application,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
84,DE,T2,DE 68911473 T2,017-726-502-602-301,1994-05-05,1994,DE 68911473 T,1989-09-29,GB 8822857 A,1988-09-29,Arzneimittelformulierungen.,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/017-726-502-602-301,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
85,NO,A1,NO 20230115 A1,095-686-649-405-981,2023-02-06,2023,NO 20230115 A,2023-02-06,US 202017066262 A;;US 2020/0056745 W,2020-10-08,GRAVEL PACK FLOW CONTROL USING SWELLABLE METALLIC MATERIAL,,HALLIBURTON ENERGY SERVICES INC,GRECI STEPHEN MICHAEL;;CHO BRIAN WILLIAMS,,https://lens.org/095-686-649-405-981,Patent Application,no,0,0,7,7,0,E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/108;;E21B43/088;;E21B43/04;;E21B43/12;;E21B33/127;;E21B34/10;;E21B43/04;;E21B43/12;;E21B43/088,E21B43/10;;E21B33/127;;E21B34/10;;E21B43/04;;E21B43/08;;E21B43/12,,0,0,,,,PENDING
86,EP,A2,EP 0366277 A2,127-531-887-081-241,1990-05-02,1990,EP 89309989 A,1989-09-29,GB 8822857 A,1988-09-29,Pharmaceutical formulations.,"Orally or rectally administrable formulations of biologically active material comprise a water-in-oil microemulsion, wherein the hydrophilic phase of the microemulsion comprises the biologically active material and the hydrophobic phase comprises chylomicra or material capable of forming chylomicra in the intestinal mucosa after administration. The biologically active material may be any of a wide range of substances including insulin, calcitonin and somatotrophin or growth hormone. Formulations of the invention are particularly suitable for the oral administration of insulin in the treatment of diabetes.  ",PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/127-531-887-081-241,Patent Application,yes,0,23,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
87,ES,T3,ES 2524398 T3,064-812-996-508-125,2014-12-09,2014,ES 11743400 T,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros,"Un método para preparar un compuesto de fórmula Ia o Ib:**Fórmula** o una sal o un ácido farmacéuticamente aceptables del mismo; en las que: cada R1, R2, R7, R22, R23 o R24 es independientemente H, OR11, NR11R12, C(O)NR11R12, -OC(O)NR11R12, C(O)OR11, OC(O)OR11, S(O)nRa, S(O)2NR11R12, N3, CN, halógeno, alquilo (C1-C8), (C3-C8)carbociclilo, carbociclilalquilo (C4-C8), alquenilo (C2-C8), alquinilo (C2-C8) o arilalquilo (C1-C8); 10 o dos cualquiera de R1, R2, R7, R22, R23 o R24 en átomos de carbono adyacentes cuando se toman juntos son -O(CO)O- o -O(CR11R12)O- o cuando se toman junto con los átomos de carbono del anillo al que están unidos forman un doble enlace; cada base es independientemente una base de purina o pirimidina de origen natural o modificada unida al anillo de furanosa a través de un átomo de carbono o nitrógeno; siempre que la base no sea uracilo; cada n es independientemente 0, 1 o 2; cada Ra, R4 o R6 es independientemente alquilo (C1-C8), alquenilo (C2-C8), alquinilo (C2-C8), carbociclilo (C3-C8), carbociclilalquilo (C4-C8), arilalquilo (C1-C8), heterociclilalquilo (C1-C8), arilo (C6-C20), heterociclilo (C2-C20) o heteroarilo; cada Rc o Rd es independientemente H, alquilo (C1-C8), alquenilo (C2-C8), alquinilo (C2-C8), carbociclilo (C3-C8), carbociclilalquilo (C4-C8), arilalquilo (C1-C8), heterociclilalquilo (C1-C8), arilo (C6-C20), heterociclilo (C2-C20) o heteroarilo siempre que Rc y Rd no sean los mismos; cada R5 es independientemente H, alquilo (C1-C8), alquenilo (C2-C8), alquinilo (C2-C8), carbociclilo (C3-C8), carbociclilalquilo (C4-C8), arilalquilo (C1-C8), heterociclilalquilo (C1-C8), arilo (C6-C20), heterociclilo (C2-C20) o 25 heteroarilo; cada R11 o R12 es independientemente H, alquilo (C1-C8), alquenilo (C2-C8), alquinilo (C2-C8), carbociclilo, (C3-C8), carbociclilalquilo (C4-C8), arilalquilo (C1-C8), heterociclilalquilo (C1-C8), arilo (C6-C20), heterociclilo (C2-C20), heteroarilo, -C(>=O)alquilo (C1-C8), -S(O)nalquilo(C1-C8) o R11 y R12 junto con un nitrógeno al que están ambos unidos forman un anillo heterocíclico de 3 a 7 miembros en el que uno cualquiera de los átomos de carbono de dicho anillo heterocíclico puede estar sustituido opcionalmente con -O-, -S(O)n- o -NRa-; y en el que cada alquilo (C1-C8), alquenilo (C2-C8), alquinilo (C2-C8), carbociclilo (C3-C8), carbociclilalquilo, (C4-C8), arilalquilo (C1-C8), heterociclilalquilo (C1-C8), arilo (C6-C20), heterociclilo (C2-C20) o heteroarilo de cada Rc, Rd, R1, R2, R22, R23, R24, R4, R5, R6, R7, R11 o R12 está, independientemente, opcionalmente sustituido con uno o más halo, hidroxi, CN, N3, N(Ra)2, NH(Ra), NH2, NO2, C(O)N(Ra)2, C(O)NH(Ra), C(O)NH2, OC(O)N(Ra)2, OC(O)NH(Ra), OC(O)NH2, C(O)ORa, OC(O)ORa, C(O)Ra, OC(O)Ra, S(O)nRa, S(O)2N(Ra)2, S(O)2NH(Ra), S(O)2NH2, ORa o Ra: comprendiendo dicho método: (a) proporcionar un compuesto de fórmula II **Fórmula** y (b) tratar el compuesto de fórmula II con un compuesto de fórmula IIIa y una base**Fórmula** formando de este modo un compuesto de fórmula Ia o (c) tratar el compuesto de fórmula II con un compuesto de fórmula IIIb y una base formando de este modo un compuesto de fórmula Ib; en la que: cada Ar es un arilo o heteroarilo (C6-C20) en el que dicho (arilo o heteroarilo (C6-C20) está sustituido con uno o más halógeno, NO2, o haloalquilo (C1-C8) y opcionalmente sustituido con uno o más de CN, N3, N(Ra)2, C(O)N(Ra)2, OC(O)N(Ra)2, C(O)ORa, OC(O)ORa, C(O)Ra, OC(O)Ra, S(O)nRa, S(O)2N(Ra)2, ORa o Ra con la condición de que Ar sea diferente de R4, comprendiendo el método además un método de preparación de un compuesto de fórmula IIIa o fórmula IIIb**Fórmula**",GILEAD SCIENCES INC,CHO AESOP;;WOLCKENHAUER SCOTT;;CLARKE MICHAEL,,https://lens.org/064-812-996-508-125,Granted Patent,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,ACTIVE
88,US,S,US D0991967 S,093-506-876-567-936,2023-07-11,2023,US 202129803422 F,2021-08-12,US 202129803422 F,2021-08-12,Electronic device display or portion thereof with a graphical user interface,,YEXT INC,CHO MICHAEL;;LUDERS MICAELA;;DOLCEE ISAIAH,YEXT INC (2021-10-15),https://lens.org/093-506-876-567-936,Design Right,no,20,0,3,3,0,,,1404;;D14/485,3,0,,,"A Better Way to Search, by Yext YouTube, YouTube [online], published on Apr. 20, 2021, [retrieved on Nov. 17, 2022], retrieved from the Internet: <URL: https://www.youtube.com/watch?v=jR1F0w_Db4Y> (Year: 2021).;;A One-Line Solution to Highlighting Search Matches, bitsofco.de [online], published on Dec. 18, 2018, [retrieved on Nov. 17, 2022], retrieved from the Internet <URL: https://bitsofco.de/a-one-line-solution-to-highlighting-search-matches/> (Year: 2018).;;The Eight Best PDF Editor Apps, by Guay, zapier.com [online], published on Aug. 28, 2018, [retrieved on Nov. 17, 2022], retrieved from the Internet <URL: https://zapier.com/blog/best-pdf-editor-apps/> (Year: 2018).",ACTIVE
89,FI,A,FI 894637 A,124-902-954-182-503,1990-03-30,1990,FI 894637 A,1989-09-29,GB 8822857 A,1988-09-29,Menetelmä mikroemulsion käsittävän farmaseuttisen formulaation valmistamiseksi,,PATRALAN LTD,YOUNG W CHO;;FLYNN MICHAEL J,,https://lens.org/124-902-954-182-503,Patent Application,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
90,NO,B1,NO 300199 B1,154-211-264-814-927,1997-04-28,1997,NO 893896 A,1989-09-29,GB 8822857 A,1988-09-29,Fremgangsmåte for fremstilling av et farmasöytisk preparat,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/154-211-264-814-927,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
91,ES,T3,ES 2060785 T3,040-642-398-705-727,1994-12-01,1994,ES 89309989 T,1989-09-29,GB 8822857 A,1988-09-29,FORMULACIONES FARMACEUTICAS.,"FORMULAS ADMINISTRABLES ORAL O RECTALMENTE DE MATERIAL ACTIVO BIOLOGICAMENTE COMPRENDEN UNA MICROEMULSION DE ACEITE EN AGUA, EN DONDE LA FASE HIDROFILICA DE LA MICROEMULSION COMPRENDE EL MATERIAL ACTIVO BIOLOGICAMENTE Y LA FASE HIDROFOBICA COMPRENDE QUILOMICRA O MATERIAL CAPAZ DE FORMAR QUILOMICRA EN LA MUCOSA INTESTINAL DESPUES DE LA ADMINISTRACION. EL MATERIAL ACTIVO BIOLOGICAMENTE DEBE SER ALGUNO DE UN AMPLIO RANGO DE SUSTANCIAS QUE INCLUYEN INSULINA, CALCITONIN Y SOMATOTROFIN O HORMONA DEL CRECIMIENTO. LAS FORMULAS DEL INVENTO SON PARTICULARMENTE CONVENIENTES PARA LA ADMINISTRACION ORAL DE INSULINA EN EL TRATAMIENTO DE DIABETES.",PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/040-642-398-705-727,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
92,WO,A1,WO 2008/079191 A1,061-240-256-289-414,2008-07-03,2008,US 2007/0024462 W,2007-11-28,US 64389706 A,2006-12-22,COOLED NOZZLE ASSEMBLY FOR UREA/WATER INJECTION,"A fluid-injecting system (82) includes a nozzle assembly (2) which includes a housing (4) defining an outlet cooling passage (26), an outlet control passage (28), at least one inlet supply passageway (53), and an injection orifice (12). The nozzle assembly also includes a shaft (10) disposed within the housing and movable between a closed position and an open position. The fluid- injecting system further includes a first valve (51) in fluid communication with the nozzle assembly configured to regulate the supply of a fluid through the at least one inlet passageway and a second valve (40) in fluid communication with the nozzle assembly to regulate a flow of fluid through the outlet passageway.",CATERPILLAR INC;;HARMON MICHAEL P;;LIANG CHO Y,HARMON MICHAEL P;;LIANG CHO Y,,https://lens.org/061-240-256-289-414,Patent Application,yes,5,2,2,2,0,F01N3/2066;;F01N3/2066;;F01N2610/02;;F01N2610/02;;F01N2610/10;;F01N2610/10;;F01N2610/11;;F01N2610/11;;F01N2610/14;;F01N2610/14;;F01N2610/1453;;F01N2610/1453;;F01N2610/1473;;F01N2610/1473;;F02B37/00;;F02B37/00;;F02M53/04;;F02M53/04;;Y02T10/12;;Y02T10/12,F02M53/04;;F01N3/20,,0,0,,,,PENDING
93,GB,A,GB 2614144 A,057-167-242-104-615,2023-06-28,2023,GB 202301612 A,2020-10-22,US 202017066262 A;;US 2020/0056745 W,2020-10-08,Gravel pack flow control using swellable metallic material,"A gravel pack flow path used to flow slurry fluids during a gravel pack phase may be closed or at least limited with a swellable metallic material prior to a production phase. An example apparatus may include a base pipe, a screen disposed about the base pipe, an inflow control device having an ICD flow path in fluid communication with an outer annulus between the screen and base pipe. The gravel pack flow path defined in part by perforations in a base pipe or by a secondary housing. A swellable metallic material is activated to close the gravel pack flow path in response to a reactive fluid.",HALLIBURTON ENERGY SERVICES INC,BRIAN WILLIAMS CHO;;STEPHEN MICHAEL GRECI,,https://lens.org/057-167-242-104-615,Patent Application,no,5,0,7,7,0,E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/108;;E21B43/088;;E21B43/04;;E21B43/12;;E21B33/127;;E21B34/10;;E21B43/04;;E21B43/12;;E21B43/088,E21B43/12;;E21B33/12;;E21B33/127;;E21B34/10;;E21B43/08,,0,0,,,,PENDING
94,CN,A,CN 1891986 A,065-074-845-044-09X,2007-01-10,2007,CN 200610095666 A,2006-06-29,US 17031805 A,2005-06-30,Regeneration assembly,,CATERPILLAR INC,LOU HARMON MICHAEL P LIANG CHO,,https://lens.org/065-074-845-044-09X,Patent Application,no,0,2,4,4,0,F01N3/0256;;F01N3/0256,F01N3/023,,0,0,,,,DISCONTINUED
95,FI,C,FI 98196 C,125-178-358-479-978,1997-05-12,1997,FI 894637 A,1989-09-29,GB 8822857 A,1988-09-29,Menetelmä mikroemulsion käsittävän farmaseuttisen formulaation valmistamiseksi,,PATRALAN LTD,YOUNG W CHO;;FLYNN MICHAEL J,,https://lens.org/125-178-358-479-978,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
96,KR,Y1,KR 900004432 Y1,138-640-744-811-413,1990-05-21,1990,KR 880000205 U,1988-01-13,KR 880000205 U,1988-01-13,MACHINE FOR CARBONATING BEVERAGE,,CHO KWAN JE;;LEE MICHAEL MUN,CHO KWAN-JE;;LEE MICHAEL MUN,,https://lens.org/138-640-744-811-413,Unknown,no,0,3,2,2,0,A23L2/54;;B01F23/2362;;B01F2101/14,,,0,0,,,,EXPIRED
97,US,B2,US 10152354 B2,173-395-116-197-419,2018-12-11,2018,US 201715445907 A,2017-02-28,US 201715445907 A,2017-02-28,Optimized thread scheduling on processor hardware with performance-relevant shared hardware components,"To schedule a software thread for execution on a CPU in a multiprocessor system, a scheduler uses both software and hardware utilization information. For a thread, resource demands (including software and hardware resource demands) are determined based on measuring resource usage while the thread executes on the multiprocessor system without being isolated from any other threads that may run concurrently. For at least two processor cores, resource usage is calculated based on any threads already running on it. The software thread is assigned to a strand in the processor core with optimum available resources given the thread's resource demands.",ORACLE INT CORP,CHEW JONATHAN;;MICHAEL NICOLAS;;CHO JUNSANG,ORACLE INTERNATIONAL CORPORATION (2017-02-28),https://lens.org/173-395-116-197-419,Granted Patent,yes,2,1,2,2,0,G06F9/5044;;G06F9/5044;;G06F9/505;;G06F9/505;;G06F2209/483;;G06F2209/483;;G06F2209/501;;G06F2209/501;;Y02D10/00,G06F9/50;;G06F9/48,,0,0,,,,ACTIVE
98,EP,A1,EP 3668382 A1,191-954-022-270-663,2020-06-24,2020,EP 18840715 A,2018-01-05,US 201715666546 A;;US 2018/0012575 W,2017-08-01,METHOD FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/191-954-022-270-663,Patent Application,yes,0,0,19,19,0,A61B5/0093;;A61B5/4872;;A61B5/0035;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/5223;;G16H50/30;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/0093;;H05K999/99,A61B5/00;;A61B8/00;;A61B8/08,,0,0,,,,ACTIVE
99,US,A1,US 2017/0231069 A1,093-289-036-024-682,2017-08-10,2017,US 201715497937 A,2017-04-26,US 201715497937 A;;US 201514671774 A,2015-03-27,Inline Wireless Module,A lighting device includes a housing and a power connector attached to the housing. The lighting device also includes a wireless lighting control device positioned inside the housing. The wireless lighting control device includes a wireless transceiver to wirelessly receive lighting control instructions and a control interface circuitry compatible with a lighting fixture driver. The wireless lighting control device further includes a controller communicably coupled to the wireless transceiver and to the control interface circuitry. The controller is configured to control the control interface circuitry based on the lighting control instructions received by the wireless transceiver.,COOPER TECHNOLOGIES CO,WINSLETT MICHAEL TROY;;CHO NAM CHIN,EATON INTELLIGENT POWER LIMITED (2017-12-31);;SIGNIFY HOLDING B.V (2020-03-02);;COOPER TECHNOLOGIES COMPANY (2017-04-27),https://lens.org/093-289-036-024-682,Patent Application,yes,37,9,2,9,0,F21V23/001;;F21V23/06;;H05B45/31;;H05B47/18;;H05B45/31;;H05B45/357;;H05B45/357;;H05B47/18;;H05B47/185;;H05B47/19;;H05B47/19,H05B37/02,,0,0,,,,ACTIVE
100,DK,D0,DK 481989 D0,118-925-978-496-86X,1989-09-29,1989,DK 481989 A,1989-09-29,GB 8822857 A,1988-09-29,FARMACEUTISKE FORMULERINGER,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/118-925-978-496-86X,Patent Application,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,DISCONTINUED
101,EP,A1,EP 3661416 A1,155-113-035-899-40X,2020-06-10,2020,EP 18842400 A,2018-01-05,US 201715666535 A;;US 2018/0012567 W,2017-08-01,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/155-113-035-899-40X,Patent Application,yes,0,0,7,7,0,A61B5/0095;;A61B5/4244;;A61B5/4872;;A61B5/7246;;A61B5/7485;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B5/7246;;A61B5/4244;;A61B8/5223;;A61B8/5261,A61B5/00;;A61B8/00;;A61B8/08,,0,0,,,,ACTIVE
102,EP,A4,EP 3668382 A4,009-626-720-352-584,2021-04-14,2021,EP 18840715 A,2018-01-05,US 201715666546 A;;US 2018/0012575 W,2017-08-01,METHOD FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/009-626-720-352-584,Search Report,no,2,0,19,19,0,A61B5/0093;;A61B5/4872;;A61B5/0035;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/5223;;G16H50/30;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/0093;;H05K999/99,A61B5/00;;A61B8/00;;A61B8/08;;G16H50/30,,0,0,,,,ACTIVE
103,CA,C,CA 1339814 C,049-499-724-631-670,1998-04-14,1998,CA 614764 A,1989-09-29,GB 8822857 A,1988-09-29,PHARMACEUTICAL FORMULATIONS,"Orally or rectally administrable formulations of biologically active material comprise a water-in-oil microemulsion, wherein the hydrophilic phase of the microemulsion comprises the biologically active material and the hydrophobic phase comprises chylomicra or material capable of forming chylomicra in the intestinal mucosa after administration. The biologically active material may be any of a wide range of substances including insulin, calcitonin and somatotrophin or growth hormone. Formulations of the invention are particularly suitable for the oral administration of insulin in the treatment of diabetes.",PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/049-499-724-631-670,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,D21670155    M;;D20320028    S,0,0,,,,EXPIRED
104,US,B2,US 11326420 B2,154-580-333-498-176,2022-05-10,2022,US 202017066262 A,2020-10-08,US 202017066262 A,2020-10-08,Gravel pack flow control using swellable metallic material,"A gravel pack flow path used to flow slurry fluids during a gravel pack phase may be closed or at least limited with a swellable metallic material prior to a production phase. An example apparatus may include a base pipe, a screen disposed about the base pipe, an inflow control device having an ICD flow path in fluid communication with an outer annulus between the screen and base pipe. The gravel pack flow path defined in part by perforations in a base pipe or by a secondary housing. A swellable metallic material is activated to close the gravel pack flow path in response to a reactive fluid.",HALLIBURTON ENERGY SERVICES INC,CHO BRIAN WILLIAMS;;GRECI STEPHEN MICHAEL,HALLIBURTON ENERGY SERVICES INC (2020-09-09),https://lens.org/154-580-333-498-176,Granted Patent,yes,54,2,7,7,0,E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/108;;E21B43/088;;E21B43/04;;E21B43/12;;E21B33/127;;E21B34/10;;E21B43/04;;E21B43/12;;E21B43/088,E21B43/04;;E21B43/08;;E21B43/12,,1,0,,,"International Search Report and Written Opinion for Application No. PCT/UW2020/056745, dated Jul. 1, 2021.",ACTIVE
105,EP,A3,EP 0366277 A3,170-930-979-942-667,1990-11-28,1990,EP 89309989 A,1989-09-29,GB 8822857 A,1988-09-29,PHARMACEUTICAL FORMULATIONS,"Orally or rectally administrable formulations of biologically active material comprise a water-in-oil microemulsion, wherein the hydrophilic phase of the microemulsion comprises the biologically active material and the hydrophobic phase comprises chylomicra or material capable of forming chylomicra in the intestinal mucosa after administration. The biologically active material may be any of a wide range of substances including insulin, calcitonin and somatotrophin or growth hormone. Formulations of the invention are particularly suitable for the oral administration of insulin in the treatment of diabetes.  ",PATRALAN LIMITED,"CHO,YOUNG W.;;FLYNN,MICHAEL JOHN",,https://lens.org/170-930-979-942-667,Search Report,yes,9,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,3,0,,,"PATENT ABSTRACTS OF JAPAN. vol.10, no. 239, (C-367) (2295), 19 August 1986, & JP-A 61 072 721 (DAIGO EIYOU KAGAKU K.K.) 14 April 1986;;PATENT ABSTRACTS OF JAPAN. vol. 6, no. 154, (C-119) (1032), 14 August 1982 & JP-A 57 072 920 (TOYAMA KAGAKU KOGYO K.K.) 7 May 1982;;PATENT ABSTRACTS OF JAPAN. vol. 7, no. 97, (C-163) (1242), 23 April 1983 & JP-A 58 021 622 (KOUWA K.K.) 8 February 1983",EXPIRED
106,US,B2,US 10561007 B2,183-984-619-731-896,2020-02-11,2020,US 201715497937 A,2017-04-26,US 201715497937 A;;US 201514671774 A,2015-03-27,Inline wireless module,A lighting device includes a housing and a power connector attached to the housing. The lighting device also includes a wireless lighting control device positioned inside the housing. The wireless lighting control device includes a wireless transceiver to wirelessly receive lighting control instructions and a control interface circuitry compatible with a lighting fixture driver. The wireless lighting control device further includes a controller communicably coupled to the wireless transceiver and to the control interface circuitry. The controller is configured to control the control interface circuitry based on the lighting control instructions received by the wireless transceiver.,EATON INTELLIGENT POWER LTD,WINSLETT MICHAEL TROY;;CHO NAM CHIN,EATON INTELLIGENT POWER LIMITED (2017-12-31);;SIGNIFY HOLDING B.V (2020-03-02);;COOPER TECHNOLOGIES COMPANY (2017-04-27),https://lens.org/183-984-619-731-896,Granted Patent,yes,77,1,2,9,0,F21V23/001;;F21V23/06;;H05B45/31;;H05B47/18;;H05B45/31;;H05B45/357;;H05B45/357;;H05B47/18;;H05B47/185;;H05B47/19;;H05B47/19,F21V23/00;;F21V23/06;;H05B45/00;;H05B47/18;;H05B47/185;;H05B47/19,,2,0,,,"International Search Report for application No. PCT/US2016/024006 dated Jun. 30, 2016.;;Casambi CBU-TED, Fact sheet, Mar. 7, 2015.",ACTIVE
107,JP,A,JP 2013118372 A,192-560-562-817-062,2013-06-13,2013,JP 2012255219 A,2012-11-21,US 201113309294 A,2011-12-01,TERNARY THERMOELECTRIC MATERIAL CONTAINING NANOPARTICLES AND METHOD FOR MANUFACTURING THE SAME,"PROBLEM TO BE SOLVED: To provide a ternary main group semiconductor material having improved properties, and a method for manufacturing the same.SOLUTION: This invention includes a thermoelectric material that comprises a ternary matrix material and nanoparticle inclusions. Examples of the nanoparticles include particles of materials having the formulas MO and/or M, where M represents a group 2 or 12 element in a 2+ oxidation state. The matrix material is a ternary main group or chalcogenide semiconductor material, preferably includes elements Bi, Se and Te, preferably has the formula BixSeyTez, where x represents from 1 to 3, y represents from 0 to 3.2, z represents from 0 to 3.3, and x, y and z represent the molar ratio based on the total moles of Bi, Se and Te, and more preferably has the formula (BiSe)Te.",TOYOTA ENG & MFG NORTH AMERICA,MICHAEL PAUL LAW;;CHO LI KIM,,https://lens.org/192-560-562-817-062,Patent Application,no,5,2,4,4,0,C01B19/007;;C01P2002/72;;C01P2006/40;;C04B35/547;;C04B35/645;;C04B2235/3284;;C04B2235/3298;;C04B2235/449;;B82Y30/00;;H10N10/852;;H10N10/17;;C01B19/007;;C04B2235/3284;;C04B35/547;;C01P2002/72;;C04B2235/449;;C04B2235/3298;;C04B35/645;;C01P2006/40;;B82Y30/00;;H10N10/17;;H10N10/852,H01L35/16;;H01L35/34,,0,0,,,,ACTIVE
108,JP,A,JP 2005344720 A,195-364-951-539-343,2005-12-15,2005,JP 2005163381 A,2005-06-03,US 85909604 A,2004-06-03,MODULAR FUEL INJECTOR HAVING DAMPER MEMBER AND NOISE REDUCING METHOD,"<P>PROBLEM TO BE SOLVED: To provide a fuel injector having a body, a filter and a noise damping member. <P>SOLUTION: The body has a wall portion extending between an inlet end and an outlet end along a longitudinal axis for defining a flow path extending between both ends. The filter is located near the inlet end in the flow path. The noise damping member is fixed between the inlet end and the filter in the flow path. The damper member has outside and inside surfaces encircling the longitudinal axis, and the outside surface contacts the wall portion of the flow path to define at least one peripheral face zone around the longitudinal axis in the flow path and the inside surface passes through the damper member to define an opening allowing the communication of fluid between the inlet end and the filter. <P>COPYRIGHT: (C)2006,JPO&NCIPI",SIEMENS VDO AUTOMOTIVE CORP,CHO YONG D;;DALLMEYER MICHAEL P,,https://lens.org/195-364-951-539-343,Patent Application,no,7,1,7,7,0,F02M51/0682;;F02M55/00;;F02M61/16;;F02M61/165;;F02M2200/09;;F02M2200/27;;F02M2200/306;;F02M2200/505;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M2200/26;;F02M2200/315;;F02M61/16;;F02M2200/505;;F02M61/165;;F02M2200/27;;F02M55/00;;F02M2200/8015;;F02M2200/8053;;F02M2200/8084;;F02M51/0682;;F02M2200/306;;F02M2200/09;;F02M2200/26;;F02M2200/315,F02M51/06;;F02M55/00;;F02M55/02;;F02M55/04;;F02M61/16;;F02M63/00,,0,0,,,,PENDING
109,US,A1,US 2007/0158466 A1,013-046-356-741-199,2007-07-12,2007,US 31937805 A,2005-12-29,US 31937805 A,2005-12-29,Nozzle assembly,"A nozzle assembly includes a housing defining a first fluid passage in fluid communication with a second fluid passage, and a sleeve disposed within the housing and fluidly connected to the first and second fluid passages. The housing defines a radial fluid passage proximate a front end of the sleeve. The nozzle assembly also includes at least one orifice in selective communication with a regeneration device.",HARMON MICHAEL P;;LIANG CHO Y,HARMON MICHAEL P;;LIANG CHO Y,CATERPILLAR INC (2006-03-13),https://lens.org/013-046-356-741-199,Patent Application,yes,57,4,5,5,0,F01N3/0253;;F01N3/36;;F01N2260/024;;F01N2610/03;;F01N2610/11;;F01N3/0253;;F01N2260/024;;F01N2610/11;;F01N3/36;;F01N2610/03,B05B7/12;;B05B7/04;;F23D11/10,239/398;;239/416;;239/418,0,0,,,,DISCONTINUED
110,US,B1,US 9980677 B1,034-248-843-076-533,2018-05-29,2018,US 201815862004 A,2018-01-04,US 201815862004 A;;US 201715666546 A,2017-08-01,System for estimating fractional fat content of an object,"A system for estimating fractional fat content of an object of interest. An energy emitter is used to direct an energy signal toward the region of interest, wherein the region of interest has an object of interest, a reference with known properties, and a boundary area with one or more boundary locations between the object of interest and the reference. Next, a plurality of thermoacoustic or ultrasonic transducers is used to receive a plurality of thermoacoustic bipolar signals from the one or more boundary locations, wherein the thermoacoustic bipolar signals are induced by the energy signal. A machine configured to accept data from the energy emitter and the plurality of thermoacoustic or ultrasonic transducers and calculate a fat concentration that is a function of a difference between two peaks of the thermoacoustic bipolar signal at each respective boundary location and a distance or distances between each respective boundary location.",ENRDA LIFE SCIENCES INC;;ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2018-01-16),https://lens.org/034-248-843-076-533,Granted Patent,yes,7,10,19,19,0,A61B5/0093;;A61B5/4872;;A61B5/0035;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/5223;;G16H50/30;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/0093;;H05K999/99,A61B5/00;;A61B8/00;;A61B8/08,,17,14,040-124-808-441-526;;034-904-177-076-664;;020-149-885-110-291;;014-847-203-540-026;;074-947-514-695-425;;033-786-059-395-583;;063-939-405-551-829;;130-368-988-819-461;;015-173-468-866-169;;003-447-272-638-21X;;012-545-815-382-384;;142-401-383-484-74X;;010-411-063-187-44X;;068-526-467-082-518,pmc3002753;;10.1016/j.mric.2010.08.013;;21094444;;17102041;;10.1148/rg.266065004;;10.1007/s10620-005-1267-z;;15712657;;10.1038/oby.2011.302;;pmc3270296;;22016092;;10.1063/1.4737414;;10.1109/tbme.2012.2210218;;22851231;;22734739;;10.1117/1.jbo.17.6.061209;;10.1117/12.2041047;;10.1364/ol.40.002253;;pmc4581454;;26393712;;10841427;;10.1118/1.598984;;28066714;;10.1016/j.pacs.2016.10.001;;pmc5200938;;8938024;;10.1088/0031-9155/41/11/001;;10.1088/0031-9155/41/11/002;;8938025;;10.1016/j.meatsci.2007.11.007;;22063039,"S. B. Reeder and C. Sirlin, “Quantification of liver fat with magnetic resonance imaging,” Magn Reson Imaging Clin N Am vol. 18, No. 3, pp. 337-357, Aug. 2010,.;;M. P. Andre et al., “Accurate diagnosis of nonalcoholic fatty liver disease in human participants via quantitative ultrasound”, 2014 IEEE International Ultrasonics Symposium, 204, pp. 2375-2377, 2014.;;O. W. Hamer et al., “Fatty liver: Imaging patterns and pitfalls”, Radiographics, vol. 26, No. 6, pp. 1637-1653, 2006.;;D. A. Sass, P. Cang, and K. B. Chopra, “Nonalcoholic fatty liver disease: a clinical review,” Dig. Dis. Sci., vol. 50, No. 1, pp. 171-180, Jan. 2005.;;M. F. Xia et al., “Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method”, Obesity, vol. 20, No. 2, pp. 444-452, 2012.;;D. R. Bauer et al., “Spectroscopic thermoacoustic imaging of water and fat composition,” Appl. Phys. Lett., vol. 101, 2012.;;K. Wang et al., “Microwave-induced thermoacoustic imaging model for potential breast cancer detection,” IEEE Trans. Biomed. Eng., vol. 59, No. 10, pp. 2782-2791, Oct. 2012.;;T. J. Allen et al., “Spectroscopic photoacoustic imaging of lipid-rich plaques in the human aorta in the 740 to 1400 nm wavelength range”, J. Biomed. Opt., vol. 17, No. 6, Jun. 2012.;;L. Pan et al., “Differentiating fatty and non-fatty tissue using photoacoustic imaging,” Proc. of SPIE vol. 8943, 2014.;;G. Xu et al., “Functional Pitch of a Liver: Fatty Liver Disease Diagnosis with Photoacoustic Spectrum Analysis,” Proc. of SPIE vol. 8943, 2014.;;C. Tian et al., “Imaging and sensing based on dual-pulse nonlinear photoacoustic contrast: a preliminary study on fatty liver,” Optics Letters, vol. 40, No. 10, pp. 2253-2256, May 2015.;;G. Ku and L. V. Wang, “Scanning thermoacoustic tomography in biological tissue,” Med. Phys., vol. 27, No. 5, pp. 1195-1202, May 2000.;;G. J. Diebold and T. Sun, “Properties of photoacoustic waves in one, two, and three dimensions,” Acta. Acust. united. Ac., vol. 80, No. 4, pp. 339-351, Jul. 1994.;;X. L. Dean-Ben, “On the link between the speckle free nature of optoacoustics and visibility of structures in limited-view tomography,” Photoacoustics, vol. 4, No. 4, pp. 133-140, Jul. 2016.;;C. Gabriel et al., “The dielectric properties of biological tissues: I. Literature survey,” Med. Phys., vol. 41, No. 11, pp. 2231-2249, Nov. 1996.;;S. Gabriel et al., “The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz,” Med. Phys., vol. 41, No. 11, pp. 2251-2269, Nov. 1996.;;S. K. Ng et al., “Determination of added fat in meat paste using microwave and millimetre wave techniques,” Meat Science, vol. 79, No. 4, pp. 748-756, Aug. 2008.",ACTIVE
111,NO,L,NO 893896 L,087-456-052-875-450,1990-03-30,1990,NO 893896 A,1989-09-29,GB 8822857 A,1988-09-29,FARMASOEYTISKE FORMULERINGER OG FREMGANGSMAATE FOR FREMSTILLING AV DISSE.,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/087-456-052-875-450,Abstract,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
112,WO,A1,WO 2007/126529 A1,092-720-563-393-526,2007-11-08,2007,US 2007/0005371 W,2007-02-28,US 39394406 A,2006-03-31,NOZZLE ASSEMBLY,"A nozzle assembly (2) includes a housing (4) defining a first fluid passage (18) and a second fluid passage (16), and a sleeve (8) disposed within the housing (4) and fluidly connected to the first and second fluid passages (18, 16). The nozzle assembly (2) also includes a shaft (10) disposed within the sleeve (8) and movable between a closed position and an open position. The nozzle assembly (2) further includes at least one orifice (12) in selective communication with a regeneration device (82).",CATERPILLAR INC;;HARMON MICHAEL P;;LIANG CHO Y,HARMON MICHAEL P;;LIANG CHO Y,,https://lens.org/092-720-563-393-526,Patent Application,yes,4,0,5,5,0,F01N3/2066;;F01N3/2066;;F01N2610/02;;F01N2610/02;;F01N2610/10;;F01N2610/10;;F01N2610/11;;F01N2610/11;;F01N2610/14;;F01N2610/14;;F01N2610/1453;;F01N2610/1453;;F02B37/00;;F02B37/00;;F02M53/04;;F02M53/04;;Y02T10/12;;Y02T10/12,F02M53/04;;F02M61/16,,0,0,,,,PENDING
113,PL,B1,PL 163635 B1,118-204-274-546-443,1994-04-29,1994,PL 28163589 A,1989-09-29,GB 8822857 A,1988-09-29,METHOD FOR PREPARATION OF PHARMACEUTICALS,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/118-204-274-546-443,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
114,DE,D1,DE 68911473 D1,100-992-564-654-887,1994-01-27,1994,DE 68911473 T,1989-09-29,GB 8822857 A,1988-09-29,Arzneimittelformulierungen.,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/100-992-564-654-887,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
115,EP,B1,EP 3730041 B1,123-306-137-045-704,2022-08-24,2022,EP 19218673 A,2018-01-05,US 201715666546 A;;EP 18840715 A;;US 2018/0012575 W,2017-08-01,SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/123-306-137-045-704,Granted Patent,yes,2,0,19,19,0,A61B5/0093;;A61B5/4872;;A61B5/0035;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/5223;;G16H50/30;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/0093;;H05K999/99,A61B5/00;;A61B8/08,,0,0,,,,ACTIVE
116,US,A1,US 2007/0228191 A1,080-300-673-793-41X,2007-10-04,2007,US 64389706 A,2006-12-22,US 64389706 A;;US 39394406 A,2006-03-31,Cooled nozzle assembly for urea/water injection,"A fluid-injecting system includes a nozzle assembly which includes a housing defining an outlet cooling passage, an outlet control passage, at least one inlet supply passageway, and an injection orifice. The nozzle assembly also includes a shaft disposed within the housing and movable between a closed position and an open position. The fluid-injecting system further includes a first valve in fluid communication with the nozzle assembly configured to regulate the supply of a fluid through the at least one inlet passageway and a second valve in fluid communication with the nozzle assembly to regulate a flow of fluid through the outlet passageway.",CATERPILLAR INC,HARMON MICHAEL P;;LIANG CHO Y,CATERPILLAR INC (2006-11-30),https://lens.org/080-300-673-793-41X,Patent Application,yes,59,23,2,2,0,F01N3/2066;;F01N3/2066;;F01N2610/02;;F01N2610/02;;F01N2610/10;;F01N2610/10;;F01N2610/11;;F01N2610/11;;F01N2610/14;;F01N2610/14;;F01N2610/1453;;F01N2610/1453;;F01N2610/1473;;F01N2610/1473;;F02B37/00;;F02B37/00;;F02M53/04;;F02M53/04;;Y02T10/12;;Y02T10/12,F02M47/02;;F02M51/00;;F02M63/00,239/533.2;;239/89;;239/585.5,0,0,,,,DISCONTINUED
117,US,A1,US 2003/0142788 A1,123-315-551-509-214,2003-07-31,2003,US 30093502 A,2002-11-21,US 30093502 A;;US 33176101 P,2001-11-21,Portable medical digital radiography assembly,"
   A portable medical digital radiography apparatus includes a ruggedized transport case housing several system components, a digital X-ray image sensor and an X-ray generator. The digital X-ray image sensor is hingedly coupled to a stand that is mounted to the ruggedized transport case. The X-ray generator is preferably positioned opposite to the center of digital X-ray image sensor. A patient support unit is disposed between digital X-ray image sensor and the X-ray generator. An image acquisition unit is connected to the X-ray generator and to the digital X-ray image sensor and fixedly mounted in the ruggedized transport case. An image display unit is connected to the image acquisition unit and spaced from the X-ray generator. 
",CHO KENNETH;;FRECKLETON MICHAEL;;MARTIN PETER,CHO KENNETH;;FRECKLETON MICHAEL;;MARTIN PETER,UNITED STATES ARMY (2004-03-22);;TREX ENTERPRISES CORP (2004-01-20),https://lens.org/123-315-551-509-214,Patent Application,yes,9,19,6,6,0,A61B6/4405;;A61B6/4405;;G01N23/04;;G01N23/04,A61B/;;A61B6/00;;G01N23/00;;G01N23/04;;G01N23/06;;G01N23/223;;H05G1/00;;H05G1/10;;H05G1/12;;H05G1/24,378/102,0,0,,,,EXPIRED
118,US,A1,US 2007/0235556 A1,150-762-553-113-399,2007-10-11,2007,US 39394406 A,2006-03-31,US 39394406 A,2006-03-31,Nozzle assembly,"A nozzle assembly includes a housing defining a first fluid passage and a second fluid passage, and a sleeve disposed within the housing and fluidly connected to the first and second fluid passages. The nozzle assembly also includes a shaft disposed within the sleeve and movable between a closed position and an open position. The nozzle assembly further includes at least one orifice in selective communication with a regeneration device.",HARMON MICHAEL P;;LIANG CHO Y,HARMON MICHAEL P;;LIANG CHO Y,CATERPILLAR INC (2006-03-29),https://lens.org/150-762-553-113-399,Patent Application,yes,53,7,5,5,0,F01N3/2066;;F01N3/2066;;F01N2610/02;;F01N2610/02;;F01N2610/10;;F01N2610/10;;F01N2610/11;;F01N2610/11;;F01N2610/14;;F01N2610/14;;F01N2610/1453;;F01N2610/1453;;F02B37/00;;F02B37/00;;F02M53/04;;F02M53/04;;Y02T10/12;;Y02T10/12,B05B1/24,239/132,0,0,,,,DISCONTINUED
119,US,A1,US 2022/0112790 A1,002-810-418-845-885,2022-04-14,2022,US 202017066262 A,2020-10-08,US 202017066262 A,2020-10-08,Gravel Pack Flow Control Using Swellable Metallic Material,"A gravel pack flow path used to flow slurry fluids during a gravel pack phase may be closed or at least limited with a swellable metallic material prior to a production phase. An example apparatus may include a base pipe, a screen disposed about the base pipe, an inflow control device having an ICD flow path in fluid communication with an outer annulus between the screen and base pipe. The gravel pack flow path defined in part by perforations in a base pipe or by a secondary housing. A swellable metallic material is activated to close the gravel pack flow path in response to a reactive fluid.",HALLIBURTON ENERGY SERVICES INC,CHO BRIAN WILLIAMS;;GRECI STEPHEN MICHAEL,HALLIBURTON ENERGY SERVICES INC (2020-09-09),https://lens.org/002-810-418-845-885,Patent Application,yes,0,2,7,7,0,E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/108;;E21B43/088;;E21B43/04;;E21B43/12;;E21B33/127;;E21B34/10;;E21B43/04;;E21B43/12;;E21B43/088,E21B43/04;;E21B43/08;;E21B43/12,,0,0,,,,ACTIVE
120,KR,B1,KR 0139641 B1,029-992-417-101-577,1998-06-01,1998,KR 890014062 A,1989-09-29,GB 8822857 A,1988-09-29,PHARMACEUTICAL FORMULATIONS OF MICROEMULSION AND MANUFACTURING METHOD THEREOF,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/029-992-417-101-577,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
121,US,A,US 5656289 A,033-506-317-091-98X,1997-08-12,1997,US 20723694 A,1994-02-16,US 20723694 A;;GB 8822857 A;;US 6150593 A;;US 90859292 A;;US 41420889 A,1988-09-29,Pharmaceutical formulations that have a biologically active hydrophilic phase and a chylomicra-containing hydrophobic phase,"Orally or rectally administrable formulations of biologically active material comprise a water-in-oil microemulsion, wherein the hydrophilic phase of the microemulsion comprises the biologically active material and the hydrophobic phase comprises chylomicra or material capable of forming chylomicra in the intestinal mucosa after administration. The biologically active material may be any of a wide range of substances including insulin, calcitonin and somatotrophin or growth hormone. Formulations of the invention are particularly suitable for the oral administration of insulin in the treatment of diabetes.",PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/033-506-317-091-98X,Granted Patent,yes,17,104,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,424/455;;424/451;;424/456;;424/463;;424/450;;514/2;;514/3;;514/21;;514/866;;514/937;;514/938;;514/941;;514/943,0,0,,,,EXPIRED
122,DK,A,DK 481989 A,124-188-327-489-586,1990-03-30,1990,DK 481989 A,1989-09-29,GB 8822857 A,1988-09-29,FARMACEUTISKE FORMULERINGER,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/124-188-327-489-586,Patent Application,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,DISCONTINUED
123,FI,A0,FI 894637 A0,138-138-449-864-324,1989-09-29,1989,FI 894637 A,1989-09-29,GB 8822857 A,1988-09-29,Menetelmä mikroemulsion käsittävän farmaseuttisen formulaation valmistamiseksi,,PATRALAN LTD,YOUNG W CHO;;FLYNN MICHAEL J,,https://lens.org/138-138-449-864-324,Patent Application,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
124,HK,A,HK 85596 A,180-794-608-979-654,1996-05-24,1996,HK 85596 A,1996-05-16,GB 8822857 A,1988-09-29,Pharmaceutical formulations,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/180-794-608-979-654,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
125,BG,B1,BG 60849 B1,001-977-170-256-275,1996-05-31,1996,BG 8987789 A,1989-09-29,GB 8901161 W;;GB 8822857 A,1988-09-29,PHARMACEUTICAL FORM AND METHOD FOR ITS PREPARATION,,CHO;;FLYNN,CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/001-977-170-256-275,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
126,US,B2,US 6565489 B2,012-339-805-477-606,2003-05-20,2003,US 95637801 A,2001-09-18,US 95637801 A;;US 80985101 A;;US 39651099 A,1999-09-15,Angled-adjustable rowing exerciser,"
    An angle-adjustable rowing exerciser, which includes a wheeled base frame, a fixed mattress and a pivoted mattress supported on the base frame, a transverse frame bar pivotally mounted on the base frame at the bottom, two handlebars respectively adjustably connected to two adjustable ratchet connectors at the ends of the transverse frame bar for turning by hand to rotate the transverse frame bar, and two actuating bars perpendicularly and fixedly connected to the transverse frame bar and forced to tilt the base frame or the movable mattress up and down upon turning of the handlebars. 
",HO SUNG-CHO;;CASEY MICHAEL E.,HO SUNG-CHO;;CASEY MICHAEL E,INVENTORSUNIVERSE.COM INC (2001-03-02);;MICHAEL CASEY (2003-03-04);;MICHAEL CASEY ENTERPRISES LLC (2005-10-17);;INTERNATIONAL EDGE INC (2005-10-17),https://lens.org/012-339-805-477-606,Granted Patent,yes,8,11,2,6,0,A63B21/068;;A63B22/0076;;A63B22/0089;;A63B23/0211;;A63B23/0222;;A63B2022/0084;;A63B2208/02;;A63B23/0211;;A63B22/0076;;A63B2022/0084;;A63B23/0222;;A63B21/068;;A63B2208/02;;A63B22/0089,A63B21/068;;A63B23/02;;A63B23/035;;A63B69/06,482/95;;482/70,0,0,,,,EXPIRED
127,FI,B,FI 98196 B,070-900-786-317-440,1997-01-31,1997,FI 894637 A,1989-09-29,GB 8822857 A,1988-09-29,Menetelmä mikroemulsion käsittävän farmaseuttisen formulaation valmistamiseksi,,PATRALAN LTD,YOUNG W CHO;;FLYNN MICHAEL J,,https://lens.org/070-900-786-317-440,Patent Application,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
128,CA,A1,CA 3191896 A1,119-696-298-355-449,2022-04-14,2022,CA 3191896 A,2020-10-22,US 202017066262 A;;US 2020/0056745 W,2020-10-08,GRAVEL PACK FLOW CONTROL USING SWELLABLE METALLIC MATERIAL,"A gravel pack flow path used to flow slurry fluids during a gravel pack phase may be closed or at least limited with a swellable metallic material prior to a production phase. An example apparatus may include a base pipe, a screen disposed about the base pipe, an inflow control device having an ICD flow path in fluid communication with an outer annulus between the screen and base pipe. The gravel pack flow path defined in part by perforations in a base pipe or by a secondary housing. A swellable metallic material is activated to close the gravel pack flow path in response to a reactive fluid.",HALLIBURTON ENERGY SERVICES INC,CHO BRIAN WILLIAMS;;GRECI STEPHEN MICHAEL,,https://lens.org/119-696-298-355-449,Patent Application,no,0,0,7,7,0,E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/108;;E21B43/088;;E21B43/04;;E21B43/12;;E21B33/127;;E21B34/10;;E21B43/04;;E21B43/12;;E21B43/088,E21B33/12;;E21B33/127;;E21B34/10;;E21B43/08;;E21B43/12,,0,0,,,,PENDING
129,US,B1,US 9888880 B1,169-766-791-221-828,2018-02-13,2018,US 201715666546 A,2017-08-01,US 201715666546 A,2017-08-01,Method and system for estimating fractional fat content of an object,"A method and system for estimating fractional fat content of an object of interest. An energy emitter is used to direct an energy signal toward the region of interest, wherein the region of interest has an object of interest, a reference, and a boundary area with one or more boundary locations between the object of interest and the reference. Next, a plurality of thermoacoustic or ultrasonic transducers is used to receive a plurality of thermoacoustic bipolar signals from the one or more boundary locations, wherein the thermoacoustic bipolar signals are induced by the energy signal. A machine configured to accept data from the energy emitter and the plurality of thermoacoustic or ultrasonic transducers and calculate a fat concentration that is a function of the thermoacoustic bipolar signal at each respective boundary location and the distance or distances between locations.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2017-08-02),https://lens.org/169-766-791-221-828,Granted Patent,yes,5,15,19,19,0,A61B5/0093;;A61B5/4872;;A61B5/0035;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/5223;;G16H50/30;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/0093;;H05K999/99,A61B5/00;;A61B8/00;;A61B8/08,,18,15,072-068-233-488-979;;040-124-808-441-526;;034-904-177-076-664;;020-149-885-110-291;;014-847-203-540-026;;074-947-514-695-425;;033-786-059-395-583;;063-939-405-551-829;;130-368-988-819-461;;015-173-468-866-169;;003-447-272-638-21X;;012-545-815-382-384;;142-401-383-484-74X;;010-411-063-187-44X;;068-526-467-082-518,10.1109/tbme.2008.919112;;19126453;;pmc3002753;;10.1016/j.mric.2010.08.013;;21094444;;17102041;;10.1148/rg.266065004;;10.1007/s10620-005-1267-z;;15712657;;10.1038/oby.2011.302;;pmc3270296;;22016092;;10.1063/1.4737414;;10.1109/tbme.2012.2210218;;22851231;;22734739;;10.1117/1.jbo.17.6.061209;;10.1117/12.2041047;;10.1364/ol.40.002253;;pmc4581454;;26393712;;10841427;;10.1118/1.598984;;28066714;;10.1016/j.pacs.2016.10.001;;pmc5200938;;8938024;;10.1088/0031-9155/41/11/001;;10.1088/0031-9155/41/11/002;;8938025;;10.1016/j.meatsci.2007.11.007;;22063039,"Xie et al., Adaptive and Robust Methods of Reconstruction (ARMOR) for Thermoacoustic Tomography, IEEE Transactions on Biomedical Engineering, vol. 55, No. 12, Dec. 2008.;;S. B. Reeder and C. Sirlin, “Quantification of liver fat with magnetic resonance imaging,” Magn Reson Imaging Clin N Am vol. 18, No. 3, pp. 337-357, Aug. 2010.;;M. P. Andre et al., “Accurate diagnosis of nonalcoholic fatty liver disease in human participants via quantitative ultrasound”, 2014 IEEE International Ultrasonics Symposium, 204, pp. 2375-2377, 2014.;;O. W. Hamer et al., “Fatty liver: Imaging patterns and pitfalls”, Radiographics, vol. 26, No. 6, pp. 1637-1653, 2006.;;D. A. Sass, P. Cang, and K. B. Chopra, “Nonalcoholic fatty liver disease: a clinical review,” Dig. Dis. Sci., vol. 50, No. 1, pp. 171-180, Jan. 2005.;;M. F. Xia et al., “Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method”, Obesity, vol. 20, No. 2, pp. 444-452, 2012.;;D. R. Bauer et al., “Spectroscopic thermoacoustic imaging of water and fat composition,” Appl. Phys. Lett., vol. 101, 2012.;;X. Wang et al., “Microwave-induced thermoacoustic imaging model for potential breast cancer detection,” IEEE Trans. Biomed. Eng., vol. 59, No. 10, pp. 2782-2791, Oct. 2012.;;T. J. Allen et al., “Spectroscopic photoacoustic imaging of lipid-rich plaques in the human aorta in the 740 to 1400 nm wavelength range”, J. Biomed. Opt., vol. 17, No. 6, Jun. 2012.;;L. Pan et al., “Differentiating fatty and non-fatty tissue using photoacoustic imaging,” Proc. of SPIE vol. 8943, 2014.;;G. Xu et al., “Functional Pitch of a Liver: Fatty Liver Disease Diagnosis with Photoacoustic Spectrum Analysis,” Proc. of SPIE vol. 8943, 2014.;;C. Tian et al., “Imaging and sensing based on dual-pulse nonlinear photoacoustic contrast: a preliminary study on fatty liver,” Optics Letters, vol. 40, No. 10, pp. 2253-2256, May 2015.;;G. Ku and L. V. Wang, “Scanning thermoacoustic tomography in biological tissue,” Med. Phys., vol. 27, No. 5, pp. 1195-1202, May 2000.;;G. J. Diebold and T. Sun, “Properties of photoacoustic waves in one, two, and three dimensions,” Acta. Acust. united. Ac., vol. 80, No. 4, pp. 339-351, Jul. 1994.;;X. L. Dean-Ben, “On the link between the speckle free nature of optoacoustics and visibility of structures in limited-view tomography,” Photoacoustics, vol. 4, No. 4, pp. 133-140, Jul. 2016.;;C. Gabriel et al., “The dielectric properties of biological tissues: I. Literature survey,” Med. Phys., vol. 41, No. 11, pp. 2231-2249, Nov. 1996.;;S. Gabriel et al., “The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz,” Med. Phys., vol. 41, No. 11, pp. 2251-2269, Nov. 1996.;;S. K. Ng et al., “Determination of added fat in meat paste using microwave and millimetre wave techniques,” Meat Science, vol. 79, No. 4, pp. 748-756, Aug. 2008.",ACTIVE
130,EP,A1,EP 3730041 A1,007-362-564-012-115,2020-10-28,2020,EP 19218673 A,2018-01-05,US 201715666546 A;;EP 18840715 A;;US 2018/0012575 W,2017-08-01,SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,"A system for estimating fractional fat content of an object of interest. An energy emitter is used to direct an energy signal toward the region of interest, wherein the region of interest has an object of interest, a reference with known properties, and a boundary area with one or more boundary locations between the object of interest and the reference. Next, a plurality of thermoacoustic or ultrasonic transducers is used to receive a plurality of thermoacoustic bipolar signals from the one or more boundary locations, wherein the thermoacoustic bipolar signals are induced by the energy signal. A machine configured to accept data from the energy emitter and the plurality of thermoacoustic or ultrasonic transducers and calculate a fat concentration that is a function of a difference between two peaks of the thermoacoustic bipolar signal at each respective boundary location and a distance or distances between each respective boundary location.
",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/007-362-564-012-115,Patent Application,yes,2,0,19,19,0,A61B5/0093;;A61B5/4872;;A61B5/0035;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/5223;;G16H50/30;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/0093;;H05K999/99,A61B5/00;;A61B8/08,,6,5,003-447-272-638-21X;;033-786-059-395-583;;068-526-467-082-518;;071-819-683-447-902;;085-443-184-386-573,10841427;;10.1118/1.598984;;10.1109/tbme.2012.2210218;;22851231;;10.1016/j.meatsci.2007.11.007;;22063039;;25529941;;10.1002/hep.27666;;pmc4670559;;10484010;;10.1016/s0002-9270(99)00433-5;;10.1111/j.1572-0241.1999.01377.x,"KU ET AL.: ""Scanning thermoacoustic tomography in biological tissue"", MED. PHYS., vol. 27, no. 5, May 2000 (2000-05-01), pages 1195 - 202, XP012011146, DOI: 10.1118/1.598984;;WANG ET AL.: ""Microwave-induced thermoacoustic imaging model for potential breast cancer detection"", IEEE TRANS. BIOMED. ENG., vol. 59, no. 10, October 2012 (2012-10-01), pages 2782 - 01, XP011490220, DOI: 10.1109/TBME.2012.2210218;;HASGALL ET AL., IT'IS DATABASE FOR THERMAL AND ELECTROMAGNETIC PARAMETERS OF BIOLOGICAL TISSUES, September 2015 (2015-09-01);;NG ET AL.: ""Determination of added fat in meat paste using microwave and millimeter wave techniques"", MEAT SCIENCE, vol. 79, no. 4, August 2008 (2008-08-01), pages 748 - 56, XP022734689, DOI: 10.1016/j.meatsci.2007.11.007;;SCHWIMMER: ""Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with non-alcoholic fatty liver disease"", HEPATOLAGY, vol. 61, 2015, pages 1887 - 1895;;BRUNT ET AL.: ""Non-alcoholic steatohepatitis: A proposal for grading and staging the histological lesions"", AM. J. GASTROENTEROL., vol. 94, no. 9, September 1999 (1999-09-01), pages 2467 - 2474",ACTIVE
131,US,B1,US 9888879 B1,056-626-865-593-105,2018-02-13,2018,US 201715666535 A,2017-08-01,US 201715666535 A,2017-08-01,Method and system for estimating fractional fat content of an object,"A method and system for estimating fractional fat content of an object of interest. An energy emitter is used to direct an energy signal with an energy signal electric field strength toward the region of interest, wherein the region of interest has an object of interest, a reference, and a boundary between the object of interest and the reference. Next, a thermoacoustic or ultrasonic transducer is used to receive a thermoacoustic bipolar signal from the boundary, wherein the thermoacoustic bipolar signal is induced by the energy signal. Finally, a machine is used to accept data from the energy emitter and thermoacoustic or ultrasonic transducer, correlate the thermoacoustic bipolar signal to an electric field strength of the reference at the boundary to generate a corrected thermoacoustic bipolar signal at the boundary, and calculate a fat concentration of the object of interest as a function of the corrected thermoacoustic bipolar signal at the boundary.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2017-08-02),https://lens.org/056-626-865-593-105,Granted Patent,yes,4,19,7,7,0,A61B5/0095;;A61B5/4244;;A61B5/4872;;A61B5/7246;;A61B5/7485;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B5/7246;;A61B5/4244;;A61B8/5223;;A61B8/5261,A61B5/00;;A61B8/00;;A61B8/08,,19,16,072-068-233-488-979;;014-590-124-533-644;;040-124-808-441-526;;034-904-177-076-664;;020-149-885-110-291;;014-847-203-540-026;;074-947-514-695-425;;033-786-059-395-583;;063-939-405-551-829;;130-368-988-819-461;;015-173-468-866-169;;003-447-272-638-21X;;012-545-815-382-384;;142-401-383-484-74X;;010-411-063-187-44X;;068-526-467-082-518,10.1109/tbme.2008.919112;;19126453;;10.1109/tbme.2012.2187649;;22345521;;pmc3002753;;10.1016/j.mric.2010.08.013;;21094444;;17102041;;10.1148/rg.266065004;;10.1007/s10620-005-1267-z;;15712657;;10.1038/oby.2011.302;;pmc3270296;;22016092;;10.1063/1.4737414;;10.1109/tbme.2012.2210218;;22851231;;22734739;;10.1117/1.jbo.17.6.061209;;10.1117/12.2041047;;10.1364/ol.40.002253;;pmc4581454;;26393712;;10841427;;10.1118/1.598984;;28066714;;10.1016/j.pacs.2016.10.001;;pmc5200938;;8938024;;10.1088/0031-9155/41/11/001;;10.1088/0031-9155/41/11/002;;8938025;;10.1016/j.meatsci.2007.11.007;;22063039,"Xie et al., Adaptive and Robust Methods of Reconstruction (ARMOR) for Thermoacoustic Tomography, IEEE Transactions on Biomedical Engineering, vol. 55, No. 12, Dec. 2008.;;Bu et al., Model-Based Reconstruction IntegratedWith Fluence Compensation for Photoacoustic Tomography, IEEE Transactions on Biomedical Engineering, vol. 59, No. 5, May 2012.;;S. B. Reeder and C. Sirlin, “Quantification of liver fat with magnetic resonance imaging,” Magn Reson Imaging Clin N Am vol. 18, No. 3, pp. 337-357, Aug. 2010.;;M. P. Andre et al., “Accurate diagnosis of nonalcoholic fatty liver disease in human participants via quantitative ultrasound”, 2014 IEEE International Ultrasonics Symposium, 204, pp. 2375-2377, 2014.;;O. W. Hamer et al., “Fatty liver: Imaging patterns and pitfalls”, Radiographics, vol. 26, No. 6, pp. 1637-1653, 2006.;;D. A. Sass, P. Cang, and K. B. Chopra, “Nonalcoholic fatty liver disease: a clinical review,” Dig. Dis. Sci., vol. 50, No. 1, pp. 171-180, Jan. 2005.;;M. F. Xia et al., “Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method”, Obesity, vol. 20, No. 2, pp. 444-452, 2012.;;D. R. Bauer et al., “Spectroscopic thermoacoustic imaging of water and fat composition,” Appl. Phys. Lett., vol. 101, 2012.;;X. Wang et al., “Microwave-induced thermoacoustic imaging model for potential breast cancer detection,” IEEE Trans. Biomed. Eng., vol. 59, No. 10, pp. 2782-2791, Oct. 2012.;;T. J. Allen et al., “Spectroscopic photoacoustic imaging of lipid-rich plaques in the human aorta in the 740 to 1400 nm wavelength range”, J. Biomed. Opt., vol. 17, No. 6, Jun. 2012.;;L. Pan et al., “Differentiating fatty and non-fatty tissue using photoacoustic imaging,” Proc. of SPIE vol. 8943, 2014.;;G. Xu et al., “Functional Pitch of a Liver: Fatty Liver Disease Diagnosis with Photoacoustic Spectrum Analysis,” Proc. of SPIE vol. 8943, 2014.;;C. Tian et al., “Imaging and sensing based on dual-pulse nonlinear photoacoustic contrast: a preliminary study on fatty liver,” Optics Letters, vol. 40, No. 10, pp. 2253-2256, May 2015.;;G. Ku and L. V. Wang, “Scanning thermoacoustic tomography in biological tissue,” Med. Phys., vol. 27, No. 5, pp. 1195-202, May 2000.;;G. J. Diebold and T. Sun, “Properties of photoacoustic waves in one, two, and three dimensions,” Acta. Acust. united. Ac., vol. 80, No. 4, pp. 339-351, Jul. 1994.;;X. L. Dean-Ben, “On the link between the speckle free nature of optoacoustics and visibility of structures in limited-view tomography,” Photoacoustics, vol. 4, No. 4, pp. 133-140, Jul. 2016.;;C. Gabriel et al., “The dielectric properties of biological tissues: I. Literature survey,” Med. Phys., vol. 41, No. 11, pp. 2231-2249, Nov. 1996.;;S. Gabriel et al., “The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz,” Med. Phys., vol. 41, No. 11, pp. 2251-2269, Nov. 1996.;;S. K. Ng et al., “Determination of added fat in meat paste using microwave and millimetre wave techniques,” Meat Science, vol. 79, No. 4, pp. 748-756, Aug. 2008.",ACTIVE
132,CZ,A3,CZ 554889 A3,106-667-663-326-415,1999-01-13,1999,CS 554889 A,1989-09-29,GB 8822857 A,1988-09-29,PHARMACEUTICAL PREPARATION AND PROCESS FOR PREPARING A GELATINOUS CAPSULE AND PERORALLY OR RECTALLY ACCEPTABLE MEANS,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/106-667-663-326-415,Patent Application,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
133,JP,A,JP 2018093220 A,140-636-337-857-131,2018-06-14,2018,JP 2018030431 A,2018-02-23,US 201113309321 A,2011-12-01,BINARY THERMOELECTRIC MATERIAL CONTAINING NANOPARTICLES AND METHOD FOR MANUFACTURING THE SAME,"PROBLEM TO BE SOLVED: To provide thermoelectric composite material having improved properties.SOLUTION: A thermoelectric composition contains binary main group semiconductor material, and metal oxide nanoparticles represented by the formula MO, where M represents at least one element selected from a group consisting of group 2 elements and group 12 elements. The nanoparticles are dispersed in a matrix of the binary main group semiconductor material.SELECTED DRAWING: None",TOYOTA ENG & MFG NORTH AMERICA,MICHAEL PAUL LAW;;CHO LI KIM,,https://lens.org/140-636-337-857-131,Patent Application,no,8,0,6,6,0,B82Y30/00;;C04B35/547;;C04B2235/3284;;C04B2235/441;;C04B2235/444;;C04B2235/449;;C04B2235/80;;H10N10/852;;B82Y30/00;;C04B2235/3284;;C04B2235/441;;C04B2235/449;;C04B35/547;;C04B2235/444;;C04B2235/80;;H10N10/852,H01L35/16;;C01B19/04;;H01L35/22;;H01L35/34,,0,0,,,,ACTIVE
134,WO,A3,WO 1990/003164 A3,185-331-747-897-510,1990-06-14,1990,GB 8901161 W,1989-09-29,GB 8822857 A,1988-09-29,PHARMACEUTICAL FORMULATIONS,,PATRALAN LTD;;CHO YOUNG W;;FLYNN MICHAEL JOHN,CHO YOUNG W;;FLYNN MICHAEL JOHN,,https://lens.org/185-331-747-897-510,Search Report,no,9,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,3,0,,,"PATENT ABSTRACTS OF JAPAN, Volume 6, No. 154 (C-119) (1032), 14 August 1982; & JP-A-5772920 (Toyama Kagaku Kogyo K.K.) 7 May 1982;;PATENT ABSTRACTS OF JAPAN, Volume 10, No. 239 (C-367) (2295), 19 August 1986; & JP-A-6172721 (Daigo Eiyou Kagaku K.K.) 14 April 1986;;PATENT ABSTRACTS OF JAPAN, Volume 7, No. 97 (C-163) (1242), 23 April 1983; & JP-A-5821622 (Kouwa K.K.) 8 February 1983",PENDING
135,DE,T5,DE 112006003609 T5,045-226-817-329-762,2008-11-06,2008,DE 112006003609 T,2006-12-11,US 31937805 A;;US 2006/0047194 W,2005-12-29,Düsenanordnung,,CATERPILLAR INC,HARMON MICHAEL PATRICK;;LIANG CHO YING,,https://lens.org/045-226-817-329-762,Patent Application,no,1,0,5,5,0,F01N3/0253;;F01N3/36;;F01N2260/024;;F01N2610/03;;F01N2610/11;;F01N3/0253;;F01N2260/024;;F01N2610/11;;F01N3/36;;F01N2610/03,F01N3/025;;F01N3/36,,0,0,,,,DISCONTINUED
136,HU,A9,HU 211633 A9,084-746-964-794-561,1995-12-28,1995,HU 9500585 P,1995-06-29,GB 8822857 A,1988-09-29,PHARMACEUTICAL FORMULATIONS,,PATRALAN LTD,FLYNN MICHAEL JOHN;;CHO YOUNG W,,https://lens.org/084-746-964-794-561,Unknown,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,PENDING
137,DE,T5,DE 112007000787 T5,023-617-305-091-439,2009-01-29,2009,DE 112007000787 T,2007-02-28,US 39394406 A;;US 2007/0005371 W,2006-03-31,Düsenanordnung,,CATERPILLAR INC,HARMON MICHAEL P;;LIANG CHO Y,,https://lens.org/023-617-305-091-439,Patent Application,no,1,0,5,5,0,F01N3/2066;;F01N3/2066;;F01N2610/02;;F01N2610/02;;F01N2610/10;;F01N2610/10;;F01N2610/11;;F01N2610/11;;F01N2610/14;;F01N2610/14;;F01N2610/1453;;F01N2610/1453;;F02B37/00;;F02B37/00;;F02M53/04;;F02M53/04;;Y02T10/12;;Y02T10/12,F02M53/04;;F02M61/16,,0,0,,,,DISCONTINUED
138,WO,A1,WO 2019/027497 A1,131-214-758-832-796,2019-02-07,2019,US 2018/0012575 W,2018-01-05,US 201715666546 A,2017-08-01,METHOD FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,"A method for estimating fractional fat content of an object. An energy emitter is used to direct an energy signal toward the region of interest, wherein the region of interest has an object of interest, a reference, and a boundary area with one or more boundary locations between the object of interest and the reference. Next, a plurality of thermoacoustic or ultrasonic transducers is used to receive a plurality of thermoacoustic bipolar signals from the one or more boundary locations, wherein the thermoacoustic bipolar signals are induced by the energy signal. A machine configured to accept data from the energy emitter and the plurality of thermoacoustic or ultrasonic transducers and calculate a fat concentration that is a function of the thermoacoustic bipolar signal at each respective boundary location and the distance or distances between locations.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/131-214-758-832-796,Patent Application,yes,1,1,19,19,0,A61B5/0093;;A61B5/4872;;A61B5/0035;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/5223;;G16H50/30;;A61B5/4872;;A61B5/0035;;A61B5/0095;;A61B5/4244;;A61B5/7246;;A61B5/7485;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/0093;;H05K999/99,A61B8/00;;A61B5/00;;A61B8/08,,1,1,072-068-233-488-979,10.1109/tbme.2008.919112;;19126453,"XIE ET AL.: ""Adaptive and Robust Methods of Reconstruction (ARMOR) for Thermoacoustic Tomography"", IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, vol. 55, no. 12, December 2008 (2008-12-01), XP011342781, DOI: doi:10.1109/TBME.2008.919112",PENDING
139,NO,D0,NO 893896 D0,181-569-563-372-263,1989-09-29,1989,NO 893896 A,1989-09-29,GB 8822857 A,1988-09-29,FARMASOEYTISKE FORMULERINGER OG FREMGANGSMAATE FOR FREMSTILLING AV DISSE.,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/181-569-563-372-263,Patent Application,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
140,US,B2,US 9899392 B2,025-896-999-125-855,2018-02-20,2018,US 201615223685 A,2016-07-29,US 201615223685 A;;KR 20140045575 A;;US 201514602671 A,2014-04-16,"Silicon precursor, method of forming a layer using the same, and method of fabricating semiconductor device using the same","The inventive concepts provide silicon precursors, methods of forming a layer using the same, and methods of fabricating a semiconductor device using the same. The silicon precursor includes a silane group including two or more silicon atoms. The silicon precursor has a high and uniform adsorption property on surfaces of layers (e.g., a silicon layer, an oxide layer, and a nitride layer) that are mainly used when semiconductor devices are fabricated.",SAMSUNG ELECTRONICS CO LTD;;DOW CORNING,CHO JUNHYUN;;TELGENHOFF MICHAEL DAVID;;ZHOU XIAOBING;;JUNG KYUNGHYE;;CHO YOUNJOUNG,DDP SPECIALTY ELECTRONIC MATERIALS US 9 LLC (2019-08-23);;JIANGSU NATA OPTO-ELECTRONIC MATERIALS CO. LTD (2020-12-14);;DOW SILICONES CORPORATION (2018-02-01);;NATA SEMICONDUCTOR MATERIALS CO. LTD (2021-05-10),https://lens.org/025-896-999-125-855,Granted Patent,yes,27,1,5,5,0,H01L21/02488;;H01L21/0262;;H01L21/32055;;H01L21/76897;;H01L21/28562;;H01L21/76876;;H01L21/76877;;H01L21/02532;;H01L21/02595;;H10B12/00;;H10B41/27;;H01L21/02532;;H01L21/02595;;H01L21/02164;;H01L21/0217;;H01L21/02211;;H01L21/02488;;H01L21/0262;;H01L21/76877;;H01L21/76897;;H01L21/32055;;H01L21/28562;;H01L21/76876;;H10B12/0335;;H10B12/315;;H10B12/00;;H10B41/27,H01L21/20;;H01L21/02;;H01L27/108;;H01L27/11556,,0,0,,,,ACTIVE
141,US,A1,US 2015/0303060 A1,144-494-680-542-772,2015-10-22,2015,US 201514602671 A,2015-01-22,KR 20140045575 A,2014-04-16,"SILICON PRECURSOR, METHOD OF FORMING A LAYER USING THE SAME, AND METHOD OF FABRICATING SEMICONDUCTOR DEVICE USING THE SAME","The inventive concepts provide silicon precursors, methods of forming a layer using the same, and methods of fabricating a semiconductor device using the same. The silicon precursor includes a silane group including two or more silicon atoms. The silicon precursor has a high and uniform adsorption property on surfaces of layers (e.g., a silicon layer, an oxide layer, and a nitride layer) that are mainly used when semiconductor devices are fabricated.",SAMSUNG ELECTRONICS CO LTD;;DOW CORNING,CHO JUNHYUN;;TELGENHOFF MICHAEL DAVID;;ZHOU XIAOBING;;JUNG KYUNGHYE;;CHO YOUNJOUNG,SAMSUNG ELECTRONICS CO. LTD (2014-11-12);;DOW SILICONES CORPORATION (2014-11-20),https://lens.org/144-494-680-542-772,Patent Application,yes,7,3,5,5,0,H01L21/02488;;H01L21/0262;;H01L21/32055;;H01L21/76897;;H01L21/28562;;H01L21/76876;;H01L21/76877;;H01L21/02532;;H01L21/02595;;H10B12/00;;H10B41/27;;H01L21/02532;;H01L21/02595;;H01L21/02164;;H01L21/0217;;H01L21/02211;;H01L21/02488;;H01L21/0262;;H01L21/76877;;H01L21/76897;;H01L21/32055;;H01L21/28562;;H01L21/76876;;H10B12/0335;;H10B12/315;;H10B12/00;;H10B41/27,H01L27/115;;H01L21/02,,0,0,,,,DISCONTINUED
142,US,A1,US 2016/0336328 A1,188-209-201-730-102,2016-11-17,2016,US 201615223685 A,2016-07-29,US 201615223685 A;;KR 20140045575 A;;US 201514602671 A,2014-04-16,"SILICON PRECURSOR, METHOD OF FORMING A LAYER USING THE SAME, AND METHOD OF FABRICATING SEMICONDUCTOR DEVICE USING THE SAME","The inventive concepts provide silicon precursors, methods of forming a layer using the same, and methods of fabricating a semiconductor device using the same. The silicon precursor includes a silane group including two or more silicon atoms. The silicon precursor has a high and uniform adsorption property on surfaces of layers (e.g., a silicon layer, an oxide layer, and a nitride layer) that are mainly used when semiconductor devices are fabricated.",SAMSUNG ELECTRONICS CO LTD;;DOW CORNING,CHO JUNHYUN;;TELGENHOFF MICHAEL DAVID;;ZHOU XIAOBING;;JUNG KYUNGHYE;;CHO YOUNJOUNG,DDP SPECIALTY ELECTRONIC MATERIALS US 9 LLC (2019-08-23);;JIANGSU NATA OPTO-ELECTRONIC MATERIALS CO. LTD (2020-12-14);;DOW SILICONES CORPORATION (2018-02-01);;NATA SEMICONDUCTOR MATERIALS CO. LTD (2021-05-10),https://lens.org/188-209-201-730-102,Patent Application,yes,12,0,5,5,0,H01L21/02488;;H01L21/0262;;H01L21/32055;;H01L21/76897;;H01L21/28562;;H01L21/76876;;H01L21/76877;;H01L21/02532;;H01L21/02595;;H10B12/00;;H10B41/27;;H01L21/02532;;H01L21/02595;;H01L21/02164;;H01L21/0217;;H01L21/02211;;H01L21/02488;;H01L21/0262;;H01L21/76877;;H01L21/76897;;H01L21/32055;;H01L21/28562;;H01L21/76876;;H10B12/0335;;H10B12/315;;H10B12/00;;H10B41/27,H01L27/108,,0,0,,,,ACTIVE
143,US,A1,US 2021/0370044 A1,053-359-691-814-816,2021-12-02,2021,US 202117325328 A,2021-05-20,US 202117325328 A;;US 202063029855 P,2020-05-26,BODY POSITION AND ACTIVITY BASED FLOW CONTROL FOR VENTRICULAR ASSIST DEVICE (VAD) WITH FULLY IMPLANTABLE CONTROLLER,"A controller for an implantable blood pump, includes an accelerometer configured to measure at least one from the group consisting of position and movement of the controller. Processing circuitry is configured to control operation of the implantable blood pump, the processing circuitry being in communication with the accelerometer, the processing circuitry being configured to adjust a speed of the implantable blood pump if the measured at least one from the group consisting of position and movement deviates from a respective predetermined threshold.",MEDTRONIC INC,CHO YONG K;;HESS MICHAEL F;;EGGEN MICHAEL E;;BROWN MICHAEL C;;REINERT MICHAEL,MEDTRONIC INC (2020-05-26),https://lens.org/053-359-691-814-816,Patent Application,yes,6,1,3,3,0,A61M60/122;;A61M60/216;;A61M60/515;;A61M2230/62;;A61M2230/63;;A61M60/178;;A61M60/242;;A61M60/515;;A61M60/546;;A61M2205/3365;;A61M60/216;;A61M2230/62;;A61M60/178,A61M60/178;;A61M60/515;;A61M60/216;;A61M60/546,,0,0,,,,PENDING
144,JP,A,JP 2000164765 A,140-731-707-424-516,2000-06-16,2000,JP 32289299 A,1999-11-12,US 19175598 A;;US 31578599 A,1998-11-13,LOW-CROSSTALK HIGH-DENSITY SIGNAL INSERT HAVING POWER SUPPLY AND GROUND LAP AND ITS MANUFACTURE,"PROBLEM TO BE SOLVED: To connect an IC chip and a printed wiring board to each other with reduced crosstalks between signal lines by insulating a power supply and a ground wiring path from a signal path so as to distribute power through a structure for wiring a power supply line and a ground conductor, and not through a structure for distributing signals. SOLUTION: An insert 100 is disposed between a printed wiring board 102 and an IC chip 104. The insert 100 includes a signal core 106 and a power supply/ground wrap 108 as two main components. A mutual connection between power supplies and a mutual connection between grounds are disposed between the substrate 102 and the chip 104, without being passed through the signal core 106. Due to this architecture, a mutual connection between the power supplies, a mutual connection between the grounds, and a mutual connection between signals are electrically insulated and thereby the noise, etc., caused by capacitive energy coupling between lines can be removed. Moreover, the wiring density of signal lines can be increased between the substrate 102 and the chip 104.",FUJITSU LTD,PETERS MICHAEL G;;WEN CHO VINCENT WANG;;TAKAHASHI YASUHITO;;WILLIAM CHO;;MICHAEL G LEE;;SOLOMON VALIN,,https://lens.org/140-731-707-424-516,Patent Application,no,0,5,4,5,0,H05K1/0219;;H05K1/0219;;H01L23/49822;;H01L23/49822;;H01L23/49833;;H01L23/49833;;H01L23/49838;;H01L23/49838;;H01L23/50;;H01L23/50;;H01L23/5383;;H01L23/5383;;H01L23/5385;;H01L23/5385;;H01L23/5386;;H01L23/5386;;H01L23/552;;H01L23/552;;H01L2224/16225;;H01L2224/16225;;H01L2224/16235;;H01L2224/16235;;H01L2924/01004;;H01L2924/01004;;H01L2924/01019;;H01L2924/01019;;H01L2924/01046;;H01L2924/01046;;H01L2924/01078;;H01L2924/01078;;H01L2924/01079;;H01L2924/01079;;H01L2924/01322;;H01L2924/01322;;H01L2924/01327;;H01L2924/01327;;H01L2924/09701;;H01L2924/09701;;H01L2924/10253;;H01L2924/10253;;H01L2924/15311;;H01L2924/15311;;H01L2924/3011;;H01L2924/3011;;H01L2924/3025;;H01L2924/3025;;H05K1/141;;H05K1/141;;H05K1/144;;H05K1/144;;H05K3/20;;H05K3/20;;H05K2201/049;;H05K2201/049;;H05K2201/055;;H05K2201/055;;H05K2201/10378;;H05K2201/10378,H01L23/12;;H01L23/498;;H01L23/50;;H01L23/538;;H01L23/552;;H05K1/02;;H05K1/14;;H05K3/20,,0,0,,,,DISCONTINUED
145,US,B2,US 11120280 B2,080-771-144-670-407,2021-09-14,2021,US 202016802970 A,2020-02-27,US 202016802970 A;;US 201962935966 P,2019-11-15,Geometry-aware instance segmentation in stereo image capture processes,"A system detects multiple instances of an object in a digital image by receiving a two-dimensional (2D) image that includes a plurality of instances of an object in an environment. For example, the system may receive the 2D image from a camera or other sensing modality of an autonomous vehicle (AV). The system uses a first object detection network to generate a plurality of predicted object instances in the image. The system then receives a data set that comprises depth information corresponding to the plurality of instances of the object in the environment. The data set may be received, for example, from a stereo camera of an AV, and the depth information may be in the form of a disparity map. The system may use the depth information to identify an individual instance from the plurality of predicted object instances in the image.",ARGO AI LLC,HU XIAOYAN;;HAPPOLD MICHAEL;;WU CHO-YING,ARGO AI LLC (2020-02-14),https://lens.org/080-771-144-670-407,Granted Patent,yes,65,1,7,7,0,G06T7/11;;G06T7/174;;G06T2207/10004;;G06T2207/10012;;G06T2207/10024;;G06T2207/20016;;G06T2207/20081;;G06T2207/20084;;G06T2207/20132;;G06T2207/30261;;G06V20/64;;G06V20/58;;G06V10/25;;G06V10/82;;G06T7/593;;G06T7/11;;B60R2300/107;;G06T2207/10028;;G06T2207/30261;;G06V20/58;;G06V10/25;;G06V10/82;;G06V20/64,B60R1/00;;G06T7/11;;G06T7/593;;G06V10/25,,23,18,007-063-801-607-535;;031-554-742-157-015;;136-578-484-871-753;;039-157-879-085-923;;042-502-173-561-417;;094-577-137-430-121;;032-301-503-627-789;;070-467-050-835-005;;098-926-109-358-108;;016-400-108-039-841;;011-407-324-570-055;;021-360-232-245-594;;071-904-133-048-575;;102-201-317-308-185;;100-428-502-602-54X;;144-369-386-422-873;;098-749-981-533-592;;130-946-435-402-270,10.1109/3dv.2017.00034;;31794388;;10.1109/cvpr.2018.00644;;10.1109/tpami.2019.2956516;;10.1007/978-3-030-01270-0_39;;10.5244/c.30.19;;10.1109/cvpr.2016.79;;10.1109/cvpr.2017.305;;10.1109/icip.2017.8296296;;10.1109/iccv.2015.300;;27295650;;10.1109/tpami.2016.2577031;;10.1109/cvpr.2017.472;;10.1109/cvpr.2018.00102;;29994331;;10.1109/tpami.2018.2844175;;10.1109/iccv.2017.322;;10.1109/cvpr.2019.00752;;10.1109/cvpr.2019.00657;;10.1109/cvpr.2018.00913;;10.1109/cvpr.2019.00864;;10.1109/cvpr.2019.00904;;10.1109/iros.2018.8594049,"Zhile Ren et al., “Cascaded Scene Flow Prediction Using Semantic Segmentation,” 2017 International Conference on 3D Vision (3DV), pp. 1-9, Jun. 7, 2018, pp. 1-8.;;Cai, Z. et al., “Cascade R-CNN: Delving into High Quality Object Detection”, [cs.CV] Dec. 3, 2017.;;Liang, M. et al., “Deep Continuous Fusion for Multi-Sensor 3D Object Detection”, ECCV 2018 paper.;;Amab, A. et al., “Bottom-up Instance Segmentation using Deep Higher-Order CRFs”, [cs.CV] Sep. 8, 2016.;;Fathi, A. et al., “Semantic Instance Segmentation via Deep Metric Learning”, [cs.CV] Mar. 30, 2017.;;Zhang, Z. et al., Instance-Level Segmentation for Autonomous Driving with Deep Densely Connected MRFs, [cs.CV] Apr. 27, 2016.;;Bai, M. et al., “Deep Watershed Transform for Instance Segmentation”, [cs.CV] May 4, 2017.;;Ye, L. et al., “Depth-Aware Object Instance Segmentation”.;;Zhang, Z. et al., “Monocular Object Instance Segmentation and Depth Ordering with CNNs” [cs.CV] Dec. 18, 2015.;;De Brabandere, B. et al., “Semantic Instance Segmentation with a Discriminative Loss Function”, [cs.CV] Aug. 8, 2017.;;Ren, S. et al., “Faster R-CNN: Towards Real-Time Object Detection with Region Proposal Networks”, [cs.CV] Jan. 6, 2016.;;Li, Y. et al., “Fully Convolutional Instance-aware Semantic Segmentation”, [cs.CV] Apr. 10, 2017.;;Qi, C.R. et al., “Frustum PointNets for 3D Object Detection from R GB-D Data”, [cs.CV] Apr. 13, 2018.;;Chen K. et al., “Hybrid Task Cascade for Instance Segmentation”, [cs.CV] Apr. 9, 2019.;;Kirillow, A. et al., “InstanceCut: from Edges to Instances with MultiCut”, [cs.CV] Nov. 24, 2016.;;Dai, J. et al., “Instance-sensitive Fully Convolutional Networks”, [cs.CV] Mar. 29, 2016.;;He, K. et al., “Mask R-CNN”, [cs.CV] Jan. 24, 2018.;;Liang M. et al., “Multi-Task Multi-Sensor Fusion for 3D Object Detection”, The IEEE Conference on Computer Vision and Pattern Recognition (CVPR), 2019.;;Huang, Z. et al., “Mask Scoring R-CNN”, [cs.CV] Mar. 1, 2019.;;Liu, S. et al., “Path Aggregation Network for Instance Segmentation”, [cs.CV] Sep. 18, 2018.;;Wang, Y. et al., “Pseudo-LiDAR from Visual Depth Estimation: Bridging the Gap in 3D Object Detection for Autonomous Driving”, [cs.CV] Jun. 14, 2019.;;Neven, D. et al., Instance Segmentation by Jointly Optimizing Spatial Embeddings and Clustering Bandwidth, The IEEE Conference on Computer Vision and Pattern Recognition (CVPR), 2019, pp. 8837-8845.;;Ku, J. et al., “Joint 3D Proposal Generation and Object Detection from View Aggregation”, [cs.CV] Jul. 12, 2018.",ACTIVE
146,US,A1,US 2007/0195183 A1,133-187-887-368-119,2007-08-23,2007,US 78554607 A,2007-04-18,US 78554607 A;;US 63367303 A,2003-08-05,Method and circuit for determining the response curve knee point in active pixel image sensors with extended dynamic range,"An apparatus and method for measuring the breakpoint of a response curve representing the voltage output of an image array having an extended dynamic range. By flooding a light-opaque pixel with a charge and then applying an intermediate reset voltage to the pixel, the signal is read from the pixel and stored. The full reset voltage is applied to the pixel, and then the signal in the pixel is read and stored. The voltage output difference is the difference between the first and second stored signal. The voltage output difference is then used to determine the voltage of the knee point. Further, a conventional saturated pixel can be reset with an intermediate reset just prior to readout. The resulting signal can then be used to determine the voltage of the knee point.",OVSIANNIKOV ILIA;;CHO KWANG-BO;;KAPLINSKY MICHAEL,OVSIANNIKOV ILIA;;CHO KWANG-BO;;KAPLINSKY MICHAEL,APTINA IMAGING CORPORATION (2008-09-26);;MICRON TECHNOLOGY INC (2003-07-15),https://lens.org/133-187-887-368-119,Patent Application,yes,13,3,4,4,0,H04N25/571;;H04N25/575;;H04N25/571,H04N5/355;;H04N5/374;;H04N5/378,348/308,0,0,,,,EXPIRED
147,CN,A,CN 111752265 A,003-521-947-853-288,2020-10-09,2020,CN 202010169480 A,2020-03-12,US 201916365517 A,2019-03-26,HYPERASSOCIATION IN EPISODE MEMORY,"An autonomous vehicle, system and method of operating the autonomous vehicle. The system includes an episodic memory, a hyper-association module and a navigation system. The episodic memory stores a plurality of episodes, recalls a plurality of candidate episodes in response to receiving a partial prefix and recalls a hypothesis episode in response to receiving an intermediate episode. The hyper-association module receives the plurality of candidate episodes from the episodic memory and obtains the intermediate episode from the plurality of candidate episodes. The navigation system navigates the autonomous vehicle using the hypothesis episode.",GM GLOBAL TECH OPERATIONS LLC,CHO YOUNGKWAN;;BHATTACHARYYA RAJAN;;DAILY MICHAEL J,,https://lens.org/003-521-947-853-288,Patent Application,no,16,0,4,4,0,G05D1/0088;;G05D1/0088;;G06N5/02;;G05D1/0088;;G05D1/021;;G06N3/02,G05D1/00,,3,0,,,"王凡;邢彦文;: ""基于地面特征块匹配的机器视觉用于平整地面AGV行驶轨迹计算方法"", 计算机与现代化, no. 10, pages 47 - 51;;朱素杰;王萌;: ""一种基于高级驱动辅助系统快速时空立体匹配方法"", 信息技术与网络安全, no. 08, pages 49 - 53;;李进;陈杰平;易克传;徐朝胜;: ""基于特征融合的视觉导航智能车辆的车道识别"", 汽车工程, no. 05, pages 101 - 106",PENDING
148,WO,A1,WO 2001/011792 A1,079-472-326-448-545,2001-02-15,2001,US 0021612 W,2000-08-07,US 37004499 A,1999-08-06,TELECOMMUNICATIONS VOICE PROMPT,A wireless local loop (WLL) apparatus (10) that locally analyzes the digits dialed on a phone (14); determines if the digits dialed are sufficient to complete the call; completes the call if the digits dialed are sufficient; and prompts the user to provide additional information necessary to complete the call if the digits dialed are not sufficient to complete the call. The prompt preferably consists of a voice message that is locally generated and played by the WLL apparatus to the user before the call is connected to the telecommunications network (12) serving the WLL apparatus. The WLL apparatus may also prompt a caller to indicate whether a call is being originated from a conventional voice phone or from other devices such as a facsmile machine. The WLL apparatus may then transmit this information as out-of-band or in-band signaling accompanying the call for use by the telecommunications network in providing service options to the originating and destination phones.,MAXON ELECTRONICS CORP OF AMER,STUPICA MICHAEL;;CHO YONG SEOK;;SHIREMAN STEPHEN,,https://lens.org/079-472-326-448-545,Patent Application,yes,3,0,2,2,0,H04W8/26;;H04W88/021;;H04W76/10;;H04M1/27485;;H04M1/724,H04M1/27485;;H04M1/724;;H04W8/26;;H04W76/02;;H04W88/02,,0,0,,,,PENDING
149,IE,B1,IE 63543 B1,136-057-566-327-272,1995-05-17,1995,IE 311889 A,1989-09-29,GB 8822857 A,1988-09-29,Pharmaceutical formulations,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J DR,,https://lens.org/136-057-566-327-272,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
150,MX,A,MX 2009006327 A,146-078-160-982-416,2009-06-23,2009,MX 2009006327 A,2007-12-17,US 87017606 P;;US 2007/0087707 W,2006-12-15,HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF.,The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.,NOVARTIS AG,SHULTZ MICHAEL;;CHO YOUNG SHIN;;JIANG LEI,,https://lens.org/146-078-160-982-416,Patent Application,no,0,0,12,12,0,A61K31/165;;A61K31/165;;A61K31/165;;A61P1/04;;A61P1/16;;A61P7/02;;A61P9/10;;A61P9/14;;A61P13/08;;A61P13/12;;A61P15/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;C07D209/16;;C07D209/10,A61K31/165,,0,0,,,,DISCONTINUED
151,AU,A,AU 1989/042432 A,061-838-653-122-235,1990-04-05,1990,AU 1989/042432 A,1989-09-29,GB 8822857 A,1988-09-29,MICROEMULSION FORMULATIONS,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J DR,,https://lens.org/061-838-653-122-235,Patent Application,no,0,4,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
152,WO,A1,WO 2007/095828 A1,064-431-951-972-363,2007-08-30,2007,CN 2007000117 W,2007-01-11,CN 200610055009 A,2006-02-25,"DIHYDROPORPHINE E6 ZINC COMPLEXES AS PHOTOSENSITIZER, THEIR PREPARATION AND THEIR USE","Dihydroporphine E6 zinc complexes as photosensitizer, their preparation and their use. The method for preparing the said zinc complexes comprises the following steps: adding dihydroporphine E6 to sodium hydrogen carbonate aqueous solution, dissolving polyvinylpyrrolidone in de-ionized water, adding the obtained solution to dihydroporphine E6 solution, slow stirring under 40 °C to obtain unstable dihydroporphine E6; adding zinc nitrate hexahydrate solution to dihydroporphine E6 solution under slow stirring; and adding the obtained dihydroporphine E6-zinc complex to polyvinylpyrrolidone under slow stirring at below 60 °C. The said zinc complexes are used as medicine in photodynamic therapy against cancer e.g. cervical carcinoma, lung cancer, kidney cancer, etc..",DING LINHONG;;CHO HONSUE MICHAEL;;OVCHINNIKOV ALEXANDER;;MURPHY MATT,CHO HONSUE MICHAEL;;OVCHINNIKOV ALEXANDER;;MURPHY MATT,,https://lens.org/064-431-951-972-363,Patent Application,yes,2,1,4,4,0,A61P35/00;;C07D487/22,C07D487/22;;A61K31/409;;A61P35/00,,0,0,,,,PENDING
153,BR,A2,BR PI0720453 A2,093-128-481-806-60X,2014-01-14,2014,BR PI0720453 A,2007-12-17,US 87017606 P;;US 2007/0087707 W,2006-12-15,COMPOSTOS HETEROCICLOS E MÉTODOS DE USO DOS MESMOS,,NOVARTIS AG,CHO YOUNG SHIN;;JIANG LEI;;SCHULTZ MICHAEL,,https://lens.org/093-128-481-806-60X,Patent Application,no,0,0,12,12,0,A61K31/165;;A61K31/165;;A61K31/165;;A61P1/04;;A61P1/16;;A61P7/02;;A61P9/10;;A61P9/14;;A61P13/08;;A61P13/12;;A61P15/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;C07D209/16;;C07D209/10,A61K31/165,,0,0,,,,DISCONTINUED
154,CA,A1,CA 2671550 A1,192-980-663-795-182,2008-06-26,2008,CA 2671550 A,2007-12-17,US 87017606 P;;US 2007/0087707 W,2006-12-15,HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF,The invention relates to the use of compounds in the treatment of deacety lase-associated diseases and for the manufacture of pharmaceutical preparati ons for the treatment of said diseases.,NOVARTIS AG,JIANG LEI;;SHULTZ MICHAEL;;CHO YOUNG SHIN,,https://lens.org/192-980-663-795-182,Patent Application,no,0,0,12,12,0,A61K31/165;;A61K31/165;;A61K31/165;;A61P1/04;;A61P1/16;;A61P7/02;;A61P9/10;;A61P9/14;;A61P13/08;;A61P13/12;;A61P15/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;C07D209/16;;C07D209/10,A61K31/165,,0,0,,,,DISCONTINUED
155,DE,A1,DE 102020103754 A1,055-757-462-560-206,2020-10-01,2020,DE 102020103754 A,2020-02-13,US 201916365517 A,2019-03-26,HYPER-ASSOZIATION IM EPISODENSPEICHER,"Ein autonomes Fahrzeug, System und Verfahren zum Betrieb des autonomen Fahrzeugs. Das System umfasst einen episodischen Speicher, ein Hyper-Assoziationsmodul und ein Navigationssystem. Der episodische Speicher speichert eine Vielzahl von Episoden, ruft in Erwiderung auf den Empfang eines Teilpräfixes eine Vielzahl von Kandidatenepisoden ab und ruft in Erwiderung auf den Empfang einer Zwischenepisode eine Hypothesenepisode ab. Das Hyper-Assoziationsmodul erhält die Vielzahl der Kandidatenepisoden aus dem episodischen Speicher und erhält die Zwischenepisode aus der Vielzahl der Kandidatenepisoden. Das Navigationssystem navigiert das autonome Fahrzeug anhand der Hypothesenepisode.",GM GLOBAL TECH OPERATIONS LLC,CHO YOUNGKWAN;;BHATTACHARYYA RAJAN;;DAILY MICHAEL J,,https://lens.org/055-757-462-560-206,Patent Application,no,0,0,4,4,0,G05D1/0088;;G05D1/0088;;G06N5/02;;G05D1/0088;;G05D1/021;;G06N3/02,B60W40/02;;G01C21/34,,0,0,,,,PENDING
156,US,A1,US 2021/0365699 A1,050-102-274-669-926,2021-11-25,2021,US 202117397399 A,2021-08-09,US 202117397399 A;;US 202016802970 A;;US 201962935966 P,2019-11-15,GEOMETRY-AWARE INSTANCE SEGMENTATION IN STEREO IMAGE CAPTURE PROCESSES,"A system detects multiple instances of an object in a digital image by receiving a two-dimensional (2D) image that includes a plurality of instances of an object in an environment. For example, the system may receive the 2D image from a camera or other sensing modality of an autonomous vehicle (AV). The system uses a first object detection network to generate a plurality of predicted object instances in the image. The system then receives a data set that comprises depth information corresponding to the plurality of instances of the object in the environment. The data set may be received, for example, from a stereo camera of an AV, and the depth information may be in the form of a disparity map. The system may use the depth information to identify an individual instance from the plurality of predicted object instances in the image.",ARGO AL LLC;;ARGO AI LLC,HU XIAOYAN;;HAPPOLD MICHAEL;;WU CHO-YING,ARGO AI LLC (2020-02-14),https://lens.org/050-102-274-669-926,Patent Application,yes,14,1,7,7,0,G06T7/11;;G06T7/174;;G06T2207/10004;;G06T2207/10012;;G06T2207/10024;;G06T2207/20016;;G06T2207/20081;;G06T2207/20084;;G06T2207/20132;;G06T2207/30261;;G06V20/64;;G06V20/58;;G06V10/25;;G06V10/82;;G06T7/593;;G06T7/11;;B60R2300/107;;G06T2207/10028;;G06T2207/30261;;G06V20/58;;G06V10/25;;G06V10/82;;G06V20/64,B60R1/00;;G06T7/11;;G06T7/593;;G06V10/25,,0,0,,,,ACTIVE
157,AU,A1,AU 2020/471657 A1,126-654-062-724-12X,2023-03-30,2023,AU 2020/471657 A,2020-10-22,US 202017066262 A;;US 2020/0056745 W,2020-10-08,Gravel pack flow control using swellable metallic material,"A gravel pack flow path used to flow slurry fluids during a gravel pack phase may be closed or at least limited with a swellable metallic material prior to a production phase. An example apparatus may include a base pipe, a screen disposed about the base pipe, an inflow control device having an ICD flow path in fluid communication with an outer annulus between the screen and base pipe. The gravel pack flow path defined in part by perforations in a base pipe or by a secondary housing. A swellable metallic material is activated to close the gravel pack flow path in response to a reactive fluid.",HALLIBURTON ENERGY SERVICES INC,CHO BRIAN WILLIAMS;;GRECI STEPHEN MICHAEL GRECI,,https://lens.org/126-654-062-724-12X,Patent Application,no,0,0,7,7,0,E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/108;;E21B43/088;;E21B43/04;;E21B43/12;;E21B33/127;;E21B34/10;;E21B43/04;;E21B43/12;;E21B43/088,E21B33/12;;E21B33/127;;E21B34/10;;E21B43/08;;E21B43/12,,0,0,,,,PENDING
158,US,B2,US 11320820 B2,136-945-521-918-680,2022-05-03,2022,US 201916365517 A,2019-03-26,US 201916365517 A,2019-03-26,Hyperassociation in episode memory,"An autonomous vehicle, system and method of operating the autonomous vehicle. The system includes an episodic memory, a hyper-association module and a navigation system. The episodic memory stores a plurality of episodes, recalls a plurality of candidate episodes in response to receiving a partial prefix and recalls a hypothesis episode in response to receiving an intermediate episode. The hyper-association module receives the plurality of candidate episodes from the episodic memory and obtains the intermediate episode from the plurality of candidate episodes. The navigation system navigates the autonomous vehicle using the hypothesis episode.",GM GLOBAL TECH OPERATIONS LLC,CHO YOUNGKWAN;;BHATTACHARYYA RAJAN;;DAILY MICHAEL J,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2019-11-28),https://lens.org/136-945-521-918-680,Granted Patent,yes,6,0,4,4,0,G05D1/0088;;G05D1/0088;;G06N5/02;;G05D1/0088;;G05D1/021;;G06N3/02,G05D1/00;;G05D1/02;;G06N3/02,,8,3,127-886-376-253-091;;031-608-203-140-83X;;022-594-628-394-500,15482072;;10.1037/0033-295x.111.4.1036;;10.1016/0004-3702(87)90050-6;;10.1145/1126004.1126005,"Anderson, et al., “An integrated theory of the mind”, Psychological Review, 2004, vol. 111, No. 4, American Psychological Association, pp. 1036-1060. DOI: 10.1037/0033-295X111.4.1036.;;Laird, et al., “SOAR: An architecture for general intelligence” Stanford University CA Dept. of Computer Science, Dec. 3, 1986, Artificial Intelligence, 33(1), 1-64. (1987).;;Langley, et al., “Hierarchical skills and cognitive architectures”, Proceedings of the Annual Meeting of the Cognitive Science Society, 26(26), 2004, pp. 779-784.;;Lew, et al., “Content-Based Multimedia Information Retrieval: State of the Art and Challenges.”, ACM Transactions on Multimedia Computing, Communications and Applications, vol. 2, No. 1, Feb. 2006, pp. 1-19.;;Nuxoll, et al., “Extending Cognitive Architecture with Episodic Memory”, AAAI'07 Proceedings of the 22nd national conference on Artificial intelligence—vol. 2, pp. 1560-1565, 2007.;;Nuxoll, et al., “A Cognitive Model of Episodic Memory Integrated With a General Cognitive Architecture”, In Proceedings of the Sixth International Conference on Cognitive Modeling, 220-225. Mahwah, NJ: Lawrence Earlbaum.;;Nuxoll, et al., “Comprehensive working memory activation in SOAR”, Proc. of the 6th Int. Conf.on Cognitive Modelling, pp. 226-230.;;Winkler, et al., Memories for Robots Performing Everday Manipulation Activities' Advances in Cognitive Systems 3 (2014), Cognitive Systems Foundation, pp. 47-66.",ACTIVE
159,WO,A1,WO 2014/008159 A1,106-434-896-123-427,2014-01-09,2014,US 2013/0048872 W,2013-07-01,US 201261667679 P,2012-07-03,SELECTIVE ESTROGEN RECEPTOR DEGRADERS FOR TREATMENT OF TAMOXIFEN RESISTANT TUMORS,"Compositions and methods for covalently bonding a polycarboxylic fatty acid and a SERD (selective estrogen receptor degrader) to form fatty acid-drug conjugate compounds are described. The conjugate compounds are useful for increasing solubility of the SERD as well as targeting the SERD to solid tumors. In particular, the compounds are surprisingly efficacious against tamoxifen-resistant tumors. These types of tumors are recalcitrant to existing therapies and often signal the end stage of cancer.",UNIV NORTH CAROLINA;;NOVOLIPID INC,CHO MOO;;HACKETT MICHAEL;;MOSSINGHOFF GREGORY J,,https://lens.org/106-434-896-123-427,Patent Application,no,2,4,1,1,0,A61K47/542;;A61P35/00;;C07C69/34;;C07C69/618;;C07C233/25;;C07C233/40,C07C69/035;;A61K31/166;;A61P35/00;;C07C235/16;;C07C237/20,,2,2,092-074-988-190-421;;128-011-358-050-519,20334372;;pmc2916745;;10.1021/jm100047k;;17909066;;10.1158/0008-5472.can-07-1590,"KAREN J.KIESER ET AL.: ""Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)."", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, 2010, pages 3320 - 3329;;BRYAN M.WITTMANN ET AL.: ""Definition of Functionally Important Mechanistic Differences among Selective Estrogen Receptor Down-regulators."", CANCER RESEARCH, vol. 67, no. 19, 2007, pages 9549 - 9560",PENDING
160,US,B2,US 7768563 B2,162-598-835-391-235,2010-08-03,2010,US 78554607 A,2007-04-18,US 78554607 A;;US 63367303 A,2003-08-05,Method and circuit for determining the response curve knee point in active pixel image sensors with extended dynamic range,"An apparatus and method for measuring the breakpoint of a response curve representing the voltage output of an image array having an extended dynamic range. By flooding a light-opaque pixel with a charge and then applying an intermediate reset voltage to the pixel, the signal is read from the pixel and stored. The full reset voltage is applied to the pixel, and then the signal in the pixel is read and stored. The voltage output difference is the difference between the first and second stored signal. The voltage output difference is then used to determine the voltage of the knee point. Further, a conventional saturated pixel can be reset with an intermediate reset just prior to readout. The resulting signal can then be used to determine the voltage of the knee point.",APTINA IMAGING CORP,OVSIANNIKOV ILIA;;CHO KWANG-BO;;KAPLINSKY MICHAEL,APTINA IMAGING CORPORATION (2008-09-26);;MICRON TECHNOLOGY INC (2003-07-15),https://lens.org/162-598-835-391-235,Granted Patent,yes,13,0,4,4,0,H04N25/571;;H04N25/575;;H04N25/571,H04N5/355;;H04N5/374;;H04N5/378,348/308;;348/241,2,1,009-406-602-689-659,10.1109/4.735551,"Steven Decker et al., ""A 256×256 CMOS Imaging Array with Wide Dynamic Range Pixels and Column-Parallel Digital Output"", IEEE Journal of Solid-State Circuits, vol. 33, No. 12, Dec. 1998, pp. 2081-2091.;;David X.D. Yang et al., ""A 640×512 Image Sensor with Ultra Wide Dynamic Range Floating-Point Pixel-Level ADC"", Electrical Engineering Department, Stanford University, Stanford, CA, Session No. 17, Nov. 1, 1998, pp. 1-11.",ACTIVE
161,DD,A5,DD 300405 A5,199-583-857-069-504,1992-06-11,1992,DD 33312789 A,1989-09-29,GB 8822857 A,1988-09-29,PHARMAZEUTISCHE REZEPTUREN,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J DR,,https://lens.org/199-583-857-069-504,Granted Patent,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
162,US,A1,US 2010/0022514 A1,008-354-184-372-596,2010-01-28,2010,US 51931907 A,2007-12-17,US 51931907 A;;US 87017606 P;;US 2007/0087707 W,2006-12-15,Heterocycle Compounds and Methods of Use Thereof,The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.,NORVARTIS AG,CHO YOUNG SHIN;;JIANG LEI;;SHULTZ MICHAEL,NOVARTIS AG (2008-01-09),https://lens.org/008-354-184-372-596,Patent Application,yes,1,13,12,12,0,A61K31/165;;A61K31/165;;A61K31/165;;A61P1/04;;A61P1/16;;A61P7/02;;A61P9/10;;A61P9/14;;A61P13/08;;A61P13/12;;A61P15/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;C07D209/16;;C07D209/10,A61K31/4035;;A61K31/4178;;A61K31/437;;A61K31/4439;;A61K31/472;;A61K31/4725;;A61K31/55;;A61P25/00;;A61P35/00;;A61P37/00;;C07D209/44;;C07D217/04;;C07D401/12;;C07D403/06;;C07D471/04,514/213.01;;548/482;;548/455;;540/594;;540/593;;546/277.1;;548/312.1;;546/121;;546/146;;514/416;;514/414;;514/217.01;;514/339;;514/397;;514/300;;514/307,0,0,,,,DISCONTINUED
163,US,A1,US 2021/0150227 A1,034-383-025-993-729,2021-05-20,2021,US 202016802970 A,2020-02-27,US 202016802970 A;;US 201962935966 P,2019-11-15,GEOMETRY-AWARE INSTANCE SEGMENTATION IN STEREO IMAGE CAPTURE PROCESSES,"A system detects multiple instances of an object in a digital image by receiving a two-dimensional (2D) image that includes a plurality of instances of an object in an environment. For example, the system may receive the 2D image from a camera or other sensing modality of an autonomous vehicle (AV). The system uses a first object detection network to generate a plurality of predicted object instances in the image. The system then receives a data set that comprises depth information corresponding to the plurality of instances of the object in the environment. The data set may be received, for example, from a stereo camera of an AV, and the depth information may be in the form of a disparity map. The system may use the depth information to identify an individual instance from the plurality of predicted object instances in the image.",ARGO AI LLC,HU XIAOYAN;;HAPPOLD MICHAEL;;WU CHO-YING,ARGO AI LLC (2020-02-14),https://lens.org/034-383-025-993-729,Patent Application,yes,0,11,7,7,0,G06T7/11;;G06T7/174;;G06T2207/10004;;G06T2207/10012;;G06T2207/10024;;G06T2207/20016;;G06T2207/20081;;G06T2207/20084;;G06T2207/20132;;G06T2207/30261;;G06V20/64;;G06V20/58;;G06V10/25;;G06V10/82;;G06T7/593;;G06T7/11;;B60R2300/107;;G06T2207/10028;;G06T2207/30261;;G06V20/58;;G06V10/25;;G06V10/82;;G06V20/64,B60R1/00;;G06T7/11;;G06T7/593;;G06V10/25,,0,0,,,,ACTIVE
164,AU,A,AU 2000/065293 A,058-822-843-994-881,2001-03-05,2001,AU 2000/065293 A,2000-08-07,US 37004499 A;;US 0021612 W,1999-08-06,Telecommunications voice prompt,,SEMAX WIRELESS INC,STUPICA MICHAEL;;CHO YONG SEOK;;SHIREMAN STEPHEN,,https://lens.org/058-822-843-994-881,Patent Application,no,0,0,2,2,0,H04W8/26;;H04W88/021;;H04W76/10;;H04M1/27485;;H04M1/724,H04M1/27485;;H04M1/724;;H04W8/26;;H04W76/02;;H04W88/02,,0,0,,,,DISCONTINUED
165,US,A1,US 2009/0151434 A1,108-525-751-139-344,2009-06-18,2009,US 263107 A,2007-12-17,US 263107 A,2007-12-17,Apparatus and method using a disk drive slider and/or a peltier plate in an atomic force microscope,"An Atomic Force Microscope (AFM) using a cantilevered probe containing a slider of a kind useable in a disk drive. The AFM may use a test surface similar to a disk surface in the disk drive and measure friction, lubricant depletion, and/or scratch test in the AFM to estimate the same under conditions experienced in the disk drive. The AFM may also include a Peltier plate thermally coupled to test object to maintain test surface at controlled test temperature. Refinements of the measurements are disclosed.",SAMSUNG ELECTRONICS CO LTD,KIM DONGMAN;;SULLIVAN MICHAEL;;CHO KEUNG YOUN,SAMSUNG ELECTRONICS CO. LTD (2007-12-14),https://lens.org/108-525-751-139-344,Patent Application,yes,0,4,1,1,0,G01Q30/10;;G01Q60/26;;G01Q60/28;;G01Q40/02;;G01Q30/10;;B82Y10/00;;G01Q60/28;;G01Q60/26,G01B5/28,73/105,0,0,,,,DISCONTINUED
166,EP,A4,EP 4058984 A4,147-612-520-195-111,2023-01-11,2023,EP 20887684 A,2020-10-15,US 201962935966 P;;US 202016802970 A;;US 2020/0055703 W,2019-11-15,GEOMETRY-AWARE INSTANCE SEGMENTATION IN STEREO IMAGE CAPTURE PROCESSES,,ARGO AI LLC,HU XIAOYAN;;HAPPOLD MICHAEL;;WU CHO-YING,,https://lens.org/147-612-520-195-111,Search Report,no,0,0,7,7,0,G06T7/11;;G06T7/174;;G06T2207/10004;;G06T2207/10012;;G06T2207/10024;;G06T2207/20016;;G06T2207/20081;;G06T2207/20084;;G06T2207/20132;;G06T2207/30261;;G06V20/64;;G06V20/58;;G06V10/25;;G06V10/82;;G06T7/593;;G06T7/11;;B60R2300/107;;G06T2207/10028;;G06T2207/30261;;G06V20/58;;G06V10/25;;G06V10/82;;G06V20/64,G06T7/11;;B60W40/02;;G06T7/174;;G06T7/55;;G06V10/25;;H04N13/271,,6,2,032-301-503-627-789;;021-360-232-245-594,10.1109/icip.2017.8296296;;29994331;;10.1109/tpami.2018.2844175;;10.1109/iccv.2017.322,"ALEX D PON ET AL: ""Object-Centric Stereo Matching for 3D Object Detection"", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 17 September 2019 (2019-09-17), XP081616520;;YE LINWEI ET AL: ""Depth-aware object instance segmentation"", 2017 IEEE INTERNATIONAL CONFERENCE ON IMAGE PROCESSING (ICIP), IEEE, 17 September 2017 (2017-09-17), pages 325 - 329, XP033322592, DOI: 10.1109/ICIP.2017.8296296;;ZHAOJIN HUANG ET AL: ""Mask Scoring R-CNN"", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 1 March 2019 (2019-03-01), XP081121919;;KAIMING HE ET AL: ""Mask R-CNN"", 2017 IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION (ICCV), 1 October 2017 (2017-10-01), pages 2980 - 2988, XP055756845, ISBN: 978-1-5386-1032-9, DOI: 10.1109/ICCV.2017.322;;CHO-YING WU ET AL: ""Geometry-Aware Instance Segmentation with Disparity Maps"", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 14 June 2020 (2020-06-14), XP081700881;;See also references of WO 2021096629A1",PENDING
167,WO,A3,WO 2008/076954 A3,016-970-063-864-227,2008-09-18,2008,US 2007/0087707 W,2007-12-17,US 87017606 P,2006-12-15,HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF,The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.,NOVARTIS AG;;CHO YOUNG SHIN;;JIANG LEI;;SHULTZ MICHAEL,CHO YOUNG SHIN;;JIANG LEI;;SHULTZ MICHAEL,,https://lens.org/016-970-063-864-227,Search Report,yes,3,0,12,12,0,A61K31/165;;A61K31/165;;A61K31/165;;A61P1/04;;A61P1/16;;A61P7/02;;A61P9/10;;A61P9/14;;A61P13/08;;A61P13/12;;A61P15/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;C07D209/16;;C07D209/10,A61K31/165,,1,1,013-689-624-622-276,17588744;;10.1016/j.bmcl.2007.06.038,"LEE ET AL: ""dESIGN SYNTHESIS AND EVALUATION OF ISOINDOLINONE HYDROXAMIC ACID DERVATIVES AS HIOSTONE DEACETLYASE (hdac) INHIBITORS."", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 17, 2007 - 2007, pages 4895 - 4900, XP002481768",PENDING
168,AU,A1,AU 2007/333799 A1,068-484-391-584-817,2008-06-26,2008,AU 2007/333799 A,2007-12-17,US 87017606 P;;US 2007/0087707 W,2006-12-15,Heterocycle compounds and methods of use thereof,,NOVARTIS AG,SHULTZ MICHAEL;;CHO YOUNG SHIN;;JIANG LEI,,https://lens.org/068-484-391-584-817,Patent Application,no,0,0,12,12,0,A61K31/165;;A61K31/165;;A61K31/165;;A61P1/04;;A61P1/16;;A61P7/02;;A61P9/10;;A61P9/14;;A61P13/08;;A61P13/12;;A61P15/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;C07D209/16;;C07D209/10,A61K31/165,,0,0,,,,DISCONTINUED
169,EP,A1,EP 4058984 A1,145-738-159-755-608,2022-09-21,2022,EP 20887684 A,2020-10-15,US 201962935966 P;;US 202016802970 A;;US 2020/0055703 W,2019-11-15,GEOMETRY-AWARE INSTANCE SEGMENTATION IN STEREO IMAGE CAPTURE PROCESSES,,ARGO AI LLC,HU XIAOYAN;;HAPPOLD MICHAEL;;WU CHO-YING,,https://lens.org/145-738-159-755-608,Patent Application,yes,0,0,7,7,0,G06T7/11;;G06T7/174;;G06T2207/10004;;G06T2207/10012;;G06T2207/10024;;G06T2207/20016;;G06T2207/20081;;G06T2207/20084;;G06T2207/20132;;G06T2207/30261;;G06V20/64;;G06V20/58;;G06V10/25;;G06V10/82;;G06T7/593;;G06T7/11;;B60R2300/107;;G06T2207/10028;;G06T2207/30261;;G06V20/58;;G06V10/25;;G06V10/82;;G06V20/64,G06T7/174;;B60W40/02;;G06T7/55;;G06V10/25;;H04N13/271,,0,0,,,,PENDING
170,KR,A,KR 20090099560 A,041-477-118-431-822,2009-09-22,2009,KR 20097014637 A,2007-12-17,US 87017606 P,2006-12-15,HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF,The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.,NOVARTIS AG,CHO YOUNG SHIN;;JIANG LEI;;SHULTZ MICHAEL,,https://lens.org/041-477-118-431-822,Patent Application,no,0,0,12,12,0,A61K31/165;;A61K31/165;;A61K31/165;;A61P1/04;;A61P1/16;;A61P7/02;;A61P9/10;;A61P9/14;;A61P13/08;;A61P13/12;;A61P15/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;C07D209/16;;C07D209/10,A61K31/165;;C07D209/10,,0,0,,,,DISCONTINUED
171,CN,A,CN 101610763 A,044-393-929-382-156,2009-12-23,2009,CN 200780051341 A,2007-12-17,US 87017606 P,2006-12-15,Heterocycle compounds and methods of use thereof,The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.,NOVARTIS AG,SHIN CHO YOUNG;;LEI JIANG;;MICHAEL SHULTZ,,https://lens.org/044-393-929-382-156,Patent Application,no,0,3,12,12,0,A61K31/165;;A61K31/165;;A61K31/165;;A61P1/04;;A61P1/16;;A61P7/02;;A61P9/10;;A61P9/14;;A61P13/08;;A61P13/12;;A61P15/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;C07D209/16;;C07D209/10,A61K31/165,,0,0,,,,DISCONTINUED
172,EP,A2,EP 2120910 A2,081-199-874-746-364,2009-11-25,2009,EP 07869336 A,2007-12-17,US 2007/0087707 W;;US 87017606 P,2006-12-15,HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF,,NOVARTIS AG,CHO YOUNG SHIN;;JIANG LEI;;SHULTZ MICHAEL,,https://lens.org/081-199-874-746-364,Patent Application,yes,0,0,12,12,0,A61K31/165;;A61K31/165;;A61K31/165;;A61P1/04;;A61P1/16;;A61P7/02;;A61P9/10;;A61P9/14;;A61P13/08;;A61P13/12;;A61P15/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;C07D209/16;;C07D209/10,A61K31/165,,1,0,,,See references of WO 2008076954A3,DISCONTINUED
173,US,A1,US 2017/0112390 A1,110-327-810-242-638,2017-04-27,2017,US 201514919854 A,2015-10-22,US 201514919854 A,2015-10-22,ATRIAL ARRYTHMIA DETECTION USING A PRESSURE SIGNAL IN AN IMPLANTABLE MEDICAL DEVICE AND MEDICAL SYSTEM,"A medical device system and method for monitoring a cardiovascular pressure signal to identify an atrial arrhythmia that includes a sensor sensing a cardiovascular pressure signal and a pressure analysis module that is configured to determine at least one of an interval dispersion and an amplitude dispersion of the sensed pressure signal, compare the at least one of an interval dispersion and an amplitude dispersion of the sensed pressure signal to a dispersion threshold, and determine whether the atrial arrhythmia is occurring in response to the comparing",MEDTRONIC INC,CHO YONG K;;HILL MICHAEL R S,MEDTRONIC INC (2015-10-19),https://lens.org/110-327-810-242-638,Patent Application,yes,10,6,2,2,0,A61B5/6869;;A61B5/02108;;A61B5/02405;;A61B5/4836;;A61N1/3702;;A61N1/395;;A61B5/7282;;A61B5/686;;A61N1/36564;;A61B5/361;;A61B5/0215;;A61B5/7282;;A61B5/686;;A61N1/36564;;A61N1/3987;;A61B5/02108;;A61N1/3702;;A61B5/02405;;A61N1/395;;A61B5/6869;;A61B5/4836;;A61B5/361,A61B5/0215;;A61B5/00;;A61B5/361;;A61N1/365;;A61N1/39,,0,0,,,,DISCONTINUED
174,WO,A1,WO 2021/096629 A1,188-721-151-024-455,2021-05-20,2021,US 2020/0055703 W,2020-10-15,US 202016802970 A;;US 201962935966 P,2019-11-15,GEOMETRY-AWARE INSTANCE SEGMENTATION IN STEREO IMAGE CAPTURE PROCESSES,"A system detects multiple instances of an object in a digital image by receiving a two-dimensional (2D) image that includes a plurality of instances of an object in an environment. For example, the system may receive the 2D image from a camera or other sensing modality of an autonomous vehicle (AV). The system uses a first object detection network to generate a plurality of predicted object instances in the image. The system then receives a data set that comprises depth information corresponding to the plurality of instances of the object in the environment. The data set may be received, for example, from a stereo camera of an AV, and the depth information may be in the form of a disparity map. The system may use the depth information to identify an individual instance from the plurality of predicted object instances in the image.",ARGO AI LLC,HU XIAOYAN;;HAPPOLD MICHAEL;;WU CHO-YING,,https://lens.org/188-721-151-024-455,Patent Application,yes,4,1,7,7,0,G06T7/11;;G06T7/174;;G06T2207/10004;;G06T2207/10012;;G06T2207/10024;;G06T2207/20016;;G06T2207/20081;;G06T2207/20084;;G06T2207/20132;;G06T2207/30261;;G06V20/64;;G06V20/58;;G06V10/25;;G06V10/82;;G06T7/593;;G06T7/11;;B60R2300/107;;G06T2207/10028;;G06T2207/30261;;G06V20/58;;G06V10/25;;G06V10/82;;G06V20/64,G06T7/174;;B60W40/02;;G06T7/55;;G06V10/25;;H04N13/271,,3,1,032-301-503-627-789,10.1109/icip.2017.8296296,"ZHILE REN; DEQING SUN; JAN KAUTZ; ERIK B. SUDDERTH: ""Cascaded Scene Flow Prediction using Semantic Segmentation"", ARXIV.ORG, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY ITHACA, NY 14853, 26 July 2017 (2017-07-26), 201 Olin Library Cornell University Ithaca, NY 14853, XP080779572, DOI: 10.1109/3DV.2017.00034;;ALEX D PON ET AL.: ""ARXIV.ORG"", 17 September 2019, CORNELL UNIVERSITY LIBRARY, 201 OLIN LIBRARY CORNELL UNIVERSITY, article ""Object-Centric Stereo Matching for 3D Object Detection"", pages: 14853;;YE LINWEI ET AL.: ""2017 IEEE INTERNATIONAL CONFERENCE ON IMAGE PROCESSING (ICIP"", 17 September 2017, IEEE, article ""Depth-aware object instance segmentation"", pages: 325 - 329",PENDING
175,AU,A,AU 1989/043417 A,065-592-772-765-442,1990-04-18,1990,AU 1989/043417 A,1989-09-29,GB 8822857 A,1988-09-29,PHARMACEUTICAL FORMULATIONS,,CHO YOUNG W;;FLYNN MICHAEL JOHN;;PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J DR,,https://lens.org/065-592-772-765-442,Patent Application,no,0,0,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,PENDING
176,AU,B2,AU 625498 B2,117-540-519-931-654,1992-07-16,1992,AU 1989/042432 A,1989-09-29,GB 8822857 A,1988-09-29,MICROEMULSION FORMULATIONS,,PATRALAN LTD,CHO YOUNG W;;FLYNN MICHAEL J DR,,https://lens.org/117-540-519-931-654,Granted Patent,no,0,2,46,46,0,A61K9/1075;;A61K9/1275;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;A61K9/50;;A61J3/00;;A61K9/48;;A61K38/28;;A61K9/1075;;A61K9/1676;;A61K9/5078;;A61K38/215;;A61K38/23;;A61K9/1275;;A61K38/27;;A61K38/36;;A61K38/49,A61K9/107;;A61K9/127;;A61K9/16;;A61K9/50;;A61K35/16;;A61K38/00;;A61K38/21;;A61K38/23;;A61K38/27;;A61K38/28;;A61K38/36;;A61K38/49;;B05C5/02,,0,0,,,,EXPIRED
177,US,A1,US 2018/0010086 A1,180-091-121-284-366,2018-01-11,2018,US 201715645657 A,2017-07-10,US 201715645657 A;;US 201662360550 P,2016-07-11,NOVEL SYRINGE SYSTEM FOR FLUID SEPARATION,"A syringe device for separating liquids of different densities is provided with a hollow syringe barrel, a perforated plunger seal with a seal hole, and a hollow plunging tube with a closed bottom with at least one tube hole. The perforated plunger seal has an outer perimeter that resides flush against an interior surface of the hollow syringe barrel. The tube hole is in operational relationship with the seal hole. Optionally, a relief hole is provided on a top portion of the hollow plunging tube to allow a user to create vacuum pressure as necessary.",BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIV,GUPTA ASHIM;;NEUMEISTER MICHAEL W;;CHO SOHYUNG,BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (2017-07-14),https://lens.org/180-091-121-284-366,Patent Application,yes,7,5,2,3,0,A61M5/31511;;A61M5/31511;;A61M5/31566;;A61M5/31566;;A61M5/34;;A61M5/34;;B01D17/0214;;B01D17/0214;;B01D17/0217;;B01D17/0217;;C12M47/04;;C12M47/04,C12M1/00;;A61M5/315;;A61M5/34;;B01D17/02,,0,0,,,,ACTIVE
178,US,A1,US 2020/0310423 A1,161-359-665-843-686,2020-10-01,2020,US 201916365517 A,2019-03-26,US 201916365517 A,2019-03-26,HYPERASSOCIATION IN EPISODE MEMORY,"An autonomous vehicle, system and method of operating the autonomous vehicle. The system includes an episodic memory, a hyper-association module and a navigation system. The episodic memory stores a plurality of episodes, recalls a plurality of candidate episodes in response to receiving a partial prefix and recalls a hypothesis episode in response to receiving an intermediate episode. The hyper-association module receives the plurality of candidate episodes from the episodic memory and obtains the intermediate episode from the plurality of candidate episodes. The navigation system navigates the autonomous vehicle using the hypothesis episode.",GM GLOBAL TECH OPERATIONS LLC,CHO YOUNGKWAN;;BHATTACHARYYA RAJAN;;DAILY MICHAEL J,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2019-11-28),https://lens.org/161-359-665-843-686,Patent Application,yes,0,2,4,4,0,G05D1/0088;;G05D1/0088;;G06N5/02;;G05D1/0088;;G05D1/021;;G06N3/02,G05D1/00;;G05D1/02;;G06N3/02,,0,0,,,,ACTIVE
179,WO,A1,WO 2022/076002 A1,001-676-300-528-963,2022-04-14,2022,US 2020/0056745 W,2020-10-22,US 202017066262 A,2020-10-08,GRAVEL PACK FLOW CONTROL USING SWELLABLE METALLIC MATERIAL,"A gravel pack flow path used to flow slurry fluids during a gravel pack phase may be closed or at least limited with a swellable metallic material prior to a production phase. An example apparatus may include a base pipe, a screen disposed about the base pipe, an inflow control device having an ICD flow path in fluid communication with an outer annulus between the screen and base pipe. The gravel pack flow path defined in part by perforations in a base pipe or by a secondary housing. A swellable metallic material is activated to close the gravel pack flow path in response to a reactive fluid.",HALLIBURTON ENERGY SERVICES INC,CHO BRIAN WILLIAMS;;GRECI STEPHEN MICHAEL GRECI,,https://lens.org/001-676-300-528-963,Patent Application,yes,5,0,7,7,0,E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/04;;E21B43/088;;E21B43/108;;E21B43/12;;E21B43/108;;E21B43/088;;E21B43/04;;E21B43/12;;E21B33/127;;E21B34/10;;E21B43/04;;E21B43/12;;E21B43/088,E21B33/12;;E21B33/127;;E21B34/10;;E21B43/08;;E21B43/12,,0,0,,,,PENDING
180,US,B2,US 10774301 B2,021-714-523-891-057,2020-09-15,2020,US 201715645657 A,2017-07-10,US 201715645657 A;;US 201662360550 P,2016-07-11,Syringe system for fluid separation,"A syringe device for separating liquids of different densities is provided with a hollow syringe barrel, a perforated plunger seal with a seal hole, and a hollow plunging tube with a closed bottom with at least one tube hole. The perforated plunger seal has an outer perimeter that resides flush against an interior surface of the hollow syringe barrel. The tube hole is in operational relationship with the seal hole. Optionally, a relief hole is provided on a top portion of the hollow plunging tube to allow a user to create vacuum pressure as necessary.",BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIV,GUPTA ASHIM;;NEUMEISTER MICHAEL W;;CHO SOHYUNG,BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (2017-07-14),https://lens.org/021-714-523-891-057,Granted Patent,yes,11,0,2,3,0,A61M5/31511;;A61M5/31511;;A61M5/31566;;A61M5/31566;;A61M5/34;;A61M5/34;;B01D17/0214;;B01D17/0214;;B01D17/0217;;B01D17/0217;;C12M47/04;;C12M47/04,A61M5/34;;A61M5/315;;B01D17/02;;C12M1/00,,0,0,,,,ACTIVE
181,WO,A1,WO 2017/070411 A1,073-768-050-282-584,2017-04-27,2017,US 2016/0058015 W,2016-10-21,US 201514919854 A,2015-10-22,ATRIAL ARRYTHMIA DETECTION USING A PRESSURE SIGNAL IN AN IMPLANTABLE MEDICAL DEVICE AND MEDICAL DEVICE SYSTEM,"A medical device system and method for monitoring a cardiovascular pressure signal to identify an atrial arrhythmia that includes a sensor sensing a cardiovascular pressure signal and a pressure analysis module that is configured to determine at least one of an interval dispersion and an amplitude dispersion of the sensed pressure signal, compare the at least one of an interval dispersion and an amplitude dispersion of the sensed pressure signal to a dispersion threshold, and determine whether the atrial arrhythmia is occurring in response to the comparing.",MEDTRONIC INC,CHO YONG K;;HILL MICHAEL R S,,https://lens.org/073-768-050-282-584,Patent Application,yes,18,0,2,2,0,A61B5/6869;;A61B5/02108;;A61B5/02405;;A61B5/4836;;A61N1/3702;;A61N1/395;;A61B5/7282;;A61B5/686;;A61N1/36564;;A61B5/361;;A61B5/0215;;A61B5/7282;;A61B5/686;;A61N1/36564;;A61N1/3987;;A61B5/02108;;A61N1/3702;;A61B5/02405;;A61N1/395;;A61B5/6869;;A61B5/4836;;A61B5/361,A61B5/00;;A61B5/021;;A61B5/024;;A61B5/361;;A61N1/365;;A61N1/37;;A61N1/39,,2,2,050-879-984-234-33X;;054-242-772-410-474,10.1111/j.1540-8159.2004.00499.x;;15125721;;24814498;;10.1016/j.jacc.2014.04.020,"JOSEPH WIESEL ET AL: ""The Use of a Modified Sphygmomanometer to Detect Atrial Fibrillation in Outpatients"", PACE - PACING AND CLINICAL ELECTROPHYSIOLOGY, BLACKWELL FUTURA PUBLISHING, MALDEN, MA, US, vol. 27, 1 May 2004 (2004-05-01), pages 639 - 643, XP002601908, ISSN: 0147-8389;;MITTAL SUNEET ED - NARULA JAGAT ET AL: ""Differentiating Paroxysmal From Persistent Atrial Fibrillation Long-Term Electrocardiographic Monitoring Is Mightier Than the Clinician"", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 63, no. 25, 1 July 2014 (2014-07-01), pages 2849 - 2851, XP028871984, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2014.04.020",PENDING
182,WO,A2,WO 2008/076954 A2,077-775-393-683-380,2008-06-26,2008,US 2007/0087707 W,2007-12-17,US 87017606 P,2006-12-15,HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF,The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.,NOVARTIS AG;;CHO YOUNG SHIN;;JIANG LEI;;SHULTZ MICHAEL,CHO YOUNG SHIN;;JIANG LEI;;SHULTZ MICHAEL,,https://lens.org/077-775-393-683-380,Patent Application,yes,0,7,12,12,0,A61K31/165;;A61K31/165;;A61K31/165;;A61P1/04;;A61P1/16;;A61P7/02;;A61P9/10;;A61P9/14;;A61P13/08;;A61P13/12;;A61P15/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/02;;A61P27/02;;A61P27/06;;A61P29/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;C07D209/16;;C07D209/10,A61K31/165,,0,0,,,,PENDING
183,US,B2,US 11669972 B2,132-974-610-332-208,2023-06-06,2023,US 202117397399 A,2021-08-09,US 202117397399 A;;US 202016802970 A;;US 201962935966 P,2019-11-15,Geometry-aware instance segmentation in stereo image capture processes,"A system detects multiple instances of an object in a digital image by receiving a two-dimensional (2D) image that includes a plurality of instances of an object in an environment. For example, the system may receive the 2D image from a camera or other sensing modality of an autonomous vehicle (AV). The system uses a first object detection network to generate a plurality of predicted object instances in the image. The system then receives a data set that comprises depth information corresponding to the plurality of instances of the object in the environment. The data set may be received, for example, from a stereo camera of an AV, and the depth information may be in the form of a disparity map. The system may use the depth information to identify an individual instance from the plurality of predicted object instances in the image.",ARGO AL LLC;;ARGO AI LLC,HU XIAOYAN;;HAPPOLD MICHAEL;;WU CHO-YING,ARGO AI LLC (2020-02-14),https://lens.org/132-974-610-332-208,Granted Patent,yes,78,0,7,7,0,G06T7/11;;G06T7/174;;G06T2207/10004;;G06T2207/10012;;G06T2207/10024;;G06T2207/20016;;G06T2207/20081;;G06T2207/20084;;G06T2207/20132;;G06T2207/30261;;G06V20/64;;G06V20/58;;G06V10/25;;G06V10/82;;G06T7/593;;G06T7/11;;B60R2300/107;;G06T2207/10028;;G06T2207/30261;;G06V20/58;;G06V10/25;;G06V10/82;;G06V20/64,G06T7/11;;B60R1/00;;G06T7/593;;G06V10/25;;G06V10/82;;G06V20/58;;G06V20/64,,25,19,031-554-742-157-015;;136-578-484-871-753;;039-157-879-085-923;;042-502-173-561-417;;094-577-137-430-121;;032-301-503-627-789;;070-467-050-835-005;;098-926-109-358-108;;016-400-108-039-841;;011-407-324-570-055;;021-360-232-245-594;;071-904-133-048-575;;102-201-317-308-185;;100-428-502-602-54X;;144-369-386-422-873;;098-749-981-533-592;;130-946-435-402-270;;007-063-801-607-535;;016-319-381-772-771,31794388;;10.1109/cvpr.2018.00644;;10.1109/tpami.2019.2956516;;10.1007/978-3-030-01270-0_39;;10.5244/c.30.19;;10.1109/cvpr.2016.79;;10.1109/cvpr.2017.305;;10.1109/icip.2017.8296296;;10.1109/iccv.2015.300;;27295650;;10.1109/tpami.2016.2577031;;10.1109/cvpr.2017.472;;10.1109/cvpr.2018.00102;;29994331;;10.1109/tpami.2018.2844175;;10.1109/iccv.2017.322;;10.1109/cvpr.2019.00752;;10.1109/cvpr.2019.00657;;10.1109/cvpr.2018.00913;;10.1109/cvpr.2019.00864;;10.1109/cvpr.2019.00904;;10.1109/iros.2018.8594049;;10.1109/3dv.2017.00034;;10.1109/icra40945.2020.9196660,"Cai, Z. et al., “Cascade R-CNN: Delving into High Quality Object Detection”, [cs.CV] Dec. 3, 2017.;;Liang, M. et al., “Deep Continuous Fusion for Multi-Sensor 3D Object Detection”, ECCV 2018 paper.;;Arnab, A. et al., “Bottom-up Instance Segmentation using Deep Higher-Order CRFs”, [cs.CV] Sep. 8, 2016.;;Fathi, A. et al., “Semantic Instance Segmentation via Deep Metric Learning”, [cs.CV] Mar. 30, 2017.;;Zhang, Z. et al., Instance-Level Segmentation for Autonomous Driving with Deep Densely Connected MRFs, [cs.CV] Apr. 27, 2016.;;Bai, M. et al., “Deep Watershed Transform for Instance Segmentation”, [cs.CV] May 4, 2017.;;Ye, L. et al., “Depth-Aware Object Instance Segmentation”.;;Zhang, Z. et al., “Monocular Object Instance Segmentation and Depth Ordering with CNNs” [cs.CV] Dec. 18, 2015.;;De Brabandere, B. et al., “Semantic Instance Segmentation with a Discriminative Loss Function”, [cs.CV] Aug. 8, 2017.;;Ren, S. et al., “Faster R-CNN: Towards Real-Time Object Detection with Region Proposal Networks”, [cs.CV] Jan. 6, 2016.;;Li, Y. et al., “Fully Convolutional Instance-aware Semantic Segmentation”, [cs.CV] Apr. 10, 2017.;;Qi, C.R. et al., “Frustum PointNets for 3D Object Detection from R GB-D Data”, [cs.CV] Apr. 13, 2018.;;Chen K. et al., “Hybrid Task Cascade for Instance Segmentation”, [cs.CV] Apr. 9, 2019.;;Kirillow, A. et al., “InstanceCut: from Edges to Instances with MultiCut”, [cs.CV] Nov. 24, 2016.;;Dai, J. et al., “Instance-sensitive Fully Convolutional Networks”, [cs.CV] Mar. 29, 2016.;;He, K. et al., “Mask R-CNN”, [cs.CV] Jan. 24, 2018.;;Liang M. et al., “Multi-Task Multi-Sensor Fusion for 3D Object Detection”, The IEEE Conference on Computer Vision and Pattern Recognition (CVPR), 2019.;;Huang, Z. et al., “Mask Scoring R-CNN”, [cs.CV] Mar. 1, 2019.;;Liu, S. et al., “Path Aggregation Network for Instance Segmentation”, [cs.CV] Sep. 18, 2018.;;Wang, Y. et al., “Pseudo-LiDAR from Visual Depth Estimation: Bridging the Gap in 3D Object Detection for Autonomous Driving”, [cs.CV] Jun. 14, 2019.;;Neven, D. et al., Instance Segmentation by Jointly Optimizing Spatial Embeddings and Clustering Bandwidth, The IEEE Conference on Computer Vision and Pattern Recognition (CVPR), 2019, pp. 8837-8845.;;Ku, J. et al., “Joint 3D Proposal Generation and Object Detection from View Aggregation”, [cs.CV] Jul. 12, 2018.;;Zhile Ren et al., “Cascaded Scene Flow Prediction Using Semantic Segmentation,” 2017 International Conference on 3D Vision (3DV), pp. 1-9, Jun. 7, 2018, pp. 1-8.;;Wu et al., “Geometry-Aware Instance Segmentation with Dispartity Maps”, ARXIV.org, Cornell Univ Library, Ithaca, NY (Jun. 2020), 4 pp.;;Pon et al., “Object-Centric Stereo Matching for 3D Object Detection”, ARXIV.org, Cornell Univ Library, Ithaca, NY (Sep. 2019), 7 pp.",ACTIVE
184,US,A1,US 2005/0030401 A1,180-928-543-425-458,2005-02-10,2005,US 63367303 A,2003-08-05,US 63367303 A,2003-08-05,Method and circuit for determining the response curve knee point in active pixel image sensors with extended dynamic range,"An apparatus and method for measuring the breakpoint of a response curve representing the voltage output of an image array having an extended dynamic range. By flooding a light-opaque pixel with a charge and then applying an intermediate reset voltage to the pixel, the signal is read from the pixel and stored. The full reset voltage is applied to the pixel, and then the signal in the pixel is read and stored. The voltage output difference is the difference between the first and second stored signal. The voltage output difference is then used to determine the voltage of the knee point. Further, a conventional saturated pixel can be reset with an intermediate reset just prior to readout. The resulting signal can then be used to determine the voltage of the knee point.",OVSIANNIKOV ILIA;;CHO KWANG-BO;;KAPLINSKY MICHAEL,OVSIANNIKOV ILIA;;CHO KWANG-BO;;KAPLINSKY MICHAEL,APTINA IMAGING CORPORATION (2008-09-26);;MICRON TECHNOLOGY INC (2003-07-15),https://lens.org/180-928-543-425-458,Patent Application,yes,10,15,4,4,0,H04N25/571;;H04N25/575;;H04N25/571,H04N5/355;;H04N5/374;;H04N5/378,348/302,0,0,,,,EXPIRED
185,US,B2,US 7456884 B2,176-063-137-923-844,2008-11-25,2008,US 63367303 A,2003-08-05,US 63367303 A,2003-08-05,Method and circuit for determining the response curve knee point in active pixel image sensors with extended dynamic range,"An apparatus and method for measuring the breakpoint of a response curve representing the voltage output of an image array having an extended dynamic range. By flooding a light-opaque pixel with a charge and then applying an intermediate reset voltage to the pixel, the signal is read from the pixel and stored. The full reset voltage is applied to the pixel, and then the signal in the pixel is read and stored. The voltage output difference is the difference between the first and second stored signal. The voltage output difference is then used to determine the voltage of the knee point. Further, a conventional saturated pixel can be reset with an intermediate reset just prior to readout. The resulting signal can then be used to determine the voltage of the knee point.",APTINA IMAGING CORP,OVSIANNIKOV ILIA;;CHO KWANG-BO;;KAPLINSKY MICHAEL,APTINA IMAGING CORPORATION (2008-09-26);;MICRON TECHNOLOGY INC (2003-07-15),https://lens.org/176-063-137-923-844,Granted Patent,yes,10,6,4,4,0,H04N25/571;;H04N25/575;;H04N25/571,H04N5/355;;H04N5/374;;H04N5/378,348/308;;348/241,2,1,009-406-602-689-659,10.1109/4.735551,"Steven Decker et al., ""A 256x256 CMOS Imaging Array with Wide Dynamic Range Pixels and Column-Parallel Digital Output"", IEEE Journal of Solid-State Circuits, vol. 33, No. 12, Dec. 1998, pp. 2081-2091.;;David X.D. Yang et al., ""A 640x512 Image Sensor with Ultra Wide Dynamic Range Floating-Point Pixel-Level ADC"", Electrical Engineering Department, Stanford University, Stanford, CA, Session No. 17, Nov. 1, 1998, pp. 1-11.",ACTIVE
186,DE,T5,DE 112021002996 T5,037-207-566-237-404,2023-03-09,2023,DE 112021002996 T,2021-05-24,US 202063029855 P;;US 202117325328 A;;US 2021/0033810 W,2020-05-26,Körperpositions- und aktivitätsbasierte Durchflusssteuerung für ventrikuläre Unterstützungsvorrichtung (VAD) mit vollständig implantierbarem Steuergerät,"Ein Steuergerät für eine implantierbare Blutpumpe schließt einen Beschleunigungsmesser ein, dafür konfiguriert, um mindestens eines aus der Gruppe bestehend aus Position und Bewegung des Steuergeräts zu messen. Die Verarbeitungsschaltung ist dafür konfiguriert, um die Bedienung der implantierbaren Blutpumpe zu steuern, wobei die Verarbeitungsschaltung mit dem Beschleunigungsmesser in Verbindung vorliegt, wobei die Verarbeitungsschaltung dafür konfiguriert ist, um eine Drehzahl der implantierbaren Blutpumpe anzupassen, wenn das gemessene mindestens eine aus der Gruppe bestehend aus Position und Bewegung von einem jeweiligen vorbestimmten Schwellenwert abweicht.",MEDTRONIC INC,CHO YONG K;;HESS MICHAEL F;;EGGEN MICHAEL D;;BROWN MICHAEL C;;REINERT MICHAEL A,,https://lens.org/037-207-566-237-404,Patent Application,no,5,0,3,3,0,A61M60/122;;A61M60/216;;A61M60/515;;A61M2230/62;;A61M2230/63;;A61M60/178;;A61M60/242;;A61M60/515;;A61M60/546;;A61M2205/3365;;A61M60/216;;A61M2230/62;;A61M60/178,A61M60/122;;A61M60/216;;A61M60/515,,0,0,,,,PENDING
187,WO,A1,WO 2021/242659 A1,166-145-865-989-004,2021-12-02,2021,US 2021/0033810 W,2021-05-24,US 202063029855 P;;US 202117325328 A,2020-05-26,BODY POSITION AND ACTIVITY BASED FLOW CONTROL FOR VENTRICULAR ASSIST DEVICE (VAD) WITH FULLY IMPLANTABLE CONTROLLER,"A controller for an implantable blood pump, includes an accelerometer configured to measure at least one from the group consisting of position and movement of the controller. Processing circuitry is configured to control operation of the implantable blood pump, the processing circuity being in communication with the accelerometer, the processing circuitry being configured to adjust a speed of the implantable blood pump if the measured at least one from the group consisting of position and movement deviates from a respective predetermined threshold.",MEDTRONIC INC,CHO YONG K;;HESS MICHAEL F;;EGGEN MICHAEL D;;BROWN MICHAEL C;;REINERT MICHAEL A,,https://lens.org/166-145-865-989-004,Patent Application,yes,8,0,3,3,0,A61M60/122;;A61M60/216;;A61M60/515;;A61M2230/62;;A61M2230/63;;A61M60/178;;A61M60/242;;A61M60/515;;A61M60/546;;A61M2205/3365;;A61M60/216;;A61M2230/62;;A61M60/178,A61M60/122;;A61M60/216;;A61M60/515,,0,0,,,,PENDING
188,EP,A1,EP 0981653 A1,069-580-991-256-645,2000-03-01,2000,EP 98903777 A,1998-01-30,US 9801584 W;;US 3632997 P,1997-01-31,METHOD OF IMPROVING FRACTURE TOUGHNESS IN ALUMINUM-LITHIUM ALLOYS,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",REYNOLDS METALS CO,CHO ALEX;;SKILLINGBERG MICHAEL H;;GREENE RICHARD E;;NIEDZINSKI MICHAEL M,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, US (2012-06-22);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, R, US (2012-06-22);;MCCOOK METALS L.L.C. (2001-09-05);;PECHINEY ROLLED PRODUCTS, LLC (2003-05-07)",https://lens.org/069-580-991-256-645,Patent Application,yes,0,0,18,18,0,C22C21/12;;C22F1/057,C22C21/12;;C22F1/057,,0,0,,,,EXPIRED
189,EP,A4,EP 0981653 A4,193-469-125-069-333,2000-05-17,2000,EP 98903777 A,1998-01-30,US 9801584 W;;US 3632997 P,1997-01-31,METHOD OF IMPROVING FRACTURE TOUGHNESS IN ALUMINUM-LITHIUM ALLOYS,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",REYNOLDS METALS CO,CHO ALEX;;SKILLINGBERG MICHAEL H;;GREENE RICHARD E;;NIEDZINSKI MICHAEL M,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, US (2012-06-22);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, R, US (2012-06-22);;MCCOOK METALS L.L.C. (2001-09-05);;PECHINEY ROLLED PRODUCTS, LLC (2003-05-07)",https://lens.org/193-469-125-069-333,Search Report,no,3,0,18,18,0,C22C21/12;;C22F1/057,C22C21/12;;C22F1/057,,2,0,,,"""Metals & Alloys in the UNIFIED NUMBERING SYSTEM, 7TH ED."", 1996, SOCIETY OF AUTOMOTIVE ENGINEERS, USA, XP002131452;;M. PETERS AND P.-J. WINKLER: ""Aluminium-Lithium"", 1992, DEUTSCHE GESELLSCHAFT FÜR MATERIALKUNDE, GERMANY, XP002131453",EXPIRED
190,WO,A1,WO 1998/033947 A1,075-277-253-536-317,1998-08-06,1998,US 9801584 W,1998-01-30,US 3632997 P,1997-01-31,METHOD OF IMPROVING FRACTURE TOUGHNESS IN ALUMINUM-LITHIUM ALLOYS,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",REYNOLDS METALS CO,CHO ALEX;;SKILLINGBERG MICHAEL H;;GREENE RICHARD E;;NIEDZINSKI MICHAEL M,,https://lens.org/075-277-253-536-317,Patent Application,yes,2,8,18,18,0,C22C21/12;;C22F1/057,C22C21/12;;C22F1/057,,0,0,,,,PATENTED
191,AT,T1,AT E250675 T1,145-896-427-381-715,2003-10-15,2003,AT 98903777 T,1998-01-30,US 3632997 P;;US 9801584 W,1997-01-31,VERFAHREN ZUR ERHÖHUNG DER BRUCHZÄHIGKEIT IN ALUMINIUM-LITHIUM-LEGIERUNGEN,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",PECHINEY ROLLED PRODUCTS LLC,CHO ALEX;;SKILLINGBERG MICHAEL H;;GREENE RICHARD E;;NIEDZINSKI MICHAEL M,,https://lens.org/145-896-427-381-715,Granted Patent,no,0,0,18,18,0,C22C21/12;;C22F1/057,C22C21/12;;C22F1/057,,0,0,,,,DISCONTINUED
192,EP,B1,EP 0981653 B1,109-362-247-431-808,2003-09-24,2003,EP 98903777 A,1998-01-30,US 9801584 W;;US 3632997 P,1997-01-31,METHOD OF IMPROVING FRACTURE TOUGHNESS IN ALUMINUM-LITHIUM ALLOYS,"An aluminum-lithium alloy is processed with controlled amounts of copper, lithium, manganese and zirconium to produce a product having improved fracture toughness in the short longitudinal (S-L) direction and acceptable strength in the short transverse (ST) direction.",PECHINEY ROLLED PRODUCTS LLC,CHO ALEX;;SKILLINGBERG MICHAEL H;;GREENE RICHARD E;;NIEDZINSKI MICHAEL M,"CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, US (2012-06-22);;CONSTELLIUM ROLLED PRODUCTS RAVENSWOOD, LLC, R, US (2012-06-22);;MCCOOK METALS L.L.C. (2001-09-05);;PECHINEY ROLLED PRODUCTS, LLC (2003-05-07)",https://lens.org/109-362-247-431-808,Granted Patent,yes,4,1,18,18,0,C22C21/12;;C22F1/057,C22C21/12;;C22F1/057,,2,0,,,": ""Metals & Alloys in the UNIFIED NUMBERING SYSTEM, 7TH ED."" 1996 , SOCIETY OF AUTOMOTIVE ENGINEERS , USA XP002131452 * alloy A92097 * * page 30 *;;M. PETERS AND P.-J. WINKLER: ""Aluminium-Lithium"" 1992 , DEUTSCHE GESELLSCHAFT FÜR MATERIALKUNDE , GERMANY XP002131453 * p.203-208: ""High toughness, high strength aluminum alloy design and practice"" *",EXPIRED
193,JP,A,JP H1081994 A,157-047-857-230-377,1998-03-31,1998,JP 19966197 A,1997-07-25,US 68771696 A,1996-07-26,METHOD FOR PLATING SHAPE OF HIGH ASPECT RATIO,"PROBLEM TO BE SOLVED: To provide a method by which apertures are filled with a plating liquid even if the aspect ratio of these apertures is very high. SOLUTION: The method for forming the blind apertures having the high aspect ratio, then filling the blind apertures with the plating liquid consists of a stage for pattern and exposing the layer 6 of a photosensitive material for delineating the apertures 7 and a stage for exposing this layer to a water soluble developer. The apertures are then washed without drying the developer or water from the apertures. The apertures 7 and the layer 6 are then exposed to the plating liquid 8 without allowing the water content from being dried from the apertures after the apertures 7 are washed. The best chances for filling the apertures 7 with the plating liquid 8 are provided by maintaining the water content in the apertures between the developing stage and the electroplating stage.",FUJITSU LTD,SOLOMON I BEIRIN;;WILLIAM T CHO;;MICHAEL G LEE;;UEN-CHO VINCENT WANG,,https://lens.org/157-047-857-230-377,Patent Application,no,0,3,2,2,0,C25D5/022;;C25D5/022;;H05K3/422;;H05K3/422,C25D5/02;;C25D5/34;;H05K3/42,,0,0,,,,DISCONTINUED
194,ZA,B,ZA 912411 B,039-978-797-783-734,1992-11-25,1992,ZA 912411 A,1991-03-28,GB 9007052 A,1990-03-29,PHARMACEUTICAL FORMULATIONS,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;YOUNG W CHO;;FLYNN MICHAEL JOHN;;MICHAEL JOHN FLYNN;;SHEPHERD THOMAS SMITH;;THOMAS SMITH SHEPHERD,,https://lens.org/039-978-797-783-734,Granted Patent,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/107;;A61K9/00;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
195,BR,A,BR 8501546 A,117-582-367-044-516,1985-11-26,1985,BR 8501546 A,1985-04-02,US 59632984 A,1984-04-03,SISTEMA CONVERSOR DE FREQUENCIA ILIMITADO DOTADO DE CARACTERISTICA HARMONICA APERFEICOADA E COMANDO DE MOTOR DE CA DE FREQUENCIA AJUSTAVEL UTILIZANDO UM SISTEMA DESTE TIPO,,WESTINGHOUSE ELECTRIC CORP,GYUGYI LASZLO;;HEINRICH THEODORE MICHAEL;;CHO GYU-HYEONG,,https://lens.org/117-582-367-044-516,Patent Application,no,0,0,18,18,0,H02M5/271;;H02P27/16;;H02M5/00;;H02P27/16;;H02M5/271,H02M5/27;;H02P27/16,,0,0,,,,DISCONTINUED
196,EP,A1,EP 2337985 A1,129-719-173-666-085,2011-06-29,2011,EP 09744370 A,2009-10-22,EP 2009063867 W;;US 10819508 P;;EP 08171051 A;;EP 09744370 A,2008-10-24,BUNDLE TRAILER FOR GAS DELIVERY,,SOLVAY FLUOR GMBH,PITTROFF MICHAEL;;PARK YUK-HWAN;;CHO WOO-JIN,,https://lens.org/129-719-173-666-085,Patent Application,yes,0,0,11,11,0,F17C13/083;;F17C13/084;;F17C2201/0104;;F17C2201/032;;F17C2201/035;;F17C2201/054;;F17C2201/056;;F17C2205/0107;;F17C2205/0111;;F17C2205/013;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C2205/0157;;F17C2205/0326;;F17C2221/01;;F17C2221/03;;F17C2250/0447;;F17C2260/01;;F17C2265/04;;F17C2265/063;;F17C2270/0171;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/08;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/083;;F17C2250/0447;;F17C2265/063;;F17C2221/01;;F17C2201/0104;;F17C2205/0157;;F17C2201/032;;F17C2205/0107;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C13/084;;F17C2201/054;;F17C2260/01;;F17C2205/013;;F17C2201/056;;F17C2205/0326;;F17C2205/0111;;F17C2221/03;;F17C2265/04;;F17C2201/035;;F17C2270/0171,F17C13/08,,0,0,,,,ACTIVE
197,US,A1,US 2021/0409033 A1,154-303-777-468-124,2021-12-30,2021,US 202117474501 A,2021-09-14,US 202117474501 A;;KR 20200007273 A;;US 202017000665 A,2020-01-20,ANALOG-TO-DIGITAL CONVERTER,"An analog-to-digital converter includes: a voltage-current converter receiving an analog input voltage, generating a first digital signal from the analog input voltage, and outputting a residual current remaining after the first digital signal; a current-time converter converting the residual current into a current time in a time domain; and a time-digital converter receiving the residual time, and generating a second digital signal from the residual time, wherein the first digital signal and the second digital signal are sequences of digital codes representing respective signal levels of the analog input voltage.",SAMSUNG ELECTRONICS CO LTD,MOON KYOUNGJUN;;OH DONGRYEOL;;CHO YOUNGJAE;;CHOI MICHAEL,,https://lens.org/154-303-777-468-124,Patent Application,yes,2,1,5,5,0,G04F10/005;;H03M1/502;;H03M1/742;;H03M1/468;;H03M1/164;;H03M1/0695;;H03M1/38;;H03M1/50;;H03M1/002;;H03M1/0612;;H03M1/1028;;H03M1/145;;G04F10/005;;H03M1/38,H03M1/10;;H03M1/14,,0,0,,,,ACTIVE
198,CN,A,CN 106163548 A,157-658-565-017-147,2016-11-23,2016,CN 201580017492 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,Methods of treating alzheimer's disease,"Methods of treating Alzheimer's disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/157-658-565-017-147,Patent Application,no,1,3,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,2,0,,,"OSKAR等: ""An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique AβBinding Properties Promotes Neuroprotection and Glial Engulfment of Aβ"", 《THE JOURNAL OF NEUROSCIENCE》;;RACHELLE等: ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease"", 《THE NEW ENGLAND JOURNAL OF MEDICINE》",PENDING
199,WO,A1,WO 2008/030865 A1,152-591-464-470-190,2008-03-13,2008,US 2007/0077625 W,2007-09-05,US 84311006 P,2006-09-08,ASSAY FOR ANTIBODIES TO MYCOBACTERIUM PARATUBERCULOSIS,"A method of detecting an immune response to a paratuberculosis- specific antigen, comprising incubating a sample from a subject with the paratuberculosis-specific antigen and detecting the presence of an antibody in the sample as an indication of an immune response to the paratuberculosis- specific antigen. The antigen may be obtained from a novel M. paratυbercυlosis strain JTC303. The antigen may be obtained from the JTC303 culture filtrate. Also provided are antibodies to the paratuberculosis- specific antigen, and a diagnostic kit for the detection of an immune response to a paratuberculosis-specific antigen in a mammal.",WISCONSIN ALUMNI RES FOUND;;COLLINS MICHAEL T;;SHIN SUNG JAE;;CHO DONGHEE,COLLINS MICHAEL T;;SHIN SUNG JAE;;CHO DONGHEE,,https://lens.org/152-591-464-470-190,Patent Application,yes,0,4,9,9,0,C07K14/35;;G01N33/5695;;C12R2001/32;;C12N1/205;;G01N33/569;;C12N1/20;;C07K14/35;;G01N33/5695;;C07K14/35;;C12N1/205;;C12R2001/32,C07K14/35;;C12N1/20;;C12R1/32;;G01N33/569,,6,4,108-247-929-915-498;;058-732-991-749-942;;039-071-221-332-185;;051-164-119-466-694,pmc368355;;10.1128/aem.70.3.1688-1697.2004;;15006794;;10.1016/j.pep.2006.12.022;;17296312;;17022102;;10.1002/pmic.200600207;;17028217;;10.1128/cvi.00058-06;;pmc1595327,"CHO D, SUNG N, COLLINS MT: ""Proteomic identification of immunogenic Mycobacterium paratuberculosis proteins"", 8TH INTERNATIONAL COLLOQUIUM ON PARATUBERCULOSIS, 14 August 2005 (2005-08-14) - 17 August 2005 (2005-08-17), COPENHAGEN, DENMARK, pages 78, XP002464448, Retrieved from the Internet <URL:http://www.paratuberculosis.org/assets/pdfs/proc8.pdf> [retrieved on 20080114];;SUNG NACKMOON ET AL: ""Possible association of GroES and antigen 85 proteins with heat resistance of Mycobacterium paratuberculosis."", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 70, no. 3, March 2004 (2004-03-01), pages 1688 - 1697, XP002464444, ISSN: 0099-2240;;CHO DONGHEE ET AL: ""Cloning, expression, purification and serodiagnostic evaluation of fourteen Mycobacterium paratuberculosis proteins"", PROTEIN EXPRESSION AND PURIFICATION, vol. 53, no. 2, June 2007 (2007-06-01), pages 411 - 420, XP002464445, ISSN: 1046-5928;;CHO DONGHEE ET AL: ""Identification of proteins of potential diagnostic value for bovine paratuberculosis"", PROTEOMICS, vol. 6, no. 21, 5 October 2006 (2006-10-05), pages 5785 - 5794, XP002464446, ISSN: 1615-9853;;CHO DONGHEE ET AL: ""Comparison of the proteosomes and antigenicities of secreted and cellular proteins produced by Mycobacterium paratuberculosis"", CLINICAL AND VACCINE IMMUNOLOGY, vol. 13, no. 10, October 2006 (2006-10-01), pages 1155 - 1161, XP002464447, ISSN: 1556-6811;;See also references of EP 2084261A1",PENDING
200,EP,A1,EP 3873435 A1,023-712-294-329-522,2021-09-08,2021,EP 19880749 A,2019-10-31,US 201862754998 P;;US 2019/0059135 W,2018-11-02,MAGNETOMECHANIC TRIGGERING OF PAYLOAD RELEASE FROM MINIATURIZED DEVICES,,BIONAUT LABS LTD,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CHO SUEHYUN;;SARGSYAN HOVHANNES,,https://lens.org/023-712-294-329-522,Patent Application,yes,0,0,8,8,0,A61M2039/0205;;A61M37/0069;;A61M31/002;;A61K9/0009;;A61K9/0024;;A61K9/0097;;A61M31/002;;A61M37/0069,A61K9/00;;A61K47/69;;A61M5/145;;A61M31/00,,0,0,,,,PENDING
201,US,A1,US 2021/0402161 A1,080-873-150-802-442,2021-12-30,2021,US 201917289682 A,2019-10-31,US 201917289682 A;;US 201862754998 P;;US 2019/0059135 W,2018-11-02,MAGNETOMECHANIC TRIGGERING OFPAYLOAD RELEASE FROM MINIATURIZED DEVICES,"A carrier device and methods of use are described. The device and methods are directed toward implanting in biological tissue and for releasing a medical payload or functional material in biological tissue according to a remote magnetic trigger. The carrier device has a cavity with an opening through an external surface of the device. The carrier device includes at least one moveable, magnetic element sensitive to a magnetic field gradient. When a magnetic field gradient, rotating magnetic field, or uniform magnetic field, or a combination of thereof is applied to the tissue, the moveable magnetic element provides release of the medical payload or functional material through the cavity opening. In some embodiments, payload release can be started, stopped, and restarted at a later time or place. In addition to payload release, devices of this invention are equipped with a propelling element, the propelling element is responsive to external stimuli that enables propulsion and navigation of the device.",BIONAUT LABS LTD,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CHO SUEHYUN;;SARGSYAN HOVHANNES,,https://lens.org/080-873-150-802-442,Patent Application,yes,5,0,8,8,0,A61M2039/0205;;A61M37/0069;;A61M31/002;;A61K9/0009;;A61K9/0024;;A61K9/0097;;A61M31/002;;A61M37/0069,A61M37/00;;A61K9/00;;A61M31/00,,0,0,,,,PENDING
202,GB,B,GB 2157101 B,145-055-698-477-421,1988-01-20,1988,GB 8507892 A,1985-03-26,US 59632984 A,1984-04-03,UNRESTRICTED FREQUENCY CHANGER SYSTEM HAVING IMPROVED HARMONIC CHARACTERISTIC AND ADJUSTABLE FREQUENCY AC MOTOR DRIVE USING SUCH A SYSTEM,,WESTINGHOUSE ELECTRIC CORP,GYUGYI LASZLO;;HEINRICH THEODORE MICHAEL;;GYU-HYEONG CHO,,https://lens.org/145-055-698-477-421,Granted Patent,no,0,0,18,18,0,H02M5/271;;H02P27/16;;H02M5/00;;H02P27/16;;H02M5/271,H02M5/27;;H02P27/16,H2F9J6;;H2F9K12;;H2F9KX;;H2F9L1;;H2F9P1;;H2F9Q;;H2F9R19C;;H2F9R39C;;H2F9R9B;;H2F9T4B;;H2FSAA;;U1S2049;;U1SH2F,0,0,,,,EXPIRED
203,EP,A4,EP 3873435 A4,161-853-805-477-168,2022-11-09,2022,EP 19880749 A,2019-10-31,US 201862754998 P;;US 2019/0059135 W,2018-11-02,MAGNETOMECHANIC TRIGGERING OF PAYLOAD RELEASE FROM MINIATURIZED DEVICES,,BIONAUT LABS LTD,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CHO SUEHYUN;;SARGSYAN HOVHANNES,,https://lens.org/161-853-805-477-168,Search Report,no,8,0,8,8,0,A61M2039/0205;;A61M37/0069;;A61M31/002;;A61K9/0009;;A61K9/0024;;A61K9/0097;;A61M31/002;;A61M37/0069,A61K9/00;;A61K47/69;;A61M5/145;;A61M31/00;;A61M37/00;;A61M39/02,,0,0,,,,PENDING
204,US,B2,US 11190202 B2,179-599-096-413-470,2021-11-30,2021,US 202017000665 A,2020-08-24,KR 20200007273 A,2020-01-20,Analog-to-digital converter,"An analog-to-digital converter includes: a voltage-current converter receiving an analog input voltage, generating a first digital signal from the analog input voltage, and outputting a residual current remaining after the first digital signal; a current-time converter converting the residual current into a current time in a time domain; and a time-digital converter receiving the residual time, and generating a second digital signal from the residual time, wherein the first digital signal and the second digital signal are sequences of digital codes representing respective signal levels of the analog input voltage.",SAMSUNG ELECTRONICS CO LTD,MOON KYOUNGJUN;;OH DONGRYEOL;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2020-07-16),https://lens.org/179-599-096-413-470,Granted Patent,yes,11,0,5,5,0,G04F10/005;;H03M1/502;;H03M1/742;;H03M1/468;;H03M1/164;;H03M1/0695;;H03M1/38;;H03M1/50;;H03M1/002;;H03M1/0612;;H03M1/1028;;H03M1/145;;G04F10/005;;H03M1/38,H03M1/10;;G04F10/00;;H03M1/14;;H03M1/38,,2,2,023-947-833-448-093;;082-593-607-080-133,10.1109/jssc.2019.2938450;;10.1109/jssc.2019.2926648,"Zhang, et al. “A 0.6-V 13-bit 20-MS/s Two-Step TDC-Assisted SAR ADC With PVT Tracking and Speed-Enhanced Techniques”, IEEE Journal of Solid-State Circuits, vol. 54, No. 12, Dec. 2019, 14 pages.;;Moon, et al. “A 9.1-ENOB 6-mW 10-Bit 500-MS/s Pipelined-SAR ADC With Current-Mode Residue Processing in 28-nm CMOS”, IEEE Journal of Solid-State Circuits, vol. 54, No. 9, Sep. 2019, 11 pages.",ACTIVE
205,IT,B,IT 1183532 B,183-297-288-555-685,1987-10-22,1987,IT 2016385 A,1985-03-29,US 59632984 A,1984-04-03,"SISTEMA A VARIAZIONE DI FREQUENZA ILLIMITATA AVENTE CARATTERISTICHE DI COMPOSIZIONE ARMONICA PERFEZIONATE, E AZIONAMENTO PER MOTORE A C.A. A FREQUENZA VARIABILE UTILIZZANTE TALE SISTEMA",,WESTINGHOUSE ELECTRIC CORP,GYUGYI LASZLO;;HEINRICH THEODORE MICHAEL;;CHO GYU HYEONG,,https://lens.org/183-297-288-555-685,Granted Patent,no,0,0,18,18,0,H02M5/271;;H02P27/16;;H02M5/00;;H02P27/16;;H02M5/271,H02M5/27;;H02P27/16,,0,0,,,,EXPIRED
206,EP,B1,EP 3102231 B1,039-281-328-146-775,2019-09-11,2019,EP 15710295 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,,HOFFMANN LA ROCHE,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/039-281-328-146-775,Granted Patent,yes,2,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,5,0,,,"RACHELLE S. DOODY ET AL: ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease"", NEW ENGLAND JOURNAL OF MEDICINE, vol. 370, no. 4, 23 January 2014 (2014-01-23), pages 311-321, XP055183832, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1312889;;NIELS D PRINS ET AL: ""Treating Alzheimer?s disease with monoclonal antibodies: current status and outlook for the future"", ALZHEIMERS RES THER, BIOMED CENTRAL LTD, LONDON, UK, vol. 5, no. 6, 11 November 2013 (2013-11-11), page 56, XP021193607, ISSN: 1758-9193, DOI: 10.1186/ALZRT220;;O. ADOLFSSON ET AL: ""An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A"", JOURNAL OF NEUROSCIENCE, vol. 32, no. 28, 11 July 2012 (2012-07-11) , pages 9677-9689, XP055097358, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.4742-11.2012;;Charlotte Jago: ""Alzheimer's Disease: One Year Later"", , 3 February 2014 (2014-02-03), XP055183816, Retrieved from the Internet: URL:http://lsconnect.thomsonreuters.com/al zheimers-disease-year-later/ [retrieved on 2015-04-17];;""Crenezumab Phase II cognition data in Alzheimer's disease presented"", , 16 July 2014 (2014-07-16), XP055183813, Retrieved from the Internet: URL:http://www.acimmune.com/content/img/pa ges/ACImmune_crenezumab_phase2_ENGLISH_201 40716_final.pdf [retrieved on 2015-04-17]",ACTIVE
207,WO,A3,WO 2022/246174 A3,094-663-168-267-700,2022-12-29,2022,US 2022/0030221 W,2022-05-20,US 202163191497 P;;US 202163191515 P;;US 202163191418 P;;US 202163191454 P;;US 202163213120 P,2021-05-21,SYSTEM AND METHOD FOR LOCALIZED THERAPEUTIC TREATMENT,"Provided are systems and miniature devices configured to navigate within a patient to a location therewithin for delivering to induce a localized therapeutic effect, such as the delivery of catalyzing energy and/or for the conversion of a prodrug to a pharmaceutically active drug. Further provided are various methods of treatment using such systems and devices.",BIONAUT LABS LTD;;CHO SUEHYUN;;CROS FLORENT;;KISELYOV ALEX;;SHPIGELMACHER MICHAEL,CHO SUEHYUN;;CROS FLORENT;;KISELYOV ALEX;;SHPIGELMACHER MICHAEL,,https://lens.org/094-663-168-267-700,Search Report,yes,7,0,6,6,0,C07K14/52;;C07K14/715;;A61K47/50;;A61P37/00;;A61M37/00;;A61M31/002;;A61M35/00;;A61K9/0097;;A61K9/0009,A61K9/50;;A61M31/00,,0,0,,,,PENDING
208,AU,A,AU 1985/040419 A,130-081-181-620-437,1985-10-10,1985,AU 1985/040419 A,1985-03-27,US 59632984 A,1984-04-03,UNRESTRICTED FREQUENCY CHANGER SYSTEM,,AEG WESTINGHOUSE IND AUTOMATION CORPORATION,GYUGYI LASZLO;;HEINRICH THEODORE MICHAEL;;CHO GYU-HYEONG,,https://lens.org/130-081-181-620-437,Patent Application,no,0,0,18,18,0,H02M5/271;;H02P27/16;;H02M5/00;;H02P27/16;;H02M5/271,H02M5/27;;H02P27/16,,0,0,,,,EXPIRED
209,US,A1,US 2020/0399352 A1,158-954-528-925-712,2020-12-24,2020,US 202016782654 A,2020-02-05,US 202016782654 A;;US 201514616261 A;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/158-954-528-925-712,Patent Application,yes,0,0,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K31/56,,0,0,,,,DISCONTINUED
210,EP,B1,EP 2337985 B1,161-741-094-330-840,2020-02-05,2020,EP 09744370 A,2009-10-22,EP 2009063867 W;;US 10819508 P;;EP 08171051 A;;EP 09744370 A,2008-10-24,BUNDLE TRAILER FOR GAS DELIVERY,,SOLVAY FLUOR GMBH,PITTROFF MICHAEL;;PARK YUK-HWAN;;CHO WOO-JIN,,https://lens.org/161-741-094-330-840,Granted Patent,yes,1,0,11,11,0,F17C13/083;;F17C13/084;;F17C2201/0104;;F17C2201/032;;F17C2201/035;;F17C2201/054;;F17C2201/056;;F17C2205/0107;;F17C2205/0111;;F17C2205/013;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C2205/0157;;F17C2205/0326;;F17C2221/01;;F17C2221/03;;F17C2250/0447;;F17C2260/01;;F17C2265/04;;F17C2265/063;;F17C2270/0171;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/08;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/083;;F17C2250/0447;;F17C2265/063;;F17C2221/01;;F17C2201/0104;;F17C2205/0157;;F17C2201/032;;F17C2205/0107;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C13/084;;F17C2201/054;;F17C2260/01;;F17C2205/013;;F17C2201/056;;F17C2205/0326;;F17C2205/0111;;F17C2221/03;;F17C2265/04;;F17C2201/035;;F17C2270/0171,F17C13/08,,0,0,,,,ACTIVE
211,CA,A1,CA 2938466 A1,027-253-429-463-645,2015-08-13,2015,CA 2938466 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/027-253-429-463-645,Patent Application,no,0,0,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,ACTIVE
212,JP,A,JP 2020073507 A,132-775-128-333-85X,2020-05-14,2020,JP 2019230200 A,2019-12-20,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"To provide methods of treating Alzheimer's disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD.SOLUTION: A humanized monoclonal anti-amyloid beta (Aβ) antibody that binds within residues 13 and 24 of amyloid β (1-42)(SEQ ID NO:1) is administered in an amount effective to slow the decline in cognitive capacity.SELECTED DRAWING: Figure 7",GENENTECH INC,WILLIAM CHO;;MICHEL FRIESENHAHN;;ROBERT PAUL;;MICHAEL WARD,,https://lens.org/132-775-128-333-85X,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/395;;A61K31/13;;A61K31/135;;A61K31/185;;A61K31/198;;A61K31/27;;A61K31/277;;A61K31/381;;A61K31/4045;;A61K31/405;;A61K31/428;;A61K31/445;;A61K31/4453;;A61K31/455;;A61K31/473;;A61K31/4745;;A61K31/48;;A61K31/55;;A61K31/565;;A61K31/573;;A61K45/00;;A61P25/28;;A61P43/00,,0,0,,,,PENDING
213,KR,A,KR 20160111039 A,139-940-973-532-03X,2016-09-23,2016,KR 20167024829 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"본원에서는 ApoE4 양성 환자 및 경증 AD를 앓는 환자를 포함하는, 약하거나 중등도의 AD를 앓는 환자에서 알츠하이머 질환(AD)을 치료하는 방법이 제공된다.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/139-940-973-532-03X,Patent Application,no,0,2,36,75,18,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K31/56;;A61K39/00;;C07K16/18,,0,0,,,,DISCONTINUED
214,AU,B2,AU 2015/214058 B2,159-203-413-863-864,2020-07-09,2020,AU 2015/214058 A,2015-02-06,US 201462081992 P;;US 201462010259 P;;US 201461971479 P;;US 201461937472 P;;US 2015/0014758 W,2014-02-08,Methods of treating Alzheimer's Disease,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/159-203-413-863-864,Granted Patent,no,1,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K39/00;;A61P25/28,,4,4,015-169-910-449-13X;;086-932-421-807-452;;131-216-810-326-268;;044-966-041-336-742,24450890;;10.1056/nejmoa1312889;;24216217;;pmc3978826;;10.1186/alzrt220;;pmc6622286;;22787053;;10.1523/jneurosci.4742-11.2012;;22871696;;10.1038/nbt0812-731,"DOODY, R.S. ET AL, ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease"", NEW ENGLAND JOURNAL OF MEDICINE, (2014), vol. 370, no. 4, pages 311 - 321;;PRINS, N.D. ET AL, ""Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future"", ALZHEIMERS RES THER, (2013), vol. 5, no. 6, page 56;;ADOLFSSON, O. ET AL, ""An Effector-Reduced Anti-Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A"", JOURNAL OF NEUROSCIENCE, (2012), vol. 32, no. 28, pages 9677 - 9689;;GARBER, K., ""Genentech's Alzheimer's antibody trial to study disease prevention"", Nature Biotechnology (2012), vol. 30, no.8 pages 731-732",ACTIVE
215,US,A1,US 2014/0197556 A1,058-677-109-931-087,2014-07-17,2014,US 201414209347 A,2014-03-13,US 201414209347 A;;US 201213564881 A;;US 41818909 A;;US 201361784124 P;;US 20112108 P;;US 4251908 P,2008-04-04,SYSTEM AND METHOD FOR LIQUID DISTRIBUTION,A liquid flow distributor for positioning above one or more packing sections in a packed exchange tower includes a plurality of troughs. At least one trough in the plurality of troughs has along a side thereto a deflecting member The deflecting member is angulated to generally follow a shape of the at least one trough. A diffuser side of the deflecting member is positioned to deposit the liquid into a discharge region. A plurality of break bars are disposed on the diffuser side of the deflecting member. A deflector side of the deflecting member is positioned for deflecting ascending vapor away from the discharge region.,GTC TECHNOLOGY US LLC,CHO JAE-MAN;;KU NAMSUN;;BINKLEY MICHAEL J,SULZER MANAGEMENT AG (2021-02-23);;SULZER GTC TECHNOLOGY US INC (2019-05-31),https://lens.org/058-677-109-931-087,Patent Application,yes,8,3,2,5,0,B01D3/008;;B01D3/008,B01F3/04,261/97,0,0,,,,ACTIVE
216,IT,A0,IT 8520163 A0,124-369-602-884-082,1985-03-29,1985,IT 2016385 A,1985-03-29,US 59632984 A,1984-04-03,"SISTEMA A VARIAZIONE DI FREQUENZA ILLIMITATA AVENTE CARATTERISTICHE DI COMPOSIZIONE ARMONICA PERFEZIONATE, E AZIONAMENTO PER MOTORE A C.A. A FREQUENZA VARIABILE UTILIZZANTE TALE SISTEMA.",,WESTINGHOUSE ELECTRIC CORP,GYUGYI LASZLO;;HEINRICH THEODORE MICHAEL;;CHO GYU HYEONG,,https://lens.org/124-369-602-884-082,Patent Application,no,0,0,18,18,0,H02M5/271;;H02P27/16;;H02M5/00;;H02P27/16;;H02M5/271,H02M5/27;;H02P27/16,,0,0,,,,EXPIRED
217,EP,A1,EP 2084261 A1,188-399-188-811-652,2009-08-05,2009,EP 07841886 A,2007-09-05,US 2007/0077625 W;;US 84311006 P,2006-09-08,ASSAY FOR ANTIBODIES TO MYCOBACTERIUM PARATUBERCULOSIS,,WISCONSIN ALUMNI RES FOUND,COLLINS MICHAEL T;;SHIN SUNG JAE;;CHO DONGHEE,,https://lens.org/188-399-188-811-652,Patent Application,yes,0,0,9,9,0,C07K14/35;;G01N33/5695;;C12R2001/32;;C12N1/205;;G01N33/569;;C12N1/20;;C07K14/35;;G01N33/5695;;C07K14/35;;C12N1/205;;C12R2001/32,C12N1/20;;C07K14/35;;C12R1/32;;G01N33/569,,1,1,007-633-147-995-87X,10.1128/cvi.00105-08;;pmc2519299;;18550730,"S. J. SHIN ET AL: ""Diagnosis of Bovine Paratuberculosis by a Novel Enzyme-Linked Immunosorbent Assay Based on Early Secreted Antigens of Mycobacterium avium subsp. paratuberculosis"", CLINICAL AND VACCINE IMMUNOLOGY, vol. 15, no. 8, 11 June 2008 (2008-06-11), pages 1277 - 1281, XP055097327, ISSN: 1556-6811, DOI: 10.1128/CVI.00105-08",DISCONTINUED
218,GB,A,GB 2157101 A,013-460-703-186-438,1985-10-16,1985,GB 8507892 A,1985-03-26,US 59632984 A,1984-04-03,UNRESTRICTED FREQUENCY CHANGER SYSTEM HAVING IMPROVED HARMONIC CHARACTERISTIC AND ADJUSTABLE FREQUENCY AC MOTOR DRIVE USING SUCH A SYSTEM,,WESTINGHOUSE ELECTRIC CORP,GYUGYI LASZLO;;HEINRICH THEODORE MICHAEL;;GYU-HYEONG CHO,,https://lens.org/013-460-703-186-438,Patent Application,no,0,0,18,18,0,H02M5/271;;H02P27/16;;H02M5/00;;H02P27/16;;H02M5/271,H02M5/27;;H02P27/16,H2F FFCS          FFCS;;H2F FSAA          FSAA;;H2F F9J18         FFCS;;H2F F9J18         FSAA;;H2F F9KX          FFCS;;H2F F9KX          FSAA;;H2F F9K12         FFCS;;H2F F9K12         FSAA;;H2F F9L1          FFCS;;H2F F9L1          FSAA;;H2F F9P1          FFCS;;H2F F9P1          FSAA;;H2F F9Q           FFCS;;H2F F9Q           FSAA;;H2F F9R19C        FSAA;;H2F F9R39C        FSAA;;H2F F9R9B         FSAA;;H2F F9T4B         FFCS;;H2F F9T4B         FSAA;;H2F F91DR         FFCS;;H2F F91V          FFCS;;U1S S2049,0,0,,,,EXPIRED
219,KR,A,KR 20230056800 A,021-127-057-236-875,2023-04-27,2023,KR 20237013210 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;KR 20217030556 A;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"본원에서는 ApoE4 양성 환자 및 경증 AD를 앓는 환자를 포함하는, 약하거나 중등도의 AD를 앓는 환자에서 알츠하이머 질환(AD)을 치료하는 방법이 제공된다.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/021-127-057-236-875,Patent Application,no,0,0,36,75,18,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K39/00;;A61P25/28,,0,0,,,,DISCONTINUED
220,TW,A,TW 201028363 A,034-924-746-946-542,2010-08-01,2010,TW 98132324 A,2009-09-24,US 10819508 P;;EP 08171051 A,2008-10-24,Bundle trailer for gas delivery,"A bundle trailer for containers including (i) a supporting frame on which a plurality of bundles are located; (ii) a plurality of bundles, each bundle comprising: a bundle frame, a plurality of containers containing a chemical, and at least one bundle value for controlling delivery of the chemical in the containers; (iii) at least one trailer valve; and (iv) at least one clamp for fixing the bundle is disclosed. The bundle trailer is capable of delivering high purity hygroscopic, corrosive chemicals, such as elemental fluorine and mixtures thereof, with good flexibility, high safety, and low cost.",SOLVAY FLUOR GMBH,PITTROFF MICHAEL;;PARK YUK-HWAN;;CHO WOO-JIN,,https://lens.org/034-924-746-946-542,Patent of Addition,no,0,0,11,11,0,F17C13/083;;F17C13/084;;F17C2201/0104;;F17C2201/032;;F17C2201/035;;F17C2201/054;;F17C2201/056;;F17C2205/0107;;F17C2205/0111;;F17C2205/013;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C2205/0157;;F17C2205/0326;;F17C2221/01;;F17C2221/03;;F17C2250/0447;;F17C2260/01;;F17C2265/04;;F17C2265/063;;F17C2270/0171;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/08;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/083;;F17C2250/0447;;F17C2265/063;;F17C2221/01;;F17C2201/0104;;F17C2205/0157;;F17C2201/032;;F17C2205/0107;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C13/084;;F17C2201/054;;F17C2260/01;;F17C2205/013;;F17C2201/056;;F17C2205/0326;;F17C2205/0111;;F17C2221/03;;F17C2265/04;;F17C2201/035;;F17C2270/0171,,,0,0,,,,PENDING
221,IN,B,IN 161123 B,094-487-775-769-112,1987-10-10,1987,IN 229CA1985 A,1985-03-28,US 59632984 A,1984-04-03,FREQUENCY CONVERSION APPARATUS,,WESTINGHOUSE ELECTRIC CORP,GYUGYI LASZLO;;HIENRICH THEODORE MICHAEL;;CHO GYU-HYEONG,,https://lens.org/094-487-775-769-112,Granted Patent,no,0,0,18,18,0,H02M5/271;;H02P27/16;;H02M5/00;;H02P27/16;;H02M5/271,H02M5/27;;H02P27/16,,0,0,,,,EXPIRED
222,JP,A,JP 2015092118 A,117-900-757-105-856,2015-05-14,2015,JP 2015021035 A,2015-02-05,US 10819508 P;;EP 08171051 A,2008-10-24,BUNDLE TRAILER FOR SENDING OUT GAS,"PROBLEM TO BE SOLVED: To solve the problems encountered in a corrosive chemical substance delivery business of unstable safety control, high maintenance cost, and poor compatibility with a system having various utilization places.SOLUTION: A bundle trailer for a container includes: (i) a support frame in which a plurality of bundles are disposed; (ii) a plurality of bundles, each of which includes a bundle frame, a plurality of containers to accommodate chemical substances, and at least one bundle valve to control the sending-out of the chemical substances in the containers; (iii) at least one trailer valve; and (iv) at least one clamp to fix the bundles. The bundle trailer not only has superior flexibility and high safety property, but also is able to send out high-purity hygroscopic and corrosive chemical substances, such as fluorine and a mixture thereof at low cost.",SOLVAY FLUOR GMBH,MICHAEL PITTROFF;;PARK YUK-HWAN;;CHO WOO-JIN,,https://lens.org/117-900-757-105-856,Patent Application,no,2,0,11,11,0,F17C13/083;;F17C13/084;;F17C2201/0104;;F17C2201/032;;F17C2201/035;;F17C2201/054;;F17C2201/056;;F17C2205/0107;;F17C2205/0111;;F17C2205/013;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C2205/0157;;F17C2205/0326;;F17C2221/01;;F17C2221/03;;F17C2250/0447;;F17C2260/01;;F17C2265/04;;F17C2265/063;;F17C2270/0171;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/08;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/083;;F17C2250/0447;;F17C2265/063;;F17C2221/01;;F17C2201/0104;;F17C2205/0157;;F17C2201/032;;F17C2205/0107;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C13/084;;F17C2201/054;;F17C2260/01;;F17C2205/013;;F17C2201/056;;F17C2205/0326;;F17C2205/0111;;F17C2221/03;;F17C2265/04;;F17C2201/035;;F17C2270/0171,F17C5/06;;B65D88/12;;F17C13/02;;F17C13/08;;G01M3/04,,0,0,,,,PENDING
223,US,A1,US 2011/0027812 A1,012-190-458-687-736,2011-02-03,2011,US 90479010 A,2010-10-14,US 90479010 A;;US 85028207 A;;US 84311006 P,2006-09-08,ASSAY FOR ANTIBODIES TO MYCOBACTERIUM PARATUBERCULOSIS,"A method of detecting an immune response to a paratuberculosis-specific antigen, comprising incubating a sample from a subject with the paratuberculosis-specific antigen and detecting the presence of an antibody in the sample as an indication of an immune response to the paratuberculosis-specific antigen. The antigen may be obtained from a novel M paratuberculosis strain JTC303. The antigen may be obtained from the JTC303 culture filtrate. Also provided are antibodies to the paratuberculosis-specific antigen, and a diagnostic kit for the detection of an immune response to a paratuberculosis-specific antigen in a mammal.",WISCONSIN ALUMNI RES FOUND,COLLINS MICHAEL T;;SHIN SUNG JAE;;CHO DONGHEE,,https://lens.org/012-190-458-687-736,Patent Application,yes,7,1,9,9,0,C07K14/35;;G01N33/5695;;C12R2001/32;;C12N1/205;;G01N33/569;;C12N1/20;;C07K14/35;;G01N33/5695;;C07K14/35;;C12N1/205;;C12R2001/32,C12N1/20;;G01N33/53,435/7.92;;435/253.1;;436/501,0,0,,,,INACTIVE
224,US,A1,US 2007/0220621 A1,013-901-277-505-58X,2007-09-20,2007,US 59112206 A,2006-10-31,US 59112206 A;;US 73147005 P,2005-10-31,Genetic characterization and prognostic significance of cancer stem cells in cancer,"The present invention is related to the identification of cancer stem cells using the MMTV-Wnt-1 transgenic mouse model. These cancer stem cells have a gene expression signature that allows them to be distinguished from their non-tumorigenic counterparts. Moreover, the gene expression pattern can also predict survival in a diverse group of solid tumors.",CLARKE MICHAEL F;;WANG XINHAO;;CHO ROBERT W,CLARKE MICHAEL F;;WANG XINHAO;;CHO ROBERT W,,https://lens.org/013-901-277-505-58X,Patent Application,yes,11,48,1,1,0,A01K2267/0331;;C12N5/0695;;C12N2517/02;;C12Q1/6886;;C12Q2600/106;;C12Q2600/118;;C12Q2600/136;;C12Q2600/158;;G01N33/5011;;G01N33/5023;;G01N33/5073;;G01N33/57415;;G01N33/57492;;G01N2333/7055;;G01N2333/70589;;G01N2333/70596;;C12N5/0695;;G01N33/5023;;G01N33/57492;;G01N2333/7055;;A01K2267/0331;;G01N33/5011;;C12Q2600/136;;C12Q1/6886;;G01N2333/70596;;G01N33/57415;;C12N2517/02;;C12Q2600/118;;G01N33/5073;;G01N2333/70589;;C12Q2600/158;;C12Q2600/106,C12N5/095;;A01K67/027;;C12Q1/68;;G01N33/574,800/18;;435/6;;435/325;;435/366;;435/7.23,0,0,,,,DISCONTINUED
225,RU,C2,RU 2724190 C2,014-958-576-827-742,2020-06-23,2020,RU 2016136081 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"FIELD: medicine.SUBSTANCE: present invention relates to a method for delaying the development of Alzheimer's disease (AD) or slowing the progression of AD in a patient with an MMSE score of 20 points or higher, without increasing the risk of adverse side effect in the given patient compared to placebo, where the adverse side effect is selected from: detectable pathology, associated with amyloid deposition, in the form of an edema (ARIA-E) and a pathology associated with deposition of amyloid in the form of hemorrhage (ARIA-H), comprising administering to patient Crenezumab in dose of 15 mg/kg to 100 mg/kg of patient's body weight, wherein said dose is introduced repeatedly every 4 weeks or every month.EFFECT: what is presented is a new effective method for delaying development or progression of asthma, which enables to reduce undesirable side effects.27 cl, 15 dwg, 1 tbl, 2 ex",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/014-958-576-827-742,Granted Patent,no,1,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61P25/28;;A61K39/00;;C07K16/18,,3,1,015-169-910-449-13X,24450890;;10.1056/nejmoa1312889,"Rachelle S. Doody et al, New England Journal of Medicine, 23.01.2014, vol. 370, N4, 311-321;;Niels D Prins et al, Alzheimers Res Ther, Biomed Central LTD, 2013, vol. 5, N 6, 56, стр. 1-6. O. Addlfsson et al, Journal of Neuroscience, 2012, vol. 32, N 28, 9677-9689;;Charlotte Jago, ""Alzheimer`s Disease: One Year later"" Clarivate. FEBRUARY 3, 2014, https://clarivate.com/cortellis/article/alzheimers-disease-one-year-later/",ACTIVE
226,AU,A1,AU 2007/292369 A1,102-829-909-346-058,2008-03-13,2008,AU 2007/292369 A,2007-09-05,US 84311006 P;;US 2007/0077625 W,2006-09-08,Assay for antibodies to Mycobacterium paratuberculosis,,WISCONSIN ALUMNI RES FOUND,SHIN SUNG JAE;;COLLINS MICHAEL T;;CHO DONGHEE,,https://lens.org/102-829-909-346-058,Patent Application,no,0,0,9,9,0,C07K14/35;;G01N33/5695;;C12R2001/32;;C12N1/205;;G01N33/569;;C12N1/20;;C07K14/35;;G01N33/5695;;C07K14/35;;C12N1/205;;C12R2001/32,C12N1/20;;C07K14/35;;C12R1/32;;G01N33/569,,0,0,,,,DISCONTINUED
227,KR,A,KR 20210121288 A,136-197-161-540-90X,2021-10-07,2021,KR 20217030556 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;KR 20167024829 A;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"본원에서는 ApoE4 양성 환자 및 경증 AD를 앓는 환자를 포함하는, 약하거나 중등도의 AD를 앓는 환자에서 알츠하이머 질환(AD)을 치료하는 방법이 제공된다.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/136-197-161-540-90X,Patent Application,no,0,0,36,75,18,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/395;;A61K31/56;;A61K39/00;;C07K16/18,,0,0,,,,DISCONTINUED
228,US,A1,US 2015/0246963 A1,057-573-101-037-256,2015-09-03,2015,US 201514616261 A,2015-02-06,US 201514616261 A;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,GENENTECH INC (2015-05-18),https://lens.org/057-573-101-037-256,Patent Application,yes,1,5,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K31/56,,1,1,011-451-856-283-514,10.2967/jnumed.107.045385;;18287270;;pmc3703818,"Mosconi et al., Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer’s Disease, and Other Dementias. THE JOURNAL OF NUCLEAR MEDICINE • Vol. 49 • No. 3 • March 2008, 390-398",DISCONTINUED
229,CA,A1,CA 2662323 A1,115-089-095-337-224,2008-03-13,2008,CA 2662323 A,2007-09-05,US 84311006 P;;US 2007/0077625 W,2006-09-08,ASSAY FOR ANTIBODIES TO MYCOBACTERIUM PARATUBERCULOSIS,"A method of detecting an immune response to a paratuberculosis- specific antigen, comprising incubating a sample from a subject with the paratubercul osis-specific antigen and detecting the presence of an antibody in the sampl e as an indication of an immune response to the paratuberculosis- specific a ntigen. The antigen may be obtained from a novel M. parat.upsilon.berc.upsil on.losis strain JTC303. The antigen may be obtained from the JTC303 culture filtrate. Also provided are antibodies to the paratuberculosis- specific ant igen, and a diagnostic kit for the detection of an immune response to a para tuberculosis-specific antigen in a mammal.",WISCONSIN ALUMNI RES FOUND,CHO DONGHEE;;COLLINS MICHAEL T;;SHIN SUNG JAE,,https://lens.org/115-089-095-337-224,Patent Application,no,0,0,9,9,0,C07K14/35;;G01N33/5695;;C12R2001/32;;C12N1/205;;G01N33/569;;C12N1/20;;C07K14/35;;G01N33/5695;;C07K14/35;;C12N1/205;;C12R2001/32,C12N1/20;;C07K14/35;;G01N33/569,,0,0,,,,DISCONTINUED
230,SG,A,SG 10201913637R A,141-772-691-592-909,2020-03-30,2020,SG 10201913637R A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,,GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/141-772-691-592-909,Unknown,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,,,0,0,,,,PENDING
231,WO,A1,WO 2020/092750 A1,179-771-057-081-671,2020-05-07,2020,US 2019/0059135 W,2019-10-31,US 201862754998 P,2018-11-02,MAGNETOMECHANIC TRIGGERING OF PAYLOAD RELEASE FROM MINIATURIZED DEVICES,"A carrier device and methods of use are described. The device and methods are directed toward implanting in biological tissue and for releasing a medical payload or functional material in biological tissue according to a remote magnetic trigger. The carrier device has a cavity with an opening through an external surface of the device. The carrier device includes at least one moveable, magnetic element sensitive to a magnetic field gradient. When a magnetic field gradient, rotating magnetic field, or uniform magnetic field, or a combination of thereof is applied to the tissue, the moveable magnetic element provides release of the medical payload or functional material through the cavity opening. In some embodiments, payload release can be started, stopped, and restarted at a later time or place. In addition to payload release, devices of this invention are equipped with a propelling element, the propelling element is responsive to external stimuli that enables propulsion and navigation of the device.",BIONAUT LABS LTD;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CHO SUEHYUN;;SARGSYAN HOVHANNES,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CHO SUEHYUN;;SARGSYAN HOVHANNES,,https://lens.org/179-771-057-081-671,Patent Application,yes,19,1,8,8,0,A61M2039/0205;;A61M37/0069;;A61M31/002;;A61K9/0009;;A61K9/0024;;A61K9/0097;;A61M31/002;;A61M37/0069,A61K9/00;;A61K47/69;;A61M5/145;;A61M31/00,,0,0,,,,PENDING
232,ZA,B,ZA 201605341 B,194-657-618-352-246,2021-01-27,2021,ZA 201605341 A,2016-08-02,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,,GENENTECH INC A CORP ORGANISED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE,WILLIAM CHO;;MICHEL FRIESENHAHN;;ROBERT PAUL;;MICHAEL WARD,,https://lens.org/194-657-618-352-246,Granted Patent,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,,,0,0,,,,ACTIVE
233,US,B2,US 8752572 B2,013-669-867-192-743,2014-06-17,2014,US 200913125273 A,2009-10-22,US 200913125273 A;;EP 08171051 A;;US 10819508 P;;EP 2009063867 W,2008-10-24,Bundle trailer for gas delivery,"A bundle trailer for containers including (i) a supporting frame on which a plurality of bundles are located; (ii) a plurality of bundles, each bundle comprising: a bundle frame, a plurality of containers containing a chemical, and at least one bundle value for controlling delivery of the chemical in the containers; (iii) at least one trailer valve; and (iv) at least one clamp for fixing the bundle is disclosed. The bundle trailer is capable of delivering high purity hygroscopic, corrosive chemicals, such as elemental fluorine and mixtures thereof, with good flexibility, high safety, and low cost.",PITTROFF MICHAEL;;PARK YUK-HWAN;;CHO WOO-JIN;;SOLVAY FLOUR GMBH,PITTROFF MICHAEL;;PARK YUK-HWAN;;CHO WOO-JIN,SOLVAY FLUOR GMBH (2009-10-23),https://lens.org/013-669-867-192-743,Granted Patent,yes,22,2,11,11,0,F17C13/083;;F17C13/084;;F17C2201/0104;;F17C2201/032;;F17C2201/035;;F17C2201/054;;F17C2201/056;;F17C2205/0107;;F17C2205/0111;;F17C2205/013;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C2205/0157;;F17C2205/0326;;F17C2221/01;;F17C2221/03;;F17C2250/0447;;F17C2260/01;;F17C2265/04;;F17C2265/063;;F17C2270/0171;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/08;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/083;;F17C2250/0447;;F17C2265/063;;F17C2221/01;;F17C2201/0104;;F17C2205/0157;;F17C2201/032;;F17C2205/0107;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C13/084;;F17C2201/054;;F17C2260/01;;F17C2205/013;;F17C2201/056;;F17C2205/0326;;F17C2205/0111;;F17C2221/03;;F17C2265/04;;F17C2201/035;;F17C2270/0171,B60P3/22,137/259;;137/267,0,0,,,,INACTIVE
234,CA,C,CA 2938466 C,039-234-254-106-743,2021-11-02,2021,CA 2938466 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/039-234-254-106-743,Granted Patent,no,0,0,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,ACTIVE
235,CN,A,CN 102203493 A,112-125-598-849-80X,2011-09-28,2011,CN 200980142025 A,2009-10-22,EP 2009063867 W;;EP 08171051 A;;US 10819508 P,2008-10-24,Bundle trailer for gas delivery,"A bundle trailer for containers including (i) a supporting frame on which a plurality of bundles are located; (ii) a plurality of bundles, each bundle comprising : a bundle frame, a plurality of containers containing a chemical, and at least one bundle value for controlling delivery of the chemical in the containers; (iii) at least one trailer valve; and (iv) at least one clamp for fixing the bundle is disclosed. The bundle trailer is capable of delivering high purity hygroscopic, corrosive chemicals, such as elemental fluorine and mixtures thereof, with good flexibility, high safety, and low cost.",SOLVAY FLUOR GMBH,MICHAEL PITTROFF;;YUK-HWAN PARK;;WOO-JIN CHO,,https://lens.org/112-125-598-849-80X,Patent Application,no,0,0,11,11,0,F17C13/083;;F17C13/084;;F17C2201/0104;;F17C2201/032;;F17C2201/035;;F17C2201/054;;F17C2201/056;;F17C2205/0107;;F17C2205/0111;;F17C2205/013;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C2205/0157;;F17C2205/0326;;F17C2221/01;;F17C2221/03;;F17C2250/0447;;F17C2260/01;;F17C2265/04;;F17C2265/063;;F17C2270/0171;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/08;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/083;;F17C2250/0447;;F17C2265/063;;F17C2221/01;;F17C2201/0104;;F17C2205/0157;;F17C2201/032;;F17C2205/0107;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C13/084;;F17C2201/054;;F17C2260/01;;F17C2205/013;;F17C2201/056;;F17C2205/0326;;F17C2205/0111;;F17C2221/03;;F17C2265/04;;F17C2201/035;;F17C2270/0171,F17C13/08,,0,0,,,,DISCONTINUED
236,US,B2,US 11581896 B2,186-260-213-368-543,2023-02-14,2023,US 202117474501 A,2021-09-14,US 202117474501 A;;KR 20200007273 A;;US 202017000665 A,2020-01-20,Analog-to-digital converter,"An analog-to-digital converter includes: a voltage-current converter receiving an analog input voltage, generating a first digital signal from the analog input voltage, and outputting a residual current remaining after the first digital signal; a current-time converter converting the residual current into a current time in a time domain; and a time-digital converter receiving the residual time, and generating a second digital signal from the residual time, wherein the first digital signal and the second digital signal are sequences of digital codes representing respective signal levels of the analog input voltage.",SAMSUNG ELECTRONICS CO LTD;;SAMSUNG ELECTORNICS CO LTD,MOON KYOUNGJUN;;OH DONGRYEOL;;CHO YOUNGJAE;;CHOI MICHAEL,,https://lens.org/186-260-213-368-543,Granted Patent,yes,12,0,5,5,0,G04F10/005;;H03M1/502;;H03M1/742;;H03M1/468;;H03M1/164;;H03M1/0695;;H03M1/38;;H03M1/50;;H03M1/002;;H03M1/0612;;H03M1/1028;;H03M1/145;;G04F10/005;;H03M1/38,H03M1/10;;G04F10/00;;H03M1/14;;H03M1/38,,3,2,082-593-607-080-133;;023-947-833-448-093,10.1109/jssc.2019.2926648;;10.1109/jssc.2019.2938450,"Moon, et al. “A 9.1-ENOB 6-mW10-Bit 500-MS/s Pipelined-SAR ADC With Current-Mode Residue Processing in 28-nm CMOS”, IEEE Journal of Solid-State Circuits, vol. 54, No. 9, Sep. 2019, 11 pages.;;Zhang, et al. “A 0.6-V 13-bit 20-MS/s Two-Step TDC-Assisted SAR ADC With PVT Tracking and Speed-Enhanced Techniques”, IEEE Journal of Solid-State Circuits, vol. 54, No. 12, Dec. 2019, 14 pages.;;Office Action dated Apr. 9, 2021 in corresponding U.S. Patent Appln. U.S. Appl. No. 17/000,665.",ACTIVE
237,SG,A,SG 11201606316X A,017-781-349-176-925,2016-08-30,2016,SG 11201606316X A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,,GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/017-781-349-176-925,Unknown,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,PENDING
238,WO,A2,WO 2022/246174 A2,102-582-692-494-380,2022-11-24,2022,US 2022/0030221 W,2022-05-20,US 202163191497 P;;US 202163191515 P;;US 202163191418 P;;US 202163191454 P;;US 202163213120 P,2021-05-21,SYSTEM AND METHOD FOR LOCALIZED THERAPEUTIC TREATMENT,"Provided are systems and miniature devices configured to navigate within a patient to a location therewithin for delivering to induce a localized therapeutic effect, such as the delivery of catalyzing energy and/or for the conversion of a prodrug to a pharmaceutically active drug. Further provided are various methods of treatment using such systems and devices.",BIONAUT LABS LTD;;CHO SUEHYUN;;CROS FLORENT;;KISELYOV ALEX;;SHPIGELMACHER MICHAEL,CHO SUEHYUN;;CROS FLORENT;;KISELYOV ALEX;;SHPIGELMACHER MICHAEL,,https://lens.org/102-582-692-494-380,Patent Application,yes,0,0,6,6,0,C07K14/52;;C07K14/715;;A61K47/50;;A61P37/00;;A61M37/00;;A61M31/002;;A61M35/00;;A61K9/0097;;A61K9/0009,G06F30/38,,0,0,,,,PENDING
239,US,A1,US 2021/0226643 A1,147-846-008-518-964,2021-07-22,2021,US 202017000665 A,2020-08-24,KR 20200007273 A,2020-01-20,ANALOG-TO-DIGITAL CONVERTER,"An analog-to-digital converter includes: a voltage-current converter receiving an analog input voltage, generating a first digital signal from the analog input voltage, and outputting a residual current remaining after the first digital signal; a current-time converter converting the residual current into a current time in a time domain; and a time-digital converter receiving the residual time, and generating a second digital signal from the residual time, wherein the first digital signal and the second digital signal are sequences of digital codes representing respective signal levels of the analog input voltage.",SAMSUNG ELECTRONICS CO LTD,MOON KYOUNGJUN;;OH DONGRYEOL;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2020-07-16),https://lens.org/147-846-008-518-964,Patent Application,yes,0,4,5,5,0,G04F10/005;;H03M1/502;;H03M1/742;;H03M1/468;;H03M1/164;;H03M1/0695;;H03M1/38;;H03M1/50;;H03M1/002;;H03M1/0612;;H03M1/1028;;H03M1/145;;G04F10/005;;H03M1/38,H03M1/10,,0,0,,,,ACTIVE
240,MX,A,MX 2016010173 A,135-718-202-673-19X,2016-10-13,2016,MX 2016010173 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE.,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,WARD MICHAEL;;PAUL ROBERT;;WILLIAM CHO;;MICHEL FRIESENHAHN,,https://lens.org/135-718-202-673-19X,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61P25/28;;A61K39/00;;C07K16/18,,0,0,,,,PENDING
241,FR,B1,FR 2566596 B1,147-711-803-362-091,1988-08-05,1988,FR 8505005 A,1985-04-02,US 59632984 A,1984-04-03,SYSTEME-CHANGEUR DE FREQUENCE NON LIMITEE A CARACTERISTIQUE D'HARMONIQUE PERFECTIONNEE ET CIRCUIT D'ENTRAINEMENT DE MOTEUR A COURANT ALTERNATIF A FREQUENCE REGLABLE UTILISANT UN TEL SYSTEME,,WESTINGHOUSE ELECTRIC CORP,GYUGYI LASZLO;;HEINRICH THEODORE MICHAEL;;CHO GYU-HYEONG,,https://lens.org/147-711-803-362-091,Granted Patent,no,0,0,18,18,0,H02M5/271;;H02P27/16;;H02M5/00;;H02P27/16;;H02M5/271,H02M5/27;;H02P27/16,,0,0,,,,EXPIRED
242,US,B2,US 9463397 B2,180-573-335-189-884,2016-10-11,2016,US 201414209347 A,2014-03-13,US 201414209347 A;;US 201213564881 A;;US 41818909 A;;US 201361784124 P;;US 20112108 P;;US 4251908 P,2008-04-04,System and method for liquid distribution,A liquid flow distributor for positioning above one or more packing sections in a packed exchange tower includes a plurality of troughs. At least one trough in the plurality of troughs has along a side thereto a deflecting member The deflecting member is angulated to generally follow a shape of the at least one trough. A diffuser side of the deflecting member is positioned to deposit the liquid into a discharge region. A plurality of break bars are disposed on the diffuser side of the deflecting member. A deflector side of the deflecting member is positioned for deflecting ascending vapor away from the discharge region.,GTC TECHNOLOGY US LLC,CHO JAE-MAN;;KU NAMSUN;;BINKLEY MICHAEL J,SULZER MANAGEMENT AG (2021-02-23);;SULZER GTC TECHNOLOGY US INC (2019-05-31),https://lens.org/180-573-335-189-884,Granted Patent,yes,107,4,2,5,0,B01D3/008;;B01D3/008,B01F3/04;;B01D3/00,,9,0,,,"Pilling Mark, et al., Mini Valve, Hydrocarbon Engineering, Apr. 2013 [3 pages].;;Glitsch, Inc., ""Ballast Tray Design Manuel"", Bulletin 4900, Sixth Edition, 1993, (40 pages).;;Kister, Henry Z., ""Distillation Design"", ch. 6, pp. 265, 296, 331, 299-301, ch. 7, pp. 382-394, ch. 9, pp. 537-554, McGraw-Hill, 1992.;;Axens IFP Group Technologies, ""Equiflow Reactor Internals for Optimal Catalyst Utilization"", Axens Process Licensing, Jun. 2006, 4 pages.;;GTC Technology, ""GT-BenZap Technology Licensing"". Engineered to Innovate, 2009, 2 pages.;;Shell, ""Shell Global Solutions' Portfolio for Reactor Engineering Technology"", Shell Global Solutions, 2002, 3 pages.;;Young, Lee W., ""International Search Report"" for the International Application PCT/IB11/02695 as mailed Apr. 17, 2012. (4 pages).;;Buttridge, Ian G., ""U.S. Appl. No. 13/564,881"", filed Aug. 2, 2012.;;Binkley, Michael J., ""U.S. Appl. No. 13/951,159"", filed Jul. 25, 2013.",ACTIVE
243,CA,A1,CA 3220736 A1,011-252-753-856-402,2022-11-24,2022,CA 3220736 A,2022-05-20,US 202163191418 P;;US 202163191454 P;;US 202163191515 P;;US 202163191497 P;;US 202163213120 P;;US 2022/0030213 W,2021-05-21,SYSTEMS AND METHODS FOR MICROBOT-MEDIATED THERAPEUTIC DELIVERY,"Provided are systems and miniature devices configured to navigate within a patient to a location therewithin for delivering to induce a localized therapeutic effect. Specifically, the present disclosure provides miniature devices configured to be remotely maneuvered along a path within the patient, where the miniature device is configured to selectively: (i) release a guide substance; (ii) release a payload that induces a physiological response; and/or (iii) produce a microtrauma at locations along the path. Further provided are various methods of treatment using such systems and devices.",BIONAUT LABS LTD,CHO SUEHYUN;;CROS FLORENT;;KISELYOV ALEX;;SHPIGELMACHER MICHAEL,,https://lens.org/011-252-753-856-402,Patent Application,no,0,0,6,6,0,C07K14/52;;C07K14/715;;A61K47/50;;A61P37/00;;A61M37/00;;A61M31/002;;A61M35/00;;A61K9/0097;;A61K9/0009,A61K9/50;;A61K39/395;;A61M31/00,,0,0,,,,PENDING
244,CA,A1,CA 3116906 A1,023-703-324-327-217,2020-05-07,2020,CA 3116906 A,2019-10-31,US 201862754998 P;;US 2019/0059135 W,2018-11-02,MAGNETOMECHANIC TRIGGERING OF PAYLOAD RELEASE FROM MINIATURIZED DEVICES,"A carrier device and methods of use are described. The device and methods are directed toward implanting in biological tissue and for releasing a medical payload or functional material in biological tissue according to a remote magnetic trigger. The carrier device has a cavity with an opening through an external surface of the device. The carrier device includes at least one moveable, magnetic element sensitive to a magnetic field gradient. When a magnetic field gradient, rotating magnetic field, or uniform magnetic field, or a combination of thereof is applied to the tissue, the moveable magnetic element provides release of the medical payload or functional material through the cavity opening. In some embodiments, payload release can be started, stopped, and restarted at a later time or place. In addition to payload release, devices of this invention are equipped with a propelling element, the propelling element is responsive to external stimuli that enables propulsion and navigation of the device.",BIONAUT LABS LTD,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CHO SUEHYUN;;SARGSYAN HOVHANNES,,https://lens.org/023-703-324-327-217,Patent Application,no,0,0,8,8,0,A61M2039/0205;;A61M37/0069;;A61M31/002;;A61K9/0009;;A61K9/0024;;A61K9/0097;;A61M31/002;;A61M37/0069,A61M31/00;;A61K9/00;;A61M37/00,,0,0,,,,PENDING
245,WO,A2,WO 2022/246170 A2,063-641-300-927-824,2022-11-24,2022,US 2022/0030213 W,2022-05-20,US 202163191418 P;;US 202163191454 P;;US 202163191515 P;;US 202163191497 P;;US 202163213120 P,2021-05-21,SYSTEMS AND METHODS FOR MICROBOT-MEDIATED THERAPEUTIC DELIVERY,"Provided are systems and miniature devices configured to navigate within a patient to a location therewithin for delivering to induce a localized therapeutic effect. Specifically, the present disclosure provides miniature devices configured to be remotely maneuvered along a path within the patient, where the miniature device is configured to selectively: (i) release a guide substance; (ii) release a payload that induces a physiological response; and/or (iii) produce a microtrauma at locations along the path. Further provided are various methods of treatment using such systems and devices.",BIONAUT LABS LTD;;CHO SUEHYUN;;CROS FLORENT;;KISELYOV ALEX;;SHPIGELMACHER MICHAEL,CHO SUEHYUN;;CROS FLORENT;;KISELYOV ALEX;;SHPIGELMACHER MICHAEL,,https://lens.org/063-641-300-927-824,Patent Application,yes,0,0,6,6,0,C07K14/52;;C07K14/715;;A61K47/50;;A61P37/00;;A61M37/00;;A61M31/002;;A61M35/00;;A61K9/0097;;A61K9/0009,C07K14/28;;A61K39/395,,0,0,,,,PENDING
246,BR,A2,BR 112016018170 A2,104-256-812-808-516,2018-02-20,2018,BR 112016018170 A,2015-02-06,US 2015/0014758 W;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,métodos para tratar doença de alzheimer,"métodos para tratar doença de alzheimer (ad) em pacientes sofrendo de ad suave a moderada, incluindo pacientes apoe4 positivos e pacientes sofrendo de ad suave são fornecidos.",GENENTECH INC,MICHAEL WARD;;MICHEL FRIESENHAHN;;ROBERT PAUL;;WILLIAM CHO,,https://lens.org/104-256-812-808-516,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,PENDING
247,US,A1,US 2011/0226368 A1,118-732-883-624-442,2011-09-22,2011,US 200913125273 A,2009-10-22,US 200913125273 A;;EP 08171051 A;;US 10819508 P;;EP 2009063867 W,2008-10-24,Bundle trailer for gas delivery,"A bundle trailer for containers including (i) a supporting frame on which a plurality of bundles are located; (ii) a plurality of bundles, each bundle comprising: a bundle frame, a plurality of containers containing a chemical, and at least one bundle value for controlling delivery of the chemical in the containers; (iii) at least one trailer valve; and (iv) at least one clamp for fixing the bundle is disclosed. The bundle trailer is capable of delivering high purity hygroscopic, corrosive chemicals, such as elemental fluorine and mixtures thereof, with good flexibility, high safety, and low cost.",SOLVAY FLUOR GMBH,PITTROFF MICHAEL;;PARK YUK-HWAN;;CHO WOO-JIN,SOLVAY FLUOR GMBH (2009-10-23),https://lens.org/118-732-883-624-442,Patent Application,yes,12,1,11,11,0,F17C13/083;;F17C13/084;;F17C2201/0104;;F17C2201/032;;F17C2201/035;;F17C2201/054;;F17C2201/056;;F17C2205/0107;;F17C2205/0111;;F17C2205/013;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C2205/0157;;F17C2205/0326;;F17C2221/01;;F17C2221/03;;F17C2250/0447;;F17C2260/01;;F17C2265/04;;F17C2265/063;;F17C2270/0171;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/08;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/083;;F17C2250/0447;;F17C2265/063;;F17C2221/01;;F17C2201/0104;;F17C2205/0157;;F17C2201/032;;F17C2205/0107;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C13/084;;F17C2201/054;;F17C2260/01;;F17C2205/013;;F17C2201/056;;F17C2205/0326;;F17C2205/0111;;F17C2221/03;;F17C2265/04;;F17C2201/035;;F17C2270/0171,B60P3/22,137/899,0,0,,,,INACTIVE
248,NZ,A,NZ 723884 A,140-177-423-348-667,2023-02-24,2023,NZ 72388415 A,2015-02-06,US 2015/0014758 W;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,Methods of treating alzheimer’s disease,"Methods of treating Alzheimer’s Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/140-177-423-348-667,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61P25/28;;A61K39/00;;C07K16/18,,0,0,,,,PENDING
249,US,A1,US 2008/0138840 A1,005-220-773-021-935,2008-06-12,2008,US 85028207 A,2007-09-05,US 85028207 A;;US 84311006 P,2006-09-08,ASSAY FOR ANTIBODIES TO MYCOBACTERIUM PARATUBERCULOSIS,"A method of detecting an immune response to a paratuberculosis-specific antigen, comprising incubating a sample from a subject with the paratuberculosis-specific antigen and detecting the presence of an antibody in the sample as an indication of an immune response to the paratuberculosis-specific antigen. The antigen may be obtained from a novel M. paratuberculosis strain JTC303. The antigen may be obtained from the JTC303 culture filtrate. Also provided are antibodies to the paratuberculosis-specific antigen, and a diagnostic kit for the detection of an immune response to a paratuberculosis-specific antigen in a mammal.",COLLINS MICHAEL T;;SHIN SUNG JAE;;CHO DONGHEE,COLLINS MICHAEL T;;SHIN SUNG JAE;;CHO DONGHEE,WISCONSIN ALUMNI RESEARCH FOUNDATION (2008-01-28),https://lens.org/005-220-773-021-935,Patent Application,yes,7,1,9,9,0,C07K14/35;;G01N33/5695;;C12R2001/32;;C12N1/205;;G01N33/569;;C12N1/20;;C07K14/35;;G01N33/5695;;C07K14/35;;C12N1/205;;C12R2001/32,G01N33/569;;C07K16/00;;C12N1/20;;C12N1/21,435/7.32;;435/253.1;;435/252.3;;530/387.1;;530/388.2;;530/389.1,0,0,,,,DISCONTINUED
250,GB,A,GB 2549373 A,054-897-428-097-754,2017-10-18,2017,GB 201702842 A,2017-02-22,US 201615049332 A,2016-02-22,Vehicle seat bottom with independently deployable devices,"A seat bottom 44 includes first 50 and second 60 thigh supports, each supported by and independently movable to adjustable positions relative to a frame 74. At least one inflator 132, 134, (130, figure 5) is in fluid communication with first 110 and second 112 deployable devices coupled to the respective thigh supports 50, 60. A controller (144, figure 7) is programmed to independently inflate the deployable devices 110, 112 based at least on adjustable positions of the thigh support 50, 60 in response to a sensed vehicle impact. Impact and/or pre-impact sensors may be in communication with the controller (144). The controller may inflate the deployable devices 110, 112 based on a sensed vehicle impact direction. The deployable devices 110, 112 (e.g. airbags) may be disposed between the thigh supports 50, 60 and at least one cushion 80. Cushion 80 may be moved into a comfortable position by independently rotatable thigh supports via first 54 and second 64 actuators. The thigh supports 50, 60 can be raised by unequal distances to the same height, reducing the likelihood of the occupant submarining below a seat belt lap portion during a front-end collision, and reducing forward travel of the occupant chest.",FORD GLOBAL TECH LLC,ROBERT WILLIAM MCCOY;;MICHAEL K RAO;;JAEHO CHO,,https://lens.org/054-897-428-097-754,Patent Application,no,2,1,9,9,0,B60N2/4263;;B60R21/0136;;B60N2/4221;;B60N2/42763;;B60N2/914;;B60N2/4279;;B60N2/62;;B60N2/427;;B60N2/42763;;B60N2/62;;B60R21/207;;B60N2/914;;B60N2/42763;;B60N2/4221;;B60N2/4279;;B60N2/62,B60N2/427;;B60N2/90;;B60N2/62;;B60R21/207,,0,0,,,,DISCONTINUED
251,MY,A,MY 179105 A,054-286-749-120-879,2020-10-28,2020,MY PI2016702789 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,PAUL ROBERT;;WARD MICHAEL;;CHO WILLIAM;;FRIESENHAHN MICHEL,,https://lens.org/054-286-749-120-879,Granted Patent,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,,,0,0,,,,ACTIVE
252,CL,A1,CL 2017002781 A1,078-384-919-761-880,2018-04-13,2018,CL 2017002781 A,2017-11-03,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,Métodos de tratamiento de enfermedad de alzheimer,"<p>Se proporcionan métodos de tratamiento de enfermedad de Alzheimer (AD) en pacientes que sufren de AD leve a moderada, incluyendo pacientes ApoE4 positivos y pacientes que sufren de AD leve.</p>",GENENTECH INC,WARD MICHAEL;;FRIESENHAHN MICHEL;;PAUL ROBERT;;CHO WILLIAMS,,https://lens.org/078-384-919-761-880,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,PENDING
253,US,B2,US 8158371 B2,115-008-096-232-507,2012-04-17,2012,US 90479010 A,2010-10-14,US 90479010 A;;US 85028207 A;;US 84311006 P,2006-09-08,Assay for antibodies to Mycobacterium paratuberculosis,"A method of detecting an immune response to a paratuberculosis-specific antigen, comprising incubating a sample from a subject with the paratuberculosis-specific antigen and detecting the presence of an antibody in the sample as an indication of an immune response to the paratuberculosis-specific antigen. The antigen may be obtained from a novel M. paratuberculosis strain JTC303. The antigen may be obtained from the JTC303 culture filtrate. Also provided are antibodies to the paratuberculosis-specific antigen, and a diagnostic kit for the detection of an immune response to a paratuberculosis-specific antigen in a mammal.",COLLINS MICHAEL T;;SHIN SUNG JAE;;CHO DONGHEE;;WISCONSIN ALUMNI RES FOUND,COLLINS MICHAEL T;;SHIN SUNG JAE;;CHO DONGHEE,,https://lens.org/115-008-096-232-507,Granted Patent,yes,10,0,9,9,0,C07K14/35;;G01N33/5695;;C12R2001/32;;C12N1/205;;G01N33/569;;C12N1/20;;C07K14/35;;G01N33/5695;;C07K14/35;;C12N1/205;;C12R2001/32,A61K39/04;;G01N33/53;;C12N1/20,435/7.1;;435/41;;435/252.3;;424/130.1;;424/184.1;;424/200.1;;424/234.1;;424/248.1,40,14,039-071-221-332-185;;051-164-119-466-694;;015-472-943-805-50X;;019-563-732-191-877;;073-606-488-940-316;;060-858-786-512-247;;038-308-787-457-936;;036-999-125-199-117;;061-278-305-247-08X;;007-633-147-995-87X;;008-415-774-838-356;;054-529-185-039-410;;108-247-929-915-498;;044-316-868-603-410,17022102;;10.1002/pmic.200600207;;17028217;;10.1128/cvi.00058-06;;pmc1595327;;11913494;;10.1007/s10096-001-0651-7;;15939741;;pmc1151972;;10.1128/cdli.12.6.685-692.2005;;16511785;;10.1111/j.1939-165x.2006.tb00082.x;;pmc263117;;8195387;;10.1128/jcm.32.3.740-745.1994;;10.1042/bj0890114;;14097352;;pmc1202279;;10.1101/pdb.prot4286;;22485799;;22485800;;10.1101/pdb.prot4287;;10834989;;10.1128/jcm.38.6.2278-2283.2000;;pmc86781;;10.1128/cvi.00105-08;;pmc2519299;;18550730;;pmc2681583;;19261776;;10.1128/cvi.00461-08;;10.1128/aem.69.11.6833-6840.2003;;pmc262281;;14602647;;pmc368355;;10.1128/aem.70.3.1688-1697.2004;;15006794;;10.1177/104063870601800102;;16566252,"Cho, et al., Proteomic Identification of Immunogenic Mycobacterium paratuberculosis Proteins, Eighth International Colloquium on paratuberculosis, Copenhagen, Denmark, Aug. 14-17, 2005, MT XP002464448 [Abstract].;;Cho, et al., Identification of Proteins of Potential Diagnostic Value for Bovine paratuberculosis, Proteomics 6 (21):5785-5794, Oct. 2006.;;Cho, et al., Comparison of the Proteosomes and Antigenicities of Secreted and Cellular Proteins Produced by Mycobacterium paratuberculosis, Clin. Vaccine Immunol. 13(10):1155-1161, Oct. 2006.;;Choudhry, et al., Detection of Mycobacterium Tuberculosis Antigens in Urinary Proteins of Tuberculosis Patients, Eur. J. Clin. Microbiol. Infect. Dis 21:1-5, 2002.;;Collins, et al., Evaluation of Five Antibody Detection Tests for Diagnosis of Bovine paratuberculosis, Clin. Diagn. Lab. Immunol. 12(6):685-692, 2005.;;Gardner, et al., Receiver-operating Characteristic Curves and Likelihood Ratios: Improvements Over Traditional Methods for the Evaluation and Application of Veterinary Clinical Pathology Tests, Vet. Clin. Pathol. 35(1):8-17, 2006.;;Glickman, et al., Rapid Identification of Mycolic Acid Patterns of Mycobacteria by High-Performance Liquid Chromatography Using Pattern Recognition Software and a Mycobacterium Library, J. Clin. Microbiol. 32(3):740-745, 1994.;;Greenwood, et al., The Preparation of (131)I-Labelled Human Growth Hormone of High Specific Radioactivity, Biochem. J. 89:114-123, 1963.;;Harlow, et al., Labeling Antibodies with Iodine, CSH Protocols, doi:10.1101/pdb.prot4287, 2006.;;Kaufman, et al., Handbook of Molecular and Cellular Methods in Biology and Medicine, CRC Press, Boca Raton, FL, 1995.;;Miller, A Short Course in Bacterial Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1992.;;Pereira, et al., Development of Antigen Detection Assay for Diagnosis of Tuberculosis Using Sputum Samples, J. Clin. Microbiol. 38(6):2278-2283, 2000.;;Sambrook, et al., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.;;Shin, et al., Diagnosis of Bovine paratuberculosis by a Novel Enzyme-Linked Immunosorbent Assay Based on Early Secreted Antigens of Mycobacterium avium Subsp. paratuberculosis, Clin. Vaccine Immunol. 15(8):1277-1281, 2008.;;Shin, et al., Rapid Mycobacterial Liquid Culture-Screening Method for Mycobacterium avium Complex Based on Secreted Antigen-Capture Enzyme-Linked Immunosorbent Assay, Clin. Vaccine Immunol. 16(5):613-620, 2009.;;Singer, et al., Genes and Genomes: A Changing Perspective, University Science Books, Mills Valley, CA, 1991.;;Sung, et al., Variation in Resistance of Mycobacterium paratuberculosis to Acid Environments as a Function of Culture Medium, Appl. Environ. Microbiol. 69(11):6833-6840, 2003.;;Sung, et al., Possible Association of GroES and Antigen 85 Proteins with Heat Resistance of Mycobacterium paratuberculosis, Appl. Environ. Microbiol. 70(3):1688-1697, 2004.;;Sweeney, et al., Longitudinal Study of ELISA Seroreactivity to Mycobacterium avium Subsp. paratuberculosis in Infected Cattle and Culture-Negative Herd Mates, J. Vet. Diagn. Invest. 18:2-6, 2006.;;PCT International Preliminary Report on Patentability, PCT/US2007/077625, Mar. 19, 2009.;;PCT International Search Report, PCT1US2009/037469, Jul. 15, 2009.;;United States Patent and Trademark Office, Office Action Summary and Detailed Action, U.S. Appl. No. 11/850,252, Jun. 24, 2008.;;Response to Restriction/Election Requirement, U.S. Appl. No. 11/850,282, Jul. 24, 2008.;;United States Patent and Trademark Office, Office Action Summary and Detailed Action, U.S. Appl. No. 11/850,282, Sep. 19, 2008.;;Amendment and Request for Reconsideration, U.S. Appl. No. 11/850,282, Jan. 7, 2009.;;United States Patent and Trademark Office, Office Action Summary and Detailed Action, U.S. Appl. No. 11/850,282, Apr. 30, 2009.;;Amendment and Request for Reconsideration, U.S. Appl. No. 11/850,282, Jun. 30, 2009.;;United States Patent and Trademark Office, Interview Summary, U.S. Appl. No. 11/850,282, Jul. 1, 2009.;;United States Patent and Trademark Office, Office Action Summary and Detailed Action, U.S. Appl. No. 11/850,282, Jul. 10, 2009.;;Amendment and Request for Reconsideration, U.S. Appl. No. 11/850,282, Oct. 12, 2009.;;United States Patent and Trademark Office, Office Action Summary and Detailed Action, U.S. Appl. No. 11/850,282, Jan. 22, 2010.;;Amendment in Response to Final Office Action, U.S. Appl. No. 11/850,282, Mar. 22, 2010.;;United States Patent and Trademark Office, Office Action Summary and Detailed Action, U.S. Appl. No. 11/850,282, Apr. 5, 2010.;;United States Patent and Trademark Office, Office Action Summary and Detailed Action, U.S. Appl. No. 11/850,282, May 17, 2010.;;United States Patent and Trademark Office, Interview Summary, U.S. Appl. No. 11/850,282, Oct. 13, 2010.;;Response to Non-Final Office Action, U.S. Appl. No. 11/850,282, Oct. 14, 2010.;;United States Patent and Trademark Office, Office Action Summary and Detailed Action, U.S. Appl. No. 11/850,282, Nov. 2, 2010.;;Intellectual Property Office of New Zealand, Examination Report, Patent Application No. 575023, Jun. 30, 2010.;;United States Patent and Trademark Office, Office Action Summary and Detailed Action, U.S. Appl. No. 12/406,253, Feb. 7, 2011.;;Applicant, Response to Restriction Requirement, U.S. Appl. No. 12/406,253, Mar. 4, 2011.",INACTIVE
254,TW,A,TW 201613636 A,166-433-853-572-996,2016-04-16,2016,TW 104104180 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,Methods of treating Alzheimer's Disease,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/166-433-853-572-996,Patent of Addition,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/395;;A61P25/28;;C07K16/18;;C07K16/46,,0,0,,,,ACTIVE
255,CA,A1,CA 3220737 A1,174-019-189-276-705,2022-11-24,2022,CA 3220737 A,2022-05-20,US 202163191497 P;;US 202163191515 P;;US 202163191418 P;;US 202163191454 P;;US 202163213120 P;;US 2022/0030221 W,2021-05-21,SYSTEM AND METHOD FOR LOCALIZED THERAPEUTIC TREATMENT,"Provided are systems and miniature devices configured to navigate within a patient to a location therewithin for delivering to induce a localized therapeutic effect, such as the delivery of catalyzing energy and/or for the conversion of a prodrug to a pharmaceutically active drug. Further provided are various methods of treatment using such systems and devices.",BIONAUT LABS LTD,CHO SUEHYUN;;CROS FLORENT;;KISELYOV ALEX;;SHPIGELMACHER MICHAEL,,https://lens.org/174-019-189-276-705,Patent Application,no,0,0,6,6,0,C07K14/52;;C07K14/715;;A61K47/50;;A61P37/00;;A61M37/00;;A61M31/002;;A61M35/00;;A61K9/0097;;A61K9/0009,G06F30/38;;A61M31/00,,0,0,,,,PENDING
256,FR,A1,FR 2566596 A1,012-531-783-319-278,1985-12-27,1985,FR 8505005 A,1985-04-02,US 59632984 A,1984-04-03,SYSTEME-CHANGEUR DE FREQUENCE NON LIMITEE A CARACTERISTIQUE D'HARMONIQUE PERFECTIONNEE ET CIRCUIT D'ENTRAINEMENT DE MOTEUR A COURANT ALTERNATIF A FREQUENCE REGLABLE UTILISANT UN TEL SYSTEME,"<P>A.SYSTEME-CHANGEUR DE FREQUENCE NON LIMITEE A CARACTERISTIQUE D'HARMONIQUE PERFECTIONNEE ET CIRCUIT D'ENTRAINEMENT DE MOTEUR A COURANT ALTERNATIF A FREQUENCE REGLABLE UTILISANT UN TEL SYSTEME.</P><P>B.SYSTEME CARACTERISE PAR UN ENSEMBLE DE CONVERTISSEURS STATIQUES LIES EN PHASE 34, 36, 53, 55, CHACUN ETANT BRANCHE ENTRE UNE SOURCE D'ALIMENTATION ALTERNATIVE POLYPHASEE DE FREQUENCE F ET UNE SORTIE ALTERNATIVE POLYPHASEE DEFREQUENCE F COMPRENANT POUR CHACUN DES CONVERTISSEURS UN ENSEMBLE D'UNITES DE COMMUTATION BILATERALES COMMANDEES; EN CONDUCTION, SUCCESSIVEMENT AU COURS D'UNE PERIODE DE TEMPS CARACTERISANT LA FREQUENCE F CHAQUE UNITE DE COMMUTATION AYANT UN INTERVALLE DE TEMPS DE CONDUCTION DEFINI PAR UN TAUX DE REPETITION COMMANDE F F; LA FREQUENCE F DE LA SORTIE ALTERNATIVE ETANT UNE FONCTION DE LA DIFFERENCE ENTRE LA FREQUENCE F DE LA SOURCE D'ALIMENTATION ALTERNATIVE ET LE TAUX DE REPETITION.</P><P>C.L'INVENTION CONCERNE UN SYSTEME CHANGEUR DE FREQUENCE NON LIMITEE A CARACTERISTIQUE D'HARMONIQUE PERFECTIONNEE ET CIRCUIT D'ENTRAINEMENT DE MOTEUR A COURANT ALTERNATIF A FREQUENCE REGLABLE UTILISANT UN TEL SYSTEME.</P>",WESTINGHOUSE ELECTRIC CORP,GYUGYI LASZLO;;HEINRICH THEODORE MICHAEL;;CHO GYU-HYEONG,,https://lens.org/012-531-783-319-278,Patent Application,no,1,0,18,18,0,H02M5/271;;H02P27/16;;H02M5/00;;H02P27/16;;H02M5/271,H02M5/27;;H02P27/16,,0,0,,,,EXPIRED
257,EP,A1,EP 3718563 A1,096-910-687-905-821,2020-10-07,2020,EP 19188687 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;EP 15710295 A;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients suffering from mild AD are provided.",HOFFMANN LA ROCHE,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/096-910-687-905-821,Patent Application,yes,89,0,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,114,82,086-932-421-807-452;;131-216-810-326-268;;015-169-910-449-13X;;008-670-508-863-063;;029-200-906-160-107;;043-348-573-940-487;;069-494-908-751-119;;015-467-620-003-813;;122-558-490-060-539;;057-789-082-803-869;;142-314-510-790-905;;001-553-770-517-492;;077-495-150-106-187;;162-646-650-680-173;;062-950-628-293-493;;030-607-398-087-475;;006-574-964-805-278;;065-608-090-342-50X;;020-855-322-534-259;;011-962-497-035-168;;048-564-471-521-204;;049-134-753-209-354;;040-428-679-610-399;;089-899-040-309-502;;002-490-451-363-036;;034-331-211-704-877;;076-294-679-339-389;;001-779-867-387-972;;044-522-255-085-902;;107-783-742-795-839;;022-133-574-143-973;;051-208-529-712-079;;030-323-674-660-051;;009-746-604-420-355;;009-483-512-107-343;;015-395-754-996-662;;106-032-800-597-23X;;003-570-249-164-056;;010-953-281-569-514;;017-695-622-077-055;;170-311-024-328-514;;006-895-260-696-111;;107-330-806-519-859;;013-584-945-188-940;;005-119-615-003-591;;012-268-510-926-843;;039-981-636-470-013;;054-876-950-584-376;;072-378-691-723-546;;031-063-853-127-197;;005-112-559-456-657;;104-212-297-137-759;;035-232-534-898-963;;010-916-105-450-247;;016-251-721-517-200;;026-048-786-530-595;;085-727-974-637-837;;018-694-084-068-187;;037-445-639-149-821;;009-275-403-380-31X;;156-501-805-490-709;;116-831-294-654-564;;022-725-321-473-914;;008-274-774-541-556;;070-280-057-407-994;;012-900-923-946-056;;020-126-213-879-311;;054-717-629-774-351;;068-264-897-850-380;;060-301-220-665-473;;035-796-690-562-525;;008-587-496-850-953;;065-430-968-783-392;;021-430-782-622-770;;051-940-176-386-905;;048-536-112-681-339;;049-637-391-464-722;;018-622-691-667-330;;018-622-691-667-330;;019-349-924-670-963;;022-988-712-445-94X;;099-150-317-608-133,24216217;;pmc3978826;;10.1186/alzrt220;;pmc6622286;;22787053;;10.1523/jneurosci.4742-11.2012;;24450890;;10.1056/nejmoa1312889;;10.1016/j.exger.2014.05.002;;24835192;;10.1001/archneur.60.8.1119;;12925369;;19595937;;10.1016/j.jalz.2007.04.381;;15229308;;10.1056/nejmra040223;;10.1212/wnl.43.8.1467;;8350998;;pmc1861657;;8669492;;15459432;;10.1161/01.str.0000143452.85382.d1;;16909007;;10.1159/000090366;;pmc4063417;;10.1016/s1474-4422(12)70015-7;;22305802;;10.1016/0958-1669(94)90053-1;;7765176;;10.1016/0959-440x(92)90091-k;;6375662;;10.1016/s0006-291x(84)80190-4;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;8654676;;10.1042/bst0231035;;1748994;;10.1016/0022-2836(91)90498-u;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;10.4049/jimmunol.133.6.3001;;6092464;;10.1016/0022-2836(87)90412-8;;3681981;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;17161664;;10.1016/j.jchromb.2006.11.018;;10.1038/352624a0;;1907718;;pmc3693547;;21784348;;10.1016/j.jalz.2011.05.2351;;10.1006/jmbi.1999.3192;;10543973;;9377574;;12514726;;10.1038/nm0103-129;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;17981654;;10.2741/2786;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;9099717;;10.1074/jbc.272.16.10678;;10.1074/jbc.271.37.22611;;8798431;;18606226;;10.1016/j.coi.2008.06.004;;10.1038/nbt1135;;16151405;;3500259;;pmc2189658;;10.1084/jem.166.5.1351;;16505368;;10.1073/pnas.0511285103;;pmc1383494;;15944943;;10.14670/hh-20.927;;10.1358/mf.2005.27.3.890876;;15834451;;10.1182/blood-2002-06-1761;;12393541;;10.1016/0022-2836(92)90639-2;;1507232;;15037082;;10.3410/f.1020100.229441;;10.1016/j.jmb.2004.01.007;;15306681;;10.1073/pnas.0401786101;;pmc515084;;14736422;;10.1016/j.jim.2003.11.001;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;10.1126/science.3925553;;3925553;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.152.11.5368;;8189055;;10.1038/nbt0792-779;;1368267;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;10.1016/0378-1119(95)00821-7;;8647439;;7897213;;10.4049/jimmunol.154.7.3310;;10.1126/science.2471267;;2471267;;10.1016/0003-9861(86)90031-7;;2428310;;16609957;;10.1002/bit.20880;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;10.1073/pnas.83.18.7059;;pmc386652;;3462743;;pmc397290;;3856277;;10.1073/pnas.82.5.1499;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;9107305;;10.1016/s0022-1759(97)00002-1;;14551143;;10.1182/blood-2003-06-2031;;17077181;;10.1093/intimm/dxl110;;10.4049/jimmunol.164.8.4178;;10754313;;10.4049/jimmunol.117.2.587;;950463;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;10.1038/nbt1028;;15529166;;886304;;10.1099/0022-1317-36-1-59;;10.1095/biolreprod23.1.243;;6774781;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1212/wnl.34.7.939;;6610841;;10.1056/nejmoa1304839;;pmc4159618;;24450891;;10.1176/ajp.141.11.1356;;6496779;;10.1176/ajp.141.11.1356;;6496779;;14716731;;10.1002/sim.1718;;1202204;;10.1016/0022-3956(75)90026-6;;0001202204;;10.1093/geront/9.3_part_1.179;;5349366,"NIELS D PRINS ET AL: ""Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future"", ALZHEIMERS RES THER, BIOMED CENTRAL LTD, LONDON, UK, vol. 5, no. 6, 11 November 2013 (2013-11-11), pages 56, XP021193607, ISSN: 1758-9193, DOI: 10.1186/ALZRT220;;O. ADOLFSSON ET AL: ""An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A"", JOURNAL OF NEUROSCIENCE, vol. 32, no. 28, 11 July 2012 (2012-07-11), pages 9677 - 9689, XP055097358, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.4742-11.2012;;CHARLOTTE JAGO: ""Alzheimer's Disease: One Year Later"", 3 February 2014 (2014-02-03), XP055183816, Retrieved from the Internet <URL:http://lsconnect.thomsonreuters.com/alzheimers-disease-year-later/> [retrieved on 20150417];;""Crenezumab Phase II cognition data in Alzheimer's disease presented"", 16 July 2014 (2014-07-16), XP055183813, Retrieved from the Internet <URL:http://www.acimmune.com/content/img/pages/ACImmune_crenezumab_phase2_ENGLISH_20140716_final.pdf> [retrieved on 20150417];;RACHELLE S. DOODY ET AL: ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease"", NEW ENGLAND JOURNAL OF MEDICINE, vol. 370, no. 4, 23 January 2014 (2014-01-23), pages 311 - 321, XP055183832, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1312889;;JONATHAN CEDERNAES ET AL: ""Efficacy of antibody-based therapies to treat Alzheimer's disease: Just a matter of timing?"", EXPERIMENTAL GERONTOLOGY, vol. 57, 1 September 2014 (2014-09-01), pages 104 - 106, XP055187152, ISSN: 0531-5565, DOI: 10.1016/j.exger.2014.05.002;;HEBERT ET AL., ARCH. NEUROL., vol. 60, 2003, pages 1119 - 22;;BROOKMEYER ET AL., ALZHEIMERS DEMENT, vol. 3, 2007, pages 186 - 91;;CUMMINGS, N. ENGL. J. MED., vol. 351, 2004, pages 56 - 67;;SAUNDERS ET AL., NEUROLOGY, vol. 43, 1993, pages 1467 - 72;;PREKUMAR ET AL., AM. J. PATHOL., vol. 148, 1996, pages 2083 - 95;;HAASSSELKOE, NATURE, vol. 8, 2007, pages 656 - 67;;DEANE ET AL., STROKE, vol. 35, no. I, 2004, pages 2628 - 31;;MORGAN, NEURODEGENER. DIS., vol. 2, 2005, pages 261 - 6;;MILES ET AL.: ""Scientific Reports"", vol. 3, 6 August 2012, JOHNSTON & JOHNSON PRESS, article ""Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-To-Moderate Alzheimer's Disease"", pages: 1 - 4;;MILES ET AL., SCIENTIFIC REPORTS, vol. 3, 2013, pages 1 - 4;;ELI LILLYCOMPANY PRESS RELEASE, ELI LILLY AND COMPANY AANOUNCES TOP-LINE RESULTS ON SOLANEZUMAB PHASE 3 CLINICAL TRIALS IN PATIENTS WITH ALZHEIMER'S DISEASE, 24 August 2012 (2012-08-24);;SPERLING ET AL., THE LANCET, vol. 11, 2012, pages 241 - 249;;HURLEGROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 - 433;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;GLENNERWONG, BIOCHEM BIOPHYS RES. COMM., vol. 129, 1984, pages 885 - 890;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 322, 1988, pages 738 - 329;;VASWANIHAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL., vol. 1, 1998, pages 105 - 115;;HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;HOOGENBOOM ET AL., NUCL. ACIDS RES., vol. 19, 1991, pages 4133 - 4137;;KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;;CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 60;;JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI USA, vol. 90, 1993, pages 2551;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255;;BRUGGERMANN ET AL., YEAR IN IMMUNOL., vol. 7, 1993, pages 33;;FLATMAN ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 79 - 87;;KINDT ET AL.: ""Kuby Immunology"", 2007, FREEMAN AND CO., pages: 91;;PORTOLANO ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623 - 887;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;PADLAN, MOL. IMMUNOL., vol. 28, 1991, pages 3242 - 498;;PREKUMAR ET AL., AM. J PATHOL., vol. 148, 1996, pages 2083 - 95;;SPERLING ET AL., ALZHEIMER'S & DEMENTIA, vol. 7, 2011, pages 367 - 385;;CHALEIA JAGOMES J, EXPERT REV. NEUROTHER., vol. 4, 2004, pages 267;;GREENBERG ET AL., LANCET NEUROL, vol. 8, 2009, pages 165 - 74;;KUMARA-N, AM J NEURORADIOL, vol. 31, 2010, pages 5;;CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599;;HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134;;WINTER ET AL., ANN. REV. IMMUNOL., vol. 113, 1994, pages 433 - 455;;HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;ALMAGROFRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633;;QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033;;DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 61 - 68;;KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260;;CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285;;BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684;;ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611 - 22618;;VAN DIJKVAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 74;;LONBERG, CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 - 459;;LONBERG, NAT. BIOTECH., vol. 23, 2005, pages 1117 - 1125;;BRUGGEMANN, M. ET AL., J. EXP. MED., vol. 166, 1987, pages 1351 - 1361;;LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562;;NIXIANDAI, MIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268;;VOLLMERSBRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937;;VOLLMERSBRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 91;;CRAGG, M.S. ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052;;MCCAFFERTY ET AL., NATURE, vol. 305, 1983, pages 537 - 554;;HOOGENBOOMWINTER, J. MOL. BIOL., vol. 226, 1992, pages 889 - 896;;OKAZAKI ET AL., J. MOL. BIOL., vol. 336, no. 5, 2004, pages 1239 - 1249;;FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472;;LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553;;GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368;;MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783;;BARBAS ET AL., PROC NAT. ACAD. SCI, vol. 91, 1994, pages 3809 - 3813;;SCHIER ET AL., GENE, vol. 169, 1996, pages 147 - 155;;JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 2004;;CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196;;CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32;;YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614;;RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545;;KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688;;RAVETCHKINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 492;;HELLSTROM, I. ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063;;HELLSTROM, I ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502;;CLYNES ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 95, 1998, pages 652 - 656;;GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163;;CRAGG, M.S.M.J. GLENNIE, BLOOD, vol. 103, 2004, pages 2738 - 2743;;PETKOVA, S.B. ET AL., INT'L. IMMUNOL., vol. 18, no. 12, 2006, pages 1759 - 1769;;SHIELDS ET AL., J. BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184;;GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587;;KAM ET AL., PROC. NATL. ACAD. SCI., vol. 102, 2005, pages 11600 - 11605;;YAZAKIWU: ""Methods in Molecular Biology"", vol. 248, 1996, HUMANA PRESS, article ""Epitope Mapping Protocols"", pages: 255 - 268;;GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414;;LI ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 - 215;;GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59;;MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251;;MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68;;URLAUB ET AL.: ""77"", PROC. NATL. ACAD. SCI. USA, 1980, pages 4216;;HARLOWLANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;""Remington's Pharmaceutical Sciences"", 1980;;MCKHANN ET AL., NEUROLOGY, vol. 34, 1984, pages 939 - 44;;SALLOWAY ET AL., N. ENGL. J. MED., vol. 370, 2014, pages 322 - 333;;ROSEN ET AL., AMER. J. PSYCH., vol. 141, 1984, pages 1356 - 1364;;MOHS ET AL., ALZHEIMER'S DISEASE ASSOC. DISORDERS, vol. 11, no. 2, 1997, pages S13 - S21;;ROSEN ET AL., AM J PSYCHIATR, vol. 141, 1984, pages 1356 - 64;;MOHS ET AL., ALZHEIMER DIS ASSOC DISORD, vol. 11, no. S2, 1997, pages S13 - S21;;MANI, STAT MED, vol. 23, 2004, pages 305 - 14;;FOLSTEIN ET AL., J. PSYCHIATR. RES., vol. 12, 1975, pages 189 - 98;;LAWTON, M.P.BRODY, E.M., GERONTOLOGIST, vol. 9, 1969, pages 179 - 186",DISCONTINUED
258,KR,A,KR 20180038998 A,154-861-387-836-100,2018-04-17,2018,KR 20170127663 A,2017-09-29,KR 20160129544 A,2016-10-07,HANGING DROP CELL CULTURE DEVICE USING POROUS MEMBRANE METHOD OF MANUFACTURING THE SAME METHOD OF HANGING DROP CELL CULTURING AND AUTOMATIC HANGING DROP CELL CULTURE DEVICE,"Provided is a slide cell culture device capable of exchanging a culture medium and injecting an external substance. Moreover, provided are a production method thereof, a cell culture method using the same, and an automatic device for slide cell culture. To this end, the slide cell culture device comprises: a porous membrane; a hydrophobic part positioned on the porous membrane; and a hydrophilic part surrounded by the hydrophobic part.",ULSAN NAT INST SCIENCE & TECH UNIST,CHO YOON KYOUNG;;KIM JUN YOUNG;;MICHAEL ISSAC,,https://lens.org/154-861-387-836-100,Patent Application,no,2,1,3,3,0,C12M23/04;;C12M1/00;;C12M1/12;;C12M1/22;;C12M1/34;;C12M23/10;;C12M23/34;;C12M41/46,C12M1/12;;C12M1/00;;C12M1/22;;C12M1/34,,0,0,,,,ACTIVE
259,CL,A1,CL 2016001979 A1,086-970-408-918-358,2017-02-10,2017,CL 2016001979 A,2016-08-05,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,Métodos de tratamiento de enfermedad de alzheimer.,"<p>MÉTODO DE TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER QUE COMPRENDE LA ADMINISTRACIÓN DE UN ANTICUERPO HUMANIZADO ANTI-AMILOIDE BETA, QUE SE UNE A UN EPITOPE ESPECÍFICO.</p>",GENENTECH INC,WARD MICHAEL;;CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT,,https://lens.org/086-970-408-918-358,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,PENDING
260,AU,A1,AU 2015/214058 A1,185-575-849-200-762,2016-08-11,2016,AU 2015/214058 A,2015-02-06,US 201462081992 P;;US 201462010259 P;;US 201461971479 P;;US 201461937472 P;;US 2015/0014758 W,2014-02-08,Methods of treating Alzheimer's Disease,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/185-575-849-200-762,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K39/00;;A61P25/28,,0,0,,,,ACTIVE
261,US,A1,US 2022/0195020 A1,084-138-430-511-257,2022-06-23,2022,US 202117394053 A,2021-08-04,US 202117394053 A;;US 202017097237 A;;US 202016782654 A;;US 201514616261 A;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/084-138-430-511-257,Patent Application,yes,2,0,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,C07K16/18;;A61K31/56,,1,1,044-966-041-336-742,22871696;;10.1038/nbt0812-731,Garber K. Genentech's Alzheimer's antibody trial to study disease prevention. Nat Biotechnol. 2012 Aug;30(8):731-2. doi: 10.1038/nbt0812-731. PMID: 22871696. (Year: 2012),DISCONTINUED
262,EP,A1,EP 3102231 A1,085-829-519-263-965,2016-12-14,2016,EP 15710295 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P;;US 2015/0014758 W,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,,HOFFMANN LA ROCHE,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/085-829-519-263-965,Patent Application,yes,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,0,0,,,,ACTIVE
263,WO,A1,WO 2010/046428 A1,124-883-127-799-541,2010-04-29,2010,EP 2009063867 W,2009-10-22,US 10819508 P;;EP 08171051 A,2008-10-24,Bundle Trailer for Gas Delivery,"A bundle trailer for containers including (i) a supporting frame on which a plurality of bundles are located; (ii) a plurality of bundles, each bundle comprising : a bundle frame, a plurality of containers containing a chemical, and at least one bundle value for controlling delivery of the chemical in the containers; (iii) at least one trailer valve; and (iv) at least one clamp for fixing the bundle is disclosed. The bundle trailer is capable of delivering high purity hygroscopic, corrosive chemicals, such as elemental fluorine and mixtures thereof, with good flexibility, high safety, and low cost.",SOLVAY FLUOR GMBH;;PITTROFF MICHAEL;;PARK YUK-HWAN;;CHO WOO-JIN,PITTROFF MICHAEL;;PARK YUK-HWAN;;CHO WOO-JIN,,https://lens.org/124-883-127-799-541,Patent Application,yes,11,7,11,11,0,F17C13/083;;F17C13/084;;F17C2201/0104;;F17C2201/032;;F17C2201/035;;F17C2201/054;;F17C2201/056;;F17C2205/0107;;F17C2205/0111;;F17C2205/013;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C2205/0157;;F17C2205/0326;;F17C2221/01;;F17C2221/03;;F17C2250/0447;;F17C2260/01;;F17C2265/04;;F17C2265/063;;F17C2270/0171;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/08;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/083;;F17C2250/0447;;F17C2265/063;;F17C2221/01;;F17C2201/0104;;F17C2205/0157;;F17C2201/032;;F17C2205/0107;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C13/084;;F17C2201/054;;F17C2260/01;;F17C2205/013;;F17C2201/056;;F17C2205/0326;;F17C2205/0111;;F17C2221/03;;F17C2265/04;;F17C2201/035;;F17C2270/0171,F17C13/08,,0,0,,,,PENDING
264,AU,B2,AU 572979 B2,156-657-096-752-382,1988-05-19,1988,AU 1985/040419 A,1985-03-27,US 59632984 A,1984-04-03,UNRESTRICTED FREQUENCY CHANGER SYSTEM,,WESTINGHOUSE ELECTRIC CORP,GYUGYI LASZLO;;HEINRICH THEODORE MICHAEL;;CHO GYU-HYEONG,,https://lens.org/156-657-096-752-382,Granted Patent,no,1,0,18,18,0,H02M5/271;;H02P27/16;;H02M5/00;;H02P27/16;;H02M5/271,H02M5/27;;H02P27/16,,0,0,,,,EXPIRED
265,WO,A3,WO 2022/246170 A3,160-502-862-893-538,2023-01-12,2023,US 2022/0030213 W,2022-05-20,US 202163191418 P;;US 202163191454 P;;US 202163191515 P;;US 202163191497 P;;US 202163213120 P,2021-05-21,SYSTEMS AND METHODS FOR MICROBOT-MEDIATED THERAPEUTIC DELIVERY,"Provided are systems and miniature devices configured to navigate within a patient to a location therewithin for delivering to induce a localized therapeutic effect. Specifically, the present disclosure provides miniature devices configured to be remotely maneuvered along a path within the patient, where the miniature device is configured to selectively: (i) release a guide substance; (ii) release a payload that induces a physiological response; and/or (iii) produce a microtrauma at locations along the path. Further provided are various methods of treatment using such systems and devices.",BIONAUT LABS LTD;;CHO SUEHYUN;;CROS FLORENT;;KISELYOV ALEX;;SHPIGELMACHER MICHAEL,CHO SUEHYUN;;CROS FLORENT;;KISELYOV ALEX;;SHPIGELMACHER MICHAEL,,https://lens.org/160-502-862-893-538,Search Report,yes,4,0,6,6,0,C07K14/52;;C07K14/715;;A61K47/50;;A61P37/00;;A61M37/00;;A61M31/002;;A61M35/00;;A61K9/0097;;A61K9/0009,A61K9/50;;A61M31/00,,1,0,,,"POLYGLYCOLIC ACID, 22 March 2021 (2021-03-22), Retrieved from the Internet <URL:https://www.sciencedirect.com/topics/engineering/polyglycolic-acid> [retrieved on 20220711]",PENDING
266,WO,A1,WO 2015/120233 A1,198-252-799-711-745,2015-08-13,2015,US 2015/0014758 W,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMER'S DISEASE,"Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided.",GENENTECH INC;;HOFFMANN LA ROCHE,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/198-252-799-711-745,Patent Application,yes,89,15,36,75,9,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K39/00;;A61P25/28;;C07K16/18,,140,104,015-169-910-449-13X;;086-932-421-807-452;;131-216-810-326-268;;029-200-906-160-107;;043-348-573-940-487;;069-494-908-751-119;;015-467-620-003-813;;122-558-490-060-539;;057-789-082-803-869;;142-314-510-790-905;;001-553-770-517-492;;062-950-628-293-493;;030-607-398-087-475;;006-574-964-805-278;;042-204-626-457-327;;162-646-650-680-173;;065-608-090-342-50X;;077-495-150-106-187;;020-855-322-534-259;;011-962-497-035-168;;048-564-471-521-204;;040-428-679-610-399;;089-899-040-309-502;;002-490-451-363-036;;015-239-659-590-870;;049-134-753-209-354;;076-294-679-339-389;;082-273-702-755-722;;001-779-867-387-972;;044-522-255-085-902;;001-779-867-387-972;;107-783-742-795-839;;110-088-048-889-302;;051-208-529-712-079;;030-323-674-660-051;;064-667-501-146-970;;022-023-983-891-895;;006-338-973-732-491;;004-601-819-239-79X;;009-746-604-420-355;;093-067-181-692-392;;009-483-512-107-343;;069-144-826-896-138;;015-395-754-996-662;;106-032-800-597-23X;;003-570-249-164-056;;010-953-281-569-514;;003-984-734-905-938;;170-311-024-328-514;;006-895-260-696-111;;107-330-806-519-859;;034-345-578-106-977;;030-630-100-818-462;;034-331-211-704-877;;020-855-322-534-259;;005-283-943-871-819;;079-666-119-599-514;;039-981-636-470-013;;054-876-950-584-376;;022-133-574-143-973;;072-378-691-723-546;;032-071-991-081-664;;117-775-899-628-564;;031-063-853-127-197;;005-112-559-456-657;;104-212-297-137-759;;035-232-534-898-963;;022-375-749-274-329;;010-916-105-450-247;;016-251-721-517-200;;026-048-786-530-595;;085-727-974-637-837;;005-119-615-003-591;;018-694-084-068-187;;012-268-510-926-843;;037-445-639-149-821;;009-275-403-380-31X;;156-501-805-490-709;;116-831-294-654-564;;022-725-321-473-914;;017-695-622-077-055;;008-274-774-541-556;;070-280-057-407-994;;013-584-945-188-940;;012-900-923-946-056;;020-126-213-879-311;;054-717-629-774-351;;068-264-897-850-380;;011-842-849-963-456;;060-301-220-665-473;;020-126-164-125-029;;035-796-690-562-525;;008-587-496-850-953;;065-430-968-783-392;;021-430-782-622-770;;051-940-176-386-905;;048-536-112-681-339;;076-294-679-339-389;;049-637-391-464-722;;018-622-691-667-330;;018-622-691-667-330;;019-349-924-670-963;;022-988-712-445-94X;;099-150-317-608-133,24450890;;10.1056/nejmoa1312889;;24216217;;pmc3978826;;10.1186/alzrt220;;pmc6622286;;22787053;;10.1523/jneurosci.4742-11.2012;;10.1001/archneur.60.8.1119;;12925369;;19595937;;10.1016/j.jalz.2007.04.381;;15229308;;10.1056/nejmra040223;;10.1212/wnl.43.8.1467;;8350998;;pmc1861657;;8669492;;15459432;;10.1161/01.str.0000143452.85382.d1;;16909007;;10.1159/000090366;;pmc4063417;;10.1016/s1474-4422(12)70015-7;;22305802;;6375662;;10.1016/s0006-291x(84)80190-4;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1016/0959-440x(92)90091-k;;8654676;;10.1042/bst0231035;;10.1016/0958-1669(94)90053-1;;7765176;;1748994;;10.1016/0022-2836(91)90498-u;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;10.4049/jimmunol.133.6.3001;;6092464;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;17161664;;10.1016/j.jchromb.2006.11.018;;10.4049/jimmunol.150.3.880;;8423344;;10.1016/0022-2836(87)90412-8;;3681981;;pmc3693547;;21784348;;10.1016/j.jalz.2011.05.2351;;10.1586/14737175.4.2.267;;15853568;;10.1006/jmbi.1999.3192;;10543973;;9377574;;10.1006/jmbi.1999.3192;;10543973;;12514726;;10.1038/nm0103-129;;10.1007/978-3-642-78432-3_11;;17981654;;10.2741/2786;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;15848072;;10.1016/j.ymeth.2005.01.003;;10.1016/0161-5890(91)90163-e;;1905784;;15848074;;10.1016/j.ymeth.2005.01.005;;15848075;;10.1016/j.ymeth.2005.01.006;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;7688398;;10.4049/jimmunol.151.4.2296;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;8360482;;10.4049/jimmunol.151.5.2623;;9099717;;10.1074/jbc.272.16.10678;;10.1074/jbc.271.37.22611;;8798431;;18606226;;10.1016/j.coi.2008.06.004;;10.1038/nbt1135;;16151405;;10.4049/jimmunol.147.1.86;;2051030;;16505368;;10.1073/pnas.0511285103;;pmc1383494;;15944943;;10.14670/hh-20.927;;10.1358/mf.2005.27.3.890876;;15834451;;11968478;;10.1385/1-59259-240-6:001;;10.1038/348552a0;;2247164;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;15066433;;10.1016/j.jmb.2004.02.050;;15236968;;10.1016/j.jmb.2004.05.051;;15306681;;10.1073/pnas.0401786101;;pmc515084;;14736422;;10.1016/j.jim.2003.11.001;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90894-p;;1404359;;10.1038/305537a0;;6137772;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;10.1126/science.3925553;;3925553;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.152.11.5368;;8189055;;1675655;;10.4049/jimmunol.147.1.60;;10.1038/nbt0792-779;;1368267;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;10.1016/0378-1119(95)00821-7;;8647439;;7897213;;10.4049/jimmunol.154.7.3310;;10.1016/0022-2836(92)90639-2;;1507232;;10.1126/science.2471267;;2471267;;15037082;;10.3410/f.1020100.229441;;10.1016/j.jmb.2004.01.007;;10.1016/0003-9861(86)90031-7;;2428310;;16609957;;10.1002/bit.20880;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;10.1073/pnas.83.18.7059;;pmc386652;;3462743;;pmc397290;;3856277;;10.1073/pnas.82.5.1499;;3500259;;pmc2189658;;10.1084/jem.166.5.1351;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;9107305;;10.1016/s0022-1759(97)00002-1;;10.1182/blood-2002-06-1761;;12393541;;14551143;;10.1182/blood-2003-06-2031;;17077181;;10.1093/intimm/dxl110;;10.4049/jimmunol.164.8.4178;;10754313;;10.4049/jimmunol.117.2.587;;950463;;3258649;;10.1038/332738a0;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;14970501;;10.1385/1-59259-666-5:245;;10.1038/nbt1028;;15529166;;886304;;10.1099/0022-1317-36-1-59;;10.1095/biolreprod23.1.243;;6774781;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1212/wnl.34.7.939;;6610841;;pmc3693547;;21784348;;10.1016/j.jalz.2011.05.2351;;10.1056/nejmoa1304839;;pmc4159618;;24450891;;10.1176/ajp.141.11.1356;;6496779;;10.1176/ajp.141.11.1356;;6496779;;14716731;;10.1002/sim.1718;;1202204;;10.1016/0022-3956(75)90026-6;;0001202204;;10.1093/geront/9.3_part_1.179;;5349366,"RACHELLE S. DOODY ET AL: ""Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease"", NEW ENGLAND JOURNAL OF MEDICINE, vol. 370, no. 4, 23 January 2014 (2014-01-23), pages 311 - 321, XP055183832, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1312889;;NIELS D PRINS ET AL: ""Treating Alzheimer?s disease with monoclonal antibodies: current status and outlook for the future"", ALZHEIMERS RES THER, BIOMED CENTRAL LTD, LONDON, UK, vol. 5, no. 6, 11 November 2013 (2013-11-11), pages 56, XP021193607, ISSN: 1758-9193, DOI: 10.1186/ALZRT220;;O. ADOLFSSON ET AL: ""An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A"", JOURNAL OF NEUROSCIENCE, vol. 32, no. 28, 11 July 2012 (2012-07-11), pages 9677 - 9689, XP055097358, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.4742-11.2012;;CHARLOTTE JAGO: ""Alzheimer's Disease: One Year Later"", 3 February 2014 (2014-02-03), XP055183816, Retrieved from the Internet <URL:http://lsconnect.thomsonreuters.com/alzheimers-disease-year-later/> [retrieved on 20150417];;""Crenezumab Phase II cognition data in Alzheimer's disease presented"", 16 July 2014 (2014-07-16), XP055183813, Retrieved from the Internet <URL:http://www.acimmune.com/content/img/pages/ACImmune_crenezumab_phase2_ENGLISH_20140716_final.pdf> [retrieved on 20150417];;HEBERT ET AL., ARCH. NEUROL., vol. 60, 2003, pages 1119 - 22;;BROOKMEYER ET AL., ALZHEIMERS DEMENT., vol. 3, 2007, pages 186 - 91;;CUMMINGS, N. ENGL. J. MED., vol. 351, 2004, pages 56 - 67;;SAUNDERS ET AL., NEUROLOGY, vol. 43, 1993, pages 1467 - 72;;PREKUMAR ET AL., AM. J. PATHOL., vol. 148, 1996, pages 2083 - 95;;HAASS; SELKOE, NATURE, vol. 8, 2007, pages 656 - 67;;DEANE ET AL., STROKE, vol. 35, no. I, 2004, pages 2628 - 31;;MORGAN, NEURODEGENER. DIS., vol. 2, 2005, pages 261 - 6;;MILES ET AL.: ""Scientific Reports"", vol. 3, 6 August 2012, JOHNSTON & JOHNSON PRESS, article ""Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-To-Moderate Alzheimer's Disease"", pages: 1 - 4;;MILES ET AL., SCIENTIFIC REPORTS, vol. 3, 2013, pages 1 - 4;;SPERLING ET AL., THE LANCET, vol. 11, 2012, pages 241 - 249;;SINGLETON: ""Dictionary of Microbiology and Molecular Biology"", 1994, J. WILEY & SONS;;MARCH: ""Advanced Organic Chemistry Reactions, Mechanisms and Structure"", 1992, JOHN WILEY & SONS;;GLENNER; WONG, BIOCHEM BIOPHYS RES. COMM., vol. 129, 1984, pages 885 - 890;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;VASWANI; HAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL., vol. 1, 1998, pages 105 - 115;;HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038;;HURLE; GROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 - 433;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597;;HOOGENBOOM ET AL., NUCL. ACIDS RES., vol. 19, 1991, pages 4133 - 4137;;KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;;BRODEUR ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 55 - 93;;BOERNER ET AL., J. IMMUNOL., vol. 147, no. 86, 1991;;JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI USA, vol. 90, 1993, pages 2551;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255;;BRUGGERMANN, YEAR IN IMMUNOL., vol. 7, 1993, pages 33;;FLATMAN ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 79 - 87;;KINDT ET AL.: ""Kuby Immunology"", 2007, W.H. FREEMAN AND CO, pages: 91;;PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887;;CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", vol. 1-3, 1991, NIH PUBLICATION 91-3242;;PREKUMAR ET AL., AM. J PATHOL., vol. 148, 1996, pages 2083 - 95;;SPERLING ET AL., ALZHEIMER'S & DEMENTIA, vol. 7, 2011, pages 367;;CHALELA J A.; GOMES J., EXPERT REV. NEUROTHER, vol. 4, 2004, pages 267;;GREENBERG ET AL., LANCET NEUROL., vol. 8, 2009, pages 165 - 74;;KUMARA-N, AM J NEURORADIOL., vol. 31, 2010, pages 5;;CHEN, J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599;;CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134;;PLUCKTHUN: ""The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315;;HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;ALMAGRO; FRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633;;QUEEN ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033;;KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34;;PADLAN, MOL. IMMUNOL., vol. 28, 1991, pages 489 - 498;;DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 43 - 60;;OSBOURN ET AL., METHODS, vol. 36, 2005, pages 61 - 68;;KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260;;SIMS, J. IMMUNOL., vol. 151, 1993, pages 2296;;CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285;;PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623;;BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684;;ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611 - 22618;;VAN DIJK; VAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 74;;LONBERG, CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 - 459;;LONBERG, NAT. BIOTECH., vol. 23, 2005, pages 1117 - 1125;;BRODEUR ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 51 - 63;;BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86;;LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562;;NI, XIANDAI MIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268;;VOLLMERS; BRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937;;VOLLMERS; BRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 91;;HOOGENBOOM ET AL.: ""Methods in Molecular Biology"", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37;;MCCAFFERTY ET AL., NATURE, vol. 348, pages 552 - 554;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1992, pages 581 - 597;;MARKS; BRADBURY: ""Methods in Molecular Biology"", vol. 248, 2003, HUMAN PRESS, pages: 161 - 175;;SIDHU ET AL., J. MOL. BIOL., vol. 338, no. 2, 2004, pages 299 - 310;;LEE ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 1093;;FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472;;LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132;;WINTER ET AL., ANN. REV. IMMUNOL., vol. 12, 1994, pages 433 - 455;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1992, pages 381 - 388;;MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537;;TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553;;GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368;;TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60;;MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783;;BARBAS ET AL., PROC NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813;;SCHIER ET AL., GENE, vol. 169, 1996, pages 147 - 155;;YELTON ET AL., J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004;;JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9;;HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896;;CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32;;OKAZAKI ET AL., J. MOL. BIOL., vol. 336, 2004, pages 1239 - 1249;;YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614;;RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545;;KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688;;RAVETCH; KINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 492;;HELLSTROM, I. ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063;;HELLSTROM, I ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502;;BRUGGEMANN, M. ET AL., J. EXP. MED., vol. 166, 1987, pages 1351 - 1361;;CLYNES ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 95, 1998, pages 652 - 656;;GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163;;CRAGG, M.S. ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052;;CRAGG, M.S.; M.J. GLENNIE, BLOOD, vol. 103, 2004, pages 2738 - 2743;;PETKOVA, S.B. ET AL., INT'L. IMMUNOL., vol. 18, no. 12, 2006, pages 1759 - 1769;;SHIELDS ET AL., J. BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184;;GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587;;KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249;;DUNCAN; WINTER, NATURE, vol. 322, 1988, pages 738 - 40;;KAM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 11600 - 11605;;CHARLTON: ""Methods in Molecular Biology"", vol. 248, 2003, HUMANA PRESS, pages: 245 - 254;;GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414;;LI ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 - 215;;GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59;;MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251;;MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68;;URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216;;YAZAKI; WU: ""Methods in Molecular Biology"", vol. 248, 2003, HUMANA PRESS, pages: 255 - 268;;MORRIS: ""Methods in Molecular Biology"", vol. 66, 1996, HUMANA PRESS, article ""Epitope Mapping Protocols"";;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;""Remington's Pharmaceutical Sciences"", 1980;;MCKHANN ET AL., NEUROLOGY, vol. 34, 1984, pages 939 - 44;;SPERLING ET AL., ALZHEIMER'S & DEMENTIA, vol. 7, 2011, pages 367 - 385;;SALLOWAY ET AL., N. ENGL. J. MED., vol. 370, 2014, pages 322 - 333;;ROSEN ET AL., AMER. J. PSYCH., vol. 141, 1984, pages 1356 - 1364;;MOHS ET AL., ALZHEIMER'S DISEASE ASSOC. DISORDERS, vol. 11, no. 2, 1997, pages S13 - S21;;ROSEN ET AL., AM J PSYCHIATR, vol. 141, 1984, pages 1356 - 64;;MOHS ET AL., ALZHEIMER DIS ASSOC DISORD, vol. 11, no. S2, 1997, pages S 13,S21;;MANI, STAT MED, vol. 23, 2004, pages 305 - 14;;FOLSTEIN ET AL., J. PSYCHIATR. RES., vol. 12, 1975, pages 189 - 98;;LAWTON, M.P.; BRODY, E.M., GERONTOLOGIST, vol. 9, 1969, pages 179 - 186",PENDING
267,KR,A,KR 20110071022 A,039-424-043-080-472,2011-06-27,2011,KR 20117011658 A,2009-10-22,EP 08171051 A;;US 10819508 P,2008-10-24,BUNDLE TRAILER FOR GAS DELIVERY,,SOLVAY FLUOR GMBH,PITTROFF MICHAEL;;PARK YUK HWAN;;CHO WOO JIN,,https://lens.org/039-424-043-080-472,Patent Application,no,4,0,11,11,0,F17C13/083;;F17C13/084;;F17C2201/0104;;F17C2201/032;;F17C2201/035;;F17C2201/054;;F17C2201/056;;F17C2205/0107;;F17C2205/0111;;F17C2205/013;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C2205/0157;;F17C2205/0326;;F17C2221/01;;F17C2221/03;;F17C2250/0447;;F17C2260/01;;F17C2265/04;;F17C2265/063;;F17C2270/0171;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/08;;Y10T137/474;;Y10T137/6855;;Y10T137/4874;;F17C13/083;;F17C2250/0447;;F17C2265/063;;F17C2221/01;;F17C2201/0104;;F17C2205/0157;;F17C2201/032;;F17C2205/0107;;F17C2205/0138;;F17C2205/0142;;F17C2205/0146;;F17C13/084;;F17C2201/054;;F17C2260/01;;F17C2205/013;;F17C2201/056;;F17C2205/0326;;F17C2205/0111;;F17C2221/03;;F17C2265/04;;F17C2201/035;;F17C2270/0171,F17C13/08,,0,0,,,,ACTIVE
268,WO,A1,WO 2018/066953 A1,040-759-397-077-131,2018-04-12,2018,KR 2017011043 W,2017-09-29,KR 20160129544 A,2016-10-07,"HANGING DROP CELL CULTURE DEVICE USING POROUS MEMBRANE, METHOD FOR MANUFACTURING SAME, HANGING DROP CELL CULTURE METHOD USING SAME, AND HANGING DROP CELL CULTURE AUTOMATION DEVICE","Provided are a hanging drop cell culture device capable of exchanging a culture medium and injecting a foreign substance, a method for manufacturing the same, and a cell culture method using the same.",ULSAN NAT INST SCIENCE & TECH UNIST,CHO YOON KYOUNG;;KIM JUN YOUNG;;ISSAC MICHAEL,,https://lens.org/040-759-397-077-131,Patent Application,yes,5,2,3,3,0,C12M23/04;;C12M1/00;;C12M1/12;;C12M1/22;;C12M1/34;;C12M23/10;;C12M23/34;;C12M41/46,C12M1/12;;C12M1/00;;C12M1/22;;C12M1/34,,0,0,,,,PENDING
269,TW,B,TW I705824 B,049-823-157-855-492,2020-10-01,2020,TW 104104180 A,2015-02-06,US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,Methods of treating alzheimer's disease,,GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/049-823-157-855-492,Granted Patent,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,,,1,1,086-932-421-807-452,24216217;;pmc3978826;;10.1186/alzrt220,"Doody et. al., “Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease” Th e new england journal of medicine, 370;4, January 23, 2014 Niels D Prins and Philip Scheltens “Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future” Prins and Scheltens Alzheimer's Research & Therapy, 5:56, 2013",ACTIVE
270,KR,A,KR 20220130719 A,089-279-357-864-478,2022-09-27,2022,KR 20227027267 A,2021-01-18,EP 20152513 A;;EP 2021050969 W,2020-01-17,엔벨로프 완전성이 변화된 유전자 변형 세균 및 이의 용도,"본 발명은 용해에 대해 과민성인 유전자 변형된 그람-음성 세균, 특히 이. 콜라이에 관한 것이다. 따라서, 이러한 세균은 핵산 추출, 바람직하게는 게놈외 핵산 추출(예: 플라스미드), 및/또는 바람직하게는 게놈외 핵산에 의해 코딩된 폴리펩티드의 수율을 개선하는 데 유용하다. 실제로, 본 발명자들은 엔벨로프 완전성을 변화시키는 적어도 2개의 돌연변이 유전자의 조합을 사용하여 이. 콜라이 균주를 조작했다. 보다 구체적으로, 적어도 하나의 돌연변이 유전자는 ompA이고, 적어도 하나의 돌연변이 유전자는, 예를 들면, lpp 유전자, ybiS 유전자, ycfS 유전자 및 erfK 유전자 등의 Lpp 기능성에 관여하는 유전자이다. 이러한 조합은 또한 ompA 유전자 및/또는 lpp 유전자와 상동성인 유전자의 돌연변이를 포함한다.",UNIV CATHOLIQUE LOUVAIN,COLLET JEAN FRANCOIS;;DEGHELT MICHAEL;;CHO SEUNG HYUN,,https://lens.org/089-279-357-864-478,Patent Application,no,0,0,8,8,42,A61K38/00;;C12N15/01;;C12N15/70;;C12N1/20;;C07K14/245;;C12N1/06;;C12R2001/185;;C07K14/245;;C12N15/70;;C12P19/34,C12N15/70;;C07K14/245;;C12N1/06;;C12N1/20;;C12R1/185,,0,0,,,,PENDING
271,US,A,US 4028627 A,088-864-332-292-507,1977-06-07,1977,US 64500375 A,1975-12-29,US 64500375 A,1975-12-29,Sample and hold valley detector,An audio signal quality detector connected to receive an audio signal from the discriminator of a radio receiver and including an envelope detector connected to the output of the discriminator and supplying a signal indicative of the envelope of the audio to a resettable valley detector which stores a voltage indicative of the lowest valley applied thereto subsequent to a reset pulse and a sample and hold gate connected to the valley detector for sampling the voltage stored in the valley detector prior to periodic reset pulses applied to the valley detector. Circuitry is also included for inhibiting the operation of the sample and hold gate when there is no output from the valley detector.,MOTOROLA INC,CHO SUSUMU;;ERICKSON PAUL MILTON;;NULL MICHAEL WILLIAM,,https://lens.org/088-864-332-292-507,Granted Patent,yes,3,19,1,1,0,G01R19/04;;G11C27/024;;H04B1/10;;G11C27/024;;G01R19/04;;H04B1/10,G01R19/04;;G11C27/02;;H04B1/10,325/349,0,0,,,,EXPIRED
272,US,A1,US 2011/0064760 A1,101-730-493-825-111,2011-03-17,2011,US 85721010 A,2010-08-16,US 85721010 A;;US 23388109 P,2009-08-14,POLYPEPTIDES COMPRISING EPITOPES OF HIV GP41 AND METHODS OF USE,An isolated polypeptide that has an amino acid sequence that is substantially homologous to consecutive amino acids of a c-terminal portion of the membrane proximal external region (MPER) of gp41 includes an immunogenic epitope reactive with at least one anti-HIV antibody.,CHO MICHAEL W;;HAN DONG P;;TAKAMOTO KEIJI,CHO MICHAEL W;;HAN DONG P;;TAKAMOTO KEIJI,CASE WESTERN RESERVE UNIVERSITY (2010-11-04),https://lens.org/101-730-493-825-111,Patent Application,yes,0,11,1,1,25,A61K39/21;;C07K14/005;;C12N2740/16134;;A61K2039/54;;A61K2039/545;;A61K2039/55505;;A61K2039/55583;;A61K39/12;;A61P31/18;;A61P37/04;;A61K39/21;;C12N2740/16134;;C07K14/005;;A61K2039/55583;;A61K2039/545;;A61K2039/54;;A61K2039/55505;;A61K39/12,A61K39/21;;A61P31/18;;A61P37/04;;C12P21/00,424/188.1;;424/208.1;;435/69.3,10,10,082-698-013-854-390;;130-948-849-146-544;;007-123-254-710-403;;107-042-784-987-937;;076-403-800-982-81X;;104-744-316-886-227;;043-088-882-309-877;;026-175-090-971-896;;011-404-830-872-909;;006-037-729-222-896,10782117;;10.1016/s0168-9525(00)02005-9;;pmc2286544;;15388860;;10.1110/ps.04872204;;10.1016/j.vetimm.2011.06.019;;pmc4461867;;21719117;;pmc2224348;;10.3410/f.1097656.553758;;10.1128/jvi.00927-07;;17942537;;16310557;;10.1016/s0140-6736(05)67395-3;;10.1126/science.1152622;;18467582;;10.1146/annurev.immunol.24.021605.090605;;16551249;;12835706;;10.1038/nm0703-861;;10.1128/jvi.67.11.6642-6647.1993;;7692082;;pmc238102;;11602729;;pmc114669;;10.1128/jvi.75.22.10892-10905.2001,"Fitch, W. M., May 2000, Homology: a personal view on some of the problems, Trends in Genetics 16(5):227-231.;;Choi, K. H., et al., 2004, Design, expression, and purification of a Flaviviridae polymerase using a high-throughput approach to facilitate crystal structure determination, Prot. Sci. 13:2685-2692.;;Abbott, J. R., et al., 2011, Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine, Vet. Immunol. Immunopath. 143:246-254.;;Alam, S. M., et al., January 2008, Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection, J. Virol. 82(1):115-125.;;Gallo, R. C., 2005, The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years, The Lancet, 366:1894-1898.;;Walker, B. D., and D. R. Burton, May 2008, Toward an AIDS vaccine, Science 320:760-764.;;McMichael, A. J., 2006, HIV vaccines, Annu. Rev. Immunol. 24:227-255.;;Letvin, N. L., and B. D. Walker, July 2003, Immunopathogenesis and immunotherapy in AIDS virus infections, Nat. Med. 9(7):861-866.;;Muster, T., et al., November 1993, A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1, J. Virol. 67(11):6642-6647.;;Zwick, M. B., et al., November 2001, Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41, J. Virol. 75(22):10892-10905.",DISCONTINUED
273,US,S,US D0295411 S,125-817-218-396-212,1988-04-26,1988,US 71240885 F,1985-03-15,US 71240885 F,1985-03-15,Combined voice and data terminal or similar article,,AMERICAN TELEPHONE AND TELEGRAPH COMPANY AT&T BELL LABORATORIES,CHO GIHYUN;;GRISHAM MICHAEL G;;PRONTNICKI DAVID F,BELL TELEPHONE LABORATORIES INCORPORATED (1985-03-04),https://lens.org/125-817-218-396-212,Design Right,yes,5,26,1,1,0,,,D14/100,0,0,,,,EXPIRED
274,HK,A1,HK 1231401 A1,104-588-642-184-210,2017-12-22,2017,HK 17105176 A,2017-05-22,US 2015/0014758 W;;US 201461937472 P;;US 201461971479 P;;US 201462010259 P;;US 201462081992 P,2014-02-08,METHODS OF TREATING ALZHEIMERS DISEASE,,GENENTECH INC,CHO WILLIAM;;FRIESENHAHN MICHEL;;PAUL ROBERT;;WARD MICHAEL,,https://lens.org/104-588-642-184-210,Patent Application,no,0,0,36,75,0,A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;A61P25/28;;A61P43/00;;A61K31/56;;A61K2039/505;;A61K39/395;;A61K39/3955;;A61P25/28;;A61P43/00;;C07K16/18;;C07K2317/24;;C07K2317/34;;C07K2317/56;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K2317/56;;A61P25/28;;A61K39/00;;A61P25/28;;C07K16/18;;A61K2039/505;;C07K2317/24;;C07K2317/34;;C07K16/18;;A61K31/56;;C07K2317/56,A61K/;;A61P/;;C07K/,,0,0,,,,PENDING
275,EP,B1,EP 1843216 B1,158-809-490-142-462,2009-10-21,2009,EP 07001725 A,2007-01-26,KR 20060030790 A,2006-04-05,Method of mounting a photosensitive drum for printer cartridge,"A photosensitive drum (50) for a printer cartridge is disclosed, which can be easily mounted on a printer cartridge wherein the positions of drum connectors (70a,70b) are fixed. The photosensitive drum comprises a cylindrical drum (52) having a photosensitive layer on a cylindrical surface thereof; and a pair of rotation shafts (60a,60b) which is respectively mounted on the sides of the cylindrical drum for rotating and supporting the cylindrical drum, wherein at least one of the rotation shafts is insert-fitted to the cylindrical drum when mounting the photosensitive drum to the printer cartridge.",PARK & OPC CO LTD,CHO MYUNG-LAE;;HAN MICHAEL;;KIM HAN-SHIK;;CHO SEONG-JIN;;JEON JUN-HO,,https://lens.org/158-809-490-142-462,Granted Patent,yes,3,2,10,10,0,F16D1/10;;G03G15/751;;G03G15/04;;F16D1/10;;G03G15/751;;G03G15/348;;G03G2217/0075;;F16D1/10;;G03G15/751,G03G15/00,,0,0,,,,ACTIVE
276,EP,A1,EP 1843216 A1,140-925-952-707-523,2007-10-10,2007,EP 07001725 A,2007-01-26,KR 20060030790 A,2006-04-05,Method of mounting a photosensitive drum for printer cartridge,"A photosensitive drum (50) for a printer cartridge is disclosed, which can be easily mounted on a printer cartridge wherein the positions of drum connectors (70a,70b) are fixed. The photosensitive drum comprises a cylindrical drum (52) having a photosensitive layer on a cylindrical surface thereof; and a pair of rotation shafts (60a,60b) which is respectively mounted on the sides of the cylindrical drum for rotating and supporting the cylindrical drum, wherein at least one of the rotation shafts is insert-fitted to the cylindrical drum when mounting the photosensitive drum to the printer cartridge.
",PARK & OPC CO LTD,CHO MYUNG-LAE;;HAN MICHAEL;;KIM HAN-SHIK;;CHO SEONG-JIN;;JEON JUN-HO,,https://lens.org/140-925-952-707-523,Patent Application,yes,6,16,10,10,0,F16D1/10;;G03G15/751;;G03G15/04;;F16D1/10;;G03G15/751;;G03G15/348;;G03G2217/0075;;F16D1/10;;G03G15/751,G03G15/00,,0,0,,,,ACTIVE
277,DE,D1,DE 602007002834 D1,016-265-631-840-757,2009-12-03,2009,DE 602007002834 T,2007-01-26,KR 20060030790 A,2006-04-05,Montageverfahren für lichtempfindliche Trommel für eine Druckerkassette,"A photosensitive drum (50) for a printer cartridge is disclosed, which can be easily mounted on a printer cartridge wherein the positions of drum connectors (70a,70b) are fixed. The photosensitive drum comprises a cylindrical drum (52) having a photosensitive layer on a cylindrical surface thereof; and a pair of rotation shafts (60a,60b) which is respectively mounted on the sides of the cylindrical drum for rotating and supporting the cylindrical drum, wherein at least one of the rotation shafts is insert-fitted to the cylindrical drum when mounting the photosensitive drum to the printer cartridge.",PARK & OPC CO LTD,CHO MYUNG-LAE;;HAN MICHAEL;;KIM HAN-SHIK;;CHO SEONG-JIN;;JEON JUN-HO,,https://lens.org/016-265-631-840-757,Granted Patent,no,0,0,10,10,0,F16D1/10;;G03G15/751;;G03G15/04;;F16D1/10;;G03G15/751;;G03G15/348;;G03G2217/0075;;F16D1/10;;G03G15/751,G03G15/00,,0,0,,,,ACTIVE
278,CN,A,CN 101051196 A,008-209-683-804-014,2007-10-10,2007,CN 200710000037 A,2007-01-05,KR 20060030790 A,2006-04-05,Photosensitive drum for printer cartridge and method for mounting the same,"A photosensitive drum (50) for a printer cartridge is disclosed, which can be easily mounted on a printer cartridge wherein the positions of drum connectors (70a,70b) are fixed. The photosensitive drum comprises a cylindrical drum (52) having a photosensitive layer on a cylindrical surface thereof; and a pair of rotation shafts (60a,60b) which is respectively mounted on the sides of the cylindrical drum for rotating and supporting the cylindrical drum, wherein at least one of the rotation shafts is insert-fitted to the cylindrical drum when mounting the photosensitive drum to the printer cartridge.",PARK & OPC CO LTD,CHO MYUNG-LAE;;HAN MICHAEL;;KIM HAN-SHIK;;CHO SEONG-JIN;;JEON JUN-HO,,https://lens.org/008-209-683-804-014,Patent Application,no,0,2,10,10,0,F16D1/10;;G03G15/751;;G03G15/04;;F16D1/10;;G03G15/751;;G03G15/348;;G03G2217/0075;;F16D1/10;;G03G15/751,G03G15/00;;G03G15/02;;G03G21/00,,0,0,,,,INACTIVE
279,KR,A,KR 20150120306 A,170-193-418-299-002,2015-10-27,2015,KR 20150053180 A,2015-04-15,KR 20140045575 A,2014-04-16,"SILICON PRECURSOR, METHOD OF FORMING A LAYER USING THE SAME AND METHOD OF FABRICATING A SEMICONDUCTOR DEVICE USING THE SAME","The present invention discloses a silicon precursor, a method for forming a thin film using the same and a producing method of a semiconductor device using the same. The silicon precursor comprises a silane group having two or more silicons and exhibits high and uniform adsorption property on a surface of a film such as silicon, an oxide film and a nitride film or the like which are used a lot when producing semiconductors.",SAMSUNG ELECTRONICS CO LTD;;DOW CORNING,CHO JUN HYUN;;TELGENHOFF MICHAEL DAVID;;ZHOU XIAOBING;;JUNG KYUNG HYE;;CHO YOUN JOUNG,,https://lens.org/170-193-418-299-002,Patent Application,no,3,3,5,5,0,H01L21/02488;;H01L21/0262;;H01L21/32055;;H01L21/76897;;H01L21/28562;;H01L21/76876;;H01L21/76877;;H01L21/02532;;H01L21/02595;;H10B12/00;;H10B41/27;;H01L21/02532;;H01L21/02595;;H01L21/02164;;H01L21/0217;;H01L21/02211;;H01L21/02488;;H01L21/0262;;H01L21/76877;;H01L21/76897;;H01L21/32055;;H01L21/28562;;H01L21/76876;;H10B12/0335;;H10B12/315;;H10B12/00;;H10B41/27,C01B33/021;;C30B29/06,,0,0,,,,ACTIVE
280,US,B2,US 7676175 B2,028-430-831-304-31X,2010-03-09,2010,US 52094106 A,2006-09-13,KR 20060030790 A,2006-04-05,Photosensitive drum for printer cartridge and method for mounting the same,"A photosensitive drum for a printer cartridge, which can be easily mounted on a printer cartridge of which the positions of drum connectors are fixed, is disclosed. The photosensitive drum for a printer cartridge comprises a cylindrical drum having a photosensitive layer on a cylindrical surface thereof; and a pair of rotation shafts which is respectively mounted on the sides of the cylindrical drum for rotating and supporting the cylindrical drum, wherein at least one of the rotation shafts is insert-fitted to the side of the cylindrical drum.",PARK & OPC CO LTD,CHO MYUNG-LAE;;HAN MICHAEL;;KIM HAN-SHIK;;CHO SEONG-JIN;;JEON JUN-HO,PARK & OPC CO. LTD (2006-07-31),https://lens.org/028-430-831-304-31X,Granted Patent,yes,2,0,10,10,0,F16D1/10;;G03G15/751;;G03G15/04;;F16D1/10;;G03G15/751;;G03G15/348;;G03G2217/0075;;F16D1/10;;G03G15/751,G03G15/00,399/117;;399/116;;399/159,0,0,,,,INACTIVE
281,US,A1,US 2007/0237545 A1,052-260-431-618-425,2007-10-11,2007,US 52094106 A,2006-09-13,KR 20060030790 A,2006-04-05,Photosensitive drum for printer cartridge and method for mounting the same,"A photosensitive drum for a printer cartridge, which can be easily mounted on a printer cartridge of which the positions of drum connectors are fixed, is disclosed. The photosensitive drum for a printer cartridge comprises a cylindrical drum having a photosensitive layer on a cylindrical surface thereof; and a pair of rotation shafts which is respectively mounted on the sides of the cylindrical drum for rotating and supporting the cylindrical drum, wherein at least one of the rotation shafts is insert-fitted to the side of the cylindrical drum.",PARK & OPC CO LTD,CHO MYUNG-LAE;;HAN MICHAEL;;KIM HAN-SHIK;;CHO SEONG-JIN;;JEON JUN-HO,PARK & OPC CO. LTD (2006-07-31),https://lens.org/052-260-431-618-425,Patent Application,yes,2,89,10,10,0,F16D1/10;;G03G15/751;;G03G15/04;;F16D1/10;;G03G15/751;;G03G15/348;;G03G2217/0075;;F16D1/10;;G03G15/751,G03G15/00,399/117,0,0,,,,INACTIVE
282,WO,A1,WO 2019/204504 A1,121-193-049-393-740,2019-10-24,2019,US 2019/0027958 W,2019-04-17,US 201862658827 P,2018-04-17,INSPECTION ROBOT FOR HORIZONTAL TUBE INSPECTION,"An inspection apparatus and methods for inspecting horizontal tubes in an industrial environment are disclosed. The apparatus can include a drive module including a pair of wheels to engage a top tube of a vertically arranged layer of tubes, a telescoping pole, a sensor carriage assembly coupled to the telescoping pole, and a lowering mechanism operationally coupled to the telescoping pole to selectively extend or retract the telescoping pole providing a selected vertical position of the sensor carriage assembly.",GECKO ROBOTICS INC,LOW KEVIN;;BRYNER EDWARD;;MACKENZIE LOGAN;;MOORE JOSHUA;;AUDA MICHAEL;;CHO MARK;;CHO EDWIN,,https://lens.org/121-193-049-393-740,Patent Application,yes,3,37,1,78,0,B62D57/02;;G01N29/043;;G01N29/225;;G01N29/265;;G01N2291/2636,F16L55/26;;F16L55/46,,0,0,,,,PENDING
283,US,B2,US 11865698 B2,073-680-488-545-813,2024-01-09,2024,US 202217716249 A,2022-04-08,US 202217716249 A;;US 202163177141 P;;US 202163255880 P,2021-04-20,Inspection robot with removeable interface plates and method for configuring payload interfaces,"Inspection robots with removeable interface plates and method for configuring payload interfaces are described. An example robot may include a payload, with at least one sensor, mounted to a housing of the inspection robot. The housing may include a removeable interface plate coupled to the at least one sensor and to an electronic board, the electronic board positioned within the housing. The removeable interface plate may define an electrical coupling interface compatible with the payload, and the electronic board may include an electrical processing configuration compatible with the payload.",GECKO ROBOTICS INC,BRYNER EDWARD A;;CHO EDWIN H;;CHO MARK;;BINGER MICHAEL A;;LOW KEVIN Y,GECKO ROBOTICS INC (2022-04-11),https://lens.org/073-680-488-545-813,Granted Patent,yes,391,0,24,24,0,B62D57/024;;G01N29/225;;G01N29/265;;G01N2291/0237;;G01N2291/02854;;G01N29/043;;G05B2219/45066;;B25J9/1694;;B25J9/1692;;B25J9/1666;;B60K7/00;;B60K7/0007;;B25J9/1653;;B25J19/027;;B25J13/087;;B25J9/0009;;B25J9/1694;;G01N29/04;;G01N29/226;;G01N29/265;;G01N2291/0289;;G01N2291/2698;;B25J9/1617;;B25J9/163;;B25J9/1664;;B25J9/1674;;B25J13/006;;B25J5/007;;B25J19/021;;B60K1/02;;B62D53/02;;B62D57/024;;B60B19/006;;B60B19/12;;B60B2360/104;;B60B2360/109;;B60B2900/931;;B60B2360/102;;G06F1/206;;G06F2200/201;;H05K1/18;;H05K2201/10151,B25J13/08;;B25J5/00;;B25J9/00;;B25J9/16;;B25J13/00;;B25J19/02;;B60B19/00;;B60B19/12;;B60K1/02;;B62D53/02;;B62D57/024;;G01N29/04;;G01N29/22;;G01N29/265;;G06F1/20;;H05K1/18,,103,19,015-202-554-475-543;;003-586-509-514-11X;;054-540-039-219-971;;047-660-386-217-965;;053-607-783-158-908;;080-519-814-875-15X;;134-217-287-880-064;;148-371-561-359-305;;096-387-808-699-363;;011-803-388-304-260;;084-515-545-463-225;;054-367-401-283-890;;087-860-043-054-057;;061-004-547-120-171;;056-100-419-584-317;;016-774-813-068-580;;072-760-625-806-703;;010-855-753-624-675;;029-590-579-625-38X,10.1109/iros.2017.8206567;;10.3390/robotics4020103;;10.1109/iros.1993.583934;;10.1109/icra.2012.6224799;;10.1109/jsyst.2016.2611244;;10.1109/ifis.1993.324212;;10.1007/978-3-642-10817-4_93;;10.1145/317456.317459;;10.1109/iros.1994.407566;;10.1109/iros.2017.8206562;;10.1109/scis-isis.2014.7044830;;15737388;;10.1016/j.ultras.2004.08.001;;10.1007/978-1-4613-8997-2_3;;10.1109/cyber.2018.8688097;;10.1109/tmech.2016.2612722;;10.1109/robio.2016.7866581;;10.1109/robio.2016.7866459;;10.1109/icems.2005.202786;;10.1109/carpi.2012.6473363,"21201397.3 , “European Application Serial No. 21201397.3, Extended European Search Report dated May 11, 2022”, Gecko Robotics, Inc., 12 pages.;;NIDEC , “Flexwave Catalog”, 2018, 52 pages.;;PCT/US2022/023993 , “International Application Serial No. PCT/US2022/023993, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jun. 16, 2022”, Gecko Robotics, Inc., 3 pages.;;Stepson, W.A.V , et al., “Design and Development of a Mobile Crawling Robot with Novel Halbach Array Based Magnetic Wheels”, IEEE/ RSJ International Conference on Intelligent Robots and Systems (IROS), Sep. 2017, 6 pages.;;Ueura, Keiji , et al., “Development of the Harmonic Drive Gear for Space Applications”, 1999, 6 pages.;;Borenstein, Johann , et al., “Where am I? Sensors and Methods for Mobile Robot Positioning”, Retrieved from the Internet :URL :http ://www-personal.umich.edu/˜johannb/Papers/pos96rep.pdf, Apr. 22, 1996, pp. 1-282.;;Few, Stephen , “Practical Rules for Using Color in Charts”, Perceptual Edge, Visual Business Intelligence Newsletter, Feb. 2008, 13 pages.;;Tufte, Edward R., “The Visual Display of Quantitative Information”, Published By Graphics Press LLC, Second edition, fifth printing, 2007, 191 pages.;;“All Metals Fabrication”, Painting Metal, Aug. 27, 2015.;;“Coordinate Systems in Two and Three Dimensions”, Oregon State University, Department of Mathematics, 2015, 3 pages.;;“Horizontal definition”, Merrian-Webster Dictionary, 2014, 1 page.;;“International Federation of Robotics,”, World Robotics, Chapter 1 section 2, 2016, 10 pages.;;“Merriam-Webster”, Definition of Pivot, 2015, 5 pages.;;“Vertical Definition”, Merriam Webster, 2014, 1 page.;;“Yaskawa Motoman Robotics,”, Robotics Glossary, 2019, 20 pages.;;17884897.4, , “European Application Serial No. 17884897.4, Extended European Search Report dated Jun. 25, 2020”, Gecko Robotics, Inc., 5 pages.;;Ams Controls, , “Encoder Tracking and Mounting”, 2015, 18 pages.;;Bell, Stephanie , “Measurement Good Practice Guide A Beginner's Guide to Uncertainty of Measurement”, National Physical Laboratory, Issue 2, 2001, 41 pages.;;Berendsen, A.M , “Ship Painting: Current Practice and Systems in Europe”, Technology Publishing Company, Sep. 1998, 10.;;Carlsten, Roy , “Understanding Corrosion and How to Protect Against It”, manufacturing.net, Mar. 11, 2002, 8.;;Connor, David et al., “Improved dead reckoning using caster wheel sensing on a differentially steered 3-wheeled autonomous vehicle”, Proceedings vol. 4195, Mobile Robots XV and Telemanipulator and Telepresence Technologies VII, 2001, 13 pages.;;Curran, Patrick , “Make the right choice for metal coating for the right application”, Design World, Jun. 2, 2016, 18.;;Felsch, Torsten et al., “Robotized Inspection of Vertical Structures of a Solar Power Plant Using NDT Techniques”, doi:10.3390/robotics4020103, 2015, pp. 103-119.;;Fowler, Kenneth A. et al., “Theory and Application of Precious Ultrasonic Thickness Gaging”, 2015, 12 pages.;;General Electric, , “BWCI Automated Boiler Wall Cleaning & Inspection”, inspection-robotics.com, 2016, 4.;;Ginzel, et al., “Acoustic Properties of the Elastomeric Materials Aqualene and ACE”, The e-Journal of Nondestructive Testing—ISSN 1435-4934, Dec. 2015, 13.;;Guglielmelli, E. et al., “Avoiding obstacles by using a proximity US/IR sensitive skin”, IEEE, 1993, pp. 2207-2214.;;Harrison, David M. , “Uncertainty in Physical Measurements”, Module 4—Repeated Measurements, Dept. of Physics, Univ. of Toronto, 2015, 18 pages.;;Lebowitz, Carol A. et al., “Ultrasonic Measurement of Pipe Thickness”, Review of Progress in Quantitative Nondestructive Evalualtion, vol. 12, 1987, 8 pages.;;Lee, Giuk et al., “Combot: Compliant Climbing Robotic Platform with Transitioning Capability and Payload Capacity”, IEEE International Conference on Robotics and Automation RiverCentre, Saint Paul, Minnesota,, 2012, 6 pages.;;Lins, Romulo G. et al., “Autonomous Robot System for Inspection of Defects in Civil Infrastructures”, IEEE, 2016, pp. 1414-1422.;;Lion Precision, , “Understanding Sensor Resolution Specifications and Performance”, TechNote, LT05-0010, 2014, pp. 1-6.;;Martinez, Angelo et al., “Fuzzy logic based collision avoidance for a mobile robot”, IEEE, 1993, pp. 66-69.;;Miskon, Muhammad F. et al., “Close Range Inspection Using Novelty Detection Results”, Intelligent Robotic Research Center (IRRC), Monash University, Australia, ICIRA2009, LNAI 5928,, 2009, pp. 947-956.;;Myers, Brad A. , “The importance of percent-done progress indicators for computer-human interfaces”, Proceedings of the SIGCHI conference on Human factors in computing systems., CHI '85. ACM, New York, NY., 1985, 11-17.;;National Geographic, , “Encyclopedic Entry Location”, 2016, 3 pages.;;NDT Resource Center, , “NDT Glossary D”, Webpage, 2016, 4 pages.;;NDT Resource Center, , “NDT Glossary R”, Webpage, 2016, 5 pages.;;NDT Resource Center, , “Transducer Types”, Webpage, 2005, 1.;;Olympus, , “BondMaster Probes and Accessories Catalog”, Catalog, 2008, 24.;;Olympus, , “Flaw Detectors Delay Line”, Olympus, Flaw Detectors Delay Line, 2014, Jan. 9, 2014, 1.;;Olympus, , “Ultrasonic Transducers Technical Notes”, Notes, 2006.;;Openstax College, , “College Physics Textbook Equity Edition”, vol. 1 of 3: Chapters 1 -12, Chapter 9 p. 294, 464 pages.;;Parallax Tutorial, , “Going the Distance—Using the Drive Distance Block Encoders and Motor Gearing”, 2017, 5 pages.;;PCT/US17/68326, , “International Application Serial No. PCT/US17/68326, International Preliminary Report on Patentability dated Jul. 4, 2019”, Gecko Robotics, Inc., 11 pages.;;PCT/US20/21779, , “International Application Serial No. PCT/US20/21779, International Preliminary Report on Patentability dated Sep. 23, 2021”, Gecko Robotics, Inc., 13 pages.;;PCT/US20/21779, , “International Application Serial No. PCT/US20/21779, International Search Report and Written Opinion dated Sep. 2, 2020”, Gecko Robotics, Inc., 14 pages.;;PCT/US20/21779, , “International Application Serial No. PCT/US20/21779, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jul. 9, 2020”, Gecko Robotics, Inc., 2 pages.;;PCT/US2017/068326, , “International Application Serial No. PCT/US2017/068326, International Search Report and Written Opinion dated May 4, 2018”, Gecko Robotics, Inc., 14 pages.;;PCT/US2017068326, , “International Application Serial No. PCT/US2017068326, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Feb. 27, 2018”, Gecko Robotics, Inc., 2 Pages.;;PCT/US2019/027958, , “International Application Serial No. PCT/US2019/027958, International Preliminary Report on Patentability dated Oct. 29, 2020”, Gecko Robotics, Inc., 8 pages.;;PCT/US2019/027958, , “International Application Serial No. PCT/US2019/027958, International Search Report and Written Opinion dated Jul. 16, 2019”, Gecko Robotics, Inc., 9 pages.;;Reinhold, Reif , “Machine Translation DE 10300383”, 2019, 4 pages.;;Sabatini, Angelo M. et al., “Correlation Techniques for Digital Time-of-Flight Measurement by Airborne Ultrasonic Rangefinders”, Published in: Proceedings of IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS'94), Date of Conference: Sep. 12-16, 1994,, 1994, pp. 2168-2175.;;Salik, John et al., “Pipe Inspections: Robotic Laser Profiling Demystified”, National Precast Concrete Association, Apr. 1, 2013, 12 pages.;;Schroeder, S C. et al., “Ultrasonic Culvert Thickness Determination”, US Army Armament Research Development and Engineering, Technical Report ARCCB-TR-95027, 1995, 36 pages.;;Sirken, Aaron et al., “Bridge Risk Investigation Diagnostic Grouped Exploratory (Bridge)”, IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), Sep. 24-28, 2017, Vancouver, BC, Canada (Year: 2017), 2017, 7 pages.;;Smith, Oliver et al., “Machine Translation KR20140040692A”, 18 pages.;;Svilainis, Linas , “Review of high resolution time of flight estimation techniques for ultrasonic signals,”, Sep. 2013 Conference: NDT 2013At: Telford Project: In-SMART, 2013, 13 pages.;;Tufte, Edward R. , “The Visual Display of Quantitative Information”, Published By Graphics Press LLC, Second edition, fifth printing, Aug. 2007, 191 pages.;;Wisegeek, , “What is an Articulated Robot?”, Webpage, 2015, 4 pages.;;Yasuda, Gen'ichi , “Behavior-based autonomous cooperative control of intelligent mobile robot systems with embedded Petri nets”, IEEE, 2014, pp. 1085-1090.;;Zaho, B. et al., “Estimation of ultrasound attenuation and dispersion using short time Fourier transform,”, Ultrasonics 43 (2005) 375-381, 2005, pp. 375-381.;;20769832.5 , “European Application Serial No. 20769832.5, Extended European Search Report dated Nov. 4, 2022”, Gecko Robotics, Inc., 8 pages.;;Gonzalez, Carlos , “What's the Difference between Pneumatic, Hydraulic, and Electrical Actuators”, Machine Design, 2015, 4 pages.;;PCT/US2022/023993 , “International Application Serial No. PCT/US2022/023993, International Search Report and Written Opinion dated Aug. 24, 2022”, Gecko Robotics, Inc., 31 pages.;;PCT/US2022/025816 , “International Application Serial No. PCT/US2022/025816, International Search Report and Written Opinion dated Sep. 28, 2022”, Gecko Robotics, Inc, 33 pages.;;PCT/US2022/025816 , “International Application Serial No. PCT/US2022/025816, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jul. 8, 2022”, Gecko Robotics, Inc., 3 pages.;;Takero, Hongo , et al., “An Automatic Guidance System of a Self-Controlled Vehicle”, In: “Autonomous Robot Vehicles”, Jan. 1, 1990 (Jan. 1, 1990), Springer New York, New York, NY,, Jan. 1, 1990, pp. 32-37.;;Cai, et al., “A Novel Pipeline Inspection Robot with Two Angle-changeable Crawler Drive Modules”, Proceedings of 2018 IEEE 8th Annual International Conference on CYBER Technology in Automation, Control, and Intelligent Systems, Jul. 2018, 6 pages.;;Hutter, et al., “Force Control for Active Chassis Balancing”, IEEE/ASME Transactions on Mechatronics, vol. 22, No. 2, Apr. 2017, 10 pages.;;Zhang, et al., “Analysis of Traveling capability and Obstacle-climbing Capability for Radially Adjustable Tracked Pipeline Robot”, Proceedings of the 2016 IEEE International Conference on Robotics and Biomimetics Gingdao, China, Dec. 2016, 6 pages.;;Zhang, et al., “Stable Motion Analysis and Verification of a Radial Adjustable Pipeline Robot”, Proceedings of the 2016 IEEE International Conference on Robotics and Biomimetics Oingdao, China, Dec. 2016, 6 pages.;;PCT/US2022/023993, Apr. 8, 2022, Pending, Edward A. Bryner.;;U.S. Appl. No. 18/303,419, filed Apr. 19, 2023, Pending, Mark J. Loosararian, et al.;;U.S. Appl. No. 18/306,408, filed Apr. 25, 2023, Pending, Mark Jake Loosararian, et al.;;U.S. Appl. No. 18/341,991, filed Jun. 27, 2023, Pending, Mark J. Loosararian, et al.;;U.S. Appl. No. 18/057,544, filed Nov. 21, 2022, Pending, Edward A. Bryner et al.;;U.S. Appl. No. 17/729,037, filed Apr. 26, 2022, Pending, Dillion R. Jourde et al.;;Haitao , et al., “Simulation, Test and Analysis of Three-phase Short-Circuit Braking in IGCT-based MV Adjustable Speed Drive Systems”, 2005 International Conference on Electrical Machines and Systems, Nanjing, China, IEEE, 2005, pp. 1437-1441.;;Papadimitriou, Vasileious , et al., “An adaptable and self-calibrating service robotic nozzle-vessel welds”, 2012 2nd International Conference on Applied Robotics for the Power Industry (CARPI), 2012, 6 pages.;;Xing , et al., “Design and Realization of DC Motor Speed Measurement and Control Based on an Electromagnetic Sensor”, Atlantis Press, DOI10.2991/cisia-15.2015.69, 2015, 4 pages.;;U.S. Appl. No. 17/752,955, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/824,656, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/824,253, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/824,261, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/824,548, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/824,534, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/741,508, filed May 11, 2022, Pending.;;U.S. Appl. No. 17/727,217, filed Apr. 22, 2022, Pending.;;U.S. Appl. No. 17/727,294, filed Apr. 22, 2022, Pending.;;U.S. Appl. No. 17/729,037, filed Apr. 26, 2022, Pending.;;U.S. Appl. No. 17/729,051, filed Apr. 26, 2022, Pending.;;U.S. Appl. No. 17/729,070, filed Apr. 26, 2022, Pending.;;U.S. Appl. No. 17/731,797, filed Apr. 28, 2022, Pending.;;U.S. Appl. No. 17/740,475, filed May 10, 2022, Pending.;;U.S. Appl. No. 17/752,059, filed May 24, 2022, Pending.;;U.S. Appl. No. 17/741,519, filed May 11, 2022, Pending.;;U.S. Appl. No. 17/740,561, filed May 10, 2022, Pending.;;U.S. Appl. No. 17/752,453, filed May 24, 2022, Pending.;;U.S. Appl. No. 17/740,572, filed May 10, 2022, Pending.;;U.S. Appl. No. 17/740,579, filed May 10, 2022, Pending.;;U.S. Appl. No. 17/752,177, filed May 24, 2022, Pending.",ACTIVE
284,KR,A,KR 20070099715 A,103-763-961-591-461,2007-10-10,2007,KR 20060030790 A,2006-04-05,KR 20060030790 A,2006-04-05,PHOTOSENSITIVE DRUM FOR PRINTER CARTRIDGE AND METHOD FOR MOUNTING THE SAME,"A photosensitive drum for a printer cartridge and a method for mounting the same are provided to mount the photosensitive drum for the printer cartridge without changing a position of a photosensitive drum connecting unit mounted in a cartridge, thereby changing the preventing photosensitive drum without separating the cartridge. A photosensitive drum for a printer cartridge comprises the followings: a cylinder type drum(52) in which a photosensitive layer is formed in a screen; and a couple of rotation shafts(60a,60b), mounted on the both sides of the cylinder type drum, for supporting and rotating the cylinder drum. At least one of the couple of rotation shafts is connected and inserted to the end point of the cylinder type drum. The rotation shaft is constructed with a shaft main body(62) for rotating and supporting the cylinder type drum and a shaft connecting unit for connecting the cylinder type drum and the shaft main body.",PARK & OPC CO LTD,CHO MYUNG LAE;;HAN MICHAEL;;KIM HAN SHIK;;CHO SEONG JIN;;JEON JUN HO,,https://lens.org/103-763-961-591-461,Patent Application,no,0,1,10,10,0,F16D1/10;;G03G15/751;;G03G15/04;;F16D1/10;;G03G15/751;;G03G15/348;;G03G2217/0075;;F16D1/10;;G03G15/751,G03G15/04;;G03G15/00,,0,0,,,,INACTIVE
285,AT,T1,AT E446531 T1,129-183-132-880-154,2009-11-15,2009,AT 07001725 T,2007-01-26,KR 20060030790 A,2006-04-05,MONTAGEVERFAHREN FÜR LICHTEMPFINDLICHE TROMMEL FÜR EINE DRUCKERKASSETTE,"A photosensitive drum (50) for a printer cartridge is disclosed, which can be easily mounted on a printer cartridge wherein the positions of drum connectors (70a,70b) are fixed. The photosensitive drum comprises a cylindrical drum (52) having a photosensitive layer on a cylindrical surface thereof; and a pair of rotation shafts (60a,60b) which is respectively mounted on the sides of the cylindrical drum for rotating and supporting the cylindrical drum, wherein at least one of the rotation shafts is insert-fitted to the cylindrical drum when mounting the photosensitive drum to the printer cartridge.",PARK & OPC CO LTD,CHO MYUNG-LAE;;HAN MICHAEL;;KIM HAN-SHIK;;CHO SEONG-JIN;;JEON JUN-HO,,https://lens.org/129-183-132-880-154,Granted Patent,no,0,0,10,10,0,F16D1/10;;G03G15/751;;G03G15/04;;F16D1/10;;G03G15/751;;G03G15/348;;G03G2217/0075;;F16D1/10;;G03G15/751,,,0,0,,,,INACTIVE
286,KR,A,KR 20160001071 A,066-500-735-416-329,2016-01-06,2016,KR 20140078805 A,2014-06-26,KR 20140078805 A,2014-06-26,METHOD FOR MANUFACTURING MULTILAYERED SCAFFOLD FOR CARTILAGE USING BIODEGRADABLE BIOPOLYMERS,"The present invention relates to a method for producing a multi-layered cartilage scaffold using a highly functional and biodegradable biopolymer. More specifically, the composition ratio of the polycaprolactone (PCL) which is a biopolymer is adjusted with sodium chloride used as a pore former in a salt leaching process, resulting in a formation of a gradient. Thus, production of the cartilage scaffold having a double layer (a hard and a soft side) with excellent material properties is possible. In addition, in the salt leaching process, via adjustment in the size and shape of the salts as a pore former and the shape of the molding frame, the production of the cartilage scaffold having a membrane-typed conformation is also possible, and the material and mechanical properties thereof is easily controllable as well.",TE BIOS CO LTD,MICHAEL CHO;;JEONG DO SUN;;CHO MIN KYUNG;;KIM DONG SOO;;KIM JAE WON,,https://lens.org/066-500-735-416-329,Patent Application,no,0,7,2,2,0,A61L27/56;;A61F2/28;;A61L27/14;;A61L27/58;;A61L2430/00;;A61L2430/06,A61L27/56;;A61F2/28;;A61L27/14;;A61L27/58,,0,0,,,,ACTIVE
287,US,S,US D0777083 S,090-470-381-961-738,2017-01-24,2017,US 201529545123 F,2015-11-10,US 201529545123 F,2015-11-10,Tire,,GOODYEAR TIRE & RUBBER,SKURICH MICHAEL STEFAN;;UMSTOT DALE EDWARD;;CICCHIANI MICHAEL GENO;;CHO JUNG WAN,GOODYEAR TIRE & RUBBER COMPANY THE (2015-11-09),https://lens.org/090-470-381-961-738,Design Right,no,0,8,1,1,0,,,1215;;D12/532,0,0,,,,ACTIVE
288,EP,B1,EP 3902490 B1,043-650-987-173-633,2024-02-14,2024,EP 19901545 A,2019-12-04,US 201816233935 A;;US 2019/0064447 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/043-650-987-173-633,Granted Patent,yes,5,0,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B18/12;;A61B5/0507;;A61B18/00;;A61B18/04;;A61B18/10;;A61B18/14;;A61B18/18,,0,0,,,,ACTIVE
289,KR,A,KR 20160031527 A,047-563-087-642-975,2016-03-22,2016,KR 20167003613 A,2014-03-14,US 201313944560 A;;US 2014/0027406 W,2013-07-17,REGENERATION OF OLEFIN TREATING ADSORBENTS FOR REMOVAL OF OXYGENATE CONTAMINANTS,"경질 탄화수소 처리 시스템에서 옥시게네이트와 물을 제거하는 방법으로서, 옥시게네이트가 옥시게네이트 흡착 유닛 상에서 상기 옥시게네이트의 흡착에 의해 경질 탄화수소스트림에서 제거되어 탈산소화된 탄화수소 스트림을 제공하고, 상기 옥시게네이트 흡착 유닛이 재생제 스트림을 통해 재생되어 상기 옥시게네이트를 포함하는 산소화된 재생제 스트림을 제공하며, 그리고 상기 산소화된 재생제 스트림은 하이드로-탈산소화를 거쳐 상기 옥시게네이트를 파라핀과 물로 전환시키되, 상기 물은 또한 상기 시스템에서 영구적으로 제거될 수 있는 것인 방법이 개시된다.",CHEVRON USA INC,CLEVERDON ROBERT FLCTCHER;;LOWE CLIFFORD MICHAEL;;TIMKEN HYEKYUNG CHO,,https://lens.org/047-563-087-642-975,Patent Application,no,0,0,5,5,0,B01D15/203;;B01J20/3408;;C10G25/00;;C10G29/205;;C10G3/00;;C10G3/42;;C10G3/50;;B01J20/18;;B01J20/345;;Y02P30/20;;C10G3/50;;B01D15/203;;C10G3/42;;B01J20/3408;;C10G25/00;;C10G29/205;;C10G3/00;;B01J20/345;;B01J20/18;;Y02P30/20;;C07C2/58;;C07C7/13,B01D15/20;;B01J20/18;;C07C2/58;;C07C7/13,,0,0,,,,DISCONTINUED
290,CN,A,CN 113624360 A,099-043-234-982-513,2021-11-09,2021,CN 202110813939 A,2019-12-04,US 201816233959 A;;CN 201980086810 A,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,The invention relates to a method and a system for monitoring tissue temperature. Disclosed are a system and a method utilizing thermoacoustic imaging to estimating tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system and the method use a thermoacoustic imaging system and one or more processors. The thermoacoustic imaging system includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest. The one or more processors are able to: process received bipolar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the bipolar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG-HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/099-043-234-982-513,Patent Application,no,0,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,G01K11/22;;G01K13/20,,0,0,,,,PENDING
291,US,B2,US 11229382 B2,127-422-693-562-44X,2022-01-25,2022,US 201414529427 A,2014-10-31,US 201414529427 A;;US 201361922404 P,2013-12-31,Self-powered analyte sensor and devices using the same,"Systems, devices and methods for monitoring analyte levels using a self-powered analyte sensor and associated sensor electronics are provided.",ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,ABBOTT DIABETES CARE INC (2014-10-27),https://lens.org/127-422-693-562-44X,Granted Patent,yes,1066,1,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/00;;A61B5/1486,,69,52,030-155-762-644-019;;070-224-419-916-221;;052-356-140-149-389;;082-626-907-191-554;;090-348-305-613-628;;081-249-097-078-543;;007-549-562-816-54X;;007-500-825-916-378;;009-725-244-669-882;;171-079-565-309-036;;007-843-397-839-744;;061-786-187-274-992;;006-955-708-092-482;;045-087-287-424-000;;054-580-942-789-395;;024-691-508-279-134;;017-843-532-202-598;;027-940-975-454-994;;123-463-952-988-118;;083-932-858-886-510;;014-872-149-941-05X;;059-395-372-675-077;;015-461-311-338-380;;033-104-669-345-427;;032-698-614-191-656;;024-720-816-976-724;;175-413-319-146-266;;034-399-976-118-379;;136-346-811-568-995;;073-398-465-792-994;;003-328-103-858-439;;035-535-925-014-211;;024-011-256-425-251;;101-236-266-667-666;;022-249-981-342-384;;138-961-462-563-877;;105-954-589-758-265;;090-280-737-637-908;;044-518-258-989-454;;116-750-608-164-513;;002-378-702-388-976;;045-040-703-542-762;;012-386-975-058-246;;006-608-444-907-070;;047-646-723-294-507;;019-169-278-044-74X;;171-079-565-309-036;;134-371-570-329-847;;076-906-852-064-45X;;094-254-319-855-001;;061-673-085-468-891;;061-673-085-468-891,2245876;;10.2337/diabetes.39.12.1519;;10.2337/diab.39.12.1519;;9358083;;10.1016/s0022-2143(97)90044-5;;10.1089/15209150252924058;;12017416;;11762520;;10.1089/15209150152607196;;10.1016/0265-928x(87)80012-3;;6721151;;10.1021/ac00268a018;;12450441;;10.1089/152091502320798222;;7733469;;10.1021/ac00103a015;;7978306;;10.1021/ac00091a022;;10.2337/diacare.27.3.722;;pmc2365475;;14988292;;10.1159/000048994;;11844938;;10.1089/152091503322526978;;14633342;;10.1006/mvre.1995.1070;;8583956;;10.1016/0925-4005(93)85356-f;;10.1016/s0967-0661(97)00046-4;;10.1016/s0967-0661(97)00053-1;;8797377;;10.1021/ac950630x;;11423524;;10.2337/diacare.24.7.1303-a;;14511412;;10.1089/152091503322250596;;10.1021/ac00047a003;;1463213;;10471679;;10.1093/clinchem/45.9.1651;;10.1016/j.jpeds.2004.03.042;;10.1016/s0022-3476(04)00242-2;;15192625;;pmc2248702;;10.1089/15209150152607141;;11762515;;10.1109/10.4581;;3209214;;12087017;;10.2337/diacare.25.7.1185;;10.2337/diacare.25.5.889;;11978686;;10.1042/cs20060203;;16961464;;17282172;;10.1109/iembs.2005.1616403;;10.1089/152091503765691901;;12828824;;10.1002/aic.690461220;;10.1016/0265-928x(87)80016-0;;3506807;;10.1007/bf00265097;;2666212;;1759711;;10.1021/ac00020a014;;10.1152/ajpendo.1995.269.1.e155;;7631771;;9699080;;10.1615/critrevtherdrugcarriersyst.v15.i3.10;;10.1016/0925-4005(93)85391-m;;10.1080/00032719608002253;;10.1073/pnas.95.1.294;;9419369;;pmc18205;;10.1016/0956-5663(91)87004-u;;1910665;;10.1007/bf00250158;;6341145;;3248784;;10.2337/diacare.9.3.298;;3731995;;10.1016/s0140-6736(82)92788-x;;10.1109/10.324525;;7959800;;10.1016/0265-928x(89)80032-x;;2751717;;10.1016/s0009-9120(86)80037-6;;3533320;;10.2337/diacare.27.3.722;;pmc2365475;;14988292;;3916272;;10.1016/0265-928x(85)85006-9;;2700068;;10.1093/clinchem/38.9.1613;;1525989;;10.1016/j.bios.2008.09.014;;19013784;;10.1016/j.bios.2008.09.014;;19013784,"Armour, J. C., et al., “Application of Chronic Intravascular Blood Glucose Sensor in Dogs”, Diabetes, vol. 39, 1990, pp. 1519-1526.;;Banile, J., et al., Glucose Measurement in Patients with Diabtes Mellitus with Dermal Interstitial Fluid, J. Lab. Clin. Med., vol. 130, No. 4, 1997, pp. 436-431.;;Bennion, N., et al., “Alternate Site Glucose Testing: A Crossover Design”, Diabetes Technology & Therapeutics, vol. 4, No. 1, 2002, pp. 25-33.;;Blank, T. B., et al., “Clinical Results From a Non-Invasive Blood Glucose Monitor”, Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, vol. 4624, 2002, pp. 1-10.;;Bremer, T. M., et al., “Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 409-418.;;Brooks, S. L., et al., “Development of an On-Line Glucose Sensor for Fermentation Monitoring”, Biosensors, vol. 3, 1987/88, pp. 45-56.;;Cass, A. E., et al., “Ferrocene-Medicated Enzyme Electrode for Amperometric Determination of Glucose”, Analytical Chemistry, vol. 56, No. 4, 1984, 667-671.;;Cheyne, E. H., et al., “Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers”, Diabetes Technology & Therapeutics, vol. 4, No. 5, 2002, pp. 607-613.;;Csoregi, E., et al., “Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on ‘Wired’ Glucose Oxidase”, Analytical Chemistry, vol. 67, No. 7, 1995, pp. 1240-1244.;;Csoregi, E., et al., “Design, Characterization, and One-Point in Vivo Calibration of a Subcutaneously Implanted Glucose Electrode”, Analytical Chemistry, vol. 66, No. 19, 1994, pp. 3131-3138.;;DIRECNET Study Group, “Accuracy of the Gluco Watch G2 Biographer and the Continuous Glucose Monitoring System During Hyoglycemia”, Diabetes Care, vol. 27, No. 3, 2004, pp. 722-726.;;Durand, S., et al., “Current-Induced Vasodilation During Water Iontophoresis (5 min, 0.10 mA) Is Delayed From Current Onset and Involves Aspirin Sensitive Mechanisms”, Journal of Vascular Research, vol. 39, 2002, pp. 59-71.;;Feldman, B., et al., “A Continuous Glucose Sensor Based on Wired EnzymeTM Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 5, No. 5, 2003, pp. 769-779.;;Feldman, B., et al., “Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change”, Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet.;;Grossmann, M., et al., “The Effect of Iontophoresis on the Cutaneous Vasculature: Evidence for Current-Induced Hyperemia”, Microvascular Research, vol. 50, 1995, pp. 444-452.;;Heller, A., et al., “Amperometric Biosensors Based on Three-Dimensional Hydrogel-Forming Epoxy Networks”, Sensors and Actuators B, vol. 13-14, 1993, pp. 180-183.;;Isermann, R., “Supervision, Fault-Detection and Fault-Diagnosis Methods—An Introduction”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 639-652.;;Isermann, R., et al., “Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 709-719.;;Jobst, G., et al., “Thin-Film Microbiosensors for Glucose-Lactate Monitoring”, Analytical Chemistry, vol. 68, No. 18, 1996, pp. 3173-3179.;;Johnson, P. C., “Peripheral Circulation”, John Wiley & Sons, 1978, pp. 198.;;Jungheim, K., et al., “How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?”, pp. 250.;;Jungheim, K., et al., “Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm”, Diabetes Care, vol. 24, No. 7, 2001, pp. 1303-1304.;;Kaplan, S. M., “Wiley Electrical and Electronics Engineering Dictionary”, IEEE Press, 2004, pp. 141, 142, 548, 549.;;Lodwig, V., et al., “Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria”, Diabetes Technology & Therapeutics, vol. 5, No. 4, 2003, pp. 573-587.;;Lortz, J., et al., “What is Bluetooth? We Explain the Newest Short-Range Connectivity Technology”, Smart Computing Learning Series, Wireless Computing, vol. 8, Issue 5, 2002, pp. 72-74.;;Maidan, R., et al., “Elimination of Electrooxidizable Interferant-Produced Currents in Amperometric Biosensors”, Analytical Chemistry, vol. 64, No. 23, 1992, pp. 2889-2896.;;Malin, S. F., et al., “Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectoscopy”, Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651-1658.;;Mauras, N., et al., “Lack of Accuracy of Continuous Glucose Sensors in Healthy, Nondiabetic Children: Results of the Diabetes Research in Children Network (DirecNet) Accuracy Study,” Journal of Pediatrics, 2004, pp. 770-775.;;McGarraugh, G., et al., “Glucose Measurements Using Blood Extracted from the Forearm and the Finger”, TheraSense, Inc., 16 Pages.;;McGarraugh, G., et al., “Physiological Influences on Off-Finger Glucose Testing”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 367-376.;;McKean, B. D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors”, IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, 1988, pp. 526-532.;;Metzger, M., et al., “Reproducibility of Glucose Measurements Using the Glucose Sensor”, Diabetes Care, vol. 25, No. 6, 2002, pp. 1185-1191.;;Monsod, T. P., et al., “Do Sensor Glucose Levels Accurately Predict Plasma Glucose Concentrations During Hypoglycemia and Hyperinsulinemia?” Diabetes Care, vol. 25, No. 5, 2002, pp. 889-893.;;Morbiducci, U, et al., “Improved Usability of the Minimal Model of Insulin Sensitivity Based on an Automated Approach and Genetic Algorithms for Parameter Estimation”, Clinical Science, vol. 112, 2007, pp. 257-263.;;Mougiakakou, et al., “A Real Time Simulation Model of Glucose-Insulin Metabolism for Type 1 Diabetes Patients”, Proceedings of the 2005 IEEE, 2005, pp. 298-301.;;Panteleon, A. E., et al., “The Role of the Independent Variable to Glucose Sensor Calibration”, Diabetes Technology & Therapeutics, vol. 5, No. 3, 2003, pp. 401-410.;;Parker, R., et al., “Robust H Glucose Control in Diabetes Using a Physiological Model”, AIChE Journal, vol. 46, No. 12, 2000, pp. 2537-2549.;;Pickup, J., et al., “Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy”, Biosensors, vol. 3, 1987/88, pp. 335-346.;;Pickup, J., et al., “In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer”, Diabetologia, vol. 32, 1989, pp. 213-217.;;Pishko, M. V., et al., “Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels”, Analytical Chemistry, vol. 63, No. 20, 1991, pp. 2268-2272.;;Quinn, C. P., et al., “Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors”, The American Physiological Society, 1995, E155-E161.;;Roe, J. N., et al., “Bloodless Glucose Measurements”, Critical Review in Therapeutic Drug Carrier Systems, vol. 15, Issue 3, 1998, pp. 199-241.;;Sakakida, M., et al., “Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations”, Artificial Organs Today, vol. 2, No. 2, 1992, pp. 145-158.;;Sakakida, M., et al., “Ferrocene-Mediated Needle-Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane”, Sensors and Actuators B, vol. 13-14, 1993, pp. 319-322.;;Salehi, C., et al., “A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors”, Analytical Letters, vol. 29, No. 13, 1996, pp. 2289-2308.;;Schmidtke, D. W., et al., “Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin”, Proceedings of the National Academy of Sciences, vol. 95, 1998, pp. 294-299.;;Shaw, G. W., et al., “In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 401-406.;;Shichiri, M., et al., “Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas”, Diabetologia, vol. 24, 1983, pp. 179-184.;;Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers”, Hormone and Metabolic Research Supplement Series, vol. 20, 1988, pp. 17-20.;;Shichiri, M., et al., “Membrane Design for Extending the Long-Life of an Sensor”, Diabetes Nutrition and Metabolism, vol. 2, 1989, pp. 309-313.;;Shichiri, M., et al., “Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas”, Implantable Sensors for Closed-Loop Prosthetic Systems, Chapter 15, 1985, pp. 197-210.;;Shichiri, M., et al., “Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals”, Diabetes Care, vol. 9, No. 3, 1986, pp. 298-301.;;Shichiri, M., et al., “Wearable Artificial Endocrine Pancreas With Needle-Sensor”, The Lancet, 1982, pp. 1129-1131.;;Shults, M. C., et al., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors”, IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, 1994, pp. 937-942.;;Sternberg, R., et al., “Study and Development of Multilayer Needle-Typ Glucose Microsensors”, Biosensors, vol. 4, 1988, pp. 27-40.;;Thompson, M., et al., “In Vivo Probes: Problems and Perspectives”, Clinical Biochemistry, vol. 19, 1986, pp. 255-261.;;Tsalikian, E., et al., “Accuracy of the GlucoWatch G2® Biographer and the Continuous Glucose Monitoring System During Hypoglycemia: Experience of the Diabetes Research in Children Network”, Diabetes Care, vol. 27, No. 3, 2004, pp. 722-726.;;Turner, A., et al., “Diabetes Mellitus: Biosensors for Research and Management”, Biosensors, vol. 1, 1985, pp. 85-115.;;Updike, S. J., et al., “Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)”, Biosensors in the Body: Continuous in vivo Monitoring, Chapter 4, 1997, pp. 117-137.;;Velho, G., et al., “Strategies for Calibrating a Subcutaneous Glucose Sensor”, Biomedica Biochimica Acta, vol. 48, 1989, pp. 957-964.;;Wilson, G. S., et al., “Progress Toward the Development of an Implantable Glucose”, Clinical Chemistry, vol. 38, No. 9, 1992, pp. 1613-1617.;;PCT Application No. PCT/US2014/063316, International Search Report and Written Opinion of the International Searching Authority dated Mar. 24, 2015.;;Ali, S., “Finite Element Modeling of Dermally-Implanted Enzymatic Microparticle Glucose Sensors”, Thesis Submitted to the Office of Graduate Studies of Texas A&M University, 2010.;;HANASHI, T. ; YAMAZAKI, T. ; TSUGAWA, W. ; FERRI, S. ; NAKAYAMA, D. ; TOMIYAMA, M. ; IKEBUKURO, K. ; SODE, K.: ""BioCapacitor-A novel category of biosensor"", BIOSENSORS AND BIOELECTRONICS, ELSEVIER SCIENCE LTD, UK, AMSTERDAM , NL, vol. 24, no. 7, 15 March 2009 (2009-03-15), Amsterdam , NL , pages 1837 - 1842, XP025958941, ISSN: 0956-5663, DOI: 10.1016/j.bios.2008.09.014;;Partial Supplementary European Search Report issued in EP Patent Application No. 14877021.7 dated Aug. 1, 2017.;;Office Action issued in corresponding RU Patent Application No. 2016131308 dated Apr. 4, 2018, with English Translation.;;Search Report issued in corresponding RU Patent Application No. 2016131308 dated Apr. 4, 2018, with English Translation.;;Notification of First Office Action issued in corresponding Chinese Patent Application No. 2014800716857 dated Jun. 27, 2018, includes English Translation.;;Hanashi, Takuya et al., “BioCapacitor—A Novel Category of Biosensor,” Biosensors and Bioelectronics, No. 24, pp. 1838-1842, published Sep. 24, 2008.",ACTIVE
292,WO,A1,WO 2020/139528 A1,178-691-394-953-585,2020-07-02,2020,US 2019/0064450 W,2019-12-04,US 201816233959 A,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,A system and method utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest (ROI) that includes an object of interest and a reference which are separated by at least one boundary with at least two boundary locations. The system and method use a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue ROI and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the ROI; and one or more processors that are able to: process received bipolar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the bipolar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/178-691-394-953-585,Patent Application,yes,6,2,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/00;;A61B18/18;;A61B5/01;;A61B8/00,,0,0,,,,PENDING
293,US,B1,US 8212576 B1,000-491-431-661-396,2012-07-03,2012,US 60610109 A,2009-10-26,US 60610109 A,2009-10-26,Method and apparatus for self-regulated burn-in of an integrated circuit,"Method and apparatus for self-regulated burn-in of an integrated circuit (IC) is described. One embodiment of a method of burn-in for the IC includes: configuring programmable resources of the IC device based on a burn-in pattern to implement a load controller, the load controller having a plurality of heat core circuits. The load controller is initialized with a number of enabled heat core circuits of the plurality of heat core circuits. A junction temperature is measured in the IC device after a measurement period has elapsed. The junction temperature is compared with a set-point temperature. The number of the enabled heat core circuits is increased if the junction temperature is less than the set-point temperature, or the number of the enabled heat core circuits is decreased if the junction temperature is greater than the set-point temperature.",CHO JAE;;O'ROURKE GLENN;;MATERA MICHAEL M;;JEONG JONGHEON;;XILINX INC,CHO JAE;;O'ROURKE GLENN;;MATERA MICHAEL M;;JEONG JONGHEON,XILIINX INC (2009-10-23),https://lens.org/000-491-431-661-396,Granted Patent,yes,2,8,1,1,0,G01R31/2856;;G01R31/2856,G01R31/00,324/750.01;;324/750.05;;324/750.06;;324/750.07,1,0,,,"Xilinx, Inc., UG192, ""Virtex- 5 FPGA System Monitor User Guide"", v1.7, Mar. 11, 2009, pp. 1-66, available from Xilinx, Inc., 2100 Logic Drive, San Jose, California 95124.",ACTIVE
294,US,B2,US 10993624 B2,010-038-244-064-964,2021-05-04,2021,US 201916279608 A,2019-02-19,US 201916279608 A,2019-02-19,Systems and methods for thermoacoustic transducer optimization,"A method and system optimize a thermoacoustic transducer functionality that is utilized in a thermoacoustic imaging system. The method and system select a pre-determined transducer geometry for the thermoacoustic imaging system, utilize the thermoacoustic imaging system with the pre-determined transducer geometry to generate at least one impulse in a field of view, acquire data from the impulse, reconstructing the data to generate N-dimensional impulse responses based upon respective channel responses, respective view responses, and a function of the acquired data, utilize the N-dimensional transforms for each image to generate a value for the pre-determined transducer functionality, and utilize the value for the pre-determined transducer functionality to determine an optimum thermoacoustic transducer functionality.",ENDRA LIFE SCIENCES INC,DOUTHAT DEAN ZAHN;;CHO JANG HWAN;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-08-01),https://lens.org/010-038-244-064-964,Granted Patent,yes,13,0,10,10,0,A61B5/0507;;A61B5/7203;;A61B2576/00;;A61B2562/0204;;A61B5/7253;;A61B8/5261;;A61B8/4477;;G01S15/8915;;G01S15/899;;A61B5/0095;;A61B2560/0223;;G01S15/8906;;A61B8/4483;;A61B2576/00;;A61B8/4416;;A61B5/0095,A61B5/00;;A61B8/00;;G01S15/89,,6,6,028-501-234-626-076;;020-601-558-518-378;;027-678-710-599-441;;037-046-260-847-547;;030-643-077-840-09X;;055-784-545-952-292,10.1109/tuffc.2003.1244756;;14609079;;10.1038/s42256-019-0095-3;;19405737;;10.1117/1.3086616;;10.1118/1.1565340;;12772993;;10.1109/tuffc.2015.007058;;26415127;;10.1016/j.pacs.2019.05.001;;pmc6595011;;31293884,"Valeriy G. Andreev, Alexander A. Karabutov, and Alexander A. Oraevsky; “Detection of Ultrawide-Band Ultrasound Pulses in Optoacoustic Tomography”; IEEE transactions on ultrasonics, ferroelectrics, and frequency control, vol. 50, No. 10, pp. 1383-1390, Oct. 2003.;;Neda Davoudi, Xosé Luís Deán-Ben, and Daniel Razansky; “Deep learning optoacoustic tomography with sparse data”; Nature Machine Intelligence; published online Sep. 16, 2019; https://doi.org/10.1038/s42256-019-0095-3.;;Sergey A. Ermilov, Tuenchit Khamapirad, Andre Conjusteau, Morton H. Leonard, Ron Lacewell, Ketan Mehta, Tom Miller, Alexander A. Oraevsky; “Laser optoacoustic imaging system for detection of breast cancer”; Journal of Biomedical Optics 14(2), 024007, pp. 024007-1 through 024007-14, Mar./Apr. 2009, published online Mar. 6, 2009. http://biomedicaloptics.spiedigitallibrary.org/.;;Robert A. Kruger, William L. Kiser Jr., Daniel R. Reinecke, and Gabe A. Kruger; “Thermoacoustic computed tomography using a conventional linear transducer array”; Medical Physics vol. 30, pp. 856-860, (May 2003); doi: 10.1118/1.1565340.;;Elena Merc̆ep, Gency Jeng, Stefan Morscher, Pai-Chi Li, and Daniel Razansky; “Hybrid Optoacoustic Tomography and Pulse-Echo Ultrasonography Using Concave Arrays”; IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 62, No. 9, Sep. 2015, pp. 1651-1661.;;Idan Steinberg, David M. Huland, Ophir Vermesh, Hadas E. Frostig, Willemieke S. Tummers, and Sanjiv S. Gambhir; “Photoacoustic clinical imaging”; Photoacoustics 14 (2019) 77-98; published online Jun. 8, 2019. https://doi.org/10.1016/j.pacs.2019.05.001.",ACTIVE
295,WO,A1,WO 2010/088341 A1,024-429-282-722-91X,2010-08-05,2010,US 2010/0022345 W,2010-01-28,US 36332109 A,2009-01-30,SYSTEM AND METHOD FOR CARDIAC LEAD SWITCHING,"An implantable medical device (IMD) can include an implantable pulse generator (IPG), such as a cardiac pacemaker or an implantable cardioverter-defibrillator (ICD). Various portions of the IMD, such as a device body, a lead body, or a lead tip, can be provided to reduce or dissipate a current and heat induced by various external environmental factors. According to various embodiments, features can be incorporated into the lead body, the lead tip, or the IMD body to reduce the creation of an induced current, or dissipate the induced current and heat created due to an induced current in the lead. The implantable medical device comprises a lead, at least one conductor, at least one tip electrode and a switch which switches between a first operational state and a second operational state based on whether an external field is present.",MEDTRONIC INC;;SOMMER JOHN L;;KIMMEL MICHAEL W;;CHO YONG K,SOMMER JOHN L;;KIMMEL MICHAEL W;;CHO YONG K,,https://lens.org/024-429-282-722-91X,Patent Application,yes,5,0,3,3,0,A61N1/056;;A61N1/37;;A61N1/3718;;A61N1/086;;A61N1/37;;A61N1/3718;;A61N1/056;;A61N1/086,A61N1/37;;A61N1/05;;A61N1/08,,0,0,,,,PENDING
296,WO,A1,WO 2020/139527 A1,047-096-629-011-589,2020-07-02,2020,US 2019/0064447 W,2019-12-04,US 201816233935 A,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,"A thermoacoustic imaging system and method for monitoring tissue temperature within a region of interest, which has an object of interest and a reference that are separated by at least one boundary. The system and method include a thermoacoustic imaging system with an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein, an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest, and one or more processors that process at least one received bipolar acoustic signal generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof and calculate a temperature at the at least one boundary using the peak-to-peak amplitude of the at least one bipolar acoustic signal.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/047-096-629-011-589,Patent Application,yes,5,0,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B18/12;;A61B18/04;;A61B18/10;;A61B18/14,,1,0,,,See also references of EP 3902490A4,PENDING
297,EP,A4,EP 3902490 A4,034-173-911-597-450,2022-09-14,2022,EP 19901545 A,2019-12-04,US 201816233935 A;;US 2019/0064447 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/034-173-911-597-450,Search Report,no,2,0,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B18/12;;A61B5/0507;;A61B18/00;;A61B18/04;;A61B18/10;;A61B18/14;;A61B18/18,,1,0,,,See also references of WO 2020139527A1,ACTIVE
298,CR,A,CR 20130063 A,055-095-082-044-015,2013-04-29,2013,CR 20130063 A,2013-02-14,US 36562110 P,2010-07-19,MÉTODOS PARA LA PREPARACIÓN DE PROFÁRMACOS DE FOSFORAMIDATO DIASTEREOMÉRICAMENTE PUROS,Se proporcionan métodos e intermedios para preparar profármacos de fosforamidato diastereoméricamente puros de nucleósidos de Fórmulas (Ia) y (Ib): Los compuestos de Fórmula Ia y Ib son útiles para el tratamiento de las infecciones por hepatitis C.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/055-095-082-044-015,Patent Application,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/10;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/20,,0,0,,,,PENDING
299,US,A1,US 2023/0171015 A1,074-655-323-697-992,2023-06-01,2023,US 202217991356 A,2022-11-21,EP 21210032 A,2021-11-23,SECURED CLOCK SYNCHRONIZATION IN A PACKET-COMPATIBLE NETWORK,"There is provided a technique of securing clock synchronization between master clock node (MCN) and client clock node (CCN). During a cycle of exchanging PTP messages between MCN and CCN, MCN generates an associated paired message for each PTP message generated thereby and informative of t 1 or t 4 timestamps provided by MCN and sends each paired message to a validation entity (VE) via a secured channel between MCN and VE. When PTP messages traverse transparent clock nodes (TCN) between MCN and CCN, each TCN generates a paired message for each version of PTP message updated thereby and sends each generated paired message to VE via a secured channel between respective TCN and VE. VE uses the received paired messages to provide a validation of the cycle, wherein synchronization-related task(s) (e.g. clock correction by the client clock node, etc.) are provided only subject to successful validation of the cycle by VE.",ADVA OPTICAL NETWORKING SE,RABINOVICH MICHAEL;;SERGEEV ANDREW;;CHO JOO YEON;;ZOU SHIHUAN,,https://lens.org/074-655-323-697-992,Patent Application,yes,0,0,2,2,0,H04J3/0667;;H04J3/14;;H04J3/0673;;H04L63/0428;;H04L63/126;;H04J3/0644;;H04J3/0667,H04J3/06,,0,0,,,,PENDING
300,FI,A,FI 924340 A,085-483-247-531-974,1992-09-28,1992,FI 924340 A,1992-09-28,GB 9007052 A;;GB 9100510 W,1990-03-29,FARMACEUTISKA BEREDNINGAR,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/085-483-247-531-974,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,PENDING
301,US,B2,US 11141067 B2,104-305-631-432-618,2021-10-12,2021,US 201816233935 A,2018-12-27,US 201816233935 A,2018-12-27,Method and system for monitoring tissue temperature,"A thermoacoustic imaging system and method for monitoring tissue temperature within a region of interest, which has an object of interest and a reference that are separated by at least one boundary. The system and method include a thermoacoustic imaging system with an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein, an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest, and one or more processors that process at least one received bipolar acoustic signal generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof and calculate a temperature at the at least one boundary using the peak-to-peak amplitude of the at least one bipolar acoustic signal.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/104-305-631-432-618,Granted Patent,yes,8,0,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B5/00;;A61B5/01;;A61B5/20;;A61B8/00;;A61B8/08,,2,1,013-000-205-460-222,pmc2774978;;19895126;;10.1117/1.3247155,"Blaine R. Copenheaver; PCT International Search Report and Written Opinion; dated Feb. 21, 2020; 9 pages total; WIPO Alexandria, VA, United States.;;Manojit Pramanik, Lihong V. Wang; Thermoacoustic and photoacoustic sensing of temperature; Journal of Biomedical Optics 14(5), 054024,Sep./Oct. 2009; pp. 054024-1 through 054024-7; published online Oct. 12, 2009.",ACTIVE
302,NZ,A,NZ 237667 A,146-171-106-391-881,1994-01-26,1994,NZ 23766791 A,1991-04-03,GB 9007052 A,1990-03-29,A PHARMACEUTICAL FORMULATION COMPRISING A BIOLOGICALLY ACTIVE MATERIAL IN,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/146-171-106-391-881,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24;;A61K9/00,,0,0,,,,PENDING
303,CN,A,CN 105899132 A,156-592-346-966-291,2016-08-24,2016,CN 201480071685 A,2014-10-31,US 201361922404 P;;US 2014/0063316 W,2013-12-31,Self-powered analyte sensor and devices using the same,"Systems, devices and methods for monitoring analyte levels using a self-powered analyte sensor and associated sensor electronics are provided.",ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,,https://lens.org/156-592-346-966-291,Patent Application,no,9,2,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/1468;;A61B5/1473,,1,1,061-673-085-468-891,10.1016/j.bios.2008.09.014;;19013784,"TAKUYA HANASHI ET AL: ""BioCapacitor-A novel category of biosensor"", 《BIOSENSORS AND BIOELECTRONICS》",ACTIVE
304,US,B2,US 11051699 B2,000-369-364-475-569,2021-07-06,2021,US 201816231895 A,2018-12-24,US 201816231895 A,2018-12-24,Method and system for estimating fractional fat content of an object of interest,"A method and system for estimating fractional fat content of an object of interest. The method and system include a thermoacoustic imaging system comprising an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the region of interest and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors. The one or more processors are able to process bipolar acoustic signals received by the acoustic receiver in response to RF energy pulses emitted into the region of interest using the RF applicator to determine a setting for the RF applicator that yields bipolar acoustic signals with at least one enhanced metric thereof, determine an impedance of the RF applicator used to yield acoustic bipolar signals with the enhanced at least one metric, and estimate fractional fat content of the object of interest using the determined impedance.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2020-01-24),https://lens.org/000-369-364-475-569,Granted Patent,yes,4,0,7,7,0,A61B8/00;;A61B5/0093;;A61B5/4872;;A61B5/7235;;A61B5/7278;;A61B8/5261;;A61B5/4244;;A61B5/0093;;A61B5/4872;;A61B5/489;;A61B2576/02;;A61B5/4244;;A61B5/7235;;A61B5/7278;;A61B5/201,A61B5/00;;A61B5/20,,1,0,,,"Lee Young; PCT International Search Report and Written Opinion; dated Apr. 24, 2020; 13 pages total; WIPO; Alexandria, VA, United States.",ACTIVE
305,US,A1,US 2010/0198311 A1,006-766-412-894-686,2010-08-05,2010,US 36332109 A,2009-01-30,US 36332109 A,2009-01-30,SYSTEM AND METHOD FOR CARDIAC LEAD SWITCHING,"An implantable medical device (IMD) can include an implantable pulse generator (IPG), such as a cardiac pacemaker or an implantable cardioverter-defibrillator (ICD). Various portions of the IMD, such as a device body, a lead body, or a lead tip, can be provided to reduce or dissipate a current and heat induced by various external environmental factors. According to various embodiments, features can be incorporated into the lead body, the lead tip, or the IMD body to reduce the creation of an induced current, or dissipate the induced current and heat created due to an induced current in the lead.",MEDTRONIC INC,SOMMER JOHN LOUIS;;KIMMEL MICHAEL WILLIAM;;CHO YONG KYUN,MEDTRONIC INC (2009-01-27),https://lens.org/006-766-412-894-686,Patent Application,yes,9,4,3,3,0,A61N1/056;;A61N1/37;;A61N1/3718;;A61N1/086;;A61N1/37;;A61N1/3718;;A61N1/056;;A61N1/086,A61N1/08,607/63,0,0,,,,DISCONTINUED
306,US,B2,US 8332045 B2,049-128-752-765-905,2012-12-11,2012,US 36332709 A,2009-01-30,US 36332709 A;;US 3595008 P,2008-03-12,System and method for cardiac lead switching,"An implantable medical device (IMD) can include an implantable pulse generator (IPG), such as a cardiac pacemaker or an implantable cardioverter-defibrillator (ICD). Various portions of the IMD, such as a device body, a lead body, or a lead tip, can be provided to reduce or dissipate a current and heat induced by various external environmental factors. According to various embodiments, features can be incorporated into the lead body, the lead tip, or the IMD body to reduce the creation of an induced current, or dissipate the induced current and heat created due to an induced current in the lead.",SOMMER JOHN LOUIS;;KIMMEL MICHAEL WILLIAM;;CHO YONG KYUN;;MEDTRONIC INC,SOMMER JOHN LOUIS;;KIMMEL MICHAEL WILLIAM;;CHO YONG KYUN,MEDTRONIC INC (2009-01-27),https://lens.org/049-128-752-765-905,Granted Patent,yes,9,3,4,4,0,A61N1/056;;A61N1/37;;A61N1/3718;;A61N1/086;;A61N1/37;;A61N1/056;;A61N1/3718;;A61N1/086,A61N1/00,607/116,1,0,,,"PCT International Search Report, PCT/US2009/036462, 5 pgs.",INACTIVE
307,HK,A1,HK 1004531 A1,065-428-128-480-206,1998-11-27,1998,HK 98103678 A,1998-04-29,GB 9007052 A;;GB 9100510 W,1990-03-29,Pharmaceutical formulations,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/065-428-128-480-206,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,DISCONTINUED
308,AU,A1,AU 2014/374361 A1,063-338-214-807-576,2016-06-30,2016,AU 2014/374361 A,2014-10-31,US 201361922404 P;;US 2014/0063316 W,2013-12-31,Self-powered analyte sensor and devices using the same,"Systems, devices and methods for monitoring analyte levels using a self-powered analyte sensor and associated sensor electronics are provided.",ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,,https://lens.org/063-338-214-807-576,Patent Application,no,0,0,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/1468;;A61B5/1473,,0,0,,,,INACTIVE
309,EP,A4,EP 3463071 A4,065-357-861-928-493,2019-12-25,2019,EP 17809491 A,2017-06-05,US 201662345814 P;;CA 2017050680 W,2016-06-05,A METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FACT CONTENT OF AN OBJECT,,ENDRA INC;;THORNTON MICHAEL M,THORNTON MICHAEL M;;CHO JANG HWAN;;MORDOVANAKIS AGHAPI G,,https://lens.org/065-357-861-928-493,Search Report,no,2,0,5,5,0,A61B5/0022;;A61B5/0093;;A61B8/0891;;A61B8/4416;;A61B8/4488;;A61B8/488;;A61B8/5246;;G06T2207/30101;;G06T7/12;;G16H50/30;;A61B5/4244;;A61B5/4872;;A61B8/085;;A61B5/0093;;A61B8/4488;;A61B5/0022;;A61B8/488;;A61B8/4416;;A61B8/5246;;A61B8/0891;;G06T2207/30101;;G06T7/12;;G16H50/30;;A61B5/4244;;A61B5/4872;;A61B8/085,A61B5/05;;A61B5/00;;A61B8/08;;A61B8/14;;A61B34/10,,0,0,,,,DISCONTINUED
310,CN,A,CN 109310357 A,071-340-884-379-69X,2019-02-05,2019,CN 201780034223 A,2017-06-05,US 201662345814 P;;CA 2017050680 W,2016-06-05,A method and system for estimating fractional fact content of an object,"A method for estimating fractional fat content of an object of interest is described. The method comprises obtaining thermoacoustic data of a region of interest containing an object of interest and areference, and estimating fractional fat content of the object of interest using the thermoacoustic data and at least one parameter of the reference.",ENDRA INC;;THORNTON MICHAEL M,THORNTON MICHAEL M;;CHO JANG HWAN;;MORDOVANAKIS AGHAPI G,,https://lens.org/071-340-884-379-69X,Patent Application,no,6,5,5,5,0,A61B5/0022;;A61B5/0093;;A61B8/0891;;A61B8/4416;;A61B8/4488;;A61B8/488;;A61B8/5246;;G06T2207/30101;;G06T7/12;;G16H50/30;;A61B5/4244;;A61B5/4872;;A61B8/085;;A61B5/0093;;A61B8/4488;;A61B5/0022;;A61B8/488;;A61B8/4416;;A61B8/5246;;A61B8/0891;;G06T2207/30101;;G06T7/12;;G16H50/30;;A61B5/4244;;A61B5/4872;;A61B8/085,A61B5/05;;A61B8/08;;A61B8/14;;A61B34/10,,1,0,,,"DANIEL R. BAUER 等: ""Spectroscopic thermoacoustic imaging of water and fat composition"", 《APPLIED PHYSICS LETTERS》",DISCONTINUED
311,AP,A,AP 2874 A,114-973-575-965-191,2014-03-31,2014,AP 2010005107 A,2008-06-26,US 95977107 P;;US 93775207 P;;US 3798808 P;;US 2008/0007927 W,2007-06-29,Antiviral compounds,,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;KIM CHONG U,,https://lens.org/114-973-575-965-191,Granted Patent,no,3,0,45,79,0,C07D401/12;;C07D401/14;;C07D403/12;;C07D403/14;;C07D413/14;;C07D487/04;;C07K5/0804;;C07K5/0808;;C07D417/14;;C07D207/16;;A61P1/16;;A61P31/12;;A61P31/14;;A61P31/16;;C07D403/12;;C07D403/14;;C07D401/12;;C07D401/14;;C07D487/04;;C07K5/0808;;C07D413/14;;C07K5/0804;;C07D417/14;;C07K5/0819;;C07K5/0821;;C07D207/16,C07D401/12;;A61K31/401;;A61K31/4025;;A61K31/407;;C07D401/14;;C07D403/12;;C07D403/14;;C07D417/14;;C07D487/04,,0,0,,,,ACTIVE
312,NO,D0,NO 923768 D0,115-891-552-239-047,1992-09-28,1992,NO 923768 A,1992-09-28,GB 9007052 A;;GB 9100510 W,1990-03-29,FARMASOEYTISKE FORMULERINGER,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/115-891-552-239-047,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/107;;A61K9/00;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,PENDING
313,AU,B2,AU 2011/282241 B2,136-379-069-580-56X,2015-07-30,2015,AU 2011/282241 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,Methods for the preparation of diasteromerically pure phosphoramidate prodrugs,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/136-379-069-580-56X,Granted Patent,no,1,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,ACTIVE
314,WO,A1,WO 2020/139529 A1,161-581-018-829-615,2020-07-02,2020,US 2019/0064453 W,2019-12-04,US 201816231895 A,2018-12-24,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT OF INTEREST,"A method and system for estimating fractional fat content of an object, including a thermoacoustic imaging system comprising an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into a region of interest (ROI) and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the ROI; and one or more processors. The one or more processors are able to process bipolar acoustic signals received by the acoustic receiver in response to RF energy pulses emitted into the ROI using the RF applicator to determine a setting for the RF applicator that yields bipolar acoustic signals with at least one enhanced metric thereof, determine an impedance of the RF applicator used to yield acoustic bipolar signals with the enhanced at least one metric, and estimate fractional fat content of the object using the determined impedance.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/161-581-018-829-615,Patent Application,yes,6,0,7,7,0,A61B8/00;;A61B5/0093;;A61B5/4872;;A61B5/7235;;A61B5/7278;;A61B8/5261;;A61B5/4244;;A61B5/0093;;A61B5/4872;;A61B5/489;;A61B2576/02;;A61B5/4244;;A61B5/7235;;A61B5/7278;;A61B5/201,G01N29/24,,1,0,,,See also references of EP 3903099A4,PENDING
315,WO,A3,WO 2019/157006 A3,175-455-025-311-313,2020-04-23,2020,US 2019/0016766 W,2019-02-06,US 201815894100 A,2018-02-12,A METHOD FOR OBTAINING THERMOACOUSTIC DATA,"A method of obtaining thermoacoustic data comprises obtaining ultrasound data of a region of interest using at least one ultrasound transducer array, the at least one ultrasound transducer array mechanically connected to at least one thermoacoustic transducer array such that a centerline of the at least one thermoacoustic transducer array is at a known angle with respect to a centerline of the at least one ultrasound transducer array, adjusting a position of the at least one ultrasound transducer array to orient the at least one thermoacoustic transducer array in at least one imaging position based on the known angle, and obtaining thermoacoustic data of the region of interest at the at least one imaging position using the at least one thermoacoustic transducer array.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M;;BELANGER SCOTT PATRICK,,https://lens.org/175-455-025-311-313,Search Report,yes,5,0,3,3,0,A61B8/0833;;A61B8/54;;A61B5/0095;;A61B5/4872;;A61B8/085;;A61B8/14;;A61B8/4416;;A61B8/4477;;A61B8/4494;;A61B8/4494;;A61B8/469,A61B5/05;;A61B8/00;;A61B8/08;;A61B8/14;;A61B34/10,,0,0,,,,PENDING
316,HU,A,HU T63341 A,172-322-606-924-857,1993-08-30,1993,HU 309392 A,1991-04-02,GB 9007052 A,1990-03-29,PHARMACEUTICAL COMPOSITION,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;STEPHERD THOMAS SMITH,,https://lens.org/172-322-606-924-857,Unknown,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/107;;A61K9/16;;A61K9/00;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,DISCONTINUED
317,CN,A,CN 108372857 A,175-949-224-824-146,2018-08-07,2018,CN 201810068341 A,2018-01-24,US 201715420946 A,2017-01-31,EFFICIENT SITUATIONAL AWARENESS BY EVENT GENERATION AND EPISODIC MEMORY RECALL FOR AUTONOMOUS DRIVING SYSTEMS,"A system and method is taught for data processing in an autonomous vehicle control system. Using information is acquired from the vehicle, network interface, and sensors mounted on the vehicle, the system can perceive situations around it with much less complexity in computation without losing crucial details, and then make navigation and control decisions. The system and method are operative to generate situation aware events, store them, and recall to predict situations for autonomous driving.",GM GLOBAL TECH OPERATIONS LLC,KWON HYUKSEONG;;BHATTACHARYYA RAJAN;;DAILY MICHAEL J;;CHO YOUNGKWAN,,https://lens.org/175-949-224-824-146,Patent Application,no,6,8,5,5,0,G05D1/0016;;G05D1/0022;;B60W30/14;;B60W50/00;;B60W2050/0002;;B60W2050/0075;;B60W2556/50;;G06N5/02;;H04L67/12;;G06N7/01;;G05D1/0088;;G06N5/02;;G06N7/01;;H04L67/12,B60W30/14;;B60W50/00;;G05D1/00,,0,0,,,,ACTIVE
318,EP,A1,EP 3463071 A1,182-476-299-684-471,2019-04-10,2019,EP 17809491 A,2017-06-05,US 201662345814 P;;CA 2017050680 W,2016-06-05,A METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FACT CONTENT OF AN OBJECT,,ENDRA INC;;THORNTON MICHAEL M,THORNTON MICHAEL M;;CHO JANG HWAN;;MORDOVANAKIS AGHAPI G,,https://lens.org/182-476-299-684-471,Patent Application,yes,0,0,5,5,0,A61B5/0022;;A61B5/0093;;A61B8/0891;;A61B8/4416;;A61B8/4488;;A61B8/488;;A61B8/5246;;G06T2207/30101;;G06T7/12;;G16H50/30;;A61B5/4244;;A61B5/4872;;A61B8/085;;A61B5/0093;;A61B8/4488;;A61B5/0022;;A61B8/488;;A61B8/4416;;A61B8/5246;;A61B8/0891;;G06T2207/30101;;G06T7/12;;G16H50/30;;A61B5/4244;;A61B5/4872;;A61B8/085,A61B5/05;;A61B8/08;;A61B8/14;;A61B34/10,,0,0,,,,DISCONTINUED
319,US,A1,US 2015/0182153 A1,188-422-961-461-42X,2015-07-02,2015,US 201414529427 A,2014-10-31,US 201414529427 A;;US 201361922404 P,2013-12-31,Self-Powered Analyte Sensor and Devices Using the Same,"Systems, devices and methods for monitoring analyte levels using a self-powered analyte sensor and associated sensor electronics are provided.",ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,ABBOTT DIABETES CARE INC (2014-10-27),https://lens.org/188-422-961-461-42X,Patent Application,yes,6,16,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145,,0,0,,,,ACTIVE
320,WO,A1,WO 2017/210778 A1,199-308-376-161-557,2017-12-14,2017,CA 2017050680 W,2017-06-05,US 201662345814 P,2016-06-05,A METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FACT CONTENT OF AN OBJECT,"A method for estimating fractional fat content of an object of interest is described. The method comprises obtaining thermoacoustic data of a region of interest containing an object of interest and a reference, and estimating fractional fat content of the object of interest using the thermoacoustic data and at least one parameter of the reference.",ENDRA INC;;THORNTON MICHAEL M,THORNTON MICHAEL M;;CHO JANG HWAN;;MORDOVANAKIS AGHAPI G,,https://lens.org/199-308-376-161-557,Patent Application,yes,2,2,5,5,0,A61B5/0022;;A61B5/0093;;A61B8/0891;;A61B8/4416;;A61B8/4488;;A61B8/488;;A61B8/5246;;G06T2207/30101;;G06T7/12;;G16H50/30;;A61B5/4244;;A61B5/4872;;A61B8/085;;A61B5/0093;;A61B8/4488;;A61B5/0022;;A61B8/488;;A61B8/4416;;A61B8/5246;;A61B8/0891;;G06T2207/30101;;G06T7/12;;G16H50/30;;A61B5/4244;;A61B5/4872;;A61B8/085,A61B5/05;;A61B8/08;;A61B8/14;;A61B34/10,,0,0,,,,PENDING
321,EP,A1,EP 3954280 A1,029-899-425-178-463,2022-02-16,2022,EP 21188055 A,2019-12-04,US 201816233959 A;;EP 19902376 A;;US 2019/0064450 W,2018-12-27,SYSTEM FOR MONITORING TISSUE TEMPERATURE,"A system utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system uses a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive multi-polar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors that are able to: process received multi-polar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the multi-polar acoustic signals and a distance between the boundary locations.
",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/029-899-425-178-463,Patent Application,yes,2,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/01;;A61B5/05,,0,0,,,,ACTIVE
322,US,A1,US 2010/0080840 A1,037-275-489-298-733,2010-04-01,2010,US 51114509 A,2009-07-29,US 51114509 A;;US 8506408 P,2008-07-31,Hybrid superporous hydrogel scaffold for cornea regeneration,The present invention features a hybrid superporous hydrogel scaffold for cornea regeneration and a method for producing the same. The hybrid hydrogel is composed of a superporous hydrogen matrix with collagen and cells embedded within the pores of the matrix.,CHO MICHAEL;;KADAKIA ARPITA;;DJALILIAN ALI;;GEMEINHART RICHARD A,CHO MICHAEL;;KADAKIA ARPITA;;DJALILIAN ALI;;GEMEINHART RICHARD A,THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2009-08-24),https://lens.org/037-275-489-298-733,Patent Application,yes,4,13,1,12,0,A61F2/14;;A61F2/14;;A61F2/142;;A61F2240/001;;A61F2250/0067;;A61K35/12;;A61K35/12;;C12N11/04;;C12N11/04,A61F2/00;;A61K35/12;;C12N11/02,424/427;;424/93.7;;435/177,0,0,,,,DISCONTINUED
323,US,A1,US 2017/0244127 A1,090-803-038-474-476,2017-08-24,2017,US 201615052640 A,2016-02-24,US 201615052640 A,2016-02-24,IMPACT OF MEMBRANE CHARACTERISTICS ON THE PERFORMANCE AND CYCLING OF THE BR2-H2 REDOX FLOW CELL,"Various embodiments may comprise an ion exchange membrane (IEM) redox flow cell comprising a IEM, a negative electrode in contact with a reactive fluid, a liquid electrolyte comprising reactants, a positive electrode in contact with the liquid electrolyte, and a diffusion barrier layer disposed between the IEM and the positive electrode, and wherein the negative electrode is isolated from the positive electrode by the IEM.",TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z;;UNIV CALIFORNIA,TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2016-02-25),https://lens.org/090-803-038-474-476,Patent Application,yes,3,7,1,1,0,H01M4/96;;H01M8/188;;H01M4/92;;H01M4/92;;H01M4/94;;H01M8/08;;H01M8/1009;;H01M8/1009;;H01M8/188;;H01M8/20;;H01M2250/10;;Y02E60/50,H01M8/18;;H01M4/92;;H01M4/94;;H01M8/08;;H01M8/1009;;H01M8/20,,0,0,,,,DISCONTINUED
324,MX,A,MX 2013000656 A,103-196-335-969-668,2013-04-03,2013,MX 2013000656 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS.,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.,GILEAD SCIENCES INC,CHO AESOP;;WOLCKENHAUER SCOTT ALAN;;CLARKE MICHAEL O'NEIL HANRAHAN,,https://lens.org/103-196-335-969-668,Patent Application,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07D309/10;;C07H19/02;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,ACTIVE
325,US,B2,US 10409279 B2,176-857-741-109-288,2019-09-10,2019,US 201715420946 A,2017-01-31,US 201715420946 A,2017-01-31,Efficient situational awareness by event generation and episodic memory recall for autonomous driving systems,"A system and method is taught for data processing in an autonomous vehicle control system. Using information is acquired from the vehicle, network interface, and sensors mounted on the vehicle, the system can perceive situations around it with much less complexity in computation without losing crucial details, and then make navigation and control decisions. The system and method are operative to generate situation aware events, store them, and recall to predict situations for autonomous driving.",GM GLOBAL TECH OPERATIONS LLC,KWON HYUKSEONG;;CHO YOUNGKWAN;;BHATTACHARYYA RAJAN;;DAILY MICHAEL J,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2017-01-31),https://lens.org/176-857-741-109-288,Granted Patent,yes,6,3,5,5,0,G05D1/0016;;G05D1/0022;;B60W30/14;;B60W50/00;;B60W2050/0002;;B60W2050/0075;;B60W2556/50;;G06N5/02;;H04L67/12;;G06N7/01;;G05D1/0088;;G06N5/02;;G06N7/01;;H04L67/12,G05B1/00;;G05D1/00;;G06N5/02;;G06N7/00;;H04L29/08,,0,0,,,,ACTIVE
326,US,A1,US 2019/0247014 A1,192-655-341-517-156,2019-08-15,2019,US 201815894100 A,2018-02-12,US 201815894100 A,2018-02-12,METHOD FOR OBTAINING THERMOACOUSTIC DATA,"A method of obtaining thermoacoustic data comprises obtaining ultrasound data of a region of interest using at least one ultrasound transducer array, the at least one ultrasound transducer array mechanically connected to at least one thermoacoustic transducer array such that a centerline of the at least one thermoacoustic transducer array is at a known angle with respect to a centerline of the at least one ultrasound transducer array, adjusting a position of the at least one ultrasound transducer array to orient the at least one thermoacoustic transducer array in at least one imaging position based on the known angle, and obtaining thermoacoustic data of the region of interest at the at least one imaging position using the at least one thermoacoustic transducer array.",ENDRA INC,BELANGER SCOTT PATRICK;;THORNTON MICHAEL M;;CHO JANG HWAN,ENDRA LIFE SCIENCES INC (2018-03-29),https://lens.org/192-655-341-517-156,Patent Application,yes,0,8,3,3,0,A61B8/0833;;A61B8/54;;A61B5/0095;;A61B5/4872;;A61B8/085;;A61B8/14;;A61B8/4416;;A61B8/4477;;A61B8/4494;;A61B8/4494;;A61B8/469,A61B8/08;;A61B8/00,,0,0,,,,DISCONTINUED
327,US,A1,US 2020/0264305 A1,020-293-702-912-117,2020-08-20,2020,US 201916279608 A,2019-02-19,US 201916279608 A,2019-02-19,SYSTEMS AND METHODS FOR THERMOACOUSTIC TRANSDUCER OPTIMIZATION,"A method and system optimize a thermoacoustic transducer functionality that is utilized in a thermoacoustic imaging system. The method and system select a pre-determined transducer geometry for the thermoacoustic imaging system, utilize the thermoacoustic imaging system with the pre-determined transducer geometry to generate at least one impulse in a field of view, acquire data from the impulse, reconstructing the data to generate N-dimensional impulse responses based upon respective channel responses, respective view responses, and a function of the acquired data, utilize the N-dimensional transforms for each image to generate a value for the pre-determined transducer functionality, and utilize the value for the pre-determined transducer functionality to determine an optimum thermoacoustic transducer functionality.",ENDRA LIFE SCIENCES INC,DOUTHAT DEAN ZAHN;;CHO JANG HWAN;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-08-01),https://lens.org/020-293-702-912-117,Patent Application,yes,6,5,10,10,0,A61B5/0507;;A61B5/7203;;A61B2576/00;;A61B2562/0204;;A61B5/7253;;A61B8/5261;;A61B8/4477;;G01S15/8915;;G01S15/899;;A61B5/0095;;A61B2560/0223;;G01S15/8906;;A61B8/4483;;A61B2576/00;;A61B8/4416;;A61B5/0095,G01S15/89;;A61B5/00;;A61B8/00,,0,0,,,,ACTIVE
328,KR,A,KR 20200052384 A,087-454-301-517-04X,2020-05-14,2020,KR 20207012760 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,화학식 (Ia) 또는 (Ib)의 뉴클레오사이드의 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물 제조를 위한 방법 및 중간체가 제공된다:화학식 (Ia)화학식 (Ib) 화학식 (Ia) 또는 (Ib)의 화합물은 C형 간염 감염 치료에 유용하다.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/087-454-301-517-04X,Patent Application,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,DISCONTINUED
329,US,A1,US 2020/0244243 A1,090-489-086-605-669,2020-07-30,2020,US 201816651098 A,2018-09-26,US 201816651098 A;;US 201762563389 P;;US 2018/0052773 W,2017-09-26,GRAPHENE MICROELECTROMECHANICAL SYSTEM (MEMS) RESONANT GAS SENSOR,A method of manufacturing a nanoelectromechanical resonator allows for uniform tuning of a resonant frequency. The nanoelectromechanical resonator can be mass produced and used to sense the presence of a selected gas.,UNIV TEXAS,CULLINAN MICHAEL;;CHO JOON-HYUNG;;CAYLL DAVID;;LADNER IAN,BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (2021-10-27),https://lens.org/090-489-086-605-669,Patent Application,yes,0,3,3,3,0,G01N29/036;;H03H3/0073;;H03H9/2463;;C01B2204/04;;C01B32/194;;G01N29/022;;G01N29/22;;C01B32/194;;B81B7/02;;C01B2204/04;;G01N29/022;;H03H3/0073,H03H3/007;;B81B7/02;;C01B32/194;;G01N29/02,,0,0,,,,ACTIVE
330,US,A1,US 2020/0237234 A1,085-778-316-559-005,2020-07-30,2020,US 202016848376 A,2020-04-14,US 202016848376 A;;US 201816233959 A,2018-12-27,SYSTEM FOR MONITORING TISSUE TEMPERATURE,A system utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system uses a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive multi-polar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors that are able to: process received multi-polar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the multi-polar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/085-778-316-559-005,Patent Application,yes,0,1,2,13,0,A61B5/0095;;A61B5/015;;A61B5/4872;;A61B5/0507;;A61B5/4887;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/015;;A61B5/4872;;A61B5/0095;;A61B5/05,A61B5/01;;A61B5/00;;A61B5/05,,0,0,,,,ACTIVE
331,EP,A4,EP 3089666 A4,107-122-481-750-30X,2018-02-21,2018,EP 14877021 A,2014-10-31,US 201361922404 P;;US 2014/0063316 W,2013-12-31,SELF-POWERED ANALYTE SENSOR AND DEVICES USING THE SAME,,ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,,https://lens.org/107-122-481-750-30X,Search Report,no,3,0,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/00;;A61B5/1468;;A61B5/1473;;A61B5/1486,,2,1,061-673-085-468-891,10.1016/j.bios.2008.09.014;;19013784,"HANASHI T ET AL: ""BioCapacitor-A novel category of biosensor"", BIOSENSORS AND BIOELECTRONICS, ELSEVIER BV, NL, vol. 24, no. 7, 15 March 2009 (2009-03-15), pages 1837 - 1842, XP025958941, ISSN: 0956-5663, [retrieved on 20080924], DOI: 10.1016/J.BIOS.2008.09.014;;See also references of WO 2015102745A1",ACTIVE
332,FI,B,FI 101043 B,118-086-325-226-083,1998-04-15,1998,FI 924340 A,1992-09-28,GB 9007052 A;;GB 9100510 W,1990-03-29,Menetelmä farmaseuttisen koostumuksen valmistamiseksi,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVEST LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/118-086-325-226-083,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,PENDING
333,AU,A,AU 1991/075842 A,109-461-466-896-318,1991-10-21,1991,AU 1991/075842 A,1991-04-02,GB 9007052 A;;GB 9100510 W,1990-03-29,PHARMACEUTICAL FORMULATIONS,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/109-461-466-896-318,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
334,BR,A2,BR 112013001267 A2,124-844-150-071-418,2016-05-17,2016,BR 112013001267 A,2011-07-19,US 2011/0044581 W;;US 36562110 P,2010-07-19,métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro,métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro. a presente invenção refere-se a métodos e intermediários para a preparação de pró-fármacos de fosforamidatos diasteromericamente puros de nucleosídeos de fórmulas (la) e (ib): os compostos de fórmula la e lb são úteis para o tratamento de infecções por hepatite c.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/124-844-150-071-418,Patent Application,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20,,0,0,,,,DISCONTINUED
335,KR,A,KR 20090078776 A,008-247-675-215-807,2009-07-20,2009,KR 20097004793 A,2007-09-05,US 84311006 P,2006-09-08,ASSAY FOR ANTIBODIES TO MYCOBACTERIUM PARATUBERCULOSIS,"A method of detecting an immune response to a paratuberculosis-specific antigen, comprising incubating a sample from a subject with the paratuberculosis-specific antigen and detecting the presence of an antibody in the sample as an indication of an immune response to the paratuberculosis-specific antigen. The antigen may be obtained from a novel M. paratebercelosis strain JTC303. The antigen may be obtained from the JTC303 culture filtrate. Also provided are antibodies to the paratuberculosis-specific antigen, and a diagnostic kit for the detection of an immune response to a paratuberculosis-specific antigen in a mammal.",WISCONSIN ALUMNI RES FOUND,COLLINS MICHAEL T;;SHIN SUNG JAE;;CHO DONG HEE,,https://lens.org/008-247-675-215-807,Patent Application,no,0,0,9,9,0,C07K14/35;;G01N33/5695;;C12R2001/32;;C12N1/205;;G01N33/569;;C12N1/20;;C07K14/35;;G01N33/5695;;C07K14/35;;C12N1/205;;C12R2001/32,C07K14/35;;C12N1/20;;C12R1/32,,0,0,,,,DISCONTINUED
336,EP,B1,EP 3089666 B1,045-047-220-079-63X,2020-08-19,2020,EP 14877021 A,2014-10-31,US 201361922404 P;;US 2014/0063316 W,2013-12-31,SELF-POWERED ANALYTE SENSOR AND DEVICES USING THE SAME,,ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,,https://lens.org/045-047-220-079-63X,Granted Patent,yes,1,0,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/00;;A61B5/1468;;A61B5/1473;;A61B5/1486,,0,0,,,,ACTIVE
337,CA,C,CA 2804375 C,059-440-561-218-457,2018-08-21,2018,CA 2804375 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.,GILEAD SCIENCES INC,CHO AESOP;;WOLCKENHAUER SCOTT ALAN;;CLARKE MICHAEL O'NEIL HANRAHAN,,https://lens.org/059-440-561-218-457,Granted Patent,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,ACTIVE
338,US,S,US D0812974 S,013-880-962-746-39X,2018-03-20,2018,US 201629572912 F,2016-08-01,US 201629572912 F,2016-08-01,Steamer plate,,CNA INT INC,AFFATATO KRISTIN MARIE;;CHO STEVE;;KIM HYUNCHUL;;PRINCE MICHAEL,CNA INTERNATIONAL INC (2017-02-22),https://lens.org/013-880-962-746-39X,Design Right,no,0,5,1,1,0,,,0702;;D 7409,0,0,,,,ACTIVE
339,CN,A,CN 113227782 A,015-775-916-897-283,2021-08-06,2021,CN 201980085956 A,2019-12-04,US 201816231895 A;;US 2019/0064453 W,2018-12-24,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT OF INTEREST,"A method and system for estimating fractional fat content of an object, including a thermoacoustic imaging system comprising an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into a region of interest (ROI) and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the ROI; and one or more processors. The one or more processors are able to process bipolar acoustic signals received by the acoustic receiver in response to RF energy pulses emitted into the ROI using the RF applicator to determine a setting for the RF applicator that yields bipolar acoustic signals with at least one enhanced metric thereof, determine an impedance of the RF applicator used to yield acoustic bipolar signals with the enhanced at least one metric, and estimate fractional fat content of the object using the determined impedance.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG-HWAN;;THORNTON MICHAEL M,,https://lens.org/015-775-916-897-283,Patent Application,no,9,1,7,7,0,A61B8/00;;A61B5/0093;;A61B5/4872;;A61B5/7235;;A61B5/7278;;A61B8/5261;;A61B5/4244;;A61B5/0093;;A61B5/4872;;A61B5/489;;A61B2576/02;;A61B5/4244;;A61B5/7235;;A61B5/7278;;A61B5/201,G01N29/24,,2,0,,,"常飞霞等: ""磁共振化学位移成像评估腰椎终板炎患者骨髓脂肪含量的研究"", 《中国CT和MRI杂志》;;张德清等: ""改良双回波成像对肝脏脂肪测量的探讨"", 《医学影像学杂志》",ACTIVE
340,US,S,US D0804235 S,036-270-503-629-430,2017-12-05,2017,US 201629572918 F,2016-08-01,US 201629572918 F,2016-08-01,Steamer basket,,CNA INT INC,AFFATATO KRISTIN MARIE;;CHO STEVE;;KIM HYUNCHUL;;PRINCE MICHAEL,CNA INTERNATIONAL INC (2017-02-22),https://lens.org/036-270-503-629-430,Design Right,no,0,7,1,1,0,,,0702;;D 7354,0,0,,,,ACTIVE
341,US,B2,US 11478153 B2,150-464-835-333-618,2022-10-25,2022,US 202016848376 A,2020-04-14,US 202016848376 A;;US 201816233959 A,2018-12-27,System for monitoring tissue temperature,A system utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system uses a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive multi-polar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors that are able to: process received multi-polar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the multi-polar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/150-464-835-333-618,Granted Patent,yes,6,0,2,13,0,A61B5/0095;;A61B5/015;;A61B5/4872;;A61B5/0507;;A61B5/4887;;A61B8/0858;;A61B8/4416;;A61B8/469;;A61B8/5223;;A61B8/5261;;A61B5/015;;A61B5/4872;;A61B5/0095;;A61B5/05,A61B5/00;;A61B5/01;;A61B5/05,,7,7,033-786-059-395-583;;003-447-272-638-21X;;012-545-815-382-384;;142-401-383-484-74X;;010-411-063-187-44X;;013-000-205-460-222;;093-756-081-427-464,10.1109/tbme.2012.2210218;;22851231;;10841427;;10.1118/1.598984;;28066714;;10.1016/j.pacs.2016.10.001;;pmc5200938;;8938024;;10.1088/0031-9155/41/11/001;;10.1088/0031-9155/41/11/002;;8938025;;pmc2774978;;19895126;;10.1117/1.3247155;;10.3109/02656731003592035;;20345268,"X. Wang et al., “Microwave-induced thermoacoustic imaging model for potential breast cancer detection,” IEEE Trans. Biomed. Eng., vol. 59, No. 10, pp. 2782-2791, Oct. 2012.;;G. Ku and L. V. Wang, “Scanning thermoacoustic tomography in biological tissue,” Med. Phys., vol. 27, No. 5, pp. 1195-1202, May 2000.;;X. L. Dean-Ben, “On the link between the speckle free nature of optoacoustics and visibility of structures in limited-view tomography,” Photoacoustics, vol. 4, No. 4, pp. 133-140, Jul. 2016.;;C. Gabriel et al., “The dielectric properties of biological tissues: I. Literature survey,” Med. Phys., vol. 41, No. 11, pp. 2231-2249, Nov. 1996.;;S. Gabriel et al., “The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz,” Med. Phys., vol. 41, No. 11, pp. 2251-2269, Nov. 1996.;;M. Pramanik et al., “Thermoacoustic and photoacoustic sensing of temperature,” J. of Biomedical Optics, vol. 14, No. 5, Sep. 2009.;;C. Lou et al., “Temperature monitoring utilising thermoacoustic signals during pulsed microwave thermotherapy: A feasibility study,” Int. J. Hyperthermia, vol. 26, No. 4, pp. 338-346, 2010.",ACTIVE
342,WO,A1,WO 2015/102745 A1,169-862-670-929-31X,2015-07-09,2015,US 2014/0063316 W,2014-10-31,US 201361922404 P,2013-12-31,SELF-POWERED ANALYTE SENSOR AND DEVICES USING THE SAME,"Systems, devices and methods for monitoring analyte levels using a self-powered analyte sensor and associated sensor electronics are provided.",ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,,https://lens.org/169-862-670-929-31X,Patent Application,yes,12,0,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/1468;;A61B5/145;;A61B5/1473,,1,0,,,See also references of EP 3089666A4,PENDING
343,EP,A1,EP 3980090 A1,180-890-038-480-260,2022-04-13,2022,EP 20746344 A,2020-05-29,US 201962858374 P;;US 202016885363 A;;US 2020/0035047 W,2019-06-07,SHIELD OPTIMIZATION FOR MAXIMIZING HEAT DISSIPATION AT THE DEVICE TISSUE INTERFACE AND IMPROVING FIXATION,,MEDTRONIC INC,EGGEN MICHAEL D;;CHO YONG K;;KUDLIK D'ANNE E,,https://lens.org/180-890-038-480-260,Patent Application,yes,0,0,4,4,0,H05K5/04;;H05K5/0086;;H05K7/20436;;A61M60/88;;A61M60/876;;A61M60/873;;A61M60/50;;A61M60/237;;A61M60/178;;A61M60/232;;A61M60/422;;A61N1/375;;A61N1/3787;;A61M60/165;;A61M60/232;;A61M60/237;;A61M60/422;;A61M60/508;;A61M60/873;;A61M60/876;;A61M2205/36;;A61M60/90;;A61M60/178;;A61M60/50;;A61M2205/0233;;A61M2205/8206;;A61M60/50;;A61M60/232;;A61M60/237;;A61M60/178;;A61M60/873;;A61M60/876;;A61M60/422,A61N1/375;;A61N1/378,,0,0,,,,DISCONTINUED
344,ZA,B,ZA 201300135 B,176-675-726-355-846,2013-09-25,2013,ZA 201300135 A,2013-01-07,US 36562110 P;;US 2011/0044581 W,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,,GILEAD CALISTOGA LLC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/176-675-726-355-846,Granted Patent,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H/;;C07D/,,0,0,,,,ACTIVE
345,US,A,US 5665700 A,186-081-387-703-651,1997-09-09,1997,US 29029394 A,1994-08-15,US 29029394 A;;GB 9100510 W;;GB 9007052 A;;US 92739492 A,1990-03-29,Pharmaceutical formulations,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/186-081-387-703-651,Granted Patent,yes,11,89,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/107;;A61K9/16;;A61K9/00;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,514/2;;514/3;;514/4;;514/8;;514/12;;514/21;;514/937,0,0,,,,EXPIRED
346,EP,A1,EP 2805960 A1,198-585-785-683-910,2014-11-26,2014,EP 14181224 A,2011-07-19,US 36562110 P;;EP 11743400 A,2010-07-19,Methods for the preparation of diasteromerically pure phosphoramidate prodrugs,"Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs ofnucleosides of Formulas Ia and Ib:
  
  The compounds of Formula Ia and Ib are useful for the treatment Hepatitis C infections.",GILEAD SCIENCES INC,CHO AESOP;;WOLCKENHAUER SCOTT ALAN;;CLARKE MICHAEL O'NEIL HANRAHAN,,https://lens.org/198-585-785-683-910,Patent Application,yes,19,1,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07F9/44;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20,,26,12,108-490-019-262-993;;009-561-066-190-730;;028-378-891-805-321;;137-403-834-378-953;;078-621-983-928-020;;028-466-258-098-772;;067-029-972-022-07X;;091-635-292-350-475;;043-694-210-553-658;;008-811-925-472-828;;019-016-515-952-657;;054-585-811-636-180,10960130;;10.1007/s001280000023;;10.1016/s0168-8278(00)80419-5;;10728798;;15633995;;10.1021/jm0400101;;11827565;;10.2165/00003495-200262030-00009;;10.1016/s0166-3542(03)00028-7;;12719002;;11259521;;11418355;;10.1016/s1386-6532(01)00167-6;;10.1128/aac.43.1.190;;9869593;;pmc89048;;12614874;;10.1016/s0968-0896(02)00552-7;;8478904;;10.1021/jm00060a013;;19725579;;10.1021/jm900447q;;10.1021/jm0502788;;16107149,"ALI H M ET AL: ""Quantitative structure-activity relationships (QSAR) of two series of O-aryl or N-aryl O-ethyl phosphoramidate and phosphorodiamidate fungicides incorporating amino acid ethyl esters"", BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, SPRINGER-VERLAG, NE, vol. 65, no. 4, 1 October 2000 (2000-10-01), pages 415 - 420, XP019698851, ISSN: 1432-0800;;BOYER, N. ET AL., J HEPATOL., vol. 32, 2000, pages 98 - 112;;CALE, P., GASTROENTEROLGY CLIN. BIOL., vol. 33, 2009, pages 958;;DI BESCEGLIE, A.M.; BACON, B. R., SCIENTIFIC AMERICAN, October 1999 (1999-10-01), pages 80 - 85;;GORDON, C. P. ET AL., J. MED. CHEM., vol. 48, 2005, pages 1 - 20;;MARADPOUR, D. ET AL., NAT. REV. MICRO., vol. 5, no. 6, 2007, pages 453 - 463;;BYMOCK ET AL., ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 11, no. 2, 2000, pages 79 - 95;;SCOTT, L. J. ET AL., DRUGS, vol. 62, 2002, pages 507 - 556;;DE FRANCESCO, R. ET AL., ANTIVIRAL RESEARCH, vol. 58, 2003, pages 1 - 16;;DE CLERCQ, E., J. PHARMACOL. EXP.THER., vol. 297, 2001, pages 1 - 10;;DE CLERCQ, E., J. CLIN. VIROL., vol. 22, 2001, pages 73 - 89;;YAMANAKA, ANTIMICROB. AGENTS CHEMOTHER., 1999, pages 190 - 193;;SCHULTZ, BIOORG. MED. CHEM., vol. 11, 2003, pages 885;;MCGUIGAN, J. MED. CHEM., vol. 36, 1993, pages 1048 - 1052;;PERRONE, J. MED. CHEM., vol. 50, 2007, pages 1840 - 49;;GARDELLI, J. MED. CHEM., vol. 52, 2009, pages 5394 - 5407;;MEPPEN: ""Abstracts of Papers"", 236TH ACS NATIONAL MEETING, 17 August 2008 (2008-08-17);;PAQUETTE, LEO A.; W.A. BENJAMIN: ""Principles of Modem Heterocyclic Chemistry"", 1968, article ""Chapters 1, 3, 4, 6, 7, and 9"";;""The Chemistry of Heterocyclic Compounds, A Series of Monographs"", vol. 13 - 28, 1950, JOHN WILEY & SONS, article ""in particular Volumes 13, 14, 16, 19, and 28"";;J. AM. CHEM. SOC., vol. 82, 1960, pages 5566;;THEODORA W. GREENE: ""Protective Groups in Organic Chemistry"", 1991, JOHN WILEY & SONS, INC.;;P. KROGSGAARD-LARSEN AND H. BUNDGAARD: ""Textbook of Drug Design and Development"", 1991, HARWOOD ACADEMIC PUBLISHERS, article BUNDGAARD, HANS: ""Design and Application of Prodrugs"", pages: 113 - 191;;S. P. PARKER: ""McGraw-Hill Dictionary of Chemical Terms"", 1984, MCGRAW-HILL BOOK COMPANY;;ELIEL, E.; WILEN, S.: ""Stereochemistry of Organic Compounds"", 1994, JOHN WILEY & SONS, INC.;;J.O.C., 2004, pages 6257;;J. MED. CHEM., vol. 48, 2005, pages 5504 - 5508",DISCONTINUED
347,CN,A,CN 113260329 A,025-689-350-163-855,2021-08-13,2021,CN 201980086810 A,2019-12-04,US 201816233959 A;;US 2019/0064450 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,A system and method utilizing thermoacoustic imaging to estimate tissue temperature within a region of interest (ROI) that includes an object of interest and a reference which are separated by at least one boundary with at least two boundary locations. The system and method use a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue ROI and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the ROI; and one or more processors that are able to: process received bipolar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the bipolar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG-HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/025-689-350-163-855,Patent Application,no,7,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B18/18;;A61B5/00;;A61B5/01;;A61B8/00,,0,0,,,,ACTIVE
348,WO,A1,WO 2019/067488 A1,027-713-635-640-563,2019-04-04,2019,US 2018/0052773 W,2018-09-26,US 201762563389 P,2017-09-26,GRAPHENE MICROELECTROMECHANICAL SYSTEM (MEMS) RESONANT GAS SENSOR,A method of manufacturing a nanoelectromechanical resonator allows for uniform tuning of a resonant frequency. The nanoelectromechanical resonator can be mass produced and used to sense the presence of a selected gas.,UNIV TEXAS,CULLINAN MICHAEL;;CHO JOON-HYUNG;;CAYLL DAVID;;LADNER IAN,,https://lens.org/027-713-635-640-563,Patent Application,yes,3,10,3,3,0,G01N29/036;;H03H3/0073;;H03H9/2463;;C01B2204/04;;C01B32/194;;G01N29/022;;G01N29/22;;C01B32/194;;B81B7/02;;C01B2204/04;;G01N29/022;;H03H3/0073,G01N29/036;;C01B32/182;;H03H9/24,,3,3,059-551-723-765-528;;160-145-741-167-73X;;035-503-410-576-921,10.1115/msec2016-8567;;10.4172/2469-410x.1000125;;17255506;;10.1126/science.1136836,"CHO ET AL.: ""A Method to Manufacture Repeatible Graphene-Based NEMS Devices at the Wafer -Scale"", ASME 2016 11TH INTERNATIONAL MANUFACTURING SCIENCE AND ENGINEERING CONFERENCE, vol. 1, 27 June 2016 (2016-06-27), Virginia, USA;;MINA ET AL.: ""Single Layer Graphene Sheet-based Nanoelectromechanical Resonator as Mass Detection"", JOURNAL OF LASERS, OPTICS & PHOTONICS, vol. 2, no. 2, 5 December 2015 (2015-12-05), pages 1000124 - 1000128, XP055585801, ISSN: 2469-410X, DOI: 10.4172/2469-410X.1000125;;BUNCH ET AL.: ""Electromechanical Resonators from Graphene Sheets"", SCIENCE, vol. 315, no. 5811, 26 January 2007 (2007-01-26), pages 490 - 493, XP007916451, DOI: doi:10.1126/science.1136836",PENDING
349,CN,A,CN 113226208 A,085-160-756-228-395,2021-08-06,2021,CN 201980086822 A,2019-12-04,US 201816233935 A;;US 2019/0064447 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,"A thermoacoustic imaging system and method for monitoring tissue temperature within a region of interest, which has an object of interest and a reference that are separated by at least one boundary. The system and method include a thermoacoustic imaging system with an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein, an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest, and one or more processors that process at least one received bipolar acoustic signal generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof and calculate a temperature at the at least one boundary using the peak-to-peak amplitude of the at least one bipolar acoustic signal.",ENDRA LIFE SCIENCES INC,CHO JANG-HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/085-160-756-228-395,Patent Application,no,6,1,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B18/12;;A61B18/04;;A61B18/10;;A61B18/14,,0,0,,,,PENDING
350,CA,A1,CA 2079233 A1,104-484-676-241-715,1991-09-30,1991,CA 2079233 A,1991-04-02,GB 9007052 A,1990-03-29,PHARMACEUTICAL FORMULATIONS,"2079233 9114454 PCTABS00007 A pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathway for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active proteins orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,SHEPHERD THOMAS S;;CHO YOUNG W;;FLYNN MICHAEL J,,https://lens.org/104-484-676-241-715,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,DISCONTINUED
351,EA,B1,EA 025311 B1,164-692-242-418-985,2016-12-30,2016,EA 201390133 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (Ia) and (Ib)The compounds of Formulas (Ia) and (Ib) are useful for the treatment Hepatitis C infections.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/164-692-242-418-985,Granted Patent,no,4,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,1,1,108-490-019-262-993,10960130;;10.1007/s001280000023,"H. M. ALI ; M. K. ALI: ""Quantitative structure-activity relationships (QSAR) of two series of O-aryl or N-aryl O-ethyl phosphoramidate and phosphorodiamidate fungicides incorporating amino acid ethyl esters"", BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, SPRINGER-VERLAG, NE, vol. 65, no. 4, 1 October 2000 (2000-10-01), Ne, pages 415 - 420, XP019698851, ISSN: 1432-0800",ACTIVE
352,ES,T3,ES 2104697 T3,163-478-255-513-697,1997-10-16,1997,ES 91907052 T,1991-04-02,GB 9007052 A,1990-03-29,FORMULADOS FARMACEUTICOS.,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/163-478-255-513-697,Granted Patent,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
353,US,A1,US 2023/0288084 A1,168-594-810-158-47X,2023-09-14,2023,US 202217691949 A,2022-03-10,US 202217691949 A,2022-03-10,"AIR DELIVERY ASSEMBLIES, METHODS, AND KITS FOR DELIVERING IONS","An air delivery assembly having a baffle and an ionizer. The baffle is constructed to affect air flow such that air flowing through the air delivery assembly has an air velocity and a direct flow to the ionizer that is effective to deliver ions through a diffuser of the air delivery assembly and up into a room. The air delivery assembly may be included with a damper and/or an upper diffuser to form an air terminal, which may be used in a raised floor air distribution system.",AIRFIXTURE LLC,MCQUEENY JR MICHAEL J;;CLARK MATTHEW RYAN;;CHO SUWAN,AIRFIXTURE L.L.C (2022-11-04),https://lens.org/168-594-810-158-47X,Patent Application,yes,0,0,1,1,0,F24F8/30;;F24F13/20;;F24F2221/40;;F24F8/192;;F24F8/30;;F24F2221/40;;F24F13/20,F24F8/30;;F24F13/20,,0,0,,,,PENDING
354,EP,A4,EP 3902495 A4,189-205-669-121-642,2022-10-12,2022,EP 19902376 A,2019-12-04,US 201816233959 A;;US 2019/0064450 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/189-205-669-121-642,Search Report,no,2,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/01;;A61B5/05;;A61B8/00,,0,0,,,,ACTIVE
355,JP,A,JP 2001068859 A,013-368-737-121-534,2001-03-16,2001,JP 2000237500 A,2000-08-04,US 37485299 A,1999-08-16,FORMING METHOD OF MULTILAYERD CIRCUIT STRUCTURE,"PROBLEM TO BE SOLVED: To enable circuit boards to be easily aligned with each other by a method wherein pawls of a roller element are inserted into apertures that are each provided to a first and a second circuit board and aligned with each other, and the first circuit board is laminated on the second circuit board. SOLUTION: A row of apertures 20 are provided to each side edge region of a first circuit board 10, the apertures 20 are bored in the board 10 through its overall length, and the pawl 32 of a roller element 30 is made to reach the aperture 51 of a second circuit board 40 penetrating through the aperture 20 of the board 10. As mentioned above, the apertures 20 and 51 of the circuit boards 10 and 40 are aligned with each other, and the boards 10 and 40 are laminated integrally so as to be formed into a multilayered circuited board when the circuit boards 10 and 40 appear out of a nip. By this setup, the circuit boards 10 and 40 can be easily aligned in a process where a pair of multilayered circuit structures are formed.",FUJITSU LTD,MICHAEL G LEE;;SOLOMON VALIN;;UEN-CHO VINCENT WANG,,https://lens.org/013-368-737-121-534,Patent Application,no,0,1,2,2,0,B32B38/1841;;B32B2457/08;;H05K3/4614;;H05K3/4638;;H05K2201/09063;;H05K2201/096;;H05K2203/068;;H05K2203/167;;Y10T29/49126;;Y10T29/49128;;Y10T29/49126;;Y10T29/49128;;H05K3/4638;;H05K2201/09063;;B32B2457/08;;B32B38/1841;;H05K2203/068;;H05K2203/167;;H05K2201/096;;H05K3/4614,H05K3/36;;H05K3/46,,0,0,,,,DISCONTINUED
356,US,B2,US 9487544 B2,033-307-067-707-195,2016-11-08,2016,US 201514746430 A,2015-06-22,US 201514746430 A;;US 201313813886 A;;US 2011/0044581 W;;US 36562110 P,2010-07-19,Methods for the preparation of diasteromerically pure phosphoramidate prodrugs,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas Ia and Ib: The compounds of Formula Ia and Ib are useful for the treatment Hepatitis C infections.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,GILEAD SCIENCES INC (2015-08-31),https://lens.org/033-307-067-707-195,Granted Patent,yes,99,36,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H21/00;;A61K31/7042;;A61K31/7052;;C07F9/24;;C07F9/6558;;C07F9/6561;;C07H1/00;;C07H19/02;;C07H19/10;;C07H19/20,,99,95,034-480-531-034-322;;108-490-019-262-993;;061-123-661-112-505;;093-772-201-928-651;;044-496-172-245-687;;048-010-526-386-050;;030-384-807-647-942;;015-260-754-309-246;;030-693-283-815-800;;066-658-824-265-040;;063-345-122-061-100;;004-232-536-342-462;;004-943-756-337-13X;;009-561-066-190-730;;009-715-453-008-555;;056-295-016-756-260;;046-369-485-361-428;;087-609-000-410-701;;079-148-993-650-697;;017-323-145-958-572;;066-435-000-957-468;;062-585-511-949-070;;077-866-841-847-558;;054-585-811-636-180;;101-008-621-057-164;;044-668-884-908-942;;067-029-972-022-07X;;028-466-258-098-772;;078-621-983-928-020;;005-449-957-619-785;;084-724-974-677-476;;019-383-263-228-519;;001-893-984-143-028;;052-601-247-824-838;;071-398-707-605-133;;160-215-119-133-08X;;026-224-336-608-906;;022-731-713-608-487;;024-285-408-175-262;;017-694-831-179-969;;059-123-527-563-16X;;019-016-515-952-657;;054-676-373-133-359;;028-378-891-805-321;;013-886-864-185-231;;034-668-234-744-381;;018-537-809-383-194;;112-423-782-113-240;;034-576-531-658-617;;033-890-563-594-59X;;134-099-955-058-048;;025-792-236-879-10X;;089-242-166-203-205;;020-358-870-701-612;;008-862-016-228-22X;;051-155-198-430-037;;028-151-089-399-462;;003-071-503-249-615;;014-904-874-166-459;;127-015-535-614-541;;037-312-338-002-608;;128-987-621-757-787;;048-856-832-965-666;;052-682-548-381-070;;029-250-930-785-479;;060-079-373-716-61X;;006-809-980-180-072;;019-802-943-770-209;;066-863-545-560-891;;135-097-693-175-267;;008-811-925-472-828;;019-939-369-016-996;;030-312-196-413-553;;099-574-074-958-524;;007-093-894-738-768;;056-697-725-814-023;;000-754-089-379-839;;025-397-642-054-04X;;018-235-408-995-030;;074-606-253-828-334;;052-020-380-633-664;;129-425-155-578-694;;054-634-923-823-456;;056-337-906-217-317;;067-415-146-630-888;;033-320-576-003-088;;045-807-436-693-988;;163-815-243-462-874;;072-215-169-736-225;;015-418-818-374-707;;061-318-647-736-32X;;035-830-569-263-132;;009-242-541-613-969;;016-675-247-669-352;;093-231-708-851-022,10.1080/07328300802217848;;10960130;;10.1007/s001280000023;;10.1177/095632029700800610;;10.1021/jo01265a026;;10.1039/p19910000490;;10.1016/s0040-4039(01)00368-9;;10.1021/jo01069a095;;10.1016/s0040-4020(00)01053-x;;10.1021/ol0486829;;15496062;;10.1021/jm960289o;;8960556;;10.1021/jo0491096;;15357584;;21041908;;pmc7733240;;10.3851/imp1667;;11263895;;10.1021/ol006992v;;10.1016/s0168-8278(00)80419-5;;10728798;;10.1517/13543780902854194;;19426125;;17521911;;10.1016/j.bmc.2007.05.020;;10.1021/jo702587e;;18307356;;10.1016/j.gcb.2009.07.020;;19717256;;10.1099/0022-1317-70-1-37;;2543738;;10.1016/0040-4020(82)87017-8;;pmc2650549;;19075052;;10.1128/aac.01032-08;;10.1128/aac.00211-07;;17576833;;pmc2043207;;pmc2224772;;18056282;;10.1128/aac.01215-07;;10.1021/jm0502788;;16107149;;10.1081/ncn-120026403;;14680024;;10.1021/ol027364b;;12633077;;11418355;;10.1016/s1386-6532(01)00167-6;;11259521;;10.1016/s0166-3542(03)00028-7;;12719002;;10.1002/chin.198227314;;10.1021/jm00030a009;;8120868;;10.1038/scientificamerican1099-80;;10533288;;10.3987/rev-08-629;;3912262;;10.1016/0378-1119(85)90017-4;;10.1021/jo00100a050;;10.1039/a905177e;;10.1039/a904065j;;10819433;;10.1177/095632020001100201;;20112915;;10.1021/jm901758f;;10.1002/jps.2600720332;;6842389;;10.1002/hep.510240606;;8938160;;10.1053/jhep.1996.v24.pm0008938160;;19725579;;10.1021/jm900447q;;13678190;;10.1039/b305790a;;15633995;;10.1021/jm0400101;;10.1016/0040-4039(96)00292-4;;17331721;;10.1016/j.bmcl.2007.02.030;;10.1135/css200810347;;10.1016/j.bmc.2009.02.011;;19254848;;10.1080/00397919208021547;;10.1080/15257779508012398;;pmc2094219;;10.1021/jm060872x;;17034123;;10.3987/com-91-5946;;10.1021/jm0701021;;17636948;;10.1002/qua.10277;;10.1021/jo00108a031;;10.1080/07328319308018558;;3136937;;10.1248/cpb.36.634;;8831776;;10.1021/jm9600757;;10.1074/jbc.m510195200;;16316989;;10.1039/p19850000621;;10.1039/p19840000229;;10.1016/0223-5234(92)90010-x;;7562927;;10.1021/jm00020a007;;10.1080/15257779508012467;;pmc4007795;;10.1021/ml100092a;;24900209;;10.1002/jhet.5570160330;;1313927;;10.1128/jvi.66.5.3225-3229.1992;;pmc241092;;10.1093/nar/gkh809;;pmc519107;;15356293;;10.1016/s0040-4039(96)02289-7;;10.1016/s0040-4039(97)00197-4;;8478904;;10.1021/jm00060a013;;10.1016/j.ejmech.2009.04.043;;19493593;;10.1074/jbc.m305041200;;12966103;;10.1039/p19920002345;;10.1002/jhet.5570210313;;1315479;;10.1016/s0065-3527(08)60035-4;;10.1038/nrmicro1645;;17487147;;10.1002/(sici)1097-0215(19970703)72:1<184::aid-ijc26>3.3.co;2-s;;10.1002/(sici)1097-0215(19970703)72:1<184::aid-ijc26>3.0.co;2-i;;9212241;;10.1128/aac.00400-06;;17101674;;pmc1797721;;10.1126/science.282.5386.103;;9756471;;10.1016/s0008-6215(01)00017-9;;11284507;;10.1021/jo00966a020;;10.1080/07328319608002423;;10.1080/07328318808056291;;10.1021/jo00250a013;;10.1080/07328319008045210;;10.1016/s0040-4039(00)73494-0;;10.1002/jhet.5570310415;;10.1002/jhet.5570300240;;17367121;;10.1021/jm0613370;;10.1002/hlca.19910740217;;10.1021/jm0603623;;17064080;;10.1021/jm0603623.s001;;10.1021/jm060202r;;10.1021/jm060202r.s001;;16884305;;8279810;;10.1016/0166-3542(93)90093-x;;3783585;;10.1021/jm00161a017,"Alessandrini, L. et al., ""Synthesis of Differently Protected 1-C-methyl-ribofuranoses Intermediates for the Preparation of Biologically Active 1'-C-methyl-ribonucleosides,"" Journal of Carbohydrate Chemistry, 27(5):332-344, 2008.;;Ali, H.M. et al., ""Quantitative structure-activity relationships (QSAR) of two series of O-aryl or N-acyl O-ethyl phosphoramidate and phosphorodiamidate fungicides incorporating amino acid ethyl esters,"" Bulletin of Environmental Contamination and Toxicology, 65(4):415-420, 2000.;;Arimilli, M.N. et al., ""Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs,"" Antiviral Chemistry & Chemotherapy, 8(6):557-564, 1997.;;Asbun, W. et al., ""Synthesis of 5-substituted Pyrimidines. II,"" Journal of Organic Chemistry, 31:140-142, 1968.;;Ballini, R. et al., ""Enantioselective Synthesis of the Lactone Moiety of the Mevinic Acids using D-Xylose as a Chiral Precursor,"" Journal of the Chemical Society, Perkin Transactions 1, pp. 490-491, 1991.;;Bandini, M. et al., ""Indium tribromide: a highly effective catalyst for the addition of trimethylsilyl cyanide to alpha-hetero-substituted ketone,"" Tetrahedron Letters, 42:3041-3043, 2001.;;Barker, R. et al., ""2,3,5-Tri-O-benzyl-D-ribosyl and -L-arabinosyl Bromides,"" Journal of Organic Chemistry, 26(11):4605-4609, 1961.;;Belokon, Y. et al., ""Optimized catalysts for the asymmetric addition of trimethylsilyl cyanide to aldehydes and ketones,"" Tetrahedron, 57:771-779, 2001.;;Benksim, A. et al., ""A Novel Stereospecific Synthesis of Glycosyl Cyanides from 1,2-O-sulfinyl Derivatives,"" Organic Letters, 6(22):3913-3915, 2004.;;Benzaria, S. et al., ""Synthesis, in Vitro Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derivatives of 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA) as Potential PMEA Prodrugs with Improved Oral Bioavailability,"" Journal of Medicinal Chemistry, 39(25):4958-4965, 1996.;;Bio, M. et al., ""Practical Synthesis of a Potent Hepatitis C Virus RNA Replication Inhibitor,"" Journal of Organic Chemistry, 69:6257-6266, 2004.;;Bobeck, D.R. et al., ""Advances in nucleoside monophosphate prodrugs as anti-HCV agents,"" Antiviral Therapy, 15:935-950, 2010.;;Bojack, G. et al., ""Design and Synthesis of Inhibitors of Adenosine and AMP Deaminases,"" Organic Letters, 3(6):839-842, 2001.;;Boyer, N. et al., ""Pathogenesis, diagnosis and management of hepatitis C,"" Journal of Hepatology, 32:98-112, 2000.;;Brown, N., ""Progress towards improving antiviral therapy for hepatitis C virus polymerase inhibitors. Part O: Nucleoside analogues,"" Expert Opinion, 18:709-725, 2009.;;Butora et al., ""Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-2'-C-methyladenosine,"" Bioorganic & Medicinal Chemistry, 15:5219-5229, 2007.;;Cabirol, F. et al., ""Robust and Efficient, yet Uncatalyzed, Synthesis of Triarylsilyl-protected Cyanohydrins from Ketones,"" Journal of Organic Chemistry, 73:2446-2449, 2008.;;Calès, P. et al., ""Treatment of liver fibrosis: clinical aspects,"" Gastroentérologie Clinique et Biologique, 33(10-11):958-966, 2009.;;Calisher, C. et al., ""Antigenic Relationships between Flaviviruses as Determined by Cross-neutralization Tests with Polyclonal Antisera,"" Journal of General Virology, 70:37-43, 1989.;;Camps, P., ""Studies on Structurally Simple -alphabeta-butenolides-II,"" Tetrahedron, 38(15):2395-2402, 1982.;;Carroll, S., ""Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees,"" Antimicrobial Agents and Chemotherapy, 53(3):926-934, 2009.;;Chapman, J. et al., ""RSV604, a Novel Inhibitor of Respiratory Syncytial Virus Replication,"" Antimicrobial Agents and Chemotherapy, 51(9):3346-53, 2007.;;Cihlar, T. et al., ""Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131,"" Antimicrobial Agents and Chemotherapy, 52(2):655-65, 2008.;;Clark, J. et al., ""Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication,"" Journal of Medicinal Chemistry, 48(17):5504-5508, 2005.;;Colacino, E. et al., ""Synthesis and Biological Evaluation of Some 5-Nitro- and 5-Amino Derivatives of 2'-Deoxycytidine, 2',3'-Dideoxyuridine, and 2',3'-Dideoxycytidine,"" Nucleoside, Nucleotides & Nucleic Acids, 22(11):2013-2026, 2003.;;Dai, Q. et al., ""Synthesis of 2'-C-beta-Fluoromethyluridine,"" Organic Letters, 5(6):807-810, 2003.;;De Clercq, E., ""Antiviral drugs: current state of the art,"" Journal of Clinical Virology, 22:73-89, 2001.;;De Clercq, E., ""Molecular Targets for Antiviral Agents,"" The Journal of Pharmacology and Experimental Therapeutics, 297(1):1-10, 2001.;;De Francesco, R. et al., ""Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase,"" Antiviral Research, 58:1-16, 2003.;;De Las Heras, ""Synthesis of Ribosyl and Arabinosyl Cyanides by Reaction of 1-O-Acyl Sugars with Trimethylsilyl Cyanide,"" Journal of the Chemical Society, Perkin Transactions 1, 1982:903-907, 1982.;;De Lombaert, S. et al., ""N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors,"" Journal of Medicinal Chemistry, 37(4):498-511, 1994.;;Di Bisceglie, A. et al., ""The Unmet Challenges of Hepatitis C,"" Scientific American, Oct. 1999:80-85, 1999.;;Dolzhenko, A.V. et al., ""Pyrazolo[1,5-a][1,3,5]triazines(5-AZA-9-deazapurines): Synthesis and Biological Activity,"" Heterocycles, 75(7):1575-1622, 2008.;;Domingo, E. et al., ""The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance-a review,"" Gene, 40:1-8, 1985.;;Dondoni, A. et al., ""Thiazole-Based Synthesis of Formyl C-Glycosides,"" Journal of Organic Chemistry, 59:6404-6414, 1994.;;Dudfeld, P.J. et al, ""Synthesis of C-ribosyl 1,2,4-triazolo[3,4-f][1,2,4]triazines as inhibitors of adenosine and AMP deaminases,"" Journal of the Chemical Society, Perkin Transactions 1, 1999:2937-2942, 1999.;;Dudfeld, P.J. et al, ""Synthesis of C-ribosyl imidazo[2,1-f ][1,2,4]triazines as inhibitors of adenosine and AMP deaminases,"" Journal of the Chemical Society, Perkin Transactions 1, 1999:2929-2936, 1999.;;Dymock, B.W. et al., ""Novel approaches to the treatment of hepatitis C virus infection,"" Antiviral Chemistry & Chemotherapy, 11(2):79-96, 2000.;;El Safadi, Y. et al., ""5-Modified-2'-dU and 2'-dC as Mutagenic Anti HIV-1 Proliferation Agents: Synthesis and Activity,"" Journal of Medicinal Chemistry, 53(4):1534-1545, 2010.;;Farquhar, D. et al., ""Biologically Reversible Phosphate-Protective Groups,"" Journal of Pharmaceutical Sciences, 72(3):324-325, 1983.;;Fukumoto, T. et al., ""Viral Dynamics of Hepatiis C Early After Orthotopic Liver Transplantation: Evidence for Rapid Turnover of Serum Virions,"" Hepatology, 24:1351-1354, 1996.;;Garcia, I. et al., ""Synthesis of (2,3,4,6-tetra-O-acetyl-alpha-D-glycopyranosyl)thiophene derivatives as new C-nucleoside analogues,"" J. Carbohydrate Chemistry 20(7/8)681-687, 2001.;;Gardelli, C. et al., ""Phosphoramidate Prodrugs of 2'-C-Methylcytidine for Therapy of Hepatitis C Virus Infection,"" Journal of Medicinal Chemistry, 52(17):5394-5407, 2009.;;Gleeson, M.P. et al., ""Prediction of the potency of inhibitors of adenosine deaminase by QM/MM calculations,"" Chemical Communications, 2003(17):2180-2181, 2003.;;Gordon, C.P. et al., ""Control of Hepatitis C: A Medicinal Chemistry Perspective,"" Journal of Medicinal Chemistry, 48(1):1-20, 2005.;;Greene, T.W., Protective Groups in Organic Chemistry (John Wiley & Sons, New York, 1991).;;Gudmundsson, K. et al., ""Synthesis of imidazo[1,2-a]pyridine C-Nucleosides with an Unexpected Site of Ribosylation,"" Journal of Organic Chemistry, 62:3453-3459, 1997.;;Gudmundsson, K. et al., ""The Condensation of 2,6-dichloroimidazo[1,2-a]pyridine C-nucleoside with an Unexpected Site of Ribosylation,"" Tetrahedron Letters, 37(14):2365-2368, 1996.;;Gunic, E. et al.., ""Cyclic monophosphate prodrugs of base-modified 2'-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication,"" Bioorganic & Medicinal Chemistry Letters, 17:2452-2455, 2007.;;Hamann, M. et al., ""Synthesis and antiviral evaluation of 7,9-dideaza-8-thiapurine C-nucleoside derivatives,"" Collection Symposium Series, 10:347-349, 2008.;;Hamann, M. et al., ""Synthesis and antiviral evaluation of thieno[3,4-d]pyrimidine C-nucleoside analogues of 2',3'-dideoxy- and 2',3'-dideoxy-2',3'-didehydro-adenosine and -inosine,"" Bioorganic & Medicinal Chemistry, 17:2321-2326, 2009.;;Han, H.K. et al., ""Synthesis of 1-Chloroacetyl-1-dehydroxy-2,3,5-tri-O-benzoyl-beta-D-ribofuranose. A Potentially Versatile Intermediate for the Synthesis of C-Nucleosides,"" Synthetic Communications, 22(19):2815-2822, 1992.;;Haraguchi, K. et al., ""Stereoselective Synthesis of 1'-C-Branched Uracil Nucleosides From Uridine,"" Nucleosides & Nucleotides, 14(3-5):417-420, 1995.;;Harki, D. et al., ""Synthesis and Antiviral Activity of 5-Substituted Cytidine Analogues: Identification of Potent Inhibitor of Viral RNA-Dependent RNA Polymerases,"" Journal of Medicinal Chemistry, 49(21):6166-6169, 2006.;;Hayashi, M. et al., ""C-Nucleosides, A Synthesis of 2-Substitued 7-(beta-D-Ribofuranosyl)- Pyrrolo[2,1-f]-1,2,4-Triazines. A New Type of 'Purine Like' C-Nucleoside,"" Heterocycles, 34(3):569-574, 1992.;;Hecker, S.J. et al., ""Liver Targeted Prodrugs of 2'-methyladenosine of Therapy of Hepatitis C Virus Infection,"" Journal of Medicinal Chemistry, 50:3891-3896, 2007.;;Hoffman, M. et al., ""When, in the Context of Drug Design, Can a Fluorine Atom Successfully Substitute a Hydroxyl Group,"" International Journal of Quantum Chemistry, 89:419-427, 2002.;;Itoh, Y. et al., ""Divergent stereocontrolled approach to the synthesis of uracil nucleosides branched at the anomeric position,"" Journal of Organic Chemistry, 60:656-662, 1995.;;Jasko, M. et al., ""5'-Phosphonates of Ribonucleosides and 2'-Deoxyribonucleosides: Synthesis and Antiviral Activity,"" Nucleosides & Nucleotides, 12(8):879-893, 1993.;;Kabat, M. et al., ""Nucleosides, CXLVIII, Synthesis of 6-(beta-D-Ribofuranosyl)picolinamide: A Novel C-Nucleoside from D-Ribonolactone,"" Chemical & Pharmaceutical Bulletin, 36(2):634-640, 1988.;;Khamnei, S. et al., ""Neighboring Group Catalysis in the Design of Nucleotide Prodrugs,"" Journal of Medicinal Chemistry, 39(20):4109-4115, 1996.;;Klumpp, K. et al., ""The Novel Nucleoside Analog R1479 (4'-Azidocytidine) is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C virus Replication in Cell Culture,"" Journal of Biological Chemistry, 281(7):3793-3799, 2006.;;Knutsen, L. et al., ""Synthesis of imidazo-fused bridgehead-nitrogen 2'-deoxyribo-C-nucleosides: coupling-elimination reactions of 2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonic acid,"" Journal of the Chemical Society, Perkin Transactions 1, 1985:621-630, 1985.;;Knutsen, L. et al., ""Synthesis of imidazo-fused bridgehead-nitrogen C-nucleosides via dehydrative coupling reactions of 2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonic acid,"" Journal of the Chemical Society, Perkin Transactions 1, 1984:229-238, 1984.;;Kobe, B. et al., ""Use of distance geometry approach for the in vitro antiviral activity evaluation of N-bridgehead C-nucleosides,"" European Journal of Medicinal Chemistry, 27:259-266, 1992.;;Lefebvre, I. et al., ""Mononucleoside Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3'-Azido-2',3'- dideoxythymidine 5'-Monophosphate,"" Journal of Medicinal Chemistry, 38(20):3941-3950, 1995.;;Lefebvre, I. et al., ""Synthesis, Decomposition Pathways and 'In Vitro' Evaluation of Bioreversible Phosphotriesters of Azt,"" Nucleosides, Nucleotides & Nucleic Acids, 14(3-5):763-766, 1995.;;Lindell, S. D. et al., ""Synthesis and Biochemical Testing of 3-(Carboxyphenylethyl)imidazo[2,1-f][1,2,4]triazines as Inhibitors of AMP Deaminase,"" ACS Medicinal Chemistry Letters, 1(6):2862-289, 2010.;;Lovelette, C.A., ""1,2,4-Triazines. Synthesis of selected members of the s-triazolo[3,4-f][1,2,4]triazine and tetrazolo[1,5-f][1,2,4]triazine ring systems,"" Journal of Heterocyclic Chemistry, 16:555-560, 1979.;;Martell, M. et al., ""Hepatitis C Virus (HCV) Circulates as a Population of Different but Closely Related Genomes: Quasispecies Nature of HCV Genome Distribution,"" Journal of Virology, 6695:3225-3229, 1992.;;Mason, S. et al., ""Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor,"" Nucleic Acids Research, 32(16):4758-4767, 2004.;;Matulic-Adamic, J. et al., ""Synthesis of 3-(beta-D-Ribofuranosyl)-2-Fluoropyridine and 3-(beta-D-Ribofuranosyl)-Pyridin-2-one,"" Tetrahedron Letters, 38(2):203-206, 1997.;;Matulic-Adamic, J. et al., ""Synthesis of 5-(beta-D-Ribofuranosyl)-Pyridin-2-one: a 'Deletion-Modified' Analogue of Uridine,"" Tetrahedron Letters, 38(10):1669-1672, 1997.;;McGuigan, C. et al., ""Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT,"" Journal of Medicinal Chemistry, 36(8):1048-1052, 1993.;;Meppen, M. et al., ""Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine,"" European Journal of Medicinal Chemistry, 44(9):3765-3770, 2009.;;Meppen, M. et al., ""Medi-404-A Prodrug Approach for the Treatment of HCV Infection,"" Abstracts of papers, 236th ACS National Meeting, Philadelphia, PA, United States, Aug. 17-21, 2008.;;Migliaccio, G. et al., ""Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in vitro,"" The Journal of Biological Chemistry, 278(49):49164-49170, 2003.;;Mitchell, A.G. et al., ""Bioreversible protection for the phospho group: bioactivation of the di(4-acyloxybenzyl) and mono(4-acyloxybenzyl) phosphoesters of methylphosphonate and phosphonoacetate,"" Journal of the Chemical Society, Perkin Transactions 1, 1992:2345-2353, 1992.;;Mitchell, W.L. et al., ""Synthesis of C-nucleoside isosteres of 9-(2-hydroxyethoxymethyl)guanine (acyclovir),"" Journal of Heterocyclic Chemistry, 21:697-699, 1984.;;Moennig, V. et al., ""The Pestiviruses,"" Advances in Virus Research, 41:53-98, 1992.;;Moradpour, D. et al., ""Replication of hepatitis C virus,"" Nature Reviews Microbiology, 5(6):453-463, 2007.;;Moscow, J. et al., ""Reduced Folate Carrier Gene (RFC1) Expression and Anti-Folate Resistance in Transfected and Non-Selected Cell Lines,"" International Journal of Cancer, 72:184-190, 1997.;;Murakami et al., ""Mechanism of Activation of Beta-D-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase,"" Antimicrob Agents Chemother. 51(2):503-509, Feb. 2007.;;Neumann, A. et al., ""Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-alpha Therapy,"" Science, 282:103-107, 1998.;;Nishimura, N., ""Synthesis of pyrrolo[2,1-f][1,2,3]triazine C-nucleosides. lsosteres of sangivamycin, tubercidin, and toyocamycin,"" Carbohydrate Research, 331:77-82, 2001.;;Ogura, H. et al., ""Reaction of Ethynyl Compounds with Lactones,"" Journal of Organic Chemistry, 37(1):72-75, 1972.;;Otter, B. et al., ""Conformational Properties of Purine-Like C-Nucleosides,"" Nucleosides & Nucleotides, 15(1-3):793-807, 1996.;;Pankiewicz, K. et al., ""C-Nucleoside Analogues of Nicotinamide Mononucleotide (NMN),"" Nucleosides and Nucleotides, 7(5&6):589-593, 1988.;;Pankiewicz, K. et al., ""Efficient Synthesis of 5-(beta-D-Ribofuranosyl)nicotinamide and its alpha-Isomer,"" Journal of Organic Chemistry, 53:3473-3479, 1988.;;Patil, S et al., ""C-Glycosylation of Substituted Heterocycles under Friedel-Crafts Conditions (II): Robosylation of Multi-Functionalized Thiophenes and Furans for the Synthesis of Purine-Like C-Nucleosides,"" Nucleosides & Nucleotides, 9(7):937-956, 1990.;;Patil, S. et al., ""4-Aza-7,9-Dideazaadenosie, a New Cytotoxic Synthetic C-Nucleoside Analogue of Adenosine,"" Tetrahedron Letters, 35(30):5339-5342, 1994.;;Patil, S.A. et al., ""Synthesis of pyrrolo[2,1-f][1,2,4]triazine congeners of nucleic acid purines via the N-amination of 2-substituted pyrroles,"" Journal of Heterocyclic Chemistry, 31(4):781-786, 1994.;;Patil, S.A. et al., ""Synthesis of some new thieno[3,4-d]pyrimidines and their C-nucleosides,"" Journal of Heterocyclic Chemistry, 30(2):509-515, 1993.;;Perrone, P. et al., ""Application of the Phosphoramidate ProTide Approach to 4'-Azidouridine Confers Sub-micromolar Potency versus Hepatitis C Virus on an Inactive Nucleoside,"" Journal of Medicinal Chemistry, 50(8):1840-1849, 2007.;;Piccirilli, J. et al., ""A Direct Route to 3-(D-Ribofuranosyl)pyridine Nucleosides,"" Helvetica Chimica Acta, 74:397-406, 1991.;;Pierra, C. et al., ""Synthesis and Pharmacokinetics of Valopicitabine (NM283), and Efficient Prodrug of the Potent Anti-HCV Agent 2'-C-Methylcytidine,"" Journal of Medicinal Chemistry, 49(22):6614-6620, 2006.;;Poduch, E. et al., ""Design of Inhibitors of Orotidine Monophosphate Decarboxylase Using Bioisosteric Replacement and Determination of Inhibition Kinetics,"" Journal of Medicinal Chemistry, 49(16):4937-4945, 2006.;;Puech, F. et al., ""Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process,"" Antiviral Research, 22(2-3):155-174, 1993.;;Ramasamy, K. et al., ""Synthesis and Antitumor Activity of Certain 3-beta-D-Ribofuranosyl-1,2-4- triazolo[3,4-f]-1,2,4-triazines Related to Formycin prepared via Ring Closure of a 1,2,4-Triazine Precursor,"" Journal of Medicinal Chemistry, 29:2231-2235, 1986.",ACTIVE
357,EP,A1,EP 3903099 A1,023-613-219-048-532,2021-11-03,2021,EP 19904747 A,2019-12-04,US 201816231895 A;;US 2019/0064453 W,2018-12-24,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT OF INTEREST,,ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/023-613-219-048-532,Patent Application,yes,0,0,7,7,0,A61B8/00;;A61B5/0093;;A61B5/4872;;A61B5/7235;;A61B5/7278;;A61B8/5261;;A61B5/4244;;A61B5/0093;;A61B5/4872;;A61B5/489;;A61B2576/02;;A61B5/4244;;A61B5/7235;;A61B5/7278;;A61B5/201,G01N29/24,,0,0,,,,DISCONTINUED
358,US,A,US 4546283 A,071-663-136-710-515,1985-10-08,1985,US 60709484 A,1984-05-04,US 60709484 A,1984-05-04,Conductor structure for thick film electrical device,A thick film device conductor arrangement suitable for making connections between a resiliently mounted element such as a surface acoustic delay line and adjacent thick film conductors and then with the device connecting pins. The thick film conductors include a double layer structure of differing noble metals each selected for desirable properties in designated areas of the device.,US AIR FORCE,ADAMO MICHAEL D;;DARTER CEDERICK U;;CHO FREDERICK Y,,https://lens.org/071-663-136-710-515,Granted Patent,yes,13,15,1,1,0,H01L24/85;;H01L24/85;;H01L21/4853;;H01L21/4853;;H01L21/4867;;H01L21/4867;;H01L23/49811;;H01L23/49811;;H01L23/49883;;H01L23/49883;;H01L24/32;;H01L24/32;;H01L24/45;;H01L24/45;;H01L24/48;;H01L24/48;;H01L24/73;;H01L24/73;;H01L24/83;;H01L24/83;;H01L2224/05624;;H01L2224/05624;;H01L2224/29111;;H01L2224/29111;;H01L2224/2919;;H01L2224/2919;;H01L2224/32225;;H01L2224/32225;;H01L2224/32245;;H01L2224/32245;;H01L2224/45015;;H01L2224/45015;;H01L2224/45124;;H01L2224/45124;;H01L2224/48091;;H01L2224/48091;;H01L2224/48227;;H01L2224/48227;;H01L2224/48247;;H01L2224/48247;;H01L2224/48455;;H01L2224/48455;;H01L2224/48472;;H01L2224/48472;;H01L2224/48724;;H01L2224/48724;;H01L2224/48764;;H01L2224/48764;;H01L2224/73265;;H01L2224/73265;;H01L2224/83194;;H01L2224/83194;;H01L2224/8385;;H01L2224/8385;;H01L2224/83951;;H01L2224/83951;;H01L2224/85205;;H01L2224/85205;;H01L2224/85444;;H01L2224/85444;;H01L2224/85464;;H01L2224/85464;;H01L2224/85469;;H01L2224/85469;;H01L2924/00014;;H01L2924/00014;;H01L2924/01006;;H01L2924/01006;;H01L2924/01013;;H01L2924/01013;;H01L2924/01014;;H01L2924/01014;;H01L2924/01015;;H01L2924/01015;;H01L2924/0102;;H01L2924/0102;;H01L2924/01022;;H01L2924/01022;;H01L2924/0103;;H01L2924/0103;;H01L2924/01046;;H01L2924/01046;;H01L2924/01047;;H01L2924/01047;;H01L2924/0105;;H01L2924/0105;;H01L2924/01078;;H01L2924/01078;;H01L2924/01079;;H01L2924/01079;;H01L2924/01082;;H01L2924/01082;;H01L2924/0132;;H01L2924/0132;;H01L2924/0133;;H01L2924/0133;;H01L2924/014;;H01L2924/014;;H01L2924/0665;;H01L2924/0665;;H01L2924/07802;;H01L2924/07802;;H01L2924/12043;;H01L2924/12043;;H01L2924/14;;H01L2924/14;;H01L2924/15724;;H01L2924/15724;;H01L2924/15787;;H01L2924/15787;;H01L2924/19041;;H01L2924/19041;;H01L2924/19043;;H01L2924/19043;;H01L2924/20752;;H01L2924/20752;;H05K3/245;;H05K3/245;;H05K2201/0391;;H05K2201/0391,H01L21/48;;H01L21/58;;H01L21/60;;H01L23/498;;H05K3/24,310313R;;310/345;;310/348;;310/364;;333/150;;361/397,0,0,,,,EXPIRED
359,EP,A1,EP 3089666 A1,124-561-253-827-96X,2016-11-09,2016,EP 14877021 A,2014-10-31,US 201361922404 P;;US 2014/0063316 W,2013-12-31,SELF-POWERED ANALYTE SENSOR AND DEVICES USING THE SAME,,ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,,https://lens.org/124-561-253-827-96X,Patent Application,yes,0,0,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/1468;;A61B5/1473,,0,0,,,,ACTIVE
360,US,B1,US 10687789 B1,121-226-890-030-008,2020-06-23,2020,US 201916279626 A,2019-02-19,US 201916279626 A,2019-02-19,Method and system for reconstructing a thermoacoustic image,"A method and system for reconstructing a thermoacoustic image that utilizes the steps of directing radio frequency (RF) energy pulses generated by an RF source into a tissue region of interest; detecting, at each of a plurality of views along a scanning trajectory of a transducer element array about the region of interest, acoustic signals generated within the region of interest in response to the RF energy pulses and generating thermoacoustic data; applying at least one correction kernel to the thermoacoustic data; and after the at least one correction kernel has been applied to the thermoacoustic data, reconstructing a thermoacoustic image therefrom.",ENDRA LIFE SCIENCES INC,DOUTHAT DEAN ZAHN;;CHO JANG HWAN;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-08-01),https://lens.org/121-226-890-030-008,Granted Patent,yes,13,0,3,3,0,A61B5/0093;;A61B5/7203;;A61B5/7225;;A61B8/5207;;A61B8/58;;A61B8/4416;;A61B8/5207;;A61B5/7203;;A61B8/58;;A61B5/0093;;A61B5/7225,A61B8/08;;A61B5/00;;A61B8/00,,0,0,,,,ACTIVE
361,CA,C,CA 2933166 C,121-997-961-944-33X,2020-10-27,2020,CA 2933166 A,2014-10-31,US 201361922404 P;;US 2014/0063316 W,2013-12-31,SELF-POWERED ANALYTE SENSOR AND DEVICES USING THE SAME,"Systems, devices and methods for monitoring analyte levels using a self-powered analyte sensor and associated sensor electronics are provided.",ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,,https://lens.org/121-997-961-944-33X,Granted Patent,no,0,2,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/1459;;A61B5/1473;;H04B1/04,,0,0,,,,ACTIVE
362,WO,A1,WO 1991/014454 A1,142-404-333-311-625,1991-10-03,1991,GB 9100510 W,1991-04-02,GB 9007052 A,1990-03-29,PHARMACEUTICAL FORMULATIONS,"A pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathway for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active proteins orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/142-404-333-311-625,Patent Application,yes,8,46,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/107;;A61K9/16;;A61K9/00;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,PATENTED
363,US,A1,US 2019/0247012 A1,010-756-607-482-791,2019-08-15,2019,US 201815894110 A,2018-02-12,US 201815894110 A,2018-02-12,SYSTEM FOR OBTAINING THERMOACOUSTIC DATA,"A system comprises an ultrasound imaging system comprising at least one ultrasound transducer array, a thermoacoustic imaging system comprising at least one thermoacoustic transducer array mechanically connected to the at least one ultrasound transducer array such that a centerline of the at least one thermoacoustic transducer array is at a known angle with respect to a centerline of the at least one ultrasound transducer array, the at least one ultrasound transducer array moveable to orient the at least one thermoacoustic transducer array in at least one imaging position based on the known angle; and a processing unit configured to obtain thermoacoustic data of a region of interest at the at least one imaging position using the at least one thermoacoustic transducer array.",ENDRA INC,BELANGER SCOTT PATRICK;;THORNTON MICHAEL M;;CHO JANG HWAN,ENDRA LIFE SCIENCES INC (2018-03-29),https://lens.org/010-756-607-482-791,Patent Application,yes,0,6,2,2,0,A61B8/14;;A61B8/4416;;A61B8/4477;;A61B8/085;;A61B8/4494;;A61B8/54;;A61B8/085;;A61B8/4494;;A61B8/5207;;A61B8/54;;A61B8/4416;;A61B8/4477;;A61B5/0095;;A61B8/0833;;A61B5/4872,A61B8/08;;A61B8/00,,0,0,,,,DISCONTINUED
364,MA,B1,MA 34471 B1,033-590-949-145-063,2013-08-01,2013,MA 35666 A,2013-02-15,US 36562110 P;;US 2011/0044581 W,2010-07-19,PROCÉDÉS DE PRÉPARATION DE PROMÉDICAMENTS AU PHOSPHORAMIDATE PUR AU PLAN DIASTÉRÉOMÈRE,L'invention concerne des procédés et des intermédiaires pour préparer des promédicaments de nucléosides au phosphoramidate pur au plan diastéréomère ayant les formules (1a) et (1b): Les composés ayant les formules 1a et 1b sont utiles pour le traitement d'infections par l'hépatite C.,GILEAD SCIENCES INC,CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN;;CHO AESOP,,https://lens.org/033-590-949-145-063,Granted Patent,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,ACTIVE
365,EP,B1,EP 3954280 B1,054-562-224-536-474,2023-03-15,2023,EP 21188055 A,2019-12-04,US 201816233959 A;;EP 19902376 A;;US 2019/0064450 W,2018-12-27,SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/054-562-224-536-474,Granted Patent,yes,1,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/01;;A61B5/05,,0,0,,,,ACTIVE
366,NZ,A,NZ 606141 A,056-246-925-550-947,2015-03-27,2015,NZ 60614111 A,2011-07-19,US 2011/0044581 W;;US 36562110 P,2010-07-19,Methods for the preparation of diasteromerically pure phosphoramidate prodrugs,"Disclosed is a method for preparing analogues of sofosbuvir as represented by the general Formula Ia or Ib, or a pharmaceutically acceptable salt or acid thereof; wherein: each Base is independently a naturally occurring or modified purine or pyrimidine base linked to the furanose ring through a carbon or nitrogen atom, provided that Base is not uracil; said method comprising: (a) providing a compound of Formula II, (b) treating the compound of Formula II with a compound of Formula lIla and a base thereby forming a compound of Formula Ia or (c) treating the compound of Formula II with a compound of Formula lIIb and a base thereby forming a compound of Formula Ib; the method further comprising a method of preparing a compound of Formula lIla or Formula IIIb said method comprising: (d) providing a diastereomeric compound of Formula VIII and (e) dissolving the compound of Formula VIII in a suitable solvent and inducing crystallization by addition of a C5-C8 hydrocarbon or C5-C8 cyclic hydrocarbon; thereby forming a pure diasteromer of Formula IlIa or Formula IIIb.",GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O’NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/056-246-925-550-947,Patent Application,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07F9/24;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,PENDING
367,US,A1,US 2022/0071106 A1,064-713-485-605-720,2022-03-10,2022,US 202117471141 A,2021-09-09,US 202117471141 A;;US 202063076276 P,2020-09-09,SYSTEMS AND METHODS OF IMPROVED PLANT CULTIVATION AND ELONGATE AIRFLOW ASSEMBLY FOR THE SAME,"An elongate air delivery assembly having a housing extending between two end caps. The housing includes a plurality of exit vents from which airflow is provided in a consistent sheet at a uniform velocity, and the housing is rotatable about a central longitudinal axis to change a direction of the airflow. A method of improving plant cultivation includes positioning one or more elongate air delivery systems adjacent rows of plants such that the sheet of air generated by the elongate air delivery system is directed horizontally across the plants underneath their plant canopy.",AIRFIXTURE LLC,MEGERSON JAMES E;;MCQUEENY JR MICHAEL J;;CHO SUWAN,AIRFIXTURE LLC (2021-04-05),https://lens.org/064-713-485-605-720,Patent Application,yes,3,1,2,2,0,F04D17/04;;F04D29/4226;;F04D29/626;;A01G9/246;;Y02A40/25;;A01G9/24;;F04D29/462;;F04D29/4226;;F04D17/16,A01G9/24;;F04D17/16;;F04D29/42;;F04D29/46,,0,0,,,,ACTIVE
368,US,A1,US 2020/0134185 A1,130-466-295-750-798,2020-04-30,2020,US 201816171595 A,2018-10-26,US 201816171595 A,2018-10-26,"METHOD TO SECURELY ALLOW A CUSTOMER TO INSTALL AND BOOT THEIR OWN FIRMWARE, WITHOUT COMPROMISING SECURE BOOT","In one or more embodiments, one or more systems, methods, and/or process may allow a customer to install and boot their own firmware securely, without compromising secure boot. A baseboard management controller (BMC) may include a BMC firmware stored via a BMC partition of a non-volatile storage, a customer firmware image including a customer firmware and a signed customer boot block (CBB) file including a CBB, a hidden root key (HRK) hash of the CBB based on a HRK, and a manufacturer signature. The BMC firmware may, when an alternate path to boot the CBB is detected, verify the manufacturer signature on the CBB and the HRK hash, verify the HRK hash based on the unique HRK, and when the manufacturer signature and the HRK hash have been verified, hardware lock the BMC partition, disable the HRK, and transfer control to the CBB.",DELL PRODUCTS LP,CHO EUGENE DAVID;;BROWN MICHAEL EMERY;;SAVAGE MARSHAL F,DELL PRODUCTS L.P (2018-10-24),https://lens.org/130-466-295-750-798,Patent Application,yes,0,20,2,2,0,G06F21/572;;G06F21/572;;G06F21/575;;G06F21/575;;G06F21/602,G06F21/57;;G06F21/60,,0,0,,,,ACTIVE
369,PT,B,PT 97199 B,125-974-298-925-709,1998-07-31,1998,PT 9719991 A,1991-03-28,GB 9007052 A,1990-03-29,PROCESSO PARA A PREPARACAO DE FORMULACOES FARMACEUTICAS A BASE DE LECTICINA OU UM PERCURSOR DE LECTICINA,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/125-974-298-925-709,Granted Patent,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/107;;A61K9/16;;A61K9/00;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
370,DK,T3,DK 0521994 T3,136-766-527-925-538,1997-07-07,1997,DK 91907052 T,1991-04-02,GB 9007052 A,1990-03-29,Farmaceutiske formuleringer,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/136-766-527-925-538,Granted Patent,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
371,EP,A1,EP 0521994 A1,167-539-673-394-223,1993-01-13,1993,EP 91907052 A,1991-04-02,GB 9100510 W;;GB 9007052 A,1990-03-29,PHARMACEUTICAL FORMULATIONS.,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/167-539-673-394-223,Patent Application,yes,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
372,US,A1,US 2013/0281686 A1,160-100-666-045-572,2013-10-24,2013,US 201113813886 A,2011-07-19,US 36562110 P;;US 2011/0044581 W;;US 201113813886 A,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas Ia and Ib: The compounds of Formula Ia and Ib are useful for the treatment Hepatitis C infections.,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN;;GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,GILEAD SCIENCES INC (2013-04-11),https://lens.org/160-100-666-045-572,Patent Application,yes,0,67,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H1/00,536/26.7;;536/26.8,0,0,,,,ACTIVE
373,US,A1,US 2020/0196872 A1,174-538-449-174-209,2020-06-25,2020,US 201816231895 A,2018-12-24,US 201816231895 A,2018-12-24,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT OF INTEREST,"A method and system for estimating fractional fat content of an object of interest. The method and system include a thermoacoustic imaging system comprising an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the region of interest and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors. The one or more processors are able to process bipolar acoustic signals received by the acoustic receiver in response to RF energy pulses emitted into the region of interest using the RF applicator to determine a setting for the RF applicator that yields bipolar acoustic signals with at least one enhanced metric thereof, determine an impedance of the RF applicator used to yield acoustic bipolar signals with the enhanced at least one metric, and estimate fractional fat content of the object of interest using the determined impedance.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2020-01-24),https://lens.org/174-538-449-174-209,Patent Application,yes,0,2,7,7,0,A61B8/00;;A61B5/0093;;A61B5/4872;;A61B5/7235;;A61B5/7278;;A61B8/5261;;A61B5/4244;;A61B5/0093;;A61B5/4872;;A61B5/489;;A61B2576/02;;A61B5/4244;;A61B5/7235;;A61B5/7278;;A61B5/201,A61B5/00;;A61B5/20,,0,0,,,,ACTIVE
374,CN,A,CN 113940150 A,173-520-990-554-320,2022-01-14,2022,CN 202080043246 A,2020-05-29,US 201962858374 P;;US 202016885363 A;;US 2020/0035047 W,2019-06-07,SHIELD OPTIMIZATION FOR MAXIMIZING HEAT DISSIPATION AT THE DEVICE TISSUE INTERFACE AND IMPROVING FIXATION,"A controller for an implantable medical device including a housing sized and configured to be received within a patient, the housing having a thermally conductive shell defining an exterior surface. At least a portion of the exterior surface of the thermally conductive shell defines at least one from the group consisting of a plurality of corrugations and a plurality of protuberances.",MEDTRONIC INC,EGGEN MICHAEL D;;CHO YONG K;;KUDLIK D'ANNE E,,https://lens.org/173-520-990-554-320,Patent Application,no,4,0,4,4,0,H05K5/04;;H05K5/0086;;H05K7/20436;;A61M60/88;;A61M60/876;;A61M60/873;;A61M60/50;;A61M60/237;;A61M60/178;;A61M60/232;;A61M60/422;;A61N1/375;;A61N1/3787;;A61M60/165;;A61M60/232;;A61M60/237;;A61M60/422;;A61M60/508;;A61M60/873;;A61M60/876;;A61M2205/36;;A61M60/90;;A61M60/178;;A61M60/50;;A61M2205/0233;;A61M2205/8206;;A61M60/50;;A61M60/232;;A61M60/237;;A61M60/178;;A61M60/873;;A61M60/876;;A61M60/422,H05K5/04;;A61M60/40;;A61M60/871;;A61M60/876;;A61M60/88;;H05K5/00;;H05K7/20,,0,0,,,,PENDING
375,US,A,US 5820564 A,181-584-494-564-696,1998-10-13,1998,US 76608396 A,1996-12-16,US 76608396 A,1996-12-16,Method and apparatus for surface ultrasound imaging,An ultrasonic imaging apparatus is suitably configured such that certain ultrasound beams from a probe are diffused perpendicular to the scanning direction to thereby enable an ultrasonic image to be produced which approximates a surface image while certain other ultrasound beams are focused to thereby enable a two-dimensional ultrasonic image to be produced. A conventional ultrasonic imaging apparatus and process can be used.,ALBATROSS TECHNOLOGIES INC;;MEDISON CO LTD,SLAYTON MICHAEL H;;CHO YOUNG-HWAN;;BARTHE PETER G,SAMSUNG MEDISON CO. LTD (1996-12-16);;ALBATROSS TECHNOLOGIES INC (1996-12-16);;ARDENT SOUND INC (2002-04-09),https://lens.org/181-584-494-564-696,Granted Patent,yes,5,103,1,1,0,B06B1/0622;;B06B1/0622;;G10K11/30;;G10K11/30,B06B1/06;;G10K11/30,600/459;;600/472,1,0,,,"Talbert, D.G. An Add on Modification for Linear Array Real Time Ultrasound Scanners to Produce 3D Displays , UTS Int l. 1977 Brighton, England (Jun. 28 30, 1977) pp. 57 67.",EXPIRED
376,KR,A,KR 20080065087 A,183-205-759-094-117,2008-07-11,2008,KR 20070002040 A,2007-01-08,KR 20070002040 A,2007-01-08,MODIFICATION METHOD OF PLASTIC SURFACE,"A method for modifying a plastic surface is provided to impart scratch resistance and wear resistance to the plastic surface, and to optimize the prevention of discoloration and crack problems. A method for modifying a plastic surface includes the steps of: molding molten plastic into a desired shape; and coating the surface of the molded plastic with silicone oil. The plastic is acrylonitrile-butadiene-styrene, methylmethacrylate-acrylonitrile-butadiene-styrene, polystyrene, polycarbonate, polycarbonate/acrylonitrile-butadiene-styrene alloy, or polymethylmethacrylate. The silicone oil comprises polydimethylsiloxane as a main component and has a number average molecular weight of 10,000-100,000.",LG CHEMICAL LTD,MICHAEL;;CHUNG JUN MYOUNG;;CHO WANG HUN;;OH JAMES,,https://lens.org/183-205-759-094-117,Patent Application,no,0,1,2,2,0,C08J2355/02;;C08J2483/04;;C08L55/02;;C08L83/04,C08J7/06;;C08J5/00;;C08J7/04;;C08K5/54,,0,0,,,,INACTIVE
377,WO,A1,WO 2019/157032 A1,190-061-789-400-027,2019-08-15,2019,US 2019/0016813 W,2019-02-06,US 201815894110 A,2018-02-12,A SYSTEM FOR OBTAINING THERMOACOUSTIC DATA,"A system comprises an ultrasound imaging system comprising at least one ultrasound transducer array, a thermoacoustic imaging system comprising at least one thermoacoustic transducer array mechanically connected to the at least one ultrasound transducer array such that a centerline of the at least one thermoacoustic transducer array is at a known angle with respect to a centerline of the at least one ultrasound transducer array, the at least one ultrasound transducer array moveable to orient the at least one thermoacoustic transducer array in at least one imaging position based on the known angle; and a processing unit configured to obtain thermoacoustic data of a region of interest at the at least one imaging position using the at least one thermoacoustic transducer array.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M;;BELANGER SCOTT PATRICK,,https://lens.org/190-061-789-400-027,Patent Application,yes,4,0,2,2,0,A61B8/14;;A61B8/4416;;A61B8/4477;;A61B8/085;;A61B8/4494;;A61B8/54;;A61B8/085;;A61B8/4494;;A61B8/5207;;A61B8/54;;A61B8/4416;;A61B8/4477;;A61B5/0095;;A61B8/0833;;A61B5/4872,A61B5/00;;A61B8/00;;A61B8/08,,0,0,,,,PENDING
378,US,B2,US 11666008 B2,060-056-183-016-020,2023-06-06,2023,US 202117471141 A,2021-09-09,US 202117471141 A;;US 202063076276 P,2020-09-09,Systems and methods of improved plant cultivation and elongate airflow assembly for the same,"An elongate air delivery assembly having a housing extending between two end caps. The housing includes a plurality of exit vents from which airflow is provided in a consistent sheet at a uniform velocity, and the housing is rotatable about a central longitudinal axis to change a direction of the airflow. A method of improving plant cultivation includes positioning one or more elongate air delivery systems adjacent rows of plants such that the sheet of air generated by the elongate air delivery system is directed horizontally across the plants underneath their plant canopy.",AIRFIXTURE LLC,MEGERSON JAMES E;;MCQUEENY JR MICHAEL J;;CHO SUWAN,AIRFIXTURE LLC (2021-04-05),https://lens.org/060-056-183-016-020,Granted Patent,yes,3,0,2,2,0,F04D17/04;;F04D29/4226;;F04D29/626;;A01G9/246;;Y02A40/25;;A01G9/24;;F04D29/462;;F04D29/4226;;F04D17/16,A01G9/24;;F04D17/16;;F04D29/42;;F04D29/46,,3,0,,,"“Acme Fan-Jet,” U.S. Global Resources, Accessed Apr. 1, 2022, <https://www.usgr.com/fans/acme_fanjet>, 10 pages.;;“Fan Jet Air Distribution System,” Acme Engineering & Manufacturing Corp., Sep. 2000, <www.acmeag.com>, 2 pages.;;“Selection and Design of Air Curtains,” Bright Hub Engineering, May 2010, <https://www.brighthubengineering.com/hvac/72430-how-to-select-air-curtains-or-air-doors/>, 5 pages.",ACTIVE
379,EP,A1,EP 3902495 A1,138-426-098-540-008,2021-11-03,2021,EP 19902376 A,2019-12-04,US 201816233959 A;;US 2019/0064450 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/138-426-098-540-008,Patent Application,yes,0,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B18/18;;A61B5/00;;A61B5/01;;A61B8/00,,0,0,,,,ACTIVE
380,AU,B9,AU 2014/374361 B9,145-362-411-839-481,2019-07-04,2019,AU 2014/374361 A,2014-10-31,US 201361922404 P;;US 2014/0063316 W,2013-12-31,Self-powered analyte sensor and devices using the same,"Systems, devices and methods for monitoring analyte levels using a self-powered analyte sensor and associated sensor electronics are provided.",ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,,https://lens.org/145-362-411-839-481,Amended Patent,no,1,0,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/1468;;A61B5/1473,,3,3,061-673-085-468-891;;032-671-962-318-721;;102-991-560-295-985,10.1016/j.bios.2008.09.014;;19013784;;pmc3208857;;22027294;;10.1177/193229681100500502;;17166711;;10.1016/j.bios.2006.11.004,"Hanashi T et al, ""BioCapacitor-A novel category of biosensor"", Biosensors And Bioelectronics, Elsevier, vol. 24, no. 7, 15 March 2009, pages 1837-1842;;Hanashi T et al, ""BioRadioTransmitter: a self-powered wireless glucose-sensing system"", Journal of Diabetes Science and Technoly. Volume 5, Issue 5, September 2011, pages 1030-1035.;;Kakehi N et al, ""A novel wireless glucose sensor employing direct electron transfer principle based enzyme fuel cell"", Biosensors and Bioelectronics 22, 2007, pages 2250-2255",INACTIVE
381,EP,B1,EP 3902495 B1,180-249-510-464-333,2023-08-02,2023,EP 19902376 A,2019-12-04,US 201816233959 A;;US 2019/0064450 W,2018-12-27,METHOD FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/180-249-510-464-333,Granted Patent,yes,1,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/01;;A61B5/05;;A61B8/00,,0,0,,,,ACTIVE
382,WO,A1,WO 2009/114441 A1,198-000-805-151-780,2009-09-17,2009,US 2009/0036462 W,2009-03-09,US 3595008 P;;US 36332709 A,2008-03-12,SYSTEM AND METHOD FOR CARDIAC LEAD SWITCHING,"An implantable medical device (IMD) can include an implantable pulse generator (IPG), such as a cardiac pacemaker or an implantable cardioverter-defibrillator (ICD). Various portions of the IMD, such as a device body, a lead body, or a lead tip, can be provided to reduce or dissipate a current and heat induced by various external environmental factors. According to various embodiments, features can be incorporated into the lead body, the lead tip, or the IMD body to reduce the creation of an induced current, or dissipate the induced current and heat created due to an induced current in the lead.",MEDTRONIC INC;;SOMMER JOHN L;;KIMMEL MICHAEL W;;CHO YONG K,SOMMER JOHN L;;KIMMEL MICHAEL W;;CHO YONG K,,https://lens.org/198-000-805-151-780,Patent Application,yes,3,0,4,4,0,A61N1/056;;A61N1/37;;A61N1/3718;;A61N1/086;;A61N1/37;;A61N1/056;;A61N1/3718;;A61N1/086,A61N1/08;;A61N1/05;;A61N1/368;;A61N1/37,,0,0,,,,PENDING
383,JP,A,JP 2001250909 A,013-010-279-088-24X,2001-09-14,2001,JP 2001027246 A,2001-02-02,US 49754200 A,2000-02-03,STRESS REDUCING INTERPOSER FOR ELECTRIC COMPONENT MOUNTING SUBSTRATE,"PROBLEM TO BE SOLVED: To provide an interposer for connecting electric components having different thermal expansion coefficients with a stress difference reduced. SOLUTION: The interposer electrically connects two electric components having different thermal expansion coefficients. The interposer includes two substrates having different thermal expansion coefficients, and the substrates have first and second surfaces, respectively. The interposer has electrical connectors provided on the first surfaces of the two substrates, and the connectors electrically connect two corresponding electrical components. A flexible circuit layer is provided between the two substrates to couple the connector on the first substrate with the connector on the second substrate. The two substrates are mounted as bent so that the second faces of the both substrates are opposed to each other.",FUJITSU LTD,UEN-CHO VINCENT WANG;;MICHAEL G LEE;;SOLOMON VALIN,,https://lens.org/013-010-279-088-24X,Patent Application,no,0,11,2,2,0,H01L23/49827;;H01L23/49833;;H01L23/4985;;H01L2224/16;;H01L2924/01078;;H01L2924/01079;;H01L2924/15311;;H01L2924/3011;;H05K1/141;;H05K1/147;;H05K1/189;;H05K3/0061;;H05K3/363;;H05K2201/049;;H05K2201/10734;;H01L2924/01019;;H01L2924/01087;;H01L2224/16225;;H01L2924/10253;;H01L2224/05573;;H01L2224/05568;;H01L2224/056;;H01L24/05;;H01L23/49827;;H05K1/147;;H01L23/4985;;H01L2924/3011;;H05K3/0061;;H01L23/49833;;H05K2201/10734;;H05K1/141;;H01L2924/01079;;H05K2201/049;;H01L2924/15311;;H05K3/363;;H01L2224/16;;H01L2924/01078;;H05K1/189;;H01L2924/01019;;H01L2924/01087;;H01L2224/16225;;H01L2924/10253;;H01L2224/05573;;H01L2224/056;;H01L2224/05568,H01L21/56;;H01L23/32;;H01L23/498;;H01L23/52;;H01L25/065;;H01L25/07;;H01L25/18;;H05K1/14;;H05K1/18;;H05K3/00;;H05K3/36,,0,0,,,,PENDING
384,SG,A1,SG 186831 A1,013-053-329-715-492,2013-02-28,2013,SG 2012095691 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/013-053-329-715-492,Patent Application,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,,,0,0,,,,PENDING
385,NO,L,NO 923768 L,034-343-735-412-11X,1992-09-28,1992,NO 923768 A,1992-09-28,GB 9007052 A;;GB 9100510 W,1990-03-29,FARMASOEYTISKE FORMULERINGER,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/034-343-735-412-11X,Abstract,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/107;;A61K9/00;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,PENDING
386,HU,A9,HU 211962 A9,058-361-559-791-148,1996-01-29,1996,HU PP00724 P,1995-06-30,GB 9007052 A,1990-03-29,PHARMACEUTICAL FORMULATIONS,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,FLYNN MICHAEL JOHN;;CHO YOUNG W;;SHEPHERD THOMAS SMITH,,https://lens.org/058-361-559-791-148,Unknown,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,PENDING
387,EP,A1,EP 2596004 A1,086-859-644-986-760,2013-05-29,2013,EP 11743400 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,,GILEAD SCIENCES INC,CHO AESOP;;WOLCKENHAUER SCOTT ALAN;;CLARKE MICHAEL O'NEIL HANRAHAN,,https://lens.org/086-859-644-986-760,Patent Application,yes,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07D309/10;;C07H19/02;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,ACTIVE
388,EP,C0,EP 3902495 C0,084-378-149-188-93X,2023-08-02,2023,EP 19902376 A,2019-12-04,US 201816233959 A;;US 2019/0064450 W,2018-12-27,METHOD FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/084-378-149-188-93X,Unknown,no,0,0,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/01;;A61B5/05;;A61B8/00,,0,0,,,,ACTIVE
389,DE,T2,DE 69126609 T2,084-177-311-436-655,1998-01-02,1998,DE 69126609 T,1991-04-02,GB 9007052 A;;GB 9100510 W,1990-03-29,PHARMAZEUTISCHE FORMULIERUNGEN,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/084-177-311-436-655,Granted Patent,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
390,US,A1,US 2022/0211305 A1,126-584-068-892-326,2022-07-07,2022,US 202117552165 A,2021-12-15,US 202117552165 A;;US 201414529427 A;;US 201361922404 P,2013-12-31,SELF-POWERED ANALYTE SENSOR AND DEVICES USING THE SAME,"Systems, devices and methods to monitoring analyte levels using a self-powered analyte sensor and associated sensor electronics are provided.",ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,ABBOTT DIABETES CARE INC (2014-10-27),https://lens.org/126-584-068-892-326,Patent Application,yes,0,0,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/00,,0,0,,,,PENDING
391,WO,A1,WO 2020/247249 A1,120-834-189-793-704,2020-12-10,2020,US 2020/0035047 W,2020-05-29,US 201962858374 P;;US 202016885363 A,2019-06-07,SHIELD OPTIMIZATION FOR MAXIMIZING HEAT DISSIPATION AT THE DEVICE TISSUE INTERFACE AND IMPROVING FIXATION,"A controller for an implantable medical device including a housing sized and configured to be received within a patient, the housing having a thermally conductive shell defining an exterior surface. At least a portion of the exterior surface of the thermally conductive shell defines at least one from the group consisting of a plurality of corrugations and a plurality of protuberances.",MEDTRONIC INC,EGGEN MICHAEL D;;CHO YONG K;;KUDLIK D'ANNE E,,https://lens.org/120-834-189-793-704,Patent Application,yes,7,0,4,4,0,H05K5/04;;H05K5/0086;;H05K7/20436;;A61M60/88;;A61M60/876;;A61M60/873;;A61M60/50;;A61M60/237;;A61M60/178;;A61M60/232;;A61M60/422;;A61N1/375;;A61N1/3787;;A61M60/165;;A61M60/232;;A61M60/237;;A61M60/422;;A61M60/508;;A61M60/873;;A61M60/876;;A61M2205/36;;A61M60/90;;A61M60/178;;A61M60/50;;A61M2205/0233;;A61M2205/8206;;A61M60/50;;A61M60/232;;A61M60/237;;A61M60/178;;A61M60/873;;A61M60/876;;A61M60/422,A61M1/12;;A61M1/10;;A61N1/375;;A61N1/378,,0,0,,,,PENDING
392,EP,B1,EP 0521994 B1,150-422-375-628-873,1997-06-18,1997,EP 91907052 A,1991-04-02,GB 9100510 W;;GB 9007052 A,1990-03-29,PHARMACEUTICAL FORMULATIONS,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/150-422-375-628-873,Granted Patent,yes,8,2,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
393,CS,A2,CS 88091 A2,001-050-076-994-673,1991-11-12,1991,CS 88091 A,1991-03-29,GB 9007052 A,1990-03-29,PHARMACEUTICALS,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/001-050-076-994-673,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,PENDING
394,PT,E,PT 2596004 E,069-152-888-717-81X,2014-11-28,2014,PT 11743400 T,2011-07-19,US 36562110 P,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,,GILEAD SCIENCES INC,CHO AESOP;;WOLCKENHAUER SCOTT ALAN;;CLARKE MICHAEL O'NEIL HANRAHAN,,https://lens.org/069-152-888-717-81X,Granted Patent,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,ACTIVE
395,PT,A,PT 97199 A,147-978-894-585-751,1991-11-29,1991,PT 9719991 A,1991-03-28,GB 9007052 A,1990-03-29,PROCESSO PARA A PREPARACAO DE FORMULACOES FARMACEUTICAS A BASE DE LECTICINA OU UM PERCURSOR DE LECTICINA,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/147-978-894-585-751,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/107;;A61K9/00;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
396,DE,A1,DE 102018102027 A1,006-154-701-638-438,2018-08-02,2018,DE 102018102027 A,2018-01-30,US 201715420946 A,2017-01-31,EFFIZIENTES SITUATIONSBEWUSSTSEIN DURCH EREIGNISERZEUGUNG UND EPISODISCHEN SPEICHERABRUF FÜR AUTONOME ANTRIEBSSYSTEME,"Ein System und Verfahren werden zur Datenverarbeitung in einem autonomen Fahrzeugsteuersystem gelehrt. Durch die Verwendung von Informationen aus dem Fahrzeug, der Netzwerkschnittstelle und den am Fahrzeug angebrachten Sensoren kann das System Situationen mit weniger Komplexität bei der Berechnung wahrnehmen, ohne wichtige Details zu verlieren, und dann Navigations- und Steuerungsentscheidungen treffen. Das System und das Verfahren dienen dazu, situationsbewusste Ereignisse zu erzeugen, sie zu speichern und abzurufen, um Situationen für autonomes Fahren vorherzusagen.",GM GLOBAL TECH OPERATIONS LLC,KWON HYUKSEONG;;CHO YOUNGKWAN;;BHATTACHARYYA RAJAN;;DAILY MICHAEL J,,https://lens.org/006-154-701-638-438,Patent Application,no,0,2,5,5,0,G05D1/0016;;G05D1/0022;;B60W30/14;;B60W50/00;;B60W2050/0002;;B60W2050/0075;;B60W2556/50;;G06N5/02;;H04L67/12;;G06N7/01;;G05D1/0088;;G06N5/02;;G06N7/01;;H04L67/12,B60W50/00;;G08G1/16,,0,0,,,,PENDING
397,GR,T3,GR 3024745 T3,045-554-486-683-013,1997-12-31,1997,GR 970402390 T,1997-09-17,GB 9007052 A;;GB 9100510 W,1990-03-29,PHARMACEUTICAL FORMULATIONS,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/045-554-486-683-013,Granted Patent,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
398,AU,B2,AU 2014/374361 B2,053-242-746-558-612,2019-06-13,2019,AU 2014/374361 A,2014-10-31,US 201361922404 P;;US 2014/0063316 W,2013-12-31,Self-powered analyte sensor and devices using the same,"Systems, devices and methods for monitoring analyte levels using a self-powered analyte sensor and associated sensor electronics are provided.",ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,,https://lens.org/053-242-746-558-612,Granted Patent,no,1,0,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/1468;;A61B5/1473,,3,3,061-673-085-468-891;;032-671-962-318-721;;102-991-560-295-985,10.1016/j.bios.2008.09.014;;19013784;;pmc3208857;;22027294;;10.1177/193229681100500502;;17166711;;10.1016/j.bios.2006.11.004,"Hanashi T et al, ""BioCapacitor-A novel category of biosensor"", Biosensors And Bioelectronics, Elsevier, vol. 24, no. 7, 15 March 2009, pages 1837-1842;;Hanashi T et al, ""BioRadioTransmitter: a self-powered wireless glucose-sensing system"", Journal of Diabetes Science and Technoly. Volume 5, Issue 5, September 2011, pages 1030-1035.;;Kakehi N et al, ""A novel wireless glucose sensor employing direct electron transfer principle based enzyme fuel cell"", Biosensors and Bioelectronics 22, 2007, pages 2250-2255",INACTIVE
399,EP,A4,EP 3903099 A4,085-652-200-533-176,2022-09-28,2022,EP 19904747 A,2019-12-04,US 201816231895 A;;US 2019/0064453 W,2018-12-24,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT OF INTEREST,,ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;THORNTON MICHAEL M,,https://lens.org/085-652-200-533-176,Search Report,no,3,0,7,7,0,A61B8/00;;A61B5/0093;;A61B5/4872;;A61B5/7235;;A61B5/7278;;A61B8/5261;;A61B5/4244;;A61B5/0093;;A61B5/4872;;A61B5/489;;A61B2576/02;;A61B5/4244;;A61B5/7235;;A61B5/7278;;A61B5/201,G01N29/24;;A61B5/00;;A61B8/00;;A61B8/08,,1,0,,,See also references of WO 2020139529A1,DISCONTINUED
400,US,A1,US 2020/0205668 A1,132-948-843-398-399,2020-07-02,2020,US 201816233935 A,2018-12-27,US 201816233935 A,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,"A thermoacoustic imaging system and method for monitoring tissue temperature within a region of interest, which has an object of interest and a reference that are separated by at least one boundary. The system and method include a thermoacoustic imaging system with an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein, an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest, and one or more processors that process at least one received bipolar acoustic signal generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof and calculate a temperature at the at least one boundary using the peak-to-peak amplitude of the at least one bipolar acoustic signal.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/132-948-843-398-399,Patent Application,yes,0,1,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B5/00;;A61B5/01;;A61B5/20,,0,0,,,,ACTIVE
401,AU,B2,AU 656134 B2,150-306-120-610-761,1995-01-27,1995,AU 1991/075842 A,1991-04-02,GB 9007052 A;;GB 9100510 W,1990-03-29,Pharmaceutical formulations,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/150-306-120-610-761,Granted Patent,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
402,US,A1,US 2020/0384174 A1,039-238-329-304-823,2020-12-10,2020,US 202016885363 A,2020-05-28,US 202016885363 A;;US 201962858374 P,2019-06-07,SHIELD OPTIMIZATION FOR MAXIMIZING HEAT DISSIPATION AT THE DEVICE TISSUE INTERFACE AND IMPROVING FIXATION,"A controller for an implantable medical device including a housing sized and configured to be received within a patient, the housing having a thermally conductive shell defining an exterior surface. At least a portion of the exterior surface of the thermally conductive shell defines at least one from the group consisting of a plurality of corrugations and a plurality of protuberances.",MEDTRONIC INC,EGGEN MICHAEL D;;CHO YONG K;;KUDLIK D'ANNE E,MEDTRONIC INC (2019-06-06),https://lens.org/039-238-329-304-823,Patent Application,yes,0,0,4,4,0,H05K5/04;;H05K5/0086;;H05K7/20436;;A61M60/88;;A61M60/876;;A61M60/873;;A61M60/50;;A61M60/237;;A61M60/178;;A61M60/232;;A61M60/422;;A61N1/375;;A61N1/3787;;A61M60/165;;A61M60/232;;A61M60/237;;A61M60/422;;A61M60/508;;A61M60/873;;A61M60/876;;A61M2205/36;;A61M60/90;;A61M60/178;;A61M60/50;;A61M2205/0233;;A61M2205/8206;;A61M60/50;;A61M60/232;;A61M60/237;;A61M60/178;;A61M60/873;;A61M60/876;;A61M60/422,A61M1/10;;A61M1/12,,0,0,,,,PENDING
403,EP,A1,EP 2265322 A1,051-043-427-503-548,2010-12-29,2010,EP 09720835 A,2009-03-09,US 2009/0036462 W;;US 3595008 P;;US 36332709 A,2008-03-12,SYSTEM AND METHOD FOR CARDIAC LEAD SWITCHING,,MEDTRONIC INC,SOMMER JOHN L;;KIMMEL MICHAEL W;;CHO YONG K,,https://lens.org/051-043-427-503-548,Patent Application,yes,0,0,4,4,0,A61N1/056;;A61N1/37;;A61N1/3718;;A61N1/086;;A61N1/37;;A61N1/056;;A61N1/3718;;A61N1/086,A61N1/05;;A61N1/08;;A61N1/368;;A61N1/37,,0,0,,,,DISCONTINUED
404,AU,A1,AU 2011/282241 A1,052-117-089-048-452,2013-01-31,2013,AU 2011/282241 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,Methods for the preparation of diasteromerically pure phosphoramidate prodrugs,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/052-117-089-048-452,Patent Application,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,ACTIVE
405,DE,D1,DE 69126609 D1,055-787-472-397-761,1997-07-24,1997,DE 69126609 T,1991-04-02,GB 9007052 A;;GB 9100510 W,1990-03-29,PHARMAZEUTISCHE FORMULIERUNGEN,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/055-787-472-397-761,Granted Patent,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,EXPIRED
406,HU,D0,HU 9203093 D0,081-951-117-773-94X,1992-12-28,1992,HU 309392 A,1991-04-02,GB 9007052 A,1990-03-29,MEDICAL PREPARATIVE,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;STEPHERD THOMAS SMITH,,https://lens.org/081-951-117-773-94X,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,DISCONTINUED
407,US,B2,US 11151255 B2,087-786-650-589-632,2021-10-19,2021,US 201816171595 A,2018-10-26,US 201816171595 A,2018-10-26,"Method to securely allow a customer to install and boot their own firmware, without compromising secure boot","In one or more embodiments, one or more systems, methods, and/or process may allow a customer to install and boot their own firmware securely, without compromising secure boot. A baseboard management controller (BMC) may include a BMC firmware stored via a BMC partition of a non-volatile storage, a customer firmware image including a customer firmware and a signed customer boot block (CBB) file including a CBB, a hidden root key (HRK) hash of the CBB based on a HRK, and a manufacturer signature. The BMC firmware may, when an alternate path to boot the CBB is detected, verify the manufacturer signature on the CBB and the HRK hash, verify the HRK hash based on the unique HRK, and when the manufacturer signature and the HRK hash have been verified, hardware lock the BMC partition, disable the HRK, and transfer control to the CBB.",DELL PRODUCTS LP,CHO EUGENE DAVID;;BROWN MICHAEL EMERY;;SAVAGE MARSHAL F,DELL PRODUCTS L.P (2018-10-24),https://lens.org/087-786-650-589-632,Granted Patent,yes,58,1,2,2,0,G06F21/572;;G06F21/572;;G06F21/575;;G06F21/575;;G06F21/602,G06F21/00;;G06F21/57;;G06F21/60,,5,1,112-818-237-189-692,10.17487/rfc5639,"NPL Search (Year: 2021).;;Lochter, Manfred, and Johannes Merkle. Elliptic curve cryptography (ECC) brainpool standard curves and curve generation. No. RFC 5639. 2010; 27 pages.;;Brown, David R. L. “SEC 2: Recommended Elliptic Curve Domain Parameters.” Certicom Research, Version 2.0, Jan. 27, 2010; 37 pages.;;Gallagher, Patrick. “Digital signature standard (DSS).” Federal Information Processing Standards Publications, vol. FIPS (2013); 130 pages.;;Bruce, Schneier. “Applied cryptography; protocols, algorithms, and source code in C.” New York: Wiley (1996); 662 pages.",ACTIVE
408,AT,T1,AT E154515 T1,093-874-506-191-168,1997-07-15,1997,AT 91907052 T,1991-04-02,GB 9007052 A,1990-03-29,PHARMAZEUTISCHE FORMULIERUNGEN,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/093-874-506-191-168,Granted Patent,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,DISCONTINUED
409,EP,A1,EP 3902490 A1,079-911-853-087-288,2021-11-03,2021,EP 19901545 A,2019-12-04,US 201816233935 A;;US 2019/0064447 W,2018-12-27,METHOD AND SYSTEM FOR MONITORING TISSUE TEMPERATURE,,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/079-911-853-087-288,Patent Application,yes,0,0,7,7,0,A61B5/01;;A61B5/0095;;A61B5/7485;;A61B5/4244;;A61B5/201;;A61B5/4519;;A61B5/489;;G01S15/899;;A61B5/0507;;A61B2018/00791;;A61B18/02;;A61B18/04;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4872;;A61B5/489;;A61B5/4836;;A61B5/7278;;A61B5/4519;;A61B8/5261;;A61B8/00,A61B18/12;;A61B18/04;;A61B18/10;;A61B18/14,,0,0,,,,ACTIVE
410,US,A1,US 2018/0217595 A1,108-922-011-906-922,2018-08-02,2018,US 201715420946 A,2017-01-31,US 201715420946 A,2017-01-31,EFFICIENT SITUATIONAL AWARENESS BY EVENT GENERATION AND EPISODIC MEMORY RECALL FOR AUTONOMOUS DRIVING SYSTEMS,"A system and method is taught for data processing in an autonomous vehicle control system. Using information is acquired from the vehicle, network interface, and sensors mounted on the vehicle, the system can perceive situations around it with much less complexity in computation without losing crucial details, and then make navigation and control decisions. The system and method are operative to generate situation aware events, store them, and recall to predict situations for autonomous driving.",GM GLOBAL TECH OPERATIONS LLC,KWON HYUKSEONG;;CHO YOUNGKWAN;;BHATTACHARYYA RAJAN;;DAILY MICHAEL J,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2017-01-31),https://lens.org/108-922-011-906-922,Patent Application,yes,7,19,5,5,0,G05D1/0016;;G05D1/0022;;B60W30/14;;B60W50/00;;B60W2050/0002;;B60W2050/0075;;B60W2556/50;;G06N5/02;;H04L67/12;;G06N7/01;;G05D1/0088;;G06N5/02;;G06N7/01;;H04L67/12,G05D1/00;;G06N7/00,,0,0,,,,ACTIVE
411,EP,A1,EP 4184814 A1,108-892-856-537-626,2023-05-24,2023,EP 21210032 A,2021-11-23,EP 21210032 A,2021-11-23,SECURED CLOCK SYNCHRONIZATION IN A PACKET-COMPATIBLE NETWORK,"There is provided a technique of securing clock synchronization between master clock node (MCN) and client clock node (CCN). During a cycle of exchanging PTP messages between MCN and CCN, MCN generates an associated paired message for each PTP message generated thereby and informative of t 1  or t 4  timestamps provided by MCN and sends each paired message to a validation entity (VE) via a secured channel between MCN and VE. When PTP messages traverse transparent clock nodes (TCN) between MCN and CCN, each TCN generates a paired message for each version of PTP message updated thereby and sends each generated paired message to VE via a secured channel between respective TCN and VE. VE uses the received paired messages to provide a validation of the cycle, wherein synchronization-related task(s) (e.g. clock correction by the client clock node, etc.) are provided only subject to successful validation of the cycle by VE.
",ADVA OPTICAL NETWORKING SE,RABINOVICH MICHAEL;;SERGEEV ANDREW;;CHO JOO YEON;;ZOU SHIHUAN,,https://lens.org/108-892-856-537-626,Patent Application,yes,7,0,2,2,0,H04J3/0667;;H04J3/14;;H04J3/0673;;H04L63/0428;;H04L63/126;;H04J3/0644;;H04J3/0667,H04J3/06;;H04J3/14,,1,1,123-772-947-487-430,10.1109/ispcs.2019.8886641,"SHEREEN EZZELDIN ET AL: ""Next Steps in Security for Time Synchronization: Experiences from implementing IEEE 1588 v2.1"", 2019 IEEE INTERNATIONAL SYMPOSIUM ON PRECISION CLOCK SYNCHRONIZATION FOR MEASUREMENT, CONTROL, AND COMMUNICATION (ISPCS), IEEE, 22 September 2019 (2019-09-22), pages 1 - 6, XP033653610, DOI: 10.1109/ISPCS.2019.8886641",PENDING
412,EP,B1,EP 2596004 B1,190-932-277-450-54X,2014-09-10,2014,EP 11743400 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,,GILEAD SCIENCES INC,CHO AESOP;;WOLCKENHAUER SCOTT ALAN;;CLARKE MICHAEL O'NEIL HANRAHAN,,https://lens.org/190-932-277-450-54X,Granted Patent,yes,4,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,1,0,,,"ALI H M ET AL: ""Quantitative structure-activity relationships (QSAR) of two series of O-aryl or N-aryl O-ethyl phosphoramidate and phosphorodiamidate fungicides incorporating amino acid ethyl esters"", BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, SPRINGER-VERLAG, NE, vol. 65, no. 4, 1 October 2000 (2000-10-01), pages 415-420, XP019698851, ISSN: 1432-0800",ACTIVE
413,KR,A,KR 20130130690 A,175-415-061-670-181,2013-12-02,2013,KR 20137003792 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/175-415-061-670-181,Patent Application,no,1,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07D309/10;;C07H19/02;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,ACTIVE
414,EP,A1,EP 2401032 A1,007-117-728-223-615,2012-01-04,2012,EP 10702960 A,2010-01-28,US 2010/0022345 W;;US 36332109 A,2009-01-30,SYSTEM AND METHOD FOR CARDIAC LEAD SWITCHING,,MEDTRONIC INC,SOMMER JOHN L;;KIMMEL MICHAEL W;;CHO YONG K,,https://lens.org/007-117-728-223-615,Patent Application,yes,0,0,3,3,0,A61N1/056;;A61N1/37;;A61N1/3718;;A61N1/086;;A61N1/37;;A61N1/3718;;A61N1/056;;A61N1/086,A61N1/37;;A61N1/05;;A61N1/08,,0,0,,,,DISCONTINUED
415,CA,A1,CA 2933166 A1,039-278-632-763-375,2015-07-09,2015,CA 2933166 A,2014-10-31,US 201361922404 P;;US 2014/0063316 W,2013-12-31,SELF-POWERED ANALYTE SENSOR AND DEVICES USING THE SAME,"Systems, devices and methods for monitoring analyte levels using a self-powered analyte sensor and associated sensor electronics are provided.",ABBOTT DIABETES CARE INC,FELDMAN BENJAMIN JAY;;HE LEI;;LOVE MICHAEL;;CHO HYUN,,https://lens.org/039-278-632-763-375,Patent Application,no,0,0,18,18,0,A61B5/7235;;A61B5/14546;;A61B2560/0204;;A61B2560/029;;A61B5/6833;;A61B5/0004;;A61B5/1451;;A61B5/1486;;A61B5/7225;;A61B2560/0214;;A61B5/14532;;A61B5/0004;;A61B5/1451;;A61B5/14546;;A61B5/6833;;A61B5/7225;;A61B5/7235;;A61B5/14532;;A61B5/6833;;A61B2560/0204;;A61B5/7225;;A61B2560/0214;;A61B5/0004;;A61B5/14546;;A61B5/7235;;A61B2560/029;;A61B5/1451;;A61B5/1486,A61B5/145;;A61B5/1459;;A61B5/1473,,0,0,,,,ACTIVE
416,US,B2,US 9090642 B2,035-338-780-434-377,2015-07-28,2015,US 201113813886 A,2011-07-19,US 36562110 P;;US 2011/0044581 W;;US 201113813886 A,2010-07-19,Methods for the preparation of diasteromerically pure phosphoramidate prodrugs,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas Ia and Ib: The compounds of Formula Ia and Ib are useful for the treatment Hepatitis C infections.,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN;;GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,GILEAD SCIENCES INC (2013-04-11),https://lens.org/035-338-780-434-377,Granted Patent,yes,99,79,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H21/00;;A61K31/7042;;A61K31/7052;;C07F9/24;;C07F9/6558;;C07F9/6561;;C07H1/00;;C07H19/02;;C07H19/10;;C07H19/20,,100,53,027-304-398-416-113;;101-008-621-057-164;;024-285-408-175-262;;134-099-955-058-048;;051-155-198-430-037;;009-242-541-613-969;;121-949-255-252-540;;004-975-486-556-741;;063-659-079-164-949;;061-123-661-112-505;;066-658-824-265-040;;063-345-122-061-100;;004-232-536-342-462;;004-943-756-337-13X;;079-148-993-650-697;;067-029-972-022-07X;;028-466-258-098-772;;078-621-983-928-020;;084-724-974-677-476;;019-383-263-228-519;;001-893-984-143-028;;026-224-336-608-906;;160-215-119-133-08X;;022-731-713-608-487;;017-694-831-179-969;;054-676-373-133-359;;028-378-891-805-321;;033-890-563-594-59X;;025-792-236-879-10X;;089-242-166-203-205;;008-862-016-228-22X;;003-071-503-249-615;;037-312-338-002-608;;127-015-535-614-541;;128-987-621-757-787;;008-811-925-472-828;;099-574-074-958-524;;007-093-894-738-768;;056-697-725-814-023;;000-754-089-379-839;;052-020-380-633-664;;054-634-923-823-456;;045-807-436-693-988;;163-815-243-462-874;;016-675-247-669-352;;093-231-708-851-022;;060-987-324-803-235;;015-967-001-492-962;;137-403-834-378-953;;009-561-066-190-730;;108-490-019-262-993;;019-016-515-952-657;;015-418-818-374-707,10.1016/s0022-0248(99)00819-2;;10.1081/ncn-120026403;;14680024;;20112915;;10.1021/jm901758f;;pmc2094219;;10.1021/jm060872x;;17034123;;10.1080/07328319308018558;;10.1021/jm060202r;;10.1021/jm060202r.s001;;16884305;;10.1021/jm100803c;;20857959;;10.1016/j.virol.2005.05.008;;15939449;;10.1021/jm00158a012;;3016264;;10.1177/095632029700800610;;10.1021/jm960289o;;8960556;;10.1021/jo0491096;;15357584;;21041908;;pmc7733240;;10.3851/imp1667;;11263895;;10.1021/ol006992v;;10.1099/0022-1317-70-1-37;;2543738;;11418355;;10.1016/s1386-6532(01)00167-6;;11259521;;10.1016/s0166-3542(03)00028-7;;12719002;;10.1021/jm00030a009;;8120868;;10.1038/scientificamerican1099-80;;10533288;;10.3987/rev-08-629;;10.1039/a904065j;;10.1039/a905177e;;10819433;;10.1177/095632020001100201;;10.1002/jps.2600720332;;6842389;;13678190;;10.1039/b305790a;;15633995;;10.1021/jm0400101;;10.1080/15257779508012398;;10.3987/com-91-5946;;10.1021/jm0701021;;17636948;;10.1021/jo00108a031;;8831776;;10.1021/jm9600757;;10.1039/p19840000229;;10.1039/p19850000621;;10.1016/0223-5234(92)90010-x;;8478904;;10.1021/jm00060a013;;10.1039/p19920002345;;10.1002/jhet.5570210313;;1315479;;10.1016/s0065-3527(08)60035-4;;10.1038/nrmicro1645;;17487147;;10.1016/s0008-6215(01)00017-9;;11284507;;10.1080/07328319608002423;;10.1016/s0040-4039(00)73494-0;;10.1002/jhet.5570310415;;8279810;;10.1016/0166-3542(93)90093-x;;3783585;;10.1021/jm00161a017;;10.1016/j.tetlet.2005.04.103;;17262707;;10.1086/511310;;11827565;;10.2165/00003495-200262030-00009;;10.1016/s0168-8278(00)80419-5;;10728798;;10960130;;10.1007/s001280000023;;19725579;;10.1021/jm900447q;;17367121;;10.1021/jm0613370,"Shekunov et al. Journal of Crystal Growth (2000), vol. 211, pp. 122-136.;;Colacino, E. et al., ""Synthesis and Biological Evaluation of Some 5-Nitro- and 5-Amino Derivatives of 2'-Deoxycytidine, 2', 3'-Dideoxyuridine, and 2', 3' -Dideoxycytidine,"" Nucleoside, Nucleotides & Nucleic Acids, vol. 22, No. 11, pp. 2013-2026 (2003).;;El Safadi, Y. et al., ""5-Modified-2'-dU and 2'-dC as Mutagenic Anti HIV-1 Proliferation Agents: Synthesis and Activity,"" J. Med. Chem., vol. 53, No. 4, pp. 1534-1545 (2010).;;Harki, D. et al., ""Synthesis and Antiviral Activity of 5-Substituted Cytidine Analogues: Identification of Potent Inhibitor of Viral RNA-Dependent RNA Polymerases,"" J. Med. Chem., vol. 49, No. 21, pp. 6166-6169 (2006).;;Jasko, M. et al., ""5'-Phosphonates of Ribonucleosides and 2'-Deoxyribonucleosides: Synthesis and Antiviral Activity,"" Nucleosides and Nucleotides, vol. 12, No. 8, pp. 879-893 (1993).;;Meppen, M. et al., ""Medi-404-A Prodrug Approach for the Treatment of HCV Infection,"" Abstracts of Papers, 236th ACS National Meeting, Philadelphia, PA, United States, Aug. 17-21, 2008.;;Poduch, E. et al., ""Design of Inhibitors of Orotidine Monophosphate Decarboxylase Using Bioisosteric Replacement and Determination of Inhibition Kinetics,"" J. Med. Chem., vol. 49, No. 16, pp. 4937-4945 (2006).;;Srivastav, N. et al., ""Antiviral Activity of Various 1-(2'-Deoxy-beta-D-Iyxofuranosyl), 1-(2'-Fluoro-beta-D-xylofuranosyl),1-(3'- Fluoro-beta-D-arabinofuranosyl), and 2'-Fluoro-2',3'-didehydro-2',3'-dideoxyribose Pyrimidine Nucleoside Analogues against Duck Hepatitis B Virus (DHBV) and Human Hepatitis B Virus (HBV) Replication,"" J. Med. Chem., vol. 53, No. 19, pp. 7156-7166 (2010).;;Tapia, N. et al., ""Combination of a Mutagenic Agent with a Reverse Transcriptase Inhibitor Results in Systematic Inhibition of HIV-1 Infection,"" Virology, vol. 338, pp. 1-8 (2005).;;Vaghefi, M. et al.,""Synthesis and Antiviral Activity of Certain Nucleoside 5'-Phosphonoformate Derivatives,"" J. Med. Chem., vol. 29, pp. 1389-1393 (1986).;;Arimilli, MN et al. (1997) ""Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs"", Antiviral Chemistry & Chemotherapy, vol. 8(6), p. 557-564.;;Benzaria, S. et al. (1996) ""Synthesis in Vitro Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derivatives of 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA) as Potential PMEA Prodrugs with Improved Oral Bioavailability"", Journal of Medicinal Chemistry, vol. 39, pp. 4958-4965.;;Bio, M. et al. (2004) ""Practical Synthesis of a Potent Hepatitis C Virus RNA Replication Inhibitor"", Journal of Organic Chemistry, vol. 69, pp. 6257-6266.;;Bobeck D.R. et al. (2010) ""Advances in nucleoside monophosphate prodrugs as anti-HCV agents"", Antiviral Therapy, vol. 15, pp. 935-950.;;Bojack G. et al. (2001), ""Design and Synthesis of Inhibitors of Adenosine and AMP Deaminases"", Organic Letters, vol. 3(6), pp. 839-842.;;International Preliminary Report on Patentability and Written Opinion for PCT/US2009/041432, mailed Oct. 26, 2010 (7 pages).;;Calisher, C. et al. (1989) ""Antigenic Relationships between Flaviviruses as Determined by Cross-neutralization Tests with Polyclonal Antisera"", Journal of General Virology, vol. 70, pp. 37-43.;;De Clercq, E. (2001) ""Antiviral drugs: current state of the art"", Journal of Clinical Virology, vol. 22, pp. 73-89.;;De Clercq, E. (2001) ""Molecular Targets for Antiviral Agents"" The Journal of Pharmacology and Experimental Therapeutics, vol. 297(1), pp. 1-10.;;De Francesco, R. et al. (2003) ""Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase"", Antiviral Research , vol. 58, pp. 1-16.;;De Lombaert, S. et al. (1994) ""N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors"", Journal of Medicinal Chemistry, vol. 37, pp. 498-511.;;Di Bisceglie, A. et al. (Oct. 1999) ""The Unmet Challenges of Hepatitis C"", Scientific American, Inc. pp. 80-85.;;Dolzhenko, A.V. et al. (2008) ""Pyrazolo[1,5-a][1,3,5]Triazines(5-AZA-9-Deazapurines):Synthesis and Biological Activity"", Heterocycles, vol. 75, No. 7, pp. 1575-1622.;;Dudfield, P. et al. (1999) ""Synthesis of C- ribosyl imidazo[2,1-f][1,2,4]triazines as inhibitors of adenosine and AMP deaminases,"" J. Chem. Soc, Perkin Trans. 1, pp. 2929-2936.;;Dudfield, P.J. et al. (1999) ""Synthesis of C-ribosyl 1,2,4-triazolo[3,4-f][1,2,4]triazines as inhibitors of adenosine and AMP deaminases"", J. Chem. Soc., Perkin Trans. 1, pp. 2937-2942.;;Dymock, B. et al. (2000) ""Novel approaches to the treatment of hepatits C virus infection"", Antiviral Chemistry & Chemotherapy, vol. 11, pp. 79-96.;;Farquhar, D. et al. (1983), ""Biologically Reversible Phosphate-Protective Groups"", Journal of Pharmaceutical Sciences, vol. 72, No. 3, pp. 324-325.;;Gleeson, P.M. et al. (2003) ""Prediction of the potency of inhibitors of adenosine deaminase by QM/MM calculations,"" Chem. Commun., pp. 2180-2181.;;Gordon, C.P. et al. (2005) ""Control of Hepatitis C: A Medicinal Chemistry Perspective"", Journal of Medicinal Chemistry, vol. 48, No. 1, pp. 1-20.;;Haraguchi, K. et al. (1995) ""Stereoselective Synthesis of 1'-C-Branched Uracil Nucleosides From Uridine,"" Nucleosides & Nucleotides, vol. 14, Nos. 3-5, pp. 417-420.;;Hayashi, M. et al. (1992) ""C-Nucleosides, A Synthesis of 2-Substituted 7-((beta-D-Ribofuranosyl)-Pyrrolo[2,1-f]-1,2,4-Triazines. A New Type of ""Purine Like"" C-Nucleoside,"" Heterocycles, vol. 34, No. 3, pp. 569-574.;;Hecker, S.J.et al. (2007) ""Liver Targeted Prodrugs of 2'-C-Methyladenosine for Therapy of Hepatitis C Virus Infection"", Journal of Medicinal Chemistry, vol. 50, pp. 3891-3896.;;International Search Report for PCT/US2009/041432 mailed on Aug. 11, 2009 (5 pages).;;International Search Report for PCT/US2009/041447, mailed on Aug. 7, 2009 (5 pages).;;International Search Report for PCT/US2010/049471, mailed Nov. 18, 2010 (5 pages).;;International Search Report for PCT/US2010/049508, mailed Nov. 5, 2010 (4 pages).;;Itoh, Y. et al. (1995) ""Divergent and Stereocontrolled Approach to the Synthesis of Uracil Nucleosides Branched at the Anomeric Position,"" J. Org. Chem., vol. 60, pp. 656-662.;;Khamnei, S. et al. (1996) ""Neighboring Group Catalysis in the Design of Nucleotide Prodrugs"", Journal of Medicinal Chemistry, vol. 39, pp. 4109-4115.;;Knutsen, L. et al. (1984) ""Synthesis of Imidazo-fused Bridgehead-nitrogen C-Nucleosides via Dehydrative Coupling Reactions of 2,5-Anhydro-3,4,6-tri-O-benzoyl-D- allonic Acid,"" J. Chem. Soc. Perkin Trans. I, pp. 229-238.;;Knutsen, L. et al. (1985) ""Synthesis of Imidazo-fused Bridgehead-nitrogen C -Nucleosides: Coupling-Elimination Reactions of 2,5-Anhydro-3,4,6-tri-O-benzoyl-D- allonic Acid,"" J. Chem. Soc. Perkin Trans. I, pp. 621-630.;;Kobe, B. et al. (1992) ""Use of distance geometry approach for the in vitro antiviral activity evaluation of N-bridgehead C-nucleosides"", European Journal of Medicinal Chemistry, vol. 27, pp. 259-266.;;McGuigan, C. et al. (1993) ""Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT"", Journal of Medicinal Chemistry, vol. 36, pp. 1048-1052.;;Mitchell, A.G. et al. (1992) ""Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono (4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonoacetate"", J. Chem. Soc. Perkin Trans. 1, pp. 2345-2353.;;Mitchell, W. L. et al. (1984) ""Synthesis of C-Nucleoside Isosteres of 9-(2- Hydroxyethoxymethyl)guanine (Acyclovir) [1]"", Journal of Heterocyclic Chemistry, vol. 21, pp. 697-699.;;Moennig, V. et al. (1992) ""The Pestiviruses"", Advances in Virus Research, vol. 41, pp. 53-98.;;Moradpour, D. et al. (2007) ""Replication of hepatitis C virus"", Nature Reviews Microbiology, vol. 5, pp. 453-463.;;Nishimura, N. et al. (2001) ""Synthesis of pyrrolo[2,1-f][1,2,4]triazine C-nucleosides. Isosteres of sangivamycin, tubercidin, and toyocamycin,"" Carbohydrate Research, vol. 331, pp. 77-82.;;Otter, B. et al. (1996) ""Conformational Properties of Purine-Like C-Nucleosides"", Nucleosides & Nucleotides, vol. 15, Nos. 1-3, pp. 793-807.;;Patil, S. et al. (1994) ""4-Aza-7,9-Dideazaadenosine, a New Cytotoxic Synthetic C-Nucleoside Analogue of Adenosine,"" Tetrahedron Letters, vol. 35, No. 30, pp. 5339-5342.;;Patil, S.A. et al. (1994) ""Synthesis of Pyrrolo[2,1-f][1,2,4]triazine Congeners of Nucleic Acid Purines via the N-Amination of 2-Substituted Pyrroles[1]"", Journal of Heterocyclic Chemistry, vol. 31, pp. 781-786.;;Puech, F. et al. (1993) ""Intracellular delivery of nucleoside monophosphates through a reductase-mediated activiation process"", Antiviral Research, vol. 22, pp. 155-174.;;Ramasamy, K. et al. (1986) ""Synthesis and Antitumor Activity of Certain 3-beta-D-Ribofuranosy1-1,2,4-triazolo[3,4-f]-1,2,4-triazines Related to Formycin Prepared via Ring Closure of a 1,2,4-Triazine Precursor"", Journal of Medicinal Chemistry, vol. 29, pp. 2231-2235.;;Reddy, K.R. et al. (2005) ""Stereoselective synthesis of nucleoside monophosphate HepDirect(TM) Prodrugs"", Tetrahedron Letters, vol. 46, pp. 4321-4324.;;Schul, W. et al. (2007) ""A Dengue Fever Viremia Model in Mice Shows Reduction in Viral Replication and Suppression of the Inflammatory Response after Treatment with Antiviral Drugs"", Journal of Infectious Diseases, vol. 195, pp. 665-674.;;Scott, L. J. et al. (2002) ""Interferon-alpha-2b Plus Ribavirin"", Drugs, vol. 62, No. 3, pp. 507-556.;;International Preliminary Report on Patentability and Written Opinion for PCT/US2010/049471, mailed Mar. 27, 2012 (7 pages).;;International Preliminary Report on Patentability and Written Opinion for PCT/US2010/049508, mailed Mar. 27, 2012 (6 pages).;;Yoshimura, Y. et al. (1996) ""Synthesis and Biological Evaluation of 1'-C-Cyano-Pyrimidine Nucleosides,"" Nucleosides & Nucleotides, vol. 15, Nos. 1-3, pp. 305-324.;;Boyer, N. et al. (2000) ""Pathogenesis, diagnosis and management of hepatitis C"", Journal of Hepatology, vol. 32, Suppl. 1, pp. 98-112.;;Ali, H. M. et al., ""Quantitative Structure-Activity Relationships (QSAR) of Two Series of O-Aryl or N-Aryl O-Ethyl Phosphoramidate and Phosphorodiamidate Fungicides Incorporating Amino Acid Ethyl Esters"", Bulletin of Environmental Contamination and Toxicology, vol. 65, No. 4, pp. 415-420 (2000).;;Gardelli, C., et al., ""Phosphoramidate Prodrugs of 2'-C-Methylcytidine for Therapy of Hepatitis C Virus Infection,"" J Med. Chem., vol. 52, No. 17, pp. 5394-5407 (2009).;;International Preliminary Report on Patentability and Written Opinion of the International Searching Authority in International Application No. PCT/US2011/038253, dated Dec. 4, 2012 (6 pages).;;International Search Report in International Application No. PCT/US2011/038253, dated Jul. 29, 2011 (4 pages).;;International Search Report in International Application No. PCT/US2011/044581, dated Jul. 11, 2011 (4 pages).;;International Preliminary Report on Patentability and Written Opinion of the International Searching Authority in International Application No. PCT/US2011/044581, dated Jan. 22, 2013 (7 pages).;;Perrone, P., et al., ""Application of the Phosphoramidate ProTide Approach to 4'-Azidouridine Confers Sub-micromolar Potency versus Hepatitis C Virus on an Inactive Nucleoside,"" J. Med. Chem., vol. 50, No. 8, pp. 1840-1849 (2007).;;Silverman, R.B., ""The Organic Chemistry of Drug Design and Drug Action,"" 2nd Edition, Elsevier Academic Press, pp. 29-34 (2004).;;Examiner-Initiated Interview Summary dated Nov. 3, 2014 for U.S. Appl. No. 12/886,248 (10 pages).;;Final Rejection mailed Nov. 4, 2014 for U.S. Appl. No. 13/189,373 (11 pages).;;Resolution No. 48031 for CO Patent Application No. 10-121.513, rec'd Oct. 7, 2014 (English translation) (8 pages).;;Office Action for JP Patent Application No. 2013-218129, dated Sep. 29, 2014 (2 pages).;;Office Action for JP Patent Application No. 2013-218139, dated Sep. 29, 2014 (with English translation) (4 pages).;;Fourth Office Action for EA Application No. 201190110/28, dated Nov. 2, 2014 (with English translation) (4 pages).;;Substantive Search and Examination Report for AP/P/2013/006767, dated Nov. 14, 2014 (6 pages).;;Notification of Defects for IL Patent Application No. 218752, dated Sep. 1, 2014 (English translation) (2 pages).;;Extended European Search Report for EP Application No. 14181224.8, dated Oct. 29, 2014 (10 pages).;;Notification of the Second Office Action for CN Patent Application No. 201180035776.1, dated Oct. 30, 2014 (with English transation) (7 pages).;;Notice of Allowance mailed Jan. 6, 2011 for U.S. Appl. No. 12/428,176.;;Notice of Allowance mailed Apr. 12, 2011 for U.S. Appl. No. 12/428,176.;;Office Action mailed Sep. 23, 2011 for U.S. Appl. No. 13/196,117.;;Notice of Allowance mailed Mar. 27, 2012 for U.S. Appl. No. 13/196,117.;;Notice of Allowance mailed Jul. 16, 2012 for U.S. Appl. No. 13/196,117.;;Office Action mailed Jan. 22, 2013 for U.S. Appl. No. 13/649,511.;;Office Action mailed Aug. 15, 2013 for U.S. Appl. No. 13/649,511.;;Notice of Allowance mailed Feb. 13, 2014 for U.S. Appl. No. 13/649,511.;;Notice of Allowance mailed Jun. 3, 2014 for U.S. Appl. No. 13/649,511.;;Office Action mailed Dec. 23, 2010 for U.S. Appl. No. 12/428,234.;;Notice of Allowance mailed Apr. 7, 2011 for U.S. Appl. No. 12/428,234.;;Office Action mailed Dec. 23, 2010 for U.S. Appl. No. 12/702,957.;;Notice of Allowance mailed Apr. 26, 2011 for U.S. Appl. No. 12/702,957.;;Notice of Allowance mailed Feb. 17, 2011 for U.S. Appl. No. 12/885,917.;;Office Action mailed Mar. 27, 2012 for U.S. Appl. No. 13/050,820.;;Office Action mailed Oct. 16, 2012 for U.S. Appl. No. 13/050,820.;;Notice of Allowance mailed Jan. 31, 2013 for U.S. Appl. No. 13/050,820.;;Office Action (Restriction Requirement) mailed Sep. 14, 2012 for U.S. Appl. No. 12/886,248.;;Office Action mailed Nov. 6, 2012 for U.S. Appl. No. 12/886,248.;;Office Action mailed Mar. 4, 2013 for U.S. Appl. No. 12/886,248.;;Final Rejection mailed Aug. 21, 2014 for U.S. Appl. No. 12/886,248.;;Notice of Allowance mailed Aug. 10, 2012 for U.S. Appl. No. 13/117,060.;;Notice of Allowance mailed Nov. 28, 2012 for U.S. Appl. No. 13/117,060.",ACTIVE
417,CO,A2,CO 6680607 A2,053-602-772-200-530,2013-05-31,2013,CO 13004205 A,2013-01-10,US 36562110 P,2010-07-19,Métodos para la preparación de profármacos de fosforamidato diastereoméricamente puros,Se proporcionan métodos e intermedios para preparar profármacos de fosforamidato diastereoméricamente puros de nucleásidos de Fórmulas (la) y (Ib):Los compuestos de Fórmula la y lb son útiles para el tratamiento de las infecciones por hepatitis C.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL ONEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/053-602-772-200-530,Patent Application,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,PENDING
418,WO,A2,WO 2019/157006 A2,063-476-463-029-037,2019-08-15,2019,US 2019/0016766 W,2019-02-06,US 201815894100 A,2018-02-12,A METHOD FOR OBTAINING THERMOACOUSTIC DATA,"A method of obtaining thermoacoustic data comprises obtaining ultrasound data of a region of interest using at least one ultrasound transducer array, the at least one ultrasound transducer array mechanically connected to at least one thermoacoustic transducer array such that a centerline of the at least one thermoacoustic transducer array is at a known angle with respect to a centerline of the at least one ultrasound transducer array, adjusting a position of the at least one ultrasound transducer array to orient the at least one thermoacoustic transducer array in at least one imaging position based on the known angle, and obtaining thermoacoustic data of the region of interest at the at least one imaging position using the at least one thermoacoustic transducer array.",ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;THORNTON MICHAEL M;;BELANGER SCOTT PATRICK,,https://lens.org/063-476-463-029-037,Patent Application,yes,0,0,3,3,0,A61B8/0833;;A61B8/54;;A61B5/0095;;A61B5/4872;;A61B8/085;;A61B8/14;;A61B8/4416;;A61B8/4477;;A61B8/4494;;A61B8/4494;;A61B8/469,A61B8/08,,0,0,,,,PENDING
419,US,A1,US 2017/0351836 A1,078-649-716-218-918,2017-12-07,2017,US 201715614125 A,2017-06-05,US 201715614125 A;;US 201662345814 P,2016-06-05,METHOD AND SYSTEM FOR ESTIMATING FRACTIONAL FAT CONTENT OF AN OBJECT,"A method for estimating fractional fat content of an object of interest is described. The method comprises obtaining thermoacoustic data of a region of interest containing an object of interest and a reference, and estimating fractional fat content of the object of interest using the thermoacoustic data and at least one parameter of the reference.",ENDRA INC,THORNTON MICHAEL M;;CHO JANG HWAN;;MORDOVANAKIS AGHAPI G,ENDRA LIFE SCIENCES INC (2018-05-23),https://lens.org/078-649-716-218-918,Patent Application,yes,2,24,5,5,0,A61B5/0022;;A61B5/0093;;A61B8/0891;;A61B8/4416;;A61B8/4488;;A61B8/488;;A61B8/5246;;G06T2207/30101;;G06T7/12;;G16H50/30;;A61B5/4244;;A61B5/4872;;A61B8/085;;A61B5/0093;;A61B8/4488;;A61B5/0022;;A61B8/488;;A61B8/4416;;A61B8/5246;;A61B8/0891;;G06T2207/30101;;G06T7/12;;G16H50/30;;A61B5/4244;;A61B5/4872;;A61B8/085,G06F19/00;;A61B5/00;;A61B8/08,,1,1,074-947-514-695-425,10.1063/1.4737414,"Bauer et al (2012) Spectroscopic thermoacoustic imaging of water and fat composition. Applied Physics Lters. 101,033705.",DISCONTINUED
420,KR,A,KR 20190077606 A,085-511-926-518-144,2019-07-03,2019,KR 20197018279 A,2011-07-19,US 36562110 P;;US 2011/0044581 W,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,화학식 (Ia) 또는 (Ib)의 뉴클레오사이드의 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물 제조를 위한 방법 및 중간체가 제공된다:화학식 (Ia)화학식 (Ib) 화학식 (Ia) 또는 (Ib)의 화합물은 C형 간염 감염 치료에 유용하다.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O'NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/085-511-926-518-144,Patent Application,no,2,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,ACTIVE
421,US,B1,US 10631734 B1,090-573-432-910-132,2020-04-28,2020,US 201816233959 A,2018-12-27,US 201816233959 A,2018-12-27,Method and system for monitoring tissue temperature,A system and method utilizing thermoacoustic imaging to estimating tissue temperature within a region of interest that includes an object of interest and a reference which are separated by at least one boundary located at least at two boundary locations. The system and method use a thermoacoustic imaging system that includes an adjustable radio frequency (RF) applicator configured to emit RF energy pulses into the tissue region of interest and heat tissue therein and an acoustic receiver configured to receive bipolar acoustic signals generated in response to heating of tissue in the region of interest; and one or more processors that are able to: process received bipolar acoustic generated in the region of interest in response to the RF energy pulses to determine a peak-to-peak amplitude thereof; and calculate a temperature at the at least two boundary locations using the peak-to-peak amplitudes of the bipolar acoustic signals and a distance between the boundary locations.,ENDRA LIFE SCIENCES INC,CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/090-573-432-910-132,Granted Patent,yes,6,2,11,13,0,G01K11/22;;G01K13/20;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B5/4519;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B2576/00;;A61B5/0093;;A61B5/015;;A61B5/201;;A61B5/4244;;A61B2576/00;;A61B5/4836;;A61B5/4872;;A61B5/489;;A61B5/7278;;A61B5/4519,A61B5/05;;A61B5/00;;A61B5/01;;A61B5/20,,7,7,033-786-059-395-583;;003-447-272-638-21X;;012-545-815-382-384;;142-401-383-484-74X;;010-411-063-187-44X;;013-000-205-460-222;;093-756-081-427-464,10.1109/tbme.2012.2210218;;22851231;;10841427;;10.1118/1.598984;;28066714;;10.1016/j.pacs.2016.10.001;;pmc5200938;;8938024;;10.1088/0031-9155/41/11/001;;10.1088/0031-9155/41/11/002;;8938025;;pmc2774978;;19895126;;10.1117/1.3247155;;10.3109/02656731003592035;;20345268,"X. Wang et al., “Microwave-induced thermoacoustic imaging model for potential breast cancer detection,” IEEE Trans. Biomed. Eng., vol. 59, No. 10, pp. 2782-2791, Oct. 2012.;;G. Ku and L. V. Wang, “Scanning thermoacoustic tomography in biological tissue,” Med. Phys., vol. 27, No. 5, pp. 1195-202, May 2000.;;X. L. Dean-Ben, “On the link between the speckle free nature of optoacoustics and visibility of structures in limited-view tomography,” Photoacoustics, vol. 4, No. 4, pp. 133-140, Jul. 2016.;;C. Gabriel et al., “The dielectric properties of biological tissues: I. Literature survey,” Med. Phys., vol. 41, No. 11, pp. 2231-2249, Nov. 1996.;;S. Gabriel et al., “The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz,” Med. Phys., vol. 41, No. 11, pp. 2251-2269, Nov. 1996.;;M. Pramanik et al., “Thermoacoustic and photoacoustic sensing of temperature,” J. of Biomedical Optics, vol. 14, No. 5, Sep. 2009.;;C. Lou et al., “Temperature monitoring utilising thermoacoustic signals during pulsed microwave thermotherapy: A feasibility study,” Int. J. Hyperthermia, vol. 26, No. 4, pp. 338-346, 2010.",ACTIVE
422,FI,A0,FI 924340 A0,091-447-343-924-718,1992-09-28,1992,FI 924340 A,1992-09-28,GB 9007052 A;;GB 9100510 W,1990-03-29,FARMACEUTISKA BEREDNINGAR.,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/091-447-343-924-718,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/00;;A61K9/107;;A61K9/16;;A61K38/18;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,PENDING
423,SG,A1,SG 54998 A1,100-619-153-191-237,1998-12-21,1998,SG 1996000854 A,1991-04-02,GB 9007052 A,1990-03-29,Pharmaceutical formulations,"A Pharmaceutical formulation comprises a biologically active material such as insulin, erythropoietin, calcitonin and growth hormone, and, associated with it, a phospholipid for forming a material which participates in the alpha-glycerol or other pathways for the formation of lecithins which are found in the intestinal epithelial cell. Biologically active protein orally administered in such a formulation are bioavailable and bioactive.",SKUA INVESTMENTS LTD,CHO YOUNG W;;FLYNN MICHAEL JOHN;;SHEPHERD THOMAS SMITH,,https://lens.org/100-619-153-191-237,Patent Application,no,0,0,33,33,0,A61K9/1075;;A61K9/1617;;A61K38/1816;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/24;;B82Y5/00;;B82Y5/00;;A61K9/1075;;A61K38/28;;A61K38/27;;A61K38/1816;;A61K9/1617;;A61K38/23;;A61K47/24,A61K9/107;;A61K9/16;;A61K38/18;;A61K9/00;;A61K38/22;;A61K38/23;;A61K38/27;;A61K38/28;;A61K47/00;;A61K47/24,,0,0,,,,PENDING
424,US,A1,US 2009/0234405 A1,148-735-469-685-815,2009-09-17,2009,US 36332709 A,2009-01-30,US 36332709 A;;US 3595008 P,2008-03-12,SYSTEM AND METHOD FOR CARDIAC LEAD SWITCHING,"An implantable medical device (IMD) can include an implantable pulse generator (IPG), such as a cardiac pacemaker or an implantable cardioverter-defibrillator (ICD). Various portions of the IMD, such as a device body, a lead body, or a lead tip, can be provided to reduce or dissipate a current and heat induced by various external environmental factors. According to various embodiments, features can be incorporated into the lead body, the lead tip, or the IMD body to reduce the creation of an induced current, or dissipate the induced current and heat created due to an induced current in the lead.",MEDTRONIC INC,SOMMER JOHN LOUIS;;KIMMEL MICHAEL WILLIAM;;CHO YONG KYUN,MEDTRONIC INC (2009-01-27),https://lens.org/148-735-469-685-815,Patent Application,yes,9,10,4,4,0,A61N1/056;;A61N1/37;;A61N1/3718;;A61N1/086;;A61N1/37;;A61N1/056;;A61N1/3718;;A61N1/086,A61N1/00;;A61N1/362,607/11;;607/30,0,0,,,,INACTIVE
425,US,A,US 4626775 A,193-193-941-392-310,1986-12-02,1986,US 60708784 A,1984-05-04,US 60708784 A,1984-05-04,Radio frequency probing apparatus for surface acoustic wave devices,Wafer probing apparatus especially adapted to probing surface acoustic wave (SAW) device die such as delay lines is disclosed; the apparatus includes a probe card especially suited to the radio frequency and multiple output nature of a SAW delay line together with a computer-aided electronic system for exciting the delay line and evaluating its output.,US AIR FORCE,CHO FREDERICK Y;;ADAMO MICHAEL D;;LEESON DAVID E,,https://lens.org/193-193-941-392-310,Granted Patent,yes,8,42,1,1,0,G01R31/2834;;G01R31/2834;;G01R1/07342;;G01R1/07342,G01R1/073;;G01R31/28,324 73R;;X324158F;;X324158P;;X324158R,1,0,,,"Faran, Jr., J. J.; Methods of Assignments . . . ; 1982 IEEE Test Conference; 1982; pp. 641 647.",EXPIRED
426,CA,A1,CA 3202931 A1,129-762-101-142-892,2022-06-09,2022,CA 3202931 A,2021-11-30,US 202063120529 P;;US 2021/0061149 W,2020-12-02,"AN APPARATUS CONFIGURED TO DRIVE AN OBJECT IN ONE LUMEN, VIA A DRIVER IN ANOTHER LUMEN","An apparatus and methods of use thereof, the apparatus comprising: a medical device, configured to reside and to be manipulated within a first lumen; and a driving system, configured to manipulate- and/or control- the medical device, via a second lumen. The driving system comprising: a catheter, configured to be inserted into- and to navigate- or to be navigated- within the second lumen; and a driver, configured to travel within the catheter, and to remotely manipulate- and/or control- the medical device residing in the first lumen.",BIONAUT LABS LTD,CROS FLORENT;;KISELYOV ALEX;;CHO SUEHYUN;;KARDOSH MICHAEL;;SHPIGELMACHER MICHAEL;;KATZNELSON BE'ERI BERL,,https://lens.org/129-762-101-142-892,Patent Application,no,0,0,5,5,0,A61B10/0233;;A61B34/73;;A61B2034/303;;A61M25/0127;;A61B2090/3782,A61B34/30;;A61B10/02;;A61M37/00,,0,0,,,,PENDING
427,EP,A1,EP 4255333 A1,096-972-070-708-063,2023-10-11,2023,EP 21901313 A,2021-11-30,US 202063120529 P;;US 2021/0061149 W,2020-12-02,"AN APPARATUS CONFIGURED TO DRIVE AN OBJECT IN ONE LUMEN, VIA A DRIVER IN ANOTHER LUMEN",,BIONAUT LABS LTD,CROS FLORENT;;KISELYOV ALEX;;CHO SUEHYUN;;KARDOSH MICHAEL;;SHPIGELMACHER MICHAEL;;KATZNELSON BE'ERI BERL,,https://lens.org/096-972-070-708-063,Patent Application,yes,0,0,5,5,0,A61B10/0233;;A61B34/73;;A61B2034/303;;A61M25/0127;;A61B2090/3782,A61B34/30;;A61B10/02;;A61M37/00,,0,0,,,,PENDING
428,US,A1,US 2021/0254522 A1,108-163-219-297-279,2021-08-19,2021,US 202117178048 A,2021-02-17,US 202117178048 A;;US 202062978232 P,2020-02-18,IMPACT ENERGY ABSORBER WITH INTEGRATED ENGINE EXHAUST NOISE MUFFLER,"Multifunction noise suppression and crash structures are disclosed. In one aspect of the disclosure, the multifunction structure includes a body, inlet and outlet pipes, and a plurality of walls within the body that bound resonator cells and that are configured to suppress exhaust noise passing through the resonator cells from the inlet to the outlet pipes. The structure may be positioned between crash rails at the rear of the vehicle and between the engine and bumper. The walls may be generally aligned with, or near, the predicted impact direction and they may crumple in a controlled manner during an impact. In various embodiments the structure is 3D printed to enable construction of a wide diversity of geometric topologies and to minimize mass.",DIVERGENT TECH INC,MARTINEZ ANTONIO BERNERD;;CHO YONG-BAE;;BUCKNELL JOHN RUSSELL;;VASILE MICHAEL;;BOLTON MICHAEL,DIVERGENT TECHNOLOGIES INC (2021-01-04),https://lens.org/108-163-219-297-279,Patent Application,yes,13,2,6,6,0,F01N1/02;;F01N2490/15;;B60R13/0876;;B33Y80/00;;Y02P10/25;;G10K11/161;;G10K11/172;;B22F10/28;;B22F5/10;;B22F10/68;;F01N1/026;;F01N1/02;;F01N13/1811;;B22F10/28;;B22F10/68;;B22F5/10;;B60R13/0876;;B60R19/02;;B62D21/152;;G10K11/162;;G10K11/161;;G10K11/172;;F01N2490/15;;F01N2470/02;;B33Y80/00;;Y02P10/25;;F01N1/02;;F01N13/1811;;B60R19/02;;F01N2470/02;;B33Y80/00;;G10K11/162;;G10K11/172;;B62D21/152,F01N1/02;;B33Y80/00;;B60R19/02;;B62D21/15;;F01N13/18;;G10K11/162;;G10K11/172,,3,0,,,"English translation of DE-102013223733-A1, accessed 2/24/2023 via USPTO Search Tool (Year: 2014);;English translation of FR-2873746-A1, accessed 2/24/2023 via USPTO Search Tool (Year: 2006);;Joe Clifford, ""Toyota MR2: a Midship Runabout 2-seater history,"" 25 February 2015, page 12, <https://mag.toyota.co.uk/toyota-mr2-history/> (Year: 2015)",PENDING
429,WO,A1,WO 2021/168152 A1,130-832-385-033-511,2021-08-26,2021,US 2021/0018628 W,2021-02-18,US 202062978232 P;;US 202117178048 A,2020-02-18,IMPACT ENERGY ABSORBER WITH INTEGRATED ENGINE EXHAUST NOISE MUFFLER,"Multifunction noise suppression and crash structures are disclosed. In one aspect of the disclosure, the multifunction structure includes a body, inlet and outlet pipes, and a plurality of walls within the body that bound resonator cells and that are configured to suppress exhaust noise passing through the resonator cells from the inlet to the outlet pipes. The structure may be positioned between crash rails at the rear of the vehicle and between the engine and bumper. The walls may be generally aligned with, or near, the predicted impact direction and they may crumple in a controlled manner during an impact. In various embodiments the structure is 3D printed to enable construction of a wide diversity of geometric topologies and to minimize mass.",DIVERGENT TECH INC,MARTINEZ ANTONIO BERNERD;;CHO YONG-BAE;;BUCKNELL JOHN RUSSELL;;VASILE MICHAEL;;BOLTON MICHAEL,,https://lens.org/130-832-385-033-511,Patent Application,yes,6,0,6,6,0,F01N1/02;;F01N2490/15;;B60R13/0876;;B33Y80/00;;Y02P10/25;;G10K11/161;;G10K11/172;;B22F10/28;;B22F5/10;;B22F10/68;;F01N1/026;;F01N1/02;;F01N13/1811;;B22F10/28;;B22F10/68;;B22F5/10;;B60R13/0876;;B60R19/02;;B62D21/152;;G10K11/162;;G10K11/161;;G10K11/172;;F01N2490/15;;F01N2470/02;;B33Y80/00;;Y02P10/25;;F01N1/02;;F01N13/1811;;B60R19/02;;F01N2470/02;;B33Y80/00;;G10K11/162;;G10K11/172;;B62D21/152,F01N1/00;;F01N1/02,,1,0,,,"RICHARDOT AMANDINE: ""Our best tips to optimize your designs for 3D printer powder removal"", 26 March 2018 (2018-03-26), XP055850332, Retrieved from the Internet <URL:https://www.sculpteo.com/blog/2018/03/26/our-best-tips-to-optimize-your-designs-for-3d-printer-powder-removal>",PENDING
430,EP,A1,EP 4107375 A1,005-730-198-867-538,2022-12-28,2022,EP 21756974 A,2021-02-18,US 202062978232 P;;US 202117178048 A;;US 2021/0018628 W,2020-02-18,IMPACT ENERGY ABSORBER WITH INTEGRATED ENGINE EXHAUST NOISE MUFFLER,,DIVERGENT TECH INC,MARTINEZ ANTONIO BERNERD;;CHO YONG-BAE;;BUCKNELL JOHN RUSSELL;;VASILE MICHAEL;;BOLTON MICHAEL,,https://lens.org/005-730-198-867-538,Patent Application,yes,0,0,6,6,0,F01N1/02;;F01N2490/15;;B60R13/0876;;B33Y80/00;;Y02P10/25;;G10K11/161;;G10K11/172;;B22F10/28;;B22F5/10;;B22F10/68;;F01N1/026;;F01N1/02;;F01N13/1811;;B22F10/28;;B22F10/68;;B22F5/10;;B60R13/0876;;B60R19/02;;B62D21/152;;G10K11/162;;G10K11/161;;G10K11/172;;F01N2490/15;;F01N2470/02;;B33Y80/00;;Y02P10/25;;F01N1/02;;F01N13/1811;;B60R19/02;;F01N2470/02;;B33Y80/00;;G10K11/162;;G10K11/172;;B62D21/152,F01N1/00;;F01N1/02,,0,0,,,,PENDING
431,KR,A,KR 20220134768 A,073-119-635-889-146,2022-10-05,2022,KR 20227029731 A,2021-02-18,US 202062978232 P;;US 202117178048 A;;US 2021/0018628 W,2020-02-18,통합된 엔진 배기 노이즈 머플러를 갖는 충격 에너지 흡수기,"다기능 노이즈 억제 및 크래시 구조체들이 개시된다. 본 개시의 일 양상에서, 다기능 구조체는 본체, 입구 및 출구 파이프, 및 공진기 셀들을 한정하고 입구 파이프로부터 출구 파이프로 공진기 셀들을 통과하는 배기 노이즈를 억제하도록 구성된 본체 내의 복수의 벽을 포함한다. 구조체는 차량 후방의 크래시 레일들 사이에 그리고 엔진과 범퍼 사이에 위치설정될 수 있다. 벽들은 일반적으로 예측된 충격 방향과 정렬되거나 그 근처에 있을 수 있고, 그것들은 충격 동안 제어된 방식으로 구겨질 수 있다. 다양한 실시예들에서, 구조체는 매우 폭넓게 다양한 기하학적 토폴로지의 구성을 가능하게 하고 질량을 최소화하도록 3D 프린팅된다.",DIVERGENT TECH INC,MARTINEZ ANTONIO BERNERD;;CHO YONG BAE;;BUCKNELL JOHN RUSSELL;;VASILE MICHAEL;;BOLTON MICHAEL,,https://lens.org/073-119-635-889-146,Patent Application,no,0,0,6,6,0,F01N1/02;;F01N2490/15;;B60R13/0876;;B33Y80/00;;Y02P10/25;;G10K11/161;;G10K11/172;;B22F10/28;;B22F5/10;;B22F10/68;;F01N1/026;;F01N1/02;;F01N13/1811;;B22F10/28;;B22F10/68;;B22F5/10;;B60R13/0876;;B60R19/02;;B62D21/152;;G10K11/162;;G10K11/161;;G10K11/172;;F01N2490/15;;F01N2470/02;;B33Y80/00;;Y02P10/25;;F01N1/02;;F01N13/1811;;B60R19/02;;F01N2470/02;;B33Y80/00;;G10K11/162;;G10K11/172;;B62D21/152,F01N1/02;;B22F5/10;;B22F10/28;;B22F10/68;;B60R13/08;;B60R19/02;;B62D21/15;;F01N13/18;;G10K11/16;;G10K11/162;;G10K11/172,,0,0,,,,PENDING
432,WO,A1,WO 2022/119816 A1,003-787-268-000-089,2022-06-09,2022,US 2021/0061149 W,2021-11-30,US 202063120529 P,2020-12-02,"AN APPARATUS CONFIGURED TO DRIVE AN OBJECT IN ONE LUMEN, VIA A DRIVER IN ANOTHER LUMEN","An apparatus and methods of use thereof, the apparatus comprising: a medical device, configured to reside and to be manipulated within a first lumen; and a driving system, configured to manipulate- and/or control- the medical device, via a second lumen. The driving system comprising: a catheter, configured to be inserted into- and to navigate- or to be navigated- within the second lumen; and a driver, configured to travel within the catheter, and to remotely manipulate- and/or control- the medical device residing in the first lumen.",BIONAUT LABS LTD;;CROS FLORENT;;KISELYOV ALEX;;CHO SUEHYUN;;KARDOSH MICHAEL;;SHPIGELMACHER MICHAEL;;KATZNELSON BEERI BERL,CROS FLORENT;;KISELYOV ALEX;;CHO SUEHYUN;;KARDOSH MICHAEL;;SHPIGELMACHER MICHAEL;;KATZNELSON BE'ERI BERL,,https://lens.org/003-787-268-000-089,Patent Application,yes,3,1,5,5,0,A61B10/0233;;A61B34/73;;A61B2034/303;;A61M25/0127;;A61B2090/3782,A61B34/30;;A61B10/02;;A61M37/00,,0,0,,,,PENDING
433,CN,A,CN 115176074 A,159-752-035-462-191,2022-10-11,2022,CN 202180015425 A,2021-02-18,US 202062978232 P;;US 202117178048 A;;US 2021/0018628 W,2020-02-18,Impact energy absorber with integrated engine exhaust noise muffler,"The invention relates to a multifunctional noise suppression and collision avoidance structure. In one aspect of the present disclosure, a multifunctional structure includes a body, an inlet duct and an outlet duct, and a plurality of walls within the body defining a resonator unit and configured to suppress exhaust noise passing through the resonator unit from the inlet duct to the outlet duct. The structure may be positioned between impact beams at a rear side of the vehicle and between an engine and a bumper. The walls may typically be aligned or proximate to a predicted impact direction, and the walls may wrinkle in a controlled manner during the impact. In various embodiments, the structure is 3D printed so as to be able to construct a wide variety of geometric topologies and minimize mass.",DIVERGENT TECH INC,MARTINEZ ANTONIO BERNERD;;CHO YONG-BAE;;BUCKNELL JOHN RUSSELL;;VASILE MICHAEL;;BOLTON MICHAEL,,https://lens.org/159-752-035-462-191,Patent Application,no,0,0,6,6,0,F01N1/02;;F01N2490/15;;B60R13/0876;;B33Y80/00;;Y02P10/25;;G10K11/161;;G10K11/172;;B22F10/28;;B22F5/10;;B22F10/68;;F01N1/026;;F01N1/02;;F01N13/1811;;B22F10/28;;B22F10/68;;B22F5/10;;B60R13/0876;;B60R19/02;;B62D21/152;;G10K11/162;;G10K11/161;;G10K11/172;;F01N2490/15;;F01N2470/02;;B33Y80/00;;Y02P10/25;;F01N1/02;;F01N13/1811;;B60R19/02;;F01N2470/02;;B33Y80/00;;G10K11/162;;G10K11/172;;B62D21/152,F01N1/00;;F01N1/02,,0,0,,,,PENDING
434,US,A1,US 2024/0079131 A1,025-383-699-208-890,2024-03-07,2024,US 18240599,2023-08-31,,,SYSTEM AND METHOD FOR REMOTELY CONTROLLING MINIATURE DEVICE WITHIN A PATIENT,"A system for facilitating performing a therapeutic activity at a predetermined treatment site in a patient is provided. The system comprises an elongated miniature device extending along a longitudinal axis spanning between a distal cutting end formed with a sharp cutting portion, and a blunt proximal abutting end. The elongated body comprises a substantially non-convex bottom surface extending substantially between the cutting end and the abutting end. The system further comprises a driving device configured to generate a varying magnetic field to remotely control motion of the miniature device.",BIONAUT LABS LTD.,Kishore Kumar KONDABATNI;;Michael KARDOSH;;SueHyun CHO;;Florent CROS;;Michael SHPIGELMACHER;;Alex KISELYOV,,https://lens.org/025-383-699-208-890,Patent Application,yes,0,0,1,1,0,G16H40/67;;G16H20/30,G16H40/67;;G16H20/30,,0,0,,,,UNKNOWN
435,US,A1,US 2022/0196445 A1,013-889-677-464-730,2022-06-23,2022,US 202217694897 A,2022-03-15,US 202217694897 A;;US 201916387237 A;;US 201715853391 A;;US 201862658827 P;;US 201662438788 P;;US 201762596737 P,2016-12-23,INSPECTION ROBOT FOR HORIZONTAL TUBE INSPECTION,"Inspection robots for horizontal tube inspection are described. An example inspection robot may include a drive module structured to engage a top tube of a vertically arranged layer of tubes, an encoder, at least one telescoping pole, and a lowering mechanism operationally coupled to the at least one telescoping pole and structured to selectively extend or retract the at least one telescoping pole, thereby providing a selected vertical position of a swappable sensor carriage assembly. The swappable sensor carriage assembly may be coupled to the at least one telescoping pole, and structured to accept at least one of a plurality of sensors, including at least one of an ultrasonic sensor, a laser profiler, or a camera and a light.",GECKO ROBOTICS INC,LOW KEVIN;;BRYNER EDWARD;;MACKENZIE LOGAN;;MOORE JOSHUA;;AUDA MICHAEL S;;CHO MARK;;CHO EDWIN H,GECKO ROBOTICS INC (2019-04-18),https://lens.org/013-889-677-464-730,Patent Application,yes,7,13,4,78,0,G01D11/30;;G01D11/30;;G01B11/24;;B25J9/1679;;B25J15/0019;;G05D3/125,G01D11/30;;B25J9/16;;B25J15/00;;G01B11/24;;G05D3/12,,0,0,,,,ACTIVE
436,US,B2,US 11307063 B2,130-825-595-272-646,2022-04-19,2022,US 201916387237 A,2019-04-17,US 201916387237 A;;US 201715853391 A;;US 201862658827 P;;US 201762596737 P;;US 201662438788 P,2016-12-23,Inspection robot for horizontal tube inspection having vertically positionable sensor carriage,"An inspection apparatus for inspecting horizontal tubes in an industrial environment includes a drive module including a pair of wheels to engage a top tube of a vertically arranged layer of tubes, a telescoping pole, a sensor carriage assembly coupled to the telescoping pole, a lowering mechanism operationally coupled to the telescoping pole to selectively extend or retract the telescoping pole providing a selected vertical position of the sensor carriage assembly, and an encoder including a passive wheel, a spring, and a sliding coupler. The spring biases the passive wheel toward the top tube to ensure contact between the passive wheel and a surface of the top tube.",GECKO ROBOTICS INC;;GTC LAW GROUP PC & AFFILIATES,LOW KEVIN;;BRYNER EDWARD;;MACKENZIE LOGAN;;MOORE JOSHUA;;AUDA MICHAEL S;;CHO MARK;;CHO EDWIN H,GECKO ROBOTICS INC (2019-04-18),https://lens.org/130-825-595-272-646,Granted Patent,yes,223,20,4,78,0,G01D11/30;;G01D11/30;;G01B11/24;;B25J9/1679;;B25J15/0019;;G05D3/125,B25J9/16;;G01D11/30;;B25J15/00;;G01B11/24;;G05D3/12,,47,8,054-540-039-219-971;;053-607-783-158-908;;080-519-814-875-15X;;134-217-287-880-064;;084-515-545-463-225;;096-387-808-699-363;;054-367-401-283-890;;003-586-509-514-11X,10.1109/iros.1993.583934;;10.1109/jsyst.2016.2611244;;10.1109/ifis.1993.324212;;10.1007/978-3-642-10817-4_93;;10.1109/scis-isis.2014.7044830;;10.1109/iros.1994.407566;;15737388;;10.1016/j.ultras.2004.08.001;;10.3390/robotics4020103,"“All Metals Fabrication”, Painting Metal, Aug. 27, 2015.;;“Coordinate Systems in Two and Three Dimensions”, Oregon State University, Department of Mathematics, 2015, 3 pages.;;“Horizontal definition”, Merrian-Webster Dictionary, 2014, 1 page.;;“Vertical Definition”, Merriam Webster, 2014, 1 page.;;Berendsen, “Ship Painting: Current Practice and Systems in Europe”, Technology Publishing Company, Sep. 1998, 10 pages.;;Carlsten, “Understanding Corrosion and How to Protect Against It”, manufacturing.net, Mar. 11, 2002, 8 pages.;;Curran, “Make the right choice for metal coating for the right application”, Design World, Jun. 2, 2016, 18 pages.;;General Electric, “BWCI Automated Boiler Wall Cleaning & Inspection”, inspection-robotics.com, 2016, 4 pages.;;Ginzel, et al., “Acoustic Properties of the Elastomeric Materials Aqualene and ACE”, The e-Journal of Nondestructive Testing—ISSN 1435-4934, Dec. 2015, 13 pages.;;NDT Resource Center, “Transducer Types”, Webpage, 2005, 1 page.;;Olympus, “BondMaster Probes and Accessories Catalog”, Catalog, 2008, 24 pages.;;Olympus, “Flaw Detectors Delay Line”, Olympus, Flaw Detectors Delay Line, 2014, Jan. 9, 2014, 1 page.;;Olympus, “Ultrasonic Transducers Technical Notes”, Notes, 2006.;;PCT/US2017/068326, “International Application Serial No. PCT/US2017/068326, International Search Report and Written Opinion dated May 4, 2018”, Gecko Robotics, Inc., 14 pages.;;PCT/US2017068326, “International Application Serial No. PCT/US2017068326, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Feb. 27, 2018”, Gecko Robotics, Inc., 2 Pages.;;Schroeder, et al., “Ultrasonic Culvert Thickness Determination”, US Army Armament Research Development and Engineering, Technical Report ARCCB-TR-95027, 1995, 36 pages.;;17884897.4 , “European Application Serial No. 17884897.4, Extended European Search Report dated Jun. 25, 2020”, Gecko Robotics, Inc., 5 pages.;;Bell, Stephanie , “Measurement Good Practice Guide A Beginner's Guide to Uncertainty of Measurement”, National Physical Laboratory, Issue 2, 2001, 41 pages.;;Fowler, Kenneih A., et al., “Theory and Application of Precious Ultrasonic Thickness Gaging”, 2015, 12 pages.;;Guglielmelli, E., et al., “Avoiding obstacles by using a proximity US/IR sensitive skin”, IEEE, 1993, pp. 2207-2214.;;Harrison, David M., “Uncertainty in Physical Measurements”, Module 4—Repeated Measurements, Dept. of Physics, Univ. of Toronto, 2015, 18 pages.;;Lebowitz, Carol A., et al., “Ultrasonic Measurement of Pipe Thickness”, Review of Progress in Quantitative Nondestructive Evalualtion, vol. 12, 1987, 8 pages.;;Lins, Romulo Goncalves, et al., “Autonomous Robot System for Inspection of Defects in Civil Infrastructures”, IEEE, 2016, pp. 1414-1422.;;Martinez, Angelo , et al., “Fuzzy logic based collision avoidance for a mobile robot”, IEEE, 1993, pp. 66-69.;;Miskon, Muhammad Fahmi, et al., “Close Range Inspection Using Novelty Detection Results”, Intelligent Robotic Research Center (IRRC), Monash University, Australia, 2009, pp. 947-956.;;PCT/US20/21779 , “International Application Serial No. PCT/US20/21779, International Search Report and Written Opinion dated Sep. 2, 2020”, Gecko Robotics, Inc., 14 pages.;;PCT/US20/21779 , “International Application Serial No. PCT/US20/21779, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jul. 9, 2020”, Gecko Robotics, Inc., 2 pages.;;PCT/US2019/027958 , “International Application Serial No. PCT/US2019/027958, International Preliminary Report on Patentability dated Oct. 29, 2020”, Gecko Robotics, Inc., 8 pages.;;Salik, John , et al., “Pipe Inspections: Robotic Laser Profiling Demystified”, National Precast Concrete Association, Apr. 1, 2013, 12 pages.;;Yasuda, Gen'ichi, “Behavior-based autonomous cooperative control of intelligent mobile robot systems with embedded Petri nets”, IEEE, 2014, pp. 1085-1090.;;“International Federation of Robotics,”, World Robotics, Chapter 1 section 2, 2016, 10 pages.;;“Merriam-Webster”, Definition of Pivot, 2015, 5 pages.;;“Yaskawa Motoman Robotics,”, Robotics Glossary, 2019, 20 pages.;;Lion Precision, “Understanding Sensor Resolution Specifications and Performance”, TechNote, LT05-0010, 2014, pp. 1-6.;;NDT Resource Center, “NDT Glossary D”, Webpage, 2016, 4 pages.;;NDT Resource Center, “NDT Glossary R”, Webpage, 2016, 5 pages.;;Openstax College, “College Physics Textbook Equity Edition”, vol. 1 of 3: Chapters 1-12, Chapter 9 p. 294, 464 pages.;;PCT/US17/68326, “International Application Serial No. PCT/US17/68326, International Preliminary Report on Patentability dated Jul. 4, 2019”, Gecko Robotics, Inc., 11 pages.;;PCT/US2019/027958, “International Application Serial No. PCT/US2019/027958, International Search Report and Written Opinion dated Jul. 16, 2019”, Gecko Robotics, Inc., 9 pages.;;Wisegeek, “What is an Articulated Robot?”, Webpage, 2015, 4 pages.;;Sabatini, et al., “Correlation Techniques for Digital Time-of-Flight Measurement by Airborne Ultrasonic Rangefinders”, Published in: Proceedings of IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS'94), 1994, pp. 2168-2175.;;Zaho, et al., “Estimation of ultrasound attenuation and dispersion using short time Fourier transform,”, Ultrasonics 43 (2005) 375-381, 2005, pp. 375-381.;;Svilainis, “Review of high resolution time of flight estimation techniques for ultrasonic signals,”, Sep. 2013Conference: NDT 2013At: Telford Project: In-SMART, 2013, 13 pages.;;Felsch, Torsten , et al., “Robotized Inspection of Vertical Structures of a Solar Power Plant Using NDT Techniques”, doi:10.3390/robotics4020103, 2015, pp. 103-119.;;PCT/US20/21779 , “International Application Serial No. PCT/US20/21779, International Preliminary Report on Patentability dated Sep. 23, 2021”, Gecko Robotics, Inc., 13 pages.;;Reinhold, Reif , “Machine Translation DE 10300383”, 2019, 4 pages.;;Smith, Oliver , et al., “Machine Translation KR20140040692A”, 18 pages.",ACTIVE
437,US,B2,US 11892322 B2,037-211-181-456-886,2024-02-06,2024,US 202217694897 A,2022-03-15,US 202217694897 A;;US 201916387237 A;;US 201715853391 A;;US 201862658827 P;;US 201662438788 P;;US 201762596737 P,2016-12-23,Inspection robot for horizontal tube inspection having sensor carriage,"An example inspection robot may include a drive module structured to engage a top tube of a vertically arranged layer of tubes, at least one telescoping pole, and a lowering mechanism operationally coupled to the at least one telescoping pole and structured to selectively extend or retract the at least one telescoping pole, thereby providing a selected vertical position of a sensor carriage assembly. The sensor carriage assembly may be coupled to the at least one telescoping pole, and structured to accept at least one of a plurality of sensors.",GECKO ROBOTICS INC,LOW KEVIN;;BRYNER EDWARD;;MACKENZIE LOGAN;;MOORE JOSHUA;;AUDA MICHAEL S;;CHO MARK;;CHO EDWIN H,GECKO ROBOTICS INC (2019-04-18),https://lens.org/037-211-181-456-886,Granted Patent,yes,329,0,4,78,0,G01D11/30;;G01D11/30;;G01B11/24;;B25J9/1679;;B25J15/0019;;G05D3/125,G01D11/30;;B25J9/16;;B25J15/00;;G01B11/24;;G05D3/12,,73,19,047-660-386-217-965;;148-371-561-359-305;;011-803-388-304-260;;003-586-509-514-11X;;054-540-039-219-971;;053-607-783-158-908;;080-519-814-875-15X;;134-217-287-880-064;;148-371-561-359-305;;096-387-808-699-363;;011-803-388-304-260;;084-515-545-463-225;;054-367-401-283-890;;061-004-547-120-171;;056-100-419-584-317;;015-202-554-475-543;;087-860-043-054-057;;016-774-813-068-580;;072-760-625-806-703,10.1109/icra.2012.6224799;;10.1145/317456.317459;;10.1109/iros.2017.8206562;;10.3390/robotics4020103;;10.1109/iros.1993.583934;;10.1109/jsyst.2016.2611244;;10.1109/ifis.1993.324212;;10.1007/978-3-642-10817-4_93;;10.1145/317456.317459;;10.1109/iros.1994.407566;;10.1109/iros.2017.8206562;;10.1109/scis-isis.2014.7044830;;15737388;;10.1016/j.ultras.2004.08.001;;10.1109/cyber.2018.8688097;;10.1109/tmech.2016.2612722;;10.1109/iros.2017.8206567;;10.1007/978-1-4613-8997-2_3;;10.1109/robio.2016.7866581;;10.1109/robio.2016.7866459,"Lee, Giuk , et al., “Combot: Compliant Climbing Robotic Platform with Transitioning Capability and Payload Capacity”, IEEE International Conference on Robotics and Automation RiverCentre, Saint Paul, Minnesota,, 2012, 6 pages.;;Myers, Brad A., “The importance of percent-done progress indicators for computer-human interfaces”, Proceedings of the SIGCHI conference on Human factors in computing systems., 1985, 11-17.;;Sirken, Aaron , et al., “Bridge Risk Investigation Diagnostic Grouped Exploratory (Bridge)”, IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), 2017, 7 pages.;;Tufte, Edward R. , “The Visual Display of Quantitative Information”, Published by Graphics Press LLC, Second edition, fifth printing, Aug. 2007, 191 pages.;;“All Metals Fabrication”, Painting Metal, Aug. 27, 2015.;;“Coordinate Systems in Two and Three Dimensions”, Oregon State University, Department of Mathematics, 2015, 3 pages.;;“Horizontal definition”, Merrian-Webster Dictionary, 2014, 1 page.;;“International Federation of Robotics,”, World Robotics, Chapter 1 section 2, 2016, 10 pages.;;“Merriam-Webster”, Definition of Pivot, 2015, 5 pages.;;“Vertical Definition”, Merriam Webster, 2014, 1 page.;;“Yaskawa Motoman Robotics,”, Robotics Glossary, 2019, 20 pages.;;17884897.4, , “European Application Serial No. 17884897.4, Extended European Search Report dated Jun. 25, 2020”, Gecko Robotics, Inc., 5 pages.;;Bell, Stephanie , “Measurement Good Practice Guide A Beginner's Guide to Uncertainty of Measurement”, National Physical Laboratory, Issue 2, 2001, 41 pages.;;Berendsen, A.M , “Ship Painting: Current Practice and Systems in Europe”, Technology Publishing Company, Sep. 1998, 10.;;Carlsten, Roy , “Understanding Corrosion and How to Protect Against It”, manufacturing.net, Mar. 11, 2002, 8.;;Curran, Patrick , “Make the right choice for metal coating for the right application”, Design World, Jun. 2, 2016, 18.;;Felsch, Torsten et al., “Robotized Inspection of Vertical Structures of a Solar Power Plant Using NDT Techniques”, doi:10.3390/robotics4020103, 2015, pp. 103-119.;;Fowler, Kenneth A et al., “Theory and Application of Precious Ultrasonic Thickness Gaging”, 2015, 12 pages.;;General Electric, , “BWCI Automated Boiler Wall Cleaning & Inspection”, inspection-robotics.com, 2016, 4.;;Ginzel, et al., “Acoustic Properties of the Elastomeric Materials Aqualene and ACE”, The e-Journal of Nondestructive Testing—ISSN 1435-4934, Dec. 2015, 13.;;Guglielmelli, E. et al., “Avoiding obstacles by using a proximity US/IR sensitive skin”, IEEE, 1993, pp. 2207-2214.;;Harrison, David M. , “Uncertainty in Physical Measurements”, Module 4—Repeated Measurements, Dept. of Physics, Univ. of Toronto, 2015, 18 pages.;;Lebowitz, Carol A. et al., “Ultrasonic Measurement of Pipe Thickness”, Review of Progress in Quantitative Nondestructive Evalualtion, vol. 12, 1987, 8 pages.;;Lins, Romulo G. et al., “Autonomous Robot System for Inspection of Defects in Civil Infrastructures”, IEEE, 2016, pp. 1414-1422.;;Lion Precision, , “Understanding Sensor Resolution Specifications and Performance”, TechNote, LT05-0010, 2014, pp. 1-6.;;Martinez, Angelo et al., “Fuzzy logic based collision avoidance for a mobile robot”, IEEE, 1993, pp. 66-69.;;Miskon, Muhammad F. et al., “Close Range Inspection Using Novelty Detection Results”, Intelligent Robotic Research Center (IRRC), Monash University, Australia, ICIRA2009, LNAI 5928,, 2009, pp. 947-956.;;Myers, Brad A. , “The importance of percent-done progress indicators for computer-human interfaces”, Proceedings of the SIGCHI conference on Human factors in computing systems., CHI '85. ACM, New York, NY., 1985, 11-17.;;NDT Resource Center, , “NDT Glossary D”, Webpage, 2016, 4 pages.;;NDT Resource Center, , “NDT Glossary R”, Webpage, 2016, 5 pages.;;NDT Resource Center, , “Transducer Types”, Webpage, 2005, 1.;;Olympus, , “BondMaster Probes and Accessories Catalog”, Catalog, 2008, 24.;;Olympus, “Flaw Detectors Delay Line”, Olympus, Flaw Detectors Delay Line, 2014, Jan. 9, 2014, 1.;;Olympus, “Ultrasonic Transducers Technical Notes”, Notes, 2006.;;Openstax College, “College Physics Textbook Equity Edition”, vol. 1 of 3: Chapters 1-12, Chapter 9 p. 294, 464 pages.;;PCT/US17/68326, “International Application Serial No. PCT/US17/68326, International Preliminary Report on Patentability dated Jul. 4, 2019”, Gecko Robotics, Inc., 11 pages.;;PCT/US20/21779, , “International Application Serial No. PCT/US20/21779, International Preliminary Report on Patentability dated Sep. 23, 2021”, Gecko Robotics, Inc., 13 pages.;;PCT/US20/21779, , “International Application Serial No. PCT/US20/21779, International Search Report and Written Opinion dated Sep. 2, 2020”, Gecko Robotics, Inc., 14 pages.;;PCT/US20/21779, , “International Application Serial No. PCT/US20/21779, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jul. 9, 2020”, Gecko Robotics, Inc., 2 pages.;;PCT/US2017/068326, , “International Application Serial No. PCT/US2017/068326, International Search Report and Written Opinion dated May 4, 2018”, Gecko Robotics, Inc., 14 pages.;;PCT/US2017068326, , “International Application Serial No. PCT/US2017068326, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Feb. 27, 2018”, Gecko Robotics, Inc., 2 Pages.;;PCT/US2019/027958, , “International Application Serial No. PCT/US2019/027958, International Preliminary Report on Patentability dated Oct. 29, 2020”, Gecko Robotics, Inc., 8 pages.;;PCT/US2019/027958, “International Application Serial No. PCT/US2019/027958, International Search Report and Written Opinion dated Jul. 16, 2019”, Gecko Robotics, Inc., 9 pages.;;Reinhold, Reif, “Machine Translation DE 10300383”, 2019, 4 pages.;;Sabatini, Angelo M. et al., “Correlation Techniques for Digital Time-of-Flight Measurement by Airborne Ultrasonic Rangefinders”, Published in: Proceedings of IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS'94), Date of Conference: Sep. 12-16, 1994,, 1994, pp. 2168-2175.;;Salik, John et al., “Pipe Inspections: Robotic Laser Profiling Demystified”, National Precast Concrete Association, Apr. 1, 2013, 12 pages.;;Schroeder, S C. et al., “Ultrasonic Culvert Thickness Determination”, US Army Armament Research Development and Engineering, Technical Report ARCCB-TR-95027, 1995, 36 pages.;;Sirken, Aaron et al., “Bridge Risk Investigation Diagnostic Grouped Exploratory (BRIDGE)”, IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), Sep. 24-28, 2017, Vancouver, BC, Canada (Year: 2017), 2017, 7 pages.;;Smith, Oliver et al., “Machine Translation KR20140040692A”, 18 pages.;;Svilainis, Linas , “Review of high resolution time of flight estimation techniques for ultrasonic signals,”, September 2013Conference: NDT 2013At: Telford Project: In-Smart, 2013, 13 pages.;;Wisegeek, , “What is an Articulated Robot?”, Webpage, 2015, 4 pages.;;Yasuda, Gen'ichi , “Behavior-based autonomous cooperative control of intelligent mobile robot systems with embedded Petri nets”, IEEE, 2014, pp. 1085-1090.;;Zaho, B. et al., “Estimation of ultrasound attenuation and dispersion using short time Fourier transform,”, Ultrasonics 43 (2005) 375-381, 2005, pp. 375-381.;;20769832.5 , “European Application Serial No. 20769832.5, Extended European Search Report dated Nov. 4, 2022”, Gecko Robotics, Inc, 8 pages.;;21201397.3 , “European Application Serial No. 21201397.3, Extended European Search Report dated May 11, 2022”, Gecko Robotics, Inc, 12 pages.;;AMS Controls , “Encoder Tracking and Mounting”, 2015, 18 pages.;;Borenstein, Johann , et al., “Where am I? Sensors and Methods for Mobile Robot Positioning”, Retrieved from the Internet :URL :http ://www-personal.umich.edu/˜johannb/Papers/pos96rep/pdf, Apr. 22, 1996, pp. 1-282.;;Cai, Mingxue , et al., “A Novel Pipeline Inspection Robot with Two Angle-changeable Crawler Drive Modules”, Proceedings of 2018 IEEE 8th Annual lntemational Conference on Cyber Technology in Automation, Control, and Intelligent Systems, Jul. 2018, 6 pages.;;Connor, David , et al., “Improved dead reckoning using caster wheel sensing on a differentially steered 3-wheeled autonomous vehicle”, Proceedings vol. 4195, Mobile Robots XV and Telemanipulator and Telepresence Technologies VII, 2001, 13 pages.;;Few, Stephen , “Practical Rules for Using Color in Charts, Perceptual Edge”, Visual Business Intelligence Newsletter, Feb. 2008, 13 pages.;;Gonzalez, Carlos , “What's the Difference between Pneumatic, Hydraulic, and Electrical Actuators”, Machine Design, 2015, 4 pages.;;Hutter, Marco , et al., “Force Control for Active Chassis Balancing”, IEEE/ASME Transactions on Mechatronics, vol. 22, No. 2, Apr. 2017, 10 pages.;;National Geographic , “Encyclopedic Entry Location”, 2016, 3 pages.;;Nidec , “Flexwave Catalog”, 2018, 52 pages.;;Parallax Tutorial , “Going the Distance—Using the Drive Distance Block Encoders and Motor Gearing”, 2017, 5 pages.;;PCT/US2022/023993 , “International Application Serial No. PCT/US2022/023993, International Search Report and Written Opinion dated Aug. 24, 2022”, Gecko Robotics, Inc., 31 pages.;;PCT/US2022/023993 , “International Application Serial No. PCT/US2022/023993, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jun. 16, 2022”, Gecko Robotics, Inc., 3 pages.;;Stepson, W.A.V , et al., “Design and Development of a Mobile Crawling Robot with Novel Halbach Array Based Magnetic Wheels”, IEEE/ RSJ International Conference on Intelligent Robots and Systems (IROS), Sep. 2017, 6 pages.;;Takero, Hongo , et al., “An Automatic Guidance System of a Self-Controlled Vehicle”, In: “Autonomous Robot Vehicles”, Jan. 1, 1990 (Jan. 1, 1990), Springer New York, New York, NY,, Jan. 1, 1990, pp. 32-37.;;Tufte, Edward R., “The Visual Display of Quantitative Information”, Published by Graphics Press LLC, Second edition, fifth printing, 2007, 191 pages.;;Ueura, Keiji , et al., “Development of the Harmonic Drive Gear for Space Applications”, 1999, 6 pages.;;Zhang, Lei , et al., “Analysis of Traveling-capability and Obstacle-climbing Capability for Radially Adjustable Tracked Pipeline Robot”, Proceedings of the 2016 IEEE International Conference on Robotics and Biomimetics Gingdao, China, Dec. 2016, 6 pages.;;Zhang, Lei , et al., “Stable Motion Analysis and Verification of a Radial Adjustable Pipeline Robot”, Proceedings of the 2016 IEEE International Conference on Robotics and Biomimetics Oingdao, China, Dec. 2016, 6 pages.",ACTIVE
438,US,A1,US 2019/0242728 A1,068-645-395-789-929,2019-08-08,2019,US 201916387237 A,2019-04-17,US 201916387237 A;;US 201715853391 A;;US 201862658827 P;;US 201762596737 P;;US 201662438788 P,2016-12-23,INSPECTION ROBOT FOR HORIZONTAL TUBE INSPECTION,"An inspection apparatus and methods for inspecting horizontal tubes in an industrial environment are disclosed. The apparatus can include a drive module including a pair of wheels to engage a top tube of a vertically arranged layer of tubes, a telescoping pole, a sensor carriage assembly coupled to the telescoping pole, and a lowering mechanism operationally coupled to the telescoping pole to selectively extend or retract the telescoping pole providing a selected vertical position of the sensor carriage assembly.",GECKO ROBOTICS INC,LOW KEVIN;;BRYNER EDWARD;;MACKENZIE LOGAN;;MOORE JOSHUA;;AUDA MICHAEL S;;CHO MARK;;CHO EDWIN H,GECKO ROBOTICS INC (2019-04-18),https://lens.org/068-645-395-789-929,Patent Application,yes,0,47,4,78,0,G01D11/30;;G01D11/30;;G01B11/24;;B25J9/1679;;B25J15/0019;;G05D3/125,G01D11/30;;B25J9/16;;B25J15/00;;G01B11/24;;G05D3/12,,0,0,,,,ACTIVE
439,US,S,US D0794363 S,008-218-965-455-62X,2017-08-15,2017,US 201529549120 F,2015-12-18,US 201529549120 F,2015-12-18,Podium,,STEELCASE INC,YOO HYUN;;HELD MICHAEL;;HO SIU CHO;;SPOELHOF MARK WILLIAM,STEELCASE INC (2015-12-14),https://lens.org/008-218-965-455-62X,Design Right,no,0,1,2,2,0,,,0604;;D 6700;;D6/641;;D6/685,0,0,,,,ACTIVE
440,US,B2,US 11228294 B2,051-826-320-758-912,2022-01-18,2022,US 201816651098 A,2018-09-26,US 201816651098 A;;US 201762563389 P;;US 2018/0052773 W,2017-09-26,Graphene microelectromechanical system (MEMS) resonant gas sensor,A method of manufacturing a nanoelectromechanical resonator allows for uniform tuning of a resonant frequency. The nanoelectromechanical resonator can be mass produced and used to sense the presence of a selected gas.,UNIV TEXAS,CULLINAN MICHAEL;;CHO JOON-HYUNG;;CAYLL DAVID;;LADNER IAN SETH,BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (2021-10-27),https://lens.org/051-826-320-758-912,Granted Patent,yes,8,0,3,3,0,G01N29/036;;H03H3/0073;;H03H9/2463;;C01B2204/04;;C01B32/194;;G01N29/022;;G01N29/22;;C01B32/194;;B81B7/02;;C01B2204/04;;G01N29/022;;H03H3/0073,H03H3/00;;B81B7/02;;C01B32/194;;G01N29/02;;H03H3/007,,5,3,059-551-723-765-528;;160-145-741-167-73X;;035-503-410-576-921,10.1115/msec2016-8567;;10.4172/2469-410x.1000125;;17255506;;10.1126/science.1136836,"Cho et al., “A Method to Manufacture Repeatable Graphene-Based NEMS Devices at the Wafer—Scale”. Jun. 27-Jul. 1, 2016, ASME 2016 11th International Manufacturing Science and Engineering Conference, vol. 1: Blacksburg Virginia, USA. http;//proceedings.asmedigitalcollectiors.asrrie.org (Year: 2016).;;International Search Report and Written Opinion in PCT/US2018/052773, dated Feb. 11, 2019. 10 pages.;;Cho et al., “A Method to Manufacture Repeatible Graphene-Based NEMS Devices at the Wafer 1-4, 7-10-Scale.” ASME 2016 11th International Manufacturing Science and Engineering Conference,vol. 1: Processing Blacksburg, Virginia, USA, Jun. 27-Jul. 1, 2016 (2016), Abstract; p. 3 col. 1; p. 5 col. 1; Fig. 2; Fig. 3.;;Mina et al., “Single Layer Graphene Sheet-based Nanoelectromechanical Resonator as Mass 1-4, 7-10 Detection.” J. Laser Opt. Photonics 2: 125. (Dec. 5, 2015), Entire Document.;;Bunch et al., “Electromechanical Resonators from Graphene Sheets.” Science Jan. 26, 2007, 1-4, 7-10 315(5811), 490-493, Entire Document.",ACTIVE
441,US,A1,US 2021/0281783 A1,081-932-582-693-140,2021-09-09,2021,US 202017060345 A,2020-10-01,KR 20200028652 A,2020-03-06,CORRELATED DOUBLE SAMPLING CIRCUIT AND IMAGE SENSOR INCLUDING THE SAME,"A flicker detection circuit is provided. The flicker detection circuit may include a flicker detection correlated double sampling (FD CDS) circuit including first to sixth switches turned on or off based on a control signal, and first to fourth capacitors, the FD CDS circuit being configured to receive a flicker pixel signal output from at least one pixel, summate with an output offset signal, and amplify the summation based on a gain to form a flicker detection signal; and an analog-to-digital converter (ADC) configured to quantize the flicker detection signal.",SAMSUNG ELECTRONICS CO LTD,NAM SANGPIL;;LEE KYUNGHOON;;LEE JUNGHO;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2020-09-09),https://lens.org/081-932-582-693-140,Patent Application,yes,0,3,4,4,0,H04N25/75;;H03M1/1295;;H03M1/1245;;H03M1/08;;H04N23/745;;H04N25/616;;H04N25/702;;H04N25/75;;H04N25/616;;H04N25/772;;H04N25/75;;H04N25/616;;H04N23/745;;H04N25/75;;H04N25/772,H04N5/357;;H01L27/146;;H03M1/12;;H03M1/46;;H04N5/235;;H04N5/3745,,0,0,,,,ACTIVE
442,CN,A,CN 109716785 A,104-924-793-563-090,2019-05-03,2019,CN 201780057835 A,2017-08-09,US 201615235382 A;;US 2017/0046146 W,2016-08-12,DUAL DIAPHRAGM MICROPHONE AND MICROPHONE COVERS,"A microphone can include a cover having a series of slits and a nest. The nest can be configured to receive a first diaphragm, a second diaphragm, and a PCB in a stacked arrangement, such that the PCBis positioned between the first diaphragm and the second diaphragm. Also the first diaphragm can define a first plane, the second diaphragm can define a second plane, and the PCB can define a third plane and the first plane, the second plane, and the third plane can extend parallel to one another. The cover can also include slits having a first length and a second length, and the first length canbe greater than the second length. The slits can extend both radially and axially.",SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,,https://lens.org/104-924-793-563-090,Patent Application,no,7,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R1/04;;H04R1/08;;H04R1/40;;H04R19/01;;H04R19/04,,0,0,,,,PENDING
443,US,B2,US 8969645 B2,010-763-354-249-988,2015-03-03,2015,US 201213715873 A,2012-12-14,US 201213715873 A,2012-12-14,Process for reducing chloride in hydrocarbon products using an ionic liquid catalyst,"We provide a process comprising: a. feeding a chlorinated-hydrocarbon and an ionic liquid catalyst to a treatment unit;b. operating the treatment unit at an elevated temperature to produce dechlorinated-hydrocarbon and HCl; andc. collecting the dechlorinated-hydrocarbon, wherein at least 90 wt % of the chlorides are removed. A second process comprises:a. creating an ionic liquid catalyst-rich zone in a distillation unit;b. passing chlorinated-hydrocarbon to the distillation unit;c. operating the unit under conditions causing removal of alkyl chloride to produce dechlorinated-hydrocarbon having a final boiling point close to a first final boiling point. A third process comprises:a. feeding alkylate gasoline blending component and ionic liquid catalyst to a treatment unit;b. operating the treatment unit; andc. collecting a dechlorinated-hydrocarbon, wherein at least 90 wt % of the chlorides have been removed and the dechlorinated-hydrocarbon has a second RON that is close to a first RON.",ZHAN BI-ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN;;CHEVRON USA INC,ZHAN BI-ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN,CHEVRON U.S.A. INC (2012-12-04),https://lens.org/010-763-354-249-988,Granted Patent,yes,14,2,11,11,0,B01J31/0284;;B01J31/0288;;B01J31/0289;;B01J2231/64;;B01D3/009;;C10G29/26;;C10G75/00;;C10G7/10;;C10G2300/1081;;C10G2300/202;;C07C7/10;;B01J31/0288;;B01J31/0289;;B01J31/0284;;B01J2231/64;;B01D3/009;;C10G29/16;;C10G2300/1081;;C10G7/10;;C10G29/26;;C10G75/00;;C10G2300/202;;B01J31/26,C07C7/10;;B01J31/26,585/852;;208/262.1;;585/312;;585/450;;585/451,2,0,,,"PCT/US2013/045221, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, Mailed Nov. 6, 2013, 81 Pages.;;U.S. Appl. No. 13/170,648, filed Jun. 28, 2011.",ACTIVE
444,SG,A,SG 11201504512V A,033-090-887-866-744,2015-07-30,2015,SG 11201504512V A,2013-06-11,US 201213715873 A;;US 2013/0045221 W,2012-12-14,PROCESS FOR REDUCING CHLORIDE IN HYDROCARBON PRODUCTS USING AN IONIC LIQUID CATALYST,,CHEVRON USA INC,ZHAN BI-ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN,,https://lens.org/033-090-887-866-744,Unknown,no,0,0,11,11,0,B01J31/0284;;B01J31/0288;;B01J31/0289;;B01J2231/64;;B01D3/009;;C10G29/26;;C10G75/00;;C10G7/10;;C10G2300/1081;;C10G2300/202;;C07C7/10;;B01J31/0288;;B01J31/0289;;B01J31/0284;;B01J2231/64;;B01D3/009;;C10G29/16;;C10G2300/1081;;C10G7/10;;C10G29/26;;C10G75/00;;C10G2300/202;;B01J31/26,B01J31/26,,0,0,,,,PENDING
445,KR,A,KR 20150095845 A,041-324-514-087-587,2015-08-21,2015,KR 20157018701 A,2013-06-11,US 201213715873 A;;US 2013/0045221 W,2012-12-14,PROCESS FOR REDUCING CHLORIDE IN HYDROCARBON PRODUCTS USING AN IONIC LIQUID CATALYST,,CHEVRON USA INC,ZHAN BI ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN,,https://lens.org/041-324-514-087-587,Patent Application,no,9,0,11,11,0,B01J31/0284;;B01J31/0288;;B01J31/0289;;B01J2231/64;;B01D3/009;;C10G29/26;;C10G75/00;;C10G7/10;;C10G2300/1081;;C10G2300/202;;C07C7/10;;B01J31/0288;;B01J31/0289;;B01J31/0284;;B01J2231/64;;B01D3/009;;C10G29/16;;C10G2300/1081;;C10G7/10;;C10G29/26;;C10G75/00;;C10G2300/202;;B01J31/26,B01J31/02;;B01J31/26;;C10G27/02,,0,0,,,,ACTIVE
446,EP,A1,EP 3497942 A1,040-183-186-118-790,2019-06-19,2019,EP 17754951 A,2017-08-09,US 201615235382 A;;US 2017/0046146 W,2016-08-12,DUAL DIAPHRAGM MICROPHONE AND MICROPHONE COVERS,,SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,,https://lens.org/040-183-186-118-790,Patent Application,yes,0,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R1/04;;H04R1/08;;H04R1/40;;H04R19/01;;H04R19/04,,0,0,,,,ACTIVE
447,US,A1,US 2019/0323702 A1,078-802-780-206-311,2019-10-24,2019,US 201916391095 A,2019-04-22,US 201916391095 A;;US 201862660800 P,2018-04-20,Luminaire With An Integrated Camera,"A luminaire includes a terminal block that receives power from a power source, a light source power supply electrically coupled to the terminal block and to a light source, a power converter electrically coupled to the terminal block and to a power over Ethernet injector, a camera coupled to the power over Ethernet injector, and a transceiver electrically coupled to the power converter. The power over Ethernet injector can supply power to and receive data from the camera. The transceiver is also coupled to the power over Ethernet injector and can communicate data to and receive data from the camera.",EATON INTELLIGENT POWER LTD,ADEJUMO TUNJI;;CHO NAM CHIN;;LU CHRIS;;SACHETTI JAY MICHAEL,EATON INTELLIGENT POWER LIMITED (2019-05-01);;SIGNIFY HOLDING B.V (2020-03-02),https://lens.org/078-802-780-206-311,Patent Application,yes,0,5,2,2,0,H04L12/2803;;F21V33/0052;;F21V33/0076;;G08B13/19619;;G08B13/19658;;G08B13/1966;;H04N23/661;;H04N23/57;;H04N23/695;;F21V33/0052;;H04L12/10;;F21V33/0076;;H04N23/56;;H04N23/661,F21V33/00;;H04L12/10;;H04N5/225;;H04N5/232,,0,0,,,,ACTIVE
448,US,B2,US 10412503 B2,099-206-731-841-643,2019-09-10,2019,US 201615235382 A,2016-08-12,US 201615235382 A,2016-08-12,Microphone and methods of assembling microphones,"A microphone can include a cover having a series of slits and a nest. The nest can be configured to receive a first diaphragm, a second diaphragm, and a PCB in a stacked arrangement, such that the PCB is positioned between the first diaphragm and the second diaphragm. Also the first diaphragm can define a first plane, the second diaphragm can define a second plane, and the PCB can define a third plane and the first plane, the second plane, and the third plane can extend parallel to one another. The cover can also include slits having a first length and a second length, and the first length can be greater than the second length. The slits can extend both radially and axially.",SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,SHURE ACQUISITION HOLDINGS INC (2017-01-23),https://lens.org/099-206-731-841-643,Granted Patent,yes,9,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R19/00;;H04R1/04;;H04R1/08;;H04R1/28;;H04R1/40;;H04R19/01;;H04R19/04,,4,0,,,"Brüel & Kjaer 4938—1/4-inch pressure-field microphone, 4 Hz to 70 kHz, 200v polarization—Jul. 22, 2016.;;Jan. 3, 2018—(PCT) Written Opinion and International Search Authority—App PCT/US2017/046146.;;Jensen, Mads Herring, MEMS Microphone Model Presented at ASA 166 in San Francisco, COMSOL Blog, Jan. 2, 2014, retrieved online at: <<https://www.comsol.com/blogs/mems-microphone-model-presented-asa-166-san-francisco/>>.;;Feb. 21, 2019—(WO) International Preliminary Report on Patentability—App PCT/US20171046146.",ACTIVE
449,EP,A4,EP 2389630 A4,152-126-015-365-359,2012-08-01,2012,EP 10733989 A,2010-01-26,US 2010/0022046 W;;US 14738509 P,2009-01-26,PROVISIONED FIRMWARE UPDATES USING OBJECT IDENTIFIERS,,ASSA ABLOY AB,MALONE MICHAEL WILLIAM;;SMITH THAD;;CHO YOONG-GOOG;;MILBRANDT RYAN,,https://lens.org/152-126-015-365-359,Search Report,no,5,0,5,5,0,G06F8/65;;G06F21/572;;G06F21/44;;G06F8/65;;G06F9/445,G06F9/445,,2,0,,,No further relevant documents disclosed;;See also references of WO 2010085781A1,DISCONTINUED
450,KR,B1,KR 101703711 B1,198-184-442-818-214,2017-02-07,2017,KR 20150118742 A,2015-08-24,KR 20150118742 A,2015-08-24,Optical printing device Recognized Security Paper with Detection Tag and Security Paper,"The present invention relates to an optical printing device for recognizing a security paper including a detection tag and a security paper, and more particularly to an optical printing device for recognizing a security paper including a detection tag and a security paper, providing a recognition method of an optical detection manner, that is not an electromagnetic manner, through a bending pattern of a detection tag (components : Co, Fe, Ni, Si, etc.) containing a magnetic substance or a non-magnetic substance, the number of tags per unit area, a color of a detection tag, etc.",KOREIT CO LTD,KWON YOUNG BAE;;OH WON SIK;;CHUNG MICHAEL;;CHO KURT,,https://lens.org/198-184-442-818-214,Granted Patent,no,5,1,1,1,0,,B41J29/38;;B42D25/36;;G01V8/10,,0,0,,,,ACTIVE
451,CN,A,CN 105492094 A,026-260-594-066-490,2016-04-13,2016,CN 201480040029 A,2014-03-14,US 2014/0027406 W;;US 201313944560 A,2013-07-17,Regeneration of olefin treating adsorbents for removal of oxygenate contaminants,"Processes for eliminating oxygenates and water from a light hydrocarbon processing system, wherein oxygenates are removed from a light hydrocarbon stream by adsorption of the oxygenates on an oxygenate adsorption unit to provide a deoxygenated hydrocarbon stream, the oxygenate adsorption unit is regenerated via a regenerant stream to provide an oxygenated regenerant stream comprising the oxygenates, and the oxygenated regenerant stream is subjected to hydro-deoxygenation to convert the oxygenates into paraffins and water, wherein the water may also be permanently removed from the system.",CHEVRON USA INC,CLEVERDON ROBERT FLETCHER;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO,,https://lens.org/026-260-594-066-490,Patent Application,no,0,0,5,5,0,B01D15/203;;B01J20/3408;;C10G25/00;;C10G29/205;;C10G3/00;;C10G3/42;;C10G3/50;;B01J20/18;;B01J20/345;;Y02P30/20;;C10G3/50;;B01D15/203;;C10G3/42;;B01J20/3408;;C10G25/00;;C10G29/205;;C10G3/00;;B01J20/345;;B01J20/18;;Y02P30/20;;C07C2/58;;C07C7/13,B01D15/20;;B01J20/34;;C07C7/12;;C10G70/04,,0,0,,,,DISCONTINUED
452,US,A1,US 2021/0160121 A1,067-381-318-026-247,2021-05-27,2021,US 201816614106 A,2018-06-15,US 201816614106 A;;US 201762521238 P;;US 2018/0037936 W,2017-06-16,CONFIGURABILITY AND SIGNALING FOR HALF-TONE SHIFT,"Described is an apparatus of a User Equipment (UE) operable to communicate with an Evolved Node-B (eNB) on a wireless network. The apparatus may comprise a first circuitry, a second circuitry, and a third circuitry. The first circuitry may be operable to process a configuration transmission carrying a half-tone shifting indicator. The second circuitry may be operable to select one or more subcarrier frequencies for Uplink (UL) transmission based on the half-tone shifting indicator. The third circuitry may be operable to generate a UL transmission for the one or more subcarrier frequencies. The half-tone shifting indicator may have a first value indicating application of a half-subcarrier offset, and a second value indicating no application of the half-subcarrier offset.",INTEL IP CORP,JEON JEONGHO;;CHO JOONYOUNG;;FAERBER MICHAEL;;HAN SEUNGHEE;;MIAO HONGLEI,APPLE INC (2019-11-30);;INTEL CORPORATION (2020-05-29),https://lens.org/067-381-318-026-247,Patent Application,yes,0,4,11,11,0,H04L5/0007;;H04L5/0053;;H04J11/0023;;H04W28/26;;H04J11/0023;;H04L5/0007;;H04L27/2666;;H04L5/0007;;H04L27/2666,H04L27/26;;H04L5/00,,0,0,,,,ACTIVE
453,US,A1,US 2016/0016980 A1,100-027-131-332-79X,2016-01-21,2016,US 201514746430 A,2015-06-22,US 201514746430 A;;US 201313813886 A;;US 2011/0044581 W;;US 36562110 P,2010-07-19,METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas Ia and Ib: The compounds of Formula Ia and Ib are useful for the treatment Hepatitis C infections.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O' NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,GILEAD SCIENCES INC (2015-08-31),https://lens.org/100-027-131-332-79X,Patent Application,yes,0,1,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07F9/24,,0,0,,,,ACTIVE
454,WO,A3,WO 2018/217466 A3,035-732-301-042-778,2019-01-03,2019,US 2018/0031886 W,2018-05-09,US 201762511198 P,2017-05-25,MEASURING CONCENTRATIONS OF RADICALS IN SEMICONDUCTOR PROCESSING,"An apparatus includes a reactive species source, a spectral measurement volume, a light source to emit a light beam into the spectral measurement volume, a spectrometer to receive the light beam from the spectral measurement volume. The apparatus includes an a controller configured to, when a reactive species is present in the spectral measurement volume, control the light source to emit the light beam into the spectral measurement volume and the spectrometer to determine an environment spectrum using the light beam, and when the reactive species is not present in the spectral measurement volume, control the light source to emit the light beam into the spectral measurement volume and the spectrometer to determine a baseline spectrum using the light beam, calculate a net spectrum based on a difference between the environment spectrum and the baseline spectrum, and estimate a concentration of the reactive species based on the net spectrum.",APPLIED MATERIALS INC,GOPALAN RAMESH;;CHO TOM K;;ALAJAJIAN GEVORK;;MARK MICHAEL J,,https://lens.org/035-732-301-042-778,Search Report,yes,5,0,6,6,0,G01N21/031;;G01N21/31;;G01N21/64;;G01N2021/1734;;G01N21/85;;G01N2021/8411;;H01J37/32972;;G01N21/031;;G01N21/31;;G01N2021/1734;;G01N21/64;;G01N21/85;;G01N2021/8411;;G01N21/62;;G01N21/84;;H01J37/32972;;H01L21/67063;;H01L22/10,H01L21/67;;C23C16/44;;H01L21/66;;H05H1/46,,0,0,,,,PENDING
455,US,B2,US 11606101 B2,085-396-956-855-941,2023-03-14,2023,US 202117406193 A,2021-08-19,KR 20200175437 A,2020-12-15,Analog-to-digital converter,"An analog-to-digital converter (ADC) includes a coarse ADC that receives an analog input voltage, generates a first digital signal based on the analog input voltage using a successive approximation register (SAR) method, and outputs a residual voltage remaining after the first digital signal is generated. The ADC further includes an amplifier that receives the residual voltage and a test voltage, generates a residual current by amplifying the residual voltage by a predetermined gain, and generates a test current by amplifying the test voltage by the gain. The ADC further includes a fine ADC that receives the residual current and generates a second digital signal based on the residual current using the SAR method, and an auxiliary path that receives the test current and generates a gain correction signal based on the test current. The gain of the amplifier is adjusted based on the gain correction signal.",SAMSUNG ELECTRONICS CO LTD,MOON KYOUNGJUN;;OH DONGRYEOL;;PARK YOUNGHYO;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2021-06-14),https://lens.org/085-396-956-855-941,Granted Patent,yes,18,0,3,3,0,H03M1/0695;;H03M1/164;;H03M1/468;;H03M1/1009;;H03M1/0604;;H03M1/1071;;H03M1/1215;;H03M1/38;;H03M1/1009;;H03M1/1071;;H03M1/46;;H03M1/462;;H03M1/0695;;H03M1/122,H03M1/06;;H03M1/12;;H03M1/46,,2,2,082-593-607-080-133;;082-593-607-080-133,10.1109/jssc.2019.2926648;;10.1109/jssc.2019.2926648,"Kyoung-Jun Moon, et al. “A 9.1-ENOB 6-mW 10-Bit 500-MS/s Pipelined-SAR ADC with Current-Mode Residue Processing in 28-nm CMOS”, IEEE Journal of Solid-State Circuits, vol. 54, No. 9, Sep. 2019. (Year: 2019).;;Kyoung-Jun Moon, et al. “A 9.1-ENOB 6-mW 10-Bit 500-MS/s Pipelined-SAR ADC With Current-Mode Residue Processing in 28-nm CMOS”, IEEE Journal of Solid-State Circuits, vol. 54, No. 9, Sep. 2019.",ACTIVE
456,KR,A,KR 20190037326 A,101-056-036-356-135,2019-04-05,2019,KR 20197007121 A,2017-08-09,US 201615235382 A;;US 2017/0046146 W,2016-08-12,듀얼 다이어프램 마이크로폰 및 마이크로폰 커버들,"마이크로폰은, 네스트 및 일련의 슬릿들을 갖는 커버를 포함할 수 있다. 네스트는 제1 다이어프램, 제2 다이어프램, 및 PCB를 적층 배열로 수용하여, PCB가 제1 다이어프램과 제2 다이어프램 사이에 위치결정되도록 구성될 수 있다. 또한, 제1 다이어프램은 제1 평면을 규정할 수 있고, 제2 다이어프램은 제2 평면을 규정할 수 있고, PCB는 제3 평면을 규정할 수 있으며, 제1 평면, 제2 평면, 및 제3 평면은 서로 평행하게 연장될 수 있다. 커버는 또한, 제1 길이 및 제2 길이를 갖는 슬릿들을 포함할 수 있고, 제1 길이는 제2 길이보다 더 길 수 있다. 슬릿들은 반경 방향과 축 방향 양측 모두로 연장될 수 있다.",SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,,https://lens.org/101-056-036-356-135,Patent Application,no,1,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R19/04;;H04R1/04;;H04R1/08;;H04R1/28;;H04R1/40;;H04R19/00;;H04R19/01,,0,0,,,,ACTIVE
457,US,A1,US 2018/0342377 A1,172-893-901-101-14X,2018-11-29,2018,US 201815975576 A,2018-05-09,US 201815975576 A;;US 201762511198 P,2017-05-25,MEASURING CONCENTRATIONS OF RADICALS IN SEMICONDUCTOR PROCESSING,"An apparatus includes a reactive species source, a spectral measurement volume, a light source to emit a light beam into the spectral measurement volume, a spectrometer to receive the light beam from the spectral measurement volume. The apparatus includes an a controller configured to, when a reactive species is present in the spectral measurement volume, control the light source to emit the light beam into the spectral measurement volume and the spectrometer to determine an environment spectrum using the light beam, and when the reactive species is not present in the spectral measurement volume, control the light source to emit the light beam into the spectral measurement volume and the spectrometer to determine a baseline spectrum using the light beam, calculate a net spectrum based on a difference between the environment spectrum and the baseline spectrum, and estimate a concentration of the reactive species based on the net spectrum.",APPLIED MATERIALS INC,GOPALAN RAMESH;;CHO TOM K;;ALAJAJIAN GEORGE;;MARK MICHAEL J,APPLIED MATERIALS INC (2018-05-15),https://lens.org/172-893-901-101-14X,Patent Application,yes,0,2,6,6,0,G01N21/031;;G01N21/31;;G01N21/64;;G01N2021/1734;;G01N21/85;;G01N2021/8411;;H01J37/32972;;G01N21/031;;G01N21/31;;G01N2021/1734;;G01N21/64;;G01N21/85;;G01N2021/8411;;G01N21/62;;G01N21/84;;H01J37/32972;;H01L21/67063;;H01L22/10,H01J37/32;;G01N21/62;;G01N21/84;;H01L21/66;;H01L21/67,,0,0,,,,ACTIVE
458,US,A,US 5414214 A,177-276-012-655-837,1995-05-09,1995,US 26598594 A,1994-06-27,US 26598594 A;;US 96199092 A,1992-10-16,"Resistance heated, sealed microfabricated device package method and apparatus","An apparatus (105, 301) for enclosing a microfabricated component (225) includes a package base (120, 405, 910), a package lid (110, 510, 950) and a seal (215) coupled to the package base (120, 405, 910) and to the package lid (110, 510, 950). The apparatus (105, 301) further includes a conductive loop (210, 610, 920) thermally coupled to the seal (215). Electrical energy is supplied to the conductive loop (210, 610, 920) to heat the conductive loop (210, 610, 920) and seal (215) to melt the seal (215) and thereby to seal the package base (120, 405, 910) to the package lid (110, 510, 950), providing a sealed environment for the microfabricated component (225).",MOTOROLA INC,CHO FREDERICK Y-T;;ANDERSON MICHAEL J;;KNUTH HOWARD D,CTS CORPORATION (1999-02-26),https://lens.org/177-276-012-655-837,Granted Patent,yes,14,22,1,1,0,H01L21/50;;H01L21/50,H01L21/50,174/52.3;;53/478;;174/52.4,0,0,,,,EXPIRED
459,WO,A1,WO 2018/052584 A1,011-619-486-880-632,2018-03-22,2018,US 2017/0046146 W,2017-08-09,US 201615235382 A,2016-08-12,DUAL DIAPHRAGM MICROPHONE AND MICROPHONE COVERS,"A microphone can include a cover having a series of slits and a nest. The nest can be configured to receive a first diaphragm, a second diaphragm, and a PCB in a stacked arrangement, such that the PCB is positioned between the first diaphragm and the second diaphragm. Also the first diaphragm can define a first plane, the second diaphragm can define a second plane, and the PCB can define a third plane and the first plane, the second plane, and the third plane can extend parallel to one another. The cover can also include slits having a first length and a second length, and the first length can be greater than the second length. The slits can extend both radially and axially.",SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,,https://lens.org/011-619-486-880-632,Patent Application,yes,2,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R1/04;;H04R1/08;;H04R1/40;;H04R19/01;;H04R19/04,,0,0,,,,PENDING
460,AU,A1,AU 2013/360304 A1,053-445-587-487-967,2015-04-02,2015,AU 2013/360304 A,2013-06-11,US 201213715873 A;;US 2013/0045221 W,2012-12-14,Process for reducing chloride in hydrocarbon products using an ionic liquid catalyst,"We provide a process comprising: a. feeding a chlorinated-hydrocarbon and an ionic liquid catalyst to a treatment unit; b. operating the treatment unit at an elevated temperature to produce dechlorinated-hydrocarbon and HCl; and c. collecting the dechlorinated-hydrocarbon, wherein at least 90 wt% of the chlorides are removed. A second process comprises: a. creating an ionic liquid catalyst-rich zone in a distillation unit; b. passing chlorinated-hydrocarbon to the distillation unit; c. operating the unit under conditions causing removal of alkyl chloride to produce dechlorinated-hydrocarbon having a final boiling point close to a first final boiling point. A third process comprises: a. feeding alkylate gasoline blending component and ionic liquid catalyst to a treatment unit; b. operating the treatment unit; and c. collecting a dechlorinated-hydrocarbon, wherein at least 90 wt% of the chlorides have been removed and the dechlorinated-hydrocarbon has a second RON that is close to a first RON.",CHEVRON USA INC,ZHAN BI-ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN,,https://lens.org/053-445-587-487-967,Patent Application,no,0,0,11,11,0,B01J31/0284;;B01J31/0288;;B01J31/0289;;B01J2231/64;;B01D3/009;;C10G29/26;;C10G75/00;;C10G7/10;;C10G2300/1081;;C10G2300/202;;C07C7/10;;B01J31/0288;;B01J31/0289;;B01J31/0284;;B01J2231/64;;B01D3/009;;C10G29/16;;C10G2300/1081;;C10G7/10;;C10G29/26;;C10G75/00;;C10G2300/202;;B01J31/26,B01J31/26,,0,0,,,,INACTIVE
461,JP,A,JP 2002008939 A,076-200-508-493-090,2002-01-11,2002,JP 2001114494 A,2001-04-12,US 54875800 A,2000-04-13,METHOD OF MANUFACTURING CERAMIC BODY BY SELECTIVE COATING,"PROBLEM TO BE SOLVED: To solve the problem of the conventional methods, that the material of a dielectric body is restricted and a large amount of wastes is produced, and then many treatment steps become necessary. SOLUTION: In this method, a ceramic raw material solvent is precipitated in a mask layer and on a conductive material. A gelled material is formed of the precipitated ceramic material solvent, and a ceramic body is formed of the gelled material.",FUJITSU LTD,KUO-CHOAN RIU;;MICHAEL G LEE;;UEN-CHO VINCENT WANG,,https://lens.org/076-200-508-493-090,Patent Application,no,0,7,1,1,0,,H01G4/12;;H01L21/8246;;H01L23/12;;H01L27/105;;H01L41/318;;H01L41/331;;H01L41/39;;H01L41/43,,0,0,,,,DISCONTINUED
462,EP,A2,EP 1193326 A2,077-348-421-190-73X,2002-04-03,2002,EP 01119258 A,2001-08-09,US 67599000 A,2000-09-29,Apparatus for reducing particle residues in a semiconductor processing chamber,An apparatus for reducing particle residues in a semiconductor wafer processing system comprising a chamber and a chamber slot extending through a sidewall of the chamber. A processing platform having at least one sidewall is coupled to the chamber and a wafer channel extends through the chamber sidewall and the at least one processing platform sidewall such that the wafer channel intersects the chamber slot. A chamber slit valve extends through the chamber slot to control particle residues in the wafer channel.,APPLIED MATERIALS INC,GUJER RUDOLF;;CHO TOM K;;KARAZIM MICHAEL P;;ISHIKAWA TETSUYA,,https://lens.org/077-348-421-190-73X,Patent Application,yes,0,1,6,6,0,C23C16/4409;;C23C16/4401;;H01L21/00,H01L21/00;;C23C16/44;;H01L21/205,,0,0,,,,DISCONTINUED
463,WO,A1,WO 2015/009336 A1,111-642-840-688-725,2015-01-22,2015,US 2014/0027406 W,2014-03-14,US 201313944560 A,2013-07-17,REGENERATION OF OLEFIN TREATING ADSORBENTS FOR REMOVAL OF OXYGENATE CONTAMINANTS,"Processes for eliminating oxygenates and water from a light hydrocarbon processing system, wherein oxygenates are removed from a light hydrocarbon stream by adsorption of the oxygenates on an oxygenate adsorption unit to provide a deoxygenated hydrocarbon stream, the oxygenate adsorption unit is regenerated via a regenerant stream to provide an oxygenated regenerant stream comprising the oxygenates, and the oxygenated regenerant stream is subjected to hydro-deoxygenation to convert the oxygenates into paraffins and water, wherein the water may also be permanently removed from the system.",CHEVRON USA INC,CLEVERDON ROBERT FLETCHER;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO,,https://lens.org/111-642-840-688-725,Patent Application,yes,10,0,5,5,0,B01D15/203;;B01J20/3408;;C10G25/00;;C10G29/205;;C10G3/00;;C10G3/42;;C10G3/50;;B01J20/18;;B01J20/345;;Y02P30/20;;C10G3/50;;B01D15/203;;C10G3/42;;B01J20/3408;;C10G25/00;;C10G29/205;;C10G3/00;;B01J20/345;;B01J20/18;;Y02P30/20;;C07C2/58;;C07C7/13,B01D15/20;;B01J20/34;;C07C7/12;;C10G70/04,,0,0,,,,PENDING
464,US,B2,US 9043437 B2,017-224-716-127-737,2015-05-26,2015,US 201313921893 A,2013-06-19,US 201313921893 A;;US 201213654197 A,2012-10-17,Targeted and dynamic content-object storage based on inter-network performance metrics,"Methods and systems for coordinating provisions of storage service for clients are provided. For each storage provider of a set of storage providers, a service-provider database stores a metric characterizing a property of a service provided by the service provider. The storage providers are independently owned and operated relative to each other. The metrics are repeatedly updated. A selection engine repeatedly selects a service provider from the set of service providers to store a content object of a client of the content delivery system. The selection is based on the repeatedly updated metrics for the set of service providers. For each service provider selected by the selection engine to store the content object of the client, a service manager coordinates with the service provider such that the service provider stores the content object of the client.",LIMELIGHT NETWORKS INC,TSUNODA KOICHI;;ASAVAREUNGCHAI MICHAEL;;CHO PAUL;;ACHARYA SOAM;;THIBEAULT JASON,LIMELIGHT NETWORKS INC (2012-10-08),https://lens.org/017-224-716-127-737,Granted Patent,yes,57,0,3,3,0,H04L67/1097;;H04L65/1073;;H04L65/403;;H04L67/1097;;H04L67/60;;H04L65/612,H04L29/08;;H04L29/06,709/217,4,1,122-237-481-505-797,10.1016/j.jnca.2009.03.004,"Broberg et al., ""MetaCDN: Harnessing 'Storage Clouds' for high performance content delivery"", Retrieved on Nov. 3, 2012 from http://citeseerx. ist.psu.edu/viewdoc/download?doi= 1 0.1.1.144. 7766&rep=rep 1 &type=pdf, Journal of Network and Computer Applications, Sep. 2009, vol. 32, Issue 5, 11 pages.;;""Cloud-Web-Hosting-Is-Basically-A-Complete-System,"" Retrieved on Nov. 3,2012 from http://www.pdf-archive.com/2012/09/04/cloud-web-hosting-is-basically-a-complete-system-69-4/cloud-web-hosting-is-basically-a-complete-D system-69-4 .pdf.;;Al-Mukkadim, Khan Pathan et al., ""A Taxonomy and Survey of Content Delivery Networks"", Retrieved on Nov. 3, 2012 from http://www.cloudbus.org/reports/CDN-Taxonomy.pdf.;;U.S. Appl. No. 13/654,197, filed Oct. 17, 2007, Notice of Allowance mailed May 29, 2013, 36 pages.",INACTIVE
465,US,S,US D0770459 S,068-932-399-564-083,2016-11-01,2016,US 201529549125 F,2015-12-18,US 201529549125 F,2015-12-18,Portable worksurface,,STEELCASE INC,YOO HYUN;;HELD MICHAEL;;HO SIU CHO;;SPOELHOF MARK WILLIAM,STEELCASE INC (2015-12-14),https://lens.org/068-932-399-564-083,Design Right,no,0,3,2,2,0,,,0807;;D14/447,0,0,,,,ACTIVE
466,US,A1,US 2014/0108598 A1,079-161-172-764-300,2014-04-17,2014,US 201313921893 A,2013-06-19,US 201313921893 A;;US 201213654197 A,2012-10-17,TARGETED AND DYNAMIC CONTENT-OBJECT STORAGE BASED ON INTER-NETWORK PERFORMANCE METRICS,"Methods and systems for coordinating provisions of storage service for clients are provided. For each storage provider of a set of storage providers, a service-provider database stores a metric characterizing a property of a service provided by the service provider. The storage providers are independently owned and operated relative to each other. The metrics are repeatedly updated. A selection engine repeatedly selects a service provider from the set of service providers to store a content object of a client of the content delivery system. The selection is based on the repeatedly updated metrics for the set of service providers. For each service provider selected by the selection engine to store the content object of the client, a service manager coordinates with the service provider such that the service provider stores the content object of the client.",LIMELIGHT NETWORKS INC,TSUNODA KOICHI;;ASAVAREUNGCHAI MICHAEL;;CHO PAUL;;ACHARYA SOAM;;THIBEAULT JASON,LIMELIGHT NETWORKS INC (2012-10-08),https://lens.org/079-161-172-764-300,Patent Application,yes,48,0,3,3,0,H04L67/1097;;H04L65/1073;;H04L65/403;;H04L67/1097;;H04L67/60;;H04L65/612,H04L29/08,709/217,0,0,,,,INACTIVE
467,CN,A,CN 103052646 A,150-919-302-496-818,2013-04-17,2013,CN 201180035281 A,2011-07-19,US 2011/0044581 W;;US 36562110 P,2010-07-19,Methods for the preparation of diasteromerically pure phosphoramidate prodrugs,Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALA,,https://lens.org/150-919-302-496-818,Patent Application,no,3,10,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/10;;C07H19/20,,1,0,,,"MAMORU UCHIYAMA，等: ""O-Selective Phosphorylation of Nucleosides without N-Protection"", 《J.ORG.CHEM.》, vol. 58, no. 2, 1 January 1993 (1993-01-01)",DISCONTINUED
468,BR,B1,BR 112015013558 B1,181-849-909-508-292,2021-04-13,2021,BR 112015013558 A,2013-11-19,IB 2013060255 W;;US 201213723614 A,2012-12-21,lenços umedecidos com maior resistência e capacidade de dispersão,"lenços umedecidos com maior resistência e capacidade de dispersão a presente divulgação é direcionada a lenços umedecidos incluindo um substrato fibroso, uma composição aglutinante catiônica e uma composição umectante. a composição umectante inclui pelo menos um ácido poliprótico tendo três ou mais grupos funcionais e ácido benzoico.",KIMBERLY CLARK CO,STEVEN MICHAEL HURLEY;;WANDUK LEE;;WILLIAM CLAYTON BUNYARD;;YOONHEE CHO,,https://lens.org/181-849-909-508-292,Granted Patent,no,0,0,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/42;;B65D83/08,,0,0,,,,ACTIVE
469,JP,A,JP 2000208901 A,021-949-517-915-178,2000-07-28,2000,JP 2000003021 A,2000-01-11,US 22950299 A,1999-01-12,MANUFACTURE OF CIRCUIT BOARD FORMING MICROSTRUCTURE LAYER ON BOTH SURFACE OF FLEXIBLE FILM,"PROBLEM TO BE SOLVED: To provide a method for manufacturing a conductive via, wherein an appropriate alignment is kept between circuit elements formed on both surfaces of a flexible board. SOLUTION: A copper layer is provided on both surfaces of a flexible film, a photoresist layer 14 is applied on the copper layer on both surfaces, a closed via 16 penetrating one copper layer and substrate is opened by laser, the photoresist layer 14 is patterned (exposed), a plating is conducted to fill the via 16 with a conductive material, the resist is developed, the line and pad structure on the copper surface are plated, and lastly the photoresist layer 14 is removed. An exposure, may be performed before opening by laser, otherwise a through-hole may be opened instead of the closed via 16, however, no process which affects the dimensions of the substrate is present between an exposure process and laser opening process.",FUJITSU LTD,ZHANG LEI;;WILLIAM CHO;;PETERS MICHAEL G;;BEILIN SOLOMON I,,https://lens.org/021-949-517-915-178,Patent Application,no,0,1,3,3,0,H05K1/0393;;H05K3/0038;;H05K3/108;;H05K3/388;;H05K3/421;;H05K3/423;;H05K3/427;;H05K2201/0394;;H05K2201/09827;;H05K2203/0733;;H05K2203/1383;;H05K3/0038;;H05K3/423;;H05K3/388;;H05K3/108;;H05K3/427;;H05K3/421;;H05K2203/0733;;H05K2201/09827;;H05K1/0393;;H05K2203/1383;;H05K2201/0394,H05K1/00;;H05K3/18;;H05K3/00;;H05K3/10;;H05K3/38;;H05K3/42,,0,0,,,,EXPIRED
470,US,A,US 4668909 A,047-816-747-537-189,1987-05-26,1987,US 60708984 A,1984-05-04,US 60708984 A,1984-05-04,Piezoelectric material testing method and apparatus,An arrangement for testing substrate material intended for use in surface acoustic wave devices such as delay lines; the arrangement includes a plurality of electrical and physical evaluations of the material in quantities suitable for a manufacturing environment. In one evaluation acoustic wave energy developed in a tooling jig mounted transducer is mechanically coupled to successive material samples and the resulting output waveforms compared to expected results while in other evaluations the polarized light indicia and chemical reagent determined properties of the material samples are considered.,US AIR FORCE,HICKERNELL FREDERICK S;;ADAMO MICHAEL D;;CHO FREDERICK Y T,,https://lens.org/047-816-747-537-189,Granted Patent,yes,7,14,1,1,0,G01R29/22;;G01R29/22;;Y10S73/04;;Y10S73/04,G01R29/22,324/56;;X 73DIG 4,1,0,,,"Grenier, Crystal Resonance Frequency Measurement by Phase Detection, 7 1970, pp. 15 19.",EXPIRED
471,CL,A1,CL 2013000076 A1,031-911-529-623-059,2013-11-08,2013,CL 2013000076 A,2013-01-08,US 36562110 P,2010-07-19,Metodos para la preparacion de profarmacos de fosforamidato diastereomericamente puros.,,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/031-911-529-623-059,Patent Application,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07H19/02;;A61K31/7042;;C07D309/10;;C07H1/06;;C07H19/10;;C07H19/20,,0,0,,,,PENDING
472,EP,B1,EP 3497942 B1,092-988-861-341-932,2021-05-26,2021,EP 17754951 A,2017-08-09,US 201615235382 A;;US 2017/0046146 W,2016-08-12,DUAL DIAPHRAGM MICROPHONE,,SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,,https://lens.org/092-988-861-341-932,Granted Patent,yes,2,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R1/04;;H04R1/08;;H04R1/40;;H04R19/01;;H04R19/04,,0,0,,,,ACTIVE
473,JP,A,JP 2002170779 A,103-816-078-961-706,2002-06-14,2002,JP 2001305705 A,2001-10-01,US 67599000 A,2000-09-29,APPARATUS FOR REDUCING PARTICLE RESIDUE IN SEMICONDUCTOR PROCESSING CHAMBER,"PROBLEM TO BE SOLVED: To provide an apparatus for reducing particle residues in a semiconductor wafer processing system. SOLUTION: The apparatus is provided with a chamber and a chamber slot 196 which extends through a side wall of the chamber. A processing platform 120 having at least one side wall 121 is coupled to the chamber, and a wafer channel 131 extends through the side wall of the chamber and at least one side wall of the processing platform 120 such that the wafer channel 131 intersects the chamber slot 196. A chamber slit valve 190 extends through the chamber slot 196 and controls particle residues in the wafer channel 131.",APPLIED MATERIALS INC,GUJER RUDOLF;;CHO TOM K;;KARAZIM MICHAEL P;;ISHIKAWA TETSUYA,,https://lens.org/103-816-078-961-706,Patent Application,no,0,0,6,6,0,C23C16/4409;;C23C16/4401;;H01L21/00,H01L21/00;;C23C16/44;;H01L21/205,,0,0,,,,DISCONTINUED
474,EP,A1,EP 2934264 A1,115-667-440-093-067,2015-10-28,2015,EP 13866125 A,2013-11-19,US 201213723614 A;;IB 2013060255 W,2012-12-21,WET WIPES WITH IMPROVED STRENGTH AND DISPERSIBILITY,,KIMBERLY CLARK CO,HURLEY STEVEN MICHAEL;;BUNYARD WILLIAM CLAYTON;;CHO YOONHEE;;LEE WANDUK,,https://lens.org/115-667-440-093-067,Patent Application,yes,0,0,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/42;;A61K8/365;;A61K8/368;;B65D83/08;;D04H1/64,,0,0,,,,ACTIVE
475,KR,A,KR 20020025823 A,138-728-992-210-170,2002-04-04,2002,KR 20010060636 A,2001-09-28,US 67599000 A,2000-09-29,APPARATUS FOR REDUCING PARTICLE RESIDUES IN A SEMICONDUCTOR PROCESSING CHAMBER,"PURPOSE: An apparatus is provided to be capable of reducing particle residues in a semiconductor wafer processing system. CONSTITUTION: The apparatus is provided with a chamber and a chamber slot(196) which extends through a side wall of the chamber. A processing platform(120) having at least one side wall(121) is coupled to the chamber, and a wafer channel(131) extends through the side wall of the chamber and at least one side wall of the processing platform(120) such that the wafer channel(131) intersects the chamber slot(196). A chamber slit valve(190) extends through the chamber slot(196) and controls particle residues in the wafer channel(131).",APPLIED MATERIALS INC,CHO TOM K;;GUJER RUDOLF;;ISHIKAWA TETSUYA;;KARAZIM MICHAEL P,,https://lens.org/138-728-992-210-170,Patent Application,no,0,0,6,6,0,C23C16/4409;;C23C16/4401;;H01L21/00,H01L21/00;;C23C16/44;;H01L21/205,,0,0,,,,EXPIRED
476,US,A1,US 2018/0048966 A1,173-403-451-875-173,2018-02-15,2018,US 201615235382 A,2016-08-12,US 201615235382 A,2016-08-12,MICROPHONE AND METHODS OF ASSEMBLING MICROPHONES,"A microphone can include a cover having a series of slits and a nest. The nest can be configured to receive a first diaphragm, a second diaphragm, and a PCB in a stacked arrangement, such that the PCB is positioned between the first diaphragm and the second diaphragm. Also the first diaphragm can define a first plane, the second diaphragm can define a second plane, and the PCB can define a third plane and the first plane, the second plane, and the third plane can extend parallel to one another. The cover can also include slits having a first length and a second length, and the first length can be greater than the second length. The slits can extend both radially and axially.",SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,SHURE ACQUISITION HOLDINGS INC (2017-01-23),https://lens.org/173-403-451-875-173,Patent Application,yes,12,4,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R19/04;;H04R1/04;;H04R1/08;;H04R19/00;;H04R19/01,,0,0,,,,ACTIVE
477,BR,A2,BR 112015013558 A2,176-096-819-646-996,2017-07-11,2017,BR 112015013558 A,2013-11-19,IB 2013060255 W;;US 201213723614 A,2012-12-21,lenços umedecidos com maior resistência e capacidade de dispersão,"resumo lenços umedecidos com maior resistência e capacidade de dispersão a presente divulgação é direcionada a lenços umedecidos incluindo um substrato fibroso, uma composição aglutinante catiônica e uma composição umectante. a composição umectante inclui pelo menos um ácido poliprótico tendo três ou mais grupos funcionais e ácido benzoico. 1/1",KIMBERLY CLARK CO,STEVEN MICHAEL HURLEY;;WANDUK LEE;;WILLIAM CLAYTON BUNYARD;;YOONHEE CHO,,https://lens.org/176-096-819-646-996,Patent Application,no,0,0,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/42;;B65D83/08,,0,0,,,,ACTIVE
478,US,A1,US 2022/0190840 A1,063-171-939-701-160,2022-06-16,2022,US 202117406193 A,2021-08-19,KR 20200175437 A,2020-12-15,ANALOG-TO-DIGITAL CONVERTER,"An analog-to-digital converter (ADC) includes a coarse ADC that receives an analog input voltage, generates a first digital signal based on the analog input voltage using a successive approximation register (SAR) method, and outputs a residual voltage remaining after the first digital signal is generated. The ADC further includes an amplifier that receives the residual voltage and a test voltage, generates a residual current by amplifying the residual voltage by a predetermined gain, and generates a test current by amplifying the test voltage by the gain. The ADC further includes a fine ADC that receives the residual current and generates a second digital signal based on the residual current using the SAR method, and an auxiliary path that receives the test current and generates a gain correction signal based on the test current. The gain of the amplifier is adjusted based on the gain correction signal.",SAMSUNG ELECTRONICS CO LTD,MOON KYOUNGJUN;;OH DONGRYEOL;;PARK YOUNGHYO;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2021-06-14),https://lens.org/063-171-939-701-160,Patent Application,yes,9,0,3,3,0,H03M1/0695;;H03M1/164;;H03M1/468;;H03M1/1009;;H03M1/0604;;H03M1/1071;;H03M1/1215;;H03M1/38;;H03M1/1009;;H03M1/1071;;H03M1/46;;H03M1/462;;H03M1/0695;;H03M1/122,H03M1/46;;H03M1/06;;H03M1/12,,1,1,082-593-607-080-133,10.1109/jssc.2019.2926648,"Kyoung-Jun Moon, et al. ""A 9.1-ENOB 6-mW 10-Bit 500-MS/s Pipelined-SAR ADC with Current-Mode Residue Processing in 28-nm CMOS"", IEEE JOURNAL OF SOLID-STATE CIRCUITS, VOL. 54, NO. 9, SEPTEMBER 2019. (Year: 2019)",ACTIVE
479,US,B1,US 8495221 B1,102-507-476-270-614,2013-07-23,2013,US 201213654197 A,2012-10-17,US 201213654197 A,2012-10-17,Targeted and dynamic content-object storage based on inter-network performance metrics,"Methods and systems for coordinating provisions of storage service for clients are provided. For each storage provider of a set of storage providers, a service-provider database stores a metric characterizing a property of a service provided by the service provider. The storage providers are independently owned and operated relative to each other. The metrics are repeatedly updated. A selection engine repeatedly selects a service provider from the set of service providers to store a content object of a client of the content delivery system. The selection is based on the repeatedly updated metrics for the set of service providers. For each service provider selected by the selection engine to store the content object of the client, a service manager coordinates with the service provider such that the service provider stores the content object of the client.",LIMELIGHT NETWORKS INC,TSUNODA KOICHI;;ASAVAREUNGCHAI MICHAEL;;CHO PAUL;;ACHARYA SOAM;;THIBEAULT JASON,LIMELIGHT NETWORKS INC (2012-10-08),https://lens.org/102-507-476-270-614,Granted Patent,yes,55,13,3,3,0,H04L67/1097;;H04L65/1073;;H04L65/403;;H04L67/1097;;H04L67/60;;H04L65/612,G06F13/00;;G06F15/173,709/226;;709/224;;709/225;;711/170;;711/171;;711/172;;711/173,3,1,122-237-481-505-797,10.1016/j.jnca.2009.03.004,"James Broberg et al., ""MetaCDN: Harnessing 'Storage Clouds' for high performance content delivery"", Retrieved on Nov. 3, 2012 from http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.144.7766&rep=rep1&type=pdf, Journal of Network and Computer Applications, Sep. 2009, vol. 32, Issue 5, pp. 1012-1022.;;""Cloud-Web-Hosting-Is-Basically-A-Complete-System"", Retrieved on Nov. 3, 2012 from http://www.pdf-archive.com/2012/09/04/cloud-web-hosting-is-basically-a-complete-system-69-4/cloud-web-hosting-is-basically-a-complete-system-69-4.pdf.;;Al-Mukaddim Khan Pathan et al., ""A Taxonomy and Survey of Content Delivery Networks"", Retrieved on Nov. 3, 2012 from http://www.cloudbus.org/reports/CDN-Taxonomy.pdf.",ACTIVE
480,US,B2,US 10685819 B2,135-067-978-635-178,2020-06-16,2020,US 201815975576 A,2018-05-09,US 201815975576 A;;US 201762511198 P,2017-05-25,Measuring concentrations of radicals in semiconductor processing,"An apparatus includes a reactive species source, a spectral measurement volume, a light source to emit a light beam into the spectral measurement volume, a spectrometer to receive the light beam from the spectral measurement volume. The apparatus includes an a controller configured to, when a reactive species is present in the spectral measurement volume, control the light source to emit the light beam into the spectral measurement volume and the spectrometer to determine an environment spectrum using the light beam, and when the reactive species is not present in the spectral measurement volume, control the light source to emit the light beam into the spectral measurement volume and the spectrometer to determine a baseline spectrum using the light beam, calculate a net spectrum based on a difference between the environment spectrum and the baseline spectrum, and estimate a concentration of the reactive species based on the net spectrum.",APPLIED MATERIALS INC,GOPALAN RAMESH;;CHO TOM K;;ALAJAJIAN GEORGE;;MARK MICHAEL J,APPLIED MATERIALS INC (2018-05-15),https://lens.org/135-067-978-635-178,Granted Patent,yes,11,0,6,6,0,G01N21/031;;G01N21/31;;G01N21/64;;G01N2021/1734;;G01N21/85;;G01N2021/8411;;H01J37/32972;;G01N21/031;;G01N21/31;;G01N2021/1734;;G01N21/64;;G01N21/85;;G01N2021/8411;;G01N21/62;;G01N21/84;;H01J37/32972;;H01L21/67063;;H01L22/10,H01J37/32;;G01N21/03;;G01N21/17;;G01N21/31;;G01N21/62;;G01N21/64;;G01N21/84;;G01N21/85;;H01L21/66;;H01L21/67,,1,0,,,"PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/US2018/031886; dated Nov. 13, 2018; 14 total pages.",ACTIVE
481,WO,A1,WO 2014/092773 A1,136-911-921-336-510,2014-06-19,2014,US 2013/0045221 W,2013-06-11,US 201213715873 A,2012-12-14,PROCESS FOR REDUCING CHLORIDE IN HYDROCARBON PRODUCTS USING AN IONIC LIQUID CATALYST,"We provide a process comprising: a. feeding a chlorinated-hydrocarbon and an ionic liquid catalyst to a treatment unit; b. operating the treatment unit at an elevated temperature to produce dechlorinated-hydrocarbon and HCl; and c. collecting the dechlorinated-hydrocarbon, wherein at least 90 wt% of the chlorides are removed. A second process comprises: a. creating an ionic liquid catalyst-rich zone in a distillation unit; b. passing chlorinated-hydrocarbon to the distillation unit; c. operating the unit under conditions causing removal of alkyl chloride to produce dechlorinated-hydrocarbon having a final boiling point close to a first final boiling point. A third process comprises: a. feeding alkylate gasoline blending component and ionic liquid catalyst to a treatment unit; b. operating the treatment unit; and c. collecting a dechlorinated-hydrocarbon, wherein at least 90 wt% of the chlorides have been removed and the dechlorinated-hydrocarbon has a second RON that is close to a first RON.",CHEVRON USA INC,ZHAN BI-ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN,,https://lens.org/136-911-921-336-510,Patent Application,yes,8,0,11,11,0,B01J31/0284;;B01J31/0288;;B01J31/0289;;B01J2231/64;;B01D3/009;;C10G29/26;;C10G75/00;;C10G7/10;;C10G2300/1081;;C10G2300/202;;C07C7/10;;B01J31/0288;;B01J31/0289;;B01J31/0284;;B01J2231/64;;B01D3/009;;C10G29/16;;C10G2300/1081;;C10G7/10;;C10G29/26;;C10G75/00;;C10G2300/202;;B01J31/26,B01J31/26,,2,0,,,"PURE & APPL. CHEM., vol. 67, no. 8/9, 1995, pages 1257 - 1306;;ANDERSON, P. C.; SHARKEY, J. M.; WALSH, R. P., JOURNAL INSTITUTE OF PETROLEUM, vol. 58, no. 560, 1972, pages 83",PENDING
482,US,A1,US 2022/0166429 A1,141-021-100-740-547,2022-05-26,2022,US 202117387221 A,2021-07-28,KR 20200157648 A,2020-11-23,MULTIPLEXER AND SEMICONDUCTOR DEVICE INCLUDING THE SAME,"A multiplexer includes a charging circuit; a plurality of sampling switches receiving a plurality of input signals; and a plurality of boosting circuits connected between the sampling switches and the charging circuit and sharing the charging circuit. First and second charging switches of the charging circuit are controlled by a first clock signal. Each of the boosting circuits includes a first boosting switch connected to a first node of the charging circuit and a gate of one of the sampling switches, a second boosting switch connected between a second node of the charging circuit and the one sampling switch, and a level shifter configured to control the first boosting switch and the second boosting switch in response to a second clock signal and a selection signal.",SAMSUNG ELECTRONICS CO LTD,LEE SANGHEON;;LIM WOONGTAEK;;LEE JUNGHO;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2021-05-21),https://lens.org/141-021-100-740-547,Patent Application,yes,3,3,2,2,0,H02M3/07;;H02M1/08;;H03M1/1245;;G11C27/024;;H03K2217/0081;;H03K17/693;;H03K17/693;;H02M3/07;;H03K19/018521;;H03K17/693;;H02M3/07;;H03M1/122,H03K17/693;;H02M3/07;;H03M1/12,,0,0,,,,PENDING
483,US,A1,US 2014/0173841 A1,154-608-338-147-844,2014-06-26,2014,US 201213723614 A,2012-12-21,US 201213723614 A,2012-12-21,WET WIPES WITH IMPROVED STRENGTH AND DISPERSIBILITY,"The present disclosure is directed to wet wipes including a fibrous substrate, a cationic binder composition, and a wetting composition. The wetting composition includes at least one polyprotic acid having three or more functional groups and benzoic acid.",KIMBERLY CLARK CO,HURLEY STEVEN MICHAEL;;BUNYARD WILLIAM CLAYTON;;CHO YOONHEE;;LEE WANDUK,KIMBERLY-CLARK WORLDWIDE INC (2012-12-20),https://lens.org/154-608-338-147-844,Patent Application,yes,9,17,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A61K8/02,15/104.93,0,0,,,,DISCONTINUED
484,US,B2,US 11539902 B2,162-169-759-562-796,2022-12-27,2022,US 202017060345 A,2020-10-01,KR 20200028652 A,2020-03-06,Correlated double sampling circuit and image sensor including the same,"A flicker detection circuit is provided. The flicker detection circuit may include a flicker detection correlated double sampling (FD CDS) circuit including first to sixth switches turned on or off based on a control signal, and first to fourth capacitors, the FD CDS circuit being configured to receive a flicker pixel signal output from at least one pixel, summate with an output offset signal, and amplify the summation based on a gain to form a flicker detection signal; and an analog-to-digital converter (ADC) configured to quantize the flicker detection signal.",SAMSUNG ELECTRONICS CO LTD,NAM SANGPIL;;LEE KYUNGHOON;;LEE JUNGHO;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2020-09-09),https://lens.org/162-169-759-562-796,Granted Patent,yes,10,0,4,4,0,H04N25/75;;H03M1/1295;;H03M1/1245;;H03M1/08;;H04N23/745;;H04N25/616;;H04N25/702;;H04N25/75;;H04N25/616;;H04N25/772;;H04N25/75;;H04N25/616;;H04N23/745;;H04N25/75;;H04N25/772,H04N5/357;;H04N5/3745;;H04N5/235;;H04N5/378,,0,0,,,,ACTIVE
485,WO,A1,WO 2018/232367 A1,183-015-433-174-267,2018-12-20,2018,US 2018/0037936 W,2018-06-15,US 201762521238 P,2017-06-16,CONFIGURABILITY AND SIGNALING FOR HALF-TONE SHIFT,"Described is an apparatus of a User Equipment (UE) operable to communicate with an Evolved Node-B (eNB) on a wireless network. The apparatus may comprise a first circuitry, a second circuitry, and a third circuitry. The first circuitry may be operable to process a configuration transmission carrying a half-tone shifting indicator. The second circuitry may be operable to select one or more subcarrier frequencies for Uplink (UL) transmission based on the half-tone shifting indicator. The third circuitry may be operable to generate a UL transmission for the one or more subcarrier frequencies. The half-tone shifting indicator may have a first value indicating application of a half-subcarrier offset, and a second value indicating no application of the half-subcarrier offset.",INTEL IP CORP,JEON JEONGHO;;CHO JOONYOUNG;;FAERBER MICHAEL;;HAN SEUNGHEE;;MIAO HONGLEI,,https://lens.org/183-015-433-174-267,Patent Application,yes,0,2,11,11,0,H04L5/0007;;H04L5/0053;;H04J11/0023;;H04W28/26;;H04J11/0023;;H04L5/0007;;H04L27/2666;;H04L5/0007;;H04L27/2666,H04J11/00;;H04L5/00;;H04L27/26;;H04W16/14,,2,0,,,"ERICSSON: ""On uplink half-tone shift and LTE/NR co-existence"", vol. RAN WG1, no. Spokane, WA, USA; 20170403 - 20170407, 2 April 2017 (2017-04-02), XP051242951, Retrieved from the Internet <URL:http://www.3gpp.org/ftp/Meetings_3GPP_SYNC/RAN1/Docs/> [retrieved on 20170402];;ERICSSON: ""On uplink half-tone shift"", vol. RAN WG1, no. Hanqzhou, China; 20170515 - 20170519, 14 May 2017 (2017-05-14), XP051274214, Retrieved from the Internet <URL:http://www.3gpp.org/ftp/Meetings_3GPP_SYNC/RAN1/Docs/> [retrieved on 20170514]",PENDING
486,EP,A1,EP 3639420 A1,030-302-774-908-824,2020-04-22,2020,EP 18742872 A,2018-06-15,US 201762521238 P;;US 2018/0037936 W,2017-06-16,CONFIGURABILITY AND SIGNALING FOR HALF-TONE SHIFT,,INTEL IP CORP,JEON JEONGHO;;CHO JOONYOUNG;;FAERBER MICHAEL;;HAN SEUNGHEE;;MIAO HONGLEI,APPLE INC. (2020-12-23),https://lens.org/030-302-774-908-824,Patent Application,yes,0,0,11,11,0,H04L5/0007;;H04L5/0053;;H04J11/0023;;H04W28/26;;H04J11/0023;;H04L5/0007;;H04L27/2666;;H04L5/0007;;H04L27/2666,H04J11/00;;H04L5/00;;H04L27/26;;H04W16/14,,0,0,,,,DISCONTINUED
487,US,A1,US 2010/0191951 A1,040-200-690-049-327,2010-07-29,2010,US 69365410 A,2010-01-26,US 69365410 A;;US 14738509 P,2009-01-26,PROVISIONED FIRMWARE UPDATES USING OBJECT IDENTIFIERS,"Methods, devices, and systems are provided for remotely updating provisioning data in devices or a population of devices. An update message is generated that includes an Object Identifier (OID) that uniquely identifies eligible devices or components for the provisioning data update. If an eligible device receives the update message, then the new provisioning data is loaded on the device, thereby replacing the old provisioning data on the device.",ASSA ABLOY AB,MALONE MICHAEL WILLIAM;;CHO YOONG-GOOG;;SMITH THAD;;MILBRANDT RYAN,ASSA ABLOY AB (2010-02-16),https://lens.org/040-200-690-049-327,Patent Application,yes,7,44,5,5,0,G06F8/65;;G06F21/572;;G06F21/44;;G06F8/65;;G06F9/445,G06F9/22;;G06F9/44;;G06F12/02;;G06F15/16,713/2;;717/172;;711/103;;X711E12008,0,0,,,,INACTIVE
488,US,A1,US 2023/0353441 A1,052-385-285-138-691,2023-11-02,2023,US 202318211661 A,2023-06-20,US 202318211661 A;;US 202217717890 A;;US 201916614106 A;;US 2018/0037936 W;;US 201762521238 P,2017-06-16,CONFIGURABILITY AND SIGNALING FOR HALF-TONE SHIFT,"Described is an apparatus of a User Equipment (UE) operable to communicate with an Evolved Node-B (eNB) on a wireless network. The apparatus may comprise a first circuitry, a second circuitry, and a third circuitry. The first circuitry may be operable to process a configuration transmission carrying a half-tone shifting indicator. The second circuitry may be operable to select one or more subcarrier frequencies for Uplink (UL) transmission based on the half-tone shifting indicator. The third circuitry may be operable to generate a UL transmission for the one or more subcarrier frequencies. The half-tone shifting indicator may have a first value indicating application of a half-subcarrier offset, and a second value indicating no application of the half-subcarrier offset.",APPLE INC,JEON JEONGHO;;CHO JOONYOUNG;;FAERBER MICHAEL;;HAN SEUNGHEE;;MIAO HONGLEI,,https://lens.org/052-385-285-138-691,Patent Application,yes,4,0,11,11,0,H04L5/0007;;H04L5/0053;;H04J11/0023;;H04W28/26;;H04J11/0023;;H04L5/0007;;H04L27/2666;;H04L5/0007;;H04L27/2666,H04L27/26;;H04L5/00,,0,0,,,,PENDING
489,MX,B,MX 363274 B,087-373-536-555-521,2019-03-15,2019,MX 2015007378 A,2013-11-19,US 201213723614 A;;IB 2013060255 W,2012-12-21,WET WIPES WITH IMPROVED STRENGTH AND DISPERSIBILITY.,"The present disclosure is directed to wet wipes including a fibrous substrate, a cationic binder composition, and a wetting composition. The wetting composition includes at least one polyprotic acid having three or more functional groups and benzoic acid.",KIMBERLY CLARK CO,WILLIAM CLAYTON BUNYARD;;STEVEN MICHAEL HURLEY;;YOONHEE CHO;;WANDUK LEE,,https://lens.org/087-373-536-555-521,Granted Patent,no,0,0,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/42;;B65D83/08,,0,0,,,,ACTIVE
490,CN,A,CN 110603758 A,168-858-035-314-190,2019-12-20,2019,CN 201880029874 A,2018-06-15,US 201762521238 P;;US 2018/0037936 W,2017-06-16,CONFIGURABILITY AND SIGNALING FOR HALF-TONE SHIFT,"Described is an apparatus of a User Equipment (UE) operable to communicate with an Evolved Node-B (eNB) on a wireless network. The apparatus may comprise a first circuitry, a second circuitry, and a third circuitry. The first circuitry may be operable to process a configuration transmission carrying a half-tone shifting indicator. The second circuitry may be operable to select one or more subcarrier frequencies for Uplink (UL) transmission based on the half-tone shifting indicator. The third circuitry may be operable to generate a UL transmission for the one or more subcarrier frequencies. Thehalf-tone shifting indicator may have a first value indicating application of a half-subcarrier offset, and a second value indicating no application of the half-subcarrier offset.",INTEL IP CORP,JEON JEONGHO;;CHO JOONYOUNG;;FAERBER MICHAEL;;HAN SEUNGHEE;;MIAO HONGLEI,,https://lens.org/168-858-035-314-190,Patent Application,no,2,2,11,11,0,H04L5/0007;;H04L5/0053;;H04J11/0023;;H04W28/26;;H04J11/0023;;H04L5/0007;;H04L27/2666;;H04L5/0007;;H04L27/2666,H04J11/00;;H04L5/00;;H04L27/26;;H04W16/14,,2,0,,,"ERICSSON: ""R1-1709056 ""On uplink half-tone shift"""", 《3GPP TSG-RAN WG1 #89 R1-1709056》;;ERICSSON AB: ""R1-1704815 ""On uplink half-tone shift and LTE/NR co-existence"""", 《TSG-RAN WG1#88BIS R1-1704815》",ACTIVE
491,US,B2,US 11228847 B2,186-566-950-759-546,2022-01-18,2022,US 202016918726 A,2020-07-01,US 202016918726 A;;US 201916528880 A;;US 201615235382 A,2016-08-12,Microphone and methods of assembling microphones,"A microphone can include a cover having a series of slits and a nest. The nest can be configured to receive a first diaphragm, a second diaphragm, and a PCB in a stacked arrangement, such that the PCB is positioned between the first diaphragm and the second diaphragm. Also, the first diaphragm can define a first plane, the second diaphragm can define a second plane, and the PCB can define a third plane and the first plane, the second plane, and the third plane can extend parallel to one another. The cover can also include slits having a first length and a second length, and the first length can be greater than the second length. The slits can extend both radially and axially.",SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,SHURE ACQUISITION HOLDINGS INC (2017-01-23),https://lens.org/186-566-950-759-546,Granted Patent,yes,20,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R19/00;;H04R1/04;;H04R1/08;;H04R1/28;;H04R1/40;;H04R19/01;;H04R19/04,,13,0,,,"Sep. 2, 2011—“Meteor Mic—USB Studio Microphone” Samson Technologies Inc.? <URL https://web.archive.org/web/20110902141522/http://www.sams ontech.com/samson/products/microphones/usb-microphones/meteormic/>https://web.archive.org/web/20110902141522/http://www.samsontech.com /samson/products/microphones/usb-microphones/meteormic/.;;Sep. 23, 2020—(CN) Office Action—Application No. 201780057835.2.;;Feb. 21, 2019—(WO) International Preliminary Report on Patentability—App PCT/US2017/046146.;;Jan. 3, 2018—(WO) Written Opinion and International Search Authority—App PCT/US2017/046146.;;Bruel & Kjaer 4938—1/4-inch pressure-field microphone, 4 Hz to 70 kHz, 200v polarization—Jul. 22, 2016.;;Jensen, Mads Herring, MEMS Microphone Model Presented at ASA 166 in San Francisco, COMSOL Blog, Jan. 2, 2014, retrieved online at: «https://www.comsol.com/blogs/mems-microphone-model-presented-asa-166-san-francisco/».;;Sep. 11, 2019—(US) Non Final Office Action—U.S. Appl. No. 16/528,880.;;Dec. 11, 2019—(EP) Office Action—Appl No. 17754951.6.;;Dec. 3, 2019—(CN) Office Action—Appln No. 201780057835.2.;;Mar. 19, 2020—(US) Final Office Action—U.S. Appl. No. 16/528,880.;;May 12, 2020—(US) Notice of Allowance—U.S. Appl. No. 16/528,880.;;Mar. 2, 2021—(TW) Office Action—Application No. 106127256.;;Mar. 3, 2021—(CN) Office Action—Application No. 201780057835.2.",ACTIVE
492,TW,B,TW I791460 B,008-935-184-882-110,2023-02-11,2023,TW 106127256 A,2017-08-11,US 201615235382 A,2016-08-12,Microphone,,SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,,https://lens.org/008-935-184-882-110,Granted Patent,no,6,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,,,0,0,,,,ACTIVE
493,EP,A1,EP 2389630 A1,092-726-279-143-084,2011-11-30,2011,EP 10733989 A,2010-01-26,US 2010/0022046 W;;US 14738509 P,2009-01-26,PROVISIONED FIRMWARE UPDATES USING OBJECT IDENTIFIERS,,ASSA ABLOY AB,MALONE MICHAEL WILLIAM;;SMITH THAD;;CHO YOONG-GOOG;;MILBRANDT RYAN,,https://lens.org/092-726-279-143-084,Patent Application,yes,0,0,5,5,0,G06F8/65;;G06F21/572;;G06F21/44;;G06F8/65;;G06F9/445,G06F9/445,,0,0,,,,DISCONTINUED
494,US,S,US D0799869 S,152-701-313-596-823,2017-10-17,2017,US 201529549123 F,2015-12-18,US 201529549123 F,2015-12-18,Podium,,STEELCASE INC,YOO HYUN;;HELD MICHAEL;;HO SIU CHO;;SPOELHOF MARK WILLIAM,STEELCASE INC (2015-12-14),https://lens.org/152-701-313-596-823,Design Right,no,0,7,2,2,0,,,0804;;D 6700;;D6/641;;D6/685,0,0,,,,ACTIVE
495,EP,A1,EP 4178128 A1,014-028-398-782-180,2023-05-10,2023,EP 22216241 A,2018-06-15,US 201762521238 P;;EP 18742872 A;;US 2018/0037936 W,2017-06-16,CONFIGURABILITY AND SIGNALING FOR HALF-TONE SHIFT,"There is provided a base station comprising: a transceiver configured to enable wireless communication with a user equipment, UE; and a processor, communicatively coupled to the transceiver. The processor is configured to: generate a configuration transmission carrying a half-tone shifting indicator, wherein the half-tone shifting indicator corresponds to one or more subcarrier frequencies to be used for an uplink transmission by the UE; transmit, using the transceiver, the configuration transmission to the UE via a higher layer signaling; and receive, using the transceiver, an Uplink, UL, transmission through the one or more subcarrier frequencies. Wherein the half-tone shifting indicator has a first value indicating application of a half-subcarrier offset and a second value indicating no application of the half-subcarrier offset.
",APPLE INC,JEON JEONGHO;;CHO JOONYOUNG;;FAERBER MICHAEL;;HAN SEUNGHEE;;MIAO HONGLEI,,https://lens.org/014-028-398-782-180,Patent Application,yes,1,0,11,11,0,H04L5/0007;;H04L5/0053;;H04J11/0023;;H04W28/26;;H04J11/0023;;H04L5/0007;;H04L27/2666;;H04L5/0007;;H04L27/2666,H04J11/00;;H04L5/00;;H04L27/26,,2,0,,,"ERICSSON: ""On uplink half-tone shift and LTE/NR co-existence"", vol. RAN WG1, no. Spokane, WA, USA; 20170403 - 20170407, 2 April 2017 (2017-04-02), XP051242951, Retrieved from the Internet <URL:http://www.3gpp.org/ftp/Meetings_3GPP_SYNC/RAN1/Docs/> [retrieved on 20170402];;ERICSSON: ""On uplink half-tone shift"", vol. RAN WG1, no. Hanqzhou, China; 20170515 - 20170519, 14 May 2017 (2017-05-14), XP051274214, Retrieved from the Internet <URL:http://www.3gpp.org/ftp/Meetings_3GPP_SYNC/RAN1/Docs/> [retrieved on 20170514]",PENDING
496,AU,B2,AU 2013/360304 B2,022-495-896-536-292,2016-07-21,2016,AU 2013/360304 A,2013-06-11,US 201213715873 A;;US 2013/0045221 W,2012-12-14,Process for reducing chloride in hydrocarbon products using an ionic liquid catalyst,"We provide a process comprising: a. feeding a chlorinated-hydrocarbon and an ionic liquid catalyst to a treatment unit; b. operating the treatment unit at an elevated temperature to produce dechlorinated-hydrocarbon and HCl; and c. collecting the dechlorinated-hydrocarbon, wherein at least 90 wt% of the chlorides are removed. A second process comprises: a. creating an ionic liquid catalyst-rich zone in a distillation unit; b. passing chlorinated-hydrocarbon to the distillation unit; c. operating the unit under conditions causing removal of alkyl chloride to produce dechlorinated-hydrocarbon having a final boiling point close to a first final boiling point. A third process comprises: a. feeding alkylate gasoline blending component and ionic liquid catalyst to a treatment unit; b. operating the treatment unit; and c. collecting a dechlorinated-hydrocarbon, wherein at least 90 wt% of the chlorides have been removed and the dechlorinated-hydrocarbon has a second RON that is close to a first RON.",CHEVRON USA INC,ZHAN BI-ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN,,https://lens.org/022-495-896-536-292,Granted Patent,no,7,0,11,11,0,B01J31/0284;;B01J31/0288;;B01J31/0289;;B01J2231/64;;B01D3/009;;C10G29/26;;C10G75/00;;C10G7/10;;C10G2300/1081;;C10G2300/202;;C07C7/10;;B01J31/0288;;B01J31/0289;;B01J31/0284;;B01J2231/64;;B01D3/009;;C10G29/16;;C10G2300/1081;;C10G7/10;;C10G29/26;;C10G75/00;;C10G2300/202;;B01J31/26,B01J31/26,,0,0,,,,INACTIVE
497,AU,B2,AU 2013/365879 B2,060-841-562-454-892,2018-01-18,2018,AU 2013/365879 A,2013-11-19,US 201213723614 A;;IB 2013060255 W,2012-12-21,Wet wipes with improved strength and dispersibility,"The present disclosure is directed to wet wipes including a fibrous substrate, a cationic binder composition, and a wetting composition. The wetting composition includes at least one polyprotic acid having three or more functional groups and benzoic acid.",KIMBERLY CLARK CO,HURLEY STEVEN MICHAEL;;BUNYARD WILLIAM CLAYTON;;CHO YOONHEE;;LEE WANDUK,,https://lens.org/060-841-562-454-892,Granted Patent,no,5,0,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/42;;B65D83/08,,0,0,,,,ACTIVE
498,WO,A1,WO 2010/085781 A1,079-493-719-766-66X,2010-07-29,2010,US 2010/0022046 W,2010-01-26,US 14738509 P,2009-01-26,PROVISIONED FIRMWARE UPDATES USING OBJECT IDENTIFIERS,"Methods, devices, and systems are provided for remotely updating provisioning data in devices or a population of devices. An update message is generated that includes an Object Identifier (OID) that uniquely identifies eligible devices or components for the provisioning data update. If an eligible device receives the update message, then the new provisioning data is loaded on the device, thereby replacing the old provisioning data on the device.",ASSA ABLOY AB;;MALONE MICHAEL WILLIAM;;SMITH THAD;;CHO YOONG-GOOG;;MILBRANDT RYAN,MALONE MICHAEL WILLIAM;;SMITH THAD;;CHO YOONG-GOOG;;MILBRANDT RYAN,,https://lens.org/079-493-719-766-66X,Patent Application,yes,5,2,5,5,0,G06F8/65;;G06F21/572;;G06F21/44;;G06F8/65;;G06F9/445,G06F12/00,,1,0,,,See also references of EP 2389630A4,PENDING
499,EP,B1,EP 2934264 B1,130-346-780-815-413,2018-05-30,2018,EP 13866125 A,2013-11-19,US 201213723614 A;;IB 2013060255 W,2012-12-21,WET WIPES WITH IMPROVED STRENGTH AND DISPERSIBILITY,,KIMBERLY CLARK CO,HURLEY STEVEN MICHAEL;;BUNYARD WILLIAM CLAYTON;;CHO YOONHEE;;LEE WANDUK,,https://lens.org/130-346-780-815-413,Granted Patent,yes,6,0,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/42;;A61K8/365;;A61K8/368;;B65D83/08;;D04H1/64,,0,0,,,,ACTIVE
500,CN,A,CN 115102676 A,194-212-081-564-457,2022-09-23,2022,CN 202210671827 A,2018-06-15,US 201762521238 P;;CN 201880029874 A;;US 2018/0037936 W,2017-06-16,Configurability and signaling of semitone offset,"The invention relates to configurability and signaling of semitone offset. An apparatus of a user equipment (UE) operable to communicate with an evolved Node B (eNB) over a wireless network is described. The apparatus may include a first circuit, a second circuit, and a third circuit. The first circuit is operable to process a configuration transmission carrying a semitone offset indicator. The second circuitry is operable to select one or more subcarrier frequencies for uplink (UL) transmissions based on the semitone offset indicator. The third circuit is operable to generate UL transmissions for one or more subcarrier frequencies. The half-tone offset indicator may have a first value indicating that the half-subcarrier offset is applied and a second value indicating that the half-subcarrier offset is not applied.",APPLE INC,JEON JEONGHO;;CHO JOONYOUNG;;FAERBER MICHAEL;;HAN SEUNGHEE;;MIAO HONGLEI,,https://lens.org/194-212-081-564-457,Patent Application,no,0,0,11,11,0,H04L5/0007;;H04L5/0053;;H04J11/0023;;H04W28/26;;H04J11/0023;;H04L5/0007;;H04L27/2666;;H04L5/0007;;H04L27/2666,H04L5/00;;H04J11/00;;H04W28/26,,2,0,,,"ERICSSON AB: ""R1-1704815 ""On uplink half-tone shift and LTE/NR co-existence"""", 3GPP TSG_RAN\\WG1_RL1, no. 1;;ERICSSON: ""R1-1709056 ""On uplink half-tone shift"""", 3GPP TSG_RAN\\WG1_RL1, no. 1",PENDING
501,US,A1,US 2015/0025285 A1,022-547-226-867-537,2015-01-22,2015,US 201313944560 A,2013-07-17,US 201313944560 A,2013-07-17,REGENERATION OF OLEFIN TREATING ADSORBENTS FOR REMOVAL OF OXYGENATE CONTAMINANTS,"Processes for eliminating oxygenates and water from a light hydrocarbon processing system, wherein oxygenates are removed from a light hydrocarbon stream by adsorption of the oxygenates on an oxygenate adsorption unit to provide a deoxygenated hydrocarbon stream, the oxygenate adsorption unit is regenerated via a regenerant stream to provide an oxygenated regenerant stream comprising the oxygenates, and the oxygenated regenerant stream is subjected to hydro-deoxygenation to convert the oxygenates into paraffins and water, wherein the water may also be permanently removed from the system.",CLEVERDON ROBERT FLETCHER;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO;;CHEVRON USA INC,CLEVERDON ROBERT FLETCHER;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO,CHEVRON U.S.A. INC (2013-07-15),https://lens.org/022-547-226-867-537,Patent Application,yes,6,9,5,5,0,B01D15/203;;B01J20/3408;;C10G25/00;;C10G29/205;;C10G3/00;;C10G3/42;;C10G3/50;;B01J20/18;;B01J20/345;;Y02P30/20;;C10G3/50;;B01D15/203;;C10G3/42;;B01J20/3408;;C10G25/00;;C10G29/205;;C10G3/00;;B01J20/345;;B01J20/18;;Y02P30/20;;C07C2/58;;C07C7/13,C07C7/13;;C07C2/58,585/331;;585/733,0,0,,,,DISCONTINUED
502,US,A1,US 2019/0356988 A1,039-865-811-400-090,2019-11-21,2019,US 201916528880 A,2019-08-01,US 201916528880 A;;US 201615235382 A,2016-08-12,Microphone and Methods of Assembling Microphones,"A microphone can include a cover having a series of slits and a nest. The nest can be configured to receive a first diaphragm, a second diaphragm, and a PCB in a stacked arrangement, such that the PCB is positioned between the first diaphragm and the second diaphragm. Also the first diaphragm can define a first plane, the second diaphragm can define a second plane, and the PCB can define a third plane and the first plane, the second plane, and the third plane can extend parallel to one another. The cover can also include slits having a first length and a second length, and the first length can be greater than the second length. The slits can extend both radially and axially.",SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,SHURE ACQUISITION HOLDINGS INC (2017-01-23),https://lens.org/039-865-811-400-090,Patent Application,yes,9,1,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R19/04;;H04R1/04;;H04R1/08;;H04R19/00;;H04R19/01,,0,0,,,,ACTIVE
503,TW,B,TW I791524 B,029-379-822-636-473,2023-02-11,2023,TW 107117191 A,2018-05-21,US 201762511198 P,2017-05-25,"Apparatus for manufacturing an electronic device, apparatus for manufacturing a semiconductor device, and method of estimating a gas concentration in a semiconductor processing chamber",,APPLIED MATERIALS INC,GOPALAN RAMESH;;CHO TOM K;;ALAJAJIAN GEVORK;;MARK MICHAEL J,,https://lens.org/029-379-822-636-473,Granted Patent,no,6,0,6,6,0,G01N21/031;;G01N21/31;;G01N21/64;;G01N2021/1734;;G01N21/85;;G01N2021/8411;;H01J37/32972;;G01N21/031;;G01N21/31;;G01N2021/1734;;G01N21/64;;G01N21/85;;G01N2021/8411;;G01N21/62;;G01N21/84;;H01J37/32972;;H01L21/67063;;H01L22/10,,,0,0,,,,ACTIVE
504,EP,A4,EP 2934264 A4,060-610-645-644-159,2016-10-19,2016,EP 13866125 A,2013-11-19,US 201213723614 A;;IB 2013060255 W,2012-12-21,WET WIPES WITH IMPROVED STRENGTH AND DISPERSIBILITY,,KIMBERLY CLARK CO,HURLEY STEVEN MICHAEL;;BUNYARD WILLIAM CLAYTON;;CHO YOONHEE;;LEE WANDUK,,https://lens.org/060-610-645-644-159,Search Report,no,1,0,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/42;;A61K8/365;;A61K8/368;;B65D83/08;;D04H1/64,,0,0,,,,ACTIVE
505,US,B2,US 10743113 B2,081-228-099-403-482,2020-08-11,2020,US 201916528880 A,2019-08-01,US 201916528880 A;;US 201615235382 A,2016-08-12,Microphone and methods of assembling microphones,"A microphone can include a cover having a series of slits and a nest. The nest can be configured to receive a first diaphragm, a second diaphragm, and a PCB in a stacked arrangement, such that the PCB is positioned between the first diaphragm and the second diaphragm. Also the first diaphragm can define a first plane, the second diaphragm can define a second plane, and the PCB can define a third plane and the first plane, the second plane, and the third plane can extend parallel to one another. The cover can also include slits having a first length and a second length, and the first length can be greater than the second length. The slits can extend both radially and axially.",SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,SHURE ACQUISITION HOLDINGS INC (2017-01-23),https://lens.org/081-228-099-403-482,Granted Patent,yes,14,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R19/00;;H04R1/04;;H04R1/08;;H04R1/28;;H04R1/40;;H04R19/01;;H04R19/04,,6,0,,,"Feb. 21, 2019—(WO) International Preliminary Report on Patentability—App PCT/US2017/046146.;;Jensen, Mads Herring, MEMS Microphone Model Presented at ASA 166 in San Francisco, COMSOL Blog, Jan. 2, 2014, retrieved online at: <<https:/fwww_comsol.com/blogs/mems-microphone-model-presented-asa-166-san-francisco/>>.;;Jan. 3, 2018—(WO) Written Opinion and International Search Authority—App PCT/US2017/046146.;;Bruel & Kjaer 4938—1/4-inch pressure-field microphone, 4Hz to 70kHz, 200v polarization—Jul. 22, 2016.;;Dec. 11, 2019—(EP) Office Action—Appl No. 17754951.6.;;Dec. 3, 2019—(CN) Office Action—Appln No. 201780057835.2.",ACTIVE
506,US,B2,US 11041617 B2,091-850-629-789-822,2021-06-22,2021,US 201916391095 A,2019-04-22,US 201916391095 A;;US 201862660800 P,2018-04-20,Luminaire with an integrated camera,"A luminaire includes a terminal block that receives power from a power source, a light source power supply electrically coupled to the terminal block and to a light source, a power converter electrically coupled to the terminal block and to a power over Ethernet injector, a camera coupled to the power over Ethernet injector, and a transceiver electrically coupled to the power converter. The power over Ethernet injector can supply power to and receive data from the camera. The transceiver is also coupled to the power over Ethernet injector and can communicate data to and receive data from the camera.",SIGNIFY HOLDING BV,ADEJUMO TUNJI;;CHO NAM CHIN;;LU CHRIS;;SACHETTI JAY MICHAEL,EATON INTELLIGENT POWER LIMITED (2019-05-01);;SIGNIFY HOLDING B.V (2020-03-02),https://lens.org/091-850-629-789-822,Granted Patent,yes,45,0,2,2,0,H04L12/2803;;F21V33/0052;;F21V33/0076;;G08B13/19619;;G08B13/19658;;G08B13/1966;;H04N23/661;;H04N23/57;;H04N23/695;;F21V33/0052;;H04L12/10;;F21V33/0076;;H04N23/56;;H04N23/661,F21V33/00;;H04L12/10;;H04N5/225;;H04N5/232,,0,0,,,,ACTIVE
507,TW,A,TW 201907150 A,112-484-620-486-14X,2019-02-16,2019,TW 107117191 A,2018-05-21,US 201762511198 P,2017-05-25,Measuring concentrations of radicals in semiconductor processing,"An apparatus includes a reactive species source, a spectral measurement volume, a light source to emit a light beam into the spectral measurement volume, a spectrometer to receive the light beam from the spectral measurement volume. The apparatus includes an a controller configured to, when a reactive species is present in the spectral measurement volume, control the light source to emit the light beam into the spectral measurement volume and the spectrometer to determine an environment spectrum using the light beam, and when the reactive species is not present in the spectral measurement volume, control the light source to emit the light beam into the spectral measurement volume and the spectrometer to determine a baseline spectrum using the light beam, calculate a net spectrum based on a difference between the environment spectrum and the baseline spectrum, and estimate a concentration of the reactive species based on the net spectrum.",APPLIED MATERIALS INC,GOPALAN RAMESH;;CHO TOM K;;ALAJAJIAN GEVORK;;MARK MICHAEL J,,https://lens.org/112-484-620-486-14X,Patent of Addition,no,0,0,6,6,0,G01N21/031;;G01N21/31;;G01N21/64;;G01N2021/1734;;G01N21/85;;G01N2021/8411;;H01J37/32972;;G01N21/031;;G01N21/31;;G01N2021/1734;;G01N21/64;;G01N21/85;;G01N2021/8411;;G01N21/62;;G01N21/84;;H01J37/32972;;H01L21/67063;;H01L22/10,G01N21/62;;G01N21/84;;H01J37/32;;H01L21/66;;H01L21/67,,0,0,,,,ACTIVE
508,US,A1,US 2020/0396548 A1,180-354-303-833-639,2020-12-17,2020,US 202016918726 A,2020-07-01,US 202016918726 A;;US 201916528880 A;;US 201615235382 A,2016-08-12,Microphone and Methods of Assembling Microphones,"A microphone can include a cover having a series of slits and a nest. The nest can be configured to receive a first diaphragm, a second diaphragm, and a PCB in a stacked arrangement, such that the PCB is positioned between the first diaphragm and the second diaphragm. Also, the first diaphragm can define a first plane, the second diaphragm can define a second plane, and the PCB can define a third plane and the first plane, the second plane, and the third plane can extend parallel to one another. The cover can also include slits having a first length and a second length, and the first length can be greater than the second length. The slits can extend both radially and axially.",SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,SHURE ACQUISITION HOLDINGS INC (2017-01-23),https://lens.org/180-354-303-833-639,Patent Application,yes,0,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R19/04;;H04R1/04;;H04R1/08;;H04R19/00;;H04R19/01,,0,0,,,,ACTIVE
509,EP,A3,EP 1193326 A3,177-116-254-418-997,2004-01-14,2004,EP 01119258 A,2001-08-09,US 67599000 A,2000-09-29,Apparatus for reducing particle residues in a semiconductor processing chamber,An apparatus for reducing particle residues in a semiconductor wafer processing system comprising a chamber and a chamber slot extending through a sidewall of the chamber. A processing platform having at least one sidewall is coupled to the chamber and a wafer channel extends through the chamber sidewall and the at least one processing platform sidewall such that the wafer channel intersects the chamber slot. A chamber slit valve extends through the chamber slot to control particle residues in the wafer channel.,APPLIED MATERIALS INC,GUJER RUDOLF;;CHO TOM K;;KARAZIM MICHAEL P;;ISHIKAWA TETSUYA,,https://lens.org/177-116-254-418-997,Search Report,yes,5,0,6,6,0,C23C16/4409;;C23C16/4401;;H01L21/00,H01L21/00;;C23C16/44;;H01L21/205,,0,0,,,,DISCONTINUED
510,BR,B1,BR 112015005927 B1,028-641-275-226-292,2016-09-06,2016,BR 112015005927 A,2013-06-11,US 2013/0045221 W;;US 201213715873 A,2012-12-14,processo para redução de cloreto em produtos de hidrocarbonetos usando um catalisador líquido iônico,"1/1 resumo processo para redução de cloreto em produtos de hidrocarbonetos usando um catalisador líquido iônico fornecemos um processo compreendendo: a. alimentar um hidrocarboneto clorado, e um catalisador líquido iônico para uma unidade de tratamento; b. operar a unidade de tratamento a uma temperatura elevada para produzir hidrocarboneto desclorado e hcl; e c. recolher o hidrocarboneto desclorado, em que pelo menos 90% em peso dos cloretos são removidos. um segundo processo compreende: a. criar uma zona rica em catalisador líquido iônico em uma unidade de destilação; b. passar hidrocarboneto clorado para a unidade de destilação; c. operar a unidade em condições que causam a remoção de cloreto de alquil para produzir hidrocarboneto desclorado tendo um ponto de ebulição final perto de um primeiro ponto de ebulição final. um terceiro processo compreende: a. alimentar o componente de mistura de gasolina alquilado e catalisador líquido iônico para uma unidade de tratamento; b. operar a unidade de tratamento; e c. recolher um hidrocarboneto desclorado, em que pelo menos 90% em peso dos cloretos foram removidos e o hidrocarboneto desclorado tem um segundo ron que está perto de uma primeiro ron.",CHEVRON USA INC,ZHAN BI-ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN,,https://lens.org/028-641-275-226-292,Granted Patent,no,0,0,11,11,0,B01J31/0284;;B01J31/0288;;B01J31/0289;;B01J2231/64;;B01D3/009;;C10G29/26;;C10G75/00;;C10G7/10;;C10G2300/1081;;C10G2300/202;;C07C7/10;;B01J31/0288;;B01J31/0289;;B01J31/0284;;B01J2231/64;;B01D3/009;;C10G29/16;;C10G2300/1081;;C10G7/10;;C10G29/26;;C10G75/00;;C10G2300/202;;B01J31/26,B01J31/26,,0,0,,,,ACTIVE
511,US,B2,US 8527613 B2,034-722-995-034-100,2013-09-03,2013,US 69365410 A,2010-01-26,US 69365410 A;;US 14738509 P,2009-01-26,Provisioned firmware updates using object identifiers,"Methods, devices, and systems are provided for remotely updating provisioning data in devices or a population of devices. An update message is generated that includes an Object Identifier (OID) that uniquely identifies eligible devices or components for the provisioning data update. If an eligible device receives the update message, then the new provisioning data is loaded on the device, thereby replacing the old provisioning data on the device.",MALONE MICHAEL WILLIAM;;CHO YOONG-GOOG;;SMITH THAD;;MILBRANDT RYAN;;ASSA ABLOY AB,MALONE MICHAEL WILLIAM;;CHO YOONG-GOOG;;SMITH THAD;;MILBRANDT RYAN,ASSA ABLOY AB (2010-02-16),https://lens.org/034-722-995-034-100,Granted Patent,yes,7,30,5,5,0,G06F8/65;;G06F21/572;;G06F21/44;;G06F8/65;;G06F9/445,G06F15/177,709/220;;709/222;;709/223,7,0,,,"""Firmware,"" from Wikipedia, the free encyclopedia, available at http://en.wikipedia.org/wiki/Firmware, page last modified Jan. 5, 2009, printed Jan. 7, 2009, 3 pages.;;""Booting,"" from Wikipedia, the free encyclopedia, available at http://en.wikipedia.org/wiki/Booting, page last modified Jan. 7, 2009, printed Jan. 7, 2009, 10 pages.;;Mitchell, B., ""Firmware Updates for Wireless Routers,"" About.com Wireless/Networking, available at http://compnetworking.about.com/od/wifihomenetworking/qt/firmwareupgrade.htm, printed Jan. 7, 2009, 2 pages.;;International Search Report for International (PCT) Patent Application No. PCT/US10/22046, mailed Mar. 2, 2010.;;Written Opinion for International (PCT) Patent Application No. PCT/US10/22046, mailed Mar. 2, 2010.;;International Preliminary Report on Patentability for International (PCT) Patent Application No. PCT/US2010/022046, mailed Aug. 4, 2011 7 pages.;;Search Report for European Patent Application No. 10733989.7, dated Jul. 4, 2012 5 pages.",INACTIVE
512,TW,A,TW 201808017 A,063-651-738-296-755,2018-03-01,2018,TW 106127256 A,2017-08-11,US 201615235382 A,2016-08-12,Microphone and methods of assembling microphones,"A microphone can include a cover having a series of slits and a nest. The nest can be configured to receive a first diaphragm, a second diaphragm, and a PCB in a stacked arrangement, such that the PCB is positioned between the first diaphragm and the second diaphragm. Also the first diaphragm can define a first plane, the second diaphragm can define a second plane, and the PCB can define a third plane and the first plane, the second plane, and the third plane can extend parallel to one another. The cover can also include slits having a first length and a second length, and the first length can be greater than the second length. The slits can extend both radially and axially.",SHURE ACQUISITION HOLDINGS INC,SEGOTA JEFF;;ALWICKER MICHAEL;;PRATT DANIEL;;MILLER JOHN;;CHO ELIZABETH,,https://lens.org/063-651-738-296-755,Patent of Addition,no,0,0,16,16,0,H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/016;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04;;H04R1/406;;H04R1/083;;H04R1/2807;;H04R2410/03;;H04R1/083;;H04R1/2807;;H04R1/406;;H04R2410/03;;H04R1/04;;H04R1/086;;H04R19/005;;H04R19/016;;H04R19/04,H04R5/027;;H04R31/00,,0,0,,,,ACTIVE
513,WO,A1,WO 2014/097012 A1,075-428-335-981-962,2014-06-26,2014,IB 2013060255 W,2013-11-19,US 201213723614 A,2012-12-21,WET WIPES WITH IMPROVED STRENGTH AND DISPERSIBILITY,"The present disclosure is directed to wet wipes including a fibrous substrate, a cationic binder composition, and a wetting composition. The wetting composition includes at least one polyprotic acid having three or more functional groups and benzoic acid.",KIMBERLY CLARK CO,HURLEY STEVEN MICHAEL;;BUNYARD WILLIAM CLAYTON;;CHO YOONHEE;;LEE WANDUK,,https://lens.org/075-428-335-981-962,Patent Application,yes,5,0,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/42;;B65D83/08,,0,0,,,,PENDING
514,EC,A,EC SP13012451 A,100-511-135-990-663,2013-05-31,2013,EC SP13012451 A,2013-02-19,US 36562110 P,2010-07-19,MÉTODOS PARA LA PREPARACIÓN DE PROFÁRMACOS DE FOSFORAMIDATO DIASTEREOMÉRICAMENTE PUROS,Se proporcionan métodos e intermedios para preparar profármacos de fosforamidato diastereoméricamente puros de nucleósidos de Fórmulas (Ia) y (Ib): Los compuestos de Fórmula Ia y Ib son útiles para el tratamiento de las infecciones por hepatitis C.,GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL O NEIL HANRAHAN;;WOLCKENHAUER SCOTT ALAN,,https://lens.org/100-511-135-990-663,Patent Application,no,0,0,38,38,0,C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;A61K31/7052;;A61K31/7042;;C07H1/00;;C07F9/2458;;A61P31/14;;A61P43/00;;C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20;;A61K31/7052;;A61K31/7042;;C07H19/02;;C07H19/10;;C07H19/20;;C07F9/65586;;C07F9/6561;;C07F9/65616;;C07H1/00;;C07F9/2458,C07D309/10;;C07H1/00;;C07H1/06;;C07H19/02;;C07H19/10;;C07H19/20,,0,0,,,,PENDING
515,TW,B,TW 511126 B,188-367-132-944-222,2002-11-21,2002,TW 90119560 A,2001-08-09,US 67599000 A,2000-09-29,Apparatus for reducing particle residues in a semiconductor processing chamber,An apparatus for reducing particle residues in a semiconductor wafer processing system comprising a chamber and a chamber slot extending through a sidewall of the chamber. A processing platform having at least one sidewall is coupled to the chamber and a wafer channel extends through the chamber sidewall and the at least one processing platform sidewall such that the wafer channel intersects the chamber slot. A chamber slit valve extends through the chamber slot to control particle residues in the wafer channel.,APPLIED MATERIALS INC,GUJER RUDOLF;;ISHIKAWA TETSUYA;;CHO THOMAS K;;KARAZIM MICHAEL P,,https://lens.org/188-367-132-944-222,Granted Patent,no,0,0,6,6,0,C23C16/4409;;C23C16/4401;;H01L21/00,H01L21/00;;C23C16/44;;H01L21/205,,0,0,,,,EXPIRED
516,US,A1,US 2014/0171720 A1,186-378-548-749-173,2014-06-19,2014,US 201213715873 A,2012-12-14,US 201213715873 A,2012-12-14,PROCESS FOR REDUCING CHLORIDE IN HYDROCARBON PRODUCTS USING AN IONIC LIQUID CATALYST,"We provide a process comprising: a. feeding a chlorinated-hydrocarbon and an ionic liquid catalyst to a treatment unit;b. operating the treatment unit at an elevated temperature to produce dechlorinated-hydrocarbon and HCl; andc. collecting the dechlorinated-hydrocarbon, wherein at least 90 wt % of the chlorides are removed. A second process comprises:a. creating an ionic liquid catalyst-rich zone in a distillation unit;b. passing chlorinated-hydrocarbon to the distillation unit;c. operating the unit under conditions causing removal of alkyl chloride to produce dechlorinated-hydrocarbon having a final boiling point close to a first final boiling point. A third process comprises:a. feeding alkylate gasoline blending component and ionic liquid catalyst to a treatment unit;b. operating the treatment unit; andc. collecting a dechlorinated-hydrocarbon, wherein at least 90 wt % of the chlorides have been removed and the dechlorinated-hydrocarbon has a second RON that is close to a first RON.",ZHAN BI-ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN;;CHEVRON USA INC,ZHAN BI-ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN,CHEVRON U.S.A. INC (2012-12-04),https://lens.org/186-378-548-749-173,Patent Application,yes,3,3,11,11,0,B01J31/0284;;B01J31/0288;;B01J31/0289;;B01J2231/64;;B01D3/009;;C10G29/26;;C10G75/00;;C10G7/10;;C10G2300/1081;;C10G2300/202;;C07C7/10;;B01J31/0288;;B01J31/0289;;B01J31/0284;;B01J2231/64;;B01D3/009;;C10G29/16;;C10G2300/1081;;C10G7/10;;C10G29/26;;C10G75/00;;C10G2300/202;;B01J31/26,C07C7/10,585/852;;585/856;;585/860;;585/864,0,0,,,,ACTIVE
517,WO,A2,WO 2018/217466 A2,034-786-554-026-239,2018-11-29,2018,US 2018/0031886 W,2018-05-09,US 201762511198 P,2017-05-25,MEASURING CONCENTRATIONS OF RADICALS IN SEMICONDUCTOR PROCESSING,"An apparatus includes a reactive species source, a spectral measurement volume, a light source to emit a light beam into the spectral measurement volume, a spectrometer to receive the light beam from the spectral measurement volume. The apparatus includes an a controller configured to, when a reactive species is present in the spectral measurement volume, control the light source to emit the light beam into the spectral measurement volume and the spectrometer to determine an environment spectrum using the light beam, and when the reactive species is not present in the spectral measurement volume, control the light source to emit the light beam into the spectral measurement volume and the spectrometer to determine a baseline spectrum using the light beam, calculate a net spectrum based on a difference between the environment spectrum and the baseline spectrum, and estimate a concentration of the reactive species based on the net spectrum.",APPLIED MATERIALS INC,GOPALAN RAMESH;;CHO TOM K;;ALAJAJIAN GEVORK;;MARK MICHAEL J,,https://lens.org/034-786-554-026-239,Patent Application,yes,0,0,6,6,0,G01N21/031;;G01N21/31;;G01N21/64;;G01N2021/1734;;G01N21/85;;G01N2021/8411;;H01J37/32972;;G01N21/031;;G01N21/31;;G01N2021/1734;;G01N21/64;;G01N21/85;;G01N2021/8411;;G01N21/62;;G01N21/84;;H01J37/32972;;H01L21/67063;;H01L22/10,H01L21/67;;C23C16/44;;H01L21/66;;H05H1/46,,0,0,,,,PENDING
518,US,B2,US 11722352 B2,064-003-873-521-362,2023-08-08,2023,US 202217717890 A,2022-04-11,US 202217717890 A;;US 201916614106 A;;US 2018/0037936 W;;US 201762521238 P,2017-06-16,Configurability and signaling for half-tone shift,"Described is an apparatus of a User Equipment (UE) operable to communicate with an Evolved Node-B (eNB) on a wireless network. The apparatus may comprise a first circuitry, a second circuitry, and a third circuitry. The first circuitry may be operable to process a configuration transmission carrying a half-tone shifting indicator. The second circuitry may be operable to select one or more subcarrier frequencies for Uplink (UL) transmission based on the half-tone shifting indicator. The third circuitry may be operable to generate a UL transmission for the one or more subcarrier frequencies. The half-tone shifting indicator may have a first value indicating application of a half-subcarrier offset, and a second value indicating no application of the half-subcarrier offset.",APPLE INC,JEON JEONGHO;;CHO JOONYOUNG;;FAERBER MICHAEL;;HAN SEUNGHEE;;MIAO HONGLEI,,https://lens.org/064-003-873-521-362,Granted Patent,yes,11,0,11,11,0,H04L5/0007;;H04L5/0053;;H04J11/0023;;H04W28/26;;H04J11/0023;;H04L5/0007;;H04L27/2666;;H04L5/0007;;H04L27/2666,H04L27/26;;H04L5/00,,5,0,,,"First Office Action in related Chinese Application No. 201880029874.6, dated Aug. 12, 2021; 9 pages.;;International Search Report and Written Opinion for PCT Application No. PCT/US18/37936, dated Nov. 6, 2018.;;Ericsson, “On uplink half-tone shift”, 3GPP Draft; R1-1709056; vol. RAN WG1; Hanqzhou, China; May 14, 2017.;;Ericsson, “On uplink half-tone shift and LTE/NR co-existence”, 3GPP Draft; R1-1704815; vol. RAN WG1; Spokane, WA, USA; Apr. 2, 2017.;;Notice of Grant in related Chinese Application No. 201880029874.6, dated Apr. 1, 2022; 5 pages.",ACTIVE
519,MX,A,MX 2015007378 A,071-537-030-224-888,2015-09-23,2015,MX 2015007378 A,2013-11-19,US 201213723614 A;;IB 2013060255 W,2012-12-21,WET WIPES WITH IMPROVED STRENGTH AND DISPERSIBILITY.,"The present disclosure is directed to wet wipes including a fibrous substrate, a cationic binder composition, and a wetting composition. The wetting composition includes at least one polyprotic acid having three or more functional groups and benzoic acid.",KIMBERLY CLARK CO,BUNYARD WILLIAM CLAYTON;;HURLEY STEVEN MICHAEL;;CHO YOONHEE;;LEE WANDUK,,https://lens.org/071-537-030-224-888,Patent Application,no,0,0,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/42;;B65D83/08,,0,0,,,,ACTIVE
520,US,A1,US 2022/0239542 A1,120-937-093-827-289,2022-07-28,2022,US 202217717890 A,2022-04-11,US 202217717890 A;;US 201916614106 A;;US 2018/0037936 W;;US 201762521238 P,2017-06-16,CONFIGURABILITY AND SIGNALING FOR HALF-TONE SHIFT,"Described is an apparatus of a User Equipment (UE) operable to communicate with an Evolved Node-B (eNB) on a wireless network. The apparatus may comprise a first circuitry, a second circuitry, and a third circuitry. The first circuitry may be operable to process a configuration transmission carrying a half-tone shifting indicator. The second circuitry may be operable to select one or more subcarrier frequencies for Uplink (UL) transmission based on the half-tone shifting indicator. The third circuitry may be operable to generate a UL transmission for the one or more subcarrier frequencies. The half-tone shifting indicator may have a first value indicating application of a half-subcarrier offset, and a second value indicating no application of the half-subcarrier offset.",APPLE INC,JEON JEONGHO;;CHO JOONYOUNG;;FAERBER MICHAEL;;HAN SEUNGHEE;;MIAO HONGLEI,,https://lens.org/120-937-093-827-289,Patent Application,yes,2,1,11,11,0,H04L5/0007;;H04L5/0053;;H04J11/0023;;H04W28/26;;H04J11/0023;;H04L5/0007;;H04L27/2666;;H04L5/0007;;H04L27/2666,H04L27/26;;H04L5/00,,0,0,,,,ACTIVE
521,AU,A1,AU 2014/290777 A1,177-097-705-784-312,2016-01-21,2016,AU 2014/290777 A,2014-03-14,US 201313944560 A;;US 2014/0027406 W,2013-07-17,Regeneration of olefin treating adsorbents for removal of oxygenate contaminants,"Processes for eliminating oxygenates and water from a light hydrocarbon processing system, wherein oxygenates are removed from a light hydrocarbon stream by adsorption of the oxygenates on an oxygenate adsorption unit to provide a deoxygenated hydrocarbon stream, the oxygenate adsorption unit is regenerated via a regenerant stream to provide an oxygenated regenerant stream comprising the oxygenates, and the oxygenated regenerant stream is subjected to hydro-deoxygenation to convert the oxygenates into paraffins and water, wherein the water may also be permanently removed from the system.",CHEVRON USA INC,CLEVERDON ROBERT FLETCHER;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO,,https://lens.org/177-097-705-784-312,Patent Application,no,0,0,5,5,0,B01D15/203;;B01J20/3408;;C10G25/00;;C10G29/205;;C10G3/00;;C10G3/42;;C10G3/50;;B01J20/18;;B01J20/345;;Y02P30/20;;C10G3/50;;B01D15/203;;C10G3/42;;B01J20/3408;;C10G25/00;;C10G29/205;;C10G3/00;;B01J20/345;;B01J20/18;;Y02P30/20;;C07C2/58;;C07C7/13,B01D15/20;;B01J20/34;;C07C7/12;;C10G70/04,,0,0,,,,DISCONTINUED
522,AU,A1,AU 2013/365879 A1,060-477-699-964-166,2015-07-23,2015,AU 2013/365879 A,2013-11-19,US 201213723614 A;;IB 2013060255 W,2012-12-21,Wet wipes with improved strength and dispersibility,"The present disclosure is directed to wet wipes including a fibrous substrate, a cationic binder composition, and a wetting composition. The wetting composition includes at least one polyprotic acid having three or more functional groups and benzoic acid.",KIMBERLY CLARK CO,HURLEY STEVEN MICHAEL;;BUNYARD WILLIAM CLAYTON;;CHO YOONHEE;;LEE WANDUK,,https://lens.org/060-477-699-964-166,Patent Application,no,0,0,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/42;;B65D83/08,,0,0,,,,ACTIVE
523,BR,A2,BR 112015005927 A2,065-496-485-302-699,2016-06-07,2016,BR 112015005927 A,2013-06-11,US 2013/0045221 W;;US 201213715873 A,2012-12-14,processo para redução de cloreto em produtos de hidrocarbonetos usando um catalisador líquido iônico,"1/1 resumo processo para redução de cloreto em produtos de hidrocarbonetos usando um catalisador líquido iônico fornecemos um processo compreendendo: a. alimentar um hidrocarboneto clorado, e um catalisador líquido iônico para uma unidade de tratamento; b. operar a unidade de tratamento a uma temperatura elevada para produzir hidrocarboneto desclorado e hcl; e c. recolher o hidrocarboneto desclorado, em que pelo menos 90% em peso dos cloretos são removidos. um segundo processo compreende: a. criar uma zona rica em catalisador líquido iônico em uma unidade de destilação; b. passar hidrocarboneto clorado para a unidade de destilação; c. operar a unidade em condições que causam a remoção de cloreto de alquil para produzir hidrocarboneto desclorado tendo um ponto de ebulição final perto de um primeiro ponto de ebulição final. um terceiro processo compreende: a. alimentar o componente de mistura de gasolina alquilado e catalisador líquido iônico para uma unidade de tratamento; b. operar a unidade de tratamento; e c. recolher um hidrocarboneto desclorado, em que pelo menos 90% em peso dos cloretos foram removidos e o hidrocarboneto desclorado tem um segundo ron que está perto de uma primeiro ron.",CHEVRON USA INC,ZHAN BI-ZENG;;TIMKEN HYE KYUNG CHO;;DRIVER MICHAEL SEAN,,https://lens.org/065-496-485-302-699,Patent Application,no,0,0,11,11,0,B01J31/0284;;B01J31/0288;;B01J31/0289;;B01J2231/64;;B01D3/009;;C10G29/26;;C10G75/00;;C10G7/10;;C10G2300/1081;;C10G2300/202;;C07C7/10;;B01J31/0288;;B01J31/0289;;B01J31/0284;;B01J2231/64;;B01D3/009;;C10G29/16;;C10G2300/1081;;C10G7/10;;C10G29/26;;C10G75/00;;C10G2300/202;;B01J31/26,B01J31/26,,0,0,,,,ACTIVE
524,US,B2,US 11303495 B2,089-087-478-561-178,2022-04-12,2022,US 201816614106 A,2018-06-15,US 201816614106 A;;US 201762521238 P;;US 2018/0037936 W,2017-06-16,Configurability and signaling for half-tone shift,"Described is an apparatus of a User Equipment (UE) operable to communicate with an Evolved Node-B (eNB) on a wireless network. The apparatus may comprise a first circuitry, a second circuitry, and a third circuitry. The first circuitry may be operable to process a configuration transmission carrying a half-tone shifting indicator. The second circuitry may be operable to select one or more subcarrier frequencies for Uplink (UL) transmission based on the half-tone shifting indicator. The third circuitry may be operable to generate a UL transmission for the one or more subcarrier frequencies. The half-tone shifting indicator may have a first value indicating application of a half-subcarrier offset, and a second value indicating no application of the half-subcarrier offset.",APPLE INC,JEON JEONGHO;;CHO JOONYOUNG;;FAERBER MICHAEL;;HAN SEUNGHEE;;MIAO HONGLEI,APPLE INC (2019-11-30);;INTEL CORPORATION (2020-05-29),https://lens.org/089-087-478-561-178,Granted Patent,yes,6,0,11,11,0,H04L5/0007;;H04L5/0053;;H04J11/0023;;H04W28/26;;H04J11/0023;;H04L5/0007;;H04L27/2666;;H04L5/0007;;H04L27/2666,H04L5/00;;H04L27/26,,4,0,,,"International Search Report and Written Opinion for PCT Application No. PCT/US18/37936, dated Nov. 6, 2018.;;Ericsson, “On uplink half-tone shift”, 3GPP Draft; R1-1709056; vol. RAN WG1; Hanqzhou, China; May 14, 2017.;;Ericsson, “On uplink half-tone shift and LTE/NR co-existence”, 3GPP Draft; R1-1704815; vol. RAN WG1; Spokane, WA, USA; Apr. 2, 2017.;;First Office Action in related Chinese Application No. 201880029874.6, dated Aug. 12, 2021; 9 pages.",ACTIVE
525,US,S,US D0792138 S,130-234-123-933-94X,2017-07-18,2017,US 201529549126 F,2015-12-18,US 201529549126 F,2015-12-18,Table leg,,STEELCASE INC,YOO HYUN;;HELD MICHAEL;;HO SIU CHO;;SPOELHOF MARK WILLIAM,STEELCASE INC (2015-12-14),https://lens.org/130-234-123-933-94X,Design Right,no,0,1,2,2,0,,,0606;;D 67092,0,0,,,,ACTIVE
526,US,A1,US 2022/0334582 A1,086-795-890-525-847,2022-10-20,2022,US 202217729051 A,2022-04-26,US 202217729051 A;;US 202217716249 A;;US 202163177141 P;;US 202163255880 P,2021-04-20,INSPECTION ROBOTS WITH CONFIGURABLE INTERFACE PLATES,"Inspection robots with configurable interface plates are described. An example inspection robot may have a housing with at least three removable interface plates, each removable interface plate having a coupling interface for an electronic component on a first side, and coupled to at least one of a plurality of electronic boards on a second side. The example inspection robot may further include a drive module configured to couple to at least one of the removable interface plates, and a payload configured to couple to at least one of the removable interface plates. The example inspection robot may further include a means for operating the inspection robot in response to the drive module coupled to one of the removable interface plates, and the payload coupled to any other one of the removable interface plates.",GECKO ROBOTICS INC,BRYNER EDWARD A;;JOURDE DILLON R;;CHO EDWIN H;;CHO MARK;;BINGER MICHAEL A;;DENNER KATHERINE VIRGINIA,GECKO ROBOTICS INC (2022-04-11),https://lens.org/086-795-890-525-847,Patent Application,yes,4,8,24,24,0,B62D57/024;;G01N29/225;;G01N29/265;;G01N2291/0237;;G01N2291/02854;;G01N29/043;;G05B2219/45066;;B25J9/1694;;B25J9/1692;;B25J9/1666;;B60K7/00;;B60K7/0007;;B25J9/1653;;B25J19/027;;B25J13/087;;B25J9/0009;;B25J9/1694;;G01N29/04;;G01N29/226;;G01N29/265;;G01N2291/0289;;G01N2291/2698;;B25J9/1617;;B25J9/163;;B25J9/1664;;B25J9/1674;;B25J13/006;;B25J5/007;;B25J19/021;;B60K1/02;;B62D53/02;;B62D57/024;;B60B19/006;;B60B19/12;;B60B2360/104;;B60B2360/109;;B60B2900/931;;B60B2360/102;;G06F1/206;;G06F2200/201;;H05K1/18;;H05K2201/10151,G01N29/04;;G05D1/00;;G01N29/22;;G01N29/265,,0,0,,,,ACTIVE
527,US,B2,US 11850726 B2,143-383-776-827-571,2023-12-26,2023,US 202217729051 A,2022-04-26,US 202217729051 A;;US 202217716249 A;;US 202163177141 P;;US 202163255880 P,2021-04-20,Inspection robots with configurable interface plates,"Inspection robots with configurable interface plates are described. An example inspection robot may have a housing with at least three removable interface plates, each removable interface plate having a coupling interface for an electronic component on a first side, and coupled to at least one of a plurality of electronic boards on a second side. The example inspection robot may further include a drive module configured to couple to at least one of the removable interface plates, and a payload configured to couple to at least one of the removable interface plates. The example inspection robot may further include a means for operating the inspection robot in response to the drive module coupled to one of the removable interface plates, and the payload coupled to any other one of the removable interface plates.",GECKO ROBOTICS INC,BRYNER EDWARD A;;JOURDE DILLON R;;CHO EDWIN H;;CHO MARK;;BINGER MICHAEL A;;DENNER KATHERINE VIRGINIA,GECKO ROBOTICS INC (2022-04-11),https://lens.org/143-383-776-827-571,Granted Patent,yes,393,0,24,24,0,B62D57/024;;G01N29/225;;G01N29/265;;G01N2291/0237;;G01N2291/02854;;G01N29/043;;G05B2219/45066;;B25J9/1694;;B25J9/1692;;B25J9/1666;;B60K7/00;;B60K7/0007;;B25J9/1653;;B25J19/027;;B25J13/087;;B25J9/0009;;B25J9/1694;;G01N29/04;;G01N29/226;;G01N29/265;;G01N2291/0289;;G01N2291/2698;;B25J9/1617;;B25J9/163;;B25J9/1664;;B25J9/1674;;B25J13/006;;B25J5/007;;B25J19/021;;B60K1/02;;B62D53/02;;B62D57/024;;B60B19/006;;B60B19/12;;B60B2360/104;;B60B2360/109;;B60B2900/931;;B60B2360/102;;G06F1/206;;G06F2200/201;;H05K1/18;;H05K2201/10151,B25J5/00;;B25J13/08;;B25J9/00;;B25J9/16;;B25J13/00;;B25J19/02;;B60B19/00;;B60B19/12;;B60K1/02;;B62D53/02;;B62D57/024;;G01N29/04;;G01N29/22;;G01N29/265;;G06F1/20;;H05K1/18,,105,0,,,"21201397.3 , “European Application Serial No. 21201397.3, Extended European Search Report dated May 11, 2022”, Gecko Robotics, Inc., 12 pages.;;NIDEC , “Flexwave Catalog”, 2018, 52 pages.;;PCT/US2022/023993 , “International Application Serial No. PCT/US2022/023993, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jun. 16, 2022”, Gecko Robotics, Inc., 3 pages.;;Stepson, W.A.V , et al., “Design and Development of a Mobile Crawling Robot with Novel Halbach Array Based Magnetic Wheels”, IEEE/ RSJ International Conference on Intelligent Robots and Systems (IROS), Sep. 2017, 6 pages.;;Ueura, Keiji , et al., “Development of the Harmonic Drive Gear for Space Applications”, 1999, 6 pages.;;“All Metals Fabrication”, Painting Metal, Aug. 27, 2015.;;“Coordinate Systems in Two and Three Dimensions”, Oregon State University, Department of Mathematics, 2015, 3 pages.;;“Horizontal definition”, Merrian-Webster Dictionary, 2014, 1 page.;;“International Federation of Robotics,”, World Robotics, Chapter 1 section 2, 2016, 10 pages.;;“Merriam-Webster”, Definition of Pivot, 2015, 5 pages.;;“Vertical Definition”, Merriam Webster, 2014, 1 page.;;“Yaskawa Motoman Robotics,”, Robotics Glossary, 2019, 20 pages.;;17884897.4, “European Application Serial No. 17884897.4, Extended European Search Report dated Jun. 25, 2020”, Gecko Robotics, Inc., 5 pages.;;AMS Controls, “Encoder Tracking and Mounting”, 2015, 18 pages.;;Bell, Stephanie, “Measurement Good Practice Guide A Beginner's Guide to Uncertainty of Measurement”, National Physical Laboratory, Issue 2, 2001, 41 pages.;;Berendsen, A.M, “Ship Painting: Current Practice and Systems in Europe”, Technology Publishing Company, Sep. 1998, 10.;;Cai, Mingxue et al., “A Novel Pipeline Inspection Robot with Two Angle-changeable Crawler Drive Modules”, Proceedings of 2018 IEEE 8th Annual International Conference on Cyber Technology in Automation, Control, and Intelligent Systems, Jul. 2018, 6 pages.;;Carlsten, Roy, “Understanding Corrosion and How to Protect Against It”, manufacturing.net, Mar. 11, 2002, 8.;;Connor, David et al., “Improved dead reckoning using caster wheel sensing on a differentially steered 3-wheeled autonomous vehicle”, Proceedings vol. 4195, Mobile Robots XV and Telemanipulator and Telepresence Technologies VII, 2001, 13 pages.;;Curran, Patrick, “Make the right choice for metal coating for the right application”, Design World, Jun. 2, 2016, 18.;;Felsch, Torsten et al., “Robotized Inspection of Vertical Structures of a Solar Power Plant Using NDT Techniques”, doi:10.3390/robotics4020103, 2015, pp. 103-119.;;Few, Stephen, “Practical Rules for Using Color in Charts”, Perceptual Edge, Visual Business Intelligence Newsletter, Feb. 2008, 13 pages.;;Fowler, Kenneth A. et al., “Theory and Application of Precious Ultrasonic Thickness Gaging”, 2015, 12 pages.;;General Electric, “BWCI Automated Boiler Wall Cleaning & Inspection”, inspection-robotics.com, 2016, 4.;;Ginzel, et al., “Acoustic Properties of the Elastomeric Materials Aqualene and ACE”, The e-Journal of Nondestructive Testing—ISSN 1435-4934, Dec. 2015, 13.;;Guglielmelli, E. et al., “Avoiding obstacles by using a proximity US/IR sensitive skin”, IEEE, 1993, pp. 2207-2214.;;Harrison, David M. , “Uncertainty in Physical Measurements”, Module 4—Repeated Measurements, Dept. of Physics, Univ. of Toronto, 2015, 18 pages.;;Hutter, Marco et al., “Force Control for Active Chassis Balancing”, IEEE/ASME Transactions on Mechatronics, vol. 22, No. 2, Apr. 2017, 10 pages.;;Lebowitz, Carol A. et al., “Ultrasonic Measurement of Pipe Thickness”, Review of Progress in Quantitative Nondestructive Evalualtion, vol. 12, 1987, 8 pages.;;Lee, Giuk et al., “Combot: Compliant Climbing Robotic Platform with Transitioning Capability and Payload Capacity”, IEEE International Conference on Robotics and Automation RiverCentre, Saint Paul, Minnesota,, 2012, 6 pages.;;Lins, Romulo G. et al., “Autonomous Robot System for Inspection of Defects in Civil Infrastructures”, IEEE, 2016, pp. 1414-1422.;;Lion Precision, , “Understanding Sensor Resolution Specifications and Performance”, TechNote, LT05-0010, 2014, pp. 1-6.;;Martinez, Angelo et al., “Fuzzy logic based collision avoidance for a mobile robot”, IEEE, 1993, pp. 66-69.;;Miskon, Muhammad F. et al., “Close Range Inspection Using Novelty Detection Results”, Intelligent Robotic Research Center (IRRC), Monash University, Australia, ICIRA2009, LNAI 5928,, 2009, pp. 947-956.;;Myers, Brad A. , “The importance of percent-done progress indicators for computer-human interfaces”, Proceedings of the SIGCHI conference on Human factors in computing systems., CHI '85. ACM, New York, NY., 1985, 11-17.;;National Geographic, , “Encyclopedic Entry Location”, 2016, 3 pages.;;NDT Resource Center, , “NDT Glossary D”, Webpage, 2016, 4 pages.;;NDT Resource Center, , “NDT Glossary R”, Webpage, 2016, 5 pages.;;NDT Resource Center, , “Transducer Types”, Webpage, 2005, 1.;;Olympus, , “BondMaster Probes and Accessories Catalog”, Catalog, 2008, 24.;;Olympus, , “Flaw Detectors Delay Line”, Olympus, Flaw Detectors Delay Line, 2014, Jan. 9, 2014, 1.;;Olympus, , “Ultrasonic Transducers Technical Notes”, Notes, 2006.;;Openstax College, , “College Physics Textbook Equity Edition”, vol. 1 of 3: Chapters 1-12, Chapter 9 p. 294, 464 pages.;;Parallax Tutorial, , “Going the Distance—Using the Drive Distance Block Encoders and Motor Gearing”, 2017, 5 pages.;;PCT/US17/68326, , “International Application Serial No. PCT/US17/68326, International Preliminary Report on Patentability dated Jul. 4, 2019”, Gecko Robotics, Inc., 11 pages.;;PCT/US20/21779, , “International Application Serial No. PCT/US20/21779, International Preliminary Report on Patentability dated Sep. 23, 2021”, Gecko Robotics, Inc., 13 pages.;;PCT/US20/21779, , “International Application Serial No. PCT/US20/21779, International Search Report and Written Opinion dated Sep. 2, 2020”, Gecko Robotics, Inc., 14 pages.;;PCT/US20/21779, , “International Application Serial No. PCT/US20/21779, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jul. 9, 2020”, Gecko Robotics, Inc., 2 pages.;;PCT/US2017/068326, , “International Application Serial No. PCT/US2017/068326, International Search Report and Written Opinion dated May 4, 2018”, Gecko Robotics, Inc., 14 pages.;;PCT/US2017068326, , “International Application Serial No. PCT/US2017068326, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Feb. 27, 2018”, Gecko Robotics, Inc., 2 Pages.;;PCT/US2019/027958, , “International Application Serial No. PCT/US2019/027958, International Preliminary Report on Patentability dated Oct. 29, 2020”, Gecko Robotics, Inc., 8 pages.;;PCT/US2019/027958, , “International Application Serial No. PCT/US2019/027958, International Search Report and Written Opinion dated Jul. 16, 2019”, Gecko Robotics, Inc., 9 pages.;;Reinhold, Reif , “Machine Translation DE 10300383”, 2019, 4 pages.;;Sabatini, Angelo M. et al., “Correlation Techniques for Digital Time-of-Flight Measurement by Airborne Ultrasonic Rangefinders”, Published in: Proceedings of IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS'94), Date of Conference: Sep. 12-16, 1994,, 1994, pp. 2168-2175.;;Salik, John et al., “Pipe Inspections: Robotic Laser Profiling Demystified”, National Precast Concrete Association, Apr. 1, 2013, 12 pages.;;Schroeder, S C. et al., “Ultrasonic Culvert Thickness Determination”, US Army Armament Research Development and Engineering, Technical Report ARCCB-TR-95027, 1995, 36 pages.;;Sirken, Aaron et al., “Bridge Risk Investigation Diagnostic Grouped Exploratory (BRIDGE)”, IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS), Sep. 24-28, 2017, Vancouver, BC, Canada (Year: 2017), 2017, 7 pages.;;Smith, Oliver et al., “Machine Translation KR20140040692A”, 18 pages.;;Svilainis, Linas , “Review of high resolution time of flight estimation techniques for ultrasonic signals,”, Sep. 2013Conference: NDT 2013At: Telford Project: In-SMART, 2013, 13 pages.;;Tufte, Edward R. , “The Visual Display of Quantitative Information”, Published By Graphics Press LLC, Second edition, fifth printing, Aug. 2007, 191 pages.;;Wisegeek, , “What is an Articulated Robot?”, Webpage, 2015, 4 pages.;;Yasuda, Gen'ichi , “Behavior-based autonomous cooperative control of intelligent mobile robot systems with embedded Petri nets”, IEEE, 2014, pp. 1085-1090.;;Zaho, B. et al., “Estimation of ultrasound attenuation and dispersion using short time Fourier transform,”, Ultrasonics 43 (2005) 375-381, 2005, pp. 375-381.;;Zhang, Lei et al., “Analysis of Traveling-capability and Obstacle-climbing Capability for Radially Adjustable Tracked Pipeline Robot”, Proceedings of the 2016 IEEE International Conference on Robotics and Biomimetics Gingdao, China, Dec. 2016, 6 pages.;;Zhang, Lei et al., “Stable Motion Analysis and Verification of a Radial Adjustable Pipeline Robot”, Proceedings of the 2016 IEEE International Conference on Robotics and Biomimetics Oingdao, China, Dec. 2016, 6 pages.;;U.S. Appl. No. 18/057,544, filed Nov. 21, 2022, Pending, Edward A. Bryner, et al.;;U.S. Appl. No. 17/729,037, filed Apr. 26, 2022, Pending, Dillon R. Jourde, et al.;;20769832.5 , “European Application Serial No. 20769832.5, Extended European Search Report dated Nov. 4, 2022”, Gecko Robotics, Inc., 8 pages.;;Borenstein, Johann , et al., “Where am I? Sensors and Methods for Mobile Robot Positioning”, Retrieved from the Internet :URL :http ://www-personal.umich.edu/˜johannb/Papers/pos96rep.pdf, Apr. 22, 1996, pp. 1-282.;;Gonzalez, Carlos , “What's the Difference between Pneumatic, Hydraulic, and Electrical Actuators”, Machine Design, 2015, 4 pages.;;PCT/US2022/023993 , “International Application Serial No. PCT/US2022/023993, International Search Report and Written Opinion dated Aug. 24, 2022”, Gecko Robotics, Inc., 31 pages.;;PCT/US2022/025816 , “International Application Serial No. PCT/US2022/025816, International Search Report and Written Opinion dated Sep. 28, 2022”, Gecko Robotics, Inc, 33 pages.;;PCT/US2022/025816 , “International Application Serial No. PCT/US2022/025816, Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jul. 8, 2022”, Gecko Robotics, Inc., 3 pages.;;Takero, Hongo , et al., “An Automatic Guidance System of a Self-Controlled Vehicle”, In: “Autonomous Robot Vehicles”, Jan. 1, 1990 (Jan. 1, 1990), Springer New York, New York, NY,, Jan. 1, 1990, pp. 32-37.;;Tufte, Edward R., “The Visual Display of Quantitative Information”, Published by Graphics Press LLC, Second edition, fifth printing, 2007, 191 pages.;;U.S. Appl. No. 17/752,955, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/824,656, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/824,253, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/824,261, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/824,548, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/824,534, filed May 25, 2022, Pending.;;U.S. Appl. No. 17/716,249, filed Apr 8, 2022, Pending.;;U.S. Appl. No. 17/741,508, filed May 11, 2022, Pending.;;U.S. Appl. No. 17/727,217, filed Apr. 22, 2022, Pending.;;U.S. Appl. No. 17/729,294, filed Apr. 22, 2022, Pending.;;U.S. Appl. No. 17/729,037, filed Apr. 26, 2022, Pending.;;U.S. Appl. No. 17/729,070, filed Apr. 26, 2022, Pending.;;U.S. Appl. No. 17/731,797, filed Apr. 28, 2022, Pending.;;U.S. Appl. No. 17/740,475, filed May 10, 2022, Pending.;;U.S. Appl. No. 17/752,059, filed May 24, 2022, Pending.;;U.S. Appl. No. 17/741,519, filed May 11, 2022, Pending.;;U.S. Appl. No. 17/740,561, filed May 10, 2022, Pending.;;U.S. Appl. No. 17/752,453, filed May 24, 2022, Pending.;;U.S. Appl. No. 17/740,572, filed May 10, 2022, Pending.;;U.S. Appl. No. 17/740,579, filed May 10, 2022, Pending.;;U.S. Appl. No. 17/752,177, filed May 24, 2022, Pending.;;U.S. Appl. No. 17/726,336, filed Apr. 21, 2022, Pending.;;PCT/US2022/025816, filed Apr. 21, 2022, Pending.;;PCT/US2022/023993, filed Apr. 8, 2022, Pending.;;Haitao , et al., “Simulation, Test and Analysis of Three-phase Short-Circuit Braking in IGCT-based MV Adjustable Speed Drive Systems”, 2005 International Conference on Electrical Machines and Systems, Nanjing, China, IEEE, 2005, pp. 1437-1441.;;Papadimitriou, Vasileious , et al., “An adaptable and self-calibrating service robotic nozzle-vessel welds”, 2012 2nd International Conference on Applied Robotics for the Power Industry (CARPI), 2012, 6 pages.;;Xing , et al., “Design and Realization of DC Motor Speed Measurement and Control Based on an Electromagnetic Sensor”, Atlantis Press, DOI10.2991/cisia-15.2015.69, 2015, 4 pages.;;U.S. Appl. No. 18/303,419, filed Apr. 19, 2023, Pending, Mark J. Loosararian, et al.;;U.S. Appl. No. 18/306,408, filed Apr. 25, 2023, Pending, Mark Jake Loosararian, et al.;;U.S. Appl. No. 18/341,991, filed Jun. 27, 2023, Pending, Mark J. Loosararian, et al.",ACTIVE
528,CN,A,CN 116583225 A,093-711-759-387-277,2023-08-11,2023,CN 202180078917 A,2021-11-30,US 202063120529 P;;US 2021/0061149 W,2020-12-02,Apparatus configured to drive object in one lumen via driver in another lumen,"An apparatus and method of use thereof, the apparatus comprising: a medical device configured to reside within and be manipulated within a first lumen; and a drive system configured to manipulate and/or control the medical device via the second lumen. The drive system includes a catheter configured to be inserted into the second lumen and navigated or navigated within the second lumen; and a driver configured to travel within the catheter and to remotely manipulate and/or control the medical device residing in the first lumen.",BIONOT LABORATORIES INC,CROS FLORENT;;KISELEV ALEX;;CHO SOO-HYUN;;KARDOSH MICHAEL;;SPIEGELMACHER MICHAEL;;KATZ NIELSEN BERRY BAER,,https://lens.org/093-711-759-387-277,Patent Application,no,0,0,5,5,0,A61B10/0233;;A61B34/73;;A61B2034/303;;A61M25/0127;;A61B2090/3782,A61B10/02,,0,0,,,,PENDING
529,US,A1,US 2024/0079124 A1,199-935-548-178-180,2024-03-07,2024,US 18242295,2023-09-05,,,SYSTEM AND METHOD FOR ADMINISTERING A TREATMENT AT A TREATMENT SITE IN THE BRAIN,"A method for providing localized treatment at a target site in the brain of a patient is provided. The method comprises providing a system comprising a miniature device configured to carry one or more therapeutic components for performing the treatment, and an external system configured to direct the miniature device; inserting the miniature device to a starting location within the patient; operating the external system to direct the miniature device to travel along an access path from the starting location to the target site; and administering the therapeutic component at the target site. A system for performing the method is further provided.",BIONAUT LABS LTD.,Alex KISELYOV;;Michael SHPIGELMACHER;;Michael KARDOSH;;Florent CROS;;Suehyun CHO;;Darrell HARRINGTON;;William G. LOUDON,,https://lens.org/199-935-548-178-180,Patent Application,yes,0,0,1,1,0,G16H40/60;;A61M5/00;;A61M2210/0693,G16H40/60;;A61M5/00,,0,0,,,,UNKNOWN
530,KR,A,KR 20150100764 A,008-669-829-167-749,2015-09-02,2015,KR 20157019355 A,2013-11-19,US 201213723614 A;;IB 2013060255 W,2012-12-21,WET WIPES WITH IMPROVED STRENGTH AND DISPERSIBILITY,,KIMBERLY CLARK CO,HURLEY STEVEN MICHAEL;;BUNYARD WILLIAM CLAYTON;;CHO YOON HEE;;LEE WANDUK,,https://lens.org/008-669-829-167-749,Patent Application,no,3,2,13,13,0,A61K8/365;;A61K8/817;;A61Q19/10;;A61K8/368;;A61K2800/5426;;D04H1/587;;D04H1/732;;A61K8/0208;;A61K8/368;;A61K8/817;;A61Q19/10;;D04H1/587;;D04H1/732;;A61K2800/5426;;A61K8/365;;A61K8/0208,A47K10/16;;A61K8/02;;A61K8/362;;A61K8/365,,0,0,,,,ACTIVE
531,US,A1,US 2016/0030934 A1,038-259-489-720-435,2016-02-04,2016,US 201514882582 A,2015-10-14,US 201514882582 A;;US 49644209 A,2009-07-01,HYDROPROCESSING CATALYST AND HYDROPROCESSING CATALYST OF MAKING THE SAME,"The present invention is directed to a hydroprocessing catalyst containing at least one catalyst support, one or more metals, optionally one or more molecular sieves, optionally one or more promoters, wherein deposition of at least one of the metals is achieved in the presence of a modifying agent.",CHEVRON USA INC,ZHAN BI-ZENG;;MAESEN THEODORUS LUDOVICUS MICHAEL;;TIMKEN HYE KYUNG CHO,,https://lens.org/038-259-489-720-435,Patent Application,yes,3,20,21,21,0,B01J21/12;;B01J29/106;;B01J29/166;;B01J37/0203;;B01J2229/20;;B01J2229/34;;B01J2229/42;;C10G45/00;;C10G45/04;;C10G45/12;;C10G45/54;;C10G49/08;;C10G2300/4018;;B01J31/0201;;B01J31/0207;;B01J31/0237;;B01J31/0238;;B01J31/0244;;B01J31/0249;;B01J31/04;;B01J2231/641;;C10G47/12;;C10G47/06;;C10G47/14;;C10G49/04;;C10G49/06;;B01J29/084;;B01J29/126;;B01J29/146;;C10G2400/04;;B01J35/617;;B01J35/635;;B01J35/638;;B01J35/647;;B01J35/615;;B01J29/084;;B01J29/106;;B01J29/126;;B01J29/146;;B01J29/166;;B01J37/20;;C10G45/12;;C10G45/54;;C10G47/06;;C10G47/18;;C10G47/12;;C10G47/06;;C10G47/14;;C10G49/04;;C10G49/06;;B01J29/084;;B01J29/126;;B01J29/146;;C10G2400/04;;B01J21/12;;B01J29/106;;B01J29/166;;B01J37/0203;;B01J2229/20;;B01J2229/34;;B01J2229/42;;C10G45/00;;C10G45/04;;C10G45/12;;C10G45/54;;C10G49/08;;C10G2300/4018;;B01J31/0237;;B01J31/0238;;B01J31/0207;;B01J31/04;;B01J31/0249;;B01J2231/641;;B01J31/0201;;B01J31/0244;;B01J35/615;;B01J35/617;;B01J35/633;;B01J35/635;;B01J35/638;;B01J35/651;;B01J35/647;;B01J31/0209,B01J31/02;;B01J29/16;;B01J35/10,,0,0,,,,DISCONTINUED
532,WO,A2,WO 2008/021800 A2,037-307-067-742-762,2008-02-21,2008,US 2007/0075310 W,2007-08-07,US 82242506 P,2006-08-15,METHOD FOR PREVENTING CRYSTALLIZATION,"A method for delaying or preventing crystallization of materials susceptible to such crystallization by the use of a microencapsulation process is disclosed. The process provides for the use of microcapsules to slow or prevent the crystallization of formulations susceptible to such crystallization. In particular, the method includes a process for delaying or preventing crystallization through the use of encapsulated droplets of a solution of an active material which is substantially insoluble in aqueous conditions, where the encapsulating agent is a film formed from a modified urea-formaldehyde polymer.",SYNGENTA PARTICIPATIONS AG;;NELSON ALAN;;CUSH SARAH;;HOPKINSON MICHAEL;;LO CHIEN-CHO;;MOORE CAROLYN,NELSON ALAN;;CUSH SARAH;;HOPKINSON MICHAEL;;LO CHIEN-CHO;;MOORE CAROLYN,,https://lens.org/037-307-067-742-762,Patent Application,yes,0,6,5,5,0,A01N25/28;;B01J13/16,C09K3/00,,0,0,,,,PENDING
533,JP,A,JP 2000077479 A,117-324-608-899-493,2000-03-14,2000,JP 22462399 A,1999-08-06,US 13087198 A,1998-08-07,STRESS-REMOVING INTERMEDIATE LAYER OF CHIP AND BOARD,"PROBLEM TO BE SOLVED: To bond a semiconductor chip through a flip-chip bonding method imposing a small stress on it by a method, wherein a flap-like region is demarcated between an upper contact pad and a lower contact pad that are mechanically isolated from a bulk intermediate layer, and the upper and the lower contact pad are displaced in the radial direction. SOLUTION: An intermediate layer 218 curves, expands or shrinks slightly between a chip contact 226 and a module contact 230 at high temperatures. A local distortion in a flap-like region allows a chip contact 226 to be displaced in the lateral direction from the module contact 230, so that thermal stresses imposed on a solder contact id reduced. A contact space 238 at a high temperature is narrower than a contact space 236 at a low temperature. With this setup, an intermediate layer structure that is of high reliability and through which a semiconductor chip can be bonded to a module in a flip-chip bonding method being less stressed can be obtained. Furthermore, the intermediate layer suitable for the manufacture of a dense ball grid array is obtained.",FUJITSU LTD,MICHAEL GUAN-TSON LEE;;BEILIN SOLOMON I;;UEN-CHO VINCENT WANG,,https://lens.org/117-324-608-899-493,Patent Application,no,0,2,2,2,0,H01L23/49833;;H01L23/49833;;H01L23/49838;;H01L23/49838;;H01L2224/16;;H01L2224/16;;H01L2924/01079;;H01L2924/01079;;H01L2924/10253;;H01L2924/10253;;H01L2924/15311;;H01L2924/15311;;H05K3/326;;H05K3/326,H01L23/12;;H01L21/60;;H01L23/498;;H05K3/32,,0,0,,,,DISCONTINUED
534,CN,A,CN 105447381 A,065-225-693-295-417,2016-03-30,2016,CN 201510600042 A,2015-09-18,KR 20140124512 A,2014-09-18,TOKEN-BASED SCHEME FOR GRANTING PERMISSIONS,"An electronic device comprising: a memory; and at least one processor configured to: install an application by using an installation file associated with the application; grant at least one permission to the application based on a permission setting token that is included in the installation file; and store, in a database, an indication that the application is granted the permission.",SAMSUNG ELECTRONICS CO LTD,OH MYEONG-JIN;;PARK JU-HA;;PAK-MICHAEL;;CHO SUNG-KYU,,https://lens.org/065-225-693-295-417,Patent Application,no,4,1,9,9,0,G06F21/51;;G06F21/51;;G06F16/245;;G06F21/44;;G06F2221/2141;;G06F16/245;;G06F21/51;;G06F8/61;;G06F21/62;;G06F16/242,G06F21/51,,0,0,,,,ACTIVE
535,US,A1,US 2023/0321303 A1,126-827-362-605-299,2023-10-12,2023,US 202318128268 A,2023-03-30,US 202318128268 A;;US 202263329479 P,2022-04-11,VOLATILE COMPOSITION DISPENSER WITH VISUAL INDICATOR,"A volatile composition dispenser including a solid article having a volatile composition and a peripheral evaporative surface. The solid article shrinks relative to the peripheral evaporative surface from an initial size to a reduced size smaller than the initial size upon exposure of the solid article to the environment in an interior space. The solid article is characterized by a shrinkage in a direction away from the peripheral evaporative surface of greater than 1% to less than 40%. A visual indicator is located proximal to the peripheral evaporative surface of the solid article. The dispenser has a first configuration in which the visual indicator is not visually perceptible, and a second configuration in which the visual indicator is visually perceptible upon shrinkage of at least a portion of the solid article from the initial size to the reduced size for indicating a state of use of the dispenser.",PROCTER & GAMBLE,VYAS RAHUL;;NG DESMOND;;CHO MEI SAN GIGI;;CANNON WILLIAM MICHAEL,THE PROCTER & GAMBLE COMPANY (2022-05-11),https://lens.org/126-827-362-605-299,Patent Application,yes,0,0,2,2,0,A61L9/048;;A61L2209/133;;A61L9/04;;A61L2209/13;;A61L2209/21;;A01M29/12;;A01M29/12;;A61L9/042;;A61L9/12,A61L9/12;;A01M29/12;;A61L9/04,,0,0,,,,PENDING
536,TW,A,TW 200831180 A,090-660-194-854-520,2008-08-01,2008,TW 96129947 A,2007-08-14,US 82242506 P,2006-08-15,Method for preventing crystallization,"A method for delaying or preventing crystallization of materials susceptible to such crystallization by the use of a microencapsulation process is disclosed. The process provides for the use of microcapsules to slow or prevent the crystallization of formulations susceptible to such crystallization. In particular, the method includes a process for delaying or preventing crystallization through the use of encapsulated droplets of a solution of an active material which is substantially insoluble in aqueous conditions where the encapsulating agent is a film formed from a a modified urea-formaldehyde polymer.",SYNGENTA PARTICIPATIONS AG,NELSON ALAN;;CUSH SARAH;;HOPKINSON MICHAEL;;LO CHIEN-CHO;;MOORE CAROLYN,,https://lens.org/090-660-194-854-520,Patent of Addition,no,0,0,5,5,0,A01N25/28;;B01J13/16,B01J13/16,,0,0,,,,PENDING
537,US,A1,US 2023/0321304 A1,052-072-199-139-551,2023-10-12,2023,US 202318128274 A,2023-03-30,US 202318128274 A;;US 202263329485 P,2022-04-11,REFILLABLE VOLATILE COMPOSITION DISPENSER WITH RELEASABLE INTERLOCK,"A flexible solid deodorizer for releasably interlocking to a volatile composition dispenser, the solid deodorizer has a first central evaporative surface, a second central evaporative surface, and a peripheral evaporative surface. The peripheral evaporative surface circumscribes at least a part of the first and second central evaporative surfaces to define a side of the deodorizer. The deodorizer is configured for releasably interlocking to the dispenser, wherein at least a portion of the deodorizer is configured to releasably interlock with at least a portion of the dispenser to form a solid surface substantially free of an opening.",PROCTER & GAMBLE,VYAS RAHUL;;NG DESMOND;;CHO MEI SAN GIGI;;CANNON WILLIAM MICHAEL,THE PROCTER & GAMBLE COMPANY (2022-05-11),https://lens.org/052-072-199-139-551,Patent Application,yes,0,0,2,2,0,A61L9/012;;A61L9/044;;A61L9/042;;A61L9/048;;A61L2209/133;;A61L9/048;;A61L9/12,A61L9/12;;A61L9/04,,0,0,,,,PENDING
538,CN,A,CN 114488831 A,167-132-464-883-368,2022-05-13,2022,CN 202210021782 A,2022-01-10,CN 202210021782 A,2022-01-10,Internet of Things home intelligent control system and method based on human-computer interaction,"The invention discloses an Internet of Things home intelligent control system and method based on man-machine interaction, and the method comprises the steps: enabling a user to regulate and control a corresponding control instruction for each group through an intelligent regulation and control module, and enabling the regulated and controlled control instruction and the corresponding group to be stored in an instruction data controller in the form of a data pair; and the identification control module acquires position action information and voice information of a user in real time, and matches an acquired result with a control instruction in each data pair in the instruction database so as to control the home devices in the corresponding group. The control instruction is limited through the position action information and the voice information monitored by the sensor, so that the control instruction is more diversified and specific, different control instructions can be conveniently and rapidly distinguished, meanwhile, the control instruction is segmented and matched in the process of matching the control instruction, the matching efficiency is guaranteed, and the matching accuracy is improved. And the accuracy of the matching result is ensured.",JIANGSU BO ISLAND INTELLIGENT INDUSTRY TECH RESEARCH INSTITUTE LIMITED COMPANY;;JIANGSU BO ISLAND INTELLIGENT SCIENCE AND TECH LIMITED COMPANY,CHO JEONG RAE;;GUI LI;;ZHOU BINGQING;;YANG LU;;WOOLDRIDGE MICHAEL,,https://lens.org/167-132-464-883-368,Patent Application,no,8,1,2,2,0,G05B15/02;;G05B19/418;;G05B2219/2642;;Y02P90/02,G05B15/02;;G05B19/418,,0,0,,,,ACTIVE
539,WO,A3,WO 2012/033878 A3,011-327-739-750-20X,2012-07-19,2012,US 2011/0050767 W,2011-09-08,US 38085810 P,2010-09-08,COMPOUNDS AND METHODS FOR ACEMIF INHIBITION AND THE TREATMENT OF PARASITES,"The screening of bioactive compound libraries can be an effective approach for repositioning FDA-approved drugs or discovering new pharmacophores, Hookworms are blood-feeding, intestinal nematode parasites infect up to 600 million people worldwide. Vaccination with recombinant Ancylostoma ceylanicum macrophage migration inhibitory factor (rAceMIF) provided partial protection from disease, thus establishing a ""proof-of-concept"" for targeting AceMIF to prevent or treat infection. A high-throughput screen (HTS) against rAceMIF identified six AceMIF-specific inhibitors. A non-steroidal anti-inflammatory drug (NSAID), sodium meclofenamate, could be tested in an animal model to assess the therapeutic efficacy in treating hookworm disease. Furosemide, an FDA-approved diuretic, exhibited submicromolar inhibition of rAceMIF tautomerase activity. Structure-activity relationships of a pharmacophore based on furosemide included one analogue that binds similarly to the active site, yet does not inhibit the Na-K-Cl symporter (NKCC1) responsible for diuretic activity. Compounds and methods for inhibiting AceMIF and treating parasitic, including hookworm infections represent additional aspects of the invention.",UNIV YALE;;LOLIS ELIAS;;CHO YOONSANG;;BUCALA RICHARD;;CAPPELLO MICHAEL;;VERMEIRE JON J,LOLIS ELIAS;;CHO YOONSANG;;BUCALA RICHARD;;CAPPELLO MICHAEL;;VERMEIRE JON J,,https://lens.org/011-327-739-750-20X,Search Report,yes,2,0,2,2,0,A61K31/341;;A61K31/122;;A61K31/194;;A61K31/196;;A61K31/495;;A61P33/00;;Y02A50/30,A61K31/19;;A61K31/045;;A61K31/185;;A61K31/195;;A61K31/496;;A61P33/00,,2,1,072-205-578-454-537,10.1002/tcm.1770040403;;6149626,"THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, no. 32, 2007;;TERATOGENESIS, CARCINOGENESIS, AND MUTAGENESIS., vol. 4, no. ISSUE, 1984, pages 329 - 340",PENDING
540,WO,A3,WO 2008/021800 A3,077-207-914-321-866,2008-10-23,2008,US 2007/0075310 W,2007-08-07,US 82242506 P,2006-08-15,METHOD FOR PREVENTING CRYSTALLIZATION,"A method for delaying or preventing crystallization of materials susceptible to such crystallization by the use of a microencapsulation process is disclosed. The process provides for the use of microcapsules to slow or prevent the crystallization of formulations susceptible to such crystallization. In particular, the method includes a process for delaying or preventing crystallization through the use of encapsulated droplets of a solution of an active material which is substantially insoluble in aqueous conditions, where the encapsulating agent is a film formed from a modified urea-formaldehyde polymer.",SYNGENTA PARTICIPATIONS AG;;NELSON ALAN;;CUSH SARAH;;HOPKINSON MICHAEL;;LO CHIEN-CHO;;MOORE CAROLYN,NELSON ALAN;;CUSH SARAH;;HOPKINSON MICHAEL;;LO CHIEN-CHO;;MOORE CAROLYN,,https://lens.org/077-207-914-321-866,Search Report,yes,1,0,5,5,0,A01N25/28;;B01J13/16,B01J13/02;;A61K9/50,,0,0,,,,PENDING
541,CN,A,CN 114431865 A,193-217-296-341-409,2022-05-06,2022,CN 202111595358 A,2021-12-24,CN 202111595358 A,2021-12-24,Intelligent teaching aid system based on brain-computer interface,"The invention discloses an intelligent teaching aid system based on a brain-computer interface in the field of brain-computer intelligent teaching aids, and the system comprises an inner helmet, a brain wave monitoring mechanism and a locking mechanism are arranged in the inner helmet, the locking mechanism comprises a sliding rod, and the bottom end of the sliding rod penetrates through the top end of the inner helmet and then is fixedly connected with the inner helmet. The top end of the sliding rod penetrates through and is slidably connected with an outer helmet, and a supporting mechanism is arranged on the surface of the sliding rod. According to the brain wave tester, by arranging the locking mechanism, the brain wave tester can be rapidly installed on the brain of a patient and can be rapidly taken down at the same time, and after the brain wave tester is taken down, the outer helmet can be continuously pulled upwards till the outer helmet is separated from the surface of the sliding rod, so that the inner helmet and the outer helmet are separated, and maintenance and detection by workers are facilitated; meanwhile, when the brain waves of the patient are monitored, a plurality of connecting wires for monitoring the brain waves do not need to be manually connected with different positions of the brain of the patient one by one and then disassembled one by one, the labor intensity is reduced, and operation and use are convenient.",JIANGSU BO ISLAND INTELLIGENT INDUSTRY TECH RESEARCH INSTITUTE LIMITED COMPANY;;JIANGSU BOBRAIN WISDOM TECH CO LTD;;JIANGSU BO ISLAND INTELLIGENT SCIENCE AND TECH LIMITED COMPANY,CHO JEONG RAE;;WOOLDRIDGE MICHAEL;;LIU FENG;;GUI LI;;ZHOU BINGQING,,https://lens.org/193-217-296-341-409,Patent Application,no,0,0,1,1,0,A61B5/256;;A61B5/271;;A61B5/291,A61B5/256;;A61B5/271;;A61B5/291,,0,0,,,,PENDING
542,US,S,US D0807387 S,039-914-784-375-229,2018-01-09,2018,US 201629579774 F,2016-10-03,US 201629579774 F,2016-10-03,Display screen with animated graphical user interface,,GOOGLE INC;;GOOGLE LLC,CHO HANNAH;;GOYAL SUNNY;;COHEN MICHAEL ADAM;;MCELHANEY REMINGTON;;LIANG TAO,GOOGLE LLC (2016-12-12),https://lens.org/039-914-784-375-229,Design Right,no,0,56,1,1,0,,,1404;;D14/486,0,0,,,,ACTIVE
543,US,A1,US 2020/0411846 A1,066-435-375-697-412,2020-12-31,2020,US 201916692967 A,2019-11-22,US 201916692967 A;;US 201962895706 P;;US 201962877528 P;;US 201962867959 P,2019-06-28,ZINC ELECTRODES WITH HIGH CAPACITY UTILIZATIONS,"A zinc electrode comprises an anode material, the anode material comprising: an electroactive material comprising at least one of zinc or a compound comprising zinc, a stabilizer additive comprising at least one of: bismuth, copper, indium, a compound comprising bismuth, a compound comprising copper, a compound comprising indium, or any combination thereof, a conductive additive, and a binder.",UNIV CITY NEW YORK RES FOUND,YADAV GAUTAM G;;CHO JUNGSANG;;WEI XIA;;NYCE MICHAEL;;BANERJEE SANJOY,RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (2020-02-12),https://lens.org/066-435-375-697-412,Patent Application,yes,0,5,5,5,0,H01M2004/027;;H01M10/36;;H01M4/38;;H01M4/42;;H01M4/46;;H01M4/48;;H01M4/628;;H01M4/625;;H01M4/661;;H01M2300/0002;;H01M50/411;;H01M4/366;;H01M4/134;;H01M2004/027;;H01M10/24;;H01M4/466;;H01M4/50;;H01M4/625;;H01M4/661;;H01M10/26;;H01M2300/0002,H01M4/134;;H01M10/24,,0,0,,,,ACTIVE
544,US,B2,US 10176333 B2,109-525-993-588-288,2019-01-08,2019,US 201514858146 A,2015-09-18,KR 20140124512 A,2014-09-18,Token-based scheme for granting permissions,"An electronic device comprising: a memory; and at least one processor configured to: install an application by using an installation file associated with the application; grant at least one permission to the application based on a permission setting token that is included in the installation file; and store, in a database, an indication that the application is granted the permission.",SAMSUNG ELECTRONICS CO LTD,OH MYEONG JIN;;PARK JU HA;;PAK MICHAEL;;CHO SUNG KYU,SAMSUNG ELECTRONICS CO. LTD (2015-08-04),https://lens.org/109-525-993-588-288,Granted Patent,yes,72,0,9,9,0,G06F21/51;;G06F21/51;;G06F16/245;;G06F21/44;;G06F2221/2141;;G06F16/245;;G06F21/51;;G06F8/61;;G06F21/62;;G06F16/242,G06F21/62;;G06F8/61;;G06F21/44;;G06F21/51,,3,0,,,"European Search Report dated Dec. 7, 2016.;;Chinese Search Report dated Nov. 24, 2017.;;European Search Report dated Mar. 3, 2018.",ACTIVE
545,US,B2,US 8649377 B2,108-622-649-054-293,2014-02-11,2014,US 201113277865 A,2011-10-20,US 201113277865 A;;US 6072308 A;;US 95778207 P,2007-08-24,Methods and systems to store state used to forward multicast traffic,"A method and system are described to multicast with an adaptive dual state. The system receives multicast traffic over a membership tree including a first plurality of nodes connected in a first topology destined for a plurality of multicast members of a first multicast group. Next, the system determines a rate of multicast traffic that exceeds a predetermined threshold based on the receiving the multicast traffic. Next, the system generates a dissemination tree including a second plurality of nodes connected in a second topology to reduce a number of hops to communicate the multicast traffic to the plurality of multicast members of the first multicast group. Finally, the system forwards the multicast traffic to the plurality of multicast members of the first multicast group over the dissemination tree.",RAMAKRISHNAN KADANGODE;;SRIVASTAVA DIVESH;;CHO TAE W;;ZHANG YIN;;RABINOVICH MICHAEL;;AT & T IP I LP,RAMAKRISHNAN KADANGODE;;SRIVASTAVA DIVESH;;CHO TAE W;;ZHANG YIN;;RABINOVICH MICHAEL,AT&T INTELLECTUAL PROPERTY I LP (2008-02-29),https://lens.org/108-622-649-054-293,Granted Patent,yes,25,4,8,8,0,H04L12/1886;;H04L45/16;;H04L45/48;;H04L12/1886;;H04L45/48;;H04L45/16,H04L12/28,370/390,3,0,,,"Cui, , ""An Architecture for Scalable OoS Multicast Provisioning"", UCLA CSD TR # 010030, http://citeseer.ist.psu.edu/cui01architecture.html, (2001), 21 pgs.;;Estrin, , ""Protocol Independent Multicast-Sparse Mode (PIM-SM): Deployment Guidelines"", Dec. 10, 1996.;;Estrin, , ""Protocol Independent Multicast-Sparse Mode (PIM-SM): Protocol Specification, RFC 2362"", Jun. 1998.",INACTIVE
546,US,A1,US 2023/0300502 A1,109-055-297-605-028,2023-09-21,2023,US 202217697597 A,2022-03-17,US 202217697597 A,2022-03-17,LOUDSPEAKER ACCESSORY TRAY,"An accessory tray for a loudspeaker includes a main portion defining a perimeter and a base surface configured to support an accessory within the perimeter. An anchor portion extends under the base surface of the main portion, the anchor portion configured to engage a portion of the loudspeaker. The main portion has a tapering height from a rear to a front thereof, forming a rake angle in side view.",BOSCH GMBH ROBERT,KASTEN MICHAEL D;;GRUNLOH ANDREW;;SULZER NICHOLAS;;FILIPEK SHAWN;;CHO ANDREW,,https://lens.org/109-055-297-605-028,Patent Application,yes,4,0,5,5,0,H04R1/025;;H04R2201/029;;H04R2201/029;;H04R1/025,H04R1/02,,0,0,,,,ACTIVE
547,EP,A1,EP 3809297 A1,005-241-716-130-652,2021-04-21,2021,EP 20212580 A,2015-09-18,KR 20140124512 A;;EP 15185942 A,2014-09-18,TOKEN-BASED SCHEME FOR GRANTING PERMISSIONS,"An electronic device comprising: a communication interface configured to perform a wireless communication with an external electronic device or a server; a memory; and at least one processor operatively coupled with the communication interface and the memory, and configured to: install an application by using an installation file associated with the application which is preloaded or downloaded from the external electronic device or the server; grant at least one permission to the application based on a key signing which is included in the installation file; detect whether the installation file includes a permission setting token; if the installation file includes the permission setting token, identify at least one permission associated with the permission setting token, wherein the permission setting token, which is independent of the key signing, is data that defines a permission range for the application to access resources of the electronic device; grant the at least one permission to the application based on the permission setting token; and store, in the memory, the at least one permission which is granted to the application using the permission setting token.
",SAMSUNG ELECTRONICS CO LTD,OH MYEONG JIN;;PARK JU HA;;PAK MICHAEL;;CHO SUNG KYU,,https://lens.org/005-241-716-130-652,Patent Application,yes,4,0,9,9,0,G06F21/51;;G06F21/51;;G06F16/245;;G06F21/44;;G06F2221/2141;;G06F16/245;;G06F21/51;;G06F8/61;;G06F21/62;;G06F16/242,G06F21/51,,0,0,,,,PENDING
548,KR,B1,KR 102189913 B1,178-108-275-113-945,2020-12-11,2020,KR 20200032510 A,2020-03-17,KR 20200032510 A,2020-03-17,Nutrient solution culture system,"An object of the present invention is to provide a nutrient solution cultivation system configured to: supply a nutrient solution in an aerosol form to a root part of a plant, thereby reducing waste of the nutrient solution; and increase an absorption rate of a nutrient solution, thereby increasing growth efficiency. The nutrient solution cultivation system according to the present invention comprises: a cultivation stack (100), wherein an accommodation groove (110) where stems and leaves of a plant are placed is formed outside thereof and a supply space (120) where a root part of a plant is placed is formed therein; a nutrient solution container (200) in which a nutrient solution required for the growth of a plant is stored; and a supply means configured to supply the nutrient solution stored in the nutrient solution container (200) to the inside of the cultivation stack (100).",OLLE FARM INC,AHN MICHAEL;;CHO SEONG IL;;HA GAP SEUNG;;LEE YOUNG SON,,https://lens.org/178-108-275-113-945,Granted Patent,no,4,1,1,1,0,A01G31/02;;A01G29/00;;F24F5/0007;;F24F6/16;;F28D1/047;;Y02B30/54;;Y02P60/21,A01G31/02;;A01G29/00;;F24F5/00;;F24F6/16;;F28D1/047,,0,0,,,,ACTIVE
549,KR,A,KR 20200033602 A,010-664-197-806-694,2020-03-30,2020,KR 20180113085 A,2018-09-20,KR 20180113085 A,2018-09-20,Centrifugal force based non-powered particle concentration apparatus and method of particle concentration,"According to an embodiment of the present invention, provided is a centrifugal power-based non-power particle concentration device which comprises: a disk unit including a filter unit in which pores of a predetermined size are formed so that particles are separated by filtering a fluid sample; a first body unit connected to an inlet side surface of the filter unit and supplying a fluid sample to the inlet side surface of the filter unit; and a second body connected to an outlet side surface of the filter unit and accommodating a permeate from which particles are separated through the filter unit; and a handle unit disposed at the center of the disk unit, wherein the disk unit can perform a relative rotatory motion with respect to the handle unit around the handle unit as a rotatory center.",ULSAN NAT INST SCIENCE & TECH UNIST,CHO YOON KYOUNG;;MICHAEL ISSAC;;KIM DONG YOUNG;;KI DONG YEOB,,https://lens.org/010-664-197-806-694,Patent Application,no,4,4,2,2,0,B04B5/005;;B04B9/12;;G01N1/4077;;G01N2001/4088,B04B5/00;;B04B9/12;;G01N1/40,,0,0,,,,ACTIVE
550,US,A1,US 2013/0044642 A1,079-737-151-502-212,2013-02-21,2013,US 201213627236 A,2012-09-26,US 201213627236 A;;US 6070908 A;;US 95778207 P,2007-08-24,METHODS AND SYSTEMS TO STORE AND FORWARD MULTICAST TRAFFIC,"Methods and systems are described to store and forward multicast traffic. The method includes receiving a request to add a first node to a membership tree including a first plurality of nodes associated with a multicast group, identifying a second node in the first plurality of nodes, communicating a node identifier that identifies the first node over a network to the second node where the node identifier is stored at the second node to add the first node to the membership tree where the node identifier is stored in the membership tree to enable the second node to forward multicast traffic to the first node, and where the first and second nodes are separated from each other by at least one other node of the first plurality of node. The first node can be associated with a multicast member that has been added to the multicast group. Other embodiments are disclosed.",AT & T IP I LP,RAMAKRISHNAN KADANGODE;;SRIVASTAVA DIVESH;;CHO TAE W;;ZHANG YIN;;RABINOVICH MICHAEL,AT&T INTELLECTUAL PROPERTY I LP (2008-02-29),https://lens.org/079-737-151-502-212,Patent Application,yes,6,2,8,8,0,H04L12/1886;;H04L45/16;;H04L45/48;;H04L12/1886;;H04L45/48;;H04L45/16,H04L12/28,370/256;;370/390,0,0,,,,INACTIVE
551,US,A1,US 2022/0334087 A1,055-608-011-820-604,2022-10-20,2022,US 202217727294 A,2022-04-22,US 202217727294 A;;US 202217716249 A;;US 202163177141 P;;US 202163255880 P,2021-04-20,INSPECTION ROBOTS WITH INDEPENDENT DRIVE MODULE SUSPENSION,"Inspection robots with independent drive module suspension are described. An example inspection robot may have a housing with a first connector on a first side of the housing, and a second connector on a second side of the housing. A first drive module, having at least one wheel and a first motor, may be operatively coupled to the first connector, and a second drive module, having at least one wheel and a first motor, may be operatively coupled to the second connector. The first and second drive modules may be coupled by a drive connector.",GECKO ROBOTICS INC,JOURDE DILLON R;;CHO MARK;;BINGER MICHAEL A;;LOW KEVIN Y,GECKO ROBOTICS INC (2022-04-11),https://lens.org/055-608-011-820-604,Patent Application,yes,6,8,24,24,0,B62D57/024;;G01N29/225;;G01N29/265;;G01N2291/0237;;G01N2291/02854;;G01N29/043;;G05B2219/45066;;B25J9/1694;;B25J9/1692;;B25J9/1666;;B60K7/00;;B60K7/0007;;B25J9/1653;;B25J19/027;;B25J13/087;;B25J9/0009;;B25J9/1694;;G01N29/04;;G01N29/226;;G01N29/265;;G01N2291/0289;;G01N2291/2698;;B25J9/1617;;B25J9/163;;B25J9/1664;;B25J9/1674;;B25J13/006;;B25J5/007;;B25J19/021;;B60K1/02;;B62D53/02;;B62D57/024;;B60B19/006;;B60B19/12;;B60B2360/104;;B60B2360/109;;B60B2900/931;;B60B2360/102;;G06F1/206;;G06F2200/201;;H05K1/18;;H05K2201/10151,G01N29/265;;B62D53/02;;G01N29/04,,0,0,,,,PENDING
552,EP,B1,EP 2998898 B1,112-340-221-787-735,2020-12-09,2020,EP 15185942 A,2015-09-18,KR 20140124512 A,2014-09-18,TOKEN-BASED SCHEME FOR GRANTING PERMISSIONS,,SAMSUNG ELECTRONICS CO LTD,OH MYEONG JIN;;PARK JU HA;;PAK MICHAEL;;CHO SUNG KYU,,https://lens.org/112-340-221-787-735,Granted Patent,yes,3,0,9,9,0,G06F21/51;;G06F21/51;;G06F16/245;;G06F21/44;;G06F2221/2141;;G06F16/245;;G06F21/51;;G06F8/61;;G06F21/62;;G06F16/242,G06F21/51,,0,0,,,,ACTIVE
553,KR,A,KR 20160033510 A,032-495-289-700-938,2016-03-28,2016,KR 20140124512 A,2014-09-18,KR 20140124512 A,2014-09-18,ELECTRONIC DEVICE USING TOKEN FOR SETTING PERMISSION,"The present invention provides an electronic device, which defines an authority setting range by using an authority setting token and confers the authority within the defined range, and a method for using the same. According to various embodiments of the present invention, the electronic device may include: an installation module which can install and run an application and installs the application by using an installation file; an authority processing module which sets authority of the application by using the authority setting token included in the installation file; and a token database which stores authority information included in the authority setting token. Various embodiments, understood through the specification, other than the present embodiments are possible.",SAMSUNG ELECTRONICS CO LTD,OH MYEONG JIN;;PARK JU HA;;PAK MICHAEL;;CHO SUNG KYU,,https://lens.org/032-495-289-700-938,Patent Application,no,3,1,9,9,0,G06F21/51;;G06F21/51;;G06F16/245;;G06F21/44;;G06F2221/2141;;G06F16/245;;G06F21/51;;G06F8/61;;G06F21/62;;G06F16/242,G06F21/12;;G06F17/30,,0,0,,,,ACTIVE
554,US,B2,US 11342548 B2,059-687-072-253-74X,2022-05-24,2022,US 201916692967 A,2019-11-22,US 201916692967 A;;US 201962895706 P;;US 201962877528 P;;US 201962867959 P,2019-06-28,Zinc electrodes with high capacity utilizations,"A zinc electrode comprises an anode material, the anode material comprising: an electroactive material comprising at least one of zinc or a compound comprising zinc, a stabilizer additive comprising at least one of: bismuth, copper, indium, a compound comprising bismuth, a compound comprising copper, a compound comprising indium, or any combination thereof, a conductive additive, and a binder.",UNIV CITY NEW YORK RES FOUND,YADAV GAUTAM G;;CHO JUNGSANG;;WEI XIA;;NYCE MICHAEL;;BANERJEE SANJOY,RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (2020-02-12),https://lens.org/059-687-072-253-74X,Granted Patent,yes,4,0,5,5,0,H01M2004/027;;H01M10/36;;H01M4/38;;H01M4/42;;H01M4/46;;H01M4/48;;H01M4/628;;H01M4/625;;H01M4/661;;H01M2300/0002;;H01M50/411;;H01M4/366;;H01M4/134;;H01M2004/027;;H01M10/24;;H01M4/466;;H01M4/50;;H01M4/625;;H01M4/661;;H01M10/26;;H01M2300/0002,H01M4/10;;H01M4/02;;H01M4/134;;H01M10/24,,0,0,,,,ACTIVE
555,CN,A,CN 114305419 A,115-925-667-688-072,2022-04-12,2022,CN 202111625712 A,2021-12-28,CN 202111625712 A,2021-12-28,AI emotion recognition mental health screening system,"The invention discloses an AI emotion recognition mental health screening system, which relates to the technical field of image recognition and comprises a processing chip, a control register, a photosensitive multi-element converter, a first frame memory unit, a second frame memory unit, a frame difference capturing unit, a frame difference summator and an external electrically-connected signal output unit, and the control register, the photosensitive multi-element converter, the first frame memory unit, the second frame memory unit, the frame difference capturing unit and the frame difference summator are integrally arranged in the processing chip. The signal output end of the first frame memory unit and the signal output end of the second frame memory unit are electrically connected to the frame difference capturing unit, the signal output end of the frame difference capturing unit is electrically connected with the frame difference summator, and the signal output end of the frame difference summator is electrically connected to the signal output unit. The method is simple and easy to use, achieves intelligent learning and multi-dimensional analysis, is wide in application, can recognize a detection area which cannot be recognized by the face technology, can recognize the face orientation of the area which cannot be detected by the face technology, can also recognize the face which is partially shielded and has light rays of 100 LUX or above, and is not affected by expressions, ages and races.",JIANGSU BO ISLAND INTELLIGENT INDUSTRY TECH RESEARCH INSTITUTE LIMITED COMPANY;;JIANGSU BOBRAIN WISDOM TECH CO LTD;;JIANGSU BO ISLAND INTELLIGENT SCIENCE AND TECH LIMITED COMPANY,GUI LI;;CHO JEONG RAE;;ZHOU BINGQING;;WOOLDRIDGE MICHAEL;;WEI XUEYAN,,https://lens.org/115-925-667-688-072,Patent Application,no,0,1,1,1,0,,A61B5/16;;A61B5/11;;G06T1/00;;G06T7/00,,0,0,,,,PENDING
556,EP,A1,EP 2998898 A1,124-661-785-352-051,2016-03-23,2016,EP 15185942 A,2015-09-18,KR 20140124512 A,2014-09-18,TOKEN-BASED SCHEME FOR GRANTING PERMISSIONS,"An electronic device comprising: a memory; and at least one processor configured to: install an application by using an installation file associated with the application; grant at least one permission to the application based on a permission setting token that is included in the installation file; and store, in a database, an indication that the application is granted the permission.
",SAMSUNG ELECTRONICS CO LTD,OH MYEONG JIN;;PARK JU HA;;PAK MICHAEL;;CHO SUNG KYU,,https://lens.org/124-661-785-352-051,Patent Application,yes,3,2,9,9,0,G06F21/51;;G06F21/51;;G06F16/245;;G06F21/44;;G06F2221/2141;;G06F16/245;;G06F21/51;;G06F8/61;;G06F21/62;;G06F16/242,G06F21/51,,0,0,,,,ACTIVE
557,US,B2,US 6660624 B2,138-484-531-814-045,2003-12-09,2003,US 7689102 A,2002-02-14,US 7689102 A,2002-02-14,Method for reducing fluorine induced defects on a bonding pad surface,"
    A method for reducing a fluorine contamination level on a semiconductor wafer process surface including providing a semiconductor wafer surface having a process surface including an uppermost polyimide containing layer; reactive ion etching the process surface to include exposure of the process surface to a hydrofluorocarbon containing plasma; and heating the process surface according to a temperature profile to reduce a fluorine contamination level. 
",TAIWAN SEMICONDUCTOR MFG,TZENG JIANN-TYNG;;TSAI JIH-REN;;WU MICHAEL;;CHO CHING-WEN,,https://lens.org/138-484-531-814-045,Granted Patent,yes,5,19,2,2,0,H01L21/31058;;H01L21/31116;;H01L21/31138;;H01L21/31144;;H01L24/11;;H01L2224/13099;;H01L2924/01005;;H01L2924/01013;;H01L2924/01015;;H01L2924/01029;;H01L2924/14;;H01L2924/19041;;H01L2924/19043;;H01L2924/01006;;H01L2924/01033;;H01L2924/01043;;H01L2924/12042;;H01L21/31116;;H01L2924/01013;;H01L2924/01029;;H01L21/31058;;H01L2924/19043;;H01L21/31144;;H01L2224/13099;;H01L2924/01015;;H01L24/11;;H01L2924/01005;;H01L21/31138;;H01L2924/14;;H01L2924/19041;;H01L2924/01033;;H01L2924/01043;;H01L2924/01006;;H01L2924/12042,H01L21/3105;;H01L21/311;;H01L21/60,438/612;;438/637;;438/660;;438/687;;438/688;;438/712;;438/715;;438/722;;438/723;;438/724;;438/725;;438/726;;438/473;;438/474;;438/475,0,0,,,,EXPIRED
558,WO,A2,WO 2012/033878 A2,026-655-701-981-085,2012-03-15,2012,US 2011/0050767 W,2011-09-08,US 38085810 P,2010-09-08,COMPOUNDS AND METHODS FOR ACEMIF INHIBITION AND THE TREATMENT OF PARASITES,"The screening of bioactive compound libraries can be an effective approach for repositioning FDA-approved drugs or discovering new pharmacophores, Hookworms are blood-feeding, intestinal nematode parasites infect up to 600 million people worldwide. Vaccination with recombinant Ancylostoma ceylanicum macrophage migration inhibitory factor (rAceMIF) provided partial protection from disease, thus establishing a ""proof-of-concept"" for targeting AceMIF to prevent or treat infection. A high-throughput screen (HTS) against rAceMIF identified six AceMIF-specific inhibitors. A non-steroidal anti-inflammatory drug (NSAID), sodium meclofenamate, could be tested in an animal model to assess the therapeutic efficacy in treating hookworm disease. Furosemide, an FDA-approved diuretic, exhibited submicromolar inhibition of rAceMIF tautomerase activity. Structure-activity relationships of a pharmacophore based on furosemide included one analogue that binds similarly to the active site, yet does not inhibit the Na-K-Cl symporter (NKCC1) responsible for diuretic activity. Compounds and methods for inhibiting AceMIF and treating parasitic, including hookworm infections represent additional aspects of the invention.",UNIV YALE;;LOLIS ELIAS;;CHO YOONSANG;;BUCALA RICHARD;;CAPPELLO MICHAEL;;VERMEIRE JON J,LOLIS ELIAS;;CHO YOONSANG;;BUCALA RICHARD;;CAPPELLO MICHAEL;;VERMEIRE JON J,,https://lens.org/026-655-701-981-085,Patent Application,yes,0,2,2,2,0,A61K31/341;;A61K31/122;;A61K31/194;;A61K31/196;;A61K31/495;;A61P33/00;;Y02A50/30,A61K31/19;;A61K31/045;;A61K31/185;;A61K31/195;;A61K31/496;;A61P33/00,,0,0,,,,PENDING
559,US,B2,US 11805343 B2,080-949-072-298-882,2023-10-31,2023,US 202217697597 A,2022-03-17,US 202217697597 A,2022-03-17,Loudspeaker accessory tray,"An accessory tray for a loudspeaker includes a main portion defining a perimeter and a base surface configured to support an accessory within the perimeter. An anchor portion extends under the base surface of the main portion, the anchor portion configured to engage a portion of the loudspeaker. The main portion has a tapering height from a rear to a front thereof, forming a rake angle in side view.",BOSCH GMBH ROBERT,KASTEN MICHAEL D;;GRUNLOH ANDREW;;SULZER NICHOLAS;;FILIPEK SHAWN;;CHO ANDREW,BOSCH SECURITY SYSTEMS INC (2021-12-06);;ROBERT BOSCH GMBH (2021-12-06),https://lens.org/080-949-072-298-882,Granted Patent,yes,9,0,5,5,0,H04R1/025;;H04R2201/029;;H04R2201/029;;H04R1/025,H04R1/02,,0,0,,,,ACTIVE
560,US,A1,US 2024/0040292 A1,139-339-518-338-617,2024-02-01,2024,US 202318483182 A,2023-10-09,US 202318483182 A;;US 202217697597 A,2022-03-17,LOUDSPEAKER ACCESSORY TRAY,"An accessory tray for a loudspeaker includes a main portion defining a perimeter and a base surface configured to support an accessory within the perimeter. An anchor portion extends under the base surface of the main portion, the anchor portion configured to engage a portion of the loudspeaker. The main portion has a tapering height from a rear to a front thereof, forming a rake angle in side view.",BOSCH GMBH ROBERT,KASTEN MICHAEL D;;GRUNLOH ANDREW;;SULZER NICHOLAS;;FILIPEK SHAWN;;CHO ANDREW,,https://lens.org/139-339-518-338-617,Patent Application,yes,0,0,5,5,0,H04R1/025;;H04R2201/029;;H04R2201/029;;H04R1/025,H04R1/02,,0,0,,,,PENDING
561,KR,A,KR 20210094184 A,161-828-518-552-343,2021-07-29,2021,KR 20200007273 A,2020-01-20,KR 20200007273 A,2020-01-20,ANALOG DIGITAL CONVERTER,"The present invention relates to an analog-digital converter (ADC) to minimize power consumption. According to an embodiment of the present invention, the ADC comprises: a successive approximation register (SAR) ADC receiving an analog input voltage, generating a first digital signal from an analog input voltage by using a SAR method, and outputting a residual current remaining after generating the first digital signal; a current-time converter converting the residual current into a residual time in a time domain; and a time-to-digital converter receiving the residual time and generating a second digital signal from the residual time. The first digital signal and the second digital signal are sequences of digital codes representing signal levels of the analog input voltage, respectively.",SAMSUNG ELECTRONICS CO LTD,MOON KYOUNG JUN;;OH DONG RYEOL;;CHO YOUNG JAE;;CHOI MICHAEL,,https://lens.org/161-828-518-552-343,Patent Application,no,0,0,5,5,0,G04F10/005;;H03M1/502;;H03M1/742;;H03M1/468;;H03M1/164;;H03M1/0695;;H03M1/38;;H03M1/50;;H03M1/002;;H03M1/0612;;H03M1/1028;;H03M1/145;;G04F10/005;;H03M1/38,H03M1/38;;H03M1/00;;H03M1/06;;H03M1/50,,0,0,,,,DISCONTINUED
562,WO,A1,WO 2014/147586 A1,021-226-443-512-990,2014-09-25,2014,IB 2014060007 W,2014-03-20,US 201361804341 P,2013-03-22,1-(2-(ETHYLAMINO)PYRIMIDIN-4-YL)PYRROLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH,"The invention is directed to a formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a–R1f, R2, R3 and R4 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.",NOVARTIS AG;;CHO YOUNG SHIN;;LEVELL JULIAN ROY;;SHAFER CYNTHIA;;SHULTZ MICHAEL DAVID,CHO YOUNG SHIN;;LEVELL JULIAN ROY;;SHAFER CYNTHIA;;SHULTZ MICHAEL DAVID,,https://lens.org/021-226-443-512-990,Patent Application,yes,6,34,1,1,0,A61P35/00;;C07D401/14;;C07D209/52;;C07D403/04;;C07D403/14;;C07D413/14;;C07D417/14;;C07D491/107,C07D403/04;;A61K31/506;;A61P35/00;;C07D401/14;;C07D403/14;;C07D413/14;;C07D417/14;;C07D491/107,,18,4,025-987-287-814-728;;030-927-218-313-125;;077-226-361-130-237;;043-972-959-295-475,pmc3069821;;10.1016/j.ajpath.2010.12.011;;21356389;;18985363;;10.1007/s00401-008-0455-2;;10.7554/elife.12626.003;;10.1016/j.ccr.2010.01.020;;pmc2849316;;10.3410/f.720539740.793505017;;20171147;;10.1126/science.1192632;;20847235,"L. DENG ET AL., TRENDS MOL. MED, vol. 16, 2010, pages 387;;T. SHIBATA ET AL., AM. J. PATHOL., vol. 178, no. 3, 2011, pages 1395;;GAAL ET AL., J. CLIN. ENDOCRINOL. METAB., 2010;;HAYDEN ET AL., CELL CYCLE, 2009;;BALSS ET AL., ACTA NEUROPATHOL., 2008;;L. DENG ET AL., NATURE, vol. 462, 2009, pages 739;;L. SELLNER ET AL., EUR. J. HAEMATOL., vol. 85, 2011, pages 457;;P.S. WARD ET AL., CANCER CELL, vol. 17, 2010, pages 225;;S. GROSS ET AL., J. EXP. MED., vol. 207, no. 2, 2010, pages 339;;KRANENDIJK, M. ET AL., SCIENCE, vol. 330, 2010, pages 336;;AMARY ET AL., NATURE GENETICS, 2011;;PANSURIYA ET AL., NATURE GENETICS, 2011;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY;;STAHL; WERMUTH: ""Handbook of Pharmaceutical Salts: Properties, Selection, and Use"", 2002, WILEY-VCH;;E. L. ELIEL; S. H. WILEN; L. N. MANDER: ""Stereochemistry of Organic Compounds"", 1994, WILEY-INTERSCIENCE;;""Reminaton's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY;;""The Handbook of Pharmaceutical Additives"", GOWER PUBLISHING LIMITED;;""The Handbook of Pharmaceutical Excipients"", AMERICAN PHARMACEUTICAL ASSOCIATION AND THE PHARMACEUTICAL PRESS",PENDING
563,US,A1,US 2003/0153196 A1,018-339-541-860-65X,2003-08-14,2003,US 7689102 A,2002-02-14,US 7689102 A,2002-02-14,Method for reducing fluorine induced defects on a bonding pad surface,"
   A method for reducing a fluorine contamination level on a semiconductor wafer process surface including providing a semiconductor wafer surface having a process surface including an uppermost polyimide containing layer; reactive ion etching the process surface to include exposure of the process surface to a hydrofluorocarbon containing plasma; and heating the process surface according to a temperature profile to reduce a fluorine contamination level. 
",TAIWAN SEMICONDUCTOR MFG,TZENG JIANN-TYNG;;TSAI JIH-REN;;WU MICHAEL;;CHO CHING-WEN,,https://lens.org/018-339-541-860-65X,Patent Application,yes,0,8,2,2,0,H01L21/31058;;H01L21/31116;;H01L21/31138;;H01L21/31144;;H01L24/11;;H01L2224/13099;;H01L2924/01005;;H01L2924/01013;;H01L2924/01015;;H01L2924/01029;;H01L2924/14;;H01L2924/19041;;H01L2924/19043;;H01L2924/01006;;H01L2924/01033;;H01L2924/01043;;H01L2924/12042;;H01L21/31116;;H01L2924/01013;;H01L2924/01029;;H01L21/31058;;H01L2924/19043;;H01L21/31144;;H01L2224/13099;;H01L2924/01015;;H01L24/11;;H01L2924/01005;;H01L21/31138;;H01L2924/14;;H01L2924/19041;;H01L2924/01033;;H01L2924/01043;;H01L2924/01006;;H01L2924/12042,H01L21/3105;;H01L21/311;;H01L21/60,438/724;;438/612;;438/906;;438/781,0,0,,,,EXPIRED
564,CN,A,CN 116782102 A,056-727-222-075-649,2023-09-19,2023,CN 202310258272 A,2023-03-16,US 202217697597 A,2022-03-17,Loudspeaker accessory disc,"The present disclosure relates to an accessory tray for a speaker. An accessory tray for a speaker includes a body portion defining a perimeter and a base surface configured to support an accessory within the perimeter. An anchor portion extends below the base surface of the body portion, the anchor portion configured to engage a portion of the speaker. The body portion has a height that gradually decreases from a rear portion to a front portion, thereby forming an inclination angle in a side view.",BOSCH GMBH ROBERT,KARSTEN MICHAEL D;;GRUNLOH ALFONS;;SULZER NICO;;FILIPEK STANISLAV;;CHO AESOP,,https://lens.org/056-727-222-075-649,Patent Application,no,0,0,5,5,0,H04R1/025;;H04R2201/029;;H04R2201/029;;H04R1/025,H04R9/06;;H04R9/02,,0,0,,,,PENDING
565,US,A1,US 2016/0085977 A1,092-624-660-186-975,2016-03-24,2016,US 201514858146 A,2015-09-18,KR 20140124512 A,2014-09-18,TOKEN-BASED SCHEME FOR GRANTING PERMISSIONS,"An electronic device comprising: a memory; and at least one processor configured to: install an application by using an installation file associated with the application; grant at least one permission to the application based on a permission setting token that is included in the installation file; and store, in a database, an indication that the application is granted the permission.",SAMSUNG ELECTRONICS CO LTD,OH MYEONG JIN;;PARK JU HA;;PAK MICHAEL;;CHO SUNG KYU,SAMSUNG ELECTRONICS CO. LTD (2015-08-04),https://lens.org/092-624-660-186-975,Patent Application,yes,35,7,9,9,0,G06F21/51;;G06F21/51;;G06F16/245;;G06F21/44;;G06F2221/2141;;G06F16/245;;G06F21/51;;G06F8/61;;G06F21/62;;G06F16/242,G06F21/62;;G06F9/445;;G06F17/30,,0,0,,,,ACTIVE
566,JP,A,JP 2000286549 A,041-968-072-719-535,2000-10-13,2000,JP 2000065347 A,2000-03-09,US 27554399 A,1999-03-24,MANUFACTURE OF SUBSTRATE PROVIDED WITH VIA CONNECTION,"PROBLEM TO BE SOLVED: To provide the manufacture method of a substrate, whose thickness of a conductive region with which a via is filled is not restricted by the thickness of a patterned metallic layer and in which conduction layers which are mutually connected by the conductive via are installed on both faces. SOLUTION: A dielectric layer 100, where conduction layers 102 and 112 are deposited or stacked on one surface or both surfaces of a substrate, is used. Laser drill work is used for piercing a non-through via 104, which passes through a dielectric and stops at the boundary of the substrate and the conduction layer. For establishing electrical connection to the conduction layer, the via is filled with a conduction material 106 through an electrolytic plating process. A second conduction layer 108 is deposited o stacked on the other surface of the substrate.",FUJITSU LTD,WILLIAM T CHOU;;BEILIN SOLOMON I;;MICHAEL G LEE;;PETERS MICHAEL G;;UEN-CHO VINCENT WANG,,https://lens.org/041-968-072-719-535,Patent Application,no,0,5,3,3,0,H05K3/0035;;H05K3/423;;H05K2201/0355;;H05K2201/0394;;H05K2203/0733;;Y10T29/49156;;Y10T29/49126;;Y10T29/49155;;Y10T29/49165;;Y10T29/49156;;Y10T29/49126;;Y10T29/49155;;Y10T29/49165;;H05K3/423;;H05K2203/0733;;H05K2201/0355;;H05K2201/0394;;H05K3/0035,H05K3/00;;H05K3/42;;H05K3/46;;H05K3/40,,0,0,,,,PENDING
567,KR,A,KR 20160035935 A,129-249-257-116-271,2016-04-01,2016,KR 20140127924 A,2014-09-24,KR 20140127924 A,2014-09-24,"WIRELESS MOUSE, MOUSE PAD AND WIRELESS MOUSE APPARATUS","Suggested are a wireless mouse, a mouse pad, and a wireless mouse apparatus comprising the wireless mouse and the mouse pad. The wireless mouse comprises: a charging unit charging a battery by receiving power in a contactless manner; a motion detecting unit detecting a user′s motion; and a control unit controlling whether to perform a charging operation of the charging unit according to the user′s motion. The mouse pad comprises: a pad body having a certain area; a charging area formed on one portion of one surface of the pad body to transmit power in a contactless manner; and an operation area distinguished from the charging area and formed on the other portion of the one surface of the pad body to support a mouse pointing operation.",SAMSUNG ELECTRO MECH,PARK SUNG HEUM;;CHO SANG HO;;CHANG MICHAEL;;SEO DU KWON;;SUNG JAE SUK;;CHO HYUNG WOOK;;HAN MARK,,https://lens.org/129-249-257-116-271,Patent Application,no,4,0,4,4,0,G06F1/266;;G06F3/0383;;G06F2203/0384;;H02J7/0042;;H02J50/10;;G06F3/03543;;G06F3/0395;;G06F3/03543;;G06F3/0383;;G06F3/0395;;G06F1/266;;H02J7/0042;;H02J50/10;;G06F2203/0384;;G06F3/03543;;G06F3/0395;;G06F2203/0384;;G06F3/0383;;G06F1/266;;H02J7/0042;;H02J50/10,G06F3/0354;;G06F3/039,,0,0,,,,ACTIVE
568,KR,A,KR 20160030804 A,128-162-777-533-257,2016-03-21,2016,KR 20140120458 A,2014-09-11,KR 20140120458 A,2014-09-11,A WIRELESS POWER RECEIVER AND A CONTROL METHOD FOR THE SAME,"According to an embodiment of the present invention, a wireless power receiver and a control method of a wireless power receiver are disclosed. According to an embodiment of the present invention, the wireless power receiver comprises: a resonance tank for receiving a power signal, and varying a resonant frequency in response to a control signal; and a determination unit for determining a wireless power transmission method based on the power signal, and outputting the control signal according to the determination result.",SAMSUNG ELECTRO MECH,CHO SANG HO;;CHO HYUNG WOOK;;PARK SUNG HEUM;;HAN MARK;;SUNG JAE SUK;;HAN JEONG MAN;;CHANG MICHAEL,,https://lens.org/128-162-777-533-257,Patent Application,no,5,3,6,6,0,H02J50/80;;H02J50/80;;H02J50/80;;H02J50/12,H02J7/00,,0,0,,,,ACTIVE
569,KR,A,KR 20160049284 A,054-910-577-330-621,2016-05-09,2016,KR 20140146154 A,2014-10-27,KR 20140146154 A,2014-10-27,"APPARATUS AND METHOD FOR RECEIVING WIRELESS POWER, AND WIRELESS POWER SUPPLY SYSTEM USING THE SAME","The present invention relates to an apparatus and a method for receiving wireless power, and a wireless power supply system using the same. The apparatus for receiving wireless power according to an embodiment of the present invention may include a power receiving part which receives wireless power by non-contact type, a switch part which operates the power receiving part, and a control part which controls an output voltage by controlling the OFF switching operation of the switch part. So, the output voltage can be controlled by simple circuit configuration.",SAMSUNG ELECTRO MECH,CHO SANG HO;;CHO HYUNG WOOK;;PARK SUNG HEUM;;HAN MARK;;SUNG JAE SUK;;HAN JEONG MAN;;CHANG MICHAEL,,https://lens.org/054-910-577-330-621,Patent Application,no,0,1,4,4,0,H02J50/12;;H02J50/80;;H02J50/12;;H01F38/14;;H02J7/0068;;H02J50/40;;H02J50/005;;H02J7/0042;;H02J50/12;;H02J50/80,H01F38/14;;H02J5/00;;H02J7/00;;H02J7/02,,0,0,,,,ACTIVE
570,US,A1,US 2022/0331986 A1,012-520-537-546-471,2022-10-20,2022,US 202217752059 A,2022-05-24,US 202217752059 A;;US 202217716249 A;;US 202163177141 P;;US 202163255880 P,2021-04-20,METHODS AND APPARATUS FOR VERIFIABLE INSPECTION OPERATIONS,Methods and apparatus for verifiable inspection operations are described. An example apparatus may have an inspection description circuit to interpret an inspection definition value and a payload status circuit to provide a payload identification value in response to at least one of a payload specific configuration or signals from a payload. The example apparatus may also have an inspection integrity circuit to determine an inspection description value in response to the inspection definition value and the payload identification value and an inspection reporting circuit to communicate the inspection description value to an external device.,GECKO ROBOTICS INC,BRYNER EDWARD A;;CHO EDWIN H;;LOW KEVIN Y;;BINGER MICHAEL A,GECKO ROBOTICS INC (2022-04-11),https://lens.org/012-520-537-546-471,Patent Application,yes,1,8,24,24,0,B62D57/024;;G01N29/225;;G01N29/265;;G01N2291/0237;;G01N2291/02854;;G01N29/043;;G05B2219/45066;;B25J9/1694;;B25J9/1692;;B25J9/1666;;B60K7/00;;B60K7/0007;;B25J9/1653;;B25J19/027;;B25J13/087;;B25J9/0009;;B25J9/1694;;G01N29/04;;G01N29/226;;G01N29/265;;G01N2291/0289;;G01N2291/2698;;B25J9/1617;;B25J9/163;;B25J9/1664;;B25J9/1674;;B25J13/006;;B25J5/007;;B25J19/021;;B60K1/02;;B62D53/02;;B62D57/024;;B60B19/006;;B60B19/12;;B60B2360/104;;B60B2360/109;;B60B2900/931;;B60B2360/102;;G06F1/206;;G06F2200/201;;H05K1/18;;H05K2201/10151,B25J13/08;;B25J9/00;;B25J9/16;;B25J19/02,,0,0,,,,PENDING
571,BR,A2,BR 112022026344 A2,027-602-350-066-535,2023-01-17,2023,BR 112022026344 A,2021-06-22,US 2021/0038525 W;;US 202063043521 P,2020-06-24,PROCESSO PARA A SINTETIZAÇÃO DE LIPÍDEOS,"PROCESSO PARA A SINTETIZAÇÃO DE LIPÍDEOS. A presente invenção refere-se a processos para sintetização de lipídeos da fórmula I, úteis na síntese de compostos solúveis em gordura para direcionar e aumentar a atividade de moléculas terapêuticas, incluindo siRNA.",BRISTOL MYERS SQUIBB CO,GREGORY LOUIS BEUTNER;;FEDERICO LORA GONZALEZ;;PATRICIA Y CHO;;MICHAEL J SMITH,,https://lens.org/027-602-350-066-535,Patent Application,no,0,0,11,11,0,C07C319/20;;Y02P20/55;;C07C319/20;;C07C321/14;;C07C319/14;;C07C323/41,A61K31/713;;A61K47/18;;A61K47/54,,0,0,,,,PENDING
572,WO,A2,WO 2012/065071 A2,081-612-669-965-871,2012-05-18,2012,US 2011/0060385 W,2011-11-11,US 41315810 P,2010-11-12,METHODS OF PREDICTING RESPONSE TO EGFR ANTIBODY THERAPY,This present invention provides methods of treating of accessing/monitoring the responsiveness of a cancer cell to EGFR antibody therapy.,BROAD INST OF MIT AND HARVARD;;DANA FARBER CANCER INST INC;;VALL D HEBRON UNIVERSITY HOSPITAL;;MEYERSON MATTHEW;;BASS ADAM;;LAWRENCE MICHAEL;;TABERNERO JOSEP;;BASLGA JOSE;;CHO JEONGHEE,MEYERSON MATTHEW;;BASS ADAM;;LAWRENCE MICHAEL;;TABERNERO JOSEP;;BASLGA JOSE;;CHO JEONGHEE,,https://lens.org/081-612-669-965-871,Patent Application,yes,0,0,2,2,0,G01N33/57407;;G01N33/57419;;G01N2333/91205,G01N33/574;;C12Q1/68;;G01N33/52,,0,0,,,,PENDING
573,KR,A,KR 20230042464 A,093-419-682-559-633,2023-03-28,2023,KR 20237002609 A,2021-06-22,US 202063043521 P;;US 2021/0038525 W,2020-06-24,지질의 합성 방법,본원은 siRNA를 비롯한 치료 분자의 표적화 및 활성 증진을 위한 지용성 화합물의 합성에 유용한 화학식 I의 지질의 합성 방법을 제공한다. TIFFpct00033.tif3240,BRISTOL MYERS SQUIBB CO,BEUTNER GREGORY LOUIS;;LORA GONZALEZ FEDERICO;;CHO PATRICIA Y;;SMITH MICHAEL J,,https://lens.org/093-419-682-559-633,Patent Application,no,0,0,11,11,0,C07C319/20;;Y02P20/55;;C07C319/20;;C07C321/14;;C07C319/14;;C07C323/41,C07C319/20;;C07C323/60,,0,0,,,,PENDING
574,WO,A1,WO 2007/095693 A1,117-814-609-527-941,2007-08-30,2007,AU 2007/000215 W,2007-02-26,AU 2006/200814 A;;US 77684206 P,2006-02-24,METHOD AND SYSTEM FOR CONTROLLING TERMITES,"A method of controlling pest termites. A vibrational signal which is perceptible to and behaviourally influential upon the pest termites is generated, and coupled into a medium for perception by the pest termites. Repellent termite alarm signals may be utilised. A new type of foraging signal is disclosed and may be applied to lure termites to a bait.",COMMW SCIENT IND RES ORG;;NEWSOUTH INNOVATIONS PTY LTD;;EVANS THEODORE ALFRED;;LENZ MICHAEL;;LAI JOSEPH CHO SAM;;INTA RA ATA,EVANS THEODORE ALFRED;;LENZ MICHAEL;;LAI JOSEPH CHO SAM;;INTA RA ATA,,https://lens.org/117-814-609-527-941,Patent Application,yes,5,10,5,7,0,A01M1/023;;A01M1/026;;A01M1/24;;A01M29/16;;A01M2200/011;;A01M1/023;;A01M1/24;;A01M29/16;;A01M2200/011;;A01M1/026,A01M1/22;;A01M1/20;;A01M29/16,,1,0,,,"DATABASE WPI Week 200320, Derwent World Patents Index; Class P14, AN 2003-202074, XP003016845",PENDING
575,US,B2,US 7870023 B2,161-645-017-756-573,2011-01-11,2011,US 86968204 A,2004-06-16,US 86968204 A;;US 99138901 A,2001-11-21,Methods and systems for selectively displaying advertisements,"A system, including a planning module, a control module and a receiver module, configured to schedule display of one or more advertising impressions of available advertising inventory. The planning module enables scheduling a requested quantity of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisement, assigning an advertising type and defining a weight for the advertisements. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisements. The one or more metadata files, with the advertisements, are delivered to the receiver module that is configured to define a display frequency for the advertisements based upon one or more of the metadata files. The receiver module selectively displays advertisement content associated with the advertisements to achieve the advertising impression goal.",MICROSOFT CORP,OZER STUART;;HART MICHAEL PATRICK;;CHO WEI WEI ADA;;CHAU CAROLYN KHANH,ZHIGU HOLDINGS LIMITED (2016-05-16);;WEBTV NETWORKS INC (2001-11-15);;MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/161-645-017-756-573,Granted Patent,yes,37,49,8,8,0,G06Q30/02;;G06Q30/0241;;G06Q30/0248;;G06Q30/0252;;G06Q30/0254;;G06Q30/0264;;G06Q30/0269;;G06Q30/0272;;G06Q30/02;;G06Q30/0241;;G06Q30/0264;;G06Q30/0248;;G06Q30/0269;;G06Q30/0272;;G06Q30/0254;;G06Q30/0252;;Y10S707/99945;;Y10S707/99948;;Y10S707/99944;;Y10S707/99942;;Y10S707/99943,G06Q30/02,705/14.4;;725/32,24,0,,,"Office Action dated Jan. 24, 2006 cited in U.S. Appl. No. 09/991,025.;;Office Action dated Jul. 10, 2006 cited in U.S. Appl. No. 09/991,025.;;Office Action dated Oct. 18, 2006 cited in U.S. Appl. No. 09/991,025.;;Office Action dated May 3, 2007 cited in U.S. Appl. No. 09/991,025.;;Office Action dated Sep. 24, 2007 cited in U.S. Appl. No. 09/991,025.;;Office Action dated Mar. 28, 2008 cited in U.S. Appl. No. 09/991,025.;;Office Action dated Sep. 11, 2008 cited in U.S. Appl. No, 09/991,025.;;Office Action dated Jun. 8, 2004 cited U.S. Appl. No. 09/991,389.;;Office Action dated Jan. 26, 2005 cited in U.S. Appl. No. 09/991,389.;;Office Action dated Jun. 2, 2005 cited in U.S. Appl. No. 09/991,389.;;Office Action dated Nov. 3, 2005 cited in U.S. Appl. No. 09/991,389.;;Office Action dated Mar. 8, 2006 cited in U.S. Appl. No. 09/991,389.;;Notice of Allowance dated Aug. 24, 2006 cited in U.S. Appl. No. 09/991,389.;;Office Action dated Jan. 27, 2005 cited in U.S. Appl. No. 10/867,493.;;Office Action dated Jun. 15, 2005 cited in U.S. Appl. No. 10/867,493.;;Office Action dated Nov. 3, 2005 cited in U.S. Appl. No. 10/867,493.;;Office Action dated Jan. 26, 2007 cited in U.S. Appl. No. 10/867,493.;;Office Action dated Nov. 28, 2007 cited in U.S. Appl. No. 10/867,493.;;Office Action dated Dec. 13, 2006 cited in U.S. Appl. No. 10/867,485.;;Notice of Allowance dated Nov. 29, 2007 cited in U.S. Appl. No. 10/867,485.;;Notice of Allowance dated Jul. 25, 2007 and cited in related U.S. Appl. No. 10/867,485.;;""Predictive Networks Launches A Director iTV Advertising Management System at Cable 2001"", Jun. 11, 2001. Business/Technology Editors. Business Wire.;;Notice of Allowance dated Dec. 5, 2008 cited in U.S. Appl. No. 10/867,493.;;Notice of Allowance dated Mar. 6, 2009 cited in U.S. Appl. No. 10/867,493.",ACTIVE
576,WO,A1,WO 2022/226340 A1,193-221-235-986-360,2022-10-27,2022,US 2022/0025995 W,2022-04-22,US 202163178055 P,2021-04-22,TOPICAL ANTISEPTIC,"An antiseptic composition for penetrating and treating the dermis and/or pilosebaceous follicle of a mammal, said antiseptic composing comprising: (a) a sebostatic agent for reducing sebum production to prevent clogging of skin pores; (b) a barrier-forming emollient for forming a protective barrier film to aid said dermis in maintaining moisture and to shield said dermis from the environment; and (c) an antiseptic agent.",YAYAC MICHAEL;;PARVIZI JAVAD;;BRITTAIN HARRY;;CHO JEONGEUN;;SAXENA ARADHNA;;PARMAR MAYANK,YAYAC MICHAEL;;PARVIZI JAVAD;;BRITTAIN HARRY;;CHO JEONGEUN;;SAXENA ARADHNA;;PARMAR MAYANK,,https://lens.org/193-221-235-986-360,Patent Application,yes,4,0,5,5,0,A01N33/12;;A01P1/00;;A61K8/675;;A61Q17/005;;A61K8/342;;A61K8/922;;A61K8/365;;A61K9/107;;A61K9/70;;A61K31/191;;A61K31/455;;A61K36/61;;A61K47/10,A01N25/04;;A01N25/02;;A01N33/04,,0,0,,,,PENDING
577,US,A1,US 2021/0288617 A1,002-661-627-845-797,2021-09-16,2021,US 202016816430 A,2020-03-12,US 202016816430 A,2020-03-12,POWER AMPLIFIER LINEARIZATION CIRCUIT AND RELATED APPARATUS,"A power amplifier linearization circuit and related apparatus is provided. In examples disclosed herein, the power amplifier linearization circuit includes an analog pre-distortion (APD) circuit coupled to an input of a power amplifier. Notably, the power amplifier can exhibit linearity response deviation, namely linearity amplitude response deviation and linearity phase response deviation, when amplifying a radio frequency (RF) signal under a compression condition. As such, the APD circuit is configured to receive a control signal corresponding to the linearity response deviation and pre-process the RF signal based on the control signal before providing the RF signal to the power amplifier. As a result, it may be possible to reduce the linearity response deviation in the power amplifier, thus helping to improve linearity and RF performance of the power amplifier.",QORVO US INC,ZYBURA MICHAEL F;;MORIUCHI TOSHIAKI;;SCOTT BAKER;;CHO MIKYUNG;;SPEARS EDWARD T,QORVO US INC (2020-02-18),https://lens.org/002-661-627-845-797,Patent Application,yes,0,1,2,2,0,H03F1/3241;;H03F2200/451;;H03F3/19;;H03F1/3241;;H03F2201/3231;;H03F2200/451;;H03F3/21,H03F1/32;;H03F3/21,,0,0,,,,ACTIVE
578,JP,A,JP 2020053049 A,019-462-657-673-83X,2020-04-02,2020,JP 2019173394 A,2019-09-24,US 201862735496 P;;US 201816221090 A,2018-09-24,APPLICATION BUILDER,"To unify GUI displays across different device types.SOLUTION: Disclosed herein are system, method, and computer program product embodiments for unifying graphical user interface (GUI) displays across different device types. In an embodiment, a unification system may convert various GUI view appearing on, for example, a desktop device into a GUI view on a mobile device. Both devices may be accessing the same application and/or may use a cloud computing platform to access the application. The unification system may aid in reproducing GUI modifications performed on one user device onto other user devices. In this manner, the unification system may maintain a consistent look-and-feel for a user across different computing device type.SELECTED DRAWING: Figure 1",SALESFORCECOM INC,ERIC JACOBSON;;MICHAEL GONZALEZ;;WAYNE CHO;;ADHEIP VARADARAJAN;;JOHN VOLLMER;;BENJAMIN SNYDER,,https://lens.org/019-462-657-673-83X,Patent Application,no,0,0,6,17,0,G06F8/34;;G06F8/38;;G06F3/0482;;G06F3/0483;;G06F3/04845,G06F8/38;;G06F3/0481;;G06F3/14;;G06F9/451,,0,0,,,,ACTIVE
579,MX,A,MX 2022016519 A,028-274-309-620-297,2023-01-30,2023,MX 2022016519 A,2021-06-22,US 202063043521 P;;US 2021/0038525 W,2020-06-24,PROCESS FOR SYNTHESIZING LIPIDS.,"The present application provides processes for synthesizing lipids of Formula I useful in the synthesis of fat-soluble compounds for targeting and enhancing activity of therapeutic molecules, including siRNA.",BRISTOL MYERS SQUIBB CO,SMITH MICHAEL J;;BEUTNER GREGORY LOUIS;;LORA GONZALEZ FEDERICO;;CHO PATRICIA Y,,https://lens.org/028-274-309-620-297,Patent Application,no,0,0,11,11,0,C07C319/20;;Y02P20/55;;C07C319/20;;C07C321/14;;C07C319/14;;C07C323/41,A61K31/713;;A61K47/18;;A61K47/54,,0,0,,,,PENDING
580,KR,A,KR 20210064267 A,118-376-562-899-818,2021-06-02,2021,KR 20217011084 A,2019-09-30,GB 201815999 A;;EP 2019076458 W,2018-10-01,부시(BUSH),튜닝 요소는 부시의 탄성체와 일체로 형성될 수 있고 사전결정된 작동 진동 주파수 범위 내에서 탄성체의 고유 모드들과 관련된 동적 강성 증가를 감소시키도록 구성될 수 있다. 튜닝 요소는 탄성체의 외부 표면에 있는 직립 벽 또는 윙과 유사할 수 있다. 탄성체는 그 사이에 축방향 통로를 갖는 복수의 반경방향 암들을 포함할 수 있다. 튜닝 요소는 통로들에 걸쳐질 수 있다. 이러한 방식으로 구성된 부시는 작동 진동 주파수 범위가 전기 차량용 엔진 마운트와 같이 고주파를 포함하는 시나리오에서 사용하기에 특히 적합할 수 있다.,DTR VMS LTD,GEISEN JAN;;MORTON JONATHAN;;STANKA CHRISTIAN;;LINES MICHAEL;;KAISER WERNER;;CHO SEONGDOSEONG,,https://lens.org/118-376-562-899-818,Patent Application,no,0,0,5,5,0,F16F1/38;;F16F7/108;;F16F1/38;;F16F7/108;;F16F1/38;;F16F7/108,F16F1/38;;F16F7/108,,0,0,,,,PENDING
581,EP,B1,EP 0728471 B1,168-474-354-677-56X,2004-11-17,2004,EP 96300587 A,1996-01-29,US 39397795 A,1995-02-24,Cosmetic compositions for enhancing the collagen synthesis of the skin,,UNILEVER PLC;;UNILEVER NV,ZNAIDEN ALEXANDER P;;CHENEY MICHAEL C;;SLAVTCHEFF CRAIG S;;CHO SUK H,,https://lens.org/168-474-354-677-56X,Granted Patent,yes,3,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
582,US,A,US 5536499 A,165-835-069-049-363,1996-07-16,1996,US 39397795 A,1995-02-24,US 39397795 A,1995-02-24,Cosmetic compositions for reducing or preventing signs of cellulite,"The invention is directed to increasing the strength and firmness of the skin and reducing the signs of cellulite. The inventive method includes applying to the skin a composition that includes inositol phosphate, particularly phytic acid and its salts, in a cosmetically acceptable carrier.",CHESEBROUGH PONDS USA,ZNAIDEN ALEXANDER P;;CHENEY MICHAEL C;;SLAVTCHEFF CRAIG S;;CHO SUK H,CHESEBROUGH-POND'S USA CO. DIVISION OF CONOPOCO INC (1995-05-22),https://lens.org/165-835-069-049-363,Granted Patent,yes,23,28,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,424/401;;514/860,12,8,048-705-703-765-037;;051-636-848-253-579;;074-391-801-509-268;;020-113-521-581-629;;062-794-453-561-094;;016-893-829-255-673;;026-863-842-554-729;;001-946-978-962-621,10.1001/jama.1969.03160390039008;;5395389;;10.1001/jama.210.13.2377;;10.1111/1523-1747.ep12532763;;14000328;;448177;;448178;;10.1038/jid.1962.122;;13993162;;10.1111/j.1365-2133.1975.tb05113.x;;1220811;;10.1056/nejm199308193290803;;8336752;;1732390;;10.1111/1523-1747.ep12556066;;2584746;;10.1111/1523-1747.ep12284425;;8326913;;10.1016/s0934-8832(11)80007-7,"Abstract of FR 2 554 344 published May 10, 1985.;;Abstract of DE 4 242 876 published Jun. 23, 1994.;;Kligman, A., Early Destructive Effect of Sunlight on Human Skin , JAMA, (Dec. 29, 1969), vol. 210, pp. 2377 2380.;;Lavker, R., Structural Alterations in Exposed and Unexposed Aged Skin , Journal of Investigative Dermatology, (1979), vol. 73, pp. 59 66.;;Smith, J. et al., Alterations in Human Dermal Connective Tissue with Age and Chronic Sun Damage , Journal of Investigative Dermatology, (1962), vol. 39, pp. 347 350.;;Shuster, S. et al., The Influence of Age and Sex on Skin Thickness, Skin Collagen and Density , British Journal of Dermatology (1975), vol. 93, pp. 639 643.;;Griffiths, Christopher E., et al., Restoration of Collagen Formation in Photodamaged Human Skin by Tretinoin (Retinoic Acid) , The New England Journal of Medicine (1993), vol. 329, pp. 530 535.;;Chen, S. et al., Effects of All Trans Retinoic Acid on UVB Irradiated and Non Irradiated Hairless Mouse Skin , Society for Investigative Dermatology, (1992), vol. 98, pp. 248 254.;;Nakagawa, et. al., Long Term Culture of Fibroblasts in Contracted Collagen Gels: Effects on Cell Growth and Biosythetic Activity , The Society for Investigative Dermatology, Inc., (1989), vol. 93, pp. 792 798.;;Jutley, J. K. et al., Influence of Retinoic Acid and TGF on Dermal Fibroblast Proliferation and Collagen Production in Monolayer Cultures and Dermal Equivalents , Matrix, (1993), vol. 13, pp. 235 241.;;Co pending application Serial No. 08/393,979.;;Co pending application Serial No. 08/394,122.",EXPIRED
583,US,B2,US 7536316 B2,192-511-273-781-031,2009-05-19,2009,US 86749304 A,2004-06-14,US 86749304 A;;US 99138901 A,2001-11-21,Methods and systems for selectively displaying advertisements,"A system, including a planning module, a control module and a receiver module, configured to schedule display of one or more advertising impressions of available advertising inventory. The planning module enables scheduling a requested quantity of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisement, assigning an advertising type and defining a weight for the advertisements. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisements. The one or more metadata files, with the advertisements, are delivered to the receiver module that is configured to define a display frequency for the advertisements based upon one or more of the metadata files. The receiver module selectively displays advertisement content associated with the advertisements to achieve the advertising impression goal.",MICROSOFT CORP,OZER STUART;;HART MICHAEL PATRICK;;CHO WEI WEI ADA;;CHAU CAROLYN KHANH,ZHIGU HOLDINGS LIMITED (2016-05-16);;WEBTV NETWORKS INC (2001-11-19);;MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2002-06-28),https://lens.org/192-511-273-781-031,Granted Patent,yes,37,97,8,8,0,G06Q30/02;;G06Q30/0241;;G06Q30/0248;;G06Q30/0252;;G06Q30/0254;;G06Q30/0264;;G06Q30/0269;;G06Q30/0272;;G06Q30/02;;G06Q30/0241;;G06Q30/0264;;G06Q30/0248;;G06Q30/0269;;G06Q30/0272;;G06Q30/0254;;G06Q30/0252;;Y10S707/99945;;Y10S707/99948;;Y10S707/99944;;Y10S707/99942;;Y10S707/99943,G06Q30/02,705/14;;725/35,17,0,,,"""Predictive Networks Launches ADirector iTV Advertising Management System At Cable 2001"", Jun. 11, 2001, Business/Technology Editors. Business Wire.;;Notice of Allowance dated Jul. 25, 2007 and cited in related U.S. Appl. No. 10,867,485.;;Office Action dated Jan. 24, 2006 cited in U.S. Appl. No. 09/991,025 (Copy Attached).;;Office Action dated Jul. 10, 2006 cited in U.S. Appl. No. 09/991,025 (Copy Attached).;;Office Action dated Oct. 18, 2006 cited in U.S. Appl. No. 09/991,025 (Copy Attached).;;Office Action dated May 3, 2007 cited in U.S. Appl. No. 09/991,025 (Copy Attached).;;Office Action dated Sep. 24, 2007 cited in U.S. Appl. No. 09/991,025 (Copy Attached).;;Office Action dated Mar. 28, 2008 cited in U.S. Appl. No. 09/991,025 (Copy Attached).;;Office Action dated Sep. 11, 2008 cited in U.S. Appl. No. 09/991,025 (Copy Attached).;;Office Action dated Jun. 8, 2004 cited in U.S. Appl. No. 09/991,389 (Copy Attached).;;Office Action dated Jan. 26, 2005 cited in U.S. Appl. No. 09/991,389 (Copy Attached).;;Office Action dated Jun. 2, 2005 cited in U.S. Appl. No. 09/991,389 (Copy Attached).;;Office Action dated Nov. 3, 2005 cited in U.S. Appl. No. 09/991,389 (Copy Attached).;;Office Action dated Mar. 8, 2006 cited in U.S. Appl. No. 09/991,389 (Copy Attached).;;Notice of Allowance dated Aug. 24, 2006 cited in U.S. Appl. No. 09/991,389 (Copy Attached).;;Office Action dated Dec. 13, 2006 cited in U.S. Appl. No. 10/867,485 (Copy Attached).;;Notice of Allowance dated Nov. 29, 2007 cited in U.S. Appl. No. 10/867,485 (Copy Attached).",EXPIRED
584,KR,A,KR 20170116045 A,022-443-017-139-107,2017-10-18,2017,KR 20177022664 A,2015-01-15,US 201514597415 A;;US 2015/0011558 W,2015-01-15,이온성 액체 용매를 이용한 분리,"기체 성분을 포함하는 공정 스트림을 제공하고, 공정 스트림으로부터의 기체 성분을 분리기의 이온성 액체 용매에 의해 포획하고, 포획된 기체 성분을 재생기에서 이온성 액체 용매로부터 회수하는 시스템 및 방법이 개시된다. 공정 스트림으로부터의 제2 기체 성분은 분리기의 이온성 액체 용매에 의해 포획되고, 제2 기체 성분은 재생기에서 이온성 액체 용매로부터 회수될 수 있다. 대안적으로, 공정 스트림으로부터의 제2 기체 성분은 이온성 액체 용매에 의해 미포획될 수 있고, 미포획된 제2 기체 성분은 막 유닛으로부터 회수될 수 있다.",CHEVRON PHILLIPS CHEMICAL CO LP;;CHEVRON USA INC,JI LEI;;CHANG AI FU;;DRIVER MICHAEL SEAN;;TIMKEN HYE KYUNG CHO,,https://lens.org/022-443-017-139-107,Patent Application,no,4,2,9,34,0,B01D53/1487;;B01D53/1493;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05;;B01D53/1493;;B01D53/1487;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05,B01D53/14,,0,0,,,,ACTIVE
585,WO,A1,WO 2016/114780 A1,084-116-186-781-521,2016-07-21,2016,US 2015/0011558 W,2015-01-15,US 201514597415 A,2015-01-15,SEPARATIONS WITH IONIC LIQUID SOLVENTS,"Disclosed are systems and methods which provide a process stream comprising a gaseous component, capture the gaseous component from the process stream by an ionic liquid solvent of a separator, and recover a captured gaseous component from the ionic liquid solvent in a regenerator. A second gaseous component from the process stream may be captured by the ionic liquid solvent of the separator, and the second gaseous component may be recovered from the ionic liquid solvent in the regenerator. Alternatively, the second gaseous component from the process stream may be uncaptured by the ionic liquid solvent, and the uncaptured second gaseous component may be recovered from a membrane unit.",CHEVRON PHILLIPS CHEMICAL CO;;CHEVRON USA INC,JI LEI;;CHANG AI-FU;;DRIVER MICHAEL SEAN;;TIMKEN HYE-KYUNG CHO,,https://lens.org/084-116-186-781-521,Patent Application,yes,15,1,9,34,0,B01D53/1487;;B01D53/1493;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05;;B01D53/1493;;B01D53/1487;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05,B01D53/14,,3,2,042-667-565-422-294;;042-667-565-422-294,10.1016/j.cej.2013.01.052;;10.1016/j.cej.2013.01.052,"""Engineering Data Book"";;MARCOS FALLANZA ET AL.: ""Screening of RTILs for propane/propylene separation using COSMO-RS methodology"", CHEM. ENG. J., vol. 220, 2013, pages 284 - 293;;MARCOS FALLANZA ET AL.: ""Screening of RTILs for propane/propylene separation using COSMO-RS methodology"", C . E . J., vol. 220, 2013, pages 284 - 293",PENDING
586,US,A1,US 2019/0111271 A1,087-512-127-926-413,2019-04-18,2019,US 201715783573 A,2017-10-13,US 201715783573 A,2017-10-13,POWER MANAGEMENT FOR IMPLANTABLE MEDICAL DEVICE SYSTEMS,"Techniques for minimizing rate of depletion of a non-rechargeable power source, to extend the operational lifetime of an implantable medical device that includes the non-rechargeable power source, by enforcing operational-mode-specific communication protocols whereby inter-device communication between the implantable medical device and another implantable medical device is such that level of power draw from the non-rechargeable power source by the implantable medical device is less than level of power draw from the rechargeable power source by the another implantable medical device for the implantable medical devices to engage in communication with each other.",MEDTRONIC INC,DEMMER WADE M;;CHO YONG K;;HESS MICHAEL F;;SHELDON TODD J,MEDTRONIC INC (2017-10-10),https://lens.org/087-512-127-926-413,Patent Application,yes,2,6,11,11,0,A61N1/3708;;A61N1/37288;;A61N1/3756;;A61N1/3787;;A61B5/318;;A61N1/3708;;A61B5/318;;A61N1/37512;;A61N1/37518;;A61N1/3684;;A61N1/37288;;A61N1/3756;;A61N1/3787,A61N1/378;;A61N1/368;;A61N1/372;;A61N1/375,,0,0,,,,ACTIVE
587,US,A1,US 2020/0138298 A1,108-019-258-652-409,2020-05-07,2020,US 201816182650 A,2018-11-07,US 201816182650 A,2018-11-07,METHOD AND SYSTEM FOR ENHANCING RF ENERGY DELIVERY DURING THERMOACOUSTIC IMAGING,"A method and system for enhancing radio frequency energy delivery to a tissue region of interest. The method and system direct with a radio frequency (RF) applicator, one or more RF energy pulses into the tissue region of interest, the tissue region of interest comprising an object of interest and at least one reference that are separated by at least one boundary; detect with an acoustic receiver, at least one bipolar acoustic signal generated in the tissue region of interest in response to the RF energy pulses and processing the at least one bipolar acoustic signal to determine a peak-to-peak amplitude thereof; adjust the RF applicator to maximize the peak-to-peak amplitude of bipolar acoustic signals generated in the tissue region of interest in response to RF energy pulses generated by the adjusted RF applicator; and direct with the adjusted RF applicator, one or more RF energy pulses into the region of interest.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/108-019-258-652-409,Patent Application,yes,0,4,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B5/00;;A61B5/02;;A61B5/20,,0,0,,,,ACTIVE
588,EP,A3,EP 1315110 A3,103-359-901-093-343,2005-03-16,2005,EP 02025700 A,2002-11-20,US 99102501 A,2001-11-21,Method and systems for planning advertising campaigns,"A system, including a planning module, a control module and a receiver module, configured to schedule display of advertisements to achieve an advertising impression goal. The planning module enables scheduling of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisements, assigning an advertising type and defining a weight for the advertisement. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisement. The one or more metadata files and advertising content for the advertisement, are delivered to the receiver module that is configured to define a display frequency for the advertising content based upon one or more of the metadata files. The receiver module selectively displays the advertising content of the advertisement to achieve the advertising impression goal.",WEBTV NETWORKS INC,OZER STUART;;HART MICHAEL PATRICK;;CHO WEI WEI ADA;;CHAU CAROLY KHANH,MICROSOFT CORPORATION (2007-02-28),https://lens.org/103-359-901-093-343,Search Report,yes,0,0,3,3,0,G06Q30/02;;G06Q30/02,G06Q30/02,,1,0,,,No Search,DISCONTINUED
589,US,A1,US 2022/0042567 A1,118-152-808-314-371,2022-02-10,2022,US 201917281526 A,2019-09-30,GB 201815999 A;;EP 2019076458 W,2018-10-01,BUSH,"A tuning element that can be integrally formed with a resilient body of a bush and configured to reduce dynamic stiffness increases associated with eigenmodes of the resilient body within a predetermined operational vibration frequency range. The tuning element may resemble an upstanding wall or wing on an outer surface of the resilient body. The resilient body may comprise a plurality of radial arms having axial passageways therebetween. The tuning element may bridge the passageways. A bush configured in this way may be particular suitable for use in scenario where the operational vibration frequency range comprises high frequency, such as an engine mount for an electric vehicle.",DTR VMS LTD,GEISEN JAN;;MORTON JONATHAN;;STANKA CHRISTIAN;;LINES MICHAEL;;KAISER WERNER;;CHO SEONDOSEONG,DN AUTOMOTIVE VMS LTD (2022-06-20);;DN AUTOMOTIVE GERMANY GMBH (2023-11-10),https://lens.org/118-152-808-314-371,Patent Application,yes,6,6,5,5,0,F16F1/38;;F16F7/108;;F16F1/38;;F16F7/108;;F16F1/38;;F16F7/108,F16F1/38;;F16F7/108,,0,0,,,,PENDING
590,WO,A3,WO 2012/065071 A3,116-083-312-129-069,2012-07-12,2012,US 2011/0060385 W,2011-11-11,US 41315810 P,2010-11-12,METHODS OF PREDICTING RESPONSE TO EGFR ANTIBODY THERAPY,This present invention provides methods of treating of accessing/monitoring the responsiveness of a cancer cell to EGFR antibody therapy.,BROAD INST OF MIT AND HARVARD;;DANA FARBER CANCER INST INC;;VALL D HEBRON UNIVERSITY HOSPITAL;;MEYERSON MATTHEW;;BASS ADAM;;LAWRENCE MICHAEL;;TABERNERO JOSEP;;BASLGA JOSE;;CHO JEONGHEE,MEYERSON MATTHEW;;BASS ADAM;;LAWRENCE MICHAEL;;TABERNERO JOSEP;;BASLGA JOSE;;CHO JEONGHEE,,https://lens.org/116-083-312-129-069,Search Report,yes,5,0,2,2,0,G01N33/57407;;G01N33/57419;;G01N2333/91205,G01N33/574;;C12Q1/68;;G01N33/52,,0,0,,,,PENDING
591,CA,C,CA 2168518 C,160-327-692-059-034,2008-11-18,2008,CA 2168518 A,1996-01-31,US 39397795 A,1995-02-24,COSMETIC COMPOSITIONS FOR REDUCING OR PREVENTING SIGNS OF CELLULITE,"The invention is directed to increasing the strength and firmness of the ski n and reducing the signs of cellulite. The inventive method includes applying to t he skin a composition that includes inositol phosphate, particularly phytic acid and i ts salts, in a cosmetically acceptable carrier.",UNILEVER PLC,ZNAIDEN ALEXANDER PAUL;;CHENEY MICHAEL CHARLES;;SLAVTCHEFF CRAIG STEVEN;;CHO SUK HYUNG,,https://lens.org/160-327-692-059-034,Granted Patent,no,0,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/55;;A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
592,EP,B1,EP 3244987 B1,171-119-373-535-251,2022-06-22,2022,EP 15702329 A,2015-01-15,US 2015/0011558 W;;US 201514597415 A,2015-01-15,SEPARATIONS WITH IONIC LIQUID SOLVENTS,,CHEVRON PHILLIPS CHEMICAL CO LP;;CHEVRON USA INC,JI LEI;;CHANG AI-FU;;DRIVER MICHAEL SEAN;;TIMKEN HYE-KYUNG CHO,,https://lens.org/171-119-373-535-251,Granted Patent,yes,5,0,9,34,0,B01D53/1487;;B01D53/1493;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05;;B01D53/1493;;B01D53/1487;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05,B01D53/14,,0,0,,,,ACTIVE
593,CN,A,CN 112789428 A,028-283-844-132-687,2021-05-11,2021,CN 201980064922 A,2019-09-30,GB 201815999 A;;EP 2019076458 W,2018-10-01,BUSH,"A tuning element that can be integrally formed with a resilient body of a bush and configured to reduce dynamic stiffness increases associated with eigenmodes of the resilient body within a predetermined operational vibration frequency range. The tuning element may resemble an upstanding wall or wing on an outer surface of the resilient body. The resilient body may comprise a plurality of radial arms having axial passageways therebetween. The tuning element may bridge the passageways. A bush configured in this way may be particular suitable for use in scenario where the operational vibration frequency range comprises high frequency, such as an engine mount for an electric vehicle.",DTR VMS LTD,GEISEN JAN;;MORTON JONATHAN;;STANKA CHRISTIAN;;LINES MICHAEL;;KAISER WERNER;;CHO SEONGDOSEONG,,https://lens.org/028-283-844-132-687,Patent Application,no,6,0,5,5,0,F16F1/38;;F16F7/108;;F16F1/38;;F16F7/108;;F16F1/38;;F16F7/108,F16F1/38;;F16F7/108,,0,0,,,,PENDING
594,EP,A1,EP 4054695 A1,043-030-542-692-345,2022-09-14,2022,EP 20884172 A,2020-11-04,US 201962930863 P;;US 2020/0058964 W,2019-11-05,A SYSTEM AND MINIATURE DEVICES FOR DELIVERING A THERAPEUTIC COMPONENT TO A TREATMENT SITE IN A PATIENT,,BIONAUT LABS LTD;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CROS FLORENT;;HARRINGTON DARRELL;;CHO SUEHYUN;;CAPUTO JOHN,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CROS FLORENT;;HARRINGTON DARRELL;;CHO SUEHYUN;;CAPUTO JOHN,,https://lens.org/043-030-542-692-345,Patent Application,yes,0,0,6,6,0,A61K9/0009;;A61K9/0007;;A61M25/0127;;A61M31/002;;A61K45/06;;A61M31/002;;A61M2205/3515,A61M31/00;;A61K9/50;;A61K9/51;;A61K47/69,,0,0,,,,PENDING
595,US,A1,US 2023/0108258 A1,063-478-387-070-538,2023-04-06,2023,US 202217881754 A,2022-08-05,US 202217881754 A;;US 202163230178 P,2021-08-06,ANTIBODY-FREE RAPID DETECTION OF SARS-COV-2 PROTEINS USING CORONA PHASE MOLECULAR RECOGNITION (COPHMORE),Corona phase molecular recognition (CoPhMoRe) that enables the molecular recognition of SARS-CoV-2 viral proteins without the need for antibody or enzymatic receptor incorporation.,MASSACHUSETTS INST TECHNOLOGY,CHO SOOYEON;;STRANO MICHAEL;;JIN XIAOJIA;;GONG XUN;;YANG SUNGYUN;;CUI JIANQIAO,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2021-08-06),https://lens.org/063-478-387-070-538,Patent Application,yes,0,0,1,1,0,C08G65/3356;;C08L71/02;;B82Y15/00;;C12Q1/70;;B82Y30/00;;C08G65/33396,C12Q1/70;;B82Y30/00;;C08G65/333,,0,0,,,,PENDING
596,EP,A2,EP 0728471 A2,087-248-576-317-285,1996-08-28,1996,EP 96300587 A,1996-01-29,US 39397795 A,1995-02-24,Cosmetic compositions for enhancing the collagen synthesis of the skin,"The invention is directed to increasing the strength and firmness of the skin and reducing the signs of cellulite. The inventive method includes applying to the skin a composition that includes inositol phosphate, particularly phytic acid and its salts, in a cosmetically acceptable carrier.",UNILEVER PLC;;UNILEVER NV,ZNAIDEN ALEXANDER P;;CHENEY MICHAEL C;;SLAVTCHEFF CRAIG S;;CHO SUK H,,https://lens.org/087-248-576-317-285,Patent Application,yes,0,5,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
597,JP,A,JP 2000188308 A,119-516-977-411-288,2000-07-04,2000,JP 35994999 A,1999-12-17,US 21878198 A,1998-12-22,UNDERFILL TREATING METHOD FOR FLIP CHIP BONDING AND SEMICONDUCTOR DEVICE,"PROBLEM TO BE SOLVED: To enable use of various kinds of underfill materials by bonding a chip to solder connecting parts on a board after the solder connecting parts are individually sealed on the chip, when underfill treatment for flip-chip bonding the chip on the board is performed. SOLUTION: Sealed solder balls 205 on a chip 200 are first physically in contact with solder balls 305 on a board 300 which are not sealed. After the solder balls 305 are heated up to a reflow temperature, the solder balls 205 on the chip 200 are made to collectively flow with the solder balls 305 in order to perform common solder bonding. Sealing material 210 distributes again the stress from solder bonding to the whole part of the chip 200, and the fatigue life of solder bonding is prolonged. Solder bonding of the boundary side of the chip 200 is subjected to passivation treatment, so that various kinds of the sealing materials 210 can be used. As a result, the above practice mode has the same merit as a well-known underfill process, and sealing materials in a wider range can be used.",FUJITSU LTD,UEN-CHO VINCENT WANG;;PETERS MICHAEL G;;DASHUN S JOU;;TAKAHASHI YASUHITO,,https://lens.org/119-516-977-411-288,Patent Application,no,0,6,2,2,0,H01L21/563;;H01L24/11;;H01L24/12;;H01L24/16;;H01L24/94;;H01L2224/131;;H01L2224/16;;H01L2224/274;;H01L2224/73203;;H01L2224/83102;;H01L2224/83191;;H01L2224/83192;;H01L2224/83856;;H01L2224/92125;;H01L2924/01004;;H01L2924/01005;;H01L2924/01009;;H01L2924/01029;;H01L2924/0105;;H01L2924/01082;;H01L2924/01322;;H01L2924/00013;;H01L2924/01006;;H01L2924/01033;;H01L2924/014;;H01L24/29;;H01L2224/73204;;H01L2224/11334;;H01L2224/06102;;H01L2924/351;;H01L2924/15787;;H01L24/94;;H01L2224/131;;H01L2224/83192;;H01L2924/01009;;H01L24/11;;H01L2224/92125;;H01L2924/01322;;H01L2224/274;;H01L2924/01004;;H01L21/563;;H01L2224/16;;H01L2224/83102;;H01L24/16;;H01L2224/83191;;H01L2924/01005;;H01L2224/83856;;H01L2924/01029;;H01L2924/01082;;H01L24/12;;H01L2224/73203;;H01L2924/0105;;H01L2924/01006;;H01L2924/00013;;H01L2924/01033;;H01L24/29;;H01L2924/014;;H01L2224/73204;;H01L2224/11334;;H01L2924/351;;H01L2924/15787;;H01L2224/06102,H01L21/56;;H01L21/60;;H01L23/29;;H01L23/31;;H01L23/12,,0,0,,,,DISCONTINUED
598,WO,A1,WO 2021/216391 A1,116-376-322-441-792,2021-10-28,2021,US 2021/0027864 W,2021-04-19,US 202063013476 P;;US 202117230480 A,2020-04-21,THERMOACOUSTIC TRANSDUCER WITH INTEGRATED SWITCH,"A thermoacoustic transducer integrating at least one piezoelectric element having a first surface and a second surface, a potential electrode that is electrically connected to the second surface, a ground electrode that is electrically connected to the first surface, a switch electrically connected to both the potential electrode and the ground electrode, a timer configured to match a pulse emanating from a radio-frequency emitter, further wherein the potential electrode and the ground electrode are electrically connected through an impedance when the switch is in an active state, further wherein the potential electrode and the ground electrode are not electrically connected when the switch is in an inactive state; and a housing accommodating the at least one piezoelectric element, potential electrode, ground electrode, and switch.",ENDRA LIFE SCIENCES INC,MUMM ZACKARY MARC;;DAVIS CHRISTOPHER NELSON;;THORNTON MICHAEL M;;CHO JANG HWAN,,https://lens.org/116-376-322-441-792,Patent Application,yes,5,0,7,7,0,G01H11/08;;G01N2291/106;;G01N29/2431;;G01N29/2437;;G01N29/343;;G01N29/0645;;G01N29/0654;;G01N29/50;;A61B5/0093;;A61B5/0035;;A61B5/0507;;A61B5/7225;;A61B5/7217;;A61B8/085;;A61B8/5261;;A61B5/0093;;A61B5/05;;A61B5/7217;;G01N29/2431;;A61B5/7225;;B06B1/0607;;A61B5/0035,A61B5/00;;A61B6/00;;A61B8/00;;A61B8/08;;A61B8/14,,0,0,,,,PENDING
599,EP,A4,EP 3893759 A4,131-742-119-129-569,2022-11-09,2022,EP 19881356 A,2019-11-07,US 201816182650 A;;US 2019/0060293 W,2018-11-07,METHOD AND SYSTEM FOR ENHANCING RF ENERGY DELIVERY DURING THERMOACOUSTIC IMAGING,,ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/131-742-119-129-569,Search Report,no,8,0,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B8/08;;A61B5/00,,1,0,,,See also references of WO 2020097351A1,PENDING
600,CA,A1,CA 3164630 A1,140-152-329-531-288,2021-06-24,2021,CA 3164630 A,2020-12-16,US 201962948472 P;;US 2020/0065207 W,2019-12-16,MAGNETIC MINIATURE DEVICE AND SYSTEM FOR REMOTELY MANEUVERING IT,"A miniature device configured to be maneuvered within a patient under manipulation by an external magnetic field and to selectively perform a predefined function is provided. The miniature device comprises a shell defining therewithin an internal cavity, and a magnetic arrangement disposed within the cavity. The miniature device is configured such that the magnetic arrangement, within a rotating magnetic field, effects one of performance of the function and propulsion of the miniature device within the patient, and, within a magnetic field gradient, effects the other of performance of the function and propulsion of the miniature device within the patient.",BIONAUT LABS LTD,CROS FLORENT;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;HARRINGTON DARRELL;;CHO SUEHYUN;;SARGSYAN HOVHANNES,,https://lens.org/140-152-329-531-288,Patent Application,no,0,0,6,6,0,A61M25/0127;;A61M31/002;;A61K9/0009;;A61K9/4808;;A61M25/0127;;A61M31/002,A61K9/00;;A61K9/50;;A61K9/51;;A61K47/69;;A61K49/18;;A61M5/145;;A61M31/00,,0,0,,,,PENDING
601,WO,A1,WO 2018/085536 A1,171-187-168-239-239,2018-05-11,2018,US 2017/0059713 W,2017-11-02,US 201615342699 A,2016-11-03,ATRIAL TRACKING IN AN INTRACARDIAC VENTRICULAR PACEMAKER,"An intracardiac ventricular pacemaker having a motion sensor is configured to produce a motion signal including an atrial systolic event and at least one ventricular diastolic event. The pacemaker is configured to set an atrial refractory period, detect a change in a ventricular diastolic event metric and adjust the atrial refractory period in response to detecting the change. The pacemaker sets set an atrioventricular pacing interval in response to detecting the atrial systolic event from the motion signal after expiration of the atrial refractory period.",MEDTRONIC INC,DEMMER WADE;;CHO YONG;;ERICKSON MARK;;HESS MICHAEL;;SHELDON TODD;;SPLETT VINCENT,,https://lens.org/171-187-168-239-239,Patent Application,yes,16,0,7,7,0,A61N1/37205;;A61N1/36578;;A61N1/3756;;A61N1/37205;;A61N1/36578;;A61N1/0573;;A61N1/36542;;A61N1/3682;;A61N1/3684;;A61N1/3756,A61N1/375;;A61N1/365;;A61N1/368;;A61N1/372,,0,0,,,,PENDING
602,AU,A1,AU 2006/200814 A1,174-152-989-071-516,2007-09-13,2007,AU 2006/200814 A,2006-02-24,AU 2006/200814 A,2006-02-24,Method and system for controlling termites,,COMMW SCIENT IND RES ORG;;NEWSOUTH INNOVATIONS PTY LTD,LAI JOSEPH CHO SAM;;LENZ MICHAEL;;EVANS THEODORE ALFRED;;INTA RA ATA,,https://lens.org/174-152-989-071-516,Patent Application,no,0,1,2,7,0,,A01M1/00;;A01M17/00,,0,0,,,,DISCONTINUED
603,CA,A1,CA 3056288 A1,026-265-453-052-696,2020-03-24,2020,CA 3056288 A,2019-09-23,US 201862735496 P;;US 201816221090 A,2018-09-24,APPLICATION BUILDER,"Disclosed herein are system, method, and computer program product embodiments for unifying graphical user interface (GUI) displays across different device types. In an embodiment, a unification system may convert various GUI view appearing on, for example, a desktop device into a GUI view on a mobile device. Both devices may be accessing the same application and/or may use a cloud computing platform to access the application. The unification system may aid in reproducing GUI modifications performed on one user device onto other user devices. In this manner, the unification system may maintain a consistent look-and-feel for a user across different computing device type.",SALESFORCE COM INC,JACOBSON ERIC;;GONZALEZ MICHAEL;;CHO WAYNE;;VARADARAJAN ADHEIP;;VOLLMER JOHN;;SNYDER BENJAMIN,,https://lens.org/026-265-453-052-696,Patent Application,no,0,0,6,17,0,G06F8/34;;G06F8/38;;G06F3/0482;;G06F3/0483;;G06F3/04845,G06F3/048;;G06F9/451,,0,0,,,,PENDING
604,DE,D1,DE 69633840 D1,047-955-913-247-428,2004-12-23,2004,DE 69633840 T,1996-01-29,US 39397795 A,1995-02-24,Kosmetische Mittel zur Erhöhung der Kollagen-Synthese,,UNILEVER NV,ZNAIDEN ALEXANDER P;;CHENEY MICHAEL C;;SLAVTCHEFF CRAIG S;;CHO SUK H,,https://lens.org/047-955-913-247-428,Granted Patent,no,0,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
605,US,B2,US 6695572 B2,077-050-774-329-934,2004-02-24,2004,US 96615601 A,2001-09-28,US 96615601 A,2001-09-28,Method and apparatus for minimizing semiconductor wafer contamination,"
    A method and apparatus for minimizing the surface contamination of semiconductor wafers (  11  ) during the semiconductor device manufacturing process. Semiconductor wafers (  11  ) are stored in a storage cassette (  12  ) with their face sides (  17  ) facing downward and their back sides (  16  ) facing upward. Particulate contamination present on the back sides of the wafers is thereby secured to the wafers by the force of gravity, and the faces of the wafers are shielded from falling debris. An automated wafer handling device (  19  ) is provided with a rotary joint (  22  ) to accomplish the wafer flipping motion before inserting a wafer into a cassette and after removing the wafer from the cassette. 
",AGERE SYSTEMS INC,ANTONELL MICHAEL;;HOUGE ERIK CHO;;PLEW LARRY E;;VARTULI CATHERINE;;JUSZCZAK JENNIFER,AGERE SYSTEMS INC (2001-09-28);;BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04),https://lens.org/077-050-774-329-934,Granted Patent,yes,14,4,2,2,0,H01L21/6732;;H01L21/6732,B65G49/07;;H01L21/673,414/810,1,0,,,"S. Wolf and R.N. Tauber, Silicon Processing for VLSI Era, vol. 1-Process Technology, pp. 122-124, Second Edition (2000), Published by Lattice Press, Sunset Beach, California.",EXPIRED
606,WO,A1,WO 2021/126905 A1,088-249-345-562-778,2021-06-24,2021,US 2020/0065207 W,2020-12-16,US 201962948472 P,2019-12-16,MAGNETIC MINIATURE DEVICE AND SYSTEM FOR REMOTELY MANEUVERING IT,"A miniature device configured to be maneuvered within a patient under manipulation by an external magnetic field and to selectively perform a predefined function is provided. The miniature device comprises a shell defining therewithin an internal cavity, and a magnetic arrangement disposed within the cavity. The miniature device is configured such that the magnetic arrangement, within a rotating magnetic field, effects one of performance of the function and propulsion of the miniature device within the patient, and, within a magnetic field gradient, effects the other of performance of the function and propulsion of the miniature device within the patient.",BIONAUT LABS LTD;;CROS FLORENT;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;HARRINGTON DARRELL;;CHO SUEHYUN;;SARGSYAN HOVHANNES,CROS FLORENT;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;HARRINGTON DARRELL;;CHO SUEHYUN;;SARGSYAN HOVHANNES,,https://lens.org/088-249-345-562-778,Patent Application,yes,3,1,6,6,0,A61M25/0127;;A61M31/002;;A61K9/0009;;A61K9/4808;;A61M25/0127;;A61M31/002,A61K9/00;;A61K9/50;;A61K9/51;;A61K47/69;;A61K49/18;;A61M5/145;;A61M31/00,,1,0,,,See also references of EP 4076394A4,PENDING
607,US,B1,US 10965299 B1,108-268-418-365-001,2021-03-30,2021,US 202016887535 A,2020-05-29,KR 20190143138 A,2019-11-11,Digital-to-analog converter and electronic system including the same,"A digital-to-analog converter (DAC) includes a current array having a plurality of unit cells in a plurality of rows and a plurality of columns, an arbitrary switch box and processing circuitry configured to randomly select a subset of rows among the plurality of rows based on a plurality of first row selection signals, the subset of rows including first unit cells among the plurality of unit cells, randomly select one row among the plurality of rows based on a plurality of second row selection signals, select a subset of columns among the plurality of columns based on column selection signals, second unit cells among the plurality of unit cells being included in both the one row and the subset of columns, and generate an analog output signal corresponding to a digital input signal based on the first unit cells and the second unit cells.",SAMSUNG ELECTRONICS CO LTD,KIM JUNGHO;;CHOI MICHAEL;;KOO BYUNGWOO;;ROH HYUNGDONG;;DO SUNGHAN;;CHO YOUNGJAE,SAMSUNG ELECTRONICS CO. LTD (2020-05-27),https://lens.org/108-268-418-365-001,Granted Patent,yes,14,1,2,2,0,G06F7/588;;H03M1/001;;H03M1/0673;;H03M1/66;;H03M1/066;;H03M1/0673;;H03M1/685;;H03M1/76;;H03M7/165,H03M1/00;;G06F7/58;;H03M1/06;;H03M1/76,,0,0,,,,ACTIVE
608,EP,A1,EP 3893759 A1,125-255-219-892-785,2021-10-20,2021,EP 19881356 A,2019-11-07,US 201816182650 A;;US 2019/0060293 W,2018-11-07,METHOD AND SYSTEM FOR ENHANCING RF ENERGY DELIVERY DURING THERMOACOUSTIC IMAGING,,ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/125-255-219-892-785,Patent Application,yes,0,0,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B8/08;;A61B5/00,,0,0,,,,PENDING
609,UA,C2,UA 75635 C2,137-741-095-608-12X,2006-05-15,2006,UA 2003087745 A,2002-02-15,US 31236101 P;;US 26868301 P;;US 0204407 W,2001-02-15,DERIVATIVES OF 3-(4-AMIDOPYROL-2-YLMETHYLIDEN)-2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE,The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceulically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.,SUGEN INC;;UPJOHN CO,TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A;;HERRINTON PAUL MATTHEW,,https://lens.org/137-741-095-608-12X,Limited Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/416;;A61K31/4178;;A61K31/437;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
610,US,A,US 5724305 A,164-856-460-255-115,1998-03-03,1998,US 49759195 A,1995-06-30,US 49759195 A,1995-06-30,Apparatus for acoustic near field scanning using conformal arrayal,"Acoustic near field measurement apparatus uniquely featuring mechanical eomy, in terms of placement and motion of one or more acoustic measurement devices, which is accorded by the geometric character of a structure having indicia of symmetry. One or more devices are arranged, and/or caused to move with up to three degrees of freedom, so as to manifest conformance with respect to the surface of the structure. If desired, virtually complete acoustic near field mapping of the structure can be effectuated. Examples of the various embodiments of this invention include: circumferentially conformal arrayal of devices in combination with longitudinal movement of the arrayal; longitudinally conformal arrayal of devices in combination with circumferential movement of the arrayal; movement of one or more devices in a path or paths which are circumferentially conformal; movement of one or more devices in a path or paths which are longitudinally conformal; movement of one or more devices in a path or paths which are radial. For some embodiments a single device can be caused to move circumferentially, longitudinally and radially, and thus is provided three degrees of freedom. The apparatus according to this invention is more feasible and reliable than previous apparatus, especially for larger structures.",US ARMY,CLARK JOSEPH A;;SARTORI MICHAEL A;;CHO MOON H;;DOZIER DANIEL F,NAVY UNITED STATES OF AMERICA THE AS REPRESENTED BY THE SECRETARY (1995-06-29);;NAVY UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE (1998-11-24),https://lens.org/164-856-460-255-115,Granted Patent,yes,10,0,1,1,0,G01N29/265;;G01N29/265;;G01N2291/2634;;G01N2291/2634;;H04R29/00;;H04R29/00,H04B17/00,367/13,0,0,,,,EXPIRED
611,CN,A,CN 115460973 A,045-999-156-534-770,2022-12-09,2022,CN 202180029901 A,2021-04-19,US 202063013476 P;;US 202117230480 A;;US 2021/0027864 W,2020-04-21,Thermoacoustic transducer with integrated switch,"A thermoacoustic transducer integrated with: at least one piezoelectric element having a first surface and a second surface; a potential electrode electrically connected to the second surface; a ground electrode electrically connected to the first surface; a switch electrically connected to both the potential electrode and the ground electrode; a timer configured to match pulses emitted from the radio frequency transmitter, further wherein the potential electrode and the ground electrode are electrically connected by an impedance when the switch is in an active state, further wherein the potential electrode and the ground electrode are not electrically connected when the switch is in an inactive state; and a case accommodating the at least one piezoelectric element, the potential electrode, the ground electrode, and the switch.",ENDRA LIFE SCIENCES INC,MUMM ZACHARY MARK;;DAVIS CHRISTOPHER NELSON;;THORNTON MICHAEL M;;CHO JUN HWAN,,https://lens.org/045-999-156-534-770,Patent Application,no,0,0,7,7,0,G01H11/08;;G01N2291/106;;G01N29/2431;;G01N29/2437;;G01N29/343;;G01N29/0645;;G01N29/0654;;G01N29/50;;A61B5/0093;;A61B5/0035;;A61B5/0507;;A61B5/7225;;A61B5/7217;;A61B8/085;;A61B8/5261;;A61B5/0093;;A61B5/05;;A61B5/7217;;G01N29/2431;;A61B5/7225;;B06B1/0607;;A61B5/0035,A61B5/00;;A61B6/00;;A61B8/00;;A61B8/08;;A61B8/14,,0,0,,,,ACTIVE
612,US,A1,US 2020/0097138 A1,099-512-213-652-485,2020-03-26,2020,US 201816221090 A,2018-12-14,US 201816221090 A;;US 201862735496 P,2018-09-24,APPLICATION BUILDER,"Disclosed herein are system, method, and computer program product embodiments for unifying graphical user interface (GUI) displays across different device types. In an embodiment, a unification system may convert various GUI view appearing on, for example, a desktop device into a GUI view on a mobile device. Both devices may be accessing the same application and/or may use a cloud computing platform to access the application. The unification system may aid in reproducing GUI modifications performed on one user device onto other user devices. In this manner, the unification system may maintain a consistent look-and-feel for a user across different computing device type.",SALESFORCE COM INC,JACOBSON ERIC;;GONZALEZ MICHAEL;;CHO WAYNE;;VARADARAJAN ADHEIP;;VOLLMER JOHN;;SNYDER BENJAMIN,SALESFORCE.COM INC (2018-11-30),https://lens.org/099-512-213-652-485,Patent Application,yes,3,3,6,17,0,G06F8/34;;G06F8/38;;G06F3/0482;;G06F3/0483;;G06F3/04845,G06F3/0482;;G06F3/0483;;G06F3/0484,,0,0,,,,PENDING
613,US,B2,US 8064446 B2,019-404-505-357-525,2011-11-22,2011,US 6072308 A,2008-04-01,US 6072308 A;;US 95778207 P,2007-08-24,Multicast with adaptive dual-state,"A method and system are described to multicast with an adaptive dual state. The system receives multicast traffic over a membership tree including a first plurality of nodes connected in a first topology destined for a plurality of multicast members of a first multicast group. Next, the system determines a rate of multicast traffic that exceeds a predetermined threshold based on the receiving the multicast traffic. Next, the system generates a dissemination tree including a second plurality of nodes connected in a second topology to reduce a number of hops to communicate the multicast traffic to the plurality of multicast members of the first multicast group. Finally, the system forwards the multicast traffic to the plurality of multicast members of the first multicast group over the dissemination tree.",RAMAKRISHNAN KADANGODE K;;SRIVASTAVA DIVESH;;CHO TAE W;;ZHANG YIN;;RABINOVICH MICHAEL;;AT & T IP I LP,RAMAKRISHNAN KADANGODE K;;SRIVASTAVA DIVESH;;CHO TAE W;;ZHANG YIN;;RABINOVICH MICHAEL,AT&T INTELLECTUAL PROPERTY I L.P (2008-02-29),https://lens.org/019-404-505-357-525,Granted Patent,yes,22,11,8,8,0,H04L12/1886;;H04L45/16;;H04L45/48;;H04L12/1886;;H04L45/48;;H04L45/16,H04L12/28;;H04J3/26,370/390;;370/432,3,0,,,"Estrin, Deborah, Protocol Independent Multicast-Sparse Mode (PIM-SM): Deployment Guidelines, Dec. 10, 1996.;;Estrin, Deborah, Protocol Independent Multicast-Sparse Mode (PIM-SM): Protocol Specification, RFC 2362, Jun. 1998.;;Cui, Jun-Hong, et al., ""An Architecture for Scalable QoS Multicast Provisioning"", UCLA CSD TR # 010030, http://citeseer.ist.psu.edu/cui01architecture.html, (2001), 21 pgs.",INACTIVE
614,ES,T3,ES 2231798 T3,035-930-969-453-814,2005-05-16,2005,ES 96300587 T,1996-01-29,US 39397795 A,1995-02-24,COMPOSICIONES COSMETICAS PARA AUMENTAR LA SINTESIS DE COLAGENO DE LA PIEL.,"LA INVENCION SE REFIERE AL AUMENTO DE LA FUERZA Y FIRMEZA DE LA PIEL PARA REDUCIR LOS SIGNOS DE CELULITIS. EL METODO DE LA INVENCION CONSISTE EN APLICAR EN LA PIEL UNA COMPOSICION QUE CONTENGA FOSFATO DE INOSITOL, EN PARTICULAR ACIDO FITICO Y SUS SALES, EN UN EXCIPIENTE COSMETICAMENTE ACEPTABLE.",UNILEVER NV,ZNAIDEN ALEXANDER P;;CHENEY MICHAEL C;;SLAVTCHEFF CRAIG S;;CHO SUK H,,https://lens.org/035-930-969-453-814,Granted Patent,no,0,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
615,US,B2,US 10751542 B2,044-705-165-144-448,2020-08-25,2020,US 201715783573 A,2017-10-13,US 201715783573 A,2017-10-13,Power management for implantable medical device systems,"Techniques for minimizing rate of depletion of a non-rechargeable power source, to extend the operational lifetime of an implantable medical device that includes the non-rechargeable power source, by enforcing operational-mode-specific communication protocols whereby inter-device communication between the implantable medical device and another implantable medical device is such that level of power draw from the non-rechargeable power source by the implantable medical device is less than level of power draw from the rechargeable power source by the another implantable medical device for the implantable medical devices to engage in communication with each other.",MEDTRONIC INC,DEMMER WADE M;;CHO YONG K;;HESS MICHAEL F;;SHELDON TODD J,MEDTRONIC INC (2017-10-10),https://lens.org/044-705-165-144-448,Granted Patent,yes,37,2,11,11,0,A61N1/3708;;A61N1/37288;;A61N1/3756;;A61N1/3787;;A61B5/318;;A61N1/3708;;A61B5/318;;A61N1/37512;;A61N1/37518;;A61N1/3684;;A61N1/37288;;A61N1/3756;;A61N1/3787,A61N1/378;;A61B5/0402;;A61N1/368;;A61N1/37;;A61N1/372;;A61N1/375,,1,0,,,"(PCT/US2018/053354) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Dec. 12, 2018, 12 pages.",ACTIVE
616,CA,A1,CA 3217492 A1,046-135-546-997-293,2022-10-27,2022,CA 3217492 A,2022-04-22,US 202163178055 P;;US 2022/0025995 W,2021-04-22,TOPICAL ANTISEPTIC,"An antiseptic composition for penetrating and treating the dermis and/or pilosebaceous follicle of a mammal, said antiseptic composing comprising: (a) a sebostatic agent for reducing sebum production to prevent clogging of skin pores; (b) a barrier-forming emollient for forming a protective barrier film to aid said dermis in maintaining moisture and to shield said dermis from the environment; and (c) an antiseptic agent.",SURGIWIPE LLC,YAYAC MICHAEL;;PARVIZI JAVAD;;BRITTAIN HARRY;;CHO JEONGEUN;;SAXENA ARADHNA;;PARMAR MAYANK,,https://lens.org/046-135-546-997-293,Patent Application,no,0,0,5,5,0,A01N33/12;;A01P1/00;;A61K8/675;;A61Q17/005;;A61K8/342;;A61K8/922;;A61K8/365;;A61K9/107;;A61K9/70;;A61K31/191;;A61K31/455;;A61K36/61;;A61K47/10,A01N25/02;;A01N25/04;;A01N33/04,,0,0,,,,PENDING
617,CA,A1,CA 2168518 A1,066-152-574-192-329,1996-08-25,1996,CA 2168518 A,1996-01-31,US 39397795 A,1995-02-24,COSMETIC COMPOSITIONS FOR REDUCING OR PREVENTING SIGNS OF CELLULITE,"The invention is directed to increasing the strength and firmness of the skin and reducing the signs of cellulite. The inventive method includes applying to the skin a composition that includes inositol phosphate, particularly phytic acid and its salts, in a cosmetically acceptable carrier.",UNILEVER PLC,ZNAIDEN ALEXANDER PAUL;;CHENEY MICHAEL CHARLES;;SLAVTCHEFF CRAIG STEVEN;;CHO SUK HYUNG,,https://lens.org/066-152-574-192-329,Patent Application,no,0,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
618,EP,A1,EP 4326062 A1,080-329-275-141-984,2024-02-28,2024,EP 22792599 A,2022-04-22,US 202163178055 P;;US 2022/0025995 W,2021-04-22,TOPICAL ANTISEPTIC,,SURGIWIPE LLC,YAYAC MICHAEL;;PARVIZI JAVAD;;BRITTAIN HARRY;;CHO JEONGEUN;;SAXENA ARADHNA;;PARMAR MAYANK,,https://lens.org/080-329-275-141-984,Patent Application,yes,0,0,5,5,0,A01N33/12;;A01P1/00;;A61K8/675;;A61Q17/005;;A61K8/342;;A61K8/922;;A61K8/365;;A61K9/107;;A61K9/70;;A61K31/191;;A61K31/455;;A61K36/61;;A61K47/10,A01N25/04;;A01N25/02;;A01N33/04,,0,0,,,,PENDING
619,US,A1,US 2003/0101454 A1,101-905-311-305-580,2003-05-29,2003,US 99102501 A,2001-11-21,US 99102501 A,2001-11-21,Methods and systems for planning advertising campaigns,"
   A system, including a planning module, a control module and a receiver module, configured to schedule display of advertisements to achieve an advertising impression goal. The planning module enables scheduling of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisements, assigning an advertising type and defining a weight for the advertisement. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisement. The one or more metadata files and advertising content for the advertisement, are delivered to the receiver module that is configured to define a display frequency for the advertising content based upon one or more of the metadata files. The receiver module selectively displays the advertising content of the advertisement to achieve the advertising impression goal. 
",OZER STUART;;HART MICHAEL PATRICK;;CHO WEI WEI ADA;;CHAU CAROLYN KHANH,OZER STUART;;HART MICHAEL PATRICK;;CHO WEI WEI ADA;;CHAU CAROLYN KHANH,WEBTV NETWORKS INC (2001-11-19);;MICROSOFT CORPORATION (2002-06-28),https://lens.org/101-905-311-305-580,Patent Application,yes,25,406,3,3,0,G06Q30/02;;G06Q30/02,G06Q30/02,725/42;;725/46;;725/35,0,0,,,,DISCONTINUED
620,CA,C,CA 2973971 C,116-303-915-768-523,2022-05-17,2022,CA 2973971 A,2015-01-15,US 201514597415 A;;US 2015/0011558 W,2015-01-15,SEPARATIONS WITH IONIC LIQUID SOLVENTS,"Disclosed are systems and methods which provide a process stream comprising a gaseous component, capture the gaseous component from the process stream by an ionic liquid solvent of a separator, and recover a captured gaseous component from the ionic liquid solvent in a regenerator. A second gaseous component from the process stream may be captured by the ionic liquid solvent of the separator, and the second gaseous component may be recovered from the ionic liquid solvent in the regenerator. Alternatively, the second gaseous component from the process stream may be uncaptured by the ionic liquid solvent, and the uncaptured second gaseous component may be recovered from a membrane unit.",CHEVRON PHILLIPS CHEMICAL CO LP;;CHEVRON USA INC,JI LEI;;CHANG AI-FU;;DRIVER MICHAEL SEAN;;TIMKEN HYE-KYUNG CHO,,https://lens.org/116-303-915-768-523,Granted Patent,no,0,0,9,34,0,B01D53/1487;;B01D53/1493;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05;;B01D53/1493;;B01D53/1487;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05,B01D53/14,,0,0,,,,PENDING
621,WO,A1,WO 2020/097351 A1,130-554-144-737-502,2020-05-14,2020,US 2019/0060293 W,2019-11-07,US 201816182650 A,2018-11-07,METHOD AND SYSTEM FOR ENHANCING RF ENERGY DELIVERY DURING THERMOACOUSTIC IMAGING,"A method and system for enhancing radio frequency energy delivery to a tissue region of interest. The method and system direct with a radio frequency (RF) applicator, one or more RF energy pulses into the tissue region of interest, the tissue region of interest comprising an object of interest and at least one reference that are separated by at least one boundary; detect with an acoustic receiver, at least one bipolar acoustic signal generated in the tissue region of interest in response to the RF energy pulses and processing the at least one bipolar acoustic signal to determine a peak-to-peak amplitude thereof; adjust the RF applicator to maximize the peak-to-peak amplitude of bipolar acoustic signals generated in the tissue region of interest in response to RF energy pulses generated by the adjusted RF applicator; and direct with the adjusted RF applicator, one or more RF energy pulses into the region of interest.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/130-554-144-737-502,Patent Application,yes,12,0,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B8/08;;A61B5/00,,1,0,,,See also references of EP 3893759A4,PENDING
622,US,B2,US 7136871 B2,150-948-561-885-052,2006-11-14,2006,US 99138901 A,2001-11-21,US 99138901 A,2001-11-21,Methods and systems for selectively displaying advertisements,"A system, including a planning module, a control module and a receiver module, configured to schedule display of one or more advertising impressions of available advertising inventory. The planning module enables scheduling a requested quantity of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisement, assigning an advertising type and defining a weight for the advertisements. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisements. The one or more metadata files, with the advertisements, are delivered to the receiver module that is configured to define a display frequency for the advertisements based upon one or more of the metadata files. The receiver module selectively displays advertisement content associated with the advertisements to achieve the advertising impression goal.",MICROSOFT CORP,OZER STUART;;HART MICHAEL PATRICK;;CHO WEI WEI ADA;;CHAU CAROLYN KHANH,ZHIGU HOLDINGS LIMITED (2016-05-16);;WEBTV NETWORKS INC (2001-11-19);;MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2002-06-28),https://lens.org/150-948-561-885-052,Granted Patent,yes,23,297,8,8,0,G06Q30/02;;G06Q30/0241;;G06Q30/0248;;G06Q30/0252;;G06Q30/0254;;G06Q30/0264;;G06Q30/0269;;G06Q30/0272;;G06Q30/02;;G06Q30/0241;;G06Q30/0264;;G06Q30/0248;;G06Q30/0269;;G06Q30/0272;;G06Q30/0254;;G06Q30/0252;;Y10S707/99945;;Y10S707/99948;;Y10S707/99944;;Y10S707/99942;;Y10S707/99943,G06F17/30;;G06F3/00;;G06Q30/02;;H04N7/00,707/104.1;;707/101;;707/102;;707/103;;705/14;;725/34;;725/42;;725/44,0,0,,,,EXPIRED
623,US,B2,US 10227274 B2,167-256-658-205-797,2019-03-12,2019,US 201514597415 A,2015-01-15,US 201514597415 A;;US 201313948861 A,2013-07-23,Separations with ionic liquid solvents,"Disclosed are systems and methods which provide a process stream comprising a gaseous component, capture the gaseous component from the process stream by an ionic liquid solvent of a separator, and recover a captured gaseous component from the ionic liquid solvent in a regenerator. A second gaseous component from the process stream may be captured by the ionic liquid solvent of the separator, and the second gaseous component may be recovered from the ionic liquid solvent in the regenerator. Alternatively, the second gaseous component from the process stream may be uncaptured by the ionic liquid solvent, and the uncaptured second gaseous component may be recovered from a membrane unit.",CHEVRON PHILLIPS CHEMICAL CO LP;;CHEVRON USA INC,JI LEI;;CHANG AI-FU;;DRIVER MICHAEL SEAN;;TIMKEN HYE-KYUNG CHO,CHEVRON U.S.A. INC (2015-01-05);;CHEVRON PHILLIPS CHEMICAL COMPANY LP (2014-12-16),https://lens.org/167-256-658-205-797,Granted Patent,yes,52,1,2,34,0,B01D53/1462;;B01D53/1462;;B01D53/1487;;B01D53/1487;;B01D53/1493;;B01D53/1493;;B01D53/229;;B01D53/229;;B01D53/526;;B01D53/526;;B01D2252/30;;B01D2252/30;;B01D2256/22;;B01D2256/22;;B01D2256/24;;B01D2256/24;;B01D2257/304;;B01D2257/304;;B01D2257/504;;B01D2257/504;;B01D2257/7022;;B01D2257/7022;;C07C7/11;;C07C7/11;;C01B17/167;;C01B17/167;;C07C7/144;;C07C7/144;;C07C7/152;;C07C7/152;;Y02P20/151;;Y02P20/151;;Y02P20/50;;Y02P20/50;;Y02P20/54;;Y02P20/54,C07C7/11;;B01D53/14;;B01D53/22;;B01D53/52;;C01B17/16;;C07C7/144;;C07C7/152,,17,3,114-748-508-694-52X;;062-893-541-054-774;;042-667-565-422-294,10.1021/ie9010244;;10.1021/ie049312r;;10.1016/j.cej.2013.01.052,"DE10333546A1_English Translation 2005.;;L.M. Galan Sanchez, “Functionalized Ionic Liquids: Absorption Solvents for Carbon Dioxide and Olefin Separation”, Doctoral Thesis, Eindhoven University of Technology Library, The Netherlands, 2008, ISBN: 978-90-386-1468-7.;;Filing receipt and specification for patent application entitled “Separations with Ionic Liquid Solvents,” by Lei Ji, et al., filed Dec. 11, 2015 as U.S. Appl. No. 14/966,208.;;Galán Sánchez, Lara M., et al., “Potential of silver-based room-temperature ionic liquids for ethylene/ethane separation,” Ind. Eng. Chem. Res., 2009, pp. 10650-10656, vol. 48, No. 23, American Chemical Society.;;Gas Processors Suppliers Association, “Engineering data book,” vol. II, Sections 17-26, Tenth Edition, 1987, p. 19-32 and cover page, Gas Processors Association.;;Camper, Dean, et al., “Low pressure hydrocarbon solubility in room temperature ionic liquids containing imidazolium rings interpreted using regular solution theory,” Ind. Eng. Chem. Res., 2005, pp. 1928-1933, vol. 44, No. 6, American Chemical Society.;;Worley Parsons brochure entitled “Tail gas unit description,” Section 3, pp. 3-1 to 3-3.;;Fallanza, Marcos, et al., “Screening of RTILs for propane/propylene separation using COSMO-RS methodology,” Chemical Engineering Journal, 2013, pp. 284-293, vol. 220, Elsevier B.V.;;Foreign communication from a related counterpart application—Communication Relating to the Results of the Partial International Search, Annex to Form PCT/ISA/206, PCT/US2014/046842, dated Oct. 15, 2014, 4 pages.;;Foreign communication from a related counterpart application—International Search Report and Written Opinion, PCT/US2014/046842, dated Jan. 5, 2015, 16 pages.;;Son, Seung J., et al., “Selective Absorption of Isoprene from C5 Mixtures by π Complexation with Cu(I),” Ind. Eng. Chem. Res., 2005, pp. 4717-4720, vol. 44, No. 13, American Chemical Society.;;International Application No. PCT/US2015/011558 Search Report dated Apr. 29, 2015.;;Office Action dated Jun. 23, 2015 (25 pages), U.S. Appl. No. 13/948,861, filed Jul. 23, 2013.;;Office Action dated Feb. 14, 2017 (12 pages), U.S. Appl. No. 14/966,208, filed Dec. 11, 2015.;;Notice of Allowance dated May 4, 2017 (5 pages), U.S. Appl. No. 14/966,2081, filed Dec. 11, 2015.;;Office Action dated Mar. 12, 2018 (34 pages), U.S. Appl. No. 15/642,550, filed Jul. 6, 2017.;;Notice of Allowance dated Jul. 13, 2018 (9 pages), U.S. Appl. No. 15/642,550, filed Jul. 6, 2017.",ACTIVE
624,AU,A1,AU 2022/277569 A1,177-287-164-322-779,2023-12-14,2023,AU 2022/277569 A,2022-05-18,US 202163190041 P;;US 2022/0029858 W,2021-05-18,NASAL ANTISEPTIC,An antimicrobial composition comprising: (1) povidone iodine (PVP-I) in a concentration of 5 to 10 % w/w of the composition; and (2) carboxymethylcellulose (CMC) in a concentration of 0.1 to 5 % w/w of the composition.,POVINEZ LLC,PARVIZI JAVAD;;YAYAC MICHAEL;;CHISARI EMANUELE;;BRITTAIN HARRY;;CHO JEONGEUN;;PARMAR MAYANK,,https://lens.org/177-287-164-322-779,Patent Application,no,0,0,4,4,0,A61P31/00;;A61K47/38;;A61K33/18;;A61K9/0043;;A61K31/717;;A61L2101/50;;A61L2/18,A61K33/18;;A61K9/00;;A61K31/79;;A61K47/36;;A61K47/38;;A61P31/00,,0,0,,,,PENDING
625,CA,A1,CA 2973971 A1,190-381-102-093-423,2016-07-21,2016,CA 2973971 A,2015-01-15,US 201514597415 A;;US 2015/0011558 W,2015-01-15,SEPARATIONS WITH IONIC LIQUID SOLVENTS,"Disclosed are systems and methods which provide a process stream comprising a gaseous component, capture the gaseous component from the process stream by an ionic liquid solvent of a separator, and recover a captured gaseous component from the ionic liquid solvent in a regenerator. A second gaseous component from the process stream may be captured by the ionic liquid solvent of the separator, and the second gaseous component may be recovered from the ionic liquid solvent in the regenerator. Alternatively, the second gaseous component from the process stream may be uncaptured by the ionic liquid solvent, and the uncaptured second gaseous component may be recovered from a membrane unit.",CHEVRON PHILLIPS CHEMICAL CO LP;;CHEVRON USA INC,JI LEI;;CHANG AI-FU;;DRIVER MICHAEL SEAN;;TIMKEN HYE-KYUNG CHO,,https://lens.org/190-381-102-093-423,Patent Application,no,0,0,9,34,0,B01D53/1487;;B01D53/1493;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05;;B01D53/1493;;B01D53/1487;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05,B01D53/14,,0,0,,,,PENDING
626,WO,A1,WO 2019/074892 A1,022-284-774-370-140,2019-04-18,2019,US 2018/0054952 W,2018-10-09,US 201762569834 P,2017-10-09,ANTIBODIES TARGETING GLIOBLASTOMA STEM-LIKE CELLS AND METHODS OF USE THEREOF,The present invention provides antibodies that target glioblastoma stem-like cells and methods and kits for their use.,WISCONSIN ALUMNI RES FOUND,ZORNIAK MICHAEL;;CLARK PAUL;;CHO YONGKU;;UMLAUF BENJAMIN;;SHUSTA ERIC;;HUO JOHN,,https://lens.org/022-284-774-370-140,Patent Application,yes,10,0,5,5,10,C07K16/18;;C07K16/30;;G01N33/57407;;A61K2039/505;;C07K2317/569;;A61P35/00;;A61K49/0058;;A61K2039/505;;C07K16/3053;;C07K2317/565;;C07K2317/622;;C07K2317/92;;G01N33/57407,C07K16/18;;A61K39/00;;A61P35/00;;C07K16/30;;G01N33/53,,88,80,044-139-486-413-246;;013-196-850-300-026;;164-041-763-164-918;;051-449-459-754-069;;065-845-026-596-467;;017-597-089-494-010;;065-067-575-525-372;;019-921-917-139-327;;001-308-283-819-689;;060-800-606-301-88X;;028-862-168-091-90X;;116-058-608-181-929;;112-206-594-779-001;;072-221-669-832-927;;000-087-532-932-840;;077-233-519-852-789;;008-661-986-771-169;;085-656-742-202-556;;035-428-777-329-102;;092-864-235-322-940;;028-981-833-063-784;;105-369-693-995-394;;019-377-086-323-88X;;054-778-738-922-420;;039-376-070-403-51X;;002-091-355-242-789;;030-327-153-441-88X;;063-180-739-005-237;;065-845-026-596-467;;044-139-486-413-246;;051-449-459-754-069;;164-041-763-164-918;;045-857-295-659-908;;024-910-342-741-241;;018-169-670-602-076;;027-628-739-240-883;;035-149-244-661-733;;071-073-635-453-103;;007-750-921-871-271;;042-513-156-090-960;;035-428-777-329-102;;127-278-436-943-010;;010-568-275-556-548;;088-006-869-449-526;;053-301-739-905-628;;094-452-013-519-715;;005-790-218-190-208;;008-387-158-819-578;;054-117-557-242-401;;013-196-850-300-026;;040-091-367-301-676;;050-643-301-507-490;;057-167-704-218-212;;024-348-041-797-510;;001-698-087-702-930;;004-929-207-346-112;;128-333-076-135-348;;071-419-968-226-297;;023-301-536-947-707;;007-057-986-430-201;;072-124-564-678-690;;132-094-885-330-409;;090-855-538-709-694;;044-055-955-198-975;;091-102-566-701-905;;037-370-743-821-194;;066-190-897-568-631;;068-232-562-966-086;;015-998-463-324-164;;002-473-848-957-436;;015-459-933-949-167;;047-143-347-080-307;;192-609-714-372-280;;009-619-262-328-708;;026-824-155-633-618;;011-020-280-584-511;;026-141-621-631-087;;097-006-524-687-437;;044-555-535-916-468;;031-529-904-715-725,20587664;;pmc2944778;;10.1158/1535-7163.mct-09-1059;;24832468;;pmc4085538;;10.1038/cdd.2014.65;;pmc3933790;;23796560;;10.1158/0008-5472.can-12-4556;;10.1016/j.biomaterials.2011.07.048;;21880363;;10.1016/j.neuint.2014.03.005;;pmc4119816;;24657832;;29158489;;10.1038/s41598-017-16066-1;;pmc5696472;;10.1016/j.omtn.2018.04.004;;29858087;;pmc5992475;;26759369;;pmc4743815;;10.1073/pnas.1524155113;;26405231;;pmc4721629;;10.1126/science.aab4077;;pmc5997667;;29895885;;10.1038/s41598-018-27264-w;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;27192568;;pmc4873959;;10.1016/j.immuni.2016.04.017;;pmc2688461;;10.1016/j.bmcl.2009.01.028;;19181522;;10.1021/nn1023363;;21609027;;21839049;;10.1016/j.nano.2011.07.007;;11156394;;10.1007/s11095-007-9379-0;;17619996;;pmc2685177;;20044633;;10.1158/1078-0432.ccr-12-0339;;pmc3597469;;22589395;;10.1056/nejmoa043330;;15758009;;26670971;;10.1001/jama.2015.16669;;10.1001/jama.2014.12146;;17051156;;10.1038/nature05236;;17140455;;pmc1697823;;10.1186/1476-4598-5-67;;pmc3384429;;22745588;;10.1596/neo.12432;;10.1038/nature03128;;15549107;;pmc7227614;;10.1016/j.stem.2009.03.003;;19427293;;20173750;;10.1038/nmeth.1430;;10.1016/j.ccr.2009.12.049;;20385361;;10.1016/j.neuint.2014.03.005;;pmc4119816;;24657832;;20587664;;pmc2944778;;10.1158/1535-7163.mct-09-1059;;10.1016/j.biomaterials.2011.07.048;;21880363;;pmc3933790;;23796560;;10.1158/0008-5472.can-12-4556;;12536217;;10.1038/nbt785;;10.1038/77325;;10888844;;16549400;;10.1093/protein/gzl008;;16099466;;10.1016/j.jim.2005.05.006;;17206151;;pmc2637222;;10.1038/nmeth993;;11075358;;10.1016/s0076-6879(00)28410-3;;pmc1207636;;10.1093/genetics/144.3.967;;8913742;;18000980;;10.1002/dvdy.21381;;10.1158/1078-0432.ccr-12-0339;;pmc3597469;;22589395;;24920661;;pmc4336181;;10.1126/scitranslmed.3007646;;25361488;;10.3171/2014.9.jns132373;;pmc4337891;;27419830;;10.3171/2016.1.jns152077;;pmc5237623;;10.1158/1078-0432.ccr-15-3169;;pmc5627655;;27635088;;19497285;;10.1016/j.stem.2009.03.014;;10.1016/j.jim.2008.11.005;;19041873;;pmc2637942;;10.1021/bp990133s;;10662486;;9702778;;10.1038/nbt0898-773;;24832468;;pmc4085538;;10.1038/cdd.2014.65;;10.1016/j.ccr.2006.03.030;;10.3410/f.30634.375123;;16697959;;16957578;;10.1097/01.jnen.0000235118.75182.94;;16151404;;10.1038/nbt1126;;10.1016/j.chembiol.2007.09.008;;17961829;;10.1002/btpr.174;;19363813;;pmc2837102;;23248284;;10.1073/pnas.1219817110;;pmc3538214;;pmc2999649;;20829328;;10.1158/1078-0432.ccr-10-1564;;10.1227/neu.0000000000000622;;25549194;;pmc4343207;;pmc5014630;;27421304;;10.1021/acs.molpharmaceut.6b00441;;10.2217/cns-2016-0017;;pmc5514628;;27616199;;27572805;;10.1080/14712598.2016.1230195;;10.1517/17425247.2016.1171315;;27020469;;10.1227/neu.0000000000001451;;27861405;;10.1023/a:1007049806660;;10696511;;10.1038/sj.gt.3302445;;15647762;;pmc4664343;;26553993;;10.1073/pnas.1502648112;;10.1158/1535-7163.mct-14-1078;;25931519;;10.1080/2162402x.2015.1008339;;26155413;;pmc4485829;;10.1038/mt.2015.199;;pmc4817815;;26514825;;10.1158/2326-6066.cir-15-0060;;26822025;;9874150;;10.1016/s0165-0270(98)00126-5;;12203386;;10.1002/glia.10094;;14522905;;10.1007/s11095-006-9778-7;;16550469;;10.1021/cb500689g;;25384269;;pmc4340354;;18781684;;10.1002/bit.22019;;10.1128/aem.01466-14;;25015885;;pmc4178591;;22449570;;pmc3405166;;10.1016/j.ymeth.2012.03.010;;10.1158/0008-5472.can-04-1364;;15466194;;pmc3189267;;21814852;;10.1007/s00259-011-1886-x,"X. ZHU ET AL: ""Identification of Internalizing Human Single-Chain Antibodies Targeting Brain Tumor Sphere Cells"", MOLECULAR CANCER THERAPEUTICS, vol. 9, no. 7, 1 July 2010 (2010-07-01), pages 2131 - 2141, XP055178095, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-09-1059;;J K LIU ET AL: ""Phage display discovery of novel molecular targets in glioblastoma-initiating cells"", CELL DEATH AND DIFFERENTIATION., vol. 21, no. 8, 16 May 2014 (2014-05-16), GB, pages 1325 - 1339, XP055544885, ISSN: 1350-9047, DOI: 10.1038/cdd.2014.65;;Y. KIM ET AL: ""Aptamer Identification of Brain Tumor-Initiating Cells"", CANCER RESEARCH, vol. 73, no. 15, 24 June 2013 (2013-06-24), US, pages 4923 - 4936, XP055544884, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-4556;;SAMUEL BECK ET AL: ""Identification of a peptide that interacts with Nestin protein expressed in brain cancer stem cells"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 32, no. 33, 16 July 2011 (2011-07-16), pages 8518 - 8528, XP028295853, ISSN: 0142-9612, [retrieved on 20110801], DOI: 10.1016/J.BIOMATERIALS.2011.07.048;;POINTER KELLI B ET AL: ""Glioblastoma cancer stem cells: Biomarker and therapeutic advances"", NEUROCHEMISTRY INTERNATIONAL, vol. 71, 19 March 2014 (2014-03-19), pages 1 - 7, XP028655023, ISSN: 0197-0186, DOI: 10.1016/J.NEUINT.2014.03.005;;MICHAEL ZORNIAK ET AL: ""Yeast display biopanning identifies human antibodies targeting glioblastoma stem-like cells"", SCIENTIFIC REPORTS, vol. 7, no. 1, 20 November 2017 (2017-11-20), XP055544982, DOI: 10.1038/s41598-017-16066-1;;ARNOLD AMY E ET AL: ""Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells."", MOLECULAR THERAPY. NUCLEIC ACIDS 01 JUN 2018, vol. 11, 1 June 2018 (2018-06-01), pages 518 - 527, XP002788205, ISSN: 2162-2531;;RODGERS ET AL.: ""Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies"", PNAS, 12 January 2006 (2006-01-12), pages E459 - E468;;WU ET AL.: ""Remote control of therapeutic T cells through a small molecule-gated chimeric receptor"", SCIENCE, vol. 350, no. 6258, 16 October 2015 (2015-10-16), pages aab4077 - 9, XP055260068, DOI: doi:10.1126/science.aab4077;;VALTON ET AL.: ""A Versatile Safeguard for Chimeric Antigen Receptor T-cell Immunotherapies"", NATURE SCIENTIFIC REPORTS, vol. 8, 2018;;KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2267 - 2268;;ALTSCHUL ET AL., NUCL. ACIDS RES., vol. 25, 1997, pages 3389 - 3402;;ZHANG ET AL.: ""Co-stimulatory and Co-inhibitory Pathways in Autoimmunity"", IMMUNITY, vol. 44, 17 May 2016 (2016-05-17), pages 1034 - 1051, XP029537983, DOI: doi:10.1016/j.immuni.2016.04.017;;GAVRILYUK ET AL.: ""3-Lactam-based Approach for Chemical Programming of Aldolast Antibody 38C2"", BIOORG MED CHEM LETT., vol. 19, no. 5, 1 March 2009 (2009-03-01), pages 1421 - 1424;;B. VAN DE BROEK ET AL., ACS NANO, vol. 5, no. 6, 2011, pages 4319 - 4328;;A. SUKHANOVA ET AL., NANOMEDICINE, vol. 8, 2012, pages 516 - 525;;SUGANO ET AL.: ""Antibody Targeting of Doxorubicin-loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice"", CANCER RESEARCH, vol. 60, 15 December 2000 (2000-12-15), pages 6942 - 6949, XP000980029;;MARTIN ET AL.: ""Nanomaterials in Analytical Chemistry"", ANALYTICAL CHEMISTRY NEWS & FEATURES, 1 May 1998 (1998-05-01), pages 322 A - 327 A;;JONES, A.R.; E.V. SHUSTA: ""Blood-brain barrier transport of therapeutics via receptor-mediation"", PHARMACEUTICAL RESEARCH, vol. 24, no. 9, 2007, pages 1759 - 1771, XP019532601, DOI: doi:10.1007/s11095-007-9379-0;;TERNYNCK; AVRAMEAS: ""Techniques immunoenzymatiques"", 1987;;G.T. HERMANSON: ""Bioconjugate Techniques"", 2010, ACADEMIC PRESS;;WONG: ""Chemistry of protein conjugation and cross-linking"", 1991, CRC PRESS;;""Merck Index"";;""Physicians' Desk Reference"";;""The Pharmacological Basis of Therapeutics"";;MINNITI ET AL.: ""Chemotherapy for Glioblastoma: Current Treatment and Further Perspectives for Cytotoxic and Targeted Agents"", ANTICANCER RESEARCH, vol. 29, no. 12, December 2009 (2009-12-01), pages 5171 - 5184;;ZORNIAK ET AL.: ""Differential Expression of 2'3'-Cyclic-Nucleotide 3'-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival"", CLINICAL CANCER RESEARCH, May 2012 (2012-05-01);;STUPP, R. ET AL.: ""Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma"", NENGL J MED, vol. 352, 2005, pages 987 - 996, XP002439490, DOI: doi:10.1056/NEJMoa043330;;STUPP, R. ET AL.: ""Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial"", JAMA : THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 314, 2015, pages 2535 - 2543;;BAO, S. ET AL.: ""Glioma stem cells promote radioresistance by preferential activation of the DNA damage response"", NATURE, vol. 444, 2006, pages 756 - 760, XP055200572, DOI: doi:10.1038/nature05236;;LIU, G. ET AL.: ""Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma"", MOLECULAR CANCER, vol. 5, 2006, pages 67, XP021024382, DOI: doi:10.1186/1476-4598-5-67;;CLARK, P. A. ET AL.: ""Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition"", NEOPLASIA, vol. 14, 2012, pages 420 - 428;;SINGH, S. K. ET AL.: ""Identification of human brain tumour initiating cells"", NATURE, vol. 432, 2004, pages 396 - 401, XP002467853, DOI: doi:10.1038/nature03128;;SON, M. J.; WOOLARD, K.; NAM, D. H.; LEE, J.; FINE, H. A.: ""SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma"", CELL STEM CELL, vol. 4, 2009, pages 440 - 452;;CLEMENT, V. ET AL.: ""Marker-independent identification of glioma-initiating cells"", NATURE METHODS, vol. 7, 2010, pages 224 - 228, XP007914533, DOI: doi:10.1038/nmeth.1430;;CHEN, R. ET AL.: ""A hierarchy of self-renewing tumor-initiating cell types in glioblastoma"", CANCER CELL, vol. 17, 2010, pages 362 - 375, XP055032071, DOI: doi:10.1016/j.ccr.2009.12.049;;POINTER, K. B.; CLARK, P. A.; ZORNIAK, M.; ALRFAEI, B. M.; KUO, J. S.: ""Glioblastoma cancer stem cells: Biomarker and therapeutic advances"", NEUROCHEM INT, vol. 71, 2014, pages 1 - 7, XP028655023, DOI: doi:10.1016/j.neuint.2014.03.005;;ZHU, X. ET AL.: ""Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells"", MOLECULAR CANCER THERAPEUTICS, vol. 9, 2010, pages 2131 - 2141, XP055178095, DOI: doi:10.1158/1535-7163.MCT-09-1059;;BECK, S. ET AL.: ""Identification of a peptide that interacts with Nestin protein expressed in brain cancer stem cells"", BIOMATERIALS, vol. 32, 2011, pages 8518 - 8528, XP028295853, DOI: doi:10.1016/j.biomaterials.2011.07.048;;KIM, Y. ET AL.: ""Aptamer Identification of Brain Tumor-Initiating Cells"", CANCER RESEARCH, vol. 73, 2013, pages 4923 - 4936;;FELDHAUS, M. J. ET AL.: ""Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library"", NATURE BIOTECHNOLOGY, vol. 21, 2003, pages 163 - 170, XP002451748;;SHUSTA, E. V.; HOLLER, P. D.; KIEKE, M. C.; KRANZ, D. M.; WITTRUP, K. D.: ""Directed evolution of a stable scaffold for T-cell receptor engineering"", NATURE BIOTECHNOLOGY, vol. 18, 2000, pages 754 - 759, XP055004062, DOI: doi:10.1038/77325;;RICHMAN, S. A. ET AL.: ""Development of a novel strategy for engineering high-affinity proteins by yeast display"", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS, vol. 19, 2006, pages 255 - 264;;WANG, X. X.; SHUSTA, E. V.: ""The use of scFv-displaying yeast in mammalian cell surface selections"", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 304, 2005, pages 30 - 42;;WANG, X. X.; CHO, Y. K.; SHUSTA, E. V.: ""Mining a yeast library for brain endothelial cell-binding antibodies"", NATURE METHODS, vol. 4, 2007, pages 143 - 145, XP008086824, DOI: doi:10.1038/nmeth993;;BODER, E. T.; WITTRUP, K. D.: ""Yeast surface display for directed evolution of protein expression, affinity, and stability"", METHODS IN ENZYMOLOGY, vol. 328, 2000, pages 430 - 444, XP009103962, DOI: doi:10.1016/S0076-6879(00)28410-3;;LIU, H.; STYLES, C. A.; FINK, G. R.: ""Saccharomyces cerevisiae S288C has a mutation in FL08, a gene required for filamentous growth"", GENETICS, vol. 144, 1996, pages 967 - 978;;CLARK, P. A.; TREISMAN, D. M.; EBBEN, J.; KUO, J. S.: ""Developmental signaling pathways in brain tumor-derived stem-like cells"", DEV DYN, vol. 236, 2007, pages 3297 - 3308;;ZORNIAK, M. ET AL.: ""Differential expression of 2',3'-cyclic-nucleotide 3'-phosphodiesterase and neural lineage markers correlate with glioblastoma xenograft infiltration and patient survival"", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 18, 2012, pages 3628 - 3636;;WEICHERT, J. P. ET AL.: ""Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy"", SCIENCE TRANSLATIONAL MEDICINE, vol. 6, 2014, pages 240ra275;;ZORNIAK, M.; CLARK, P. A.; KUO, J. S.: ""Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells"", J NEUROSURG, vol. 122, 2015, pages 69 - 77;;CLARK, P. A. ET AL.: ""Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration"", J NEUROSURG, 2016, pages 1 - 13;;POINTER, K. B. ET AL.: ""Non-torsadogenic human Ether-a-go-go Related Gene (hERG) inhibitors are associated with better survival for high hERG-expressing glioblastoma patients"", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 2016;;POLLARD, S. M. ET AL.: ""Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens"", CELL STEM CELL, vol. 4, 2009, pages 568 - 580, XP002665238, DOI: doi:10.1016/j.stem.2009.03.014;;CHO, Y. K.; CHEN, I.; WEI, X.; LI, L.; SHUSTA, E. V.: ""A yeast display immunoprecipitation method for efficient isolation and characterization of antigens"", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 341, 2009, pages 117 - 126, XP025913977, DOI: doi:10.1016/j.jim.2008.11.005;;VANANTWERP, J. J.; WITTRUP, K. D.: ""Fine affinity discrimination by yeast surface display and flow cytometry"", BIOTECHNOLOGY PROGRESS, vol. 16, 2000, pages 31 - 37;;SHUSTA, E. V.; RAINES, R. T.; PLUCKTHUN, A.; WITTRUP, K. D.: ""Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments"", NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 773 - 777, XP002138520, DOI: doi:10.1038/nbt0898-773;;LIU, J. K. ET AL.: ""Phage display discovery of novel molecular targets in glioblastoma-initiating cells"", CELL DEATH DIFFER, vol. 21, 2014, pages 1325 - 1339;;LEE, J. ET AL.: ""Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines"", CANCER CELL, vol. 9, 2006, pages 391 - 403, XP002550739, DOI: doi:10.1016/j.ccr.2006.03.030;;HOMMA, T. ET AL.: ""Correlation among pathology, genotype, and patient outcomes in glioblastoma"", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, vol. 65, 2006, pages 846 - 854, XP009132036;;HOOGENBOOM, H. R.: ""Selecting and screening recombinant antibody libraries"", NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1105 - 1116, XP002348401, DOI: doi:10.1038/nbt1126;;LIPOVSEK, D. ET AL.: ""Selection of horseradish peroxidase variants with enhanced enantioselectivity by yeast surface display"", CHEMISTRY & BIOLOGY, vol. 14, 2007, pages 1176 - 1185, XP009091881, DOI: doi:10.1016/j.chembiol.2007.09.008;;ACKERMAN, M. ET AL.: ""Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display"", BIOTECHNOLOGY PROGRESS, vol. 25, 2009, pages 774 - 783;;CHOI, B. D. ET AL.: ""Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 110, 2013, pages 270 - 275, XP055156305, DOI: doi:10.1073/pnas.1219817110;;LOCKMAN, P. R. ET AL.: ""Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer"", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 16, 2010, pages 5664 - 5678;;SWANSON, K. I. ET AL.: ""Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection"", NEUROSURGERY, vol. 76, 2015, pages 115 - 123;;CLARK, P. A. ET AL.: ""Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood-Brain Barrier Model"", MOL PHARM, vol. 13, 2016, pages 3341 - 3349;;ZHANG, R. R.; SWANSON, K. I.; HALL, L. T.; WEICHERT, J. P.; KUO, J. S.: ""Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies"", CNS ONCOL, vol. 5, 2016, pages 223 - 231;;PARDRIDGE, W. M.: ""Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies"", EXPERT OPIN BIOL THER, 2016, pages 1 - 14;;PARDRIDGE, W. M.: ""CSF, blood-brain barrier, and brain drug delivery"", EXPERT OPIN DRUG DELIV, vol. 13, 2016, pages 963 - 975;;LIU, H. L. ET AL.: ""Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment"", RADIOLOGY, vol. 281, 2016, pages 99 - 108;;RAPOPORT, S. I.: ""Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications"", CELLULAR AND MOLECULAR NEUROBIOLOGY, vol. 20, 2000, pages 217 - 230;;LIU, R.; MARTUZA, R. L.; RABKIN, S. D.: ""Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain"", GENE THERAPY, vol. 12, 2005, pages 647 - 654;;YANG, Y. ET AL.: ""Targeting CD 146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 112, 2015, pages E6525 - 6534, XP055453695, DOI: doi:10.1073/pnas.1502648112;;HAMBLETT, K. J. ET AL.: ""AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma"", MOLECULAR CANCER THERAPEUTICS, vol. 14, 2015, pages 1614 - 1624;;SURYADEVARA, C. M. ET AL.: ""Are BiTEs the ''missing link'' in cancer therapy?"", ONCOIMMUNOLOGY, vol. 4, 2015, pages el008339;;KRENCIUTE, G. ET AL.: ""Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Ralpha2-positive Glioma"", MOL THER, vol. 24, 2016, pages 354 - 363, XP055462357, DOI: doi:10.1038/mt.2015.199;;SHIINA, S. ET AL.: ""CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains"", CANCER IMMUNOL RES, vol. 4, 2016, pages 259 - 268;;SVENDSEN, C. N. ET AL.: ""A new method for the rapid and long term growth of human neural precursor cells"", JNEUROSCI METHODS, vol. 85, 1998, pages 141 - 152, XP002902582, DOI: doi:10.1016/S0165-0270(98)00126-5;;IGNATOVA, T. N. ET AL.: ""Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro"", GLIA, vol. 39, 2002, pages 193 - 206, XP009044599, DOI: doi:10.1002/glia.10094;;SINGH, S. K. ET AL.: ""Identification of a cancer stem cell in human brain tumors"", CANCER RESEARCH, vol. 63, 2003, pages 5821 - 5828;;HACKEL, B. J.; HUANG, D.; BUBOLZ, J. C.; WANG, X. X.; SHUSTA, E. V.: ""Production of soluble and active transferrin receptor-targeting single-chain antibody using Saccharomyces cerevisiae"", PHARMACEUTICAL RESEARCH, vol. 23, 2006, pages 790 - 797, XP019405238, DOI: doi:10.1007/s11095-006-9778-7;;MARSHALL, C. J. ET AL.: ""An evolved Mxe GyrA intein for enhanced production of fusion proteins"", ACS CHEM BIOL, vol. 10, 2015, pages 527 - 538;;HUANG, D.; GORE, P. R.; SHUSTA, E. V.: ""Increasing yeast secretion of heterologous proteins by regulating expression rates and post-secretory loss"", BIOTECHNOL BIOENG, vol. 101, 2008, pages 1264 - 1275;;BUMS, M. L. ET AL.: ""Directed evolution of brain-derived neurotrophic factor for improved folding and expression in Saccharomyces cerevisiae"", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 80, 2014, pages 5732 - 5742;;TILLOTSON, B. J.; CHO, Y. K.; SHUSTA, E. V.: ""Cells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface display"", METHODS, vol. 60, 2013, pages 27 - 37;;GALLI, R. ET AL.: ""Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma"", CANCER RESEARCH, vol. 64, 2004, pages 7011 - 7021, XP002550845, DOI: doi:10.1158/0008-5472.CAN-04-1364;;YANG, Y. ET AL.: ""In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis"", EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 38, 2011, pages 2066 - 2076, XP019961557, DOI: doi:10.1007/s00259-011-1886-x",PENDING
627,WO,A1,WO 2021/262746 A1,020-835-261-964-117,2021-12-30,2021,US 2021/0038525 W,2021-06-22,US 202063043521 P,2020-06-24,PROCESS FOR SYNTHESIZING LIPIDS,"The present application provides processes for synthesizing lipids of Formula I useful in the synthesis of fat-soluble compounds for targeting and enhancing activity of therapeutic molecules, including siRNA.",BRISTOL MYERS SQUIBB CO,BEUTNER GREGORY LOUIS;;LORA GONZALEZ FEDERICO;;CHO PATRICIA Y;;SMITH MICHAEL J,,https://lens.org/020-835-261-964-117,Patent Application,yes,4,0,11,11,0,C07C319/20;;Y02P20/55;;C07C319/20;;C07C321/14;;C07C319/14;;C07C323/41,A61K31/713;;A61K47/18;;A61K47/54,,0,0,,,,PENDING
628,EP,A1,EP 4133009 A1,051-104-693-095-432,2023-02-15,2023,EP 21730312 A,2021-04-05,US 202063005948 P;;US 2021/0025737 W,2020-04-06,"ULTRA-LOW FRICTION MATERIALS FOR LUBRICATING SURFACES, DEVICES THEREWITH, AND METHODS OF MANUFACTURE AND USE THEREOF",,DURA LINE LLC,FAN FEI;;CHO SUNG KI;;LUKUBIRA SAM;;SPRADLING CALEB MICHAEL;;VALENCIA ARTURO,,https://lens.org/051-104-693-095-432,Patent Application,yes,0,0,9,9,0,C09D183/04;;C08K3/042;;C10N2030/06;;C10M2213/0623;;C10N2020/06;;C10N2020/04;;C10M2229/025;;C10M2205/022;;C10M157/10;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10M169/041;;C10M2201/0413;;C10M2205/022;;C10M2213/02;;C10M2213/0623;;C10M2229/025;;C10N2040/32;;C10N2050/08;;A47C27/001;;A47C27/002;;A47C27/04;;A47C27/20;;A47C31/001,C08L27/18;;C08J3/22;;C08K3/04;;C09D5/00;;C09D183/04;;F16L9/12,,0,0,,,,PENDING
629,US,B2,US 11304606 B2,105-289-684-116-992,2022-04-19,2022,US 201816182650 A,2018-11-07,US 201816182650 A,2018-11-07,Method and system for enhancing RF energy delivery during thermoacoustic imaging,"A method and system for enhancing radio frequency energy delivery to a tissue region of interest. The method and system direct with a radio frequency (RF) applicator, one or more RF energy pulses into the tissue region of interest, the tissue region of interest comprising an object of interest and at least one reference that are separated by at least one boundary; detect with an acoustic receiver, at least one bipolar acoustic signal generated in the tissue region of interest in response to the RF energy pulses and processing the at least one bipolar acoustic signal to determine a peak-to-peak amplitude thereof; adjust the RF applicator to maximize the peak-to-peak amplitude of bipolar acoustic signals generated in the tissue region of interest in response to RF energy pulses generated by the adjusted RF applicator; and direct with the adjusted RF applicator, one or more RF energy pulses into the region of interest.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,ENDRA LIFE SCIENCES INC (2019-01-24),https://lens.org/105-289-684-116-992,Granted Patent,yes,5,2,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B5/00;;A61B5/02;;A61B5/20,,4,3,033-786-059-395-583;;013-000-205-460-222;;067-917-708-067-522,10.1109/tbme.2012.2210218;;22851231;;pmc2774978;;19895126;;10.1117/1.3247155;;10.1109/ultsym.2011.0587,"Xiong Wang et al., “Microwave-Induced Thermoacoustic Imaging Model for Potential Breast Cancer Detection”, Oct. 2012, IEEE Transactions on Biomedical Engineering, vol. 59, No. 10, 2782-2791 (Year: 2012).;;Manojit Pramanik et al., “Thermoacoustic and Photoacoustic Sensing of Temperature”, Oct. 2009, Journal of Biomedical Optics, vol. 14(5) (Year: 2009).;;Daniel Bauer et al., “Thermoacoustic Imaging and Spectroscopy for Enhanced Breast Cancer Detection”, 2011 IEEE International Ultrasonics Symposium Proceedings (Year: 2011).;;Shane Thomas; PCT International Search Report and Written Opinion; dated Jan. 27, 2020; 7 pages total; WIPO; Alexandria, VA, United States.",ACTIVE
630,US,A1,US 2003/0110171 A1,119-065-607-889-073,2003-06-12,2003,US 99138901 A,2001-11-21,US 99138901 A,2001-11-21,Methods and systems for selectively displaying advertisements,"
   A system, including a planning module, a control module and a receiver module, configured to schedule display of one or more advertising impressions of available advertising inventory. The planning module enables scheduling a requested quantity of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisement, assigning an advertising type and defining a weight for the advertisements. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisements. The one or more metadata files, with the advertisements, are delivered to the receiver module that is configured to define a display frequency for the advertisements based upon one or more of the metadata files. The receiver module selectively displays advertisement content associated with the advertisements to achieve the advertising impression goal. 
",OZER STUART;;HART MICHAEL PATRICK;;ADA CHO WEI WEI;;CHAU CAROLYN KHANH,OZER STUART;;HART MICHAEL PATRICK;;ADA CHO WEI WEI;;CHAU CAROLYN KHANH,ZHIGU HOLDINGS LIMITED (2016-05-16);;WEBTV NETWORKS INC (2001-11-19);;MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2002-06-28),https://lens.org/119-065-607-889-073,Patent Application,yes,23,214,8,8,0,G06Q30/02;;G06Q30/0241;;G06Q30/0248;;G06Q30/0252;;G06Q30/0254;;G06Q30/0264;;G06Q30/0269;;G06Q30/0272;;G06Q30/02;;G06Q30/0241;;G06Q30/0264;;G06Q30/0248;;G06Q30/0269;;G06Q30/0272;;G06Q30/0254;;G06Q30/0252;;Y10S707/99945;;Y10S707/99948;;Y10S707/99944;;Y10S707/99942;;Y10S707/99943,G06Q30/02,707 1,0,0,,,,EXPIRED
631,IL,A,IL 299263 A,101-667-690-714-788,2023-02-01,2023,IL 29926322 A,2022-12-19,US 202063043521 P;;US 2021/0038525 W,2020-06-24,Process for synthesizing lipids,,BRISTOL MYERS SQUIBB CO;;BEUTNER GREGORY LOUIS;;LORA GONZALEZ FEDERICO;;CHO PATRICIA Y;;SMITH MICHAEL J,BEUTNER GREGORY LOUIS;;LORA GONZALEZ FEDERICO;;CHO PATRICIA Y;;SMITH MICHAEL J,,https://lens.org/101-667-690-714-788,Patent Application,no,0,0,11,11,0,C07C319/20;;Y02P20/55;;C07C319/20;;C07C321/14;;C07C319/14;;C07C323/41,,,0,0,,,,PENDING
632,DE,T2,DE 69633840 T2,133-325-598-981-091,2005-12-01,2005,DE 69633840 T,1996-01-29,US 39397795 A,1995-02-24,Kosmetische Mittel zur Erhöhung der Kollagen-Synthese,,UNILEVER NV,ZNAIDEN ALEXANDER P;;CHENEY MICHAEL C;;SLAVTCHEFF CRAIG S;;CHO SUK H,,https://lens.org/133-325-598-981-091,Granted Patent,no,0,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
633,US,A1,US 2004/0243470 A1,154-468-770-628-143,2004-12-02,2004,US 86749304 A,2004-06-14,US 86749304 A;;US 99138901 A,2001-11-21,Methods and systems for selectively displaying advertisements,"
   A system, including a planning module, a control module and a receiver module, configured to schedule display of one or more advertising impressions of available advertising inventory. The planning module enables scheduling a requested quantity of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisement, assigning an advertising type and defining a weight for the advertisements. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisements. The one or more metadata files, with the advertisements, are delivered to the receiver module that is configured to define a display frequency for the advertisements based upon one or more of the metadata files. The receiver module selectively displays advertisement content associated with the advertisements to achieve the advertising impression goal. 
",MICROSOFT CORP,OZER STUART;;HART MICHAEL PATRICK;;ADA CHO WEI WEI;;CHAU CAROLYN KHANH,ZHIGU HOLDINGS LIMITED (2016-05-16);;WEBTV NETWORKS INC (2001-11-19);;MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2002-06-28),https://lens.org/154-468-770-628-143,Patent Application,yes,34,83,8,8,0,G06Q30/02;;G06Q30/0241;;G06Q30/0248;;G06Q30/0252;;G06Q30/0254;;G06Q30/0264;;G06Q30/0269;;G06Q30/0272;;G06Q30/02;;G06Q30/0241;;G06Q30/0264;;G06Q30/0248;;G06Q30/0269;;G06Q30/0272;;G06Q30/0254;;G06Q30/0252;;Y10S707/99945;;Y10S707/99948;;Y10S707/99944;;Y10S707/99942;;Y10S707/99943,G06Q30/02,705/14,0,0,,,,EXPIRED
634,US,B2,US 11752353 B2,063-921-414-715-201,2023-09-12,2023,US 202016990188 A,2020-08-11,US 202016990188 A;;US 201715783573 A,2017-10-13,Power management for implantable medical device systems,"Techniques for minimizing rate of depletion of a non-rechargeable power source, to extend the operational lifetime of an implantable medical device that includes the non-rechargeable power source, by enforcing operational-mode-specific communication protocols whereby inter-device communication between the implantable medical device and another implantable medical device is such that level of power draw from the non-rechargeable power source by the implantable medical device is less than level of power draw from the rechargeable power source by the another implantable medical device for the implantable medical devices to engage in communication with each other.",MEDTRONIC INC,DEMMER WADE M;;CHO YONG K;;HESS MICHAEL F;;SHELDON TODD J,MEDTRONIC INC (2017-10-10),https://lens.org/063-921-414-715-201,Granted Patent,yes,39,0,11,11,0,A61N1/3708;;A61N1/37288;;A61N1/3756;;A61N1/3787;;A61B5/318;;A61N1/3708;;A61B5/318;;A61N1/37512;;A61N1/37518;;A61N1/3684;;A61N1/37288;;A61N1/3756;;A61N1/3787,A61N1/378;;A61B5/318;;A61N1/368;;A61N1/37;;A61N1/372;;A61N1/375,,1,0,,,"Prosecution History from U.S. Appl. No. 15/783,573, dated Apr. 8, 2019 through Apr. 15, 2020, 53 pp.",ACTIVE
635,EP,A1,EP 3861228 A1,102-992-006-987-110,2021-08-11,2021,EP 19779891 A,2019-09-30,GB 201815999 A;;EP 2019076458 W,2018-10-01,BUSH,,DTR VMS LTD,GEISEN JAN;;MORTON JONATHAN;;STANKA CHRISTIAN;;LINES MICHAEL;;KAISER WERNER;;CHO SEONGDOSEONG,DN AUTOMOTIVE GERMANY GMBH (2023-12-20),https://lens.org/102-992-006-987-110,Patent Application,yes,0,0,5,5,0,F16F1/38;;F16F7/108;;F16F1/38;;F16F7/108;;F16F1/38;;F16F7/108,F16F1/38;;F16F7/108,,0,0,,,,PENDING
636,EP,A1,EP 4076394 A1,102-499-753-751-671,2022-10-26,2022,EP 20901754 A,2020-12-16,US 201962948472 P;;US 2020/0065207 W,2019-12-16,MAGNETIC MINIATURE DEVICE AND SYSTEM FOR REMOTELY MANEUVERING IT,,BIONAUT LABS LTD,CROS FLORENT;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;HARRINGTON DARRELL;;CHO SUEHYUN;;SARGSYAN HOVHANNES,,https://lens.org/102-499-753-751-671,Patent Application,yes,0,0,6,6,0,A61M25/0127;;A61M31/002;;A61K9/0009;;A61K9/4808;;A61M25/0127;;A61M31/002,A61K9/00;;A61K9/50;;A61K9/51;;A61K47/69;;A61K49/18;;A61M5/145;;A61M31/00,,0,0,,,,PENDING
637,EP,A1,EP 1986492 A1,120-835-330-156-494,2008-11-05,2008,EP 07701544 A,2007-02-26,AU 2007/000215 W;;AU 2006/200814 A;;US 77684206 P,2006-02-24,METHOD AND SYSTEM FOR CONTROLLING TERMITES,,COMMW SCIENT IND RES ORG;;NEWSOUTH INNOVATIONS PTY LTD,EVANS THEODORE ALFRED;;LENZ MICHAEL;;LAI JOSEPH CHO SAM;;INTA RA ATA,,https://lens.org/120-835-330-156-494,Patent Application,yes,0,0,5,7,0,A01M1/023;;A01M1/026;;A01M1/24;;A01M29/16;;A01M2200/011;;A01M1/023;;A01M1/24;;A01M29/16;;A01M2200/011;;A01M1/026,A01M1/20;;A01M1/22;;A01M29/16,,0,0,,,,DISCONTINUED
638,CN,A,CN 112969416 A,176-690-671-491-319,2021-06-15,2021,CN 201980073250 A,2019-11-07,US 201816182650 A;;US 2019/0060293 W,2018-11-07,METHOD AND SYSTEM FOR ENHANCING RF ENERGY DELIVERY DURING THERMOACOUSTIC IMAGING,"A method and system for enhancing radio frequency energy delivery to a tissue region of interest. The method and system direct with a radio frequency (RF) applicator, one or more RF energy pulses into the tissue region of interest, the tissue region of interest comprising an object of interest and at least one reference that are separated by at least one boundary; detect with an acoustic receiver, at least one bipolar acoustic signal generated in the tissue region of interest in response to the RF energy pulses and processing the at least one bipolar acoustic signal to determine a peak-to-peak amplitude thereof; adjust the RF applicator to maximize the peak-to-peak amplitude of bipolar acoustic signals generated in the tissue region of interest in response to RF energy pulses generated by the adjusted RF applicator; and direct with the adjusted RF applicator, one or more RF energy pulses into the region of interest.",ENDRA LIFE SCIENCES INC,DAVIS CHRISTOPHER NELSON;;CHO JANG-HWAN;;PICOT PAUL A;;THORNTON MICHAEL M,,https://lens.org/176-690-671-491-319,Patent Application,no,0,0,6,6,0,A61B5/0093;;A61B5/201;;A61B5/4244;;A61B5/4872;;A61B5/0093;;A61B5/4872;;A61B5/4244;;A61B5/201;;A61B5/02007,A61B8/08;;A61B5/00,,0,0,,,,PENDING
639,US,A1,US 2015/0133711 A1,186-955-051-706-079,2015-05-14,2015,US 201514597415 A,2015-01-15,US 201514597415 A;;US 201313948861 A,2013-07-23,Separations With Ionic Liquid Solvents,"Disclosed are systems and methods which provide a process stream comprising a gaseous component, capture the gaseous component from the process stream by an ionic liquid solvent of a separator, and recover a captured gaseous component from the ionic liquid solvent in a regenerator. A second gaseous component from the process stream may be captured by the ionic liquid solvent of the separator, and the second gaseous component may be recovered from the ionic liquid solvent in the regenerator. Alternatively, the second gaseous component from the process stream may be uncaptured by the ionic liquid solvent, and the uncaptured second gaseous component may be recovered from a membrane unit.",CHEVRON PHILLIPS CHEMICAL CO;;CHEVRON USA INC,JI LEI;;CHANG AI-FU;;DRIVER MICHAEL SEAN;;TIMKEN HYE-KYUNG CHO,CHEVRON U.S.A. INC (2015-01-05);;CHEVRON PHILLIPS CHEMICAL COMPANY LP (2014-12-16),https://lens.org/186-955-051-706-079,Patent Application,yes,5,7,2,34,0,B01D53/1462;;B01D53/1462;;B01D53/1487;;B01D53/1487;;B01D53/1493;;B01D53/1493;;B01D53/229;;B01D53/229;;B01D53/526;;B01D53/526;;B01D2252/30;;B01D2252/30;;B01D2256/22;;B01D2256/22;;B01D2256/24;;B01D2256/24;;B01D2257/304;;B01D2257/304;;B01D2257/504;;B01D2257/504;;B01D2257/7022;;B01D2257/7022;;C07C7/11;;C07C7/11;;C01B17/167;;C01B17/167;;C07C7/144;;C07C7/144;;C07C7/152;;C07C7/152;;Y02P20/151;;Y02P20/151;;Y02P20/50;;Y02P20/50;;Y02P20/54;;Y02P20/54,C07C7/11;;B01D53/14;;C07C7/00;;C07C7/144,585/802;;585/844,2,0,,,"DE10333546A1_English Translation 2005;;L.M. Galan Sanchez, ""Functionalized Ionic Liquids: Absorption Solvents for Carbon Dioxide and Olefin Separation"", Doctoral Thesis, Eindhoven University of Technology Library, The Netherlands, 2008, ISBN: 978-90-386-1468-7.",ACTIVE
640,EP,A1,EP 3694601 A1,056-883-987-025-023,2020-08-19,2020,EP 18786636 A,2018-09-28,US 201715783573 A;;US 2018/0053354 W,2017-10-13,POWER MANAGEMENT FOR IMPLANTABLE MEDICAL DEVICE SYSTEMS,,MEDTRONIC INC,DEMMER WADE M;;CHO YONG K;;HESS MICHAEL F;;SHELDON TODD J,,https://lens.org/056-883-987-025-023,Patent Application,yes,0,0,11,11,0,A61N1/3708;;A61N1/37288;;A61N1/3756;;A61N1/3787;;A61B5/318;;A61N1/3708;;A61B5/318;;A61N1/37512;;A61N1/37518;;A61N1/3684;;A61N1/37288;;A61N1/3756;;A61N1/3787,A61N1/372;;A61N1/375,,0,0,,,,ACTIVE
641,US,A1,US 2023/0263849 A1,098-136-787-805-492,2023-08-24,2023,US 202318174111 A,2023-02-24,US 202318174111 A;;US 202263372209 P,2022-02-24,FUNCTIONALIZED CELLULOSE NANOCRYSTALS STABILIZED SMART PICKERING EMULSION FOR ENHANCED PROBIOTIC DELIVERY,"The efficacy in the use of probiotics is compromised due to their lack of survivability in gastric conditions (pH 1.5-3), leading to a large reduction in viable probiotic cells. The present disclosure describes cellulose nanocrystals (CNCs) modified with ferulic acid (FA) and shellac (SH) to produce two types of new coating materials, which are environment friendly and harmless to humans. These coating materials were developed and utilized to formulate Pickering emulsions (W 1 /O/W 2 and W/O) for probiotic encapsulation. Based on their pKa values, greater than pKa, carboxyl groups from the CNCFA and CNCSH based Pickering emulsions were deprotonated, inducing phase separation and allow yeast releasing. This system could be further investigated for functionalized food-based applications to deliver active substances, such as probiotics, at high pH. Such delivery systems can be applied to human, animal, and aquatic systems.",UNIV WATERLOO,TAM MICHAEL KAM CHIU;;BAEK JIYOO;;RAMASAMY MOHANKANDHASAMY;;CHO GUN-HEE DAVID,UNIVERSITY OF WATERLOO (2023-02-14),https://lens.org/098-136-787-805-492,Patent Application,yes,0,0,1,1,0,A61K9/113;;A61K9/146;;A61K9/5161;;A23L33/135;;A23P10/30;;A61K36/064;;A61K9/113;;A61K47/12;;C12Q1/06;;A61K47/36;;A61K47/02;;A61K47/38,A61K36/064;;A61K9/113;;A61K47/02;;A61K47/12;;A61K47/36;;A61K47/38;;C12Q1/06,,0,0,,,,PENDING
642,US,B2,US 11374636 B2,119-244-371-679-486,2022-06-28,2022,US 202016737116 A,2020-01-08,US 202016737116 A,2020-01-08,System and method for nullforming with anti-jam antenna electronics,"An antenna system may include an antenna array configured to receive one or more signals. In embodiments, the antenna system further includes one or more signal processors configured to: determine a beamforming weight vector (W bf ) for the antenna array; determine a first seeding weight vector (W seed1 ) for the antenna array, wherein the first seeding weight vector (W seed1 ) comprises a first nulling weight vector (W nul1 ) or a second beamforming weight vector (W bf ); determine a first nullforming adjustment factor (η 1 ) for the antenna array; calculate a first nullforming weight vector (W nf1 ) based on at least the beamforming weight vector (W bf ), the first seeding weight vector (W seed1 ) and the first nullforming adjustment factor (η 1 ); and form a first antenna pattern based on the first nullforming weight vector (W nf1 ) to generate a first antenna electronics (AE) output signal, wherein the first antenna pattern generates a first set of one or more nulls.",ROCKWELL COLLINS INC,LAI YING CHO;;BISHOP JEFFREY B;;HERTING BRIAN J;;STOCKMASTER MICHAEL H,ROCKWELL COLLINS INC (2019-12-17),https://lens.org/119-244-371-679-486,Granted Patent,yes,11,0,3,3,0,H04B7/0617;;H01Q3/2617;;H04B7/0617;;H04B7/086,H04B7/06;;H01Q3/26;;H04B7/08,,1,0,,,"Extended Search Report for European Application No. 21150763.7 dated Mar. 16, 2021, 8 pages.",ACTIVE
643,US,B2,US 11233485 B2,119-982-853-301-261,2022-01-25,2022,US 202016816430 A,2020-03-12,US 202016816430 A,2020-03-12,Power amplifier linearization circuit and related apparatus,"A power amplifier linearization circuit and related apparatus is provided. In examples disclosed herein, the power amplifier linearization circuit includes an analog pre-distortion (APD) circuit coupled to an input of a power amplifier. Notably, the power amplifier can exhibit linearity response deviation, namely linearity amplitude response deviation and linearity phase response deviation, when amplifying a radio frequency (RF) signal under a compression condition. As such, the APD circuit is configured to receive a control signal corresponding to the linearity response deviation and pre-process the RF signal based on the control signal before providing the RF signal to the power amplifier. As a result, it may be possible to reduce the linearity response deviation in the power amplifier, thus helping to improve linearity and RF performance of the power amplifier.",QORVO US INC,ZYBURA MICHAEL F;;MORIUCHI TOSHIAKI;;SCOTT BAKER;;CHO MIKYUNG;;SPEARS EDWARD T,QORVO US INC (2020-02-18),https://lens.org/119-982-853-301-261,Granted Patent,yes,6,2,2,2,0,H03F1/3241;;H03F2200/451;;H03F3/19;;H03F1/3241;;H03F2201/3231;;H03F2200/451;;H03F3/21,H03F1/32;;H03F3/21,,4,4,169-128-461-689-624;;066-910-788-075-005;;000-004-302-309-432;;034-267-198-297-627,10.1109/tmtt.2019.2914900;;10.1109/apmc.2009.5385385;;10.1109/mwsym.1996.512194;;10.1109/apmc.2006.4429554,"Ali, Sheikh Nijam., et al., “Transformer-based predistortion linearizer for high linearity and high modulation efficiency in mm-wave 5G CMOS power amplifiers,” IEEE Transactions on Microwave Theory and Techniques, vol. 67, No. 7, Jul. 2019, pp. 3074-3087.;;Ando, Akihiro, et al. “A predistortion linearizer for a class-F GaN HEMT power amplifier using two independently controlled diodes,” Asia-Pacific Microwave Conf., 2009, IEEE, pp. 269-272.;;Leke, Achankeng et al.“Behavioral modeling of narrowband microwave power amplifiers with applications in simulating spectral regrowth,” IEEE MTT-S Digest, 1996, pp. 1385-1388.;;Yamauchi, K. et al., “Series anti-parallel diode linearizer for class-B power amplifiers with a gain expansion,” Asia-Pacific Microwave Conf., 2006, 4 pages.",ACTIVE
644,US,B2,US 6713409 B2,142-310-108-698-459,2004-03-30,2004,US 30328002 A,2002-11-25,US 30328002 A;;US 64237600 A,2000-08-21,Semiconductor manufacturing using modular substrates,"
    A manufacturing method using a modular substrate-based processing scheme for producing semiconductor devices, provides multiple modular processing units which may be arranged together to form any of various cohesive processing units or individually or sequentially processed through standard semiconductor processing equipment. The cohesive processing units are processed unitarily providing for multiple modular processing units to be processed simultaneously. The modular processing units may be formed of a thick semiconductor substrate or a semiconductor substrate mounted on a further substrate such as a ceramic material. The modular processing units may each contain ribs, grooves, posts or other features to aid in handling and placement of the individual units. 
",AGERE SYSTEMS INC,ANTONELL MICHAEL;;HOUGE ERIK CHO;;PATEL NITIN;;PLEW LARRY E;;VARTULI CATHERINE,BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04),https://lens.org/142-310-108-698-459,Granted Patent,yes,11,0,3,3,0,H01L21/67346;;H01L21/67346;;H01L22/20;;H01L22/20;;H01L22/34;;H01L22/34,H01L21/00;;H01L21/66;;H01L21/673;;H01L23/06;;H01L23/544,438/800;;257/684;;257/701;;257/706;;257/717;;257/719;;257/730;;257/735;;257/777,0,0,,,,EXPIRED
645,US,A1,US 2003/0021782 A1,168-027-200-960-675,2003-01-30,2003,US 91092001 A,2001-07-24,US 91092001 A,2001-07-24,Chlamydia infection,"
   Chlamydia binds to the mannose-6-phosphate receptor on mammalian cells. Molecules that prevent binding of elementary bodies to the mammalian cells can be therapeutically beneficial in treating and/or preventing Chlamydial infection. 
",KUO CHO-CHOU;;LIN TSUN-MEI;;CAMPBELL LEE ANN;;ROSENFELD MICHAEL E.,KUO CHO-CHOU;;LIN TSUN-MEI;;CAMPBELL LEE ANN;;ROSENFELD MICHAEL E,THE UNIVERSITY OF WASHINGTON (2001-08-21),https://lens.org/168-027-200-960-675,Patent Application,yes,0,0,1,1,0,A61K2039/505;;C07K16/28;;C07K16/28;;A61K2039/505,C07K16/28,424/145.1,0,0,,,,DISCONTINUED
646,US,A1,US 2008/0202101 A1,187-951-905-427-582,2008-08-28,2008,US 70980907 A,2007-02-23,US 70980907 A,2007-02-23,Exhaust treatment system,"An exhaust gas treatment system of an internal combustion engine includes a selective catalytic reduction catalyst fluidly connected to the internal combustion engine, a particulate filter fluidly connected downstream of the selective catalytic reduction catalyst, and an induction line configured to direct a portion of a filtered exhaust flow of the internal combustion engine toward an inlet of the engine.",DRISCOLL JAMES J;;LIANG CHO Y;;ROBEL WADE J;;WOODS MICHAEL L,DRISCOLL JAMES J;;LIANG CHO Y;;ROBEL WADE J;;WOODS MICHAEL L,CATERPILLAR INC (2007-06-18),https://lens.org/187-951-905-427-582,Patent Application,yes,17,32,2,2,0,F01N3/206;;F01N3/206;;F01N3/035;;F01N3/035;;F01N3/0821;;F01N3/0821;;F01N3/2066;;F01N3/2066;;F01N13/009;;F01N13/009;;F01N2250/02;;F01N2250/02;;F02B29/0406;;F02B29/0406;;F02M26/08;;F02M26/08;;F02M26/15;;F02M26/15;;F02M26/28;;F02M26/28;;Y02T10/12;;Y02T10/12,F01N3/00,60/286,0,0,,,,DISCONTINUED
647,CN,A,CN 101483996 A,024-742-373-595-160,2009-07-15,2009,CN 200780014647 A,2007-02-26,AU 2006/200814 A,2006-02-24,Method and system for controlling termites,"A method of controlling pest termites. A vibrational signal which is perceptible to and behaviourally influential upon the pest termites is generated, and coupled into a medium for perception by the pest termites. Repellent termite alarm signals may be utilised. A new type of foraging signal is disclosed and may be applied to lure termites to a bait.",COMMW SCIENT IND RES ORG,ALFRED EVANS THEODORE;;MICHAEL LENZ;;SAM LAI JOSEPH CHO;;ATA INTA RA,,https://lens.org/024-742-373-595-160,Patent Application,no,0,4,2,7,0,,A01M1/22,,0,0,,,,DISCONTINUED
648,US,A1,US 2024/0058492 A1,064-409-374-193-19X,2024-02-22,2024,US 202318386831 A,2023-11-03,US 202318386831 A;;US 2022/0029858 W;;US 202163190041 P,2021-05-18,NASAL ANTISEPTIC,An antimicrobial composition comprising: (1) povidone iodine (PVP-I) in a concentration of 5 to 10% w/w of the composition; and (2) carboxymethylcellulose (CMC) in a concentration of 0.1 to 5 % w/w of the composition.,POVINEZ LLC,PARVIZI JAVAD;;YAYAC MICHAEL;;CHISARI EMANUELE;;BRITTAIN HARRY;;CHO JEONGEUN;;PARMAR MAYANK,POVINEZ LLC (2022-07-05),https://lens.org/064-409-374-193-19X,Patent Application,yes,0,0,4,4,0,A61P31/00;;A61K47/38;;A61K33/18;;A61K9/0043;;A61K31/717;;A61L2101/50;;A61L2/18,A61L2/18,,0,0,,,,PENDING
649,EP,A1,EP 3627300 A1,119-908-535-212-081,2020-03-25,2020,EP 19199074 A,2019-09-24,US 201862735496 P;;US 201816221090 A,2018-09-24,APPLICATION BUILDER,"Disclosed herein are system, method, and computer program product embodiments for unifying graphical user interface (GUI) displays across different device types. In an embodiment, a unification system may convert various GUI view appearing on, for example, a desktop device into a GUI view on a mobile device. Both devices may be accessing the same application and/or may use a cloud computing platform to access the application. The unification system may aid in reproducing GUI modifications performed on one user device onto other user devices. In this manner, the unification system may maintain a consistent look-and- feel for a user across different computing device type.
",SALESFORCE COM INC,JACOBSON ERIC;;GONZALEZ MICHAEL;;CHO WAYNE;;VARADARAJAN ADHEIP;;VOLLMER JOHN;;SNYDER BENJAMIN,,https://lens.org/119-908-535-212-081,Patent Application,yes,5,0,6,17,0,G06F8/34;;G06F8/38;;G06F3/0482;;G06F3/0483;;G06F3/04845,G06F3/048;;G06F8/34,,1,0,,,"BOOTSTRAP STUDIO: ""Creating a Website with Bootstrap Studio (Tutorial)"", YOUTUBE, 17 August 2016 (2016-08-17), pages 1 pp., XP054979963, Retrieved from the Internet <URL:https://www.youtube.com/watch?v=10SwsoYNkVc> [retrieved on 20191129]",PENDING
650,CA,A1,CA 3183522 A1,183-225-888-970-935,2021-12-30,2021,CA 3183522 A,2021-06-22,US 202063043521 P;;US 2021/0038525 W,2020-06-24,PROCESS FOR SYNTHESIZING LIPIDS,"The present application provides processes for synthesizing lipids of Formula I useful in the synthesis of fat-soluble compounds for targeting and enhancing activity of therapeutic molecules, including siRNA.",BRISTOL MYERS SQUIBB CO,BEUTNER GREGORY LOUIS;;LORA GONZALEZ FEDERICO;;CHO PATRICIA Y;;SMITH MICHAEL J,,https://lens.org/183-225-888-970-935,Patent Application,no,0,0,11,11,0,C07C319/20;;Y02P20/55;;C07C319/20;;C07C321/14;;C07C319/14;;C07C323/41,A61K31/713;;A61K47/18;;A61K47/54,,0,0,,,,PENDING
651,EP,B1,EP 3694601 B1,187-227-098-498-271,2023-12-13,2023,EP 18786636 A,2018-09-28,US 201715783573 A;;US 2018/0053354 W,2017-10-13,POWER MANAGEMENT FOR IMPLANTABLE MEDICAL DEVICE SYSTEMS,,MEDTRONIC INC,DEMMER WADE M;;CHO YONG K;;HESS MICHAEL F;;SHELDON TODD J,,https://lens.org/187-227-098-498-271,Granted Patent,yes,5,0,11,11,0,A61N1/3708;;A61N1/37288;;A61N1/3756;;A61N1/3787;;A61B5/318;;A61N1/3708;;A61B5/318;;A61N1/37512;;A61N1/37518;;A61N1/3684;;A61N1/37288;;A61N1/3756;;A61N1/3787,A61N1/372;;A61N1/375,,0,0,,,,ACTIVE
652,US,A1,US 2003/0063967 A1,049-108-038-088-750,2003-04-03,2003,US 96615601 A,2001-09-28,US 96615601 A,2001-09-28,Method and apparatus for minimizing semiconductor wafer contamination,"
    A method and apparatus for minimizing the surface contamination of semiconductor wafers ( 11 ) during the semiconductor device manufacturing process. Semiconductor wafers ( 11 ) are stored in a storage cassette ( 12 ) with their face sides ( 17 ) facing downward and their back sides ( 16 ) facing upward. Particulate contamination present on the back sides of the wafers is thereby secured to the wafers by the force of gravity, and the faces of the wafers are shielded from falling debris. An automated wafer handling device ( 19 ) is provided with a rotary joint ( 22 ) to accomplish the wafer flipping motion before inserting a wafer into a cassette and after removing the wafer from the cassette. 
",ANTONELL MICHAEL;;HOUGE ERIK CHO;;PLEW LARRY E.;;VARTULI CATHERINE;;JUSZCZAK JENNIFER,ANTONELL MICHAEL;;HOUGE ERIK CHO;;PLEW LARRY E;;VARTULI CATHERINE;;JUSZCZAK JENNIFER,AGERE SYSTEMS INC (2001-09-28);;BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04),https://lens.org/049-108-038-088-750,Patent Application,yes,0,4,2,2,0,H01L21/6732;;H01L21/6732,B65G49/07;;H01L21/673,414/416.03;;414/416.08;;414/758;;414/937;;414/936,0,0,,,,EXPIRED
653,US,A1,US 2021/0321873 A1,048-239-665-874-172,2021-10-21,2021,US 202117230480 A,2021-04-14,US 202117230480 A;;US 202063013476 P,2020-04-21,THERMOACOUSTIC TRANSDUCER WITH INTEGRATED SWITCH,"A thermoacoustic transducer integrating at least one piezoelectric element having a first surface and a second surface, a potential electrode that is electrically connected to the second surface, a ground electrode that is electrically connected to the first surface, a switch electrically connected to both the potential electrode and the ground electrode, a timer configured to match a pulse emanating from a radio-frequency emitter, further wherein the potential electrode and the ground electrode are electrically connected through an impedance when the switch is in an active state, further wherein the potential electrode and the ground electrode are not electrically connected when the switch is in an inactive state; and a housing accommodating the at least one piezoelectric element, potential electrode, ground electrode, and switch.",ENDRA LIFE SCIENCES INC,MUMM ZACKARY MARC;;DAVIS CHRISTOPHER NELSON;;THORNTON MICHAEL M;;CHO JANG HWAN,ENDRA LIFE SCIENCES INC (2021-09-27),https://lens.org/048-239-665-874-172,Patent Application,yes,0,0,7,7,0,G01H11/08;;G01N2291/106;;G01N29/2431;;G01N29/2437;;G01N29/343;;G01N29/0645;;G01N29/0654;;G01N29/50;;A61B5/0093;;A61B5/0035;;A61B5/0507;;A61B5/7225;;A61B5/7217;;A61B8/085;;A61B8/5261;;A61B5/0093;;A61B5/05;;A61B5/7217;;G01N29/2431;;A61B5/7225;;B06B1/0607;;A61B5/0035,A61B5/00;;A61B5/05;;B06B1/06;;G01N29/24,,0,0,,,,ACTIVE
654,US,B1,US 6534851 B1,053-787-787-773-028,2003-03-18,2003,US 64237600 A,2000-08-21,US 64237600 A,2000-08-21,Modular semiconductor substrates,"
    A modular substrate-based processing scheme for producing semiconductor devices provides multiple modular processing units which may be arranged together to form any of various cohesive processing units or they may be individually or sequentially processed through standard semiconductor processing equipment. The cohesive processing units are processed unitarily providing for multiple modular processing units to be processed simultaneously. The modular processing units may be formed of a thick semiconductor substrate or a semiconductor substrate mounted on a further substrate such as a ceramic material. The modular processing units may each contain ribs, grooves, posts or other features to aid in handling and placement of the individual units. 
",AGERE SYSTEMS INC,ANTONELL MICHAEL;;HOUGE ERIK CHO;;PATEL NITIN;;PLEW LARRY E;;VARTULI CATHERINE,BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04);;LUCENT TECHNOLOGIES INC (2000-07-31),https://lens.org/053-787-787-773-028,Granted Patent,yes,6,0,3,3,0,H01L21/67346;;H01L21/67346;;H01L22/20;;H01L22/20;;H01L22/34;;H01L22/34,H01L21/00;;H01L21/66;;H01L21/673;;H01L23/06;;H01L23/544,257/684;;257/723;;257/724;;257/707,0,0,,,,EXPIRED
655,WO,A1,WO 2022/245963 A1,059-597-999-322-166,2022-11-24,2022,US 2022/0029858 W,2022-05-18,US 202163190041 P,2021-05-18,NASAL ANTISEPTIC,An antimicrobial composition comprising: (1) povidone iodine (PVP-I) in a concentration of 5 to 10 % w/w of the composition; and (2) carboxymethylcellulose (CMC) in a concentration of 0.1 to 5 % w/w of the composition.,PARVIZI JAVAD;;YAYAC MICHAEL;;CHISARI EMANUELE;;BRITTAIN HARRY;;CHO JEONGEUN;;PARMAR MAYANK,PARVIZI JAVAD;;YAYAC MICHAEL;;CHISARI EMANUELE;;BRITTAIN HARRY;;CHO JEONGEUN;;PARMAR MAYANK,,https://lens.org/059-597-999-322-166,Patent Application,yes,4,0,4,4,0,A61P31/00;;A61K47/38;;A61K33/18;;A61K9/0043;;A61K31/717;;A61L2101/50;;A61L2/18,A61K33/18;;A61K9/00;;A61K31/79;;A61K47/36;;A61K47/38;;A61P31/00,,0,0,,,,PENDING
656,US,A1,US 2023/0250056 A1,071-465-686-393-422,2023-08-10,2023,US 202118003228 A,2021-06-22,US 202118003228 A;;US 202063043521 P;;US 2021/0038525 W,2020-06-24,PROCESS FOR SYNTHESIZING LIPIDS,"The present application provides processes for synthesizing lipids of Formula I useful in the synthesis of fat-soluble compounds for targeting and enhancing activity of therapeutic molecules, including siRNA.",BRISTOL MYERS SQUIBB CO,BEUTNER GREGORY LOUIS;;LORA GONZALEZ FEDERICO;;CHO PATRICIA Y;;SMITH MICHAEL J,BRISTOL-MYERS SQUIBB COMPANY (2022-04-04),https://lens.org/071-465-686-393-422,Patent Application,yes,0,0,11,11,0,C07C319/20;;Y02P20/55;;C07C319/20;;C07C321/14;;C07C319/14;;C07C323/41,C07C323/41;;C07C319/14,,0,0,,,,PENDING
657,EP,A1,EP 3244987 A1,071-947-181-530-980,2017-11-22,2017,EP 15702329 A,2015-01-15,US 2015/0011558 W;;US 201514597415 A,2015-01-15,SEPARATIONS WITH IONIC LIQUID SOLVENTS,,CHEVRON PHILLIPS CHEMICAL CO LP;;CHEVRON USA INC,JI LEI;;CHANG AI-FU;;DRIVER MICHAEL SEAN;;TIMKEN HYE-KYUNG CHO,,https://lens.org/071-947-181-530-980,Patent Application,yes,0,0,9,34,0,B01D53/1487;;B01D53/1493;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05;;B01D53/1493;;B01D53/1487;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05,B01D53/14,,0,0,,,,ACTIVE
658,US,B2,US 8295203 B2,079-179-446-252-093,2012-10-23,2012,US 6070908 A,2008-04-01,US 6070908 A;;US 95778207 P,2007-08-24,Methods and systems to store state used to forward multicast traffic,Methods and systems are described to store state used to forward multicast traffic. The system includes a receiving module to receive request to add a first node to a membership tree. The membership tree includes a first plurality of nodes associated with a multicast group. The system further includes a processing module to identify a second node in the first plurality of nodes and to communicate a node identifier that identifies the first node over a network to the second node. The node identifier is to be stored at the second node to add the first node to the membership tree. The node identifier is further to be stored in the membership tree exclusively at the second node to enable the second node to forward the multicast traffic to the first node.,RAMAKRISHNAN KADANGODE K;;SRIVASTAVA DIVESH;;CHO TAE W;;ZHANG YIN;;RABINOVICH MICHAEL;;AT & T IP I LP,RAMAKRISHNAN KADANGODE K;;SRIVASTAVA DIVESH;;CHO TAE W;;ZHANG YIN;;RABINOVICH MICHAEL,AT&T INTELLECTUAL PROPERTY I L.P (2008-02-29),https://lens.org/079-179-446-252-093,Granted Patent,yes,24,8,8,8,0,H04L12/1886;;H04L45/16;;H04L45/48;;H04L12/1886;;H04L45/48;;H04L45/16,H04L12/28,370/256;;370/312;;370/390;;370/432;;455/519,1,0,,,"Cui, Jun-Hong, et al., ""An Architecture for Scalable QoS Multicast Provisioning"", UCLA CSD TR # 010030, http://citeseer.ist.psu.edu/cui01architecture.html, (2001), 21 pgs.",ACTIVE
659,EP,A1,EP 4171579 A1,080-390-601-538-008,2023-05-03,2023,EP 21829943 A,2021-06-22,US 202063043521 P;;US 2021/0038525 W,2020-06-24,PROCESS FOR SYNTHESIZING LIPIDS,,BRISTOL MYERS SQUIBB CO,BEUTNER GREGORY LOUIS;;LORA GONZALEZ FEDERICO;;CHO PATRICIA Y;;SMITH MICHAEL J,,https://lens.org/080-390-601-538-008,Patent Application,yes,0,0,11,11,0,C07C319/20;;Y02P20/55;;C07C319/20;;C07C321/14;;C07C319/14;;C07C323/41,A61K31/713;;A61K47/18;;A61K47/54,,0,0,,,,PENDING
660,US,A1,US 2022/0409871 A1,123-474-235-016-969,2022-12-29,2022,US 202017772999 A,2020-11-04,US 202017772999 A;;US 201962930863 P;;US 2020/0058964 W,2019-11-05,SYSTEM AND MINIATURE DEVICES FOR DELIVERING A THERAPEUTIC COMPONENT TO A TREATMENT SITE IN A PATIENT,"A miniature device is provided for use in a system configured to deliver a therapeutic component to a treatment site in a patient. The miniature device comprises at least one steering portion comprising a magnetic material, and at least one carrier portion affixed to the steering portion and comprising the therapeutic component. The carrier portion is configured to at least partially dissipate under one or more predetermined conditions at the treatment site, thereby releasing the therapeutic component. Further provided is a system comprising one or more such miniature devices and a magnetic inducing apparatus configured to be operated to generate a varying magnetic field, thereby remotely controlling motion of the miniature device.",BIONAUT LABS LTD,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CROS FLORENT;;HARRINGTON DARRELL;;CHO SUEHYUN;;CAPUTO JOHN,BIONAUT LABS LTD (2020-08-31),https://lens.org/123-474-235-016-969,Patent Application,yes,0,0,6,6,0,A61K9/0009;;A61K9/0007;;A61M25/0127;;A61M31/002;;A61K45/06;;A61M31/002;;A61M2205/3515,A61M31/00;;A61K45/06,,0,0,,,,PENDING
661,US,B1,US 7317480 B1,162-515-246-748-420,2008-01-08,2008,US 66001 A,2001-10-30,US 66001 A;;US 25432800 P;;US 24441200 P,2000-10-30,Imaging apparatus providing black level compensation of a successive approximation A/D converter,"Image sensor with a successive approximation A/D converter that automatically compensates for black level and provides a signal indicative of the difference between the reset level and the signal level. Black level for each of a plurality of color pixels may be obtained. This may be obtained from, for example, an image sensor with intentionally darkened pixels. Levels from these pixels are sampled, and an average of these pixels is used to form a black level for similarly-colored pixels. That black level is stored, and used to drive a D/A converter. Another D/A converter forms the actual conversion, and is compared to a reference. The reference is selected such that the output signal is automatically compensated for black level, and also corresponds to the difference between signal and reset.",MICRON TECHNOLOGY INC,CHO KWANG-BO;;KAPLINSKY MICHAEL;;BARNA SANDOR L;;TOROS ZEYNEP;;SUBBOTIN IGOR,PHOTOBIT CORPORATION (2001-10-30);;APTINA IMAGING CORPORATION (2008-09-26);;MICRON TECHNOLOGY INC (2001-11-21),https://lens.org/162-515-246-748-420,Granted Patent,yes,17,15,1,1,0,H03M1/1019;;H03M1/1215;;H03M1/46;;H04N25/63;;H04N25/70;;H04N25/76;;H03M1/1019;;H03M1/1215;;H03M1/46;;H04N25/63;;H04N25/70;;H04N25/76,H03M1/12;;H03M1/38;;H04N5/361;;H04N5/374;;H04N5/378;;H04N9/64,348/243;;348/241;;341/172,0,0,,,,ACTIVE
662,WO,A1,WO 2019/074691 A1,171-466-651-606-459,2019-04-18,2019,US 2018/0053354 W,2018-09-28,US 201715783573 A,2017-10-13,POWER MANAGEMENT FOR IMPLANTABLE MEDICAL DEVICE SYSTEMS,"Techniques for minimizing rate of depletion of a non-rechargeable power source, to extend the operational lifetime of an implantable medical device that includes the non-rechargeable power source, by enforcing operational-mode-specific communication protocols whereby inter-device communication between the implantable medical device and another implantable medical device is such that level of power draw from the non-rechargeable power source by the implantable medical device is less than level of power draw from the rechargeable power source by the another implantable medical device for the implantable medical devices to engage in communication with each other.",MEDTRONIC INC,DEMMER WADE M;;CHO YONG K;;HESS MICHAEL F;;SHELDON TODD J,,https://lens.org/171-466-651-606-459,Patent Application,yes,5,0,11,11,0,A61N1/3708;;A61N1/37288;;A61N1/3756;;A61N1/3787;;A61B5/318;;A61N1/3708;;A61B5/318;;A61N1/37512;;A61N1/37518;;A61N1/3684;;A61N1/37288;;A61N1/3756;;A61N1/3787,A61N1/372;;A61N1/375,,0,0,,,,PENDING
663,US,A1,US 2012/0033582 A1,007-491-970-054-012,2012-02-09,2012,US 201113277865 A,2011-10-20,US 201113277865 A;;US 6072308 A;;US 95778207 P,2007-08-24,METHODS AND SYSTEMS TO STORE STATE USED TO FORWARD MULTICAST TRAFFIC,"A method and system are described to multicast with an adaptive dual state. The system receives multicast traffic over a membership tree including a first plurality of nodes connected in a first topology destined for a plurality of multicast members of a first multicast group. Next, the system determines a rate of multicast traffic that exceeds a predetermined threshold based on the receiving the multicast traffic. Next, the system generates a dissemination tree including a second plurality of nodes connected in a second topology to reduce a number of hops to communicate the multicast traffic to the plurality of multicast members of the first multicast group. Finally, the system forwards the multicast traffic to the plurality of multicast members of the first multicast group over the dissemination tree.",RAMAKRISHNAN KADANGODE K;;SRIVASTAVA DIVESH;;CHO TAE WON;;ZHANG YIN;;RABINOVICH MICHAEL;;AT & T IP I LP,RAMAKRISHNAN KADANGODE K;;SRIVASTAVA DIVESH;;CHO TAE WON;;ZHANG YIN;;RABINOVICH MICHAEL,AT&T INTELLECTUAL PROPERTY I LP (2008-02-29),https://lens.org/007-491-970-054-012,Patent Application,yes,1,2,8,8,0,H04L12/1886;;H04L45/16;;H04L45/48;;H04L12/1886;;H04L45/48;;H04L45/16,H04L12/26;;H04L12/28,370/253;;370/254;;370/255,0,0,,,,INACTIVE
664,CA,A1,CA 3159322 A1,011-991-050-473-906,2021-05-14,2021,CA 3159322 A,2020-11-04,US 201962930863 P;;US 2020/0058964 W,2019-11-05,A SYSTEM AND MINIATURE DEVICES FOR DELIVERING A THERAPEUTIC COMPONENT TO A TREATMENT SITE IN A PATIENT,"A miniature device is provided for use in a system configured to deliver a therapeutic component to a treatment site in a patient. The miniature device comprises at least one steering portion comprising a magnetic material, and at least one carrier portion affixed to the steering portion and comprising the therapeutic component. The carrier portion is configured to at least partially dissipate under one or more predetermined conditions at the treatment site, thereby releasing the therapeutic component. Further provided is a system comprising one or more such miniature devices and a magnetic inducing apparatus configured to be operated to generate a varying magnetic field, thereby remotely controlling motion of the miniature device.",BIONAUT LABS LTD;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CROS FLORENT;;HARRINGTON DARRELL;;CHO SUEHYUN;;CAPUTO JOHN,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CROS FLORENT;;HARRINGTON DARRELL;;CHO SUEHYUN;;CAPUTO JOHN,,https://lens.org/011-991-050-473-906,Patent Application,no,0,0,6,6,0,A61K9/0009;;A61K9/0007;;A61M25/0127;;A61M31/002;;A61K45/06;;A61M31/002;;A61M2205/3515,A61M31/00;;A61K9/50;;A61K9/51;;A61K47/69;;A61M25/01,,0,0,,,,PENDING
665,US,A1,US 2021/0211170 A1,021-522-493-606-465,2021-07-08,2021,US 202016737116 A,2020-01-08,US 202016737116 A,2020-01-08,System and Method for Nullforming with Anti-Jam Antenna Electronics,"An antenna system may include an antenna array configured to receive one or more signals. In embodiments, the antenna system further includes one or more signal processors configured to: determine a beamforming weight vector (W bf ) for the antenna array; determine a first seeding weight vector (W seed1 ) for the antenna array, wherein the first seeding weight vector (W seed1 ) comprises a first nulling weight vector (W nul1 ) or a second beamforming weight vector (W bf ); determine a first nullforming adjustment factor (n 1 ) for the antenna array; calculate a first nullforming weight vector (W nf1 ) based on at least the beamforming weight vector (W bf ), the first seeding weight vector (W seed1 ) and the first nullforming adjustment factor (n 1 ); and form a first antenna pattern based on the first nullforming weight vector (W nf1 ) to generate a first antenna electronics (AE) output signal, wherein the first antenna pattern generates a first set of one or more nulls.",ROCKWELL COLLINS INC,LAI YING CHO;;BISHOP JEFFREY B;;HERTING BRIAN J;;STOCKMASTER MICHAEL H,ROCKWELL COLLINS INC (2019-12-17),https://lens.org/021-522-493-606-465,Patent Application,yes,0,0,3,3,0,H04B7/0617;;H01Q3/2617;;H04B7/0617;;H04B7/086,H04B7/06;;H01Q3/26;;H04B7/08,,0,0,,,,ACTIVE
666,US,A1,US 2004/0243623 A1,053-765-011-734-729,2004-12-02,2004,US 86968204 A,2004-06-16,US 86968204 A;;US 99138901 A,2001-11-21,Methods and systems for selectively displaying advertisements,"
   A system, including a planning module, a control module and a receiver module, configured to schedule display of one or more advertising impressions of available advertising inventory. The planning module enables scheduling a requested quantity of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisement, assigning an advertising type and defining a weight for the advertisements. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisements. The one or more metadata files, with the advertisements, are delivered to the receiver module that is configured to define a display frequency for the advertisements based upon one or more of the metadata files. The receiver module selectively displays advertisement content associated with the advertisements to achieve the advertising impression goal. 
",MICROSOFT CORP,OZER STUART;;HART MICHAEL PATRICK;;CHO WEI WEI ADA;;CHAU CAROLYN KHANH,ZHIGU HOLDINGS LIMITED (2016-05-16);;WEBTV NETWORKS INC (2001-11-15);;MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14),https://lens.org/053-765-011-734-729,Patent Application,yes,36,79,8,8,0,G06Q30/02;;G06Q30/0241;;G06Q30/0248;;G06Q30/0252;;G06Q30/0254;;G06Q30/0264;;G06Q30/0269;;G06Q30/0272;;G06Q30/02;;G06Q30/0241;;G06Q30/0264;;G06Q30/0248;;G06Q30/0269;;G06Q30/0272;;G06Q30/0254;;G06Q30/0252;;Y10S707/99945;;Y10S707/99948;;Y10S707/99944;;Y10S707/99942;;Y10S707/99943,G06Q30/02,707/102,0,0,,,,EXPIRED
667,CN,A,CN 107427758 A,109-846-316-261-066,2017-12-01,2017,CN 201580075367 A,2015-01-15,US 2015/0011558 W;;US 201514597415 A,2015-01-15,Separations with ionic liquid solvents,"Disclosed are systems and methods which provide a process stream comprising a gaseous component, capture the gaseous component from the process stream by an ionic liquid solvent of a separator, and recover a captured gaseous component from the ionic liquid solvent in a regenerator. A second gaseous component from the process stream may be captured by the ionic liquid solvent of the separator, and the second gaseous component may be recovered from the ionic liquid solvent in the regenerator. Alternatively, the second gaseous component from the process stream may be uncaptured by the ionic liquid solvent, and the uncaptured second gaseous component may be recovered from a membrane unit.",CHEVRON PHILLIPS CHEMICAL CO;;CHEVRON USA INC,JI LEI;;CHANG AI-FU;;DRIVER MICHAEL SEAN;;TIMKEN HYE-KYUNG CHO,,https://lens.org/109-846-316-261-066,Patent Application,no,8,4,9,34,0,B01D53/1487;;B01D53/1493;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05;;B01D53/1493;;B01D53/1487;;B01D2252/30;;B01D2256/16;;B01D2256/20;;B01D2256/24;;B01D2256/245;;B01D2257/304;;B01D2257/504;;B01D2257/7022;;B01D2258/05,B01D53/14,,0,0,,,,ACTIVE
668,US,A1,US 2024/0041790 A1,119-749-685-110-27X,2024-02-08,2024,US 202318382741 A,2023-10-23,US 202318382741 A;;US 2022/0025995 W;;US 202163178055 P,2021-04-22,TOPICAL ANTISEPTIC,"An antiseptic composition for penetrating and treating the dermis and/or pilosebaceous follicle of a mammal, said antiseptic composing comprising: (a) a sebostatic agent for reducing sebum production to prevent clogging of skin pores; (b) a barrier-forming emollient for forming a protective barrier film to aid said dermis in maintaining moisture and to shield said dermis from the environment; and (c) an antiseptic agent.",SURGIWIPE LLC,YAYAC MICHAEL;;PARVIZI JAVAD;;BRITTAIN HARRY;;CHO JEONGEUN;;SAXENA ARADHNA;;PARMAR MAYANK,SURGIWIPE LLC (2021-11-11),https://lens.org/119-749-685-110-27X,Patent Application,yes,0,0,5,5,0,A01N33/12;;A01P1/00;;A61K8/675;;A61Q17/005;;A61K8/342;;A61K8/922;;A61K8/365;;A61K9/107;;A61K9/70;;A61K31/191;;A61K31/455;;A61K36/61;;A61K47/10,A61K9/70;;A61K9/107;;A61K31/191;;A61K31/455;;A61K36/61;;A61K47/10,,0,0,,,,PENDING
669,WO,A1,WO 2020/070069 A1,154-679-925-694-429,2020-04-09,2020,EP 2019076458 W,2019-09-30,GB 201815999 A,2018-10-01,BUSH,"A tuning element that can be integrally formed with a resilient body of a bush and configured to reduce dynamic stiffness increases associated with eigenmodes of the resilient body within a predetermined operational vibration frequency range. The tuning element may resemble an upstanding wall or wing on an outer surface of the resilient body. The resilient body may comprise a plurality of radial arms having axial passageways therebetween. The tuning element may bridge the passageways. A bush configured in this way may be particular suitable for use in scenario where the operational vibration frequency range comprises high frequency, such as an engine mount for an electric vehicle.",DTR VMS LTD,GEISEN JAN;;MORTON JONATHAN;;STANKA CHRISTIAN;;LINES MICHAEL;;KAISER WERNER;;CHO SEONGDOSEONG,,https://lens.org/154-679-925-694-429,Patent Application,yes,5,4,5,5,0,F16F1/38;;F16F7/108;;F16F1/38;;F16F7/108;;F16F1/38;;F16F7/108,F16F1/38;;F16F7/108,,0,0,,,,PENDING
670,EP,A4,EP 4138647 A4,159-959-137-730-28X,2023-10-18,2023,EP 21793538 A,2021-04-19,US 202063013476 P;;US 202117230480 A;;US 2021/0027864 W,2020-04-21,THERMOACOUSTIC TRANSDUCER WITH INTEGRATED SWITCH,,ENDRA LIFE SCIENCES INC,MUMM ZACKARY MARC;;DAVIS CHRISTOPHER NELSON;;THORNTON MICHAEL M;;CHO JANG HWAN,,https://lens.org/159-959-137-730-28X,Search Report,no,4,0,7,7,0,G01H11/08;;G01N2291/106;;G01N29/2431;;G01N29/2437;;G01N29/343;;G01N29/0645;;G01N29/0654;;G01N29/50;;A61B5/0093;;A61B5/0035;;A61B5/0507;;A61B5/7225;;A61B5/7217;;A61B8/085;;A61B8/5261;;A61B5/0093;;A61B5/05;;A61B5/7217;;G01N29/2431;;A61B5/7225;;B06B1/0607;;A61B5/0035,A61B5/00;;A61B5/0507;;A61B8/00;;A61B8/08;;G01H11/08;;G01N29/06;;G01N29/24;;G01N29/34;;G01N29/50,,0,0,,,,PENDING
671,DE,A1,DE 102023202293 A1,176-635-600-933-317,2023-09-21,2023,DE 102023202293 A,2023-03-14,US 202217697597 A,2022-03-17,Lautsprecher-Zubehörablage,"Eine Zubehörablage für einen Lautsprecher weist einen Hauptabschnitt auf, der einen Umfang und eine Grundfläche definiert, die dazu ausgebildet ist, ein Zubehör innerhalb des Umfangs zu tragen. Ein Verankerungsabschnitt erstreckt sich unter der Grundfläche des Hauptabschnitts, wobei der Verankerungsabschnitt dazu ausgebildet ist, mit einem Abschnitt des Lautsprechers in Eingriff zu treten. Der Hauptabschnitt weist eine abnehmende Höhe von einer Rückseite zu einer Vorderseite davon auf, die in der Seitenansicht einen Neigungswinkel bildet.",BOSCH GMBH ROBERT,GRUNLOH ANDREW M;;FILIPEK SHAWN;;CHO ANDREW;;KASTEN MICHAEL;;SULZER NICHOLAS J,,https://lens.org/176-635-600-933-317,Patent Application,no,0,0,5,5,0,H04R1/025;;H04R2201/029;;H04R2201/029;;H04R1/025,H04R1/02,,0,0,,,,PENDING
672,AU,A1,AU 2022/261138 A1,032-383-524-583-334,2023-12-07,2023,AU 2022/261138 A,2022-04-22,US 202163178055 P;;US 2022/0025995 W,2021-04-22,TOPICAL ANTISEPTIC,"An antiseptic composition for penetrating and treating the dermis and/or pilosebaceous follicle of a mammal, said antiseptic composing comprising: (a) a sebostatic agent for reducing sebum production to prevent clogging of skin pores; (b) a barrier-forming emollient for forming a protective barrier film to aid said dermis in maintaining moisture and to shield said dermis from the environment; and (c) an antiseptic agent.",SURGIWIPE LLC,YAYAC MICHAEL;;PARVIZI JAVAD;;BRITTAIN HARRY;;CHO JEONGEUN;;SAXENA ARADHNA;;PARMAR MAYANK,,https://lens.org/032-383-524-583-334,Patent Application,no,0,0,5,5,0,A01N33/12;;A01P1/00;;A61K8/675;;A61Q17/005;;A61K8/342;;A61K8/922;;A61K8/365;;A61K9/107;;A61K9/70;;A61K31/191;;A61K31/455;;A61K36/61;;A61K47/10,A01N25/02;;A01N25/04;;A01N33/04,,0,0,,,,PENDING
673,US,S,US D0808264 S,057-024-395-551-522,2018-01-23,2018,US 201629553221 F,2016-01-29,US 201629553221 F,2016-01-29,Bottle cap,,BAYER HEALTHCARE LLC,NEUHALFEN MARK G;;CHO SEAN HANG;;BRAUN CRAIG A;;CARPENTER MICHAEL SCOTT,BEIERSDORF AG (2020-05-08);;BAYER HEALTHCARE LLC (2016-04-18),https://lens.org/057-024-395-551-522,Design Right,no,0,5,1,1,0,,,0907;;D 9448;;D9/449,0,0,,,,ACTIVE
674,EP,A1,EP 4138647 A1,070-437-459-446-18X,2023-03-01,2023,EP 21793538 A,2021-04-19,US 202063013476 P;;US 202117230480 A;;US 2021/0027864 W,2020-04-21,THERMOACOUSTIC TRANSDUCER WITH INTEGRATED SWITCH,,ENDRA LIFE SCIENCES INC,MUMM ZACKARY MARC;;DAVIS CHRISTOPHER NELSON;;THORNTON MICHAEL M;;CHO JANG HWAN,,https://lens.org/070-437-459-446-18X,Patent Application,yes,0,0,7,7,0,G01H11/08;;G01N2291/106;;G01N29/2431;;G01N29/2437;;G01N29/343;;G01N29/0645;;G01N29/0654;;G01N29/50;;A61B5/0093;;A61B5/0035;;A61B5/0507;;A61B5/7225;;A61B5/7217;;A61B8/085;;A61B8/5261;;A61B5/0093;;A61B5/05;;A61B5/7217;;G01N29/2431;;A61B5/7225;;B06B1/0607;;A61B5/0035,A61B5/00;;A61B6/00;;A61B8/00;;A61B8/08;;A61B8/14,,0,0,,,,PENDING
675,US,A1,US 2024/0072782 A1,056-157-740-994-221,2024-02-29,2024,US 202318176371 A,2023-02-28,KR 20220109559 A,2022-08-31,"DIGITAL DROOP DETECTOR, SEMICONDUCTOR DEVICE INCLUDING THE SAME, AND CALIBRATION METHOD THEREOF","A digital droop detector for detecting whether a droop occurs in a power supply voltage, may include processing circuitry configured to, detect a voltage level change of a power supply voltage in response to a clock signal, the detecting the voltage level change including converting the detected voltage level change into a first code, correct at least one nonlinearity included in the first code, the correcting including converting the first code into a second code and a target range, and adjust a delay magnitude of the clock signal based on the second code.",SAMSUNG ELECTRONICS CO LTD,LEE SANGHEON;;SHIN HEEWOOK;;LEE HEEJUNE;;LEE JUNGHO;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2023-02-14),https://lens.org/056-157-740-994-221,Patent Application,yes,0,0,3,3,0,G06F1/28;;G06F1/30;;G01R19/16552,H03K5/135;;G01R19/25,,0,0,,,,PENDING
676,US,A1,US 2023/0038074 A1,070-780-618-242-263,2023-02-09,2023,US 202017784329 A,2020-12-16,US 202017784329 A;;US 201962948472 P;;US 2020/0065207 W,2019-12-16,MAGNETIC MINIATURE DEVICE AND SYSTEM FOR REMOTELY MANEUVERING IT,"A miniature device configured to be maneuvered within a patient under manipulation by an external magnetic field and to selectively perform a predefined function is provided. The miniature device comprises a shell defining therewithin an internal cavity, and a magnetic arrangement disposed within the cavity. The miniature device is configured such that the magnetic arrangement, within a rotating magnetic field, effects one of performance of the function and propulsion of the miniature device within the patient, and, within a magnetic field gradient, effects the other of performance of the function and propulsion of the miniature device within the patient.",BIONAUT LABS LTD,CROS FLORENT;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;HARRINGTON DARRELL;;CHO SUEHYUN;;SARGSYAN HOVHANNES,BIONAUT LABS LTD (2020-09-16),https://lens.org/070-780-618-242-263,Patent Application,yes,0,0,6,6,0,A61M25/0127;;A61M31/002;;A61K9/0009;;A61K9/4808;;A61M25/0127;;A61M31/002,A61M31/00;;A61K9/48;;A61M25/01,,0,0,,,,PENDING
677,EP,A4,EP 4054695 A4,080-096-502-460-201,2024-01-03,2024,EP 20884172 A,2020-11-04,US 201962930863 P;;US 2020/0058964 W,2019-11-05,A SYSTEM AND MINIATURE DEVICES FOR DELIVERING A THERAPEUTIC COMPONENT TO A TREATMENT SITE IN A PATIENT,,BIONAUT LABS LTD;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CROS FLORENT;;HARRINGTON DARRELL;;CHO SUEHYUN;;CAPUTO JOHN,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CROS FLORENT;;HARRINGTON DARRELL;;CHO SUEHYUN;;CAPUTO JOHN,,https://lens.org/080-096-502-460-201,Search Report,no,4,0,6,6,0,A61K9/0009;;A61K9/0007;;A61M25/0127;;A61M31/002;;A61K45/06;;A61M31/002;;A61M2205/3515,A61M31/00;;A61K9/50;;A61K9/51;;A61K47/69,,1,0,,,See also references of WO 2021092076A1,PENDING
678,WO,A1,WO 2008/103230 A1,086-028-899-794-210,2008-08-28,2008,US 2008/0001335 W,2008-01-31,US 70980907 A,2007-02-23,EXHAUST TREATMENT SYSTEM,"An exhaust gas treatment system (10, 100, 200, 300) of an internal combustion engine (12) includes a selective catalytic reduction catalyst (19) fluidly connected to the internal combustion engine (12), a particulate filter (16, 36) fluidly connected downstream of the selective catalytic reduction catalyst (19), and an induction line (24) configured to direct a portion of a filtered exhaust flow of the internal combustion engine (12) toward an inlet (21) of the engine (12).",CATERPILLAR INC;;DRISCOLL JAMES J;;LIANG CHO Y;;ROBEL WADE J;;WOODS MICHAEL L,DRISCOLL JAMES J;;LIANG CHO Y;;ROBEL WADE J;;WOODS MICHAEL L,,https://lens.org/086-028-899-794-210,Patent Application,yes,4,9,2,2,0,F01N3/206;;F01N3/206;;F01N3/035;;F01N3/035;;F01N3/0821;;F01N3/0821;;F01N3/2066;;F01N3/2066;;F01N13/009;;F01N13/009;;F01N2250/02;;F01N2250/02;;F02B29/0406;;F02B29/0406;;F02M26/08;;F02M26/08;;F02M26/15;;F02M26/15;;F02M26/28;;F02M26/28;;Y02T10/12;;Y02T10/12,F01N3/20;;F01N3/035;;F01N3/08;;F02M25/07,,0,0,,,,PENDING
679,CA,A1,CA 3219774 A1,142-038-600-979-578,2022-11-24,2022,CA 3219774 A,2022-05-18,US 202163190041 P;;US 2022/0029858 W,2021-05-18,NASAL ANTISEPTIC,An antimicrobial composition comprising: (1) povidone iodine (PVP-I) in a concentration of 5 to 10 % w/w of the composition; and (2) carboxymethylcellulose (CMC) in a concentration of 0.1 to 5 % w/w of the composition.,POVINEZ LLC,PARVIZI JAVAD;;YAYAC MICHAEL;;CHISARI EMANUELE;;BRITTAIN HARRY;;CHO JEONGEUN;;PARMAR MAYANK,,https://lens.org/142-038-600-979-578,Patent Application,no,0,0,4,4,0,A61P31/00;;A61K47/38;;A61K33/18;;A61K9/0043;;A61K31/717;;A61L2101/50;;A61L2/18,A61K33/18;;A61K9/00;;A61K31/79;;A61K47/36;;A61K47/38;;A61P31/00,,0,0,,,,PENDING
680,US,A1,US 2005/0021403 A1,136-340-637-042-033,2005-01-27,2005,US 86748504 A,2004-06-14,US 86748504 A;;US 99138901 A,2001-11-21,Methods and systems for selectively displaying advertisements,"A system, including a planning module, a control module and a receiver module, configured to schedule display of one or more advertising impressions of available advertising inventory. The planning module enables scheduling a requested quantity of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisement, assigning an advertising type and defining a weight for the advertisements. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisements. The one or more metadata files, with the advertisements, are delivered to the receiver module that is configured to define a display frequency for the advertisements based upon one or more of the metadata files. The receiver module selectively displays advertisement content associated with the advertisements to achieve the advertising impression goal.",MICROSOFT CORP,OZER STUART;;HART MICHAEL PATRICK;;CHO WEI WEI ADA;;CHAU CAROLYN KHANH,ZHIGU HOLDINGS LIMITED (2016-05-16);;WEBTV NETWORKS INC (2001-11-19);;MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2002-06-28),https://lens.org/136-340-637-042-033,Patent Application,yes,30,220,8,8,0,G06Q30/02;;G06Q30/0241;;G06Q30/0248;;G06Q30/0252;;G06Q30/0254;;G06Q30/0264;;G06Q30/0269;;G06Q30/0272;;G06Q30/02;;G06Q30/0241;;G06Q30/0264;;G06Q30/0248;;G06Q30/0269;;G06Q30/0272;;G06Q30/0254;;G06Q30/0252;;Y10S707/99945;;Y10S707/99948;;Y10S707/99944;;Y10S707/99942;;Y10S707/99943,G06Q30/02,705/14,0,0,,,,EXPIRED
681,US,A1,US 2003/0107117 A1,141-783-743-145-750,2003-06-12,2003,US 30328002 A,2002-11-25,US 30328002 A;;US 64237600 A,2000-08-21,Semiconductor manufacturing using modular substrates,"
   A manufacturing method using a modular substrate-based processing scheme for producing semiconductor devices, provides multiple modular processing units which may be arranged together to form any of various cohesive processing units or individually or sequentially processed through standard semiconductor processing equipment. The cohesive processing units are processed unitarily providing for multiple modular processing units to be processed simultaneously. The modular processing units may be formed of a thick semiconductor substrate or a semiconductor substrate mounted on a further substrate such as a ceramic material. The modular processing units may each contain ribs, grooves, posts or other features to aid in handling and placement of the individual units. 
",AGERE SYSTEMS INC,ANTONELL MICHAEL;;HOUGE ERIK CHO;;PATEL NITIN;;PLEW LARRY E;;VARTULI CATHERINE,BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04),https://lens.org/141-783-743-145-750,Patent Application,yes,0,158,3,3,0,H01L21/67346;;H01L21/67346;;H01L22/20;;H01L22/20;;H01L22/34;;H01L22/34,H01L21/00;;H01L21/66;;H01L21/673;;H01L23/06;;H01L23/544,257/684,0,0,,,,EXPIRED
682,EP,A2,EP 1315110 A2,147-620-552-148-336,2003-05-28,2003,EP 02025700 A,2002-11-20,US 99102501 A,2001-11-21,Method and systems for planning advertising campaigns,"A system, including a planning module, a control module and a receiver module, configured to schedule display of advertisements to achieve an advertising impression goal. The planning module enables scheduling of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisements, assigning an advertising type and defining a weight for the advertisement. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisement. The one or more metadata files and advertising content for the advertisement, are delivered to the receiver module that is configured to define a display frequency for the advertising content based upon one or more of the metadata files. The receiver module selectively displays the advertising content of the advertisement to achieve the advertising impression goal.",WEBTV NETWORKS INC,OZER STUART;;HART MICHAEL PATRICK;;CHO WEI WEI ADA;;CHAU CAROLY KHANH,MICROSOFT CORPORATION (2007-02-28),https://lens.org/147-620-552-148-336,Patent Application,yes,0,4,3,3,0,G06Q30/02;;G06Q30/02,G06Q30/02,,0,0,,,,DISCONTINUED
683,US,B2,US 11172829 B2,191-507-200-585-007,2021-11-16,2021,US 202117230480 A,2021-04-14,US 202117230480 A;;US 202063013476 P,2020-04-21,Thermoacoustic transducer with integrated switch,"A thermoacoustic transducer integrating at least one piezoelectric element having a first surface and a second surface, a potential electrode that is electrically connected to the second surface, a ground electrode that is electrically connected to the first surface, a switch electrically connected to both the potential electrode and the ground electrode, a timer configured to match a pulse emanating from a radio-frequency emitter, further wherein the potential electrode and the ground electrode are electrically connected through an impedance when the switch is in an active state, further wherein the potential electrode and the ground electrode are not electrically connected when the switch is in an inactive state; and a housing accommodating the at least one piezoelectric element, potential electrode, ground electrode, and switch.",ENDRA LIFE SCIENCES INC,MUMM ZACKARY MARC;;DAVIS CHRISTOPHER NELSON;;THORNTON MICHAEL M;;CHO JANG HWAN,ENDRA LIFE SCIENCES INC (2021-09-27),https://lens.org/191-507-200-585-007,Granted Patent,yes,10,0,7,7,0,G01H11/08;;G01N2291/106;;G01N29/2431;;G01N29/2437;;G01N29/343;;G01N29/0645;;G01N29/0654;;G01N29/50;;A61B5/0093;;A61B5/0035;;A61B5/0507;;A61B5/7225;;A61B5/7217;;A61B8/085;;A61B8/5261;;A61B5/0093;;A61B5/05;;A61B5/7217;;G01N29/2431;;A61B5/7225;;B06B1/0607;;A61B5/0035,A61B5/00;;A61B5/05;;B06B1/06;;G01N29/24,,4,4,040-385-912-839-820;;010-119-114-592-501;;060-051-899-175-040;;005-049-936-051-024,23287507;;10.1177/0161734612471664;;10.1063/1.4983166;;10.3389/fbuil.2019.00064;;10.1063/1.4824709,"Roggenbuck et al. “Volumetric Thermoacoustic Imaging over Large Fields of View”. Ultrasonic Imaging, 35(1) 57-67, 2013 (Year: 2013).;;Wenzheng Ding, Zhong Ji, Da Xing; Microwave-excited ultrasound and thermoacoustic dual imaging; Applied Physics Letters 110, 183701 (2017); pp. 1-4, published online May 5, 2017.;;Konstantinos Marakakis, Georgios K. Tairidis, Panagiotis Koutsianitis, Georgios E. Stavroulakis; Shunt Piezoelectric Systems for Noise and Vibration Control; Frontiers in Built Environment | www.frontiersin.org; May 2019 | vol. 5 | Article 64; pp. 1-15; published: May 15, 2019 doi: 10.3389/fbuil.2019.00064.;;Stephan Kellnberger, Murad Omar, George Sergiadis, Vasilis Ntziachristos; Second harmonic acoustic responses induced in matter by quasi continuous radiofrequency fields; Applied Physics Letters 103, 153706 (2013); pp. 1-4; published online Oct. 11, 2013.",ACTIVE
684,US,A1,US 2009/0303053 A1,190-107-521-886-960,2009-12-10,2009,US 22421707 A,2007-02-26,US 22421707 A;;AU 2006/200814 A;;US 77684206 P;;AU 2007/000215 W,2006-02-24,Method and System for Controlling Termites,"A method of controlling pest termites. A vibrational signal which is perceptible to and behaviourally influential upon the pest termites is generated, and coupled into a medium for perception by the pest termites. Repellent termite alarm signals may be utilised. A new type of foraging signal is disclosed and may be applied to lure termites to a bait.",COMMW SCIENT IND RES ORG;;NEWSOUTH INNOVATIONS PTY LTD,EVANS THEODORE ALFRED;;LENZ MICHAEL;;LAI JOSEPH CHO SAM;;INTA RA ATA,NEWSOUTH INNOVATIONS PTY LIMITED (2009-06-01);;COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (2009-06-01),https://lens.org/190-107-521-886-960,Patent Application,yes,9,7,5,7,0,A01M1/023;;A01M1/026;;A01M1/24;;A01M29/16;;A01M2200/011;;A01M1/023;;A01M1/24;;A01M29/16;;A01M2200/011;;A01M1/026,A01M29/16;;G08B23/00,340/573.2,0,0,,,,DISCONTINUED
685,WO,A1,WO 2021/092076 A1,013-630-504-762-462,2021-05-14,2021,US 2020/0058964 W,2020-11-04,US 201962930863 P,2019-11-05,A SYSTEM AND MINIATURE DEVICES FOR DELIVERING A THERAPEUTIC COMPONENT TO A TREATMENT SITE IN A PATIENT,"A miniature device is provided for use in a system configured to deliver a therapeutic component to a treatment site in a patient. The miniature device comprises at least one steering portion comprising a magnetic material, and at least one carrier portion affixed to the steering portion and comprising the therapeutic component. The carrier portion is configured to at least partially dissipate under one or more predetermined conditions at the treatment site, thereby releasing the therapeutic component. Further provided is a system comprising one or more such miniature devices and a magnetic inducing apparatus configured to be operated to generate a varying magnetic field, thereby remotely controlling motion of the miniature device.",BIONAUT LABS LTD;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CROS FLORENT;;HARRINGTON DARRELL;;CHO SUEHYUN;;CAPUTO JOHN,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;CROS FLORENT;;HARRINGTON DARRELL;;CHO SUEHYUN;;CAPUTO JOHN,,https://lens.org/013-630-504-762-462,Patent Application,yes,3,2,6,6,0,A61K9/0009;;A61K9/0007;;A61M25/0127;;A61M31/002;;A61K45/06;;A61M31/002;;A61M2205/3515,A61M31/00;;A61K9/50;;A61K9/51;;A61K47/69,,1,0,,,See also references of EP 4054695A4,PENDING
686,US,A1,US 2023/0390566 A1,044-851-620-838-026,2023-12-07,2023,US 202318453110 A,2023-08-21,US 202318453110 A;;US 202016990188 A;;US 201715783573 A,2017-10-13,POWER MANAGEMENT FOR IMPLANTABLE MEDICAL DEVICE SYSTEMS,"Techniques for minimizing rate of depletion of a non-rechargeable power source, to extend the operational lifetime of an implantable medical device that includes the non-rechargeable power source, by enforcing operational-mode-specific communication protocols whereby inter-device communication between the implantable medical device and another implantable medical device is such that level of power draw from the non-rechargeable power source by the implantable medical device is less than level of power draw from the rechargeable power source by the another implantable medical device for the implantable medical devices to engage in communication with each other.",MEDTRONIC INC,DEMMER WADE M;;CHO YONG K;;HESS MICHAEL F;;SHELDON TODD J,MEDTRONIC INC (2017-10-10),https://lens.org/044-851-620-838-026,Patent Application,yes,0,0,11,11,0,A61N1/3708;;A61N1/37288;;A61N1/3756;;A61N1/3787;;A61B5/318;;A61N1/3708;;A61B5/318;;A61N1/37512;;A61N1/37518;;A61N1/3684;;A61N1/37288;;A61N1/3756;;A61N1/3787,A61N1/378;;A61B5/318;;A61N1/368;;A61N1/372;;A61N1/375,,0,0,,,,PENDING
687,AU,A1,AU 2007/219063 A1,072-429-402-207-471,2007-08-30,2007,AU 2007/219063 A,2007-02-26,AU 2006/200814 A;;US 77684206 P;;AU 2007/000215 W;;AU 2007/219063 A,2006-02-24,Method and system for controlling termites,,COMMW SCIENT IND RES ORG;;NEWSOUTH INNOVATIONS PTY LTD,EVANS THEODORE ALFRED;;INTA RA ATA;;LAI JOSEPH CHO SAM;;LENZ MICHAEL,,https://lens.org/072-429-402-207-471,Patent Application,no,0,0,5,7,0,A01M1/023;;A01M1/026;;A01M1/24;;A01M29/16;;A01M2200/011;;A01M1/023;;A01M1/24;;A01M29/16;;A01M2200/011;;A01M1/026,A01M1/22;;A01M1/20;;A01M29/16,,0,0,,,,DISCONTINUED
688,US,A1,US 2020/0368540 A1,085-237-482-687-932,2020-11-26,2020,US 202016990188 A,2020-08-11,US 202016990188 A;;US 201715783573 A,2017-10-13,POWER MANAGEMENT FOR IMPLANTABLE MEDICAL DEVICE SYSTEMS,"Techniques for minimizing rate of depletion of a non-rechargeable power source, to extend the operational lifetime of an implantable medical device that includes the non-rechargeable power source, by enforcing operational-mode-specific communication protocols whereby inter-device communication between the implantable medical device and another implantable medical device is such that level of power draw from the non-rechargeable power source by the implantable medical device is less than level of power draw from the rechargeable power source by the another implantable medical device for the implantable medical devices to engage in communication with each other.",MEDTRONIC INC,DEMMER WADE M;;CHO YONG K;;HESS MICHAEL F;;SHELDON TODD J,MEDTRONIC INC (2017-10-10),https://lens.org/085-237-482-687-932,Patent Application,yes,1,0,11,11,0,A61N1/3708;;A61N1/37288;;A61N1/3756;;A61N1/3787;;A61B5/318;;A61N1/3708;;A61B5/318;;A61N1/37512;;A61N1/37518;;A61N1/3684;;A61N1/37288;;A61N1/3756;;A61N1/3787,A61N1/368;;A61N1/378;;A61N1/372;;A61N1/375,,0,0,,,,ACTIVE
689,CN,A,CN 111201062 A,095-726-698-171-417,2020-05-26,2020,CN 201880066304 A,2018-09-28,US 201715783573 A;;US 2018/0053354 W,2017-10-13,POWER MANAGEMENT FOR IMPLANTABLE MEDICAL DEVICE SYSTEMS,"Techniques for minimizing rate of depletion of a non-rechargeable power source, to extend the operational lifetime of an implantable medical device that includes the non-rechargeable power source, byenforcing operational-mode-specific communication protocols whereby inter-device communication between the implantable medical device and another implantable medical device is such that level of powerdraw from the non-rechargeable power source by the implantable medical device is less than level of power draw from the rechargeable power source by the another implantable medical device for the implantable medical devices to engage in communication with each other.",MEDTRONIC INC,DEMMER WADE M;;CHO YONG K;;HESS MICHAEL F;;SHELDON TODD J,,https://lens.org/095-726-698-171-417,Patent Application,no,4,0,11,11,0,A61N1/3708;;A61N1/37288;;A61N1/3756;;A61N1/3787;;A61B5/318;;A61N1/3708;;A61B5/318;;A61N1/37512;;A61N1/37518;;A61N1/3684;;A61N1/37288;;A61N1/3756;;A61N1/3787,A61N1/372;;A61N1/375,,0,0,,,,PENDING
690,JP,A,JP 2001274528 A,109-309-472-375-168,2001-10-05,2001,JP 2001012391 A,2001-01-19,US 48929400 A,2000-01-21,INTER-SUBSTRATE TRANSFER METHOD FOR THIN FILM DEVICE,"PROBLEM TO BE SOLVED: To provide a method for transferring a device to a device substrate. SOLUTION: The array of the devices is provided on a carrier substrate and the array is provided with many device composite bodies. The respective device composite bodies form the practically same pattern and are arranged in a device area on a corresponding device substrate by the method provided with a process for forming first plural devices 16(a) and second plural devices on a formation substrate, the process for transferring the first plural devices and the second plural devices to the carrier substrate 14, the process for arranging the first plural devices in first plural device areas on a first device substrate 17(a), and the process for arranging the second plural devices in second plural device areas on a second device substrate.",FUJITSU LTD,YOSHIMURA TETSUZO;;UEN-CHO VINCENT WANG;;INAO MASAAKI;;MARK MACCORMACK;;MICHAEL PETERS,,https://lens.org/109-309-472-375-168,Patent Application,no,0,4,3,3,0,H01L21/6835;;H01L24/73;;H01L24/82;;H01L2221/68359;;H01L2221/68368;;H01L2224/18;;H01L2924/01004;;H01L2924/01013;;H01L2924/01015;;H01L2924/01029;;H01L2924/0103;;H01L2924/01039;;H01L2924/01046;;H01L2924/01051;;H01L2924/01074;;H01L2924/01077;;H01L2924/01078;;H01L2924/01079;;H01L2924/01105;;H01L2924/09701;;H01L2924/10329;;H01L2924/14;;H01L2924/19041;;H01L2924/19042;;H01L2924/19043;;H01L2924/01005;;H01L2924/01006;;H01L2924/01019;;H01L2924/01023;;H01L2924/01033;;H01L2924/01066;;H01L2924/01072;;H01L2924/01075;;H01L2924/014;;H01L2224/16225;;H01L2924/12042;;H01L2924/12043;;H01L2224/05573;;H01L2224/05568;;Y10T156/1089;;H01L2224/24137;;H01L21/568;;H01L2224/04105;;H01L2224/82005;;H01L24/24;;H01L2224/13111;;H01L2224/13144;;H01L2224/13147;;H01L2224/95136;;Y10T156/1089;;H01L24/73;;H01L2224/18;;H01L2924/01015;;H01L2924/01029;;H01L2924/01046;;H01L2221/68359;;H01L2924/01078;;H01L24/82;;H01L2924/01051;;H01L2924/10329;;H01L2221/68368;;H01L21/6835;;H01L2924/19041;;H01L2924/01105;;H01L2924/01079;;H01L24/18;;H01L2924/01004;;H01L2924/01074;;H01L2924/01039;;H01L2924/19042;;H01L2924/09701;;H01L2924/19043;;H01L2924/0103;;H01L2924/01077;;H01L2924/01013;;H01L2924/14;;H01L2924/01023;;H01L2924/01005;;H01L2924/01075;;H01L2924/01019;;H01L2924/014;;H01L2924/01006;;H01L2924/01066;;H01L2924/01033;;H01L2924/01072;;H01L2224/16225;;H01L2924/12043;;H01L2924/12042;;H01L2224/05568;;H01L2224/05573,G02B6/122;;H01L21/60;;H01L21/68;;H01L31/12;;H05K1/18,,0,0,,,,DISCONTINUED
691,AU,A1,AU 2021/296801 A1,108-535-839-087-162,2023-02-23,2023,AU 2021/296801 A,2021-06-22,US 202063043521 P;;US 2021/0038525 W,2020-06-24,Process for synthesizing lipids,"The present application provides processes for synthesizing lipids of Formula I useful in the synthesis of fat-soluble compounds for targeting and enhancing activity of therapeutic molecules, including siRNA.",BRISTOL MYERS SQUIBB CO,BEUTNER GREGORY LOUIS;;LORA GONZALEZ FEDERICO;;CHO PATRICIA Y;;SMITH MICHAEL J,,https://lens.org/108-535-839-087-162,Patent Application,no,0,0,11,11,0,C07C319/20;;Y02P20/55;;C07C319/20;;C07C321/14;;C07C319/14;;C07C323/41,A61K31/713;;A61K47/18;;A61K47/54,,0,0,,,,PENDING
692,ZA,B,ZA 96737 B,133-489-330-673-929,1997-07-31,1997,ZA 96737 A,1996-01-31,US 39397795 A,1995-02-24,Cosmetic compositions for reducing or preventing signs of cullulite,,UNILEVER PLC,CHENEY MICHAEL CHARLES;;ZNAIDEN ALEXANDER PAUL;;CHO SUK HYUNG;;SLAVTCHEFF CRAIG STEVEN,,https://lens.org/133-489-330-673-929,Granted Patent,no,0,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
693,EP,A4,EP 4076394 A4,139-409-637-117-797,2023-12-20,2023,EP 20901754 A,2020-12-16,US 201962948472 P;;US 2020/0065207 W,2019-12-16,MAGNETIC MINIATURE DEVICE AND SYSTEM FOR REMOTELY MANEUVERING IT,,BIONAUT LABS LTD,CROS FLORENT;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;HARRINGTON DARRELL;;CHO SUEHYUN;;SARGSYAN HOVHANNES,,https://lens.org/139-409-637-117-797,Search Report,no,2,0,6,6,0,A61M25/0127;;A61M31/002;;A61K9/0009;;A61K9/4808;;A61M25/0127;;A61M31/002,A61K9/00;;A61K9/50;;A61K9/51;;A61K47/69;;A61K49/18;;A61M5/145;;A61M25/01;;A61M31/00,,1,0,,,See also references of WO 2021126905A1,PENDING
694,US,B2,US 7356547 B2,140-834-690-782-211,2008-04-08,2008,US 86748504 A,2004-06-14,US 86748504 A;;US 99138901 A,2001-11-21,Methods and systems for selectively displaying advertisements,"A system, including a planning module, a control module and a receiver module, configured to schedule display of one or more advertising impressions of available advertising inventory. The planning module enables scheduling a requested quantity of advertising impressions in accordance with target criteria. Further, the planning module enables selecting an advertising impression goal for advertisement, assigning an advertising type and defining a weight for the advertisements. The control module receives the schedule, the advertising type and the defined weights and generates one or more metadata files that contain target criteria, advertising type and weights for the advertisements. The one or more metadata files, with the advertisements, are delivered to the receiver module that is configured to define a display frequency for the advertisements based upon one or more of the metadata files. The receiver module selectively displays advertisement content associated with the advertisements to achieve the advertising impression goal.",MICROSOFT CORP,OZER STUART;;HART MICHAEL PATRICK;;CHO WEI WEI ADA;;CHAU CAROLYN KHANH,ZHIGU HOLDINGS LIMITED (2016-05-16);;WEBTV NETWORKS INC (2001-11-19);;MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2002-06-28),https://lens.org/140-834-690-782-211,Granted Patent,yes,36,59,8,8,0,G06Q30/02;;G06Q30/0241;;G06Q30/0248;;G06Q30/0252;;G06Q30/0254;;G06Q30/0264;;G06Q30/0269;;G06Q30/0272;;G06Q30/02;;G06Q30/0241;;G06Q30/0264;;G06Q30/0248;;G06Q30/0269;;G06Q30/0272;;G06Q30/0254;;G06Q30/0252;;Y10S707/99945;;Y10S707/99948;;Y10S707/99944;;Y10S707/99942;;Y10S707/99943,G06F7/00;;G06F17/30;;G06Q30/02,707/104.1;;707/10;;707/101;;707/102,0,0,,,,EXPIRED
695,AU,A1,AU 2019/236632 A1,159-354-016-167-492,2020-04-09,2020,AU 2019/236632 A,2019-09-24,US 201862735496 P;;US 201816221090 A,2018-09-24,Application builder,"APPLICATION BUILDER Disclosed herein are system, method, and computer program product embodiments for unifying graphical user interface (GUI) displays across different device types. In an embodiment, a unification system may convert various GUI view appearing on, for example, a desktop device into a GUI view on a mobile device. Both devices may be accessing the same application and/or may use a cloud computing platform to access the application. The unification system may aid in reproducing GUI modifications performed on one user device onto other user devices. In this manner, the unification system may maintain a consistent look and-feel for a user across different computing device type. x > -C) o 0 4.04 C -;l E N- 'E LU ul cu r-4 CU U 4-. co. o4 00 .0 I. xcu L 0- 0 a -a 0) C )-o E -0 0) 0) u 0CU r' 0 r'w. U- .4- E Ei 4 E mf E - CU V)~ ~ 0 c 0 c) E =5 E 0CU 0 4- -0 -E 0 C OZ a) a ) -c 4- 0 V ~IA j -~ 0 9-C~ 4-a C -JC w 4 ._ __ _ WUJ U4 m-",SALESFORCE COM INC,JACOBSON ERIC;;GONZALEZ MICHAEL;;CHO WAYNE;;VARADARAJAN ADHEIP;;VOLLMER JOHN;;SNYDER BENJAMIN,,https://lens.org/159-354-016-167-492,Patent Application,no,0,0,6,17,0,G06F8/34;;G06F8/38;;G06F3/0482;;G06F3/0483;;G06F3/04845,G06F9/451;;G06F3/048,,0,0,,,,PENDING
696,US,A1,US 2009/0052448 A1,019-676-747-407-328,2009-02-26,2009,US 6070908 A,2008-04-01,US 6070908 A;;US 95778207 P,2007-08-24,METHODS AND SYSTEMS TO STORE STATE USED TO FORWARD MULTICAST TRAFFIC,Methods and systems are described to store state used to forward multicast traffic. The system includes a receiving module to receive request to add a first node to a membership tree. The membership tree includes a first plurality of nodes associated with a multicast group. The system further includes a processing module to identify a second node in the first plurality of nodes and to communicate a node identifier that identifies the first node over a network to the second node. The node identifier is to be stored at the second node to add the first node to the membership tree. The node identifier is further to be stored in the membership tree exclusively at the second node to enable the second node to forward the multicast traffic to the first node.,AT & T IP I LP,RAMAKRISHNAN KADANGODE K;;SRIVASTAVA DIVESH;;CHO TAE WON;;ZHANG YIN;;RABINOVICH MICHAEL,AT&T INTELLECTUAL PROPERTY I L.P (2008-02-29),https://lens.org/019-676-747-407-328,Patent Application,yes,22,48,8,8,0,H04L12/1886;;H04L45/16;;H04L45/48;;H04L12/1886;;H04L45/48;;H04L45/16,H04L12/56,370/390,0,0,,,,ACTIVE
697,US,A1,US 2009/0052449 A1,021-543-296-925-750,2009-02-26,2009,US 6072308 A,2008-04-01,US 6072308 A;;US 95778207 P,2007-08-24,MULTICAST WITH ADAPTIVE DUAL-STATE,"A method and system are described to multicast with an adaptive dual state. The system receives multicast traffic over a membership tree including a first plurality of nodes connected in a first topology destined for a plurality of multicast members of a first multicast group. Next, the system determines a rate of multicast traffic that exceeds a predetermined threshold based on the receiving the multicast traffic. Next, the system generates a dissemination tree including a second plurality of nodes connected in a second topology to reduce a number of hops to communicate the multicast traffic to the plurality of multicast members of the first multicast group. Finally, the system forwards the multicast traffic to the plurality of multicast members of the first multicast group over the dissemination tree.",AT & T IP I LP,RAMAKRISHNAN KADANGODE K;;SRIVASTAVA DIVESH;;CHO TAE WON;;ZHANG YIN;;RABINOVICH MICHAEL,AT&T INTELLECTUAL PROPERTY I L.P (2008-02-29),https://lens.org/021-543-296-925-750,Patent Application,yes,21,26,8,8,0,H04L12/1886;;H04L45/16;;H04L45/48;;H04L12/1886;;H04L45/48;;H04L45/16,H04L12/28,370/390,0,0,,,,INACTIVE
698,EP,A3,EP 0728471 A3,025-335-027-256-017,2000-07-19,2000,EP 96300587 A,1996-01-29,US 39397795 A,1995-02-24,Cosmetic compositions for reducing or preventing signs of cellulite,"The invention is directed to increasing the strength and firmness of the skin and reducing the signs of cellulite. The inventive method includes applying to the skin a composition that includes inositol phosphate, particularly phytic acid and its salts, in a cosmetically acceptable carrier.",UNILEVER PLC;;UNILEVER NV,ZNAIDEN ALEXANDER P;;CHENEY MICHAEL C;;SLAVTCHEFF CRAIG S;;CHO SUK H,,https://lens.org/025-335-027-256-017,Search Report,yes,3,0,12,12,0,A61K8/55;;A61Q19/06;;A61Q19/06;;A61K8/55,A61K8/00;;A61K8/36;;A61K8/365;;A61K8/49;;A61K8/55;;A61K8/58;;A61K8/65;;A61Q19/06,,0,0,,,,EXPIRED
699,EP,A1,EP 4332730 A1,138-502-137-645-278,2024-03-06,2024,EP 23173227 A,2023-05-12,KR 20220109559 A,2022-08-31,"DIGITAL DROOP DETECTOR, SEMICONDUCTOR DEVICE INCLUDING THE SAME, AND CALIBRATION METHOD THEREOF","A digital droop detector (100) for detecting whether a droop occurs in a power supply voltage (VDD), may include processing circuitry (1100, 1200, 1300, 1400) configured to, detect a voltage level change of a power supply voltage (VDD) in response to a clock signal (FCLK), the detecting the voltage level change including converting the detected voltage level change into a first code (S_TAPS), correct at least one nonlinearity included in the first code (S_TAPS), the correcting including converting the first code into a second code (OUT) and a target range, and adjust a delay magnitude of the clock signal based on the second code (OUT).
",SAMSUNG ELECTRONICS CO LTD,LEE SANGHEON;;SHIN HEEWOOK;;LEE HEEJUNE;;LEE JUNGHO;;CHO YOUNGJAE;;CHOI MICHAEL,,https://lens.org/138-502-137-645-278,Patent Application,yes,6,0,3,3,0,G06F1/28;;G06F1/30;;G01R19/16552,G06F1/30;;G06F1/28,,0,0,,,,PENDING
700,EP,A2,EP 4309726 A2,150-250-368-663-955,2024-01-24,2024,EP 23214298 A,2018-09-28,US 201715783573 A;;EP 18786636 A;;US 2018/0053354 W,2017-10-13,POWER MANAGEMENT FOR IMPLANTABLE MEDICAL DEVICE SYSTEMS,"Techniques for minimizing rate of depletion of a non-rechargeable power source, to extend the operational lifetime of an implantable medical device that includes the non- rechargeable power source, by enforcing operational-mode-specific communication protocols whereby inter-device communication between the implantable medical device and another implantable medical device is such that level of power draw from the non-rechargeable power source by the implantable medical device is less than level of power draw from the rechargeable power source by the another implantable medical device for the implantable medical devices to engage in communication with each other.",MEDTRONIC INC,DEMMER WADE M;;CHO YONG K;;HESS MICHAEL F;;SHELDON TODD J,,https://lens.org/150-250-368-663-955,Patent Application,yes,0,0,11,11,0,A61N1/3708;;A61N1/37288;;A61N1/3756;;A61N1/3787;;A61B5/318;;A61N1/3708;;A61B5/318;;A61N1/37512;;A61N1/37518;;A61N1/3684;;A61N1/37288;;A61N1/3756;;A61N1/3787,A61N1/375,,0,0,,,,PENDING
701,US,B1,US 6192829 B1,111-962-139-108-983,2001-02-27,2001,US 39874699 A,1999-09-17,US 39874699 A;;US 13257199 P,1999-05-05,Antenna coil assemblies for substrate processing chambers,"The present invention provides exemplary antenna coil assemblies and substrate processing chambers using such assemblies. In one embodiment, an antenna coil assembly (100) for a substrate processing chamber includes an antenna coil (102) disposed in a frame (104). The frame includes a plurality of spaced apart tabs (120) around a periphery of the frame, with the coil coupled to the frame at the tabbed locations. At least one notch (122) is provided between each pair of adjacent tabs. The notches are adapted to facilitate thermal expansion and contraction of the frame at the notched locations to reduce stresses on the frame and coil connections.",APPLIED MATERIALS INC,KARAZIM MICHAEL P;;ISHIKAWA TETSUYA;;GUJER RUDOLF;;KRING THOMAS;;STARYUK PAVEL;;DESAI ABHI;;CHO TOM;;DOUGLAS MICHAEL,,https://lens.org/111-962-139-108-983,Granted Patent,yes,3,22,6,6,0,H01J37/321;;H01L21/18;;H01J37/321,H01J37/32;;H01L21/18;;H01L21/302;;H01L21/205;;H01L21/3065,118723AN;;X118723 I;;118/724;;156/345;;315/111.51,0,0,,,,EXPIRED
702,KR,A,KR 20160008086 A,108-523-755-441-509,2016-01-21,2016,KR 20140151324 A,2014-11-03,KR 20140084824 A,2014-07-07,"NON CONTACT TYPE POWER TRANSMISSION APPARATUS, MOBILE TERMINAL, SERVER AND SERVICE SYSTEM BASED LOCATION USING THE SAME","According to an embodiment of the present invention, provided are a non-contact type power transmitting apparatus which can provide a location-based service of a user by using information about a location where wireless power charging is carried out, a mobile terminal, a server, and a location-based service system using the same. According to the embodiment of the present invention, the location-based service system comprises: the non-contact type power transmitting apparatus which provides power in a non-contact method, provides assigned location information, and displays the received location-based service; a non-contact type power receiving apparatus which receives the power from the non-contact type power transmitting apparatus; the mobile terminal charged with the power from the non-contact type power receiving apparatus; and the server which provides location-based service data in accordance with the location information of the non-contact type power transmitting apparatus.",SAMSUNG ELECTRO MECH,PARK SUNG HEUM;;CHO HYUNG WOOK;;CHO SANG HO;;PARK CHUL GYUN;;SUNG JAE SUK;;KANG CHANG SOO;;CHANG MICHAEL,,https://lens.org/108-523-755-441-509,Patent Application,no,4,0,1,7,0,H04W4/023;;H02J7/00045;;H02J50/12;;H02J50/80;;H04W88/02;;H04W88/16,H02J7/00,,0,0,,,,DISCONTINUED
703,US,B2,US 11135575 B2,125-131-906-176-823,2021-10-05,2021,US 201815928690 A,2018-03-22,US 201815928690 A;;US 201615010168 A,2016-01-29,Apparatus for regeneration of acidic ionic liquid without addition of a hydrogenation catalyst,"We provide a process for regenerating a spent acidic ionic liquid, comprising contacting the spent acidic ionic liquid with hydrogen and without an addition of a hydrogenation catalyst; wherein a conjunct polymer content is decreased in the spent acidic ionic liquid to produce regenerated acidic ionic liquid. We also provide a process for making an alkylate gasoline blending component, comprising: a) alkylating a mixture of isoparaffins and olefins using an acidic ionic liquid and an alkyl halide or a hydrogen halide, wherein a conjunct polymer accumulates in a spent acidic ionic liquid; and b) feeding the spent acidic ionic liquid and a hydrogen, and without an addition of a hydrogenation catalyst, to a regeneration reactor operated under selected hydrogenation conditions to produce a regenerated acidic ionic liquid that is used for the alkylating, wherein the conjunct polymer in the regenerated acidic ionic liquid is decreased by at least 50 wt %.",CHEVRON USA INC,GIRGIS MICHAEL JOHN;;LUO HUPING;;CHANG BONG KYU;;TIMKEN HYE-KYUNG CHO;;SONG STEVEN XUGI;;DRIVER MICHAEL SEAN,CHEVRON U.S.A. INC (2018-03-26),https://lens.org/125-131-906-176-823,Granted Patent,yes,15,0,4,14,0,C10G29/205;;C10G45/60;;C10G47/02;;C10G50/00;;Y02P20/584;;B01J31/0298;;B01J31/40;;B01J38/10;;C07C2/62;;B01J2231/44;;C07C2531/02;;B01J35/27;;B01J31/40;;B01J31/0284;;B01J38/10;;C07C2/62;;C10L1/06;;B01J2231/44;;C07C2531/02;;C10L2290/12;;C10L2270/023;;C10G29/205;;C10G45/60;;C10G47/02;;C10G50/00;;Y02P20/584;;B01J31/0298;;B01J35/27,C07C2/58;;B01J31/02;;B01J31/40;;B01J35/12;;B01J38/10;;C07C2/56;;C07C2/62;;C10G29/20;;C10G45/60;;C10G47/02;;C10G50/00;;C10L1/06,,8,1,064-928-044-925-858,10.1016/s1381-1169(03)00216-4,"Pines, H., The Chemistry of Catalytic Hydrocarbon Conversions, Wiley, 1981, p. 39ff.;;Pines, H., Chemtech, 1982, p. 150.;;Miron, S. and Lee, R.J., J. Chem. Eng. Data, 1963, p. 150.;;Ingred M. Angulo et. al., Journal of Molecular Catalysis A: Chemical 202 (2003) 97-106.;;U.S. Appl. No. 14/481,145, filed Sep. 9, 2014.;;Gadalla, A.M., T.C. Chan and R.G. Anthony, Int. J. Chem Kinet 15, 579 (1983).;;Sano, T., O., Kiyomi, H. Hadiwara, H. Takaya, J. Shoji, and K. Matsuzaki, J. Mol Catal., 40, 113 (1987).;;Garwood, William E., and Dwyer Frances G., Shape Selective Catalysis in Industrial Applications, 146-147.",ACTIVE
704,WO,A1,WO 2015/107454 A1,003-130-525-772-834,2015-07-23,2015,IB 2015050245 W,2015-01-13,EP 14151392 A,2014-01-16,HOLE TRANSPORTING AND LIGHT ABSORBING MATERIAL FOR SOLID STATE SOLAR CELLS,"The present invention relates to a compound of formula (I) based on quinozilino acridine and used as hole transporting and light absorbing material in a photovoltaic device, in particular in a solid state solar cell. (I)",ECOLE POLYTECH,QIN PENG;;NAZEERUDDIN MOHAMMAD KAJA;;GRAETZEL MICHAEL;;KO JAEJUNG;;PAEK SANGHYUN;;CHO NARA,,https://lens.org/003-130-525-772-834,Patent Application,yes,25,2,9,9,0,C09K11/06;;C09B57/00;;C09B57/008;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1096;;Y02E10/549;;Y02E10/542;;H10K85/652;;H10K85/655;;H10K85/6576;;H10K85/6572;;H10K85/657;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;H10K85/50;;C07D409/14;;C07F7/0816;;C09B57/008;;C09K11/06;;C09K2211/1096;;C09K2211/1092;;C09K2211/1051;;C09K2211/1029;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;C09B57/008;;C09B57/00;;C09K11/06;;C09K2211/1096;;C09K2211/1051;;C09K2211/1029;;C09K2211/1092;;Y02E10/549;;H10K85/40;;H10K85/652;;H10K85/655;;H10K85/657;;H10K85/791;;H10K85/6572;;H10K30/151;;H10K85/6576;;H01G9/2013;;H01G9/2018;;H01G9/2031;;H01G9/2059,C09K11/06;;C09B57/00;;H01L51/00;;H05B33/14,,3,2,052-761-979-207-854;;052-761-979-207-854,23043296;;10.1021/ja307789s;;23043296;;10.1021/ja307789s,"ETGAR, L. ET AL., J. AM. CHEM. SOC., vol. 134, 2012, pages 17396 - 17399;;NOH, J. H. ET AL., NANO LETT., 2013;;ETGAR ET AL., JAM. CHEM. SOC., vol. 134, 2012, pages 17396 - 17399",PENDING
705,WO,A1,WO 2008/015516 A1,082-070-362-918-58X,2008-02-07,2008,IB 2007002031 W,2007-07-16,US 82064206 P,2006-07-28,FUSED TRICYCLIC HETEROCYCLES FOR THE TREATMENT OF SCHIZOPHRENIA,"Disclosed are compounds of Formula (1), pharmaceutical compositions containing compounds of Formula (1), and the use of compounds of Formula (1) to treat central nervous system disorders, including schizophrenia and other psychotic disorders, wherein L, Z 1 , Z 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 R 8 , R 9 and R 10 in Formula (1) are defined in the specification.",PFIZER PROD INC;;AWASTHI ALOK KUMAR;;CHO STEPHEN SUNG YONG;;GRAHAM JAMES MICHAEL;;NIKAM SHAM SHRIDHAR,AWASTHI ALOK KUMAR;;CHO STEPHEN SUNG YONG;;GRAHAM JAMES MICHAEL;;NIKAM SHAM SHRIDHAR,,https://lens.org/082-070-362-918-58X,Patent Application,yes,4,10,2,2,0,A61P25/00;;A61P25/18;;C07D471/06;;C07D455/04;;C07D487/06,C07D455/04;;A61K31/4375;;A61P25/18;;C07D471/06;;C07D487/06,,0,0,,,,PENDING
706,US,A1,US 2008/0085538 A1,092-243-015-642-350,2008-04-10,2008,US 87406807 A,2007-10-17,US 87406807 A;;US 31575205 A;;US 72796805 P;;US 68097705 P;;US 65574405 P;;US 63861604 P,2004-12-22,Methods for Expression and Purification of Recombinant Human Growth Hormone,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,AMBRX INC (2006-03-31),https://lens.org/092-243-015-642-350,Patent Application,yes,9,15,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C07K16/00;;C12P21/04,435/69.4;;530/417,0,0,,,,INACTIVE
707,US,B2,US 7382407 B2,105-330-285-052-014,2008-06-03,2008,US 23020502 A,2002-08-29,US 23020502 A,2002-08-29,High intrascene dynamic range NTSC and PAL imager,"The invention provides a new method and apparatus for NTSC and PAL image sensors which employs fusion of adjacent row pixel charge samples to generate image data for a row. A variety of fusion schemes are possible for fusing the pixel signals from the adjacent rows. The rows of pixels are scanned so that each scan takes an odd row signal sample and, in some cases, an adjacent even row signal sample when specified conditions are met. One sampled row of the two adjacent rows integrate an image with a first integration period while the other adjacent row integrates an image with a second integration period.",MICRON TECHNOLOGY INC,CHO KWANG-BO;;SUBBOTIN IGOR;;KAPLINSKY MICHAEL;;BARNA SANDOR L;;SLAYTON GARY E,APTINA IMAGING CORPORATION (2009-07-08);;MICRON TECHNOLOGY INC (2002-10-30),https://lens.org/105-330-285-052-014,Granted Patent,yes,24,47,4,4,0,H04N23/70;;H04N23/741;;H04N25/583;;H04N25/616;;H04N25/75;;H04N3/155;;H04N23/741;;H04N23/70,H04N5/235;;H04N5/345;;H04N5/353;;H04N5/355;;H04N5/374;;H04N5/378,348/296;;348/304;;348/305;;348/308;;257/291;;257/292,6,2,174-102-508-157-787;;119-748-087-426-317,10.1109/40.743681;;10.1109/4.972156,"I.L. Fujimori, (C.G. Sodini), A Differential CMOS Passive Pixel Imager, pp. 28-29, no date.;;Jim Adams, Ken Parulski, Kevin Spaulding; Color Processing in Digital Cameras, Micro, IEEE, pp. 20-29, Nov.-Dec. 1998, Micro, IEEE.;;Stuart Kleinfelder, Sukhwan Lim, Xinqiao Liu, and Abbas El Gamal; A 10,000 Frames/s CMOS Digital Pixel Sensor, IEEE Journal of Solid-State Circuits, vol. 36, No. 12, pp. 2049-2059, Dec. 2001.;;PB-0100/PB-0101 1/5 Inch CMOS Active-Pixel Digital Image Sensors, Product Specification, Mar. 2000 (Version 3.0).;;Kevin Buckley, Selecting an Analog Front End for Imaging Applications, vol. 34, No. 06, pp. 1-8, Oct. 2000; [retrieved on Jul. 26, 2002]. Retrived from the Internet: <URL: http://www.analog.com/library/analogdialogue/archives/34-06/imaging/>.;;Stuart A. Taylor, CCD and CMOS Imaging Array Technologies: Technology Review; Technical Report EPC-1998-106, pp. 1-14, 1998.",ACTIVE
708,DE,B4,DE 19941319 B4,130-934-281-201-231,2006-05-24,2006,DE 19941319 A,1999-08-31,US 14460798 A,1998-08-31,Verringerung des Schwefelgehaltes von Benzin beim Fliessbettkracken,,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/130-934-281-201-231,Granted Patent,no,3,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,C10G11/05;;C10G35/085;;B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
709,US,S,US D0806737 S,128-338-758-324-827,2018-01-02,2018,US 201629579776 F,2016-10-03,US 201629579776 F,2016-10-03,Display screen with graphical user interface,,GOOGLE INC;;GOOGLE LLC,CHUNG EUNKYUNG;;HUME TOM;;HUANG ALLEN;;CHO HANNAH;;COHEN MICHAEL ADAM;;MURPHY GLEN,GOOGLE LLC (2017-02-21),https://lens.org/128-338-758-324-827,Design Right,no,0,78,1,1,0,,,1404;;D14/486,0,0,,,,ACTIVE
710,EP,B1,EP 3084872 B1,018-942-235-986-939,2019-02-20,2019,EP 14870855 A,2014-12-18,US 201361918014 P;;US 201361918859 P;;US 2014/0071214 W,2013-12-19,HYDROGEN/BROMINE FLOW BATTERY IN WHICH HYDROGEN IS FREELY EXCHANGED BETWEEN TWO CELL COMPARTMENTS,,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/018-942-235-986-939,Granted Patent,yes,7,0,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M8/18,,0,0,,,,ACTIVE
711,CA,A1,CA 2355679 A1,034-985-121-736-384,2000-07-06,2000,CA 2355679 A,1999-12-16,US 22210298 A;;US 9929799 W,1998-12-29,CETANE UPGRADING VIA AROMATIC ALKYLATION,"A process of increasing the cetane index of a distillate pool comprising contacting a first refinery-grade feedstream of an aromatic compounds- containing heavy gasoline or distillate fuel feedstream with a second refine ry- grade feedstream containing olefins in the presence of an acidic solid alkylation catalyst under alkylation conditions, wherein both the aromatic- containing feedstream and the olefin-containing feedstream are simultaneousl y upgraded to suitable fuel products without addition of hydrogen.",MOBIL OIL CORP,TREWELLA JEFFREY C;;TIMKEN HYE KYUNG CHO;;COLLINS NICK ALLEN;;LANDIS MICHAEL E,,https://lens.org/034-985-121-736-384,Patent Application,no,0,0,7,7,0,C10G29/205,C10G29/20,,0,0,,,,DISCONTINUED
712,CN,A,CN 104661974 A,066-685-944-610-228,2015-05-27,2015,CN 201380035076 A,2013-05-17,US 2013/0041591 W;;US 201213477391 A,2012-05-22,Methods of separating strengthened glass sheets by mechanical scribing,"A method of separating a strengthened glass sheet includes positioning a serrated scribing wheel at a position spaced apart from a first edge of the glass sheet and offset below a top surface of the glass sheet, where the glass sheet comprises a surface compression layer of layer depth DOL and a central region. The method also includes translating the serrated scribing wheel in a first direction at an initiation speed such that the serrated scribing wheel forms a crack initiation site comprising surface indentations extending into the surface compression layer, accelerating the serrated scribing wheel in the first direction from the initiation speed to a scoring speed to scribe a score line extending into the glass sheet to a median crack depth greater than DOL, and stopping the serrated scribing wheel in the first direction before the score line reaches a second edge of the glass sheet.",CORNING INC,BROWN JAMES WILLIAM;;HSIEH CHO-CHENG;;JOSEPH II MICHAEL ALBERT;;PAI YEN CHIA,,https://lens.org/066-685-944-610-228,Patent Application,no,3,0,13,13,0,B26F3/00;;B26F3/00;;C03B33/023;;C03B33/023;;C03B33/023;;C03B33/105;;C03B33/107;;C03B33/107;;C03B33/107;;C03C21/002;;C03C21/002;;C03C21/002;;Y10T83/0341;;Y10T83/0341;;Y10T225/12;;Y10T225/12,C03B33/023;;C03B33/10,,0,0,,,,ACTIVE
713,SE,L,SE 9903054 L,097-077-680-225-726,2000-03-01,2000,SE 9903054 A,1999-08-31,US 14460798 A,1998-08-31,Svavelreduktion i bensin vid katalytisk krackning i svävbädd,,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;ROBERIE TERRY G;;TIMKEN HYE KYUNG CHO;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/097-077-680-225-726,Abstract,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;C10G35/085;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
714,TW,B,TW I814855 B,124-361-253-529-157,2023-09-11,2023,TW 108123523 A,2019-07-04,EP 18181981 A,2018-07-05,Transparent conductive film,,BASF COATINGS GMBH,CHO BORAM;;FLORES JEAN-CHARLES;;REINKE MICHAEL;;SUNG MYUNG MO;;JUNG JIN WON,,https://lens.org/124-361-253-529-157,Granted Patent,no,6,0,9,9,0,C03C17/38;;C03C2217/94;;C23C16/45525;;C23C28/00;;C23C28/322;;C23C28/34;;C23C28/345;;C23C28/3455;;C23C28/40;;C23C28/42;;Y02E10/549;;H10K30/50;;C23C28/3455;;C23C28/322;;C23C28/42;;C23C16/45529;;C23C16/405;;H01B5/14;;B05D1/60;;H10K30/50;;C23C16/45531;;C23C28/30;;C23C28/42;;C23C28/44;;C23C28/02;;Y10T428/31678;;C23C28/322;;C23C28/3455;;H10K30/82;;H10K30/451,,,0,0,,,,ACTIVE
715,US,B2,US 6958098 B2,148-169-877-471-214,2005-10-25,2005,US 42150103 A,2003-04-22,US 42150103 A;;US 79721401 A;;US 18528300 P,2000-02-28,Semiconductor wafer support lift-pin assembly,"A modular lift-pin assembly includes a lift-pin having a distal end, a connector, and an actuator pin. The connector includes an actuator end having a plurality of catch fingers disposed around the actuator end. Each of the plurality of catch fingers includes a lip extending radially inwards. A lift-pin end is coupled to the distal end of the lift-pin, and the actuator pin is coupled to the actuator end of the connector.",APPLIED MATERIALS INC,GUJER RUDOLF;;CHO THOMAS K;;PANG LILY L;;KARAZIM MICHAEL P;;ISHIKAWA TETSUYA,APPLIED MATERIALS INC (2003-04-18),https://lens.org/148-169-877-471-214,Granted Patent,yes,7,12,2,11,0,C23C16/405;;C23C16/4401;;C23C16/4409;;C23C16/4412;;C23C16/45561;;C23C16/4586;;Y10T279/23;;Y10T279/11;;Y10T279/23;;Y10T279/11;;C23C16/405;;C23C16/4412;;C23C16/45561;;C23C16/4586;;C23C16/4409;;C23C16/4401,C23C16/40;;C23C16/44;;C23C16/458,118/728;;118/724;;118/725;;118/500;;118/715;;156/345.51;;156/345.52;;156/345.53;;204/192.1;;204/298.01;;361/234;;279/128;;279/3,1,0,,,"Pang et al. ""Apparatus for Cleaning a Semiconductor Process Chamber"" U.S. Appl. No. 09/721,060, filed Nov. 21, 2000.",EXPIRED
716,EP,A1,EP 1153105 A1,145-984-407-825-999,2001-11-14,2001,EP 99965275 A,1999-12-16,US 9929799 W;;US 22210298 A,1998-12-29,CETANE UPGRADING VIA AROMATIC ALKYLATION,,EXXONMOBIL OIL CORP,COLLINS NICK ALLEN;;LANDIS MICHAEL E;;TIMKEN HYE KYUNG CHO;;TREWELLA JEFFREY C,,https://lens.org/145-984-407-825-999,Patent Application,yes,0,0,7,7,0,C10G29/205,C10G29/20,,0,0,,,,DISCONTINUED
717,WO,A1,WO 2018/064604 A1,171-205-736-116-189,2018-04-05,2018,US 2017/0054558 W,2017-09-29,US 201662402238 P;;US 201662410919 P;;US 201662410922 P;;US 201662414302 P;;US 201662419202 P;;US 201662419247 P,2016-09-30,"PHOSPHORUS-CONTAINING SOLID CATALYSTS AND REACTIONS CATALYZED THEREBY, INCLUDING SYNTHESIS OF P-XYLENE","Methods and phosphorus-containing solid catalysts for catalyzing dehydration of cyclic ethers (e.g., furans, such as 2,5-dimethylfuran) and alcohols (e.g., ethanol and isopropanol). The alcohols and cyclic ethers may be derived from biomass. One example includes a tandem Diels-Alder cycloaddition and dehydration of biomass-derived 2,5-dimethyl-furan and ethylene to renewable p-xylene. The phosphorus-containing solid catalysts are also active and selective for dehydration of alcohols to alkenes.",CHO HONG JE;;FAN WEI;;TSAPATSIS MICHAEL;;DAUENHAUER PAUL;;REN LIMIN;;LOBO RAUL,CHO HONG JE;;FAN WEI;;TSAPATSIS MICHAEL;;DAUENHAUER PAUL;;REN LIMIN;;LOBO RAUL,,https://lens.org/171-205-736-116-189,Patent Application,yes,3,4,6,6,0,B01J37/28;;B01J29/40;;B01J29/7007;;B01J29/82;;B01J29/85;;B01J2229/16;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;Y02P20/582;;Y02P20/52;;B01J29/40;;B01J29/7007;;B01J29/85;;B01J37/28;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;C07C51/42;;C07C2521/04;;C07C2521/06;;C07C2521/08;;C07C2521/10;;C07C2521/12;;C07C2521/18;;C07C2523/10;;C07C2523/20;;C07C2527/167;;C07C2527/18;;C07C2527/188;;C07C2529/08;;B01J37/0201;;C07C2529/85;;C07C2529/82;;B01J2229/186;;B01J2229/18;;B01J2229/183;;B01J35/67;;B01J35/69,B01J37/00;;B01J29/40;;B01J29/85,,0,0,,,,PENDING
718,EP,B1,EP 2697241 B1,169-420-812-014-564,2019-06-12,2019,EP 12716969 A,2012-04-13,US 201161474848 P;;US 2012/0033675 W,2011-04-13,1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT,,GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/169-420-812-014-564,Granted Patent,yes,3,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;A61K31/7068;;A61K31/7072;;A61K38/21;;A61P31/14;;C07H19/067;;C07H19/073;;C07H19/10,,0,0,,,,ACTIVE
719,CA,A1,CA 2830689 A1,159-217-875-712-232,2012-10-18,2012,CA 2830689 A,2012-04-13,US 201161474848 P;;US 2012/0033675 W,2011-04-13,1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT,"Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2- haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.",GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/159-217-875-712-232,Patent Application,no,0,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;A61K31/7068;;A61K38/21;;A61P31/14;;C07H19/067;;C07H19/073;;C07H19/09;;C07H19/10;;C07H19/11,,0,0,,,,DISCONTINUED
720,KR,A,KR 20140019832 A,161-319-994-996-441,2014-02-17,2014,KR 20137029678 A,2012-04-13,US 201161474848 P;;US 2012/0033675 W,2011-04-13,1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT,,GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/161-319-994-996-441,Patent Application,no,0,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;A61K31/7064;;A61P31/12,,0,0,,,,DISCONTINUED
721,EP,B1,EP 3094688 B1,195-200-457-973-979,2017-09-13,2017,EP 15701256 A,2015-01-13,EP 14151392 A;;IB 2015050245 W;;EP 15701256 A,2014-01-16,HOLE TRANSPORTING AND LIGHT ABSORBING MATERIAL FOR SOLID STATE SOLAR CELLS,,ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL),QIN PENG;;NAZEERUDDIN MOHAMMAD KHAJA;;GRAETZEL MICHAEL;;KO JAEJUNG;;PAEK SANGHYUN;;CHO NARA,,https://lens.org/195-200-457-973-979,Granted Patent,yes,7,0,9,9,0,C09K11/06;;C09B57/00;;C09B57/008;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1096;;Y02E10/549;;Y02E10/542;;H10K85/652;;H10K85/655;;H10K85/6576;;H10K85/6572;;H10K85/657;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;H10K85/50;;C07D409/14;;C07F7/0816;;C09B57/008;;C09K11/06;;C09K2211/1096;;C09K2211/1092;;C09K2211/1051;;C09K2211/1029;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;C09B57/008;;C09B57/00;;C09K11/06;;C09K2211/1096;;C09K2211/1051;;C09K2211/1029;;C09K2211/1092;;Y02E10/549;;H10K85/40;;H10K85/652;;H10K85/655;;H10K85/657;;H10K85/791;;H10K85/6572;;H10K30/151;;H10K85/6576;;H01G9/2013;;H01G9/2018;;H01G9/2031;;H01G9/2059,C09B57/00;;C09K11/06;;H01L51/00;;H05B33/14,,0,0,,,,ACTIVE
722,AU,A,AU 1999/044687 A,198-589-810-661-982,2000-03-30,2000,AU 1999/044687 A,1999-08-25,US 14460798 A,1998-08-31,Gasoline sulfur reduction in fluid catalytic cracking,,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;ZIEBARTH MICHAEL SCOTT;;ROBERIE TERRY G;;TIMKEN HYE KYUNG CHO,,https://lens.org/198-589-810-661-982,Patent Application,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,C10G35/085;;B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
723,US,B2,US 6572708 B2,018-764-702-489-976,2003-06-03,2003,US 79721401 A,2001-02-28,US 79721401 A;;US 18528300 P,2000-02-28,Semiconductor wafer support lift-pin assembly,"
    A modular lift-pin assembly comprises a lift-pin having a distal end and a connector having a lift-pin end and an actuator end. The lift-pin end of the connector is coupled to the distal end of the lift-pin and an actuator pin is then coupled to the actuator end of the connector to actuate the lift-pin through the connector. 
",APPLIED MATERIALS INC,GUJER RUDOLF;;CHO THOMAS K;;PANG LILY L;;KARAZIM MICHAEL P;;ISHIKAWA TETSUYA,APPLIED MATERIALS INC (2001-01-31),https://lens.org/018-764-702-489-976,Granted Patent,yes,7,25,2,11,0,C23C16/4409;;C23C16/4409;;C23C16/405;;C23C16/405;;C23C16/4401;;C23C16/4401;;C23C16/4412;;C23C16/4412;;C23C16/45561;;C23C16/45561;;C23C16/4586;;C23C16/4586,C23C16/40;;C23C16/44;;C23C16/458,118/728;;156/345.51;;156/345.54;;118/500,1,0,,,"Pang et al. ""Apparatus for Cleaning a Semiconductor Process Chamber"" U.S. patent application Ser. No. 09/721,060, filed Nov. 21, 2000.",EXPIRED
724,MX,A,MX 2013011915 A,041-727-613-873-600,2013-11-01,2013,MX 2013011915 A,2012-04-13,US 201161474848 P;;US 2012/0033675 W,2011-04-13,1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT.,"Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R<sup>6</sup> is CN, ethenyl, 2- haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.",GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/041-727-613-873-600,Patent Application,no,0,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;C07H19/067;;C07H19/073;;C07H19/09;;C07H19/10;;C07H19/11,,0,0,,,,DISCONTINUED
725,US,B2,US 7481048 B2,051-937-466-292-344,2009-01-27,2009,US 17031805 A,2005-06-30,US 17031805 A,2005-06-30,Regeneration assembly,A regeneration assembly includes a first portion including a combustion chamber connected to a combustor head. The regeneration assembly also includes a second portion including a housing. The first portion is removably connectable to the second portion.,CATERPILLAR INC,HARMON MICHAEL P;;LIANG CHO Y;;KAUFMANN GREGORY J;;BALMER-MILLAR MARI LOU,CATERPILLAR INC (2005-06-29),https://lens.org/051-937-466-292-344,Granted Patent,yes,56,84,4,4,0,F01N3/0256;;F01N3/0256,F01N3/10,60/303;;60/274;;60/286;;60/289;;60/295;;60/297;;60/311,1,0,,,"""APBF-DEC: Diesel-Fueled ECS Management Burner,"" http://www.southwestresearchinstitute.com/, Jun. 2005.",ACTIVE
726,US,A1,US 2002/0153283 A1,071-564-598-597-226,2002-10-24,2002,US 22154098 A,1998-12-28,US 22154098 A,1998-12-28,GASOLINE SULFUR REDUCTION IN FLUID CATALYTIC CRACKING,"
   The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reduction catalyst composition comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve as well as a cerium component which enhances the stability and sulfur reduction activity of the catalyst. The molecular sieve is normally a faujasite such as USY. The primary sulfur reduction component is normally a metal of Period 3 of the Periodic Table, preferably vanadium. The sulfur reduction catalyst may be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst. 
",CHESTER ARTHUR W;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL S,CHESTER ARTHUR W;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL S,MOBIL OIL CORPORATION (1999-02-08);;W.R. GRACE & CO.-CONN (1999-04-06),https://lens.org/071-564-598-597-226,Patent Application,yes,0,22,4,75,0,B01J29/166;;B01J2229/42;;C10G11/05;;C10G11/05;;B01J2229/42;;B01J29/166,B01J29/16;;C10G11/05,208/120.2;;208/208;;208/244;;208/247;;208/249;;208/120.01;;208/120.25;;208/120.35,0,0,,,,DISCONTINUED
727,US,A1,US 2013/0306355 A1,174-104-356-900-672,2013-11-21,2013,US 201313895934 A,2013-05-16,US 201313895934 A;;US 201261647754 P,2012-05-16,Electrical Insulator Apparatus and Methods of Retaining an Electrical Conductor with an Electrical Insulator Apparatus,"An electrical insulator apparatus and methods of using the same are provided. The apparatus includes an insulator body formed about a central axis, the insulator body having a plurality of spaced fins positioned along an exterior of the insulator body. A first jaw portion is positioned on an upper portion of the insulator body. A second jaw portion is positioned proximate to the first jaw portion and is movable with respect to the first jaw portion. At least one fastener is connected between the first and second jaw portions. A jaw platform is positioned at least partially between the first and second jaw portions, wherein the first and second jaw portions and the jaw platform form a notch sized to receive an electrical conductor, wherein the jaw platform substantially lies within a first plane angled substantially between 6° and 184° with respect to the central axis of the insulator body.",MARMON UTILITY LLC,CLEMENT CHARLES J;;MERCEDAT GUBERSON;;WILLIAMS MICHAEL L;;CHO MAY;;JEAN LEONARD P,MARMON UTILITY LLC (2013-05-16),https://lens.org/174-104-356-900-672,Patent Application,yes,5,3,2,2,0,H01B17/22;;H01B17/16;;H01B17/22,H01B17/16,174/168,0,0,,,,ACTIVE
728,EP,B1,EP 3095152 B1,009-543-851-418-009,2018-09-26,2018,EP 14873586 A,2014-12-22,US 201361919926 P;;US 2014/0071835 W,2013-12-23,"SYSTEM AND METHOD FOR RETURNING MATERIAL FROM THE BR2 , SIDE OF AN H2/BR2 FLOW BATTERY BACK AFTER CROSSOVER",,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/009-543-851-418-009,Granted Patent,yes,6,0,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/18;;H01M8/20,,0,0,,,,ACTIVE
729,TW,B,TW 546368 B,030-565-026-345-493,2003-08-11,2003,TW 88114951 A,1999-08-31,US 14460798 A,1998-08-31,Gasoline sulfur reduction in fluid catalytic cracking,"The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reduction additive comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve. The molecular sieve is normally a large pore size zeolite such as USY or zeolite beta or an intermediate pore size zeolite such as ZSM-5. The metal is normally a metal of Period 3 of the Periodic Table, preferablyzinc or vanadium. The sulfur reduction catalyst may be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst.",MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/030-565-026-345-493,Granted Patent,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;C10G35/085;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
730,EP,A1,EP 2852561 A1,041-320-720-679-606,2015-04-01,2015,EP 13724709 A,2013-05-17,US 201213477391 A;;US 2013/0041591 W,2012-05-22,METHODS OF SEPARATING STRENGTHENED GLASS SHEETS BY MECHANICAL SCRIBING,,CORNING INC,BROWN JAMES WILLIAM;;HSIEH CHO-CHENG;;JOSEPH MICHAEL ALBERT II;;PAI CHIA-YEN,,https://lens.org/041-320-720-679-606,Patent Application,yes,0,0,13,13,0,C03B33/023;;C03B33/107;;C03C21/002;;C03B33/107;;C03C21/002;;Y10T225/12;;Y10T83/0341;;B26F3/00;;C03B33/023;;C03B33/105;;Y10T225/12;;Y10T83/0341;;B26F3/00;;C03C21/002;;C03B33/107;;C03B33/023,C03B33/023;;C03B33/10;;C03C21/00,,0,0,,,,DISCONTINUED
731,US,A1,US 2016/0322653 A1,080-768-742-605-026,2016-11-03,2016,US 201415105874 A,2014-12-22,US 201415105874 A;;US 201361919926 P;;US 2014/0071835 W,2013-12-23,System and Method for Returning Material from the BR2 Side of an H2/BR2 Flow Battery Back after Crossover,"A flow battery system includes a first tank having a hydrogen reactant, a second tank having a bromine electrolyte, at least one cell including a hydrogen reactant side operably connected to the first tank through an ¾ feed and return system and a bromine electrolyte side operably connected to the second tank, and a crossover return system. The crossover return system includes a vessel operably connected to the ¾ feed and return system and configured to receive an effluent containing a first portion of the hydrogen reactant and a second portion of the bromine electrolyte, the vessel configured to separate the first portion from the second portion. A first return line returns the first portion of the hydrogen reactant to the first tank and a second return line returns the bromine electrolyte to the second tank.",BOSCH GMBH ROBERT;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO TAEK KYU;;WEBER ADAM Z,ROBERT BOSCH GMBH (2016-10-31),https://lens.org/080-768-742-605-026,Patent Application,yes,0,4,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/04089;;H01M8/04007;;H01M8/04082;;H01M8/04276;;H01M8/18;;H01M8/20,,0,0,,,,ACTIVE
732,MX,A,MX 2007007591 A,146-171-275-838-322,2007-07-25,2007,MX 2007007591 A,2005-12-21,US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P;;US 2005/0046486 W,2004-12-22,METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE.,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/146-171-275-838-322,Patent Application,no,0,0,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,A61K38/00;;C07H21/04;;C07K14/61;;C12Q1/00,,0,0,,,,ACTIVE
733,SG,A1,SG 161210 A1,159-578-048-112-27X,2010-05-27,2010,SG 2010020295 A,2005-12-21,US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P,2004-12-22,METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules. NO SUITABLE FIGURE",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/159-578-048-112-27X,Patent Application,no,0,0,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,,,0,0,,,,PENDING
734,WO,A1,WO 2000/039253 A1,174-278-829-900-315,2000-07-06,2000,US 9929799 W,1999-12-16,US 22210298 A,1998-12-29,CETANE UPGRADING VIA AROMATIC ALKYLATION,"A process of increasing the cetane index of a distillate pool comprising contacting a first refinery-grade feedstream of an aromatic compounds-containing heavy gasoline or distillate fuel feedstream with a second refinery-grade feedstream containing olefins in the presence of an acidic solid alkylation catalyst under alkylation conditions, wherein both the aromatic-containing feedstream and the olefin-containing feedstream are simultaneously upgraded to suitable fuel products without addition of hydrogen.",MOBIL OIL CORP,COLLINS NICK ALLEN;;LANDIS MICHAEL E;;TIMKEN HYE KYUNG CHO;;TREWELLA JEFFREY C,,https://lens.org/174-278-829-900-315,Patent Application,yes,11,18,7,7,0,C10G29/205,C10G29/20,,1,0,,,See also references of EP 1153105A4,PENDING
735,US,B1,US 6852214 B1,194-191-867-846-018,2005-02-08,2005,US 14460798 A,1998-08-31,US 14460798 A,1998-08-31,Gasoline sulfur reduction in fluid catalytic cracking,"The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reduction additive comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve. The molecular sieve is normally a large pore size zeolite such as USY or zeolite beta or an intermediate pore size zeolite such as ZSM-5. The metal is normally a metal of Period 4 of the Periodic Table, preferably zinc or vanadium. The sulfur reduction catalyst may be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst.",MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR W;;TIMKEN HYE KYUNG CHO;;ZIEBARTH MICHAEL S;;ROBERIE TERRY G,MOBIL OIL CORPORATION (1998-10-08);;W.R. GRACE & CO.-CONN (1999-06-23),https://lens.org/194-191-867-846-018,Granted Patent,yes,33,50,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;C10G35/085;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,208/113;;X208208 R;;208/244;;208/245;;208/247;;208/248;;208/249;;208/120.01;;208/120.2;;208/120.25;;208/120.35,2,1,039-565-969-520-282,10.1016/0021-9517(86)90078-3,"Krishna et al. Additives Improve FCC Process, Hydrocarbon Processing, Nov. 1991, pp. 59-66.;;Wormsbecher et al. Vanadium Poisoning of Cracking Catalysts: Mechanism of Poisoning and Design of Vanadium Tolerant Catalyst System, J. Catalysis 100, 130-137 (1986).",EXPIRED
736,DK,B1,DK 176486 B1,030-179-930-162-34X,2008-05-13,2008,DK PA199901178 A,1999-08-25,US 14460798 A,1998-08-31,"Fremgangsmåde til reduktion af svovlindholdet i en jordoliefraktion, fluidiserbart katalysator additiv til reduktion af svovlindhold, samt integreret fluidserbar katalysator til svovlreduktion i katalytisk krakningsprodukt",,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/030-179-930-162-34X,Granted Patent,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,C10G11/05;;B01J29/00;;C10G35/085;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/65;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
737,SE,C2,SE 523254 C2,027-675-184-754-013,2004-04-06,2004,SE 9903054 A,1999-08-31,US 14460798 A,1998-08-31,"Förfarande för reduktion av svavelhalten i en flytande katalytiskt krackad petroleumfraktion, fluidiserbar katalysatortillsats samt integrerad fluidiserbar katalysator",,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;ROBERIE TERRY G;;TIMKEN HYE KYUNG CHO;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/027-675-184-754-013,Granted Patent,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;C10G35/085;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
738,US,B2,US 7476638 B2,056-367-251-289-826,2009-01-13,2009,US 1370804 A,2004-12-16,US 1370804 A;;US 14460798 A,1998-08-31,Gasoline sulfur reduction in fluid catalytic cracking,"The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reduction additive comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve. The molecular sieve is normally a large pore size zeolite such as USY or zeolite beta or an intermediate pore size zeolite such as ZSM- 5 . The metal is normally a metal of Period 3 of the Periodic Table, preferably zinc or vanadium. The sulfur reduction catalyst may be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst.",GRACE W R & CO,CHESTER ARTHUR W;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL S,,https://lens.org/056-367-251-289-826,Granted Patent,yes,5,8,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J21/06;;B01J29/00;;C10G35/085;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,502/64;;502/60;;502/65;;502/73;;502/79,0,0,,,,EXPIRED
739,US,A1,US 2002/0011204 A1,101-930-915-634-750,2002-01-31,2002,US 79721401 A,2001-02-28,US 79721401 A;;US 18528300 P,2000-02-28,Semiconductor wafer support lift-pin assembly,"
   A modular lift-pin assembly comprises a lift-pin having a distal end and a connector having a lift-pin end and an actuator end. The lift-pin end of the connector is coupled to the distal end of the lift-pin and an actuator pin is then coupled to the actuator end of the connector to actuate the lift-pin through the connector. 
",APPLIED MATERIALS INC,GUJER RUDOLF;;CHO THOMAS K;;PANG LILY L;;KARAZIM MICHAEL P;;ISHIKAWA TETSUYA,APPLIED MATERIALS INC (2001-01-31),https://lens.org/101-930-915-634-750,Patent Application,yes,0,36,2,11,0,C23C16/4409;;C23C16/4409;;C23C16/405;;C23C16/405;;C23C16/4401;;C23C16/4401;;C23C16/4412;;C23C16/4412;;C23C16/45561;;C23C16/45561;;C23C16/4586;;C23C16/4586,C23C16/40;;C23C16/44;;C23C16/458,1185;;118/729,0,0,,,,EXPIRED
740,WO,A1,WO 2013/176987 A1,167-296-054-238-674,2013-11-28,2013,US 2013/0041591 W,2013-05-17,US 201213477391 A,2012-05-22,METHODS OF SEPARATING STRENGTHENED GLASS SHEETS BY MECHANICAL SCRIBING,"A method of separating a strengthened glass sheet includes positioning a serrated scribing wheel at a position spaced apart from a first edge of the glass sheet and offset below a top surface of the glass sheet, where the glass sheet comprises a surface compression layer of layer depth DOL and a central region. The method also includes translating the serrated scribing wheel in a first direction at an initiation speed such that the serrated scribing wheel forms a crack initiation site comprising surface indentations extending into the surface compression layer, accelerating the serrated scribing wheel in the first direction from the initiation speed to a scoring speed to scribe a score line extending into the glass sheet to a median crack depth greater than DOL, and stopping the serrated scribing wheel in the first direction before the score line reaches a second edge of the glass sheet.",CORNING INC;;BROWN JAMES WILLIAM;;HSIEH CHO-CHENG;;JOSEPH MICHAEL ALBERT II;;PAI YEN CHIA,BROWN JAMES WILLIAM;;HSIEH CHO-CHENG;;JOSEPH MICHAEL ALBERT II;;PAI YEN CHIA,,https://lens.org/167-296-054-238-674,Patent Application,yes,3,0,13,13,0,C03B33/023;;C03B33/107;;C03C21/002;;C03B33/107;;C03C21/002;;Y10T225/12;;Y10T83/0341;;B26F3/00;;C03B33/023;;C03B33/105;;Y10T225/12;;Y10T83/0341;;B26F3/00;;C03C21/002;;C03B33/107;;C03B33/023,C03B33/023;;C03B33/10,,0,0,,,,PENDING
741,EP,A1,EP 3849101 A1,194-877-584-974-892,2021-07-14,2021,EP 21150763 A,2021-01-08,US 202016737116 A,2020-01-08,SYSTEM AND METHOD FOR NULLFORMING WITH ANTI-JAM ANTENNA ELECTRONICS,"An antenna system may include an antenna array (104) configured to receive one or more signals. In embodiments, the antenna system further includes one or more signal processors (106) configured to: determine a beamforming weight vector ( W bf ) for the antenna array; determine a first seeding weight vector ( W seed 1 ) for the antenna array, wherein the first seeding weight vector ( W seed 1 ) comprises a first nulling weight vector ( W nul 1 ) or a second beamforming weight vector ( W bf ); determine a first nullforming adjustment factor ( η 1 ) for the antenna array; calculate a first nullforming weight vector ( W nf 1 ) based on at least the beamforming weight vector ( W bf ), the first seeding weight vector ( W seed 1 ) ,  and the first nullforming adjustment factor ( η 1 ); and form a first antenna pattern based on the first nullforming weight vector ( W nf 1 ) to generate a first antenna electronics (AE) output signal, wherein the first antenna pattern generates a first set of one or more nulls.
",ROCKWELL COLLINS INC,LAI YING-CHO J;;BISHOP JEFFREY B;;HERTING BRIAN J;;STOCKMASTER MICHAEL H,,https://lens.org/194-877-584-974-892,Patent Application,yes,2,0,3,3,0,H04B7/0617;;H01Q3/2617;;H04B7/0617;;H04B7/086,H04B7/06,,0,0,,,,PENDING
742,US,A1,US 2003/0205329 A1,015-385-866-072-342,2003-11-06,2003,US 42150103 A,2003-04-22,US 42150103 A;;US 79721401 A;;US 18528300 P,2000-02-28,Semiconductor wafer support lift-pin assembly,"
   A modular lift-pin assembly includes a lift-pin having a distal end, a connector, and an actuator pin. The connector includes an actuator end having a plurality of catch fingers disposed around the actuator end. Each of the plurality of catch fingers includes a lip extending radially inwards. A lift-pin end is coupled to the distal end of the lift-pin, and the actuator pin is coupled to the actuator end of the connector. 
",GUJER RUDOLF;;CHO THOMAS K.;;PANG LILY L.;;KARAZIM MICHAEL P.;;ISHIKAWA TETSUYA,GUJER RUDOLF;;CHO THOMAS K;;PANG LILY L;;KARAZIM MICHAEL P;;ISHIKAWA TETSUYA,APPLIED MATERIALS INC (2003-04-18),https://lens.org/015-385-866-072-342,Patent Application,yes,3,167,2,11,0,C23C16/405;;C23C16/4401;;C23C16/4409;;C23C16/4412;;C23C16/45561;;C23C16/4586;;Y10T279/23;;Y10T279/11;;Y10T279/23;;Y10T279/11;;C23C16/405;;C23C16/4412;;C23C16/45561;;C23C16/4586;;C23C16/4409;;C23C16/4401,C23C16/40;;C23C16/44;;C23C16/458,156/345.51;;118/728,0,0,,,,EXPIRED
743,KR,A,KR 20100135061 A,046-387-400-896-191,2010-12-24,2010,KR 20090053510 A,2009-06-16,KR 20090053510 A,2009-06-16,ARM PROTECTOR FOR TKD,PURPOSE: An arm protector for a Taekwondo including two or more materials is provided to reduce the impact absorbed into inside can be reduced altogether than the protective equipment achieved to the material of one existing. CONSTITUTION: An arm protector(300) for a Taekwondo including two or more materials is manufactured by laminating two or more materials. One of two materials is the strong rigidity material such as the fiber-reinforced plastic. The inside of contacting PAL among material is more than two different materials. The arm protector for a Taekwondo including two or more materials is manufactured with the rubber.,SNU R&DB FOUNDATION,AHN SUNG HOON;;KIM JI SOO;;DAVID MICHAEL O SULLIVAN;;CHO DONG WOOK,,https://lens.org/046-387-400-896-191,Patent Application,no,0,1,1,1,0,A63B69/26;;A63B71/14;;A63B2244/10;;A63B2209/02;;A63B2209/00,A63B71/08,,0,0,,,,DISCONTINUED
744,EP,A1,EP 2896660 A1,049-923-322-312-060,2015-07-22,2015,EP 14151392 A,2014-01-16,EP 14151392 A,2014-01-16,Hole transporting and light absorbing material for solid state solar cells,"The present invention relates to a compound of formula (I) based on quinozilino acridine and used as hole transporting and light absorbing material in a photovoltaic device, in particular in a solid state solar cell.
 ",ECOLE POLYTECH,QIN PENG;;NAZEERUDDIN MOHAMMAD KHAJA;;GRAETZEL MICHAEL;;KO JAEJUNG;;PAEK SANHYUN;;CHO NARA,,https://lens.org/049-923-322-312-060,Patent Application,yes,24,0,9,9,0,C09K11/06;;C09B57/00;;C09B57/008;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1096;;Y02E10/549;;Y02E10/542;;H10K85/652;;H10K85/655;;H10K85/6576;;H10K85/6572;;H10K85/657;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;H10K85/50;;C07D409/14;;C07F7/0816;;C09B57/008;;C09K11/06;;C09K2211/1096;;C09K2211/1092;;C09K2211/1051;;C09K2211/1029;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;C09B57/008;;C09B57/00;;C09K11/06;;C09K2211/1096;;C09K2211/1051;;C09K2211/1029;;C09K2211/1092;;Y02E10/549;;H10K85/40;;H10K85/652;;H10K85/655;;H10K85/657;;H10K85/791;;H10K85/6572;;H10K30/151;;H10K85/6576;;H01G9/2013;;H01G9/2018;;H01G9/2031;;H01G9/2059,C09B57/00;;C09K11/06;;H01L51/00;;H05B33/14,,3,2,052-761-979-207-854;;052-761-979-207-854,23043296;;10.1021/ja307789s;;23043296;;10.1021/ja307789s,"ETGAR, L. ET AL., J. AM. CHEM. SOC., vol. 134, 2012, pages 17396 - 17399;;NOH, J. H. ET AL., NANO LETT., 2013;;ETGAR ET AL., J. AM. CHEM. SOC., vol. 134, 2012, pages 17396 - 17399",DISCONTINUED
745,US,A1,US 2010/0007795 A1,068-279-002-390-232,2010-01-14,2010,US 17019808 A,2008-07-09,US 17019808 A,2008-07-09,System and Method for Clock Offset Detection,"A system and method for detecting a sampling clock offset of an analog-to-digital converter used to digitize an analog image signal. A method comprises buffering samples of an analog image signal, computing a value of an autocorrelation function using the buffered samples and a delayed version of the buffered samples, and repeating the computing a value for delays in a range of delays. The method also comprises computing a sampling frequency offset from the values of the autocorrelation function and changing a sampling frequency using the sampling frequency offset.",OUYANG BING;;HAYDEN JOHN MICHAEL;;ETHRIDGE TROY LANE;;CHO HONG JIN;;KORDEL JEFF,OUYANG BING;;HAYDEN JOHN MICHAEL;;ETHRIDGE TROY LANE;;CHO HONG JIN;;KORDEL JEFF,TEXAS INSTRUMENTS INCORPORATED (2008-07-01),https://lens.org/068-279-002-390-232,Patent Application,yes,17,13,2,2,0,G09G3/001;;G09G3/2096;;G09G5/008;;G09G2320/02;;H03M1/127;;H04N5/04;;H03M1/127;;G09G2320/02;;G09G3/001;;G09G3/2096;;G09G5/008;;H04N5/04,H03M1/12,348/572;;341/155,0,0,,,,ACTIVE
746,SG,A1,SG 85130 A1,088-389-714-490-314,2001-12-19,2001,SG 1999004234 A,1999-08-31,US 14460798 A,1998-08-31,GASOLINE SULFUR REDUCTION IN FLUID CATALYTIC CRACKING,,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;ROBERIE TERRY G;;TIMKEN HYE KYUNG CHO;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/088-389-714-490-314,Patent Application,no,4,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;C10G35/085;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,PENDING
747,US,B2,US 7507686 B2,116-123-500-654-518,2009-03-24,2009,US 11853905 A,2005-04-29,US 11853905 A;;US 30873702 A,2002-12-03,Gasoline sulfur reduction in fluid catalytic cracking,"The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reduction catalyst composition comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve as well as a cerium component which enhances the stability and sulfur reduction activity of the catalyst. The molecular sieve is normally a faujasite such as USY. The primary sulfur reduction component is normally a metal of Period 3 of the Periodic Table, preferably vanadium. The sulfur reduction catalyst may be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst.",GRACE W R & CO,CHESTER ARTHUR W;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL S,MOBIL OIL CORPORATION (1999-02-08);;W. R. GRACE & CO. - CONN (1999-04-06),https://lens.org/116-123-500-654-518,Granted Patent,yes,58,6,2,2,0,B01J29/076;;B01J29/088;;B01J29/166;;B01J29/80;;B01J37/0045;;B01J2229/186;;B01J2229/20;;B01J2229/42;;C10G11/02;;C10G11/182;;C10G11/02;;B01J2229/42;;C10G11/182;;B01J37/0045;;B01J29/80;;B01J29/166;;B01J29/088;;B01J2229/20;;B01J29/076;;B01J2229/186,B01J29/06;;B01J29/076;;B01J29/08;;B01J29/16;;B01J29/80;;B01J37/00;;C10G11/02;;C10G11/18,502/65;;502/60;;502/64;;502/73;;502/79,10,2,039-565-969-520-282;;020-680-838-131-264,10.1016/0021-9517(86)90078-3;;10.1021/bk-1991-0452.ch021,"Venuto and Habib, Fluid Catalytic Cracking with Zeolite Catalysts, Marcel Dekker, New York 1979, ISBN 0-8247-6870-1, pp. 32-37.;;Richard F. Wormsbecher, Alan W. Peters, and James M. Maselli, ""Vanadium Poisoning of Cracking Catalysts: Mechanism of Poisoning and Design of Vanadium Tolerant Catalyst System"", Journal of Catalyst, Vol. 100, pp. 130-187 (1986).;;Occelli, M.L., ""Metal Resistant Fluid Cracking Catalysts"", ACS Symposium Series, Ch 21, pp. 343-362 (1990).;;""Shape Selective Catalysis in Industrial Applications""; Chen et al., Marcel Dekker Inc., New York 1969, ISBN 0-8247-7856-1, pp. 7-38.;;J ournal of Catalysis, vol. 67, pp. 218-222 (1981) by Frilette et al.;;Stud. Surf. Catal., vol. 37, Sep. 13-27 (1987).;;Journal of Catalysis, vol. 4, pp. 527-529 (1965); vol. 6, pp. 278-287 (1966); and vol. 61, pp. 390-396 (1980).;;Scherzer, ""Octane Enhancing Zeolitic FCC Catalysts"", Marcel Dekker, New York, 1990, ISBN 0-8247-8399-9, pp. 165-182.;;Intercat, Refining Developments, ""Additives Improve FCC Process"", Hydrocarbon Processing, Nov. 1991, pp. 59-66, by A.S. Krishna, C.R. Hsieh, A.R. English, T.A. Pecararo and C.W. Kuehler, Chevron Research and Technology Company, Richmond, CA.;;""Fluid Catalytic Cracking Handbook"", Sadeghbeigi, Gulf Publishing, Houston, Texas, ISBN 0-88415-290-1, Ch. 3, pp. 79 and 88-91, no date.",INACTIVE
748,CN,A,CN 112334602 A,134-113-925-928-792,2021-02-05,2021,CN 201980043492 A,2019-07-03,EP 18181981 A;;EP 2019067821 W,2018-07-05,TRANSPARENT CONDUCTIVE FILM,"The present invention is in the field of transparent conductive films. In particular, the present invention relates to a transparent conductive film comprising: a) a first laminate comprising: at least two layers containing TiO2, ZrO2 or HfO2 and a layer containing an organic compound in between the two layers containing TiO2, ZrO2 or HfO2, b) a metal layer, and c) a second laminate comprising: atleast two layers containing ZnO and a layer containing an organic compound between the two layers containing ZnO, a metallic dopant other than zinc.",BASF COATINGS GMBH,CHO BORAM;;FLORES JEAN-CHARLES;;REINKE MICHAEL;;SUNG MYUNG MO;;JUNG JIN WON,,https://lens.org/134-113-925-928-792,Patent Application,no,17,0,9,9,0,C03C17/38;;C03C2217/94;;C23C16/45525;;C23C28/00;;C23C28/322;;C23C28/34;;C23C28/345;;C23C28/3455;;C23C28/40;;C23C28/42;;Y02E10/549;;H10K30/50;;C23C28/3455;;C23C28/322;;C23C28/42;;C23C16/45529;;C23C16/405;;H01B5/14;;B05D1/60;;H10K30/50;;C23C16/45531;;C23C28/30;;C23C28/42;;C23C28/44;;C23C28/02;;Y10T428/31678;;C23C28/322;;C23C28/3455;;H10K30/82;;H10K30/451,C23C28/00;;C03C17/36;;C23C16/455,,2,0,,,"CHEN, YY等: ""Single-step direct fabrication of luminescent Cu-doped ZnxCd1-xS quantum dot thin films via a molecular precursor solution approach and their application in luminescent, transparent, and conductive thin films"", 《NANOSCALE》;;吴芳: ""Ga掺杂ZnO透明导电薄膜的制备与特性研究"", 《中国优秀硕士学位论文全文数据库工程科技Ⅱ辑》",ACTIVE
749,EP,A4,EP 3084872 A4,165-863-013-108-510,2017-11-01,2017,EP 14870855 A,2014-12-18,US 201361918014 P;;US 201361918859 P;;US 2014/0071214 W,2013-12-19,HYDROGEN/BROMINE FLOW BATTERY IN WHICH HYDROGEN IS FREELY EXCHANGED BETWEEN TWO CELI COMPARTMENTS,,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/165-863-013-108-510,Search Report,no,2,0,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M8/18,,1,0,,,See also references of WO 2015095555A1,ACTIVE
750,CA,C,CA 2590462 C,162-203-719-263-229,2017-02-28,2017,CA 2590462 A,2005-12-21,US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P;;US 2005/0046486 W,2004-12-22,METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/162-203-719-263-229,Granted Patent,no,0,0,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12P21/02;;A61K38/27;;C07K1/16;;C07K14/61,,0,0,,,,INACTIVE
751,US,A1,US 2016/0308237 A1,187-634-435-223-657,2016-10-20,2016,US 201415104161 A,2014-12-18,US 201415104161 A;;US 201361918014 P;;US 201361918859 P;;US 2014/0071214 W,2013-12-19,Hydrogen/Bromine Flow Battery in which Hydrogen is Freely Exchanged between Two Cell Compartments,"A flow battery system includes a first tank including a hydrogen reactant, a second tank including a bromine electrolyte, and at least one cell including a first electrolyte side operably connected to the first tank and a second electrolyte side operably connected to the second tank. The battery system further includes a direct connection line directly connecting the first tank and the second tank and configured such that the hydrogen reactant passes between the first tank and the second tank.",BOSCH GMBH ROBERT;;UNIV CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO TAEK KYU;;WEBER ADAM Z,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2017-02-15);;ROBERT BOSCH GMBH (2016-10-31),https://lens.org/187-634-435-223-657,Patent Application,yes,5,4,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M8/18;;H01M8/04082;;H01M8/20;;H01M8/22,,0,0,,,,ACTIVE
752,GB,B,GB 2341191 B,197-660-902-730-845,2003-04-09,2003,GB 9920179 A,1999-08-25,US 14460798 A,1998-08-31,Gasoline sulfur reduction in fluid catalytic cracking,,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/197-660-902-730-845,Granted Patent,no,7,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;C10G35/085;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,C1A ACA           ACA;;C1A AD31          ACA;;C1A AG13          ACA;;C1A AG37          ACA;;C1A AG39          ACA;;C1A AG55          ACA;;C1A AG9           ACA;;C5E ESR           ESR,0,0,,,,EXPIRED
753,EP,A1,EP 3094688 A1,015-691-938-988-84X,2016-11-23,2016,EP 15701256 A,2015-01-13,EP 14151392 A;;IB 2015050245 W;;EP 15701256 A,2014-01-16,HOLE TRANSPORTING AND LIGHT ABSORBING MATERIAL FOR SOLID STATE SOLAR CELLS,,ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE EPFL,QIN PENG;;NAZEERUDDIN MOHAMMAD KHAJA;;GRAETZEL MICHAEL;;KO JAEJUNG;;PAEK SANGHYUN;;CHO NARA,,https://lens.org/015-691-938-988-84X,Patent Application,yes,0,0,9,9,0,C09K11/06;;C09B57/00;;C09B57/008;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1096;;Y02E10/549;;Y02E10/542;;H10K85/652;;H10K85/655;;H10K85/6576;;H10K85/6572;;H10K85/657;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;H10K85/50;;C07D409/14;;C07F7/0816;;C09B57/008;;C09K11/06;;C09K2211/1096;;C09K2211/1092;;C09K2211/1051;;C09K2211/1029;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;C09B57/008;;C09B57/00;;C09K11/06;;C09K2211/1096;;C09K2211/1051;;C09K2211/1029;;C09K2211/1092;;Y02E10/549;;H10K85/40;;H10K85/652;;H10K85/655;;H10K85/657;;H10K85/791;;H10K85/6572;;H10K30/151;;H10K85/6576;;H01G9/2013;;H01G9/2018;;H01G9/2031;;H01G9/2059,C09B57/00;;C09K11/06;;H01L51/00;;H05B33/14,,0,0,,,,ACTIVE
754,US,A1,US 2012/0263678 A1,039-976-755-792-852,2012-10-18,2012,US 201213447017 A,2012-04-13,US 201213447017 A;;US 201161474848 P,2011-04-13,1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT,"Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R 6 is CN, ethenyl, 2-haloethen-1-yl, or (C 2 -C 8 )-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.",CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL;;GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,GILEAD SCIENCES INC (2012-05-17),https://lens.org/039-976-755-792-852,Patent Application,yes,3,22,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,A61K31/7072;;A61K31/7068;;A61K38/21;;A61P31/14;;C07H19/06;;C07H19/067;;C07H19/073;;C07H19/10,424/85.4;;536/28.53;;514/50;;536/28.5;;514/49;;536/28.55;;536/28.52;;536/26.26;;514/51;;536/26.8;;536/26.14,3,2,092-453-210-643-987;;023-501-176-436-01X,10.1002/1521-3765(20010601)7:11<2332::aid-chem23320>3.0.co;2-w;;11446636;;10.1080/07328319608002386,"Grouiller et al, Synlett, 1993, vol. 3, pp 221-222.;;Kodama et al., Chemistry - A European Journal, 2001, vol 7(11), pp. 2332-2340.;;Yoshimura et al., Nucleosides & Nucleotides, 15(1-3), 1996, pp. 305-324.",ACTIVE
755,US,A1,US 2021/0269917 A1,064-865-122-872-662,2021-09-02,2021,US 201917257398 A,2019-07-03,EP 18181981 A;;EP 2019067821 W,2018-07-05,TRANSPARENT CONDUCTIVE FILM,"Described herein is a transparent conductive film including (a) a first laminate including at least two layers containing TiO 2 , ZrO 2 or HfO 2 , anda layer containing an organic compound in between the two layers containing TiO 2 , ZrO 2 or HfO 2 ,(b) a metal layer, and(c) a second laminate including at least two layers containing ZnO,a layer containing an organic compound between the two layers containing ZnO, anda metallic dopant other than zinc.",BASF COATINGS GMBH,CHO BORAM;;FLORES JEAN-CHARLES;;REINKE MICHAEL;;SUNG MYUNG MO;;JUNG JIN WON,BASF COATINGS GMBH (2019-02-22);;BASF SCHWEIZ AG (2018-07-24);;HANYANG UNIVERSITY (2019-02-21),https://lens.org/064-865-122-872-662,Patent Application,yes,10,0,9,9,0,C03C17/38;;C03C2217/94;;C23C16/45525;;C23C28/00;;C23C28/322;;C23C28/34;;C23C28/345;;C23C28/3455;;C23C28/40;;C23C28/42;;Y02E10/549;;H10K30/50;;C23C28/3455;;C23C28/322;;C23C28/42;;C23C16/45529;;C23C16/405;;H01B5/14;;B05D1/60;;H10K30/50;;C23C16/45531;;C23C28/30;;C23C28/42;;C23C28/44;;C23C28/02;;Y10T428/31678;;C23C28/322;;C23C28/3455;;H10K30/82;;H10K30/451,C23C16/455;;C23C28/00;;H01L51/42;;H01L51/44,,1,0,,,Okawa - JP 2016-012555 A - PCT D3 - MT - multiple metal+oxide layers - 2016 (Year: 2016),PENDING
756,JP,A,JP 2000234198 A,088-897-206-318-113,2000-08-29,2000,JP 2000002026 A,2000-01-07,US 22940099 A,1999-01-11,ELECTRODEPOSITION METHOD IN APERTURE,"PROBLEM TO BE SOLVED: To provide an improved method in which an electrically conductive material is easily deposited in a small aperture of a substrate at a relatively low price to form a via structure. SOLUTION: A method to deposit an electrically conductive material in an aperture of a substrate 10 includes a process to deposit a pre-treatment solution 100 in the aperture. The pre-treatment solution contains ions of the electrically conductive material to be plated, and preferably and substantially contains no protons. After the pre-treatment solution is deposited in the aperture, the substrate is immersed in a plating solution, and at least a part of the pre- treatment solution is left in the aperture at the same time. When the substrate is immersed in the plating solution, the electrically conductive material is electrically plated to form a via structure.",FUJITSU LTD,MICHAEL G LEE;;BEILIN SOLOMON I;;WILLIAM T CHOU;;UEN-CHO VINCENT WANG,,https://lens.org/088-897-206-318-113,Patent Application,no,0,2,1,1,0,,H05K3/40;;C25D7/00,,0,0,,,,DISCONTINUED
757,FR,A1,FR 2782727 A1,116-911-700-667-951,2000-03-03,2000,FR 9910903 A,1999-08-30,US 14460798 A,1998-08-31,ABAISSEMENT DE LA TENEUR EN SOUFFRE DE L'ESSENCE LORS DU CRAQUAGE CATHALYTIQUE FLUIDE,"<P>La présente invention se rapporte à l'abaissement de la teneur en soufre des essences et autres produits pétroliers, obtenu par des procédés de cracking catalytique. La présente invention a également pour objet une composition catalytique pour abaisser la teneur en soufre produite et un procédé d'abaissement de la teneur en soufre produite faisant usage de cette composition.Ce procédé pour abaisser la teneur en soufre d'une fraction de pétrole craquée catalytiquement, qui comprend le cracking catalytique d'une fraction de charge de pétrole contenant des composés organo-sulfurés à température élevée en présence d'un catalyseur abaissant la teneur en soufre du produit, consiste à utiliser un tamis moléculaire poreux ayant un constituant métallique situé à l'intérieur de la structure de pores du tamis moléculaire lequel comprend un métal dans un état d'oxydation supérieur à zéro, pour produire des produits de cracking liquide à teneur réduite en soufre.</P>",MOBIL OIL CORP,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/116-911-700-667-951,Patent Application,no,3,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;B01J29/06;;C10G35/085;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
758,NL,C2,NL 1012893 C2,125-543-982-616-828,2003-03-14,2003,NL 1012893 A,1999-08-24,US 14460798 A,1998-08-31,Verminderen van zwavel in benzine tijdens gefluïdiseerd katalytisch kraken.,,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/125-543-982-616-828,Granted Patent,no,3,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;C10G35/085;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
759,KR,A,KR 20160111431 A,124-191-787-267-594,2016-09-26,2016,KR 20167022346 A,2015-01-13,EP 14151392 A;;IB 2015050245 W,2014-01-16,HOLE TRANSPORTING AND LIGHT ABSORBING MATERIAL FOR SOLID STATE SOLAR CELLS,"본 발명은 퀴노질리노 아크리딘 기반이며, 광전기 장치, 특히 고체 상태 태양 전지에서 정공 수송 및 광 흡수 물질로서 사용되는 화학식 (I)의 화합물에 관한 것이다.",ECOLE POLYTECHNIQUE FED DE LAUSANNE (EPFL),QIN PENG;;NAZEERUDDIN MOHAMMAD KHAJA;;GRAETZEL MICHAEL;;KO JAEJUNG;;PAEK SANGHYUN;;CHO NARA,,https://lens.org/124-191-787-267-594,Patent Application,no,0,2,9,9,0,C09K11/06;;C09B57/00;;C09B57/008;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1096;;Y02E10/549;;Y02E10/542;;H10K85/652;;H10K85/655;;H10K85/6576;;H10K85/6572;;H10K85/657;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;H10K85/50;;C07D409/14;;C07F7/0816;;C09B57/008;;C09K11/06;;C09K2211/1096;;C09K2211/1092;;C09K2211/1051;;C09K2211/1029;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;C09B57/008;;C09B57/00;;C09K11/06;;C09K2211/1096;;C09K2211/1051;;C09K2211/1029;;C09K2211/1092;;Y02E10/549;;H10K85/40;;H10K85/652;;H10K85/655;;H10K85/657;;H10K85/791;;H10K85/6572;;H10K30/151;;H10K85/6576;;H01G9/2013;;H01G9/2018;;H01G9/2031;;H01G9/2059,C07D409/14;;C09B57/00;;C09K11/06;;H01L51/00,,0,0,,,,DISCONTINUED
760,IT,A0,IT MI991848 A0,151-796-427-775-641,1999-08-30,1999,IT MI991848 A,1999-08-30,US 14460798 A,1998-08-31,PROCEDIMENTO PER RIDURRE IL CONTENUTO DI ZOLFO DI UNA FRAZIONE DI PETR OLIO OTTENUTA MEDIANTE CRACKING CATALITICO,,GRACE W R & CO;;MOBIL OIL CORP,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/151-796-427-775-641,Patent Application,no,0,1,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,C10G35/085;;B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
761,US,B2,US 10326153 B2,155-596-649-969-846,2019-06-18,2019,US 201415105874 A,2014-12-22,US 201415105874 A;;US 201361919926 P;;US 2014/0071835 W,2013-12-23,System and method for returning material from the Br2 side of an H2/Br2 flow battery back after crossover,"A flow battery system includes a first tank having a hydrogen reactant, a second tank having a bromine electrolyte, at least one cell including a hydrogen reactant side operably connected to the first tank through an ¾ feed and return system and a bromine electrolyte side operably connected to the second tank, and a crossover return system. The crossover return system includes a vessel operably connected to the ¾ feed and return system and configured to receive an effluent containing a first portion of the hydrogen reactant and a second portion of the bromine electrolyte, the vessel configured to separate the first portion from the second portion. A first return line returns the first portion of the hydrogen reactant to the first tank and a second return line returns the bromine electrolyte to the second tank.",BOSCH GMBH ROBERT;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,ROBERT BOSCH GMBH (2016-10-31),https://lens.org/155-596-649-969-846,Granted Patent,yes,11,2,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/04007;;H01M8/04082;;H01M8/04089;;H01M8/04276;;H01M8/18;;H01M8/20,,1,0,,,"International Search Report corresponding to PCT Application No. PCT/US2014/071835, dated Apr. 17, 2015 (4 pages).",ACTIVE
762,US,A1,US 2018/0139199 A1,158-770-567-583-43X,2018-05-17,2018,US 201615354155 A,2016-11-17,US 201615354155 A,2016-11-17,SELECTIVE AUTHENTICATION SYSTEM,A method and authentication mechanism is provided. A request is sent to authenticate a user of the application from a mobile device to an authentication server. The authentication server identifies a user profile for the user containing one or more authentication schemes available to authenticate the user. The authentication schemes comprise a direct scheme in which the user provides a password and a federated authentication scheme. The authentication server determines a favored authentication scheme from one or more authentication schemes available based on a policy associated with the user profile. The mobile device displays a menu showing the authentication schemes available to allow the user to select an authentication scheme. The favored authentication scheme is displayed ahead of a remainder of the authentication schemes. The authentication server verifies credentials for the user profile using the selected authentication scheme to authenticate the user.,ADP LLC,AHUJA SANJOLI;;BRAUMAN MICHAEL JUSTIN;;CHO HANWOONG DARREN;;KOSOVAN BRENDA JANE;;VILLAVICENCIO FRANCISCO,ADP INC (2016-11-10),https://lens.org/158-770-567-583-43X,Patent Application,yes,0,21,2,2,0,H04L63/083;;H04L63/083;;H04L63/108;;H04L63/108;;H04L67/02;;H04L67/02;;H04L67/306;;H04L67/306;;H04W12/77;;H04W12/77,H04L29/06;;H04L29/08,,0,0,,,,ACTIVE
763,US,B2,US 9343204 B2,171-080-537-073-116,2016-05-17,2016,US 201313895934 A,2013-05-16,US 201313895934 A;;US 201261647754 P,2012-05-16,Electrical insulator apparatus and methods of retaining an electrical conductor with an electrical insulator apparatus,"An electrical insulator apparatus and methods of using the same are provided. The apparatus includes an insulator body formed about a central axis, the insulator body having a plurality of spaced fins positioned along an exterior of the insulator body. A first jaw portion is positioned on an upper portion of the insulator body. A second jaw portion is positioned proximate to the first jaw portion and is movable with respect to the first jaw portion. At least one fastener is connected between the first and second jaw portions. A jaw platform is positioned at least partially between the first and second jaw portions, wherein the first and second jaw portions and the jaw platform form a notch sized to receive an electrical conductor, wherein the jaw platform substantially lies within a first plane angled substantially between 6° and 184° with respect to the central axis of the insulator body.",MARMON UTILITY LLC,CLEMENT CHARLES J;;MERCEDAT GUBERSON;;WILLIAMS MICHAEL L;;CHO MAY;;JEAN LEONARD P,MARMON UTILITY LLC (2013-05-16),https://lens.org/171-080-537-073-116,Granted Patent,yes,6,4,2,2,0,H01B17/22;;H01B17/16;;H01B17/22,H01B17/16;;H01B17/22,,0,0,,,,ACTIVE
764,ZA,B,ZA 200704924 B,015-599-234-147-370,2009-04-29,2009,ZA 200704924 A,2005-12-21,US 63861604 P,2004-12-22,Methods for expression and purification of recombinant human growth hormone,,AMBRX INC,YING BUECHLER;;RICKY LIEU;;MICHAEL ONG;;STUART BUSSELL;;NIC KNUDSEN;;SUNG CHO HO,,https://lens.org/015-599-234-147-370,Granted Patent,no,0,0,7,195,0,A61K38/27;;A61K38/00;;A61K38/21;;A61K47/60;;C07H21/04;;C07K14/475;;C07K14/52;;C07K14/61;;C08G65/33396;;G01N33/6875;;G01N2500/00,A61K38/00;;A61K38/21;;A61K38/27;;A61K47/60;;C07H/;;C07H21/04;;C07K/;;C07K14/56;;C07K14/61;;C12Q/;;C12Q1/68;;G01N33/68;;G01N33/74,,0,0,,,,ACTIVE
765,WO,A3,WO 2006/073846 A3,019-036-126-366-249,2008-11-06,2008,US 2005/0046486 W,2005-12-21,US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P,2004-12-22,METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/019-036-126-366-249,Search Report,yes,3,0,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12N15/09;;A23J1/00,,0,0,,,,PENDING
766,US,A1,US 2020/0360609 A1,030-297-022-464-235,2020-11-19,2020,US 202016984605 A,2020-08-04,US 202016984605 A;;US 201715645657 A;;US 201662360550 P,2016-07-11,NOVEL SYRINGE SYSTEM FOR FLUID SEPARATION,"A syringe device and methods for device for separating liquids of different densities are provided where the syringe device includes a hollow syringe barrel, a perforated plunger seal with a seal hole, and a hollow plunging tube with a closed bottom with at least one tube hole.",BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIV,GUPTA ASHIM;;NEUMEISTER MICHAEL W;;CHO SOHYUNG;;MOORE SCOTT;;ZAJESKI JR ROBERT B,,https://lens.org/030-297-022-464-235,Patent Application,yes,4,1,1,3,0,A61M5/19;;A61M5/31511;;A61M5/3213;;A61M5/19;;C12M47/04;;A61M5/3213;;A61M5/31511,A61M5/19;;A61M5/315;;A61M5/32;;C12M1/00,,0,0,,,,PENDING
767,BR,A2,BR 112013026219 A2,058-564-204-295-946,2016-07-26,2016,BR 112013026219 A,2012-04-13,US 2012/0033675 W;;US 201161474848 P,2011-04-13,análogos de n-nucleosídeo 1'-substituída pirimidina para tratamento antiviral,"resumo patente de invenção: ""análogos de n-nucleosídeo 1'-substituída pirimidina para tratamento antiviral"". a presente invenção refere-se a compostos de fórmula i: nucleosídeos, fosfatos nucleosídicos e profármacos dos mesmos, em que r6 é cn, etenila, 2-haloeten-1-ila, ou (c2-c8)-alquin-1-ila. os compostos, composições, e métodos fornecidos são úteis para o tratamento de infecções por vírus flaviviridae.",GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;MISH MICHAEL R;;SQUIRES NEIL;;KIRSCHBERG THORSTEN A,,https://lens.org/058-564-204-295-946,Patent Application,no,0,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;C07H19/067;;C07H19/073;;C07H19/09;;C07H19/10;;C07H19/11,,0,0,,,,DISCONTINUED
768,EP,A4,EP 1153105 A4,060-666-026-108-632,2003-03-26,2003,EP 99965275 A,1999-12-16,US 9929799 W;;US 22210298 A,1998-12-29,CETANE UPGRADING VIA AROMATIC ALKYLATION,,EXXONMOBIL OIL CORP,COLLINS NICK ALLEN;;LANDIS MICHAEL E;;TIMKEN HYE KYUNG CHO;;TREWELLA JEFFREY C,,https://lens.org/060-666-026-108-632,Search Report,no,7,0,7,7,0,C10G29/205,C10G29/20,,1,0,,,See also references of WO 0039253A1,DISCONTINUED
769,EP,A4,EP 1836316 A4,087-638-956-143-495,2009-07-22,2009,EP 05857169 A,2005-12-21,US 2005/0046486 W;;US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P,2004-12-22,METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE,,AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/087-638-956-143-495,Search Report,no,1,0,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C07K14/61,,0,0,,,,DISCONTINUED
770,FR,B1,FR 2782727 B1,118-654-073-803-990,2005-11-04,2005,FR 9910903 A,1999-08-30,US 14460798 A,1998-08-31,ABAISSEMENT DE LA TENEUR EN SOUFFRE DE L'ESSENCE LORS DU CRAQUAGE CATHALYTIQUE FLUIDE,,MOBIL OIL CORP,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/118-654-073-803-990,Granted Patent,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;B01J29/06;;C10G35/085;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
771,CA,A1,CA 2281445 A1,115-470-148-464-175,2000-02-29,2000,CA 2281445 A,1999-08-25,US 14460798 A,1998-08-31,GASOLINE SULFUR REDUCTION IN FLUID CATALYTIC CRACKING,"The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reduction additive comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve. The molecular sieve is normally a large pore size zeolite such as USY or zeolite beta or an intermediate pore size zeolite such as ZSM-5. The metal is normally a metal of Period 3 of the Periodic Table, preferably zinc or vanadium. The sulfur reduction catalyst may be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst.",MOBIL OIL CORP;;GRACE W R & CO,TIMKEN HYE KYUNG CHO;;CHESTER ARTHUR WARREN;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/115-470-148-464-175,Patent Application,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,C10G35/085;;B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
772,IT,A1,IT MI991848 A1,131-835-244-113-980,2001-03-02,2001,IT MI991848 A,1999-08-30,US 14460798 A,1998-08-31,PROCEDIMENTO PER RIDURRE IL CONTENUTO DI ZOLFO DI UNA FRAZIONE DI PETROLIO OTTENUTA MEDIANTE CRACKING CATALITICO,,GRACE W R & CO;;MOBIL OIL CORP,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/131-835-244-113-980,Patent Application,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,C10G35/085;;B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
773,WO,A1,WO 2021/030378 A1,140-624-218-250-849,2021-02-18,2021,US 2020/0045827 W,2020-08-11,US 201962885529 P,2019-08-12,FLUORESCENCE-BASED DETECTION OF PROTEIN AGGREGATION AND FIBER OPTIC-BASED BENCHTOP INSTRUMENT,A sensor can include a nanostructure in a housing configured to contact a sample.,MASSACHUSETTS INST TECHNOLOGY,STRANO MICHAEL;;KOZAWA DAICHI;;GONG XUN;;SALEM DANIEL;;CHO SOOYEON;;NGUYEN FREDDY T,,https://lens.org/140-624-218-250-849,Patent Application,yes,2,0,2,2,6,G01N2021/6484;;G01N33/587;;G01N21/6489;;G01N2021/6434;;G01N21/645;;G01N2021/7786;;G01N2021/7723;;G01N2021/773;;G01N2021/772;;G01N2021/6419;;G01N21/6486;;G01N2021/6484;;G01N33/6809,B82Y15/00;;G01N21/64;;G01N33/52;;G01N33/53,,0,0,,,,PENDING
774,NZ,A,NZ 616732 A,142-823-286-261-974,2016-09-30,2016,NZ 61673212 A,2012-04-13,US 2012/0033675 W;;US 201161474848 P,2011-04-13,1’-substituted pyrimidine n-nucleoside analogs for antiviral treatment,"Disclosed is a set of 36 specific compounds which are uracil and cytosine nitrile containing pyrimidine N-nucleoside analogues / cyano sofosbuvir analogs for treating viruses of the flaviviridae family including the treatment of hepatitis C virus (HCV), wherein for the general formula I, Base is selected from uracil and cytosine; R1 is H or alkyl; R2 is H or ORa; or R1 and R2 taken together with the carbon to which they are attached form a 3- to 6-membered cycloalkyl ring wherein 1 to 3 carbon atoms of said cycloalkyl ring is optionally replaced by oxygen; R3, R4, and R5 are each independently H, ORa, or azido; R6 is cyano; each Ra is independently H, alkyl, or acyl; R7 is a phosphate or phosphoramidate analogue or derivative; R8 is H or alkyl; and wherein the remaining substituents are as defined herein. Also disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound as defined above and a pharmaceutically acceptable carrier, and optionally further comprising at least one additional therapeutic agent selected from the group consisting of interferons, ribavirin analogs, NS3 protease inhibitors, NS5a inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, cyclophilin inhibitors, hepatoprotectants, other nucleoside inhibitors of HCV, non-nucleoside inhibitors of HCV, and other drugs for treating HCV. Some of the 36 specific compounds include isopropyl (2S)-2-[[[(2R,3R,4R,5S)-5-cyano-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate, (2S)-2-[[[(2R,3R,4R,5S)-5-cyano-5-(2-oxo-4-amino-pyrimidin-1-yl)-3,4-dihydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate and (2S)-2-[[[(1R)-1-[(2R,3R,4R,5S)-5-cyano-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-4-methyl-tetrahydrofuran-2-yl]ethoxy]-phenoxy-phosphoryl]amino]propanoate.",GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/142-823-286-261-974,Patent Application,no,0,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;A61K31/661;;A61K31/6615;;A61K31/664;;A61K31/675;;A61K31/7068;;A61K31/7072;;C07D239/47;;C07D239/54;;C07H19/067;;C07H19/073;;C07H19/09;;C07H19/10;;C07H19/11,,0,0,,,,DISCONTINUED
775,DE,T5,DE 112021003905 T5,160-105-135-725-782,2023-05-11,2023,DE 112021003905 T,2021-06-28,US 202016935433 A;;US 2021/0039363 W,2020-07-22,THERMISCHE STIMULATION UND NACHFOLGENDE KÜHLUNG FÜR EINE VOLLSTÄNDIG IMPLANTIERBARE LVAD-STEUERUNG,"Ein Verfahren zum Kühlen eines Säugetiers mit einer implantierbaren Blutpumpe. Das Verfahren schließt das Messen einer Temperatur einer internen Steuerung ein, wobei die interne Steuerung, die mit der implantierbaren Blutpumpe kommuniziert, eine Warnung erzeugt wird, wenn die Temperatur der internen Steuerung einen vorbestimmten Temperaturschwellenwert überschreitet.",MEDTRONIC INC,EGGEN MICHAEL D;;CHO YONG K;;SCHEINER AVRAM;;RAGHUPATHY RAMESH;;RADTKE THOMAS W,,https://lens.org/160-105-135-725-782,Patent Application,no,2,0,3,3,0,A61M60/122;;A61M60/205;;A61M60/508;;A61M60/585;;A61M60/592;;A61M2205/18;;A61M2205/3368;;A61M2205/3507;;A61M2205/3606;;A61M60/135;;A61M60/50;;A61F7/08;;A61F7/10;;A61F2007/0011;;A61M2205/18;;A61M2205/3372;;A61M2205/3584;;A61M2205/3606;;A61M2205/50;;A61M2205/8206;;A61M2230/50,A61M60/585;;A61B5/01;;A61M60/122;;A61M60/205;;A61M60/508;;A61M60/592,,0,0,,,,PENDING
776,US,B2,US 7973842 B2,045-724-608-714-287,2011-07-05,2011,US 8130208 A,2008-04-14,US 8130208 A;;US 23020502 A,2002-08-29,High intrascene dynamic range NTSC and PAL imager,"The invention provides a new method and apparatus for NTSC and PAL image sensors which employs fusion of adjacent row pixel charge samples to generate image data for a row. A variety of fusion schemes are possible for fusing the pixel signals from the adjacent rows. The rows of pixels are scanned so that each scan takes an odd row signal sample and, in some cases, an adjacent even row signal sample when specified conditions are met. One sampled row of the two adjacent rows integrate an image with a first integration period while the other adjacent row integrates an image with a second integration period.",APTINA IMAGING CORP,CHO KWANG-BO;;SUBBOTIN IGOR;;KAPLINSKY MICHAEL;;BARNA SANDOR L;;SLAYTON GARY E,APTINA IMAGING CORPORATION (2009-07-08);;MICRON TECHNOLOGY INC (2002-10-30),https://lens.org/045-724-608-714-287,Granted Patent,yes,24,2,4,4,0,H04N23/70;;H04N23/741;;H04N25/583;;H04N25/616;;H04N25/75;;H04N3/155;;H04N23/741;;H04N23/70,H04N5/335;;H04N5/235;;H04N5/345;;H04N5/353;;H04N5/355;;H04N5/374;;H04N5/378,348/296;;348/304;;348/305;;348/308;;257/291;;257/292,6,2,174-102-508-157-787;;119-748-087-426-317,10.1109/40.743681;;10.1109/4.972156,"I.L. Fujimori, (C.G. Sodini), A Differential CMOS Passive Pixel Imager, pp. 28-29.;;Jim Adams, Ken Parulski, Kevin Spaulding; Color Processing in Digital Cameras, Micro, IEEE, pp. 20-29, Nov.-Dec. 1998, Micro, IEEE.;;Stuart Kleinfelder, Sukhwan Lim, Xinqiao Liu, and Abbas El Gamal; A 10,000 Frames/s CMOS Digital Pixel Sensor, IEEE Journal of Solid-State Circuits, vol. 36, No. 12, pp. 2049-2059, Dec. 2001.;;PB-0100/PB-0101 1/5 Inch CMOS Active-Pixel Digital Image Sensors, Product Specification, Mar. 2000 (Version 3.0).;;Kevin Buckley, Selecting an Analog Front End for Imaging Applications, vol. 34, No. 06, pp. 1-8, Oct. 2000; [retrieved on Jul. 26, 2002]. Retrived from the Internet: .;;Stuart A. Taylor, CCD and CMOS Imaging Array Technologies: Technology Review; Technical Report EPC-1998-106, pp. 1-14, 1998.",EXPIRED
777,US,A1,US 2003/0089639 A1,052-203-483-434-256,2003-05-15,2003,US 30873702 A,2002-12-03,US 30873702 A;;US 22154098 A,1998-12-28,Gasoline sulfur reduction in fluid catalytic cracking,"
   The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reduction catalyst composition comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve as well as a cerium component which enhances the stability and sulfur reduction activity of the catalyst. The molecular sieve is normally a faujasite such as USY. The primary sulfur reduction component is normally a metal of Period 3 of the Periodic Table, preferably vanadium. The sulfur reduction catalyst may be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst. 
",CHESTER ARTHUR W.;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G.;;ZIEBARTH MICHAEL S.,CHESTER ARTHUR W;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL S,MOBIL OIL CORPORATION (1999-02-08);;W.R. GRACE & CO.-CONN (1999-04-06),https://lens.org/052-203-483-434-256,Patent Application,yes,52,26,4,75,0,B01J29/166;;B01J2229/42;;C10G11/05;;C10G11/05;;B01J2229/42;;B01J29/166,B01J29/16;;C10G11/05,208/120.01;;208/120.2;;208/120.25;;208/120.35;;208/208,0,0,,,,EXPIRED
778,AU,B2,AU 2005/323106 B2,050-038-122-093-290,2010-07-29,2010,AU 2005/323106 A,2005-12-21,US 68097705 P;;US 65574405 P;;US 63861604 P;;US 72796805 P;;US 2005/0046486 W,2004-12-22,Methods for expression and purification of recombinant human growth hormone,,AMBRX INC,BUSSELL STUART;;ONG MICHAEL;;CHO HO SUNG;;KNUDSEN NICK;;LIEU RICKY;;BUECHLER YING,,https://lens.org/050-038-122-093-290,Granted Patent,no,1,0,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12N15/09;;A23J1/00,,0,0,,,,INACTIVE
779,DK,A,DK 199901178 A,078-599-959-013-762,2000-03-01,2000,DK PA199901178 A,1999-08-25,US 14460798 A,1998-08-31,Benzinsvovl-reduktion ved fluid-katalytisk krakning,,MOBIL OIL CORP;;GRACE W R & CO,WARREN CHESTER ARTHUR;;CHO TIMKEN HYE KYUNG;;ROBERIE TERRY G;;SCOTT ZIEBARTH MICHAEL,,https://lens.org/078-599-959-013-762,Patent Application,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;B01J29/06;;C10G35/085;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
780,CN,A,CN 101356269 A,089-717-471-723-078,2009-01-28,2009,CN 200580044463 A,2005-12-21,US 63861604 P,2004-12-22,Methods for expression and purification of recombinant human growth hormone,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,YING BUECHLER;;RICKY LIEU;;MICHAEL ONG;;STUART BUSSELL;;NICK KNUDSEN;;SUNG CHO HO,,https://lens.org/089-717-471-723-078,Patent Application,no,0,1,7,195,0,A61K38/27;;A61K38/00;;A61K38/21;;A61K47/60;;C07H21/04;;C07K14/475;;C07K14/52;;C07K14/61;;C08G65/33396;;G01N33/6875;;G01N2500/00,C12N15/09;;A23J1/00;;A61K38/00;;A61K38/21;;A61K38/27;;A61K47/60;;C07H21/04;;C07K14/56;;C07K14/61;;C12Q1/68;;G01N33/68;;G01N33/74,,0,0,,,,DISCONTINUED
781,US,B2,US 7947473 B2,129-326-739-395-476,2011-05-24,2011,US 87410008 A,2008-01-31,US 87410008 A;;US 31575205 A;;US 72796805 P;;US 68097705 P;;US 65574405 P;;US 63861604 P,2004-12-22,Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,AMBRX INC (2006-03-31),https://lens.org/129-326-739-395-476,Granted Patent,yes,105,19,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12N15/09;;A61K38/27;;C07K14/00,435/69.4;;424/123;;424/124;;514/11.4;;530/399;;530/416,99,97,030-545-746-430-807;;006-157-672-562-73X;;000-223-149-311-914;;074-890-940-229-924;;015-459-649-895-675;;003-471-282-689-694;;084-492-105-054-015;;098-174-731-651-292;;003-631-534-496-072;;006-786-192-019-844;;041-664-696-817-712;;042-241-278-130-768;;090-657-904-276-044;;100-381-451-046-460;;006-095-947-008-535;;003-101-140-171-904;;095-689-091-070-353;;104-526-803-164-736;;027-740-307-377-384;;052-526-807-575-466;;094-619-099-798-015;;027-221-602-638-634;;117-298-184-780-248;;104-335-738-580-036;;028-862-168-091-90X;;056-201-471-905-934;;070-383-251-783-098;;028-567-118-036-513;;005-712-635-226-116;;050-825-529-117-306;;150-512-327-210-48X;;047-237-206-017-563;;017-940-142-904-249;;081-098-345-341-182;;010-847-093-078-575;;027-829-588-585-761;;153-232-460-964-283;;126-128-839-153-523;;122-388-810-565-095;;062-095-790-501-25X;;083-348-315-692-16X;;085-498-590-431-913;;104-063-848-067-130;;069-591-544-766-903;;010-872-968-433-256;;027-127-290-904-954;;037-574-244-923-342;;018-560-322-257-247;;068-050-852-096-624;;029-171-836-207-263;;001-076-067-628-36X;;001-137-247-333-266;;028-668-540-796-174;;079-996-842-246-699;;006-451-527-297-818;;043-632-912-449-253;;032-412-591-971-193;;039-289-782-216-880;;050-491-094-261-212;;048-739-184-191-048;;004-571-213-214-147;;139-370-722-026-325;;117-298-184-780-248;;001-168-243-787-836;;003-692-671-892-767;;146-959-413-651-106;;022-597-328-979-199;;097-412-635-296-694;;026-151-208-979-214;;101-171-874-734-776;;007-242-440-136-566;;010-401-085-673-837;;010-929-566-271-076;;100-286-864-518-416;;012-388-439-961-094;;030-979-115-550-499;;022-879-584-224-460;;084-341-539-493-404;;088-437-095-235-130;;019-911-024-298-495;;120-184-720-533-797;;030-130-464-546-217;;110-094-292-858-47X;;091-231-835-456-006;;005-631-024-674-820;;101-575-504-070-651;;005-426-365-134-686;;008-878-757-321-700;;008-340-022-598-528;;004-574-009-337-856;;169-736-421-398-039;;040-375-581-789-283;;029-884-043-437-78X;;093-281-504-176-200;;014-268-011-522-679;;064-029-904-826-616;;047-362-058-327-502,8756685;;10.1021/bi960513b;;1609277;;10.1126/science.256.5064.1673;;10.1016/s0969-2126(96)00152-9;;8994971;;1932028;;10.1021/bi00110a004;;11297608;;10.1210/jc.86.4.1716;;10.1210/jcem.86.4.7403;;8505324;;10.1016/s0021-9258(19)50299-x;;10.1046/j.1365-2265.2002.01507.x;;11966740;;10.1006/jmbi.2001.5348;;11851338;;10.1073/pnas.81.17.5403;;6089201;;pmc391712;;7169009;;10.1089/dna.1.1982.1.239;;10.1210/me.10.5.508;;10.1210/mend.10.5.8732682;;8732682;;8454051;;10.1016/0014-5793(93)80028-s;;10.1210/jcem.82.2.3725;;09024232;;10.1210/jc.82.2.435;;9024232;;10.1073/pnas.92.4.959;;pmc42616;;7862673;;10.1016/s0021-9258(18)68577-1;;3372509;;10.1073/pnas.93.22.12394;;pmc38002;;8901592;;8943276;;10.1074/jbc.271.50.32197;;10.1038/26773;;9774108;;10.2210/pdb1blw/pdb;;10.1677/joe.0.1750055;;12379490;;10.1016/s0021-9258(18)48266-x;;3571265;;10.1016/0959-440x(95)80016-t;;7773741;;15501033;;10.1016/j.bmcl.2004.09.059;;10.1002/anie.199506211;;6467175;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;6363212;;10.1016/0378-1119(83)90222-6;;11880038;;10.1016/s1074-5521(02)00094-7;;10.1002/macp.1978.021790204;;7763976;;10.1016/0958-1669(93)90011-k;;10.1021/ja00202a052;;6220717;;10.1016/0006-291x(83)91828-4;;10.1073/pnas.88.1.189;;pmc50775;;1986365;;10.1016/s0040-4020(01)90305-9;;10.1126/science.3140377;;3140377;;1923780;;pmc328820;;10.1093/nar/19.18.5081;;6757758;;10.1038/300706a0;;10.1016/0003-2697(83)90131-8;;6193731;;875032;;10.1016/s0022-2836(77)80200-3;;10.1016/s0021-9258(18)82348-1;;8340419;;10.1038/nsb0594-283;;7664033;;2994214;;10.1126/science.2994214;;8352595;;10.1146/annurev.bi.62.070193.002411;;1332541;;10.1016/0003-2697(92)90433-8;;10.1111/j.1432-1033.1995.0788h.x;;10.1111/j.1432-1033.1995.tb20622.x;;7607253;;10.1006/jmbi.1997.1132;;9245591;;10.1096/fasebj.13.1.41;;9872928;;10.1006/prep.1997.0744;;9226723;;pmc252500;;2993646;;10.1128/jvi.56.1.153-160.1985;;10.1021/jo034984x;;14604354;;3541892;;10.1042/bj2370001;;pmc1146940;;pmc321798;;10.1093/nar/13.12.4431;;2989795;;10.1016/0076-6879(87)54086-1;;2828857;;7030620;;10.3109/10409238109108703;;12148987;;10.1021/ja027007w;;10.1073/pnas.172226299;;12154230;;pmc123203;;12920298;;10.1126/science.1084772;;12404640;;10.1002/1439-7633(20021104)3:11<1135::aid-cbic1135>3.0.co;2-m;;10.1002/chin.198535327;;8703002;;10.1074/jbc.271.36.21969;;10.1126/science.3685986;;3685986;;10.1021/ja961216x;;10.1002/anie.199506211;;10.1021/jo00241a009;;pmc369166;;3915774;;10.1128/mcb.5.12.3376-3385.1985;;10.1128/mcb.5.12.3376;;10.1038/1921227a0;;13882203;;8850022;;10.1385/0-89603-332-5:369;;pmc215567;;10.1128/jb.158.3.1165-1167.1984;;6327630;;10966479;;10.1146/annurev.biochem.69.1.923;;6337371;;10.1073/pnas.80.1.21;;pmc393301;;10.1128/jb.154.2.737-742.1983;;pmc217523;;6841315;;8314773;;10.1016/s0021-9258(19)85209-2;;10.1021/ja0370037;;14505376;;1458545;;12119302;;10.1074/jbc.m205854200;;9398858;;10.1038/ng1297-491;;10.1126/science.1057718;;11313495;;11102869;;10.1016/s1367-5931(00)00148-4;;10.1021/bi9617973;;9116020;;pmc311518;;10.1093/nar/14.12.5115;;3460029;;1883529;;10.1007/bf01024990;;2187475;;10.1016/0076-6879(91)02017-4;;1784180;;10.1126/science.1553546;;1553546;;9989500;;10.1016/s0092-8674(00)80962-9;;pmc397852;;10.1073/pnas.82.11.3688;;3159018;;10.1002/bit.260290911;;18576565;;12754376;;pmc164450;;10.1073/pnas.1132122100;;10.1016/j.chembiol.2003.11.004;;14652071;;2647707;;10.1007/bf02628459;;10.1021/ja01523a064;;10.1093/nar/16.14.6987;;3405755;;pmc338346;;3862099;;10.1073/pnas.82.17.5824;;pmc390645;;10.1002/pro.5560070223;;9521119;;pmc2143905;;10.1021/bc00015a010;;1381617;;7510283;;10.1016/s0021-9258(17)37271-x;;10.1016/s1074-5521(97)90312-4;;9375252,"Pearce, KH et al. ""Structural and mutational analysis of affinity-inert contact residues at the growth hormone-receptor interface,"" Biochemistry. Aug. 13, 1996;35(32)10300-7.;;Powers, R et al. ""Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy,"" Science Jun. 19, 1992;256(5064):1673-7.;;Radhakrishnan, R et al. ""Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography,"" Structure Dec. 15, 1996;4(12):1453-63.;;Redfield, C et al. ""Secondary structure and topology of human interleukin 4 in solution,"" Biochemistry Nov. 19, 1991;30(46):11029-35.;;Ross, RJM et al. ""Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer,"" J Clin Endocrinol Metab. Apr. 2001;86(4):1716-23.;;Rottman, JN et JI Gordon. ""Comparison of the patterns of expression of rat intestinal fatty acid binding protein/ human growth hormone fusion genes in cultured intestinal epithelial cell lines and in the gut epithelium of transgenic mice,"" J Biol Chem. Jun. 5, 1993;268(16):11994-2002.;;Rowland, JE et al. ""A novel bioassay for human somatogenic activity in serum samples supports the clinical reliability of immunoassays,"" Clin Endocrinol (Oxf). Apr. 2002;56(4):475-85.;;Schiffer, C et al. ""Structure of a phage display-derived variant of human growth hormone complexed to two copies of the extracellular domain of its receptor: evidence for strong structural coupling between receptor binding sites,"" J Mol Biol. Feb. 15, 2002;316(2):277-89.;;Schoner, BE et al. ""Role of mRNA translational efficiency in bovine growth hormone expression in Escherichia coli,"" Proc Natl Acad Sci U S A. Sep. 1984;81(17):5403-7.;;Seeburg, PH. ""The human growth hormone gene family: nucleotide sequences show recent divergence and predict a new polypeptide hormone,"" DNA 1982;1(3):239-49.;;Silva, CM et al. ""Characterization and cloning of STAT5 from IM-9 cells and its activation by growth hormone,"" Mol Endocrinol. May 1996;10(5):508-18.;;Sobrier, ML et al. ""Expression and binding properties of two isoforms of the human growth hormone receptor,"" FEBS Lett. Mar. 15, 1993;319(1-2)16-20.;;Sobrier, ML et al. ""Nine novel growth hormone receptor gene mutations in patients with Laron syndrome,"" J Clin Endocrinol Metab. Feb. 1997;82(2):435-7.;;Souza, SC et al. ""A single arginine residue determines species specificity of the human growth hormone receptor,"" Proc Natl Acad Sci U S A. Feb. 14, 1995;92(4):959-63.;;Spencer, SA et al. ""Rabbit liver growth hormone receptor and serum binding protein. Purification, characterization, and sequence,"" J Biol Chem. Jun. 5, 1988;263(16):7862-7.;;Stallings-Mann, ML et al. ""Alternative splicing of exon 3 of the human growth hormone receptor is the result of an unusual genetic polymorphism,"" Proc Natl Acad Sci U S A. Oct. 29, 1996;93(22):12394-9.;;Sundstrom, Metal. ""Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 A resolution,"" J Biol Chem. Dec. 13, 1996;271(50):32197-203.;;Syed, RS et al. ""Efficiency of signalling through cytokine receptors depends critically on receptor orientation,"" Nature. Oct. 1, 1998;395(6701):511-6.;;Talamantes, F et R Ortiz. ""Structure and regulation of expression of the mouse GH receptor,"" J Endocrinol. Oct. 2002; 175(1):55-9.;;Teh, LC et al. ""Methionine oxidation in human growth hormone and human chorionic somatomammotropin. Effects on receptor binding and biological activities,"" J Biol Chem. May 15, 1987;262(14):6472-7.;;Mott et al., ""Four-helix Bundle Growth Factors and Their Receptors: Protein-Protein Interactions"" Current Opinion in Structural Biology, 1995 5:114-121.;;Deiters et al., ""Site-specific PEGylation of Proteins Containing Unnatural Amino Acids"", Bioorganic & Medicinal Chemistry Letters, Dec. 6, 2004, 14(23):5743-5745.;;E.A. Cornish, ""Probing Protein Structure and Function with Expanded Genetic Code"", Angew. Chem. Int. Ed. Eng, 1995 34:621-633.;;Abuchowski, A. et al. ""Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates,"" Cancer Biochem Biophys. Jun. 1984;7(2):175-86.;;Altschul, SF et al. ""Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,"" Nucleic Acids Res. Sep. 1, 1997;25(17):3389-402.;;Altschul, SF et al. ""Basic local alignment search tool,"" J Mol Biol. Oct. 5, 1990;215(3):403-10.;;Amann, E et al., ""Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli,"" Gene. Nov. 1983;25(2-3):167-78.;;Anderson, JC et al., ""Exploring the limits of codon and anticodon size,"" Chem Biol. Feb. 2002;9(2):237-44.;;Andresz, H et al. Abstract of ""Chemische Synthese verzweigter Polysaccharide, 5; Kopplung von Oligosacchariden und Amylose an verschiedene Träger durch Hydrazonbindung,"" Makromol. Chem. 1978;179:301 Abstract.;;Arnold, FH. ""Protein engineering for unusual environments,"" Curr Opin Biotechnol. Aug. 1993;4(4):450-5.;;Azoulay, M., et al. ""Glutamine analogues as Potential Antimalarials,"" Eur. J. Med. Chem. (1991); 26(2):201-5.;;Bain, JD, et al. ""Biosynthetic site-specific incorporation of a non-natural amino acid into a polypeptide,"" J. Am Chem Soc 1989;111(20):8013-8014.;;Ballance, Dj et al., ""Transformation of Aspergillus nidulans by the orotidine-5'-phosphate decarboxylase gene of Neurospora crassa,"" Biochem Biophys Res Commun. Apr. 15, 1983;112(1):284-9.;;Barany, F. et al., ""Genetic disease detection and DNA amplification using cloned thermostable ligase,"" Proc Natl Acad Sci U S A. Jan. 1, 1991;88(1):189-93.;;Barton, DHR et al., ""Synthesis of Novel alpha-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-alpha-Amino-Adipic Acids, L-alpha-aminopimelic Acid and Appropriate Unsaturated Derivatives,"" Tetrahedron (1987) 43:4297-4308.;;Bass, S et al., ""Mutant Trp repressors with new DNA-binding specificities,"" Science (1988) 242:240-245.;;Batzer, MA et al., ""Enhanced evolutionary PCR using oligonucleotides with inosine at the 3'-terminus,"" Nucleic Acids Res. Sep. 25, 1991;19(18):5081.;;Beach, D et al., ""Functionally homologous cell cycle control genes in budding and fission yeast,"" Nature Dec. 1982; 300:706-709.;;Beauchamp, CO et al., ""A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin,"" Anal Biochem. May 1983;131(1):25-33.;;Bernstein, FC, et al. ""The protein data bank: a computer-based archival file for macromolecular structures,"" J. Mol. Biol. 1977; 112:535-542.;;Boissel, JP et al., ""Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure,"" J Biol Chem. Jul. 25, 1993;268(21):15983-93.;;Boles, JO et al. ""Bio-incorporation of telluromethionine into buried residues of dihydrofolate reductase,"" Nat Struct Biol. May 1994;1(5):283-4.;;Botstein, D et D Shortle, ""Strategies and applications of in vitro mutagenesis,"" Science. Sep. 20, 1985;229 (4719):1193-201.;;Brunner, J. ""New photolabeling and crosslinking methods,"" Annu Rev Biochem. 1993;62:483-514.;;Buchner, J. et al., ""A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies,"" Anal. Biochem. 1992; 205(2): 263-270.;;Bückmann et al. ""Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol),"" Makromol. Chem. 1981;182:1379-84.;;Budisa, N. et al. ""High-level biosynthetic substitution of methionine in proteins by its analogs 2-aminohexanoic acid, selenomethionine, telluromethionine and ethionine in Escherichia coli,"" Eur J Biochem. Jun. 1, 1995;230(2):788-96.;;Budisa, N. et al., ""Bioincorporation of telluromethionine into proteins: a promising new approach for X-ray structure analysis of proteins,"" J Mol Biol. Jul. 25, 1997;270(4):616-23.;;Budisa, N. et al., ""Toward the experimental codon reassignment in vivo: protein building with an expanded amino acid repertoire,"" FASEB J. Jan. 1999;13(1):41-51.;;Cai, X-Y et al., ""Expression, Purification, and Characterization of an Activated Cytokine-Suppressive Anti-inflammatory Drug-Binding Protein 2 (CSBP2) Kinase from Baculovirus-Infected Insect Cells,"" Protein Expression and Purification 1997; 10(2):263-74.;;Carbonell, LF et al., ""Baculovirus-mediated expression of bacterial genes in dipteran and mammalian cells,"" J Virol. Oct. 1985;56(1):153-60.;;Carrasco, M. and R. Brown, ""A Versatile Set of Aminooxy Amino Acids for the Synthesis of Neoglycopeptides,"" J. Org. Chem. (2003); 68(23): 8853-8858.;;Carter, P. ""Site-directed mutagenesis,"" Biochem J. Jul. 1, 1986; 237(1):1-7.;;Carter, Petal. ""Improved oligonucleotide site-directed mutagenesis using M13 vectors"" Nucleic Acids Res. Jun. 25, 1985;13(12):4431-43.;;Carter, P. ""Improved oligonucleotide-directed mutagenesis using M13 vectors"" Methods Enzymol. 1987;154:382-403.;;Chaiken, IM. ""Semisynthetic peptides and proteins,"" CRC Crit Rev Biochem. 1981;11(3):255-301.;;Chin, JW et al., ""Addition of p-azido-L-phenylalanine to the genetic code of E. coli,"" J Am Chem Soc. Aug. 7, 2002;124 (31):9026-7.;;Chin, JW et al., ""Addition of a photocrosslinking amino acid to the genetic code of Escherichia coli,"" Proc Nati Acad Sci U S A. Aug. 20, 2002;99(17):11020-4. Epub Aug. 1, 2002.;;Chin, JW et al., ""An expanded eukaryotic genetic code,"" Science. Aug. 15, 2003;301(5635):964-7.;;Chin, JW & P. G. Schultz, ""In vivo photocrosslinking with unnatural amino acid mutagenesis,"" Chembiochem. Nov. 4, 2002; 3(11): 1135-7.;;Christie, B.D. & Rapoport, H. ""Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization,"" J. Org. Chem. 1985;50(8):1239-1246.;;Clark, R et al., ""Long-acting growth hormones produced by conjugation with polyethylene glycol,"" J Biol Chem. Sep. 6, 1996;271(36):21969-77.;;Corey, D.R., Schultz, P.G. ""Generation of a hybrid sequence-specific single-stranded deoxyribonuclease,"" Science 1987; 238(4832):1401-1403.;;Cornish, VW, et al., ""Site-Specific Protein Modification Using a Ketone Handle,"" J. Am. Chem. Soc. 1996; 118 (34):8150-8151.;;Cornish, VW et al., ""Probing Protein Structure and Function with an Expanded Genetic Code,""Angew Chem Int Ed Engl,1995;34(6):621-33.;;Craig, J.C. et al. ""Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylamino)-1-methylbutyl]amino] quinoline (Chloroquine),"" J. Org. Chem. 1988; 53(6):1167-1170.;;Cregg, JM et al., ""Pichia pastoris as a host system for transformations,"" Mol Cell Biol. Dec. 1985;5(12):3376-85.;;Crick, FHC, et al. ""General nature of the genetic code for proteins,"" Nature. Dec. 30, 1961;192:1227-32.;;Dale et al., Oligonucleotide-directed random mutagenesis using the phosphorothioate method, Methods Mol. Biol.1996;57:369-374.;;Das, S et al., ""Transformation of Kluyveromyces fragilis,"" J Bacteriol. Jun. 1984;158(3):1165-7.;;Dawson, P. E. and S. B. H. Kent, ""Synthesis of native proteins by chemical ligation,"" Annu. Rev. Biochem. 2000; 69:923-60.;;De Boer, HA et al., ""The tac promoter: a functional hybrid derived from the trp and lac promoters,"" Proc Natl Acad Sci U S A. Jan. 1983;80(1):21-5.;;De Louvencourt, L et al., ""Transformation of Kluyveromyces lactis by killer plasmid DNA,"" J Bacteriol. May 1983;154(2):737-42.;;Debinski, W et al. ""A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin,"" J Biol Chem. Jul. 5, 1993;268(19):14065-70.;;Deiters, A., et al., ""Adding Amino Acids with Novel Reactivity to the Genetic Code of Saccharomyces cerevisiae,"" J. Am. Chem. Soc. 2003; 125(39):11782-11783.;;Delgado, C et al., ""The uses and properties of PEG-linked proteins,"" Crit Rev Ther Drug Carrier Syst. 1992;9 (3-4):249-304.;;Dennis, MS et al., ""Albumin binding as a general strategy for improving the pharmacokinetics of proteins,"" J Biol Chem. Sep. 20, 2002;277(38):35035-43. Epub Jul. 15, 2002.;;Dolphin, CT et al., ""Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome,"" Nat Genet. Dec. 1997;17(4):491-4.;;Doring, V et al., ""Enlarging the amino acid set of Escherichia coli by infiltration of the valine coding pathway,"" Science. Apr. 20, 2001;292(5516):501-4.;;Dougherty, DA. ""Unnatural amino acids as probes of protein structure and function,"" Curr Opin Chem Biol. Dec. 2000;4(6):645-52.;;Duewel, H et al., ""Incorporation of trifluoromethionine into a phage lysozyme: implications and a new marker for use in protein 19F NMR,"" Biochemistry. Mar. 18, 1997;36(11):3404-16.;;Eghtedarzadeh MK & S Henikoff ""Use of oligonucleotides to generate large deletions"" Nucleic Acids Res. Jun. 25, 1986;14(12):5115.;;Elling L et MR Kula., ""Immunoaffinity partitioning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies,"" Biotechnol Appl Biochem. Jun. 1991;13(3):354-62.;;Elliott, S et al., ""Yeast-derived recombinant human insulin-like growth factor I: production, purification, and structural characterization,"" J Protein Chem. Feb. 1990;9(1):95-104.;;Ellman, J.A., Mendel, D., Anthony-Cahill, S., Noren, C.J., Schultz, P.G. ""Biosynthetic method for introducing unnatural amino acids site-specifically into proteins,"" Methods in Enz., 1992; 202:301-336.;;Ellman, JA, et al. ""Site-specific incorporation of novel backbone structures into proteins,"" Science. Jan. 10, 1992;255 (5041):197-200.;;England, P. M., et al., ""Backbone mutations in transmembrane domains of a ligand-gated ion channel: implications for the mechanism of gating,"" Cell. Jan. 8, 1999;96(1):89-98.;;Eppstein et al., ""Biological Activity of Liposome-Encapsulated Murine Interferon is Mediated by a Cell Membrane Receptor,"" Proc. Natl. Acad. Sci. U.S.A.(1985); 82: 3688-3692.;;Fieschko, JC et al., ""Controlled expression and purification of human immune interferon from high-cell-density fermentations of Saccharomyces cerevisiae,"" Biotech. Bioeng. (1987) 29(9):1113-21.;;Forster, AC et al., ""Programming peptidomimetic syntheses by translating genetic codes designed de novo,"" Proc Natl Acad Sci U S A. May 27, 2003;100(11):6353-7. Epub May 16, 2003.;;Frankel, A et al., ""Encodamers: unnatural peptide oligomers encoded in RNA,"" Chem Biol. Nov. 2003;10 (11):1043-50.;;Fraser, MJ et al., ""Expression of eucaryotic genes in insect cell cultures,"" In Vitro Cell. Dev. Biol. 1989; 25:225-235.;;Friedman, O.M. & R. Chatterrji. ""Synthesis of Derivatives of Glutamine as Model Substrates for Anti-Tumor Agents,"" J. Am. Chem. Soc. 1959; 81(14):3750-3752.;;Fritz HJ et al., ""Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro,"" Nucleic Acids Res. Jul. 25, 1988;16(14B):6987-99.;;Fromm, M. et al., ""Expression of Genes Transferred into Monocot and Dicot Plant Cells by Electroporation,"" Proc. Natl. Acad. Sci. USA (1985) 82:5824-8.;;Furter, R. ""Expansion of the genetic code: site-directed p-fluoro-phenylalanine incorporation in Escherichia coli,"" Protein Sci. Feb. 1998;7(2):419-26.;;Gaertner, HF et al., ""Construction of protein analogues by site-specific condensation of unprotected fragments,"" Bioconjug Chem. May-Jun. 1992;3(3):262-8.;;Gaertner, HF et al., ""Chemo-enzymic backbone engineering of proteins. Site-specific incorporation of synthetic peptides that mimic the 64-74 disulfide loop of granulocyte colony-stimulating factor,"" J Biol Chem. Mar. 11, 1994;269 (10):7224-30.;;Gallivan, JP et al., ""Site-specific incorporation of biotinylated amino acids to identify surface-exposed residues in integral membrane proteins,"" Chem Biol. Oct. 1997;4(10):739-49.",INACTIVE
782,EP,A2,EP 2697241 A2,150-667-695-677-207,2014-02-19,2014,EP 12716969 A,2012-04-13,US 201161474848 P;;US 2012/0033675 W,2011-04-13,1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT,,GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/150-667-695-677-207,Patent Application,yes,0,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;A61K31/7068;;A61K31/7072;;A61K38/21;;A61P31/14;;C07H19/067;;C07H19/073;;C07H19/10,,0,0,,,,ACTIVE
783,WO,A1,WO 2015/095555 A1,138-250-051-731-45X,2015-06-25,2015,US 2014/0071214 W,2014-12-18,US 201361918859 P;;US 201361918014 P,2013-12-19,HYDROGEN/BROMINE FLOW BATTERY IN WHICH HYDROGEN IS FREELY EXCHANGED BETWEEN TWO CELI COMPARTMENTS,"A flow battery system includes a first tank including a hydrogen reactant, a second tank including a bromine electrolyte, and at least one cell including a first electrolyte side operably connected to the first tank and a second electrolyte side operably connected to the second tank. The battery system further includes a direct connection line directly connecting the first tank and the second tank and configured such that the hydrogen reactant passes between the first tank and the second tank.",BOSCH GMBH ROBERT;;ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z;;UNIV CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/138-250-051-731-45X,Patent Application,yes,7,2,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M8/18;;H01M8/02,,1,0,,,See also references of EP 3084872A4,PENDING
784,EP,A1,EP 3818192 A1,128-754-807-181-686,2021-05-12,2021,EP 19737693 A,2019-07-03,EP 18181981 A;;EP 2019067821 W,2018-07-05,TRANSPARENT CONDUCTIVE FILM,,BASF COATINGS GMBH,CHO BORAM;;FLORES JEAN-CHARLES;;REINKE MICHAEL;;SUNG MYUNG MO;;JUNG JIN WON,,https://lens.org/128-754-807-181-686,Patent Application,yes,0,0,9,9,0,C03C17/38;;C03C2217/94;;C23C16/45525;;C23C28/00;;C23C28/322;;C23C28/34;;C23C28/345;;C23C28/3455;;C23C28/40;;C23C28/42;;Y02E10/549;;H10K30/50;;C23C28/3455;;C23C28/322;;C23C28/42;;C23C16/45529;;C23C16/405;;H01B5/14;;B05D1/60;;H10K30/50;;C23C16/45531;;C23C28/30;;C23C28/42;;C23C28/44;;C23C28/02;;Y10T428/31678;;C23C28/322;;C23C28/3455;;H10K30/82;;H10K30/451,C23C28/00;;C03C17/36;;C23C16/455,,0,0,,,,PENDING
785,US,B2,US 6923903 B2,165-206-542-945-12X,2005-08-02,2005,US 30873702 A,2002-12-03,US 30873702 A;;US 22154098 A,1998-12-28,Gasoline sulfur reduction in fluid catalytic cracking,"The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reduction catalyst composition comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve as well as a cerium component which enhances the stability and sulfur reduction activity of the catalyst. The molecular sieve is normally a faujasite such as USY. The primary sulfur reduction component is normally a metal of Period 3 of the Periodic Table, preferably vanadium. The sulfur reduction catalyst may be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst.",GRACE W R & CO,CHESTER ARTHUR W;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL S,MOBIL OIL CORPORATION (1999-02-08);;W.R. GRACE & CO.-CONN (1999-04-06),https://lens.org/165-206-542-945-12X,Granted Patent,yes,57,26,4,75,0,B01J29/166;;B01J2229/42;;C10G11/05;;C10G11/05;;B01J2229/42;;B01J29/166,B01J29/16;;C10G11/05,208/113;;208/120.2;;208/120.25;;208/120.35;;X208208 R;;208/120.01;;208/244;;208/245;;208/247;;208/248;;208/249,10,3,039-565-969-520-282;;020-680-838-131-264;;040-156-601-117-004,10.1016/0021-9517(86)90078-3;;10.1021/bk-1991-0452.ch021;;10.1016/0021-9517(81)90273-6,"Venuto and Habib, Fluid Catalytic Cracking with Zeolite Catalysts, Marcel Dekker, New York 1979, ISBN 0-8247-6870-1, pp. 32-37.;;Richard F. Wormsbecher Alan W. Peters, and James M. Maselli, ""Vanadium Poisoning of Cracking Catalysts: Mechanism of Poisoning and Design of Vanadium Tolerant Catalyst System"", Journal of Catalyst, vol. 100, pp. 130-137 (1986).;;Occelii, M.L., ""Metal Resistant Fluid Cracking Catalysts"", ACS Symposium Series, Ch 21, pp. 343-362 (1990).;;""Shape Selective Catalysis in Industrial Applications"", Chen et al. Marcel Dekker Inc., New York 1969, ISBN 0-8247-7856-1, pp. 7-38.;;J. Catalysis 67, pp. 218-222 (1981) by Frilette et al.;;Stud. Surf. Catal. 37, pp. 13-27 (1987).;;Journal of Catalysis, vol. 4, pp. 527-529 (1965); vol. 6, pp. 278-287 (1966); and vol. 61, pp. 390-396 (1980).;;Scherzer, ""Octane Enhancing Zeolitic FCC Catalysts"", Marcel Dekker, New York, 1990, ISBN 0-8247-8399-9, pp. 165-182.;;Intercat, Refining Developments, ""Additives Improve FCC Process"", Hydrocarbon Processing, Nov. 1991, pp. 59-66, by A.S. Krisha, C.R. Hsieh, A.R. English, T.A. Pecararo and C.W. Kuehler, Cheveron Research and Technology Company, Richmond, CA.;;""Fluid Catalytic Cracking Handbook"", Sadeghbeigi, Gulf Publishing, Houston, Texas, ISBN 0-88415-290-1, Ch. 3, pp. 79 and 88-91.",EXPIRED
786,WO,A2,WO 2012/142523 A2,184-434-494-989-50X,2012-10-18,2012,US 2012/0033675 W,2012-04-13,US 201161474848 P,2011-04-13,1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT,"Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R 6 is CN, ethenyl, 2- haloethen-1-yl, or (C 2 -C 8 )-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.",GILEAD SCIENCES INC;;CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/184-434-494-989-50X,Patent Application,yes,29,46,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,A61K31/7068;;A61K31/7072;;A61K38/21;;A61P31/14;;C07H19/06;;C07H19/067;;C07H19/073;;C07H19/10,,62,26,009-561-066-190-730;;028-378-891-805-321;;028-466-258-098-772;;067-029-972-022-07X;;137-403-834-378-953;;074-606-253-828-334;;052-601-247-824-838;;006-809-980-180-072;;066-435-000-957-468;;009-715-453-008-555;;078-621-983-928-020;;016-665-200-594-26X;;017-694-831-179-969;;003-071-503-249-615;;016-675-247-669-352;;066-658-824-265-040;;092-377-162-654-611;;010-756-666-018-876;;035-830-569-263-132;;015-967-001-492-962;;030-312-196-413-553;;014-904-874-166-459;;125-591-890-257-115;;029-106-650-046-923;;062-585-511-949-070;;077-866-841-847-558,10.1016/s0168-8278(00)80419-5;;10728798;;15633995;;10.1021/jm0400101;;11259521;;11418355;;10.1016/s1386-6532(01)00167-6;;11827565;;10.2165/00003495-200262030-00009;;10.1126/science.282.5386.103;;9756471;;3912262;;10.1016/0378-1119(85)90017-4;;1313927;;10.1128/jvi.66.5.3225-3229.1992;;pmc241092;;pmc2650549;;19075052;;10.1128/aac.01032-08;;10.1517/13543780902854194;;19426125;;10.1016/s0166-3542(03)00028-7;;12719002;;pmc2556034;;18598914;;10.1016/j.drudis.2008.03.024;;10.1002/jps.2600720332;;6842389;;8831776;;10.1021/jm9600757;;8279810;;10.1016/0166-3542(93)90093-x;;10.1021/jm960289o;;8960556;;15428180;;10.1016/0021-8707(50)90059-1;;10.1016/0091-6749(85)90002-8;;2578492;;10.1021/jm0603623;;17064080;;10.1021/jm0603623.s001;;17262707;;10.1086/511310;;10.1074/jbc.m305041200;;12966103;;10.1074/jbc.m510195200;;16316989;;10.1016/s0166-3542(02)00014-1;;12076756;;10.1093/infdis/153.2.346;;3003207;;10.1128/aac.00211-07;;17576833;;pmc2043207;;pmc2224772;;18056282;;10.1128/aac.01215-07,"CALISHER ET AL., J. GEN. VIROL., vol. 70, no. 3, 1993, pages 7 - 43;;MOENNIG, V. ET AL., ADV. VIR. RES., vol. 48, 1992, pages 53 - 98;;BOYER, N. ET AL., J HEPATOL., vol. 32, 2000, pages 98 - 112;;DI BESCEGLIE, A.M.; BACON, B. R., SCIENTIFIC AMERICAN, October 1999 (1999-10-01), pages 80 - 85;;GORDON, C. P. ET AL., J. MED. CHEM., vol. 48, 2005, pages 1 - 20;;MARADPOUR, D. ET AL., NAT. REV. MICRO., vol. 5, no. 6, 2007, pages 453 - 463;;BYMOCK ET AL., ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 11, no. 2, 2000, pages 79 - 95;;DE CLERCQ, E., J. PHARMACOL. EXP.THER., vol. 297, 2001, pages 1 - 10;;DE CLERCQ, E., J. CLIN. VIROL., vol. 22, 2001, pages 73 - 89;;SCOTT, L. J. ET AL., DRUGS, vol. 62, 2002, pages 507 - 556;;NEUMANN ET AL., SCIENCE, vol. 282, 1998, pages 103 - 7;;FUKIMOTO ET AL., HEPATOLOGY, vol. 24, 1996, pages 1351 - 4;;DOMINGO ET AL., GENE, vol. 40, 1985, pages 1 - 8;;MARTELL ET AL., J. VIROL., vol. 66, 1992, pages 3225 - 9;;MIGLIACCIO ET AL., J. BIOL. CHEM., 2003, pages 926;;CARROLL ET AL., ANTIMICROBIAL AGENTS CHEMOTHERAPY, 2009, pages 926;;BROWN, A. B., EXPERT OPIN. INVESTIG. DRUGS, vol. 18, 2009, pages 709 - 725;;DE FRANCESCO, R. ET AL., ANTIVIRAL RESEARCH, vol. 58, 2003, pages 1 - 16;;MEMOLI ET AL., DRUG DISCOVERY TODAY, vol. 13, 2008, pages 590 - 595;;PAQUETTE, LEO A.: ""Principles of Modem Heterocyclic Chemistry"", 1968, W.A. BENJAMIN;;""The Chemistry of Heterocyclic Compounds, A Series of Monographs"", vol. 13, 14,, 1950, JOHN WILEY & SONS;;J. AM. CHEM. SOC., vol. 82, 1960, pages 5566;;THEODORA W. GREENE: ""Protective Groups in Organic Chemistry"", 1991, JOHN WILEY & SONS, INC.;;BUNDGAARD, HANS: ""Textbook of Drug Design and Development"", 1991, HARWOODACADEMIC PUBLISHERS, article ""Design and Application of Prodrugs"", pages: 113 - 191;;FARQUHAR ET AL., J. PHARM. 8CI, vol. 72, 1983, pages 324;;DELAMBERT ET AL., J. MED. CHEM., vol. 37, 1994, pages 498;;KHAMNEI; TORRENCE, J. MED. CHEM., vol. 39, 1996, pages 4109 - 4115;;MITCHELL ET AL., J. CHEM. SOC. PERKIN TRANS., vol. 12345, 1992;;PUECH ET AL., ANTIVIRAL RES., vol. 22, 1993, pages 155 - 174;;BENZARIA ET AL., J. MED. CHEM., vol. 39, 1996, pages 4958;;""McGraw-Hill Dictionary of Chemical Terms"", 1984, MCGRAW-HILL BOOK COMPANY;;ELIEL, E.; WILEN, S.: ""Stereochemistry of Organic Compounds"", 1994, JOHN WILEY & SONS, INC.;;""Handbook of Pharmaceutical Excipients"", 1986;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING CO.;;CARRYER, JOURNAL OF ALLERGY, vol. 21, 1950, pages 282 - 287;;MORRIS, J. ALLERGY CLIN. IMMUNOL., vol. 75, no. 1, 1985, pages 1 - 13;;TETRAHEDRON LETTERS, 1993, pages 8579;;JOUMAL OF ORGANIC CHEMISTRY, 2004, pages 1831;;J. ORGANIC CHEMISTRY, 1968, pages 2490;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, 2000, pages 2566;;JOURNAL OF ORGANIC CHEMISTRY, vol. 46, 1981, pages 3603;;ORGANIC BIOMOLECULAR CHEMISTRY, vol. 1, 2003, pages 3513;;ARCH.PHARM.RES., 1995, pages 364;;ANTIVIRAL CHEMISTRY AND CHEMOTHERAPY, 2009, pages 99;;BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, 2007, pages 2570;;JOURNAL OF MEDICINAL CHEMISTRY, 1992, pages 1440;;JOUMAL OF MEDICINAL CHEMISTRY, 2007, pages 5463;;JOURNAL OF MEDICINAL CHEMISTRY, 2009, pages 2971;;SYNLETT, 2011, pages 57;;TETRAHEDRON, 2000, pages 5363;;TETRAHEDRON LETTERS, 1995, pages 1683;;JOUMAL OF MEDICINAL CHEMISTRY, vol. 49, 2006, pages 6614;;ORGANIC LETTERS, vol. 6, 2003, pages 807;;EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, 2009, pages 3769;;BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 17, 2007, pages 2452;;SCHUL ET AL., J. INFECTIOUS DIS., vol. 195, 2007, pages 665 - 74;;MIGLIACCIO ET AL., J. BIOL. CHEM., 2003, pages 49164 - 49170;;KLUMPP ET AL., J. BIOL. CHEM., 2006, pages 3793 - 3799;;SCHMIDTKE, ANTIVIR. RES., vol. 55, 2002, pages 117 - 127;;STRIKAS ET AL., J. INFECT. DIS., vol. 153, 1986, pages 346 - 351;;CHAPMAN ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 51, no. 9, 2007, pages 3346 - 53;;CIHLAR ET AL., ANTIMICROB AGENTS CHEMOTHER., vol. 52, no. 2, 2008, pages 655 - 65",PENDING
787,CN,A,CN 103476783 A,000-479-287-426-276,2013-12-25,2013,CN 201280018102 A,2012-04-13,US 2012/0033675 W;;US 201161474848 P,2011-04-13,1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment,"Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.",GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/000-479-287-426-276,Patent Application,no,0,3,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;C07H19/067;;C07H19/073;;C07H19/09;;C07H19/10;;C07H19/11,,0,0,,,,DISCONTINUED
788,AU,B2,AU 2012/242517 B2,022-666-043-896-214,2016-12-15,2016,AU 2012/242517 A,2012-04-13,US 201161474848 P;;US 2012/0033675 W,2011-04-13,1'-substituted pyrimidine N-nucleoside analogs for antiviral treatment,"Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R",GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/022-666-043-896-214,Granted Patent,no,2,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;C07H19/067;;C07H19/073;;C07H19/09;;C07H19/10;;C07H19/11,,6,5,055-756-583-157-62X;;102-534-308-468-502;;092-453-210-643-987;;062-770-784-133-389;;023-501-176-436-01X,19173657;;pmc2635492;;10.1021/ja807705z;;10.1021/jo049062o;;15497980;;10.1002/1521-3765(20010601)7:11<2332::aid-chem23320>3.0.co;2-w;;11446636;;10.1016/s0040-4020(01)96264-7;;10.1080/07328319608002386,"HAIDONG HUANG ET AL, JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (20090204), vol. 131, no. 4, doi:10.1021/ja807705z, ISSN 0002-7863, PAGE 1344 - 1345;;PETER GRÜNEFELD ET AL, THE JOURNAL OF ORGANIC CHEMISTRY, (20041001), vol. 69, no. 22, doi:10.1021/jo049062o, ISSN 0022-3263, PAGE 7543 - 7551;;Kodama et al., Chemistry-A European Journal, 2001, vol. 7(11), pp. 2332-2340;;VALÉRIE UTEZA ET AL, TETRAHEDRON, (19930901), vol. 49, no. 38, doi:10.1016/S0040-4020(01)96264-7, ISSN 0040-4020, PAGE 8579 - 8588;;Grouiller et al, Synlett, 1993, vol. 3, pp. 221-222;;Yoshimura et al., Nucleosides & Nucleotides, 15(1-3), 1996, pp. 305-324",INACTIVE
789,CN,A,CN 108395087 A,036-108-893-153-857,2018-08-14,2018,CN 201810588938 A,2013-05-17,US 201213477391 A;;CN 201380035076 A,2012-05-22,Methods of separating strengthened glass sheets by mechanical scribing,"A method of separating a strengthened glass sheet includes positioning a serrated scribing wheel at a position spaced apart from a first edge of the glass sheet and offset below a top surface of the glass sheet, where the glass sheet comprises a surface compression layer of layer depth DOL and a central region. The method also includes translating the serrated scribing wheel in a first direction at an initiation speed such that the serrated scribing wheel forms a crack initiation site comprising surface indentations extending into the surface compression layer, accelerating the serrated scribing wheel in the first direction from the initiation speed to a scoring speed to scribe a score line extending into the glass sheet to a median crack depth greater than DOL, and stopping the serrated scribing wheel in the first direction before the score line reaches a second edge of the glass sheet.",CORNING INC,BROWN JAMES WILLIAM;;HSIEH CHO-CHENG;;JOSEPH II MICHAEL ALBERT;;PAI YEN-CHIA,,https://lens.org/036-108-893-153-857,Patent Application,no,5,0,13,13,0,B26F3/00;;B26F3/00;;C03B33/023;;C03B33/023;;C03B33/023;;C03B33/105;;C03B33/107;;C03B33/107;;C03B33/107;;C03C21/002;;C03C21/002;;C03C21/002;;Y10T83/0341;;Y10T83/0341;;Y10T225/12;;Y10T225/12,C03B33/023;;C03B33/10,,0,0,,,,ACTIVE
790,TW,B,TW I621597 B,075-917-957-997-907,2018-04-21,2018,TW 102118081 A,2013-05-22,US 201213477391 A,2012-05-22,Methods of separating strengthened glass sheets by mechanical scribing,,CORNING INC,BROWN JAMES WILLIAM;;HSIEH CHO CHENG;;JOSEPH II MICHAEL ALBERT;;PAI CHIA YEN,,https://lens.org/075-917-957-997-907,Granted Patent,no,6,0,13,13,0,B26F3/00;;B26F3/00;;C03B33/023;;C03B33/023;;C03B33/023;;C03B33/105;;C03B33/107;;C03B33/107;;C03B33/107;;C03C21/002;;C03C21/002;;C03C21/002;;Y10T83/0341;;Y10T83/0341;;Y10T225/12;;Y10T225/12,,,0,0,,,,INACTIVE
791,US,B2,US 8178108 B2,092-993-479-746-142,2012-05-15,2012,US 87408607 A,2007-10-17,US 87408607 A;;US 31575205 A;;US 72796805 P;;US 68097705 P;;US 65574405 P;;US 63861604 P,2004-12-22,Methods for expression and purification of recombinant human growth hormone,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG;;AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,AMBRX INC (2006-03-31),https://lens.org/092-993-479-746-142,Granted Patent,yes,104,19,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,A61K38/27;;A61K38/18;;A61K39/00;;C07H21/04;;C07K1/14;;C07K1/16;;C07K1/18,424/198.1;;424/123;;424/124;;424/200.1;;514/3.2;;514/11.4;;530/399;;530/412;;530/416;;530/417;;435/69.4;;435/69.1;;536/23.51,100,100,034-100-850-293-359;;070-348-515-045-686;;049-483-235-922-85X;;009-284-916-008-075;;055-705-917-439-994;;025-530-747-094-646;;046-473-428-079-944;;055-530-228-599-552;;048-042-102-423-678;;001-070-048-090-528;;050-530-703-184-013;;045-671-200-913-593;;032-017-301-447-204;;009-974-167-480-046;;011-195-401-779-716;;038-740-230-444-962;;026-310-126-212-55X;;105-031-815-492-819;;007-607-119-061-595;;122-043-240-658-789;;053-539-488-560-898;;001-599-285-296-917;;074-085-219-235-358;;023-112-900-710-958;;029-171-384-219-086;;003-916-587-575-849;;027-978-758-897-565;;033-154-485-941-377;;012-965-258-058-354;;027-295-337-919-663;;054-538-179-794-377;;073-068-984-155-354;;171-819-465-325-654;;011-539-406-502-050;;020-760-033-937-906;;102-775-767-090-243;;044-478-960-098-121;;111-373-437-818-355;;015-808-625-309-566;;083-885-498-849-345;;071-168-446-077-606;;097-080-301-825-404;;026-738-005-053-457;;065-753-482-536-793;;020-312-701-947-992;;054-538-164-035-896;;022-040-530-874-077;;020-589-059-757-172;;002-091-944-669-043;;004-932-164-344-439;;011-715-515-620-371;;034-068-833-115-414;;017-545-542-868-371;;010-754-991-840-83X;;047-163-936-169-471;;038-434-358-484-087;;046-830-730-221-158;;026-196-745-323-826;;005-613-652-908-094;;014-978-026-283-267;;002-119-532-659-035;;012-728-507-765-086;;050-786-135-149-138;;018-443-427-999-877;;016-305-322-178-847;;126-088-206-672-514;;050-861-244-353-872;;009-755-617-730-381;;019-330-233-823-553;;050-882-422-342-790;;033-647-927-544-631;;043-921-127-972-381;;042-973-429-479-822;;093-314-921-738-786;;044-051-728-567-349;;123-904-781-929-13X;;108-365-299-335-209;;090-038-329-131-865;;110-666-204-380-05X;;002-764-043-331-997;;114-854-824-282-69X;;041-067-829-634-042;;005-255-839-259-250;;041-487-661-080-082;;014-549-027-288-910;;021-706-010-433-114;;011-209-988-567-476;;006-995-546-372-911;;046-581-452-608-373;;120-448-891-062-797;;025-437-584-603-525;;030-792-509-092-646;;003-496-488-978-994;;008-410-555-537-921;;038-439-210-215-107;;027-665-676-300-035;;042-913-428-203-758;;058-204-189-632-991;;026-263-397-448-936;;077-079-385-316-426,10742244;;pmc92025;;10.1128/aem.66.4.1572-1579.2000;;10189266;;10.1021/js980175v;;8983207;;10.1021/bp960068b;;10.1023/a:1016286600229;;7724484;;7856886;;10.1021/ac00098a600;;10.1111/j.1399-3011.1994.tb00163.x;;7822097;;3527743;;10.1016/0014-5793(86)81403-x;;pmc2751308;;10.1208/ps040419;;12645991;;12711344;;10.1016/s0003-2697(03)00059-9;;2180927;;10.1016/s0021-9258(19)39390-1;;10.1023/a:1011034425896;;11442262;;12916910;;pmc2750591;;10.1208/pt040228;;10.1016/s0939-6411(98)00005-8;;9653627;;2666192;;10.1042/bst0170335;;10.1016/s0021-9258(19)69793-0;;7462247;;8378257;;10.1023/a:1018994102218;;8125322;;10.1016/0378-1119(94)90777-3;;14567625;;10.1023/a:1025771421906;;10.1110/ps.0235703;;pmc2323861;;12717013;;8997176;;10.1016/s0031-6865(96)00049-0;;10.1126/science.7529940;;7529940;;9828461;;10.1016/s0168-1656(98)00113-8;;10.1074/jbc.m003635200;;11152671;;9360546;;10.1210/jc.82.11.3813;;10.1210/jcem.82.11.4358;;10.1006/prep.1997.0774;;9367817;;10.1126/science.278.5340.1125;;9353194;;10.1083/jcb.87.2.360;;pmc2110742;;6253502;;pmc51688;;2034689;;10.1073/pnas.88.10.4498;;10.1210/edrv-12-4-424;;1760996;;2171545;;10.1016/0167-5699(90)90139-z;;10.1073/pnas.87.18.6934;;2169613;;pmc54656;;1631562;;10.1126/science.1631562;;3219192;;10828073;;10.1074/jbc.275.22.17000;;10.1016/s0021-9258(17)39503-0;;3859485;;pmc298707;;12552121;;10.1073/pnas.0235023100;;10.1021/bi00840a007;;5365779;;10.1016/s0378-1119(97)00173-x;;9266678;;10.1016/s0021-9258(17)41865-5;;8106371;;2832068;;10.1016/0092-8674(88)90488-6;;10.1080/10826068908544912;;2616540;;2689454;;pmc2115925;;10.1083/jcb.109.6.3231;;10.1074/jbc.m001236200;;10748003;;8107110;;10.1006/jmbi.1994.1135;;8360189;;10.1016/s0021-9258(17)46730-5;;10.1016/s0140-6736(01)06844-1;;11734231;;10.1210/mend.12.1.0054;;10.1210/me.12.1.146;;9440818;;pmc2323993;;12930995;;10.1110/ps.03133903;;1569568;;10.1016/0022-2836(92)90470-5;;10.2210/pdb1csg/pdb;;7534308;;10.1074/jbc.270.11.6261;;10.1073/pnas.160252097;;10908667;;pmc16802;;8552582;;10.1073/pnas.93.1.1;;pmc40168;;8077236;;10.1016/s0021-9258(17)31721-0;;1281794;;10.1016/0014-5793(92)81521-m;;10.1021/bi00194a009;;10.2210/pdb1gnc/pdb;;7518249;;1535167;;10.1126/science.256.5064.1677;;pmc125043;;10.1073/pnas.152294299;;12105275;;10.1074/jbc.271.40.24482;;8798708;;02813379;;2813379;;pmc298219;;10.1073/pnas.86.20.8083;;386136;;10.1038/281544a0;;10.1002/pro.5560070611;;009655339;;9655339;;pmc2144027;;6992985;;pmc46676;;7685117;;10.1073/pnas.90.11.5167;;10.2210/pdb1rhg/pdb;;10.1146/annurev.ph.47.030185.002345;;2986539;;10.1146/annurev.physiol.47.1.469;;pmc317896;;10.1093/nar/17.10.3998;;2660109;;10.1146/annurev.physiol.47.1.483;;10.1146/annurev.ph.47.030185.002411;;3888078;;10.1046/j.1365-2265.2000.00940.x;;10762289;;10.1210/en.2002-0123;;pmc2923915;;12933669;;9758661;;10.1021/bp980071q;;10.1006/jmbi.1997.1396;;9417943;;12372843;;10.1210/er.2001-0022;;10.1016/0304-4165(87)90197-8;;3620504;;10524245;;10.1016/s0378-1119(99)00313-3;;7627809;;10.1089/jir.1995.15.341;;10.1038/330537a0;;2825030;;1348280;;1871037;;10.1023/a:1015834724528;;14524717;;10.1021/bp034030s;;10.1345/aph.10054;;10928404;;10.1023/a:1011902215383;;9523304;;10.1016/s0021-9673(01)82190-7;;3346343;;3434796;;10.1016/0003-2697(87)90152-7;;18465256;;15198505;;pmc2750939;;10.1208/ps060104;;8552145;;10.1056/nejm199602153340704;;15032301;;10.1023/b:pham.0000016234.73023.75;;10.1042/ba20030183;;15270709;;10.1042/ba20030143;;15270710;;12033388;;10.1023/a:1015108115452;;15190059;;10.1074/jbc.m405155200;;3654843;;10.1016/s0021-9673(01)96517-3;;2329152;;10.1016/s0021-9673(00)96094-1;;14990496;;pmc1304004;;10.1016/s0006-3495(04)74237-x;;9950632;;10.1021/js980423n;;10.1159/000080507;;15539807;;10514980;;10.1016/s0021-9673(99)00669-x;;15296527;;10.1093/chromsci/42.6.285;;12054815;;10.1016/s0022-2836(02)00137-7;;9514759;;10.1006/jmbi.1997.1613;;10.1081/pdt-100002252;;11485185;;7562409;;10.1002/jps.2600840609,"Barth et al., Compatible-Solute-Supported Periplasmic Expression of Functional Recombinant Proteins under Stress Conditions. Applied and environmental microbiology, 66, 1572-1579, 2000.;;Bam, NB et al. ""Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions,"" J Pharm Sci. Dec. 1998;87(12):1554-9.;;Bam, NB et al. ""Molten globule intermediate of recombinant human growth hormone: stabilization with surfactants,"" Biotechnol Prog. Nov.-Dec. 1996;12(6):801-9.;;Bam, NB et al. ""Stability of protein formulations: investigation of surfactant effects by a novel EPR spectroscopic technique,"" Pharm Res. Jan. 1995;12(1):2-11.;;Battersby, JE et al. ""Affinity purification and microcharacterization of recombinant DNA-derived human growth hormone isolated from an in vivo model,"" Anal Chem. Jan. 15, 1995;67(2):447-55.;;Battersby, JE et al. ""Diketopiperazine formation and N-terminal degradation in recombinant human growth hormone,"" Int J Pept Protein Res. Sep. 1994;44(3):215-22.;;Becker, GW et JM Hsiung. ""Expression, secretion and folding of human growth hormone in Escherichia coli. Purification and characterization,"" FEBS Lett. Aug. 11, 1986;204(1):145-50.;;Bedu-Addo, F et al. ""Preformulation development of recombinant pegylated staphylokinase SY161 using statistical design,"" AAPS PharmSci. 2002;4(4):E19.;;Bondos, SE et A Bicknell. ""Detection and prevention of protein aggregation before, during, and after purification,"" Anal Biochem. May 15, 2003;316(2):223-31.;;Brems, DN et al. ""Equilibrium denaturation of human growth hormone and its cysteine-modified forms,"" J Biol Chem. Apr. 5, 1990;265(10):5504-11.;;Callahan, WJ et al. ""Sodium chloride enhances the storage and conformational stability of BDNF and PEG-BDNF,"" Pharm Res. Mar. 2001;18(3):261-6.;;Capan, Y et al. ""Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone,"" AAPS PharmSciTech. 2003;4(2):E28.;;Carpenter, JF et al. ""Application of infrared spectroscopy to development of stable lyophilized protein formulations,"" Eur J Pharm Biopharm. May 1998;45(3):231-8.;;Chang, JYH et al. ""Periplasmic secretion of human growth hormone by Escherichia coli,"" Biochem Soc Trans. Apr. 1989;17(2):335-7.;;Chapman, GE et al. ""The 20,000 molecular weight variant of human growth hormone. Preparation and some physical and chemical properties,"" J Biol Chem. Mar. 10, 1981;256(5):2395-401.;;Charman, SA et al. ""Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone,"" Pharm Res. Jul. 1993;10(7):954-62.;;Cheah, K-C et al. ""Secretion of eukaryotic growth hormones in Escherichia coli is influenced by the sequence of the mature proteins,"" Gene. Jan. 28, 1994;138(1-2):9-15.;;Chi, EY et al. ""Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation,"" Pharm Res. Sep. 2003;20(9):1325-36.;;Chi, EY et al. ""Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor,"" Protein Sci. May 2003;12(5):903-13.;;Cholewinski, M et al. ""Degradation pathways, analytical characterization and formulation strategies of a peptide and a protein. Calcitonine and human growth hormone in comparison,"" Pharm Acta Helv. Dec. 1996;71(6):405-19.;;Clackson, T et JA Wells. ""A hot spot of binding energy in a hormone-receptor interface,"" Science. Jan. 20, 1995;267 (5196):383-6.;;Alam, KS et al. ""Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro,"" J Biotechnol. Oct. 27, 1998;65(2-3):183-90.;;Alves Dos Santos, CM et al. ""The signal transduction of the growth hormone receptor is regulated by the ubiquitin/proteasome system and continues after endocytosis,"" J Biol Chem. Apr. 6, 2001;276(14):10839-46. Epub Jan. 10, 2001.;;Amit, T et al. ""A membrane-fixed, truncated isoform of the human growth hormone receptor,"" J Clin Endocrinol Metab. Nov. 1997;82(11):3813-7.;;Appa Rao, KBC et al. ""High-level expression of ovine growth hormone in Escherichia coli: single-step purification and characterization,"" Protein Expr Purif. Nov. 1997;11(2):201-8.;;Atwell, S et al. ""Structural plasticity in a remodeled protein-protein interface,"" Science. Nov. 7, 1997;278 (5340):1125-8.;;Barazzone, P et al. ""Binding, internalization, and lysosomal association of 125I-human growth hormone in cultured human lymphocytes: a quantitative morphological and biochemical study,"" J Cell Biol. Nov. 1980;87(2 Pt 1):360-9.;;Bass, SH et al. ""A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor,"" Proc Natl Acad Sci U S A. May 15, 1991;88(10):4498-502.;;Baumann, G. ""Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins,"" Endocr Rev. Nov. 1991;12(4):424-49.;;Bazan, JF. ""Haemopoietic receptors and helical cytokines,"" Immunology Today (1990); 11: 350-354.;;Bazan, JF. ""Structural design and molecular evolution of a cytokine receptor superfamily,"" Proc Natl Acad Sci U S A. Sep. 1990;87(18):6934-8.;;Bazan, JF et DB McKay. ""Unraveling the structure of IL-2,"" Science. Jul. 17, 1992;257(5068):410-3.;;Becker, GW et al. ""Isolation and characterization of a sulfoxide and a desamido derivative of biosynthetic human growth hormone,"" Biotechnol Appl Biochem. Aug. 1988;10(4):326-37.;;Behncken, SN et al. ""Growth hormone (GH)-independent dimerization of GH receptor by a leucine zipper results in constitutive activation,"" J Biol Chem. Jun. 2, 2000;275(22):17000-7.;;Bell, JA et al. ""Crystallization and preliminary x-ray characterization of bovine growth hormone. Purification of bovine prolactin and growth hormone,"" J Biol Chem. Jul. 15, 1985;260(14):8520-5.;;Bernat, B et al. ""Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization,"" Proc Natl Acad Sci U S A. Feb. 4, 2003;100(3):952-7. Epub Jan. 27, 2003.;;Bewley, TA et al. ""Human pituitary growth hormone. Physicochemical investigations of the native and reduced-alkylated protein,"" Biochemistry Dec. 1969;8(12):4701-8.;;Bieth, E et al. ""Human growth hormone receptor: cloning and expression of the full-length complementary DNA after site-directed inactivation ion of a cryptic bacterial promoter,"" Gene Jul. 18, 1997;194(1):97-105.;;Bignon, C et al. ""Preparation of the extracellular domain of the rabbit prolactin receptor expressed in Escherichia coli and its interaction with lactogenic hormones,"" J Biol Chem. Feb. 4, 1994;269(5):3318-24.;;Boutin, JM, et al. ""Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family,"" Cell Apr. 8, 1988;53(1):69-77.;;Brostedt, P and P Roos. ""Isolation of dimeric forms of human pituitary growth hormone,"" Prep Biochem. 1989;19(3):217-29.;;Trahair, JF et al. ""Use of transgenic mice to study the routing of secretory proteins in intestinal epithelial cells: analysis of human growth hormone compartmentalization as a function of cell type and differentiation,"" J Cell Biol. Dec. 1989;109(6 Pt 2):3231-42.;;Tsunekawa, B et al. ""The binding between the stem regions of human growth hormone (GH) receptor compensates for the weaker site 1 binding of 20-kDa human GH (hGH) than that of 22-kDa hGH,"" J Biol Chem. May 26, 2000;275 (21):15652-6.;;Ultsch, MH et al. ""The crystal structure of affinity-matured human growth hormone at 2 A resolution,"" J Mol Biol. Feb. 11, 1994;236(1):286-99.;;Urbanek, M et al. ""Functional characterization of the alternatively spliced, placental human growth hormone receptor,"" J Biol Chem. Sep. 5, 1993;268(25):19025-32.;;Van Der Lely, AJ et al. ""Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist,"" Lancet Nov. 24, 2001;358(9295):1754-9.;;Wada, M. et al. ""The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma,"" Mol Endocrinol. Jan. 1998;12(1):146-56.;;Walsh, STR et al. ""Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization,"" Protein Sci. Sep. 2003;12(9):1960-70.;;Walter, MR et al. ""Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor,"" J Mol Biol. Apr. 20, 1992;224(4):1075-85.;;Wang, X et al. ""A 40-amino acid segment of the growth hormone receptor cytoplasmic domain is essential for GH-induced tyrosine-phosphorylated cytosolic proteins,"" J Biol Chem. Mar. 17, 1995;270(11):6261-6.;;Weiss, GA et al. ""Rapid mapping of protein functional epitopes by combinatorial alanine scanning,"" Proc Natl Acad Sci U S A. Aug. 1, 2000;97(16):8950-4.;;Wells, JA. ""Binding in the growth hormone receptor complex,"" Proc Natl Acad Sci U S A. Jan. 9, 1996;93(1):1-6.;;Wen, D et al. ""Erythropoietin structure-function relationships. Identification of functionally important domains,"" J. Biol. Chem. 1994; 269(36):22839-22846.;;Zink, T et al. ""Secondary structure of human granulocyte colony-stimulating factor derived from NMR spectroscopy,"" FEBS Lett. Dec. 21, 1992;314(3):435-9.;;Zink, T et al. ""Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy. Loop mobility in a four-helix-bundle protein,"" Biochemistry Jul. 19, 1994;33(28):8453-63.;;Fuh, G et al. ""Rational design of potent antagonists to the human growth hormone receptor,"" Science Jun. 19, 1992;256(5064):1677-80.;;Gent, J et al. ""Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis,"" Proc Natl Acad Sci U S A. Jul. 23, 2002;99(15):9858-63. Epub Jul. 8, 2002.;;Gertler, A et al. ""Real-time kinetic measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization,"" J Biol Chem. Oct. 4, 1996;271(40):24482-91.;;Godowski, PJ et al. ""Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism,"" Proc Natl Acad Sci U S A. Oct. 1989;86(20):8083-7.;;Goeddel, DV et al. ""Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone"" Nature Oct. 18, 1979;281(5732):544-8.;;Gomez-Orellana, I et al. ""Thermodynamic characterization of an intermediate state of human growth hormone,"" Protein Sci. Jun. 1998;7(6):1352-8.;;Gout, PW et al. ""Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas,"" Cancer Res. Jul. 1980;40(7):2433-6.;;Hill, CP et al. ""The Structure of Granulocyte-Colony-Stimulating Factor and its Relationship to Other Growth Factors,"" Proc. Natl. Acad. Sci. USA (1993); 90:5167-71.;;Hughes, JP and HG Friesen. ""The nature and regulation of the receptors for pituitary growth hormone,"" Annu Rev Physiol. 1985;47:469-82.;;Igout, A, et al. ""Expression and secretion of the human placental growth hormone in Escherichia coli,"" Nucleic Acids Res. May 25, 1989;17(10):3998.;;Isaksson, OG, et al. ""Mode of action of pituitary growth hormone on target cells,"" Annu Rev Physiol. 1985;47:483-99.;;Johnston, LB et al. ""Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short stature,"" Clin Endocrinol (Oxf). Apr. 2000;52(4):463-9.;;Kasukawa, Y et al. ""Evidence that sensitivity to growth hormone (GH) is growth period and tissue type dependent: studies in GH-deficient lit/lit mice,"" Endocrinology. Sep. 2003;144(9):3950-7.;;Khan, RH et al. ""Solubilization of recombinant ovine growth hormone with retention of native-like secondary structure and its refolding from the inclusion bodies of Escherichia coli,"" Biotechnol Prog. Sep.-Oct. 1998;14(5):722-8.;;Klaus, W et al. ""The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution,"" J Mol Biol. Dec. 12, 1997;274(4):661-75.;;Kopchick, JJ et al. ""Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly,"" Endocr Rev. Oct. 2002;23(5):623-46.;;Kostyo, JL et al. ""Biological characterization of purified native 20-kDa human growth hormone,"" Biochim Biophys Acta. Sep. 11, 1987;925(3):314-24.;;Krawczak, M et al. ""Evolution of the proximal promoter region of the mammalian growth hormone gene,"" Gene Sep. 3, 1999;237(1):143-51.;;Lee, N. et al. ""Interferon-alpha 2 variants in the human genome,"" J Interferon Cytokine Res. Apr. 1995;15(4):341-9.;;Leung, DW et al. ""Growth hormone receptor and serum binding protein: purification, cloning and expression,"" Nature Dec. 10-16, 1997;330(6148):537-43.;;Pearlman, R et T Nguyen. ""Pharmaceutics of protein drugs,"" J Pharm Pharmacol. Feb. 1992;44 Suppl 1:178-85.;;Pikal, MJ et al. ""The effects of formulation variables on the stability of freeze-dried human growth hormone,"" Pharm Res. Apr. 1991;8(4):427-36.;;Rathore, AS et al. ""Optimization of an osmotic shock procedure for isolation of a protein product expressed in E. coli,"" Biotechnol Prog. Sep.-Oct. 2003;19(5):1541-6.;;Reddy, KR. ""Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs,"" Ann Pharmacother. Jul.-Aug. 2000;34(7-8):915-23.;;Remmele, RL et al. ""Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry,"" Pharm Res. Feb. 1998;15(2):200-8.;;Riggin, RM et al. ""High-performance size-exclusion chromatographic determination of the potency of biosynthetic human growth hormone products,"" J Chromatogr. Jan. 8, 1988;435(2):307-18.;;Riggin, RM et al. ""A reversed-phase high-performance liquid chromatographic method for characterization of biosynthetic human growth hormone,"" Anal Biochem. Nov. 15, 1987;167(1):199-209.;;Sharma, VK et DS Kalonia. ""Polyethylene glycol-induced precipitation of interferon alpha-2a followed by vacuum drying: development of a novel process for obtaining a dry, stable powder,"" AAPS PharmSci. Jan. 26, 2004;6(1):E4.;;Takahashi, Y et al. ""Brief report: short stature caused by a mutant growth hormone,"" N. Engl J Med. Feb. 15, 1996;334 (7):432-6.;;Tang, X et MJ Pikal. ""Design of freeze-drying processes for pharmaceuticals: practical advice,"" Pharm Res. Feb. 2004;21(2):191-200.;;Tatford, OC et al. ""Analytical techniques for the evaluation of liquid protein therapeutics,"" Biotechnol Appl Biochem. Aug. 2004;40(Pt 1):67-81.;;Tkac, J et al. ""Evaluation of disruption methods for the release of intracellular recombinant protein from Escherichia coli for analytical purposes,"" Biotechnol Appl Biochem. Aug. 2004;40(Pt 1):83-8.;;Treuheit, MJ et al. ""Inverse relationship of protein concentration and aggregation,"" Pharm Res. Apr. 2002;19(4):511-6.;;Tsubery, H et al. ""Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification,"" J Biol Chem. Sep. 10, 2004;279(37):38118-24. Epub Jun. 8, 2004.;;Welinder, BS et al. ""Reversed-phase high-performance liquid chromatography of human growth hormone,"" J Chromatogr. Jul. 10, 1987;398:309-16.;;Wu, SL et al. ""Application of high-performance hydrophobic-interaction chromatography to the characterization of recombinant DNA-derived human growth hormone,"" J Chromatogr. Feb. 2, 1990;500:595-606.;;Yan, Y-B et al. ""Protein thermal aggregation involves distinct regions: sequential events in the heat-induced unfolding and aggregation of hemoglobin,"" Biophys J. Mar. 2004;86(3):1682-90.;;Yang, T-H et al. ""Use of Infrared Spectroscopy to Assess Secondary Structure of Human Growth Hormone within Biodegradable Microspheres,"" J Pharm Sci Feb. 1999; 88(2):161-165.;;Kappelgaard, A-M et al. ""Liquid growth hormone: preservatives and buffers,"" Horm Res. 2004;62 Suppl 3:98-103.;;Karlsson, G et al. ""Separation of oxidized and deamidated human growth hormone variants by isocratic reversed-phase high-performance liquid chromatography,"" J Chromatogr A. Sep. 3, 1999;855(1):147-55.;;Karlsson, G et al. ""Usage of nonporous polymeric particles for reversed-phase high-performance liquid chromatography of oxidized and deamidated forms of recombinant human growth hormone,"" J Chromatogr Sci. Jul. 2004;42(6):285-7.;;Kasimova, MR et al. ""NMR studies of the backbone flexibility and structure of human growth hormone: a comparison of high and low pH conformations,"" J Mol Biol. May 3, 2002;318(3):679-95.;;Kasimova, MR et al. ""The conformational equilibrium of human growth hormone,"" J Mol Biol. Mar. 27, 1998;277(2):409-18.;;Kasraian, K et al. ""Sustained in vivo activity of recombinant bovine granulocyte colony stimulating factor (rbG-CSF) using HEPES buffer,"" Pharm Dev Technol. Aug. 2001;6(3):441-7.;;Katakam, M et al. ""Effect of surfactants on the physical stability of recombinant human growth hormone,"" J Pharm Sci. Jun. 1995;84(6):713-6.",INACTIVE
792,WO,A3,WO 2012/142523 A3,114-926-019-393-864,2013-06-27,2013,US 2012/0033675 W,2012-04-13,US 201161474848 P,2011-04-13,1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT,"Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2- haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.",GILEAD SCIENCES INC;;CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/114-926-019-393-864,Search Report,no,1,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;C07H19/067;;C07H19/073;;C07H19/09;;C07H19/10;;C07H19/11,,4,4,055-756-583-157-62X;;102-534-308-468-502;;092-453-210-643-987;;062-770-784-133-389,19173657;;pmc2635492;;10.1021/ja807705z;;10.1021/jo049062o;;15497980;;10.1002/1521-3765(20010601)7:11<2332::aid-chem23320>3.0.co;2-w;;11446636;;10.1016/s0040-4020(01)96264-7,"HAIDONG HUANG ET AL: ""Competitive Inhibition of Uracil DNA Glycosylase by a Modified Nucleotide Whose Triphosphate is a Substrate for DNA Polymerase"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 131, no. 4, 4 February 2009 (2009-02-04), pages 1344 - 1345, XP055054894, ISSN: 0002-7863, DOI: 10.1021/ja807705z;;PETER GRÜNEFELD ET AL: ""Synthesis of a 1'-Aminomethylthymidine and Oligodeoxyribonucleotides with 1'-Acylamidomethylthymidine Residues"", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 69, no. 22, 1 October 2004 (2004-10-01), pages 7543 - 7551, XP055054901, ISSN: 0022-3263, DOI: 10.1021/jo049062o;;TETSUYA KODAMA ET AL: ""Nucleosides and nucleotides. Part 205. An efficient method for the preparation of 1'.alpha.-branched-chain sugar pyrimidine ribonucleosides from uridine: the first conversion of a natural nucleoside into 1'-substituted ribonucleosides"", CHEMISTRY - A EUROPEAN JOURNAL, vol. 7, no. 11, 1 June 2001 (2001-06-01), pages 2332 - 2340, XP055054907, ISSN: 0947-6539, DOI: 10.1002/1521-3765(20010601)7:11<2332::AID-CHEM23320>3.0.CO;2-W 2332;;VALÉRIE UTEZA ET AL: ""Synthesis and structure determination of the first 1'-C-cyano-[beta]-D-nucleosides"", TETRAHEDRON, vol. 49, no. 38, 1 September 1993 (1993-09-01), pages 8579 - 8588, XP055054911, ISSN: 0040-4020, DOI: 10.1016/S0040-4020(01)96264-7",PENDING
793,NL,A1,NL 1012893 A1,138-789-929-128-907,2000-03-02,2000,NL 1012893 A,1999-08-24,US 14460798 A,1998-08-31,Verminderen van zwavel in benzine tijdens gefluïdiseerd katalytisch kraken.,,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/138-789-929-128-907,Granted Patent,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;C10G35/085;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
794,ES,T3,ES 2744587 T3,133-273-920-215-407,2020-02-25,2020,ES 12716969 T,2012-04-13,US 201161474848 P;;US 2012/0033675 W,2011-04-13,Análogos de N-nucleósido de pirimidina 1-sustituidos para un tratamiento antiviral,Un Compuesto seleccionado de:**Fórmula** o una sal farmacéuticamente aceptable de los mismos.,GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/133-273-920-215-407,Granted Patent,no,0,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;A61K31/7068;;A61K31/7072;;A61K38/21;;A61P31/14;;C07H19/067;;C07H19/073;;C07H19/10,,0,0,,,,ACTIVE
795,AU,A1,AU 2010/236095 A1,152-876-033-016-42X,2010-11-18,2010,AU 2010/236095 A,2010-10-28,AU 2005/323106 A;;AU 2010/236095 A;;US 2005/0046486 W;;US 68097705 P;;US 65574405 P;;US 63861604 P;;US 72796805 P,2004-12-22,Method of purifying human growth hormone,,AMBRX INC,CHO HO SUNG;;ONG MICHAEL;;KNUDSEN NICK;;LIEU RICKY;;BUSSELL STUART;;BUECHLER YING,,https://lens.org/152-876-033-016-42X,Patent Application,no,0,0,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12N15/09;;A23J1/00,,0,0,,,,DISCONTINUED
796,US,A1,US 2022/0023515 A1,158-739-865-793-245,2022-01-27,2022,US 202016935433 A,2020-07-22,US 202016935433 A,2020-07-22,THERMAL STIMULATION AND SUBSEQUENT COOLING FOR FULLY IMPLANTABLE LVAD CONTROLLER,"A method of cooling a mammal with an implantable blood pump. The method includes measuring a temperature of an internal controller, the internal controller being in communication with the implantable blood pump. an alert is generated if the temperature of the internal controller exceeds a predetermined temperature threshold.",MEDTRONIC INC,EGGEN MICHAEL D;;CHO YONG K;;SCHEINER AVRAM;;RAGHUPATHY RAMESH;;RADTKE THOMAS W,MEDTRONIC INC (2020-07-06),https://lens.org/158-739-865-793-245,Patent Application,yes,4,1,3,3,0,A61M60/122;;A61M60/205;;A61M60/508;;A61M60/585;;A61M60/592;;A61M2205/18;;A61M2205/3368;;A61M2205/3507;;A61M2205/3606;;A61M60/135;;A61M60/50;;A61F7/08;;A61F7/10;;A61F2007/0011;;A61M2205/18;;A61M2205/3372;;A61M2205/3584;;A61M2205/3606;;A61M2205/50;;A61M2205/8206;;A61M2230/50,A61M1/10;;A61M1/12,,0,0,,,,PENDING
797,EP,B9,EP 3094688 B9,181-651-950-268-67X,2017-12-20,2017,EP 15701256 A,2015-01-13,EP 14151392 A;;IB 2015050245 W;;EP 15701256 A,2014-01-16,HOLE TRANSPORTING AND LIGHT ABSORBING MATERIAL FOR SOLID STATE SOLAR CELLS,,ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL),QIN PENG;;NAZEERUDDIN MOHAMMAD KHAJA;;GRAETZEL MICHAEL;;KO JAEJUNG;;PAEK SANGHYUN;;CHO NARA,,https://lens.org/181-651-950-268-67X,Amended Patent,yes,7,0,9,9,0,C09K11/06;;C09B57/00;;C09B57/008;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1096;;Y02E10/549;;Y02E10/542;;H10K85/652;;H10K85/655;;H10K85/6576;;H10K85/6572;;H10K85/657;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;H10K85/50;;C07D409/14;;C07F7/0816;;C09B57/008;;C09K11/06;;C09K2211/1096;;C09K2211/1092;;C09K2211/1051;;C09K2211/1029;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;C09B57/008;;C09B57/00;;C09K11/06;;C09K2211/1096;;C09K2211/1051;;C09K2211/1029;;C09K2211/1092;;Y02E10/549;;H10K85/40;;H10K85/652;;H10K85/655;;H10K85/657;;H10K85/791;;H10K85/6572;;H10K30/151;;H10K85/6576;;H01G9/2013;;H01G9/2018;;H01G9/2031;;H01G9/2059,C09B57/00;;C09K11/06;;H01L51/00;;H05B33/14,,0,0,,,,ACTIVE
798,IT,B1,IT 1313614 B1,169-738-474-267-12X,2002-09-09,2002,IT MI991848 A,1999-08-30,US 14460798 A,1998-08-31,PROCEDIMENTO PER RIDURRE IL CONTENUTO DI ZOLFO DI UNA FRAZIONE DIPETROLIO OTTENUTA MEDIANTE CRACKING CATALITICO,,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/169-738-474-267-12X,Granted Patent,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;C10G35/085;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
799,NO,L,NO 20013239 L,185-214-095-716-282,2001-08-29,2001,NO 20013239 A,2001-06-28,US 22210298 A;;US 9929799 W,1998-12-29,Cetan-oppgradering via aromatisk alkylering,,MOBIL OIL CORP,COLLINS NICK ALLEN;;LANDIS MICHAEL E;;TIMKEN HYE KYUNG CHO;;TREWELLA JEFFREY CHARLES,,https://lens.org/185-214-095-716-282,Abstract,no,0,0,7,7,0,C10G29/205,C10G29/20,,0,0,,,,DISCONTINUED
800,JP,A,JP 2000154388 A,181-325-142-567-045,2000-06-06,2000,JP 24510599 A,1999-08-31,US 14460798 A,1998-08-31,REDUCTION OF SULFUR IN GASOLINE IN FLUID CATALYTIC CRACKING,"PROBLEM TO BE SOLVED: To reduce the sulfur content of a liquid cracking product of catalytic cracking process, especially gasoline obtained by cracking. SOLUTION: The sulfur content of a liquid cracking product of catalytic cracking process, especially gasoline subjected to cracking is reduced by using a sulfur-reducing additive containing a porous molecular sieve having a metal in an oxidation state larger than 0 in the interior of small pore structure of the molecular sieve. The molecular sieve is usually a zeolite having large pore size, e.g. USY or zeolite β or a zeolite having an intermediate pore size, e.g. ZSM-5. The metal is usually a metal in the third period of the periodic table, preferably zinc or vanadium. The sulfur-reducing catalyst may be used in an independent granular additive form or integrated form of cracking/sulfur- reducing catalyst components.",MOBIL OIL CORP;;WR GRACE & CO CONNECTICUT,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL S,,https://lens.org/181-325-142-567-045,Patent Application,no,0,9,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;C10G35/085;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
801,KR,A,KR 20150021514 A,014-561-436-978-324,2015-03-02,2015,KR 20147034495 A,2013-05-17,US 201213477391 A;;US 2013/0041591 W,2012-05-22,METHODS OF SEPARATING STRENGTHENED GLASS SHEETS BY MECHANICAL SCRIBING,,CORNING INC,BROWN JAMES WILLIAM;;HSIEH CHO CHENG;;JOSEPH MICHAEL ALBERT II;;PAI YEN CHIA,,https://lens.org/014-561-436-978-324,Patent Application,no,0,1,13,13,0,B26F3/00;;B26F3/00;;C03B33/023;;C03B33/023;;C03B33/023;;C03B33/105;;C03B33/107;;C03B33/107;;C03B33/107;;C03C21/002;;C03C21/002;;C03C21/002;;Y10T83/0341;;Y10T83/0341;;Y10T225/12;;Y10T225/12,C03B33/023;;C03B33/10,,0,0,,,,DISCONTINUED
802,US,B2,US 8080391 B2,026-349-939-680-228,2011-12-20,2011,US 31575205 A,2005-12-21,US 31575205 A;;US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P,2004-12-22,Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG;;AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,AMBRX INC (2006-03-31),https://lens.org/026-349-939-680-228,Granted Patent,yes,108,12,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12N15/09;;A61K38/27;;C07K14/00,435/69.4;;435/123;;514/11.4;;530/399;;530/416,99,99,001-599-285-296-917;;074-085-219-235-358;;023-112-900-710-958;;029-171-384-219-086;;003-916-587-575-849;;027-978-758-897-565;;033-154-485-941-377;;012-965-258-058-354;;027-295-337-919-663;;054-538-179-794-377;;073-068-984-155-354;;171-819-465-325-654;;011-539-406-502-050;;020-760-033-937-906;;102-775-767-090-243;;044-478-960-098-121;;111-373-437-818-355;;015-808-625-309-566;;083-885-498-849-345;;071-168-446-077-606;;105-806-066-420-957;;002-923-554-091-791;;003-296-524-259-772;;068-634-949-083-44X;;075-319-015-049-081;;005-572-819-442-954;;018-694-084-068-187;;011-000-734-630-319;;020-734-114-119-682;;035-533-694-153-011;;010-246-008-415-167;;052-388-498-620-784;;024-390-732-485-486;;022-396-961-254-336;;021-301-666-722-431;;099-342-530-619-778;;001-191-566-932-415;;008-885-205-675-805;;013-823-087-572-457;;061-098-262-098-935;;038-434-358-484-087;;046-830-730-221-158;;026-196-745-323-826;;005-613-652-908-094;;014-978-026-283-267;;002-119-532-659-035;;012-728-507-765-086;;050-786-135-149-138;;018-443-427-999-877;;016-305-322-178-847;;126-088-206-672-514;;050-861-244-353-872;;009-755-617-730-381;;019-330-233-823-553;;050-882-422-342-790;;033-647-927-544-631;;043-921-127-972-381;;042-973-429-479-822;;093-314-921-738-786;;044-051-728-567-349;;039-630-429-967-217;;051-028-782-527-194;;033-137-559-002-58X;;035-574-511-125-693;;067-271-741-810-373;;020-077-913-179-174;;025-101-902-648-114;;083-799-059-658-343;;124-686-428-289-163;;122-562-796-318-32X;;023-882-499-006-921;;077-169-348-159-440;;082-101-485-871-557;;094-619-099-798-015;;031-858-803-001-667;;001-595-578-344-697;;007-284-302-828-236;;038-267-723-757-587;;077-225-285-207-268;;033-564-293-374-947;;030-545-746-430-807;;006-157-672-562-73X;;000-223-149-311-914;;074-890-940-229-924;;015-459-649-895-675;;003-471-282-689-694;;084-492-105-054-015;;098-174-731-651-292;;003-631-534-496-072;;006-786-192-019-844;;041-664-696-817-712;;042-241-278-130-768;;090-657-904-276-044;;100-381-451-046-460;;006-095-947-008-535;;003-101-140-171-904;;095-689-091-070-353;;104-526-803-164-736;;027-740-307-377-384,9828461;;10.1016/s0168-1656(98)00113-8;;10.1074/jbc.m003635200;;11152671;;9360546;;10.1210/jc.82.11.3813;;10.1210/jcem.82.11.4358;;10.1006/prep.1997.0774;;9367817;;10.1126/science.278.5340.1125;;9353194;;10.1083/jcb.87.2.360;;pmc2110742;;6253502;;pmc51688;;2034689;;10.1073/pnas.88.10.4498;;10.1210/edrv-12-4-424;;1760996;;2171545;;10.1016/0167-5699(90)90139-z;;10.1073/pnas.87.18.6934;;2169613;;pmc54656;;1631562;;10.1126/science.1631562;;3219192;;10828073;;10.1074/jbc.275.22.17000;;10.1016/s0021-9258(17)39503-0;;3859485;;pmc298707;;12552121;;10.1073/pnas.0235023100;;10.1021/bi00840a007;;5365779;;10.1016/s0378-1119(97)00173-x;;9266678;;10.1016/s0021-9258(17)41865-5;;8106371;;2832068;;10.1016/0092-8674(88)90488-6;;10.1080/10826068908544912;;2616540;;10.1016/0378-1119(87)90279-4;;3311882;;10.1146/annurev.me.34.020183.002511;;6344776;;10.1074/jbc.272.8.5133;;9030580;;1314596;;10.1016/0006-291x(92)91220-k;;10.1159/000053067;;9554469;;11785980;;10.1006/bbrc.2001.6261;;10.1126/science.2471267;;2471267;;2466339;;10.1126/science.2466339;;pmc51456;;2014261;;10.1073/pnas.88.8.3407;;10.1126/science.1948064;;1948064;;7504735;;10.1006/jmbi.1993.1611;;pmc38222;;10.1073/pnas.93.20.10723;;8855247;;7721840;;10.1074/jbc.270.16.9222;;8390097;;10.1126/science.8390097;;1549776;;10.1126/science.1549776;;10.2210/pdb1gmf/pdb;;0001837174;;1837174;;10.1126/science.1837174;;10.1021/bc990112j;;10995207;;10966654;;10.1038/79047;;10.1210/endo.143.1.8607;;11751584;;10.1210/en.143.1.2;;2406245;;10.1016/s0021-9258(19)39741-8;;1535167;;10.1126/science.256.5064.1677;;pmc125043;;10.1073/pnas.152294299;;12105275;;10.1074/jbc.271.40.24482;;8798708;;02813379;;2813379;;pmc298219;;10.1073/pnas.86.20.8083;;386136;;10.1038/281544a0;;10.1002/pro.5560070611;;009655339;;9655339;;pmc2144027;;6992985;;pmc46676;;7685117;;10.1073/pnas.90.11.5167;;10.2210/pdb1rhg/pdb;;10.1146/annurev.ph.47.030185.002345;;2986539;;10.1146/annurev.physiol.47.1.469;;pmc317896;;10.1093/nar/17.10.3998;;2660109;;10.1146/annurev.physiol.47.1.483;;10.1146/annurev.ph.47.030185.002411;;3888078;;10.1046/j.1365-2265.2000.00940.x;;10762289;;10.1210/en.2002-0123;;pmc2923915;;12933669;;9758661;;10.1021/bp980071q;;10.1006/jmbi.1997.1396;;9417943;;12372843;;10.1210/er.2001-0022;;10.1016/0304-4165(87)90197-8;;3620504;;10524245;;10.1016/s0378-1119(99)00313-3;;7627809;;10.1089/jir.1995.15.341;;10.1038/330537a0;;2825030;;10.1016/s0021-9258(17)40874-x;;632293;;863899;;10.1016/s0021-9258(17)40308-5;;7028740;;10.1016/s0021-9258(19)68453-x;;10.1007/bf00215579;;7050655;;10.1016/s0021-9258(17)39273-6;;2991252;;11371582;;10.1093/oxfordjournals.molbev.a003895;;8626839;;10.1210/jcem.81.5.8626839;;10.1210/jc.81.5.1806;;2722883;;10.1016/s0021-9258(18)81745-8;;pmc38452;;10.1073/pnas.93.18.9471;;8790354;;10.1126/science.2502842;;2502842;;10.1038/363172a0;;8483502;;10.2210/pdb1hul/pdb;;10.1210/endo-107-2-391;;7389660;;1798669;;10.1023/a:1015836720294;;10.1016/0959-440x(95)80016-t;;7773741;;10.1002/prot.340170109;;8234245;;11377066;;10.1016/s0731-7085(01)00359-4;;12946357;;10.1016/s0022-2836(03)00898-2;;10764769;;10.1074/jbc.m001615200;;pmc398293;;7744001;;10.1002/j.1460-2075.1995.tb07186.x;;9890885;;10.1021/bi9817008;;8756685;;10.1021/bi960513b;;1609277;;10.1126/science.256.5064.1673;;10.1016/s0969-2126(96)00152-9;;8994971;;1932028;;10.1021/bi00110a004;;11297608;;10.1210/jc.86.4.1716;;10.1210/jcem.86.4.7403;;8505324;;10.1016/s0021-9258(19)50299-x;;10.1046/j.1365-2265.2002.01507.x;;11966740;;10.1006/jmbi.2001.5348;;11851338;;10.1073/pnas.81.17.5403;;6089201;;pmc391712;;7169009;;10.1089/dna.1.1982.1.239;;10.1210/me.10.5.508;;10.1210/mend.10.5.8732682;;8732682;;8454051;;10.1016/0014-5793(93)80028-s;;10.1210/jcem.82.2.3725;;09024232;;10.1210/jc.82.2.435;;9024232;;10.1073/pnas.92.4.959;;pmc42616;;7862673;;10.1016/s0021-9258(18)68577-1;;3372509;;10.1073/pnas.93.22.12394;;pmc38002;;8901592;;8943276;;10.1074/jbc.271.50.32197;;10.1038/26773;;9774108;;10.2210/pdb1blw/pdb;;10.1677/joe.0.1750055;;12379490,"Alam, KS et al. ""Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro,"" J Biotechnol. Oct. 27, 1998;65(2-3):183-90.;;Alves Dos Santos, CM et al. ""The signal transduction of the growth hormone receptor is regulated by the ubiquitin/proteasome system and continues after endocytosis,"" J Biol Chem. Apr. 6, 2001;276(14):10839-46. Epub Jan. 10, 2001.;;Amit, T et al. ""A membrane-fixed, truncated isoform of the human growth hormone receptor,"" J Clin Endocrinol Metab. Nov. 1997;82(11):3813-7.;;Appa Rao, KBC et al. ""High-level expression of ovine growth hormone in Escherichia coli: single-step purification and characterization,"" Protein Expr Purif. Nov. 1997;11(2):201-8.;;Atwell, S et al. ""Structural plasticity in a remodeled protein-protein interface,"" Science. Nov. 7, 1997;278(5340):1125-8.;;Barazzone, P et al. ""Binding, internalization, and lysosomal association of 125I-human growth hormone in cultured human lymphocytes: a quantitative morphological and biochemical study,"" J Cell Biol. Nov. 1980;87(2 Pt 1):360-9.;;Bass, SH et al. ""A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor,"" Proc Natl Acad Sci U S A. May 15, 1991;88(10):4498-502.;;Baumann, G. ""Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins,"" Endocr Rev. Nov. 1991;12(4):424-49.;;Bazan, JF. ""Haemopoietic receptors and helical cytokines,"" Immunology Today (1990); 11: 350-354.;;Bazan, JF. ""Structural design and molecular evolution of a cytokine receptor superfamily,"" Proc Natl Acad Sci U S A. Sep. 1990;87(18):6934-8.;;Bazan, JF et DB McKay. ""Unraveling the structure of IL-2,"" Science. Jul. 17, 1992;257(5068):410-3.;;Becker, GW et al. ""Isolation and characterization of a sulfoxide and a desamido derivative of biosynthetic human growth hormone,"" Biotechnol Appl Biochem. Aug. 1988;10(4):326-37.;;Behncken, SN et al. ""Growth hormone (GH)-independent dimerization of GH receptor by a leucine zipper results in constitutive activation,"" J Biol Chem. Jun. 2, 2000;275(22):17000-7.;;Bell, JA et al. ""Crystallization and preliminary x-ray characterization of bovine growth hormone. Purification of bovine prolactin and growth hormone,"" J Biol Chem. Jul. 15, 1985;260(14):8520-5.;;Bernat,.B et al. ""Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization,"" Proc Natl Acad Sci U S A. Feb. 4, 2003;100(3):952-7. Epub Jan. 27, 2003.;;Bewley, TA et al. ""Human pituitary growth hormone. Physicochemical investigations of the native and reduced-alkylated protein,"" Biochemistry Dec. 1969;8(12):4701-8.;;Bieth, E et al. ""Human growth hormone receptor: cloning and expression of the full-length complementary DNA after site-directed inactivation of a cryptic bacterial promoter,"" Gene Jul. 18, 1997;194(1):97-105.;;Bignon, C et al. ""Preparation of the extracellular domain of the rabbit prolactin receptor expressed in Escherichia coli and its interaction with lactogenic hormones,"" J Biol Chem. Feb. 4, 1994;269(5):3318-24.;;Boutin, JM, et al. ""Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family,"" Cell Apr. 8, 1988;53(1):69-77.;;Brostedt, P and P Roos. ""Isolation of dimeric forms of human pituitary growth hormone,"" Prep Biochem. 1989;19(3):217-29.;;Chang, CN et al. ""High-level secretion of human growth hormone by Escherichia coli"" Gene 1987;55(2-3):189-96.;;Chawla, RK et al. ""Structural variants of human growth hormone: biochemical, genetic, and clinical aspects,"" Annu Rev Med. 1983;34:519-47.;;Chen, C et al. ""The role of receptor dimerization domain residues in growth hormone signaling,"" J Biol Chem. Feb. 21, 1997;272(8):5133-40.;;Chiba, T et al. ""Tryptophan residue of Trp-Ser-X-Trp-Ser motif in extracellular domains of erythropoietin receptor is essential for signal transduction,"" Biochim. Biophys. Res. Comm. (1992);184:485-490.;;Chihara, K et al. ""Short stature caused by a natural growth hormone antagonist,"" Horm Res. 1998;49 Suppl 1:41-5.;;Conte, F et al. ""Identification of a region critical for proteolysis of the human growth hormone receptor,"" Biochem Biophys Res Commun. Jan. 18, 2002;290(2):851-7.;;Cunningham, BC et JA Wells. ""High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis,"" Science Jun. 2, 1989;244(4908):1081-5.;;Cunningham, BC et al. ""Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis,"" Science Mar. 10, 1989;243(4896):1330-6.;;Cunningham, BC and JA Wells. ""Rational design of receptor-specific variants of human growth hormone,"" Proc Natl Acad Sci U S A. Apr. 15, 1991;88(8):3407-11.;;Cunningham, BC et al. ""Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule,"" Science Nov. 8, 1991;254(5033):821-5.;;Cunningham, BC et JA Wells. ""Comparison of a structural and a functional epitope,"" J. Mol Biol. Dec. 5, 1993;234(3):554-63.;;Dastot, F et al. ""Alternatively spliced forms in the cytoplasmic domain of the human growth hormone (GH) receptor regulate its ability to generate a soluble GH-binding protein,"" Proc Natl Acad Sci U S A. Oct. 1, 1996;93(20):10723-8.;;Dattani, MT et al. ""G120R, a human growth hormone antagonist, shows zinc-dependent agonist and antagonist activity on Nb2 cells,"" J Biol Chem. Apr. 21, 1995;270(16):9222-6.;;Davis, S et al. ""LIFRbeta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor,"" Science 1993; 260: 1805-1808.;;De Vos, AM et al. ""Human growth hormone and extracellular domain of its receptor: crystal structure of the complex"" Science Jan. 17, 1992;255(5042):306-12.;;Diederichs, K et al. ""Novel fold and putative receptor binding site of granulocyte-macrophage colony-stimulating factor,"" Science 1991; 154: 1779-1782.;;Dienys, G et al. ""Dimerization of human growth hormone in the presence of metal ions,"" Bioconjug Chem. Sep.-Oct. 2000;11(5):646-51.;;Elkins, PA et al. ""Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor,"" Nat Struct Biol. Sep. 2000;7(9):808-15.;;Frank, SJ. ""Receptor dimerization in GH and erythropoietin action-it takes two to tango, but how?"" Endocrinology. Jan. 2002;143(1):2-10.;;Fuh, G et al. ""The human growth hormone receptor. Secretion from Escherichia coli and disulfide bonding pattern of the extracellular binding domain,"" J Biol Chem. Feb. 25, 1990;265(6):3111-5.;;Fuh, G et al. ""Rational design of potent antagonists to the human growth hormone receptor,"" Science Jun. 19, 1992;256(5064):1677-80.;;Gent, J et al. ""Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis,"" Proc Natl Acad Sci U S A. Jul. 23, 2002;99(15):9858-63. Epub Jul. 8, 2002.;;Gertler, A et al. ""Real-time kinetic measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization,"" J Biol Chem. Oct. 4, 1996;271(40):24482-91.;;Godowski, PJ et al. ""Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism,"" Proc Natl Acad Sci U S A. Oct. 1989;86(20):8083-7.;;Goeddel, DV et al. ""Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone"" Nature Oct. 18, 1979;281(5732):544-8.;;Gomez-Orellana, I et al. ""Thermodynamic characterization of an intermediate state of human growth hormone,"" Protein Sci. Jun. 1998;7(6):1352-8.;;Gout, PW et al. ""Prolactin-stimulated growth of cell cultures established from malignant NB rat lymphomas,"" Cancer Res. Jul. 1980;40(7):2433-6.;;Hill, CP et al. ""The Structure of Granulocyte-Colony-Stimulating Factor and its Relationship to Other Growth Factors,"" Proc. Natl. Acad. Sci. USA (1993); 90:5167-71.;;Hughes, JP and HG Friesen. ""The nature and regulation of the receptors for pituitary growth hormone,"" Annu Rev Physiol. 1985;47:469-82.;;Igout, A, et al. ""Expression and secretion of the human placental growth hormone in Escherichia coli,"" Nucleic Acids Res. May 25, 1989;17(10):3998.;;Isaksson, OG, et al. ""Mode of action of pituitary growth hormone on target cells,"" Annu Rev Physiol. 1985;47:483-99.;;Johnston, LB et al. ""Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short stature,"" Clin Endocrinol (Oxf). Apr. 2000;52(4):463-9.;;Kasukawa, Y et al. ""Evidence that sensitivity to growth hormone (GH) is growth period and tissue type dependent: studies in GH-deficient lit/lit mice,"" Endocrinology. Sep. 2003;144(9):3950-7.;;Khan, RH et al. ""Solubilization of recombinant ovine growth hormone with retention of native-like secondary structure and its refolding from the inclusion bodies of Escherichia coli,"" Biotechnol Prog. Sep.-Oct. 1998;14(5):722-8.;;Klaus, W et al. ""The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution,"" J Mol Biol. Dec. 12, 1997;274(4):661-75.;;Kopchick, JJ et al. ""Growth hormone receptor antagonists: discovery, development, and use in patients'with acromegaly,"" Endocr Rev. Oct. 2002;23(5):623-46.;;Kostyo, JL et al. ""Biological characterization of purified native 20-kDa human growth hormone,"" Biochim Biophys Acta. Sep. 11, 1987;925(3):314-24.;;Krawczak, M et al. ""Evolution of the proximal promoter region of the mammalian growth hormone gene,"" Gene Sep. 3, 1999;237(1):143-51.;;Lee, N et al. ""Interferon-alpha 2 variants in the human genome,"" J Interferon Cytokine Res. Apr. 1995;15(4):341-9.;;Leung, DW et al. ""Growth hormone receptor and serum binding protein: purification, cloning and expression,"" Nature Dec. 10-16, 1987;330(6148):537-43.;;Lewis, UJ et al. ""A naturally occurring structural variant of human growth hormone,"" J Biol Chem. Apr. 25, 1978;253(8):2679-87.;;Lewis, UJ et al. ""An interchain disulfide dimer of human growth hormone,"" J Biol Chem. Jun. 10, 1977;252(11):3697-702.;;Lewis, UJ et al. ""Altered proteolytic cleavage of human growth hormone as a result of deamidation,"" J Biol Chem. Nov. 25, 1981;256(22):11645-50.;;Li, CH, ""Human growth hormone: 1974-1981,"" Mol Cell Biochem. Jul. 7, 1982;46(1):31-41.;;Linzer, Dih et F. Talamantes. ""Nucleotide sequence of mouse prolactin and growth hormone mRNAs and expression of these mRNAs during pregnancy,"" J Biol Chem. Aug. 15, 1985;260(17):9574-9.;;Liu, JC et al. ""Episodic evolution of growth hormone in primates and emergence of the species specificity of human growth hormone receptor,"" Mol Biol Evol. Jun. 2001;18(6):945-53.;;MacGillivray, MH et al. ""Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group."" J Clin Endocrinol Metab. May, 1996;81(5):1806-9.;;Mathews, LS et al. ""Regulation of rat growth hormone receptor gene expression,"" J Biol Chem. Jun. 15, 1989;264(17):9905-10.;;Matthews, DJ et al. ""A sequential dimerization mechanism for erythropoietin receptor activation,"" Proc Natl Acad Sci U S A. Sep. 3, 1996;93(18):9471-6.;;McFarland, KC et al. ""Lutropin-choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family,"" Science Aug. 4, 1989;245(4917):494-9.;;Milburn, MV et al. ""A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5"" Nature 1993; 363:172-176.;;Mills, JB, et al. ""Fragments of human growth hormone produced by digestion with thrombin: chemistry and biological properties,"" Endocrinology Aug. 1980;107(2):391-9.;;Mordenti, J et al. ""Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins,"" Pharm Res. Nov. 1991;8(11):1351-9.;;Mott, HR and ID Campbell. ""Four-helix bundle growth factors and their receptors: protein-protein interactions,"" Curr Opin Struct Biol. Feb. 1995;5(1):114-21.;;Murgolo, NJ et al. ""A homology model of human interferon alpha-2,"" Proteins Sep. 1993;17(1):62-74.;;Oliva, A et al. ""Comparative study of protein molecular weights by size-exclusion chromatography and laser-light scattering,"" J Pharm Biomed Anal. Jul. 2001;25(5-6):833-41.;;Pal, G et al. ""The functional binding epitope of a high affinity variant of human growth hormone mapped by shotgun alanine-scanning mutagenesis: insights into the mechanisms responsible for improved affinity,"" J Mol Biol. Sep. 5, 2003;332(1):195-204.;;Pantel, J et al. ""Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution,"" J Biol Chem. Jun. 23, 2000;275(25):18664-9.;;Paonessa, G et al. ""Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signaling,"" EMBO J. May 1, 1995;14(9):1942-51.;;Pearce, KH et al. ""Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity,"" Biochemistry. Jan. 5, 1999;38(1):81-9.;;Pearce, KH et al. ""Structural and mutational analysis of affinity-inert contact residues at the growth hormone-receptor interface,"" Biochemistry. Aug. 13, 1996;35(32):10300-7.;;Powers, R et al. ""Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy,"" Science Jun. 19, 1992;256(5064):1673-7.;;Radhakrishnan, R et al. ""Zinc mediated dimer of human interferon- alpha 2b revealed by X-ray crystallography,"" Structure Dec. 15, 1996;4(12):1453-63.;;Redfield, C et al. ""Secondary structure and topology of human interleukin 4 in solution,"" Biochemistry Nov. 19, 1991;30(46):11029-35.;;Ross, RJM et al. ""Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer,"" J Clin Endocrinol Metab. Apr. 2001;86(4):1716-23.;;Rottman, JN et JI Gordon. ""Comparison of the patterns of expression of rat intestinal fatty acid binding protein/human growth hormone fusion genes in cultured intestinal epithelial cell lines and in the gut epithelium of transgenic mice,"" J Biol Chem. Jun. 5, 1993;268(16):11994-2002.;;Rowland, JE et al. ""A novel bioassay for human somatogenic activity in serum samples supports the clinical reliability of immunoassays,"" Clin Endocrinol (Oxf). Apr. 2002;56(4):475-85.;;Schiffer, C et al. ""Structure of a phage display-derived variant of human growth hormone complexed to two copies of the extracellular domain of its receptor: evidence for strong structural coupling between receptor binding sites,"" J Mol Biol. Feb. 15, 2002;316(2):277-89.;;Schoner, BE et al. ""Role of mRNA translational efficiency in bovine growth hormone expression in Escherichia coli,"" Proc Natl Acad Sci U S A. Sep. 1984;81(17):5403-7.;;Seeburg, PH. ""The human growth hormone gene family: nucleotide sequences show recent divergence and predict a new polypeptide hormone,"" DNA 1982;1(3):239-49.;;Silva, CM et al. ""Characterization and cloning of STAT5 from IM-9 cells and its activation by growth hormone,"" Mol Endocrinol. May 1996;10(5):508-18.;;Sobrier, ML et al. ""Expression and binding properties of two isoforms of the human growth hormone receptor,"" FEBS Lett. Mar. 15, 1993;319(1-2):16-20.;;Sobrier, Ml et al. ""Nine novel growth hormone receptor gene mutations in patients with Laron syndrome,"" J Clin Endocrinol Metab. Feb. 1997;82(2):435-7.;;Souza, SC et al. ""A single arginine residue determines species specificity of the human growth hormone receptor,"" Proc Natl Acad Sci U S A. Feb. 14, 1995;92(4):959-63.;;Spencer, SA et al. ""Rabbit liver growth hormone receptor and serum binding protein. Purification, characterization, and sequence,"" J Biol Chem. Jun. 5, 1988;263(16):7862-7.;;Stallings-Mann, ML et al. ""Alternative splicing of exon 3 of the human growth hormone receptor is the result of an unusual genetic polymorphism,"" .Proc Natl Acad Sci U S A. Oct. 29, 1996;93(22):12394-9.;;Sundstrom, M et al. ""Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 A resolution,"" J Biol Chem. Dec. 13, 1996;271(50):32197-203.;;Syed, RS et al. ""Efficiency of signalling through cytokine receptors depends critically on receptor orientation,"" Nature. Oct. 1, 1998;395(6701):511-6.;;Talamantes, F et R Ortiz. ""Structure and regulation of expression of the mouse GH receptor,"" J Endocrinol. Oct. 2002;175(1):55-9.",INACTIVE
803,EP,A1,EP 3084872 A1,038-870-199-246-276,2016-10-26,2016,EP 14870855 A,2014-12-18,US 201361918014 P;;US 201361918859 P;;US 2014/0071214 W,2013-12-19,HYDROGEN/BROMINE FLOW BATTERY IN WHICH HYDROGEN IS FREELY EXCHANGED BETWEEN TWO CELL COMPARTMENTS,,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/038-870-199-246-276,Patent Application,yes,0,0,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M8/18;;H01M8/02,,0,0,,,,ACTIVE
804,US,A1,US 2021/0048392 A1,050-865-258-920-717,2021-02-18,2021,US 202016991013 A,2020-08-11,US 202016991013 A;;US 201962885529 P,2019-08-12,FLUORESCENCE-BASED DETECTION OF PROTEIN AGGREGATION AND FIBER OPTIC-BASED BENCHTOP INSTRUMENT,A sensor can include a nanostructure in a housing configured to contact a sample.,MASSACHUSETTS INST TECHNOLOGY,STRANO MICHAEL;;KOZAWA DAICHI;;GONG XUN;;SALEM DANIEL;;CHO SOOYEON;;NGUYEN FREDDY T,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2020-08-09),https://lens.org/050-865-258-920-717,Patent Application,yes,4,1,2,2,0,G01N2021/6484;;G01N33/587;;G01N21/6489;;G01N2021/6434;;G01N21/645;;G01N2021/7786;;G01N2021/7723;;G01N2021/773;;G01N2021/772;;G01N2021/6419;;G01N21/6486;;G01N2021/6484;;G01N33/6809,G01N21/64;;G01N33/68,,0,0,,,,PENDING
805,BR,A2,BR PI0518661 A2,061-919-091-012-409,2008-12-02,2008,BR PI0518661 A,2005-12-21,US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P;;US 2005/0046486 W,2004-12-22,mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante,"MÉTODOS PARA EXPRESSçO E PURIFICAÇçO DO HORMâNIO DO CRESCIMENTO HUMANO RECOMBINANTE. A presente invenção se refere em linhas gerais à produção, purificação e isolamento de hormônio de crescimento humano (Hgh). Mais especificamente, a invenção se refere à produção, purificação e isolamento de hGH substancialmente purificado a partir de células hospedeiras recombinantes ou do meio de cultura, incluindo, por exemplo, células de levedura, de insetos, de mamíferos e bacterianas. O processo da presente invenção é também útil para a purificação de hGH ligado a polímeros ou a outras moléculas.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/061-919-091-012-409,Patent Application,no,0,0,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12Q1/68;;A61K38/27;;C07H21/04;;C07K14/61,,0,0,,,,DISCONTINUED
806,US,A1,US 2006/0183198 A1,060-190-560-953-771,2006-08-17,2006,US 31575205 A,2005-12-21,US 31575205 A;;US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P,2004-12-22,Methods for expression and purification of recombinant human growth hormone,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO S,AMBRX INC (2006-03-31),https://lens.org/060-190-560-953-771,Patent Application,yes,99,39,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12P21/06;;C07H21/04;;C07K14/61,435/69.4;;435/320.1;;435/325;;530/399;;536/23.5,0,0,,,,INACTIVE
807,EP,A1,EP 3095152 A1,119-583-036-675-660,2016-11-23,2016,EP 14873586 A,2014-12-22,US 201361919926 P;;US 2014/0071835 W,2013-12-23,"SYSTEM AND METHOD FOR RETURNING MATERIAL FROM THE BR2 , SIDE OF AN H2/BR2 FLOW BATTERY BACK AFTER CROSSOVER",,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/119-583-036-675-660,Patent Application,yes,0,0,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/18;;H01M8/20,,0,0,,,,ACTIVE
808,TW,A,TW 201418176 A,122-105-470-500-195,2014-05-16,2014,TW 102118081 A,2013-05-22,US 201213477391 A,2012-05-22,Methods of separating strengthened glass sheets by mechanical scribing,"A method of separating a strengthened glass sheet includes positioning a serrated scribing wheel at a position spaced apart from a first edge of the glass sheet and offset below a top surface of the glass sheet, where the glass sheet comprises a surface compression layer of layer depth DOL and a central region. The method also includes translating the serrated scribing wheel in a first direction at an initiation speed such that the serrated scribing wheel forms a crack initiation site comprising surface indentations extending into the surface compression layer, accelerating the serrated scribing wheel in the first direction from the initiation speed to a scoring speed to scribe a score line extending into the glass sheet to a median crack depth greater than DOL, and stopping the serrated scribing wheel in the first direction before the score line reaches a second edge of the glass sheet.",CORNING INC,BROWN JAMES WILLIAM;;HSIEH CHO-CHENG;;JOSEPH MICHAEL ALBERT II;;PAI CHIA-YEN,,https://lens.org/122-105-470-500-195,Patent of Addition,no,0,0,13,13,0,B26F3/00;;B26F3/00;;C03B33/023;;C03B33/023;;C03B33/023;;C03B33/105;;C03B33/107;;C03B33/107;;C03B33/107;;C03C21/002;;C03C21/002;;C03C21/002;;Y10T83/0341;;Y10T83/0341;;Y10T225/12;;Y10T225/12,C03B33/02;;C03B33/023;;C03B33/10,,0,0,,,,INACTIVE
809,GB,A,GB 2341191 A,127-190-657-777-558,2000-03-08,2000,GB 9920179 A,1999-08-25,US 14460798 A,1998-08-31,Method for combined fluid catalytic cracking and sulphur content reduction using a metal containing molecular sieve-based catalyst,"The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reduction additive comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve. The molecular sieve is normally a large pore size zeolite such as USY or zeolite beta or an intermediate pore size zeolite such as ZSM-5. The metal is normally a metal of Period 3 of the Periodic Table, preferably zinc or vanadium. The sulfur reduction catalyst may be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst.",MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/127-190-657-777-558,Patent Application,no,6,10,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;C10G35/085;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,C1A ACA           ACA;;C1A AD31          ACA;;C1A AG13          ACA;;C1A AG37          ACA;;C1A AG39          ACA;;C1A AG55          ACA;;C1A AG9           ACA;;C5E ESR           ESR,0,0,,,,EXPIRED
810,KR,A,KR 20070100299 A,151-122-623-983-80X,2007-10-10,2007,KR 20077016445 A,2007-07-18,US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P,2004-12-22,METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/151-122-623-983-80X,Patent Application,no,0,1,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,A61K38/00;;A61K38/27;;C12Q1/68,,0,0,,,,DISCONTINUED
811,CA,C,CA 2281445 C,164-150-720-263-580,2006-01-24,2006,CA 2281445 A,1999-08-25,US 14460798 A,1998-08-31,GASOLINE SULFUR REDUCTION IN FLUID CATALYTIC CRACKING,"The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reductio n additive comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve. The molecular sieve is normally a large pore size zeolite such as USY or zeolite beta or an intermediate pore size zeolite such as ZSM-5. The metal is normally a metal of Period 3 o f the Periodic Table, preferably zinc or vanadium. The sulfur reduction catalyst m ay be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst.",MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;ZIEBARTH MICHAEL SCOTT;;ROBERIE TERRY G;;TIMKEN HYE KYUNG CHO,,https://lens.org/164-150-720-263-580,Granted Patent,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,C10G11/05;;C10G35/085;;B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
812,AU,A1,AU 2005/323106 A1,002-280-726-119-732,2006-07-13,2006,AU 2005/323106 A,2005-12-21,US 68097705 P;;US 65574405 P;;US 63861604 P;;US 72796805 P;;US 2005/0046486 W,2004-12-22,Methods for expression and purification of recombinant human growth hormone,,AMBRX INC,BUSSELL STUART;;ONG MICHAEL;;CHO HO SUNG;;KNUDSEN NICK;;LIEU RICKY;;BUECHLER YING,,https://lens.org/002-280-726-119-732,Patent Application,no,0,0,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12Q1/68;;A61K38/27;;C07H21/04;;C07K14/61,,0,0,,,,INACTIVE
813,NO,D0,NO 20013239 D0,021-280-437-853-892,2001-06-28,2001,NO 20013239 A,2001-06-28,US 22210298 A;;US 9929799 W,1998-12-29,Oppgradering av cetan via aromatisk alkylering,,MOBIL OIL CORP,COLLINS NICK ALLEN;;LANDIS MICHAEL E;;TIMKEN HYE KYUNG CHO;;TREWELLA JEFFREY CHARLES,,https://lens.org/021-280-437-853-892,Patent Application,no,0,0,7,7,0,C10G29/205,C10G29/20,,0,0,,,,DISCONTINUED
814,SE,D0,SE 9903054 D0,032-988-254-226-303,1999-08-31,1999,SE 9903054 A,1999-08-31,US 14460798 A,1998-08-31,Svavelreduktion i bensin i flytande fas vid katalytisk krackning,,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;ROBERIE TERRY G;;TIMKEN HYE KYUNG CHO;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/032-988-254-226-303,Patent Application,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;C10G35/085;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
815,AU,B2,AU 734365 B2,067-711-401-184-739,2001-06-14,2001,AU 1999/044687 A,1999-08-25,US 14460798 A,1998-08-31,Gasoline sulfur reduction in fluid catalytic cracking,,MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/067-711-401-184-739,Granted Patent,no,2,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,C10G35/085;;B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
816,US,A1,US 2008/0218621 A1,075-541-729-483-135,2008-09-11,2008,US 8130208 A,2008-04-14,US 8130208 A;;US 23020502 A,2002-08-29,High intrascene dynamic range NTSC and PAL imager,"The invention provides a new method and apparatus for NTSC and PAL image sensors which employs fusion of adjacent row pixel charge samples to generate image data for a row. A variety of fusion schemes are possible for fusing the pixel signals from the adjacent rows. The rows of pixels are scanned so that each scan takes an odd row signal sample and, in some cases, an adjacent even row signal sample when specified conditions are met. One sampled row of the two adjacent rows integrate an image with a first integration period while the other adjacent row integrates an image with a second integration period.",MICRON TECHNOLOGY INC,CHO KWANG-BO;;SUBBOTIN IGOR;;KAPLINSKY MICHAEL;;BARNA SANDOR L;;SLAYTON GARY E,APTINA IMAGING CORPORATION (2009-07-08);;MICRON TECHNOLOGY INC (2002-10-30),https://lens.org/075-541-729-483-135,Patent Application,yes,24,11,4,4,0,H04N23/70;;H04N23/741;;H04N25/583;;H04N25/616;;H04N25/75;;H04N3/155;;H04N23/741;;H04N23/70,H04N5/235;;H04N5/345;;H04N5/353;;H04N5/355;;H04N5/374;;H04N5/378,348/308;;X348E05091,0,0,,,,EXPIRED
817,US,A1,US 2007/0000242 A1,104-292-194-307-316,2007-01-04,2007,US 17031805 A,2005-06-30,US 17031805 A,2005-06-30,Regeneration assembly,A regeneration assembly includes a first portion including a combustion chamber connected to a combustor head. The regeneration assembly also includes a second portion including a housing. The first portion is removably connectable to the second portion.,CATERPILLAR INC,HARMON MICHAEL P;;LIANG CHO Y;;KAUFMANN GREGORY J;;BALMER-MILLAR MARI LOU,CATERPILLAR INC (2005-06-29),https://lens.org/104-292-194-307-316,Patent Application,yes,54,75,4,4,0,F01N3/0256;;F01N3/0256,F01N3/00,60/295;;60/297;;60/289,0,0,,,,ACTIVE
818,DE,A1,DE 102006022075 A1,180-566-899-817-377,2007-03-01,2007,DE 102006022075 A,2006-05-11,US 17031805 A,2005-06-30,Regenerationsanordnung,"Eine Regenerationsanordnung weist einen ersten Teil auf, der eine Brennkammer aufweist, die mit einem Brennerkopf verbunden ist. Die Regenerationsanordnung weist auch einen zweiten Teil auf, der ein Gehäuse aufweist. Der erste Teil ist entfernbar mit dem zweiten Teil zu verbinden.",CATERPILLAR INC,HARMON MICHAEL P;;LIANG CHO Y;;KAUFMANN GREGORY J;;BALMER-MILLAR MARI LOU,,https://lens.org/180-566-899-817-377,Patent Application,no,0,2,4,4,0,F01N3/0256;;F01N3/0256,F01N3/025;;F23N1/02,,0,0,,,,DISCONTINUED
819,EP,A4,EP 3095152 A4,179-574-700-063-040,2017-07-26,2017,EP 14873586 A,2014-12-22,US 201361919926 P;;US 2014/0071835 W,2013-12-23,"SYSTEM AND METHOD FOR RETURNING MATERIAL FROM THE BR2 , SIDE OF AN H2/BR2 FLOW BATTERY BACK AFTER CROSSOVER",,BOSCH GMBH ROBERT;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/179-574-700-063-040,Search Report,no,1,0,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/18;;H01M8/20,,0,0,,,,ACTIVE
820,US,B2,US 10135810 B2,068-943-648-831-730,2018-11-20,2018,US 201615354155 A,2016-11-17,US 201615354155 A,2016-11-17,Selective authentication system,A method and authentication mechanism is provided. A request is sent to authenticate a user of the application from a mobile device to an authentication server. The authentication server identifies a user profile for the user containing one or more authentication schemes available to authenticate the user. The authentication schemes comprise a direct scheme in which the user provides a password and a federated authentication scheme. The authentication server determines a favored authentication scheme from one or more authentication schemes available based on a policy associated with the user profile. The mobile device displays a menu showing the authentication schemes available to allow the user to select an authentication scheme. The favored authentication scheme is displayed ahead of a remainder of the authentication schemes. The authentication server verifies credentials for the user profile using the selected authentication scheme to authenticate the user.,ADP LLC,AHUJA SANJOLI;;BRAUMAN MICHAEL JUSTIN;;CHO HANWOONG DARREN;;KOSOVAN BRENDA JANE;;VILLAVICENCIO FRANCISCO,ADP INC (2016-11-10),https://lens.org/068-943-648-831-730,Granted Patent,yes,13,0,2,2,0,H04L63/083;;H04L63/083;;H04L63/108;;H04L63/108;;H04L67/02;;H04L67/02;;H04L67/306;;H04L67/306;;H04W12/77;;H04W12/77,H04L29/06;;H04L29/08,,1,1,008-928-771-459-08X,10.1145/643550.643562,"Duncan Wong., “An Optimized Authentication Protocol for Mobile Network Reconsidered”, Oct. 2002, ACM, pp. 74-76 (Year: 2002).",ACTIVE
821,GB,A,GB 2438760 A,099-133-791-195-968,2007-12-05,2007,GB 0713654 A,2005-12-21,US 2005/0046486 W;;US 63861604 P;;US 65574405 P;;US 72796805 P;;US 68097705 P,2004-12-22,Methods for expression and purification of recombinant human growth hormone,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/099-133-791-195-968,Patent Application,no,0,0,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C07K14/61;;A61K38/27;;C07H21/04;;C12Q1/68,,1,0,,,Not yet advised,DISCONTINUED
822,US,A1,US 2008/0050777 A1,128-379-666-604-566,2008-02-28,2008,US 87408607 A,2007-10-17,US 87408607 A;;US 31575205 A;;US 72796805 P;;US 68097705 P;;US 65574405 P;;US 63861604 P,2004-12-22,Methods for Expression and Purification of Recombinant Human Growth Hormone,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,AMBRX INC (2006-03-31),https://lens.org/128-379-666-604-566,Patent Application,yes,8,24,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12N15/09;;C12N5/00,435/69.4;;435/406,0,0,,,,INACTIVE
823,ZA,B,ZA 995501 B,190-441-643-621-550,2001-02-26,2001,ZA 995501 A,1999-08-26,US 14460798 A,1998-08-31,Gasoline sulfur reduction in fluid catalytic cracking.,,MOBIL OIL CORP;;GRACE W R & CO,ROBERIE TERRY G;;CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/190-441-643-621-550,Granted Patent,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,B01J29/00;;B01J29/03;;C10G35/085;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
824,AU,A,AU 2000/031226 A,169-995-906-336-537,2000-07-31,2000,AU 2000/031226 A,1999-12-16,US 22210298 A;;US 9929799 W,1998-12-29,Cetane upgrading via aromatic alkylation,,MOBIL OIL CORP,COLLINS NICK ALLEN;;LANDIS MICHAEL E;;TIMKEN HYE KYUNG CHO;;TREWELLA JEFFREY C,,https://lens.org/169-995-906-336-537,Patent Application,no,0,0,7,7,0,C10G29/205,C10G29/20,,0,0,,,,DISCONTINUED
825,WO,A1,WO 2022/020065 A1,188-555-814-681-35X,2022-01-27,2022,US 2021/0039363 W,2021-06-28,US 202016935433 A,2020-07-22,THERMAL STIMULATION AND SUBSEQUENT COOLING FOR FULLY IMPLANTABLE LVAD CONTROLLER,"A method of cooling a mammal with an implantable blood pump. The method includes measuring a temperature of an internal controller, the internal controller being in communication with the implantable blood pump. an alert is generated if the temperature of the internal controller exceeds a predetermined temperature threshold.",MEDTRONIC INC,EGGEN MICHAEL D;;CHO YONG K;;SCHEINER AVRAM;;RAGHUPATHY RAMESH;;RADTKE THOMAS W,,https://lens.org/188-555-814-681-35X,Patent Application,yes,5,0,3,3,0,A61M60/122;;A61M60/205;;A61M60/508;;A61M60/585;;A61M60/592;;A61M2205/18;;A61M2205/3368;;A61M2205/3507;;A61M2205/3606;;A61M60/135;;A61M60/50;;A61F7/08;;A61F7/10;;A61F2007/0011;;A61M2205/18;;A61M2205/3372;;A61M2205/3584;;A61M2205/3606;;A61M2205/50;;A61M2205/8206;;A61M2230/50,A61M60/122;;A61M60/205;;A61M60/508;;A61M60/585;;A61M60/592,,0,0,,,,PENDING
826,US,B2,US 8446531 B2,007-908-598-809-888,2013-05-21,2013,US 17019808 A,2008-07-09,US 17019808 A,2008-07-09,System and method for clock offset detection,"A system and method for detecting a sampling clock offset of an analog-to-digital converter used to digitize an analog image signal. A method comprises buffering samples of an analog image signal, computing a value of an autocorrelation function using the buffered samples and a delayed version of the buffered samples, and repeating the computing a value for delays in a range of delays. The method also comprises computing a sampling frequency offset from the values of the autocorrelation function and changing a sampling frequency using the sampling frequency offset.",OUYANG BING;;HAYDEN JOHN MICHAEL;;ETHRIDGE TROY LANE;;CHO HONG JIN;;KORDEL JEFF;;TEXAS INSTRUMENTS INC,OUYANG BING;;HAYDEN JOHN MICHAEL;;ETHRIDGE TROY LANE;;CHO HONG JIN;;KORDEL JEFF,TEXAS INSTRUMENTS INCORPORATED (2008-07-01),https://lens.org/007-908-598-809-888,Granted Patent,yes,17,0,2,2,0,G09G3/001;;G09G3/2096;;G09G5/008;;G09G2320/02;;H03M1/127;;H04N5/04;;H03M1/127;;G09G2320/02;;G09G3/001;;G09G3/2096;;G09G5/008;;H04N5/04,H03L7/00;;H03M1/12,348/572;;348/537,3,2,138-795-340-249-686;;038-083-160-927-880,10.1109/tassp.1977.1162905;;10.1109/tassp.1974.1162598,"""Autolock Enhancements-Timing Rule: Autolock Algorithm White Paper: Draft 1,"" DDP2230 Component: DLP® FP Tutorial Library, Mar. 31, 2008, pp. 1-12, Texas Instruments, Dallas, TX.;;Rabiner, L.R., ""On the Use of Autocorrelation Analysis for Pitch Detection,"" IEEE Transactions on Acoustics, Speech and Signal Processing, Feb. 1977, pp. 24-33, vol. ASSP-25, No. 1, IEEE, Los Alamitos, CA.;;Ross, M.J., et al., ""Average Magnitude Difference Function Pitch Extractor,"" IEEE Transactions on Acoustics, Speech and Signal Processing, Oct. 1974, pp. 353-362, vol. ASSP-22, No. 5, IEEE, Los Alamitos, CA.",ACTIVE
827,WO,A1,WO 2020/007900 A1,012-885-932-420-096,2020-01-09,2020,EP 2019067821 W,2019-07-03,EP 18181981 A,2018-07-05,TRANSPARENT CONDUCTIVE FILM,"The present invention is in the field of transparent conductive films. In particular, the present invention relates to a transparent conductive film comprising: a) a first laminate comprising: - at least two layers containing TiO 2 , ZrO 2 or HfO 2 and - a layer containing an organic compound in between the two layers containing TiO 2 , ZrO 2 or HfO 2 , b) a metal layer, and c) a second laminate comprising: - at least two layers containing ZnO and - a layer containing an organic compound between the two layers containing ZnO, - a metallic dopant other than zinc.",BASF COATINGS GMBH,CHO BORAM;;FLORES JEAN-CHARLES;;REINKE MICHAEL;;SUNG MYUNG MO;;JUNG JIN WON,,https://lens.org/012-885-932-420-096,Patent Application,yes,8,0,9,9,0,C03C17/38;;C03C2217/94;;C23C16/45525;;C23C28/00;;C23C28/322;;C23C28/34;;C23C28/345;;C23C28/3455;;C23C28/40;;C23C28/42;;Y02E10/549;;H10K30/50;;C23C28/3455;;C23C28/322;;C23C28/42;;C23C16/45529;;C23C16/405;;H01B5/14;;B05D1/60;;H10K30/50;;C23C16/45531;;C23C28/30;;C23C28/42;;C23C28/44;;C23C28/02;;Y10T428/31678;;C23C28/322;;C23C28/3455;;H10K30/82;;H10K30/451,C23C28/00;;C03C17/36;;C23C16/455,,0,0,,,,PENDING
828,US,A1,US 2008/0199909 A1,129-422-062-222-724,2008-08-21,2008,US 87410008 A,2008-01-31,US 87410008 A;;US 31575205 A;;US 72796805 P;;US 68097705 P;;US 65574405 P;;US 63861604 P,2004-12-22,Methods for Expression and Purification of Recombinant Human Growth Hormone,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,AMBRX INC (2006-03-31),https://lens.org/129-422-062-222-724,Patent Application,yes,99,13,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12P21/00,435/69.4,0,0,,,,INACTIVE
829,US,B2,US 7959926 B2,143-391-134-232-437,2011-06-14,2011,US 87406807 A,2007-10-17,US 87406807 A;;US 31575205 A;;US 72796805 P;;US 68097705 P;;US 65574405 P;;US 63861604 P,2004-12-22,Methods for expression and purification of recombinant human growth hormone mutants,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH comprising non-naturally encoded amino acids and hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,AMBRX INC (2006-03-31),https://lens.org/143-391-134-232-437,Granted Patent,yes,104,20,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,A61K39/00;;A61K38/02;;A61K38/27;;C07H21/00;;C07K1/16;;C12P21/00,424/200.1;;424/198.1;;424/124;;536/23.51;;514/11.4;;435/7.6;;435/69.1;;530/417,99,99,038-434-358-484-087;;046-830-730-221-158;;026-196-745-323-826;;005-613-652-908-094;;014-978-026-283-267;;002-119-532-659-035;;012-728-507-765-086;;050-786-135-149-138;;018-443-427-999-877;;016-305-322-178-847;;126-088-206-672-514;;050-861-244-353-872;;009-755-617-730-381;;019-330-233-823-553;;050-882-422-342-790;;033-647-927-544-631;;043-921-127-972-381;;042-973-429-479-822;;093-314-921-738-786;;044-051-728-567-349;;097-080-301-825-404;;026-738-005-053-457;;065-753-482-536-793;;020-312-701-947-992;;054-538-164-035-896;;022-040-530-874-077;;020-589-059-757-172;;002-091-944-669-043;;004-932-164-344-439;;011-715-515-620-371;;034-068-833-115-414;;017-545-542-868-371;;010-754-991-840-83X;;047-163-936-169-471;;008-410-555-537-921;;038-439-210-215-107;;027-665-676-300-035;;042-913-428-203-758;;058-204-189-632-991;;026-263-397-448-936;;077-079-385-316-426;;147-197-496-476-064;;006-818-687-776-090;;005-390-264-823-878;;092-351-743-786-019;;004-383-062-518-283;;038-829-082-801-518;;021-430-614-333-670;;020-863-223-792-607;;005-158-462-978-663;;020-671-018-984-937;;072-640-581-733-306;;055-486-180-233-758;;077-253-587-030-275;;039-630-429-967-217;;051-028-782-527-194;;033-137-559-002-58X;;035-574-511-125-693;;067-271-741-810-373;;020-077-913-179-174;;025-101-902-648-114;;083-799-059-658-343;;124-686-428-289-163;;122-562-796-318-32X;;023-882-499-006-921;;077-169-348-159-440;;082-101-485-871-557;;094-619-099-798-015;;031-858-803-001-667;;001-595-578-344-697;;007-284-302-828-236;;038-267-723-757-587;;077-225-285-207-268;;033-564-293-374-947;;123-904-781-929-13X;;108-365-299-335-209;;090-038-329-131-865;;110-666-204-380-05X;;002-764-043-331-997;;114-854-824-282-69X;;041-067-829-634-042;;005-255-839-259-250;;041-487-661-080-082;;014-549-027-288-910;;021-706-010-433-114;;011-209-988-567-476;;006-995-546-372-911;;046-581-452-608-373;;028-383-058-454-759;;120-448-891-062-797;;025-437-584-603-525;;030-792-509-092-646;;003-496-488-978-994;;030-545-746-430-807;;006-157-672-562-73X;;000-223-149-311-914;;074-890-940-229-924;;015-459-649-895-675;;003-471-282-689-694,1535167;;10.1126/science.256.5064.1677;;pmc125043;;10.1073/pnas.152294299;;12105275;;10.1074/jbc.271.40.24482;;8798708;;02813379;;2813379;;pmc298219;;10.1073/pnas.86.20.8083;;386136;;10.1038/281544a0;;10.1002/pro.5560070611;;009655339;;9655339;;pmc2144027;;6992985;;pmc46676;;7685117;;10.1073/pnas.90.11.5167;;10.2210/pdb1rhg/pdb;;10.1146/annurev.ph.47.030185.002345;;2986539;;10.1146/annurev.physiol.47.1.469;;pmc317896;;10.1093/nar/17.10.3998;;2660109;;10.1146/annurev.physiol.47.1.483;;10.1146/annurev.ph.47.030185.002411;;3888078;;10.1046/j.1365-2265.2000.00940.x;;10762289;;10.1210/en.2002-0123;;pmc2923915;;12933669;;9758661;;10.1021/bp980071q;;10.1006/jmbi.1997.1396;;9417943;;12372843;;10.1210/er.2001-0022;;10.1016/0304-4165(87)90197-8;;3620504;;10524245;;10.1016/s0378-1119(99)00313-3;;7627809;;10.1089/jir.1995.15.341;;10.1038/330537a0;;2825030;;2689454;;pmc2115925;;10.1083/jcb.109.6.3231;;10.1074/jbc.m001236200;;10748003;;8107110;;10.1006/jmbi.1994.1135;;8360189;;10.1016/s0021-9258(17)46730-5;;10.1016/s0140-6736(01)06844-1;;11734231;;10.1210/mend.12.1.0054;;10.1210/me.12.1.146;;9440818;;pmc2323993;;12930995;;10.1110/ps.03133903;;1569568;;10.1016/0022-2836(92)90470-5;;10.2210/pdb1csg/pdb;;7534308;;10.1074/jbc.270.11.6261;;10.1073/pnas.160252097;;10908667;;pmc16802;;8552582;;10.1073/pnas.93.1.1;;pmc40168;;8077236;;10.1016/s0021-9258(17)31721-0;;1281794;;10.1016/0014-5793(92)81521-m;;10.1021/bi00194a009;;10.2210/pdb1gnc/pdb;;7518249;;10.1159/000080507;;15539807;;10514980;;10.1016/s0021-9673(99)00669-x;;15296527;;10.1093/chromsci/42.6.285;;12054815;;10.1016/s0022-2836(02)00137-7;;9514759;;10.1006/jmbi.1997.1613;;10.1081/pdt-100002252;;11485185;;7562409;;10.1002/jps.2600840609;;10.1016/s0378-5173(01)00852-3;;11604263;;10.1016/0021-9673(91)85014-7;;10514359;;10.1021/js9802289;;10.1023/a:1011998331254;;9587962;;10.1021/js970308x;;9519146;;10.1016/s0021-9673(00)94144-x;;2777948;;10.1023/a:1015929109894;;2687836;;8522194;;10.1016/0378-1119(95)00525-b;;10.1016/0141-0229(90)90134-c;;1366783;;10.1038/293408a0;;7024824;;8491820;;10.1016/0378-4347(93)80149-x;;12930093;;10.1007/3-540-36466-8_3;;10.1016/s0021-9673(01)83383-5;;3700508;;10.1016/s0021-9258(17)40874-x;;632293;;863899;;10.1016/s0021-9258(17)40308-5;;7028740;;10.1016/s0021-9258(19)68453-x;;10.1007/bf00215579;;7050655;;10.1016/s0021-9258(17)39273-6;;2991252;;11371582;;10.1093/oxfordjournals.molbev.a003895;;8626839;;10.1210/jcem.81.5.8626839;;10.1210/jc.81.5.1806;;2722883;;10.1016/s0021-9258(18)81745-8;;pmc38452;;10.1073/pnas.93.18.9471;;8790354;;10.1126/science.2502842;;2502842;;10.1038/363172a0;;8483502;;10.2210/pdb1hul/pdb;;10.1210/endo-107-2-391;;7389660;;1798669;;10.1023/a:1015836720294;;10.1016/0959-440x(95)80016-t;;7773741;;10.1002/prot.340170109;;8234245;;11377066;;10.1016/s0731-7085(01)00359-4;;12946357;;10.1016/s0022-2836(03)00898-2;;10764769;;10.1074/jbc.m001615200;;pmc398293;;7744001;;10.1002/j.1460-2075.1995.tb07186.x;;9890885;;10.1021/bi9817008;;1348280;;1871037;;10.1023/a:1015834724528;;14524717;;10.1021/bp034030s;;10.1345/aph.10054;;10928404;;10.1023/a:1011902215383;;9523304;;10.1016/s0021-9673(01)82190-7;;3346343;;3434796;;10.1016/0003-2697(87)90152-7;;18465256;;15198505;;pmc2750939;;10.1208/ps060104;;8552145;;10.1056/nejm199602153340704;;15032301;;10.1023/b:pham.0000016234.73023.75;;10.1042/ba20030183;;15270709;;10.1042/ba20030143;;15270710;;12033388;;10.1023/a:1015108115452;;15190059;;10.1074/jbc.m405155200;;10.1016/s0378-5173(99)00152-0;;10460913;;3654843;;10.1016/s0021-9673(01)96517-3;;2329152;;10.1016/s0021-9673(00)96094-1;;14990496;;pmc1304004;;10.1016/s0006-3495(04)74237-x;;9950632;;10.1021/js980423n;;8756685;;10.1021/bi960513b;;1609277;;10.1126/science.256.5064.1673;;10.1016/s0969-2126(96)00152-9;;8994971;;1932028;;10.1021/bi00110a004;;11297608;;10.1210/jc.86.4.1716;;10.1210/jcem.86.4.7403;;8505324;;10.1016/s0021-9258(19)50299-x,"Fuh, G et al. ""Rational design of potent antagonists to the human growth hormone receptor,"" Science Jun. 19, 1992;256(5064):1677-80.;;Gent, J et al. ""Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis,"" Proc Natl Acad Sci U S A. Jul. 23, 2002;99(15):9858-63. Epub Jul. 8, 2002.;;Gertler, A et al. ""Real-time kinetic measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization,"" J Biol Chem. Oct. 4, 1996;271(40):24482-91.;;Godowski, PJ et al. ""Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism,"" Proc Natl Acad Sci U S A. Oct. 1989;86(20):8083-7.;;Goeddel, DV et al. ""Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone"" Nature Oct. 18, 1979;281(5732):544-8.;;Gomez-Orellana, I et al. ""Thermodynamic characterization of an intermediate state of human growth hormone,"" Protein Sci. Jun. 1998;7(6):1352-8.;;Gout, PW et al. ""Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas,"" Cancer Res. Jul. 1980;40(7):2433-6.;;Hill, CP et al. ""The Structure of Granulocyte-Colony-Stimulating Factor and its Relationship to Other Growth Factors,"" Proc. Natl. Acad. Sci. USA (1993); 90:5167-71.;;Hughes, JP and HG Friesen. ""The nature and regulation of the receptors for pituitary growth hormone,"" Annu Rev Physiol. 1985;47:469-82.;;Igout, A, et al. ""Expression and secretion of the human placental growth hormone in Escherichia coli,"" Nucleic Acids Res. May 25, 1989;17(10):3998.;;Isaksson, OG, et al. ""Mode of action of pituitary growth hormone on target cells,"" Annu Rev Physiol. 1985;47:483-99.;;Johnston, LB et al. ""Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short stature,"" Clin Endocrinol (Oxf). Apr. 2000;52(4):463-9.;;Kasukawa, Y et al. ""Evidence that sensitivity to growth hormone (GH) is growth period and tissue type dependent: studies in GH-deficient lit/lit mice,"" Endocrinology. Sep. 2003;144(9):3950-7.;;Khan, RH et al. ""Solubilization of recombinant ovine growth hormone with retention of native-like secondary structure and its refolding from the inclusion bodies of Escherichia coli,"" Biotechnol Prog. Sep.-Oct. 1998;14(5):722-8.;;Klaus, W et al. ""The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution,"" J Mol Biol. Dec. 12, 1997;274(4):661-75.;;Kopchick, JJ et al. ""Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly,"" Endocr Rev. Oct. 2002;23(5):623-46.;;Kostyo, JL et al. ""Biological characterization of purified native 20-kDa human growth hormone,"" Biochim Biophys Acta. Sep. 11, 1987;925(3):314-24.;;Krawczak, M et al. ""Evolution of the proximal promoter region of the mammalian growth hormone gene,"" Gene Sep. 3, 1999;237(1):143-51.;;Lee, N et al. ""Interferon-alpha 2 variants in the human genome,"" J Interferon Cytokine Res. Apr. 1995;15(4):341-9.;;Leung, DW et al. ""Growth hormone receptor and serum binding protein: purification, cloning and expression,"" Nature Dec. 10-16, 1987;330(6148):537-43.;;Trahair, JF et al. ""Use of transgenic mice to study the routing of secretory proteins in intestinal epithelial cells: analysis of human growth hormone compartmentalization as a function of cell type and differentiation,"" J Cell Biol. Dec. 1989;109(6 Pt 2):3231-42.;;Tsunekawa, B et al. ""The binding between the stem regions of human growth hormone (GH) receptor compensates for the weaker site 1 binding of 20-kDa human GH (hGH) than that of 22-kDa hGH,"" J Biol Chem. May 26, 2000;275 (21):15652-6.;;Ultsch, MH et al. ""The crystal structure of affinity-matured human growth hormone at 2 A resolution,"" J Mol Biol. Feb. 11, 1994;236(1):286-99.;;Urbanek, M et al. ""Functional characterization of the alternatively spliced, placental human growth hormone receptor,"" J Biol Chem. Sep. 5, 1993;268(25):19025-32.;;Van Der Lely, AJ et al. ""Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist,"" Lancet Nov. 24, 2001;358(9295):1754-9.;;Wada, M. et al. ""The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma,"" Mol Endocrinol. Jan. 1998;12(1):146-56.;;Walsh, STR et al. ""Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization,"" Protein Sci. Sep. 2003;12(9):1960-70.;;Walter, MR et al. ""Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor,"" J Mol Biol. Apr. 20, 1992;224(4):1075-85.;;Wang, X et al. ""A 40-amino acid segment of the growth hormone receptor cytoplasmic domain is essential for GH-induced tyrosine-phosphorylated cytosolic proteins,"" J Biol Chem. Mar. 17, 1995;270(11):6261-6.;;Weiss, GA et al. ""Rapid mapping of protein functional epitopes by combinatorial alanine scanning,"" Proc Natl Acad Sci U S A. Aug. 1, 2000;97(16):8950-4.;;Wells, JA. ""Binding in the growth hormone receptor complex,"" Proc Natl Acad Sci U S A. Jan. 9, 1996;93(1):1-6.;;Wen, D et al. ""Erythropoietin structure-function relationships. Identification of functionally important domains,"" J. Biol. Chem. 1994; 269(36):22839-22846.;;Zink, T et al. ""Secondary structure of human granulocyte colony-stimulating factor derived from NMR spectroscopy,"" FEBS Lett. Dec. 21, 1992;314(3):435-9.;;Zink, T et al. ""Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy. Loop mobility in a four-helix-bundle protein,"" Biochemistry Jul. 19, 1994;33(28):8453-63.;;Kappelgaard, A-M et al. ""Liquid growth hormone: preservatives and buffers,"" Horm Res. 2004;62 Suppl 3:98-103.;;Karlsson, G et al. ""Separation of oxidized and deamidated human growth hormone variants by isocratic reversed-phase high-performance liquid chromatography,"" J Chromatogr A. Sep. 3, 1999;855(1):147-55.;;Karlsson, G et al. ""Usage of nonporous polymeric particles for reversed-phase high-performance liquid chromatography of oxidized and deamidated forms of recombinant human growth hormone,"" J Chromatogr Sci. Jul. 2004;42(6):285-7.;;Kasimova, MR et al. ""NMR studies of the backbone flexibility and structure of human growth hormone: a comparison of high and low pH conformations,"" J Mol Biol. May 3, 2002;318(3):679-95.;;Kasimova, MR et al. ""The conformational equilibrium of human growth hormone,"" J Mol Biol. Mar. 27, 1998;277 (2):409-18.;;Kasraian, K et al. ""Sustained in vivo activity of recombinant bovine granulocyte colony stimulating factor (rbG-CSF) using HEPES buffer,"" Pharm Dev Technol. Aug. 2001;6(3):441-7.;;Katakam, M et al. ""Effect of surfactants on the physical stability of recombinant human growth hormone,"" J Pharm Sci. Jun. 1995;84(6):713-6.;;Kim, He et al. ""Microencapsulation of dissociable human growth hormone aggregates within poly(D,L-lactic-co-glycolic acid) microparticles for sustained release,"" Intl J of Pharm 2001; 229:107-16.;;Kunitani, M et al. ""On-line characterization of polyethylene-glycol modified proteins,"" J Chromatogr. 1991;588:125-137.;;Lai, MC et al. ""Chemical stability of peptides in polymers. 2. Discriminating between solvent and plasticizing effects of water on peptide deamidation in poly(vinylpyrrolidone),"" J Pharm Sci. Oct. 1999;88(10):1081-9.;;Liu, JL et al. ""In vitro methionine oxidation of recombinant human leptin,"" Pharm Res. Apr. 1998;15(4):632-40.;;Maa, Y-F et al. ""Spray-drying of air-liquid interface sensitive recombinant human growth hormone,"" J Pharm Sci. Feb. 1998;87(2):152-9-F et al. ""Spray-drying of air-liquid interface sensitive recombinant human growth hormone,"" J Pharm Sci. Feb. 1998;87(2):152-9.;;Maisano, F et al. ""Immobilized metal-ion affinity chromatography of human growth hormone,"" J Chromatogr. Jun. 23, 1989;472(2):422-7.;;Manning, MC et al. ""Stability of protein pharmaceuticals,"" Pharm Res. Nov. 1989;6(11):903-18.;;Mukhija, R et al. ""High-level production and one-step purification of biologically active human growth hormone in Escherichia coli,"" Gene. Nov. 20, 1995;165(2):303-6.;;Naglak, TJ et Hy Wang. ""Recovery of a foreign protein from the periplasm of Escherichia coli by chemical permeabilization,"" Enzyme Microb Technol. Aug. 1990;12(8):603-11.;;Olson, KC et al. ""Purified human growth hormone from E. coli is biologically active,"" Nature. Oct. 1, 1981;293 (5831):408-11.;;Pan, F-M et W-C Chang. ""Purification of growth hormones by reversed-phase high-performance liquid chromatography,"" J Chromatogr. Apr. 2, 1993;613(2):326-9.;;Panda, AK. ""Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli,"" Adv Biochem Eng Biotechnol. 2003;85:43-93.;;Patience, RL and LH Rees. ""Comparison of reversed-phase and anion-exchange high-performance liquid chromatography for the analysis of human growth hormones,"" J Chromatogr. Feb. 21, 1986;352:241-53.;;Lewis, UJ et al. ""A naturally occurring structural variant of human growth hormone,"" J Biol Chem. Apr. 25, 1978;253(8):2679-87.;;Lewis, UJ et al. ""An interchain disulfide dimer of human growth hormone,"" J Biol Chem. Jun. 10, 1977;252(11):3697-702.;;Lewis, UJ et al. ""Altered proteolytic cleavage of human growth hormone as a result of deamidation,"" J Biol Chem. Nov. 25, 1981;256(22):11645-50.;;Li, CH, ""Human growth hormone: 1974-1981,"" Mol Cell Biochem. Jul. 7, 1982;46(1):31-41.;;Linzer, Dih et F. Talamantes. ""Nucleotide sequence of mouse prolactin and growth hormone mRNAs and expression of these mRNAs during pregnancy,"" J Biol Chem. Aug. 15, 1985;260(17):9574-9.;;Liu, JC et al. ""Episodic evolution of growth hormone in primates and emergence of the species specificity of human growth hormone receptor,"" Mol Biol Evol. Jun. 2001;18(6):945-53.;;MacGillivray, MH et al. ""Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group."" J Clin Endocrinol Metab. May 1996;81(5):1806-9.;;Mathews, LS et al. ""Regulation of rat growth hormone receptor gene expression,"" J Biol Chem. Jun. 15, 1989;264(17):9905-10.;;Matthews, DJ et al. ""A sequential dimerization mechanism for erythropoietin receptor activation,"" Proc Nati Acad Sci U S A. Sep. 3, 1996;93(18):9471-6.;;McFarland, KC et al. ""Lutropin-choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family,"" Science Aug. 4, 1989;245(4917):494-9.;;Milburn, MV et al. ""A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5"" Nature 1993; 363:172-176.;;Mills, JB, et al. ""Fragments of human growth hormone produced by digestion with thrombin: chemistry and biological properties,"" Endocrinology Aug. 1980;107(2):391-9.;;Mordenti, J et al. ""Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins,"" Pharm Res. Nov. 1991;8(11):1351-9.;;Mott, HR and ID Campbell. ""Four-helix bundle growth factors and their receptors: protein-protein interactions,"" Curr Opin Struct Biol. Feb. 1995;5(1):114-21.;;Murgolo, NJ et al. ""A homology model of human interferon alpha-2,"" Proteins Sep. 1993;17(1):62-74.;;Oliva, A et al. ""Comparative study of protein molecular weights by size-exclusion chromatography and laser-light scattering,"" J Pharm Biomed Anal. Jul. 2001;25(5-6):833-41.;;Pal, G et al. ""The functional binding epitope of a high affinity variant of human growth hormone mapped by shotgun alanine-scanning mutagenesis: insights into the mechanisms responsible for improved affinity,"" J Mol Biol. Sep. 5, 2003;332(1):195-204.;;Pantel, J et al. ""Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution,"" J Biol Chem. Jun. 23, 2000;275(25):18664-9.;;Paonessa, G et al. ""Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signaling,"" EMBO J. May 1, 1995;14(9):1942-51.;;Pearce, KH et al. ""Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity,"" Biochemistry. Jan. 5, 1999;38(1):81-9.;;Pearlman, R et T Nguyen. ""Pharmaceutics of protein drugs,"" J Pharm Pharmacol. Feb. 1992;44 Suppl 1:178-85.;;Pikal, MJ et al. ""The effects of formulation variables on the stability of freeze-dried human growth hormone,"" Pharm Res. Apr. 1991;8(4):427-36.;;Rathore, AS et al. ""Optimization of an osmotic shock procedure for isolation of a protein product expressed in E. coli,"" Biotechnol Prog. Sep.-Oct. 2003;19(5):1541-6.;;Reddy, KR. ""Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs,"" Ann Pharmacother. Jul.-Aug. 2000;34(7-8):915-23.;;Remmele, RL et al. ""Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry,"" Pharm Res. Feb. 1998;15(2):200-8.;;Riggin, RM et al. ""High-performance size-exclusion chromatographic determination of the potency of biosynthetic human growth hormone products,"" J Chromatogr. Jan. 8, 1988;435(2):307-18.;;Riggin, RM et al. ""A reversed-phase high-performance liquid chromatographic method for characterization of biosynthetic human growth hormone,"" Anal Biochem. Nov. 15, 1987;167(1):199-209.;;Sharma, VK et DS Kalonia. ""Polyethylene glycol-induced precipitation of interferon alpha-2a followed by vacuum drying: development of a novel process for obtaining a dry, stable powder,"" AAPS PharmSci. Jan. 26, 2004;6(1):E4.;;Takahashi, Y et al. ""Brief report: short stature caused by a mutant growth hormone,"" N Engl J Med. Feb. 15, 1996;334 (7):432-6.;;Tang, X et MJ Pikal. ""Design of freeze-drying processes for pharmaceuticals: practical advice,"" Pharm Res. Feb. 2004;21(2):191-200.;;Tatford, OC et al. ""Analytical techniques for the evaluation of liquid protein therapeutics,"" Biotechnol Appl Biochem. Aug. 2004;40(Pt 1):67-81.;;Tkac, J et al. ""Evaluation of disruption methods for the release of intracellular recombinant protein from Escherichia coli for analytical purposes,"" Biotechnol Appl Biochem. Aug. 2004;40(Pt 1):83-8.;;Treuheit, MJ et al. ""Inverse relationship of protein concentration and aggregation,"" Pharm Res. Apr. 2002;19(4):511-6.;;Tsubery, H et al. ""Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification,"" J Biol Chem. Sep. 10, 2004;279(37):38118-24. Epub Jun. 8, 2004.;;Wang, W. ""Instability, stabilization, and formulation of liquid protein pharmaceuticals,"" Int J Pharm. Aug. 20, 1999;185(2):129-88.;;Welinder, BS et al. ""Reversed-phase high-performance liquid chromatography of human growth hormone,"" J Chromatogr. Jul. 10, 1987;398:309-16.;;Wu, SL et al. ""Application of high-performance hydrophobic-interaction chromatography to the characterization of recombinant DNA-derived human growth hormone,"" J Chromatogr. Feb. 2, 1990;500:595-606.;;Yan, Y-B et al. ""Protein thermal aggregation involves distinct regions: sequential events in the heat-induced unfolding and aggregation of hemoglobin,"" Biophys J. Mar. 2004;86(3):1682-90.;;Yang, T-H et al. ""Use of Infrared Spectroscopy to Assess Secondary Structure of Human Growth Hormone within Biodegradable Microspheres,"" J Pharm Sci Feb. 1999; 88(2):161-165.;;Pearce, KH et al. ""Structural and mutational analysis of affinity-inert contact residues at the growth hormone-receptor interface,"" Biochemistry. Aug. 13, 1996;35(32)10300-7.;;Powers, R et al. ""Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy,"" Science Jun. 19, 1992;256(5064):1673-7.;;Radhakrishnan, R et al. ""Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography,"" Structure Dec. 15, 1996;4(12):1453-63.;;Redfield, C et al. ""Secondary structure and topology of human interleukin 4 in solution,"" Biochemistry Nov. 19, 1991;30(46):11029-35.;;Ross, RJM et al. ""Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer,"" J Clin Endocrinol Metab. Apr. 2001;86(4):1716-23.;;Rottman, JN et JI Gordon. ""Comparison of the patterns of expression of rat intestinal fatty acid binding protein/human growth hormone fusion genes in cultured intestinal epithelial cell lines and in the gut epithelium of transgenic mice,"" J Biol Chem. Jun. 5, 1993;268(16):11994-2002.",INACTIVE
830,US,A1,US 2003/0075481 A1,170-727-099-378-240,2003-04-24,2003,US 30869702 A,2002-12-03,US 30869702 A;;US 22154098 A,1998-12-28,Gasoline sulfur reduction in fluid catalytic cracking,"
   The sulfur content of liquid cracking products, especially the cracked gasoline, of the catalytic cracking process is reduced by the use of a sulfur reduction catalyst composition comprising a porous molecular sieve which contains a metal in an oxidation state above zero within the interior of the pore structure of the sieve as well as a cerium component which enhances the stability and sulfur reduction activity of the catalyst. The molecular sieve is normally a faujasite such as USY. The primary sulfur reduction component is normally a metal of Period 3 of the Periodic Table, preferably vanadium. The sulfur reduction catalyst may be used in the form of a separate particle additive or as a component of an integrated cracking/sulfur reduction catalyst. 
",CHESTER ARTHUR W.;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G.;;ZIEBARTH MICHAEL S.,CHESTER ARTHUR W;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL S,,https://lens.org/170-727-099-378-240,Patent Application,yes,58,19,4,75,0,B01J29/166;;B01J2229/42;;C10G11/05;;C10G11/05;;B01J2229/42;;B01J29/166,B01J29/16;;C10G11/05,208/120.01;;208/213,0,0,,,,DISCONTINUED
831,US,B2,US 6606371 B2,007-061-121-388-317,2003-08-12,2003,US 74523600 A,2000-12-19,US 74523600 A;;US 17265499 P,1999-12-20,X-ray system,"
    A reflective lens with at least one curved surface formed of polycrystalline material. In one embodiment, a lens structure includes a substrate having a surface of predetermined curvature and a film formed along a surface of the substrate with multiple individual members each having at least one similar orientation relative to the portion of the substrate surface adjacent the member such that collectively the members provide predictable angles for diffraction of x-rays generated from a common source. A system is also provided for performing an operation with x-rays. In one embodiment, a system includes a source for generating the x-rays, a polycrystalline surface region having crystal spacing suitable for reflecting a plurality of x-rays at the same Bragg angle along the region, and transmitting the reflected x-rays to a reference position. An associated method includes providing x-rays to polycrystalline surface region having crystal spacings suitable for reflecting a plurality of x-rays at the same Bragg angle along the region, transmitting the reflected x-rays to a reference position and positioning a sample between the surface region and the reference position so that the x-rays are transmitted through the sample. 
",AGERE SYSTEMS INC,ANTONELL MICHAEL;;HOUGE ERIK CHO;;MCINTOSH JOHN MARTIN;;PLEW LARRY E;;VARTULI CATHERINE,AGERE SYSTEMS INC (2001-03-15);;BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04),https://lens.org/007-061-121-388-317,Granted Patent,yes,12,11,6,6,0,G21K1/06;;G21K2201/062;;G21K2201/064;;G21K2201/067;;G21K1/06;;G21K2201/064;;G21K2201/062;;G21K2201/067,G21K1/06,378/84;;378/85,2,2,002-110-217-045-171;;040-690-805-945-856,10.1557/proc-391-347;;10.1016/s0042-207x(98)00089-x,"Microtexture Meausurements of Aluminum VLSI Metallization, Barr, et al, 1995, pp. 347-351.;;Texture and Secondary Extinction Measurements in AL/Ti Stratified Films by X-ray Diffraction, Tomov, et al, May 1997, 497-502.",EXPIRED
832,US,B2,US 11594749 B2,012-304-759-128-412,2023-02-28,2023,US 201415104161 A,2014-12-18,US 201415104161 A;;US 201361918014 P;;US 201361918859 P;;US 2014/0071214 W,2013-12-19,Hydrogen/bromine flow battery in which hydrogen is freely exchanged between two cell compartments,"A flow battery system includes a first tank including a hydrogen reactant, a second tank including a bromine electrolyte, and at least one cell including a first electrolyte side operably connected to the first tank and a second electrolyte side operably connected to the second tank. The battery system further includes a direct connection line directly connecting the first tank and the second tank and configured such that the hydrogen reactant passes between the first tank and the second tank.",BOSCH GMBH ROBERT;;UNIV CALIFORNIA;;THE REGENTS OF THE UNIVERISTY OF CALIFORNIA,ALBERTUS PAUL;;KNUDSEN EDWARD;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2017-02-15);;ROBERT BOSCH GMBH (2016-10-31),https://lens.org/012-304-759-128-412,Granted Patent,yes,10,0,6,6,0,H01M8/184;;H01M8/04208;;Y02E60/50;;H01M8/184;;H01M8/04208;;Y02B90/10;;Y02E60/50;;H01M8/04201;;H01M8/188;;H01M8/20;;H01M8/22;;H01M2250/10,H01M4/36;;H01M4/58;;H01M6/04;;H01M6/20;;H01M6/24;;H01M8/04082;;H01M8/18;;H01M8/20;;H01M8/22,,4,0,,,"Machine translation of Hamel et al. (WO2013/086100) “Hydrogen bromide flow battery system for distributed scale applications using pressure balanced cells”, pp. 1-40. (Year: 2013).;;International Search Report corresponding to PCT Application No. PCT/US2014/071214, dated Mar. 31, 2015 (4 pages).;;Supplementary Partial European Search Report corresponding to European Patent Application No. 14 87 0855 (13 pages), dated May 2017.;;Supplementary European Search Report corresponding to European Patent Application No. 14 87 0855 (13 pages), dated May 2017.",ACTIVE
833,KR,A,KR 20210029186 A,016-627-740-123-023,2021-03-15,2021,KR 20217000043 A,2019-07-03,EP 18181981 A;;EP 2019067821 W,2018-07-05,투명 전도성 필름,"본 발명은 투명 전도성 필름 분야에 관한 것이다. 특히, 본 발명은 a) - TiO2, ZrO2 또는 HfO2를 함유하는 적어도 2개의 층, 및 - TiO2, ZrO2 또는 HfO2를 함유하는 2개의 층들 사이의, 유기 화합물을 함유하는 층을 포함하는 제1 라미네이트, b) 금속 층, 및 c) - ZnO를 함유하는 적어도 2개의 층, 및 - ZnO를 함유하는 2개의 층들 사이의, 유기 화합물을 함유하는 층, - 아연 이외의 금속성 도펀트를 포함하는 제2 라미네이트를 포함하는 투명 전도성 필름에 관한 것이다.",BASF COATINGS GMBH,CHO BORAM;;FLORES JEAN CHARLES;;REINKE MICHAEL;;SUNG MYUNG MO;;JUNG JIN WON,,https://lens.org/016-627-740-123-023,Patent Application,no,0,0,9,9,0,C03C17/38;;C03C2217/94;;C23C16/45525;;C23C28/00;;C23C28/322;;C23C28/34;;C23C28/345;;C23C28/3455;;C23C28/40;;C23C28/42;;Y02E10/549;;H10K30/50;;C23C28/3455;;C23C28/322;;C23C28/42;;C23C16/45529;;C23C16/405;;H01B5/14;;B05D1/60;;H10K30/50;;C23C16/45531;;C23C28/30;;C23C28/42;;C23C28/44;;C23C28/02;;Y10T428/31678;;C23C28/322;;C23C28/3455;;H10K30/82;;H10K30/451,C23C28/00;;B05D1/00;;C23C16/40;;C23C16/455;;H01B5/14,,0,0,,,,PENDING
834,NZ,A,NZ 555206 A,030-080-512-426-533,2010-09-30,2010,NZ 55520605 A,2005-12-21,US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P;;US 2005/0046486 W,2004-12-22,Methods for expression and purification of recombinant human growth hormone,"Provided is a process for purifying a human growth hormone polypeptide (hGH) comprising: a) culturing recombinant E. coli host cells comprising: (i) a polynucleotide in operable connection with a control sequence that is inducible by arabinose in E. coli wherein said polynucleotide encodes hGH and comprises one or more selector codons; (ii) one or more orthogonal tRNAs; and (iii) one or more orthogonal RNA synthetases, said culturing being in a liquid nutrient medium comprising one or more non-naturally encoded amino acids and under conditions which favour growth of E. coli; b) inducing production ofhGH comprising the non-naturally encoded amino acid by adding arabinose to the liquid nutrient medium; and c) purifying said hGB comprising the one or more non-naturally encoded amino acids from said cells or culture medium.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/030-080-512-426-533,Patent Application,no,0,0,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12Q1/68;;A61K38/27;;C07H21/04;;C07K14/61,,0,0,,,,DISCONTINUED
835,DE,A1,DE 19941319 A1,066-694-942-965-839,2000-03-16,2000,DE 19941319 A,1999-08-31,US 14460798 A,1998-08-31,Verringerung des Schwefelgehaltes von Benzin beim Fliessbettkracken,"Der Schwefelgehalt von flüssigen Krackprodukten, insbesondere von gekracktem Benzin, wird durch die Verwendung eines Schwefelverringerungsadditivs reduziert, der ein poröses Molekularsieb umfaßt, das ein Metall mit einem Oxidationsgrad über Null im Inneren der Porenstruktur des Siebes enthält. Das Molekularsieb ist normalerweise ein Zeolith mit großer Porengröße wie USY oder Zeolith Beta oder ein Zeolith mit mittlerer Porengröße wie ZSM-5. Das Metall ist normalerweise ein Metall der Periode 3 des Periodensystems, vorzugsweise Zink oder Vanadium. Der Schwefelverringerungskatalysator kann in Form eines separaten Partikeladditivs oder als Komponente eines Komposit-Krack/Schwefelverringerungs-Katalysators verwendet werden.",MOBIL OIL CORP;;GRACE W R & CO,CHESTER ARTHUR WARREN;;TIMKEN HYE KYUNG CHO;;ROBERIE TERRY G;;ZIEBARTH MICHAEL SCOTT,,https://lens.org/066-694-942-965-839,Patent Application,no,0,0,33,75,0,B01J29/0308;;B01J29/0333;;B01J29/072;;B01J29/076;;B01J29/088;;B01J29/146;;B01J29/166;;B01J29/24;;B01J29/405;;B01J29/46;;B01J29/48;;B01J29/7057;;B01J29/7088;;B01J29/7615;;B01J29/7638;;B01J29/7676;;B01J29/7815;;B01J29/7838;;B01J29/7876;;B01J29/84;;B01J29/88;;B01J2229/42;;C10G11/05;;C10G35/085;;C10G11/05;;B01J29/7815;;B01J29/7057;;B01J29/0308;;B01J29/088;;B01J29/072;;B01J29/146;;B01J29/405;;B01J29/076;;B01J29/46;;B01J29/7638;;B01J29/7876;;B01J29/7088;;B01J29/7615;;B01J29/7838;;B01J29/88;;B01J29/166;;B01J29/0333;;B01J29/48;;B01J29/24;;B01J2229/42;;B01J29/84;;B01J29/7676,C10G35/085;;B01J29/00;;B01J29/03;;B01J29/06;;B01J29/072;;B01J29/076;;B01J29/08;;B01J29/14;;B01J29/16;;B01J29/24;;B01J29/26;;B01J29/40;;B01J29/46;;B01J29/48;;B01J29/70;;B01J29/76;;B01J29/78;;B01J29/84;;B01J29/88;;C01B39/00;;C10G11/00;;C10G11/05;;C10G11/18;;C10G25/05;;C10G45/04;;C10G55/06,,0,0,,,,EXPIRED
836,US,A1,US 2001/0043667 A1,066-910-861-205-276,2001-11-22,2001,US 74523600 A,2000-12-19,US 74523600 A;;US 17265499 P,1999-12-20,X-ray system,"
   A reflective lens with at least one curved surface formed of polycrystalline material. In an example embodiment a lens structure includes a substrate having a surface of predetermined curvature and a film formed along a surface of the substrate with multiple individual members each having at least one similar orientation relative to the portion of the substrate surface adjacent the member such that collectively the members provide predictable angles for diffraction of x-rays generated from a common source. 

   A system is also provided for performing an operation with x-rays. In one form of the invention the system includes a source for generating the x-rays and a polycrystalline surface region having crystal spacings suitable for reflecting a plurality of x-rays at the same Bragg angle along the region and transmitting the reflected x-rays to a reference position. An associated method includes providing x-rays to a polycrystalline surface region having crystal spacings suitable for reflecting a plurality of x-rays at the same Bragg angle along the region, transmitting the reflected x-rays to a reference position; and positioning a sample between the surface region and the reference position so that x-rays are transmitted through the sample. 
",ANTONELL MICHAEL;;HOUGE ERIK CHO;;MCLNTOSH JOHN MARTIN;;PLEW LARRY E.;;VARTULI CATHERINE,ANTONELL MICHAEL;;HOUGE ERIK CHO;;MCLNTOSH JOHN MARTIN;;PLEW LARRY E;;VARTULI CATHERINE,AGERE SYSTEMS INC (2001-03-15);;BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04),https://lens.org/066-910-861-205-276,Patent Application,yes,0,13,6,6,0,G21K1/06;;G21K2201/062;;G21K2201/064;;G21K2201/067;;G21K1/06;;G21K2201/064;;G21K2201/062;;G21K2201/067,G21K1/06,378/84;;378/85;;378/145,0,0,,,,EXPIRED
837,WO,A1,WO 2015/100216 A1,091-232-852-854-203,2015-07-02,2015,US 2014/0071835 W,2014-12-22,US 201361919926 P,2013-12-23,SYSTEM AND METHOD FOR RETURNING MATERIAL FROM THE BR2 SIDE OF AN H2/BR2 FLOW BATTERY BACK AFTER CROSSOVER,"A flow battery system includes a first tank having a hydrogen reactant, a second tank having a bromine electrolyte, at least one cell including a hydrogen reactant side operably connected to the first tank through an ¾ feed and return system and a bromine electrolyte side operably connected to the second tank, and a crossover return system. The crossover return system includes a vessel operably connected to the ¾ feed and return system and configured to receive an effluent containing a first portion of the hydrogen reactant and a second portion of the bromine electrolyte, the vessel configured to separate the first portion from the second portion. A first return line returns the first portion of the hydrogen reactant to the first tank and a second return line returns the bromine electrolyte to the second tank.",BOSCH GMBH ROBERT;;KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z;;UNIV CALIFORNIA,KNUDSEN EDWARD;;ALBERTUS PAUL;;TUCKER MICHAEL C;;CHO KYU TAEK;;WEBER ADAM Z,,https://lens.org/091-232-852-854-203,Patent Application,yes,6,6,6,6,0,H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/20;;H01M8/188;;H01M8/04197;;Y02E60/50;;H01M8/04007;;H01M8/04097;;H01M8/04216;;H01M8/04283,H01M8/20;;H01M8/18,,0,0,,,,PENDING
838,WO,A2,WO 2006/073846 A2,098-246-201-744-475,2006-07-13,2006,US 2005/0046486 W,2005-12-21,US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P,2004-12-22,METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE,"The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/098-246-201-744-475,Patent Application,yes,0,15,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12Q1/68;;A61K38/27;;C07H21/04;;C07K14/61,,0,0,,,,PENDING
839,CN,A,CN 103290084 A,174-599-169-385-182,2013-09-11,2013,CN 201310247182 A,2005-12-21,US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P,2004-12-22,Method for expression and purification of recombinant human growth hormone,"The invention discloses a method for expression and purification of recombinant human growth hormone. The present invention relates generally to the production, purification, and isolation of human growth hormone (hGH). More particularly, the invention relates to the production, purification, and isolation of substantially purified hGH from recombinant host cells or culture medium including, for example, yeast, insect, mammalian and bacterial host cells. The process of the present invention is also useful for purification of hGH linked to polymers or other molecules.",AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/174-599-169-385-182,Patent Application,no,4,1,29,195,0,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12P21/02;;C07K1/107;;C07K1/18;;C07K1/20;;C07K14/61,,0,0,,,,DISCONTINUED
840,CA,A1,CA 2590462 A1,193-097-245-152-583,2006-07-13,2006,CA 2590462 A,2005-12-21,US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P;;US 2005/0046486 W,2004-12-22,METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMANGROWTH HORMONE,,AMBRX INC,ONG MICHAEL;;CHO HO SUNG;;LIEU RICKY;;BUSSELL STUART;;BUECHLER YING;;KNUDSEN NICK,,https://lens.org/193-097-245-152-583,Patent Application,no,0,0,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C12Q1/68;;A61K38/27;;C07H21/04;;C07K14/61,,0,0,,,,INACTIVE
841,US,A1,US 2016/0329162 A1,071-087-571-138-688,2016-11-10,2016,US 201515109023 A,2015-01-13,EP 14151392 A;;IB 2015050245 W,2014-01-16,HOLE TRANSPORTING AND LIGHT ABSORBING MATERIAL FOR SOLID STATE SOLAR CELLS,"The present invention relates to a compound of formula (I) based on quinozilino acridine and used as hole transporting and light absorbing material in a photovoltaic device, in particular in a solid state solar cell.",ECOLE POLYTECHNIQUE FED DE LAUSANNE (EPFL),QIN PENG;;NAZEERUDDIN MOHAMMAD KHAJA;;GRAETZEL MICHAEL;;KO JAEJUNG;;PAEK SANGHYUN;;CHO NARA,ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (2016-04-05),https://lens.org/071-087-571-138-688,Patent Application,yes,1,2,9,9,0,C09K11/06;;C09B57/00;;C09B57/008;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1096;;Y02E10/549;;Y02E10/542;;H10K85/652;;H10K85/655;;H10K85/6576;;H10K85/6572;;H10K85/657;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;H10K85/50;;C07D409/14;;C07F7/0816;;C09B57/008;;C09K11/06;;C09K2211/1096;;C09K2211/1092;;C09K2211/1051;;C09K2211/1029;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;C09B57/008;;C09B57/00;;C09K11/06;;C09K2211/1096;;C09K2211/1051;;C09K2211/1029;;C09K2211/1092;;Y02E10/549;;H10K85/40;;H10K85/652;;H10K85/655;;H10K85/657;;H10K85/791;;H10K85/6572;;H10K30/151;;H10K85/6576;;H01G9/2013;;H01G9/2018;;H01G9/2031;;H01G9/2059,H01G9/20;;C09B57/00;;H01L51/00,,1,1,001-167-424-406-583,10.1021/ol303045p;;23214406,"Paek, et al., J. Org. Lett. 2012, 14, 6326- 6329.",DISCONTINUED
842,AU,A1,AU 2012/242517 A1,086-121-666-738-388,2013-10-03,2013,AU 2012/242517 A,2012-04-13,US 201161474848 P;;US 2012/0033675 W,2011-04-13,1'-substituted pyrimidine N-nucleoside analogs for antiviral treatment,"Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R",GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,,https://lens.org/086-121-666-738-388,Patent Application,no,0,0,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,C07H19/06;;C07H19/067;;C07H19/073;;C07H19/09;;C07H19/10;;C07H19/11,,0,0,,,,INACTIVE
843,EP,A2,EP 1836316 A2,101-319-961-590-254,2007-09-26,2007,EP 05857169 A,2005-12-21,US 2005/0046486 W;;US 63861604 P;;US 65574405 P;;US 68097705 P;;US 72796805 P,2004-12-22,METHODS FOR EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN GROWTH HORMONE,,AMBRX INC,BUECHLER YING;;LIEU RICKY;;ONG MICHAEL;;BUSSELL STUART;;KNUDSEN NICK;;CHO HO SUNG,,https://lens.org/101-319-961-590-254,Patent Application,yes,0,0,29,195,3,C07K14/61;;A61P5/06;;A61K38/27;;C07H21/04;;C07K14/61;;C12Q1/68;;A61K38/27;;C07K14/61;;C07K14/61,C07K14/61,,0,0,,,,DISCONTINUED
844,US,A1,US 2004/0041927 A1,104-441-265-674-284,2004-03-04,2004,US 23020502 A,2002-08-29,US 23020502 A,2002-08-29,High intrascene dynamic range NTSC and PAL imager,"
   The invention provides a new method and apparatus for NTSC and PAL image sensors which employs fusion of adjacent row pixel charge samples to generate image data for a row. A variety of fusion schemes are possible for fusing the pixel signals from the adjacent rows. The rows of pixels are scanned so that each scan takes an odd row signal sample and, in some cases, an adjacent even row signal sample when specified conditions are met. One sampled row of the two adjacent rows integrate an image with a first integration period while the other adjacent row integrates an image with a second integration period. 
",CHO KWANG-BO;;SUBBOTIN IGOR;;KAPLINSKY MICHAEL;;BARNA SANDOR L.;;SLAYTON GARY E.,CHO KWANG-BO;;SUBBOTIN IGOR;;KAPLINSKY MICHAEL;;BARNA SANDOR L;;SLAYTON GARY E,APTINA IMAGING CORPORATION (2009-07-08);;MICRON TECHNOLOGY INC (2002-10-30),https://lens.org/104-441-265-674-284,Patent Application,yes,24,71,4,4,0,H04N23/70;;H04N23/741;;H04N25/583;;H04N25/616;;H04N25/75;;H04N3/155;;H04N23/741;;H04N23/70,H04N5/235;;H04N5/345;;H04N5/353;;H04N5/355;;H04N5/374;;H04N5/378,348/254,0,0,,,,EXPIRED
845,US,B2,US 8877733 B2,120-538-780-097-515,2014-11-04,2014,US 201213447017 A,2012-04-13,US 201213447017 A;;US 201161474848 P,2011-04-13,1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment,"Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R 6 is CN, ethenyl, 2-haloethen-1-yl, or (C 2 -C 8 )-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.",CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL;;GILEAD SCIENCES INC,CHO AESOP;;KIM CHOUNG U;;KIRSCHBERG THORSTEN A;;MISH MICHAEL R;;SQUIRES NEIL,GILEAD SCIENCES INC (2012-05-17),https://lens.org/120-538-780-097-515,Granted Patent,yes,11,35,19,19,0,C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06;;A61P31/12;;A61P31/14;;A61P43/00;;C07H19/06;;A61K31/7064;;C07H19/067;;C07H19/073;;C07H19/10;;C07H19/09;;C07H19/11;;A61K38/21;;A61K45/06;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;C07H19/06,A61K31/70;;A61K31/13;;A61K31/196;;A61K31/245;;A61K31/351;;A61K31/7068;;A61K31/7072;;A61K38/21;;A61K45/06;;C07H19/06;;C07H19/067;;C07H19/073;;C07H19/09;;C07H19/10;;C07H19/11,514/49;;536/28.4,11,6,092-453-210-643-987;;023-501-176-436-01X;;055-756-583-157-62X;;102-534-308-468-502;;092-453-210-643-987;;062-770-784-133-389,10.1002/1521-3765(20010601)7:11<2332::aid-chem23320>3.0.co;2-w;;11446636;;10.1080/07328319608002386;;19173657;;pmc2635492;;10.1021/ja807705z;;10.1021/jo049062o;;15497980;;10.1002/1521-3765(20010601)7:11<2332::aid-chem23320>3.0.co;2-w;;11446636;;10.1016/s0040-4020(01)96264-7,"Grouiller et al, Synlett, 1993, vol. 3, pp. 221-222.;;Kodama et al., Chemistry-A European Journal, 2001, vol. 7(11), pp. 2332-2340.;;Yoshimura et al., Nucleosides & Nucleotides, 15(1-3), 1996, pp. 305-324.;;Huang, H., et al., ""Competitive Inhibition of Uracil DNA Glycosylase by a Modified Nucleotide Whose Triphosphate is a Substrate for DNA Polymerase,"" J. Am. Chem. Soc., vol. 131, No. 4, pp. 1344-1345 (2009).;;Grunefeld, P., et al., ""Synthesis of a 1'-Aminomethylthymidine and Oligodeoxyribonucleotides with 1'-Acylamidomethylthymidine Residues,"" J. Org. Chem., vol. 69, No. 22, pp. 7543-7551 (2004).;;Kodama, T., et al., ""An Efficient Method for the Preparation of 1'-a-Branched-Chain Sugar Pyrimidine Ribonucleosides from Uridine: The First Conversion of a Natural Nucleoside into 1'-Substituted Ribonucleosides,"" Chem. Eur. J., vol. 7, No. 11, pp. 2332-2340 (2001).;;Uteza, V., et al., ""Synthesis and Structure Determination of the First 1'-C-Cyano-B-D-Nucleosides,"" Tetrahedron, vol. 49, No. 38, pp. 8579-8588 (1993).;;International Search Report issued in International Application No. PCT/US2012/033675, mailed Mar. 7, 2013 (4 pages).;;Written Opinion of the International Searching Authority issued in International Application No. PCT/US2012/033675, mailed Mar. 7, 2013 (8 pages).;;Written Opinion of the International Searching Authority issued in PCT/US2012/033675, dated Oct. 13, 2013 (6 pages).;;International Preliminary Report on Patentability issued in PCT/US2012/033675, dated Oct. 15, 2013 (1 page).",ACTIVE
846,US,A1,US 2022/0265312 A1,087-963-577-967-696,2022-08-25,2022,US 202017628089 A,2020-07-28,US 202017628089 A;;US 201962879846 P;;US 202063019574 P;;US 2020/0043859 W,2019-07-29,DEVICES FOR SAFE AND RELIABLE ACCESS TO SUB ARACHNOID AND SUBDURAL SPACE,A method and apparatus for safely and reliably accessing a subarachnoid space (SAS) or other target area of a patient is provided in which a tube having at least one lumen with a tissue puncture device therein is inserted into the patient near the tissue. The lumen has a suction port at one end adapted to suction the dura/arachnoid tissue away from the pia mater so that the tissue can be punctured to access the SAS space. The movement of the needle in the lumen is controlled by controlling a magnetic field. Tissue puncture devices for use alone or in connection with the apparatus are also provided.,MICHAEL SHPIGELMACHER;;BIONAUT LABS LTD,SHPIGELMACHER MICHAEL;;KARDOSH MICHAEL;;KATZNELSON BE'ERI BERL;;OREN ERAN;;KISELYOV ALEX;;CROS FLORENT;;CHO SUEHYUN;;HARRINGTON DARRELL;;PALMER OLIN,BIONAUT LABS LTD (2020-05-07),https://lens.org/087-963-577-967-696,Patent Application,yes,0,0,6,6,0,A61B17/3401;;A61B2017/00876;;A61B5/1072;;A61B5/0084;;A61B5/0538;;A61B5/6848;;A61B5/6852;;A61B5/407;;A61B8/488;;A61B8/12;;A61B5/036;;A61B5/061;;A61B2090/378;;A61B2090/378;;A61B5/062;;A61B17/3401;;A61B2017/00876;;A61B2017/3413,A61B17/34;;A61B5/06,,0,0,,,,PENDING
847,WO,A1,WO 2021/021800 A1,199-599-872-415-053,2021-02-04,2021,US 2020/0043859 W,2020-07-28,US 201962879846 P;;US 202063019574 P,2019-07-29,DEVICES FOR SAFE AND RELIABLE ACCESS TO SUB ARACHNOID AND SUBDURAL SPACE,A method and apparatus for safely and reliably accessing a subarachnoid space (SAS) or other target area of a patient is provided in which a tube having at least one lumen with a tissue puncture device therein is inserted into the patient near the tissue. The lumen has a suction port at one end adapted to suction the dura/arachnoid tissue away from the pia mater so that the tissue can be punctured to access the SAS space. The movement of the needle in the lumen is controlled by controlling a magnetic field. Tissue puncture devices for use alone or in connection with the apparatus are also provided.,BIONAUT LABS LTD;;SHPIGELMACHER MICHAEL,SHPIGELMACHER MICHAEL;;KARDOSH MICHAEL;;KATZNELSON BE'ERI BERL;;OREN ERAN;;KISELYOV ALEX;;CROS FLORENT;;CHO SUEHYUN;;HARRINGTON DARRELL;;PALMER OLIN,,https://lens.org/199-599-872-415-053,Patent Application,yes,16,0,6,6,0,A61B17/3401;;A61B2017/00876;;A61B5/1072;;A61B5/0084;;A61B5/0538;;A61B5/6848;;A61B5/6852;;A61B5/407;;A61B8/488;;A61B8/12;;A61B5/036;;A61B5/061;;A61B2090/378;;A61B2090/378;;A61B5/062;;A61B17/3401;;A61B2017/00876;;A61B2017/3413,A61B17/34;;A61B5/00;;A61M19/00,,1,0,,,See also references of EP 4003194A4,PENDING
848,US,A1,US 2023/0402262 A1,131-769-338-174-319,2023-12-14,2023,US 202217869987 A,2022-07-21,US 202217869987 A;;US 202263351645 P,2022-06-13,APPARATUS FOR GENERATING ETCHANTS FOR REMOTE PLASMA PROCESSES,"A remote plasma source (RPS) for generating etchants leverages symmetrical hallow cathode cavities to increase etchant rates. The RPS includes an upper electrode with a first hollow cavity configured to induce a hollow cathode effect within the first hollow cavity, a lower electrode with a second hollow cavity configured to induce a hollow cathode effect within the second hollow cavity, wherein the first hollow cavity and the second hollow cavity are symmetrical, a first gap positioned between and electrically separating the upper electrode and the lower electrode, and an annular dielectric cover in direct contact with the lower electrode in the first gap and forms a second gap between an uppermost surface of the annular dielectric cover and a lowermost surface of the upper electrode. The annular dielectric cover fills approximately 50% to approximately 95% of a height of the first gap.",APPLIED MATERIALS INC,CHO TAE SEUNG;;BENJAMINSON DAVID MICHAEL;;SCHATZ KENNETH;;PAKULSKI RYAN MICHAEL;;CHOY MARTIN YUE;;GUNASEELAN PRATHEEP;;HUANG CHIH-YUNG,APPLIED MATERIALS INC (2022-07-28),https://lens.org/131-769-338-174-319,Patent Application,yes,1,0,2,2,0,H01J37/32357;;H01J37/3244;;H01J37/32596;;H01J37/32541;;H01J37/32568;;H01J37/32091;;H01J37/32596;;H01J37/3244;;H01J37/32357,H01J37/32,,0,0,,,,PENDING
849,WO,A1,WO 2023/244258 A1,194-932-921-012-774,2023-12-21,2023,US 2022/0046186 W,2022-10-10,US 202263351645 P;;US 202217869987 A,2022-06-13,APPARATUS FOR GENERATING ETCHANTS FOR REMOTE PLASMA PROCESSES,"A remote plasma source (RPS) for generating etchants leverages symmetrical hallow cathode cavities to increase etchant rates. The RPS includes an upper electrode with a first hollow cavity configured to induce a hollow cathode effect within the first hollow cavity, a lower electrode with a second hollow cavity configured to induce a hollow cathode effect within the second hollow cavity, wherein the first hollow cavity and the second hollow cavity are symmetrical, a first gap positioned between and electrically separating the upper electrode and the lower electrode, and an annular dielectric cover in direct contact with the lower electrode in the first gap and forms a second gap between an uppermost surface of the annular dielectric cover and a lowermost surface of the upper electrode. The annular dielectric cover fills approximately 50% to approximately 95% of a height of the first gap.",APPLIED MATERIALS INC,CHO TAE SEUNG;;BENJAMINSON DAVID MICHAEL;;SCHATZ KENNETH;;PAKULSKI RYAN MICHAEL;;CHOY MARTIN YUE;;GUNASEELAN PRATHEEP;;HUANG CHIH-YUNG,,https://lens.org/194-932-921-012-774,Patent Application,yes,5,0,2,2,0,H01J37/32357;;H01J37/3244;;H01J37/32596;;H01J37/32541;;H01J37/32568;;H01J37/32091;;H01J37/32596;;H01J37/3244;;H01J37/32357,H01J37/32;;H01L21/67,,0,0,,,,PENDING
850,EP,A1,EP 4003194 A1,031-541-718-324-60X,2022-06-01,2022,EP 20847650 A,2020-07-28,US 201962879846 P;;US 202063019574 P;;US 2020/0043859 W,2019-07-29,DEVICES FOR SAFE AND RELIABLE ACCESS TO SUB ARACHNOID AND SUBDURAL SPACE,,BIONAUT LABS LTD,KARDOSH MICHAEL;;KATZNELSON BE'ERI BERL;;OREN ERAN;;KISELYOV ALEX;;CROS FLORENT;;CHO SUEHYUN;;HARRINGTON DARRELL;;PALMER OLIN;;SHPIGELMACHER MICHAEL,,https://lens.org/031-541-718-324-60X,Patent Application,yes,0,0,6,6,0,A61B17/3401;;A61B2017/00876;;A61B5/1072;;A61B5/0084;;A61B5/0538;;A61B5/6848;;A61B5/6852;;A61B5/407;;A61B8/488;;A61B8/12;;A61B5/036;;A61B5/061;;A61B2090/378;;A61B2090/378;;A61B5/062;;A61B17/3401;;A61B2017/00876;;A61B2017/3413,A61B17/34;;A61B5/00;;A61M19/00,,0,0,,,,PENDING
851,CA,A1,CA 3148031 A1,083-696-636-512-116,2021-02-04,2021,CA 3148031 A,2020-07-28,US 201962879846 P;;US 202063019574 P;;US 2020/0043859 W,2019-07-29,DEVICES FOR SAFE AND RELIABLE ACCESS TO SUB ARACHNOID AND SUBDURAL SPACE,A method and apparatus for safely and reliably accessing a subarachnoid space (SAS) or other target area of a patient is provided in which a tube having at least one lumen with a tissue puncture device therein is inserted into the patient near the tissue. The lumen has a suction port at one end adapted to suction the dura/arachnoid tissue away from the pia mater so that the tissue can be punctured to access the SAS space. The movement of the needle in the lumen is controlled by controlling a magnetic field. Tissue puncture devices for use alone or in connection with the apparatus are also provided.,BIONAUT LABS LTD,SHPIGELMACHER MICHAEL;;KARDOSH MICHAEL;;KATZNELSON BE'ERI BERL;;OREN ERAN;;KISELYOV ALEX;;CROS FLORENT;;CHO SUEHYUN;;HARRINGTON DARRELL;;PALMER OLIN,,https://lens.org/083-696-636-512-116,Patent Application,no,0,0,6,6,0,A61B17/3401;;A61B2017/00876;;A61B5/1072;;A61B5/0084;;A61B5/0538;;A61B5/6848;;A61B5/6852;;A61B5/407;;A61B8/488;;A61B8/12;;A61B5/036;;A61B5/061;;A61B2090/378;;A61B2090/378;;A61B5/062;;A61B17/3401;;A61B2017/00876;;A61B2017/3413,A61B17/34;;A61B5/00;;A61M19/00,,0,0,,,,PENDING
852,EP,A4,EP 4003194 A4,070-741-475-834-111,2023-08-30,2023,EP 20847650 A,2020-07-28,US 201962879846 P;;US 202063019574 P;;US 2020/0043859 W,2019-07-29,DEVICES FOR SAFE AND RELIABLE ACCESS TO SUB ARACHNOID AND SUBDURAL SPACE,,BIONAUT LABS LTD,KARDOSH MICHAEL;;KATZNELSON BE'ERI BERL;;OREN ERAN;;KISELYOV ALEX;;CROS FLORENT;;CHO SUEHYUN;;HARRINGTON DARRELL;;PALMER OLIN;;SHPIGELMACHER MICHAEL,,https://lens.org/070-741-475-834-111,Search Report,no,5,0,6,6,0,A61B17/3401;;A61B2017/00876;;A61B5/1072;;A61B5/0084;;A61B5/0538;;A61B5/6848;;A61B5/6852;;A61B5/407;;A61B8/488;;A61B8/12;;A61B5/036;;A61B5/061;;A61B2090/378;;A61B2090/378;;A61B5/062;;A61B17/3401;;A61B2017/00876;;A61B2017/3413,A61B17/34;;A61B5/00;;A61B5/03;;A61B5/0538;;A61B5/06;;A61B5/107;;A61B8/08;;A61B8/12;;A61B17/00;;A61B90/00,,1,0,,,See also references of WO 2021021800A1,PENDING
853,EP,A1,EP 3362141 A1,066-070-922-842-801,2018-08-22,2018,EP 16760302 A,2016-08-26,US 201562242554 P;;US 201514934466 A;;US 2016/0048817 W,2015-10-16,INTRACARDIAC MEDICAL DEVICE WITH PRESSURE SENSING,,MEDTRONIC INC,CHO YONG K;;HESS MICHAEL F;;RAPALLINI LEONARDO;;SHELDON TODD J;;URKE BRIAN D,,https://lens.org/066-070-922-842-801,Patent Application,yes,0,0,4,4,0,A61N1/3756;;A61B5/026;;A61N1/36564;;A61N1/37205;;A61B5/6882;;A61B5/0006;;A61B5/076;;A61B5/4836;;A61B5/0215;;A61B5/6869;;A61B5/283;;A61B5/363;;A61B5/352;;A61B5/026;;A61N1/36564;;A61N1/37205;;A61N1/3756;;A61B5/6882;;A61B5/0006;;A61B5/4836;;A61B5/076;;A61B5/283;;A61B5/287;;A61B5/352;;A61B5/363;;A61B5/02141;;A61B5/0215;;A61B5/686;;A61B5/6869;;A61N1/3621,A61N1/365;;A61B5/021;;A61B5/0215;;A61B5/026;;A61N1/375;;G01L9/00;;G01L9/12,,0,0,,,,DISCONTINUED
854,US,B2,US 11668311 B2,082-800-218-491-317,2023-06-06,2023,US 202117520578 A,2021-11-05,US 202117520578 A,2021-11-05,Blowers with variable nozzles,"Blowers with variable nozzles are provided. A blower includes a fan, and a main body housing the fan, the main body defining an airflow path extending between an inlet end and an outlet end. A blower further includes a variable nozzle disposed at the outlet end. The variable nozzle includes an attachment collar, the attachment collar comprising a body defining an exterior surface and an interior surface and extending along a longitudinal axis. The variable nozzle further includes a plurality of air control bodies, each of the plurality of air control bodies movably connected to the attachment collar and comprising an air control surface and an extension rod. The variable nozzle further includes an adjustment collar, the adjustment collar disposed around the attachment collar and defining a plurality of adjustment channels, wherein each of the plurality of extension rods is disposed in one of the plurality of adjustment channels.",TECHTRONIC CORDLESS GP,CHO HANG MAN;;COLTHARP MICHAEL;;HAN DONG HEON;;KAMINSKI PETER;;LANGFORD GRAHAM;;LEE PEYTON,TECHTRONIC CORDLESS GP (2021-12-21),https://lens.org/082-800-218-491-317,Granted Patent,yes,7,0,2,2,0,A01G20/47;;F04D27/002;;F04D29/464;;F04D29/563;;F04D27/002;;A01G20/47;;F04D29/403,A01G20/47;;F04D27/00;;F04D29/40,,0,0,,,,ACTIVE
855,US,B2,US 9330490 B2,020-364-809-927-875,2016-05-03,2016,US 201213456967 A,2012-04-26,US 201213456967 A;;US 201161480534 P,2011-04-29,Methods and systems for visualization of 3D parametric data during 2D imaging,"Methods and systems for visualization of 3D parametric data in a 2D image. The set of 3D parametric data includes a plurality of voxels in 3D space each associated with at least one parametric value, and the set of 2D image data includes information about a known camera position and a known camera orientation at which the 2D image was obtained. A graphical representation is generated of the parametric values of the voxels corresponding to a viewing surface in 3D space. A virtual 2D view of the viewing surface is determined. The 2D image is displayed registered with the graphical representation of the parametric values of the voxels corresponding to the virtual 2D view.",WEERSINK ROBERT;;JAFFRAY DAVID A;;QIU JIMMY;;HOPE ANDREW;;CHO JOHN;;SHARPE MICHAEL B;;UNIV HEALTH NETWORK,WEERSINK ROBERT;;JAFFRAY DAVID A;;QIU JIMMY;;HOPE ANDREW;;CHO JOHN;;SHARPE MICHAEL B,,https://lens.org/020-364-809-927-875,Granted Patent,yes,4,7,2,2,0,G06T19/00;;G06T2210/41;;G06T2219/008;;A61B6/032;;A61B6/037;;A61B6/5247;;A61B6/542;;A61N5/1071;;A61N5/1002;;A61N5/1065;;A61N2005/1074;;G06T19/00;;G06T2210/41;;G06T2219/008;;A61B6/032;;A61B6/037;;A61B6/5247;;A61B6/542;;A61N5/1071;;A61N5/1002;;A61N5/1065;;A61N2005/1074;;G06T15/20;;A61B6/03,G06T15/20;;A61B6/00;;A61B6/03;;A61N5/10;;G06T19/00,,30,29,010-387-051-385-126;;027-186-635-460-317;;087-143-872-165-676;;094-046-941-128-596;;163-989-043-862-822;;006-492-669-470-111;;046-761-492-485-601;;014-744-761-156-692;;098-520-300-485-789;;025-363-762-552-304;;066-821-314-125-109;;006-788-470-924-190;;002-122-281-496-928;;075-073-850-027-743;;107-746-071-221-582;;090-921-135-674-223;;041-706-205-422-488;;004-744-230-464-810;;000-935-057-321-467;;010-688-378-245-773;;150-053-340-919-979;;057-708-869-188-954;;006-556-243-525-146;;058-545-178-696-960;;008-866-046-255-77X;;048-107-589-699-899;;107-746-071-221-582;;047-275-367-712-011;;087-267-745-755-192,10.5626/jcse.2010.4.4.368;;10.1117/12.710216;;12843232;;18575020;;18391767;;10.1097/mlg.0b013e31816bce76;;10.1016/j.compmedimag.2008.08.001;;2032882;;10.1016/0360-3016(91)90171-y;;10.1016/j.ijrobp.2009.09.040;;pmc3431964;;20171515;;18660560;;10.1088/0031-9155/53/16/009;;10.1117/12.466909;;10.1007/s00330-001-1200-6;;11870473;;17786595;;10.1080/10929080701526872;;10.3109/10929080701526872;;10.1118/1.2761698;;10.1145/360825.360839;;10.1145/37402.37422;;10.1118/1.1287050;;10984217;;10571217;;10.1016/s0360-3016(99)00270-9;;10477012;;10.1016/s0360-3016(99)00163-7;;10.1118/1.598014;;9243473;;7596316;;10.1118/1.597451;;18561689;;10.1118/1.2907707;;10.1016/j.ijrobp.2009.05.070;;20171523;;pmc3587781;;pmc2833104;;20171520;;10.1016/j.ijrobp.2009.03.079;;10.1016/j.ijrobp.2009.04.087;;19747783;;10.1109/tpami.1979.4766927;;21868863;;10.1109/tpami.1979.4766928;;21868862;;21868906;;10.1109/tpami.1980.4767029;;10.1145/37402.37422;;10.1016/s0895-6111(00)00084-7;;11390195;;10.1016/j.ijrobp.2010.07.228,"Yim, Yeny, et al. ""Registration of 3D CT Data to 2D Endoscopic Image using a Gradient Mutual Information based Viewpoint Matching for Image-Guided Medialization Laryngoplasty."" JCSE 4.4 (2010): 368-387.;;Potesil, Vaclav, Xiaolei Huang, and Xiang Sean Zhou. ""Automated tumor delineation using joint PET/CT information."" Medical Imaging. International Society for Optics and Photonics, 2007.;;Slomka, Piotr J., et al., NPL, ""Automated 3-dimensional registration of stand-alone 18F-FDG whole-body PET with CT."" Journal of Nuclear Medicine 44.7 (2003): 1156-1167.;;M. Caversaccio, J. G. Giraldez, R. Thoranaghatte, G. Zheng, P. Eggli, L. P. Nolte, and M. A. G. Ballester, M. A. G., Rhinology 46, 156-158 (2008).;;M. P. Fried, S. R. Parikh, and B. Sadoughi, Laryngoscope 118, 1287-1292 (2008).;;W. E. Higgins, J. P. Helferty, K. K. Lu, S. A. Merritt, L. Rai, and K. C. Yu, Computerized Medical Imaging and Graphics 32, 159-173 (2008).;;B. Emami, J. Lyman, A. Brown, L. Coia, M. Goitein, J. E. Munzenrider, B. Shank, L. J. Solin, and M. Wesson, International Journal of Radiation Oncology Biology Physics 21, 109-122 (1991).;;S. M. Bentzen, L. S. Constine, J. O. Deasy, A. Eisbruch, A. Jackson, L. B. Marks, R. K. Ten Haken, and E. D. Yorke, International Journal of Radiation Oncology Biology Physics 76, S3-S9 (2010).;;N. C. Atuegwu and R. L. Galloway, Physics in Medicine and Biology 53, 4355-4368 (2008).;;J. Hummel, W. Birkfellner, T. Figl, C. Haider, R. Hanel, and H. Bergmann, Medical Imaging 2002: Visualization, Image-Guided Procedures, and Display 4681, 94-99 (2002).;;P. Reittner, M. Tillich, W. Luxenberger, R. Weinke, K. Preidler, W. Kole, H. Stammberger, and D. Szolar, European Radiology 12, 592-596 (2002).;;A. Khoury, J. H. Siewerdsen, C. M. Whyne, M. J. Daly, H. J. Kreder, D. J. Moseley, and D. A. Jaffray, Computer Aided Surgery 12, 195-207 (2007).;;M. Daly, J. Siewerdsen, D. Moseley, Y. Cho, S. Ansell, G. Wilson, and D. Jaffray, Medical Physics 34, 2635-2635 (2007).;;B. T. Phong, Communications of the Acm 18, 311-317 (1975).;;W. E. Lorensen and C. H. E., Computer Graphics 21, 163-169 (1987).;;S. M. Zhou, L. B. Marks, G. S. Tracton, G. S. Sibley, K. L. Light, P. D. Maguire, and M. S. Anscher, Medical Physics 27, 1727-1731 (2000).;;G. J. Meijer, M. Van Den Brink, M. S. Hoogeman, J. Meinders, and J. V. Lebesque, International Journal of Radiation Oncology Biology Physics 45, 1073-1080 (1999).;;P. D. Maguire, G. S. Sibley, S. M. Zhou, T. A. Jamieson, K. L. Light, P. A. Antoine, J. E. Herndon, M. S. Anscher, and L. B. Marks, L. B., International Journal of Radiation Oncology Biology Physics 45, 97-103 (1999).;;S. D. Li, A. Boyer, Y. Lu, and G. T. Y. Chen, Medical Physics 24, 1107-1116 (1997).;;Y. Lu, S. S Li, D. D Spelbring, P. Song, S. Vijayakumar, C. Pelizzari, and G. T. Y. Chen, Medical Physics 22, 279-284 (1995).;;R. Munbodh, A. Jackson, J. Bauer, C. R. Schmidtlein, and M. J. Zelefsky, Medical Physics 35, 2137-2150 (2008).;;M. Werner-Wasik, E. Yorke, J. Deasy, J. Nam, and L. B. Marks, International Journal of Radiation Oncology Biology Physics 76, S86-S93 (2010).;;T. Rancati, M. Schwarz, A. M. Allen, F. Feng, A. Popovtzer, B. Mittal, and A. Eisbruch, International Journal of Radiation Oncology Biology Physics 76, S64-S69 (2010).;;T. Rancati, C. Fiorino, and G. Sanguineti, International Journal of Radiation Oncology Biology Physics 75, 915-923 (2009).;;T. Pavlidis, ""The Use of a Syntactic Shape Analyzer for Contour Matching,"" IEEE Trans. Pattern Analysis and Machine Intelligence, PAMI-1 (1979), pp. 307-310.;;T. Pavlidis, ""Algorithms for Shape Analysis of Contours and Waveforms,"" IEEE Trans. Pattern Analysis and Machine Intelligence, PAMI-2 (1980), pp. 301-312.;;P. Bourke, ""Conrec: A Contouring Subroutine"", Byte Magazine, 1987.;;W. E. Lorensen, H. E. Cline: Marching Cubes: A high resolution 3D surface construction algorithm. In: Computer Graphics, vol. 21, Nr. 4, Jul. 1987.;;T. Y. Lee, C. H. Lin, Growing-cube isosurface extraction algorithm for medical volume data, Comput Med Imaging Graph. Sep.-Oct. 2001;25(5):405-15.;;C.I. Dickie; A. Griffin; A. Parent; P. Chung; C. Catton; J. Wunder; P. Ferguson; M. Sharpe; R. Bell; B. O'Sullivan, ""Phase II Study of Preoperative Intensity Modulated Radiation Therapy for Lower Limb Soft Tissue Sarcoma"", International Journal of Radiation Oncology, Biology, Physics (Nov. 2010), 78 (3), Supplement, p. S84-S85.",ACTIVE
856,WO,A1,WO 2011/047240 A1,104-543-641-502-564,2011-04-21,2011,US 2010/0052810 W,2010-10-15,US 25177009 P;;US 29619110 P,2009-10-15,MECHANICAL NANORESONATOR FOR EXTREMELY BROADBAND RESONANCE,"In an embodiment, provided are nanoresonators, nanoresonator components and related methods using the nanoresonators to measure parameters of interest. In an aspect, provided is a nanoresonator component comprising an elongated nanostructure having a central portion, a first end, and a second end and an electrode having a protrusion ending in a tip that is positioned adjacent to the elongated nanostructure. The electrode is used to impart a highly-localized driving force in a perpendicular direction to the nanostructure to induce geometric nonlinear deformation, thereby generating non-linear resonance having a broadband resonance range that spans a frequency range of at least one times the elongated nanostructure natural resonance frequency.",UNIV ILLINOIS;;YU MIN-FENG;;CHO HAN NA;;MCFARLAND D MICHAEL;;BERGMAN LAWRENCE A;;VAKAKIS ALEXANDER,YU MIN-FENG;;CHO HAN NA;;MCFARLAND D MICHAEL;;BERGMAN LAWRENCE A;;VAKAKIS ALEXANDER,,https://lens.org/104-543-641-502-564,Patent Application,yes,3,4,2,2,0,B82Y30/00;;B82Y30/00;;G01N29/022;;G01N29/022;;G01N2291/014;;G01N2291/014;;G01N2291/02491;;G01N2291/02491;;G01N2291/0256;;G01N2291/0256;;G01N2291/02818;;G01N2291/02818;;G01N2291/02863;;G01N2291/02863,G01N27/26,,2,1,021-824-186-422-029,10.1021/cr0681041;;18229951,"BABIC ET AL.: ""Intrinsic Thermal Vibrations of Suspended Doubly Clamped Single-Wall Carbon"", NANOTUBE., 2003, Retrieved from the Internet <URL:http://faculty.washington.edu/cobden/papers/babic03.pdf> [retrieved on 20101130];;GOEDERS ET AL.: ""Microcantilevers: Sensing Chemical Interactions via Mechanical Motion."", 2008, pages 522 - 542, XP007907852, Retrieved from the Internet <URL:http://www.me.gatech.edu/jonathan.colton/microcantilevers.pdf> [retrieved on 20101130], DOI: doi:10.1021/cr0681041",PENDING
857,WO,A1,WO 2019/240960 A1,113-295-422-595-189,2019-12-19,2019,US 2019/0034679 W,2019-05-30,US 201816007815 A,2018-06-13,LINKED TEXT BOXES,"The present disclosure relates to linking text boxes and features associated with linked text boxes. A user interface feature in a document authoring application program for creating text boxes may include a text box creation graphical menu item presented on a display of an electronic device. In response to receiving user input indicative of a selection of the text box graphical menu item, the application program is configured to cause the electronic device to render a text box that includes a bounding edge in the document on the display. Additionally, the user interface feature includes a selectable visual indicator displayed as an integral part of the text box. The selectable visual indicator is indicative of a thread of text boxes in which the text box is included.",APPLE INC,FRAZER KATHERINE ELIZABETH;;LUCAS ALLEN WAYNE;;CHO JONATHAN;;LINDSEY MICHAEL SCOTT;;SMYTH KEVIN R,,https://lens.org/113-295-422-595-189,Patent Application,yes,6,0,3,3,0,G06F40/114;;G06F40/134;;G06F3/0481;;G06F3/0482;;G06F3/04847;;G06F3/0488;;G06F40/166;;G06F40/166,G06F17/21;;G06F17/24,,1,0,,,"ANONYMOUS: ""Text overflow indicator | Adobe Community"", 2 February 2016 (2016-02-02), XP055615092, Retrieved from the Internet <URL:https://forums.adobe.com/thread/2081718> [retrieved on 20190823]",PENDING
858,SG,A,SG 11202100058R A,130-713-370-048-129,2021-03-30,2021,SG 11202100058R A,2019-08-27,US 201862724317 P;;US 2019/0048394 W,2018-08-29,NON-UV HIGH HARDNESS LOW K FILM DEPOSITION,,APPLIED MATERIALS INC,MUKHERJEE SHAUNAK;;XIE BO;;CHO KEVIN MICHAEL;;YIM KANG SUB;;PADHI DEENESH;;GARG ASTHA,,https://lens.org/130-713-370-048-129,Unknown,no,0,0,7,7,0,C23C16/401;;H01L21/02126;;H01L21/02216;;H01L21/02274;;C23C16/505;;C23C16/401;;C23C16/4481;;C23C16/505;;C23C16/52;;C23C16/4583;;H01L21/02126;;H01L21/02274;;H01L21/02126;;H01L21/02274;;H01L21/02216;;H01L21/67167;;C23C16/50;;H01L21/76807;;C23C16/401,C23C16/40;;C23C16/448;;C23C16/458;;C23C16/505;;C23C16/52;;H01L21/02,,0,0,,,,PENDING
859,WO,A1,WO 2020/046980 A1,190-958-335-914-329,2020-03-05,2020,US 2019/0048394 W,2019-08-27,US 201862724317 P,2018-08-29,NON-UV HIGH HARDNESS LOW K FILM DEPOSITION,Embodiments described herein provide a method of forming a low-k carbon-doped silicon oxide (CDO) layer having a high hardness by a plasma-enhanced chemical vapor deposition (PECVD) process. The method includes providing a carrier gas at a carrier gas flow rate and a CDO precursor at a precursor flow rate to a process chamber. A radio frequency (RF) power is applied at a power level and a frequency to the CDO precursor. The CDO layer is deposited on a substrate within the process chamber.,APPLIED MATERIALS INC,MUKHERJEE SHAUNAK;;XIE BO;;CHO KEVIN MICHAEL;;YIM KANG SUB;;PADHI DEENESH;;GARG ASTHA,,https://lens.org/190-958-335-914-329,Patent Application,yes,5,1,7,7,0,C23C16/401;;H01L21/02126;;H01L21/02216;;H01L21/02274;;C23C16/505;;C23C16/401;;C23C16/4481;;C23C16/505;;C23C16/52;;C23C16/4583;;H01L21/02126;;H01L21/02274;;H01L21/02126;;H01L21/02274;;H01L21/02216;;H01L21/67167;;C23C16/50;;H01L21/76807;;C23C16/401,C23C16/40;;C23C16/448;;C23C16/458;;C23C16/505;;C23C16/52;;H01L21/02,,0,0,,,,PENDING
860,US,A1,US 2003/0162481 A1,058-751-950-127-008,2003-08-28,2003,US 12137002 A,2002-04-12,US 12137002 A;;US 35922202 P,2002-02-22,Chemical mechanical polishing of dual orientation polycrystalline materials,"
   A chemical mechanical polishing (CMP) process using a chemically active slurry having a polarity selected to affect the relative oxidation rates of respective crystalline planes of a polycrystalline surface being polished. The slurry polarity is controlled to equilibrate the material removal rates from the respective crystalline planes during the CMP process. A polar solute may be added to a base solvent to achieve the desired polarity. A CMP process for a tungsten film may utilize a water-based slurry containing an abrasive agent, an oxidizing agent, and a solute having a polarity less than that of water. The abrasive agent may be colloidal silica, the oxidizing agent may be hydrogen peroxide, and the solute may be benzene. 
",ANTONELL MICHAEL;;ANTONELL JENNIFER A.;;HOUGE ERIK CHO;;MAYNARD RYAN KEITH;;SIMPSON DARRELL L.,ANTONELL MICHAEL;;ANTONELL JENNIFER A;;HOUGE ERIK CHO;;MAYNARD RYAN KEITH;;SIMPSON DARRELL L,AGERE SYSTEMS INC (2002-06-10);;BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04),https://lens.org/058-751-950-127-008,Patent Application,yes,4,3,8,33,0,B24B37/044;;C09G1/02;;C09G1/02;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;C09K13/00;;H01L21/304;;H01L21/306,451/41,0,0,,,,EXPIRED
861,AU,A,AU 1999/028921 A,052-395-226-487-671,1999-09-20,1999,AU 1999/028921 A,1999-03-03,US 7665898 P;;US 9904705 W,1998-03-03,Cell cycle regulated genes,,AFFYMETRIX INC,CHO RAYMOND J;;CAMPBELL MICHAEL J;;WODICKA LISA;;LOCKHART DAVID J;;DAVIS RONALD W,,https://lens.org/052-395-226-487-671,Patent Application,no,0,0,2,2,0,C07K14/395,C07K14/395,,0,0,,,,DISCONTINUED
862,US,A1,US 2022/0336864 A1,197-001-662-134-649,2022-10-20,2022,US 202017640449 A,2020-09-03,US 202017640449 A;;US 201962896147 P;;US 202063009703 P;;US 2020/0049098 W,2019-09-05,AQUEOUS ELECTROCHEMICAL CELLS USING POLYMER GEL ELECTROLYTES,"A battery comprises an anode, a cathode, and a polymer electrolyte disposed between the anode and the cathode. The polymer electrolyte can include an inert hydrophilic polymer matrix impregnated with an aqueous electrolyte. The hydrophilic polymer matrix can include a polar vinyl monomer, an initiator, and a cross-linker. A gassing inhibitor can be included in the polymer electrolyte to help avoid issues with overcharging of the electrodes.",URBAN ELECTRIC POWER INC,HUANG JINCHAO;;YADAV GAUTAM;;CHO JUNGSANG;;WEINER MEIR;;UPRETI ADITYA;;BANERJEE SANJOY;;NYCE MICHAEL,URBAN ELECTRIC POWER INC (2022-05-25),https://lens.org/197-001-662-134-649,Patent Application,yes,0,0,3,3,0,H01M50/417;;H01M2300/0014;;H01M2300/0005;;H01M2300/0082;;H01M6/045;;H01M50/609;;H01M50/44;;H01M4/244;;H01M4/32;;H01M4/34;;H01M4/628;;H01M10/36;;H01M2004/027;;H01M2004/028;;H01M2300/0005,H01M10/36;;H01M4/24;;H01M4/32;;H01M4/34;;H01M4/62;;H01M50/44,,0,0,,,,PENDING
863,US,B2,US 11498062 B2,011-852-514-162-250,2022-11-15,2022,US 201716337603 A,2017-09-29,US 201716337603 A;;US 201662419247 P;;US 201662419202 P;;US 201662414302 P;;US 201662410922 P;;US 201662410919 P;;US 201662402238 P;;US 2017/0054558 W,2016-09-30,"Phosphorus-containing solid catalysts and reactions catalyzed thereby, including synthesis of p-xylene","Methods and phosphorus-containing solid catalysts for catalyzing dehydration of cyclic ethers (e.g., furans, such as 2,5-dimethylfuran) and alcohols (e.g., ethanol and isopropanol). The alcohols and cyclic ethers may be derived from biomass. One example includes a tandem Diels-Alder cycloaddition and dehydration of biomass-derived 2,5-dimethyl-furan and ethylene to renewable p-xylene. The phosphorus-containing solid catalysts are also active and selective for dehydration of alcohols to alkenes.",UNIV MINNESOTA;;UNIV OF MASSACHUSETTS AMHERST;;UNIV DELAWARE,CHO HONG JE;;FAN WEI;;TSAPATSIS MICHAEL;;DAUENHAUER PAUL J;;REN LIMIN;;LOBO RAUL,REGENTS OF THE UNIVERSITY OF MINNESOTA (2019-07-11);;UNIVERSITY OF MASSACHUSETTS (2021-07-15);;UNIVERSITY OF DELAWARE (2021-09-13),https://lens.org/011-852-514-162-250,Granted Patent,yes,37,0,6,6,0,B01J37/28;;B01J29/40;;B01J29/7007;;B01J29/82;;B01J29/85;;B01J2229/16;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;Y02P20/582;;Y02P20/52;;B01J29/40;;B01J29/7007;;B01J29/85;;B01J37/28;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;C07C51/42;;C07C2521/04;;C07C2521/06;;C07C2521/08;;C07C2521/10;;C07C2521/12;;C07C2521/18;;C07C2523/10;;C07C2523/20;;C07C2527/167;;C07C2527/18;;C07C2527/188;;C07C2529/08;;B01J37/0201;;C07C2529/85;;C07C2529/82;;B01J2229/186;;B01J2229/18;;B01J2229/183;;B01J35/67;;B01J35/69,C07C1/24;;B01J29/40;;B01J29/70;;B01J29/85;;B01J35/10;;B01J37/02;;B01J37/28;;C07C2/86;;C07C6/06;;C07C51/42,,57,47,010-163-764-789-347;;010-163-764-789-347;;054-047-423-031-296;;043-993-419-583-188;;045-959-043-779-847;;066-047-071-802-303;;123-469-778-155-344;;001-257-671-378-160;;065-839-296-414-909;;069-809-046-857-553;;009-650-459-799-218;;018-562-220-888-880;;009-606-541-526-069;;013-651-853-825-815;;128-064-484-435-080;;059-567-684-687-120;;098-648-195-061-601;;057-532-463-884-232;;063-943-832-600-738;;063-278-878-784-256;;025-179-354-559-857;;048-231-544-969-259;;077-494-912-953-194;;021-528-524-085-218;;025-239-645-426-589;;022-238-280-831-712;;108-167-629-985-152;;034-091-146-308-770;;050-712-596-776-116;;047-741-444-168-482;;022-876-865-099-869;;004-507-110-607-419;;033-904-593-331-867;;038-038-551-106-059;;150-670-748-404-833;;055-144-252-904-849;;013-079-541-152-354;;065-809-338-900-36X;;014-877-133-100-718;;166-200-406-908-577;;154-604-984-527-106;;025-286-660-523-223;;010-500-246-698-650;;119-503-310-552-186;;036-803-919-357-175;;015-931-084-082-453;;118-564-821-194-969,10.1016/j.apcata.2015.07.011;;10.1016/j.apcata.2015.07.011;;10.1021/acs.energyfuels.8b04485;;10.1016/j.cattod.2005.06.002;;34067754;;10.3390/ma14102609;;pmc8156553;;10.1039/cc9960002365;;10.1039/c5gc02164b;;10.1039/c2ra21381h;;10.1039/c3gc40740c;;10.1021/ja2038358;;21736345;;10.1002/cctc.201601294;;10.1038/nmat1705;;16892049;;10.1038/nature08288;;19741706;;10.1021/cs300265d;;10.1016/j.apcata.2014.12.006;;10.1021/cr00035a007;;10.1007/bf00909833;;10.1021/ja00189a016;;10.1016/0921-3449(90)90018-y;;10.1039/b517510k;;10.1016/j.apcata.2005.10.054;;12405821;;10.1021/ja020947w;;23945710;;pmc3744081;;10.1038/srep02445;;10.1039/c5cy02211h;;10.1021/jp035110h;;21162573;;10.1021/ja107942n;;10.1016/0144-4565(84)90039-8;;16852024;;10.1021/jp0441893;;10.1021/cs100042r;;18179218;;10.1021/ja077711i;;24993100;;10.1039/c4cs00105b;;20136135;;10.1021/ja908382n;;22887922;;10.1002/cssc.201100780;;10.1016/j.catcom.2004.05.006;;10.1021/ja0478734;;15521742;;10.1107/s0021889895014191;;10.1007/bf01083812;;10.1007/bf00907677;;10.1021/ja01170a013;;10.1002/cctc.201600710;;10.1002/cctc.200900278;;10.1002/anie.200705755;;18435514;;10.1016/0144-2449(94)90134-1;;20437452;;10.1002/cssc.200900285;;10.1038/nchembio.580;;21602812;;10.1021/ja065071y;;17044675;;22745424;;10.1126/science.1221111,"Ding et al., “Combined desilication and phosphorus modification for high-silica ZSM-5 zeolite with related study of hydrocarbon cracking”, Applied Catalysis A: General 503, (2015), pp. 147-155.;;Machine Translation, JP 2011225401, Nov. 20, 2011.;;J. Ding et al., Applied Catalysis A: General 503 (2015), pp. 147-155.;;Manrique et al., “Phosphorus-Modified Beta Zeolite and Its Performance in Vacuum Fas Oil Hydrocracking Activity”, Energy & Fuels, 2019, 33, pp. 3483-3491.;;Pitchumani et al., “Tuning of nanostructured SBA-15 silica using phosphoric acid”, Catalysis Today, vol. 105, 3-4, 2005, pp. 618-622.;;Machin et al., “One-Dimensional (1D) Nanostructured Materials for Energy Applications”, Materials, 14, 2021, pp. 1-47.;;Abdelrahman et al., “Biomass-Derived Butadiene by Dehydra-Decyclization of Tetrahydrofuran” ACS Sustain, Chem. Eng., 5:3732-6, Apr. 2017.;;Camblor et al., “Spontaneous nucleation and growth of pure silica zeolite-beta free of connectivity defects,” Chem. Comm., 2365-6, Jul. 1996.;;Chang et al., “Lewis acid zeolites for tandem Diels-Alder cycloaddition and dehydration of biomass-derived dimethylfuran and ethylene to renewable p-xylenem,” Green Chem, 18:1368-76, 2016.;;Chang et al., “Rapid synthesis of Sn-Beta for the isomerization of cellulosic sugars,” RSC Adv., 2(28): 10475-7, Sep. 2012.;;Chang et al., “Ultra-selective cycloaddition of dimethylfuran for renewable p-xylene with H-BEA,” Green Chem., 16:585-88, 2014.;;Chia et al., “Selective Hydrogenolysis of Polyols and Cyclic Ethers over Bifunctional Surface Sites on Rhodium-Rhenium Catalysts” J. Am. Chem. Soc., 133:12675-89, Jul. 2011.;;Cho et al., “Renewable p-Xylene from 2,5-Dinethylfuran and Ethylene Using Phosphorus-Containing Zeolite Catalysts,” ChemCatChem., 9(3):398-402, Feb. 2017.;;Choi et al., “Amphiphilic organosilane-directed synthesis of crystalline zeolite with tunable mesoporosity,” Nat. Mater., 5: 718-23, Sep. 2006.;;Choi et al., “Stable single-unit-cell nanosheets of active and long-lived catalysts,” Nature, 461:246-9, Sep. 2009.;;Choudhary et al.,“ Conversion of Xylose to Furfural Using Lewis and Brønsted Acid Catalysts in Aqueous Media,” ACS Catalysis 2(9):2022-8, Aug. 2012.;;Duan et al., “Efficient production of 1,3-butadiene in the catalytic dehydration of 2,3-butanediol,” Applied Catalysis A: General 491:163-9, Feb. 2015.;;Farneth and Gorte, “Methods for Characterizing Zeolite Acidity,” Chem. Rev., 95(3):615-35, May 1995.;;Freidlin and Sharf, “Two paths for the dehydration of 1,4-butandiol to divinyl with a tricalcium phosphate catalyst,” Bull. Acad. Sci. USSR, Div. Chem. Sci. 9(9):1577-9, Feb. 1960.;;Fyfe et al., “Detailed Investigation of the Lattice Structure of Zeolite ZSM-11 by a Combination of Solid-State NMR and Synchrotron X-ray Diffraction Techniques,” J. Am. Chem. Soc., 111(7):2470-4, Mar. 1989.;;Godawa et al., “Palladium catalyzed hydrogenation of furan: optimization of production conditions for tetrahydrofuran,” Resources, Conservation and Recycling 3(4):201-16, Jun. 1990.;;Gorte, “What do we know about the acidity of solid acids?, Catalysis Letters,” 62(1):1-13, Sep. 1999.;;Groen et al., “Desilication: on the controlled generation of mesoporosity in MFI zeolites,” Mater. Chem., 16:2121-31, Mar. 2006.;;Ichikawa et al., “Catalytic reaction of 1,3-butanediol over solid acids,” J. Mol. Catal. A: Chem. 256(1-2): 106-12, Aug. 2006.;;Igarashi et al., “Dehydration of butanediols over CeO2 catalysts with different particle sizes,” Applied Catalysis A: General 300(l):50-7, Jan. 2006.;;Jeong et al., “Oriented Molecular Sieve Membranes by Heteroepitaxial Growth,” J. Am. Chem. Soc., 124(44):12966-8, Nov. 2002.;;Jiang et al. “Biodegradation-inspired bioproduction of methylacetoin and 2-methyl-2, 3-butanediol” Sci. Rep., 3:1-7, Aug. 2013.;;Jing et al., “Direct Dehydration of 1,3-butanediol into butadiene over aluminosilicate catalysts,” Catal. Sci. Technol., 6(15):5830-40, Feb. 2016.;;Kragten et al., “Structure of the Silica Phase Extracted from Silica/(TPA)OH Solutions Containing Nanoparticles,” J. Phys. Chem. B, 107(3 7): 10006-16, Sep. 2003.;;Lee et al., “Sub-40 nm Zeolite Suspensions via Disassembly of Three-Dimensionally Ordered Mesoporous-Imprinted Silicalite-1,” J. Am. Chem. Soc., 133(3):493-502, Jan. 2011.;;Lejemble et al., “From biomass to furan through decarbonylation of furfural under mild conditions,” Biomass, 4(4):263-74, Jan. 1984.;;Li et al., “Pure-Silica-Zeolite MEL Low-k Films from Nanoparticle Suspensions,” J. Phys. Chem. B., 109(18):8652-8, May 2005.;;Liu et al., Catalytic Behavior of Bronsted Acid Sites in MWW and MFI Zeolites with Dual Meso- and Microporosity ACS Catal., 1(1):7-17, Jan. 2011.;;Maheshwari et al., “Layer Structure Preservation during Swelling, Pillaring, and Exfoliation of a Zeolite Precursor,” J. Am. Chem. Soc., 130(4): 1507-16, Jan. 2008.;;Makshina et al., “Review of old chemistry and new catalytic advances in the on-purpose synthesis of butadiene,” Chem. Soc. Rev., 43(22), 7917-53, Mar. 2014.;;Na et al., “Pillared MFI Zeolite Nanosheets of a single-Unit-Cell Thickness,” J. Am. Chem. Soc., 132(12):4169-77, Mar. 2010.;;Nair et al., “Zeolite-β grown epitaxially on SSZ-31 nanofibers,” Chem. Commun., 10:921-2, Mar. 1999.;;Pace et al., “2-Methyltetrahydrofuran (2-MeTHF): A Biomass-Derived Solvent with Broad Application in Organic Chemistry,” ChemSusChem., 5(8): 1369-79, Aug. 2012.;;PCT International Preliminary Report on Patentability in International Appln. No. PCT/US17/54558 dated Apr. 11, 2019, 9 pages.;;PCT International Search Report and Written Opinion in International Appln. No. PCT/US17/54558 dated Jan. 26, 2018, 18 pages.;;Roth et al., “MCM-36: The first pillared molecular sieve with zeolite properties,” Stud. Surf. Sci. and Catal., 94:301, Jan. 1995.;;Sato et al., “Dehydration of 1,4-butanediol into 3-buten-1-ol catalyzed by ceria,” Catal. Comm., 5(8):397-400, Aug. 2004.;;Sato et al., “Dehydration of diols catalyzed by CeO2,” J. Mol. Catal. A: Chem., 221(1-2):177-83, Nov. 2004.;;Sayari et al., “Simple Synthesis Route to Monodispersed SBA-15 Silica Rods,” J. Am. Chem. Soc., 126(44)14348-9, Oct. 2004.;;Schlenker et al., “Computed X-ray Powder Diffraction Patterns for Ultrasmall Zeolite Crystals,” J. Appl. Cryst., 29(2): 178-85, Apr. 1996.;;Sharf et al., “Production of isoprene from formaldehyde and isobutylene through 3-methylbutanediol-1, 3,” Bull. Acad. Sci. USSR, Div. Chem. Sci., 14(9), 1621-3, Sep. 1965.;;Shuikin and An, “Dehydration of tetrahydropyran over TiO2-A12O3,” Bull. Acad. Sci. USSR, Div. Chem. Sci., 9(8):1400-140, Jan. 1960.;;Smith and Fuzek, “Catalytic Hydrogenation of Furan and Substituted Furans on Platinum,” J. Am. Chem. Soc., 71(2):415-9, Feb. 1949.;;Spanjers et al., “Branched Diol Monomers from the Sequential Hydrogenation of Renewable Carboxylic Acids,” ChemCatChem., 8(19):3031-5, Oct. 2016.;;Tsapatsis et al., “A New, Yet Familiar, Lamellar Zeolite,” ChemCatChem., 2:246-8, Mar. 2010.;;Tsapatsis et al., “Pores by Pillaring: Not Always a Maze,” Angew. Chem. Int. Ed., 47(23):4262-3, May 2008.;;Van Koningsveld et al., “The monoclinic framework structure of zeolite H-ZSM-5. Comparison with the orthorhombic framework of as-synthesized ZSM-5”, Zeolites, 10:235-42, May 1990.;;Yang and Seng, “One-Step Catalytic Transformation of Carbohydrates and Cellulosic Biomass to 2,5-Dimethyltetrahydrofuran for Liquid Fuels,” ChemSusChem., 3(5):597-603, May 2010.;;Yim et al., “Metabolic engineering of Escherichia coli for direct production of 1,4-butanediol,” Nat. Chem. Biol., 7(7):445-52, May 2011.;;Yokoi et al.,“ Periodic Arrangement of Silica Nanospheres Assisted by Amino Acids,” J. Am. Chem. Soc., 128(42) 13664-5, Oct. 2006.;;Zhang et al., “Synthesis of Self-Pillared Zeolite Nanosheets by Repetitive Branching,” Science 336(6089):1684-7, Jun. 2012.;;U.S. Appl. No. 16/337,600, filed Mar. 28, 2019, Omar A. Abdelrahman, Published.",ACTIVE
864,US,A1,US 2019/0344252 A1,018-054-619-368-181,2019-11-14,2019,US 201716337603 A,2017-09-29,US 201716337603 A;;US 201662419247 P;;US 201662419202 P;;US 201662414302 P;;US 201662410922 P;;US 201662410919 P;;US 201662402238 P;;US 2017/0054558 W,2016-09-30,"PHOSPHORUS-CONTAINING SOLID CATALYSTS AND REACTIONS CATALYZED THEREBY, INCLUDING SYNTHESIS OF P-XYLENE","Methods and phosphorus-containing solid catalysts for catalyzing dehydration of cyclic ethers (e.g., furans, such as 2,5-dimethylfuran) and alcohols (e.g., ethanol and isopropanol). The alcohols and cyclic ethers may be derived from biomass. One example includes a tandem Diels-Alder cycloaddition and dehydration of biomass-derived 2,5-dimethyl-furan and ethylene to renewable p-xylene. The phosphorus-containing solid catalysts are also active and selective for dehydration of alcohols to alkenes.",UNIV MINNESOTA;;UNIV OF MASSACHUSETTS AMHERST,CHO HONG JE;;FAN WEI;;TSAPATSIS MICHAEL;;DAUENHAUER PAUL J;;REN LIMIN;;LOBO RAUL,REGENTS OF THE UNIVERSITY OF MINNESOTA (2019-07-11);;UNIVERSITY OF MASSACHUSETTS (2021-07-15);;UNIVERSITY OF DELAWARE (2021-09-13),https://lens.org/018-054-619-368-181,Patent Application,yes,0,5,6,6,0,B01J37/28;;B01J29/40;;B01J29/7007;;B01J29/82;;B01J29/85;;B01J2229/16;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;Y02P20/582;;Y02P20/52;;B01J29/40;;B01J29/7007;;B01J29/85;;B01J37/28;;B01J2229/37;;C07C1/24;;C07C2/865;;C07C6/06;;C07C2529/40;;C07C2529/70;;C07C51/42;;C07C2521/04;;C07C2521/06;;C07C2521/08;;C07C2521/10;;C07C2521/12;;C07C2521/18;;C07C2523/10;;C07C2523/20;;C07C2527/167;;C07C2527/18;;C07C2527/188;;C07C2529/08;;B01J37/0201;;C07C2529/85;;C07C2529/82;;B01J2229/186;;B01J2229/18;;B01J2229/183;;B01J35/67;;B01J35/69,B01J29/85;;B01J29/40;;B01J29/70;;B01J37/28;;C07C1/24;;C07C2/86;;C07C6/06,,0,0,,,,ACTIVE
865,WO,A1,WO 2023/073420 A1,073-454-789-871-510,2023-05-04,2023,IB 2021062353 W,2021-12-27,US 202117516487 A,2021-11-01,SYSTEMS AND METHODS FOR GENERATING A PERSONALIZED ADVERTISEMENT,"Systems and methods of generating, for display on a graphical user interface (GUI), a personalized advertisement. The systems and methods can include receiving data indicative of initiating a browsing session, aggregating user activity data associated with a user of the application, the user activity data including current session data and/or past session data, applying machine learning on the user activity data to generate one or more excluded products, applying the one or more excluded products to a product database to generate a list of relevant products, ranking, using one or more ranking rules, the list of relevant products to generate a ranked list of relevant products, and sending, to the mobile device, the personalized advertisement including one or more relevant products from the ranked list of relevant products.",COUPANG CORP,VERMA VINAY;;LI JING;;BAO XINLI;;CHO HYUN JUNG;;VADLAMUDI SATYAVARAPRASAD;;SAVIO MICHAEL ROWAN,,https://lens.org/073-454-789-871-510,Patent Application,yes,5,0,5,5,0,G06Q30/0271;;G06Q30/0256;;G06Q30/0631;;G06N20/20;;G06N5/01;;G06Q30/0277;;G06Q30/0269;;G06Q30/0255;;G06F16/9535;;G06N20/00;;G06Q30/0271;;G06Q30/0256;;G06Q30/0282;;G06Q30/0261;;G06Q30/0259;;G06N20/00;;G06Q30/0271;;G06Q30/0631;;G06F16/24578;;G06N20/00;;G06Q30/0256,G06Q30/02,,0,0,,,,PENDING
866,US,B2,US 10650184 B2,110-367-422-709-327,2020-05-12,2020,US 201816007815 A,2018-06-13,US 201816007815 A,2018-06-13,Linked text boxes,"The present disclosure relates to linking text boxes and features associated with linked text boxes. A user interface feature in a document authoring application program for creating text boxes may include a text box creation graphical menu item presented on a display of an electronic device. In response to receiving user input indicative of a selection of the text box graphical menu item, the application program is configured to cause the electronic device to render a text box that includes a bounding edge in the document on the display. Additionally, the user interface feature includes a selectable visual indicator displayed as an integral part of the text box. The selectable visual indicator is indicative of a thread of text boxes in which the text box is included.",APPLE INC,FRAZER KATHERINE ELIZABETH;;LUCAS ALLEN WAYNE;;CHO JONATHAN;;LINDSEY MICHAEL SCOTT;;SMYTH KEVIN R,APPLE INC (2018-06-12),https://lens.org/110-367-422-709-327,Granted Patent,yes,11,2,3,3,0,G06F40/114;;G06F40/134;;G06F3/0481;;G06F3/0482;;G06F3/04847;;G06F3/0488;;G06F40/166;;G06F40/166,G06F40/134;;G06F3/0481;;G06F3/0482;;G06F3/0484;;G06F3/0488;;G06F17/00;;G06F40/166,,2,0,,,"Anonymous: “Text overflow indicator: Adobe Community”, Feb. 2, 2016, XP055615092; https://forums.adobe.com/thread/2081718 (retrieved on Aug. 23, 2019).;;International Search Report and Written Opinion for PCT Application No. PCT/2019/034679 dated Sep. 3, 2019 14 pgs.",ACTIVE
867,US,B2,US 11867757 B2,178-958-133-217-424,2024-01-09,2024,US 202117465337 A,2021-09-02,KR 20200174634 A,2020-12-14,Built-in self-test circuits and semiconductor integrated circuits including the same,"A semiconductor integrated circuit includes a digital-to-analog converter and a built-in self-test circuit. The digital-to-analog converter performs a normal conversion operation to generate an analog output signal by converting a digital input signal corresponding to an external digital signal that is provided from an external device outside the semiconductor integrated circuit and provide the analog output signal to the external device. The built-in self-test circuit, while the digital-to-analog converter performs the normal conversion operation, performs a real-time monitoring operation to generate a comparison alarm signal based on the digital input signal and the analog output signal such that the comparison alarm signal indicates whether the digital-to-analog converter operates normally. Performance and reliability of the digital-to-analog converter and the semiconductor integrated circuit including the digital-to-analog converter may be enhanced by monitoring in real-time abnormality of the digital-to-analog converter using the on-time monitor.",SAMSUNG ELECTRONICS CO LTD,LEE HEEJUNE;;PARK JINWOO;;PARK YOUNGHYO;;OH EUNHYE;;LEE SUNGNO;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2021-06-24),https://lens.org/178-958-133-217-424,Granted Patent,yes,12,0,3,3,0,H03M1/108;;H03M1/66;;G01R31/3187;;G01R31/318328;;G01R31/31937;;G01R31/31703;;G08B21/182;;G01R31/31725;;H03M1/1071;;G01R31/31724,G01R31/317;;H03M1/10,,0,0,,,,ACTIVE
868,IN,A,IN 3740DEN2015 A,051-730-312-637-508,2015-09-18,2015,IN 3740DEN2015 A,2015-05-01,US 201261710857 P;;US 2013/0063790 W,2012-10-08,SELF CONTAINED PV POWERED DOMESTIC TOILET AND WASTEWATER TREATMENT SYSTEM,A wastewater treatment system and method for remediating wastewater and human waste that is self contained and that has no connection to a municipal wastewater system and no connection to an electrical grid. The domestic toilet and wastewater treatment system can be powered by a photovoltaic panel as a source of electricity. The system includes an electrochemical cell that allows a waste stream to be disinfected in a few hours to a condition where no viable bacterial colonies can be cultured. The system produces a liquid stream that is suitable for system flushing or for uses in which non potable water is acceptable. The system can generate hydrogen as a product that can be used to generate power. The system can generate nitrate urea ammonia and phosphate for use as fertilizer. The disinfected residual organic solids are also completely disinfected for potential use as an organic soil amendment for agriculture.,CALIFORNIA INST OF TECHN,HOFFMANN MICHAEL R;;ARYANFAR ASGHAR;;CHO KANGWOO;;CID CLEMENT A;;KWON DAEJUNG;;QU YAN,,https://lens.org/051-730-312-637-508,Patent Application,no,0,0,6,6,0,C02F1/444;;C02F3/28;;C02F2001/007;;C02F2001/46142;;C02F2103/002;;C02F2103/005;;C02F2201/008;;C02F2201/009;;C02F2201/46165;;C02F2209/005;;C02F2209/29;;C02F2305/10;;Y02W10/33;;Y02W10/37;;Y02A20/211;;Y02A20/212;;C02F1/4674;;C02F1/444;;C02F2201/46165;;C02F2201/008;;C02F3/28;;C02F2209/29;;C02F2305/10;;C02F2001/46142;;C02F2103/002;;C02F2209/005;;C02F2001/007;;C02F2103/005;;C02F2201/009;;Y02W10/33;;Y02W10/37;;Y02A20/212;;Y02A20/211;;C02F1/4674;;C02F2103/00;;C02F2201/4611;;C02F2201/4612,C02F1/46,,0,0,,,,PENDING
869,WO,A1,WO 2021/046151 A1,099-799-712-084-487,2021-03-11,2021,US 2020/0049098 W,2020-09-03,US 201962896147 P;;US 202063009703 P,2019-09-05,AQUEOUS ELECTROCHEMICAL CELLS USING POLYMER GEL ELECTROLYTES,"A battery comprises an anode, a cathode, and a polymer electrolyte disposed between the anode and the cathode. The polymer electrolyte can include an inert hydrophilic polymer matrix impregnated with an aqueous electrolyte. The hydrophilic polymer matrix can include a polar vinyl monomer, an initiator, and a cross-linker. A gassing inhibitor can be included in the polymer electrolyte to help avoid issues with overcharging of the electrodes.",URBAN ELECTRIC POWER INC,HUANG JINCHAO;;YADAV GAUTAM;;CHO JUNGSANG;;WEINER MEIR;;UPRETI ADITYA;;BANERJEE SANJOY;;NYCE MICHAEL,,https://lens.org/099-799-712-084-487,Patent Application,yes,8,3,3,3,0,H01M50/417;;H01M2300/0014;;H01M2300/0005;;H01M2300/0082;;H01M6/045;;H01M50/609;;H01M50/44;;H01M4/244;;H01M4/32;;H01M4/34;;H01M4/628;;H01M10/36;;H01M2004/027;;H01M2004/028;;H01M2300/0005,H01M10/26;;H01M4/38,,0,0,,,,PENDING
870,TW,A,TW 202319988 A,124-848-059-150-199,2023-05-16,2023,TW 110149731 A,2021-12-30,US 202117516487 A,2021-11-01,Systems and methods for generating a personalized advertisement,"Systems and methods of generating, for display on a graphical user interface (GUI), a personalized advertisement. The systems and methods can include receiving data indicative of initiating a browsing session, aggregating user activity data associated with a user of the application, the user activity data including current session data and/or past session data, applying machine learning on the user activity data to generate one or more excluded products, applying the one or more excluded products to a product database to generate a list of relevant products, ranking, using one or more ranking rules, the list of relevant products to generate a ranked list of relevant products, and sending, to the mobile device, the personalized advertisement including one or more relevant products from the ranked list of relevant products.",COUPANG CORP,VERMA VINAY;;LI JING;;BAO XINLI;;CHO HYUN-JUNG;;VADLAMUDI SATYAVARAPRASAD;;SAVIO MICHAEL ROWAN,,https://lens.org/124-848-059-150-199,Patent of Addition,no,0,0,5,5,0,G06Q30/0271;;G06Q30/0256;;G06Q30/0631;;G06N20/20;;G06N5/01;;G06Q30/0277;;G06Q30/0269;;G06Q30/0255;;G06F16/9535;;G06N20/00;;G06Q30/0271;;G06Q30/0256;;G06Q30/0282;;G06Q30/0261;;G06Q30/0259;;G06N20/00;;G06Q30/0271;;G06Q30/0631;;G06F16/24578;;G06N20/00;;G06Q30/0256,G06Q30/02;;G06F3/048;;G06N20/00,,0,0,,,,PENDING
871,US,A1,US 2017/0105635 A1,145-719-082-631-653,2017-04-20,2017,US 201514934466 A,2015-11-06,US 201514934466 A;;US 201562242554 P,2015-10-16,INTRACARDIAC MEDICAL DEVICE WITH PRESSURE SENSING,"An implantable medical device includes a housing having a proximal end and a distal end, a control module enclosed by the housing, and a pressure sensor electrically coupled to the control module. A fixation member is coupled to the housing distal end for anchoring the housing distal end at a fixation site within a cardiovascular system of a patient, and the pressure sensor is spaced apart proximally from the fixation member.",MEDTRONIC INC,CHO YONG K;;HESS MICHAEL F;;RAPALLINI LEONARDO;;SHELDON TODD J;;URKE BRIAN D,MEDTRONIC INC (2015-11-04),https://lens.org/145-719-082-631-653,Patent Application,yes,17,17,4,4,0,A61N1/3756;;A61B5/026;;A61N1/36564;;A61N1/37205;;A61B5/6882;;A61B5/0006;;A61B5/076;;A61B5/4836;;A61B5/0215;;A61B5/6869;;A61B5/283;;A61B5/363;;A61B5/352;;A61B5/026;;A61N1/36564;;A61N1/37205;;A61N1/3756;;A61B5/6882;;A61B5/0006;;A61B5/4836;;A61B5/076;;A61B5/283;;A61B5/287;;A61B5/352;;A61B5/363;;A61B5/02141;;A61B5/0215;;A61B5/686;;A61B5/6869;;A61N1/3621,A61B5/0215;;A61B5/00;;A61B5/021;;A61B5/042;;A61N1/362,,0,0,,,,DISCONTINUED
872,KR,A,KR 20150049291 A,189-939-545-331-405,2015-05-08,2015,KR 20130129622 A,2013-10-29,KR 20130129622 A,2013-10-29,METHOD FOR MANUFACTURING POLYHYDROXYETHYL METHACRYLATE/POLYMETHYL METHACRYLATE MEMBRANE,"The present invention relates to a manufacturing method of a membrane inducing regeneration of periodontal tissue using polyhydroxyethyl methacrylate (PHEMA) and polymethyl methacrylate (PMMA), and particularly, can manufacture the membrane having advantages of both cell/tissue compatibility of an absorbent membrane and the strength of a nonabsorbent membrane. In addition, according to the manufacturing method of the present invention, material properties of the membrane can be improved for clinical applications, and can be harmonized with surrounding tissue without generating inflammatory response after being implanted in the body.",TE BIOS CO LTD,MICHAEL CHO;;KANG MI NA;;KIM JAE WON;;JEONG DO SUN;;KIM DONG SOO,,https://lens.org/189-939-545-331-405,Patent Application,no,0,2,2,2,0,A61L27/16;;A61C8/0006;;A61L27/3608;;A61L27/3687;;A61L27/50;;A61L2430/02,A61L27/54;;A61C5/00;;A61C13/107;;A61L27/14,,0,0,,,,ACTIVE
873,US,A1,US 2023/0071628 A1,198-102-413-659-128,2023-03-09,2023,US 202217748746 A,2022-05-19,KR 20210117944 A,2021-09-03,DIGITAL-TO-ANALOG CONVERTER AND APPARATUS INCLUDING THE SAME,"An apparatus configured to transmit and receive a radio frequency (RF) signal is provided. The apparatus includes a digital-to-analog converter (DAC) configured to convert a digital signal into an analog signal, a power amplifier configured to amplify the analog signal, and an antenna configured to output, as the RF signal, the amplified analog signal to the outside. The DAC includes a current cell matrix including a plurality of current cells configured to generate the analog signal, a plurality of normal paths configured to control the plurality of current cells to be turned on or off, based on the digital signal, and a plurality of alternative paths configured to selectively consume power, based on a pattern of the digital signal.",SAMSUNG ELECTRONICS LTD,KOO BYUNGWOO;;NAM SANGPIL;;DO SUNGHAN;;PARK JUNSANG;;LEE JUNGHO;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2022-02-04),https://lens.org/198-102-413-659-128,Patent Application,yes,2,0,6,6,0,H03M1/747;;H03M1/0863;;H03M1/0678;;H03M1/0614;;H03M1/0845;;H03M1/66;;H03M1/002;;H03M7/165;;H03F3/20;;H03M1/66;;H04B1/005,H03M1/66;;H03F3/20;;H04B1/00,,0,0,,,,PENDING
874,KR,A,KR 20220085891 A,022-125-498-723-545,2022-06-23,2022,KR 20200175437 A,2020-12-15,KR 20200175437 A,2020-12-15,ANALOG DIGITAL CONVERTER,"본 발명의 실시 형태에 따른 아날로그 디지털 컨버터는 아날로그 입력 전압을 수신하고, SAR 방식을 이용하여 상기 아날로그 입력 전압으로부터 제1 디지털 신호를 생성하고, 상기 제1 디지털 신호를 생성한 후 남은 잔류(residue) 전압을 출력하는 코스 ADC와, 상기 잔류 전압과 테스트 전압을 수신하고, 상기 잔류 전압을 미리 정해진 이득만큼 증폭하여 잔류 전류를 생성하고, 상기 테스트 전압을 상기 이득만큼 증폭하여 테스트 전류를 생성하는 증폭기와, 상기 잔류 전류를 수신하고, SAR 방식을 이용하여 상기 잔류 전류로부터 제2 디지털 신호를 생성하는 파인 ADC와, 상기 테스트 전류를 수신하고, 상기 테스트 전류에 기초하여 상기 증폭기의 상기 이득을 조절하기 위한 이득 보정 신호를 생성하는 보조 경로를 포함한다.",SAMSUNG ELECTRONICS CO LTD,MOON KYOUNG JUN;;OH DONG RYEOL;;PARK YOUNG HYO;;CHO YOUNG JAE;;CHOI MICHAEL,,https://lens.org/022-125-498-723-545,Patent Application,no,0,0,3,3,0,H03M1/0695;;H03M1/164;;H03M1/468;;H03M1/1009;;H03M1/0604;;H03M1/1071;;H03M1/1215;;H03M1/38;;H03M1/1009;;H03M1/1071;;H03M1/46;;H03M1/462;;H03M1/0695;;H03M1/122,H03M1/12;;H03M1/10;;H03M1/38;;H03M1/46,,0,0,,,,PENDING
875,WO,A2,WO 2000/078992 A2,057-740-799-906-69X,2000-12-28,2000,US 0016773 W,2000-06-16,US 13993699 P;;US 19461800 P,1999-06-18,MASS TRANSPORT LIMITED IN VIVO ANALYTE SENSOR,"An in vivo electrochemical sensor including a working electrode, and an analyte-responsive sensing layer proximate the working electrode. The sensing layer is exposed at an edge of the sensor, wherein the sensor signal is limited, at least in part, by mass transport of analyte to the sensing layer. The sensor is configured and arranged for implantation into the body of a mammal for contact with body fluids of the mammal. The analyte diffuses to the sensing element via the edge of the sensor, thereby restricting mass transport of the analyte to the sensing element. This is because the solution-contacting surface area of the sensor edge is much smaller than an open face of the sensing layer.",THERASENSE INC,SAY JAMES;;TOMASCO MICHAEL F;;SAKSLUND HENNING;;AUDETT JAY D;;CHO BRIAN;;YAMASAKI DUANE,,https://lens.org/057-740-799-906-69X,Patent Application,yes,0,232,10,10,0,A61B5/1486;;A61B5/14865;;C12Q1/002;;C12Q1/006;;Y10S977/925;;A61B5/14865;;C12Q1/002;;A61B5/1486;;C12Q1/006;;Y10S977/925,G01N33/483;;A61B5/00;;A61B5/145;;A61B5/1468;;A61B5/1486;;C12Q1/00;;G01N27/327;;G01N27/416;;G01N27/49;;G01N33/487,,0,0,,,,PENDING
876,US,A1,US 2013/0113802 A1,161-394-333-862-673,2013-05-09,2013,US 201213456967 A,2012-04-26,US 201213456967 A;;US 201161480534 P,2011-04-29,METHODS AND SYSTEMS FOR VISUALIZATION OF 3D PARAMETRIC DATA DURING 2D IMAGING,"Methods and systems for visualization of 3D parametric data in a 2D image. The set of 3D parametric data includes a plurality of voxels in 3D space each associated with at least one parametric value, and the set of 2D image data includes information about a known camera position and a known camera orientation at which the 2D image was obtained. A graphical representation is generated of the parametric values of the voxels corresponding to a viewing surface in 3D space. A virtual 2D view of the viewing surface is determined. The 2D image is displayed registered with the graphical representation of the parametric values of the voxels corresponding to the virtual 2D view.",WEERSINK ROBERT;;JAFFRAY DAVID A;;QIU JIMMY;;HOPE ANDREW;;CHO JOHN;;SHARPE MICHAEL B;;UNIV HEALTH NETWORK,WEERSINK ROBERT;;JAFFRAY DAVID A;;QIU JIMMY;;HOPE ANDREW;;CHO JOHN;;SHARPE MICHAEL B,,https://lens.org/161-394-333-862-673,Patent Application,yes,4,58,2,2,0,G06T19/00;;G06T2210/41;;G06T2219/008;;A61B6/032;;A61B6/037;;A61B6/5247;;A61B6/542;;A61N5/1071;;A61N5/1002;;A61N5/1065;;A61N2005/1074;;G06T19/00;;G06T2210/41;;G06T2219/008;;A61B6/032;;A61B6/037;;A61B6/5247;;A61B6/542;;A61N5/1071;;A61N5/1002;;A61N5/1065;;A61N2005/1074;;G06T15/20;;A61B6/03,G06T15/20,345/427,3,3,010-387-051-385-126;;027-186-635-460-317;;087-143-872-165-676,10.5626/jcse.2010.4.4.368;;10.1117/12.710216;;12843232,"Yim, Yeny, et al. ""Registration of 3D CT Data to 2D Endoscopic Image using a Gradient Mutual Information based Viewpoint Matching for Image-Guided Medialization Laryngoplasty."" JCSE 4.4 (2010): 368-387.;;Potesil, Vaclav, Xiaolei Huang, and Xiang Sean Zhou. ""Automated tumor delineation using joint PET/CT information."" Medical Imaging. International Society for Optics and Photonics, 2007.;;Slomka, Piotr J., et al., NPL, ""Automated 3-dimensional registration of stand-alone 18F-FDG whole-body PET with CT."" Journal of Nuclear Medicine 44.7 (2003): 1156-1167.",ACTIVE
877,US,A1,US 2020/0075321 A1,061-475-492-732-787,2020-03-05,2020,US 201916552294 A,2019-08-27,US 201916552294 A;;US 201862724317 P,2018-08-29,NON-UV HIGH HARDNESS LOW K FILM DEPOSITION,Embodiments described herein provide a method of forming a low-k carbon-doped silicon oxide (CDO) layer having a high hardness by a plasma-enhanced chemical vapor deposition (PECVD) process. The method includes providing a carrier gas at a carrier gas flow rate and a CDO precursor at a precursor flow rate to a process chamber. A radio frequency (RF) power is applied at a power level and a frequency to the CDO precursor. The CDO layer is deposited on a substrate within the process chamber.,APPLIED MATERIALS INC,MUKHERJEE SHAUNAK;;XIE BO;;CHO KEVIN MICHAEL;;YIM KANG SUB;;PADHI DEENESH;;GARG ASTHA,APPLIED MATERIALS INC (2019-08-28),https://lens.org/061-475-492-732-787,Patent Application,yes,3,1,7,7,0,C23C16/401;;H01L21/02126;;H01L21/02216;;H01L21/02274;;C23C16/505;;C23C16/401;;C23C16/4481;;C23C16/505;;C23C16/52;;C23C16/4583;;H01L21/02126;;H01L21/02274;;H01L21/02126;;H01L21/02274;;H01L21/02216;;H01L21/67167;;C23C16/50;;H01L21/76807;;C23C16/401,H01L21/02;;C23C16/40;;C23C16/50,,1,0,,,JP 2009132855 Google Patents (Year: 2009),DISCONTINUED
878,KR,A,KR 20210112948 A,149-144-910-004-905,2021-09-15,2021,KR 20200028652 A,2020-03-06,KR 20200028652 A,2020-03-06,CORRELATED DOUBLE SAMLING CIRCUIT AND IMAGE SENSOR INCLUDING THEREOF,"A flicker detection circuit is disclosed. The flicker detection circuit includes: a flicker detection (FD) correlated double sampling (CDS) circuit amplifying first to sixth switches which are turned on or turned off according to the control signal, first to fourth capacitors, and a flicker pixel signal output from the pixel for flicker detection according to a gain, and summing and outputting an output offset; and an analog-to-digital converter (ADC) quantizing the amplified output signal.",SAMSUNG ELECTRONICS CO LTD,NAM SANG PIL;;LEE KYUNG HOON;;LEE JUNG HO;;CHO YOUNG JAE;;CHOI MICHAEL,,https://lens.org/149-144-910-004-905,Patent Application,no,0,0,4,4,0,H04N25/75;;H03M1/1295;;H03M1/1245;;H03M1/08;;H04N23/745;;H04N25/616;;H04N25/702;;H04N25/75;;H04N25/616;;H04N25/772;;H04N25/75;;H04N25/616;;H04N23/745;;H04N25/75;;H04N25/772,H04N5/378;;H04N5/357;;H04N5/3745,,0,0,,,,PENDING
879,WO,A1,WO 2014/058825 A1,172-460-284-290-227,2014-04-17,2014,US 2013/0063790 W,2013-10-08,US 201261710857 P,2012-10-08,"SELF-CONTAINED, PV-POWERED DOMESTIC TOILET AND WASTEWATER TREATMENT SYSTEM","A wastewater treatment system and method for remediating wastewater and human waste that is self-contained and that has no connection to a municipal wastewater system and no connection to an electrical grid. The domestic toilet and wastewater treatment system can be powered by a photovoltaic panel as a source of electricity. The system includes an electrochemical cell that allows a waste stream to be disinfected in a few hours to a condition where no viable bacterial colonies can be cultured. The system produces a liquid stream that is suitable for system flushing or for uses in which non-potable water is acceptable. The system can generate hydrogen as a product that can be used to generate power. The system can generate nitrate, urea, ammonia and phosphate for use as fertilizer. The disinfected residual organic solids are also completely disinfected for potential use as an organic soil amendment for agriculture.",CALIFORNIA INST OF TECHN;;HOFFMANN MICHAEL R;;ARYANFAR ASGHAR;;CHO KANGWOO;;CID CLEMENT A;;KWON DAEJUNG;;QU YAN,HOFFMANN MICHAEL R;;ARYANFAR ASGHAR;;CHO KANGWOO;;CID CLEMENT A;;KWON DAEJUNG;;QU YAN,,https://lens.org/172-460-284-290-227,Patent Application,yes,5,9,6,6,0,C02F1/444;;C02F3/28;;C02F2001/007;;C02F2001/46142;;C02F2103/002;;C02F2103/005;;C02F2201/008;;C02F2201/009;;C02F2201/46165;;C02F2209/005;;C02F2209/29;;C02F2305/10;;Y02W10/33;;Y02W10/37;;Y02A20/211;;Y02A20/212;;C02F1/4674;;C02F1/444;;C02F2201/46165;;C02F2201/008;;C02F3/28;;C02F2209/29;;C02F2305/10;;C02F2001/46142;;C02F2103/002;;C02F2209/005;;C02F2001/007;;C02F2103/005;;C02F2201/009;;Y02W10/33;;Y02W10/37;;Y02A20/212;;Y02A20/211;;C02F1/4674;;C02F2103/00;;C02F2201/4611;;C02F2201/4612,C02F1/46,,0,0,,,,PENDING
880,US,B1,US 6506953 B1,181-723-700-583-415,2003-01-14,2003,US 49043300 A,2000-01-24,US 49043300 A,2000-01-24,Hydroalkylation of aromatic hydrocarbons,"
    There is described a process the hydroalkylation of an aromatic hydrocarbon, particularly benzene, to produce a cycloalkyl-substituted aromatic compound, particularly cyclohexylbenzene, comprising the step of contacting the aromatic hydrocarbon with hydrogen in the presence of a catalyst comprising MCM-68 and at least one metal having hydrogenation activity. 
",EXXONMOBIL OIL CORP,CHENG JANE CHI-YA;;DANDEKAR AJIT B;;STECKEL MICHAEL ALAN;;TIMKEN HYE KYUNG CHO,EXXONMOBIL OIL CORPORATION (2000-05-02),https://lens.org/181-723-700-583-415,Granted Patent,yes,14,30,3,3,0,C07C2/74;;C07C2/74;;C07C2523/06;;C07C2523/06;;C07C2523/14;;C07C2523/14;;C07C2523/44;;C07C2523/44;;C07C2523/46;;C07C2523/46;;C07C2523/75;;C07C2523/75;;C07C2523/755;;C07C2523/755;;C07C2529/70;;C07C2529/70,C07C2/74,585/269;;585/270;;585/268;;585/427;;585/467,3,2,052-503-084-205-012;;044-064-293-134-597,10.1016/0021-9517(65)90059-x;;10.1016/0021-9517(66)90059-5,"Journal of Catalysts 4, pp. 527-529 (1965), Superactive Crystalline Aluminosilicate Hydrocarbon Catalysts, P.B. Weisz and J.N. Maile.;;Journal of Catalysts 6, pp. 278-287 (1966), Catalysts by Crystalline Aluminosilicates IV. Attainable Catalytic Cracking Rate Constants, and Superactivity, J.N. Miale, N.Y. Chen and P.B. Weisz.;;Journal of Catalysts 61, pp. 390-396 (1980), Chemical and Physical Properties of the ZSM-5 Substitutional Series, D.H. Olsen, W.O. Haag and R.M. Lago.",EXPIRED
881,US,A1,US 2012/0279306 A1,049-001-474-292-694,2012-11-08,2012,US 201013501829 A,2010-10-15,US 201013501829 A;;US 25177009 P;;US 29619110 P;;US 2010/0052810 W,2009-10-15,Mechanical Nanoresonator for Extremely Broadband Resonance,"In an embodiment, provided are nanoresonators, nanoresonator components and related methods using the nanoresonators to measure parameters of interest. In an aspect, provided is a nanoresonator component comprising an elongated nanostructure having a central portion, a first end, and a second end and an electrode having a protrusion ending in a tip that is positioned adjacent to the elongated nanostructure. The electrode is used to impart a highly-localized driving force in a perpendicular direction to the nanostructure to induce geometric non-linear deformation, thereby generating non-linear resonance having a broadband resonance range that spans a frequency range of at least one times the elongated nanostructure natural resonance frequency.",YU MIN-FENG;;CHO HAN NA;;MCFARLAND D MICHAEL;;BERGMAN LAWRENCE A;;VAKAKIS ALEXANDER;;UNIV ILLINOIS,YU MIN-FENG;;CHO HAN NA;;MCFARLAND D MICHAEL;;BERGMAN LAWRENCE A;;VAKAKIS ALEXANDER,THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (2010-10-27),https://lens.org/049-001-474-292-694,Patent Application,yes,11,2,2,2,0,B82Y30/00;;B82Y30/00;;G01N29/022;;G01N29/022;;G01N2291/014;;G01N2291/014;;G01N2291/02491;;G01N2291/02491;;G01N2291/0256;;G01N2291/0256;;G01N2291/02818;;G01N2291/02818;;G01N2291/02863;;G01N2291/02863,G01N29/22;;H01P7/00,73/579;;333/219,0,0,,,,DISCONTINUED
882,KR,A,KR 20210039489 A,075-968-203-964-738,2021-04-09,2021,KR 20217008609 A,2019-08-27,US 201862724317 P;;US 2019/0048394 W,2018-08-29,비-UV 고경도 저 K 막 증착,"본원에 기술된 구체예들은 플라즈마 강화 화학 기상 증착(PECVD) 프로세스에 의해 고경도를 갖는 저-k 탄소 도핑된 실리콘 옥사이드(CDO) 층을 형성하는 방법을 제공한다. 이 방법은 캐리어 가스를 캐리어 가스 유량으로, 그리고 CDO 전구체를 전구체 유량으로 프로세스 챔버에 제공하는 단계를 포함한다. 무선 주파수(RF) 전력이 소정 전력 레벨 및 소정 주파수로 CDO 전구체에 인가된다. CDO 층이 프로세스 챔버 내의 기판 상에 증착된다.",APPLIED MATERIALS INC,MUKHERJEE SHAUNAK;;XIE BO;;CHO KEVIN MICHAEL;;YIM KANG SUB;;PADHI DEENESH;;GARG ASTHA,,https://lens.org/075-968-203-964-738,Patent Application,no,0,0,7,7,0,C23C16/401;;H01L21/02126;;H01L21/02216;;H01L21/02274;;C23C16/505;;C23C16/401;;C23C16/4481;;C23C16/505;;C23C16/52;;C23C16/4583;;H01L21/02126;;H01L21/02274;;H01L21/02126;;H01L21/02274;;H01L21/02216;;H01L21/67167;;C23C16/50;;H01L21/76807;;C23C16/401,C23C16/40;;C23C16/448;;C23C16/458;;C23C16/505;;C23C16/52;;H01L21/02,,0,0,,,,PENDING
883,US,A1,US 2023/0139513 A1,112-452-993-296-756,2023-05-04,2023,US 202117516487 A,2021-11-01,US 202117516487 A,2021-11-01,SYSTEMS AND METHODS FOR GENERATING A PERSONALIZED ADVERTISEMENT,"Systems and methods of generating, for display on a graphical user interface (GUI), a personalized advertisement. The systems and methods can include receiving data indicative of initiating a browsing session, aggregating user activity data associated with a user of the application, the user activity data including current session data and/or past session data, applying machine learning on the user activity data to generate one or more excluded products, applying the one or more excluded products to a product database to generate a list of relevant products, ranking, using one or more ranking rules, the list of relevant products to generate a ranked list of relevant products, and sending, to the mobile device, the personalized advertisement including one or more relevant products from the ranked list of relevant products.",COUPANG CORP,VERMA VINAY;;LI JING;;BAO XINLI;;CHO HYUN JUNG;;VADLAMUDI SATYAVARAPRASAD;;SAVIO MICHAEL ROWAN,COUPANG CORP (2021-10-26),https://lens.org/112-452-993-296-756,Patent Application,yes,15,0,5,5,0,G06Q30/0271;;G06Q30/0256;;G06Q30/0631;;G06N20/20;;G06N5/01;;G06Q30/0277;;G06Q30/0269;;G06Q30/0255;;G06F16/9535;;G06N20/00;;G06Q30/0271;;G06Q30/0256;;G06Q30/0282;;G06Q30/0261;;G06Q30/0259;;G06N20/00;;G06Q30/0271;;G06Q30/0631;;G06F16/24578;;G06N20/00;;G06Q30/0256,G06Q30/02;;G06F16/2457;;G06N20/00;;G06Q30/06,,2,0,,,“2 Different Abandoned Cart Strategies Courtesy of eBay and Amazon” (published on April 18 2018 https://www.sailthru.com/marketing-blog/abandoned-cart-strategies-ebay-amazon/) (Year: 2018);;“2 Different Abandoned Cart Strategies Courtesy of eBay and Amazon” (published on April 18 2018 https://www.sailthru.com/marketing-blog/abandoned-cart-strategies-ebay-amazon/) (Year: 2018),ACTIVE
884,US,A1,US 2023/0147771 A1,157-194-020-787-018,2023-05-11,2023,US 202117520578 A,2021-11-05,US 202117520578 A,2021-11-05,BLOWERS WITH VARIABLE NOZZLES,"Blowers with variable nozzles are provided. A blower includes a fan, and a main body housing the fan, the main body defining an airflow path extending between an inlet end and an outlet end. A blower further includes a variable nozzle disposed at the outlet end. The variable nozzle includes an attachment collar, the attachment collar comprising a body defining an exterior surface and an interior surface and extending along a longitudinal axis. The variable nozzle further includes a plurality of air control bodies, each of the plurality of air control bodies movably connected to the attachment collar and comprising an air control surface and an extension rod. The variable nozzle further includes an adjustment collar, the adjustment collar disposed around the attachment collar and defining a plurality of adjustment channels, wherein each of the plurality of extension rods is disposed in one of the plurality of adjustment channels.",TECHTRONIC CORDLESS GP,CHO HANG MAN;;COLTHRAP MICHAEL;;HAN DONG HEON;;KAMINSKI PETER;;LANGFORD GRAHAM;;LEE PEYTON,TECHTRONIC CORDLESS GP (2021-12-21),https://lens.org/157-194-020-787-018,Patent Application,yes,0,0,2,2,0,A01G20/47;;F04D27/002;;F04D29/464;;F04D29/563;;F04D27/002;;A01G20/47;;F04D29/403,A01G20/47;;F04D27/00;;F04D29/40,,0,0,,,,ACTIVE
885,CN,A,CN 112513321 A,171-247-317-769-535,2021-03-16,2021,CN 201980048633 A,2019-08-27,US 201862724317 P;;US 2019/0048394 W,2018-08-29,NON-UV HIGH HARDNESS LOW K FILM DEPOSITION,Embodiments described herein provide a method of forming a low-k carbon-doped silicon oxide (CDO) layer having a high hardness by a plasma-enhanced chemical vapor deposition (PECVD) process. The method includes providing a carrier gas at a carrier gas flow rate and a CDO precursor at a precursor flow rate to a process chamber. A radio frequency (RF) power is applied at a power level and a frequency to the CDO precursor. The CDO layer is deposited on a substrate within the process chamber.,APPLIED MATERIALS INC,MUKHERJEE SHAUNAK;;XIE BO;;CHO KEVIN MICHAEL;;YIM KANG SUB;;PADHI DEENESH;;GARG ASHISH,,https://lens.org/171-247-317-769-535,Patent Application,no,8,1,7,7,0,C23C16/401;;H01L21/02126;;H01L21/02216;;H01L21/02274;;C23C16/505;;C23C16/401;;C23C16/4481;;C23C16/505;;C23C16/52;;C23C16/4583;;H01L21/02126;;H01L21/02274;;H01L21/02126;;H01L21/02274;;H01L21/02216;;H01L21/67167;;C23C16/50;;H01L21/76807;;C23C16/401,C23C16/40;;C23C16/448;;C23C16/458;;C23C16/505;;C23C16/52;;H01L21/02,,0,0,,,,DISCONTINUED
886,US,A1,US 2019/0384805 A1,198-665-096-258-476,2019-12-19,2019,US 201816007815 A,2018-06-13,US 201816007815 A,2018-06-13,Linked Text Boxes,"The present disclosure relates to linking text boxes and features associated with linked text boxes. A user interface feature in a document authoring application program for creating text boxes may include a text box creation graphical menu item presented on a display of an electronic device. In response to receiving user input indicative of a selection of the text box graphical menu item, the application program is configured to cause the electronic device to render a text box that includes a bounding edge in the document on the display. Additionally, the user interface feature includes a selectable visual indicator displayed as an integral part of the text box. The selectable visual indicator is indicative of a thread of text boxes in which the text box is included.",APPLE INC,FRAZER KATHERINE ELIZABETH;;LUCAS ALLEN WAYNE;;CHO JONATHAN;;LINDSEY MICHAEL SCOTT;;SMYTH KEVIN R,APPLE INC (2018-06-12),https://lens.org/198-665-096-258-476,Patent Application,yes,0,8,3,3,0,G06F40/114;;G06F40/134;;G06F3/0481;;G06F3/0482;;G06F3/04847;;G06F3/0488;;G06F40/166;;G06F40/166,G06F17/22;;G06F3/0482;;G06F3/0484;;G06F17/24,,0,0,,,,ACTIVE
887,US,A1,US 2014/0209479 A1,179-510-455-625-210,2014-07-31,2014,US 201314048163 A,2013-10-08,US 201314048163 A;;US 201261710857 P,2012-10-08,"SELF-CONTAINED, PV-POWERED DOMESTIC TOILET AND WASTEWATER TREATMENT SYSTEM","A wastewater treatment system and method for remediating wastewater and human waste that is self-contained and that has no connection to a municipal wastewater system and no connection to an electrical grid. The domestic toilet and wastewater treatment system can be powered by a photovoltaic panel as a source of electricity. The system includes an electrochemical cell that allows a waste stream to be disinfected in a few hours to a condition where no viable bacterial colonies can be cultured. The system produces a liquid stream that is suitable for system flushing or for uses in which non-potable water is acceptable. The system can generate hydrogen as a product that can be used to generate power. The system can generate nitrate, urea, ammonia and phosphate for use as fertilizer. The disinfected residual organic solids are also completely disinfected for potential use as an organic soil amendment for agriculture.",HOFFMANN MICHAEL R;;ARYANFAR ASGHAR;;CHO KANGWOO;;CID CLEMENT A;;KWON DAEJUNG;;QU YAN;;CALIFORNIA INSTITUE OF TECHNOLOGY,HOFFMANN MICHAEL R;;ARYANFAR ASGHAR;;CHO KANGWOO;;CID CLEMENT A;;KWON DAEJUNG;;QU YAN,CALIFORNIA INSTITUTE OF TECHNOLOGY (2014-05-30),https://lens.org/179-510-455-625-210,Patent Application,yes,15,16,6,6,0,C02F1/444;;C02F3/28;;C02F2001/007;;C02F2001/46142;;C02F2103/002;;C02F2103/005;;C02F2201/008;;C02F2201/009;;C02F2201/46165;;C02F2209/005;;C02F2209/29;;C02F2305/10;;Y02W10/33;;Y02W10/37;;Y02A20/211;;Y02A20/212;;C02F1/4674;;C02F1/444;;C02F2201/46165;;C02F2201/008;;C02F3/28;;C02F2209/29;;C02F2305/10;;C02F2001/46142;;C02F2103/002;;C02F2209/005;;C02F2001/007;;C02F2103/005;;C02F2201/009;;Y02W10/33;;Y02W10/37;;Y02A20/212;;Y02A20/211;;C02F1/4674;;C02F2103/00;;C02F2201/4611;;C02F2201/4612,C02F1/467,205/743;;204/278,3,1,017-197-890-745-994,10.1109/gcis.2010.70,"Rogers, Michael. ""Caltech Scientist Awarded Grant to Develop Solar-Powered Sanitation System."" Press Release. 19 July 2011. Last accessed 31 Oct 2014;;Lemley, A.T. and Wagenet, L.P. ""Water treatment notes: Terminology for onsite sewage treatment systems"" Fact Sheet 9. Cornell Cooperative Extension, College of Human Ecology. Dec 2005. Retrieved from <http://waterquality.cce.cornell.edu/publications/CCEWQ-09-TerminologyOnsiteSewage.pdf> on 6 Jan 2016;;X. Xu, Q. Liu, Y. Zuo. ""A Study on All-Weather Flexible Auto-Tracking Control Strategy of High-Efficiency Solar Concentrating Photovoltaic Power Generation System"" 2010 Second WRI Global Congress on Intelligent Systems. Vol. 3. Institute of Electrical and Electronics Engineers (IEEE). December 2010. pp. 375-378",ACTIVE
888,AU,A,AU 2000/057471 A,197-933-131-368-999,2001-01-09,2001,AU 2000/057471 A,2000-06-16,US 13993699 P;;US 19461800 P;;US 0016773 W,1999-06-18,Mass transport limited in vivo analyte sensor,,THERASENSE INC,SAY JAMES;;TOMASCO MICHAEL F;;SAKSLUND HENNING;;AUDETT JAY D;;CHO HYUN;;YAMASAKI DUANE,,https://lens.org/197-933-131-368-999,Patent Application,no,0,0,10,10,0,A61B5/14865;;A61B5/14865;;A61B5/1486;;A61B5/1486;;C12Q1/002;;C12Q1/002;;C12Q1/006;;C12Q1/006;;Y10S977/925;;Y10S977/925,G01N33/483;;A61B5/00;;A61B5/145;;A61B5/1468;;A61B5/1486;;C12Q1/00;;G01N27/327;;G01N27/416;;G01N27/49;;G01N33/487,,0,0,,,,DISCONTINUED
889,KR,A,KR 20220072005 A,029-356-348-690-728,2022-06-02,2022,KR 20200157648 A,2020-11-23,KR 20200157648 A,2020-11-23,MULTIPLEXER AND SEMICONDUCTOR DEVICE INCLUDING THE SAME,"본 발명의 일 실시예에 따른 멀티플렉서는, 제1 전원 전압을 출력하는 제1 전원 노드에 연결되는 제1 충전 스위치, 상기 제1 전원 전압보다 작은 제2 전원 전압을 출력하는 제2 전원 노드에 연결되는 제2 충전 스위치, 및 상기 제1 충전 스위치에 연결되는 제1 노드와 상기 제2 충전 스위치에 연결되는 제2 노드 사이에 연결되는 커패시터를 포함하는 충전 회로, 복수의 입력 신호들을 입력받는 복수의 샘플링 스위치들, 및 상기 샘플링 스위치들과 상기 충전 회로 사이에 연결되며, 상기 충전 회로를 공유하는 복수의 부스팅 회로들을 포함하며, 상기 제1 충전 스위치와 상기 제2 충전 스위치는 제1 클럭 신호에 의해 제어되며, 상기 부스팅 회로들 각각은, 상기 제1 노드 및 상기 샘플링 스위치의 게이트에 연결되는 제1 부스팅 스위치, 상기 제2 노드와 상기 샘플링 스위치 사이에 연결되는 제2 부스팅 스위치, 및 제2 클럭 신호와 선택 신호에 응답하여 상기 제1 부스팅 스위치와 상기 제2 부스팅 스위치를 제어하는 레벨 시프터를 포함한다.",SAMSUNG ELECTRONICS CO LTD,LEE SANG HEON;;LIM WOONG TAEK;;LEE JUNG HO;;CHO YOUNG JAE;;CHOI MICHAEL,,https://lens.org/029-356-348-690-728,Patent Application,no,0,0,2,2,0,H02M3/07;;H02M1/08;;H03M1/1245;;G11C27/024;;H03K2217/0081;;H03K17/693;;H03K17/693;;H02M3/07;;H03K19/018521;;H03K17/693;;H02M3/07;;H03M1/122,H03K17/693;;H02M3/07;;H03K19/0185,,0,0,,,,PENDING
890,CN,A,CN 104755431 A,053-248-894-934-082,2015-07-01,2015,CN 201380052639 A,2013-10-08,US 2013/0063790 W;;US 201261710857 P,2012-10-08,"Self-contained, PV-powered domestic toilet and wastewater treatment system","A wastewater treatment system and a method for remediating wastewater and human waste are self-contained and have no connection to a municipal wastewater system and no connection to an electrical grid are provided. The domestic toilet and wastewater treatment system can be powered by a photovoltaic panel as a source of electricity. The system includes an electrochemical cell that allows a waste stream to be disinfected in a few hours to a condition where no viable bacterial colonies can be cultured. The system produces a liquid stream that is suitable for system flushing or for uses in which non-potable water is acceptable. The system can generate hydrogen as a product that can be used to generate power. The system can generate nitrate, urea, ammonia and phosphate for use as fertilizers. The disinfected residual organic solids are also completely disinfected for potential use as an organic soil amendment for agriculture.",CALIFORNIA INST OF TECHN,HOFFMANN MICHAEL R;;ARYANFAR ASGHAR;;CHO KANGWOO;;CID CLEMENT A;;KWON DAEJUNG;;QU YAN,,https://lens.org/053-248-894-934-082,Patent Application,no,5,0,6,6,0,C02F1/444;;C02F3/28;;C02F2001/007;;C02F2001/46142;;C02F2103/002;;C02F2103/005;;C02F2201/008;;C02F2201/009;;C02F2201/46165;;C02F2209/005;;C02F2209/29;;C02F2305/10;;Y02W10/33;;Y02W10/37;;Y02A20/211;;Y02A20/212;;C02F1/4674;;C02F1/444;;C02F2201/46165;;C02F2201/008;;C02F3/28;;C02F2209/29;;C02F2305/10;;C02F2001/46142;;C02F2103/002;;C02F2209/005;;C02F2001/007;;C02F2103/005;;C02F2201/009;;Y02W10/33;;Y02W10/37;;Y02A20/212;;Y02A20/211;;C02F1/4674;;C02F2103/00;;C02F2201/4611;;C02F2201/4612,C02F1/46,,0,0,,,,DISCONTINUED
891,WO,A1,WO 2023/286629 A1,085-887-801-961-324,2023-01-19,2023,JP 2022026275 W,2022-06-30,JP 2021117545 A,2021-07-16,METHOD FOR PRODUCING PLASMID DNA USING ESCHERICHIA COLI,"The purpose of the present invention is to collect plasmid DNA from a cell body of Escherichia coli with high efficiency in the production of the plasmid DNA using the Escherichia coli. Provided is a method for producing plasmid DNA, the method comprising the following steps (a) to (c): (a) preparing Escherichia coli that has a mutation in a gene region involved in the retention of the properties of an outer membrane thereof and carries a desired plasmid; (b) culturing the Escherichia coli prepared in the step (a); and (c) collecting the desired plasmid from the cultured cells.",KANEKA CORP;;KANEKA EUROGENTEC S A;;UNIV CATHOLIQUE LOUVAIN,TOKUNAGA TOMOHISA;;NISHIYAMA TOZO;;MINAKUCHI KAZUNOBU;;CHO SEUNG HYUN;;COLLET JEAN-FRANCOIS;;DEGHELT MICHAEL,,https://lens.org/085-887-801-961-324,Patent Application,yes,6,0,1,1,83,C07K14/195;;C12N9/48;;C12P19/34;;C12N15/52;;C12N15/74,C12P19/34;;C12N1/21;;C12N15/31;;C12N15/52;;C12N15/57,,15,2,117-233-516-674-621;;101-148-211-862-851,10.1021/acssynbio.7b00400;;29668266;;pmc3783015;;23832002;;10.1099/mic.0.069211-0,"GAO WEN, YIN JUN, BAO LICHEN, WANG QUN, HOU SHAN, YUE YALI, YAO WENBING, GAO XIANGDONG: ""Engineering Extracellular Expression Systems in Escherichia coli Based on Transcriptome Analysis and Cell Growth State"", ACS SYNTHETIC BIOLOGY, AMERICAN CHEMICAL SOCIETY, WASHINGTON DC ,USA, vol. 7, no. 5, 18 May 2018 (2018-05-18), Washington DC ,USA , pages 1291 - 1302, XP055794672, ISSN: 2161-5063, DOI: 10.1021/acssynbio.7b00400;;SANDERS AKEISHA N., PAVELKA MARTIN S.: ""Phenotypic analysis of Eschericia coli mutants lacking l,d-transpeptidases"", MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, vol. 159, no. Pt_9, 1 September 2013 (2013-09-01), Reading , pages 1842 - 1852, XP093023960, ISSN: 1350-0872, DOI: 10.1099/mic.0.069211-0;;H. C. BIMNOIMJ. DOLY, NUCLEIC ACIDS RES., vol. 7, no. 6, 1979, pages 1513 - 1523;;""GenBank"", Database accession no. CAD5993943.1;;""NCBI"", Database accession no. NP_418559.1;;FEMS MICROBIOLOGY LETTERS, vol. 165, 1998, pages 335 - 340;;JOURNAL OF BACTERIOLOGY, December 1995 (1995-12-01), pages 7171 - 7177;;CURR GENET, vol. 10, no. 8, 1986, pages 573 - 578;;DATSENKO K.AWANNER B.L, PROC. NATL. ACAD. SCI., U.S.A., vol. 97, no. 12, 2000, pages 6640 - 6645;;LINK A. J. ET AL., J. BACTERIOL, vol. 179, 1997, pages 6228 - 6237;;CASCALES ELLOUBES R, MOL. MICROBIOL, vol. 51, no. 3, 2004, pages 873 - 885;;M. BRAUNT. J. SILHAVY, MOL MICROBIOL, vol. 45, no. 5, 2002, pages 1289 - 302;;THOMASON ET AL., PLASMID, vol. 58, no. 2, September 2007 (2007-09-01), pages 148 - 58;;BABA ET AL., MOL SYST BIOL, vol. 2, 2006, pages 2006;;CURR PROTOC MOL BIOL, July 2007 (2007-07-01)",PENDING
892,CN,A,CN 108348753 A,025-187-484-266-526,2018-07-31,2018,CN 201680060622 A,2016-08-26,US 201562242554 P;;US 201514934466 A;;US 2016/0048817 W,2015-10-16,INTRACARDIAC MEDICAL DEVICE WITH PRESSURE SENSING,"An implantable medical device includes a housing having a proximal end and a distal end, a control module enclosed by the housing, and a pressure sensor electrically coupled to the control module. A fixation member is coupled to the housing distal end for anchoring the housing distal end at a fixation site within a cardiovascular system of a patient, and the pressure sensor is spaced apart proximally from the fixation member.",MEDTRONIC INC,CHO YONG K;;HESS MICHAEL F;;RAPALLINI LEONARDO;;SHELDON TODD J;;URKE BRIAN D,,https://lens.org/025-187-484-266-526,Patent Application,no,14,3,4,4,0,A61N1/3756;;A61B5/026;;A61N1/36564;;A61N1/37205;;A61B5/6882;;A61B5/0006;;A61B5/076;;A61B5/4836;;A61B5/0215;;A61B5/6869;;A61B5/283;;A61B5/363;;A61B5/352;;A61B5/026;;A61N1/36564;;A61N1/37205;;A61N1/3756;;A61B5/6882;;A61B5/0006;;A61B5/4836;;A61B5/076;;A61B5/283;;A61B5/287;;A61B5/352;;A61B5/363;;A61B5/02141;;A61B5/0215;;A61B5/686;;A61B5/6869;;A61N1/3621,A61N1/365;;A61B5/021;;A61B5/0215;;A61B5/026;;A61N1/375;;G01L9/00;;G01L9/12,,0,0,,,,DISCONTINUED
893,EP,A1,EP 4145707 A1,069-768-689-340-058,2023-03-08,2023,EP 22193673 A,2022-09-02,KR 20210117944 A,2021-09-03,DIGITAL-TO-ANALOG CONVERTER AND APPARATUS INCLUDING THE SAME,"An apparatus configured to transmit and receive a radio frequency (RF) signal is provided. The apparatus includes a digital-to-analog converter (DAC) configured to convert a digital signal into an analog signal, a power amplifier configured to amplify the analog signal, and an antenna configured to output, as the RF signal, the amplified analog signal to the outside. The DAC includes a current cell matrix including a plurality of current cells configured to generate the analog signal, a plurality of normal paths configured to control the plurality of current cells to be turned on or off, based on the digital signal, and a plurality of alternative paths configured to selectively consume power, based on a pattern of the digital signal.
 
",SAMSUNG ELECTRONICS CO LTD,KOO BYUNGWOO;;NAM SANGPIL;;DO SUNGHAN;;PARK JUNSANG;;LEE JUNGHO;;CHO YOUNGJAE;;CHOI MICHAEL,,https://lens.org/069-768-689-340-058,Patent Application,yes,5,0,6,6,0,H03M1/747;;H03M1/0863;;H03M1/0678;;H03M1/0614;;H03M1/0845;;H03M1/66;;H03M1/002;;H03M7/165;;H03F3/20;;H03M1/66;;H04B1/005,H03M1/06;;H03M1/08;;H03M1/74,,0,0,,,,PENDING
894,US,B2,US 6899596 B2,072-933-368-884-841,2005-05-31,2005,US 12137002 A,2002-04-12,US 12137002 A;;US 35922202 P,2002-02-22,Chemical mechanical polishing of dual orientation polycrystalline materials,"A chemical mechanical polishing (CMP) process using a chemically active slurry having a polarity selected to affect the relative oxidation rates of respective crystalline planes of a polycrystalline surface being polished. The slurry polarity is controlled to equilibrate the material removal rates from the respective crystalline planes during the CMP process. A polar solute may be added to a base solvent to achieve the desired polarity. A CMP process for a tungsten film may utilize a water-based slurry containing an abrasive agent, an oxidizing agent, and a solute having a polarity less than that of water. The abrasive agent may be colloidal silica, the oxidizing agent may be hydrogen peroxide, and the solute may be benzene.",AGERE SYSTEMS INC,ANTONELL MICHAEL;;ANTONELL JENNIFER A;;HOUGE ERIK CHO;;MAYNARD RYAN KEITH;;SIMPSON DARRELL L,AGERE SYSTEMS INC (2002-06-10);;BELL SEMICONDUCTOR LLC (2017-12-08);;AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04),https://lens.org/072-933-368-884-841,Granted Patent,yes,10,3,8,33,0,B24B37/044;;C09G1/02;;C09G1/02;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;C09K13/00;;H01L21/304;;H01L21/306,451/41;;451/60,0,0,,,,EXPIRED
895,JP,A,JP 2003297782 A,157-913-940-735-50X,2003-10-17,2003,JP 2003043453 A,2003-02-21,US 35922202 P;;US 12137002 A,2002-02-22,CHEMICAL MECHANICAL POLISHING PROCESS OF DUAL ORIENTATION POLYCRYSTALLINE MATERIAL,"<P>PROBLEM TO BE SOLVED: To provide a chemical mechanical polishing (CMP) process employing chemically active slurry having polarity selected to have an effect on the relative oxidation rate of respective crystal faces of a polished polycrystalline surface. <P>SOLUTION: The polarity of slurry is controlled to keep the equilibrium of a material removing rate from respective crystal faces during a CMP process. A polar solute may be added to a base solvent in order to obtain a desired polarity. The CMP process of a tungsten thin film normally utilizes aqueous slurry containing an abrasive, an oxidizing agent, and a solute having polarity lower than that of water. Colloidal silica, hydrogen peroxide and benzene may be employed, respectively, as the abrasive, oxidizing agent and solute. <P>COPYRIGHT: (C)2004,JPO",AGERE SYSTEMS INC,ANTONELL MICHAEL;;ANTONELL JENNIFER A;;HOUGE ERIK CHO;;MAYNARD RYAN KEITH;;SIMPSON DARRELL L,,https://lens.org/157-913-940-735-50X,Patent Application,no,6,0,8,33,0,B24B37/044;;C09G1/02;;C09G1/02;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;C09K13/00;;H01L21/304;;H01L21/306,,0,0,,,,EXPIRED
896,GB,B,GB 2385595 B,037-492-933-418-641,2005-09-14,2005,GB 0228514 A,2002-12-06,US 12137002 A;;US 35922202 P,2002-02-22,Chemical mechanical polishing of dual orientation polycrystalline materials,,AGERE SYSTEMS INC,ANTONELL MICHAEL;;ANTONELL JENNIFER A;;HOUGE ERIK CHO;;MAYNARD RYAN KEITH;;SIMPSON DARRELL L,,https://lens.org/037-492-933-418-641,Granted Patent,no,4,0,8,33,0,B24B37/044;;C09G1/02;;C09G1/02;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;C09K13/00;;H01L21/304;;H01L21/306,C4V V150          V2;;C4V V190          V2;;C4V V2            V2,0,0,,,,EXPIRED
897,TW,A,TW 202006752 A,047-102-359-175-767,2020-02-01,2020,TW 108123523 A,2019-07-04,EP 18181981 A,2018-07-05,Transparent conductive film,"The present invention is in the field of transparent conductive films. In particular, the present invention relates to a transparent conductive film comprising (a) a first laminate comprising - at least two layers containing TiO2, ZrO2 or HfO2 and - a layer containing an organic compound in between the two layers containing TiO2, ZrO2 or HfO2 (b) a metal layer, and (c) a second laminate comprising - at least two layers containing ZnO and - a layer containing an organic compound between the two layers containing ZnO - a metallic dopant other than zinc.",BASF COATINGS GMBH,CHO BO-RAM;;FLORES JEAN-CHARLES;;REINKE MICHAEL;;SUNG MYUNG-MO;;JUNG JIN-WON,,https://lens.org/047-102-359-175-767,Patent of Addition,no,0,0,9,9,0,C03C17/38;;C03C2217/94;;C23C16/45525;;C23C28/00;;C23C28/322;;C23C28/34;;C23C28/345;;C23C28/3455;;C23C28/40;;C23C28/42;;Y02E10/549;;H10K30/50;;C23C28/3455;;C23C28/322;;C23C28/42;;C23C16/45529;;C23C16/405;;H01B5/14;;B05D1/60;;H10K30/50;;C23C16/45531;;C23C28/30;;C23C28/42;;C23C28/44;;C23C28/02;;Y10T428/31678;;C23C28/322;;C23C28/3455;;H10K30/82;;H10K30/451,H01B5/14;;B32B15/04;;H01L31/0224;;H01L51/44,,0,0,,,,ACTIVE
898,US,B2,US 11763350 B2,086-419-774-903-100,2023-09-19,2023,US 202117516487 A,2021-11-01,US 202117516487 A,2021-11-01,Systems and methods for generating a personalized advertisement,"Systems and methods of generating, for display on a graphical user interface (GUI), a personalized advertisement. The systems and methods can include receiving data indicative of initiating a browsing session, aggregating user activity data associated with a user of the application, the user activity data including current session data and/or past session data, applying machine learning on the user activity data to generate one or more excluded products, applying the one or more excluded products to a product database to generate a list of relevant products, ranking, using one or more ranking rules, the list of relevant products to generate a ranked list of relevant products, and sending, to the mobile device, the personalized advertisement including one or more relevant products from the ranked list of relevant products.",COUPANG CORP,VERMA VINAY;;LI JING;;BAO XINLI;;CHO HYUN JUNG;;VADLAMUDI SATYAVARAPRASAD;;SAVIO MICHAEL ROWAN,COUPANG CORP (2021-10-26),https://lens.org/086-419-774-903-100,Granted Patent,yes,13,0,5,5,0,G06Q30/0271;;G06Q30/0256;;G06Q30/0631;;G06N20/20;;G06N5/01;;G06Q30/0277;;G06Q30/0269;;G06Q30/0255;;G06F16/9535;;G06N20/00;;G06Q30/0271;;G06Q30/0256;;G06Q30/0282;;G06Q30/0261;;G06Q30/0259;;G06N20/00;;G06Q30/0271;;G06Q30/0631;;G06F16/24578;;G06N20/00;;G06Q30/0256,G06Q30/02;;G06F16/2457;;G06N20/00;;G06Q30/0251;;G06Q30/0601,,2,0,,,"“2 Different Abandoned Cart Strategies Courtesy of eBay and Amazon” (published on Apr. 18, 2018 https://www.sailthru.com/marketing-blog/abandoned-cart-strategies-ebay-amazon/) (Year: 2018).;;International Search Report and Written Opinion in corresponding PCT Application No. PCT/IB2021/062353; dated Jul. 29, 2022 (10 pages).",ACTIVE
899,TW,A,TW 202022154 A,161-533-116-792-426,2020-06-16,2020,TW 108130726 A,2019-08-28,US 201862724317 P,2018-08-29,Non-UV high hardness low k film deposition,Embodiments described herein provide a method of forming a low-k carbon-doped silicon oxide (CDO) layer having a high hardness by a plasma-enhanced chemical vapor deposition (PECVD) process. The method includes providing a carrier gas at a carrier gas flow rate and a CDO precursor at a precursor flow rate to a process chamber. A radio frequency (RF) power is applied at a power level and a frequency to the CDO precursor. The CDO layer is deposited on a substrate within the process chamber.,APPLIED MATERIALS INC,MUKHERJEE SHAUNAK;;XIE BO;;CHO KEVIN MICHAEL;;YIM KANG-SUB;;PADHI DEENESH;;GARG ASTHA,,https://lens.org/161-533-116-792-426,Patent of Addition,no,0,0,7,7,0,C23C16/401;;H01L21/02126;;H01L21/02216;;H01L21/02274;;C23C16/505;;C23C16/401;;C23C16/4481;;C23C16/505;;C23C16/52;;C23C16/4583;;H01L21/02126;;H01L21/02274;;H01L21/02126;;H01L21/02274;;H01L21/02216;;H01L21/67167;;C23C16/50;;H01L21/76807;;C23C16/401,C23C16/40;;C23C16/448;;C23C16/458;;C23C16/505;;C23C16/52,,0,0,,,,PENDING
900,CN,A,CN 113365008 A,043-269-097-135-747,2021-09-07,2021,CN 202110246691 A,2021-03-05,KR 20200028652 A,2020-03-06,Correlated double sampling circuit and image sensor including same,"A flicker detection circuit is provided. The flicker detection circuit may include a flicker detection correlated double sampling (FD CDS) circuit including first to sixth switches turned on or off based on a control signal, and first to fourth capacitors, the FD CDS circuit being configured to receive a flicker pixel signal output from at least one pixel, summate with an output offset signal, and amplify the summation based on a gain to form a flicker detection signal; and an analog-to-digital converter (ADC) configured to quantize the flicker detection signal.",SAMSUNG ELECTRONICS CO LTD,NAM SANG-PIL;;LEE KYUNG-HOON;;LEE KYUNG-HOON;;CHO YOUNG-JAE;;CHOI MICHAEL,,https://lens.org/043-269-097-135-747,Patent Application,no,0,0,4,4,0,H04N25/75;;H03M1/1295;;H03M1/1245;;H03M1/08;;H04N23/745;;H04N25/616;;H04N25/702;;H04N25/75;;H04N25/616;;H04N25/772;;H04N25/75;;H04N25/616;;H04N23/745;;H04N25/75;;H04N25/772,H04N5/378,,0,0,,,,PENDING
901,US,B1,US 8463591 B1,056-258-683-000-165,2013-06-11,2013,US 84674110 A,2010-07-29,US 84674110 A;;US 23066909 P,2009-07-31,Efficient polynomial mapping of data for use with linear support vector machines,"Methods, systems, and apparatus, including computer programs encoded on computer storage media, for polynomial mapping of data for linear SVMs. In one aspect, a method includes training a linear classifier by receiving feature vectors and generating a condensed representation of a mapped vector corresponding to a polynomial mapping of each feature vector, the condensed representation including an index into a weight vector for each non-zero component of the mapped vector. A linear classifier is trained on the condensed representations. In another aspect, a method includes receiving a feature vector, identifying non-zero components resulting from a polynomial mapping of the feature vector, and mapping the combination of one or more elements of each non-zero component to a weight in a weight vector to determine a set of weights. The feature vector is classified according to a classification score derived by summing the set of weights.",CHANG YIN-WEN;;HSIEH CHO-JUI;;CHANG KAI-WEI;;RINGGAARD MICHAEL;;LIN CHIH-JEN;;GOOGLE INC,CHANG YIN-WEN;;HSIEH CHO-JUI;;CHANG KAI-WEI;;RINGGAARD MICHAEL;;LIN CHIH-JEN,GOOGLE LLC (2010-07-20),https://lens.org/056-258-683-000-165,Granted Patent,yes,19,18,1,1,0,G06N20/00;;G06F40/216;;G06F40/211;;G06N20/10;;G06N20/00;;G06F40/216;;G06F40/211;;G06N20/10,G06F17/27;;G06N20/10,704/1;;704/9;;706/12,41,18,059-786-079-109-47X;;096-092-477-805-863;;065-326-329-259-797;;023-087-367-728-807;;038-857-782-390-594;;090-536-141-230-628;;053-600-206-822-766;;028-312-442-242-939;;045-463-467-603-846;;052-701-657-906-391;;070-337-195-793-824;;089-926-204-972-695;;138-008-739-299-858;;089-830-699-377-268;;042-681-983-171-88X;;134-531-628-661-026;;024-523-153-454-040;;026-720-563-329-176,10.1007/bf00994018;;10.1137/s1052623400374379;;10.3115/1557690.1557758;;10.1145/1390156.1390208;;10.1109/72.991427;;18244442;;10.1145/1401890.1401936;;10.3115/1072228.1072282;;10.1145/1150402.1150429;;12816571;;10.1162/089976603321891855;;10.1162/089976601300014493;;10.1145/1401890.1401942;;10.3115/1117794.1117797;;10.3115/1075096.1075100;;10.1137/1.9781611972719.13;;10.1109/72.788643;;18252605;;10.21236/ada273556;;10.1145/1273496.1273598;;10.1145/1553374.1553516,"Boser, B. et al. ""A Training Algorithm for Optimal Margin Classifiers."" in: Proceedings of the Fifth Annual Workshop of Computational Learning Theory (ACM Press, 1992), pp. 144-152.;;Bottou, L. Stochastic Gradient Descent Examples on Toy Problems. Leon Bottou Website [online], 2007. Retrieved from the internet:. 5 pages.;;Chang, C., and Lin, C. LIBSVM: A Library for Support Vector Machines. CSIE-NTU [online], 2001. Retrieved from the internet:, 4 pages.;;Cortes, C. and Vapnik, V. 'Support-Vector Network', Machine Learning, vol. 20, No. 3 (1995), pp. 273-297.;;Crammer, K., Singer, Y. ""On the Learnability and Design of Output Codes for Multiclass Problems."" in: Machine Learning (2002), pp. 201-233.;;Fan, R., et al. 'Working Set Selection Using Second Order Information for Training SVM', Journal of Machine Learning Research, 2005, vol. 6, Retrieved from the internet:, pp. 1889-1918.;;Fan, R., et al. 'LIBLINEAR: A Library for Large Linear Classification', Journal of Machine Learning Research, 2008, vol. 9. Retrieved from the internet:, pp. 1871-1874.;;Ferris, M. and Munson, T. ""Interior Point Methods for Massive Support Vector Machines."" in: SIAM Journal on Optimization, vol. 13, Issue 3 (2003), pp. 783-804.;;Gertz, E., and Griffin, J. 'Support Vector Machine Classifiers for Large Data Sets', Technical Report ANL/MCS-TW-289, Argonne National Laboratory, 2005, 22 pages.;;Goldberg, Y., and Elhadad, M. ""SplitSVM: Fast, Space-Efficient, Non-Heuristic, Polynomial Kernel Computation for NLP Applications"". In: Proceedings of ACL, 2008, pp. 237-240.;;Hsieh, C., et al. 'A Dual Coordinate Descent Method for Large-Scale Linear SVM', Proceedings of the Twenty Fifth International Conference on Machine Learning (ICML) [online], 2008. Retrieved from the internet:. pp. 408-415.;;Hsu, C., and Lin, C. ""A Comparison of Methods for Multi-Class Support Vector Machines."" in: IEEE Transactions on Neural Networks, vol. 13, No. 2 (2002), pp. 415-425.;;Hsu, C., et al. 'A Practical Guide to Support Vector Classification', Technical Report, Department of Computer Science, National Taiwan University [online], 2003. Retrieved from the internet:, pp. 1-12.;;Ifrim, G., et al. ""Fast Logistic Regression for Text Categorization with Variable-Length N-grams"". in: Proceedings of the 14th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (2008), pp. 354-382.;;Isozaki, H., and Kazawa, H. ""Efficient Support Vector Classifiers for Named Entity Recognition."" in: Proceedings of COLING (2002), pp. 390-396.;;Joachims, T. ""Making Large-Scale SVM Leaning Practical."" in: Schölkopf, B., et al., Advances in Kernel Methods-Support Vector Learning (Cambridge, MA: MIT Press, 1998), pp. 169-184.;;Joachims, T. ""Training Linear SVMs in Linear Time."" in: Proceedings of the ACM Conference on Knowledge Discovery and Data Mining (KDD) (ACM, 2006), pp. 217-226.;;Jung, J., et al. ""Adaptive Constraint Reduction for Training Support Vector Machines."" in: Electronic Transactions on Numerical Analysis (2008), vol. 31, pp. 156-177.;;Keerthi, S., and Lin, C. ""Asymptotic Behaviors of Support Vector Machines with Gaussian Kernel."" in: Neural Computation (2003), vol. 15, No. 7, pp. 1667-1689.;;Keerthi, S., et al. ""Improvements to Platt's SMO Algorithm for SVM Classifier Design."" in: Neural Computation (2001), vol. 13, pp. 637-649.;;Keerthi, S., et al. ""Building Support Vector Machines with Reduced Classifier Complexity."" in: Journal of Machine Learning Research (2006), vol. 7, pp. 1493-1515.;;Keerthi, S., et al. 'A Sequential Dual Method for Large Scale Multi-Class Linear SVMs', Proceedings of the 14th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining [online], 2008. Retrieved from the internet:.;;Kudo, T., and Matsumoto, Y. ""Japanese Dependency Structure Analysis Based on Support Vector Machines."" in: Proceedings of the 2000 Joint SIGDAT Conference on Empirical Methods in Natural Language Processing and Very Large Corpora (2000), vol. 13, pp. 18-25.;;Kudo, T., and Matsumoto, Y. ""Fast Methods for Kernel-Based Text Analysis."" in: Proceedings of the 41st Annual Meeting of the Association of Computational Linguistics (ACL) (2003), pp. 24-31.;;Langford, J., et al. ""Sparse Online Learning via Truncated Gradient."" in: Journal of Machine Learning Research (2009), vol. 10, pp. 771-801.;;Lee, Y., and Mangasarian, O. ""RSVM: Reduced Support Vector Machines."" in: Proceedings of the First SIAM International Conference on Data Mining (2001).;;Lin, C., et al. 'Trust Region Newton Method for a Large-Scale Logistic Regression', Journal of Machine Learning Research [online], 2008, vol. 9. Retrieved from the Internet:,, pp. 627-650.;;Lippert, R., and Rifkin, R. ""Infinite-sigma Limits for Tikhonov Regularization."" in: Journal of Machine Learning Research (2006), vol. 7, pp. 855-876.;;Mangasarian, O., and Musicant, D. ""Successive Overrelaxation for Support Vector Machines."" in: IEEE Transactions on Neural Networks (1999), vol. 10, No. 5, pp. 1032-1037.;;Marcus, M., et al. ""Building a Large Annotated Corpus of English: The Penn Treebank."" in: Computational Linguistics (1993), vol. 19, pp. 313-330.;;McDonald, R., and Nivre, J. ""Characterizing the Errors of Data-Driven Dependency Parsing Models."" in: Proceedings of the Joint Conferences on Empirical Methods in Natural Language Processing and Computational Natural Language Learnings (EMNLP-CoNLL) (2007), pp. 122-131.;;McDonald, R., and Pereira, F. ""Online Learning of Approximate Dependency Parsing Algorithms."" in: Proceedings of the 11th Conference of the European Chapter of the Association for Computational Linguistics (EACL) (2006), pp. 81-88.;;Moh, Y., and Buhmann, J. ""Kernel Expansion for Online Preference Tracking."" in: Proceedings of the International Society for Music Information Retrieval (ISMIR) (2008), pp. 167-172.;;Nivre, J. ""An Efficient Algorithm for Projective Dependency Parsing."" in: Proceedings of the 8th International Workshop on Parsing Technologies (IWPT 03) (2003), pp. 149-160.;;Nivre, J., and Hall, J. ""MaltParser: A Language-Independent System for Data-Driven Dependency Parsing."" in: Proceedings of the Fourth Workshop on Treebanks and Linguistic Theories (2005), 12 pages.;;Nivre, J., et al. ""MaltParser: A Language-Independent System for Data-Driven Dependency Parsing."" in: National Language Engineering (2007), vol. 13, No. 2, pp. 95-135.;;Ravichandran, D., et al. ""The Terascale Challenge."" in: Proceedings of KDD Workshop on Mining for and from the Semantic Web (MSW-04) (2004), pp. 1-11.;;Shalev-Shwartz, S., et al. ""Pegasos: Primal Estimated Sub-gradient Solver for SVM."" in: Proceedings of the 24th International Conference on Machine Learning (ICML) (2007). pp. 807-814.;;Weinberger, K., et al. ""Feature Hashing for Large Scale Multitask Learning."" in: Proceedings of the 26th International Conference on Machine Learning (ICML) (2009), pp. 1113-1120.;;Yamada, H., and Matsumoto, Y. ""Statistical Dependency Analysis with Support Vector Machines."" in: Proceedings of the 8th International Workshop on Parsing Technologies (IWPT 03) (2003), 12 pages.;;Yuan, G., et al. 'A Comparison of Optimization Methods for Large-Scale 11-Regularized Linear Classification,' Technical Report, Department of Computer Science, National Taiwan University [online] 2009. Retrieved from the Internet:, pp. 1-51.",INACTIVE
902,WO,A1,WO 1999/045021 A1,105-190-695-751-457,1999-09-10,1999,US 9904705 W,1999-03-03,US 7665898 P,1998-03-03,CELL CYCLE REGULATED GENES,"Progression through the eukaryotic cell cycle is known to be both regulated and accompanied by periodic fluctation of the expression levels of numerous genes. We report here the genome-wide characterization of mRNA transcript levels during the cell cycle of the budding yeast Saccharomyces cerevisae. Cell cycle-dependent periodicity was found for 422 of the 6,220 monitored transcripts. Fewer than a quarter of the 422 genes identified in our screen have been previously implicated in cell cycle period-specific activities, and more than 40 % have no known biological role. Surprisingly, nearly 30 % of the 422 genes were found directly adjacent to other genes that displayed induction in the same cell cycle phase, suggesting a mechanism for local chromosomal organization in global mRNA regulation. Analysis of regions upstream of these genes indicates that most cell cycle-dependent transcription is driven by previously uncharacterized promoter and enhancer elements. Using statistical analysis of nucleotide frequencies in regions upstream of coinduced genes, candidate cell cycle-dependent regulatory elements were identified.",AFFYMETRIX INC;;CHO RAYMOND J;;CAMPBELL MICHAEL J;;WODICKA LISA;;LOCKHART DAVID J;;DAVIS RONALD W,CHO RAYMOND J;;CAMPBELL MICHAEL J;;WODICKA LISA;;LOCKHART DAVID J;;DAVIS RONALD W,,https://lens.org/105-190-695-751-457,Patent Application,yes,2,1,2,2,0,C07K14/395,C07K14/395,,2,2,143-256-633-056-675;;059-955-978-113-418,7559598;;10.1074/jbc.270.42.24794;;9331090,"PLOCHOCKA-ZULINSKA D., RASMUSSEN G., RASMUSSEN C.: ""REGULATION OF CALCINEURIN GENE EXPRESSION IN SCHIZOSACCHAROMYCES POMBE."", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 270., no. 42., 20 October 1999 (1999-10-20), US, pages 24794 - 24797., XP002920857, ISSN: 0021-9258;;O'CONNOR P. M., ET AL.: ""CHARACTERIZATION OF THE P53 TUMOR SUPPRESSOR PATHWAY IN CELL LINES OF THE NATIONAL CANCER INSTITUTE ANTICANCER DRUG SCREEN AND CORRELATIONS WITH THE GROWTH-INHIBITORY POTENCY OF 123 ANTICANCER AGENTS."", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 57., no. 19., 1 October 1997 (1997-10-01), US, pages 4285 - 4300., XP002920858, ISSN: 0008-5472",PENDING
903,WO,A1,WO 2017/065877 A1,139-782-068-857-79X,2017-04-20,2017,US 2016/0048817 W,2016-08-26,US 201562242554 P;;US 201514934466 A,2015-10-16,INTRACARDIAC MEDICAL DEVICE WITH PRESSURE SENSING,"An implantable medical device includes a housing having a proximal end and a distal end, a control module enclosed by the housing, and a pressure sensor electrically coupled to the control module. A fixation member is coupled to the housing distal end for anchoring the housing distal end at a fixation site within a cardiovascular system of a patient, and the pressure sensor is spaced apart proximally from the fixation member.",MEDTRONIC INC,CHO YONG K;;HESS MICHAEL F;;RAPALLINI LEONARDO;;SHELDON TODD J;;URKE BRIAN D,,https://lens.org/139-782-068-857-79X,Patent Application,yes,17,0,4,4,0,A61N1/3756;;A61B5/026;;A61N1/36564;;A61N1/37205;;A61B5/6882;;A61B5/0006;;A61B5/076;;A61B5/4836;;A61B5/0215;;A61B5/6869;;A61B5/283;;A61B5/363;;A61B5/352;;A61B5/026;;A61N1/36564;;A61N1/37205;;A61N1/3756;;A61B5/6882;;A61B5/0006;;A61B5/4836;;A61B5/076;;A61B5/283;;A61B5/287;;A61B5/352;;A61B5/363;;A61B5/02141;;A61B5/0215;;A61B5/686;;A61B5/6869;;A61N1/3621,A61N1/365;;A61B5/021;;A61B5/0215;;A61B5/026;;A61N1/375;;G01L9/00;;G01L9/12,,0,0,,,,PENDING
904,KR,A,KR 20230063292 A,038-977-980-687-192,2023-05-09,2023,KR 20220045687 A,2022-04-13,US 202117516487 A,2021-11-01,SYSTEMS AND METHODS FOR GENERATING A PERSONALIZED ADVERTISEMENT,"그래픽 사용자 인터페이스에 표시하기 위해, 개인 맞춤형 광고를 생성하는 시스템 및 방법이 개시된다. 이 시스템 및 방법은 브라우징 세션 개시를 나타내는 데이터를 수신하고, 애플리케이션의 사용자와 연관된 사용자 활동 데이터를 집계하고 - 사용자 활동 데이터는 현재 세션 데이터 및/또는 과거 세션 데이터를 포함함 - , 사용자 활동 데이터에 기계 학습을 적용하여 하나 이상의 제외 제품을 생성하고, 하나 이상의 제외 제품을 제품 데이터베이스에 적용하여 관련 제품 리스트를 생성하고, 하나 이상의 순위지정 규칙을 이용하여, 관련 제품 리스트를 순위지정하여 순위지정된 관련 제품 리스트를 생성하고, 그리고 순위지정된 관련 제품 리스트로부터의 하나 이상의 관련 제품을 포함하는 개인 맞춤형 광고를 모바일 디바이스로 전송하는 것을 포함할 수 있다.",COUPANG CORP,VERMA VINAY;;LI JING;;BAO XINLI;;CHO HYUN JUNG;;VADLAMUDI SATYAVARAPRASAD;;SAVIO MICHAEL ROWAN,,https://lens.org/038-977-980-687-192,Patent Application,no,0,0,5,5,0,G06Q30/0271;;G06Q30/0256;;G06Q30/0631;;G06N20/20;;G06N5/01;;G06Q30/0277;;G06Q30/0269;;G06Q30/0255;;G06F16/9535;;G06N20/00;;G06Q30/0271;;G06Q30/0256;;G06Q30/0282;;G06Q30/0261;;G06Q30/0259;;G06N20/00;;G06Q30/0271;;G06Q30/0631;;G06F16/24578;;G06N20/00;;G06Q30/0256,G06Q30/02;;G06N20/00,,0,0,,,,PENDING
905,US,B2,US 10981811 B2,081-920-592-793-593,2021-04-20,2021,US 201314048163 A,2013-10-08,US 201314048163 A;;US 201261710857 P,2012-10-08,"Self-contained, PV-powered domestic toilet and wastewater treatment system","A wastewater treatment system and method for remediating wastewater and human waste that is self-contained and that has no connection to a municipal wastewater system and no connection to an electrical grid. The domestic toilet and wastewater treatment system can be powered by a photovoltaic panel as a source of electricity. The system includes an electrochemical cell that allows a waste stream to be disinfected in a few hours to a condition where no viable bacterial colonies can be cultured. The system produces a liquid stream that is suitable for system flushing or for uses in which non-potable water is acceptable. The system can generate hydrogen as a product that can be used to generate power. The system can generate nitrate, urea, ammonia and phosphate for use as fertilizer. The disinfected residual organic solids are also completely disinfected for potential use as an organic soil amendment for agriculture.",THE CALIFORNIA INSTITUTE OF TECH;;CALIFORNIA INST OF TECHN,HOFFMAN MICHAEL R;;ARYANFAR ASGHAR;;CHO KANGWOO;;CID CLEMENT A;;KWON DAEJUNG;;QU YAN,CALIFORNIA INSTITUTE OF TECHNOLOGY (2014-05-30),https://lens.org/081-920-592-793-593,Granted Patent,yes,28,2,6,6,0,C02F1/444;;C02F3/28;;C02F2001/007;;C02F2001/46142;;C02F2103/002;;C02F2103/005;;C02F2201/008;;C02F2201/009;;C02F2201/46165;;C02F2209/005;;C02F2209/29;;C02F2305/10;;Y02W10/33;;Y02W10/37;;Y02A20/211;;Y02A20/212;;C02F1/4674;;C02F1/444;;C02F2201/46165;;C02F2201/008;;C02F3/28;;C02F2209/29;;C02F2305/10;;C02F2001/46142;;C02F2103/002;;C02F2209/005;;C02F2001/007;;C02F2103/005;;C02F2201/009;;Y02W10/33;;Y02W10/37;;Y02A20/212;;Y02A20/211;;C02F1/4674;;C02F2103/00;;C02F2201/4611;;C02F2201/4612,C02F1/467;;C02F1/00;;C02F1/44;;C02F1/461;;C02F3/28;;C02F103/00,,16,5,017-197-890-745-994;;013-796-005-029-59X;;058-132-260-302-849;;025-981-116-892-230;;102-432-175-442-140,10.1109/gcis.2010.70;;10.1007/978-3-319-05041-6_18;;10.1021/jp710723p;;10.1021/jp802807e;;18656909;;10.1021/jp810331w,"Rogers, Michael. “Caltech Scientist Awarded Grant to Develop Solar-Powered Sanitation System.” Press Release. Jul. 19, 2011. <http://www.caltech.edu/article/13432> Last accessed Oct. 31, 2014.;;Lemley, A.T. and Wagenet, L.P. “Water treatment notes: Terminology for onsite sewage treatment systems” Fact Sheet 9. Cornell Cooperative Extension, College of Human Ecology. Dec. 2005. Retrieved from <http://waterquality.cce.cornell.edu/publications/CCEWQ-09-TerminologyOnsiteSewage.pdf> on Jan. 6, 2016.;;X. Xu, Q. Liu, Y. Zuo. “A Study on All-Weather Flexible Auto-Tracking Control Strategy of High-Efficiency Solar Concentrating Photovoltaic Power Generation System” 2010 Second WRI Global Congress on Intelligent Systems. vol. 3. Institute of Electrical and Electronics Engineers (IEEE). Dec. 2010. pp. 375-378.;;Minden Gardnersville Sanitation District. “Glossary of Wastewater Terms” <http://www.mgsdistrict.org/wp-content/uploads/2011/11/Glossary-of-Wastewater-Terms.pdf> retrieved Sep. 22, 2017 (Year: 2017).;;Brain, Marshall. “How Toilets Work” Apr. 1, 2000. HowStuffWorks.com <http://home.howstuffworks.com/toilet.htm> (Year: 2000).;;Choi, J; Qu, Y.; Hoffmann M.R. “SnO2, IrO2, Ta2O5, Bi2O3, and TiO2 nanoparticle anodes: electrochemical oxidation coupled with the cathodic reduction of water to yield molecular H2” Journal of Nanoparticle Research. vol. 14, Article 983. 12 pages. (Year: 2012).;;Park, H.; Vecitis, C.D.; Choi, W.; Weres, O.; Hoffmann, M.R. “Solar-powered production of molecular hydrogen from water.” Journal of Physical Chemistry Letters C. Jan. 4, 2008. vol. 112, Issue 4. pp. 885-889 (Year: 2008).;;Park, H.; Vecitis, C.D.; Hoffmann, M.R. “Solar-powered electrochemical oxidation of organic compounds coupled with the cathodic production of molecular hydrogen” Jul. 26, 2008. Journal of Physical Chemistry A. vol. 112, Issue 33. pp. 7616-7626 (Year: 2008).;;Park, H.; Vecitis, C.D.; Hoffmann, M.R. “Electrochemical water splitting coupled with organic compound oxidation: The role of active chlorine species” Journal of Physical Chemistry C. Apr. 13, 2009. vol. 113, Issue 18. pp. 7935-7945 (Year: 2009).;;Hoffmann, Michael Robert, Self-Contained, Photovoltaic Powered Domestic Toilet, Division of Engineering and Applied Science, Aug. 15, 2012.;;Stecker et al., “Build a Better Toilet to Get Rich and Popular”, Scientific American, Aug. 22, 2012.;;Woo, Marcus, “Caltech Wins Toilet Challenge”, Caltech, Aug. 15, 2012.;;Kihwan Moon, International Preliminary Report on Patentability, PCT/US2013/063790, dated Apr. 16, 2015.;;M. Erova, International Search Report and Written Opinion, PCT/US2013/063790, dated Mar. 27, 2014.;;Hendricks, Keith D., International Preliminary Report on Patentability, PCT/US2013/063790, dated Oct. 24, 2014.;;Hoffmann, Michael, “Self-Contained, PV-Powered Domestic Toilet and Wastewater Treatment System”, Aug. 8, 2012, www.youtube.com/watch?v=eVQaMsvBLb8.",ACTIVE
906,US,A1,US 2022/0187366 A1,154-019-607-850-197,2022-06-16,2022,US 202117465337 A,2021-09-02,KR 20200174634 A,2020-12-14,BUILT-IN SELF-TEST CIRCUITS AND SEMICONDUCTOR INTEGRATED CIRCUITS INCLUDING THE SAME,"A semiconductor integrated circuit includes a digital-to-analog converter and a built-in self-test circuit. The digital-to-analog converter performs a normal conversion operation to generate an analog output signal by converting a digital input signal corresponding to an external digital signal that is provided from an external device outside the semiconductor integrated circuit and provide the analog output signal to the external device. The built-in self-test circuit, while the digital-to-analog converter performs the normal conversion operation, performs a real-time monitoring operation to generate a comparison alarm signal based on the digital input signal and the analog output signal such that the comparison alarm signal indicates whether the digital-to-analog converter operates normally. Performance and reliability of the digital-to-analog converter and the semiconductor integrated circuit including the digital-to-analog converter may be enhanced by monitoring in real-time abnormality of the digital-to-analog converter using the on-time monitor.",SAMSUNG ELECTRONICS CO LTD,LEE HEEJUNE;;PARK JINWOO;;PARK YOUNGHYO;;OH EUNHYE;;LEE SUNGNO;;CHO YOUNGJAE;;CHOI MICHAEL,SAMSUNG ELECTRONICS CO. LTD (2021-06-24),https://lens.org/154-019-607-850-197,Patent Application,yes,5,0,3,3,0,H03M1/108;;H03M1/66;;G01R31/3187;;G01R31/318328;;G01R31/31937;;G01R31/31703;;G08B21/182;;G01R31/31725;;H03M1/1071;;G01R31/31724,G01R31/317;;H03M1/10,,0,0,,,,ACTIVE
907,JP,A,JP 2023037615 A,187-093-957-216-463,2023-03-15,2023,JP 2022140041 A,2022-09-02,KR 20210117944 A,2021-09-03,"DIGITAL-TO-ANALOG CONVERTER, AND DEVICE INCLUDING THE SAME","To provide a digital-to-analog converter and a device including the same.SOLUTION: A device that transmits/receives an RF (radio frequency) signal, includes: a digital-to-analog converter (DAC) configured to convert a digital signal into an analog signal; a power amplifier configured to amplify the analog signal; and an antenna configured to output the amplified analog signal as an RF signal to the exterior. The digital-to-analog converter (DAC) includes: a current cell matrix that includes a plurality of current cells for generating the analog signal; a plurality of general paths configured to on/off-control the plurality of current cells on the basis of: the digital signal; and a plurality of alternative paths configured to generate selective power consumption on the basis of a pattern of the digital signal.SELECTED DRAWING: Figure 1",SAMSUNG ELECTRONICS CO LTD,KOO BYUNGWOO;;NAM SANGPIL;;DO SUNGHAN;;PARK JUNSANG;;LEE JUNGHO;;CHO YOUNGJAE;;MICHAEL CHOI,,https://lens.org/187-093-957-216-463,Patent Application,no,0,0,6,6,0,H03M1/747;;H03M1/0863;;H03M1/0678;;H03M1/0614;;H03M1/0845;;H03M1/66;;H03M1/002;;H03M7/165;;H03F3/20;;H03M1/66;;H04B1/005,H03M1/66;;H03M1/74;;H04B1/04,,0,0,,,,PENDING
908,US,A1,US 2024/0066306 A1,014-676-585-243-209,2024-02-29,2024,US 202318225884 A,2023-07-25,US 202318225884 A;;US 202263373635 P,2022-08-26,INTEGRATED CARDIOVERTER DEFIBRILLATOR-MUSCLE STIMULATOR FOR CARDIOMYOPLASTY,"An example implantable medical device includes a stimulating lead includes receive one or more signals indicative of one or more physiologic parameters; deliver electrical therapy to stimulate a muscle wrapped around a heart via one or more electrodes of a stimulating lead; and adjust an amount of the electrical therapy delivered, via the stimulating electrodes, based on the one or more physiologic parameters.",MEDTRONIC INC,EGGEN MICHAEL D;;FARRELL SEAN R;;YANG ZHONGPING;;O'BRIEN RICHARD J;;CHO YONG K,,https://lens.org/014-676-585-243-209,Patent Application,yes,0,0,1,1,0,A61N1/36514;;A61N1/3627;;A61N1/3702,A61N1/365;;A61N1/362;;A61N1/37,,0,0,,,,PENDING
909,CN,A,CN 109775816 A,180-058-551-221-678,2019-05-21,2019,CN 201910147714 A,2013-10-08,US 201261710857 P;;CN 201380052639 A,2012-10-08,"Self-contained, PV-powered domestic toilet and wastewater treatment system","A wastewater treatment system and a method for remediating wastewater and human waste are self-contained and have no connection to a municipal wastewater system and no connection to an electrical gridare provided. The domestic toilet and wastewater treatment system can be powered by a photovoltaic panel as a source of electricity. The system includes an electrochemical cell that allows a waste stream to be disinfected in a few hours to a condition where no viable bacterial colonies can be cultured. The system produces a liquid stream that is suitable for system flushing or for uses in which non-potable water is acceptable. The system can generate hydrogen as a product that can be used to generate power. The system can generate nitrate, urea, ammonia and phosphate for use as fertilizers. The disinfected residual organic solids are also completely disinfected for potential use as an organic soil amendment for agriculture.",CALIFORNIA INSTITUE OF TECH,HOFFMANN MICHAEL R;;ARYANFAR ASGHAR;;CHO KANGWOO;;CID CLEMENT A;;KWON DAEJUNG;;QU YAN,,https://lens.org/180-058-551-221-678,Patent Application,no,3,0,6,6,0,C02F1/444;;C02F3/28;;C02F2001/007;;C02F2001/46142;;C02F2103/002;;C02F2103/005;;C02F2201/008;;C02F2201/009;;C02F2201/46165;;C02F2209/005;;C02F2209/29;;C02F2305/10;;Y02W10/33;;Y02W10/37;;Y02A20/211;;Y02A20/212;;C02F1/4674;;C02F1/444;;C02F2201/46165;;C02F2201/008;;C02F3/28;;C02F2209/29;;C02F2305/10;;C02F2001/46142;;C02F2103/002;;C02F2209/005;;C02F2001/007;;C02F2103/005;;C02F2201/009;;Y02W10/33;;Y02W10/37;;Y02A20/212;;Y02A20/211;;C02F1/4674;;C02F2103/00;;C02F2201/4611;;C02F2201/4612,C02F1/467,,0,0,,,,PENDING
910,GB,A,GB 2385595 A,194-814-581-613-970,2003-08-27,2003,GB 0228514 A,2002-12-06,US 12137002 A;;US 35922202 P,2002-02-22,Chemical mechanical polishing of dual orientation polycrystalline materials,"A chemical mechanical polishing (CMP) process using a chemically active slurry having a polarity selected to affect the relative oxidation rates of respective crystalline planes of a polycrystalline surface being polished. The slurry polarity is controlled to equilibrate the material removal rates from the respective crystalline planes during the CMP process. A polar or non-polar solute may be added to a base solvent to achieve the desired polarity. A CMP process for a tungsten film may utilize a water-based slurry containing an abrasive agent, an oxidizing agent, and a solute having a polarity less than that of water. The abrasive agent may be colloidal silica, the oxidizing agent may be hydrogen peroxide, and the solute may be benzene.",AGERE SYSTEMS INC,ANTONELL MICHAEL;;ANTONELL JENNIFER A;;HOUGE ERIC CHO;;MAYNARD RYAN KEITH;;SIMPSON DARRELL L,,https://lens.org/194-814-581-613-970,Patent Application,no,4,0,8,33,0,B24B37/044;;C09G1/02;;C09G1/02;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;C09K13/00;;H01L21/304;;H01L21/306,C4V V150          V2;;C4V V190          V2;;C4V V2            V2,0,0,,,,EXPIRED
911,US,A1,US 2022/0331987 A1,088-136-205-379-743,2022-10-20,2022,US 202217752177 A,2022-05-24,US 202217752177 A;;US 202217716249 A;;US 202163177141 P;;US 202163255880 P,2021-04-20,"SYSTEMS, METHODS AND APPARATUS FOR TEMPERATURE CONTROL AND ACTIVE COOLING OF AN INSPECTION ROBOT","Systems, methods, and apparatus for temperature control and active cooling of an inspection robot are disclosed. An example apparatus may include a temperature determination circuit to interpret an inspection temperature value, a temperature management circuit to determine a temperature management command in response to the inspection temperature value, and a temperature response circuit to provide the temperature management command to a temperature management device associated with an inspection robot.",GECKO ROBOTICS INC,BRYNER EDWARD A;;JOURDE DILLON R;;CHO EDWIN H;;CHO MARK;;BINGER MICHAEL A;;LOW KEVIN Y;;WESTENBERG SAMUEL THEODORE;;TROGU FRANCESCO H,GECKO ROBOTICS INC (2022-04-11),https://lens.org/088-136-205-379-743,Patent Application,yes,0,8,24,24,0,B62D57/024;;G01N29/225;;G01N29/265;;G01N2291/0237;;G01N2291/02854;;G01N29/043;;G05B2219/45066;;B25J9/1694;;B25J9/1692;;B25J9/1666;;B60K7/00;;B60K7/0007;;B25J9/1653;;B25J19/027;;B25J13/087;;B25J9/0009;;B25J9/1694;;G01N29/04;;G01N29/226;;G01N29/265;;G01N2291/0289;;G01N2291/2698;;B25J9/1617;;B25J9/163;;B25J9/1664;;B25J9/1674;;B25J13/006;;B25J5/007;;B25J19/021;;B60K1/02;;B62D53/02;;B62D57/024;;B60B19/006;;B60B19/12;;B60B2360/104;;B60B2360/109;;B60B2900/931;;B60B2360/102;;G06F1/206;;G06F2200/201;;H05K1/18;;H05K2201/10151,B25J13/08;;B25J9/00;;B25J9/16;;B25J19/02,,0,0,,,,PENDING
912,KR,A,KR 20170128258 A,001-701-192-159-436,2017-11-22,2017,KR 20177024405 A,2016-03-08,US 201514656967 A;;US 2016/0021320 W,2015-03-13,반응열을 제거하는 기화를 이용하는 공기압으로 교반된 이온성 액체 촉매화된 발열성 탄화수소 변환 반응,"이온성 액체 반응기로부터 반응열을 제거하고 그 내부에서 혼합을 제공하기 위해 기화를 이용하여 이온성 액체 촉매화된 탄화수소 변환, 예컨대 알킬화를 위한 시스템들 및 장치, 탄화수소 증기들은 이온성 액체 반응기로부터 회수되고 회수된 탄화수소 증기는 응결된 탄화수소들을 이온성 액체 반응기로 재순환시키기 위해 이온성 액체 반응기와 유체 연통하는 탄화수소 증기 재활용 유닛에 의해 재생된다. 이온성 액체 촉매화된 알킬화를 위한 프로세스들이 또한 개시된다.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYOUNG CHO;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;CHANG BONG KYU,,https://lens.org/001-701-192-159-436,Patent Application,no,8,0,12,12,0,C07C2/58;;C10G50/00;;C10G29/205;;C10G2300/1088;;C07C2/58;;C10G19/00;;C10G21/00;;C10G29/205;;C07C2/58;;C10G2300/1088;;C07C2/58;;C10G29/205;;C10G2300/1088,C10G29/20;;C07C2/58,,0,0,,,,ACTIVE
913,US,B2,US 9796642 B2,042-834-544-603-112,2017-10-24,2017,US 201514656967 A,2015-03-13,US 201514656967 A,2015-03-13,Pneumatically agitated ionic liquid alkylation using vaporization to remove reaction heat,"Systems and apparatus for ionic liquid catalyzed hydrocarbon conversion, such as alkylation, using vaporization to remove reaction heat from an ionic liquid reactor and to provide mixing therein, wherein hydrocarbon vapors are withdrawn from the ionic liquid reactor and the withdrawn hydrocarbon vapor is recovered by a hydrocarbon vapor recovery unit in fluid communication with the ionic liquid reactor for recycling condensed hydrocarbons to the ionic liquid reactor. Processes for ionic liquid catalyzed alkylation are also disclosed.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;CHANG BONG-KYU,CHEVRON U.S.A. INC (2015-03-11),https://lens.org/042-834-544-603-112,Granted Patent,yes,9,0,12,12,0,C07C2/58;;C10G50/00;;C10G29/205;;C10G2300/1088;;C07C2/58;;C10G19/00;;C10G21/00;;C10G29/205;;C07C2/58;;C10G2300/1088;;C07C2/58;;C10G29/205;;C10G2300/1088,C07C2/58;;C07C9/00;;C10G29/20,,2,1,119-970-177-250-228,10.1016/j.catcom.2012.04.022,"Xing, X. et al., Isobutane alkylation using acidic ionic liquid catalysts., Catalyst Communications. 2012. vol. 26, pp. 68-71.;;Al-Azzi, et al., Influence of Draft Tube Diameter on Operation Behavior of Air Loop Reactors, Al-Khwarizmi Engineering Journal, vol. 6, No. 2, pp. 21-32 (2010).",ACTIVE
914,WO,A1,WO 2016/148971 A1,123-370-854-339-015,2016-09-22,2016,US 2016/0021315 W,2016-03-08,US 201514656950 A,2015-03-13,PNEUMATICALLY AGITATED IONIC LIQUID ALKYLATION USING VAPORIZATION TO REMOVE REACTION HEAT,"Systems and apparatus for ionic liquid catalyzed hydrocarbon conversion, such as alkylation, using vaporization to remove reaction heat from an ionic liquid reactor and to provide mixing therein, wherein hydrocarbon vapors are withdrawn from the ionic liquid reactor and the withdrawn hydrocarbon vapor is recovered by a hydrocarbon vapor recovery unit in fluid communication with the ionic liquid reactor for recycling condensed hydrocarbons to the ionic liquid reactor. Processes for ionic liquid catalyzed alkylation are also disclosed.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;CHANG BONG-KYU,,https://lens.org/123-370-854-339-015,Patent Application,yes,9,0,3,3,0,B01J19/2465;;B01J4/002;;B01J4/004;;C07C2/58;;B01J2219/00047;;B01J2219/00108;;B01J2219/182;;B01J2219/185;;B01J2219/1943;;C07C2527/125;;B01J19/0013;;B01J2219/00103;;B01J2219/0011;;B01J19/246;;B01J19/26;;B01J19/0013;;B01J2219/00103;;B01J2219/0011;;B01J2219/24;;B01J19/2405;;B01J19/246;;B01J4/002;;C07C2/58;;B01J2219/182;;B01J19/2465;;B01J2219/00047;;B01J4/004;;B01J2219/185;;C07C2527/125;;B01J2219/1943;;B01J2219/00108,B01J19/24;;B01J19/26;;C07C2/58,,0,0,,,,PENDING
915,EP,A1,EP 3194022 A1,149-097-348-500-987,2017-07-26,2017,EP 15742479 A,2015-07-14,US 201462025716 P;;US 201514645038 A;;US 2015/0040298 W,2014-07-17,MULTI-CHAMBER INTRACARDIAC PACING SYSTEM,,MEDTRONIC INC,CHO YONG K;;DEMMER WADE M;;EGGEN MICHAEL D;;HILPISCH KATHRYN;;HESS MICHAEL F;;SHELDON TODD J;;GREENHUT SAUL E,,https://lens.org/149-097-348-500-987,Patent Application,yes,0,0,13,13,0,A61B5/686;;A61N1/36;;A61N1/3622;;A61N1/36592;;A61N1/3706;;A61N1/37205;;A61N1/3756;;A61B5/4836;;A61N1/3682;;A61N1/3688;;A61B5/363;;A61B5/349;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318;;A61N1/3706;;A61N1/36592;;A61N1/3622;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318,A61N1/375;;A61B5/363;;A61N1/36,,0,0,,,,ACTIVE
916,WO,A1,WO 2016/148974 A1,178-348-452-975-144,2016-09-22,2016,US 2016/0021320 W,2016-03-08,US 201514656967 A,2015-03-13,PNEUMATICALLY AGITATED IONIC LIQUID ALKYLATION USING VAPORIZATION TO REMOVE REACTION HEAT,"Systems and apparatus for ionic liquid catalyzed hydrocarbon conversion, such as alkylation, using vaporization to remove reaction heat from an ionic liquid reactor and to provide mixing therein, wherein hydrocarbon vapors are withdrawn from the ionic liquid reactor and the withdrawn hydrocarbon vapor is recovered by a hydrocarbon vapor recovery unit in fluid communication with the ionic liquid reactor for recycling condensed hydrocarbons to the ionic liquid reactor. Processes for ionic liquid catalyzed alkylation are also disclosed.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;CHANG BONG-KYU,,https://lens.org/178-348-452-975-144,Patent Application,yes,4,0,12,12,0,C07C2/58;;C10G50/00;;C10G29/205;;C10G2300/1088;;C07C2/58;;C10G19/00;;C10G21/00;;C10G29/205;;C07C2/58;;C10G2300/1088;;C07C2/58;;C10G29/205;;C10G2300/1088,C10G21/00;;C10G19/00,,1,1,119-970-177-250-228,10.1016/j.catcom.2012.04.022,"XING, X. ET AL.: ""Isobutane alkylation using acidic ionic liquid catalysts."", CATALYST COMMUNICATIONS., vol. 26, September 2012 (2012-09-01), pages 68 - 71, XP055239246",PENDING
917,GB,A,GB 2551666 A,117-917-894-312-342,2017-12-27,2017,GB 201713788 A,2016-03-08,US 2016/0021320 W;;US 201514656967 A,2015-03-13,Pneumatic agitated ionic liquid alkylation using vaporization to remove reaction heat,"Systems and apparatus for ionic liquid catalyzed hydrocarbon conversion, such as alkylation, using vaporization to remove reaction heat from an ionic liquid reactor and to provide mixing therein, wherein hydrocarbon vapors are withdrawn from the ionic liquid reactor and the withdrawn hydrocarbon vapor is recovered by a hydrocarbon vapor recovery unit in fluid communication with the ionic liquid reactor for recycling condensed hydrocarbons to the ionic liquid reactor. Processes for ionic liquid catalyzed alkylation are also disclosed.",CHEVRON USA INC,DONALD HENRY MOHR;;HUPING LUO;;CLIFFORD MICHAEL LOWE;;HYE KYUNG CHO TIMKEN;;KRISHNIAH PARIMI;;MICHAEL JOHN GIRGIS;;BONG-KYU CHANG,,https://lens.org/117-917-894-312-342,Patent Application,no,4,0,12,12,0,C07C2/58;;C10G50/00;;C10G29/205;;C10G2300/1088;;C07C2/58;;C10G19/00;;C10G21/00;;C10G29/205;;C07C2/58;;C10G2300/1088;;C07C2/58;;C10G29/205;;C10G2300/1088,C10G21/00;;C10G19/00,,1,1,119-970-177-250-228,10.1016/j.catcom.2012.04.022,"XUEQI XING, GUOYING ZHAO, JIANZHONG CUI, SUOJIANG ZHANG: ""Isobutane alkylation using acidic ionic liquid catalysts"", CATALYSIS COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 26, 1 September 2012 (2012-09-01), AMSTERDAM, NL, pages 68 - 71, XP055239246, ISSN: 1566-7367, DOI: 10.1016/j.catcom.2012.04.022",DISCONTINUED
918,CA,A1,CA 2976703 A1,126-751-117-042-789,2016-09-22,2016,CA 2976703 A,2016-03-08,US 201514656967 A;;US 2016/0021320 W,2015-03-13,PNEUMATICALLY AGITATED IONIC LIQUID ALKYLATION USING VAPORIZATION TO REMOVE REACTION HEAT,"Systems and apparatus for ionic liquid catalyzed hydrocarbon conversion, such as alkylation, using vaporization to remove reaction heat from an ionic liquid reactor and to provide mixing therein, wherein hydrocarbon vapors are withdrawn from the ionic liquid reactor and the withdrawn hydrocarbon vapor is recovered by a hydrocarbon vapor recovery unit in fluid communication with the ionic liquid reactor for recycling condensed hydrocarbons to the ionic liquid reactor. Processes for ionic liquid catalyzed alkylation are also disclosed.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;CHANG BONG-KYU,,https://lens.org/126-751-117-042-789,Patent Application,no,0,0,12,12,0,C07C2/58;;C10G50/00;;C10G29/205;;C10G2300/1088;;C07C2/58;;C10G19/00;;C10G21/00;;C10G29/205;;C07C2/58;;C10G2300/1088;;C07C2/58;;C10G29/205;;C10G2300/1088,,,0,0,,,,PENDING
919,US,A1,US 2016/0263547 A1,164-945-970-613-407,2016-09-15,2016,US 201514656950 A,2015-03-13,US 201514656950 A,2015-03-13,PNEUMATICALLY AGITATED IONIC LIQUID ALKYLATION USING VAPORIZATION TO REMOVE REACTION HEAT,"Systems and apparatus for ionic liquid catalyzed hydrocarbon conversion, such as alkylation, using vaporization to remove reaction heat from an ionic liquid reactor and to provide mixing therein, wherein hydrocarbon vapors are withdrawn from the ionic liquid reactor and the withdrawn hydrocarbon vapor is recovered by a hydrocarbon vapor recovery unit in fluid communication with the ionic liquid reactor for recycling condensed hydrocarbons to the ionic liquid reactor. Processes for ionic liquid catalyzed alkylation are also disclosed.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;CHANG BONG-KYU,CHEVRON U.S.A. INC (2012-03-12),https://lens.org/164-945-970-613-407,Patent Application,yes,0,1,3,3,0,B01J19/2465;;B01J4/002;;B01J4/004;;C07C2/58;;B01J2219/00047;;B01J2219/00108;;B01J2219/182;;B01J2219/185;;B01J2219/1943;;C07C2527/125;;B01J19/0013;;B01J2219/00103;;B01J2219/0011;;B01J19/246;;B01J19/26;;B01J19/0013;;B01J2219/00103;;B01J2219/0011;;B01J2219/24;;B01J19/2405;;B01J19/246;;B01J4/002;;C07C2/58;;B01J2219/182;;B01J19/2465;;B01J2219/00047;;B01J4/004;;B01J2219/185;;C07C2527/125;;B01J2219/1943;;B01J2219/00108,B01J19/26;;B01J19/00,,0,0,,,,ACTIVE
920,US,A1,US 2021/0052330 A1,177-752-164-587-057,2021-02-25,2021,US 201917052118 A,2019-05-02,US 201917052118 A;;US 201862666517 P;;US 201862754834 P;;US 2019/0030390 W,2018-05-03,INTEGRATED MEDICAL IMAGING SYSTEM FOR TRACKING OF MICRO-NANO SCALE OBJECTS,"Apparatus and methods for imaging and tracking of nano- and micro-scale objects with acceptable latency for relevant medical procedures, such as delivery of therapeutic payload or minimally invasive surgery are disclosed, including the capability to superimpose accurate anatomical data over a tracking image. Software applications are provided for data logging via a remote-control station; and software interface with remote motion control mechanism, controlling the motion of internal device.",KISELYOV ALEX;;BIONAUT LABS LTD,KISELYOV ALEX;;SHPIGELMACHER MICHAEL;;SHENKAR DINA;;OREN ERAN;;KARDOSH MICHAEL;;ELNEKAVE ELDAD;;GAO EDWARD;;CHO SUEHYUN;;CAPUTO JOHN;;SEELY DENNIS,BIONAUT LABS LTD (2018-12-04),https://lens.org/177-752-164-587-057,Patent Application,yes,1,3,5,5,0,A61B8/4416;;A61B8/461;;A61B8/481;;A61B5/0071;;A61K49/0091;;A61K49/1818;;A61K49/223;;A61K49/04;;A61B34/20;;A61B2034/2055;;A61B2034/2063;;A61B5/0071;;A61B5/0077;;A61B5/0515;;A61B6/032;;A61B6/463;;A61B8/0833;;A61B8/461;;A61B8/488;;A61B8/5269,A61B34/20;;A61B5/00;;A61B5/05;;A61B6/00;;A61B6/03;;A61B8/00;;A61B8/08,,0,0,,,,PENDING
921,CA,C,CA 2976703 C,080-162-683-012-055,2022-08-30,2022,CA 2976703 A,2016-03-08,US 201514656967 A;;US 2016/0021320 W,2015-03-13,PNEUMATICALLY AGITATED IONIC LIQUID ALKYLATION USING VAPORIZATION TO REMOVE REACTION HEAT,"Systems and apparatus for ionic liquid catalyzed hydrocarbon conversion, such as alkylation, using vaporization to remove reaction heat from an ionic liquid reactor and to provide mixing therein, wherein hydrocarbon vapors are withdrawn from the ionic liquid reactor and the withdrawn hydrocarbon vapor is recovered by a hydrocarbon vapor recovery unit in fluid communication with the ionic liquid reactor for recycling condensed hydrocarbons to the ionic liquid reactor. Processes for ionic liquid catalyzed alkylation are also disclosed.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;CHANG BONG-KYU,,https://lens.org/080-162-683-012-055,Granted Patent,no,0,0,12,12,0,C07C2/58;;C10G50/00;;C10G29/205;;C10G2300/1088;;C07C2/58;;C10G19/00;;C10G21/00;;C10G29/205;;C07C2/58;;C10G2300/1088;;C07C2/58;;C10G29/205;;C10G2300/1088,,,0,0,,,,PENDING
922,EP,A4,EP 3787478 A4,056-440-987-678-689,2022-01-26,2022,EP 19795784 A,2019-05-02,US 201862666517 P;;US 201862754834 P;;US 2019/0030390 W,2018-05-03,INTEGRATED MEDICAL IMAGING SYSTEM FOR TRACKING OF MICRO-NANO SCALE OBJECTS,,BIONAUT LABS LTD;;KISELYOV ALEX,SHPIGELMACHER MICHAEL;;SHENKAR DINA;;OREN ERAN;;KARDOSH MICHAEL;;ELNEKAVE ELDAD;;GAO EDWARD;;CHO SUEHYUN;;CAPUTO JOHN;;SEELY DENNIS;;KISELYOV ALEX,,https://lens.org/056-440-987-678-689,Search Report,no,2,0,5,5,0,A61B8/4416;;A61B8/461;;A61B8/481;;A61B5/0071;;A61K49/0091;;A61K49/1818;;A61K49/223;;A61K49/04;;A61B34/20;;A61B2034/2055;;A61B2034/2063;;A61B5/0071;;A61B5/0077;;A61B5/0515;;A61B6/032;;A61B6/463;;A61B8/0833;;A61B8/461;;A61B8/488;;A61B8/5269,A61B5/00;;A61B5/06;;A61B8/00;;A61B8/08;;A61B8/13;;A61K49/00;;A61K49/22,,2,1,030-066-085-073-962,10.1038/srep06562;;25297843;;pmc4190509,"SHENG YANG ET AL: ""Rare-Earth Doped Particles as Dual-Modality Contrast Agent for Minimally-Invasive Luminescence and Dual-Wavelength Photoacoustic Imaging"", SCIENTIFIC REPORTS, 9 October 2014 (2014-10-09), England, pages 1 - 8, XP055874778, Retrieved from the Internet <URL:https://www.nature.com/articles/srep06562.pdf> [retrieved on 20211220], DOI: 10.1038/srep06562;;See also references of WO 2019213389A1",DISCONTINUED
923,JP,A,JP 2000003831 A,129-696-748-842-600,2000-01-07,2000,JP 11836799 A,1999-04-26,US 8312198 P,1998-04-27,POWER TRANSMISSION SUBSTRATE WITH INTEGRATED SUBSTRATE CAPACITOR HAVING HIGH YIELD,"PROBLEM TO BE SOLVED: To improve reliability by arranging an insulating layer and a patch around the selected region of the main section dielectric layer of a capacitor, and incorporating low impedance connection with a lower electrode into a capacitor structure. SOLUTION: The substrate capacitor 10 has a base conductive substrate (a substrate) 12 and a plurality of projecting body section contacts (contacts) 20, and the substrate 12 and the contacts 20 are electrically connected mutually. The layer 14 of a material capable of being conductive-anodized is formed among the substrate 12 and the contacts 20. The substrate capacitor 10 has main-section dielectric layers 34 and a large number of multilayer capacitor substrates 30, and thin conductive layers 32, 33 are formed on the lower sides of the layers 34 and used as the lower electrodes of capacitor structures 30. The layer 14, the layers 32, 33 and the substrate 12 integrally constitute the lower electrodes of the substrate capacitor, and the contacts 20 are brought into contact electrically with the lower electrodes from top faces. Conductive layers 35 are formed onto the layers 34 and employed as the upper electrodes of the capacitor structures 30, and the layers 35 and the layers 40 integrally configure the upper electrodes of the substrate capacitor 10.",FUJITSU LTD,BEILIN SOLOMON I;;WILLIAM T CHO;;MICHAEL G LEE;;DAVID DUNN NOGO;;PETERS MICHAEL G;;JAMES J ROMAN;;TAKAHASHI YASUHITO,,https://lens.org/129-696-748-842-600,Patent Application,no,0,2,3,3,0,H01L23/50;;H01L23/5383;;H01L2924/3011;;H05K1/056;;H05K1/162;;H05K3/045;;H05K3/388;;H05K3/44;;H05K2201/0154;;H05K2201/0195;;H05K2201/09481;;H05K2201/09509;;H05K2201/09554;;H05K2203/0315;;H01L2924/0002;;H01L23/50;;H05K2201/09554;;H05K1/056;;H05K2201/0154;;H05K3/045;;H01L23/5383;;H05K2201/09509;;H05K1/162;;H05K3/388;;H05K2203/0315;;H05K3/44;;H01L2924/3011;;H05K2201/09481;;H05K2201/0195;;H01L2924/0002,H01L21/822;;H01L23/50;;H01L23/538;;H01L27/01;;H01L27/04;;H01G4/33;;H05K1/05;;H05K1/16;;H05K3/04;;H05K3/38;;H05K3/44,,0,0,,,,EXPIRED
924,US,B2,US 9545614 B2,165-054-887-736-200,2017-01-17,2017,US 201514656950 A,2015-03-13,US 201514656950 A,2015-03-13,Pneumatically agitated ionic liquid alkylation using vaporization to remove reaction heat,"Systems and apparatus for ionic liquid catalyzed hydrocarbon conversion, such as alkylation, using vaporization to remove reaction heat from an ionic liquid reactor and to provide mixing therein, wherein hydrocarbon vapors are withdrawn from the ionic liquid reactor and the withdrawn hydrocarbon vapor is recovered by a hydrocarbon vapor recovery unit in fluid communication with the ionic liquid reactor for recycling condensed hydrocarbons to the ionic liquid reactor. Processes for ionic liquid catalyzed alkylation are also disclosed.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;CHANG BONG-KYU,CHEVRON U.S.A. INC (2012-03-12),https://lens.org/165-054-887-736-200,Granted Patent,yes,14,5,3,3,0,B01J19/2465;;B01J4/002;;B01J4/004;;C07C2/58;;B01J2219/00047;;B01J2219/00108;;B01J2219/182;;B01J2219/185;;B01J2219/1943;;C07C2527/125;;B01J19/0013;;B01J2219/00103;;B01J2219/0011;;B01J19/246;;B01J19/26;;B01J19/0013;;B01J2219/00103;;B01J2219/0011;;B01J2219/24;;B01J19/2405;;B01J19/246;;B01J4/002;;C07C2/58;;B01J2219/182;;B01J19/2465;;B01J2219/00047;;B01J4/004;;B01J2219/185;;C07C2527/125;;B01J2219/1943;;B01J2219/00108,B01J19/24;;B01J19/00;;B01J19/26,,1,0,,,"Al-Azzi, et al., Influence of Draft Tube Diameter on Operation Behavior of Air Loop Reactors, Al-Khwarizmi Engineering Journal, vol. 6, No. 2, pp. 21-32 (2010).",ACTIVE
925,WO,A1,WO 2016/010976 A1,167-337-390-911-029,2016-01-21,2016,US 2015/0040298 W,2015-07-14,US 201462025716 P;;US 201514645038 A,2014-07-17,MULTI-CHAMBER INTRACARDIAC PACING SYSTEM,A medical device system including at least a first implantable medical device and a second implantable medical device is configured to establish by a control module of the first implantable medical device whether the second implantable medical device is present in a patient and self-configure an operating mode of the control module in response to establishing that the second implantable medical device is present.,MEDTRONIC INC,CHO YONG K;;DEMMER WADE M;;EGGEN MICHAEL D;;HILPISCH KATHRYN;;HESS MICHAEL F;;SHELDON TODD J;;GREENHUT SAUL E,,https://lens.org/167-337-390-911-029,Patent Application,yes,23,3,13,13,0,A61B5/686;;A61N1/36;;A61N1/3622;;A61N1/36592;;A61N1/3706;;A61N1/37205;;A61N1/3756;;A61B5/4836;;A61N1/3682;;A61N1/3688;;A61B5/363;;A61B5/349;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318;;A61N1/3706;;A61N1/36592;;A61N1/3622;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318,A61N1/375;;A61B5/363;;A61N1/36,,0,0,,,,PENDING
926,EP,A1,EP 3787478 A1,138-265-487-542-627,2021-03-10,2021,EP 19795784 A,2019-05-02,US 201862666517 P;;US 201862754834 P;;US 2019/0030390 W,2018-05-03,INTEGRATED MEDICAL IMAGING SYSTEM FOR TRACKING OF MICRO-NANO SCALE OBJECTS,,BIONAUT LABS LTD;;KISELYOV ALEX,SHPIGELMACHER MICHAEL;;SHENKAR DINA;;OREN ERAN;;KARDOSH MICHAEL;;ELNEKAVE ELDAD;;GAO EDWARD;;CHO SUEHYUN;;CAPUTO JOHN;;SEELY DENNIS;;KISELYOV ALEX,,https://lens.org/138-265-487-542-627,Patent Application,yes,0,0,5,5,0,A61B8/4416;;A61B8/461;;A61B8/481;;A61B5/0071;;A61K49/0091;;A61K49/1818;;A61K49/223;;A61K49/04;;A61B34/20;;A61B2034/2055;;A61B2034/2063;;A61B5/0071;;A61B5/0077;;A61B5/0515;;A61B6/032;;A61B6/463;;A61B8/0833;;A61B8/461;;A61B8/488;;A61B8/5269,A61B5/00;;A61B5/06;;A61B8/08;;A61B8/13;;A61K49/00;;A61K49/22,,0,0,,,,DISCONTINUED
927,CN,A,CN 107429170 A,195-775-189-901-887,2017-12-01,2017,CN 201680015400 A,2016-03-08,US 201514656967 A;;US 2016/0021320 W,2015-03-13,PNEUMATICALLY AGITATED IONIC LIQUID ALKYLATION USING VAPORIZATION TO REMOVE REACTION HEAT,"Systems and apparatus for ionic liquid catalyzed hydrocarbon conversion, such as alkylation, using vaporization to remove reaction heat from an ionic liquid reactor and to provide mixing therein, wherein hydrocarbon vapors are withdrawn from the ionic liquid reactor and the withdrawn hydrocarbon vapor is recovered by a hydrocarbon vapor recovery unit in fluid communication with the ionic liquid reactor for recycling condensed hydrocarbons to the ionic liquid reactor. Processes for ionic liquid catalyzed alkylation are also disclosed.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;CHANG BONG-KYU,,https://lens.org/195-775-189-901-887,Patent Application,no,5,0,12,12,0,C07C2/58;;C10G50/00;;C10G29/205;;C10G2300/1088;;C07C2/58;;C10G19/00;;C10G21/00;;C10G29/205;;C07C2/58;;C10G2300/1088;;C07C2/58;;C10G29/205;;C10G2300/1088,C10G50/00;;C07C2/58,,0,0,,,,ACTIVE
928,CN,A,CN 106535988 A,018-651-495-441-214,2017-03-22,2017,CN 201580038861 A,2015-07-14,US 201462025716 P;;US 201514645038 A;;US 2015/0040298 W,2014-07-17,Multi-chamber intracardiac pacing system,A medical device system including at least a first implantable medical device and a second implantable medical device is configured to establish by a control module of the first implantable medical device whether the second implantable medical device is present in a patient and self-configure an operating mode of the control module in response to establishing that the second implantable medical device is present.,MEDTRONIC INC,CHO YONG K;;DEMMER WADE M;;EGGEN MICHAEL D;;HILPISCH KATHRYN;;HESS MICHAEL F;;SHELDON TODD J;;GREENHUT SAUL E,,https://lens.org/018-651-495-441-214,Patent Application,no,5,1,13,13,0,A61B5/686;;A61N1/36;;A61N1/3622;;A61N1/36592;;A61N1/3706;;A61N1/37205;;A61N1/3756;;A61B5/4836;;A61N1/3682;;A61N1/3688;;A61B5/363;;A61B5/349;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318;;A61N1/3706;;A61N1/36592;;A61N1/3622;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318,A61N1/37;;A61B5/363;;A61N1/365;;A61N1/375,,0,0,,,,ACTIVE
929,US,B2,US 9981135 B2,086-192-145-465-036,2018-05-29,2018,US 201514645038 A,2015-03-11,US 201514645038 A;;US 201462025716 P,2014-07-17,Multi-chamber intracardiac pacing system,A medical device system including at least a first implantable medical device and a second implantable medical device is configured to establish by a control module of the first implantable medical device whether the second implantable medical device is present in a patient and self-configure an operating mode of the control module in response to establishing that the second implantable medical device is present.,MEDTRONIC INC,CHO YONG K;;DEMMER WADE M;;EGGEN MICHAEL D;;HILPISCH KATHRYN;;HESS MICHAEL F;;SHELDON TODD J;;GREENHUT SAUL E,MEDTRONIC INC (2015-03-10),https://lens.org/086-192-145-465-036,Granted Patent,yes,27,0,13,13,0,A61B5/686;;A61N1/36;;A61N1/3622;;A61N1/36592;;A61N1/3706;;A61N1/37205;;A61N1/3756;;A61B5/4836;;A61N1/3682;;A61N1/3688;;A61B5/363;;A61B5/349;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318;;A61N1/3706;;A61N1/36592;;A61N1/3622;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318,A61N1/37;;A61B5/00;;A61B5/363;;A61N1/36;;A61N1/362;;A61N1/365;;A61N1/372;;A61N1/375,,1,0,,,"(PCT/US2015/040298) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Sep. 228, 2015, 10 pages.",ACTIVE
930,EP,B1,EP 3194022 B1,164-366-405-114-019,2018-09-26,2018,EP 15742479 A,2015-07-14,US 201462025716 P;;US 201514645038 A;;US 2015/0040298 W,2014-07-17,MULTI-CHAMBER INTRACARDIAC PACING SYSTEM,,MEDTRONIC INC,CHO YONG K;;DEMMER WADE M;;EGGEN MICHAEL D;;HILPISCH KATHRYN;;HESS MICHAEL F;;SHELDON TODD J;;GREENHUT SAUL E,,https://lens.org/164-366-405-114-019,Granted Patent,yes,4,0,13,13,0,A61B5/686;;A61N1/36;;A61N1/3622;;A61N1/36592;;A61N1/3706;;A61N1/37205;;A61N1/3756;;A61B5/4836;;A61N1/3682;;A61N1/3688;;A61B5/363;;A61B5/349;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318;;A61N1/3706;;A61N1/36592;;A61N1/3622;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318,A61N1/375;;A61B5/00;;A61B5/363;;A61N1/36;;A61N1/362;;A61N1/365;;A61N1/37;;A61N1/372,,0,0,,,,ACTIVE
931,US,A1,US 2016/0015985 A1,023-803-349-295-264,2016-01-21,2016,US 201514645038 A,2015-03-11,US 201514645038 A;;US 201462025716 P,2014-07-17,MULTI-CHAMBER INTRACARDIAC PACING SYSTEM,A medical device system including at least a first implantable medical device and a second implantable medical device is configured to establish by a control module of the first implantable medical device whether the second implantable medical device is present in a patient and self-configure an operating mode of the control module in response to establishing that the second implantable medical device is present.,MEDTRONIC INC,CHO YONG K;;DEMMER WADE M;;EGGEN MICHAEL D;;HILPISCH KATHRYN;;HESS MICHAEL F;;SHELDON TODD J;;GREENHUT SAUL E,MEDTRONIC INC (2015-03-10),https://lens.org/023-803-349-295-264,Patent Application,yes,1,21,13,13,0,A61B5/686;;A61N1/36;;A61N1/3622;;A61N1/36592;;A61N1/3706;;A61N1/37205;;A61N1/3756;;A61B5/4836;;A61N1/3682;;A61N1/3688;;A61B5/363;;A61B5/349;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318;;A61N1/3706;;A61N1/36592;;A61N1/3622;;A61N1/3756;;A61N1/37205;;A61B5/686;;A61B5/363;;A61B5/318,A61N1/37;;A61B5/363;;A61N1/362;;A61N1/365,,0,0,,,,ACTIVE
932,US,A1,US 2016/0264494 A1,115-518-361-949-868,2016-09-15,2016,US 201514656967 A,2015-03-13,US 201514656967 A,2015-03-13,PNEUMATICALLY AGITATED IONIC LIQUID ALKYLATION USING VAPORIZATION TO REMOVE REACTION HEAT,"Systems and apparatus for ionic liquid catalyzed hydrocarbon conversion, such as alkylation, using vaporization to remove reaction heat from an ionic liquid reactor and to provide mixing therein, wherein hydrocarbon vapors are withdrawn from the ionic liquid reactor and the withdrawn hydrocarbon vapor is recovered by a hydrocarbon vapor recovery unit in fluid communication with the ionic liquid reactor for recycling condensed hydrocarbons to the ionic liquid reactor. Processes for ionic liquid catalyzed alkylation are also disclosed.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;TIMKEN HYE KYUNG CHO;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;CHANG BONG-KYU,CHEVRON U.S.A. INC (2015-03-11),https://lens.org/115-518-361-949-868,Patent Application,yes,2,4,12,12,0,C07C2/58;;C10G50/00;;C10G29/205;;C10G2300/1088;;C07C2/58;;C10G19/00;;C10G21/00;;C10G29/205;;C07C2/58;;C10G2300/1088;;C07C2/58;;C10G29/205;;C10G2300/1088,C07C2/58,,0,0,,,,ACTIVE
933,DE,T5,DE 112016001182 T5,148-427-269-293-935,2017-11-30,2017,DE 112016001182 T,2016-03-08,US 201514656967 A;;US 2016/0021320 W,2015-03-13,Pneumatisch bewegte Alkylierung mit ionischer Flüssigkeit unter Verwendung von Verdampfung zur Entfernung von Reaktionshitze,"Systeme und Vorrichtung zur Umwandlung von durch ionische Flüssigkeit katalysiertem Kohlenwasserstoff, zum Beispiel Alkylierung, unter Verwendung von Verdampfung zur Entfernung von Reaktionswärme aus einem Reaktor für ionische Flüssigkeiten und zum Bereitstellen eines Mischens darin, wobei die Kohlenwasserstoffdämpfe dem Reaktor für ionische Flüssigkeiten entzogen werden und der entzogene Kohlenwasserstoffdampf über eine Rückgewinnungseinheit für Kohlenwasserstoffdampf in Fluidverbindung mit dem Reaktor für ionische Flüssigkeiten zum Rückführen kondensierter Kohlenwasserstoffe an den Reaktor für ionische Flüssigkeiten zurückgeführt wird. Verfahren zur durch ionische Flüssigkeit katalysierten Alkylierung werden ebenfalls offenbart.",CHEVRON USA INC,MOHR DONALD HENRY;;LUO HUPING;;LOWE CLIFFORD MICHAEL;;PARIMI KRISHNIAH;;GIRGIS MICHAEL JOHN;;TIMKEN HYE KYUNG CHO;;CHANG BONG-KYU,,https://lens.org/148-427-269-293-935,Patent Application,no,0,0,12,12,0,C07C2/58;;C10G50/00;;C10G29/205;;C10G2300/1088;;C07C2/58;;C10G19/00;;C10G21/00;;C10G29/205;;C07C2/58;;C10G2300/1088;;C07C2/58;;C10G29/205;;C10G2300/1088,C10G21/00;;C10G19/00,,0,0,,,,PENDING
934,WO,A1,WO 2019/213389 A1,142-528-931-841-989,2019-11-07,2019,US 2019/0030390 W,2019-05-02,US 201862666517 P;;US 201862754834 P,2018-05-03,INTEGRATED MEDICAL IMAGING SYSTEM FOR TRACKING OF MICRO-NANO SCALE OBJECTS,"Apparatus and methods for imaging and tracking of nano- and micro- scale objects with acceptable latency for relevant medical procedures, such as delivery of therapeutic payload or minimally invasive surgery are disclosed, including the capability to superimpose accurate anatomical data over a tracking image. Software applications are provided for data logging via a remote-control station; and software interface with remote motion control mechanism, controlling the motion of internal device.",BIONAUT LABS LTD;;KISELYOV ALEX,KISELYOV ALEX;;SHPIGELMACHER MICHAEL;;SHENKAR DINA;;OREN ERAN;;KARDOSH MICHAEL;;ELNEKAVE ELDAD;;GAO EDWARD;;CHO SUEHYUN;;CAPUTO JOHN;;SEELY DENNIS,,https://lens.org/142-528-931-841-989,Patent Application,yes,4,2,5,5,0,A61B8/4416;;A61B8/461;;A61B8/481;;A61B5/0071;;A61K49/0091;;A61K49/1818;;A61K49/223;;A61K49/04;;A61B34/20;;A61B2034/2055;;A61B2034/2063;;A61B5/0071;;A61B5/0077;;A61B5/0515;;A61B6/032;;A61B6/463;;A61B8/0833;;A61B8/461;;A61B8/488;;A61B8/5269,A61B5/00;;A61B5/06;;A61B8/08;;A61B8/13;;A61K49/00;;A61K49/22,,4,3,015-459-490-729-025;;067-006-607-919-936;;038-814-268-218-644,10.1038/s41598-017-10095-6;;pmc5573356;;28842662;;10.1109/tuffc.2017.2778941;;29389649;;pmc5798010;;10.1021/acsami.5b08802;;26484385,"PREGLER, B ET AL.: ""Low tube voltage liver MDCT with sinogram-affirmed iterative reconstructions for the detection of hepatocellular carcinoma"", SCIENTIFIC REPORTS, vol. 7, no. 1, 25 August 2017 (2017-08-25), pages 9460, XP055649763;;SONG, P ET AL.: ""Improved super-resolution ultrasound microvessel imaging with spatiotemporal nonlocal means filtering and bipartite graph-based microbubble tracking"", IEEE TRANS ULTRASON FERROELECTR FREQ CONTROL, vol. 65, no. 2, 5 February 2018 (2018-02-05), XP011676446, DOI: 10.1109/TUFFC.2017.2778941;;WANG, X ET AL.: ""Tri-functional nanocomposites incorporated with Fe304/iodine-containing rare earth complex for CT, MR, and optical imaging"", APPLIED MATERIALS AND INTERFACES, vol. 7, no. 44, 19 October 2015 (2015-10-19), pages 24523 - 24532, XP055649776;;See also references of EP 3787478A4",PENDING
935,JP,A,JP 2011014932 A,088-970-271-776-557,2011-01-20,2011,JP 2010227017 A,2010-10-06,US 10372698 P;;US 29543199 A,1998-10-09,"MULTILAYER PHOTOELECTRIC SUBSTRATE WITH ELECTRICAL INTERCONNECTION AND OPTICAL INTERCONNECTION, AND METHOD FOR MANUFACTURING THE SAME","PROBLEM TO BE SOLVED: To provide a photoelectric substrate for achieving electrical interconnection and optical interconnection without using a driver circuit or an amplifier circuit.SOLUTION: The substrate includes: a first layer having a polymer waveguide formed therein; a second layer having a polymer waveguide formed therein; a first vertical type optical coupler formed in the first layer and optically connected to the first waveguide in the first layer; and a second vertical type optical coupler formed in the second layer and optically connected to the second waveguide in the second layer, wherein the first vertical type optical coupler is arranged adjacent to the second vertical type optical coupler to couple light between the first waveguide and the second waveguide.",FUJITSU LTD,YOSHIMURA TETSUZO;;TAKAHASHI YASUHITO;;INAO MASAAKI;;MICHAEL G LEE;;WILLIAM CHO;;BEILIN SOLOMON I;;WEN CHO VINCENT WANG;;JAMES J ROMAN;;THOMAS J MASSINGIL,,https://lens.org/088-970-271-776-557,Patent Application,no,1,16,5,14,0,G02B6/12002;;G02B6/132;;G02B6/4214;;G02B6/43;;H01L21/6835;;H01L23/48;;H01L23/5389;;H01L24/82;;H01L25/167;;H01L2221/68345;;H01L2221/6835;;H01L2221/68359;;H01L2221/68368;;H01L2224/16225;;H01L2924/01004;;H01L2924/0101;;H01L2924/01013;;H01L2924/01015;;H01L2924/01018;;H01L2924/01027;;H01L2924/01029;;H01L2924/0103;;H01L2924/01032;;H01L2924/01039;;H01L2924/01046;;H01L2924/01049;;H01L2924/01074;;H01L2924/01078;;H01L2924/01079;;H01L2924/01082;;H01L2924/10329;;H01L2924/10336;;H01L2924/12044;;H01L2924/14;;H01L2924/19041;;H01L2924/19043;;H01L2924/30105;;H01L2924/3011;;H01L2924/3025;;H01L2924/01005;;H01L2924/01006;;H01L2924/01023;;H01L2924/01024;;H01L2924/01033;;H01L2924/01047;;H01L2924/014;;H01L2924/12041;;H01L2924/10253;;H01L2924/15788;;H01L2924/12043;;H01L2224/05573;;H01L2224/05568;;H01L2224/05147;;H01L2224/05184;;H01L2224/05644;;H01L2224/05647;;H01L2924/3512;;H01L2224/04105;;H01L2224/32225;;H01L2224/73267;;H01L2224/92244;;H01L21/568;;H01L2224/24137;;H01L24/19;;H01L24/05;;G02B6/43;;H01L23/5389;;H01L24/18;;H01L23/48;;G02B6/4214;;H01L24/82;;H01L2924/10329;;H01L2924/14;;H01L2924/12044;;H01L2221/6835;;G02B6/132;;H01L2221/68345;;H01L2924/01074;;H01L2924/3025;;H01L2224/18;;H01L2924/01029;;H01L2924/01018;;H01L2924/01027;;H01L2924/10336;;H01L2924/01032;;H01L2924/3011;;H01L2924/01039;;H01L2924/0103;;H01L2924/19041;;H01L2924/30105;;G02B6/12002;;H01L2224/16225;;H01L2924/19043;;H01L21/6835;;H01L25/167;;H01L2924/01078;;H01L2924/01079;;H01L2924/01082;;H01L2221/68359;;H01L2924/01049;;H01L2221/68368;;H01L2924/01015;;H01L2924/01013;;H01L2924/0101;;H01L2924/01004;;H01L2924/01046;;H01L2924/01023;;H01L2924/014;;H01L2924/01006;;H01L2924/01033;;H01L2924/01024;;H01L2924/01005;;H01L2924/01047;;H01L2924/12041;;H01L2924/10253;;H01L2924/15788;;H01L2924/12043;;H01L2224/05147;;H01L2224/05573;;H01L2224/05568;;H01L2224/05184;;H01L2224/05644;;H01L2224/05647;;H01L2924/3512;;H01L2224/24137;;H01L2224/92244;;H01L2224/32225;;H01L2224/04105;;H01L21/568;;H01L2224/73267,H01L31/12;;G02B6/12;;G02B6/122;;G02B6/132;;G02B6/42;;G02B6/43;;H01L21/60;;H01L21/68;;H01L23/48;;H01L23/538;;H01L25/16,,0,0,,,,INACTIVE
936,JP,A,JP 2000114581 A,030-190-260-233-432,2000-04-21,2000,JP 28738099 A,1999-10-07,US 10372698 P;;US 29543199 A,1998-10-09,"MULTILAYERED PHOTOELECTRON SUBSTRATE WITH ELECTRICAL INTERCOUPLING AND OPTICAL INTERCOUPLING, AND MANUFACTURE THEREOF","PROBLEM TO BE SOLVED: To reduce losses in optical connections and to improve optical coupling efficiency by forming a polymer waveguide integrally with an optical switch and a light receiving element. SOLUTION: An intercoupling substrate 10 includes both inter-chip connections and intra-chip connections for signals from one or more IC chips 1a to 1d using both optical links and electrical paths. The substrate 10 includes a base substrate 12 and an activated layer 20. The layer 20 includes optical waveguides 24a to 24b, photoelectron switching devices 26a to 26c, light receiving devices 28a to 28c, electrical paths 30, and electrical connection pads 32 for the chips 1. The waveguides 24 and the devices 26 and 28 are preferably embedded in the layer 20. Signals between chips are electrically propagated through the paths 30, or optically propagated through the waveguides 24. When a signal is propagated through a waveguide 24 by means of light, the devices 26 and 28 perform a conversion between an optical representation and an electrical representation of the signal.",FUJITSU LTD,YOSHIMURA TETSUZO;;TAKAHASHI YASUHITO;;INAO MASAAKI;;MICHAEL G LEE;;WILLIAM CHO;;BEILIN SOLOMON I;;WEN CHO VINCENT WANG;;JAMES J ROMAN;;THOMAS J MASSINGIL,,https://lens.org/030-190-260-233-432,Patent Application,no,1,47,5,14,0,G02B6/12002;;G02B6/132;;G02B6/4214;;G02B6/43;;H01L21/6835;;H01L23/48;;H01L23/5389;;H01L24/82;;H01L25/167;;H01L2221/68345;;H01L2221/6835;;H01L2221/68359;;H01L2221/68368;;H01L2224/16225;;H01L2924/01004;;H01L2924/0101;;H01L2924/01013;;H01L2924/01015;;H01L2924/01018;;H01L2924/01027;;H01L2924/01029;;H01L2924/0103;;H01L2924/01032;;H01L2924/01039;;H01L2924/01046;;H01L2924/01049;;H01L2924/01074;;H01L2924/01078;;H01L2924/01079;;H01L2924/01082;;H01L2924/10329;;H01L2924/10336;;H01L2924/12044;;H01L2924/14;;H01L2924/19041;;H01L2924/19043;;H01L2924/30105;;H01L2924/3011;;H01L2924/3025;;H01L2924/01005;;H01L2924/01006;;H01L2924/01023;;H01L2924/01024;;H01L2924/01033;;H01L2924/01047;;H01L2924/014;;H01L2924/12041;;H01L2924/10253;;H01L2924/15788;;H01L2924/12043;;H01L2224/05573;;H01L2224/05568;;H01L2224/05147;;H01L2224/05184;;H01L2224/05644;;H01L2224/05647;;H01L2924/3512;;H01L2224/04105;;H01L2224/32225;;H01L2224/73267;;H01L2224/92244;;H01L21/568;;H01L2224/24137;;H01L24/19;;H01L24/05;;G02B6/43;;H01L23/5389;;H01L24/18;;H01L23/48;;G02B6/4214;;H01L24/82;;H01L2924/10329;;H01L2924/14;;H01L2924/12044;;H01L2221/6835;;G02B6/132;;H01L2221/68345;;H01L2924/01074;;H01L2924/3025;;H01L2224/18;;H01L2924/01029;;H01L2924/01018;;H01L2924/01027;;H01L2924/10336;;H01L2924/01032;;H01L2924/3011;;H01L2924/01039;;H01L2924/0103;;H01L2924/19041;;H01L2924/30105;;G02B6/12002;;H01L2224/16225;;H01L2924/19043;;H01L21/6835;;H01L25/167;;H01L2924/01078;;H01L2924/01079;;H01L2924/01082;;H01L2221/68359;;H01L2924/01049;;H01L2221/68368;;H01L2924/01015;;H01L2924/01013;;H01L2924/0101;;H01L2924/01004;;H01L2924/01046;;H01L2924/01023;;H01L2924/014;;H01L2924/01006;;H01L2924/01033;;H01L2924/01024;;H01L2924/01005;;H01L2924/01047;;H01L2924/12041;;H01L2924/10253;;H01L2924/15788;;H01L2924/12043;;H01L2224/05147;;H01L2224/05573;;H01L2224/05568;;H01L2224/05184;;H01L2224/05644;;H01L2224/05647;;H01L2924/3512;;H01L2224/24137;;H01L2224/92244;;H01L2224/32225;;H01L2224/04105;;H01L21/568;;H01L2224/73267,H01L31/12;;G02B6/12;;G02B6/122;;G02B6/132;;G02B6/42;;G02B6/43;;H01L21/60;;H01L21/68;;H01L23/48;;H01L23/538;;H01L25/16,,0,0,,,,EXPIRED
937,US,B2,US 11472232 B2,002-347-281-150-860,2022-10-18,2022,US 201916718754 A,2019-12-18,US 201916718754 A,2019-12-18,Tire with tread elements including dual angled chamfer,"A tire includes a tread formed with tread elements that include a dual angled chamfer. The tire includes a pair of sidewalls extending radially outward to a ground-engaging tread. A plurality of circumferentially-extending grooves extend about the tread and define a plurality of ribs. A plurality of laterally-extending grooves cooperate with the circumferential grooves to divide the ribs into tread elements. A plurality of selected tread elements are formed with a dual angled chamfer. Each of the selected tread elements includes a body, a radially outer, ground-engaging surface, a chamfer side, and a dual angled chamfer that is formed in the body between the ground-engaging surface and the chamfer side.",GOODYEAR TIRE & RUBBER,SKURICH MICHAEL STEFAN;;JUERGENS ZACHARY WILLIAM;;ROBERTS JEREMY LEE;;CHO JUNG WAN;;STRACH GREGORY MARVIN,GOODYEAR TIRE & RUBBER COMPANY (2020-01-14),https://lens.org/002-347-281-150-860,Granted Patent,yes,22,0,4,4,0,B60C11/0306;;B60C11/1392;;B60C11/1392;;B60C2011/133;;B60C11/11,B60C11/13;;B60C11/11,,3,0,,,"English machine translation of JP2019-043306. (Year: 2019).;;English machine translation of JPH03-132403. (Year: 1991).;;EPO search report dated Mar. 18, 2021.",ACTIVE
938,BR,A2,BR 112022020200 A2,059-480-411-995-927,2022-12-13,2022,BR 112022020200 A,2021-04-05,US 2021/0025737 W;;US 202063005948 P,2020-04-06,"MISTURA DE MATERIAL POLIMÉRICO, TUBO COEXTRUDADO FLEXÍVEL, MÉTODO PARA FABRICAR UM TUBO COEXTRUDADO FLEXÍVEL, MÉTODO PARA TRANSPORTAR UM MATERIAL ATRAVÉS DE UM TUBO, DISPOSITIVO E MISTURA","MISTURA DE MATERIAL POLIMÉRICO, TUBO COEXTRUDADO FLEXÍVEL, MÉTODO PARA FABRICAR UM TUBO COEXTRUDADO FLEXÍVEL, MÉTODO PARA TRANSPORTAR UM MATERIAL ATRAVÉS DE UM TUBO, DISPOSITIVO E MISTURA. Uma mistura de material polimérico compreendendo um polímero contendo flúor, um polímero de siloxano e pelo menos dois aditivos de processamento de polímero (PPA), em que os pelo menos dois aditivos de processamento de polímero têm química diferente. Por exemplo, pode haver um tubo coextrudado flexível para prover um alojamento protetor para cabos, fluidos, lodo ou sólidos, o tubo compreendendo um par de camadas internas e externas relacionadas telescopicamente, onde a referida camada interna é lubrificada com a mistura de material polimérico.",DURA LINE LLC,H THOMAS CHUNG;;FEI FAN;;SUNG KI CHO;;SAM LUKUBIRA;;CALEB MICHAEL SPRADLING;;ARTURO VALENCIA,,https://lens.org/059-480-411-995-927,Patent Application,no,0,0,9,9,0,C09D183/04;;C08K3/042;;C10N2030/06;;C10M2213/0623;;C10N2020/06;;C10N2020/04;;C10M2229/025;;C10M2205/022;;C10M157/10;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10M169/041;;C10M2201/0413;;C10M2205/022;;C10M2213/02;;C10M2213/0623;;C10M2229/025;;C10N2040/32;;C10N2050/08;;A47C27/001;;A47C27/002;;A47C27/04;;A47C27/20;;A47C31/001,C08L27/18;;C08J3/22;;C08K3/04;;C09D5/00;;C09D183/04;;F16L9/12,,0,0,,,,PENDING
939,US,S,US D0713822 S,104-920-588-037-923,2014-09-23,2014,US 201329460841 F,2013-07-16,US 201329460841 F,2013-07-16,Headset for a communication device,,MOTOROLA MOBILITY LLC,PARADISE MICHAEL F;;CHO JU HWAN J;;HOUGHTON CHRISTOPHER B;;ISAACS DICKON;;NGUYEN THINH T,MOTOROLA MOBILITY LLC (2013-07-17),https://lens.org/104-920-588-037-923,Design Right,no,0,30,1,1,0,,,1401;;D14/223;;D14/206,0,0,,,,ACTIVE
940,CN,A,CN 114667626 A,143-716-894-811-418,2022-06-24,2022,CN 202080069830 A,2020-09-03,US 201962896147 P;;US 202063009703 P;;US 2020/0049098 W,2019-09-05,Aqueous electrochemical cell using polymer gel electrolyte,"A battery includes an anode, a cathode, and a polymer electrolyte disposed between the anode and the cathode. The polymer electrolyte may include an inert hydrophilic polymer matrix impregnated with an aqueous electrolyte. The hydrophilic polymer matrix may include a polar vinyl monomer, an initiator, and a crosslinker. A gassing inhibitor may be included in the polymer electrolyte to help avoid the problem of electrode overcharge.",URBAN ELECTRIC POWER COMPANY,HUANG JINCHAO;;YADAV GAUTAM;;CHO JUNG-SANG;;WEHNER MEIR;;UPRETI ADITYA;;BANERJEA SUSANNA;;NYCE MICHAEL,,https://lens.org/143-716-894-811-418,Patent Application,no,0,1,3,3,0,H01M50/417;;H01M2300/0014;;H01M2300/0005;;H01M2300/0082;;H01M6/045;;H01M50/609;;H01M50/44;;H01M4/244;;H01M4/32;;H01M4/34;;H01M4/628;;H01M10/36;;H01M2004/027;;H01M2004/028;;H01M2300/0005,H01M10/26;;H01M4/38;;H01M50/414;;H01M50/417;;H01M50/423;;H01M50/426;;H01M50/44;;H01M50/446;;H01M50/449,,0,0,,,,PENDING
941,EP,B1,EP 3838627 B1,165-812-985-839-289,2023-07-19,2023,EP 20214350 A,2020-12-15,US 201916718754 A,2019-12-18,TIRE WITH TREAD ELEMENTS INCLUDING DUAL ANGLED CHAMFER,,GOODYEAR TIRE & RUBBER,SKURICH MICHAEL STEFAN;;JUERGENS ZACHARY WILLIAM;;ROBERTS JEREMY LEE;;CHO JUNG WAN;;STRACH GREGORY MARVIN,,https://lens.org/165-812-985-839-289,Granted Patent,yes,3,0,4,4,0,B60C11/0306;;B60C11/1392;;B60C11/1392;;B60C2011/133;;B60C11/11,B60C11/03;;B60C11/13,,0,0,,,,ACTIVE
942,WO,A1,WO 2021/207056 A1,134-349-712-161-04X,2021-10-14,2021,US 2021/0025737 W,2021-04-05,US 202063005948 P,2020-04-06,"ULTRA-LOW FRICTION MATERIALS FOR LUBRICATING SURFACES, DEVICES THEREWITH, AND METHODS OF MANUFACTURE AND USE THEREOF","A polymeric material mixture comprising a fluorine-containing polymer, a siloxane polymer, and at least two polymer processing additives (PPA), wherein the at least two polymer processing additives have different chemistries. For example, there can be a flexible coextruded pipe for providing a protective housing for cables, fluids, sludge or solids, the pipe comprising a pair of telescopically related inner and outer layers, where said inner layer is lubricated with the polymeric material mixture.",DURA LINE CORP,FAN FEI;;CHO SUNG KI;;LUKUBIRA SAM;;SPRADLING CALEB MICHAEL;;VALENCIA ARTURO;;CHUNG H THOMAS,,https://lens.org/134-349-712-161-04X,Patent Application,yes,23,0,9,9,0,C09D183/04;;C08K3/042;;C10N2030/06;;C10M2213/0623;;C10N2020/06;;C10N2020/04;;C10M2229/025;;C10M2205/022;;C10M157/10;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10M169/041;;C10M2201/0413;;C10M2205/022;;C10M2213/02;;C10M2213/0623;;C10M2229/025;;C10N2040/32;;C10N2050/08;;A47C27/001;;A47C27/002;;A47C27/04;;A47C27/20;;A47C31/001,C08J3/22;;C08L27/18;;C08K3/04;;C09D5/00;;C09D183/04;;F16L9/12,,0,0,,,,PENDING
943,EP,A1,EP 3873370 A1,170-510-346-233-819,2021-09-08,2021,EP 19877808 A,2019-10-31,US 201862754948 P;;US 2019/0059178 W,2018-11-02,"PROPELLING DEVICES FOR PROPELLING THROUGH A MEDIUM, USING EXTERNAL MAGNETIC STIMULI APPLIED THEREON",,BIONAUT LABS LTD;;CHO SUEHYUN,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;SARGSYAN HOVHANNES;;CHO SUEHYUN;;CAPUTO JOHN;;VAN CLEVE ELI;;OREN ERAN,,https://lens.org/170-510-346-233-819,Patent Application,yes,0,0,5,5,0,A61B34/30;;A61B34/73;;A61B2034/302;;A61B2034/303;;A61B34/72;;A61B2034/733;;A61B2034/302;;A61B2034/303;;A61B34/73;;A61K49/0002,A61B34/30;;A61B34/00;;A61B34/20;;A61K9/14;;A61K9/50;;A61K9/51;;A61K49/18,,0,0,,,,DISCONTINUED
944,CO,A2,CO 6251245 A2,168-623-469-866-172,2011-02-21,2011,CO 09145305 A,2009-12-18,US 93775207 P;;US 95977107 P;;US 3798808 P,2007-06-29,COMPUESTOS DE PROLINA MODIFICADOS CON PROPIEDADES INHIBITORIAS DEL VIRUS DE LA HEPATITIS C,"1.- Un compuesto de formula I:o una sal farmacéuticamente aceptable, o profármaco del mismo, en donde:Y1 es O, S, o NR3; Y2 es O, S, o NR3; Z es O, S, o NR3;Z1 se selecciona de las siguientes estructuras:cada Ra es alquilo(C1-10), en donde uno o más átomos de carbono de dicho alquilo (C1-10) es opcionalmente reemplazado por O y cuyo alquilo(C1-10) está opcionalmente sustituido con uno o más heterociclilo y cuyo heterociclilo está opcionalmente sustituido con uno o más A3; cada Rb es R1, H, F, CI, Br, I, CF3, alquilo(C1-10), o XR3; cada Rc es R1, H, ciano, F, CI, Br, I, -C(=O)NRdRe, C(=O)NRsRt, NRsRt, S(=O)2NRsRt, alquilo(C1-10), alquenilo(C2-10), alquinilo(C2-10), alcoxi(C1-10), cicloalquilo, ORr, SRr, S(O)Rr, S(O)2Rr, arilo, o heteroarilo, cuyo alquilo(C1-10), alcoxi(C1-10), cícloalquilo, arilo o heteroarilo está opcionalmente sustituido con uno o más grupos seleccionados independientemente de halo, hidroxi, alquilo(C1-10), alquenilo(C2-10), alquinilo(C2-10), alcanoilo(C1-10), alcoxi(C1-10), alcanoiloxi(C1-10), alcoxi(C1-10)carbonilo, NRnRp; SRr, S(O)Rn o S(O)2Rr; Rd y Re son cada uno independientemente H o alquilo(C1-10); cada Rf es H, hidroxi, carboxi, ciano, alquilo(C1-10), alquenilo(C2-10), alquinilo(C2-10), alcanoilo(C1-10), alcoxi(C1-10), alcanoiloxi(C1-10), alcoxicarbonilo(C1-10), NRnRp, SRr, S(O)Rr, o S(O)2Rr; cada Rh es H, A3, C(=O)2NRsRt, o S(=O)2NRsRt; cada Rm es H, ciano, F, CI, Br, I, -C(=O)NRdRe, alcoxi(C1-10), cicloalquilo, o fenilo que está opcionalmente sustituido con uno o más F, CI, Br, I, alquilo(C1-10), o alcoxi(C1-10);cada L es independientemente CH o N; uno de E o D es O, S, o NRf t el otro E o D es CRh o N; Z2a es H, alquilo(C1-10), alquenilo(C2-10), ...",GILEAD SCIENCES INC,CHO AESOP;;CLARKE MICHAEL;;ONEIL HANRAHAN;;KIM CHOUNG;;PYUN HYUNG-JUNG;;SHENG XIAONING;;WU QIAOYIN,,https://lens.org/168-623-469-866-172,Patent Application,no,0,0,45,79,0,C07D401/12;;C07D401/14;;C07D403/12;;C07D403/14;;C07D413/14;;C07D487/04;;C07K5/0804;;C07K5/0808;;C07D417/14;;C07D207/16;;A61P1/16;;A61P31/12;;A61P31/14;;A61P31/16;;C07D403/12;;C07D403/14;;C07D401/12;;C07D401/14;;C07D487/04;;C07K5/0808;;C07D413/14;;C07K5/0804;;C07D417/14;;C07K5/0819;;C07K5/0821;;C07D207/16,A61K31/4025;;A61K31/407;;C07D401/12;;C07D417/14,,0,0,,,,ACTIVE
945,WO,A2,WO 2004/005972 A2,000-052-369-762-609,2004-01-15,2004,US 0321230 W,2003-07-02,US 39293802 P,2002-07-02,ELECTRO-OPTICAL INTEGRATED TRANSMITTER CHIP FOR ARBITRARY QUADRATURE MODULATION OF OPTICAL SIGNALS,"An optical device includes, a first Mach-Zehnder modulator (105, 106) that produces a first output and a second Mach-Zehnder modulator (205, 206) which produces a second output. A splitter (212 )couples the first and second Mach-Zehnder modulators. A combiner (213) combines the first and second outputs. A phase shifter (107, 207) is coupled to the first and second Mach-Zehnder modulators. The first Mach-Zehnder modulator, second Mach-Zehnder modulator, splitter, combiner and the phase shifter are each formed as part of a single chip made of electro-optical material. Such two similar optical device integrated together with polarization combiner provide a two-polarization performance.",CELIGHT INC;;KAPLAN ARKADY;;ACHIAM YAAKOV;;GREENBLATT ARTHUR;;SHPANTZER ISAAC;;CHO PAK SHING;;TSEYTLIN MICHAEL;;SALAMON AVIV,KAPLAN ARKADY;;ACHIAM YAAKOV;;GREENBLATT ARTHUR;;SHPANTZER ISAAC;;CHO PAK SHING;;TSEYTLIN MICHAEL;;SALAMON AVIV,,https://lens.org/000-052-369-762-609,Patent Application,yes,0,27,5,110,0,G02F1/225;;G02F2203/06;;H04B10/505;;H04B10/5051;;H04B10/5053;;H04B10/5057;;H04B10/50577;;H04B10/532;;H04B10/541;;H04B10/5561,G02F1/225;;H04B10/50;;H04B10/532;;H04B10/54;;H04B10/556,,0,0,,,,PENDING
946,US,A1,US 2013/0313301 A1,161-394-149-298-742,2013-11-28,2013,US 201213477391 A,2012-05-22,US 201213477391 A,2012-05-22,METHODS OF SEPARATING STRENGTHENED GLASS SHEETS BY MECHANICAL SCRIBING,"A method of separating a strengthened glass sheet includes positioning a serrated scribing wheel at a position spaced apart from a first edge of the glass sheet and offset below a top surface of the glass sheet, where the glass sheet comprises a surface compression layer of layer depth DOL and a central region. The method also includes translating the serrated scribing wheel in a first direction at an initiation speed such that the serrated scribing wheel forms a crack initiation site comprising surface indentations extending into the surface compression layer, accelerating the serrated scribing wheel in the first direction from the initiation speed to a scoring speed to scribe a score line extending into the glass sheet to a median crack depth greater than DOL, and stopping the serrated scribing wheel in the first direction before the score line reaches a second edge of the glass sheet.",BROWN JAMES WILLIAM;;HSIEH CHO-CHENG GEORGE;;JOSEPH II MICHAEL ALBERT;;PAI YEN CHIA GINA,BROWN JAMES WILLIAM;;HSIEH CHO-CHENG GEORGE;;JOSEPH II MICHAEL ALBERT;;PAI YEN CHIA GINA,CORNING INCORPORATED (2012-06-04),https://lens.org/161-394-149-298-742,Patent Application,yes,10,10,13,13,0,B26F3/00;;B26F3/00;;C03B33/023;;C03B33/023;;C03B33/023;;C03B33/105;;C03B33/107;;C03B33/107;;C03B33/107;;C03C21/002;;C03C21/002;;C03C21/002;;Y10T83/0341;;Y10T83/0341;;Y10T225/12;;Y10T225/12,C03B33/02;;B26D3/08;;B26F3/00,225/2;;83/880,0,0,,,,ACTIVE
947,US,B1,US 6404196 B1,165-101-460-020-659,2002-06-11,2002,US 76202601 A,2001-04-04,US 76202601 A;;US 9476598 P;;US 9917288 W,1998-07-31,Method for correction of MRI motion artifacts and main field fluctuation,"
    A method for correcting MRI motion artifacts and main field fluctuations. A series of data prints are acquired at read points along a radial axis to form a view (  210  ). Subsequent views define a NMR data set. A processor stores the NMR data set and reconstructs an image array from a stored NMR data set by; a) reconstructing the NMR data set along a radial axis; b) producing a correction data array including correction values where each of the correction values is calculated as a function of the corresponding stored NMR datum and the stored NMR datum for the intersection of the first and subsequent projection (  200  ) axes; c) applying the data in the correction array to the NMR data set to produce a final NMrR data set. 
",UNIV CASE WESTERN RESERVE,DUERK JEFFREY L;;WENDT MICHAEL;;SHANKARANARAVANAN AJIT;;CHUNG YIU-CHO;;LEWIN JONATHAN S;;MERKLE ELMAR,CASE WESTERN RESERVE UNIVERSITY (2001-04-02),https://lens.org/165-101-460-020-659,Granted Patent,yes,4,19,4,4,0,A61B5/055;;A61B5/7257;;G01R33/482;;G01R33/56509;;G01R33/56563;;G01R33/5676;;G01R33/56509;;G01R33/56563;;A61B5/7257;;G01R33/482;;A61B5/055;;G01R33/5676,A61B5/055;;G01R33/565;;G01R33/567,324/309;;324/307,0,0,,,,EXPIRED
948,CO,A2,CO 2022015783 A2,013-201-990-311-943,2023-01-26,2023,CO 2022015783 A,2022-11-01,US 2021/0025737 W;;US 202063005948 P,2020-04-06,"Materiales de ultra baja fricción para superficies lubricantes, dispositivos con los mismos, y métodos de fabricación y uso de los mismos","Una mezcla de materiales poliméricos que comprende un polímero que contiene flúor, un polímero de siloxano y al menos dos aditivos de procesamiento de polímeros (PPA), en la que al menos dos aditivos de procesamiento de polímeros tienen químicas diferentes. Por ejemplo, puede haber una tubería coextruida flexible para proporcionar una carcasa protectora para cables, fluidos, lodos o sólidos, la tubería comprende un par de capas interna y externa telescópicamente relacionadas, donde dicha capa interna está lubricada con la mezcla de material polimérico.",DURA LINE LLC,FAN FEI;;CHO SUNG KI;;LUKUBIRA SAM;;SPRADLING CALEB MICHAEL;;VALENCIA ARTURO;;CHUNG H THOMAS,,https://lens.org/013-201-990-311-943,Patent Application,no,0,0,9,9,0,C09D183/04;;C08K3/042;;C10N2030/06;;C10M2213/0623;;C10N2020/06;;C10N2020/04;;C10M2229/025;;C10M2205/022;;C10M157/10;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10M169/041;;C10M2201/0413;;C10M2205/022;;C10M2213/02;;C10M2213/0623;;C10M2229/025;;C10N2040/32;;C10N2050/08;;A47C27/001;;A47C27/002;;A47C27/04;;A47C27/20;;A47C31/001,C08L27/18;;C08J3/22;;C08K3/04;;C09D5/00;;C09D183/04;;F16L9/12,,0,0,,,,PENDING
949,CA,A1,CA 3116907 A1,068-269-629-391-678,2020-05-07,2020,CA 3116907 A,2019-10-31,US 201862754948 P;;US 2019/0059178 W,2018-11-02,"PROPELLING DEVICES FOR PROPELLING THROUGH A MEDIUM, USING EXTERNAL MAGNETIC STIMULI APPLIED THEREON","A propelling device and methods of use thereof. The device is configured to propel through a medium, using external magnetic stimuli applied thereon; the device comprises: a propelling-element and a magnet in communication with the propelling element. The magnet is configured to respond to the applied magnetic stimuli and to rotate the propelling-element; the propelling-element is configured to convert rotary motion thereof into translation motion, and thereby to propel the device through the medium.",BIONAUT LABS LTD,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;SARGSYAN HOVHANNES;;CHO SUEHYUN;;CAPUTO JOHN;;VAN CLEVE ELI;;OREN ERAN,,https://lens.org/068-269-629-391-678,Patent Application,no,0,0,5,5,0,A61B34/30;;A61B34/73;;A61B2034/302;;A61B2034/303;;A61B34/72;;A61B2034/733;;A61B2034/302;;A61B2034/303;;A61B34/73;;A61K49/0002,A61B34/30;;A61B34/00;;A61B34/20;;A61K9/14;;A61K9/50;;A61K9/51;;A61K49/18,,0,0,,,,PENDING
950,US,B2,US 10351460 B2,077-091-691-969-398,2019-07-16,2019,US 201213477391 A,2012-05-22,US 201213477391 A,2012-05-22,Methods of separating strengthened glass sheets by mechanical scribing,"A method of separating a strengthened glass sheet includes positioning a serrated scribing wheel at a position spaced apart from a first edge of the glass sheet and offset below a top surface of the glass sheet, where the glass sheet comprises a surface compression layer of layer depth DOL and a central region. The method also includes translating the serrated scribing wheel in a first direction at an initiation speed such that the serrated scribing wheel forms a crack initiation site comprising surface indentations extending into the surface compression layer, accelerating the serrated scribing wheel in the first direction from the initiation speed to a scoring speed to scribe a score line extending into the glass sheet to a median crack depth greater than DOL, and stopping the serrated scribing wheel in the first direction before the score line reaches a second edge of the glass sheet.",BROWN JAMES WILLIAM;;HSIEH CHO CHENG GEORGE;;JOSEPH II MICHAEL ALBERT;;PAI YEN CHIA GINA;;CORNING INC,BROWN JAMES WILLIAM;;HSIEH CHO-CHENG (GEORGE);;JOSEPH II MICHAEL ALBERT;;PAI YEN CHIA (GINA),CORNING INCORPORATED (2012-06-04),https://lens.org/077-091-691-969-398,Granted Patent,yes,90,1,13,13,0,B26F3/00;;B26F3/00;;C03B33/023;;C03B33/023;;C03B33/023;;C03B33/105;;C03B33/107;;C03B33/107;;C03B33/107;;C03C21/002;;C03C21/002;;C03C21/002;;Y10T83/0341;;Y10T83/0341;;Y10T225/12;;Y10T225/12,C03B33/02;;B26F3/00;;C03B33/023;;C03B33/10;;C03C21/00,,16,0,,,"Office Action dated Feb. 14, 2014 filed in European Patent Application No. 11711203.7.;;Office Action dated Apr. 9, 2014 filed in U.S. Appl. No. 13/935,085.;;International Search Report and Written Opinion; PCT/US2011/043510 filed Jul. 11, 2011; ISR dated Jun. 10, 2011.;;International Search Report and Written Opinion; PCT/US2011/028777 filed Mar. 11, 2011; ISR dated Jul. 21, 2011.;;European Patent Office Communication pursuant to Rules 161(1) and 162 EPC; EP Application No. 11738888.4.;;International Search Report & Written Opinion filed in PCT/US2013/041591 filed May 17, 2013; ISR dated Aug. 21, 2013.;;Chinese Office Action filed in Patent Application No. 201180014471.2 dated Jul. 2, 2014.;;Advisory Action filed in U.S. Appl. No. 13/050,281 dated Jul. 25, 2014.;;Glass Basics: Scoring and Separating Recommendations, Technical Information Paper, Coming Display Technologies copyright 2004, available at (Jan. 15, 2015): http://pdf.directindustry.com/pdf/coming-display-technologies/glass-basics-scoring-separating-recommendations/57416-562792.html.;;Visiontek Systems Ltd., “Glass”, Jun. 8, 2002, http://visionteksystems.co.uk/glass.htm.;;B. R. Lawn and D. B. Marshall, “Compact Fracture Resistance of Physically and Chemically Tempered Glass Plates: A V Theoretical Model”, Feb. 1977, Physics and Chemistry of Glasses, vol. 18, No. 1, pp. 7-18.;;Lema, Parma. “The Glass Chemical Tempering Process” May 1, 2005, http://www.allbusiness.com/nonmetallic- mineral/glass-glass-manufacturing/468622-1.html.;;Corning Incorporated, “Corning Gorilla Glass,” Aug. 2008, http://pdf.directindustry.com/pdf/coming/gorilla-glass-product-information-sheet/12631-67069-_2.html.;;English Translation of CN201380035076.1 First Office Action dated May 30, 2016; Chinese Patent Office; China.;;Taiwanese Search Report issued in TW Application No. 102118081 dated Mar. 15, 2017, 1 page.;;English Translation of JP2015514069 Office Action dated Apr. 11, 2017; 6 Pages; Japanese Patent Office.",ACTIVE
951,EP,A1,EP 2322645 A1,001-852-553-334-833,2011-05-18,2011,EP 10011675 A,2000-06-16,EP 00942919 A;;US 13993699 P;;US 19461800 P,1999-06-18,MASS TRANSPORT LIMITED IN VIVO ANALYTE SENSOR,"An in vivo electrochemical sensor (500) includes in one embodiment a body (501) having a top layer (516), a bottom layer (512), a working electrode (506), a sensing layer (534), and a counter/reference electrode (508). The sensor body (501) includes a small channel (552) in the top layer (516) to permit analyte diffusion to the sensing layer (534). To eliminate or reduce the need for a mass transport limiting membrane, the channel is typically small enough to restrict mass transport of the analyte to the sensing layer. The channel may be formed by a number of methods, including use of a laser, die cutting, or slitting the surface. The sensor is configured and arranged for implantation into the body of a mammal for contact with body fluids of the mammal.
",ABBOTT DIABETES CARE INC,SAY JAMES;;TOMASCO MICHAEL F;;SAKSLUND HENNING;;AUDETT JAY D;;CHO HYUN;;YAMASAKI DUANE O,,https://lens.org/001-852-553-334-833,Patent Application,yes,21,0,10,10,0,A61B5/14865;;A61B5/14865;;A61B5/1486;;A61B5/1486;;C12Q1/002;;C12Q1/002;;C12Q1/006;;C12Q1/006;;Y10S977/925;;Y10S977/925,C12Q1/00;;G01N33/483;;A61B5/00;;A61B5/145;;A61B5/1468;;A61B5/1486;;G01N27/327;;G01N27/416;;G01N27/49;;G01N33/487,,16,15,047-699-335-063-87X;;092-858-941-579-929;;050-455-134-638-128;;006-551-352-957-447;;027-927-639-674-836;;021-178-819-724-040;;007-835-007-410-732;;132-477-256-994-251;;075-865-950-350-64X;;024-924-442-462-343;;006-029-737-148-964;;007-739-671-476-828;;092-695-114-436-031;;053-272-736-944-39X;;028-691-567-694-173,7164245;;10.1021/ac00105a010;;4061843;;10.1021/ac00289a042;;10.1016/0956-5663(92)85056-g;;11701486;;10.1146/annurev.bioeng.1.1.153;;8018316;;10.1016/0956-5663(94)80107-x;;10.1021/ac970932u;;9608851;;10.1016/0925-4005(91)80225-9;;10.1016/0925-4005(91)80234-b;;10.1016/0925-4005(91)80122-z;;10.1016/s0021-9673(01)93770-7;;10.1016/0003-2670(93)85040-q;;10.1016/0956-5663(96)88413-2;;10.1021/ac00120a027;;10.2337/diacare.5.3.190;;7172982,"FISCHER U ET AL: ""MEMBRANE COMBINATION FOR IMPLANTABLE GLUCOSE SENSORS. MEASUREMENTS IN UNDILUTED BIOLOGICAL FLUIDS"", TRANSACTIONS - AMERICAN SOCIETY FOR ARTIFICIAL INTERNAL ORGANS, VOLUME 28.;CHICAGO, IL, USA, vol. 28, 1982, Transactions - American Society for Artificial Internal Organs 1982 American Soc for Artificial Internal Organs, Boca Raton, Fla, USA, pages 245 - 248, XP000940837;;BAKER D A ET AL: ""A CONTINUOUS, IMPLANTABLE LACTATE SENSOR"", ANALYTICAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. COLUMBUS, vol. 67, no. 9, 1 May 1995 (1995-05-01), pages 1536 - 1540, XP000509985, ISSN: 0003-2700;;GOUGH DAVID A ET AL: ""TWO-DIMENSIONAL ENZYME ELECTRODE SENSOR FOR GLUCOSE"", ANAL CHEM OCT 1985, vol. 57, no. 12, October 1985 (1985-10-01), pages 2351 - 2357, XP000940918;;ELIZABETH A.-H. HALL: ""Biosensors, pages 30-39, 97-140, 216-267"", 1990, OPEN UNIVERSITY PRESS, Buckingham, ISBN: 0-335-15161-2, XP002621225;;URBAN G ET AL: ""Miniaturized multi-enzyme biosensors integrated with pH sensors on flexible polymer carriers for in vivo applications"", BIOSENSORS AND BIOELECTRONICS, ELSEVIER BV, NL, vol. 7, no. 10, 1 January 1992 (1992-01-01), pages 733 - 739, XP026569247, ISSN: 0956-5663, [retrieved on 19920101], DOI: 10.1016/0956-5663(92)85056-G;;HELLER A: ""IMPLANTED ELECTROCHEMICAL GLUCOSE SENSORS FOR THE MANAGEMENT OF DIABETES"", ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, ANNUAL REVIEW INCO., PALO ALTO, CA, US, 1 August 1999 (1999-08-01), pages 153 - 175, XP008055837;;LINKE B ET AL: ""Amperometric biosensor for in vivo glucose sensing based on glucose oxidase immobilized in a redox hydrogel"", BIOSENSORS AND BIOELECTRONICS, ELSEVIER BV, NL, vol. 9, no. 2, 1 January 1994 (1994-01-01), pages 151 - 158, XP026594246, ISSN: 0956-5663, [retrieved on 19940101], DOI: 10.1016/0956-5663(94)80107-X;;SCHMIDTKE D W ET AL: ""Accuracy of the one-point in vivo calibration of ""wired"" glucose oxidase electrodes implanted in jugular veins of rats in periods of rapid rise and decline of the glucose concentration."", ANALYTICAL CHEMISTRY 15 MAY 1998 LNKD- PUBMED:9608851, vol. 70, no. 10, 15 May 1998 (1998-05-15), pages 2149 - 2155, XP002621226, ISSN: 0003-2700;;JOHNSON K W: ""REPRODUCIBLE ELECTRODEPOSITION OF BIOMOLECULES FOR THE FABRICATION OF MINIATURE ELECTROENZYMATIC BIOSENSORS"", SENSORS AND ACTUATORS B, ELSEVIER SEQUOIA S.A., LAUSANNE, CH, vol. B05, no. 1 / 04, 1 August 1991 (1991-08-01), pages 85 - 89, XP000265941, ISSN: 0925-4005, DOI: 10.1016/0925-4005(91)80225-9;;MASTROTOTARO J J ET AL: ""An electroenzymatic glucose sensor fabricated on a flexible substrate"", SENSORS AND ACTUATORS B, ELSEVIER SEQUOIA S.A., LAUSANNE, CH, vol. 5, no. 1-4, 1 August 1991 (1991-08-01), pages 139 - 144, XP026569286, ISSN: 0925-4005, [retrieved on 19910801], DOI: 10.1016/0925-4005(91)80234-B;;SCHALKHAMMER T ET AL: ""Electrochemical glucose sensors on permselective non-conducting substituted pyrrole polymers"", SENSORS AND ACTUATORS B, ELSEVIER SEQUOIA S.A., LAUSANNE, CH, vol. 4, no. 3-4, 1 June 1991 (1991-06-01), pages 273 - 281, XP026553331, ISSN: 0925-4005, [retrieved on 19910601], DOI: 10.1016/0925-4005(91)80122-Z;;SCHALKHAMMER T ET AL: ""Electrochemical biosensors on thin-film metals and conducting polymers"", JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V, NL, vol. 510, 27 June 1990 (1990-06-27), pages 355 - 366, XP026656332, ISSN: 0021-9673, [retrieved on 19900627], DOI: 10.1016/S0021-9673(01)93770-7;;CARDOSI M F ET AL: ""SCREEN PRINTED GLUCOSE ELECTRODES BASED ON PLATINISED CARBON PARTICLES AND GLUCOSE OXIDASE"", ANALYTICA CHIMICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 276, no. 1, 1 January 1993 (1993-01-01), pages 69 - 74, XP009014215, ISSN: 0003-2670, DOI: 10.1016/0003-2670(93)85040-Q;;HART A L ET AL: ""On the use of screen- and ink-jet printing to produce amperometric enzyme electrodes for lactate"", BIOSENSORS AND BIOELECTRONICS, vol. 11, no. 3, 1996, pages 263 - 270, XP002623385, ISSN: 0956-5663;;NEWMAN J D ET AL: ""CATALYTIC MATERIALS, MEMBRANES, AND FABRICATION TECHNOLOGIES SUITABLE FOR THE CONSTRUCTION OF AMPEROMETRIC BIOSENSORS"", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 67, no. 24, 1 January 1995 (1995-01-01), pages 4594 - 4599, XP000861726, ISSN: 0003-2700, DOI: 10.1021/AC00120A027;;DIABETES CARE, vol. 5, no. 3, May 1982 (1982-05-01), pages 190 - 198",DISCONTINUED
952,US,S,US D0806736 S,048-642-148-707-966,2018-01-02,2018,US 201629579769 F,2016-10-03,US 201629579769 F,2016-10-03,Display screen with animated graphical user interface,,GOOGLE INC;;GOOGLE LLC,CHUNG EUNKYUNG;;CHO HANNAH;;GOYAL SUNNY;;COHEN MICHAEL ADAM;;HUANG JESSICA;;NATH BOBBY;;CONRAGAN KAI,GOOGLE LLC (2017-02-21),https://lens.org/048-642-148-707-966,Design Right,no,0,35,1,1,0,,,1404;;D14/486,0,0,,,,ACTIVE
953,EP,A1,EP 3838627 A1,078-651-324-301-723,2021-06-23,2021,EP 20214350 A,2020-12-15,US 201916718754 A,2019-12-18,TIRE WITH TREAD ELEMENTS INCLUDING DUAL ANGLED CHAMFER,"A tire with a tread (108) formed with tread elements (124) including a dual angled chamfer (132) id disclosed. The tire (100) comprises a pair of sidewalls (106) extending radially outward to a tread (108) for ground engagement; a plurality of circumferentially extending grooves (118) extending about the tread (108) and defining a plurality of ribs (120); a plurality of laterally extending grooves (122) cooperating with the circumferential grooves (118) to divide the ribs (120) into tread elements (124); and a plurality of selected tread elements (124) being formed with a dual angled chamfer (132). Each of the selected tread elements (124) includes a body (126), a radially outer surface (128) for ground-engagement, a chamfer side (130) and a dual angled chamfer (132) being formed in the body (126) between the radially outer surface (128) and the chamfer side (130).
",GOODYEAR TIRE & RUBBER,SKURICH MICHAEL STEFAN;;JUERGENS ZACHARY WILLIAM;;ROBERTS JEREMY LEE;;CHO JUNG WAN;;STRACH GREGORY MARVIN,,https://lens.org/078-651-324-301-723,Patent Application,yes,3,0,4,4,0,B60C11/0306;;B60C11/1392;;B60C11/1392;;B60C2011/133;;B60C11/11,B60C11/03;;B60C11/13,,0,0,,,,ACTIVE
954,US,A1,US 2021/0309931 A1,065-804-590-197-749,2021-10-07,2021,US 202117222245 A,2021-04-05,US 202117222245 A;;US 202063005948 P,2020-04-06,"ULTRA-LOW FRICTION MATERIALS FOR LUBRICATING SURFACES, DEVICES THEREWITH, AND METHODS OF MANUFACTURE AND USE THEREOF","A polymeric material mixture comprising a fluorine-containing polymer, a siloxane polymer, and at least two polymer processing additives (PPA), wherein the at least two polymer processing additives have different chemistries. For example, there can be a flexible coextruded pipe for providing a protective housing for cables, fluids, sludge or solids, the pipe comprising a pair of telescopically related inner and outer layers, where said inner layer is lubricated with the polymeric material mixture.",DURA LINE CORP,CHUNG H THOMAS;;FAN FEI;;CHO SUNG KI;;LUKUBIRA SAM;;SPRADLING CALEB MICHAEL;;VALENCIA ARTURO,DURA-LINE LLC (2022-04-19);;DURA-LINE CORPORATION (2021-04-06),https://lens.org/065-804-590-197-749,Patent Application,yes,1,0,9,9,0,C09D183/04;;C08K3/042;;C10N2030/06;;C10M2213/0623;;C10N2020/06;;C10N2020/04;;C10M2229/025;;C10M2205/022;;C10M157/10;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10M169/041;;C10M2201/0413;;C10M2205/022;;C10M2213/02;;C10M2213/0623;;C10M2229/025;;C10N2040/32;;C10N2050/08;;A47C27/001;;A47C27/002;;A47C27/04;;A47C27/20;;A47C31/001,C10M169/04;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02,,0,0,,,,ACTIVE
955,TW,A,TW 201717889 A,091-049-113-821-170,2017-06-01,2017,TW 105122492 A,2016-07-15,US 201562193307 P;;US 201562263192 P,2015-07-16,Microencapsulation of compounds into natural spores and pollen grains,"In one aspect, provided herein are whole spores engineered to capsulate a compound(s) or substance(s). In certain embodiments, the whole spore encapsulating the compound(s) or substance(s) is coated with or co-encapsulated with a hydrogel or other agent(s) to control the rate release of the compound(s) or substance(s) from the spore. In another aspect, provided herein are methods of producing whole spores encapsulating a compound(s) or substance(s). In another aspect, provided herein are formulations comprising either a whole spore, or a whole spore encapsulating a compound(s) or substance(s), and uses of those formulations.",UNIV NANYANG TECH,CHO NAM-JOON;;POTROZ MICHAEL GRAEME;;MUNDARGI RAGHAVENDRA CHALUVAYYA;;PARK JAE HYEON;;JACKMAN JOSHUA ALEXANDER,,https://lens.org/091-049-113-821-170,Patent of Addition,no,0,0,2,2,0,A23P10/30;;A23P10/30;;A01N25/00;;A01N25/08;;A61K8/0279;;A61K8/11;;A61K8/922;;A61K8/9722;;A61K8/9722;;A61K8/9728;;A61K8/9728;;A61K8/9755;;A61K8/9755;;A61K8/9789;;A61K8/9789;;A61K8/9794;;A61K8/9794;;A61K8/99;;A61K8/99;;A61K9/0014;;A61K9/0019;;A61K9/5063;;A61K2800/10;;A61K2800/28;;A61K2800/412;;A61K2800/56;;A61Q19/00;;A61Q19/10,A61K8/02;;A61K8/97;;A61Q19/00,,0,0,,,,PENDING
956,WO,A1,WO 2012/025155 A1,156-205-692-253-507,2012-03-01,2012,EP 2010062520 W,2010-08-26,EP 2010062520 W,2010-08-26,HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES,"The present teachings relate to compounds of Formula I and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R 1 , R 2 , R 3 , ring A, and ( formula II) are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.",NOVARTIS AG;;CHO YOUNG SHIN;;JIANG LEI;;SHULTZ MICHAEL;;CHEN CHRISTINE HIU-TUNG;;LIU GANG;;LI JIANKE,CHO YOUNG SHIN;;JIANG LEI;;SHULTZ MICHAEL;;CHEN CHRISTINE HIU-TUNG;;LIU GANG;;LI JIANKE,,https://lens.org/156-205-692-253-507,Patent Application,yes,3,11,1,1,0,C07D295/205;;C07D211/34;;C07D213/64;;C07D213/75;;C07D217/22;;C07D235/30;;C07D241/42;;C07D295/155;;C07D295/185;;C07D295/192;;C07D295/26;;C07D401/04;;C07D401/10;;C07D405/04;;C07D409/04;;C07D413/04;;C07D413/14;;C07D471/04;;C07D471/10;;C07D491/107;;C07D491/113;;C07D498/10,C07D211/34;;C07D213/75;;C07D217/22;;C07D235/30;;C07D241/42;;C07D295/185;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/04;;C07D409/04;;C07D413/04;;C07D471/04;;C07D471/10;;C07D498/10,,4,1,050-247-819-044-289,10.1002/0470053488,"T. HIGUCHI I; V. STCLLA: ""Biorever.sible Carriers in Drug Design"", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article ""Pro-drugs as Novel Delivery Systems,"" Vol. 14 of the A.C.S. Symposium Series"";;""Remington: The Science and Practice of Pharmacy"", 2000, LIPPINCOTT WILLIAMS & WILKINS;;GREENE: ""Protective Groups in Organic Synthesis"", 2006, WILEY & SONS;;SYNTHESIS, 1974, pages 354 - 356",PENDING
957,US,A1,US 2008/0155972 A1,161-831-809-618-952,2008-07-03,2008,US 64651406 A,2006-12-28,US 64651406 A,2006-12-28,Exhaust treatment system,"An exhaust gas treatment system of an internal combustion engine includes a selective catalytic reduction catalyst fluidly connected to the internal combustion engine, an oxidation catalyst fluidly connected upstream of the selective catalytic reduction catalyst, and a particulate filter fluidly connected upstream of the selective catalytic reduction catalyst. The exhaust gas treatment system further includes a recirculation line configured to direct a portion of an exhaust flow of the internal combustion engine toward an inlet of the engine.",DRISCOLL JAMES JOSHUA;;CHAVANNAVAR PRAVEEN SHIVSHANKA;;LIANG CHO Y;;PAULSON THOMAS EDWARD;;WOODS MICHAEL L,DRISCOLL JAMES JOSHUA;;CHAVANNAVAR PRAVEEN SHIVSHANKA;;LIANG CHO Y;;PAULSON THOMAS EDWARD;;WOODS MICHAEL L,CATERPILLAR INC (2007-03-12),https://lens.org/161-831-809-618-952,Patent Application,yes,17,32,2,2,0,F01N3/023;;F01N3/023;;F01N3/035;;F01N3/035;;F01N3/0814;;F01N3/0814;;F01N3/0821;;F01N3/0821;;F01N3/206;;F01N3/206;;F01N9/002;;F01N9/002;;F01N13/009;;F01N13/009;;F02B37/013;;F02B37/013;;F02M26/06;;F02M26/06;;Y02T10/12;;Y02T10/12;;Y02T10/40;;Y02T10/40,F01N3/00,60/299,0,0,,,,DISCONTINUED
958,US,A1,US 2023/0321301 A1,018-655-877-106-575,2023-10-12,2023,US 202318192705 A,2023-03-30,US 202318192705 A;;US 202263329486 P,2022-04-11,VOLATILE DISPENSING DEVICE WITH DISPENSER MOUNT,"A volatile dispensing device having a housing having opposing first and second walls that are joined along their peripheries to one another. Each of the first and second walls has at least one aperture and define a cavity for receiving a solid article having a volatile composition. A dispenser mount is located at a center of one of the first wall and the second wall and extending from an exterior surface of the one of the first wall and the second wall, wherein the dispenser mount has a planar mount surface and is characterized by a height greater than a thickness of the one of the first wall and the second wall.",PROCTER & GAMBLE,VYAS RAHUL;;NG DESMOND;;CHO MEI SAN GIGI;;SEAH MAGGIE;;RAJWANI BHAVESH;;CANNON WILLIAM MICHAEL,THE PROCTER & GAMBLE COMPANY (2022-05-11),https://lens.org/018-655-877-106-575,Patent Application,yes,0,0,2,2,0,A61L9/04;;A61L9/042;;A61L9/12;;A61L2209/15;;A01M29/12;;A61L9/042;;A61L9/12;;A61L2209/133;;A61L2209/15,A61L9/04;;A61L9/12,,0,0,,,,PENDING
959,WO,A3,WO 2000/078992 A3,035-030-872-100-971,2001-07-19,2001,US 0016773 W,2000-06-16,US 13993699 P;;US 19461800 P,1999-06-18,MASS TRANSPORT LIMITED IN VIVO ANALYTE SENSOR,"An in vivo electrochemical sensor including a working electrode, and an analyte-responsive sensing layer proximate the working electrode. The sensing layer is exposed at an edge of the sensor, wherein the sensor signal is limited, at least in part, by mass transport of analyte to the sensing layer. The sensor is configured and arranged for implantation into the body of a mammal for contact with body fluids of the mammal. The analyte diffuses to the sensing element via the edge of the sensor, thereby restricting mass transport of the analyte to the sensing element. This is because the solution-contacting surface area of the sensor edge is much smaller than an open face of the sensing layer.",THERASENSE INC,SAY JAMES;;TOMASCO MICHAEL F;;SAKSLUND HENNING;;AUDETT JAY D;;CHO HYUN;;YAMASAKI DUANE O,,https://lens.org/035-030-872-100-971,Search Report,yes,3,0,10,10,0,A61B5/1486;;A61B5/14865;;C12Q1/002;;C12Q1/006;;Y10S977/925;;A61B5/14865;;C12Q1/002;;A61B5/1486;;C12Q1/006;;Y10S977/925,G01N33/483;;A61B5/00;;A61B5/145;;A61B5/1468;;A61B5/1486;;C12Q1/00;;G01N27/327;;G01N27/416;;G01N27/49;;G01N33/487,,3,3,047-699-335-063-87X;;092-858-941-579-929;;050-455-134-638-128,7164245;;10.1021/ac00105a010;;4061843;;10.1021/ac00289a042,"FISCHER U ET AL: ""MEMBRANE COMBINATION FOR IMPLANTABLE GLUCOSE SENSORS. MEASUREMENTS IN UNDILUTED BIOLOGICAL FLUIDS"", TRANSACTIONS - AMERICAN SOCIETY FOR ARTIFICIAL INTERNAL ORGANS, VOLUME 28.;CHICAGO, IL, USA, vol. 28, 1982, Transactions - American Society for Artificial Internal Organs 1982 American Soc for Artificial Internal Organs, Boca Raton, Fla, USA, pages 245 - 248, XP000940837;;BAKER D A ET AL: ""A CONTINUOUS, IMPLANTABLE LACTATE SENSOR"", ANALYTICAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. COLUMBUS, vol. 67, no. 9, 1 May 1995 (1995-05-01), pages 1536 - 1540, XP000509985, ISSN: 0003-2700;;GOUGH DAVID A ET AL: ""TWO-DIMENSIONAL ENZYME ELECTRODE SENSOR FOR GLUCOSE"", ANAL CHEM OCT 1985, vol. 57, no. 12, October 1985 (1985-10-01), pages 2351 - 2357, XP000940918",PENDING
960,EP,A1,EP 3531462 A1,030-737-848-524-501,2019-08-28,2019,EP 18158263 A,2018-02-23,EP 18158263 A,2018-02-23,TRANSPARENT CONDUCTIVE FILM,"The present invention is in the field of transparent conductive films. In particular, the present invention relates to a transparent conductive film comprising 
(a) at least two layers containing zinc oxide 
(b) a layer containing an organic compound between the two layers containing zinc oxide, 
(c) a metallic dopant other than zinc.",BASF COATINGS GMBH,CHO BORAM;;DR FLORES JEAN-CHARLES;;REINKE MICHAEL;;PROF SUNG MYUNG MO;;JUNG JIN WON,,https://lens.org/030-737-848-524-501,Patent Application,yes,7,1,1,1,0,Y02E10/549;;H10K71/60;;H10K30/82;;H10K50/816;;H10K50/828,H01L51/00,,0,0,,,,DISCONTINUED
961,JP,A,JP 2001160687 A,083-839-446-488-392,2001-06-12,2001,JP 2000328753 A,2000-10-27,US 42985499 A,1999-10-28,METHOD OF MANUFACTURING MULTILAYER CIRCUIT STRUCTURE,"PROBLEM TO BE SOLVED: To provide a method of manufacturing a multilayer circuit structure having a high reliability and a high density in embodiments superior in cost- effect. SOLUTION: Conductive layers, dielectric layers and conductive posts are formed on both surfaces of a core structure formed with circuits, and the conductive posts are provided on the dielectric layers and laminated to form approximately longitudinal conducting passages running at least partly through the multilayer circuit structure. The formed multilayer circuit structure has a smaller occupied space than a multilayer circuit structure having a laminated via structure.",FUJITSU LTD,HANTO HAN JIAN;;TAKAHASHI YASUHITO;;MICHAEL GWANG-TWONG LEE;;UEN-CHO VINCENT WANG;;MARK MACCORMACK,,https://lens.org/083-839-446-488-392,Patent Application,no,4,8,4,10,0,H01L24/96;;H01L24/96;;H01L21/486;;H01L21/486;;H01L2221/68359;;H01L2221/68359;;H01L2224/16237;;H01L2224/16237;;H01L2924/01004;;H01L2924/01004;;H01L2924/01005;;H01L2924/01005;;H01L2924/01006;;H01L2924/01006;;H01L2924/01013;;H01L2924/01013;;H01L2924/01023;;H01L2924/01023;;H01L2924/01027;;H01L2924/01027;;H01L2924/01029;;H01L2924/01029;;H01L2924/0103;;H01L2924/0103;;H01L2924/01033;;H01L2924/01033;;H01L2924/01046;;H01L2924/01046;;H01L2924/01047;;H01L2924/01047;;H01L2924/01051;;H01L2924/01051;;H01L2924/01078;;H01L2924/01078;;H01L2924/01079;;H01L2924/01079;;H01L2924/01082;;H01L2924/01082;;H01L2924/01322;;H01L2924/01322;;H01L2924/01327;;H01L2924/01327;;H01L2924/12042;;H01L2924/12042;;H01L2924/3011;;H01L2924/3011;;H05K3/0035;;H05K3/0035;;H05K3/108;;H05K3/108;;H05K3/243;;H05K3/243;;H05K3/4602;;H05K3/4602;;H05K3/4647;;H05K3/4647;;H05K2203/066;;H05K2203/066;;H05K2203/0733;;H05K2203/0733;;H05K2203/1383;;H05K2203/1383,H01L21/48;;H05K3/00;;H05K3/10;;H05K3/24;;H05K3/46,,0,0,,,,EXPIRED
962,US,S,US D0631001 S,092-809-493-488-204,2011-01-18,2011,US 35180409 F,2009-12-11,US 35180409 F,2009-12-11,Tire,,GOODYEAR TIRE & RUBBER,HUGHES SHANNON JOSEPH;;SKURICH MICHAEL STEFAN;;CHO JUNG WAN;;OKONIESKI RALPH EDWARD;;HUNT NATHAN ANDREW,GOODYEAR TIRE & RUBBER COMPANY THE (2009-12-10),https://lens.org/092-809-493-488-204,Design Right,no,0,22,1,1,0,,,1215;;D12/601,0,0,,,,ACTIVE
963,WO,A2,WO 2000/006245 A2,100-776-456-068-147,2000-02-10,2000,US 9917288 W,1999-07-30,US 9476598 P,1998-07-31,METHOD FOR CORRECTION OF MRI MOTION ARTIFACTS AND MAIN FIELD FLUCTUATION,A method for correcting MRI motion artifacts and main field fluctuations. A series of data prints are acquired at read points along a radial axis to form a view (210). Subsequent views define a NMR data set. A processor stores the NMR data set and reconstructs an image array from a stored NMR data set by; a) reconstructing the NMR data set along a radial axis; b) producing a correction data array including correction values where each of the correction values is calculated as a function of the corresponding stored NMR datum and the stored NMR datum for the intersection of the first and subsequent projection (200) axes; c) applying the data in the correction array to the NMR data set to produce a final NMrR data set.,UNIV CASE WESTERN RESERVE;;DUERK JEFFREY L;;WENDT MICHAEL;;SHANKARANARAYANAN AJIT;;CHUNG YIU CHO;;LEWIN JONATHAN S;;MERKLE ELMAR,DUERK JEFFREY L;;WENDT MICHAEL;;SHANKARANARAYANAN AJIT;;CHUNG YIU-CHO;;LEWIN JONATHAN S;;MERKLE ELMAR,,https://lens.org/100-776-456-068-147,Patent Application,yes,0,7,4,4,0,A61B5/055;;A61B5/7257;;G01R33/482;;G01R33/56509;;G01R33/56563;;G01R33/5676;;G01R33/56509;;G01R33/56563;;A61B5/7257;;G01R33/482;;A61B5/055;;G01R33/5676,A61B5/055;;G01R33/565;;G01R33/567,,0,0,,,,PENDING
964,AU,A,AU 1999/056691 A,117-835-390-018-298,2000-02-21,2000,AU 1999/056691 A,1999-07-30,US 9476598 P;;US 9917288 W,1998-07-31,Method for correction of mri motion artifacts and main field fluctuation,,UNIV CASE WESTERN RESERVE,DUERK JEFFREY L;;WENDT MICHAEL;;SHANKARANARAYANAN AJIT;;CHUNG YIU-CHO;;LEWIN JONATHAN S;;MERKLE ELMAR,,https://lens.org/117-835-390-018-298,Patent Application,no,0,0,4,4,0,A61B5/055;;A61B5/7257;;G01R33/482;;G01R33/56509;;G01R33/56563;;G01R33/5676;;G01R33/56509;;G01R33/56563;;A61B5/7257;;G01R33/482;;A61B5/055;;G01R33/5676,A61B5/055;;G01R33/565;;G01R33/567,,0,0,,,,DISCONTINUED
965,WO,A1,WO 2020/092781 A1,109-388-474-686-574,2020-05-07,2020,US 2019/0059178 W,2019-10-31,US 201862754948 P,2018-11-02,"PROPELLING DEVICES FOR PROPELLING THROUGH A MEDIUM, USING EXTERNAL MAGNETIC STIMULI APPLIED THEREON","A propelling device and methods of use thereof. The device is configured to propel through a medium, using external magnetic stimuli applied thereon; the device comprises: a propelling-element and a magnet in communication with the propelling element. The magnet is configured to respond to the applied magnetic stimuli and to rotate the propelling-element; the propelling-element is configured to convert rotary motion thereof into translation motion, and thereby to propel the device through the medium.",BIONAUT LABS LTD;;SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;SARGSYAN HOVHANNES;;CHO SUEHYUN;;CAPUTO JOHN;;VAN CLEVE ELI;;OREN ERAN,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;SARGSYAN HOVHANNES;;CHO SUEHYUN;;CAPUTO JOHN;;VAN CLEVE ELI;;OREN ERAN,,https://lens.org/109-388-474-686-574,Patent Application,yes,5,0,5,5,0,A61B34/30;;A61B34/73;;A61B2034/302;;A61B2034/303;;A61B34/72;;A61B2034/733;;A61B2034/302;;A61B2034/303;;A61B34/73;;A61K49/0002,A61B34/30;;A61B34/00;;A61B34/20;;A61K9/14;;A61K9/50;;A61K9/51;;A61K49/18,,0,0,,,,PENDING
966,US,B2,US 11753601 B2,197-065-289-429-854,2023-09-12,2023,US 202217670796 A,2022-02-14,US 202217670796 A;;US 202117222245 A;;US 202063005948 P,2020-04-06,"Ultra-low friction materials for lubricating surfaces, devices therewith, and methods of manufacture and use thereof","A polymeric material mixture comprising a fluorine-containing polymer, a siloxane polymer, and at least two polymer processing additives (PPA), wherein the at least two polymer processing additives have different chemistries. For example, there can be a flexible coextruded pipe for providing a protective housing for cables, fluids, sludge or solids, the pipe comprising a pair of telescopically related inner and outer layers, where said inner layer is lubricated with the polymeric material mixture.",DURA LINE LLC;;CHUNG JIN,CHUNG H THOMAS;;FAN FEI;;CHO SUNG KI;;LUKUBIRA SAM;;SPRADLING CALEB MICHAEL;;VALENCIA ARTURO,DURA-LINE LLC (2022-04-19);;DURA-LINE CORPORATION (2021-04-06),https://lens.org/197-065-289-429-854,Granted Patent,yes,26,0,9,9,0,C09D183/04;;C08K3/042;;C10N2030/06;;C10M2213/0623;;C10N2020/06;;C10N2020/04;;C10M2229/025;;C10M2205/022;;C10M157/10;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10M169/041;;C10M2201/0413;;C10M2205/022;;C10M2213/02;;C10M2213/0623;;C10M2229/025;;C10N2040/32;;C10N2050/08;;A47C27/001;;A47C27/002;;A47C27/04;;A47C27/20;;A47C31/001,C10M169/04;;A47C27/00;;A47C27/04;;A47C27/20;;A47C31/00;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10N40/32;;C10N50/08,,5,2,020-657-272-255-00X;;109-699-234-621-788,10.1016/b978-1-4377-3461-4.00006-4;;10.1080/01932691.2016.1257390,"Bell, The effect of PTFE thickener particle characteristics on grease formulation and performance, Material Science, NLGI Spokesman, 1996, vol. 60, pp. 12-15.;;Canada Office Action dated Jan. 7, 2022 in related Application 3113778 filed Jan. 7, 2014 (4 pages).;;Ebnesajjad et al., Fluoropolymer Additives, Chapter 6, Application of Fluorinated Additives for Lubricants, 2012, pp. 69-106.;;International Search Report and Written Opinion dated Jul. 7, 2021 for Application PCT/US21/25737 filed Apr. 5, 2021 (16 pages).;;Kamel et al., Tribological Properties of Graphene Nanosheets as an Additive in Calcium Grease, Journal of Dispersion Science and Technology, 2017, vol. 38, No. 10, pp. 1495-1500.",ACTIVE
967,EP,A2,EP 1518142 A2,185-121-894-223-991,2005-03-30,2005,EP 03763302 A,2003-07-02,US 0321230 W;;US 39293802 P,2002-07-02,ELECTRO-OPTICAL INTEGRATED TRANSMITTER CHIP FOR ARBITRARY QUADRATURE MODULATION OF OPTICAL SIGNALS,,CELIGHT INC,KAPLAN ARKADY;;ACHIAM YAAKOV;;GREENBLATT ARTHUR;;SHPANTZER ISAAC;;CHO PAK SHING;;TSEYTLIN MICHAEL;;SALAMON AVIV,,https://lens.org/185-121-894-223-991,Patent Application,yes,0,0,5,110,0,G02F1/225;;G02F2203/06;;H04B10/505;;H04B10/5051;;H04B10/5053;;H04B10/5057;;H04B10/50577;;H04B10/532;;H04B10/541;;H04B10/5561,G02F1/225;;H04B10/50;;H04B10/532;;H04B10/54;;H04B10/556,,1,0,,,See references of WO 2004005972A3,DISCONTINUED
968,US,A1,US 2021/0188010 A1,156-851-286-552-743,2021-06-24,2021,US 201916718754 A,2019-12-18,US 201916718754 A,2019-12-18,TIRE WITH TREAD ELEMENTS INCLUDING DUAL ANGLED CHAMFER,"A tire includes a tread formed with tread elements that include a dual angled chamfer. The tire includes a pair of sidewalls extending radially outward to a ground-engaging tread. A plurality of circumferentially-extending grooves extend about the tread and define a plurality of ribs. A plurality of laterally-extending grooves cooperate with the circumferential grooves to divide the ribs into tread elements. A plurality of selected tread elements are formed with a dual angled chamfer. Each of the selected tread elements includes a body, a radially outer, ground-engaging surface, a chamfer side, and a dual angled chamfer that is formed in the body between the ground-engaging surface and the chamfer side.",GOODYEAR TIRE & RUBBER,SKURICH MICHAEL STEFAN;;JUERGENS ZACHARY WILLIAM;;ROBERTS JEREMY LEE;;CHO JUNG WAN;;STRACH GREGORY MARVIN,GOODYEAR TIRE & RUBBER COMPANY (2020-01-14),https://lens.org/156-851-286-552-743,Patent Application,yes,2,0,4,4,0,B60C11/0306;;B60C11/1392;;B60C11/1392;;B60C2011/133;;B60C11/11,B60C11/03,,1,0,,,English machine translation of JPH03-132403. (Year: 1991),ACTIVE
969,US,B2,US 11702612 B2,196-922-611-506-81X,2023-07-18,2023,US 202117222245 A,2021-04-05,US 202117222245 A;;US 202063005948 P,2020-04-06,"Ultra-low friction materials for lubricating surfaces, devices therewith, and methods of manufacture and use thereof","A polymeric material mixture comprising a fluorine-containing polymer, a siloxane polymer, and at least two polymer processing additives (PPA), wherein the at least two polymer processing additives have different chemistries. For example, there can be a flexible coextruded pipe for providing a protective housing for cables, fluids, sludge or solids, the pipe comprising a pair of telescopically related inner and outer layers, where said inner layer is lubricated with the polymeric material mixture.",DURA LINE LLC,CHUNG H THOMAS;;FAN FEI;;CHO SUNG KI;;LUKUBIRA SAM;;SPRADLING CALEB MICHAEL;;VALENCIA ARTURO,DURA-LINE LLC (2022-04-19);;DURA-LINE CORPORATION (2021-04-06),https://lens.org/196-922-611-506-81X,Granted Patent,yes,25,0,9,9,0,C09D183/04;;C08K3/042;;C10N2030/06;;C10M2213/0623;;C10N2020/06;;C10N2020/04;;C10M2229/025;;C10M2205/022;;C10M157/10;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10M169/041;;C10M2201/0413;;C10M2205/022;;C10M2213/02;;C10M2213/0623;;C10M2229/025;;C10N2040/32;;C10N2050/08;;A47C27/001;;A47C27/002;;A47C27/04;;A47C27/20;;A47C31/001,C10M169/04;;A47C27/00;;A47C27/04;;A47C27/20;;A47C31/00;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10N40/32;;C10N50/08,,5,2,020-657-272-255-00X;;109-699-234-621-788,10.1016/b978-1-4377-3461-4.00006-4;;10.1080/01932691.2016.1257390,"Bell, The effect of PTFE thickener particle characteristics on grease formulation and performance, Material Science, NLGI Spokesman, 1996, vol. 60, pp. 12-15.;;Canada Office Action dated Jan. 7, 2022 in related Application 3113778 filed Jan. 7, 2014 (4 pages).;;Ebnesajjad et al., Fluoropolymer Additives, Chapter 6, Application of Fluorinated Additives for Lubricants, 2012, pp. 69-106.;;International Search Report and Written Opinion dated Jul. 7, 2021 for Application PCT/US21/25737 filed Apr. 5, 2021 (16 pages).;;Kamel et al., Tribological Properties of Graphene Nanosheets as an Additive in Calcium Grease, Journal of Dispersion Science and Technology, 2017, vol. 38, No. 10, pp. 1495-1500.",ACTIVE
970,US,A1,US 2022/0167757 A1,198-387-142-413-020,2022-06-02,2022,US 202217670796 A,2022-02-14,US 202217670796 A;;US 202117222245 A;;US 202063005948 P,2020-04-06,"ULTRA-LOW FRICTION MATERIALS FOR LUBRICATING SURFACES, DEVICES THEREWITH, AND METHODS OF MANUFACTURE AND USE THEREOF","A polymeric material mixture comprising a fluorine-containing polymer, a siloxane polymer, and at least two polymer processing additives (PPA), wherein the at least two polymer processing additives have different chemistries. For example, there can be a flexible coextruded pipe for providing a protective housing for cables, fluids, sludge or solids, the pipe comprising a pair of telescopically related inner and outer layers, where said inner layer is lubricated with the polymeric material mixture.",DURA LINE CORP,CHUNG H THOMAS;;FAN FEI;;CHO SUNG KI;;LUKUBIRA SAM;;SPRADLING CALEB MICHAEL;;VALENCIA ARTURO,DURA-LINE LLC (2022-04-19);;DURA-LINE CORPORATION (2021-04-06),https://lens.org/198-387-142-413-020,Patent Application,yes,2,0,9,9,0,C09D183/04;;C08K3/042;;C10N2030/06;;C10M2213/0623;;C10N2020/06;;C10N2020/04;;C10M2229/025;;C10M2205/022;;C10M157/10;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10M169/041;;C10M2201/0413;;C10M2205/022;;C10M2213/02;;C10M2213/0623;;C10M2229/025;;C10N2040/32;;C10N2050/08;;A47C27/001;;A47C27/002;;A47C27/04;;A47C27/20;;A47C31/001,A47C31/00;;A47C27/00,,0,0,,,,ACTIVE
971,US,A1,US 2004/0028418 A1,003-874-940-958-494,2004-02-12,2004,US 61377203 A,2003-07-02,US 61377203 A;;US 96224301 A;;US 96233901 A;;US 8405702 A;;US 39293802 P,2001-09-26,Electro-optical integrated transmitter chip for arbitrary quadrature modulation of optical signals,"
   An optical device includes, a first Mach-Zehnder modulator that produces a first output, and a second Mach-Zehnder modulator which produces a second output. A splitter couples the first and second Mach-Zehnder modulators. A combiner combines the first and second outputs. A phase shifter is coupled to the first and second Mach-Zehnder modulators. The first Mach-Zehnder modulator, second Mach-Zehnder modulator, splitter, combiner and the phase shifter are each formed as part of a single chip made of electro-optical material. Such two similar optical device integrated together with polarization combiner provide a two-polarization performance. 
",KAPLAN ARKADY;;ACHIAM YAAKOV;;GREENBLATT ARTHUR;;SHPANTZER ISAAC;;CHO PAK SHING;;TSEYTLIN MICHAEL;;SALAMON AVIV,KAPLAN ARKADY;;ACHIAM YAAKOV;;GREENBLATT ARTHUR;;SHPANTZER ISAAC;;CHO PAK SHING;;TSEYTLIN MICHAEL;;SALAMON AVIV,CELIGHT INC (2006-10-31),https://lens.org/003-874-940-958-494,Patent Application,yes,18,86,2,110,0,G02F1/225;;G02F1/225;;G02F2203/06;;G02F2203/06;;H04L7/0075;;H04L7/0075;;H04B10/2543;;H04B10/2543;;H04B10/505;;H04B10/505;;H04B10/5053;;H04B10/5053;;H04B10/5057;;H04B10/5057;;H04B10/50577;;H04B10/50577;;H04B10/508;;H04B10/508;;H04B10/532;;H04B10/532;;H04B10/541;;H04B10/541;;H04B10/5561;;H04B10/5561;;H04B10/60;;H04B10/60;;H04J14/005;;H04J14/005;;H04J14/02;;H04J14/02;;H04J14/08;;H04J14/08,G02F1/225;;H04B10/148;;H04B10/155;;H04B10/18;;H04J14/00;;H04J14/02;;H04J14/08;;H04L7/00,398/188,0,0,,,,EXPIRED
972,US,B1,US 7491653 B1,073-989-646-988-923,2009-02-17,2009,US 31826805 A,2005-12-23,US 31826805 A,2005-12-23,Metal-free catalysts for pulsed deposition layer process for conformal silica laminates,"A metal- and metalloid-free nanolaminate dielectric film can be formed according to a pulsed layer deposition (PDL) process. A metal- and metalloid-free compound is used to catalyze the reaction of silica deposition by surface reaction of alkoxysilanols. Films can be grown at rates faster than 30 nm per exposure cycle. The invention can be used for the deposition of both doped (e.g., PSG) and undoped silicon oxide films. The films deposited are conformal, hence the method can accomplish void free gap-fill in high aspect ratio gaps encountered in advanced technology nodes (e.g., the 45 nm technology node and beyond), and can be used in other applications requiring conformal dielectric deposition.",NOVELLUS SYSTEMS INC,PAPASOULIOTIS GEORGE D;;CHO SEON-MEE;;RULKENS RON;;BURETEA MIHAI;;HAUSMANN DENNIS M;;BARNES MICHAEL,NOVELLUS SYSTEMS INC (2006-01-24),https://lens.org/073-989-646-988-923,Granted Patent,yes,74,6,1,1,0,H01L21/02129;;H01L21/02164;;H01L21/02216;;H01L21/02271;;H01L21/0228;;H01L21/76837;;H01L21/31612;;H01L21/31629;;H01L21/31633;;H01L21/31625;;H01L21/02216;;H01L21/02129;;H01L21/0228;;H01L21/76837;;H01L21/02271;;H01L21/02164,H01L21/469;;H01L21/31,438/778;;X257E2117;;X257E21546;;438/787,64,18,062-656-145-434-514;;031-101-182-891-155;;028-640-432-101-158;;035-975-106-740-964;;078-768-024-970-596;;081-888-986-238-990;;013-856-645-673-561;;014-631-670-368-672;;013-456-349-505-931;;099-507-823-786-716;;064-760-991-916-611;;044-692-429-339-32X;;026-575-667-968-302;;000-346-110-072-16X;;099-818-468-706-766;;041-682-257-076-827;;000-579-588-230-072;;106-851-785-492-729,12376699;;10.1126/science.1073552;;10.1002/cvde.200390005;;10.1116/1.588828;;10.1016/s0167-9317(00)00431-7;;10.1117/12.360573;;10.1109/iitc.1998.704920;;10.4028/www.scientific.net/msf.287-288.235;;10.1021/cm0007104;;10.1021/cm0007095;;10.1039/b002830o;;10.1116/1.580913;;10.1039/a607098a;;10.1149/1.1391860;;10.1149/1.1391742;;10.1149/1.1391599;;10.1149/1.1342186;;10.1149/1.2048634;;10.1016/b978-012512908-4/50005-9,"""Atomic Layer Deposition of Metal Oxide Thin Films,"" A thesis presented by Dennis Michael Hausmann, Harvard University, 186 pages, Jul. 2002.;;Hausmann et al., ""Rapid Vapor Deposition of Highly Conformal Silica Nanolaminates,"" Science, vol. 308, Oct. 2002, 5 Pages.;;Gordon et al., ""A Kinetic Model for Step Coverage by Atomic Layer Deposition in Narrow Holes or Trenches"", Chemical Vapor Deposition 2003, 9, No. 2, pp. 73-78.;;U.S. Office Action mailed May 31, 2005, from U.S. Appl. No. 10/746,274.;;Hausmann et al., ""Plasma Treatments to Improve the Properties of Silica Thin Films Produced by a Rapid Vapor Deposition (RVD)"", Novellus Systems, Inc., filed Dec. 23, 2000, U.S. Appl. No. 10/746,274, pp. 1-29.;;Greer et al., ""Method and Apparatus to Reduce the Frequency of Chamber Cleans in Rapid Vapor Deposition (RVD) of Silicon Oxide"", Novellus Systems, Inc., filed Jul. 12, 2004, U.S. Appl. No. 10/890,376, pp. 1-25.;;Hausmann et al., ""Silica Thin Films Produced by Rapid Surface Catalyzed Vapor Deposition (RVD) Using a Nucleation Layer"", Novellus Systems, Inc., filed Jun. 22, 2004, U.S. Appl. No. 10/875,158, pp. 1-25.;;U.S. Office Action mailed Sep. 22, 2005, from U.S. Appl. No. 10/874,814.;;Rulkens et al., ""Mixed Alkoxy Precursors and Methods of Their Use for Rapid Vapor Deposition of SiO2 Films"", Novellus Systems, Inc., filed Jun. 22, 2004, U.S. Appl. No. 10/874,814, pp. 1-26.;;U.S. Office Action mailed Jun. 23, 2005, from U.S. Appl. No. 10/874,808.;;Hausmann et al., ""Aluminum Phosphate Incorporation in Silica Thin Films Produced by Rapid Surface Catalyzed Vapor Deposition (RVD)"", Novellus Systems, Inc., filed Jun. 22, 2004, U.S. Appl. No. 10/874,808, pp. 1-21.;;Papsouliotis et al., ""Method for Controlling Properties of Conformal Silica Nanolaminates Formed by Rapid Vapor Deposition"", Novellus Systems, Inc., filed Jun. 22, 2004, U.S. Appl. No. 10/874,696, pp. 1-30.;;Gaillard et al., ""Silicon dioxide chemical vapor deposition using silane and hydrogen peroxide"", Rapid Communications, J. Vac. Sci. Technol. B 14(4), Jul./Aug. 1996, pp. 2767-2769.;;Beekmann, et al., ""Properties of posttreated low kappa flowfill(TM) films and their stability after etch, resist and polymer strip processes"", Microelectronic Engineering 55(2001), pp. 73-79.;;Robl et al., ""Integration of Flowfill(R) and Forcefill(R) for cost effective via applications"" Sep. 1999, pp. 77-83.;;Penka et al., ""Integration Aspects of Flowfill and Spin-on-Glass Process for Sub-0.35mum Interconnects"", pp. 1-3.;;Hockele et al., ""Flowfill-Process as a New Concept for Inter-Metal-Dielectrics"", Siemens AG, Semiconductor Group, 1998, pp. 235-238.;;Roland et al., ""Theoretical Modeling of SiO2 Photochemical Vapor Deposition and Comparison to Experimental Results for Three Oxidant Chemistries: SiH4+O2, H2O/O2, and H2O2"", Chem Mater 2001, 13, 2501-2510.;;Roland et al., ""Low Temperature Photochemical Vapor Deposition of SiO2 Using 172 nm Xe2* Excimer Lamp Radiation with Three Oxidant Chemistries: O2, H2O/O2, and H2O2"", Chem Mater 2001, 13, 2493-2500.;;Moore et al., ""Reaction of hydrogen peroxide with organosilanes under chemical vapour deposition conditions"", J. Chem. Soc., Dalton Trans., 2000, 2673-2677.;;Gaillard et al., ""Effect of plasma and thermal annealing on chemical vapor deposition dielectrics grown using SIH4-H2O2 gas mixtures"", J. Vac. Sci. Technol. A 15(5), Sep./Oct. 1997, pp. 2478-2484.;;Taylor et al., ""Studies on the reaction between silane and hydrogen peroxide vapour; surface formation of planarized silica layers"", J. Chem. Soc., Dalton Trans., 1997, pp. 1049-1053.;;Xia et al., ""High Aspect Ratio Trench Filling Using Two-Step Subatmospheric Chemical Vapor Deposited Borophosphosilicated Glass for <0.18 mum Device Application"", Journal of The Electrochemical Society, 146 (5) 1884-1888 (1999).;;Xia et al., ""High Temperature Subatmospheric Chemical Vapor Deposited Undoped Silicated Glass-A Solution for Next Generation Shallow Trench Isolation"", Journal of The Electrochemical Society, 146 (3) 1181-1185 (1999).;;Arno et al., ""Fourier Transform Infrared Characterization of Downstream Gas-Phase Species Generated by Tetraethylorthosilicate/Ozone Atmospheric Pressure Reactions"", Journal of The Electrochemical Society, 146 (1) 276-280 (1999).;;Romet et al., ""Modeling of Silicon Dioxide Chemical Vapor Deposition from Tetraethoxysilane and Ozone"", Journal of The Electrochemical Society, 148 (2) G82-G90 (2001).;;Ikeda et al., ""The Effects of Alkoxy Functional Groups on Atomospheric-Pressure Chemical Vapor Deposition Using Alkoxysilane and Ozone"", J. Electrochem. Soc., vol. 142, No. 5, May 1995, pp. 1659-1662.;;""Customer A low k Gapfill Trikon FlowFill vs FHDP"", Novellus Systems, Inc., pp. 1-12.;;Ritala et al., ""Atomic Layer Deposition"", Handbook of Thin Films Materials, vol. 1, 2002, pp. 103-159.;;Rulkens et al., ""Methods for the Use of Alkoxysilanol Precursors for Vapor Deposition of SiO2 Films"", Novellus Systems, Inc., filed Dec. 23, 2004, U.S. Appl. No. 11/021,558, pp. 1-24.;;Papasouliotis et al., ""Dynamic Rapid Vapor Deposition Process for Conformal Silica Laminates"", Novellus Systems, Inc., filed Dec. 30, 2004, U.S. Appl. No. 11/027,480, pp. 1-29.;;Papasouliotis et al., ""Multi-Step Nanolaminate Dielectric Deposition and Etch Back Gap Fill Process"", Novellus Systems, Inc., filed Dec. 30, 2004, U.S. Appl. No. 11/026,563, pp. 1-28.;;Rulkens et al., ""Chamber and Chamber Surface Materials to Inhibit Deposition and Methods of Making Same"", Novellus Systems, Inc., filed Dec. 23, 2004, U.S. Appl. No. 11/027,388, pp. 1-26.;;Papasouliotis et al., ""Methods for Forming High Density, Conformal, Silica Nanolaminate Films Via Pulsed Deposition Layer In Structures of Confined Geometry"", Novellus Systems, Inc., filed Dec. 30, 2004, U.S. Appl. No. 11/026,284, pp. 1-24.;;U.S. Office Action mailed Oct. 6, 2005, from U.S. Appl. No. 10/975,028.;;Tarafdar et al., ""Sequential Deposition/Anneal Film Densification Method"", Novellus Systems, Inc., filed Oct. 26, 2004, U.S. Appl. No. 10/975,028, pp. 1-34.;;Papasouliotis, George D., ""Optimal Operation of Conformal Silica Deposition Reactors"", Novellus Systems, Inc., U.S. Appl. No. 11/077,198, filed Mar. 9, 2005, pp. 1-32.;;Papasouliotis, George D., ""Optimal Operation of Conformal Silica Deposition Reactors"", Novellus Systems, Inc., U.S. Appl. No. 11/077,108, filed Mar. 9, 2005, pp. 1-31.;;Cho et al., "" Hydroxyl Bond Removal and Film Densification Method for Oxide Films Using Microwave Post Treatment"", Novellus Systems, Inc., U.S. Appl. No. 11/280,076, filed Nov. 15, 2005, pp. 1-27.;;U.S. Office Action mailed Nov. 10, 2005, from U.S. Appl. No. 11/021,558.;;U.S. Office Action mailed Dec. 30, 2005, from U.S. Appl. No. 11/026,284.;;U.S. Office Action mailed Dec. 5, 2005, from U.S. Appl. No. 10/746,274.;;U.S. Office Action mailed Dec. 7, 2005, from U.S. Appl. No. 10/874,808.;;U.S. Office Action mailed Dec. 22, 2005, from U.S. Appl. No. 11/026,563.;;Cho et al., ""Localized Energy Pulse Rapid Thermal Anneal Dielectric Film Densification Method"", Novellus Systems, Inc., U.S. Appl. No. 11/327,668, filed Jan. 5, 2006, pp. 1-28.;;Papasouliotis et al., ""Reactive Seam Healing Methods for Improving Film Integrity In Structures of Confined Geometry"", Novellus Systems, Inc., U.S. Appl. No. 11/334,762, filed Jan. 17, 2006, pp. 1-24.;;U.S. Office Action mailed Feb. 24, 2006, from U.S. Appl. No. 11/077,108.;;U.S. Office Action mailed Mar. 24, 2006, from U.S. Appl. No. 10/975,028.;;U.S. Office Action mailed Jul. 7, 2006, from U.S. Appl. No. 10/875,158.;;U.S. Office Action mailed Sep. 27, 2006, from U.S. Appl. No. 11/021,558.;;U.S. Office Action mailed Sep. 27, 2006, from U.S. Appl. No. 11/026,284.;;U.S. Office Action mailed Sep. 29, 2006, from U.S. Appl. No. 11/027,480.;;U.S. Office Action mailed Jan. 16, 2007, from U.S. Appl. No. 10/874,696.;;U.S. Office Action mailed Mar. 21, 2007, from U.S. Appl. No. 11/414,459.;;U.S. Office Action mailed Apr. 13, 2007, from U.S. Appl. No. 11/026,284.;;U.S. Office Action mailed Mar. 23, 2007, from U.S. Appl. No. 11/021,558.;;Papasouliotis et al., ""Pulsed Deposition Layer Gap Fill With Expansion Material,"" Novellus Systems, Inc., U.S. Appl. No. 11/414,459, filed Apr. 28, 2006, pp. 1-28.;;Papasouliotis et al., ""Conformal Nanolaminate Dielectric Deposition and Etch Back Gap Fill Process and Apparatus,"" Novellus Systems, Inc., U.S. Appl. No. 11/524,502, filed Sep. 19, 2006, pp. 1-38.;;U.S. Office Action mailed May 23, 2006, from U.S. Appl. No. 11/077,198.;;U.S. Office Action mailed May 24, 2006, from U.S. Appl. No. 11/026,284.;;U.S. Office Action mailed May 31, 2006, from U.S. Appl. No. 11/026,563.;;U.S. Office Action mailed May 15, 2006, from U.S. Appl. No. 11/027,480.;;U.S. Office Action mailed Apr. 25, 2006, from U.S. Appl. No. 11/021,558.;;U.S. Office Action mailed May 8, 2006, from U.S. Appl. No. 11/327,668.",INACTIVE
973,AU,A8,AU 2003/278698 A8,109-471-931-548-597,2004-01-23,2004,AU 2003/278698 A,2003-07-02,US 39293802 P;;US 0321230 W,2002-07-02,Electro-optical integrated transmitter chip for arbitrary quadrature modulation of optical signals,,CELIGHT INC,TSEYTLIN MICHAEL;;GREENBLATT ARTHUR;;SHPANTZER ISAAC;;KAPLAN ARKADY;;SALAMON AVIV;;ACHIAM YAAKOV;;CHO PAK SHING,,https://lens.org/109-471-931-548-597,Patent Application,no,0,0,5,110,0,G02F1/225;;G02F2203/06;;H04B10/505;;H04B10/5051;;H04B10/5053;;H04B10/5057;;H04B10/50577;;H04B10/532;;H04B10/541;;H04B10/5561,G02F1/225;;H04B10/50;;H04B10/532;;H04B10/54;;H04B10/556,,0,0,,,,DISCONTINUED
974,CR,A,CR 11680 A,055-200-456-646-339,2010-11-23,2010,CR 11680 A,2010-09-21,US 3967408 P,2008-03-26,Inhibidores de Desacetilasas B a Base de Hidroxamato,"Las ensenanzas de la presente invencion se refieren a los compuestos de la Formula I:y sales, hidratos, esteres, y profarmacos farmaceuticamente aceptables de los mismos, en donde R1, R2, R3, Y, Z, y son tal como se define en la presente invencion.",NOVARTIS AG,SHULTZ MICHAEL;;CHEN CHRISTINE;;CHO YOUNG SHIN;;JIANG LEI;;FAN JIANMEI;;LIU GANG;;MAJUMDAR DYUTI,,https://lens.org/055-200-456-646-339,Patent Application,no,0,0,46,46,0,C07D207/08;;C07D401/06;;C07D403/06;;C07D405/06;;C07D413/06;;C07D471/04;;A61P13/08;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/04;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/10;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;A61P9/04;;A61P9/10;;C07D207/08;;C07D405/06;;C07D401/06;;C07D471/04;;C07D403/06;;C07D413/06,A61K31/4025;;A61P35/00;;C07D207/08;;C07D401/06;;C07D403/06;;C07D405/06;;C07D413/06;;C07D471/04,,0,0,,,,DISCONTINUED
975,EP,A2,EP 1192269 A2,059-525-341-351-38X,2002-04-03,2002,EP 00942919 A,2000-06-16,US 0016773 W;;US 13993699 P;;US 19461800 P,1999-06-18,MASS TRANSPORT LIMITED i IN VIVO /i ANALYTE SENSOR,,THERASENSE INC,SAY JAMES;;TOMASCO MICHAEL F;;SAKSLUND HENNING;;AUDETT JAY D;;CHO HYUN;;YAMASAKI DUANE O,ABBOTT DIABETES CARE INC. (2008-06-04),https://lens.org/059-525-341-351-38X,Patent Application,yes,0,0,10,10,0,A61B5/14865;;A61B5/14865;;A61B5/1486;;A61B5/1486;;C12Q1/002;;C12Q1/002;;C12Q1/006;;C12Q1/006;;Y10S977/925;;Y10S977/925,G01N33/483;;A61B5/00;;A61B5/145;;A61B5/1468;;A61B5/1486;;C12Q1/00;;G01N27/327;;G01N27/416;;G01N27/49;;G01N33/487,,1,0,,,See references of WO 0078992A3,DISCONTINUED
976,US,A1,US 2021/0401526 A1,053-467-625-705-855,2021-12-30,2021,US 201917289675 A,2019-10-31,US 201917289675 A;;US 201862754948 P;;US 2019/0059178 W,2018-11-02,"PROPELLING DEVICES FOR PROPELLING THROUGH A MEDIUM, USING EXTERNAL MAGNETIC STIMULI APPLIED THEREON","A propelling device and methods of use thereof. The device is configured to propel through a medium, using external magnetic stimuli applied thereon; the device comprises: a propelling-element and a magnet in communication with the propelling element. The magnet is configured to respond to the applied magnetic stimuli and to rotate the propelling-element; the propelling-element is configured to convert rotary motion thereof into translation motion, and thereby to propel the device through the medium.",SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;SARGSYAN HOVHANNES;;CAPUTO JOHN;;VAN CLEVE ELI;;OREN ERAN;;CHO SUCHYUN;;BIONAUT LABS LTD,SHPIGELMACHER MICHAEL;;KISELYOV ALEX;;SARGSYAN HOVHANNES;;CAPUTO JOHN;;VAN CLEVE ELI;;OREN ERAN;;CHO SUEHYUN,,https://lens.org/053-467-625-705-855,Patent Application,yes,0,1,5,5,0,A61B34/30;;A61B34/73;;A61B2034/302;;A61B2034/303;;A61B34/72;;A61B2034/733;;A61B2034/302;;A61B2034/303;;A61B34/73;;A61K49/0002,A61K49/00;;A61B34/00,,0,0,,,,PENDING
977,RU,C2,RU 2737765 C2,106-014-215-711-215,2020-12-02,2020,RU 2017101868 A,2013-04-29,US 201261642844 P,2012-05-04,PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES,"FIELD: biotechnology.SUBSTANCE: invention provides (a) isolated immunogenic PAA polypeptides; (b) recovered nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions containing an immunogenic polypeptide PAA or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to use of said polypeptides, nucleic acid molecules and compositions; and (e) a vaccine-based immunotherapy regimen which involve combined administration of the vaccine in a combination with an immune-effector cell enhancer.EFFECT: presented are prostate-associated antigens and immunotherapeutic regimens based on vaccines.28 cl, 43 dwg, 32 tbl, 20 ex",PFIZER,BINDER JOSEPH JOHN;;(US);;CHO HELEN KIM;;(US);;DERMYER MICHAEL ROBERT;;(US);;JOOSS KARIN UTE,,https://lens.org/106-014-215-711-215,Granted Patent,no,0,0,70,72,0,A61K31/404;;C12N9/485;;C12Y304/17021;;C07K14/4748;;A61K2039/585;;A61K2039/53;;A61K2039/55516;;A61K39/001195;;A61K39/001193;;A61K39/001194;;C12Y304/17021;;C12N9/485;;A61K31/404;;C12N9/6445;;A61K31/7088;;A61P13/08;;A61P35/00;;A61P37/02;;A61P37/04;;A61P43/00;;A61K39/001194;;A61K39/001195;;A61K39/001193;;C07K14/705;;A61K39/00;;A61K39/395;;C07K14/705;;C07K14/71;;C12N9/48;;C12N15/00;;A61K39/001194;;A61K39/001195;;A61K39/001193;;A61K39/39;;C07K14/82;;C12N15/85;;A61K39/001195;;A61K39/001193;;A61K39/001194;;A61K31/404;;A61K39/00;;C12Q1/6806;;C12N9/485;;C12Y304/17021;;A61K39/001195;;A61K39/001193;;A61K39/001194;;A61K39/39;;A61K39/3955;;A61K31/404;;A61K2039/53;;A61K2039/55561;;C07K14/4748;;C12N9/6445;;A61K9/0019;;A61K31/7088;;C07K16/2818;;C07K16/3023;;C07K16/303;;C07K16/3069;;C07K2317/21;;C07K2317/76,C12Q1/68;;A61K38/57;;C07K14/82,,0,0,,,,ACTIVE
978,CN,A,CN 106062086 A,106-917-381-029-841,2016-10-26,2016,CN 201580004553 A,2015-01-13,EP 14151392 A;;IB 2015050245 W,2014-01-16,Hole transporting and light absorbing material for solid state solar cells,"The present invention relates to a compound of formula (I) based on quinozilino acridine and used as hole transporting and light absorbing material in a photovoltaic device, in particular in a solid state solar cell. (I)",ECOLE POLYTECHNIQUE FED LAUSANNE EPFL,QIN PENG;;NAZEERUDDIN MOHAMMAD KAJA;;GRAETZEL MICHAEL;;KO JAE-JUNG;;PAEK SANGH-YUN;;CHO NARA,,https://lens.org/106-917-381-029-841,Patent Application,no,7,1,9,9,0,C09K11/06;;C09B57/00;;C09B57/008;;C09K2211/1029;;C09K2211/1051;;C09K2211/1092;;C09K2211/1096;;Y02E10/549;;Y02E10/542;;H10K85/652;;H10K85/655;;H10K85/6576;;H10K85/6572;;H10K85/657;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;H10K85/50;;C07D409/14;;C07F7/0816;;C09B57/008;;C09K11/06;;C09K2211/1096;;C09K2211/1092;;C09K2211/1051;;C09K2211/1029;;H10K85/791;;H10K85/40;;H10K30/151;;H10K30/50;;C09B57/008;;C09B57/00;;C09K11/06;;C09K2211/1096;;C09K2211/1051;;C09K2211/1029;;C09K2211/1092;;Y02E10/549;;H10K85/40;;H10K85/652;;H10K85/655;;H10K85/657;;H10K85/791;;H10K85/6572;;H10K30/151;;H10K85/6576;;H01G9/2013;;H01G9/2018;;H01G9/2031;;H01G9/2059,C09B57/00;;C09K11/06;;H01L51/00;;H05B33/14,,0,0,,,,DISCONTINUED
979,WO,A1,WO 2008/082467 A1,197-369-253-824-521,2008-07-10,2008,US 2007/0025257 W,2007-12-11,US 64651406 A,2006-12-28,EXHAUST TREATMENT SYSTEM,"An exhaust gas treatment system (10, 100, 200, 300) of an internal combustion engine (12) includes a selective catalytic reduction catalyst (19) fluidly connected to the internal combustion engine (12), an oxidation catalyst fluidly connected upstream of the selective catalytic reduction catalyst (19), and a particulate filter (16, 36) fluidly connected upstream of the selective catalytic reduction catalyst (19). The exhaust gas treatment system (10, 100, 200, 300) further includes a recirculation line (24) configured to direct a portion of an exhaust flow of the internal combustion engine (12) toward an inlet (21) of the engine (12).",CATERPILLAR INC;;DRISCOLL JAMES JOSHUA;;CHAVANNAVAR PRAVEEN S;;PAULSON THOMAS E;;LIANG CHO Y;;WOODS MICHAEL L,DRISCOLL JAMES JOSHUA;;CHAVANNAVAR PRAVEEN S;;PAULSON THOMAS E;;LIANG CHO Y;;WOODS MICHAEL L,,https://lens.org/197-369-253-824-521,Patent Application,yes,5,1,2,2,0,F01N3/023;;F01N3/023;;F01N3/035;;F01N3/035;;F01N3/0814;;F01N3/0814;;F01N3/0821;;F01N3/0821;;F01N3/206;;F01N3/206;;F01N9/002;;F01N9/002;;F01N13/009;;F01N13/009;;F02B37/013;;F02B37/013;;F02M26/06;;F02M26/06;;Y02T10/12;;Y02T10/12;;Y02T10/40;;Y02T10/40,F01N3/023;;F01N3/035;;F01N3/08;;F01N3/20;;F01N9/00;;F02D41/00,,0,0,,,,PENDING
980,WO,A1,WO 2017/010945 A1,199-892-568-498-23X,2017-01-19,2017,SG 2016050333 W,2016-07-15,US 201562193307 P;;US 201562263192 P,2015-07-16,MICROENCAPSULATION OF COMPOUNDS INTO NATURAL SPORES AND POLLEN GRAINS,"In one aspect, provided herein are whole spores engineered to capsulate a compound(s) or substance(s). In certain embodiments, the whole spore encapsulating the compound(s) or substance(s) is coated with or co-encapsulated with a hydrogel or other agent(s) to control the rate release of the compound(s) or substance(s) from the spore. In another aspect, provided herein are methods of producing whole spores encapsulating a compound(s) or substance(s). In another aspect, provided herein are formulations comprising either a whole spore, or a whole spore encapsulating a compound(s) or substance(s), and uses of those formulations.",UNIV NANYANG TECH,CHO NAM-JOON;;POTROZ MICHAEL GRAEME;;MUNDARGI RAGHAVENDRA CHALUVAYYA;;PARK JAE HYEON;;JACKMAN JOSHUA ALEXANDER,,https://lens.org/199-892-568-498-23X,Patent Application,yes,6,17,2,2,0,A23P10/30;;A23P10/30;;A01N25/00;;A01N25/08;;A61K8/0279;;A61K8/11;;A61K8/922;;A61K8/9722;;A61K8/9722;;A61K8/9728;;A61K8/9728;;A61K8/9755;;A61K8/9755;;A61K8/9789;;A61K8/9789;;A61K8/9794;;A61K8/9794;;A61K8/99;;A61K8/99;;A61K9/0014;;A61K9/0019;;A61K9/5063;;A61K2800/10;;A61K2800/28;;A61K2800/412;;A61K2800/56;;A61Q19/00;;A61Q19/10,A61K9/50;;A23P10/30;;A61K8/11;;A61K9/52;;A61Q19/10,,6,5,012-912-094-141-40X;;065-304-053-703-131;;013-468-706-064-061;;068-230-727-717-223;;002-000-979-144-398,10.1128/aem.00153-14;;24837390;;pmc4148785;;10.3390/pharmaceutics6010080;;24638098;;pmc3978527;;26516033;;10.1002/smll.201500860;;10.1002/adfm.201502322;;10.1016/j.jiec.2016.01.022,"SHI L. ET AL.: ""Use of Yeast Spores for Microencapsulation of Enzymes."", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 80, no. 15, 16 May 2014 (2014-05-16), pages 4502 - 4510, XP055351861, [retrieved on 20160920];;XOVAIN: ""The DIY honey mask/scrub that makes my skin glow."", 6 October 2014 (2014-10-06), XP055351864, Retrieved from the Internet <URL:https://web.archive.org/web/20141006065037/ http://www.xovain.com/skin/3- ingredient-honey-face-mask-and-scrub> [retrieved on 20160920];;DIEGO-TABOADA A. ET AL.: ""Hollow Pollen Shells to Enhance Drug Delivery."", PHARMACEUTICS, vol. 6, no. 1, 14 March 2014 (2014-03-14), pages 80 - 96, XP055351865, [retrieved on 20160920];;MUNDARGI R.C. ET AL.: ""Natural Sunflower Pollen as a Drug Delivery Vehicle."", SMALL, vol. 12, no. 9, 30 October 2015 (2015-10-30), pages 1167 - 1173, XP055351867, [retrieved on 20160920];;MUNDARGI R.C. ET AL.: ""Lycopodium Spores: A Naturally Manufactured, Superrobust Biomaterial for Drug Delivery."", ADVANCED FUNCTIONAL MATERIALS, vol. 26, no. 4, 7 December 2015 (2015-12-07), pages 487 - 497, XP055351868, [retrieved on 20160920];;MUNDARGI R.C. ET AL.: ""Encapsulation and controlled release formulations of 5-fluorouracil from natural Lycopodium clavatum spores."", JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY, vol. 36, 5 February 2016 (2016-02-05), pages 102 - 108, XP029521967, [retrieved on 20160920]",PENDING
981,US,B2,US 7272271 B2,035-783-822-206-934,2007-09-18,2007,US 61377203 A,2003-07-02,US 61377203 A;;US 96224301 A;;US 96233901 A;;US 8405702 A;;US 39293802 P,2001-09-26,Electro-optical integrated transmitter chip for arbitrary quadrature modulation of optical signals,"An optical device includes, a first Mach-Zehnder modulator that produces a first output, and a second Mach-Zehnder modulator which produces a second output. A splitter couples the first and second Mach-Zehnder modulators. A combiner combines the first and second outputs. A phase shifter is coupled to the first and second Mach-Zehnder modulators. The first Mach-Zehnder modulator, second Mach-Zehnder modulator, splitter, combiner and the phase shifter are each formed as part of a single chip made of electro-optical material. Such two similar optical device integrated together with polarization combiner provide a two-polarization performance.",CELIGHT INC,KAPLAN ARKADY;;ACHIAM YAAKOV;;GREENBLATT ARTHUR;;SHPANTZER ISAAC;;CHO PAK SHING;;TSEYTLIN MICHAEL;;SALAMON AVIV,CELIGHT INC (2006-10-31),https://lens.org/035-783-822-206-934,Granted Patent,yes,19,77,2,110,0,G02F1/225;;G02F1/225;;G02F2203/06;;G02F2203/06;;H04L7/0075;;H04L7/0075;;H04B10/2543;;H04B10/2543;;H04B10/505;;H04B10/505;;H04B10/5053;;H04B10/5053;;H04B10/5057;;H04B10/5057;;H04B10/50577;;H04B10/50577;;H04B10/508;;H04B10/508;;H04B10/532;;H04B10/532;;H04B10/541;;H04B10/541;;H04B10/5561;;H04B10/5561;;H04B10/60;;H04B10/60;;H04J14/005;;H04J14/005;;H04J14/02;;H04J14/02;;H04J14/08;;H04J14/08,G02F1/035;;G02B6/26;;G02B6/42;;G02F1/225;;H04B10/148;;H04B10/155;;H04B10/18;;H04J14/00;;H04J14/02;;H04J14/08;;H04L7/00,385/3;;385/39;;359/246;;359/254,4,3,040-525-302-811-160;;084-057-266-624-588;;042-029-377-345-934,10.1007/bf00619566;;10.1109/50.50731;;10.1109/68.917854,"G. Nicholson, ""Optical Source linewidth criteria for heterodyne communication systems with PSK modulation"", Optical and Quantum Electronics, vol. 17, pp. 399-410, 1985.;;R.A. Griffin, et al., ""10 Gb/s optical differential quadtrature phase shift key (DQPSK) transmission using GaAs/AlGaAs integration"", Proceedings OFC-2002, Mar. 2002, Anaheim, CA, post-deadline paper.;;G. Kazovsky, et al, ""ASK and FSK coherent lightwave systems: a simplified approximate analysis"", IEEE Journal of Lightwave Technology, vol. 8, No. 3, pp. 338-353, 1990.;;S. Shimotsu, et al., ""Single Side-Band Modulation Performance of LiNbO3 Integrated Modulator Consisting of Four-Phase Modulator Waveguides"", IEEE Photon. Tech. Letters, vol. 13, No. 4, pp. 365-366, 2001.",EXPIRED
982,WO,A3,WO 2004/005972 A3,108-427-150-715-220,2004-07-15,2004,US 0321230 W,2003-07-02,US 39293802 P,2002-07-02,ELECTRO-OPTICAL INTEGRATED TRANSMITTER CHIP FOR ARBITRARY QUADRATURE MODULATION OF OPTICAL SIGNALS,"An optical device includes, a first Mach-Zehnder modulator (105, 106) that produces a first output and a second Mach-Zehnder modulator (205, 206) which produces a second output. A splitter (212 )couples the first and second Mach-Zehnder modulators. A combiner (213) combines the first and second outputs. A phase shifter (107, 207) is coupled to the first and second Mach-Zehnder modulators. The first Mach-Zehnder modulator, second Mach-Zehnder modulator, splitter, combiner and the phase shifter are each formed as part of a single chip made of electro-optical material. Such two similar optical device integrated together with polarization combiner provide a two-polarization performance.",CELIGHT INC;;KAPLAN ARKADY;;ACHIAM YAAKOV;;GREENBLATT ARTHUR;;SHPANTZER ISAAC;;CHO PAK SHING;;TSEYTLIN MICHAEL;;SALAMON AVIV,KAPLAN ARKADY;;ACHIAM YAAKOV;;GREENBLATT ARTHUR;;SHPANTZER ISAAC;;CHO PAK SHING;;TSEYTLIN MICHAEL;;SALAMON AVIV,,https://lens.org/108-427-150-715-220,Search Report,yes,2,1,5,110,0,G02F1/225;;G02F2203/06;;H04B10/505;;H04B10/5051;;H04B10/5053;;H04B10/5057;;H04B10/50577;;H04B10/532;;H04B10/541;;H04B10/5561,G02F1/225;;H04B10/50;;H04B10/532;;H04B10/54;;H04B10/556,,0,0,,,,PENDING
983,CA,A1,CA 3174663 A1,161-149-283-690-674,2021-10-14,2021,CA 3174663 A,2021-04-05,US 202063005948 P;;US 2021/0025737 W,2020-04-06,"ULTRA-LOW FRICTION MATERIALS FOR LUBRICATING SURFACES, DEVICES THEREWITH, AND METHODS OF MANUFACTURE AND USE THEREOF","A polymeric material mixture comprising a fluorine-containing polymer, a siloxane polymer, and at least two polymer processing additives (PPA), wherein the at least two polymer processing additives have different chemistries. For example, there can be a flexible coextruded pipe for providing a protective housing for cables, fluids, sludge or solids, the pipe comprising a pair of telescopically related inner and outer layers, where said inner layer is lubricated with the polymeric material mixture.",DURA LINE LLC,FAN FEI;;CHO SUNG KI;;LUKUBIRA SAM;;SPRADLING CALEB MICHAEL;;VALENCIA ARTURO;;CHUNG H THOMAS,,https://lens.org/161-149-283-690-674,Patent Application,no,0,0,9,9,0,C09D183/04;;C08K3/042;;C10N2030/06;;C10M2213/0623;;C10N2020/06;;C10N2020/04;;C10M2229/025;;C10M2205/022;;C10M157/10;;C10M103/02;;C10M107/38;;C10M107/50;;C10M111/04;;C10M143/02;;C10M147/02;;C10M157/02;;C10M169/041;;C10M2201/0413;;C10M2205/022;;C10M2213/02;;C10M2213/0623;;C10M2229/025;;C10N2040/32;;C10N2050/08;;A47C27/001;;A47C27/002;;A47C27/04;;A47C27/20;;A47C31/001,C08L27/18;;C08J3/22;;C08K3/04;;F16L9/12,,0,0,,,,PENDING
984,US,A1,US 2011/0053925 A1,064-130-207-556-127,2011-03-03,2011,US 87012310 A,2010-08-27,US 87012310 A;;US 23775509 P,2009-08-28,Hydroxamate-Based Inhibitors of Deacetylases,"The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R 1 , R 2 , R 3 , ring A, and are as defined herein. The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.",NOVARTIS AG,CHO YOUNG SHIN;;JIANG LEI;;SHULTZ MICHAEL;;CHEN CHRISTINE HIU-TUNG;;LIU GANG;;LI JIANKE,NOVATIS AG (2010-09-02);;NOVARTIS AG (2010-08-27),https://lens.org/064-130-207-556-127,Patent Application,yes,7,6,1,1,0,C07D213/74;;C07D217/22;;C07D235/30;;C07D241/42;;C07D241/50;;C07D295/155;;C07D295/185;;C07D295/205;;C07D295/26;;C07D401/04;;C07D401/10;;C07D405/04;;C07D409/04;;C07D413/04;;C07D471/04;;C07D491/107;;C07D491/113;;C07D498/10;;A61P19/02;;A61P25/16;;A61P25/28;;A61P35/00;;A61P7/02;;A61P9/04;;A61P9/10;;C07D295/205;;C07D217/22;;C07D295/155;;C07D295/185;;C07D241/50;;C07D235/30;;C07D401/04;;C07D213/74;;C07D491/113;;C07D401/10;;C07D413/04;;C07D241/42;;C07D295/26;;C07D471/04;;C07D491/107;;C07D409/04;;C07D498/10;;C07D405/04,A61K31/537;;A61K31/437;;A61K31/438;;A61K31/454;;A61K31/495;;A61K31/5377;;A61P7/02;;A61P9/04;;A61P9/10;;A61P19/02;;A61P25/16;;A61P25/28;;A61P35/00;;C07D295/205;;C07D401/02;;C07D413/02;;C07D413/14;;C07D471/04;;C07D471/10;;C07D498/10;;C12N5/00,514/230.5;;435/375;;514/235.2;;514/236.8;;514/255.01;;514/278;;514/292;;514/323;;544/71;;544/130;;544/137;;544/138;;544/389;;546/20;;546/87;;546/201,0,0,,,,DISCONTINUED
985,ES,T3,ES 2251580 T3,133-814-946-142-962,2006-05-01,2006,ES 02714897 T,2002-02-15,US 26868301 P;;US 31236101 P,2001-02-15,DERIVADOS DE 3-(4-AMIDOPIRROL-2-ILMETILIDEN)-2-INDOLINONA COMO INHIBIDORES DE PROTEINQUINASA.,"Un Compuesto de **Fórmula** en donde: R1 es seleccionado del grupo compuesto por hidrógeno, halo, alquilo C1-C10, haloalcoxi C1-C4, cicloalquilo monocíclico C3-C8, [5, 6]- o [6, 6]-cicloalquilo bicíclico fusionado, adamantil, un grupo heteroalicíclico de 5-9 miembros con 1 ó 2 heteroátomos seleccionados entre N, O ó -S(O)n donde n = 0-2, hidroxi, alcoxi C1-C10, cicloalcoxi C3-C8 no sustituido, -C(O)-R8, -NR9R10 y -C(O) NR12R13; R2 es seleccionado del grupo compuesto por hidrógeno, halo, alquilo C1-C10, trihalometilo, hidroxi, alcoxi C1- C10, cicloalcoxi C3-C8 no sustituido, ciano, -NR9R10, - NR9C(O)R10, -C(O)R8, -S(O)2NR9R10 y -SO2R14 (donde R14 es un alquilo C1-C10, arilo C6-C12, alquilo C1-C4 sustituido con arilo C6-C12, un heteroarilo de 5-12 miembros que contiene 1-4 heteroátomos anulares seleccionados del grupo de N, O ó S, y alquilo C1-C4 sustituido con un heteroarilo de 5-12 miembros que contiene 1-4 heteroátomos anulares seleccionados entre N, O ó S; R3, R4 y R5 son independientemente hidrógeno o alquilo C1-C10.",PHARMACIA & UPJOHN CO LLC;;SUGEN INC,GUAN HUIPING;;LIANG CONGXIN;;SUN LI;;TANG PENG CHO;;WEI CHUNG CHEN;;MAURAGIS MICHAEL A,,https://lens.org/133-814-946-142-962,Granted Patent,no,0,0,64,65,0,C07D403/06;;C07D403/14;;C07D471/04;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;A61P9/00;;A61P3/10;;C07D403/14;;C07D403/06;;C07D403/14;;C07D471/04,A61K31/404;;A61K31/4178;;A61K31/437;;A61K31/5377;;A61K31/541;;A61P3/10;;A61P9/00;;A61P17/06;;A61P19/02;;A61P29/00;;A61P35/00;;C07D/;;C07D403/06;;C07D403/14;;C07D413/14;;C07D471/04,,0,0,,,,EXPIRED
986,WO,A3,WO 2000/006245 A3,158-353-681-189-068,2000-05-18,2000,US 9917288 W,1999-07-30,US 9476598 P,1998-07-31,METHOD FOR CORRECTION OF MRI MOTION ARTIFACTS AND MAIN FIELD FLUCTUATION,A method for correcting MRI motion artifacts and main field fluctuations. A series of data prints are acquired at read points along a radial axis to form a view (210). Subsequent views define a NMR data set. A processor stores the NMR data set and reconstructs an image array from a stored NMR data set by; a) reconstructing the NMR data set along a radial axis; b) producing a correction data array including correction values where each of the correction values is calculated as a function of the corresponding stored NMR datum and the stored NMR datum for the intersection of the first and subsequent projection (200) axes; c) applying the data in the correction array to the NMR data set to produce a final NMrR data set.,UNIV CASE WESTERN RESERVE;;DUERK JEFFREY L;;WENDT MICHAEL;;SHANKARANARAYANAN AJIT;;CHUNG YIU CHO;;LEWIN JONATHAN S;;MERKLE ELMAR,DUERK JEFFREY L;;WENDT MICHAEL;;SHANKARANARAYANAN AJIT;;CHUNG YIU-CHO;;LEWIN JONATHAN S;;MERKLE ELMAR,,https://lens.org/158-353-681-189-068,Search Report,yes,3,0,4,4,0,A61B5/055;;A61B5/7257;;G01R33/482;;G01R33/56509;;G01R33/56563;;G01R33/5676;;G01R33/56509;;G01R33/56563;;A61B5/7257;;G01R33/482;;A61B5/055;;G01R33/5676,A61B5/055;;G01R33/565;;G01R33/567,,0,0,,,,PENDING
987,AU,A1,AU 2003/278698 A1,188-687-109-132-51X,2004-01-23,2004,AU 2003/278698 A,2003-07-02,US 39293802 P;;US 0321230 W,2002-07-02,ELECTRO-OPTICAL INTEGRATED TRANSMITTER CHIP FOR ARBITRARY QUADRATURE MODULATION OF OPTICAL SIGNALS,,CELIGHT INC,ACHIAM YAAKOV;;GREENBLATT ARTHUR;;SHPANTZER ISAAC;;CHO PAK SHING;;TSEYTLIN MICHAEL;;SALAMON AVIV;;KAPLAN ARKADY,,https://lens.org/188-687-109-132-51X,Patent Application,no,0,0,5,110,0,G02F1/225;;G02F2203/06;;H04B10/505;;H04B10/5051;;H04B10/5053;;H04B10/5057;;H04B10/50577;;H04B10/532;;H04B10/541;;H04B10/5561,G02F1/225;;H04B10/50;;H04B10/532;;H04B10/54;;H04B10/556,,0,0,,,,DISCONTINUED
988,BR,A,BR 0316108 A,012-322-858-742-45X,2005-09-27,2005,BR 0316108 A,2003-10-27,US 42521902 P;;IB 0304805 W,2002-11-08,Derivados de fenilalquil e piridilalquil piperazina e composição farmacêutica compreendendo os mesmos,"""DERIVADOS DE FENILALQUIL E PIRIDILALQUIL PIPERAZINA E COMPOSIçãO FARMACêUTICA COMPREENDENDO OS MESMOS"". Esta invenção refere-se aos compostos da fórmula (1), em que R¬ 1¬, R¬ 3¬, R¬ 4¬, X¬ 1¬, e X¬ 2¬ são definidos como no relatório descritivo, às composições farmacêuticas que os contêm e ao seu uso no tratamento de distúrbios do sistema nervoso central e de outros distúrbios.",WARNER LAMBERT CO,CHO STEPHEN SUNG YONG;;DAVIS JAMIE MARIE;;GRAHAM JAMES MICHAEL;;GREGORY TRACY FAY;;HOWARD HARRY RALPH;;NIKAM SHAM SHRIDHAR;;WALTERS MICHAEL ANTHONY,,https://lens.org/012-322-858-742-45X,Patent Application,no,0,0,9,9,0,A61P25/00;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/22;;A61P25/28;;A61P25/30;;A61P27/02;;A61P27/06;;C07D231/56;;C07D231/56;;C07D275/04;;C07D275/04;;C07D275/06;;C07D275/06;;C07D417/12;;C07D417/12,A61P25/18;;C07D231/56;;C07D275/04;;C07D275/06;;C07D417/12,,0,0,,,,DISCONTINUED
989,DE,A1,DE 102020005096 A1,126-123-676-359-531,2021-03-04,2021,DE 102020005096 A,2020-08-19,US 201962893203 P;;US 201916573009 A,2019-08-29,Laufstreifen und Luftreifen mit einem solchen Laufstreifen,"Es wird ein Laufstreifen für einen Reifen (1) und ein entsprechender Reifen (1) vorgeschlagen. Der Laufstreifen umfasst eine erste Laufstreifenzone (11), die sich in Umfangsrichtung durchgehend und vollständig um den Reifen (1) erstreckt, wenn der Laufstreifen (10) auf den Reifen (1) aufgebracht ist, wobei die erste Laufstreifenzone (11) aus einer ersten Zusammensetzung gebildet ist; eine zweite Laufstreifenzone (12), die sich in Umfangsrichtung durchgehend und vollständig um den Reifen (1) erstreckt, wenn die Lauffläche (10) auf den Reifen (1) aufgebracht ist, wobei die zweite Laufstreifenzone (12) aus einer zweiten Zusammensetzung gebildet ist, die sich von der ersten Zusammensetzung unterscheidet; und eine Begrenzungsrille (13), die die erste Laufstreifenzone (11) axial von der zweiten Laufstreifenzone (12) trennt; wobei die erste Laufstreifenzone (11), die zweite Laufstreifenzone (12) und die Begrenzungsrille (13) die Lauffläche (10) vollständig bilden oder zumindest den Teil oder die Schicht der Lauffläche (10) vollständig bilden, der bzw. die mit einer Straße in Kontakt gelangt, wenn die Lauffläche (10) auf den Reifen (1) aufgebracht ist und der Reifen (1) an einem Fahrzeug montiert ist, bei normalem Reifendruck aufgepumpt ist und unter Standardlast steht. Die Begrenzungsrille (13) weist eine axiale Mittellinie auf, die um einen axialen Abstand (D) von einer Längsmittellinienebene (LE) des Reifens (1) oder der Lauffläche (10) beabstandet angeordnet ist. Die erste Laufstreifenzone (11) weist eine erste Umfangsrille (112) und einen Seitenwandabschnitt auf, der eine Zwischenumfangsrippe (113) der ersten Laufstreifenzone (11) und eine Schulterumfangsrippe (114) der ersten Laufstreifenzone (11) definiert.",GOODYEAR TIRE & RUBBER,SKURICH MICHAEL STEFAN;;JUERGENS ZACHARY WILLIAM;;CRANO MICHAEL RICHARD;;CHO JUNG WAN;;SMESKO KENNETH WILLIAM;;GUEVARA LEOCADIO HANS-PETER;;WIELAND RICHARD MARK,,https://lens.org/126-123-676-359-531,Patent Application,no,0,0,3,3,0,B60C2011/1213;;B60C2011/1209;;B60C2011/1227;;B60C2011/1338;;B60C2011/0365;;B60C2011/0344;;B60C2011/0341;;B60C2011/0381;;B60C2011/0383;;B60C2011/1361;;B60C11/0304;;B60C11/1236;;B29D30/58;;B29D2030/685;;B29D30/68;;B60C13/003;;B29D30/60;;B60C11/0066;;B60C11/0309;;B60C11/1259;;B60C11/1272;;B60C2011/1245;;B60C2011/1254;;B60C11/0066;;B60C11/0304;;B60C11/1204;;B60C11/1236;;B60C11/1272;;B60C2011/0358;;B60C2011/1213;;B60C2011/1231;;B60C2011/1245;;B60C2011/1254;;B60C2011/1277,B60C11/03;;B29D30/06,,0,0,,,,PENDING
990,US,A1,US 2021/0061017 A1,028-413-475-268-759,2021-03-04,2021,US 201916573009 A,2019-09-17,US 201916573009 A;;US 201962893203 P,2019-08-29,TREAD FOR A PNEUMATIC TIRE,"A tread for a tire includes: a first tread zone extending circumferentially, continuously, and entirely around the tire, the first tread zone being formed of a first compound; a second tread zone extending circumferentially, continuously, and entirely around the tire, the second tread zone being formed of a second compound different from the first compound; and a boundary groove axially separating the first tread zone from the second tread zone, the first tread zone, the second tread zone, and the boundary groove entirely forming the tread, the boundary groove having an axial centerline disposed an axial distance from an equatorial plane of the tire. The first tread zone has a first circumferential groove and a sidewall portion defining an intermediate circumferential rib of the first tread zone and a shoulder circumferential rib of the first tread zone.",GOODYEAR TIRE & RUBBER,SKURICH MICHAEL STEFAN;;JUERGENS ZACHARY WILLIAM;;CRANO MICHAEL RICHARD;;CHO JUNG WAN;;SMESKO KENNETH WILLIAM;;LEOCADIO HANS-PETER GUEVARA;;WIELAND RICHARD MARK,THE GOODYEAR TIRE & RUBBER COMPANY (2019-09-04),https://lens.org/028-413-475-268-759,Patent Application,yes,0,1,3,3,0,B60C2011/1213;;B60C2011/1209;;B60C2011/1227;;B60C2011/1338;;B60C2011/0365;;B60C2011/0344;;B60C2011/0341;;B60C2011/0381;;B60C2011/0383;;B60C2011/1361;;B60C11/0304;;B60C11/1236;;B29D30/58;;B29D2030/685;;B29D30/68;;B60C13/003;;B29D30/60;;B60C11/0066;;B60C11/0309;;B60C11/1259;;B60C11/1272;;B60C2011/1245;;B60C2011/1254;;B60C11/0066;;B60C11/0304;;B60C11/1204;;B60C11/1236;;B60C11/1272;;B60C2011/0358;;B60C2011/1213;;B60C2011/1231;;B60C2011/1245;;B60C2011/1254;;B60C2011/1277,B60C11/03;;B60C11/12,,0,0,,,,ACTIVE
991,US,B2,US 11298982 B2,084-883-703-418-091,2022-04-12,2022,US 201916573009 A,2019-09-17,US 201916573009 A;;US 201962893203 P,2019-08-29,Tread for a pneumatic tire,"A tread for a tire includes: a first tread zone extending circumferentially, continuously, and entirely around the tire, the first tread zone being formed of a first compound; a second tread zone extending circumferentially, continuously, and entirely around the tire, the second tread zone being formed of a second compound different from the first compound; and a boundary groove axially separating the first tread zone from the second tread zone, the first tread zone, the second tread zone, and the boundary groove entirely forming the tread, the boundary groove having an axial centerline disposed an axial distance from an equatorial plane of the tire. The first tread zone has a first circumferential groove and a sidewall portion defining an intermediate circumferential rib of the first tread zone and a shoulder circumferential rib of the first tread zone.",GOODYEAR TIRE & RUBBER,SKURICH MICHAEL STEFAN;;JUERGENS ZACHARY WILLIAM;;CRANO MICHAEL RICHARD;;CHO JUNG WAN;;SMESKO KENNETH WILLIAM;;LEOCADIO HANS-PETER GUEVARA;;WIELAND RICHARD MARK,THE GOODYEAR TIRE & RUBBER COMPANY (2019-09-04),https://lens.org/084-883-703-418-091,Granted Patent,yes,34,0,3,3,0,B60C2011/1213;;B60C2011/1209;;B60C2011/1227;;B60C2011/1338;;B60C2011/0365;;B60C2011/0344;;B60C2011/0341;;B60C2011/0381;;B60C2011/0383;;B60C2011/1361;;B60C11/0304;;B60C11/1236;;B29D30/58;;B29D2030/685;;B29D30/68;;B60C13/003;;B29D30/60;;B60C11/0066;;B60C11/0309;;B60C11/1259;;B60C11/1272;;B60C2011/1245;;B60C2011/1254;;B60C11/0066;;B60C11/0304;;B60C11/1204;;B60C11/1236;;B60C11/1272;;B60C2011/0358;;B60C2011/1213;;B60C2011/1231;;B60C2011/1245;;B60C2011/1254;;B60C2011/1277,B60C11/11;;B60C11/00;;B60C11/03;;B60C11/12;;B60C11/13,,5,0,,,Machine translation for Japan 2005-153812 (Year: 2021).;;Machine translation for Japan 11-321237 (Year: 2021).;;Machine translation for Japan 07-228106 (Year: 2021).;;Translation for Japan 07-186633 (Year: 2021).;;Machine translation for Europe 618091 (Year: 2021).,ACTIVE
992,TW,B,TW I747033 B,077-809-443-647-162,2021-11-21,2021,TW 108130729 A,2019-08-28,US 201816131972 A,2018-09-14,SEMICONDUCTOR SUBSTRATE SUPPORTS WITH EMBEDDED RF SHIELD,,APPLIED MATERIALS INC,BENJAMINSON DAVID;;GRACE MICHAEL;;PARK SOONAM;;LUBOMIRSKY DMITRY;;CHO JAEYONG;;KALNIN NIKOLAI;;KALUARACHCHI DON CHANNA K,,https://lens.org/077-809-443-647-162,Granted Patent,no,5,0,10,10,0,H01J37/32091;;H01J37/3244;;H01J37/32724;;H01L21/683;;H01L21/67103;;H01L21/68785;;H01L21/67248;;H01J37/32174;;H05H1/46;;H01L21/6833;;H01L21/67069;;H01L21/67103;;H01J37/3244;;H01L21/67167;;H01J2237/002;;H01J37/32091;;H01J37/32724,,,0,0,,,,ACTIVE
993,US,B1,US 7835780 B1,180-544-645-530-432,2010-11-16,2010,US 24021901 A,2001-03-30,US 24021901 A;;US 19329400 P;;US 0110041 W,2000-03-30,MR invasive device and method for active MR guidance of invasive devices with target navigation,"An invasive device having an inductive coupling element. One embodiment of the invasive device includes a plurality of receive coils inductively coupled to a communicating coil. The receive coils are selectively tuned and detuned to receive MR signals for providing coordinate information used for device tracking. A second embodiment of the invasive device includes a receive coil having a plurality of winding elements separated from each other by different distances. A method of rapidly acquiring both the invasive device orientation and position information to dynamically adapt MR scan planes to continuously follow the invasive device relative to a target is provided. The target-navigation technique automatically defines the MR scan plane and a time domain multiplexing technique is applied for MR imaging and device tracking. Using these techniques, the acquired MR images shows both the invasive device and the target tissue.",DUERK JEFFREY L;;ZHANG QIANG;;WENDT MICHAEL;;CHUNG YIU-CHO;;LEWIN JONATHAN S;;MERKLE ELMAR M,DUERK JEFFREY L;;ZHANG QIANG;;WENDT MICHAEL;;CHUNG YIU-CHO;;LEWIN JONATHAN S;;MERKLE ELMAR M,CASE WESTERN RESERVE UNIVERSITY (2003-03-17);;LG CHEM LTD (2002-07-05),https://lens.org/180-544-645-530-432,Granted Patent,yes,11,13,3,3,0,G01R33/287;;G01R33/34084;;G01R33/287;;G01R33/34084,G01R33/28;;A61B5/05;;G01R33/34,600/410;;600/411;;600/417;;600/420;;600/421;;600/422,0,0,,,,EXPIRED
994,CN,A,CN 105209460 A,026-848-070-092-652,2015-12-30,2015,CN 201480028054 A,2014-03-13,IB 2014059758 W;;US 201361782211 P,2013-03-14,3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH,"The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.",NOVARTIS AG,CHO YOUNG SHIN;;LEVELL JULIAN ROY;;LIU GANG;;SHULTZ MICHAEL DAVID;;VAN DER PLAS SIMON CORNELIS,,https://lens.org/026-848-070-092-652,Patent Application,no,5,8,15,15,0,C07D413/14;;A61K31/506;;C07D417/14;;A61K45/06;;C07D413/04;;A61K31/5377;;C07D487/08;;A61P35/00;;A61P43/00;;C07D413/14;;A61K31/506;;C07D417/14;;A61K45/06;;C07D413/04;;A61K31/5377;;C07D487/08,C07D413/14;;A61K31/506;;A61P35/00;;C07D413/04;;C07D417/14,,1,1,000-290-929-702-895,10.1021/jm1013693;;21413808,"NICHOLAS A. MEANWELL: ""“Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design”"", 《J. MED. CHEM.》",DISCONTINUED
995,US,A1,US 2016/0039802 A1,042-187-709-350-507,2016-02-11,2016,US 201414774741 A,2014-03-13,US 201414774741 A;;US 201361782211 P;;IB 2014059758 W,2013-03-14,3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH,"The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2a , R 2b and R 3 -R 7 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant I DH proteins including, but not limited to, cell-proliferation disorders, such as cancer.",CHO YOUNG SHIN;;LEVELL JULIAN ROY;;LIU GANG;;SHULTZ MICHAEL DAVID;;VAN DER PLAS SIMON CORNELIS;;NOVARTIS AG,CHO YOUNG SHIN;;LEVELL JULIAN ROY;;LIU GANG;;SHULTZ MICHAEL DAVID;;VAN DER PLAS SIMON CORNELIS,NOVARTIS AG (2014-05-07);;NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC (2014-05-07),https://lens.org/042-187-709-350-507,Patent Application,yes,3,5,15,15,0,C07D413/14;;A61K31/506;;C07D417/14;;A61K45/06;;C07D413/04;;A61K31/5377;;C07D487/08;;A61P35/00;;A61P43/00;;C07D413/14;;A61K31/506;;C07D417/14;;A61K45/06;;C07D413/04;;A61K31/5377;;C07D487/08,C07D413/04;;A61K31/506;;A61K31/5377;;C07D413/14;;C07D417/14;;C07D487/08,,2,2,000-290-929-702-895;;000-290-929-702-895,10.1021/jm1013693;;21413808;;10.1021/jm1013693;;21413808,"Meanwell, N.A., J. Med. Chem. Vol. 54 pages 2529-2591. Published 2011.;;Meanwell (J. Med. Chem. Vol. 54 pages 2529-2591, published 2011).",DISCONTINUED
996,MX,A,MX 2013002322 A,066-110-311-142-770,2013-06-28,2013,MX 2013002322 A,2010-08-27,EP 2010062594 W,2010-08-27,HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES.,"The present teachings relate to compounds of Formula (I): and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, R4, R5, ring A, and Z are as defined herein. The present teachings also provide methods of preparing compounds of Formula (I) and methods of use compounds of Formula (I) in treating pathologic conditions or disorders mediated wholly or in part by deacetylases.",NOVARTIS AG,LIU GANG;;SHULTZ MICHAEL;;CHEN CHRISTINE HIU-TUNG;;CHO YOUNG SHIN;;JIANG LEI;;BROOKS CLINTON A,,https://lens.org/066-110-311-142-770,Patent Application,no,0,0,11,11,0,A61K31/4015;;A61K31/4025;;A61K31/4155;;A61K31/416;;A61K31/4192;;A61K31/4245;;A61K31/4427;;A61K31/4439;;C07D207/06;;C07D403/06;;C07D403/14;;C07D407/14;;C07D413/06;;A61P13/08;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/10;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D403/06;;A61K31/404;;C07D403/06;;A61K31/4427;;A61K31/4015;;A61K31/4245;;C07D207/06;;C07D407/14;;A61K31/4155;;A61K31/416;;A61K31/4439;;A61K31/4192;;A61K31/4025;;C07D403/14;;C07D413/06;;C07D401/14,C07D207/06;;A61K31/4015;;A61K31/4025;;A61K31/4155;;A61K31/416;;A61K31/4192;;A61K31/4245;;A61K31/4427;;A61K31/4439;;A61P9/00;;A61P29/00;;C07D403/06;;C07D403/14;;C07D407/14;;C07D413/06,,0,0,,,,DISCONTINUED
997,DK,T3,DK 3371313 T3,133-325-160-859-294,2021-01-18,2021,DK 16763143 T,2016-08-26,US 201562252229 P;;US 2016/0049132 W,2015-11-06,FREMGANGSMÅDER OG SAMMENSÆTNINGER TIL FORBEDRET PLANTETRANSFORMATION,,PIONEER HI BRED INT,ANAND AJITH;;BASS STEVEN HENRY;;CHO HYEON-JE;;KLEIN THEODORE MITCHELL;;MCBRIDE KEVIN E;;LASSNER MICHAEL,,https://lens.org/133-325-160-859-294,Granted Patent,no,0,0,12,12,0,C12N15/8205;;C12N15/8205;;C07K14/195;;C07K14/195;;C07K14/245;;C12N15/8202;;C12N15/8202,C12N15/82;;C07K14/195,,0,0,,,,ACTIVE
998,CA,A1,CA 2807738 A1,171-075-137-531-214,2012-03-01,2012,CA 2807738 A,2010-08-27,EP 2010062594 W,2010-08-27,HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES,"The present teachings relate to compounds of Formula (I): and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, R4, R5, ring A, and Z are as defined herein. The present teachings also provide methods of preparing compounds of Formula (I) and methods of use compounds of Formula (I) in treating pathologic conditions or disorders mediated wholly or in part by deacetylases.",NOVARTIS AG,BROOKS CLINTON A;;CHEN CHRISTINE HIU-TUNG;;CHO YOUNG SHIN;;JIANG LEI;;LIU GANG;;SHULTZ MICHAEL,,https://lens.org/171-075-137-531-214,Patent Application,no,0,0,11,11,0,A61K31/4015;;A61K31/4025;;A61K31/4155;;A61K31/416;;A61K31/4192;;A61K31/4245;;A61K31/4427;;A61K31/4439;;C07D207/06;;C07D403/06;;C07D403/14;;C07D407/14;;C07D413/06;;A61P13/08;;A61P17/00;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/14;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/10;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;C07D403/06;;A61K31/404;;C07D403/06;;A61K31/4427;;A61K31/4015;;A61K31/4245;;C07D207/06;;C07D407/14;;A61K31/4155;;A61K31/416;;A61K31/4439;;A61K31/4192;;A61K31/4025;;C07D403/14;;C07D413/06;;C07D401/14,C07D207/06;;A61K31/4015;;A61K31/4025;;A61K31/4155;;A61K31/416;;A61K31/4192;;A61K31/4245;;A61K31/4427;;A61K31/4439;;A61P9/00;;A61P29/00;;C07D403/06;;C07D403/14;;C07D407/14;;C07D413/06,,0,0,,,,DISCONTINUED
999,MX,A,MX 2015012822 A,199-726-241-763-659,2016-05-31,2016,MX 2015012822 A,2014-03-13,US 201361782211 P;;IB 2014059758 W,2013-03-14,3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH.,"The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant I DH proteins including, but not limited to, cell-proliferation disorders, such as cancer.",NOVARTIS AG,SHULTZ MICHAEL DAVID;;LIU GANG;;CHO YOUNG SHIN;;LEVELL JULIAN ROY;;PLAS SIMON CORNELIS VAN DER,,https://lens.org/199-726-241-763-659,Patent Application,no,0,0,15,15,0,C07D413/14;;A61K31/506;;C07D417/14;;A61K45/06;;C07D413/04;;A61K31/5377;;C07D487/08;;A61P35/00;;A61P43/00;;C07D413/14;;A61K31/506;;C07D417/14;;A61K45/06;;C07D413/04;;A61K31/5377;;C07D487/08,C07D413/14;;A61K31/506;;A61P35/00;;C07D413/04;;C07D417/14,,0,0,,,,PENDING
1000,KR,A,KR 20210044906 A,005-407-504-251-994,2021-04-23,2021,KR 20217011053 A,2019-08-22,US 201816131972 A;;US 2019/0047690 W,2018-09-14,내장형 RF 차폐부를 갖는 반도체 기판 지지부들,"예시적인 지지 조립체들은 기판 지지 표면을 한정하는 최상부 퍽을 포함할 수 있고, 최상부 퍽은 또한, 높이를 특징으로 한다. 조립체들은, 기판 지지 표면에 대향하는, 최상부 퍽의 제2 표면 상에서 최상부 퍽과 결합된 스템을 포함할 수 있다. 조립체들은 기판 지지 표면에 근접하여 최상부 퍽 내에 내장된 RF 전극을 포함할 수 있다. 조립체들은 최상부 퍽 내에 내장된 가열기를 포함할 수 있다. 조립체들은 또한, 최상부 퍽 내에 내장된 접지 차폐부를 포함할 수 있다. 접지 차폐부는 최상부 퍽을 통해 방사상으로 연장되는 내측 영역을 특징으로 할 수 있다. 접지 차폐부는 내측 영역에 수직으로 연장되는 외측 영역을 더 특징으로 할 수 있다.",APPLIED MATERIALS INC,BENJAMINSON DAVID;;GRACE MICHAEL;;PARK SOONAM;;LUBOMIRSKY DMITRY;;CHO JAEYONG;;KALNIN NIKOLAI;;KALUARACHCHI DON CHANNA K,,https://lens.org/005-407-504-251-994,Patent Application,no,4,0,10,10,0,H01J37/32091;;H01J37/3244;;H01J37/32724;;H01L21/683;;H01L21/67103;;H01L21/68785;;H01L21/67248;;H01J37/32174;;H05H1/46;;H01L21/6833;;H01L21/67069;;H01L21/67103;;H01J37/3244;;H01L21/67167;;H01J2237/002;;H01J37/32091;;H01J37/32724,H01L21/683;;H01J37/32;;H01L21/67;;H01L21/687;;H05H1/46,,0,0,,,,ACTIVE
